PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Patomella, AH; Kottorp, A; Tham, K				Patomella, Ann-Helen; Kottorp, Anders; Tham, Kerstin			Awareness of driving disability in people with stroke tested in a simulator	SCANDINAVIAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						Automobile driving; metacognition; occupational therapy; rehabilitation; simulation; stroke	TRAUMATIC BRAIN-INJURY; COMPETENCE RATING-SCALE; SELF-AWARENESS; ALZHEIMER-DISEASE; OLDER DRIVERS; PERFORMANCE; ABILITY; DEFICITS; FITNESS; ADULTS	The aim of this study was to explore and describe awareness of driving disability in people with driving difficulties after stroke. The study comprised a consecutive sample of 38 participants with stroke who showed difficulties in a technically advanced, interactive driving simulator. Driving ability in the simulator was measured using Performance Analysis of Driving Ability (P-Drive). Awareness of driving disability was measured using a modified version of Assessment of Awareness of Disability (AAD), measuring the discrepancy between observed driving actions and self-reported disability after a driving evaluation in a simulator. A majority of the participants (n =36) demonstrated driving ability that was below the cut-off criterion for P-Drive. Furthermore, a majority of the items measuring awareness of driving disability were scored low, indicating that participants with stroke who did not pass a driving evaluation also had limited awareness of driving disability. A General Linear Model analysis indicated that awareness of driving disability and cognitive screening outcome explained 74% of the variance in driving ability. This study indicated that a majority of the people with stroke who fail a driving evaluation also have limited awareness of their disability, which indicates the need to address awareness in driving evaluations.	[Patomella, Ann-Helen; Kottorp, Anders; Tham, Kerstin] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Occupat Therapy, S-14183 Stockholm, Sweden	Patomella, AH (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Occupat Therapy, Alfred Nobels Alle 23, S-14183 Stockholm, Sweden.	ann-helen.patomella@ki.se	; Tham, Kerstin/T-3964-2018	Kottorp, Anders/0000-0002-8976-2612; Patomella, Ann-Helen/0000-0003-2667-4073; Tham, Kerstin/0000-0001-7025-5226	Postgraduate School of Health Care Sciences at Karolinska Institutet; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)	The study was supported by the Postgraduate School of Health Care Sciences at Karolinska Institutet and the Swedish Council for Working Life and Social Research. The authors would like to thank Gorel Caneman, Karolinska University Hospital for her support.	Bond T.G., 2001, APPL RASCH MODEL FUN; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Cotrell V, 1999, ALZ DIS ASSOC DIS, V13, P151, DOI 10.1097/00002093-199907000-00007; Ekstam L, 2007, AM J OCCUP THER, V61, P503, DOI 10.5014/ajot.61.5.503; Evans L., 2004, TRAFFIC SAFETY; Fisher AG, 1998, AM J OCCUP THER, V52, P509, DOI 10.5014/ajot.52.7.509; Fisher AG, 2006, ASSESSMENT MOTOR PRO, V1; Fisk GD, 1997, ARCH PHYS MED REHAB, V78, P1338, DOI 10.1016/S0003-9993(97)90307-5; Fleming JM, 1996, BRAIN INJURY, V10, P1; Foerch C, 2005, LANCET, V366, P392, DOI 10.1016/S0140-6736(05)67024-9; Hakamies-Blomqvist L, 1998, ACCIDENT ANAL PREV, V30, P305, DOI 10.1016/S0001-4575(97)00106-1; Hatakka M., 2002, TRANSPORTATION RES F, V5, P201, DOI [10.1016/S1369-8478(02)00018-9., 10.1016/S1369-8478]; Heikkila VM, 1999, ACTA NEUROL SCAND, V99, P349, DOI 10.1111/j.1600-0404.1999.tb07363.x; Kielhofner G, 2002, MODEL HUMAN OCCUPATI; Kottorp A, 2003, J INTELL DISABIL RES, V47, P597, DOI 10.1046/j.1365-2788.2003.00475.x; Kottorp A, 2006, ASSESSMENT AWARENESS; LARSSON H, 2007, SCAND J OCCUP THER, V4, P215; Lundberg C, 2003, SCAND J PSYCHOL, V44, P23, DOI 10.1111/1467-9450.00317; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Marottoli RA, 1998, ACCIDENT ANAL PREV, V30, P331, DOI 10.1016/S0001-4575(97)00100-0; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Michon JA., 1985, CRITICAL VIEW DRIVER; *NAT STROK REG SWE, 2006, RIKS STROK AN RAPP R; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; Patomella A., 2004, SCAND J OCCUP THER, V11, P70, DOI [DOI 10.1080/11038120410020520., 10.1080/11038120410020520]; Patomella A, 2005, P 3 INT DRIV S HUM F; Patomella AH, 2006, J REHABIL MED, V38, P273, DOI 10.1080/16501970600632594; PRIGATANO GP, 1991, AWARENESS DEFICITS B; Reckase M.D., 1979, J EDUC STAT, V4, P207, DOI 10.3102/10769986004003207; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; SVENSON O, 1981, ACTA PSYCHOL, V47, P143, DOI 10.1016/0001-6918(81)90005-6; Tham K, 2001, AM J OCCUP THER, V55, P46, DOI 10.5014/ajot.55.1.46; Tham K, 1996, Occup Ther Health Care, V10, P65, DOI 10.1080/J003v10n03_07; Tham K., 1999, SCANDINAVIAN J OCCUP, V6, P184, DOI [DOI 10.1080/110381, DOI 10.1080/110381299443663]; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; Wright BD., 1994, RASCH MEASUREMENT T, V8, P370, DOI DOI 10.1177/01461672012710004	41	12	12	0	13	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1103-8128			SCAND J OCCUP THER	Scand. J. Occup. Ther.	SEP	2008	15	3					184	192		10.1080/11038120802087600			9	Rehabilitation	Rehabilitation	364QR	WOS:000260350700006	18609244				2021-06-18	
J	Slomine, B; Eikenberg, J; Salorio, C; Suskauer, S; Trovato, M; Christensen, J				Slomine, Beth; Eikenberg, Janine; Salorio, Cynthia; Suskauer, Stacy; Trovato, Melissa; Christensen, James			Preliminary evaluation of the Cognitive and Linguistic Scale: A measure to assess recovery in inpatient rehabilitation following pediatric brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; brain injury; children and adolescents; cognition; language; measurement; rehabilitation	PERFORMANCE; ORIENTATION; CHILDREN; WEEFIM; COMA	Objective: A preliminary investigation of the psychometric properties of the Cognitive and Linguistic Scale (CALS), a measure of cognitive and linguistic recovery following brain injury in children and adolescents. Participants: One hundred children and adolescents (aged 2-14 years) with acquired or traumatic brain injury were included. Methods: The CALS was administered at inpatient rehabilitation admission and discharge. Results: Internal consistency and interrater reliability were high. Factor analysis revealed 2 factors (basic responding, higher-level cognitive skills). Correlations with the Functional Independence Measure for Children (WeeFIM) ranged from 0.51 to 0.89; highest correlation was between WeeFIM cognitive domain and CALS total score. CALS scores improved significantly between admission and discharge. Conclusion: On the basis of these preliminary analyses, the CALS is a promising measure to track cognitive and linguistic recovery in children and adolescents with brain injury during inpatient rehabilitation.	[Slomine, Beth] Johns Hopkins Univ, Sch Med, Dept Neuropsychol, Kennedy Krieger Inst, Baltimore, MD 21205 USA; [Slomine, Beth] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Eikenberg, Janine] Kennedy Krieger Inst, Dept Commun Sci & Disorders Program, Baltimore, MD USA; [Salorio, Cynthia; Suskauer, Stacy; Trovato, Melissa; Christensen, James] Johns Hopkins Univ, Sch Med, Dept Rehabil, Kennedy Krieger Inst, Baltimore, MD 21205 USA; [Salorio, Cynthia; Suskauer, Stacy; Trovato, Melissa; Christensen, James] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21205 USA	Slomine, B (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neuropsychol, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	slomine@kennedykrieger.org					Alderson AL, 2003, ARCH PHYS MED REHAB, V84, P668, DOI 10.1016/S0003-9993(03)04842-6; BARON JS, 2004, NEUROPSYCHOLOGICAL E; Chen CC, 2004, AM J OCCUP THER, V58, P44, DOI 10.5014/ajot.58.1.44; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Costello A., 2005, PRACT ASSESS RES EVA, V10, DOI 10.7275/jyj1-4868.; Delis DC, 2001, DELISKAPLAN EXECUTIV; DeVellis R., 2003, SCALE DEV THEORY APP; Donders J, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P91; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Dunkleberger K, 2006, J HEAD TRAUMA REHAB, V21, P410, DOI 10.1097/00001199-200609000-00010; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; FORSYTH RJ, 2007, DEV NEUROREHABIL, V10, P288; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Haley S.M., 1992, PEDIAT EVALUATION DI; HALEY SM, 1991, PHYS MED REH CLIN N, V2, P689; Hotz G, 2001, J HEAD TRAUMA REHAB, V16, P426, DOI 10.1097/00001199-200110000-00003; Israelian MK, 2000, REHABIL PSYCHOL, V45, P284, DOI 10.1037/0090-5550.45.3.284; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kane RL, 1997, UNDERSTANDING HLTH C, P17; Korkman M., 2007, CLIN INTERPRETIVE MA; Kothari DH, 2003, PHYS THER, V83, P776, DOI 10.1093/ptj/83.9.776; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; *NO CAL NEUR GROUP, 1995, COGN NEUR COGN STAT; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Nunnally J., 1970, INTRO PSYCHOL MEASUR; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Sander AM, 2007, AM J SPEECH-LANG PAT, V16, P316, DOI 10.1044/1058-0360(2007/036); Sattler J. M., 2008, ASSESSMENT CHILDREN; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Slomine B, 2006, J HEAD TRAUMA REHAB, V21, P419, DOI 10.1097/00001199-200609000-00030; Slomine BS, 2004, ARCH PHYS MED REHAB, V85, P512, DOI 10.1016/S0003-9993(03)00769-X; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; *STAT U NEW YORK C, 1998, GUID UN DAT SET MED; Suskauer S, 2006, J HEAD TRAUMA REHAB, V21, P420, DOI 10.1097/00001199-200609000-00031; Thomas-Stonell N, 2006, Pediatr Rehabil, V9, P14, DOI 10.1080/13638490500050097; Wechsler D., 2003, TECHNICAL INTERPRETI; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	40	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2008	23	5					286	293		10.1097/01.HTR.0000336841.53338.2f			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357GN	WOS:000259834400003	18815505				2021-06-18	
J	Brossart, DF; Meythaler, JM; Parker, RI; McNamara, J; Elliott, TR				Brossart, Daniel F.; Meythaler, Jay M.; Parker, Richard I.; McNamara, James; Elliott, Timothy R.			Advanced regression methods for single-case designs: Studying propranolol in the treatment for agitation associated with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article						single-case design; logistic regression; propranolol; brain injury; agitation	CLOSED HEAD-INJURY; LOGISTIC-REGRESSION; VISUAL INSPECTION; SUBJECT RESEARCH; PRESSURE SORES; EFFECT SIZES; BASE-LINE; REHABILITATION; BEHAVIOR; RESTLESSNESS	Objective: The use of single-case designs in intervention research is discussed. Regression methods for analyzing data from these designs are considered, and an innovative use of logistic regression to analyze data from a double-blind, randomized clinical trial of propranolol for agitation among persons with traumatic brain injury (TBI) is used. Method. Double-blind, randomized clinical trial performed in an outpatient rehabilitation setting. Participants: Nine men and 4 women with TBI. Results: Logistic models indicated that propranolol was not associated with less agitation for most participants (phi=.135; 90% exact confidence interval was -.03 <.135 <.29). Four participants displayed a significant response to propanolol. Two participants demonstrated significant improvement, and the other 2 experienced significantly more agitation in the treatment phase. Summary: Advanced regression methods can be used to analyze data from single-case designs to obtain information of clinical and statistical significance from a variety of psychological and medical treatments.	[Brossart, Daniel F.; Parker, Richard I.; McNamara, James; Elliott, Timothy R.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77845 USA; [Meythaler, Jay M.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; [Meythaler, Jay M.] Rehabil Inst Michigan, Detroit, MI USA	Brossart, DF (corresponding author), Texas A&M Univ, Dept Educ Psychol, 4225 TAMU, College Stn, TX 77845 USA.	brossart@tamu.edu	Brossart, Daniel/B-9770-2015; Elliott, Timothy R./I-5301-2012	Brossart, Daniel/0000-0003-2619-1450; Elliott, Timothy R./0000-0002-6608-7714			AESCHLEMAN SR, 1991, REHABIL PSYCHOL, V36, P43, DOI 10.1037/0090-5550.36.1.43; ALLISON DB, 1993, BEHAV RES THER, V31, P621, DOI 10.1016/0005-7967(93)90115-B; ALLISON DB, 1994, BEHAV RES THER, V32, P885, DOI 10.1016/0005-7967(94)90170-8; Backman CL, 1997, ARCH PHYS MED REHAB, V78, P1145, DOI 10.1016/S0003-9993(97)90142-8; Baltes P.B., 1979, LONGITUDINAL RES STU, P1; Barlow D.H., 1984, SINGLE CASE EXPT DES; Blampied NM, 2000, AM PSYCHOL, V55, P960, DOI 10.1037/0003-066X.55.8.960; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Brossart DF, 2006, BEHAV MODIF, V30, P531, DOI 10.1177/0145445503261167; BROSSART DF, 2001, HOUST 2001 NAT COUNS; BRUCKER BS, 1977, ARCH PHYS MED REHAB, V58, P49; Busk P. L., 1992, SINGLE CASE RES DESI, P159; Callahan CD, 2005, REHABIL PSYCHOL, V50, P24, DOI 10.1037/0090-5550.50.1.24; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; CASSIDY JW, 1990, J HEAD TRAUMA REHAB, V5, P83; CENTER BA, 1985, J SPEC EDUC, V19, P387, DOI 10.1177/002246698501900404; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLTART DJ, 1970, BRIT MED J, V3, P731, DOI 10.1136/bmj.3.5725.731; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Cox D. R., 1989, ANAL BINARY DATA, V2nd; CROSBIE J, 1993, J CONSULT CLIN PSYCH, V61, P966, DOI 10.1037/0022-006X.61.6.966; Crosbie J., 1995, ANAL CHANGE, P361; Davison A.C., 1997, BOOTSTRAP METHODS TH; DEPROSPERO A, 1979, J APPL BEHAV ANAL, V12, P573, DOI 10.1901/jaba.1979.12-573; DUNN D, REHABILITAT IN PRESS; EICHELMAN B, 1987, 3 GENERATION PROGR; Elliott TR, 2007, EXP CLIN PSYCHOPHARM, V15, P511, DOI 10.1037/1064-1297.15.6.511; Faith M. S., 1996, DESIGN ANAL SINGLE C, P245, DOI DOI 10.4324/9781315806402; Fidler F, 2002, EDUC PSYCHOL MEAS, V62, P749, DOI 10.1177/001316402236876; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; FLOR H, 1985, J CONSULT CLIN PSYCH, V53, P354, DOI 10.1037/0022-006X.53.3.354; FOX J, 2000, MULTIPLE GEN NONPARA; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Goldfried MR, 1996, AM PSYCHOL, V51, P1007, DOI 10.1037/0003-066X.51.10.1007; Good P.I., 2001, RESAMPLING METHODS P, V2nd ed.; GORSUCH RL, 1983, BEHAV ASSESS, V5, P141; HARBST KB, 1991, PHYS THER, V71, P107, DOI 10.1093/ptj/71.2.107; HILLIARD RB, 1993, J CONSULT CLIN PSYCH, V61, P373, DOI 10.1037/0022-006X.61.3.373; Hintze J, 2007, NCSS PASS GESS COMPU; Huitema B. E., 2004, Understanding Statistics, V3, P27, DOI 10.1207/s15328031us0301_2; INCE LP, 1978, J COMP PHYSIOL PSYCH, V92, P796, DOI 10.1037/h0077545; Kazdin A. E., 1982, SINGLE CASE RES DESI; KRATOCHWILL TR, 1978, BEHAV MODIF, V2, P291, DOI 10.1177/014544557823001; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lunneborg C. E., 2000, DATA ANAL RESAMPLING; MALAMENT IB, 1975, ARCH PHYS MED REHAB, V56, P161; Matyas T. A., 1996, DESIGN ANAL SINGLE C, P215; Menard S. W., 2002, APPL LOGISTIC REGRES; MICZEK KA, 1994, NEUROSCI BIOBEHAV R, V18, P97, DOI 10.1016/0149-7634(94)90040-X; Morgan DL, 2001, AM PSYCHOL, V56, P119, DOI 10.1037/0003-066X.56.2.119; MORRISON JH, 1979, SCIENCE, V205, P313, DOI 10.1126/science.451605; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; NESSELROADE JR, 1991, RECENT ADV UNANSWERE, P92; Oakley A, 2002, EDUC REV, V54, P277, DOI 10.1080/0013191022000016329; OTTENBACHER KJ, 1990, MENT RETARD, V28, P283; Pampel F. C., 2000, LOGISTIC REGRESSION; PARK HS, 1990, J EXP EDUC, V58, P311, DOI 10.1080/00220973.1990.10806545; Parker RI, 2006, SCHOOL PSYCHOL QUART, V21, P46, DOI 10.1521/scpq.2006.21.1.46; Parker RI, 2003, BEHAV THER, V34, P189, DOI 10.1016/S0005-7894(03)80013-8; Parker RI, 2005, SCHOOL PSYCHOL REV, V34, P116; Parker RI, 2007, BEHAV THER, V38, P95, DOI 10.1016/j.beth.2006.05.002; Parker RI, 2007, BEHAV MODIF, V31, P919, DOI 10.1177/0145445507303452; Parker RI, 2006, BEHAV THER, V37, P326, DOI 10.1016/j.beth.2006.01.007; Parker RI, 2006, SCHOOL PSYCHOL QUART, V21, P418, DOI 10.1037/h0084131; Parsonson B. S., 1992, SINGLE CASE RES DESI, P15; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Pijnenborg GHM, 2007, REHABIL PSYCHOL, V52, P236, DOI 10.1037/0090-5550.52.2.236; PRESS SJ, 1978, J AM STAT ASSOC, V73, P699, DOI 10.2307/2286261; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Rosenthal R, 1991, META ANAL PROCEDURES; ROWLAND T, 1995, NEUROREHABILITATION, V5, P219, DOI 10.3233/NRE-1995-5305; Shavelson R.J., 2002, SCI RES ED; Silver Jonathan M., 1994, P313; SIMON JL, 1999, RESAMPLING NEW STAT; Spring B, 2005, ANN BEHAV MED, V30, P125, DOI 10.1207/s15324796abm3002_5; Stevens J., 2007, INTERMEDIATE STAT MO; Tabachnick BG, 2013, USING MULTIVARIATE S; Tucker JA, 2006, ADDICTION, V101, P918, DOI 10.1111/j.1360-0443.2006.01396.x; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WHITE GW, 1989, J APPL BEHAV ANAL, V22, P287, DOI 10.1901/jaba.1989.22-287; Whyte J, 1993, REHABILITATION MED P, P825; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218	85	12	12	0	9	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2008	53	3					357	369		10.1037/a0012973			13	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	343XQ	WOS:000258890000010					2021-06-18	
J	Cho, J; Moon, CT; Kang, HS; Choe, WJ; Chang, SK; Koh, YC; Roh, HG				Cho, Joon; Moon, Chang Taek; Kang, Hyun Seung; Choe, Woo Jin; Chang, Sang Keun; Koh, Young Cho; Roh, Hong Gee			Traumatic entrapment of the vertebrobasilar junction due to a longitudinal clival fracture: A case report	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						cranial fossa, posterior; skull fracture, basilar; vertebral artery; brain infarction	BASILAR ARTERY; OCCLUSION; INCARCERATION; SKULL	Vertebrobasilar junction entrapment due to a clivus fracture is a rare clinical observation. The present case report describes a 54-yr-old man who sustained a major craniofacial injury. The patient displayed a stuporous mental state (Glasgow Coma Scale [GCS]=8) and left hemiparesis (Grade 3). The initial computed tomography (CT) scan revealed a right subdural hemorrhage in the frontotemporal region, with a midline shift and longitudinal clival fracture. A decompressive craniectomy with removal of the hematoma was performed. Two days after surgery, a follow-up CT scan showed cerebellar and brain stem infarction, and a CT angiogram revealed occlusion of the left vertebral artery and entrapment of vertebrobasilar junction by the clival fracture, A decompressive suboccipital craniectomy was performed and the patient gradually recovered, This appears to be a rare case of traumatic vertebrobasilar junction entrapment due to a longitudinal clival fracture, including a cerebellar infarction caused by a left vertebral artery occlusion. A literature review is provided.	[Cho, Joon; Moon, Chang Taek; Kang, Hyun Seung; Choe, Woo Jin; Chang, Sang Keun; Koh, Young Cho] Konkuk Univ Hosp, Dept Neurosurg, Seoul 143729, South Korea; [Roh, Hong Gee] Konkuk Univ Hosp, Dept Radiol, Seoul 143729, South Korea	Moon, CT (corresponding author), Konkuk Univ Hosp, Dept Neurosurg, 4-12 Hwayang Dong, Seoul 143729, South Korea.	ctmoon@kuh.ac.kr	Kang, Hyun-Seung/J-5365-2012				ANTHONY DC, 1987, J NEUROSURG, V66, P929, DOI 10.3171/jns.1987.66.6.0929; Bala A, 2004, J CLIN NEUROSCI, V11, P660, DOI 10.1016/j.jocn.2003.11.008; CORRADINO G, 1990, NEUROSURGERY, V27, P592, DOI 10.1227/00006123-199010000-00015; GUHA A, 1989, CAN J NEUROL SCI, V16, P81, DOI 10.1017/S0317167100028560; JOSLYN JN, 1988, RADIOLOGY, V166, P817, DOI 10.1148/radiology.166.3.3340778; LINDENBERG R, 1966, J NEUROSURG, V24, P908, DOI 10.3171/jns.1966.24.5.0908; LOOP JW, 1964, RADIOLOGY, V83, P36, DOI 10.1148/83.1.36; Menku A, 2004, NEUROSURG REV, V27, P194, DOI 10.1007/s10143-004-0320-2; SATO H, 1990, Neurological Surgery, V18, P1147; Sato M, 1999, SURG NEUROL, V51, P613, DOI 10.1016/S0090-3019(98)00091-3; Sato S, 2001, NEUROL MED-CHIR, V41, P541, DOI 10.2176/nmc.41.541; SHAW CM, 1972, J NEUROL NEUROSUR PS, V35, P247, DOI 10.1136/jnnp.35.2.247; SIGHTS WP, 1968, J NEUROSURG, V28, P588, DOI 10.3171/jns.1968.28.6.0588; Taguchi Y, 2000, J TRAUMA, V48, P1148, DOI 10.1097/00005373-200006000-00023; Zhu BL, 2002, FORENSIC SCI INT, V126, P40, DOI 10.1016/S0379-0738(02)00029-4	15	12	12	0	3	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934			J KOREAN MED SCI	J. Korean Med. Sci.	AUG	2008	23	4					747	751		10.3346/jkms.2008.23.4.747			5	Medicine, General & Internal	General & Internal Medicine	344OG	WOS:000258936600033	18756072	Bronze, Green Published			2021-06-18	
J	Oosterman, J; van Harten, B; Vogels, R; Gouw, A; Weinstein, H; Scheltens, P; Scherder, E				Oosterman, J.; van Harten, B.; Vogels, R.; Gouw, A.; Weinstein, H.; Scheltens, P.; Scherder, E.			Distortions in rest-activity rhythm in aging relate to white matter hyperintensities	NEUROBIOLOGY OF AGING			English	Article						aging; rest-activity rhythm; white matter; actigraphy	EXTERNALLY TRIGGERED MOVEMENTS; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; SLEEP-WAKE; AGE; DISTURBANCES; ALZHEIMERS; DISEASE; LESIONS; LIGHT	Distortions in the rest-activity rhythm in aging are commonly observed. Neurodegenerative changes of the suprachiasmatic nucleus have been proposed to underlie this disrupted rhythm. However, based on previous studies, it can be proposed that white matter hyperimensities (WMH) may also play a role in the altered rest-activity rhythm in aging. The present study focused on the rest-activity rhythm, as assessed with actigraphy, and WMH in nondemented aging. With regard to the rest-activity rhythm, the interdaily stability (IS), intradaily variability (IV) and the amplitude (AMP) of the rhythm were of interest. The white matter hyperintensities were examined separately for the periventricular (PVH) and deep white matter (DWMH) regions, while distinguishing between the various locations within these regions (e.g. occipital PVH). The results indicated that frontal DWMH related to both IS and AMP. A reduction in the most active 10-h period mediated the relationship between frontal DWMH and AMP. Possible underlying mechanisms of these associations are discussed. (c) 2007 Elsevier Inc. All rights reserved.	[Oosterman, J.] Vrije Univ Amsterdam, Dept Clin Neuropsychol, NL-1081 BT Amsterdam, Netherlands; [van Harten, B.; Vogels, R.; Weinstein, H.] Sint Lucas Andreas Hosp, Dept Neurol, NL-1061 AE Amsterdam, Netherlands; [Gouw, A.; Scheltens, P.] Vrije Univ Amsterdam, Univ Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; [Gouw, A.; Scheltens, P.] Vrije Univ Amsterdam, Univ Med Ctr, Alzheimers Ctr, NL-1007 MB Amsterdam, Netherlands; [Scherder, E.] Univ Groningen, Inst Human Movement Sci, NL-9713 AV Groningen, Netherlands	Oosterman, J (corresponding author), Univ Utrecht, Dept Expt Psychol, Helmholtz Inst, Heidelberglaan 2, NL-3584 CS Utrecht, Netherlands.	j.m.oosterman@fss.uu.nl	Scheltens, Philip/AAL-9631-2020; WEINSTEIN, HAREL/O-8245-2019; Scheltens, Philip/E-1205-2012; Oosterman, Joukje/D-6125-2012	Scheltens, Philip/0000-0002-1046-6408; WEINSTEIN, HAREL/0000-0003-3473-9818; Oosterman, Joukje/0000-0003-0549-8832			AHARONPERETZ J, 1991, NEUROLOGY, V41, P1616; ARRINDELL WA, 1986, HANDLEIDING BIJ MULT; Bliwise DL, 2005, AM J GERIAT PSYCHIAT, V13, P1077, DOI 10.1176/appi.ajgp.13.12.1077; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; Duffy JF, 2007, NEUROBIOL AGING, V28, P799, DOI 10.1016/j.neurobiolaging.2006.03.005; Elia M, 2000, EUR J CLIN NUTR, V54, pS92, DOI 10.1038/sj.ejcn.1601030; Firbank MJ, 2005, INT J GERIATR PSYCH, V20, P674, DOI 10.1002/gps.1342; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRUT M, 1993, ACTA NEUROL SCAND, V87, P312, DOI 10.1111/j.1600-0404.1993.tb05514.x; Haimov I, 1997, SLEEP, V20, P294, DOI 10.1093/sleep/20.4.294; Harbison J, 2003, NEUROLOGY, V61, P959, DOI 10.1212/01.WNL.0000086818.57992.B8; Harper DG, 2001, ARCH GEN PSYCHIAT, V58, P353, DOI 10.1001/archpsyc.58.4.353; Harrington ME, 1997, NEUROSCI BIOBEHAV R, V21, P705, DOI 10.1016/S0149-7634(96)00019-X; Haynes PL, 2006, PSYCHOL MED, V36, P1363, DOI 10.1017/S0033291706008208; Huang YL, 2002, PHYSIOL BEHAV, V76, P597, DOI 10.1016/S0031-9384(02)00733-3; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; Jenkins IH, 2000, BRAIN, V123, P1216, DOI 10.1093/brain/123.6.1216; Jo I, 2001, J HYPERTENS, V19, P1523, DOI 10.1097/00004872-200109000-00002; Kanda A, 2003, J AM GERIATR SOC, V51, P432, DOI 10.1046/j.1532-5415.2003.51125.x; Kapeller P, 2003, STROKE, V34, P441, DOI 10.1161/01.STR.0000049766.26453.E9; Lazarus R, 2005, INT J GERIATR PSYCH, V20, P274, DOI 10.1002/gps.1283; Liao DP, 1997, NEUROEPIDEMIOLOGY, V16, P149, DOI 10.1159/000368814; MEGURO K, 1995, SLEEP, V18, P109, DOI 10.1093/sleep/18.2.109; Miller AM, 1998, P NATL ACAD SCI USA, V95, P8957, DOI 10.1073/pnas.95.15.8957; Mishima K, 1997, NEUROBIOL AGING, V18, P105, DOI 10.1016/S0197-4580(96)00167-4; Moore RY, 2002, CELL TISSUE RES, V309, P89, DOI 10.1007/s00441-002-0575-2; MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304; Nordahl CW, 2006, J COGNITIVE NEUROSCI, V18, P418, DOI 10.1162/089892906775990552; Olson LJ, 2006, CHEST, V129, P218, DOI 10.1378/chest.129.2.218; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; SATLIN A, 1992, AM J PSYCHIAT, V149, P1028; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; Scherder EJA, 1999, BEHAV BRAIN RES, V101, P105, DOI 10.1016/S0166-4328(98)00150-8; Stolk RP, 1997, AM J EPIDEMIOL, V145, P24, DOI 10.1093/oxfordjournals.aje.a009028; Tobler I, 1993, Adv Space Biol Med, V3, P163; Van Someren EJW, 2000, EXP GERONTOL, V35, P1229, DOI 10.1016/S0531-5565(00)00191-1; van Straaten ECW, 2006, STROKE, V37, P836, DOI 10.1161/01.STR.0000202585.26325.74; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; VanSomeren EJW, 1997, J BIOL RHYTHM, V12, P146, DOI 10.1177/074873049701200206; vanSomeren EJW, 1996, BIOL PSYCHIAT, V40, P259, DOI 10.1016/0006-3223(95)00370-3; Varma AR, 2002, ACTA NEUROL SCAND, V105, P355, DOI 10.1034/j.1600-0404.2002.01147.x; Walhovd KB, 2005, NEUROBIOL AGING, V26, P1261, DOI 10.1016/j.neurobiolaging.2005.05.020; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P2677, DOI 10.1016/j.clinph.2004.06.015; Wiese H, 2006, NEUROIMAGE, V30, P1292, DOI 10.1016/j.neuroimage.2005.11.012; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171; Yoon IY, 2003, J SLEEP RES, V12, P87, DOI 10.1046/j.1365-2869.2003.00345.x	47	12	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	AUG	2008	29	8					1265	1271		10.1016/j.neurobiolaging.2007.02.014			7	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	321KF	WOS:000257302900017	17368870				2021-06-18	
J	Yard, EE; Comstock, RD				Yard, E. E.; Comstock, R. D.			A comparison of pediatric freestyle and Greco-Roman wrestling injuries sustained during a 2006 US national tournament	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						sports; injury; tournament; risk factors	HIGH-SCHOOL SPORTS; CATASTROPHIC INJURIES; PATTERNS	The purpose of this study was to compare the epidemiology of freestyle and Greco-Roman wrestling injuries sustained during a 2006 United States (US) national tournament. A prospective injury surveillance study was conducted at the US 2006 ASICS/Vaughan Cadet and Junior National Championships. There were 83 freestyle- and 55 Greco-Roman-related injuries sustained, with the rate of injury per 1000 athlete-matches higher in freestyle (7.0) compared with Greco-Roman (4.6) wrestling [Rate ratio (RR)=1.51, 95% confidence interval (CI): 1.07-2.12]. Compared with Greco-Roman wrestling, there was a greater proportion of knee injuries in freestyle wrestling [injury proportion ratio (IPR)=4.17, 95% CI: 1.30-13.41]. In GrecoRoman wrestling, there were greater proportions of elbow (IPR=9.11, 95% CI: 1.13-73.59) and head/face/neck (IPR=1.72, 95% CI: 1.10-2.67) injuries and a greater proportion of concussions (IPR=1.95, 95% CI: 0.92-4.12), although the latter was statistically insignificant. Greco-Roman wrestlers sustained a greater proportion of injuries from being driven into the mat (IPR=2.97, 95% CI: 1.72-5.14). There were no statistically significant differences in injury outcome by wrestling style. The differing injury rates and patterns of injury between freestyle and Greco-Roman wrestling are likely due to the different rules between these styles that allow lower leg attacks in freestyle wrestling and encourage the use of throws in Greco-Roman wrestling.	[Yard, E. E.; Comstock, R. D.] Childrens Hosp, Columbia Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. D.] Ohio State Univ, Div Epidemiol, Dept Pediat, Coll Med, Columbus, OH 43210 USA; [Comstock, R. D.] Ohio State Univ, Div Epidemiol, Coll Publ Hlth, Columbus, OH 43210 USA	Yard, EE (corresponding author), Childrens Hosp, Columbia Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	YardE@pediatrics.ohio-state.edu					ACIKGOZ B, 1990, PARAPLEGIA, V28, P265, DOI 10.1038/sc.1990.34; *AM SPORTS DAT INC, 2004, SUP STUD SPORTS PART, V2; Beachy G, 1997, AM J SPORT MED, V25, P675, DOI 10.1177/036354659702500515; Berson B L, 1979, Am J Sports Med, V7, P348; Boden Barry P, 2005, Curr Sports Med Rep, V4, P45; Boden BP, 2002, AM J SPORT MED, V30, P791, DOI 10.1177/03635465020300060601; Brindle TJ, 1998, J ORTHOP SPORT PHYS, V27, P444, DOI 10.2519/jospt.1998.27.6.444; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; Cohn B T, 1986, Orthop Rev, V15, P590; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Estwanik J J, 1978, Am J Sports Med, V6, P335, DOI 10.1177/036354657800600605; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; GIFFIN CS, 1992, ANN PLAS SURG, V28, P131, DOI 10.1097/00000637-199202000-00002; Hoffman HS, 1990, J ATHL TRAINING, V25, P125; Jarrett GJ, 1998, AM J SPORT MED, V26, P674, DOI 10.1177/03635465980260051301; Johnson R, 2004, CLIN SPORT MED, V23, P473, DOI 10.1016/j.csm.2004.02.003; KERSEY RD, 1983, AM J SPORT MED, V11, P147, DOI 10.1177/036354658301100307; Lightfoot Andrew J, 2005, Iowa Orthop J, V25, P145; LORISH TR, 1992, AM J SPORT MED, V20, P199, DOI 10.1177/036354659202000218; MARTIN WR, 1999, PHYS MED REHABIL CLI, V10, pR7; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; MYSNYK MC, 1986, AM J SPORT MED, V14, P46, DOI 10.1177/036354658601400109; *NAT FED STAT HIGH, 2005 06 HIGH SCH ATH; Pasque CB, 2000, AM J SPORT MED, V28, P509, DOI 10.1177/03635465000280041101; Powell JW, 1999, J ATHL TRAINING, V34, P277; RONTOYANNIS GP, 1988, INT J SPORTS MED, V9, P353, DOI 10.1055/s-2007-1025040; SNOOK GA, 1982, AM J SPORT MED, V10, P142, DOI 10.1177/036354658201000303; STANISH WD, 1986, CAN J APPL SPORT SCI, V11, P173; STRAUSS RH, 1982, JAMA-J AM MED ASSOC, V248, P2016, DOI 10.1001/jama.248.16.2016; WROBLE RR, 1986, AM J SPORT MED, V14, P55, DOI 10.1177/036354658601400110; WROBLE RR, 1986, CLIN SPORT MED, V5, P295	31	12	13	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	AUG	2008	18	4					491	497		10.1111/j.1600-0838.2007.00716.x			7	Sport Sciences	Sport Sciences	332JA	WOS:000258078100012	18067522				2021-06-18	
J	Stocchetti, N; Longhi, L; Zanier, ER				Stocchetti, N.; Longhi, L.; Zanier, E. R.			Intracranial pressure monitoring for traumatic brain injury: available evidence and clinical implications	MINERVA ANESTESIOLOGICA			English	Article						intracranial pressure; intracranial hypertension; brain injuries	SEVERE HEAD-INJURY; PULMONARY-ARTERY CATHETER; INTENSIVE-CARE MANAGEMENT; EARLY-DIAGNOSIS; HYPERTENSION; COMPLICATIONS; TOMOGRAPHY; MORTALITY; INFECTION; DRAINAGE	Following traumatic brain injury, uncontrollable intracranial hypertension remains the most frequent cause of death. Despite general agreement on the deleterious effects of elevated intracranial pressure (ICP), however, the evidence supporting the use of ICP monitoring has recently been questioned. The aim of this review was to evaluate the pros and cons of ICP monitoring and to discuss the hypothetical desirability and feasibility of a trial testing the benefits of ICP monitoring.	Univ Milan, Dept Anesthesia & Crit Care Med, I-20122 Milan, Italy; IRCCS Hosp Milan, Maggiore Policlin, Neurosci ICU, Milan, Italy	Stocchetti, N (corresponding author), Osped Maggiore Policlin, Mangiagalli & Regina Elena IRCCS, Neurosci ICU, Via F Sforza 35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Longhi, Luca/AAF-9903-2021; Zanier, Elisa/AAA-8095-2020; Stocchetti, Nino/O-7444-2017	Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718			American Society of Anesthesiologists, STAND BAS AN MON; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Birnbaum S, 2007, BMJ-BRIT MED J, V334, P1006, DOI 10.1136/bmj.39205.757870.47; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Chieregato A, 2007, CRIT CARE MED, V35, P673, DOI 10.1097/01.CCM.0000254054.56103.35; CLARK WC, 1989, NEUROSURGERY, V25, P20; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Ferdinande P, 1997, INTENS CARE MED, V23, P226, DOI 10.1007/s001340050321; Friese RS, 2006, CRIT CARE MED, V34, P1597, DOI 10.1097/01.CCM.0000217918.03343.AA; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; HOLLIDAY PO, 1982, NEUROSURGERY, V10, P25, DOI 10.1227/00006123-198201000-00005; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; Le H, 2001, J NEUROSURG, V95, P720, DOI 10.3171/jns.2001.95.4.0720; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MAGNANO M, 1994, AUDIOLOGY, V33, P237; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MILLER JD, 1989, INTRACRANIAL PRESSUR, V7, P5; OSPINATASCON GA, 2008, INTENSIVE CARE MED; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929; PITLYK PJ, 1985, NEUROSURGERY, V17, P581, DOI 10.1227/00006123-198510000-00008; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Rossi S, 1998, ACT NEUR S, V71, P91; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Shimbles S, 2005, PHYSIOL MEAS, V26, P1085, DOI 10.1088/0967-3334/26/6/017; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stocchetti N, 2007, INTENS CARE MED, V33, P1682, DOI 10.1007/s00134-007-0798-5; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; Takala J, 2006, CRIT CARE, V10, DOI 10.1186/cc5021; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Ueno T, 2003, AVIAT SPACE ENVIR MD, V74, P882; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213	49	12	16	0	5	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0375-9393	1827-1596		MINERVA ANESTESIOL	Minerva Anestesiol.	MAY	2008	74	5					199	205					7	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	299MU	WOS:000255760500006	18414362				2021-06-18	
J	Vassar, M; Ridge, JW; Hill, AD				Vassar, Matt; Ridge, Jason W.; Hill, Aaron D.			Inducing score reliability from previous reports: An examination of life satisfaction studies	SOCIAL INDICATORS RESEARCH			English	Article						reliability induction; life satisfaction; satisfaction with life scale; SWLS	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; REHABILITATION OUTCOMES; PERCEIVED STRESS; COLLEGE-STUDENTS; SOCIAL SUPPORT; CEREBRAL-PALSY; SELF-ESTEEM; SCALE	The sample specific nature of reliability is often overlooked in substantive research, with investigators frequently referencing reliability estimates from previous studies as the basis for presuming the score integrity for their data. The purpose of the current study was to examine this practice, known as reliability induction, across studies using a popular life satisfaction (LS) measure, the Satisfaction with Life Scale. A comprehensive literature search was conducted, yielding a final sample of 196 studies using the instrument. Fifty-two studies involving 76 samples induced reliability coefficients from other sources. These studies were coded in terms of sample characteristics and variability estimates to derive comparisons in these two areas between the induced reports and the original studies. Results suggest that none of the studies inducing reliability had sufficient justification for induction. It was also found that estimating reliability coefficients for the data in hand has increased relative to induced reports and studies omitting reliability information. Practical implications for substantive researchers are discussed and suggestions for additional research are provided.	[Vassar, Matt] Oklahoma State Univ, Coll Osteopath Med, Tulsa, OK 74107 USA; [Ridge, Jason W.; Hill, Aaron D.] Oklahoma State Univ, William S Spears Sch Business, Dept Management, Stillwater, OK 74078 USA	Vassar, M (corresponding author), Oklahoma State Univ, Coll Osteopath Med, 1111 W 17th St, Tulsa, OK 74107 USA.	matt.vassar@okstate.edu	Vassar, Matt/AAD-5385-2020	Vassar, Ben Matthew/0000-0003-2859-6152			ARRINDELL WA, 1991, PERS INDIV DIFFER, V12, P117, DOI 10.1016/0191-8869(91)90094-R; ATKINSON M, 1996, QUALITY LIFE MEASURE; Baker LM, 2004, WOMEN HEALTH, V39, P83, DOI 10.1300/J013v39n02_06; Bettencourt BA, 1997, PERS SOC PSYCHOL B, V23, P955, DOI 10.1177/0146167297239005; Biswas-Diener R, 2005, J HAPPINESS STUD, V6, P205, DOI [10.1007/s10902-005-5683-8, DOI 10.1007/S10902-005-5683-8]; BLAIS MR, 1989, CAN J BEHAV SCI, V21, P210, DOI 10.1037/h0079854; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Brillhart Barbara, 2004, Rehabil Nurs, V29, P122; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Buhi ER, 2005, J SCHOOL HEALTH, V75, P63, DOI 10.1111/j.1746-1561.2005.tb00012.x; Carless David, 2006, Eur J Cardiovasc Nurs, V5, P237, DOI 10.1016/j.ejcnurse.2006.03.004; Compton WC, 1998, PSYCHOL REP, V83, P371, DOI 10.2466/PR0.83.5.371-381; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Crocker L., 1986, INTRO CLASSICAL MODE; Diener E, 1996, PSYCHOL SCI, V7, P181, DOI 10.1111/j.1467-9280.1996.tb00354.x; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dominy NL, 2000, J PSYCHOL, V134, P23, DOI 10.1080/00223980009600846; Dorahy M., 1998, MENTAL HLTH RELIG CU, V1, P37, DOI DOI 10.1080/13674679808406496; Dorahy M. J., 1996, J PERSONALITY CLIN S, V12, P1; Dowler R, 2001, J Spinal Cord Med, V24, P87; EMMONS RA, 1985, PERS SOC PSYCHOL B, V11, P89, DOI 10.1177/0146167285111008; Engel JM, 2003, ARCH PHYS MED REHAB, V84, P1125, DOI 10.1016/S0003-9993(03)00263-6; FERRARI JR, 1997, J PREVENTION INTERVE, V15, P83; Ferrario SR, 2003, PSYCHO-ONCOL, V12, P1, DOI 10.1002/pon.626; Gronlund N.E., 1990, MEASUREMENT EVALUATI; GULLICKSEN H, 1950, THEORY MENTAL TESTS; Halpin SA, 2004, J HOMOSEXUAL, V47, P109, DOI 10.1300/J082v47n02_07; Hamarat E, 2001, EXP AGING RES, V27, P181, DOI 10.1080/036107301750074051; HAMILTON SB, 1989, J ADOLESCENCE, V12, P55, DOI 10.1016/0140-1971(89)90089-4; Hammarberg K, 2001, HUM REPROD, V16, P374, DOI 10.1093/humrep/16.2.374; Harrington R, 2001, J PSYCHOL, V135, P439, DOI 10.1080/00223980109603710; HONG SM, 1994, PSYCHOL REP, V74, P99, DOI 10.2466/pr0.1994.74.1.99; Kafka GJ, 2002, SOC INDIC RES, V57, P171, DOI 10.1023/A:1014451725204; LARSEN RJ, 1986, J PERS SOC PSYCHOL, V51, P803, DOI 10.1037/0022-3514.51.4.803; Meade MA, 2004, ARCH PHYS MED REHAB, V85, P1782, DOI 10.1016/j.apmr.2004.05.001; Minardi HA, 2004, J ADV NURS, V46, P23, DOI 10.1111/j.1365-2648.2003.02962.x; NETO F, 1993, J YOUTH ADOLESCENCE, V22, P125, DOI 10.1007/BF01536648; Oishi S, 2006, J RES PERS, V40, P411, DOI 10.1016/j.jrp.2005.02.002; Patterson DR, 2000, J BURN CARE REHABIL, V21, P490, DOI 10.1097/00004630-200021060-00004; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; Perna FM, 1999, SPORT PSYCHOL, V13, P144, DOI 10.1123/tsp.13.2.144; Petersen RW, 2005, GYNECOL ONCOL, V97, P535, DOI 10.1016/j.ygyno.2005.01.015; Pilcher JJ, 1998, SOC INDIC RES, V43, P291, DOI 10.1023/A:1006883231707; Prince PN, 2001, QUAL LIFE RES, V10, P117, DOI 10.1023/A:1016742628834; Putzke JD, 2000, REHABIL PSYCHOL, V45, P386, DOI 10.1037/0090-5550.45.4.386; Putzke JD, 2003, J SPINAL CORD MED, V26, P37; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P555, DOI 10.1053/apmr.2002.31173; Putzke JD, 2001, J CLIN PSYCHOL MED S, V8, P101, DOI 10.1023/A:1009555910604; Putzke JD, 2001, AM J PHYS MED REHAB, V80, P404, DOI 10.1097/00002060-200106000-00002; Reinhardt B., 1996, ADV SOCIAL SCI METHO, P3; Reistetter TA, 2005, NEUROREHABILITATION, V20, P139; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; Riley BB, 1998, ARCH PHYS MED REHAB, V79, P258, DOI 10.1016/S0003-9993(98)90004-1; Sawilowsky SS, 2000, EDUC PSYCHOL MEAS, V60, P157, DOI 10.1177/00131640021970439; SCHUMAKER JF, 1993, J PSYCHOL, V127, P65, DOI 10.1080/00223980.1993.9915543; Schwarz N., 1999, WELL BEING FOUND HED, P61; Sherman JE, 2004, REHABIL PSYCHOL, V49, P140, DOI 10.1037/0090-5550.49.2.140; Simpson PL, 1996, J SOC PSYCHOL, V136, P783, DOI 10.1080/00224545.1996.9712255; Skok A, 2006, J INTELLECT DEV DIS, V31, P53, DOI 10.1080/13668250600561929; SMEAD VS, 1991, MEASUINGG WELL BEING; Smith D, 2005, J SPORT MED PHYS FIT, V45, P401; STOLBERG VB, 2003, J ETHNICITY SUBSTANC, V2, P77; Tate DG, 1997, ARCH PHYS MED REHAB, V78, pS18, DOI 10.1016/S0003-9993(97)90217-3; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Tucker KL, 2006, SOC INDIC RES, V78, P341, DOI 10.1007/s11205-005-1037-5; Vacha-Haase T, 2000, EDUC PSYCHOL MEAS, V60, P509, DOI 10.1177/00131640021970682; Vacha-Haase T, 1998, EDUC PSYCHOL MEAS, V58, P6, DOI 10.1177/0013164498058001002; Vacha-Haase T, 2002, EDUC PSYCHOL MEAS, V62, P562, DOI 10.1177/001316402128775012; VASSAR M, IN PRESS SOCIAL INDI; Vassar M, 2007, SOC INDIC RES, V83, P487, DOI 10.1007/s11205-006-9074-2; Wardell DW, 2006, J HOLIST NURS, V24, P231, DOI 10.1177/0898010106289840; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WEINMAN J, 1995, HLTH STATUS HLTH REL; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Wu CH, 2006, PERS INDIV DIFFER, V40, P1259, DOI 10.1016/j.paid.2005.11.012; YETIM U, 1993, SOC INDIC RES, V29, P277, DOI 10.1007/BF01079516; Yetim U, 2003, SOC INDIC RES, V61, P297, DOI 10.1023/A:1021911504113	83	12	12	0	6	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0303-8300			SOC INDIC RES	Soc. Indic. Res.	MAY	2008	87	1					27	45		10.1007/s11205-007-9157-8			19	Social Sciences, Interdisciplinary; Sociology	Social Sciences - Other Topics; Sociology	283GT	WOS:000254625400002					2021-06-18	
J	Whyte, J; Hart, T; Ellis, CA; Chervoneva, I				Whyte, John; Hart, Tessa; Ellis, Colin A.; Chervoneva, Inna			The moss attention rating scale for traumatic brain injury: Further explorations of reliability and sensitivity to change	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						attention; brain injuries; rehabilitation	NETWORKS	Objective: To examine the interrater agreement and responsiveness to change of the Moss Attention Rating Scale (MARS), 22-item version, during acute inpatient rehabilitation after traumatic brain injury (TBI). Design: Observational Study of clinician ratings (physical therapy [PT], occupational therapy [OT], speech-lanouage pathology [SLP], nursing) of each patient's attentional function at 2 points in time, near the time of admission and near the time of discharge from inpatient rehabilitation. Setting: Dedicated acute inpatient brain injury rehabilitation program. Participants: Inpatients (N=149) with moderate to severe TBI (58% enrolled in the National Institute on Disability Rehabilitation Research-funded Traumatic Brain Injury Model System); age 16 years or older; receiving OT, PT, SLP, and nursing care on the inpatient TBI rehabilitation unit; and having Rancho Los Amigos Levels of Cognitive Functioning Scale scores of IV (confused/agitated) or higher at enrollment. Patients were excluded if they had premorbid history of attention deficit hyperactivity disorder, major psychiatric disorder (eg, bipolar), or neurologic impairment (eg, stroke). Interventions: Not applicable. Main Outcome Measure: Scores on the MARS (12-item version) and its 3 factor scores. Results: Intraclass correlations among ratings from PT. OT, and SLP ranged from .69 to .78 at the initial assessment and .67 to .72 at the follow-up assessment. Agreement between nursing and the other disciplines Was somewhat lower (at initial assessment, .59-68; at follow-up, .48-59), although still substantial. Agreement for 2 of the factor scores (restlessness and/or distractibility, initiation) was similar but agreement for the third factor (consistent and/or Sustained attention) was lower (.25-.27). The total MARS scores were highly significantly improved (P<.001) at follow-up compared with initial assessment (mean, 27.6d between ratings: median, 21d; range, 4-125d) for each of the rating disciplines. with change scores ranging from 7.8 points (OT) to 13.1 points (nursing). Factor scores also improved significantly during the same interval. When different Occupational therapists provided the initial and follow-up OT ratings, these follow-up ratings were significantly cantly lower, but this pattern was not seen among other rating disciplines. Conclusions: The 22-item MARS showed good interrater C agreement among PT, OT, and SLP and lower but still acceptable agreement between nursing and the other disciplines. Two of the 3 factor scores also showed good agreement. The 22 item total score and all 3 factor scores were highly sensitive to change occurring during inpatient rehabilitation. These results show that the 22-item MARS is a reliable instrument for the observational rating of attentiveness in an acute TBI rehabilitation sample. Lower agreement between nursing and the other, disciplines suggests that the less structured environment of the nursing unit compared with therapy sessions reduces interrater agreement. The utility of the factor scores, particularly the least reliable sustained and/or consistent attention factor, requires additional investigation. Further research on construct validity and impact of the use of the MARS on clinical practice are warranted.	[Whyte, John; Hart, Tessa; Ellis, Colin A.] Moss Rehabil Res Inst, Philadelphia, PA 19027 USA; [Whyte, John; Hart, Tessa] Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; [Chervoneva, Inna] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Div Biostat, Philadelphia, PA 19107 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 60 E Township Line Rd,Elkins Pk, Philadelphia, PA 19027 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research [H133A020505]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A020505).	Chinchilli, 1997, LINEAR NONLINEAR MOD; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fernandez-Duque D, 2001, J CLIN EXP NEUROPSYC, V23, P74, DOI 10.1076/jcen.23.1.74.1217; Hart T, 2006, ARCH PHYS MED REHAB, V87, P647, DOI 10.1016/j.apmr.2006.01.016; HOAGLIN DC, 1986, J AM STAT ASSOC, V81, P991, DOI 10.2307/2289073; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Rousson V, 2002, STAT MED, V21, P3431, DOI 10.1002/sim.1253; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2003, ARCH PHYS MED REHAB, V84, P268, DOI 10.1053/apmr.2003.50108; Whyte J., 2004, REHABILITATION MED P, P1677	10	12	12	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					966	973		10.1016/j.apmr.2007.12.031			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900024	18452747				2021-06-18	
J	Hoerold, D; Dockree, PM; O'Keeve, FM; Bates, H; Pertl, M; Robertson, IH				Hoerold, Doreen; Dockree, Paul M.; O'Keeve, Fiadhnait M.; Bates, Helen; Pertl, Maria; Robertson, Ian H.			Neuropsychology of self-awareness in young adults	EXPERIMENTAL BRAIN RESEARCH			English	Article						insight; self-awareness; sustained attention; frontal lobes; executive functions	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; ALZHEIMERS-DISEASE; ERROR-AWARENESS; ANOSOGNOSIA; DEFICITS; DEMENTIA; HEMIPLEGIA; DEPRESSION; INSIGHT	Disorders of self-awareness are common following cortical damage, particularly to the frontal lobes, but there have been few studies of individual differences in self-awareness in the normal population. In the current study, we explored patterns of metacognitive awareness among healthy young adults, based on discrepancies of self- and other-ratings on the Frontal Systems Behavior Scale (FrSBe; Grace and Malloy, 2002). Those who showed poor metacognitive awareness showed more frequent lapses of attention, and higher levels of everyday absentmindedness, than those who accurately appraised their own behavior or those who overestimated their own FrSBe scores. Furthermore, among those with poor metacognitive awareness, online emergent awareness correlated positively with prospective memory performance, and negatively with anxiety scores. Our results suggest that accurate self-awareness in non-neurological participants relies on efficient sustained attention functioning, supporting the role of frontal control systems in neuroanatomical models of self-awareness.	[Hoerold, Doreen; Dockree, Paul M.; O'Keeve, Fiadhnait M.; Bates, Helen; Pertl, Maria; Robertson, Ian H.] Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Hoerold, Doreen; Dockree, Paul M.; O'Keeve, Fiadhnait M.; Bates, Helen; Pertl, Maria; Robertson, Ian H.] Univ Dublin Trinity Coll, Trinity Coll, Sch Psychol, Dublin 2, Ireland	Hoerold, D (corresponding author), Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Dublin 2, Ireland.	hoeroldd@tcd.ie		Robertson, Ian H/0000-0001-8637-561X; Pertl, Maria/0000-0001-7326-2763			Aalten P, 2005, AGING MENT HEALTH, V9, P414, DOI 10.1080/13607860500143075; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Berti A, 2005, SCIENCE, V309, P488, DOI 10.1126/science.1110625; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BREIER JI, 1995, NEUROLOGY, V45, P65, DOI 10.1212/WNL.45.1.65; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DALLABARBA G, 1995, NEUROPSYCHOLOGIA, V33, P247; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Evyapan D, 1999, NEUROLOGY, V53, P647, DOI 10.1212/WNL.53.3.647; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Grace J, 2002, FRONTAL SYSTEMS BEHA; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Jehkonen M, 2000, ACTA NEUROL SCAND, V102, P378, DOI 10.1034/j.1600-0404.2000.102006378.x; Karnath HO, 2005, J NEUROSCI, V25, P7134, DOI 10.1523/JNEUROSCI.1590-05.2005; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCDANIEL KD, 1995, ALZ DIS ASSOC DIS, V9, P101, DOI 10.1097/00002093-199509020-00007; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Morin A, 2007, BRAIN RES BULL, V74, P387, DOI 10.1016/j.brainresbull.2007.06.013; Nelson H., 1991, REVISED NATL ADULT R; Nelson HE, 1982, NATL ADULT READING T; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Orfei MD, 2007, BRAIN, V130, P3075, DOI 10.1093/brain/awm106; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1996, BLACKWELL DICT NEURO, P80; Rankin KP, 2005, J NEUROL NEUROSUR PS, V76, P632, DOI 10.1136/jnnp.2004.042879; REED BR, 1993, J CLIN EXP NEUROPSYC, V15, P231, DOI 10.1080/01688639308402560; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Souchay C, 2003, NEUROCASE, V9, P482, DOI 10.1076/neur.9.6.482.29376; Spreen O., 1998, COMPENDIUM NEUROPSYC, P2; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STUSS DT, 2001, FRONTAL IOBES NEUROP; Taylor SF, 2007, NEUROSCIENTIST, V13, P160, DOI 10.1177/1073858406298184; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; WALKER D, 2003, THESIS U READING; Wechsler D, 1998, WECHSLER MEMORY SCAL; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	55	12	12	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	APR	2008	186	3					509	515		10.1007/s00221-008-1341-9			7	Neurosciences	Neurosciences & Neurology	277XT	WOS:000254248700016	18340439				2021-06-18	
J	Keenan, HT				Keenan, Heather T.			Practical aspects of conducting a prospective statewide incidence study: The incidence of serious inflicted traumatic brain injury in north Carolina	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							YOUNG-CHILDREN	The article describes practical problems encountered in setting up and maintaining an active statewide surveillance system for a low-frequency but high-impact injury, inflicted traumatic brain injury (inflicted TBI). A system was designed to identify prospectively all children aged <2 years with a traumatic brain injury (TBI) admitted to any of the nine pediatric intensive care units (ICUs) in North Carolina in 2000 and 2001. Children who died prior to admission to hospital were identified from the records of the Office of the Chief Medical Examiner. The study design had strengths and weaknesses for ongoing surveillance. Strengths included a clear definition of a case, mechanisms to jury undecided cases, and a high level of quality control. Difficulties included appropriately addressing investigators' ethical and legal obligations in the study of child abuse, differing requirements of multiple institutional review boards (IRBs), and the time-intensive nature of the system. The described surveillance system produced high-quality data, but may not be practical for ongoing multi-year injury surveillance. Incorporation of inflicted TBI into an existing surveillance system, such as a trauma database, may be a feasible solution to many of the problems encountered.	[Keenan, Heather T.] Univ Utah, Dept Pediat, Salt Lake City, UT USA	Keenan, HT (corresponding author), 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040, K23 HD041040-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER		Alexander J, 2001, N C Med J, V62, P359; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; *PRACT MAN INF COR, 1998, INT CLASS DIS 9 REV; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	10	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797			AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S120	S125		10.1016/j.amepre.2007.11.001			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300005	18374261	Green Accepted			2021-06-18	
J	Runyan, DK; Berger, RP; Barr, RG				Runyan, Desmond K.; Berger, Rachel P.; Barr, Ronald G.			Defining an ideal system to establish the incidence of inflicted traumatic brain injury - Summary of the consensus conference	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							HEAD-INJURY; CHILDHOOD; SURVEILLANCE; MALTREATMENT; CHILDREN; EXPERIENCES; CHALLENGES; PREVENTION; ISSUES; ABUSE	A conference addressing how to establish the incidence of inflicted traumatic brain injury in young children provided the opportunity to examine issues of definitions, passive versus active surveillance, study designs, proxy measures, and statistical issues. Data were presented that had been collected in alternative ways. The participants concluded that an ideal System for measurement of the incidence does not yet exist. A new surveillance system will take a significant amount of time and money to establish. Such a system will require a combination of ascertainment approaches, attention to case finding, a large population, careful attention to coding and data quality. The ethical issues involved in measuring stigmatized and illegal behavior are not inconsequential. In an ideal system data from different sources-medical, legal, and social service, among others-will need to be linked. Perhaps most importantly, any surveillance approach will need to be maintained so that trend data can be used to assess the effectiveness of prevention efforts.	[Runyan, Desmond K.] Univ N Carolina, Dept Social Med, Chapel Hill, NC 27599 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Barr, Ronald G.] Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, Vancouver, BC V5Z 1M9, Canada	Runyan, DK (corresponding author), Univ N Carolina, Dept Social Med, Campus Box 7240, Chapel Hill, NC 27599 USA.	drunyan@unc.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029			Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2008, AM J PREV MED, V34, pS106, DOI 10.1016/j.amepre.2008.01.021; Bennett S, 2008, AM J PREV MED, V34, pS140, DOI 10.1016/j.amepre.2008.01.026; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Dong MX, 2005, ARCH PEDIAT ADOL MED, V159, P1104, DOI 10.1001/archpedi.159.12.1104; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; GARRISON HG, 1994, ANN EMERG MED, V24, P849, DOI 10.1016/S0196-0644(94)70203-9; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Keenan HT, 2008, AM J PREV MED, V34, pS120, DOI 10.1016/j.amepre.2007.11.001; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Melton G B, 1990, Violence Vict, V5, P67; Minns RA, 2008, AM J PREV MED, V34, pS126, DOI 10.1016/j.amepre.2008.01.016; *PREV CHILD AB AM, 2001, TEST EST COST CHILD; Reece RM, 2008, AM J PREV MED, V34, pS116, DOI 10.1016/j.amepre.2007.11.005; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Rivara FP, 2008, AM J PREV MED, V34, pS148, DOI 10.1016/j.amepre.2007.11.021; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Runyan DK, 2005, CHILD ABUSE NEGLECT, V29, P461, DOI 10.1016/j.chiabu.2004.06.015; RUNYAN DK, 2006, 13 INT C CHILD AB NE; Ryan MAK, 2008, AM J PREV MED, V34, pS143, DOI 10.1016/j.amepre.2007.12.020; Shapiro ED, 2008, AM J PREV MED, V34, pS153, DOI 10.1016/j.amepre.2008.01.022; SOCOLAR RS, 1995, J FAM ISSUES, V16, P565, DOI 10.1177/019251395016005004; Straus MA, 1998, CHILD ABUSE NEGLECT, V22, P249, DOI 10.1016/S0145-2134(97)00174-9; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; *USDHHS, 2007, CHILD MEAS 2005; Wirtz SJ, 2008, AM J PREV MED, V34, pS134, DOI 10.1016/j.amepre.2007.11.004	30	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S163	S168		10.1016/j.amepre.2008.01.010			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300013	18374269				2021-06-18	
J	Kunene, KN; Weistroffer, HR				Kunene, K. Niki; Weistroffer, H. Roland			An approach for predicting and describing patient outcome using multicriteria decision analysis and decision rules	EUROPEAN JOURNAL OF OPERATIONAL RESEARCH			English	Article; Proceedings Paper	23rd EURO Summer Institute on OR in Health Care	JUL 24, 2005	Univ Southampton, Southampton, ENGLAND	EURO	Univ Southampton	data mining; knowledge-based systems; decision support systems; multicriteria decision analysis; traumatic brain injury	SEVERE HEAD-INJURY	Patient outcome in brain trauma patients is affected by a multiplicity of factors, beginning with ambulatory transportation and routing, to the grade of the receiving facility and treatment therein, and finally the treatment and monitoring in definitive care (the brain trauma intensive care unit). Factors and events in each of these phases can be modeled as a multicriteria problem, where the objective is to optimize patient outcome; moreover, a more comprehensive model can embody the interactions of all three phases. This study focuses on modeling the factors that affect patient outcome in definitive care and on expressing these in machine readable format so that we can better describe or predict patient outcome using data mining tools. We use multicriteria decision analysis and decision rules for knowledge representation. Preliminary results suggest that the incorporation of a priori knowledge does help better predict or describe patient outcome when using decision tree induction. (C) 2006 Elsevier B.V.. All rights reserved.	Univ Louisville, Coll Business, Louisville, KY 40292 USA; Virginia Commonwealth Univ, Sch Business, Dept Informat Syst, Richmond, VA 23284 USA	Weistroffer, HR (corresponding author), Univ Louisville, Coll Business, Louisville, KY 40292 USA.	hrweistr@vcu.edu	Weistroffer, Heinz Roland/B-8389-2009	Weistroffer, Heinz Roland/0000-0002-3745-5143			Belton V., 2002, MULTIPLE CRITERIA DE; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 2000, GUIDELINES MANAGEMEN; Cabena P., 1997, DISCOVERING DATA MIN; DANIELS H, 2001, COMBINING DOMAIN KNO; Fayyad U, 1996, COMMUN ACM, V39, P27, DOI 10.1145/240455.240464; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Feelders A, 2000, INFORM MANAGE, V37, P271, DOI 10.1016/S0378-7206(99)00051-8; Figueira J, 2005, INT SER OPER RES MAN, V78, P1, DOI 10.1007/b100605; Freitas AA, 1999, KNOWL-BASED SYST, V12, P309, DOI 10.1016/S0950-7051(99)00019-2; Han J, 2001, DATA MINING CONCEPTS; Hilderman R. J., 2001, Advances in Knowledge Discovery and Data Mining. 5th Pacific-Asia Conference, PAKDD 2001. Proceedings (Lecture Notes in Artificial Intelligence Vol.2035), P247; Hilderman RJ, 2000, LECT NOTES COMPUT<D>, V1910, P432; HUBER PJ, 1997, P 3 INT C KNOWL DIS; JENNETT B, 1975, LANCET, V1, P480; KOHAVI R, 1998, DATA MINING MINESET; Kopanas I, 2002, LECT NOTES ARTIF INT, V2308, P288; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Nathens AB, 2003, J TRAUMA, V55, P444, DOI 10.1097/01.TA.0000047809.64699.59; Saaty T. L., 1994, FUNDAMENTALS DECISIO; SAATY T. L., 1992, MULTICRITERIA DECISI; SAATY TL, 1990, EUR J OPER RES, V48, P9, DOI 10.1016/0377-2217(90)90057-I; SAATY TL, 1994, EUR J OPER RES, V74, P426, DOI 10.1016/0377-2217(94)90222-4; SAATY TL, 1990, FUNDAMENTALS DECISIO; Sibbritt David, 2004, Health Care Manag Sci, V7, P163, DOI 10.1023/B:HCMS.0000039379.32963.9e; TEASDALE G, 1974, LANCET, V2, P81	28	12	12	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0377-2217	1872-6860		EUR J OPER RES	Eur. J. Oper. Res.	MAR 16	2008	185	3					984	997		10.1016/j.ejor.2006.02.054			14	Management; Operations Research & Management Science	Business & Economics; Operations Research & Management Science	233DL	WOS:000251070500007					2021-06-18	
J	Arroyos-Jurado, E; Savage, TA				Arroyos-Jurado, Elsa; Savage, Todd A.			Intervention Strategies for Serving Students With Traumatic Brain Injury	INTERVENTION IN SCHOOL AND CLINIC			English	Article						interventions; traumatic brain injury; children			[Arroyos-Jurado, Elsa] New Mexico State Univ, Dept Counseling & Educ Psychol, Sch Psychol, Las Cruces, NM 88003 USA	Arroyos-Jurado, E (corresponding author), New Mexico State Univ, Dept Counseling & Educ Psychol, Sch Psychol, POB 30001,MSC 3CEP, Las Cruces, NM 88003 USA.	elsaaj@nmsu.edu					Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; BEGALI V, 1992, HEAD INJURY CHILDREN; *BRAIN INJ ASS, 2005, FACTS TRAUM BRAIN IN; Bullock LM, 2005, PREV SCH FAIL, V49, P6, DOI 10.3200/PSFL.49.4.6-10; Clark E, 1999, SCHOOL PSYCHOL REV, V28, P242; CLARK E, 2002, CHILDRENS NEEDS, V3, P897; Clark E., 1997, CHILDHOOD TRAUMATIC, P191; COHEN SB, 1991, J HEAD TRAUMA REHAB, V6, P56; Deidrick KKM, 2005, PREV SCH FAIL, V49, P23, DOI 10.3200/PSFL.49.4.23-33; DOELLING J, 1997, TEACHING EXCEPTIONAL, V30, P56; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; GARCIA JG, 1998, PROFESSIONAL SCH COU, V2, P33; HARVEY JM, 2006, BEST PRACTICES SCH P, V4, P1433; JANUS PL, 1994, ED DIMENSIONS ACQUIR, P475; Mayfield J, 2005, PREV SCH FAIL, V49, P17, DOI 10.3200/PSFL.49.4.17-22; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006	18	12	12	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1053-4512			INTERV SCH CLIN	Interv. Sch. Clin.	MAR	2008	43	4					252	254		10.1177/1053451208314907			3	Education, Special	Education & Educational Research	370MY	WOS:000260767500010					2021-06-18	
J	Kockler, TR; Stanford, MS				Kockler, Tim R.; Stanford, Matthew S.			Using a clinically aggressive sample to examine the association between impulsivity, executive functioning, and verbal learning and memory	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						CVLT; memory; executive function; impulsivity; BIS-11; aggression; verbal learning	PERSONALITY DISORDERED OFFENDERS; TRAUMATIC BRAIN-INJURY; DECISION-MAKING; WORKING-MEMORY; CORTEX	Impulsive behavior has been conceptualized from several vantage points including biological, sociological and psychological phenomenon. A comprehensive review of the empirical literature revealed that there is a paucity of research examining the association between working memory, executive functioning and impulsivity. A total sample of 170 aggressive outpatient participants was recruited for the study. Participants were administered a comprehensive neuropsychological battery. Principal components analysis of the 19 CVLT indices revealed five factors, accounting for 68% of the total variance. Results from the canonical correlation revealed one significant canonical variate with loadings from three CVLT factors (General Verbal Learning, Response Discrimination, and Proactive Interference), two executive functioning measures (Trail Making Test and Controlled Oral Word Association Test), and one impulsivity subscale, (Attentional Impulsiveness). The findings of this study underscore the importance of memory functioning in determining impulsive aggressive behavior. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Stanford, Matthew S.] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA; [Kockler, Tim R.] Dixie Reg Med Ctr, St George, UT 84770 USA	Stanford, MS (corresponding author), Baylor Univ, Dept Psychol & Neurosci, 1 Bear Pl,97334 Waco, Waco, TX 76798 USA.	Matthew_Stanford@Baylor.edu					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barratt E. S., 1994, VIOLENCE MENTAL DISO, P61; Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2004, NEUROPSYCHOLOGY, V18, P152, DOI 10.1037/0894-4105.18.1.152; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI 10.1023/A:1021223113233; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Damasio A., 1994, DESCARTESERROR EMOTI; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; DELIS DC, 1987, CALIFORNAI VERBAL LE; Dolan M, 2002, J FORENSIC PSYCHIATR, V13, P503, DOI 10.1080/0958518021000019452; Dolan M, 2002, PSYCHOL MED, V32, P105, DOI 10.1017/S0033291701004688; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Finn PR, 1999, PSYCHOPHARMACOLOGY, V146, P465, DOI 10.1007/PL00005492; Fuster J, 1989, PREFRONTAL CORTEX; Goldberg E, 2001, EXECUTIVE BRAIN FRON; Hare R.D., 2003, HARE PSYCHOPATHY CHE; Heaton R., 1993, WISCONSIN CARD SORTI; Hemphill JF, 2003, AM PSYCHOL, V58, P78, DOI 10.1037/0003-066X.58.1.78; Hinson JM, 2003, J EXP PSYCHOL LEARN, V29, P298, DOI 10.1037/0278-7393.29.2.298; Kockler TR, 2006, AM J ORTHOPSYCHIAT, V76, P80, DOI 10.1037/0002-9432.76.1.80; LAUTENSCHLAGER GJ, 1989, MULTIVAR BEHAV RES, V24, P365, DOI 10.1207/s15327906mbr2403_6; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MELOY JR, 2000, VIOLENCE RISK THREAT; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Raine A, 1998, BEHAV SCI LAW, V16, P319, DOI 10.1002/(SICI)1099-0798(199822)16:3<319::AID-BSL311>3.0.CO;2-G; REITAN RM, 1958, HALSTEAD REITAN NEUR; Ruff R. M., 1988, RUFF FIGURAL FLUENCY; Spreen O, 1969, NEUROSENSORY CTR COM; *SPSS INC, 2002, SPSS STAT PROGR SOC; Stanford MS, 1997, PERS INDIV DIFFER, V23, P961, DOI 10.1016/S0191-8869(97)00120-7; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss D.T., 1986, FRONTAL LOBES; Swann AC, 2002, BIOL PSYCHIAT, V51, P988, DOI 10.1016/S0006-3223(01)01357-9; Tabachnick BG, 2013, USING MULTIVARIATE S; VANDERPLOEG RD, 1994, J CLIN EXP NEUROPSYC, V16, P243, DOI 10.1080/01688639408402635; Villemarette-Pittman NR, 2003, PERS INDIV DIFFER, V34, P1533, DOI 10.1016/S0191-8869(02)00136-8; Whitney P, 2004, PERS INDIV DIFFER, V37, P417, DOI 10.1016/j.paid.2003.09.013	42	12	14	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2008	23	2					165	173		10.1016/j.acn.2007.10.006			9	Psychology, Clinical; Psychology	Psychology	283SS	WOS:000254657400005	18055163	Bronze			2021-06-18	
J	Lange, RT; Iverson, GL; Franzen, MD				Lange, Rael T.; Iverson, Grant L.; Franzen, Michael D.			Comparability of neuropsychological test profiles in patients with chronic substance abuse and mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	26th Annual Meeting of the National-Academy-of-Neuropsychology	OCT 25-28, 2006	San Antonio, TX	Natl Acad Neuropsychol		cluster analysis; mild traumatic brain injury; substance abuse	TERM BENZODIAZEPINE USE; EMOTIONAL RISK-FACTORS; FAKE-BAD SCALE; HEAD-INJURY; ALCOHOL-USE; CONCUSSION; OUTCOMES; COMPENSATION; PERCEPTION; SYMPTOMS	The purpose of this study was to compare 104 patients with acute uncomplicated mild traumatic brain injury (MTBI) to a sample of 104 patients from an inpatient substance abuse program to determine whether these patients could be differentiated by their pattern of relative cognitive strengths and weaknesses. Patients were matched on age, education, and gender. Eight cognitive measures were used that included tests of attention, memory, and processing speed. There were no statistically significant differences between the two groups on any of the cognitive measures. Using a two-step cluster analysis procedure (i.e., hierarchical and k-means analyses), seven common profiles were identified. There was no significant difference in the proportions of patients from the MTBI or substance abuse group in each of the seven profiles. These results show that patients with uncomplicated MTBIs could not be reliably differentiated from patients with substance abuse problems on these cognitive measures. This is of particular concern for clinicians evaluating the neuropsychological effects of MTBI in individuals with a comorbid history of substance abuse.	[Lange, Rael T.; Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Riverview Hosp, Dept Res, Coquitlam, BC V3C 4J2, Canada; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Franzen, Michael D.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Lange, RT (corresponding author), British Columbia Mental Hlth & Addict Serv, Riverview Hosp, Dept Res, Room 124-ADMIN Bldg,Main Floor,2601 Lougheed High, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			Aldenderfer FA, 1984, CLUSTER ANAL; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; Barker MJ, 2004, CNS DRUGS, V18, P37, DOI 10.2165/00023210-200418010-00004; Bates ME, 1999, ASSESSMENT OF NEUROPSYCHOLOGICAL FUNCTIONS IN PSYCHIATRIC DISORDERS, P373; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Beatty M. E., 1994, DRUG ALCOHOL DEPEN, V37, P247; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; *CAN I HLTH INF, 2002, ONT TRAUM REG B; CARLIN AS, 1996, NEUROPSYCHOLOGICAL A, P486; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDCP, 2003, TRAUM BRAIN INF US R; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; COWIE SE, 2005, DOCUMENTATION SUBSTA; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Davis PE, 2002, DRUG ALCOHOL DEPEN, V67, P105, DOI 10.1016/S0376-8716(02)00012-1; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; ERRICO AL, 1990, PSYCHOL ASSESSMENT, V2, P45, DOI DOI 10.1037/1040-3590.2.1.45; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Everitt B.S., 1993, CLUSTER ANAL; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Heaton RK, 2004, REVISED COMPREHENSIV; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Hoff AL, 1996, PSYCHIAT RES, V60, P167, DOI 10.1016/0165-1781(96)02758-8; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; JERNIGAN T, 1992, IMAGING ALCOHOL RES, P121; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lange R.T., 2002, Journal of Cognitive Rehabilitation, V20, P16; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; MEEK PS, 1989, J PSYCHOACTIVE DRUGS, V21, P153, DOI 10.1080/02791072.1989.10472155; Miller Norman S., 1994, P471; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MORRIS JA, 1998, ALCOHOLISM TREATMENT, V16, P101; MORRIS R, 1981, Journal of Clinical Neuropsychology, V3, P79, DOI 10.1080/01688638108403115; MUURONEN A, 1989, ALCOHOL CLIN EXP RES, V13, P137, DOI 10.1111/j.1530-0277.1989.tb00298.x; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paraherakis A, 2001, SUBST USE MISUSE, V36, P257, DOI 10.1081/JA-100102625; Parsons OA, 1998, ALCOHOL CLIN EXP RES, V22, P954, DOI 10.1097/00000374-199806000-00029; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; POPE HG, 1995, DRUG ALCOHOL DEPEN, V38, P25, DOI 10.1016/0376-8716(95)01097-I; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan R. M., 1992, TRAIL MAKING TEST MA; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Rosselli M, 1996, J CLIN EXP NEUROPSYC, V18, P122, DOI 10.1080/01688639608408268; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schinka J A, 1997, J Int Neuropsychol Soc, V3, P120; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Selby MJ, 1998, DRUG ALCOHOL DEPEN, V50, P39, DOI 10.1016/S0376-8716(98)00002-7; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; STRANG J, 1989, BRIT J ADDICT, V84, P1011; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Wechsler D., 1987, WECHSLER MEMORY SCAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	81	12	12	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAR	2008	22	2					209	227		10.1080/13854040701290062			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	279ZA	WOS:000254393500003	17853134				2021-06-18	
J	Nikitin, AG; Chudakova, DA; Strokov, IA; Bursa, TR; Chistiakov, DA; Nosikov, VV				Nikitin, Alexey G.; Chudakova, Dariya A.; Strokov, Igor A.; Bursa, Tamara R.; Chistiakov, Dimitry A.; Nosikov, Valery. V.			Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						diabetic polyneuropathy; poly(ADP-ribose)polymerase-1; Leu54Phe and Val762Ala; polymorphisms; type 1 diabetes; association	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; ENDOTHELIAL DYSFUNCTION; POLYMERASE ACTIVATION; PERIPHERAL NEUROPATHY; POLY(ADP-RIBOSYL)ATION; DNA; DISEASE; TESTS; RISK	Poly(ADP-ribose) polymerase-1 (PARP-1) is an ubiquitous DNA-binding protein involved in the cellular response to various genotoxic agents. Excessive PARP-1 activation is known to lead to the depletion of intracellular NAD+ and ATP pools and hence to threat cell survival. Therefore, PARP-1 could be involved in neuronal death and contribute to the development of diabetic polyneuropathy (DPN). This study addressed the association of Leu54Phe and Val762Ala polymorphisms of PARP-1 with DPN in Russian type 1 diabetic (T1D) patients. Eighty-six T1D patients with severe DPN and 93 T1D patients with no clinical signs of DPN have been studied by a polymerase chain reaction restriction fragment length polymorphism approach. Using Fisher's exact test revealed the association of the Phe54 and Val762 variants of PARP-1 (odds ratio (OR), 1.66 and 2.88, respectively) with increased risk of DPN in T1D. These results suggest that the PARP1 gene is involved in the pathogenesis of diabetic neuropathy in a Russian population. Additionally, a logistic regression analysis revealed a significant association between the neurological variances such as vibration detection threshold (OR, 2.08), vibration and temperature perception thresholds (OR, 1.32 and 1.67, respectively), and sensory and motor nerve conduction velocities (OR, 2.34 and 2.58, respectively), with DPN. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	[Nikitin, Alexey G.; Chudakova, Dariya A.; Chistiakov, Dimitry A.; Nosikov, Valery. V.] Natl Res Ctr GosNIIgenetika, Moscow 113545, Russia; [Strokov, Igor A.; Bursa, Tamara R.] IM Sechenov Med Acad, Dept Neurol, Moscow, Russia	Chistiakov, DA (corresponding author), Natl Res Ctr GosNIIgenetika, Bldg 1,1st Dorozhny Proezd, Moscow 113545, Russia.	dmitry_chistyakov@verizon.net	Nikitin, Alexey G/M-7220-2014	Strokov, Igor/0000-0001-6950-7166			Baba M, 2001, Arch Physiol Biochem, V109, P234, DOI 10.1076/apab.109.3.234.11595; Berciano MT, 1999, J NEUROPATH EXP NEUR, V58, P1234, DOI 10.1097/00005072-199912000-00004; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Boulton AJM, 2005, DIABETES CARE, V28, P956, DOI 10.2337/diacare.28.4.956; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Chistiakov DA, 2006, DIABETES METAB, V32, P63, DOI 10.1016/S1262-3636(07)70248-3; Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653; Cottet F, 2000, J MOL MED, V78, P431, DOI 10.1007/s001090050488; Dantzer F, 2006, METHOD ENZYMOL, V409, P493, DOI 10.1016/S0076-6879(05)09029-4; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; DYCK PJ, 1992, NEUROLOGY, V42, P1164, DOI 10.1212/WNL.42.6.1164; DYCK PJ, 1991, NEUROLOGY, V41, P799, DOI 10.1212/WNL.41.6.799; DYCK PJ, 1993, NEUROLOGY, V43, P1508, DOI 10.1212/WNL.43.8.1508; Dyck PJ, 1997, DIABETES, V46, pS5, DOI 10.2337/diab.46.2.S5; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; Infante J, 2007, J NEUROL SCI, V256, P68, DOI 10.1016/j.jns.2007.02.008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Koh DW, 2005, CELL MOL LIFE SCI, V62, P760, DOI 10.1007/s00018-004-4508-y; Komjati K, 2005, CNS NEUROL DISORD-DR, V4, P179, DOI 10.2174/1568007053544138; Kuchmerovska T, 2004, J DIABETES COMPLICAT, V18, P198, DOI 10.1016/S1056-8727(03)00039-4; Lockett KL, 2004, CANCER RES, V64, P6344, DOI 10.1158/0008-5472.CAN-04-0338; Marchini J, 2006, AM J HUM GENET, V78, P437, DOI 10.1086/500808; Masutani M, 2005, CELL MOL LIFE SCI, V62, P769, DOI 10.1007/s00018-004-4509-x; Mathew C.C, 1984, METHODS MOL BIOL HUM, V2, P31, DOI [10.1385/0-89603-064-4:31, DOI 10.1385/0-89603-064-4:31]; Olaleye D, 2001, DIABETES RES CLIN PR, V54, P115, DOI 10.1016/S0168-8227(01)00278-9; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; PARTANEN J, 1995, NEW ENGL J MED, V333, P89, DOI 10.1056/NEJM199507133330203; ROLLI V, 2000, DNA DAMAGE STRESS SI, P35; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Siemionow M, 2004, J RECONSTR MICROSURG, V20, P241; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Soriano FG, 2001, NAT MED, V7, P108; Strokov IA, 2003, ACTA DIABETOL, V40, pS375, DOI 10.1007/s00592-003-0123-x; van de Poll-Franse LV, 2002, DIABETIC MED, V19, P771, DOI 10.1046/j.1464-5491.2002.00778.x; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Yorek MA, 2003, FREE RADICAL RES, V37, P471, DOI 10.1080/1071576031000083161; Zhang XM, 2005, CANCER RES, V65, P722; Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960	45	12	15	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	MAR	2008	79	3					446	452		10.1016/j.diabres.2007.10.020			7	Endocrinology & Metabolism	Endocrinology & Metabolism	281OC	WOS:000254506200010	18054108				2021-06-18	
J	Lovell, M				Lovell, Mark			The neurophysiology and assessment of sports-related head injuries	NEUROLOGIC CLINICS			English	Article							HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; CEREBRAL CONCUSSION; RECOVERY; PERFORMANCE; IMPAIRMENT; RETURN; PLAY	This article provides a review of contemporary standards for the management of athletes who have sustained a sports-related head injury. Recent research regarding concussion management is reviewed with specific reference to clinical care. The use of neuropsychologic testing in sports also is reviewed, and a systematic protocol for the management of sports-related concussion is presented.	Univ Pittsburgh, Med Ctr Sports Med, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA	Lovell, M (corresponding author), Univ Pittsburgh, Med Ctr Sports Med, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Bergschneider M, 2003, J NEUROSURG, V86, P241; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; COLLINS MW, 1999, JAMA-J AM MED ASSOC, V282, P2383; *CTR DIS CONTR, 2006, HEADS SPORTS CONC; DELANEY JS, 2004, CLIN J SPORT MED, V12, P331; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Schnirring L, 2001, PHYSICIAN SPORTSMED, V29, P11; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WOJYTS ED, 1999, AM J SPORTS MED, V27, P676	44	12	12	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2008	26	1					45	+		10.1016/j.ncl.2007.12.001			19	Clinical Neurology; Neurosciences	Neurosciences & Neurology	281ID	WOS:000254489200004	18295083				2021-06-18	
J	Matschke, J; Glatzel, M				Matschke, J.; Glatzel, M.			Neuropathological assessment of non-accidental head injury in infants and toddlers	RECHTSMEDIZIN			English	Article						non-accidental head injury; shaken baby syndrome; neuropathology; forensic expertise	SHAKEN BABY SYNDROME; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; ABUSE; DIAGNOSIS; HEMORRHAGE; PATTERNS; HEMATOMA	Non-accidental head injury/shaken baby syndrome (NAHI/SBS) is the most common cause of unnatural death in toddlers and infants. Clinically NAHI/SBS features encephalopathy, subdural and intraocular bleeding as well as fractures of the long bones in various combinations. It is estimated that between 15-30/100,000 children suffer from NAHI/SBS per year, but the neuropathology has received relatively little attention. Since a full assessment of the neuropathology in a given case requires sophisticated laboratory techniques and extensive morphological experience, histological investigations of the brain and spinal cord including the dura mater as well as the eyeballs by an experienced forensic neuropathologist should be mandatory in each case. We review the neuropathology most pertinent for the forensic practitioner.	[Matschke, J.; Glatzel, M.] Univ Klinikum Hamburg Eppendorf, D-20246 Hamburg, Germany	Matschke, J (corresponding author), Univ Klinikum Hamburg Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.	matschke@uke.de	Glatzel, Markus/G-3356-2011; Glatzel, Markus/V-8844-2019; Matschke, Jakob/F-6641-2013	Glatzel, Markus/0000-0002-7720-8817; Glatzel, Markus/0000-0002-7720-8817; Matschke, Jakob/0000-0001-6080-0198			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Agner C, 2005, CHILD NERV SYST, V21, P416, DOI 10.1007/s00381-004-1056-6; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Ciurea AV, 2007, CHILD NERV SYST, V23, P335, DOI 10.1007/s00381-006-0230-4; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Dolinak D, 2006, ARCH PATHOL LAB MED, V130, P712; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ghahreman A, 2005, J NEUROSURG, V103, P213, DOI 10.3171/ped.2005.103.3.0213; Gleckman AM, 2000, J FORENSIC SCI, V45, P1151; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Golden N, 2005, J CLIN NEUROSCI, V12, P235, DOI 10.1016/j.jocn.2004.11.001; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Herrmann B, 2008, RECHTSMEDIZIN, V18, P9, DOI 10.1007/s00194-007-0482-7; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; Itabashi HH., 2007, FORENSIC NEUROPATHOL; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kairys SW, 2001, PEDIATRICS, V108, P206; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Lam CH, 1996, NEUROSURGERY, V39, P1252, DOI 10.1097/00006123-199612000-00041; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Matschke J, 2008, RECHTSMEDIZIN, V18, P7, DOI 10.1007/s00194-007-0490-7; Maxeiner H, 2002, KLIN PADIATR, V214, P30, DOI 10.1055/s-2002-19862; Maxeiner H, 2001, J FORENSIC SCI, V46, P85; MORI K, 1993, CHILD NERV SYST, V9, P282, DOI 10.1007/BF00306274; Oehmichen M, 2006, FORENSIC NEUROPATHOL; Reichard RR, 2003, J NEUROPATH EXP NEUR, V62, P237, DOI 10.1093/jnen/62.3.237; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SPERHAKE JP, 2007, RECHTSMEDIZIN; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Warrington SA, 2001, ARCH DIS CHILD, V85, P104, DOI 10.1136/adc.85.2.104	42	12	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9819			RECHTSMEDIZIN	Rechtsmedizin	FEB	2008	18	1					29	35		10.1007/s00194-007-0487-2			7	Medicine, Legal	Legal Medicine	316KH	WOS:000256947800006					2021-06-18	
J	Bloom, GA; Loughead, TM; Shapcott, EJB; Johnston, KM; Delaney, JS				Bloom, Gordon A.; Loughead, Todd M.; Shapcott, Erin J. B.; Johnston, Karen M.; Delaney, J. Scott			The prevalence and recovery of concussed male and female collegiate athletes	EUROPEAN JOURNAL OF SPORT SCIENCE			English	Article						concussion; university athletes; team sports	TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; GENDER-DIFFERENCES; UNITED-STATES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; UNIVERSITY FOOTBALL; CONTACT SPORTS; ICE HOCKEY; SYMPTOMS	The aims of the present study were two-fold: (1) to examine whether gender and explanatory style influence the number of concussions an athlete has sustained and the amount of time to recover from this type of injury; and (2) to determine whether gender and the type of sport influence the number of and recovery from concussion injuries. University varsity athletes (n=170) who had sustained at least one concussion over the previous 12 months from six sports completed both the Sport History Questionnaire (Delaney, Lacroix, Leclerc, & Johnston, 2000), used to measure concussions, and the Attributional Style Questionnaire (Peterson et al., 1982), used to measure explanatory style. Overall, males sustained more concussions than female athletes (F-1,F-153=43.92, P<0.05). Regarding the type of concussion, male athletes sustained more unrecognized concussions than female athletes (F-1,F-168=6.18, P<0.05), but there was no difference between the sexes for recognized concussions (F-1,F-168=0.44, P>0.05). Male basketball players took longer to recover (mean=6.17 days) than female basketball players (mean=1.15 days). In contrast, female hockey players took longer to recover (mean=9.56 days) than male hockey players (mean=1.00 day). Finally, gender did not influence an athlete's explanatory style.	[Bloom, Gordon A.; Shapcott, Erin J. B.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ H2W 1S4, Canada; [Loughead, Todd M.] Univ Windsor, Dept Kinesiol, Windsor, ON N9B 3P4, Canada; [Johnston, Karen M.] Univ Toronto, Toronto Rehabil Hosp, Toronto, ON, Canada; [Delaney, J. Scott] McGill Univ, McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada	Bloom, GA (corresponding author), McGill Univ, Dept Kinesiol & Phys Educ, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	gordon.bloom@mcgill.ca					Almeida SA, 1999, MED SCI SPORT EXER, V31, P1807, DOI 10.1097/00005768-199912000-00017; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bloom GA, 2004, AM SOC TEST MATER, V1446, P12, DOI 10.1520/STP11605S; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Bunce SC, 1997, PERS INDIV DIFFER, V23, P639, DOI 10.1016/S0191-8869(97)00072-X; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1979, J PERS SOC PSYCHOL, V37, P1186, DOI 10.1037/0022-3514.37.7.1186; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DAVIS MA, 1981, J HEALTH SOC BEHAV, V22, P298, DOI 10.2307/2136523; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gould D, 1997, SPORT PSYCHOL, V11, P379, DOI 10.1123/tsp.11.4.379; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hjelle L, 1996, PSYCHOL REP, V78, P507, DOI 10.2466/pr0.1996.78.2.507; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kroenke K, 1998, PSYCHOSOM MED, V60, P150, DOI 10.1097/00006842-199803000-00006; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Martinez R., 2000, COLL STUDENT J, V34, P72; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Nunally J.C., 1978, PSYCHOMETRIC THEORY; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; PETERSON C, 1984, PSYCHOL REV, V91, P347, DOI 10.1037/0033-295X.91.3.347; PETERSON C, 1982, COGNITIVE THER RES, V6, P287, DOI 10.1007/BF01173577; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REED GM, 1994, HEALTH PSYCHOL, V13, P299, DOI 10.1037/0278-6133.13.4.299; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Schilsky M L, 2001, Curr Gastroenterol Rep, V3, P54, DOI 10.1007/s11894-001-0041-4; Seligman M.E.P., 1998, LEARNED OPTIMISM CHA; Shapcott EJB, 2007, NEUROREHABILITATION, V22, P161; Tabachnick B., 2001, USING MULTIVARIATE S; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Udry E, 1997, J SPORT EXERCISE PSY, V19, P71, DOI 10.1123/jsep.19.1.71; VANWIJK CMTG, 1991, WOMEN HEALTH, V17, P91	48	12	12	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1746-1391	1536-7290		EUR J SPORT SCI	Eur. J. Sport Sci.		2008	8	5					295	303		10.1080/17461390802251836			9	Sport Sciences	Sport Sciences	356EV	WOS:000259762400008					2021-06-18	
J	Duff, MC; Wszalek, T; Tranel, D; Cohen, NJ				Duff, Melissa C.; Wszalek, Tracey; Tranel, Daniel; Cohen, Neal J.			Successful life outcome and management of real-world memory demands despite profound anterograde amnesia	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Memory; Amnesia; Outcome; Compensation; Rehabilitation	COGNITIVE NEUROSCIENCE; PATIENT; IMPAIRMENT; SELF; DISSOCIATION; RECOGNITION; INFORMATION; RETENTION; KNOWLEDGE; PATTERN	We describe the case of Angie, a 50-year-old woman with profound amnesia (General Memory Index = 49, Full Scale IQ = 126) following a closed head injury in 1985. This case is unique in comparison to other cases reported in the literature in that, despite the severity of her amnesia, she has developed remarkable real-world life abilities, shows impressive self-awareness and insight into the impairment and sparing of various functional memory abilities, and exhibits ongoing maturation of her identity and sense of self following amnesia. The case provides insights into the interaction of different memory and cognitive systems in handling real-world memory demands and has implications for rehabilitation and for successful life outcome after amnesia.	[Duff, Melissa C.; Tranel, Daniel] Univ Iowa, Dept Neurol, Coll Med, Div Cognit Neurosci, Iowa City, IA 52242 USA; [Wszalek, Tracey] Univ Illinois, Biomed Imaging Ctr, Urbana, IL 61801 USA; [Cohen, Neal J.] Univ Illinois, Beckman Inst, Urbana, IL 61801 USA	Duff, MC (corresponding author), Univ Iowa, Dept Neurol, Coll Med, Div Cognit Neurosci, 200 Hawkins Dr,2100 RCP, Iowa City, IA 52242 USA.	melissa-duff@uiowa.edu		Tranel, Daniel/0000-0002-1338-1389	NIDCD (National Institute on Deafness and Other Communication Disorders)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1F32DC008825]; NINDS (National Institute of Neurological Disorders and Stroke)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19632]; NIMH (National Institute of Mental Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RO1 MH062500]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS019632, P50NS019632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F32DC008825] Funding Source: NIH RePORTER	This research was supported by NIDCD (National Institute on Deafness and Other Communication Disorders) Grant 1F32DC008825, NINDS (National Institute of Neurological Disorders and Stroke) Program Project Grant NINDS NS 19632, and NIMH (National Institute of Mental Health) Grant RO1 MH062500.	ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BENTON A, 1994, BENTON LAB TESTS; Benton A., 1994, MULTILINGUAL APHASIA; Berg, 1993, WISCONSIN CARD SORTI; BUTTERS N, 1986, ALCOHOLIC KORSAKOFFS; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; Claparede E, 1911, ARCH PSYCHOLOGIE, V11, P79; Cohen N.J., 1984, NEUROPSYCHOLOGY MEMO, P83; Cohen N.J., 2001, CONDITIONING CONSCIO; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; COHEN NJ, 2003, NEUROPSYCHOLOGY NEUR; Conway MA, 2005, J MEM LANG, V53, P594, DOI 10.1016/j.jml.2005.08.005; CORKIN S, 1984, SEMINARS NEUROLOGY, V4, P252; Dam~asio A., 1999, FEELING WHAT HAPPENS; DAMASIO A, 1989, HDB NEUROPSYCHOLOGY, V3; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P263, DOI 10.1001/archneur.1985.04060030081013; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DESPOSITO M, 1995, NEUROLOGY, V45, P1546, DOI 10.1212/WNL.45.8.1546; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Duff MC, 2006, NAT NEUROSCI, V9, P140, DOI 10.1038/nn1601; ELLIOTT M, 1990, COGNITIVE REHABILITA, V8, P8; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; Golden C., 1978, STROOP COLOR WORD TE; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hutchins E., 1995, COGNITION WILD; Jones RD, 1998, NEUROCASE, V4, P471, DOI 10.1093/neucas/4.6.471; Kaplan E., 1983, BOSTON NAMING TEST; Kihlstrom JF, 2003, HANDBOOK OF SELF AND IDENTITY, P68; Klein SB, 2002, SOC COGNITION, V20, P105, DOI 10.1521/soco.20.2.105.20991; Klein SB, 1996, J EXP PSYCHOL GEN, V125, P250, DOI 10.1037/0096-3445.125.3.250; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Lieberman MD, 2001, PSYCHOL SCI, V12, P135, DOI 10.1111/1467-9280.00323; Manier D., 2004, MIND CULT ACT, V11, P251, DOI DOI 10.1207/S15327884MCA1104_2; MORRIS MK, 1992, BRAIN, V115, P1827, DOI 10.1093/brain/115.6.1827; Ochsner KN, 2005, NEUROIMAGE, V28, P797, DOI 10.1016/j.neuroimage.2005.06.069; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OCONNOR MG, 1995, BROKEN MEMORIES CASE, P45; PARKIN AJ, 1993, NEUROPSYCHOLOGY AMNE; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Ryan JD, 2000, PSYCHOL SCI, V11, P454, DOI 10.1111/1467-9280.00288; Ryan JD, 2004, NEUROPSYCHOLOGIA, V42, P497, DOI 10.1016/j.neuropsychologia.2003.08.011; Schmolck H, 2002, HIPPOCAMPUS, V12, P520, DOI 10.1002/hipo.10039; Sokol K, 1999, 127 ANN M AM PUBL HL; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; TATE R, 2002, HDB MEMORY DISORDERS, P785; Tranel D, 2006, J CLIN EXP NEUROPSYC, V28, P43, DOI 10.1080/13803390490919344; Tranel D, 2006, NEUROPSYCHOLOGY, V20, P1, DOI 10.1037/0894-4105.20.1.1; Tranel D, 2005, J CLIN EXP NEUROPSYC, V27, P102, DOI 10.1080/138033990513663; TRANEL D, 1993, J COGNITIVE NEUROSCI, V5, P79, DOI 10.1162/jocn.1993.5.1.79; TRANEL D, 2000, HDB NEUROPSYCHOLOGY, V2, P85; VERDERWERF Y, 2000, NEUROPSYCHOLOGIA, V38, P613; Verfaellie M, 1995, J Int Neuropsychol Soc, V1, P443; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson B.A., 2002, HDB MEMORY DISORDERS, P655; Wilson B. A, 1999, CASE STUDIES NEUROPS; WILSON BA, 1995, J CLIN EXP NEUROPSYC, V17, P668, DOI 10.1080/01688639508405157; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson BA, 1995, BROKEN MEMORIES CASE, P14; Ylvisaker M., 1998, COLLABORATIVE BRAIN; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	69	12	12	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2008	30	8					931	945		10.1080/13803390801894681			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	362OJ	WOS:000260206700008	18608659	Green Accepted			2021-06-18	
J	Elting, JW; Maurits, N; van Weerden, T; Spikman, J; De Keyser, J; van der Naalt, J				Elting, Jan Willem; Maurits, Natasha; van Weerden, Tom; Spikman, Joke; De Keyser, Jacques; van der Naalt, Joukje			P300 analysis techniques in cognitive impairment after brain injury: Comparison with neuropsychological and imaging data	BRAIN INJURY			English	Article						P300; brain injury; source analysis; imaging	CLOSED-HEAD-INJURY; EVENT-RELATED POTENTIALS; AUDITORY ODDBALL TASK; CLINICAL UTILITY; DIAGNOSIS THREAT; LATENCY; LONG; ATTENTION; DISTRACTIBILITY; DETERMINANTS	Primary objective: To compare P300 source analysis with conventional analysis in patients with cognitive impairment after brain injury. Methods and procedures: P300 results were compared with neuropsychological test data and imaging data in 21 healthy control subjects and 33 patients with brain injury. Latency and amplitude parameters were obtained for both P300 analysis methods. Magnetic Resonance Imaging (MRI) was performed between 3-12 months after the injury. Main outcomes and results: For both P300 analysis methods, only amplitude parameters correlated with neuropsychological test data. Diagnostic accuracy was better with source analysis than conventional analysis, when compared to the VLT (p = 0.03) and the PASAT (p = 0.04, only for those patients with imaging abnormalities). Patients with normal MRI results and patients with MRI abnormalities had decreased mean P3A amplitude compared to controls. In patients with focal frontal or temporal injury, the presence of mediofrontal lesions was associated with P3A amplitude reduction, while orbitofrontal lesions tended to increase P3A amplitude. Conclusions: Source analysis of P300 resulted in improved detection of neuropsychological abnormality in patients with brain injury. It is advisable to analyse P300 results in conjunction with imaging results. This approach may further facilitate the interpretation and diagnostic applicability of source analysis P300 results in patients with brain injury.	[Elting, Jan Willem; Maurits, Natasha; van Weerden, Tom; Spikman, Joke; De Keyser, Jacques; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9731 GZ Groningen, Netherlands	Elting, JW (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9731 GZ Groningen, Netherlands.	j.w.j.elting@neuro.umcg.nl	De Keyser, Jacques/D-3725-2013; De Keyser, Jacques/AAA-8721-2021	De Keyser, Jacques/0000-0002-3394-7757; De Keyser, Jacques/0000-0002-3394-7757; Maurits, Natasha/0000-0001-6231-7044; Spikman, Jacoba/0000-0002-6477-0763			Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bledowski C, 2004, J NEUROSCI, V24, P9353, DOI 10.1523/JNEUROSCI.1897-04.2004; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; Elting JW, 2005, CLIN NEUROPHYSIOL, V116, P2606, DOI 10.1016/j.clinph.2005.07.014; Elting JW, 2003, J CLIN NEUROPHYSIOL, V20, P26, DOI 10.1097/00004691-200302000-00003; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; GOODIN D, 1994, ELECTROEN CLIN NEURO, V91, P18, DOI 10.1016/0013-4694(94)90014-0; GOODIN DS, 1990, ELECTROEN CLIN NEURO, V76, P2, DOI 10.1016/0013-4694(90)90051-K; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFEFFERBAUM A, 1990, ELECTROEN CLIN NEURO, V76, P6, DOI 10.1016/0013-4694(90)90052-L; POLICH J, 1989, J CLIN NEUROPHYSIOL, V6, P277, DOI 10.1097/00004691-198907000-00003; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; POLICH J, 1998, P300 CLIN APPL ELECT, P1073; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; REY A, 1964, EXAMIN PSYCHOL CAS E; Reza MF, 2007, NEUROPSYCHOL REHABIL, V17, P723, DOI 10.1080/09602010601082441; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Rule RR, 2002, COGN AFFECT BEHAV NE, V2, P264, DOI 10.3758/CABN.2.3.264; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Simons RF, 2001, BIOL PSYCHOL, V56, P207, DOI 10.1016/S0301-0511(01)00078-3; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDERNAALT J, 1998, J NEUROTRAUM, V15, P454; VANZOMEREN AH, 2003, ASSESSMENT ATTENTION; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	46	12	14	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	11					870	881		10.1080/02699050802403581			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700006	18850345				2021-06-18	
J	Martelli, MF; Nicholson, K; Zasler, ND				Martelli, Michael F.; Nicholson, Keith; Zasler, Nathan D.			Skill reacquisition after acquired brain injury: A holistic habit retraining model of neurorehabilitation	NEUROREHABILITATION			English	Article						neurorehabilitation; holistic rehabilitation; cognitive rehabilitation; traumatic brain injury; habit retraining	INDUCED MOVEMENT THERAPY; COGNITIVE REHABILITATION; VANISHING CUES; ERRORLESS; ASSOCIATIONS; ACQUISITION; DISABILITY; AVOIDANCE; AMNESIA; STROKE	Persistent cognitive, emotional and behavioral dysfunction following brain injury present formidable challenges in the area of neurorehabilitation. This paper reviews a model and practical methodology for community based neurorehabilitation based upon: 1. Evidence from the "automatic learning" and "errorless learning" literature for skills relearning after brain injury; 2. A widely applicable task analytic approach to designing relevant skills retraining protocols; 3. Analysis of organic, reactive, developmental, and characterological obstacles to strategy utilization and relearning, and generation of effective therapeutic interventions; and 4. Procedures for (a) promoting rehabilitative strategy use adapted to acute and chronic neurologic losses, (b) an individual's inherent reinforcement preferences and coping style, (c) reliant on naturalistic reinforcers which highlight relationships to functional goals, utilize social networks, and (d) employ a simple and appealing cognitive attitudinal system and set of procedures. This Holistic Habit Retraining Model and methodology integrates core psychotherapeutic and learning principles as rehabilitation process ingredients necessary for optimal facilitation of skills retraining. It presents a model that generates practical, utilitarian strategies for retraining adaptive cognitive, emotional, behavioral and social skills, as well as strategies for overcoming common obstacles to utilizing methods that promote effective skills acquisition.	[Martelli, Michael F.; Zasler, Nathan D.] Tree Life Serv Inc, Glen Allen, VA USA; [Martelli, Michael F.] Virginia Commonwealth Univ, Dept Psychol & Psychiat, Richmond, VA USA; [Martelli, Michael F.; Zasler, Nathan D.] Univ Virginia, Dept Phys Med & Rehabil, Charlottesville, VA USA; [Nicholson, Keith] Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada; [Zasler, Nathan D.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Zasler, Nathan D.] NW Ctr Special Care, Lake Katrine, NY USA	Martelli, MF (corresponding author), Tree Life Serv Inc, 13458 N Gayton, Richmond, VA 23233 USA.	mfmartelli@villamartelli.com					Akhtar S, 2006, NEUROPSYCHOL REHABIL, V16, P329, DOI 10.1080/09602010500176674; Anderson ND, 2006, NEUROPSYCHOLOGIA, V44, P2806, DOI 10.1016/j.neuropsychologia.2006.05.026; Bender M. C., 2003, WILL TRAUM BRAIN INJ; BENYISHAY Y, 2000, INT HDB NEUROPSYCHOL; Bergin A.E., 1994, HDB PSYCHOTHERAPY BE; Clare L, 2002, NEUROPSYCHOLOGY, V16, P538, DOI 10.1037//0894-4105.16.4.538; DUBOVSKY SL, 1997, MIND BODY DECEPTIONS; Ducharme JM, 2003, J HEAD TRAUMA REHAB, V18, P88, DOI 10.1097/00001199-200301000-00009; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Frank J.D., 1993, PERSUASION HEALING C; FRANK JD, 1974, J NERV MENT DIS, V159, P325, DOI 10.1097/00005053-197411000-00003; FRANK JD, 1983, BEHAV BRAIN SCI, V6, P291, DOI 10.1017/S0140525X00015958; Frank JD, 1991, PERSUASION HEALING C; FRANK JD, 1982, PSYCHOTHERAPY RES BE, P9; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; Goldstein, 1995, ORGANISM HOLISTIC AP; Greenwood R, 2001, BRIT MED J, V323, P1082, DOI 10.1136/bmj.323.7321.1082; Haslam C, 2006, NEUROPSYCHOL REHABIL, V16, P505, DOI 10.1080/09602010500231867; HOPEWELL CA, 2001, NEUROPSYCHOLOGICAL A; Hubble M. A., 1999, HEART SOUL CHANGE WH; James W., 1890, PRINCIPLES PSYCHOL, VII; Jerome J, 2007, J APPL BEHAV ANAL, V40, P185, DOI 10.1901/jaba.2007.41-06; Jonassen D.H., 1999, TASK ANAL METHODS IN; Kern RS, 2002, AM J PSYCHIAT, V159, P1921, DOI 10.1176/appi.ajp.159.11.1921; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 2003, PSYCHOL MED, V33, P433, DOI 10.1017/S0033291702007298; KESSELS RP, 2005, J INT NEUROPSYCHOLOG, V11; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; LENG NRC, 1991, BEHAV PSYCHOTHER, V19, P173, DOI 10.1017/S0141347300012209; MACMILLAN P, 1989, REH PROGR ANN M RICH; Martelli MF, 1999, ARCH CLIN NEUROPSYCH, V14, P804, DOI 10.1016/S0887-6177(99)80356-4; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 2005, BRAIN INJURY PROFESS, V2, P10; MARTELLI MF, 1999, HEADS RSS NEWSLETTER, V2; MARTELLI MF, 1999, V MARTELLI INTERNET; MARTELLI MF, 1997, 1 COMB TRAIN C VA RE; MARTELLI MF, 2002, NEW YORK AC TRAUM BR; MARTELLI MF, 2003, U SEV CENTR REH DAN; MARTELLI MF, 2002, 21 ANN S BRAIN INJ A; MARTELLI MF, 2003, 4 ANN M BRAIN INJ AS; MARTELLI MF, 2003, ANN M COAL CLIN PRAC; MARTELLI MF, 2005, ANN M COAL CLIN PRAC; MARTELLI MF, 2002, B NATL ACAD NEUROPSY, V17, P8; Martins S, 2006, NEUROPSYCHOLOGIA, V44, P2792, DOI 10.1016/j.neuropsychologia.2006.05.022; MASTERS JC, 1987, BEHAV THERAPY TECHNI; MASTERS RS, 2007, CONSCIOUS COGNI 0428; Masters RSW, 2004, REHABIL PSYCHOL, V49, P79, DOI 10.1037/0090-5550.49.1.79; Miller L, 2000, NEUROREHABILITATION, V14, P25; MILLER L, 1998, SHOCKS SYSTEM PSYCHO; Miller SD, 1997, ESCAPE BABEL UNIFYIN; Miotto EC, 2007, NEUROPSYCHOL REHABIL, V17, P551, DOI 10.1080/09602010701202188; Ormrod J.E., 1999, HUMAN LEARNING; Orrell AJ, 2006, PHYS THER, V86, P369, DOI 10.1093/ptj/86.3.369; Page M, 2006, NEUROPSYCHOLOGIA, V44, P90, DOI 10.1016/j.neuropsychologia.2005.04.004; PATTERSON CH, 1989, PSYCHOTHERAPY, V26, P427, DOI 10.1037/h0085461; Pitel AL, 2006, BRAIN INJURY, V20, P1099, DOI 10.1080/02699050600909961; Pope JW, 2006, J CLIN EXP NEUROPSYC, V28, P101, DOI 10.1080/13803390490918138; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Riley GA, 2004, BRAIN INJURY, V18, P871, DOI 10.1080/02699050410001671829; RIM DC, 1979, BEHAV THERAPY TECHNI; Sbordone R.J., 1990, PSYCHOTHERAPY PRIVAT, V8, P129; SCHACTER D, 1996, SEARCHING MEMORY; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schutz LE, 2007, BRAIN INJURY, V21, P545, DOI 10.1080/02699050701426923; SELIGMAN MEP, 2000, ENCY STRESS; SPIEGLER MD, CONT BEHAV THERAPY; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; Taub Edward, 2003, Phys Med Rehabil Clin N Am, V14, pS77, DOI 10.1016/S1047-9651(02)00052-9; TODD DD, 1998, COGNIPHOBIA SCLAE C; VERFAELLIE M, 1990, BRAIN COGNITION, V13, P178, DOI 10.1016/0278-2626(90)90049-T; Wampold B. E., 2001, GREAT PSYCHOTHERAPY; Wilson FC, 2003, NEUROPSYCHOL REHABIL, V13, P537, DOI 10.1080/09602010343000200; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Zasler N.D., 2005, TXB TRAUMATIC BRAIN, P419; ZASLER ND, 2002, STATE ART REV FUNCTI	78	12	12	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	2					115	126					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	311II	WOS:000256593500001	18525133				2021-06-18	
J	Namiki, C; Yamada, M; Yoshida, H; Hanakawa, T; Fukuyama, H; Murai, T				Namiki, Chihiro; Yamada, Makiko; Yoshida, Hidefumi; Hanakawa, Takashi; Fukuyama, Hidenao; Murai, Toshiya			Small orbitofrontal traumatic lesions detected by high resolution MRI in a patient with major behavioural changes	NEUROCASE			English	Article						Traumatic brain injury; Orbitofrontal cortex damage; Personality changes; High resolution MRI; Social problems	PREFRONTAL CORTEX; DECISION-MAKING; HEAD-INJURY; DAMAGE; EMOTION	We report a case of a male patient who showed personality changes and marked social problems after a traumatic brain injury. Although suspected to have lesions in the orbitofrontal cortex because of the typical characteristics of his behavioural change, lesions were not apparent using conventional imaging techniques. However, investigation using high-resolution MRI revealed lesions in the orbitofrontal cortex. Our case suggests that standard MRI scanning techniques may have only limited power. Hence, we stress the important role played by qualitative assessments of emotion, personality, and social behaviour in evaluating sequelae of traumatic orbitofrontal injuries.	[Namiki, Chihiro] Kyoto Univ, Grad Sch Med, Dept Neuropsychiat, Sakyo Ku, Kyoto 6068507, Japan; [Namiki, Chihiro; Yoshida, Hidefumi; Hanakawa, Takashi; Fukuyama, Hidenao] Human Brain Res Ctr, Kyoto, Japan	Namiki, C (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neuropsychiat, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	cnamiki@kuhp.kyoto-u.ac.jp	Hanakawa, Takashi/A-6536-2011; Fukuyama, Hidenao/AAI-7118-2020		Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [16500367]	This report was supported by the Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science ( 16500367).	Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benton A. L., 1983, FACIAL RECOGNITION S; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Ekman P., 1975, PICTURES FACIAL AFFE; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Holland PC, 2004, CURR OPIN NEUROBIOL, V14, P148, DOI 10.1016/j.conb.2004.03.007; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Soussignan R, 2005, NEUROCASE, V11, P114, DOI 10.1080/13554790590922513; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Yoshizumi U. K., 2007, SEISHIN IGAKU, V49, P137	25	12	12	0	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1355-4794			NEUROCASE	Neurocase		2008	14	6					474	479	PII 905557322	10.1080/13554790802459494			6	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	372OQ	WOS:000260911300002	19012167				2021-06-18	
J	Rusnak, M; Mauritz, W; Lecky, F; Kaniansky, M; Brazinova, A				Rusnak, M.; Mauritz, W.; Lecky, F.; Kaniansky, M.; Brazinova, A.			Evaluation of traumatic brain injury guidelines using AGREE instrument	BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY			English	Article						guidelines; traumatic brain injury; AGREE	SEVERE HEAD-INJURY; CARE MANAGEMENT; QUALITY; COMA	Background: This study aims to assess the quality of four selected traumatic brain injuries management guidelines used mainly in the US and in Europe. Methods: The instrument Appraisal of Guidelines Research & Evaluation was selected to provide a framework for guidelines appraisal. Four guidelines addressing a specific topic related to the treatment of traumatic brain injury were selected for evaluation: three developed in the United States of America and one from the United Kingdom. A trauma surgeon, one anaesthesiologist, one emergency physician and a public health specialist evaluated the guidelines. Results: In the overall assessment of all guidelines, the United Kingdom guidelines attracted the best score, achieving the highest score of all four guidelines in five of six domains. The scientific quality of collected evidence was excellent and well documented in all four guidelines. Overall, the domains of Stakeholder involvement and Applicability were the lowest scoring for all the guidelines. Conclusion: A Broad spectrum of stakeholders should be represented in the brain trauma management guidelines development. The potential organizational and financial barriers for the application of guidelines need to be considered during their development. The paper provides suggestions for those who develop new guidelines for the management of patients with head injuries (Tab. 8, Ref. 29). Full Text (Free, PDF) www.bmj.sk.	[Rusnak, M.; Mauritz, W.; Brazinova, A.] Int Neurotrauma Res Org, A-1080 Vienna, Austria; [Rusnak, M.] Trnava Univ, Sch Hlth & Social Work, Dept Publ Hlth, Trnava, Slovakia; [Mauritz, W.] Trauma Hosp Lorenz Boehler, Vienna, Austria; [Lecky, F.] Univ Manchester, Hope Hosp, Salford M6 8HD, Lancs, England; [Kaniansky, M.] FD Roosevelt Hosp, Dept Traumatol, Banska, Bystrica, Slovakia	Brazinova, A (corresponding author), Int Neurotrauma Res Org, Molkergasse 4-3, A-1080 Vienna, Austria.	abrazinova@igeh.org	Brazinova, Alexandra/C-4265-2016; Rusnak, Martin/K-9349-2016	Brazinova, Alexandra/0000-0003-0625-256X; Rusnak, Martin/0000-0003-3321-1042			AGREE Collaboration, APPR GUID RES EV AGR; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Boluyt N, 2005, PEDIATRICS, V115, P1378, DOI 10.1542/peds.2004-0575; *BRAIN TRAUM FDN, 1996, GUID MAN SEV HEAD IN; Brain Trauma Foundation, 2000, GUID PREH MAN TRAUM; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Elit L M, 2006, Curr Oncol, V13, P94; Fervers B, 2005, INT J QUAL HEALTH C, V17, P123, DOI 10.1093/intqhc/mzi011; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hulshof C, 2007, IND HEALTH, V45, P26, DOI 10.2486/indhealth.45.26; Hurdowar A, 2007, J EVAL CLIN PRACT, V13, P657, DOI 10.1111/j.1365-2753.2007.00708.x; Keris V, 2007, WORLD J SURG, V31, P1352, DOI 10.1007/s00268-007-9002-x; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; *MAN PROGN PEN BRA, 2001, J TRAUMA INJURY IN S, V51; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; *NICE UK NHS, 2003, HEAD INJ TRIAG ASS I; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Stiegler M, 2005, EUR PSYCHIAT, V20, P554, DOI 10.1016/j.eurpsy.2005.05.012; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81	29	12	12	0	8	COMENIUS UNIV	BRATISLAVA I	SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA	0006-9248	1336-0345		BRATISL MED J	Bratisl. Med. J.		2008	109	8					374	380					7	Medicine, General & Internal	General & Internal Medicine	355MH	WOS:000259712500011	18837249				2021-06-18	
J	Schwartz, I; Tuchner, M; Tsenter, J; Shochina, M; Shoshan, Y; Katz-Leurer, M; Meiner, Z				Schwartz, Isabella; Tuchner, Maya; Tsenter, Jeanna; Shochina, Mara; Shoshan, Yigal; Katz-Leurer, Michal; Meiner, Zeev			Cognitive and functional outcomes of terror victims who suffered from traumatic brain injury	BRAIN INJURY			English	Article						traumatic; brain; injury; terrorism; outcomes; rehabilitation	SPINAL-CORD INJURY; SEVERITY SCORE; REHABILITATION OUTCOMES; INDEPENDENCE; VALIDATION; DISABILITY; PREDICTION; EXPLOSION; RECOVERY; VALIDITY	Primary objective: To describe the outcomes of terror victims suffered from traumatic brain injury (TBI). Research design: Retrospective chart review of 17 terror and 39 non-terror TBI patients treated in a rehabilitation department during the same period. Methods and procedure: Variables include demographic data, Injury Severity Scale (ISS), length of stay (LOS) and imaging results. ADL was measured using the Functional Independence Measurement (FIM), cognitive and memory functions were measured using the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) battery and the Rivermead Battery Memory Test (RBMT), respectively. Main outcome and results: Terror TBI patients were significantly younger, had higher ISS score and higher rates of intracerebral haemorrhage (ICH), brain surgery and penetrating brain injuries than the non-terror TBI group. There was no difference in mean LOS, mean FIM values, mean FIM gain and mean cognitive and memory improvement between groups. Terror victims suffered from a higher percentage of post-traumatic epilepsy (35% vs. 10%, p = 0.05), whereas the rate of PTSD and the rate of return to previous occupation were similar between groups. Conclusions: Although TBI terror victims had more severe injury, they gained most of ADL functions and their rehabilitation outcomes were similar to non-terror TBI patients. These favourable results were achieved due to a comprehensive interdisciplinary approach to terror victims and also by national support which allowed an adequate period of treatment and sufficient resources as needed.	[Schwartz, Isabella; Tuchner, Maya; Tsenter, Jeanna; Shochina, Mara; Meiner, Zeev] Hadassah Univ Hosp, Dept Phys Med & Rehabil, IL-91420 Jerusalem, Israel; [Katz-Leurer, Michal] Tel Aviv Univ, Sch Hlth Profess, Dept Phys Therapy, Ramat Aviv, Israel; [Shoshan, Yigal] Hadassah Univ Hosp, Dept Neurosurg, IL-91420 Jerusalem, Israel	Meiner, Z (corresponding author), Hadassah Univ Hosp, Dept Phys Med & Rehabil, POB 24035 Mt Scopus, IL-91420 Jerusalem, Israel.	meiner@hadassah.org.il					Aharonson-Daniel L, 2003, PEDIATRICS, V112, pE280, DOI 10.1542/peds.112.4.e280; Arnold JL, 2004, ANN EMERG MED, V43, P263, DOI 10.1016/S0196-0644(03)00723-6; AVENSANI R, 2005, BRAIN INJURY, V19, P933; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cockburn J, 1996, EUR REV APPL PSYCHOL, V46, P201; COCKCROFT VB, 1990, MOL NEUROBIOL, V4, P129, DOI 10.1007/BF02780338; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; Derogatis LR, 1982, ADM PROCEDURES BSI M, VI; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Einav S, 2006, ANN SURG, V243, P533, DOI 10.1097/01.sla.0000206417.58432.48; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Gidron Y, 2004, ISRAEL MED ASSOC J, V6, P387; Granger CV, 1986, GUIDE USE UNIFORM DA; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jehel L, 2001, ENCEPHALE, V27, P393; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; KATZ N, 1989, AM J OCCUP THER, V43, P184, DOI 10.5014/ajot.43.3.184; Katz N, 2000, OCCUP THER J RES, V20, P3, DOI 10.1177/153944920002000101; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Kluger Y, 2003, ISRAEL MED ASSOC J, V5, P235; Kluger Y, 2004, Scand J Surg, V93, P11; Maurer E, 2004, TRAUMA, P87; Mintz Y, 2002, ISRAEL MED ASSOC J, V4, P554; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Peleg K, 2006, J AM COLL SURGEONS, V202, P643, DOI 10.1016/j.jamcollsurg.2005.12.019; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Schlenger WE, 2002, JAMA-J AM MED ASSOC, V288, P581, DOI 10.1001/jama.288.5.581; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Shalev AY, 2005, AM J PSYCHIAT, V162, P1188, DOI 10.1176/appi.ajp.162.6.1188; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Singer Pierre, 2005, Crit Care Med, V33, pS61, DOI 10.1097/01.CCM.0000151068.33935.3E; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Yasuda S, 2002, NEUROREHABILITATION, V17, P177	49	12	12	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					255	263		10.1080/02699050801941763			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500006	18297597				2021-06-18	
J	Sharp, NCC				Sharp, N. C. Craig			The human genome and sport, including epigenetics and athleticogenomics: A brief look at a rapidly changing field	JOURNAL OF SPORTS SCIENCES			English	Article						athleticogenomics; epigenetics; gene doping; genome; sport	TRAUMATIC BRAIN-INJURY; HUMAN GENE; EXPRESSION; EXERCISE; FATIGUE; MAP	Since Hugh Montgomery discovered the first of what are now nearly 200 fitness genes, together with rapid advances in human gene therapy, there is now a real prospect of the use of genes, genetic elements, and/or cells that have the capacity to enhance athletic performance (to paraphrase the World Anti-Doping Agency's definition of gene doping). This overview covers the main areas of interface between genetics and sport, attempts to provide a context against which gene doping may be viewed, and suggests a futuristic legitimate use of genomic (and possibly epigenetic) information in sport.	Brunel Univ, Ctr Sports Med & Human Performance, Uxbridge UB8 3PH, West London, England	Sharp, NCC (corresponding author), Brunel Univ, Ctr Sports Med & Human Performance, Uxbridge UB8 3PH, West London, England.	c.sharp90@btinternet.com					Abbott A, 2006, NATURE, V443, P488, DOI 10.1038/443488a; *AM PHYSL SOC, PHYSL GENOMICS; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Booth FW, 2005, AM SCI, V93, P28; BOUCHARD C, 1999, GENETICS FITNESS PHY; Brenner S, 2007, NATURE, V446, P725, DOI 10.1038/446725a; Budgett R, 2000, BRIT J SPORT MED, V34, P67, DOI 10.1136/bjsm.34.1.67; Check E, 2007, NATURE, V448, P11; Cox JJ, 2006, NATURE, V444, P894, DOI 10.1038/nature05413; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; DELACHAPELLE A, 1993, LANCET, V341, P82, DOI 10.1016/0140-6736(93)92558-B; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Dunlap KA, 2006, P NATL ACAD SCI USA, V103, P14390, DOI 10.1073/pnas.0603836103; Eccleston A, 2007, NATURE, V447, P395, DOI 10.1038/447395a; GEE H, 2004, J LADDER HIST HUMAN; GOLDSPINK G, 1992, NEW SCI, V135, P28; HAMER C, 1998, LIVING OUR GENES; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kaushik N, 2005, J CLIN PATHOL, V58, P826, DOI 10.1136/jcp.2005.025718; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Knight J, 2003, NATURE, V426, P114, DOI 10.1038/426114a; KODADEK T, 2007, NATURE, V446, P472; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lyon Mary F., 2007, Biologist (London), V54, P94; MacArthur DG, 2004, BIOESSAYS, V26, P786, DOI 10.1002/bies.20061; MACARTHUR DG, 2007, E AFRICAN RUNNING CR, P217; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Miah A., 2004, GENETICALLY MODIFIED; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Nicholas Wade is a good example of this proclivity, 2001, LIFE SCRIPT HUMAN GE; Noakes TD, 2004, BRIT J SPORT MED, V38, P511, DOI 10.1136/bjsm.2003.009860; PANDO OJ, 2007, CELL, V128, P655; Parisotto R., 2006, BLOOD SPORTS INSIDE; Rankinen T, 2006, MED SCI SPORT EXER, V38, P1863, DOI 10.1249/01.mss.0000233789.01164.4f; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; RIGGS AD, 1996, EPIGENETICS MECH GEN; Rogers YH, 2005, NATURE, V437, P326, DOI 10.1038/437326a; Savulescu J., 2005, GENETIC TECHNOLOGY S, P136; SCHJERLING P, 2005, GENETIC TECHNOLOGY S, P19; Shadan S, 2007, NATURE, V447, P275, DOI 10.1038/447275b; Sharp C, 1999, NATURE, V398, P675; SHARP NCC, 2007, E AFRICAN RUNNING CR, P1; SHARP NCC, 2006, PEAK PERFORMANCE, V230, P8; SHARP NCC, 2004, PHYSL NEWS, V57, P15; Slot O, 2006, TIMES           0202; Sweeney HL, 2004, SCI AM, V291, P62, DOI 10.1038/scientificamerican0704-62; Tamburrini Claudio M, 2005, GENETIC TECHNOLOGY S; Waddington C. H., 1942, Endeavour London, V1, P18; Wagner RW, 1998, NATURE, V391, P744, DOI 10.1038/35750; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com; Weiss A, 1999, P NATL ACAD SCI USA, V96, P2958, DOI 10.1073/pnas.96.6.2958; Yang N, 2003, AM J HUM GENET, V73, P627, DOI 10.1086/377590; Zamore PD, 2007, NATURE, V446, P864, DOI 10.1038/446864a	60	12	13	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0264-0414	1466-447X		J SPORT SCI	J. Sports Sci.		2008	26	11					1127	1133		10.1080/02640410801912117			7	Sport Sciences	Sport Sciences	345YY	WOS:000259036600002	18618365				2021-06-18	
J	Silverberg, ND; Hanks, RA; Buchanan, L; Fichtenberg, N; Millis, SR				Silverberg, Noah D.; Hanks, Robin A.; Buchanan, Lori; Fichtenberg, Norm; Millis, Scott R.			Detecting response bias with performance patterns on an expanded version of the controlled oral word association test	CLINICAL NEUROPSYCHOLOGIST			English	Article						effort; malingering; phonemic fluency; response bias; traumatic brain injury; verbal fluency	VERBAL-LEARNING TEST; QUALITATIVE-ANALYSIS; INCOMPLETE EFFORT; NORMATIVE DATA; POOR EFFORT; FLUENCY; VALIDATION; RELIABILITY; STRATEGIES; EDUCATION	The present study investigated whether speeded word generation performance patterns seen in healthy subjects are also produced in genuine and feigned traumatic brain injury ( TBI). An expanded version of the Controlled Oral Word Association Test was administered to healthy controls, TBI patients, simulated malingerers, and probable clinical malingerers. Four performance patterns were operationalized. Three of these patterns were replicated in the healthy control sample and found to he unaltered by genuine TBI. They were then combined into a logistic regression model that discriminated well between examinees who put forth adequate effort and those who evidenced response bias.	[Silverberg, Noah D.; Buchanan, Lori] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Hanks, Robin A.; Fichtenberg, Norm; Millis, Scott R.] Rehabil Inst Michigan, Detroit, MI USA; [Hanks, Robin A.; Fichtenberg, Norm; Millis, Scott R.] Wayne State Univ, Detroit, MI 48202 USA	Silverberg, ND (corresponding author), Univ Windsor, Dept Psychol, 173 Chrysler Hall S,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	noahsilverberg@hotmail.com					Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Benton A., 1994, MULTILINGUAL APHASIA; BENTON AL, 1969, J NEUROL SCI, V9, P39, DOI 10.1016/0022-510X(69)90057-4; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Burgess C, 1998, BEHAV RES METH INS C, V30, P272, DOI 10.3758/BF03200655; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Crowe SF, 1998, J CLIN EXP NEUROPSYC, V20, P391, DOI 10.1076/jcen.20.3.391.810; Crowe SF, 2001, BRAIN COGNITION, V47, P323; da Silva CG, 2004, J CLIN EXP NEUROPSYC, V26, P266, DOI 10.1076/jcen.26.2.266.28089; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Demakis GJ, 2003, CLIN NEUROPSYCHOL, V17, P322, DOI 10.1076/clin.17.3.322.18081; Diaz M, 2004, BRAIN LANG, V89, P108, DOI 10.1016/S0093-934X(03)00307-9; Fossati P, 2003, PSYCHIAT RES, V117, P17, DOI 10.1016/S0165-1781(02)00300-1; Gouvier WD, 1999, STUD NEUROPSYCHOL DE, P27; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 1996, WORLD MEMORY TEST US; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Hilsabeck RC, 2003, ARCH CLIN NEUROPSYCH, V18, P71, DOI 10.1016/S0887-6177(01)00180-9; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Kucera H, 1967, COMPUTATIONAL ANAL P; Lamar M, 2002, NEUROPSYCHOLOGIA, V40, P435, DOI 10.1016/S0028-3932(01)00125-7; Mayr U, 2002, NEUROPSYCHOLOGIA, V40, P562, DOI 10.1016/S0028-3932(01)00132-4; Millikin CP, 2004, J CLIN EXP NEUROPSYC, V26, P933, DOI 10.1080/13803390490510842; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MILLIS SR, 2002, NEUROPSYCHOLOGY, V2, P147; Milner B., 1964, FRONTAL GRANULAR COR; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 2002, J FORENSIC NEUROPSYC, V3, P227, DOI DOI 10.1300/J151V03N01_03; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Robert PH, 1998, J INT NEUROPSYCH SOC, V4, P539, DOI 10.1017/S1355617798466025; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Rogers R, 1998, LAW HUMAN BEHAV, V22, P273, DOI 10.1023/A:1025702405865; Ross TP, 2003, ARCH CLIN NEUROPSYCH, V18, P153, DOI 10.1016/S0887-6177(01)00192-5; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Silverberg N, 2005, J CLIN EXP NEUROPSYC, V27, P907, DOI 10.1080/13803390490919326; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr J, 2004, J CLIN EXP NEUROPSYC, V26, P416, DOI 10.1080/13803390490510121; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Thurstone L.L., 1962, PRIMARY MENTAL ABILI; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Tombaugh TN, 1996, TEST MEMORY MALINGER; Troster AI, 1998, NEUROPSYCHOLOGIA, V36, P295, DOI 10.1016/S0028-3932(97)00153-X; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370	56	12	12	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN	2008	22	1					140	157		10.1080/13854040601160597			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	258TF	WOS:000252891700011	17853150				2021-06-18	
J	Sivak, S; Kurca, E; Hladka, M; Zelenak, K; Turcanova-Koprusakova, M; Michalik, J				Sivak, S.; Kurca, E.; Hladka, M.; Zelenak, K.; Turcanova-Koprusakova, M.; Michalik, J.			Early and delayed auditory oddball ERPs and brain MRI in patients with MTBI	BRAIN INJURY			English	Article						mild traumatic brain injury; cognitive impairment; magnetic resonance imaging; event-related potentials; oddball paradigm	CLOSED-HEAD INJURY; P300; CONCUSSION; LATENCY; INDEXES; LONG	Introduction: Mild traumatic brain injury (MTBI) is a common neurotraumatologic diagnosis. It is possible to confirm objective cognitive impairment in MTBI patients not only by complex neuropsychological testing but also by event-related potentials (ERPs). The most common ERPs used in clinical practice are based on an oddball paradigm. Magnetic resonance imaging (MRI) is not routinely used in MTBI despite its proven greater sensitivity and specificity in comparison with computer tomography (CT). Methods: This study investigated 31 MTBI patients and 31 sex and age-matched healthy controls. Both groups underwent clinical neurological examinations. Auditory oddball ERPs and brain MRI were done early after the injury and 3-7 months later. Results: There were no significant sex, age and education differences between the analysed groups. No significant differences were found in N2 and P3 wave parameters in both ERP examinations. Conclusion: Standard auditory oddball ERPs are not sensitive enough to detect and/or quantify subtle objective neuropsychological changes in selected MTBI patients, especially those with traumatic MRI brain lesions. More complex auditory or other oddball paradigms have to be tested in the future.	[Sivak, S.; Kurca, E.; Turcanova-Koprusakova, M.; Michalik, J.] Comenius Univ, Neurol Clin, Jessenius Fac Med, Martin 06359, Slovakia; [Hladka, M.; Zelenak, K.] Comenius Univ, Clin Radiol, Jessenius Fac Med, Martin 03659, Slovakia	Sivak, S (corresponding author), Comenius Univ, Neurol Clin, Jessenius Fac Med, Kollarova 2, Martin 06359, Slovakia.	sivak@jfmed.uniba.sk	Zelenak, Kamil/X-6293-2018; Sivak, Stefan/O-4237-2018	Zelenak, Kamil/0000-0002-0416-2985; Sivak, Stefan/0000-0002-0348-3082			Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Gaetz M, 2000, BRAIN INJURY, V14, P815; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; NAATANEN R, 1991, PSYCHOPHYSIOLOGY, V28, P478, DOI 10.1111/j.1469-8986.1991.tb00735.x; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31	18	12	14	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					193	197		10.1080/02699050801895431			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600010	18240048				2021-06-18	
J	Stallones, L; Gibbs-Long, J; Gabella, B; Kakefuda, I				Stallones, Lorann; Gibbs-Long, Julie; Gabella, Barbara; Kakefuda, Itsumi			Community readiness and prevention of traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury (TBI); prevention; community readiness; community-based intervention; surveillance	PUBLIC-HEALTH; HEAD-INJURY	Primary objective: The study aimed to understand the readiness of rural communities to engage in community-initiated traumatic brain injury (TBI) prevention. The utility of state-wide TBI surveillance to monitor outcomes of local TBI prevention efforts was also assessed. Research design: A quasi-experimental design was used to evaluate the effects of community-initiated TBI prevention programmes. Methods and procedures: The Community Readiness model was used to assess changes in communities before and after programmes. Four rural counties in Colorado, US, were selected based on population composition and TBI rates. Key informants in each county were interviewed to determine community readiness stages to engage in prevention. The interviews were repeated 2 years later. Results: In two study counties TBI prevention activities were initiated. One county conducted a number of prevention activities and moved from 'vague awareness' to 'preplanning' stage. Three counties moved from 'denial' to 'vague awareness'. TBI surveillance did not capture rate changes in the counties. Conclusions: The Community Readiness model identified counties more likely to engage in prevention and change was observed in readiness where programmes were undertaken as well as in counties where no new programmes were initiated. Detailed local TBI data is necessary to monitor outcomes of community interventions.	[Stallones, Lorann] Colorado State Univ, Dept Psychol, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA; [Gabella, Barbara] Colorado Traumat Brain Injury Surveillance, Colorado Dept Publ Hlth & Environm, Denver, CO USA	Stallones, L (corresponding author), Colorado State Univ, Dept Psychol, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA.	lorann@colostate.edu	Stallones, Lorann/AAC-6248-2021	Stallones, Lorann/0000-0001-7616-582X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR811509] Funding Source: Medline		ALCALDE MG, 2002, CHILD FATALITY REV U; ANISKIEWICZ R, 1990, POLICY STUD REV, V9, P727; Boyd C R, 1989, J Med Assoc Ga, V78, P341; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUKASKI W, 1994, DRUG ABUSE PREVENTIO; *COL DEP PUBL HLTH, COL HLTH INF DAT; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Donnermeyer J. F., 1997, J COMMUNITY DEV SOC, V28, P65; Edwards RW, 2000, J COMMUNITY PSYCHOL, V28, P291, DOI 10.1002/(SICI)1520-6629(200005)28:3<291::AID-JCOP5>3.0.CO;2-9; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GAMM LD, 2004, RURAL HLTH PEOPLE 20, V3; GARKOVICH LE, 1989, LOCAL ORG LEADERSHIP; HALPERIN W, 1992, PUBLIC HLTH SURVEILL; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KELLY KJ, 2003, MARKETING THEORY, V3, P411, DOI DOI 10.1177/1470593103042006; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Marr AL., 2004, CENTRAL NERVOUS SYST; Minkler M., 2003, COMMUNITY BASED PART; NICHOLSON R, 2002, COMMON GROUND COMMON; Nolen Sixten, 2002, Inj Control Saf Promot, V9, P89, DOI 10.1076/icsp.9.2.89.8695; OETTING ER, 1995, INT J ADDICT, V30, P659, DOI 10.3109/10826089509048752; Oetting ER, 2001, SUBST USE MISUSE, V36, P825, DOI 10.1081/JA-100104093; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROGERS EM, 1989, SOCIAL CHANGES RURAL; Rogers Everett M, 1962, DIFFUSION INNOVATION; Roussos ST, 2000, ANNU REV PUBL HEALTH, V21, P369, DOI 10.1146/annurev.publhealth.21.1.369; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 1996, WESTERN J MED, V165, P192; Warren R., 1978, COMMUNITY AM; Ytterstad Borge, 2003, Int J Circumpolar Health, V62, P61	32	12	12	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					555	564		10.1080/02699050802132487			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300006	18568708				2021-06-18	
J	Figaji, AA; Fieggen, AG; Sandler, SJI; Argent, AC; Le Roux, PD; Peter, JC				Figaji, A. A.; Fieggen, A. G.; Sandler, S. J. I.; Argent, A. C.; Le Roux, P. D.; Peter, J. C.			Intracranial pressure and cerebral oxygenation changes after decompressive craniectomy in a child with traumatic brain swelling	CHILDS NERVOUS SYSTEM			English	Article						decompressive craniectomy; cerebral tissue oxygenation; raised intracranial pressure; monitoring; traumatic brain injury; children	SEVERE HEAD-INJURY; TISSUE OXYGEN; INSPIRED OXYGEN; BLOOD-FLOW; HYPERTENSION; CRANIOTOMY; MORTALITY; RELEVANCE; LACTATE	Case report The authors present the case of a 5-year-old child with severe traumatic brain injury in whom decompressive hemicraniectomy was performed for progressive increased intracranial pressure (ICP) unresponsive to medical treatment. Data from ICP and cerebral tissue oxygenation monitoring in the contralateral hemisphere were recorded, which demonstrated the immediate and delayed mechanical and physiological changes occurring after bony and dural decompression. Discussion The role of the procedure and that of the monitoring approach are discussed.	Univ Cape Town, Red Cross Childrens Hosp, Div Neurosurg, Inst Child Hlth, ZA-7700 Cape Town, South Africa; Univ Cape Town, Red Cross Childrens Hosp, Div Pediat Crit Care, Inst Child Hlth, ZA-7700 Cape Town, South Africa; Univ Penn, Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA	Figaji, AA (corresponding author), Univ Cape Town, Red Cross Childrens Hosp, Div Neurosurg, Inst Child Hlth, Klipfontein Rd, ZA-7700 Cape Town, South Africa.	afigaji@ich.uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Fieggen, Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Marshall RS, 2004, CURR OPIN NEUROL, V17, P705, DOI 10.1097/00019052-200412000-00010; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reithmeier T, 2005, ACTA NEUROCHIR, V147, P947, DOI 10.1007/s00701-005-0543-1; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299	21	12	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	NOV	2007	23	11					1331	1335		10.1007/s00381-007-0388-4			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	212TJ	WOS:000249619400018	17632729				2021-06-18	
J	Hiekikanen, H; Kurki, T; Brandstack, N; Kairisto, V; Tenovuo, O				Hiekikanen, Heli; Kurki, Timo; Brandstack, Nina; Kairisto, Veli; Tenovuo, Olli			MRI changes and ApoE genotype, a prospective 1-year follow-up of traumatic brain injury: A pilot study	BRAIN INJURY			English	Article						apolipoprotein E genotype; magnetic resonance imaging; traumatic brain injury	APOLIPOPROTEIN-E POLYMORPHISM; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; PROMOTER POLYMORPHISMS; POSTTRAUMATIC AMNESIA; REGULATORY REGION; GENE; ASSOCIATION; RISK; E4	Primary objective: To examine the association between apolipoprotein E (ApoE) genotype and visibility of traumatic brain lesions during the first year after traumatic brain injury (TBI). Research design: A prospective 1-year follow-up study in unselected victims of TBI. Methods: The number and extent of contusions, ventricular size index and semi-quantitative score of other traumatic intraparenchymal lesions were determined with MRI similar to 1 week and 1 year after TBI and the results were analysed in relation to the ApoE genotype in 33 patients after acute non-trivial TBI. Results: The ApoE genotype was not associated with the visible changes occurring during this follow-up. Conclusions: The presence of ApoE4 was not associated with MRI changes during the first year after TBI. This suggests that if the ApoE4 is associated with an unfavourable outcome after TBI, the processes responsible for the repair of visible lesions are not dependent on ApoE genotype.	[Hiekikanen, Heli; Tenovuo, Olli] Univ Turku, Dept Neurol, Cent Hosp, FIN-20520 Turku, Finland; [Kurki, Timo; Brandstack, Nina] Univ Turku, Dept Radiol, Cent Hosp, FIN-20520 Turku, Finland; [Kairisto, Veli] Univ Turku, Dept Clin Chem, Cent Hosp, FIN-20520 Turku, Finland	Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, Cent Hosp, Kiinanmyllynkatu 4-8, FIN-20520 Turku, Finland.	olli.tenovuo@tyks.fi		Kurki, Timo/0000-0001-5532-3534			Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Berr C, 2001, NEUROBIOL AGING, V22, P227, DOI 10.1016/S0197-4580(00)00227-X; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Donohoe GG, 2000, CLIN CHEM, V46, P1540; Donohoe GG, 1999, CLIN CHEM, V45, P143; EHNHOLM C, 1986, J LIPID RES, V27, P227; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Graham DI, 1999, ACT NEUR S, V73, P89; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; Heesen C, 2006, J NEUROL NEUROSUR PS, V77, P34, DOI 10.1136/jnnp.2005.065805; Heijmans BT, 2002, AM J MED GENET, V107, P201, DOI 10.1002/ajmg.10142; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; JENNETT B, 1975, LANCET, V1, P480; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerr ME, 1999, ADV EXP MED BIOL, V471, P117; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Laws SM, 1999, NEUROREPORT, V10, P879, DOI 10.1097/00001756-199903170-00038; Laws SM, 2002, MOL PSYCHIATR, V7, P886, DOI 10.1038/sj.mp.4001097; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mui S, 1996, NEUROLOGY, V47, P196, DOI 10.1212/WNL.47.1.196; Myllykangas L, 2002, AM J MED GENET, V114, P288, DOI 10.1002/ajmg.10202; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pahnke J, 2003, ACTA NEUROPATHOL, V105, P25, DOI 10.1007/s00401-002-0602-0; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Roks G, 2002, AM J MED GENET, V114, P570, DOI 10.1002/ajmg.10407; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Son BC, 2000, ACT NEUR S, V76, P13; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 2004, J MOL NEUROSCI, V23, P167, DOI 10.1385/JMN:23:3:167; Ti LK, 2003, J THORAC CARDIOV SUR, V125, P211, DOI 10.1067/mtc.2003.123; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401	70	12	12	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2007	21	12					1307	1314		10.1080/02699050701739549			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	249HP	WOS:000252219200010	18236205				2021-06-18	
J	Karon, SL; Lazarus, JAC; Holman, L				Karon, Sarita L.; Lazarus, Jo-Anne C.; Holman, Laurie			Challenges and approaches to the identification of traumatic brain injury among nursing home residents	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; nursing homes; screening; prevalence		The Minimum Data Set (MDS) is a standardized, federally mandated assessment tool used to identify the needs of nursing home residents and rehabilitation and nursing services received on a routine basis. These data can be used to identify people with traumatic brain injury (TBI), where a diagnosis is recorded. However, both limitations of the MDS and the presence of other neurological issues that can be confused with TBI can reduce the likelihood that brain injury is identified where it exists. The article discusses innovative methodological approaches and challenges to using the MDS data to identify people with TBI in nursing homes.	Univ Wisconsin, Ctr Hlth Syst Res & Anal, Madison, WI 53706 USA; Univ Wisconsin, Dept Kinesiol, Madison, WI USA	Karon, SL (corresponding author), Univ Wisconsin, Ctr Hlth Syst Res & Anal, Madison, WI 53706 USA.						BAKKENIST K, 1999, NURS HOMES, V48, P47; BERUBE J, 2003, J HEAD TRAUMA REHAB, V68, P68926; Buchanan RJ, 2003, BRAIN INJURY, V17, P507, DOI 10.1080/0269905031000070215; *CTR MED MED SERV, 2005, MDS QUAL MEAS IND RE; *CTR MED MED SERV, 2007, REV LONG TERM CAR FA; *CTR MED MED SERV, 2004, MDS CURR RES INF REP; *CTR MED MED SERV, MED WAIV DEM LIST; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gabella BA, 2007, J HEAD TRAUMA REHAB, V22, P368, DOI 10.1097/01.HTR.0000300232.98242.ce; Marr AL., 2004, CENTRAL NERVOUS SYST; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	12	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2007	22	6					350	359		10.1097/01.HTR.0000300230.13490.11			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	234RN	WOS:000251181500005	18025967				2021-06-18	
J	Vicente, E; Tramontina, F; Leite, MC; Nardin, P; Silva, M; Karkow, AR; Adolf, R; Lucion, AB; Netto, CA; Gottfried, C; Goncalves, CA				Vicente, Evelin; Tramontina, Francine; Leite, Marina C.; Nardin, Patricia; Silva, Mariane; Karkow, Ana R.; Adolf, Rafael; Lucion, Aldo B.; Netto, Carlos A.; Gottfried, Carmem; Goncalves, Carlos A.			S100b levels in the cerebrospinal fluid of rats are sex and anaesthetic dependent	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						anaesthesia; astrocyte; S100B; sex-dependent glial differentiation; thiopental	TRAUMATIC BRAIN-INJURY; PROTEIN CONCENTRATIONS; CULTURED ASTROCYTES; NEONATAL-RAT; AGE; SERUM; GLUTAMATE; BLOOD; STRESS; NEURODEGENERATION	1. In the present study, we investigated the effect of anaesthetics (thiopental, ketamine and halothane) on CSF concentrations of S100B, as well as a possible sex dependence, because several studies have suggested astrocytes as putative targets for oestrogen. 2. S100B is a calcium-binding protein that acts as a neurotrophic cytokine and is expressed in the central nervous system, predominantly by astrocytes. At nanomolar concentrations, S100B stimulates neurite outgrowth and glial glutamate uptake, as well as protecting neurons against glutamate excitoxicity. 3. Peripheral S100B concentrations, particularly in the serum and cerebrospinal fluid (CSF), have been used as a parameter of glial activation or death in several physiological and pathological conditions. 4. Higher levels of CSF S100B were found when rats were anaesthetized with thiopental; these levels, independently of anaesthetic, were sex dependent. Conversely, no effect of anaesthetic or sex was observed on serum concentrations of S100B. 5. The increase in CSF concentrations of S100B induced by thiopental was confirmed in non-anaesthetized neonatal rats and cortical astrocyte cultures. 6. Assuming CSF S100B as a marker of development, glial activation or even brain damage, investigations regarding the sex dependence of its concentration may be useful in gaining an understanding of sex variations in the behaviour and the pathological course of, as well as susceptibility to, many brain disorders. The findings of the present study reinforce the sex effect on synaptic plasticity and suggest a sex dependence of neural communication mediated by extracellular S100B without restricting the influence of astrocytes on the developmental phase.	Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Post Grad Programmes Neurosci, Porto Alegre, RS, Brazil; Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Post Grad Programmes Biochem, Porto Alegre, RS, Brazil; Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Post Grad Programmes Physiol, Porto Alegre, RS, Brazil	Goncalves, CA (corresponding author), Univ Fed Rio Grande do Sul, ICBS, Dept Bioquim, Ramiro Barcelos,2600-Anxo, Porto Alegre, RS, Brazil.	casg@ufrgs.br	Goncalves, Carlos AS/K-1851-2014; Lucion, Aldo/L-1518-2014; Gottfried, Carmem/AAG-2355-2019	Gottfried, Carmem/0000-0001-8838-1300; Nardin, Patricia/0000-0003-0719-9369; /0000-0002-1907-6051; Netto, Carlos Alexandre/0000-0002-0596-5667			Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Bruschettini M, 2005, DEV BRAIN RES, V159, P113, DOI 10.1016/j.devbrainres.2005.07.003; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; ESOUZA MT, 2000, PHYSIOL BEHAV, V71, P29; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2000, CLIN CHEM, V46, P998; Gerlai R, 1996, NEUROBIOL LEARN MEM, V66, P143, DOI 10.1006/nlme.1996.0055; Gottfried C, 2003, NEUROSCIENCE, V121, P553, DOI 10.1016/S0306-4522(03)00557-8; Hachem S, 2005, GLIA, V51, P81, DOI 10.1002/glia.20184; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Leite MC, 2006, BRAIN RES BULL, V70, P179, DOI 10.1016/j.brainresbull.2006.05.003; Margis R, 2004, BRAIN RES, V1028, P213, DOI 10.1016/j.brainres.2004.09.013; Mong JA, 2006, NEUROSCIENCE, V138, P967, DOI 10.1016/j.neuroscience.2005.10.017; Morale MC, 2006, NEUROSCIENCE, V138, P869, DOI 10.1016/j.neuroscience.2005.07.060; Netto CBO, 2006, ARCH MED RES, V37, P683, DOI 10.1016/j.arcmed.2005.11.005; Nygaard O, 1997, CLIN CHEM, V43, P541; ODowd BS, 1997, NEUROBIOL LEARN MEM, V67, P197, DOI 10.1006/nlme.1997.3766; Portela LVC, 2002, CLIN CHEM, V48, P950; Qu H, 1999, BIOCHEM PHARMACOL, V58, P1075, DOI 10.1016/S0006-2952(99)00175-6; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; SAIJA A, 1989, NEUROPHARMACOLOGY, V28, P997, DOI 10.1016/0028-3908(89)90202-5; Scaccianoce S, 2004, BRAIN RES, V1004, P208, DOI 10.1016/j.brainres.2004.01.028; Schousboe A, 2003, NEUROCHEM RES, V28, P347, DOI 10.1023/A:1022397704922; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tort ABL, 2003, CLIN BIOCHEM, V36, P629, DOI 10.1016/S0009-9120(03)00107-3; Tramontina F, 2006, CELL MOL NEUROBIOL, V26, P81, DOI 10.1007/s10571-006-9099-8; Tramontina F, 2000, BRAIN RES PROTOC, V6, P86, DOI 10.1016/S1385-299X(00)00041-6; Tramontina F, 2006, NEUROCHEM RES, V31, P815, DOI 10.1007/s11064-006-9085-z; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Van den Hove DLA, 2006, NEUROREPORT, V17, P1077, DOI 10.1097/01.wnr.0000223391.74575.c9; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Vicente E, 2004, NEUROTOXICOLOGY, V25, P771, DOI 10.1016/j.neuro.2004.03.001; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x	38	12	12	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	NOV	2007	34	11					1126	1130		10.1111/j.1440-1681.2007.04687.x			5	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	210VK	WOS:000249483500007	17880365				2021-06-18	
J	Chung, RS; Fung, SJ; Leung, YK; Walker, AK; McCormack, GH; Chuah, MI; Vickers, JC; West, AK				Chung, R. S.; Fung, S. J.; Leung, Y. K.; Walker, A. K.; McCormack, G. H.; Chuah, M. I.; Vickers, J. C.; West, A. K.			Metallothionein expression by NG2 glial cells following CNS injury	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						traumatic brain injury; reactive glia; axon regeneration; inhibitory molecules	CHONDROITIN SULFATE PROTEOGLYCAN; NEURITE GROWTH; BRAIN-INJURY; GENE-EXPRESSION; AXON GROWTH; ASTROCYTES; DIFFERENTIATION; REGENERATION; INHIBITION; PATHOLOGY	Metallothionein (MT) expression is rapidly up-regulated following CNS injury, and there is a strong correlation between the presence or absence of MTand improved or impaired (respectively) recovery from such trauma.We now report that a distinct subset of NG2-positive, GFAP-negative glial cells bordering the injury tract express MT following focal injury to the adult rat neocortex. To confirm the ability of these NG2 glial cells to express MT, we have isolated and cultured them and identified that they can express MT following stimulation with zinc. To investigate the functional importance of MT expression by NG2 glial cells, we plated cortical neurons onto these cells and found that expression of MT enhanced the permissivity of NG2 glial cells to neurite outgrowth. Our data suggest that expression of MT by NG2 glial cells may contribute to the overall permissiveness of these cells to axon regeneration.	Univ Tasmania, NeuroRepair Grp, Menzies Res Inst, Hobart, Tas 7001, Australia	Chung, RS (corresponding author), Univ Tasmania, NeuroRepair Grp, Menzies Res Inst, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Chung, Roger/ABF-8395-2020; Walker, Adam Keith/B-7418-2009; Vickers, James C/J-7464-2014; Chuah, Meng Inn/J-7671-2014; Fung, Samantha/C-9660-2011	Walker, Adam Keith/0000-0001-7954-5801; Vickers, James C/0000-0001-5671-4879; Chung, Roger/0000-0002-9286-947X			Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Carrasco J, 2006, NEUROSCIENCE, V143, P911, DOI 10.1016/j.neuroscience.2006.08.054; Chen ZJ, 2002, J NEUROCYTOL, V31, P481, DOI 10.1023/A:1025791614468; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; de Castro R, 2005, EXP NEUROL, V192, P299, DOI 10.1016/j.expneurol.2004.11.027; DOU CL, 1994, J NEUROSCI, V14, P7616; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Jones LL, 2003, J NEUROSCI, V23, P9276; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Kohler LB, 2003, BRAIN RES, V992, P128, DOI 10.1016/j.brainres.2003.08.049; Nielsen JA, 2004, MOL CELL NEUROSCI, V25, P111, DOI 10.1016/j.mcn.2003.10.001; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 2001, EXP NEUROL, V170, P1, DOI 10.1006/exnr.2001.7675; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2006, FEBS J, V273, P1857, DOI 10.1111/j.1742-4658.2006.05207.x; Shearer MC, 2003, MOL CELL NEUROSCI, V24, P913, DOI 10.1016/j.mcn.2003.09.004; Stankovic RK, 2007, INT J BIOCHEM CELL B, V39, P484, DOI 10.1016/j.biocel.2006.09.010; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; Ughrin YM, 2003, J NEUROSCI, V23, P175; West AK, 2004, REV NEUROSCIENCE, V15, P157; Xie T, 2004, J NEUROSCI, V24, P7043, DOI 10.1523/JNEUROSCI.1626-04.2004; Yang ZS, 2006, J NEUROSCI, V26, P3829, DOI 10.1523/JNEUROSCI.4247-05.2006	28	12	12	0	5	BIRKHAUSER VERLAG AG	BASEL	VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	OCT	2007	64	19-20					2716	2722		10.1007/s00018-007-7267-8			7	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	225SQ	WOS:000250538200023	17896077				2021-06-18	
J	Lew, HL; Thomander, D; Gray, M; Poole, JH				Lew, Henry L.; Thomander, Darryl; Gray, Max; Poole, John H.			The effects of increasing stimulus complexity in event-related Potentials and reaction time testing: Clinical applications in evaluating patients with traumatic brain injury	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						event related potential; P300; reaction time; traumatic brain injury; posttraurnatic amnesia	MILD HEAD-INJURY; BIOLOGICAL DETERMINANTS; P300; RECOVERY; ERP; PERFORMANCE; MODERATE; LATENCY; TASK	This study compared the effectiveness of P300 event related potentials (ERPs) and reaction time (RT) in discriminating patients with traumatic brain injury (TBI) from healthy control subjects. In particular, we examined how the use of more complex, ecologically relevant stimuli may affect the clinical utility of these tasks. We also evaluated how length of posttraumatic amnesia (PTA) and loss of consciousness (LOC) related to P300 and RT measures in our patient sample. There were 22 subjects (I I patients with TBI and I I age-matched healthy control subjects). Four stimulus detection procedures were used: two using simple, conventional stimuli (auditory tone discrimination, AT; visual color discrimination, VC), and two using complex, ecologically relevant stimuli in the auditory and visual modalities (auditory word category discrimination, AWC; visual facial affect discrimination, VFA). Our results showed that RT measures were more effective in identifying TBI patients when complex stimuli were used (AWC and VFA). On the other hand, ERP measures were more effective in identifying TBI patients when simple stimuli were used (AT and VC). We also found a remarkably high correlation between duration of PTA and P300 amplitude.	VAPAHCS, PM&R Serv, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; VA Palo Alto Hlth Care Syst, Def & Vet & Brain Injury Ctr, Palo Alto, CA USA; VA Palo Alto Hlth Care Syst, Dept Psychol, Palo Alto, CA USA	Lew, HL (corresponding author), VAPAHCS, PM&R Serv, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.	henrylew@stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD01097] Funding Source: Medline		Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; CARDENAS V, 1996, BRAIN INJURY, V10, P79; CICERONE K, 2006, BRAIN INJURY, V10, P79; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Eger E, 2003, NEUROPSYCHOLOGIA, V41, P808, DOI 10.1016/S0028-3932(02)00287-7; Ekman P., 1976, PICTURES FACIAL AFFE; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; Hogan AM, 2006, BRAIN, V129, P2177, DOI 10.1093/brain/awl160; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lew HL, 2006, J HEAD TRAUMA REHAB, V21, P350, DOI 10.1097/00001199-200607000-00006; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; Novitski N, 2004, COGNITIVE BRAIN RES, V20, P26, DOI 10.1016/j.cogbrainres.2003.12.011; Ohnuma A, 1994, Rinsho Shinkeigaku, V34, P5; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Viggiano MP, 1996, J CLIN EXP NEUROPSYC, V18, P631, DOI 10.1080/01688639608408288; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; WAYMAN JW, 1992, J ACOUST SOC AM, V91, P3527, DOI 10.1121/1.402841	34	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	OCT	2007	24	5					398	404		10.1097/WNP.0b013e318150694b			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	221FS	WOS:000250213400005	17912064				2021-06-18	
J	Bennouna, M; Greene, VB; Defranoux, L				Bennouna, M.; Greene, V. B.; Defranoux, L.			Cholinergic hypothesis in psychosis following traumatic brain injury and cholinergic hypothesis in schizophrenia: a link?	ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE			French	Article						acetylcholine; acetylcholinesterase inhibitors; Galantamine; schizophrenia; schizophrenia-like psychosis; traumatic brain injury	MUSCARINIC RECEPTOR-BINDING; CLOSED-HEAD INJURY; ACETYLCHOLINE-RELEASE; ADJUVANT GALANTAMINE; SUSTAINED ATTENTION; NEGATIVE SYMPTOMS; PATIENT; CORTEX; RIVASTIGMINE; DISORDER	Introduction - While traumatic brain injury is a major public health issue, schizophrenia-like psychosis following traumatic brain injury is relatively rare and poorly studied. Yet the risk of developing schizophrenia-like psychosis after traumatic brain injury is 3 times more important than in the general population. Literature findings - Risk factors associated with onset of psychosis after traumatic brain injury include: left hemispheric lesions, closed head injury and coma of duration superior to 24 hours. Most patients develop symptoms of psychosis after a moderate to severe traumatic brain injury and often have lesions of the frontal and temporal lobes. Cholinergic hypothesis: arguments - Neuropathologic, electrophysiological and pharmacologic evidence show that cognitive impairment including attention, memory and executive functioning impairment may be related with cholinergic dysfunction in patients with traumatic brain injury. The cholinergic hypothesis is also incriminated in the genesis of schizophrenia. The same biochemical disorders found in schizophrenia which imply many neurotransmitters are often present immediately after traumatic brain injury. However in chronic cognitive disorders secondary to traumatic brain injury, the cholinergic system alone seems to be specifically implied. This is due to the fragility of the cholinergic fibres and a chronic yet reversible reduction of the cholinergic reserves after traumatic brain injury. Cholinergic function can be studied by the P50 evoked response to paired auditory stimuli. While this is disturbed in patients presenting with cognitive impairment after traumatic brain injury its normalisation can be obtained after administration of an acetylcholine esterase inhibitor. In schizophrenic patients there is also an abnormal P50 evoked response due in part to a low number of alpha 7 nicotinic receptors which are implicated in sensory filtering in the frontal lobe. Moreover in schizophrenia, post-mortem studies show a negative correlation between the activity of acetylcholine transferase in the parietal cortex and the severity of the cognitive deficits, as well as a lesser density of the muscarinic M1 and M4 receptors in the frontal lobe. The lower concentration of M1 receptors in the frontal cortex is correlated with the severity of the positive symptoms. Therapeutical perspectives - Antipsychotics have emerged as the first line treatment of psychotic disorders. In research, their ability for enhancing cognitive function could result in the increase of acetylcholine in the medial prefrontal cortex. Acetylcholinesterase inhibitors have been widely used for treatment of cognitive impairment in Alzheimer's disease. Galantamine could be interesting in schizophrenia and psychosis following traumatic brain injury because it has a dual mechanism of action: selective competitive inhibition of acetylcholinesterase and allosteric potentialisation of nicotinic receptor response. Therefore Galantamine remains active in nicotine addicted schizophrenic patients who may smoke as an auto treatment. Galantamine has shown efficacy in adjunction to Risperidone in one patient presenting with psychosis following traumatic brain injury and in 3 case reports of schizophrenic patients. Conclusion - Further systematic studies are needed to confirm this hypothesis.	[Bennouna, M.] CHS Sarreguemines, F-57206 Sarreguemines, France; [Defranoux, L.] CHU Strasbourg, Chef Serv 2E Secteur, Strasbourg, France	Bennouna, M (corresponding author), CHS Sarreguemines, 3E Secteur,1 Rue Calmette, F-57206 Sarreguemines, France.						Aasen I, 2005, J CLIN PSYCHOPHARM, V25, P311, DOI 10.1097/01.jcp.0000169267.36797.76; ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Allen T, 2003, 11 C INT PSYCH ASS I; Allen TB, 2002, AM J PSYCHIAT, V159, P1244, DOI 10.1176/appi.ajp.159.7.1244; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Arnold DS, 2004, J CLIN PSYCHIAT, V65, P1723, DOI 10.4088/JCP.v65n1219e; Bennouna M, 2005, J CLIN PSYCHOPHARM, V25, P505, DOI 10.1097/01.jcp.0000177851.31157.66; Bora E, 2005, CLIN NEUROPHARMACOL, V28, P139, DOI 10.1097/01.wnf.0000162555.68729.04; Butler PV, 2000, AUST NZ J PSYCHIAT, V34, P684, DOI 10.1046/j.1440-1614.2000.00758.x; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Crook JM, 2001, AM J PSYCHIAT, V158, P918, DOI 10.1176/appi.ajp.158.6.918; DAVISON K, 1969, BRIT J PSYCHIAT, V114, P113; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Drimer T, 2004, INT CLIN PSYCHOPHARM, V19, P27, DOI 10.1097/00004850-200401000-00005; Friedman JI, 2004, PSYCHOPHARMACOLOGY, V174, P45, DOI 10.1007/s00213-004-1794-x; Fujii D, 2004, J NEUROPSYCH CLIN N, V16, P306, DOI 10.1176/appi.neuropsych.16.3.306; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Guan ZZ, 1999, NEUROREPORT, V10, P1779, DOI 10.1097/00001756-199906030-00028; Ichikawa J, 2002, NEUROPSYCHOPHARMACOL, V26, P325, DOI 10.1016/S0893-133X(01)00312-8; KANE JM, 1982, ARCH GEN PSYCHIAT, V39, P473; KRAEPELIN E, 1919, DEMEMTIA PRAECOX PAR; LADDOMADA A, 1999, EUR NEUROPSYCHOPHARM, V9, P257; Lawrie SM, 2002, BIOL PSYCHIAT, V51, P1008, DOI 10.1016/S0006-3223(02)01316-1; Lenzi A, 2003, CLIN NEUROPHARMACOL, V26, P317, DOI 10.1097/00002826-200311000-00011; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Lovell Mark R., 1994, P133; McAllister TW, 2002, NEUROREHABILITATION, V17, P357; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nelson CL, 2002, PSYCHOPHARMACOLOGY, V161, P168, DOI 10.1007/s00213-002-1004-7; Nomikos GG, 2000, BEHAV BRAIN RES, V113, P97, DOI 10.1016/S0166-4328(00)00204-7; Powchik P, 1998, SCHIZOPHRENIA BULL, V24, P325, DOI 10.1093/oxfordjournals.schbul.a033330; Raedler TJ, 1998, CURR OPIN NEUROBIOL, V8, P157, DOI 10.1016/S0959-4388(98)80019-6; Raedler TJ, 2003, AM J PSYCHIAT, V160, P118, DOI 10.1176/appi.ajp.160.1.118; Rosse RB, 2002, CLIN NEUROPHARMACOL, V25, P272, DOI 10.1097/00002826-200209000-00010; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; TANDON R, 1992, PSYCHOPHARMACOL BULL, V28, P297; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Umansky R, 2000, INT J NEUROPSYCHOPH, V3, P81, DOI 10.1017/S1461145700001723; VONFRAFTEBING R, 1868, UEBER DURCH GEHIRNER	43	12	13	0	5	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0013-7006			ENCEPHALE	Enceph.-Rev. Psychiatr. Clin. Biol. Ther.	SEP	2007	33	4					616	620					5	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	257IX	WOS:000252793600013	18033152				2021-06-18	
J	Keiski, MA; Shore, DL; Hamilton, JM				Keiski, Michelle A.; Shore, Douglas L.; Hamilton, Joanna M.			The role of depression in verbal memory following traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						depression; memory; traumatic brain injury	MAJOR DEPRESSION; LEARNING TEST; HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; SUBCORTICAL DYSFUNCTION; CLINICAL DEPRESSION; RECOGNITION MEMORY; PREFRONTAL CORTEX; TEST-PERFORMANCE; EPISODIC MEMORY	The purpose of this study was to characterize the relationship between verbal memory and depression scores on the Personality Assessment Inventory folio wing traumatic brain injury. Depression was associated with diminished delayed recall and recognition on the California Verbal Learning Test-H (CVLT-II), even after controlling for a neuropsychological composite score and/or a measure of motivation (i.e., the TOMM). There was no relationship between depression and recall on Verbal Paired Associates or Logical Memory when controlling for the same covariates. The findings were most consistent with depressed subjects failing to utilize the semantic organization of the CVLT-II list to enhance their learning.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada	Keiski, MA (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	keiski@uwindsor.ca					ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; [Anonymous], 1997, WECHSLER MEMORY SCAL; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOONE KB, 1995, NEUROPSYCHOLOGY, V9, P390, DOI 10.1037/0894-4105.9.3.390; BRAND AN, 1992, J AFFECT DISORDERS, V25, P77, DOI 10.1016/0165-0327(92)90095-N; CALEV A, 1985, BRIT J CLIN PSYCHOL, V24, P127, DOI 10.1111/j.2044-8260.1985.tb01323.x; CHANNON S, 1993, J ABNORM PSYCHOL, V102, P323, DOI 10.1037/0021-843X.102.2.323; COHEN RM, 1982, ARCH GEN PSYCHIAT, V39, P593; Coleman EA, 1996, BIOL PSYCHIAT, V39, P346, DOI 10.1016/0006-3223(95)00185-9; COUGHLAN AK, 1984, BRIT J PSYCHIAT, V145, P164, DOI 10.1192/bjp.145.2.164; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DOLAN RJ, 1994, PSYCHOL MED, V24, P849, DOI 10.1017/S0033291700028944; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fletcher PC, 1998, BRAIN, V121, P1239, DOI 10.1093/brain/121.7.1239; FOSSATI P, 1995, ENCEPHALE, V21, P295; GASS CS, 1986, J CONSULT CLIN PSYCH, V54, P261, DOI 10.1037/0022-006X.54.2.261; GOLINKOFF M, 1989, J AFFECT DISORDERS, V17, P105, DOI 10.1016/0165-0327(89)90032-3; Grant MM, 2001, BIOL PSYCHIAT, V50, P35, DOI 10.1016/S0006-3223(00)01072-6; Heaton R.K., 1991, COMPREHENSIVE NORMS; HERTEL PT, 1990, J EXP PSYCHOL GEN, V119, P45, DOI 10.1037/0096-3445.119.1.45; Hertel PT, 2000, PSYCHOL LEARN MOTIV, V39, P47, DOI 10.1016/S0079-7421(00)80030-4; ILSLEY JE, 1995, J AFFECT DISORDERS, V35, P1, DOI 10.1016/0165-0327(95)00032-I; Kramer JH, 2005, NEUROPSYCHOLOGY, V19, P799, DOI 10.1037/0894-4105.19.6.799; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Morey LC, 1991, PERSONALITY ASSESMEN; NEWMAN PJ, 1986, INT J CLIN NEUROPSYC, V8, P109; NEWMAN PJ, 1992, HDB NEUROPSYCHOLOGIC, P263; Nitschke JB, 2004, BIOL PSYCHOL, V67, P125, DOI 10.1016/j.biopsycho.2004.03.004; Novack TA, 2000, BRAIN INJURY, V14, P987; OTTO MW, 1994, ARCH CLIN NEUROPSYCH, V9, P81, DOI 10.1016/0887-6177(94)90016-7; Payne HC, 2000, BRAIN INJURY, V14, P479, DOI 10.1080/026990500120583; PRIGATANO GP, 1987, NEUROBEHAVIORAL RECO, P216; Purcell R, 1997, PSYCHOL MED, V27, P1277, DOI 10.1017/S0033291797005448; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; RICHARDS PM, 1989, J CONSULT CLIN PSYCH, V57, P396, DOI 10.1037/0022-006X.57.3.396; RUTTAN LA, 1998, DISSERTAION ABSTRACT, V59, P2432; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; SWEET JJ, 1992, CLIN PSYCHOL REV, V12, P21, DOI 10.1016/0272-7358(92)90090-U; TABACHNICK BG, 2001, USING MULIVARIATE ST; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; VEIEL HOF, 1997, J CLIN ECPT NEUROPSY, V19, P487; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; WOLFE J, 1987, J AFFECT DISORDERS, V13, P83, DOI 10.1016/0165-0327(87)90077-2; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	59	12	12	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2007	21	5					744	761		10.1080/13854040600775346			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	210KO	WOS:000249455300002	17676541				2021-06-18	
J	Campbell, KA; Berger, RP; Ettaro, L; Roberts, MS				Campbell, Kristine A.; Berger, Rachel P.; Ettaro, Lorraine; Roberts, Mark S.			Cost-effectiveness of head computed tomography in infants with possible inflicted traumatic brain injury	PEDIATRICS			English	Article						abuse; shaken-baby syndrome; cost-effectiveness; computed tomography	QUALITY-OF-LIFE; CHILD-ABUSE; YOUNG-CHILDREN; ECONOMIC-ANALYSIS; CARE PROVIDERS; HEALTH-STATUS; OUTCOMES; INTERVENTIONS; HEMORRHAGES; PARENTS	Objective. Early diagnosis of inflicted traumatic brain injury may reduce morbidity and mortality associated with repeated inflicted traumatic brain injuries. We undertook this study to estimate the cost-effectiveness of a policy of head computed tomography (CT) for inflicted traumatic brain injury in selected infants seen in an emergency department. Methods. We constructed Markov models to compare a policy of CT to no CT in an asymptomatic 5-week-old infant with either (1) unexplained scalp bruising or (2) a history of an apparent life-threatening event. Health states modeled were no inflicted traumatic brain injury, misdiagnosed inflicted traumatic brain injury, mild inflicted traumatic brain injury (diagnosed or undiagnosed), and severe and fatal inflicted traumatic brain injury. Infants with undiagnosed inflicted traumatic brain injury were at increased risk of repeat inflicted traumatic brain injury. We used available literature to estimate probabilities, costs, and outcomes. The models terminated at death or at 52 weeks of age. Outcomes considered were severe and fatal inflicted traumatic brain injury cases averted through early detection of mild inflicted traumatic brain injury. Data Sources. We conducted a literature review for estimates of inflicted traumatic brain injury incidence, outcome probabilities, and medical and societal costs. Wide ranges were set for sensitivity and Monte Carlo analyses. Results. From a medical payer perspective, head CT for inflicted traumatic brain injury in infants with unexplained scalp bruising saved money. Sensitivity analysis demonstrated costs less than $50 000 per severe or fatal inflicted traumatic brain injury averted in scenarios in which initial inflicted traumatic brain injury prevalence was > 3%. From a societal perspective, costs of child protection made head CT for inflicted traumatic brain injury more expensive. Conclusions. From a medical payer perspective, our models demonstrate that CT for inflicted traumatic brain injury can be cost-effective and improve outcomes. The finding of higher societal cost reflects the substantial short-term costs of child protection. Our study supports a low medical threshold for CT screening and highlights the need for improved understanding of long-term costs and outcomes of child abuse.	Univ Utah, Dept Pediat, Div Safe & Healthy Families, Salt Lake City, UT 84158 USA; Childrens Hosp Pittsburgh, Div Child Advocacy, Dept Pediat, Pittsburgh, PA USA; Univ Pittsburgh, Ctr Rural Hlth Practice, Bradford, PA, England; Univ Pittsburgh, Div Gen Internal Med, Sect Decis Sci, Div Gen Internal Med, Bradford, PA, England; Univ Pittsburgh, Div Gen Internal Med, Clin Syst Modeling, Div Gen Internal Med, Bradford, PA, England	Campbell, KA (corresponding author), Univ Utah, Dept Pediat, Div Safe & Healthy Families, 296 Chipeta Way,Box 581289, Salt Lake City, UT 84158 USA.	kristine.campbell@hsc.utah.edu			NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [D55HP05156-01-00] Funding Source: Medline		ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ARMSTRONG KA, 1983, CHILD WELFARE, V62, P3; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; BENEDICT MI, 1994, CHILD ABUSE NEGLECT, V18, P577, DOI 10.1016/0145-2134(94)90084-1; Bennett JE, 2000, ARCH PEDIAT ADOL MED, V154, P43; Bishop S J, 2001, Child Maltreat, V6, P243, DOI 10.1177/1077559501006003005; BOPP K, 1997, EC COSTS SBS SURVIVO; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brenner RA, 1999, PEDIATRICS, V103, P968, DOI 10.1542/peds.103.5.968; Carty H, 2002, EUR RADIOL, V12, P2919, DOI 10.1007/s00330-002-1436-9; Corso PS, 2006, CHILD ABUSE NEGLECT, V30, P727, DOI 10.1016/j.chiabu.2005.12.006; Courtney ME, 1999, CHILD ABUSE NEGLECT, V23, P975, DOI 10.1016/S0145-2134(99)00073-3; Courtney ME, 1998, FUTURE CHILD, V8, P88, DOI 10.2307/1602630; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUBOWITZ H, 1990, CHILD ABUSE NEGLECT, V14, P177, DOI 10.1016/0145-2134(90)90029-S; Erly WK, 2003, AM J ROENTGENOL, V180, P1727, DOI 10.2214/ajr.180.6.1801727; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Flaherty EG, 2000, ARCH PEDIAT ADOL MED, V154, P489, DOI 10.1001/archpedi.154.5.489; Glaser AW, 1997, QUAL LIFE RES, V6, P43; GOLD MR, 1996, COSTEFFECTIVENESS HL; GOULD MS, 1995, CHILD MALTREATMENT C; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Griebsch I, 2005, PEDIATRICS, V115, pE600, DOI 10.1542/peds.2004-2127; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Irazuzta JE, 1997, CHILD ABUSE NEGLECT, V21, P751, DOI 10.1016/S0145-2134(97)00036-7; Ireys HT, 1997, PEDIATRICS, V100, P197, DOI 10.1542/peds.100.2.197; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; JELLINEK MS, 1995, CHILD ABUSE NEGLECT, V19, P1051, DOI 10.1016/0145-2134(95)00067-I; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lavin A, 1999, JAMA-J AM MED ASSOC, V282, P1421, DOI 10.1001/jama.282.15.1421; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Miller T.R., 1990, J FORENSIC EC, V3, P17; Morad Y, 2004, J AAPOS, V8, P445, DOI 10.1016/j.jaapos.2004.06.007; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Panepinto JA, 2000, J PEDIATR-US, V136, P201, DOI 10.1016/S0022-3476(00)70102-8; Pitetti RD, 2002, PEDIATRICS, V110, P557, DOI 10.1542/peds.110.3.557; Plotnick RD, 1999, CHILD WELFARE, V78, P381; Quinn GE, 2004, ARCH OPHTHALMOL-CHIC, V122, P1659; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; RIVARA FP, 1985, CHILD ABUSE NEGLECT, V9, P81, DOI 10.1016/0145-2134(85)90095-X; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Saigal S, 1999, JAMA-J AM MED ASSOC, V281, P1991, DOI 10.1001/jama.281.21.1991; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; Sane SM, 2000, PEDIATRICS, V105, P1345; SCARCELLA CA, 2004, COST PROTECTING VULN; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; *US DEP HHS, 2006, CHILD MALTR 2004; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; VISCUSI WK, 1993, J ECON LIT, V31, P1912	57	12	12	1	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2007	120	2					295	304		10.1542/peds.2007-0437			10	Pediatrics	Pediatrics	196SY	WOS:000248503500006	17671055				2021-06-18	
J	Doi, R; Morita, K; Shigemori, M; Tokutomi, T; Maeda, H				Doi, R.; Morita, K.; Shigemori, M.; Tokutomi, T.; Maeda, H.			Characteristics of cognitive function in patients after traumatic brain injury assessed by visual and auditory event-related potentials	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; event-related potentials; visual and auditory stimuli; facial affect	CLOSED-HEAD-INJURY; FACIAL AFFECT RECOGNITION; P300; STIMULI	Objective: Using auditory and visual stimuli including facial affective stimuli, we analyzed the P300 components of event-related potentials (ERPs) in patients after traumatic brain injury (TBI) to assess their cognitive characteristics. Design: Twenty TBI patients and 32 age-matched control subjects were recruited. Using conventional oddball paradigms, visual ERPs were recorded using images of crying and smiling babies as visual stimuli. Auditory ERPs were obtained using 2-kHz tones as stimuli without affective stimuli. The peak amplitude and latency for P300, and the latency for N200, were recorded. Results: In visual ERPs, the P300 amplitudes were significantly smaller in patients than in controls for the crying baby, but the amplitudes were similar between groups for the smiling baby. Controls showed smaller P300 amplitudes for the smiling baby than for the crying baby, but patients showed no, difference. In patients, the P300 latency for both smiling and crying babies was longer than in the controls. Patients' auditory ERPs showed smaller P300 amplitudes but similar P300 latencies compared with controls. The N200 latency In patients was significantly longer than in controls only for the crying baby. Conclusions: Visual ERPs are a potentially useful marker for evaluating cognitive dysfunction in patients after TBI.	Kurume Univ, Sch Med, Cognit & Mol Res Inst & Neuropsychiat, Dept Neurosurg, Kurume, Fukuoka 830, Japan	Morita, K (corresponding author), Kurume Univ, Sch Med, Cognit & Mol Res Inst & Neuropsychiat, Dept Neurosurg, Asahimachi67, Kurume, Fukuoka 830, Japan.				Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591617, 19591383] Funding Source: KAKEN		CAMPBELL K, 1986, ELECTROENCEPHALOGR C, V38, P48; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; JOHNSTON VS, 1986, PSYCHOPHYSIOLOGY, V23, P684, DOI 10.1111/j.1469-8986.1986.tb00694.x; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; LANG SF, 1990, J CLIN EXP NEUROPSYC, V12, P946, DOI 10.1080/01688639008401033; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Maeda H, 1996, BIOL PSYCHIAT, V39, P743, DOI 10.1016/0006-3223(95)00612-5; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Mazzini Letizia, 2004, Phys Med Rehabil Clin N Am, V15, P163, DOI 10.1016/S1047-9651(03)00101-3; Morita Y, 2001, NEUROSCI RES, V41, P89, DOI 10.1016/S0168-0102(01)00248-6; Muller SV, 2002, ARCH PHYS MED REHAB, V83, P115, DOI 10.1053/apmr.2002.27472; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; POLICH J, 1991, American Journal of EEG Technology, V31, P201; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; PRICHARD WS, 1986, PSYCHOL BULL, V100, P43; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; Yamamoto Masashi, 2000, Kurume Medical Journal, V47, P285; YEE CM, 1987, CURRENT TRENDS EVE S, V40, P300	27	12	15	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2007	86	8					641	649		10.1097/PHM.0b013e318115aca9			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	194ZX	WOS:000248383400006	17667194				2021-06-18	
J	Jacka, MJ; Zygun, D				Jacka, Michael J.; Zygun, David			Survey of management of severe head injury in Canada	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; GUIDELINES; HYPERVENTILATION	Objective: To determine: 1. the degrees of consensus and disagreement among Canadian critical care clinicians regarding the appropriateness (benefit exceeding risk) of common therapeutic manoeuvres in patients with severe closed head injury (CHI), and 2. the frequency with which clinicians employed these manoeuvres. Methods: The study design was a systematic scenario-based survey of all neurosurgeons and critical care physicians treating patients with severe CHI in Canada. Results: In the scenario of acute epidural hematoma with mass effect, respondents agreed very strongly that surgery was appropriate. Clinicians reported mannitol and hypertonic saline as appropriate. Beyond these two interventions, agreement was less strong, and the use of the extraventricular drain (EVD), phenytoin, cooling, hyperventilation, nimodipine, and jugular venous oximetry (JVO) were of uncertain appropriateness. Steroids were considered inappropriate. In a scenario of diffuse axonal injury (DAI), clinicians agreed strongly that fever reduction, early enteral feeding, intensive glucose control, and cerebral perfusion pressure (CPP)-directed management were appropriate. The use of mannitol, hypertonic saline, EVD, JVO, narcotics and propofol were also appropriate. Neuromuscular blockade, surgery, and hyperventilation were of uncertain appropriateness. The appropriateness ratings of the interventions considered in the scenario of an intracranial contusion mirrored the DAI scenario. In general, correlations between the reported appropriateness and frequency of use of each intervention were very high. An exception noted was the use of the JVO. The correlation between CPP-guided therapy and the use of the EVD was weak. Conclusions: This survey has described current practice with regard to treatment of patients with severe CHI. Areas of variation in perceived appropriateness were identified that may benefit from further evaluation. Suggested priorities for evaluation include the use of osmotic diuretics, anticonvulsants, and intracranial manometry.	Univ Alberta, Dept Anesthesiol, Div Crit Care, Edmonton, AB T6G 2M7, Canada; Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada	Jacka, MJ (corresponding author), Univ Alberta, WCM HSC, GSICU, 112 St NW, Edmonton, AB T6G 2B7, Canada.						Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Hutchinson PJ, 2005, ACTA NEUROCHIR SUPPL, V95, P441; Kerr J, 2005, EMERG MED J, V22, P850, DOI 10.1136/emj.2004.022673; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; Price SJ, 2003, INJURY, V34, P834, DOI 10.1016/S0020-1383(03)00028-7; Sekula Raymond F Jr, 2005, Clin Neurosurg, V52, P306; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930; 2000, J NEUTOTRAUMA, V17, P450	18	12	12	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	AUG	2007	34	3					307	312		10.1017/S0317167100006727			6	Clinical Neurology	Neurosciences & Neurology	199BD	WOS:000248670300008	17803027				2021-06-18	
J	Philbin, N; Handrigan, M; Rice, J; McNickle, K; McGwin, G; Williams, R; Warndorf, M; Arnaud, F; Malkevich, N; McCarron, R; Freilich, D				Philbin, Nora; Handrigan, Michael; Rice, Jennifer; McNickle, Kyle; McGwin, Gerald; Williams, Rita; Warndorf, Mathew; Arnaud, Francoise; Malkevich, Nina; McCarron, Richard; Freilich, Daniel			Resuscitation following severe, controlled hemorrhage associated with a 24 h delay to surgical intervention in swine using a hemoglobin based oxygen carrier as an oxygen bridge to definitive care	RESUSCITATION			English	Article						hemorrhage; trauma; hypovolemic shock; resuscitation; HBOC-201; swine	BOVINE POLYMERIZED HEMOGLOBIN; TRAUMATIC BRAIN-INJURY; LIVER-INJURY; VOLUME RESUSCITATION; COMBAT CASUALTIES; HETASTARCH HEX; BLOOD-LOSS; HBOC-201; MODEL; SHOCK	Objectives: To test our hypothesis that the hemoglobin based oxygen carrier HBOC-201 would have similar or superior efficacy to 6% hetastarch (HEX) as a pre-hospital 'bridging' fluid for hemorrhagic shock when delay to definitive medical care is prolonged to 24 h. Methods: Twenty-four pigs were anesthetized, instrumented, given a soft tissue injury, and bled 55% estimated blood volume. Pigs were randomized to receive HBOC-201, HEX, or no resuscitation fluids (NON). At 4h post-injury, surgical sites were repaired and pigs were recovered from anesthesia. Animals were non-invasively monitored, administered blood for anemia or saline for hypotension at 24 and 48 h, and monitored for 72 h. Results: Survival to 72 h was 87.5% (7/8) in HBOC-201 and HEX pigs compared to 25% (2/8) in NON pigs (p=0.01). Increased mean arterial pressure was observed in the HBOC-201 group (p < 0.0001). Cardiac index was highest in HEX pigs (overall p < 0.001, HBOC-201 versus HEX p = 0.002). Transcutaneous tissue oxygenation was higher with HBOC-201 (overall p = 0.04, HBOC-201 versus HEX p < 0.01). HBOC-201 and HEX pigs had comparable heart rates, pulmonary pressures, pre-hospital fluid requirements, venous O-2 saturation, base deficit, and lactic acid. Hemoglobin was decreased with HEX (overall p < 0.0001, HBOC-201 versus HEX p < 0.0002). At 24 h, 14.3% (1/7) HBOC-201 pigs required blood transfusions versus 100% HEX (7/7) and NON (2/2) pigs (p > 0.001). Conclusions: HBOC-201 restored hemodynamics, maintained tissue oxygenation, and decreased blood transfusions in comparison to HEX in severe controlled HS with 24h delay to simulated hospital care. These results support the potential use of HBOC-201 as a bridging resuscitation fluid for HS. (C) 2007 Published by Elsevier Ireland Ltd.	Naval Med Res Ctr, Silver Spring, MD USA; Univ Alabama Birmingham, Birmingham, AL USA	Handrigan, M (corresponding author), Naval Med Res Ctr, Combat Casulaty Care, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Handriganm.ctr@nmrc.navy.mil					Arnoldo B D, 2001, Curr Opin Crit Care, V7, P431, DOI 10.1097/00075198-200112000-00010; Balogh Z, 2005, J TRAUMA, V58, P778, DOI 10.1097/01.TA.0000158251.40760.B2; Fitzpatrick CM, 2004, J AM COLL SURGEONS, V199, P693, DOI 10.1016/j.jamcollsurg.2004.07.025; Fitzpatrick MCM, 2005, J TRAUMA, V59, P273, DOI 10.1097/01.ta.0000174730.62338.88; Gould SA, 2002, J AM COLL SURGEONS, V195, P445, DOI 10.1016/S1072-7515(02)01335-2; Gurney J, 2004, J TRAUMA, V57, P726, DOI 10.1097/01.TA.0000147520.84792.B4; Hall RI, 2005, CAN J ANAESTH, V52, P895, DOI 10.1007/BF03022048; Handrigan MT, 2005, SHOCK, V23, P337, DOI 10.1097/01.shk.0000156667.04628.1f; Hiippala S, 1998, VOX SANG, V74, P399, DOI 10.1111/j.1423-0410.1998.tb05449.x; Kaplan LJ, 2006, J TRAUMA, V61, P90, DOI 10.1097/01.ta.0000222578.85413.4e; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; Lee SK, 2002, ACAD EMERG MED, V9, P969; Levy JH, 2003, EXPERT OPIN BIOL TH, V3, P509, DOI 10.1517/14712598.3.3.509; Levy JH, 2002, J THORAC CARDIOV SUR, V124, P35, DOI 10.1067/mtc.2002.121505; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; Martel Marie-Jocelyne, 2002, J Obstet Gynaecol Can, V24, P504; McNeil JD, 2001, J TRAUMA, V50, P1063, DOI 10.1097/00005373-200106000-00015; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Philbin N, 2005, RESUSCITATION, V66, P367, DOI 10.1016/j.resuscitation.2005.03.019; Rhee P, 2003, J TRAUMA, V54, pS52, DOI 10.1097/01.TA.0000064507.80390.10; RICE J, 2006, P 35 CRIT CAR C SOC; Rice J, 2006, SHOCK, V26, P302, DOI 10.1097/01.shk.0000226338.48033.c2; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F	27	12	16	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	AUG	2007	74	2					332	343		10.1016/j.resuscitation.2006.12.018			12	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	236EP	WOS:000251286100019	17383073				2021-06-18	
J	Kreipke, CW; Morgan, R; Roberts, G; Bagchi, M; Rafols, JA				Kreipke, Christian W.; Morgan, Randy; Roberts, George; Bagchi, Mihir; Rafols, Jose A.			Calponin phosphorylation in cerebral cortex microvessels mediates sustained vasoconstriction after brain trauma	NEUROLOGICAL RESEARCH			English	Article						contractile protein; microvascular tone; traumatic brain injury	INOS EXPRESSION; ENDOTHELIN-1; CONTRACTION; CALDESMON; INJURY; RATS; MICROCIRCULATION; CYTOSKELETON; HIPPOCAMPUS; PLASMA	Objectives: The purpose of this study was to determine the molecular and biochemical changes in the contractile protein, calponin (Cp), which temporally coincide with a previously reported state of sustained contractility following traumatic brain injury (TBI). Methods: Double immunofluorescence, western analysis and two- dimensional non-equilibrium pH gradient gel electrophoresis (NEPHGE)/SDS-PAGE techniques were utilized to determine both the location and extent of Cp within smooth muscle cells (SM) and the phosphorylation state of Cp following TBI, as induced using a weight drop acceleration impact model. Results: Double immunofluorescence for Cp and SM indicate that following injury, Cp migrates from the cytosol to a location subjacent to the SM membrane. Western analysis revealed a significant increase in Cp protein expression following injury that was maintained up to 48 hours post-injury. Combined Western analysis and NEPHGE indicated that Cp is phosphorylated following TBI. Discussion: Cp migration and phosphorylation may underlie the mechanism for increased vasoreactivity leading to hypoperfusion following TBI.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Scott Hall,Room 9312,540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS039860] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		BARANY K, 1992, BIOCHEM BIOPH RES CO, V187, P847, DOI 10.1016/0006-291X(92)91274-T; Egnaczyk GF, 2003, PROTEOMICS, V3, P689, DOI 10.1002/pmic.200300407; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Gimona M, 1996, BIOCH SMOOTH MUSCLE, P91; *I LAB AN RES COMM, 1996, NIH PUBL; Kallakuri S, 2007, NEUROL RES, V29, P362, DOI 10.1179/016164107X204675; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; KREIPKE CW, 2007, NEUROL RES, V29; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; LIN Y, 1993, J BIOCHEM-TOKYO, V113, P643, DOI 10.1093/oxfordjournals.jbchem.a124096; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MINO T, 1995, BIOCHEM BIOPH RES CO, V208, P397, DOI 10.1006/bbrc.1995.1351; NORTH AJ, 1994, J CELL SCI, V107, P437; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Petrov T, 2003, J NEUROL SCI, V209, P31, DOI 10.1016/S0022-510X(02)00461-6; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; RAFOLS JA, 2007, NEUROL RES, V29; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; SUZUKI N, 1990, BIOCHEM BIOPH RES CO, V167, P941, DOI 10.1016/0006-291X(90)90614-S; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; Worth NF, 2001, CELL MOTIL CYTOSKEL, V49, P130, DOI 10.1002/cm.1027; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; Yang JX, 2004, ACTA BIOCH BIOPH SIN, V36, P529, DOI 10.1093/abbs/36.8.529; Yuasa U, 1999, J MOL CELL CARDIOL, V31, P1281, DOI 10.1006/jmcc.1999.0960	29	12	12	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2007	29	4					369	374		10.1179/016164107X204684			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	192PM	WOS:000248214200006	17626732				2021-06-18	
J	Kuhne, CA; Zettl, RP; Baume, B; Vogt, FM; Taeger, G; Ruchholtz, S; Stolke, D; Nast-Kolb, D				Kuehne, C. A.; Zettl, R. P.; Baume, B.; Vogt, F. M.; Taeger, G.; Ruchholtz, S.; Stolke, D.; Nast-Kolb, D.			Penetrating gunshot injuries to the head and brain. Diagnosis, management and prognosis	UNFALLCHIRURG			German	Article						gunshot injuries to the head; standard diagnosis; standard management; mortality; prognosis	CRANIOCEREBRAL MISSILE INJURIES; GLASGOW COMA SCALE; WOUNDS; INFECTIONS; CIVILIANS; MODEL	Gunshot injuries to the head and brain are rare in Germany and the rest of western Europe. With the relatively low number of these injuries here, there are no standard methods of diagnosis and management, and there is some controversy over both. Quite a high proportion of such injuries result from suicide attempts and accidents. The main diagnostic procedure available is computed tomography of the head with contrast medium; in certain cases MRI is indicated. The operative management depends on the extent and prognosis of the injury; a ventricular drain is probably indicated in most cases. Debridement of the bullet's path and removal of the projectile are more controversial. Mortality is extremely high after such injuries; if the victim does survive the prognosis is comparable to that following closed cranial injuries.	Univ Klinikum Essen, Unfallchirurg Klin, D-45122 Essen, Germany; Univ Klinikum Essen, Klin & Poliklin Neurochirurg, D-45122 Essen, Germany; Univ Klinikum Essen, Abt Diagnost & Intervent Radiol & Neuroradiol, D-45122 Essen, Germany	Kuhne, CA (corresponding author), Univ Klinikum Essen, Unfallchirurg Klin, Hufelandstr 55, D-45122 Essen, Germany.	christian.kuehne@uni-essen.de					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BERG SO, 1974, CRIMINOLOGIST, V9, P51; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; CROCKARD HA, 1975, J TRAUMA, V15, P339, DOI 10.1097/00005373-197504000-00011; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; GERBER AM, 1972, J NEUROSURG, V36, P43, DOI 10.3171/jns.1972.36.1.0043; GIESE A, 2002, RECHTSMEDIZIN, V1, P13; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; GRUMME T, 1986, CHIRURG, V57, P674; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; Hess U, 2000, J TRAUMA, V49, P704, DOI 10.1097/00005373-200010000-00019; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; JACOBS DG, 1995, AM SURGEON, V61, P647; JOURDAN P, 1989, Journal de Radiologie (Paris), V70, P685; KARGER B, 1995, INT J LEGAL MED, V108, P53, DOI 10.1007/BF01369905; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013	30	12	12	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0177-5537			UNFALLCHIRURG	Unfallchirurg	APR	2007	110	4					341	349		10.1007/s00113-007-1244-4			9	Emergency Medicine; Surgery	Emergency Medicine; Surgery	156SN	WOS:000245670000007	17364161				2021-06-18	
J	Mace, BE; Wang, HC; Lynch, JR; Moss, J; Sullivan, P; Colton, H; Morgan, K; Renauld, JC; Laskowitz, DT				Mace, Brian E.; Wang, Haichen; Lynch, John R.; Moss, Jason; Sullivan, Patrick; Colton, Heidi; Morgan, Kevin; Renauld, Jean-Christophe; Laskowitz, Daniel T.			Apolipoprotein E modifies the CNS response to injury via a histamine-mediated pathway	NEUROLOGICAL RESEARCH			English	Article						apolipoprotein E; closed head injury; histamine; inflammation; interleukin-9 receptor	E-DEFICIENT MICE; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; TRANSGENIC MICE; E POLYMORPHISM; APOE GENOTYPE; TYPE-4 ALLELE; SUSCEPTIBILITY; ONSET; ASSOCIATION	Recent evidence demonstrates that apolipoprotein E ( apoE) influences the central nervous system (CNS) response to both acute and chronic injury. To address the mechanisms by which apoE influences neurological disease, we examined differential gene expression in the brains of apoE transgenic mice after closed head injury. Apart from confirming the knockout of apoE, the largest differential gene expression occurred for the interleukin-9 receptor (IL-9R), which was > 100-fold up-regulated in apoE-deficient versus wild-type mice. We observed a similar pattern of post-traumatic IL-9R up-regulation in APOE4 targeted replacement mice as compared with their APOE3 counterparts. This difference in gene expression was associated with increased neuronal protein expression of IL-9R in E4 animals compared with E3 as demonstrated by immunohistochemistry. The consequence of IL-9R binding in mast cells is the induction of proliferation and differentiation. This indirectly favors degranulation and release of histamine and inflammatory mediators, which have previously been demonstrated to exacerbate secondary neuronal injury. We found that apoE-deficient animals had increased levels of systemic histamine after injury and that pre-treatment with antihistamines improved functional outcomes in apoE-deficient but not wild-type animals after head injury. These results suggest that apoE modifies secondary neuronal injury caused by histamine release and are consistent with previous observations that apoE affects the CNS inflammatory response in an isoform-specific manner.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; Sanofi Aventis, Chapel Hill, NC 27514 USA; Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium; Univ Louvain, Expt Med Unit, Brussels, Belgium	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Bryan Res Bldg Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu	Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bart RD, 1998, NEUROREPORT, V9, P2615, DOI 10.1097/00001756-199808030-00035; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cowell LG, 2002, GENOME BIOL, V3; Demoulin J B, 1998, Int Rev Immunol, V16, P345, DOI 10.3109/08830189809043001; Dines KC, 1997, J NEUROPATH EXP NEUR, V56, P627; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; Patkai J, 2001, PEDIATR RES, V50, P222, DOI 10.1203/00006450-200108000-00010; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SZTRIHA L, 1987, NEUROSCI LETT, V75, P334, DOI 10.1016/0304-3940(87)90545-3; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	39	12	13	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	APR	2007	29	3					243	250		10.1179/016164107X158974			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	165JJ	WOS:000246301100005	17509222				2021-06-18	
J	Salluh, JIF; Martins, GAR; Santino, MS; Araujo, LV; Freitas, GG; Verdeal, JCR				Salluh, J. I. F.; Martins, G. A. R.; Santino, M. S.; Araujo, L. V.; Freitas, G. G.; Verdeal, J. C. R.			Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						traumatic brain injury; terlipressin; shock; vasopressin; cerebral perfusion pressure; jugular oxygen venous saturation	SEPTIC SHOCK; VASOPRESSIN; PATIENT	Background Maintaining adequate cerebral perfusion pressure is an essential aspect in the treatment of severe acute brain injury. To accomplish this therapeutic goal vasopressors are usually required. Vasopressin is an important endogenous stress hormone and the infusion of low-dose vasopressin and terlipressin has been used to reverse severe hypotension. Case report A 14-year-old male patient was admitted to the emergency room after a motorcycle accident. The patient had suffered severe traumatic brain injury, the Glasgow coma score (GCS) was four and there were signs of aspiration of gastric contents. Systemic inflammatory response syndrome and shock refractory to fluid management, norepinephrine and steroid replacement ensued. A terlipressin infusion, as a bolus dose of 1 mg, is associated with the ability to improve cerebral perfusion pressure with concomitant reduction of 80% of norepinephrine doses. Discussion The present report illustrates the potential benefits of terlipressin in refractory shock in a patient with severe traumatic brain injury. An increase in cerebral perfusion pressure (CPP) and a huge decrease in the dose of norepinephrine were observed. In the setting of severe brain injury associated with refractory hypotension, terlipressin may improve mean arterial pressure and cerebral perfusion pressure. Conclusions In the setting of severe brain injury associated with refractory hypotension, terlipressin may have a role as a rescue therapy.	Hosp Barra DOr, Intens Care Unit, Rio De Janeiro, Brazil; Hosp Canc 1, Inst Nacl Canc, Rio De Janeiro, Brazil; Fundacao Oswaldo Cruz, Immunopharmacol Lab, IOC, Rio De Janeiro, Brazil	Salluh, JIF (corresponding author), Hosp Barra DOr, Intens Care Unit, Rio De Janeiro, Brazil.	jorgesalluh@yahoo.com.br	Salluh, Jorge/AAF-2682-2021; Salluh, Jorge IF/F-6779-2012; dantas, vicente c souza/L-2648-2013	Salluh, Jorge/0000-0002-8164-1453; 			Boerma EC, 2005, ACTA ANAESTH SCAND, V49, P1387, DOI 10.1111/j.1399-6576.2005.00752.x; Bradley PG, 2004, ANAESTHESIA, V59, P619, DOI 10.1111/j.1365-2044.2004.03816.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dunser MW, 2003, CRIT CARE MED, V31, P1394, DOI 10.1097/01.CCM.0000059722.94182.79; Holmes Cheryl L, 2004, Curr Opin Crit Care, V10, P442, DOI 10.1097/01.ccx.0000144769.19213.0c; Kam PCA, 2004, ANAESTHESIA, V59, P993, DOI 10.1111/j.1365-2044.2004.03877.x; Landry DW, 1997, CIRCULATION, V95, P1122; Leone M, 2004, SHOCK, V22, P314, DOI 10.1097/01.shk.0000136097.42048.bd; Nolan JP, 2004, NEW ENGL J MED, V350, P2206; O'Brien A, 2002, LANCET, V359, P1209, DOI 10.1016/S0140-6736(02)08225-9; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Sharshar T, 2003, CRIT CARE MED, V31, P1752, DOI 10.1097/01.CCM.0000063046.82359.4A; Shawcross DL, 2004, HEPATOLOGY, V39, P471, DOI 10.1002/hep.20044; SUZUKI Y, 1993, STROKE, V24, P1049, DOI 10.1161/01.STR.24.7.1049; Yeh CC, 2003, ANESTH ANALG, V97, P577, DOI 10.1213/01.ANE.0000070231.16378.A6	15	12	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2007	51	4					505	508		10.1111/j.1399-6576.2006.01252.x			4	Anesthesiology	Anesthesiology	145PR	WOS:000244877500019	17378791				2021-06-18	
J	Hachemi, M; Jourdan, C; Di Roio, C; Turjman, F; Ricci-Franchi, A; Mottolese, C; Artru, F				Hachemi, M.; Jourdan, C.; Di Roio, C.; Turjman, F.; Ricci-Franchi, A.; Mottolese, C.; Artru, F.			Delayed rupture of traumatic aneurysm after civilian craniocerebral gunshot injury in children	CHILDS NERVOUS SYSTEM			English	Article						traumatic aneurysm; civilian craniocerebral gunshot injury; pediatrics; endovascular treatment; high-velocity missile injury	INTRACRANIAL ANEURYSMS; CEREBELLAR ARTERY; CEREBRAL-ARTERIES; MISSILE INJURIES; WOUNDS; BRAIN; MANAGEMENT; SECONDARY	Background There are few published large series on civilian craniocerebral gunshot injuries in children. Traumatic intracranial aneurysms (TICAs) are rare and highly unstable lesions. They represent less than 1% of all aneurysms and can either rupture within minutes after formation or remain quiescent for several weeks or years, manifesting with delayed hemorrhage and neurologic deterioration. Case history We report the case of a 10-year-old girl who was referred for coma after high-velocity craniocerebral gunshot wound and neurological deterioration 7 days after the initial injury. A massive right posterior occipital hematoma caused by the rupture of an unsuspected right posterior cerebral artery TICA was discovered. TICA was treated by coil embolization, with a good neurological recovery at 6-month follow-up. Discussion We discuss the pathogenesis and the management of TICA in a child after civilian craniocerebral gunshot injuries. Conclusions TICAs should be suspected in patients with civilian craniocerebral gunshot injuries, presenting with secondary neurological deterioration, to carry out emergent CT scan and angiographic exploration before contemplating definitive endovascular treatment. Endovascular management may be a prompt safe-to-use technique and a valuable option, especially when surgery is highly risky.	Hop Neurol & Neurochirurg P Wertheimer, Dept Anesthesia, F-69677 Bron, France; Hop Neurol & Neurochirurg P Wertheimer, Dept Neuroradiol, F-69677 Bron, France; Hop Neurol & Neurochirurg P Wertheimer, Dept Neurosurg B, F-69677 Bron, France	Hachemi, M (corresponding author), Hop Neurol & Neurochirurg P Wertheimer, Dept Anesthesia, F-69677 Bron, France.	mohamed.hachemi@chu-lyon.fr					AMATO JJ, 1970, ARCH SURG-CHICAGO, V101, P167; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; Chedid MK, 2001, J NEUROSURG, V94, P637, DOI 10.3171/jns.2001.94.4.0637; Cohen JE, 2005, J NEUROSURG, V102, P555, DOI 10.3171/jns.2005.102.3.0555; Coughlan MD, 2003, CHILD NERV SYST, V19, P348, DOI 10.1007/s00381-003-0736-y; CROWELL RM, 1995, SURG MANAGEMENT NEUR, P377; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; GERBER AM, 1972, J NEUROSURG, V36, P43, DOI 10.3171/jns.1972.36.1.0043; Guyot LL, 2001, NEUROL RES, V23, P291, DOI 10.1179/016164101101198442; HADDAD FS, 1978, CAN J SURG, V21, P233; HARVEY EN, 1948, ADV MILITARY MED, V1, P191; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; JOURDAN C, 1993, PEDIATRIE, V48, P389; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; Kumar M, 1998, NEUROSURG CLIN N AM, V9, P577; Lasjaunias P, 2005, CHILD NERV SYST, V21, P437, DOI 10.1007/s00381-004-1125-x; MINER ME, 1990, NEUROSURGERY, V26, P20, DOI 10.1227/00006123-199001000-00002; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; Nishioka T, 2002, ACTA NEUROCHIR, V144, P839, DOI 10.1007/s00701-002-0952-3; Proust F, 1997, J NEUROSURG, V87, P950, DOI 10.3171/jns.1997.87.6.0950; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; Tan TC, 2001, BRIT J NEUROSURG, V15, P137	29	12	12	0	4	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	MAR	2007	23	3					283	287		10.1007/s00381-006-0269-2			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	130MD	WOS:000243802800003	17119977				2021-06-18	
J	Kit, KA; Mateer, CA; Graves, RE				Kit, Karen A.; Mateer, Catherine A.; Graves, Roger E.			The influence of memory beliefs in individuals with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; metamemory; affective functioning	MILD HEAD-INJURY; POSTCONCUSSION SYMPTOMS; SELF-AWARENESS; EXPECTATION; METAMEMORY; DEPRESSION; SEQUELAE; ANXIETY; STRESS; ADULTS	Objective: To explore metamemory (memory beliefs) and affective functioning in individuals with traumatic brain injury (TBI). Participants: Twenty-six individuals with mild TBI (MTBI), 16 individuals with severe TBI (STBI), and 42 uninjured adults. Outcome Measures: Metamemory in Adulthood questionnaire, Postconcussion Syndrome Checklist, Perceived Stress Scale, Beck Depression Inventory (2nd ed.), Beck Anxiety Inventory. Results: The control group endorsed higher memory self-efficacy, fewer depressive symptoms, fewer memory strategies, and fewer postconcussion symptoms than the MTBI or STBI group. The MTBI group placed high importance on success in memory tasks. Memory self-efficacy and memory-strategies use mediated the relation between TBI and depression. Conclusion: Individuals with brain injury hold negative beliefs about their memory functioning, and such beliefs contribute to depression.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Kit, KA (corresponding author), Univ Victoria, Dept Psychol, POB 3050 STN CSC, Victoria, BC V8W 3P5, Canada.	kkit@uvic.ca					BANDURA A, 1989, DEV PSYCHOL, V25, P729, DOI 10.1037/0012-1649.25.5.729; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; CaprioPrevette MD, 1996, EXP AGING RES, V22, P281, DOI 10.1080/03610739608254012; Charles J. Brainerd, 1988, COGNITIVE DEV ADULTH, P65, DOI DOI 10.1007/978-1-4612-3852-2; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Dellefield KS, 1996, NURS RES, V45, P284, DOI 10.1097/00006199-199609000-00006; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIXON RA, 1983, J GERONTOL, V38, P682, DOI 10.1093/geronj/38.6.682; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FISKE ST, 1982, J EXP SOC PSYCHOL, V18, P105, DOI 10.1016/0022-1031(82)90046-4; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; HERTZOG C, 1999, SOCIAL COGNITION AGI, P43, DOI DOI 10.1016/B978-012345260-3/50004-5; Hertzog C., 1994, METACOGNITION KNOWIN, DOI 10.1016/s0166-4115(08)60158-2; Hovland D., 2000, NEUROPSYCHOLOGICAL M, P171; HULTSCH DF, 1987, CAN J PSYCHOL, V41, P193, DOI 10.1037/h0084153; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Perlmutter M, 1987, Annu Rev Gerontol Geriatr, V7, P57; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; TEASDALE G, 1974, LANCET, V2, P81; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2	37	12	12	0	1	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2007	52	1					25	32		10.1037/0090-5550.52.1.25			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	142CI	WOS:000244626200003					2021-06-18	
J	Le Roux, AA; Nadvi, SS				Le Roux, A. A.; Nadvi, S. S.			Acute extradural haematoma in the elderly	BRITISH JOURNAL OF NEUROSURGERY			English	Article; Proceedings Paper	Congress of the World-Federation-of Neurosurgical-Societies (WFNS)	JUN 19-24, 2005	Marrakesh, MOROCCO	WFNS		acute extradural haematoma; elderly	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURIES; INTRACRANIAL HEMATOMAS; MANAGEMENT; MORTALITY; COMA	The world's population of persons over 65 years of age (elderly) is increasing. Acute extradural haematoma (AEDH) in the elderly is rare. There has not been a publication dedicated solely to the evaluation of AEDH in the elderly. We undertook this study in order to establish a clinical profile in this important subgroup. It took the form of a retrospective evaluation of the inpatient charts of elderly patients with AEDH, performed over a 23-year period (1983 - 2005) at a single institution. Of 3249 patients with AEDH, 32 (< 1%) were defined as elderly. Assault was the commonest causative factor (56%), followed by falls (25%) and motor vehicle accidents (19%). Eight patients died (25% mortality). Only a third of patients, (34%) made a good outcome, the majority of these were assault victims. No patient in coma, or over 75 years made a good outcome. The prognosis of elderly patients with AEDH is poor. Conservative treatment for comatose patients and the over 75s is justified.	Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Neurosurg, Inkosi Albert Luthuli Cent Hosp, Durban, South Africa	Nadvi, SS (corresponding author), POB 31076, ZA-4058 Durban, KwaZulu Natal, South Africa.	mwnadvi@iafrica.com					AMACHER AL, 1987, NEUROSURGERY, V20, P954; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; GALLAGHE.JP, 1968, J NEUROSURG, V29, P1, DOI 10.3171/jns.1968.29.1.0001; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Heiskanen O, 1975, Surg Neurol, V4, P23; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Jennett B., 1982, NEUROLOGICAL DISORDE, P202; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P5, DOI 10.1080/02688699944104; MAURICEWILLIAMS RS, 1993, AGE AGEING, V22, P337, DOI 10.1093/ageing/22.5.337; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; OHNO K, 1987, Neurological Surgery, V15, P607; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Rakier A., 2000, Harefuah, V138, P359; SIBATA S, 1989, Neurological Surgery, V17, P177; STRANG I, 1978, INJURY, V10, P154; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	30	12	12	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	FEB	2007	21	1					16	20		10.1080/02688690601170692			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	159GR	WOS:000245853900006	17453769				2021-06-18	
J	Ballesteros, MA; Lopez-Hoyos, M; Munoz, P; Marin, MJ; Minambres, E				Ballesteros, Maria Angeles; Lopez-Hoyos, Marcos; Munoz, Pedro; Marin, Maria Jose; Minambres, Eduardo			Apoptosis of neuronal cells induced by serum of patients with acute brain injury: a new in vitro prognostic model	INTENSIVE CARE MEDICINE			English	Article						acute brain injury; apoptosis; in vitro; PC12 cells; outcome	FATAL HEAD-INJURY; CEREBROSPINAL-FLUID; JUGULAR BULB; DEATH; BCL-2; VALIDATION; CONTUSIONS	Objective: To investigate whether serum draining from the jugular bulb of patients with traumatic or haemorrhagic brain injury induced apoptosis of neuronal PC12 cells in vitro and whether the apoptotic rate correlated with patients' outcome at 6 months. Design and setting: Prospective clinical investigation in a 21-bed intensive care unit (ICU) in a university hospital. Patients: Seventy patients who had suffered from acute brain injury requiring intensive care. Interventions: Jugular bulb vein and systemic samples were obtained on admission to the ICU and after 48 h. PC12 cells were incubated in the presence of 10% of heat-inactivated patient's sera and apoptotic rate was determined by flow cytometry using annexin V and 7-aminoactinomycin D. Results: Regional serum draining from the lesions induced higher early apoptosis of PC12 cells than systemic serum. Early apoptotic rate, Glasgow coma score, APACHE II score and the presence of pupil abnormalities were associated with mortality at 6 months in univariate statistical analyses. In logistic regression analysis only early apoptotic rate was an independent factor associated with mortality at 6 months ( odds ratio: 1.502, 95% CI 1.2-1.9; p < 0.001). The final model has a sensitivity of 82.4% and a specificity of 84.8% for predicting death within 6 months. Conclusions: We developed a simple and reproducible in vitro model for predicting outcome in patients with traumatic or haemorrhagic brain injury that survived in the early phase. Our in vitro model combined with clinical and radiological measurements might improve the value of prognostic models to predict acute brain injury patients' outcome.	Hosp Univ Marques de Valdecilla, Dept Med Intens, Santander 39008, Spain; Fdn Publ Marques de Valdecilla, IFIMAV, Santander, Spain; Hosp Univ Marques de Valdecilla, Serv Inmunol, Santander 39008, Spain; Atenc Primaria, Serv Cantabro Salud, Santander, Spain	Minambres, E (corresponding author), Hosp Univ Marques de Valdecilla, Dept Med Intens, Avda Valdecilla S-N, Santander 39008, Spain.	eminambres@yahoo.es	MUNOZ, PEDRO/C-8361-2015; Minambres, Eduardo/H-7761-2019; Lopez-Hoyos, Marcos/ABC-1024-2020	Lopez-Hoyos, Marcos/0000-0003-0562-427X; Ballesteros, Maria A/0000-0002-4032-9973			ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bilbault P, 2004, INTENS CARE MED, V30, P408, DOI 10.1007/s00134-003-2118-z; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; Castellanos M, 2005, J NEUROL NEUROSUR PS, V76, P691, DOI 10.1136/jnnp.2004.044347; Diaz-Reganon G, 2002, INTENS CARE MED, V28, P1724, DOI 10.1007/s00134-002-1543-8; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hosmer D, 1989, APPL LOGISTIC REGRES; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Katz MH, 2003, ANN INTERN MED, V138, P644, DOI 10.7326/0003-4819-138-8-200304150-00012; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Le Berre R, 2004, INTENS CARE MED, V30, P1204, DOI 10.1007/s00134-004-2165-0; Lopez-Escribano H, 2002, ARTHRITIS RHEUM, V46, P3290, DOI 10.1002/art.10684; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; MINAMBRES E, 2004, MED INTENSIVA, V28, P319; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; RINK A, 1995, AM J PATHOL, V147, P1575; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; TEASDALE G, 1974, LANCET, V2, P81; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Zhang F, 2004, NEUROL RES, V26, P835, DOI 10.1179/016164104X3824	38	12	15	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JAN	2007	33	1					58	65		10.1007/s00134-006-0361-9			8	Critical Care Medicine	General & Internal Medicine	125TB	WOS:000243464300011	16964482				2021-06-18	
J	Bennett, SS; Graffagnino, C; Borel, CO; James, ML				Bennett, Stacey S.; Graffagnino, Carmelo; Borel, Cecil O.; James, Michael L.			Use of High Frequency Oscillatory Ventilation (HFOV) in neurocritical care patients	NEUROCRITICAL CARE			English	Article						high frequency ventilation; intracranial pressure; acute respiratory distress syndrome; traumatic brain injury; neurological intensive care	RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; INTRACRANIAL-PRESSURE; NEUROLOGIC ILLNESS; BRAIN INJURY; HEAD-INJURY; MANAGEMENT; ADULTS	Introduction Adult respiratory distress syndrome (ARDS) can be a cornmon problem associated with the treatment of acute brain injury. High frequency oscillatory ventilation (HFOV) is a developing therapy for the treatment of ARDS in adult patients that can be life saving. However, often patients with acute, severe brain injury demonstrate intracranial hypertension (hICP) due to a variety of injuries (e.g., traumatic brain injury, mass lesion, acute hydrocephalus). There is concern over the use of HFOV due to its effects on intracranial pressure in patients with hICP. Methods Retrospective case series study. Results We describe the effects of HFOV on hemodynamics, respiratory function, and intracranial pressure in five patients with acute brain injury being treated for ARDS. Conclusions HFOV did not cause unmanageable or sustained increases in ICP in our series of patients. It appears HFOV may be a relatively safe and effective means of oxygenating patients with severe ARDS and concomitant hICP secondary to acute brain injury.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Nursing, Durham, NC USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC USA	James, ML (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	james040@mc.duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008600] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008600, T32 GM008600-13] Funding Source: Medline		Bein T, 2005, CRIT CARE MED, V33, P667, DOI 10.1097/01.CCM.0000155776.60160.50; Borel CO, 1998, RESP PHYSIOL, V111, P45, DOI 10.1016/S0034-5687(97)00098-4; BOREL CO, 1995, NEUROL CLIN, V13, P627, DOI 10.1016/S0733-8619(18)30036-7; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P571, DOI 10.1097/00000542-198910000-00016; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; Muench E, 2005, CRIT CARE MED, V33, P2367, DOI 10.1097/01.CCM.0000181732.37319.DF; *RESP CAR SERV DUM, 2004, HIGH FREQ OSC VENT A, P1; Salim A, 2004, J TRAUMA, V57, P542, DOI 10.1097/01.TA.0000135159.94744.5F; SINGH JM, 2003, CRIT CARE ROUNDS, V4, P1; WARNER DS, 1987, STROKE, V18, P142, DOI 10.1161/01.STR.18.1.142; Wijdicks EFM, 1998, NEUROLOGY, V50, P11, DOI 10.1212/WNL.50.1.11	15	12	15	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2007	7	3					221	226		10.1007/s12028-007-0084-y			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	237SO	WOS:000251396900007	17805492	Green Accepted			2021-06-18	
J	Brewer, KL; Nolan, TA				Brewer, Kori L.; Nolan, Todd A.			Spinal and supraspinal changes in tumor necrosis factor-alpha expression following excitotoxic spinal cord injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						inflammation; excitotoxicity; cytokines; spinal cord injury pain; quisqualic acid	TNF-ALPHA; MESSENGER-RNA; CELL-DEATH; INFLAMMATORY CYTOKINE; TRAUMATIC INJURY; PAIN; INTERLEUKIN-10; INCREASE; NEURONS; BRAIN	The role of tumor necrosis factor-alpha (TNF-alpha) after spinal cord injury (SCI) is well characterized in the cord, but the impact of this inflammatory process on supraspinal levels is unknown. This study examines TNF-alpha mRNA and protein levels in the brains and spinal cords of mice after SCL Mice received intraspinal injections of quisqualic acid (QUIS) to create an excitotoxic injury that is known to result in pain behaviors. An ELISA determined serum levels of TNF-alpha, whereas real-time PCR and Western blot analysis were used to determine mRNA and protein levels, respectively, at 3,6,12,24,48, 72 h, or 14 d postinjury. No difference existed in serum TNF-(x levels between sham- and QUIS-injected animals. TNF-alpha mRNA in the cord was increased at 3, 6, 12, and 24 h in QUIS-injected animals relative to shams. TNF-a protein was elevated at 12 and 48 h postinjury. TNF-alpha mRNA levels in the brain were elevated at 12 and 24 h, with elevated protein levels at 6 h. Animals that developed pain behaviors had increased levels of TNF-alpha mRNA in the brain. Excitotoxic SCI results in altered TNF-alpha mRNA and protein levels in the cords and brains of mice within 6 h of injury These changes likely contribute to the pathogenesis of injury within the cord. The role of TNF-alpha in the brain postinjury has not been defined but might contribute to the development of pain post-SCI.	E Carolina Univ, Brody Sch Med, Dept Accid & Emergency, PCMH,3ED304, Greenville, NC 27834 USA	Brewer, KL (corresponding author), E Carolina Univ, Brody Sch Med, Dept Accid & Emergency, PCMH,3ED304, Greenville, NC 27834 USA.	brewerk@ecu.edu					Abraham KE, 2004, NEUROSCIENCE, V124, P945, DOI 10.1016/j.neuroscience.2004.01.004; Abraham KE, 2001, PAIN, V90, P181, DOI 10.1016/S0304-3959(00)00402-4; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Brewer KL, 2003, MOL BRAIN RES, V118, P171, DOI 10.1016/j.molbrainres.2003.08.006; Carlson NG, 1999, J IMMUNOL, V163, P3963; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Covey WC, 2002, REGION ANESTH PAIN M, V27, P357, DOI 10.1053/rapm.2002.31930; Covey WC, 2000, BRAIN RES, V859, P113, DOI 10.1016/S0006-8993(00)01965-X; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Ignatowski TA, 1999, BRAIN RES, V841, P70, DOI 10.1016/S0006-8993(99)01782-5; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lenz F A, 2000, Prog Brain Res, V129, P259; LENZ FA, 1987, PAIN, V31, P225, DOI 10.1016/0304-3959(87)90038-8; Melzack R, 2001, J Dent Educ, V65, P1378; Morrow TJ, 2000, EXP NEUROL, V161, P220, DOI 10.1006/exnr.1999.7246; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Pan WH, 2003, J NEUROIMMUNOL, V134, P111, DOI 10.1016/S0165-5728(02)00426-5; Pan WH, 2000, EXP NEUROL, V170, P357, DOI 10.1006/exnr.2001.7702; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Ren K, 2002, PAIN, V100, P1, DOI 10.1016/S0304-3959(02)00368-8; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; Shinpo K, 1999, BRAIN RES, V819, P170, DOI 10.1016/S0006-8993(98)01354-7; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; Vierck CJ, 2000, PAIN, V89, P1, DOI 10.1016/S0304-3959(00)00463-2; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang YP, 2002, POLYM ADVAN TECHNOL, V13, P11, DOI 10.1002/pat.100; Watkins LR, 2003, ADV EXP MED BIOL, V521, P1; WATKINS LR, 1995, BRAIN RES, V692, P244, DOI 10.1016/0006-8993(95)00715-3; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; YEZIERSKI RP, 1993, NEUROSCI LETT, V157, P115, DOI 10.1016/0304-3940(93)90656-6; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116	41	12	13	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.		2007	31	1					13	21		10.1007/BF02686114			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	144ML	WOS:000244800200002	17416966				2021-06-18	
J	Bute, JJ; Donovan-Kicken, E; Martins, N				Bute, Jennifer J.; Donovan-Kicken, Erin; Martins, Nicole			Effects of communication-debilitating illnesses and injuries on close relationships: A relational maintenance perspective	HEALTH COMMUNICATION			English	Article; Proceedings Paper	89th Annual Meeting of the National-Communication-Association	NOV 19-23, 2003	MIAMI, FL	Natl Commun Assoc			TRAUMATIC BRAIN-INJURY; STROKE; INDIVIDUALS; CAREGIVERS; HUSBANDS; DISTRESS; APHASIA; SUPPORT; NEEDS	A communication-debilitating illness or injury (CDI) presents significant challenges for patients as well as for friends and family. In a qualitative study of the effects of a CDI on close relationships, 28 individuals with loved ones who had experienced a CDI were interviewed. Participants described adjustments in communication with the patient and explained what it is like to experience a relationship with a CDI patient. Themes that emerged transcended the type of illness and relationship. Recommendations are made for further research that focuses on patients' relationships with a variety of social network members, beyond primary caregivers.	Ohio Univ, Sch Commun Studies, Athens, OH 45701 USA; Univ Illinois, Dept Speech Commun, Urbana, IL 61801 USA	Bute, JJ (corresponding author), Ohio Univ, Sch Commun Studies, Lasher Hall, Athens, OH 45701 USA.	bute@ohio.edu		Bute, Jennifer/0000-0001-7203-5585			ALLEN P, 1994, AGR HUM VALUES, V9, P29; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Baxter LA, 2002, J APPL COMMUN RES, V30, P1, DOI 10.1080/00909880216576; BRERETON L, 2000, J CLIN NURS, V11, P22; Burleson B.R., 2000, CLOSE RELATIONSHIPS, V1st ed., P245; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Canary D. J., 2000, COMMUNICATION YB, V23, P305, DOI [10.1080/23808985.2000.11678976, DOI 10.1080/23808985.2000.11678976]; Canary D.J., 1993, COMMUNICATION RES RE, V10, P3, DOI [10.1080/08824099309359913, DOI 10.1080/08824099309359913]; Canary DJ, 2001, CLOSED ROMANTIC RELATIONSHIPS: MAINTENANCE AND ENHANCEMENT, P133; CANARY DJ, 1992, COMMUN MONOGR, V59, P242; CANARY DJ, 1993, INTERPERSONAL COMMUN, P237; Denman A, 1998, DISABIL REHABIL, V20, P411, DOI 10.3109/09638289809166103; Ellis DG, 1996, COMMUN RES, V23, P472, DOI 10.1177/009365096023004007; Garvin-Doxas Kathy, 1994, DYNAMICS RELATIONSHI, P1; GEISTMARTIN P, 2001, QUALITATIVE RES APPL, P121; Grant JS, 2001, REHABIL PSYCHOL, V46, P44, DOI 10.1037/0090-5550.46.1.44; GUAY J, 1982, CANADAS MENTAL HLTH, V30, P22; Johnson JL., 1991, ILLNESS EXPERIENCE D; JONGBLOED L, 1994, AM J OCCUP THER, V48, P1006, DOI 10.5014/ajot.48.11.1006; KEMPER S, 1995, DISCOURSE PROCESS, V20, P205, DOI 10.1080/01638539509544938; Lyons R.F., 1995, RELATIONSHIPS CHRONI; Michallet B, 2001, APHASIOLOGY, V15, P731, DOI 10.1080/02687040143000087; Mishel M H, 1999, Annu Rev Nurs Res, V17, P269; MORGAN M, 1984, SOC SCI MED, V19, P489, DOI 10.1016/0277-9536(84)90044-3; Orange JB, 1998, J APPL COMMUN RES, V26, P120, DOI 10.1080/00909889809365495; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Pring T, 1999, APHASIOLOGY, V13, P914, DOI 10.1080/026870399401687; ROBERTSON EK, 1968, J PSYCHOSOM RES, V12, P189, DOI 10.1016/0022-3999(68)90045-7; Rusbult C.E., 1987, READINGS SOCIAL PSYC, P147; Rusbult CE, 2001, CLOSED ROMANTIC RELATIONSHIPS: MAINTENANCE AND ENHANCEMENT, P87; Santos ME, 1999, BRAIN INJURY, V13, P23, DOI 10.1080/026990599121845; SMAGTDUIJNSTEE ME, 2001, J ADV NURS, V33, P301; STAFFORD L, 1991, J SOC PERS RELAT, V8, P217, DOI 10.1177/0265407591082004; Strauss A., 1990, BASICS QUALITATIVE R; Strauss A.L., 1975, CHRONIC ILLNESS QUAL; Sundin K, 2000, J CLIN NURS, V9, P481, DOI 10.1046/j.1365-2702.2000.00379.x; Sundin Karin, 2002, Nurs Inq, V9, P93, DOI 10.1046/j.1440-1800.2002.00135.x; WILLIAMSON GM, 1990, PSYCHOL AGING, V5, P502, DOI 10.1037/0882-7974.5.4.502	38	12	12	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1041-0236	1532-7027		HEALTH COMMUN	Health Commun.		2007	21	3					235	246		10.1080/10410230701307675			12	Communication; Health Policy & Services	Communication; Health Care Sciences & Services	188SX	WOS:000247940700004	17567255				2021-06-18	
J	Campbell, L; Wilson, FC; McCann, J; Kernahan, G; Rogers, RG				Campbell, Loretta; Wilson, F. Colin; McCann, John; Kernahan, George; Rogers, Rosalind Gray			Single case experimental design study of Carer facilitated Efforless Learning in a patient with severe memory impairment following TBI	NEUROREHABILITATION			English	Article						memory rehabilitation; errorless learning; family and carers; brain injury	ACQUIRED BRAIN-INJURY; COGNITIVE REHABILITATION; ERRORLESS; AMNESIA; PROGRAM	Objectives: To investigate if errorless learning applied by carer(s) in an everyday setting can reduce the frequency of everyday memory problems following severe traumatic brain injury (TBI). Research design: Multiple baseline single case experimental design. Methods and procedures: A patient with severe memory impairment, six years post TBI was recruited via an outpatient neurorehabilitation clinic. ABA analysis was conducted using daily frequency counts of everyday memory problems as an index of change. Experimental intervention: Errorless learning delivered by the patient's carer, aimed at reducing the occurrence of identified everyday memory problems. The carer was guided in treatment implementation by an Occupational Therapist. Main outcomes and results: Incidence of frequently occurring memory lapses was significantly reduced (p < 0.001) and this was maintained at 3 months post intervention. Conclusion: This study highlights the potential clinical value of errorless learning with self-generated cues applied by carers within an everyday setting.	Royal Victoria Hosp, Dept Rehabil Med, Occupat Therapy Dept, Belfast Hlth & Social Care Trust, Belfast BT12 6BA, Antrim, North Ireland; Belfast Hlth & Social Care Trust, Musgrave Pk Hosp, Reg Acquired Brain Injury Unit, Belfast, Antrim, North Ireland; Univ Ulster, Sch Nursing, Jordanstown, North Ireland; Univ Ulster, Sch Commun, Jordanstown, North Ireland	Campbell, L (corresponding author), Royal Victoria Hosp, Dept Rehabil Med, Occupat Therapy Dept, Belfast Hlth & Social Care Trust, Belfast BT12 6BA, Antrim, North Ireland.	loretta.campbell@belfasttrust.hscni.net		Kernohan, George/0000-0002-1309-446X			BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Bier N, 2003, J COGNITIVE REHABILI, V20, P12; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clare L, 2003, AGING MENT HEALTH, V7, P15, DOI 10.1080/1360786021000045854; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kim K.H., 1999, SCI MATH, V2, P147; Kime SK, 1996, BRAIN INJURY, V10, P17; MATEER C, 2002, CARD U C SEPT; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; WILSON BA, 1995, HDB MEMORY DISORDERS, P452; Wilson BA, 1996, BEHAV ASSESSMENT DYS	21	12	12	0	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2007	22	4					325	333					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	233KE	WOS:000251089000011	17971624				2021-06-18	
J	Crawford, MA; Knight, RG; Alsop, BL				Crawford, Maria A.; Knight, Robert G.; Alsop, Brent L.			Speed of word retrieval in postconcussion syndrome	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						postconcussion syndrome; information processing; retrieval speed; word fluency; memory; attention	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; SEMANTIC MEMORY; VERBAL FLUENCY; SPORTS	Speed of information processing in persons with postconcussion syndrome (PCS) was examined using word fluency tasks. Twenty patients with PCS and twenty controls matched for age, gender, and occupation were given two word fluency tasks, and the speed of word generation was measured. Response latencies were analyzed to determine whether slowed retrieval or degradation of words in semantic memory was responsible for problems with word retrieval after traumatic brain injury. The PCS group recalled fewer words, had significantly longer interresponse times, and took significantly longer to generate their first word than the controls. There was no evidence that either structure loss or slowness in word retrieval from semantic memory could account for the word fluency deficits. Rather, the findings suggest that the primary cause of word retrieval difficulties in patients with PCS is a generalized slowness of cognitive processing.	Univ Otago, Dept Psychol, Dunedin, New Zealand	Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz					*ACC REH COMP INS, 2001, AGR PROV MILD TRAUM; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Benton A., 1976, MULTILINGUAL APHASIA; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; LEVIN HS, 2000, CEREBRAL REORGANIZAT, P218; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; RANDOLPH C, 1998, REPEATABLE BATTERY A; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; ROEDIGER HL, 1977, J EXP PSYCHOL-HUM L, V3, P174, DOI 10.1037/0278-7393.3.2.174; Rohrer D, 1999, NEUROPSYCHOLOGY, V13, P381, DOI 10.1037/0894-4105.13.3.381; ROHRER D, 1995, J EXP PSYCHOL LEARN, V21, P1127, DOI 10.1037/0278-7393.21.5.1127; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9	14	12	13	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2007	13	1					178	182		10.1017/S135561770707021X			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	127PO	WOS:000243599000020	17166317				2021-06-18	
J	Greve, KW; Bianchini, KJ; Roberson, T				Greve, Kevin W.; Bianchini, Kevin J.; Roberson, Triche			The booklet category test and malingering in traumatic brain injury: Classification accuracy in known groups	CLINICAL NEUROPSYCHOLOGIST			English	Article							CARD SORTING TEST; MILD HEAD-INJURY; NEUROPSYCHOLOGICAL EVALUATION; NEUROCOGNITIVE DYSFUNCTION; RESPONSE BIAS; PERFORMANCE; VALIDATION; INDICATORS; BATTERY; FAKING	A known-groups design was used to determine the classification accuracy of 12 Booklet Category Test variables in the detection of malingered neurocognitive dysfunction ( MND) in traumatic brain injury ( TBI). Participants were 206 TBI and 60 general clinical patients seen for neuropsychological evaluation. Slick, Sherman, and Iverson's ( 1999) criteria were used to classify the TBI patients into non-malingering, suspect, and MND groups. Classification accuracy of the BCT depended on the specific variable and injury severity examined, with some scores detecting more than 40% of malingerers with false positive error rates of 10% or less. However, the BCT variables are often influenced by cognitive ability as well as malingering, so caution is indicated in applying the BCT to the diagnosis of malingering. Application of these data in clinical practice is discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1993, PORTLAND DIGIT RECOG; Bolter J. F., 1985, ANN M NAT AC NEUR OC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DeFilippis NA, 1997, BOOKLET CATEGORY TES; DiCarlo MA, 2000, ARCH CLIN NEUROPSYCH, V15, P399, DOI 10.1016/S0887-6177(99)00031-1; Ellwanger J, 1999, J CLIN EXP NEUROPSYC, V21, P866, DOI 10.1076/jcen.21.6.866.850; Forrest TJ, 2004, CLIN NEUROPSYCHOL, V18, P334, DOI 10.1080/13854040490501673; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P783; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; GREVE KW, CLIN NEUROPSYCHOLOGI; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton SK, 1993, WISCONSIN CARD SORTI; Hennekens CH, 1987, EPIDEMIOLOGY MED; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet J. J., 2002, J FORENSIC NEUROPSYC, V3, P241; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williamson D. J., 2003, J FORENSIC NEUROPSYC, V3, P19	43	12	12	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2007	21	2					318	337		10.1080/13854040500488552			20	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	158GW	WOS:000245780800008	17455021				2021-06-18	
J	Moiyadi, AV; Devi, BI; Nair, KPS				Moiyadi, Aliasgar V.; Devi, B. Indira; Nair, K. P. Sivaraman			Urinary disturbances following traumatic brain injury: Clinical and urodynamic evaluation	NEUROREHABILITATION			English	Article						traumatic brain injury; urinary disturbances; urodynamics; overactive bladder; rehabilitation	INCONTINENCE; MICTURITION; CONSCIOUSNESS; ACTIVATION; SEVERITY; MODERATE; OUTCOMES; STROKE; INDEX; COMA	Aim: To detect presence of urodynamic abnormalities in patients with traumatic brain injuries. Materials and Methods: A prospective study was conducted recruiting patients sustaining moderate or severe head injuries. Clinical and radiological evaluation was done. Neurocognitive and functional outcomes were assessed. Patients then underwent standardized urodynamic studies. The urodynamic findings were correlated with outcome and statistically analyzed. Results: 11 of 20 patients recruited had urodynamic abnormalities, in spite of only two being symptomatic. An overactive detrussor was detected in 8 (one with sphincter dyssynergia) and reduced detrussor compliance was found in 3. Only presence of motor deficits correlated statistically with the occurrence of these abnormalities. Conclusions: Asymptomatic urodynamic abnormalities may be common in patients with moderate/severe traumatic brain injury. Presence of motor deficits may predict the occurrence of such abnormalities.	Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Psychiat & Neurol Rehabil, Bangalore 560029, Karnataka, India	Devi, BI (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India.	bindira@nimhans.kar.nic.in	Nair, Krishnan/AAE-3474-2020	Nair, Krishnan/0000-0002-4004-2315			Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; ALLISON SC, 1995, J NEUROL, V242, P699, DOI 10.1007/BF00866923; ANDREW J, 1964, BRAIN, V87, P233, DOI 10.1093/brain/87.2.233; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Blok BFM, 1998, BRAIN, V121, P2033, DOI 10.1093/brain/121.11.2033; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fowler CJ, 1999, BRAIN, V122, P1213, DOI 10.1093/brain/122.7.1213; GELBER DA, 1993, STROKE, V24, P378, DOI 10.1161/01.STR.24.3.378; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; JENNETT B, 1975, LANCET, V1, P480; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Nour S, 2000, BRAIN, V123, P781, DOI 10.1093/brain/123.4.781; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; RUSHTON DN, 1994, HDB NEUROUROLOGY; SAKAKIBARA R, 1999, BLUE BOOK PRACT NEUR, V23, P229; Sandvik H, 2000, NEUROUROL URODYNAM, V19, P137, DOI 10.1002/(SICI)1520-6777(2000)19:2<137::AID-NAU4>3.0.CO;2-G; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stohrer M, 1999, NEUROUROL URODYNAM, V18, P139; TEASDALE G, 1974, LANCET, V2, P81; WADE DT, 1985, Q J MED, V56, P601; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956	29	12	12	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	2					93	98					6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	195LB	WOS:000248412600003	17656833				2021-06-18	
J	Olson, DM; Thoyre, SM; Turner, DA; Bennett, S; Graffagnino, C				Olson, DaiWai M.; Thoyre, Suzanne M.; Turner, Dennis A.; Bennett, Stacey; Graffagnino, Carmelo			Changes in intracranial pressure associated with chest physiotherapy	NEUROCRITICAL CARE			English	Article						intracranial hypertensions; brain injury; chest physiotherapy		Introduction Management of intracranial hypertension is pivotal in the care of brain-injured patients. Summary of Case We report the case of a patient with both a closed head injury and anoxic encephalopathy, who subsequently experienced episodes of refractory intracranial hypertension. The patient's care was complicated by the development of a pneumonia, which required frequent turning of the patient and chest physiotherapy. Conventional wisdom suggests that these interventions may stimulate the patient and worsen intracranial pressure, and therefore should be avoided. Results Our observations on this patient, however, contradict this belief. This single-subject study presents data to support the use of chest physiotherapy in patients at risk for intracranial hypertension. Conclusions Further, the evidence is compelling that a randomized-controlled trial is indicated to test the hypothesis that chest physiotherapy may actually result in short-term resolution of high intracranial pressure, and thus provide one more clinical tool in the management of elevated intracranial pressure.	Univ N Carolina, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Durham, NC USA	Olson, DM (corresponding author), Univ N Carolina, Chapel Hill, NC 27599 USA.	dmolson@email.unc.edu		Olson, DaiWai/0000-0002-9280-078X			ALSPACH J, 1998, CORE CURRICULUM CRIT; Beeby J P, 2000, Intensive Crit Care Nurs, V16, P151, DOI 10.1054/iccn.2000.1490; BULLOCK MR, 2000, MANAGEMENT PROGNOSIS; deBoisblanc BP, 1997, CRIT CARE MED, V25, P1456, DOI 10.1097/00003246-199709000-00008; ERSSON U, 1990, ACTA ANAESTH SCAND, V34, P99, DOI 10.1111/j.1399-6576.1990.tb03051.x; Grap Mary Jo, 2004, Crit Care Nurs Clin North Am, V16, P349, DOI 10.1016/j.ccell.2004.03.005; Greenberg MS, 2001, HDB NEUROSURGERY; Koch SM, 1996, J CRIT CARE, V11, P176, DOI 10.1016/S0883-9441(96)90028-3; Mahanes Dea, 2004, Crit Care Nurs Clin North Am, V16, P387, DOI 10.1016/j.ccell.2004.03.007; March K, 2000, Crit Care Nurs Clin North Am, V12, P429; Marik PE, 2002, CRIT CARE MED, V30, P2146, DOI 10.1097/00003246-200209000-00035; Ntoumenopoulos G, 2002, INTENS CARE MED, V28, P850, DOI 10.1007/s00134-002-1342-2; Tablan Ofelia C, 2004, MMWR Recomm Rep, V53, P1; Wijdicks EFM, 1998, NEUROLOGY, V50, P11, DOI 10.1212/WNL.50.1.11; Yanko J R, 2001, Crit Care Nurs Q, V23, P1	15	12	12	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2007	6	2					100	103		10.1007/s12028-007-0015-y			4	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	179DW	WOS:000247270700005	17522792				2021-06-18	
J	Otani, N; Nawashiro, H; Fukui, S; Ooigawa, H; Ohsumi, A; Toyooka, T; Shima, K				Otani, Naoki; Nawashiro, Hiroshi; Fukui, Shinji; Ooigawa, Hidetoshi; Ohsumi, Atsushi; Toyooka, Terushige; Shima, Katsuji			Role of the activated extracellular signal-regulated kinase pathway on histological and behavioral outcome after traumatic brain injury in rats	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						extracellular signal-regulated kinase (ERK); lateral fluid percussion; signal transduction; traumatic brain injury; U0126	PROTEIN-KINASES; HEAD TRAUMA; INHIBITION; EXPRESSION; PROTECTION; ISCHEMIA; DEFICITS; CULTURES; NEURONS; DAMAGE	The extracellular signal-regulated kinase (ERK) pathway, which modulates the activity of many transcriptional factors leading to the proliferation of various cells, is activated in lesions in regions of selective vulnerability after traumatic brain injury (TBI). In the present study, using the ERK inhibitor U0126, we investigated the role of the ERK pathway in histopathological and behavioral outcomes after TBI. Adult male Sprague-Dawley rats, weighing 300-400 g were subjected to lateral fluid percussion brain injury. The ERK inhibitor U0126 was injected intravenously before injury at 100, 200 and 400 mu g/kg. The severity of CA3 neuronal damage was evaluated by the number of surviving CA3 neurons 7 days after injury. The contusional lesion volume 72 h after injury was analysed using a computer-assisted analysis system. Three different motor skill tasks were measured on days 1-5, 7, 14 anal 21 after injury. Pretreatment with U0126 significantly reduced both CA3 neuronal damage and contusional lesion volume after injury. In addition, administration of U0126 ameliorated motor function recovery on days 3, 4 and 5 after injury. Therefore, inhibition of ERK phosphorylation could be a potentially effective therapeutic target after TBI. (C) 2006 Elsevier Ltd. All rights reserved.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan	Otani, N (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	naotani1993@aol.com					Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Lal BK, 2001, MICROVASC RES, V62, P252, DOI 10.1006/mvre.2001.2338; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Long JB, 1996, J NEUROTRAUM, V13, P149, DOI 10.1089/neu.1996.13.149; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pereira DB, 2002, NEUROPHARMACOLOGY, V42, P9, DOI 10.1016/S0028-3908(01)00162-9; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Runden E, 1998, J NEUROSCI, V18, P7296; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SEGER R, 1995, FASEB J, V9, P726; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Zubkov AY, 2000, STROKE, V31, P526, DOI 10.1161/01.STR.31.2.526	33	12	16	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	JAN	2007	14	1					42	48		10.1016/j.jocn.2005.11.044			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	122EN	WOS:000243208600009	17138068				2021-06-18	
J	Pavlovskaya, M; Hochstein, S; Keren, O; Mordvinov, E; Groswasser, Z				Pavlovskaya, Marina; Hochstein, Shaul; Keren, Ofer; Mordvinov, Eugene; Groswasser, Zeev			Methylphenidate effect on hemispheric attentional imbalance in patients with traumatic brain injury: A psychophysical study	BRAIN INJURY			English	Article						attention; traumatic brain injury; neglect; asymmetry; methylphenidate; ritalin	DEFICIT HYPERACTIVITY DISORDER; SELECTIVE ATTENTION; VISUAL-ATTENTION; SUSTAINED ATTENTION; PATTERN-RECOGNITION; PARIETAL; NEGLECT; CT; FACILITATION; ORIENTATION	Primary objective: We found spatially asymmetric allocation of attention in patients with traumatic brain injury ( TBI) without overt asymmetry on neurological examination. The possible effect of Methylphenidate in reducing this asymmetry is evaluated in the current research. Research design: Psychophysical study using a visual spatial attention task. Identification rates were measured after precuing attention to different visual field loci. TBI patients were tested before, during and after administration of Methylphenidate. Methods and procedures: After precuing to a locus 5 degrees into the left or right hemifield, target patterns were presented briefly at the cued location ( valid), or on the opposite side ( invalid) - requiring an attentional shift. Patients were treated with a gradually increasing dosage of a psychostimulant over two weeks, followed by a similar two-week period of gradually diminishing dosage. Patients were tested before treatment, at its peak, and ( twice) following its completion. Main outcome and results: Patients demonstrated significantly worse performance with leftward than with rightward cross-hemifield shifts of attention. This difference was significantly reduced during and following treatment. Conclusions: Asymmetric performance and improvement with treatment suggest that diffuse TBI damage leads to a lateralized attention-related deficit. These findings support the hypotheses that attention is a distributed and asymmetrically lateralized function. The findings are consistent with the conclusion that Methylphenidate may be an effective treatment for attentional deficits in TBI patients.	Loewenstein Hosp & Rehabil Ctr, Dept Neurophysiol, IL-43100 Raanana, Israel; Loewenstein Hosp & Rehabil Ctr, Dept Traumat Brain Injury, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Neurobiol, Inst Life Sci, Jerusalem, Israel; Hebrew Univ Jerusalem, Neural Computat Ctr, Jerusalem, Israel; Charles E Smith Lab Collaborat Res Psychobiol, Jerusalem, Israel	Groswasser, Z (corresponding author), Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, 278 Ahuza Str, IL-43100 Raanana, Israel.	zeevgros@post.tau.ac.il					Ahissar M, 2004, TRENDS COGN SCI, V8, P457, DOI 10.1016/j.tics.2004.08.011; Ahissar M, 2001, PSYCHOL SCI, V12, P56, DOI 10.1111/1467-9280.00310; Alvarez JA, 2004, DEV NEUROPSYCHOL, V26, P627, DOI 10.1207/s15326942dn2602_6; Audet T, 2000, BRAIN COGNITION, V43, P17; BACHYRITA P, 1991, SCAND J REHABIL MED, V23, P219; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; BENDER MB, 1952, DISORDERS PERCEPTION; Berlucchi G, 1997, NEUROPSYCHOLOGIA, V35, P941, DOI 10.1016/S0028-3932(97)00022-5; Bisiach E., 1988, HDB NEUROPSYCHOLOGY, VVol 1, P195; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755; CARTER CS, 1995, BIOL PSYCHIAT, V37, P789, DOI 10.1016/0006-3223(94)00217-Q; CHEAL ML, 1994, Q J EXP PSYCHOL-A, V47, P699, DOI 10.1080/14640749408401134; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; DESIMONE R, 1990, Society for Neuroscience Abstracts, V16, P621; Duncan J, 1999, J EXP PSYCHOL GEN, V128, P450, DOI 10.1037/0096-3445.128.4.450; Duncan J, 1998, PHILOS T ROY SOC B, V353, P1307, DOI 10.1098/rstb.1998.0285; Duncan J., 2004, COGNITIVE NEUROSCIEN, P105; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY, P279; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; Hochstein S, 2002, NEURON, V36, P791, DOI 10.1016/S0896-6273(02)01091-7; Hurford P, 1998, ARCH PHYS MED REHAB, V79, P346, DOI 10.1016/S0003-9993(98)90019-3; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; Jonides J., 1981, ATTENTION PERFORMANC, P187; Kajs-Wyllie Marylyn, 2002, J Neurosci Nurs, V34, P303; Karnath HO, 2003, NEUROREPORT, V14, P437, DOI 10.1097/01.wnr.0000059778.23521.88; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Leibovitch FS, 1998, NEUROLOGY, V50, P901, DOI 10.1212/WNL.50.4.901; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24; MELAMED S, 1985, SCAND J REHABIL MED, P16; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Mort DJ, 2003, BRAIN, V126, P1986, DOI 10.1093/brain/awg200; Muller MM, 1998, NAT NEUROSCI, V1, P631, DOI 10.1038/2865; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PAVLOVSKAYA M, 1992, OPHTHAL PHYSL OPT, V12, P165, DOI 10.1111/j.1475-1313.1992.tb00282.x; Pavlovskaya M, 2002, J COGNITIVE NEUROSCI, V14, P745, DOI 10.1162/08989290260138645; Pavlovskaya M, 2001, SPATIAL VISION, V14, P151, DOI 10.1163/156856801300202913; Pavlovskaya M, 2001, BRAIN COGNITION, V47, P346; Pavlovskaya M, 1997, J COGNITIVE NEUROSCI, V9, P824, DOI 10.1162/jocn.1997.9.6.824; PAVLOVSKAYA M, 2006, IN PRESS BRAIN COGNI; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner MI, 1999, P NATL ACAD SCI USA, V96, P2585, DOI 10.1073/pnas.96.6.2585; POSNER MI, 1984, ATTENTION PERFORM, V10, P531; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Schendel KL, 2001, PERCEPT PSYCHOPHYS, V63, P577, DOI 10.3758/BF03194423; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Solanto MV, 1998, BEHAV BRAIN RES, V94, P127, DOI 10.1016/S0166-4328(97)00175-7; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; VALLAR G, 1994, J NEUROL NEUROSUR PS, V57, P464, DOI 10.1136/jnnp.57.4.464; VALLAR G, 1986, NEUROPSYCHOLOGIA, V24, P609, DOI 10.1016/0028-3932(86)90001-1; Vallar G, 2001, NEUROIMAGE, V14, pS52, DOI 10.1006/nimg.2001.0822; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Vandenberghe R., 1997, Society for Neuroscience Abstracts, V23, P300; Vandenberghe R, 1996, BRAIN, V119, P1263, DOI 10.1093/brain/119.4.1263; VANVOORHIS S, 1977, PERCEPT PSYCHOPHYS, V22, P54, DOI 10.3758/BF03206080; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VOLKOW ND, 2001, J NEUROSCI, V21, P1; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WILSON B, 1987, ARCH PHYS MED REHAB, V68, P98	73	12	13	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	5					489	497		10.1080/02699050701311117			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000005	17522988				2021-06-18	
J	Preece, MHW; Geffen, GM				Preece, Megan Haf Wyn; Geffen, Gina Malke			The contribution of pre existing depression to the acute cognitive sequelae of mild traumatic brain injury	BRAIN INJURY			English	Article						mild traumatic brain injury; concussion; depression; verbal memory; information processing speed	MAJOR DEPRESSION; RAPID SCREEN; HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; UNIPOLAR DEPRESSION; HIPPOCAMPAL VOLUME; WORD REPETITION; YOUNGER ADULTS; SYMPTOMS; MRI	Primary objective: To determine the effect of pre-existing depression on the cognitive sequelae of mild traumatic brain injury ( mTBI) within 24 hours of injury. Research design: A 2 x 2 between-subjects design was used to examine the effect of depression and injury type on neuropsychological test performance. The independent variables were the injury type ( mTBI or control) and the presence of depression ( depressed or not depressed). Methods and procedures: Participants who had sustained mTBI ( 30 with depression, 30 without depression) within the previous 24 hours and control participants ( 19 with depression, 30 without depression) were assessed on the Digit Symbol Substitution Test ( DSS), Hopkins Verbal Learning Test ( HVLT) and the Speed of Comprehension Test. Results: Participants with mTBI performed worse than controls on the tests, particularly HVLT delayed recall and DSS total correct. Participants with depression did not perform worse than participants without depression. However, there was a significant univariate interaction for HVLT recognition, participants who had sustained mTBI and were classified in the depressed group exhibited worse recognition compared to mTBI participants without depression. Conclusions: The results indicate that depression may interact with mTBI to impair word recognition during the acute phase after a head injury.	Univ Queensland, Sch Psychol, Cognit Psychophysiol Lab, Brisbane, Qld 4072, Australia	Preece, MHW (corresponding author), Univ Queensland, Sch Psychol, Cognit Psychophysiol Lab, McElwain Bldg, Brisbane, Qld 4072, Australia.	m.preece@psy.uq.edu.au	Preece, Megan/A-7186-2013	Preece, Megan/0000-0003-4852-8712			ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrews G, 1999, MENTAL HLTH AUSTR; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; BENCH CJ, 1995, PSYCHOL MED, V25, P247, DOI 10.1017/S0033291700036151; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BIVER F, 1994, BIOL PSYCHIAT, V36, P381, DOI 10.1016/0006-3223(94)91213-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Bremner JD, 2004, AM J PSYCHIAT, V161, P637, DOI 10.1176/appi.ajp.161.4.637; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; De Monte VE., 2005, BRAIN IMPAIR, V6, P109, DOI [10.1375/brim.2005.6.2.109, DOI 10.1375/BRIM.2005.6.2.109]; Falconer EK, 2006, BRAIN INJURY, V20, P1251, DOI 10.1080/02699050601049601; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Grant MM, 2001, BIOL PSYCHIAT, V50, P35, DOI 10.1016/S0006-3223(00)01072-6; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kolb B., 2003, FUNDAMENTALS HUMAN N; Korten A, 2000, BRIT J PSYCHIAT, V177, P325, DOI 10.1192/bjp.177.4.325; Kwapil KJ., 2003, BRAIN IMPAIR, V4, P155; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liotti M, 2001, J CLIN EXP NEUROPSYC, V23, P121, DOI 10.1076/jcen.23.1.121.1223; Lovibond S.H., 1995, MANUAL DEPRESSION AN; MARKOWITSCH HJ, 2000, OXFORD HDB MEMORY, P465; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Mayberg HS, 2004, ESSENTIALS NEUROPSYC, P489; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCULLOUGH CM, 2006, BRAIN IMPAIR, V7, P16; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; Rogers MA, 2004, NEUROSCI RES, V50, P1, DOI 10.1016/j.neures.2004.05.003; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SHEEDY J, IN PRESS EMERGENCY D; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheline YI, 2002, EUR PSYCHIAT, V17, p300S; Stanislaw H, 1999, BEHAV RES METH INS C, V31, P137, DOI 10.3758/BF03207704; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; von Gunten A, 2000, J NEUROPSYCH CLIN N, V12, P493, DOI 10.1176/appi.neuropsych.12.4.493; Wang CE, 2006, J AFFECT DISORDERS, V92, P283, DOI 10.1016/j.jad.2006.02.008; WESCHLER D, 1981, WESCHLER ADULT INTEL; Wilson, 1991, NATL ADULT READING T	77	12	12	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					951	961		10.1080/02699050701481647			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600007	17729048				2021-06-18	
J	Prins, SA; De Hoog, M; Blok, JH; Tibboel, D; Visser, GH				Prins, Sandra A.; De Hoog, Matthijs; Blok, Joleen H.; Tibboel, Dick; Visser, Gerhard H.			Continuous noninvasive monitoring of barbiturate coma in critically ill children using the Bispectral (TM) index monitor	CRITICAL CARE			English	Article							CARE	Introduction Traumatic brain injury and generalized convulsive status epilepticus (GCSE) are conditions that require aggressive management. Barbiturates are used to lower intracranial pressure or to stop epileptiform activity, with the aim being to improve neurological outcome. Dosing of barbiturates is usually guided by the extent of induced burst-suppression pattern on the electroencephalogram (EEG). Dosing beyond the point of burst suppression may increase the risk for complications without offering further therapeutic benefit. For this reason, careful monitoring of EEG parameters is mandatory. A prospective study was conducted to evaluate the usefulness of the bispectral index suppression ratio for monitoring barbiturate coma. Methods A prospective observational pilot study was performed at a paediatric (surgical) intensive care unit, including all children with barbiturate-induced coma after traumatic brain injury or GCSE. The BIS (TM) (Bispectral (TM) index) monitor expresses a suppression ratio, which represents the percentage of epochs per minute in which the EEG was suppressed. Suppression ratios from the BIS monitor were compared with suppression ratios of full-channel EEG as assessed by quantitative visual analysis. Results Five patients with GCSE and three patients after traumatic brain injury (median age 11.6 years, range 4 months to 15 years) were included. In four patients the correlation between the suppression ratios of the BIS and EEG could be determined; the average correlation was 0.68. In two patients, suppression ratios were either high or low, with no intermediate values. This precluded determination of correlation values, as did the isoelectric EEG in a further two patients. In the latter patients, the mean +/- standard error BIS suppression ratio was 95 +/- 1.6. Conclusion Correlations between suppression ratios of the BIS and EEG were found to be only moderate. In particular, asymmetrical EEGs and EEGs with short bursts (less than 1 second) may result in aberrant BIS suppression ratios. The BIS monitor potentially aids monitoring of barbiturate-induced coma because it provides continuous data on EEG suppression between full EEG registrations, but it should be used with caution.	[Prins, Sandra A.; Tibboel, Dick] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat Surg,Intens Care Unit, NL-3015 GJ Rotterdam, Netherlands; [De Hoog, Matthijs] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat,Intens Care Unit, NL-3015 GJ Rotterdam, Netherlands; [Blok, Joleen H.; Visser, Gerhard H.] Erasmus Univ, Med Ctr, Dept Clin Neurophysiol, NL-3015 CE Rotterdam, Netherlands	Tibboel, D (corresponding author), Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat Surg,Intens Care Unit, Dr Molewaterplein 60, NL-3015 GJ Rotterdam, Netherlands.	d.tibboel@erasmusmc.nl	de Hoog, Matthijs/A-3882-2013	Blok, Joleen/0000-0001-9661-5816; Prins, Sandra/0000-0002-4695-5246			ADELSON PD, 2003, PEDIAT CRIT CARE S3, pS49; Arbour Richard, 2003, AACN Clin Issues, V14, P185, DOI 10.1097/00044067-200305000-00009; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Grindstaff Ryan J, 2004, J Intensive Care Med, V19, P111, DOI 10.1177/0885066603262066; Hinkle DE, 1998, APPL STAT BEHAV SCI; Jaggi P, 2003, PEDIATR NEUROL, V28, P219, DOI 10.1016/S0887-8994(02)00633-1; Kwan P, 2004, EPILEPSIA, V45, P1141, DOI 10.1111/j.0013-9580.2004.12704.x; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; TASKER RC, 1990, INTENS CARE MED, V16, P60, DOI 10.1007/BF01706327; van Gestel JPJ, 2005, NEUROLOGY, V65, P591, DOI 10.1212/01.wnl.0000173066.89001.f9; WINER JW, 1991, NEUROSURGERY, V29, P739, DOI 10.1227/00006123-199111000-00016; Winer JW, 1991, NEUROSURGERY, V29, P741; Yanay O, 2004, J CRIT CARE, V19, P174, DOI 10.1016/j.jcrc.2004.07.008	15	12	14	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2007	11	5							R108	10.1186/cc6138			7	Critical Care Medicine	General & Internal Medicine	264KO	WOS:000253286400015	17897479	DOAJ Gold, Green Published			2021-06-18	
J	Quintana, A; Giralt, M; Molinero, A; Campbell, IL; Penkowa, M; Hidalgo, J				Quintana, Albert; Giralt, Mercedes; Molinero, Amalia; Campbell, Iain L.; Penkowa, Milena; Hidalgo, Juan			Analysis of the cerebral transcriptome in mice subjected to traumatic brain injury: Importance of IL-6	NEUROIMMUNOMODULATION			English	Article; Proceedings Paper	2nd Iberoamerican Congress on Neuroimmunomodulation	APR 19-22, 2007	Madrid, SPAIN			IL-6 microarrays; cryoinjury; GFAP-IL6 mice; transcriptome	ASTROCYTE-TARGETED EXPRESSION; CENTRAL-NERVOUS-SYSTEM; II-DEFICIENT MICE; IMPAIRED INFLAMMATORY RESPONSE; GENE-EXPRESSION; METALLOTHIONEIN-I; TRANSGENIC MICE; PLUS II; MICROARRAY TECHNOLOGY; OXIDATIVE STRESS	Traumatic brain injury is one of the leading causes of incapacity and death among young people. Injury to the brain elicits a potent inflammatory response, comprising recruitment of inflammatory cells, reactive astrogliosis and activation of brain macrophages. Under the influence of presumably several cytokines and growth factors, a cascade of events is activated that result ultimately in increased oxidative stress and tissue damage, but also in activation of counterregulatory factors and tissue regeneration. The complexity of this response is being unraveled by high-throughput methodologies such as microarrays. The combination of these modern techniques with the comparison of normal and genetically modified mice boosts the significance of the results obtained. With this approach, we have demonstrated that a cytokine such as interleukin-6 is one of the key players in the response of the brain to injury. Copyright (C) 2007 S. Karger AG, Basel.	Univ Autonoma Barcelona, Fac Sci, Anim Physiol Unit, Dept Cell Biol Physiol & Immunol,Inst Neurosci, ES-08193 Barcelona, Spain; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW, Australia; Univ Copenhagen, Fac Hlth Sci, Ctr Inflammat & Metab, Sect Neuroprotect, Copenhagen, Denmark	Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Sci, Anim Physiol Unit, Dept Cell Biol Physiol & Immunol,Inst Neurosci, ES-08193 Barcelona, Spain.	juan.hidalgo@uab.cat	molinero, amalia/K-2147-2014; Hidalgo, Juan/C-9082-2011; Giralt, Mercedes/K-1626-2014; Quintana, Albert/N-5544-2015	molinero, amalia/0000-0001-8661-8570; Hidalgo, Juan/0000-0003-0921-1122; Giralt, Mercedes/0000-0002-1806-1528; Quintana, Albert/0000-0003-1674-7160			Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Collins FS, 2007, CELL, V128, P9, DOI 10.1016/j.cell.2006.12.018; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; Gebicke-Haerter PJ, 2005, J NEUROSCI RES, V81, P327, DOI 10.1002/jnr.20479; Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Insel TR, 2004, NAT NEUROSCI, V7, P426, DOI 10.1038/nn0504-426; Kury P, 2004, EUR J NEUROSCI, V19, P1708, DOI 10.1111/j.1460-9568.2004.03226.x; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lu XCM, 2004, J NEUROSCI RES, V77, P843, DOI 10.1002/jnr.20218; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mirnics K, 2004, NAT NEUROSCI, V7, P434, DOI 10.1038/nn1230; Molinero A, 2003, J NEUROPATH EXP NEUR, V62, P315, DOI 10.1093/jnen/62.3.315; Natale JE, 2004, J NEUROSCI RES, V78, P303, DOI 10.1002/jnr.20265; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Quintana A, 2007, J NEUROSCI RES, V85, P2668, DOI 10.1002/jnr.21126; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Read SJ, 2001, J CEREBR BLOOD F MET, V21, P755, DOI 10.1097/00004647-200107000-00001; Roth A, 2003, MOL CELL NEUROSCI, V22, P353, DOI 10.1016/S1044-7431(02)00039-8; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x	44	12	12	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401			NEUROIMMUNOMODULAT	Neuroimmunomodulation		2007	14	3-4					139	143		10.1159/000110637			5	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	238HI	WOS:000251437700005	18073505				2021-06-18	
J	Simpson, G; Franke, B; Gillett, L				Simpson, Grahame; Franke, Bernie; Gillett, Lauren			Suicide prevention training outside the mental health service system - Evaluation of a state-wide program in Australia for rehabilitation and disability staff in the field of traumatic brain injury	CRISIS-THE JOURNAL OF CRISIS INTERVENTION AND SUICIDE PREVENTION			English	Article						traumatic brain injury; training; suicide prevention	INTERVENTION; ASSOCIATION; CONTACT; PEOPLE	The training needs of staff working in mainstream (i.e., noncrisis) health settings with client groups that have moderate levels of suicide risk have not been extensively addressed. An initiative to train rehabilitation and disability staff working in the field of traumatic brain injury TBI) is described. A program was adapted from a generic state health department training program, and disseminated by means of established training networks within the brain injury field. Program efficacy was evaluated as the training was provided across the state of Victoria in a series of 1-day workshops. Participants (n = 86) completed two evaluation measures designed for this purpose (objective knowledge test, self-rating of knowledge and skills) on three occasions (pre- and postworkshop, 6-month follow-up). Compared to a control group of rehabilitation and disability workers who did not receive the training (n = 27), the workshop participants made significant gains in objective knowledge and reported skills, and maintained these gains at the 6-month follow-up. The Suicide Interview Response Inventory-2 (Neimeyer & Pfeiffer, 1994) was administered to a subgroup of participants as a validating measure, and correlated significantly with scores from the objective knowledge test. This process may provide a template for developing more fine-grained suicide prevention strategies among other health-related at-risk groups.	Liverpool Hosp, Brain Ijury Rehabil Unit, Sydney, NSW, Australia; McKellar Ctr, Training & Secondary Consultat Project, Geelong, Vic, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool bc, NSW 1871, Australia.	grahame.simpson@swsahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060			ADRIAN J, 1996, INF TRAINING STRATEG; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Appleby L, 1999, BRIT MED J, V318, P1235; Beautrais AL, 2005, CRISIS, V26, P1, DOI 10.1027/0227-5910.26.1.1; Booth N, 2000, INT REV PSYCHIATR, V12, P27, DOI 10.1080/09540260074085; Burgess P, 2000, PSYCHIATR SERV, V51, P1555, DOI 10.1176/appi.ps.51.12.1555; CLARK D. C., 1992, SUICIDE GUIDELINES A, P16; Commonwealth Department of Health and Ageing, 2000, LIF FRAM PREV SUIC S; Connolly John, 2002, Crisis, V23, P143, DOI 10.1027//0227-5910.23.4.143; Crawford MJ, 1998, J ACCID EMERG MED, V15, P18; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Gorsuch R. L., 1974, FACTOR ANAL; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; Metha A, 1998, SUICIDE LIFE-THREAT, V28, P150; Neimeyer RA, 1997, DEATH STUD, V21, P59; NEIMEYER RA, 1994, DEATH STUD, V18, P179; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; *NEW S WAL HLTH, 1999, SUIC RISK ASS MAN RE; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ramberg Inga-Lill, 2004, Arch Suicide Res, V8, P331, DOI 10.1080/13811110490476707; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2003, J HEAD TRAUMA REHAB, V18, P445, DOI 10.1097/00001199-200309000-00006; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMPSON GK, 2001, SUICIDE PREVENTION T; STREINER DL, 1993, CAN J PSYCHIAT, V38, P140, DOI 10.1177/070674379303800214; Tabachnick BG, 2013, USING MULTIVARIATE S; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tierney R J, 1994, Crisis, V15, P69; TURLEY B, 1998, LIVING WORKS AUSTR F; *VICT DEP HUM SERV, 2004, ACQ BRAIN INJ MENT I; *WHO, 1999, FACTS FIG SUIC TECHN; *WHO, 1996, GLOB BURD DIS INJ SE	39	12	12	0	2	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY	0227-5910			CRISIS	Crisis		2007	28	1					35	43		10.1027/0227-5910.28.1.35			9	Psychiatry; Psychology, Multidisciplinary	Psychiatry; Psychology	167GW	WOS:000246440600006	17555031				2021-06-18	
J	Tilford, JM; Aitken, ME; Goodman, AC; Fiser, DH; Killingsworth, JB; Green, JW; Adelson, PD				Tilford, John M.; Aitken, Mary E.; Goodman, Allen C.; Fiser, Debra H.; Killingsworth, Jeffrey B.; Green, Jerril W.; Adelson, P. David			Child health-related quality of life following neurocritical care for traumatic brain injury: an analysis of preference-weighted outcomes	NEUROCRITICAL CARE			English	Article						utility values; economic evaluation; outcome assessment; quality of life	PEDIATRIC INTENSIVE-CARE; SEVERE HEAD-INJURY; STATES WORSE; UTILITY; SF-6D; MANAGEMENT; VALIDITY; THERAPY; DISEASE; TRIAL	Background Cost-effectiveness analysis relies on preference-weighted health outcome measures as they form the basis for quality adjusted life years. Studies of preference-weighted outcomes for children following traumatic brain injury are lacking. Objective This study seeks to describe the preference-weighted health outcomes of children following a traumatic brain injury at 3- and 6-months following pediatric intensive care unit (ICU) discharge. Setting/Patients Children aged 5-17 who required ICU admission and endotracheal intubation or mechanical ventilation. Main Outcome Measures The Quality of Well-being (QWB) score was used to describe preference-weighted outcomes. Clinical measures from the intensive care unit stay were used to estimate risk of mortality. Risk of mortality, Glasgow coma scores, patient length of stay in the intensive care unit, and parent-reported items from the Child Health Questionnaire (CHQ) were used to test construct validity. Methods Subject data were obtained from nine pediatric intensive care units with consent procedures approved by representative institutional review boards. Medical records containing clinical information from the ICU stay were abstracted by the study coordinating center. Caregivers of children were contacted by telephone for follow-up interviews at 3- and 6-months following ICU discharge. All interviews were conducted by telephone with the primary caregiver of the injured child. Preference score statistics are presented overall and in relation to characteristics of the patient and their ICU admission. Results A response rate of 59% was achieved for the 3-month interviews (N = 56) and 67% for the 6-month interviews (N = 65) for caregivers of children aged 5 years and above that consented to participate. Overall, QWB scores averaged 0.508 (95% Cl: 0.454-0.562) at the 3-month interview and 0.582 (95% Cl: 0.526-0.639) at the 6-month interview. For both interview periods, scores ranged from 0.093 to 1.0 on a 0-1 value scale, where 0 represents death and 1 represents perfect health. Specific acute and chronic health problems from the QWB scale were present more often in patients with higher injury severity. Mortality risk, ICU length of stay, Glasgow Coma Scales, and parental reported summary scores from the CHQ all correlated correctly with the QWB scores. Conclusions The findings support the use of the QWB score with parental report to measure preference-weighted health outcomes of children following a traumatic brain injury. Information from the study can be used in economic evaluations of interventions to prevent or treat traumatic brain injuries in children.	Univ Arkansas Med Sci, Arkansas Childrens Hosp, Coll Med, Dept Pediat, Little Rock, AR 72202 USA; Wayne State Univ, Dept Econ, Detroit, MI 48212 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA	Tilford, JM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Coll Med, Dept Pediat, Little Rock, AR 72202 USA.	tilfordmickj@uams.edu	Adelson, David/W-2083-2019	Aitken, Mary/0000-0002-8318-9755			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Aitken ME, 2002, PEDIATRICS, V110, P337, DOI 10.1542/peds.110.2.337; BELL CM, 1999, MED DECIS MAKING, V19, P519; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866; Brent RJ, 2003, COST-BENEFIT ANALYSIS AND HEALTH CARE EVALUATIONS, P1; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; CZYZEWSKI DI, 1994, MED CARE, V32, P965, DOI 10.1097/00005650-199409000-00007; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Frosch DL, 2004, ARTHRIT RHEUM-ARTHR, V51, P28, DOI 10.1002/art.20071; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JB, 1996, NEUROTRAUMA; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Gold MR., 1996, COST EFFECTIVENESS H, P82; Griebsch I, 2005, PEDIATRICS, V115, pE600, DOI 10.1542/peds.2004-2127; Groessl EJ, 2004, AM J PREV MED, V26, P126, DOI 10.1016/j.amepre.2003.10.007; Groessl EJ, 2003, ARTHRIT RHEUM-ARTHR, V49, P23, DOI 10.1002/art.10903; Hatoum HT, 2004, VALUE HEALTH, V7, P602, DOI 10.1111/j.1524-4733.2004.75011.x; Heard C, 2002, CRIT CARE MED, V30, P1403, DOI 10.1097/00003246-200206000-00059; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; KAPLAN RM, 1996, QUALITY LIFE PHARMAC, P309; Killingsworth JB, 2005, PEDIATRICS, V115, pE316, DOI 10.1542/peds.2004-1585; KUMAR R, 1991, CHILD NERV SYST, V7, P299, DOI 10.1007/BF00304824; Landgraf JM, 1998, MEASURING HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS, P105; LANDGRAF JM, 1996, CHQ USERS MANUAL; Marra CA, 2005, SOC SCI MED, V60, P1571, DOI 10.1016/j.socscimed.2004.08.034; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Neumann PJ, 2000, ANNU REV PUBL HEALTH, V21, P587, DOI 10.1146/annurev.publhealth.21.1.587; O'Brien BJ, 2003, HEALTH ECON, V12, P975, DOI 10.1002/hec.789; Parsons SK, 1999, INT J CANCER, P46; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; Pyne JM, 2003, J AFFECT DISORDERS, V76, P237, DOI 10.1016/S0165-0327(03)00106-X; Robinson A, 2006, HEALTH ECON, V15, P393, DOI 10.1002/hec.1069; Skinner JS, 2006, HEALTH AFFAIR, V25, pW34, DOI 10.1377/hlthaff.25.w34; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; SMITHOLINDE L, 2006, HLTH STATE PREFERENC; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tilford JM, 2002, AMBUL PEDIATR, V2, P330, DOI 10.1367/1539-4409(2002)002<0330:CEAAEM>2.0.CO;2; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TILFORD JM, 2006, AM ASS HLTH EC NAT M; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043	50	12	14	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2007	7	1					64	75		10.1007/s12028-007-0037-5			12	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	200EN	WOS:000248746800012	17657658				2021-06-18	
J	Ang, JHY; Man, DWK				Ang, Josephine Hui Yung; Man, David Wai Kwong			The discriminative power of the Wolf motor function test in assessing upper extremity functions in persons with stroke	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						assessment; function; motor; rehabilitation; stroke	TRAUMATIC BRAIN-INJURY; UPPER-LIMB FUNCTION; BARTHEL INDEX; REHABILITATION; RELIABILITY; PERFORMANCE; POSTSTROKE; RECOVERY	The Wolf motor function test is a new time-based method to evaluate upper extremity function both on a joint-specific level and on total limb movements, while performing some functional tasks. The purpose of this paper is to investigate the discriminating power of the Wolf motor function test in classifying individuals with stroke into different levels according to Brunnstrom's stages of recovery. Discriminant analysis was used and the results showed that the Wolf motor function test can classify 86.7% of original grouped cases into the correct groupings. A high correlation was found between the Wolf motor function test, the Brunnstrom stages of recovery and the Fugl-Meyer Assessment. The Wolf motor function test is found to be an instrument capable of discriminating the upper extremity motor function of the individuals with stroke into different functional groups.	Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China; Hosp Author, Occupat Therapy Dept, MacLehose Med Rehab Ctr, Hong Kong, Hong Kong, Peoples R China	Man, DWK (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.	rsdavid@polyu.edu.hk					ARNADOTTIR G, 1990, BRAIN BEHAV ASSESSIN; AUGER C, 1991, PHYSIOTHER CAN, V43, P6; Bogousslavsky J, 2001, STROKE SYNDROMES; Brunnstrom S, 1966, Phys Ther, V46, P357; Caplan LR, 2000, CAPLANS STROKE CLIN; CLARKE B, 1983, PHYSIOTHER CAN, V35, P207; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; De Souza L H, 1980, Int Rehabil Med, V2, P3; DESROSIERS J, 1991, TEMPA ADM MANUAL; Ebrahim S, 1999, STROKE EPIDEMIOLOGY; FILIATRAULT J, 1991, AM J OCCUP THER, V45, P806, DOI 10.5014/ajot.45.9.806; FUGLMEYER AR, 1980, SCAND J REHABIL MED, P85; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1990, STROKE, V21, P46; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; GRANGER CV, 1982, KRUSENS HDB PHYSICAL, P253; GRESHAM GE, 1984, FUNCTIONAL ASSESSMEN, P65; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Higgins J, 2005, J REHABIL RES DEV, V42, P65, DOI 10.1682/JRRD.2003.10.0156; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Kaste M, 1998, PUBLIC HEALTH, V112, P103; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Lincoln N, 1979, Physiotherapy, V65, P48; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; MAHONEY F I, 1965, Md State Med J, V14, P61; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Parker V M, 1986, Int Rehabil Med, V8, P69; Perry C E, 1967, Am J Phys Med, V46, P789; Richards L, 2001, OCCUP THER J RES, V21, P201, DOI 10.1177/153944920102100304; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Smith Rosemary Hastings, 1994, Physiotherapy Theory and Practice, V10, P87, DOI 10.3109/09593989409047445; Sodring KM, 1995, SCAND J REHABIL MED, V27, P211; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; WILSON DJ, 1984, AM J OCCUP THER, V38, P159, DOI 10.5014/ajot.38.3.159; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; YARKONY GM, 1987, ARCH NEUROL-CHICAGO, V44, P93, DOI 10.1001/archneur.1987.00520130071020	39	12	16	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0342-5282	1473-5660		INT J REHABIL RES	Int. J. Rehabil. Res.	DEC	2006	29	4					357	361					5	Rehabilitation	Rehabilitation	134JP	WOS:000244079600016	17106357				2021-06-18	
J	Bornstein, SR; Wong, ML; Licinio, J				Bornstein, S. R.; Wong, M. -L.; Licinio, J.			150 years of Sigmund Freud: what would Freud have said about the obesity epidemic?	MOLECULAR PSYCHIATRY			English	Article						Sigmund Freud; unconscious; obesity	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; AMYGDALA; MODELS; MEMORY	The 150th birthday of Sigmund Freud has triggered widespread interest and media coverage on his unique contribution and impact on society. Recent evidence from neuroscience and advanced imaging technology has provided support for some of his major concepts including the unconscious and the key role of early life events. In this perspective, we attempt to write on his behalf an updated version of a Freudian way of thinking focused on the current high rates of obesity and depression.	Univ Dresden, Dept Med, D-01307 Dresden, Germany; Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33152 USA	Bornstein, SR (corresponding author), Univ Dresden, Dept Med, Carl Gustav Carus,Fetscherstr 74, D-01307 Dresden, Germany.	Stefan.Bornstein@uniklinikum-dresden.de	Licinio, Julio/L-4244-2013; Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020	Licinio, Julio/0000-0001-6905-5884; Wong, Ma-Li/0000-0003-1512-3073; 			BORNSTEIN SR, 2006, MOL PSYCHIAT    0801; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; Dahlquist G, 2006, DIABETOLOGIA, V49, P20, DOI 10.1007/s00125-005-0076-4; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gunstad J, 2006, PSYCHIAT RES, V142, P31, DOI 10.1016/j.psychres.2005.11.007; Jo YH, 2005, NEURON, V48, P1055, DOI 10.1016/j.neuron.2005.10.021; Keeley MB, 2006, LEARN MEMORY, V13, P135, DOI 10.1101/lm.86906; Kirkham T. C., 2006, CNS & Neurological Disorders-Drug Targets, V5, P275, DOI 10.2174/187152706777452272; Kosten TA, 2006, BRAIN RES, V1087, P142, DOI 10.1016/j.brainres.2006.03.009; Matias I, 2006, J CLIN ENDOCR METAB, V91, P3171, DOI 10.1210/jc.2005-2679; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Wells JCK, 2006, BIOL REV, V81, P183, DOI 10.1017/S1464793105006974	15	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	DEC	2006	11	12					1070	1072		10.1038/sj.mp.4001912			3	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	110ZH	WOS:000242419600004	17130885	Bronze			2021-06-18	
J	Demir, SO; Altinok, N; Aydin, G; Koseoglu, F				Demir, Sibel Ozbudak; Altinok, Nermin; Aydin, Gulumser; Koseoglu, Fusun			Functional and cognitive progress in aphasic patients with traumatic brain injury during post-acute phase	BRAIN INJURY			English	Article						traumatic brain injury; aphasia; functional-cognitive outcome; rehabilitation	REHABILITATION; THERAPY; RECOVERY; LANGUAGE; IMPAIRMENT; EFFICACY; SPEECH	Objectives: To investigate the relationship between language functions and cognitive and functional outcome and to evaluate the effects of a conventional language rehabilitation programme on aphasic adult patients in the post-acute stage of traumatic brain injury (TBI). Design: Non-concurrent prospective study. Patients were assessed pre-treatment and post-treatment with standardized assessment tools. Subjects: Sixty-one aphasic patients with TBI who were admitted to a rehabilitation centre in the post-acute phase for a late inpatient rehabilitation programme. Methods: The motor sub-scales of the Functional Independence Measures and Disability Rating Scale were used to assess functional status and disability. Cognitive status was evaluated with the Mini-Mental Status Examination and the Functional Independence Measure cognitive sub-scale. The language function was evaluated with the Gulhane Aphasia Test. Results: All functional, cognitive and language scores increased significantly during the rehabilitation programme. Language functions at admission were correlated with the Functional Independence Measure motor change scores and the Mini-Mental Status Examination change scores. Regression analyses revealed that auditory comprehension at admission was the most important independent determinant of functional and cognitive gain during rehabilitation. Conclusion: Post-acute language functions after late admission to a rehabilitation centre appear to be related to measures of cognitive and functional progress in patients with TBI. Functional and cognitive outcome is mainly affected by auditory comprehension. Results also showed the effectiveness of post-acute conventional rehabilitation in improving language functions.	Hosp Minist Hlth, Ankara Phys Med & Rehabil Educ & Res, Ankara, Turkey; Kirikkale Univ, Dept Phys Med & Rehabil, Fac Med, Kirikkale, Turkey	Demir, SO (corresponding author), 12 Cadde 11-6 Aytekinler Apt, TR-06450 Ankara, Turkey.	sibiozbudak@hotmail.com	Aydin, Gulumser/AAC-3912-2020; Aydin, Gulumser/AAS-4112-2020				Aftonomos LB, 1997, ARCH PHYS MED REHAB, V78, P841, DOI 10.1016/S0003-9993(97)90197-0; Aftonomos LB, 1999, STROKE, V30, P1370, DOI 10.1161/01.STR.30.7.1370; BASSO A, 1979, ARCH NEUROL-CHICAGO, V36, P190, DOI 10.1001/archneur.1979.00500400044005; Basso A, 2001, APHASIOLOGY, V15, P307, DOI 10.1080/02687040042000304; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Carlomagno S, 2001, ARCH PHYS MED REHAB, V82, P1073, DOI 10.1053/apmr.2001.25155; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Darley F L, 1975, Adv Neurol, V7, P111; DEMIR OS, 2005, J REHABILITATION MED, V37, P1; Diamond PT, 1996, AM J PHYS MED REHAB, V75, P40, DOI 10.1097/00002060-199601000-00011; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gil M, 1996, BRAIN INJURY, V10, P39, DOI 10.1080/026990596124700; Goodglass H., 1983, ASSESSMENT APHASIA R; Heruti RJ, 2002, ARCH PHYS MED REHAB, V83, P742, DOI 10.1053/apmr.2002.32739; Hesketh A, 1997, EUR J DISORDER COMM, V32, P189; Isaki E, 2000, BRAIN INJURY, V14, P441; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Laganaro M, 2006, NEUROPSYCHOLOGIA, V44, P534, DOI 10.1016/j.neuropsychologia.2005.07.005; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; Musso M, 1999, BRAIN, V122, P1781, DOI 10.1093/brain/122.9.1781; NICHOLAS ML, 1993, ARCH PHYS MED REHAB, V74, P830, DOI 10.1016/0003-9993(93)90009-Y; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Rao RP, 1996, PHYS MED REHABILITAT, P55; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rey GJ, 2001, CLIN NEUROPSYCHOL, V15, P13, DOI 10.1076/clin.15.1.13.1911; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; WHURR R, 1992, EUR J DISORDER COMM, V27, P1; Worrall L, 2000, APHASIOLOGY, V14, P911, DOI 10.1080/02687030050127711; Yavuzer G, 2001, INT J REHABIL RES, V24, P241, DOI 10.1097/00004356-200109000-00011; Youse KM, 2004, BRAIN INJURY, V18, P825, DOI 10.1080/02699000410001671784	35	12	13	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1383	1390		10.1080/02699050601081844			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100008	17378230				2021-06-18	
J	Stoll, M; Capper, D; Dietz, K; Warth, A; Schleich, A; Schlaszus, H; Meyermann, R; Mittelbronn, M				Stoll, M.; Capper, D.; Dietz, K.; Warth, A.; Schleich, A.; Schlaszus, H.; Meyermann, R.; Mittelbronn, M.			Differential microglial regulation in the human spinal cord under normal and pathological conditions	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						human; microglia; regulation; spinal cord	INFLAMMATORY FACTOR-I; AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; BRAIN-INJURY; RAT-BRAIN; EXPRESSION; ACTIVATION; LESIONS; CELLS	As the primary intrinsic immune effector cells of the central nervous system, microglia are involved in virtually all pathological processes of the brain and spinal cord including inflammatory, neurodegenerative, traumatic, neoplastic and vascular diseases. Despite this important role, there is a lack of data concerning microglial distribution and protein expression in the human spinal cord. In this study, we immunohistochemically investigated 10 normal human spinal cords to establish reference data and compared these results with 15 pathological human spinal cords deriving from distinct pathologies. Each spinal cord was evaluated at eight different levels for three white and two grey matter areas for both constitutive (MHC-II, CD68, IL-16, AIF-1, LCA, CD4) and reactive (MRP-8, MRP-14) microglial antigens. Whereas previous studies revealed significant regional differences in microglial distribution and protein expression in human brain, normal spinal cord displayed a uniform expression pattern, reaching levels of up to 17% MHC-II positive cells of the total cell population. This datum formed the basis for the further evaluation of microglia expression levels in pathological spinal cords, where levels of up to 45% positive cells were observed. Our results represent important reference values for future neuropathological diagnostic and therapeutical approaches in spinal cord pathologies.	Univ Tubingen, Inst Brain Res, Sch Med, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Biometry, Tubingen, Germany; Univ Tubingen, Inst Pathol, D-7400 Tubingen, Germany	Mittelbronn, M (corresponding author), Univ Tubingen, Inst Brain Res, Sch Med, Calwer St 3, D-72076 Tubingen, Germany.	michel-guy-andr.mittelbronn@med.uni-tuebingen.de	Dietz, Klaus/R-9268-2016; Capper, David/I-8500-2014	Dietz, Klaus/0000-0001-8503-9737; Mittelbronn, Michel/0000-0002-2998-052X; Capper, David/0000-0003-1945-497X			Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; Baron P, 2005, MUSCLE NERVE, V32, P541, DOI 10.1002/mus.20376; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Center DM, 2000, IMMUNOL TODAY, V21, P273, DOI 10.1016/S0167-5699(00)01629-7; Center DM, 1997, INT J BIOCHEM CELL B, V29, P1231, DOI 10.1016/S1357-2725(97)00053-8; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; Deininger MH, 2002, FEBS LETT, V514, P115, DOI 10.1016/S0014-5793(02)02430-4; Drew PD, 2000, BRAIN RES BULL, V52, P391, DOI 10.1016/S0361-9230(00)00275-6; ENGELHARDT JI, 1990, ARCH NEUROL-CHICAGO, V47, P1210, DOI 10.1001/archneur.1990.00530110068019; FALINI B, 1993, AM J PATHOL, V142, P1359; FREI K, 1994, J IMMUNOL, V152, P2720; GEHRMANN J, 1993, J NEUROIMMUNOL, V48, P189, DOI 10.1016/0165-5728(93)90191-Z; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Guo LH, 2004, J NEUROIMMUNOL, V146, P39, DOI 10.1016/j.jneuroim.2003.09.017; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Hirikoshi Y, 2003, ACTA NEUROPATHOL, V105, P157, DOI 10.1007/s00401-002-0627-4; HOLNESS CL, 1993, BLOOD, V81, P1607; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jellinger K, 1975, Acta Neuropathol Suppl, VSuppl 6, P95; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; LING EA, 1976, ACTA ANAT, V96, P188; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; Mathy NL, 2000, J IMMUNOL, V164, P4429, DOI 10.4049/jimmunol.164.9.4429; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; MORI S, 1969, J COMP NEUROL, V135, P57, DOI 10.1002/cne.901350104; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138; Postler E, 2000, J NEUROIMMUNOL, V108, P244, DOI 10.1016/S0165-5728(00)00283-6; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Rauschka H, 2003, EUR J NEUROL, V10, P479, DOI 10.1046/j.1468-1331.2003.00644.x; Rezaie P, 1999, DEV BRAIN RES, V115, P71, DOI 10.1016/S0165-3806(99)00043-7; Rezaie P, 1999, MICROSC RES TECHNIQ, V45, P359, DOI 10.1002/(SICI)1097-0029(19990615)45:6<359::AID-JEMT4>3.0.CO;2-D; Rezaie Payam, 2002, J Hist Neurosci, V11, P325, DOI 10.1076/jhin.11.4.325.8531; Sasaki A, 2004, NEUROPATH APPL NEURO, V30, P447, DOI 10.1111/j.1365-2990.2004.00556.x; Schluesener HJ, 1998, ACTA NEUROPATHOL, V96, P575, DOI 10.1007/s004010050938; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Schmitt AB, 2000, ACTA NEUROPATHOL, V100, P528, DOI 10.1007/s004010000221; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab JM, 2001, J NEUROIMMUNOL, V119, P214, DOI 10.1016/S0165-5728(01)00375-7; Shibata M, 2004, STROKE, V35, P2598, DOI 10.1161/01.STR.0000143725.19053.60; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Turrin NP, 2004, NEUROBIOL DIS, V16, P321, DOI 10.1016/j.nbd.2004.03.010; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; VASS K, 1990, AM J PATHOL, V137, P789; VOLK HD, 1991, BEHRING I MITT, V88, P208; Wierzba-Bobrowicz T, 2001, FOLIA NEUROPATHOL, V39, P49; Zeinstra E, 2000, NEUROREPORT, V11, P89, DOI 10.1097/00001756-200001170-00018; Zhou Y, 2005, MOL CELL PROTEOMICS, V4, P1471, DOI 10.1074/mcp.M500114-MCP200	53	12	13	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	DEC	2006	32	6					650	661		10.1111/j.1365-2990.2006.00774.x			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	101XM	WOS:000241774600009	17083479				2021-06-18	
J	Barrow, IM; Collins, JN; Britt, LD				Barrow, Irene M.; Collins, Jay N.; Britt, L. D.			The influence of an auditory distraction on rapid naming after a mild traumatic brain injury: A longitudinal study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury; latency; accuracy; naming; auditory distraction; recovery	HEAD-INJURY; REACTION-TIME; PERCEPTUAL DIFFERENTIATION; OBJECT RECOGNITION; ATTENTION DEFICITS; LEXICAL RETRIEVAL; TASK; IMPAIRMENTS; ADOLESCENTS; ACQUISITION	Objective: The purpose of this investigation was to examine speeded performance over time and the impact of a common auditory distraction on performance after a mild traumatic brain injury (MTBI). Methods: Fourteen adults (ages 1853) treated for a MTBI and 14 age and education-matched controls were asked to perform two speeded naming tasks. Both tasks were presented with or without the presence a common auditory distraction. The MTBI group was tested within 5 days, 30 days, 60 days, and 6 months postinjury. Latency (ms) and accuracy of response were recorded. Results: Initially, the MTBI group demonstrated significantly longer response latencies and lower accuracy levels for both tasks. Similar results were found at 30 days postinjury. At 60 days postinjury, no significant difference was found for task 1 accuracy. Significant differences remained for task 1 latency, task 2 latency, and task 2 accuracy. At 6 months postinjury, no significant differences were found. The presence of an auditory distraction differentially affected the MTBI group for task 2 accuracy upon initial testing and at 30 days postinjury only. Conclusions: The MTBI group performed both tasks significantly slower and less accurately than the control group upon initial testing and at 30 days postinjury. The presence of pop music further influenced accuracy of complex processing. At 60 days postinjury, accuracy of simple processing returned to preinjury levels and the auditory distraction no longer differentially influenced the MTBI group. All performance differences were resolved at 6 months postinjury.	Hampton Univ, Dept Communicat Sci & Disorders, Hampton, VA 23668 USA; Eastern Virginia Med Sch, Dept Surg, Norfolk, VA 23501 USA	Barrow, IM (corresponding author), Hampton Univ, Dept Communicat Sci & Disorders, 201 Sci & Technol, Hampton, VA 23668 USA.	irene.barrow@hamptonu.edu					ABBOUD H, 1997, SUPERLAB PRO COMPUTE; Adamovich B. B., 1992, SCALES COGNITIVE ABI; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Barrow IM, 2003, J TRAUMA, V54, P888, DOI 10.1097/01.TA.0000057150.60668.7C; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COEHLO CA, 1996, J SPEECH HEARING S 1, V39, pS5; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Cycowicz YM, 1997, J EXP CHILD PSYCHOL, V65, P171, DOI 10.1006/jecp.1996.2356; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; Ellis AW, 1998, J EXP PSYCHOL LEARN, V24, P515, DOI 10.1037/0278-7393.24.2.515; Gerlach C, 1999, BRAIN, V122, P2159, DOI 10.1093/brain/122.11.2159; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; Hayden M E, 1997, AAOHN J, V45, P635; HUMPHREYS GW, 1987, VISUAL OBJECT PROCES; JENKINS A, 1986, LANCET, V2, P445; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LloydJones T, 1997, MEM COGNITION, V25, P606, DOI 10.3758/BF03211303; LloydJones TJ, 1997, MEM COGNITION, V25, P18, DOI 10.3758/BF03197282; LordMaes J, 1996, J LEARN DISABIL, V29, P609, DOI 10.1177/002221949602900605; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MARTIN N, 1989, J MEM LANG, V28, P462, DOI 10.1016/0749-596X(89)90022-3; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORRISON CM, 1992, MEM COGNITION, V20, P705, DOI 10.3758/BF03202720; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perani D, 1999, NEUROPSYCHOLOGIA, V37, P293, DOI 10.1016/S0028-3932(98)00073-6; Robinson-Boone KA, 1999, J MED SPEECH-LANG PA, V7, P47; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Snodgrass JG, 1996, BEHAV RES METH INSTR, V28, P516, DOI 10.3758/BF03200540; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; THEIOS J, 1989, PSYCHOL REV, V96, P5, DOI 10.1037/0033-295X.96.1.5; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VITKOVITCH M, 1993, J EXP PSYCHOL LEARN, V19, P243; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	38	12	12	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1142	1149		10.1097/01.ta.0000241238.70269.c1			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	105TB	WOS:000242054100019	17099520				2021-06-18	
J	Doninger, NA; Ehde, DM; Bode, RK; Knight, K; Bombardier, CH; Heinemann, AW				Doninger, Nicholas A.; Ehde, Dawn M.; Bode, Rita K.; Knight, Kristin; Bombardier, Charles H.; Heinemann, Allen W.			Measurement properties of the Neurobehavioral Cognitive Status Examination (Cognistat) in traumatic brain injury rehabilitation	REHABILITATION PSYCHOLOGY			English	Article						neuropsychological tests; brain injury; psychometrics; rating scale analysis	STATUS EXAMINATION NCSE; NEUROPSYCHOLOGICAL IMPAIRMENT; HEAD-INJURY; VALIDITY; ACCURACY; PATTERNS; SCALE	Objective: Evaluate measurement properties of the Neurobehavioral Cognitive Status Examination (Cognistat) using Rasch analysis. Design: Calibration of item responses from 120 individuals admitted to a rehabilitation medicine service for traumatic brain injury (TBI) and 296 community-dwelling adults with TBI. Results: Three strata of performance were differentiated despite a skewed distribution toward high performance among the community sample. Elimination of easier items created a better targeted instrument (i.e., generated more spread among individuals) without a significant increase in error. Memory and verbal reasoning were the most difficult domains for each sample; however, analyses indicated significant measurement error. Conclusions: As a screening instrument, the Cognistat reliably classifies multiple levels of cognitive status in both acute and postacute TBI settings; however, this measure is unsuitable for generating a profile of neurocognitive strengths and weaknesses.	Wright State Univ, Sch Med, Dayton, OH 45435 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Northwestern Univ, Evanston, IL 60208 USA	Doninger, NA (corresponding author), Wallace Kettering Neurosci Inst, 3533 So Blvd,Suite 5200, Kettering, OH 45429 USA.	nicholas.doninger@kmcnetwork.org	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Ehde, Dawn/K-1883-2016	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Ehde, Dawn/0000-0002-9555-2347			Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; BOND MR, 1990, REHABILITATION ADULT, P59; Cammermeyer M, 1988, J Neurosci Nurs, V20, P314; Cammermeyer M, 1997, J Neurosci Nurs, V29, P163; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; Drane DL, 2003, J CLIN EXP NEUROPSYC, V25, P133, DOI 10.1076/jcen.25.1.133.13628; FalsStewart W, 1997, EXP CLIN PSYCHOPHARM, V5, P269, DOI 10.1037/1064-1297.5.3.269; Fields S D, 1992, Int Psychogeriatr, V4, P93, DOI 10.1017/S1041610292000929; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; Fladby T, 1999, J GERIATR PSYCH NEUR, V12, P16, DOI 10.1177/089198879901200105; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LINACRE JM, 1999, WINSTEPS PC COMPATIB; LOGUE PE, 1993, J CLIN PSYCHOL, V49, P80, DOI 10.1002/1097-4679(199301)49:1<80::AID-JCLP2270490111>3.0.CO;2-Z; Marcotte TD, 1997, J CLIN EXP NEUROPSYC, V19, P386, DOI 10.1080/01688639708403867; MITRUSHINA M, 1994, J PSYCHIATR RES, V28, P85, DOI 10.1016/0022-3956(94)90037-X; Nabors NA, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199706000-00008; *NO CAL NEUR GROUP, 1988, MAN NEUR COGN STAT E; Oehlert ME, 1997, J CLIN PSYCHOL, V53, P733, DOI 10.1002/(SICI)1097-4679(199711)53:7<733::AID-JCLP11>3.0.CO;2-M; OSMON DC, 1992, ARCH PHYS MED REHAB, V73, P414; Poon WS, 2005, ACT NEUR S, V93, P207; Rasch G., 1980, PROBABILISTIC MODELS; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; Tabachnick BG, 2013, USING MULTIVARIATE S; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wallace JJ, 2000, BRAIN INJURY, V14, P63, DOI 10.1080/026990500120934; Wright B. D., 2002, RASCH MEASUREMENT T, V16, P888; Wright B. D., 1982, RATING SCALE ANAL RA	36	12	12	0	7	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2006	51	4					281	288		10.1037/0090-5550.51.4.281			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	107AY	WOS:000242144300002					2021-06-18	
J	Eftekhari, M; Assadi, M; Kazemi, M; Saghari, M; Mojtahedi, A; Fard-Esfahani, A; Sichani, BF; Beiki, D				Eftekhari, Mohammad; Assadi, Majid; Kazemi, Majid; Saghari, Mohsen; Mojtahedi, Alireza; Fard-Esfahani, Armagan; Sichani, Babak Fallahi; Beiki, Davood			Brain perfusion single photon emission computed tomography findings in patients with posttraumatic anosmia and comparison with radiological imaging	AMERICAN JOURNAL OF RHINOLOGY			English	Article; Proceedings Paper	51st Annual Meeting of the American-Rhinologic-Society	SEP 24, 2005	Los Angeles, CA	Amer Rhinol Soc			CLOSED HEAD-INJURY; OLFACTORY EVOKED-POTENTIALS; POST-TRAUMATIC ANOSMIA; CEREBRAL-BLOOD-FLOW; SMELL DISORDERS; SPECT; CORTEX; CT	Background: Different techniques in neuroimaging have been proposed for assessment of olfactory dysfunction but they are not without limitations. Recently, some studies showed the usefulness of single photon emission-computed tomography (SPECT) in evaluation of patients with posttraumatic anosmia. This study was designed to assess the possible diagnostic value of SPECT findings in patients with posttraumatic anosmia in comparison with magnetic resonance imaging (MRI)/CT imaging. Methods: Sixteen patients who had head trauma and consequently anosmia, which was defined according to Cain's identification test, were included in this study. Two nonanosmic groups, traumatic patients and nontraumatic healthy individuals, were selected as control groups for this study. Qualitative and semiquantitative brain perfusion SPECT was performed by measuring the uptake ratio of the orbital frontal cortex to occipital pole in the sagittal projections (uptake index). All 16 target patients had a previous CT scan and/or MRI. Semiquantitative and qualitative brain perfusion SPECT were compared with radiological imaging. Results: Semiquantitative assessment of brain perfusion SPECT revealed remarkable orbital frontal hypoperfusion as compared with two control groups. 87.5% of anosmic patients showed orbital frontal hypoperfusion (>= 2 SD below the lowest level in healthy controls). In addition, the semiquantitative SPECT method detected more orbitofrontal abnormality than the qualitative method or radiological imaging (MRI and/or CT). Conclusion: Findings suggest that by using SPECT, posttraumatic anosmia corresponds to the hypoperfusion in the orbital frontal cortex in a great number of patients. Because of its availability, rather low cost, technical ease, and possibility to obtain objective quantitative information, brain perfusion SPECT can be complementary to other diagnostic techniques in the evaluation of olfactory function, although additional neurophysiological and imaging studies are needed.	Shariati Hosp, Res Inst Nucl Med, Tehran 14114, Iran; Univ Tehran Med Sci, Amiralam Hosp, Dept Otolaryngol Head & Neck Surg, Tehran, Iran	Assadi, M (corresponding author), Shariati Hosp, Res Inst Nucl Med, Karger Shomali St, Tehran 14114, Iran.	assadipoya@yahoo.com	Assadi, Majid/H-2812-2017; Beiki, Davood/J-2595-2016; Assadi, Majid/U-5316-2019	Assadi, Majid/0000-0003-3862-9472; Beiki, Davood/0000-0002-2862-0581; 			Abolmaali ND, 2002, AM J NEURORADIOL, V23, P157; ALLISON T, 1967, ELECTROEN CLIN NEURO, V23, P558, DOI 10.1016/0013-4694(67)90022-3; AUFFERMANN H, 1993, ANN OTO RHINOL LARYN, V102, P6, DOI 10.1177/000348949310200102; CAIN WS, 1983, AM J OTOLARYNG, V4, P252, DOI 10.1016/S0196-0709(83)80068-4; COSTANZO RM, 1991, CIBA F SYMP, V160, P233; COSTANZO RM, 1987, NY ACAD SCI, V510, P242; DEROSSI G, 1992, RADIOL DIAGN, V33, P236; Di Nardo W, 2000, AM J RHINOL, V14, P57, DOI 10.2500/105065800781602984; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Eftekhari Mohammad, 2005, BMC Nucl Med, V5, P6, DOI 10.1186/1471-2385-5-6; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; GUERRIER Y, 1988, OTORHINOLARYNGOLOG A, V10, P20285; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Kobal G., 1996, Rhinology (Utrecht), V34, P222; KOIZUKA I, 1994, ORL J OTO-RHINO-LARY, V56, P273, DOI 10.1159/000276672; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MATERN G, 1995, LARYNGO RHINO OTOL, V74, P118, DOI 10.1055/s-2007-997702; MCLAUGHLIN T, 1992, J CEREBR BLOOD F MET, V12, P535, DOI 10.1038/jcbfm.1992.77; MOOREGILLON V, 1997, BMJ-BRIT MED J, V294, P793; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Ottaviani F, 1997, AUDIOLOGY, V36, P241; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; RING HA, 1991, EUR J NUCL MED, V18, P133, DOI 10.1007/BF00950760; Sasajima T, 2000, AM J NEURORADIOL, V21, P717; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SUMNER D, 1976, HDB CLIN NEUROLOGY, P235; Tokumaru AM, 1999, AM J NEURORADIOL, V20, P845; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; WHITTET HB, 1991, J ROY SOC MED, V84, P400; ZATORRE RJ, 1992, NATURE, V360, P339, DOI 10.1038/360339a0; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	34	12	12	0	2	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1050-6586			AM J RHINOL	Am. J. Rhinol.	NOV-DEC	2006	20	6					577	581		10.2500/ajr.2006.20.2906			5	Otorhinolaryngology	Otorhinolaryngology	113JN	WOS:000242594300006	17181096				2021-06-18	
J	Zhang, XP; Alber, S; Watkins, SC; Kochanek, PM; Marion, DW; Graham, SH; Clark, RSB				Zhang, Xiaopeng; Alber, Sean; Watkins, Simon C.; Kochanek, Patrick M.; Marion, Donald W.; Graham, Steven H.; Clark, Robert S. B.			Proteolysis consistent with activation of caspase-7 after severe traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; cysteine protease; head injury; inflammation; programmed cell death	NEURONAL APOPTOSIS; EXPRESSION; DEATH; RATS; RECRUITMENT; SUBSTRATE; PATHWAYS; ISCHEMIA; CLEAVAGE; EPILEPSY	The expression and proteolysis of caspase family proteins are involved in the initiation and execution of apoptosis, which has been reported to occur in human and experimental traumatic brain injury (TBI). Caspase-3, -6, and -7 belong to the group of executioner caspases, which are cleaved and activated at the late, irreversible stage of apoptosis. Our previous studies demonstrated roles for caspase-1, -3, and -8 in humans after severe TBI. Here we report expression of caspase-7 mRNA and protein in humans after TBI (n = 16) and control brain-bank tissue (n = 6). Semiquantitative reverse transcription polymerase chain reaction showed no differences between caspase-7 mRNA in TBI patients versus controls (73 +/- 24 vs. 85 +/- 56 relative optical density [ROD], respectively). In contrast, Western blot analysis showed increased pro-caspase-7 in TBI patients versus controls (214 +/- 30 vs. 1 +/- 1 ROD, respectively), as well as an increase in the similar-to-20 kD proteolytic fragment in TBI patients versus controls (86 +/- 13 vs. 22 +/- 12 ROD, respectively), consistent with activation of caspase-7 after TBI in humans. Immunohistochemical analysis showed that cells expressing caspase-7 included astrocytes and neurons and possibly other glial cell types and infiltrated inflammatory cells. These data show that caspase-7 and its cleavage product are increased in human brain after TBI in many central nervous system, as well as noncentral nervous system, cell types. Thus, caspase-7 may play a role in the glial and inflammatory responses, and possibly neuronal death, after TBI in humans.	Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA USA; Univ Pittsburgh, Brain Tumor Res Ctr, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 38620, P50 NS 30318] Funding Source: Medline		Araya R, 2002, CELL DEATH DIFFER, V9, P322, DOI 10.1038/sj.cdd.4400949; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Fellin T, 2004, J PHYSIOL-LONDON, V559, P3, DOI 10.1113/jphysiol.2004.063214; Guegn C, 2001, J NEUROSCI, V21, P6569; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Namura S, 1998, J NEUROSCI, V18, P3659; Pompl PN, 2003, ARCH NEUROL-CHICAGO, V60, P369, DOI 10.1001/archneur.60.3.369; Qiu JH, 2002, J NEUROSCI, V22, P3504; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	27	12	14	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2006	23	11					1583	1590		10.1089/neu.2006.23.1583			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	106RK	WOS:000242118200001	17115905				2021-06-18	
J	Whiteside, JW				Whiteside, John W.			Management of head and neck injuries by the sideline physician	AMERICAN FAMILY PHYSICIAN			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; CERVICAL-SPINE INJURY; FOOTBALL EQUIPMENT; CONTACT-SPORTS; 2ND IMPACT; SEVERITY; RETURN; REMOVAL	Injuries to the head and neck are common in sports. Sideline physicians must be attentive and prepared with an organized approach to detect and manage these injuries. Because head and neck injuries often occur simultaneously, the sideline physician can combine the head and neck evaluations. When assessing a conscious athlete, the physician initially evaluates the neck for spinal cord injury and determines whether the athlete can be moved safely to the sideline for further evaluation. This decision is made using an on-field assessment of the athlete's peripheral sensation and strength, as well as neck tenderness and range of motion. If these evaluations are normal, axial loading and Spurling testing can be performed. Once the neck has been determined to be normal, the athlete can be assisted to the sideline for assessment of concussion symptoms and severity. This assessment should include evaluations of the athlete's reported symptoms, recently acquired memory, and postural stability. Injured athletes should be monitored with serial examinations, and those with severe, prolonged, or progressive findings require transport to an emergency department for further evaluation.	Mayo Clin, Dept Family Med, Scottsdale, AZ 85259 USA; Mayo Clin, Coll Med, Rochester, MN USA	Whiteside, JW (corresponding author), Mayo Clin, Dept Family Med, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.						Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Donaldson WF, 1998, SPINE, V23, P1729, DOI 10.1097/00007632-199808150-00003; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; FELDICK HG, 1976, PHYSICIAN SPORTSMED, V4, P77; Gastel JA, 1998, ANN EMERG MED, V32, P411, DOI 10.1016/S0196-0644(98)70168-4; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Ghiselli G, 2003, CLIN SPORT MED, V22, P445, DOI 10.1016/S0278-5919(02)00109-6; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Haight RR, 2001, PHYSICIAN SPORTSMED, V29, P45, DOI 10.3810/psm.2001.03.672; HAIGHT RR, 2001, PHYSICIAN SPORTSMED, V29, P59; HAIGHT RR, 2001, PHYSICIAN SPORTSMED, V29, P62; HAIGHT RR, 2001, PHYSICIAN SPORTSMED, V29, P53; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Nissen SJ, 1996, PHYSICIAN SPORTSMED, V24, P57, DOI 10.3810/psm.1996.06.1378; Palumbo MA, 1996, AM J SPORT MED, V24, P446, DOI 10.1177/036354659602400407; PATTERSON D, 1987, CLIN SPORT MED, V6, P197; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	35	12	13	0	5	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	OCT 15	2006	74	8					1357	1362					6	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	097ES	WOS:000241430300009	17087430				2021-06-18	
J	Sarajuuri, JM; Koskinen, SK				Sarajuuri, Jaana M.; Koskinen, Sanna K.			Holistic neuropsychological rehabilitation in Finland: The INSURE program - a transcultural outgrowth of perspectives from Israel to Europe via the USA	INTERNATIONAL JOURNAL OF PSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY	Given the interaction of cognitive, behavioural, psychological, and physical factors resulting from traumatic brain injury (TBI), a comprehensive, multidisciplinary, and neuropsychologically oriented rehabilitation could prove to be particularly promising and efficacious in the neuropsychological rehabilitation of post-acute brain-injured individuals. Kurt Goldstein, an eminent pioneer in the development of holistic rehabilitation, stated that brain-injured patients need environments that help them to avoid catastrophic reactions. In his view, the tasks of rehabilitation are to create, for the brain-injured individual, an environment that will minimize the chances for the occurrence of catastrophic responses. In this environment, the individual can engage optimally in various remedial activities, which will gradually culminate in the individual finding new meaning in life after rehabilitation. Yehuda Ben-Yishay incorporated many of Goldstein's ideas and developed a milieu or holistic rehabilitation program in 1978 in New York. The emerging role of psychotherapy for patients and their family members was characteristic of the Neuropsychological Rehabilitation Program that Prigatano established in 1980 in Oklahoma. In Europe, Anne-Lise Christensen, who was also influenced by the work of A. R. Luria, started a holistic program at Copenhagen University in 1985. Based on these pioneering programs, several similar programs were established in Europe. A Finnish program, INSURE, was established in 1993 in Helsinki. The INSURE program is a post-acute, interdisciplinary, 6-week rehabilitation program for selected groups of TBI patients. The core of the program is neuropsychological rehabilitation and psychotherapy with vocational interventions, and follow-up support. In recent years, a holistic rehabilitation program was also established in Turku for children with acquired brain injury. The European Holistic Working Group was founded in 2001, and the authors will also discuss their personal experiences and future of holistic neurospychological rehabilitation in terms of ongoing research work, computer-administered cognitive remediation, and quality of life assessment.	Kapyla Rehabil Ctr, FIN-00251 Helsinki, Finland	Sarajuuri, JM (corresponding author), Kapyla Rehabil Ctr, Nordenskioldinkatu 18 B,POB 103, FIN-00251 Helsinki, Finland.	jaana.sarajuuri@invalidiliitto.fi	Sarajuuri, Jaana/AAD-8665-2019	Sarajuuri, Jaana/0000-0002-6432-0295			Ben-Yishay Y, 2000, REHABIL PSYCHOL, V45, P112, DOI 10.1037/0090-5550.45.2.112; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; BENYISHAY Y, 2001, JAPANESE J REHABIL S, V38, P6465; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BULLINGER M, 2002, RESTORATIVE NEUROLOG, V20, P1; Christensen A. L, 2000, INT HDB NEUROPSYCHOL, P151; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; EAMES P, 1989, MODELS BRAIN INJURY, P31; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; GOLDSTEIN K, 1959, J INDIV PSYCHOL, V15, P5; Goldstein K, 1942, EFFECTS BRAIN INJURI; JANSSON T, 1962, TALES MOOMINVALLEY; Kaipio M.-L., 2000, INT HDB NEUROPSYCHOL, P247; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KOSKINEN S, 2004, 9 C EUR MULT NEUR BU; Koskinen S. K., 2004, SVENSK NEUROPSYKOLOG, V4, P10; MAKI H, 2004, 8 NORD M NEUR TURK F; PRIGATANO G, 2004, INT S HOL REH INSURE; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 2000, INT HDB NEUROPSYCHOL, P115, DOI DOI 10.1007/978-1-4757-5569-5_7; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SARAJUURI J, 2003, BRAIN INJURY S1, V17, P155; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; TRUELLE JL, 2004, 9 C EUR MULT NEUR BU; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	34	12	12	0	8	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0020-7594			INT J PSYCHOL	Int. J. Psychol.	OCT	2006	41	5					362	370		10.1080/01650250500346103			9	Psychology, Multidisciplinary	Psychology	095WF	WOS:000241338300007					2021-06-18	
J	Reisner, AD				Reisner, Andrew D.			A case of lightning injury with delayed-onset psychiatric and cognitive symptoms	BRAIN INJURY			English	Article						lightning injury; lightning stroke; cognitive deficits; post traumatic stress disorder; PTSD; delayed symptoms; oxidative stress; neurodegenerative disease; ALS	ELECTRICAL INJURY; OXIDATIVE STRESS; DISORDERS; BRAIN; NEUROREHABILITATION; CONSEQUENCES; TRAUMA	A case is presented of a man who was struck by lighting but, per his report, developed psychiatric and cognitive symptoms between 1-2 years after the incident. The case is discussed in light of the literature on lightning injury with particular emphasis on the aetiology of delayed symptoms. In this case it appears that some cognitive dysfunction may have occurred at the time of the lightning injury, but deficits were exacerbated after a delayed-onset of PTSD and other psychiatric symptoms. The author suggests possible mechanisms for delayed memory impairment in cases of lightning injury.	Appalachian Behav Healthcare, Cambridge, OH 43725 USA	Reisner, AD (corresponding author), Appalachian Behav Healthcare, Cambridge Campus,66737 Old 21 Rd, Cambridge, OH 43725 USA.	reisnera@mh.state.oh.us					AIDMAN EV, 2001, 14 MENTAL MEASUREMEN, P168; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Chamberlin E, 1998, HARVARD REV PSYCHIAT, V5, P307, DOI 10.3109/10673229809003579; Cherington M, 2005, NEUROREHABILITATION, V20, P3; Cherington M, 2003, NEUROLOGY, V60, P182, DOI 10.1212/01.WNL.0000033801.15204.B5; Cooper MA, 2003, LIGHTNING INJURY RES; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEVANAND DP, 1994, AM J PSYCHIAT, V151, P957; Duff K, 2001, NEUROPSYCHOL REV, V11, P101, DOI 10.1023/A:1016623318049; Duman RS, 1998, J ECT, V14, P181; Janus Todd J., 1996, Journal of Burn Care and Rehabilitation, V17, P409, DOI 10.1097/00004630-199609000-00007; Martin TA, 2003, BRAIN INJURY, V17, P817, DOI 10.1080/0269905031000088604; MEHTA S, 2001, 14 MENTAL MEASUREMEN, P170; Muehlberger T, 2001, BURNS, V27, P829, DOI 10.1016/S0305-4179(01)00029-8; PRIMEAU M, 1995, SEMIN NEUROL, V15, P279, DOI 10.1055/s-2008-1041033; Primeau M, 2005, NEUROREHABILITATION, V20, P25; Reisner AD, 2003, NEUROPSYCHOL REV, V13, P199, DOI 10.1023/B:NERV.0000009484.76564.58; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; STEWART C, 1994, NEUROREPORT, V5, P1041, DOI 10.1097/00001756-199405000-00006; Tonkonogy J, 1997, BRIEF NEUROPSYCHOLOG; van Zomeren AH, 1998, J NEUROL NEUROSUR PS, V64, P763, DOI 10.1136/jnnp.64.6.763; WEINER RD, 1984, BEHAV BRAIN SCI, V7, P1, DOI 10.1017/S0140525X00025887; Yarnell PR, 2005, NEUROREHABILITATION, V20, P15	25	12	12	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1093	1097		10.1080/02699050600832007			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100012	17060143				2021-06-18	
J	Iosifidis, MI; Giannoulis, I; Traios, S; Giantsis, G				Iosifidis, Michael I.; Giannoulis, Ioannis; Traios, Stavros; Giantsis, Georgios			Simultaneous bilateral posterior dislocation of the shoulder: diagnostic problems and management	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						bilateral posterior shoulder dislocation; computed tomography; reverse Hill-Sachs lesion	CHRONIC UNREDUCED DISLOCATIONS; FRACTURE-DISLOCATION; RECONSTRUCTION	We present the case of a patient who sustained simultaneous bilateral posterior dislocation of the shoulder after a possible epileptic fit. The confirmation of the diagnosis was reached only by a computed tomography (CT) scan, after the clinical suspicion. Under general anesthesia, close reduction of both shoulder dislocations was done. Posterior dislocation of the shoulder-especially the bilateral one-is very rare. When the history describes an electric shock or convulsive seizure, any shoulder injury demands a careful clinical and radiological evaluation. It is usually associated with reverse Hill-Sachs lesion (an impression defect of the anteromedial aspect of the humeral head), in which the size determines the treatment options.	Naoussa Gen Hosp, Dept Orthopaed, Naousa, Greece	Iosifidis, MI (corresponding author), Filiaton 21 Ikarou, Thessaloniki, Greece.	iosfyl@med.auth.gr					Aparicio G, 2000, J Orthop Sci, V5, P37, DOI 10.1007/s007760050006; ARNDT JH, 1965, AMER J ROENTGENOL RA, V94, P639; BECKER R, 1990, UNFALLCHIRURG, V93, P66; CAVE ER, 1974, TRAUMA MANAGEMENT; Checchia SL, 1998, J SHOULDER ELB SURG, V7, P53, DOI 10.1016/S1058-2746(98)90183-5; Cheng SL, 1997, J SHOULDER ELB SURG, V6, P11, DOI 10.1016/S1058-2746(97)90065-3; CICAK N, 2003, EUR INSTR COURSE LEC, V6, P24; CISTERNINO SJ, 1978, AM J ROENTGENOL, V130, P951, DOI 10.2214/ajr.130.5.951; Connor PM, 1997, J SHOULDER ELB SURG, V6, P480, DOI 10.1016/S1058-2746(97)80002-X; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Delcogliano A, 2005, KNEE SURG SPORT TR A, V13, P151, DOI 10.1007/s00167-004-0524-6; DIMON JH, 1967, SOUTHERN MED J, V60, P661, DOI 10.1097/00007611-196706000-00022; Dubousset J, 1967, Rev Chir Orthop Reparatrice Appar Mot, V53, P65; ELLMAN H, 1986, J BONE JOINT SURG AM, V68A, P1136, DOI 10.2106/00004623-198668080-00002; Engel T, 1999, UNFALLCHIRURG, V102, P897, DOI 10.1007/s001130050499; FINKELSTEIN JA, 1995, J ORTHOP TRAUMA, V9, P190; Gerber C, 1996, J BONE JOINT SURG AM, V78A, P376, DOI 10.2106/00004623-199603000-00008; Hashmi FR, 2002, AM J EMERG MED, V20, P127, DOI 10.1053/ajem.2002.31132; Hawkins R J, 1985, Instr Course Lect, V34, P258; HAWKINS RJ, 1987, J BONE JOINT SURG AM, V69A, P9, DOI 10.2106/00004623-198769010-00003; HELLER KD, 1995, UNFALLCHIRURG, V98, P6; HUGHES M, 1975, PHYS THER, V9, P37; KEPPLER P, 1994, J ORTHOP TRAUMA, V8, P286, DOI 10.1097/00005131-199408000-00003; MCLAUGHLIN H, 1952, J BONE JOINT SURG AM, V24, P584; MICHOS IB, 1993, ACTA ORTHOP SCAND, V64, P599, DOI 10.3109/17453679308993703; Montoli E, 1968, Minerva Ortop, V19, P146; PAGE AE, 1995, J ORTHOP TRAUMA, V9, P526, DOI 10.1097/00005131-199509060-00012; Petersen SA, 2000, ORTHOP CLIN N AM, V31, P263, DOI 10.1016/S0030-5898(05)70146-2; PRITCHETT JW, 1987, CLIN ORTHOP RELAT R, P89; RANDELLI M, 2001, CHRONIC POSTERIOR DI; ROCKWOOD CA, 1965, J BONE JOINT SURG AM, V46, P1220; ROWE CR, 1982, J BONE JOINT SURG AM, V64, P494, DOI 10.2106/00004623-198264040-00004; SHAW JL, 1971, J BONE JOINT SURG AM, VA 53, P1437, DOI 10.2106/00004623-197153070-00023; VOKUV V, 1985, INT ORTHOP, V9, P37	34	12	12	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	AUG	2006	14	8					766	770		10.1007/s00167-006-0066-1			5	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	081ID	WOS:000240309700012	16501951				2021-06-18	
J	Mann, NM; Vento, JA				Mann, Norman M.; Vento, John A.			A Study, comparing SPECT and MRI in patients with anosmia after traumatic brain injury	CLINICAL NUCLEAR MEDICINE			English	Article						anosmia; head trauma; SPECT; MRI	TECHNETIUM-99M-HMPAO SPECT; SMELL; TASTE	Purpose: The initial or first clinical presentation of altered sensation of smell is directly linked to the degree of impaired sensitivity. We took the opportunity to examine normal and nonspecific MRI findings in 6 patients with known anosmia after traumatic brain injury with perfusion SPECT brain imaging. Material and Methods: Patients included those with primary loss of smell after bead injury. All patients under-went standard testing by the Taste & Smell Center. Normal or nonspecific near normal brain MRI studies were subsequently referred for SPECT perfusion neuroimaging. Results: MRI studies were negative in 3 cases. In the remaining studies, one case showed nonspecific white matter change, another low signal in the left frontal gyrus, and the sixth case merely some cortical atrophy. All 6 cases demonstrated lesions on SPECT involving the frontal, temporal, and temporoparietal cortex. Conclusion: This study identified altered blood perfusion pattern in otherwise normal anatomic structures on MRI.	Univ Connecticut, Ctr Hlth, Dept Med, Taste & Smell Clin Div, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Diagnost Imaging & Therapeut, Div Nucl Med, Farmington, CT 06030 USA	Mann, NM (corresponding author), Univ Connecticut, Ctr Hlth, Dept Med, Taste & Smell Clin Div, Farmington, CT 06030 USA.	tasteandsmell@neuron.uchc.edu					ALLISON AC, 1949, BRAIN, V72, P186, DOI 10.1093/brain/72.2.186; ALTOCHI PH, 1996, NEUROLOGY, V46, P278; Fujibayashi Y, 1998, NUCL MED BIOL, V25, P375, DOI 10.1016/S0969-8051(97)00221-7; ICHISE M, 1994, J NUCL MED, V35, P217; JUNI JE, 1994, J NUCL MED, V35, P1891; LEVIN JM, 1994, J NUCL MED, V35, P1902; Mann NM, 2004, OTOLARYNG CLIN N AM, V37, P289, DOI 10.1016/S0030-6665(03)00157-9; Mann NM, 2002, CLEV CLIN J MED, V69, P329, DOI 10.3949/ccjm.69.4.329; Mann Norman M, 2003, Conn Med, V67, P545; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; ROGER SN, 1991, J NUCL MED, V32, P1684; Scott A E, 1989, Ear Nose Throat J, V68, P297; Small DM, 2005, NEURON, V47, P593, DOI 10.1016/j.neuron.2005.07.022; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; TIKOFSKY RS, 1994, J NUCL MED, V34, P227	16	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-9762	1536-0229		CLIN NUCL MED	Clin. Nucl. Med.	AUG	2006	31	8					458	462		10.1097/01.rlu.0000227010.72925.6d			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	091KP	WOS:000241026700004	16855430				2021-06-18	
J	Jin, JS; Sakaeda, T; Kakumoto, M; Nishiguchi, K; Nakamura, T; Okamura, N; Okumura, K				Jin, Jiang-shu; Sakaeda, Toshiyuki; Kakumoto, Mikio; Nishiguchi, Kohshi; Nakamura, Tsutomu; Okamura, Noboru; Okumura, Katsuhiko			Effect of therapeutic moderate hypothermia on multi-drug resistance protein 1-mediated transepithelial transport of drugs	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						therapeutic moderate hypothermia; pharmacokinetics; multi-drug resistance protein 1; digoxin; quinidine; tetracycline	TRAUMATIC BRAIN-INJURY; P-GLYCOPROTEIN; MILD HYPOTHERMIA; COMATOSE SURVIVORS; ORGANIC CATIONS; INFANTS; PHARMACOKINETICS; PHARMACOGENETICS; PHARMACODYNAMICS; FEASIBILITY	To clarify the effect of therapeutic moderate hypothermia on drug distribution, transepithelial transport via multi-drug resistance protein 1 (MDR1) (also called P-glycoprotein or ABCB1) was evaluated at various temperatures in vitro using LLC-GA5-COL150 cells, which were established by transfecting human MDR1 complementary deoxyribonucleic acid into kidney epithelial LLC-PK1 cells and express MDR1 on the apical membrane. MDR1 is expressed in the blood-brain barrier to limit drug distribution to the brain by exporting exogenous substances including calcium blockers and antiarrhythmic drugs. Digoxin was used as a typical substrate, as well as the non-substrate tetracycline and paracellular marker inulin. MDR1-mediated transport of digoxin decreased at lower temperatures. Transport of tetracycline also decreased at lower temperatures, probably due to changes in membrane fluidity. However, no change was found at over 32 degrees C, suggesting that passive diffusion does not change during moderate hypothermia. The distribution of MDR1 substrates should be considered during hypothermic conditions, as the clinical outcome could be affected.	Kobe Univ, Sch Med, Dept Hosp Pharm, Kobe, Hyogo 650, Japan; Kobe Univ, Grad Sch Med, Dept Clin Evaluat Pharmacotherapy, Kobe, Hyogo, Japan	Sakaeda, T (corresponding author), Kobe Univ, Sch Med, Dept Hosp Pharm, Kobe, Hyogo 650, Japan.	sakaedat@med.kobe-u.ac.jp		Nakamura, Tsutomu/0000-0001-7395-4305			Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Babu E, 2002, JPN J PHARMACOL, V88, P69, DOI 10.1254/jjp.88.69; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Beaufort TM, 2001, ANESTHESIOLOGY, V94, P270, DOI 10.1097/00000542-200102000-00017; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Darby JM, 2002, NEW ENGL J MED, V347, P63; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fromm MF, 2004, TRENDS PHARMACOL SCI, V25, P423, DOI 10.1016/j.tips.2004.06.002; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Heier T, 2002, ANESTHESIOLOGY, V97, P90, DOI 10.1097/00000542-200207000-00013; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; HORI R, 1993, AM J PHYSIOL, V264, pF975; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Karibe H, 2000, NEUROSURGERY, V47, P594, DOI 10.1097/00006123-200009000-00012; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lin JH, 2003, DRUG METAB REV, V35, P417, DOI 10.1081/DMR-120026871; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; OTT RJ, 1993, PHARMACEUT RES, V10, P1169, DOI 10.1023/A:1018968218573; Padosch SA, 2002, NEW ENGL J MED, V347, P63; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Polderman KH, 2004, INTENS CARE MED, V30, P1860, DOI 10.1007/s00134-004-2383-5; Polderman KH, 2002, NEW ENGL J MED, V347, P64; Polderman KH, 2001, J NEUROSURG, V94, P853; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; SAITO H, 1992, AM J PHYSIOL, V262, pC59; Sakaeda T, 1998, J DRUG TARGET, V6, P261, DOI 10.3109/10611869808996834; Sakaeda T, 2004, CURR TOP MED CHEM, V4, P1385; Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747; Sakaeda T, 2002, J PHARM PHARMACOL, V54, P419, DOI 10.1211/0022357021778493; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Somogyi AA, 1996, J PHARMACOL EXP THER, V278, P31; Su J, 2003, INT J DEV NEUROSCI, V21, P353, DOI 10.1016/S0736-5748(03)00070-4; Tabayashi K, 2002, ACTA CHIR BELG, V102, P224; TAKANO M, 1992, BIOCHIM BIOPHYS ACTA, V1108, P133, DOI 10.1016/0005-2736(92)90017-G; Takara K, 2002, LIFE SCI, V70, P1491, DOI 10.1016/S0024-3205(01)01494-1; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; UEDA K, 1992, J BIOL CHEM, V267, P24248; Withington D, 2000, CAN J ANAESTH, V47, P1188, DOI 10.1007/BF03019867; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X; Zhang JN, 2004, J TRAUMA, V57, P216, DOI 10.1097/01.TA.0000093366.98819.FE; Zuideveld KP, 2002, EUR J PHARMACOL, V445, P43, DOI 10.1016/S0014-2999(02)01665-5	54	12	13	0	2	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	JUL	2006	46	7					321	327		10.2176/nmc.46.321			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	063UA	WOS:000239044200001	16861824	Bronze			2021-06-18	
J	Ongali, R; Hellal, F; Rodi, D; Plotkine, M; Marchand-Verrecchia, C; Pruneau, D; Couture, R				Ongali, Rice; Hellal, Farida; Rodi, Donata; Plotkine, Michel; Marchand-Verrecchia, Catherine; Pruneau, Didier; Couture, Rejean			Autoradiographic analysis of mouse brain kinin B-1 and B-2 receptors after closed head trauma and ability of anatibant mesylate to cross the blood-brain barrier	JOURNAL OF NEUROTRAUMA			English	Article						anatibant mesylate (LF 16-0687 Ms); autoradiography; B-1 receptor; B-2 receptor; blood-brain barrier; bradykinin; brain	ANTAGONIST LF 16-0687MS; FOCAL CEREBRAL-ISCHEMIA; BRADYKININ B-2; RAT MODEL; EDEMA FORMATION; CEREPORT RMP-7; INJURY; POTENT; TUMORS; CARBOPLATIN	The potent non-peptide B-2 receptor (R) antagonist, Anatibant mesylate (Ms) (LF 16-0687 Ms), reduces brain edema and improves neurological function recovery in various focal land diffuse models of traumatic brain injury in rodents. In the present study, alteration of kinin B-1 and B2R after closed head trauma (CHT) and in vivo binding properties of Anatibant Ms (3 mg/kg, s.c.) injected 30 min after CHT were studied in mice by autoradiography using the radioligands [I-125]HPP-Hoe 140 (B2R), and [I-125]HPP-des-Arg(10)-Hoe 140 (B1R). Whereas B1R is barely detected in most brain regions, B2R is extensively distributed, displaying the highest densities in the hindbrain. CHT was associated with a slight increase of B1R and a decrease of B2R (10-50%) in several brain regions. Anatibant Ms (Ki = 22 pM) displaced the B2R radioligand from its binding sites in several areas of the forebrain, basal ganglia and hindbrain. Displacement was achieved in 1 h and persisted at 4 h post-injection. The inhibition did not exceed 50% of the total specific binding in non-injured mice. After CHT, the displacement by Anatibant Ms was higher and almost complete in the cortex, caudate putamen, thalamus, hippocampus, medial geniculate nucleus, ventral tegmental area, and raphe. Evans blue extravasation in brain tissue at 4 h after CHT was abolished by Anatibant Ms. It appeared that Anatibant Ms penetrated into the brain in sufficient amounts, particularly after disruption of the blood-brain barrier, to account for its B2R-mediated neuro- and vascular protective effects. The diminished binding of B2R after CHT may reflect the occupancy or internalization of B2R following the endogenous production of bradykinin (BK).	Univ Montreal, Fac Med, Dept Physiol, Montreal, PQ H3C 3J7, Canada; Univ Paris 05, Lab Pharmacol & Circulat Cerebrale, Paris, France; Labs Fournier SA, Ctr Rech, Daix, France	Ongali, R (corresponding author), Univ Montreal, Fac Med, Dept Physiol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Hellal, Farida/E-8533-2013; MARCHAND-LEROUX, Catherine/L-7453-2017; Hellal, Farida/D-1834-2015	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Hellal, Farida/0000-0002-9344-1846			Asa I, 2003, J TRAUMA, V54, P881, DOI 10.1097/01.TA.0000046700.45106.4B; Buck HD, 2002, CAN J PHYSIOL PHARM, V80, P249, DOI 10.1139/Y02-050; Couture R, 2004, EUR J PHARMACOL, V500, P467, DOI 10.1016/j.ejphar.2004.07.045; Couture R, 2000, HAND CHEM N, V16, P241; Emerich DF, 2000, PHARMACEUT RES, V17, P1212, DOI 10.1023/A:1026462629438; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Li DZ, 2003, BRIT J PHARMACOL, V139, P1539, DOI 10.1038/sj.bjp.0705385; Marceau F, 2002, INT IMMUNOPHARMACOL, V2, P1729, DOI 10.1016/S1567-5769(02)00189-3; Marceau F, 1998, PHARMACOL REV, V50, P357; Murone C, 1996, EUR J PHARMACOL, V306, P237, DOI 10.1016/0014-2999(96)00190-2; Murone C, 1997, J COMP NEUROL, V381, P203, DOI 10.1002/(SICI)1096-9861(19970505)381:2<203::AID-CNE7>3.0.CO;2-7; Ongali B, 2003, J COMP NEUROL, V461, P506, DOI 10.1002/cne.10706; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Rodi D, 2005, CURR PHARM DESIGN, V11, P1313, DOI 10.2174/1381612053507422; Schulz J, 2000, ACT NEUR S, V76, P137; Sobey CG, 2003, BRIT J PHARMACOL, V139, P1369, DOI 10.1038/sj.bjp.0705415; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; Thomas HD, 2000, CANCER CHEMOTH PHARM, V45, P284, DOI 10.1007/s002800050042; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Warren KE, 2001, CANCER CHEMOTH PHARM, V48, P275, DOI 10.1007/s002800100356; WIRTH K, 1991, EUR J PHARMACOL, V205, P217, DOI 10.1016/0014-2999(91)90824-A; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6	38	12	14	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2006	23	5					696	707					12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	042LJ	WOS:000237529200008	16689671				2021-06-18	
J	Nayak, C; Nayak, D; Raja, A; Rao, AJ				Nayak, C; Nayak, D; Raja, A; Rao, AJ			Time-level relationship between indicators of oxidative stress and Glasgow Coma Scale scores of severe head injury patients	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						ceruloplasmin; Glasgow Coma Scale; head injury; lipid peroxidation	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TRAUMA; FREE-RADICALS; LIPID-PEROXIDATION; CERULOPLASMIN; DAMAGE; PROTEINS; STROKE; RATS	Background: Oxidative stress is said to strongly influence the neurological recovery of patients following a severe head injury. Estimation of the markers of oxidative stress in the blood of such patients can hence aid in predicting the prognosis of head injury. Methods: Erythrocyte thiobarbituric acid-reactive substances ( TBARS) and plasma ceruloplasmin ( CP) levels were estimated in 24 severe head-injury patients on days 1, 7 and 21 of the post-traumatic period and compared with levels in 25 healthy age- and sex-matched controls. These parameters reflecting oxidative stress status were related to the Glasgow Coma Scale ( GCS) scores of patients noted at the same time points of the study period. Results: Lipid peroxidation as indicated by increased levels of erythrocyte TBARS remained significantly elevated in severe head injury patients compared to controls on day 1 ( p<0.001), day 7 ( p<0.001) and 21 ( p<0.001) of the post-traumatic period. Plasma CP levels remained significantly elevated ( p<0.001) at these three time points compared to controls. The significant decrease in lipid peroxidation products ( p<0.01) and significant increase in CP levels ( p<0.001) on day 21 compared to day 1 in head injury patients correlated well with the significant improvement in GCS scores of patients on day 21 compared to day 1 ( p<0.05). Conclusion: The above results could account for the adaptation of the study patients to severe oxidative stress, as evidenced by their clinical recovery trend during the study period.	Int Ctr Hlth Sci, Melaka Manipal Med Coll, Dept Biochem, Manipal 576104, Karnataka, India; Kasturba Med Coll & Hosp, Dept Pediat, Manipal, Karnataka, India; Kasturba Med Coll & Hosp, Dept Neurosurg, Manipal, Karnataka, India; Kasturba Med Coll & Hosp, Dept Biochem, Manipal, Karnataka, India	Nayak, C (corresponding author), Int Ctr Hlth Sci, Melaka Manipal Med Coll, Dept Biochem, Manipal Campus, Manipal 576104, Karnataka, India.	chandrikadinesh@yahoo.com		Rao, Anjali/0000-0002-2676-2762; Nayak, Dinesh M/0000-0001-7384-8916; Nayak, Chandrika D/0000-0002-4674-7359			Atanasiu RL, 1998, MOL CELL BIOCHEM, V189, P127, DOI 10.1023/A:1006945713860; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHERUBINI A, 2001, 2 VIRT C CARD; DESILVA DM, 1993, CAN J PHYSIOL PHARM, V71, P715, DOI 10.1139/y93-107; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; GOLDSTEIN IM, 1982, ANN NY ACAD SCI, V389, P368, DOI 10.1111/j.1749-6632.1982.tb22150.x; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; JAIN SK, 1989, DIABETES, V38, P1539, DOI 10.2337/diabetes.38.12.1539; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Nishio S, 1997, ACT NEUR S, V70, P84; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; RAO GM, 1998, THESIS MANIPAL ACAD; RAVIN HA, 1961, J LAB CLIN MED, V58, P161; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; REITER RJ, 1995, FASEB J, V9, P526; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SIEMS WG, 2000, CLIN NEPHROL, V53, P17; Tentori L, 1981, Methods Enzymol, V76, P707, DOI 10.1016/0076-6879(81)76152-4; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	30	12	13	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621	1437-4331		CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	APR	2006	44	4					460	463		10.1515/CCLM.2006.068			4	Medical Laboratory Technology	Medical Laboratory Technology	034UO	WOS:000236956300017	16599841				2021-06-18	
J	Gonzalez-Rothi, LJ				Gonzalez-Rothi, LJ			Cognitive rehabilitation - The role of theoretical rationales and respect for the maturational process needed for our evidence	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Galveston Brain Injury Conference (GBIC)	APR, 2005	Galveston, TX	Moody Fdn		clinical trials; cognition; rehabilitation		The challenge to presenters at the Galveston Brain Injury Conference held in April 2005 was to discuss examples of the use of theory to motivate the design of treatments for cognitive deficits resulting from traumatic brain injury This article considers the role of theoretical rationales as well as the new optimism embracing neurorehabilitation today. However, caution to respect the maturational process needed to adequately prepare treatment evidence for clinical application is affected.	Univ Florida, Gainesville, FL 32610 USA; Malcom Randall VA Med Ctr, VA RR&D Brain Rehabil Res Ctr, Gainesville, FL USA	Gonzalez-Rothi, LJ (corresponding author), Univ Florida, Gainesville, FL 32610 USA.	gonzalj@neurology.ufl.edu					Balas EA, 2004, MED CARE, V42, P610, DOI 10.1097/01.mlr.0000128008.12117.f8; BERNDT RS, 1992, NIH PUBLICATION; CAJA RYS, 1928, DEGENERATION REGENER; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; ERGEZINGER ER, 2000, CEREBRAL REORGANIZAT, P68; FERGUSON JH, 1994, NEUROLOGY, V44, P566; FINGER S, 1994, ORIGINGS NEUROSCIENC; FRATTALI CM, 1998, MEASURING OUTCOMES S, P1; GORDON WA, 2006, TREATMENT POST TBI E, V21; Hillis AE, 1998, J INT NEUROPSYCH SOC, V4, P648, DOI 10.1017/S135561779846613X; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kolb B., 1995, BRAIN PLASTICITY BEH; Merriam-Webster, 1991, WEBSTERS 9 NEW COLLE; Mitchum C. C., 1992, NIH PUBLICATION, V93-3424; Nudo RJ, 1997, SEMIN NEUROSCI, V9, P13, DOI 10.1006/smns.1997.0102; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Robey RR, 1998, APHASIOLOGY, V12, P787, DOI 10.1080/02687039808249573; Vanderploeg RD, 2006, J HEAD TRAUMA REHAB, V21, P179, DOI 10.1097/00001199-200603000-00010; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; WHYTE J, 2006, USING TREATMENT THEO, V21	21	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2006	21	2					194	197		10.1097/00001199-200603000-00011			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	031PK	WOS:000236716300010	16569992				2021-06-18	
J	Moreira, T; Cebers, G; Salehi, M; Wagner, A; Liljequist, S				Moreira, T; Cebers, G; Salehi, M; Wagner, A; Liljequist, S			Impaired long-term habituation is dissociated from increased locomotor activity after sensorimotor cortex compression	BEHAVIOURAL BRAIN RESEARCH			English	Article						open-field; cognitive impairments; brain injury; hippocampal damage; thalamus; striatum; Fluoro-Jade	TRAUMATIC BRAIN-INJURY; FLUORO-JADE; EXTRADURAL COMPRESSION; ACETYLCHOLINE-RELEASE; OPEN-FIELD; HIPPOCAMPAL ACETYLCHOLINE; SOMATOSENSORY CORTEX; CEREBRAL-ISCHEMIA; RAT; MODEL	Behavioural habituation to a novel environment is a simple form of learning in rodents. We Studied the habituation and locomotor activity (LMA) of Wistar rats subjected to unilateral, transient (30 min) extradural compression (EC of the right sensorimotor cortex. One group of rats was tested every 24 h during the first 5 days (D1-D5) post-EC. Two other groups were tested for the first time in the LMA boxes on D3 and D6 post-EC and their performance was compared with the group tested on D1 (activity in a novel environment). Total and center locomotion, vertical activity and time spent in the center of the LMA box were reduced on D1 post-EC and normalized by D2. The EC-induced motor paresis was undetectable on the rotarod by D2 and on the beam-walking by D3. Total locomotion, vertical activity and time spent in the center of EC-rats significantly increased from D1 to D3. EC caused neurodegeneration in the cortex, caudate putamen and thalamus as detected by Fluoro-Jade staining. The size of the cortical damage decreased from D2 to D5 in the medial and caudal regions of the compressed hemisphere, in accordance with recovery of motor function. LMA provided additional information in the follow-up of recovery from brain injury and habituation to the environment. Thus, long-term, inter-session habituation was impaired from D1 to D3 but dissociated front increased LMA intra-session on D3, when the motor deficits provoked by EC were already undetectable in the rotarod and beam-walking tests. (c) 2005 Elsevier B.V. All rights reserved.	Karolinska Univ Hosp, Dept Clin Neurosci, Div Drug Dependence Res, SE-17176 Stockholm, Sweden; Karolinska Inst, Div Neurol, SE-17176 Stockholm, Sweden	Liljequist, S (corresponding author), AstraZeneca R&D Sodertalje, S-15185 Sodertalje, Sweden.	Sture.Liliequist@cns.ki.se					Acquas E, 1996, J NEUROSCI, V16, P3089; Aggleton JP, 2001, PHILOS T R SOC B, V356, P1467, DOI 10.1098/rstb.2001.0946; Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Arckens L, 1998, NEUROSCIENCE, V83, P381, DOI 10.1016/S0306-4522(97)00422-3; Aspey BS, 2000, NEUROPATH APPL NEURO, V26, P232, DOI 10.1046/j.1365-2990.2000.00221.x; Barba R, 2000, STROKE, V31, P1494, DOI 10.1161/01.STR.31.7.1494; BORLONGAN CV, 1995, PHARMACOL BIOCHEM BE, V52, P225, DOI 10.1016/0091-3057(95)00108-9; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Braun C, 2001, CLIN NEUROPHYSIOL, V112, P336, DOI 10.1016/S1388-2457(00)00508-3; BuchkremerRatzmann I, 1997, NEUROREPORT, V8, P519, DOI 10.1097/00001756-199701200-00028; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; CASSADAY HJ, 1995, BEHAV NEUROSCI, V109, P594, DOI 10.1037/0735-7044.109.4.594; Cassaday HJ, 1997, BEHAV NEUROSCI, V111, P1228, DOI 10.1037/0735-7044.111.6.1228; CERBONE A, 1994, NEUROSCI BIOBEHAV R, V18, P497, DOI 10.1016/0149-7634(94)90004-3; Conti AC, 1998, J NEUROSCI, V18, P5663; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; Desmond DW, 2002, STROKE, V33, P2254, DOI 10.1161/01.STR.0000028235.91778.95; Eysel UT, 1999, CEREB CORTEX, V9, P101, DOI 10.1093/cercor/9.2.101; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GERFEN CR, 1996, HDB CHEM NEUROANATOM, V12, P365; Giovannini MG, 2001, NEUROSCIENCE, V106, P43, DOI 10.1016/S0306-4522(01)00266-4; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1; Kelly MK, 1999, J NEUROSCI, V19, P9117, DOI 10.1523/JNEUROSCI.19-20-09117.1999; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; KOSOWSKI A, 2004, BEHAV BRAIN RES; Krinke GJ, 2001, EXP TOXICOL PATHOL, V53, P365, DOI 10.1078/0940-2993-00202; Kundrotiene J, 2004, ACTA NEUROBIOL EXP, V64, P153; Kundrotiene J, 2004, J NEUROTRAUM, V21, P83, DOI 10.1089/089771504772695977; Kundrotiene J, 2002, J NEUROTRAUM, V19, P69, DOI 10.1089/089771502753460259; Laviola G, 2003, NEUROSCI BIOBEHAV R, V27, P19, DOI 10.1016/S0149-7634(03)00006-X; Lipton P, 1999, PHYSIOL REV, V79, P1431; McNeill TH, 2003, J COMP NEUROL, V467, P32, DOI 10.1002/cne.10907; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; Moreira T, 2005, BEHAV BRAIN RES, V164, P250, DOI 10.1016/j.bbr.2005.06.013; NOVACK GD, 1982, DRUG DEVELOP RES, V2, P383, DOI 10.1002/ddr.430020407; O'Keefe J, 1999, HIPPOCAMPUS, V9, P352, DOI 10.1002/(SICI)1098-1063(1999)9:4<352::AID-HIPO3>3.0.CO;2-1; OKeefe J, 1996, NATURE, V381, P425, DOI 10.1038/381425a0; Orsetti M, 1996, BRAIN RES, V724, P89, DOI 10.1016/0006-8993(96)00292-2; Passetti F, 2000, EUR J NEUROSCI, V12, P3051, DOI 10.1046/j.1460-9568.2000.00183.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ranganath C, 2003, NAT REV NEUROSCI, V4, P193, DOI 10.1038/nrn1052; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shapiro ML, 1999, HIPPOCAMPUS, V9, P365, DOI 10.1002/(SICI)1098-1063(1999)9:4<365::AID-HIPO4>3.3.CO;2-K; Stephens S, 2004, INT J GERIATR PSYCH, V19, P1053, DOI 10.1002/gps.1209; Thiel CM, 1998, NEUROSCIENCE, V85, P1253, DOI 10.1016/S0306-4522(98)00030-X; THOMPSON RF, 1966, PSYCHOL REV, V73, P16, DOI 10.1037/h0022681; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Torres-Munoz JE, 2004, MOL BRAIN RES, V127, P105, DOI 10.1016/j.molbrainres.2004.05.017; van Groen T, 2003, J COMP NEUROL, V463, P249, DOI 10.1002/cne.10757; van Groen T, 2002, BEHAV BRAIN RES, V136, P329, DOI 10.1016/S0166-4328(02)00199-7; Veinante P, 2003, J COMP NEUROL, V464, P98, DOI 10.1002/cne.10769; Watanabe S, 2001, STROKE, V32, P2615, DOI 10.1161/hs1101.097384; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	63	12	13	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 15	2006	167	1					9	22		10.1016/j.bbr.2005.06.048			14	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	008QL	WOS:000235055700002	16337698				2021-06-18	
J	Bishop, CV; Drummond, KJ				Bishop, CV; Drummond, KJ			Rural neurotrauma in Australia: Implications for surgical training	ANZ JOURNAL OF SURGERY			English	Article						Australia; craniocerebral trauma; education; neurosurgical procedures; rural health services	PERIPHERAL NERVOUS SYSTEMS; ROAD TRAFFIC FATALITIES; NEW-SOUTH-WALES; I TRAUMA CENTER; HEAD-INJURY; MANAGEMENT; MORTALITY; EPIDEMIOLOGY; CRANIOTOMY; VICTORIA	Australia's vast size and small population preclude a neurosurgical service in most rural areas. Thus, general surgeons often initially manage rural neurotrauma. This study aimed to define the neurotrauma surgical caseload in rural Australia and to examine the level of training and confidence of rural surgeons for neurotrauma management. A questionnaire was sent to all Australian members of the Division of Rural Surgery of the Royal Australasian College of Surgeons. Responses were grouped by distance from a neurosurgical centre and analysed using one-way ANOVA. The response rate was 91%, and 161 rural surgeons were included. In total, 90 surgeons carried out approximately 600 procedures for neurotrauma in 5 years. The number of procedures per surgeon increased with distance from a neurosurgical centre (P < 0.0001), as did pretransport delays (P < 0.001). Combined pretransport and transport time was at least 2 h for 84% of surgeons. The majority (75% or more) of rural surgeons accessed hospitals with necessary basic infrastructure, including 24-h computed tomography scan, emergency department, and intensive care unit. There was no association between distance from a neurosurgical centre and level of neurosurgical training. Only 28% of rural surgeons had neurosurgery training more advanced than resident level. However, confidence with management of cranial trauma increased significantly with distance. More distant surgeons felt more confident with computed tomography reading (P = 0.02); burr hole (P = 0.02); craniotomy (P = 0.03) and intracranial pressure monitor insertion (P < 0.0001). A significant volume of neurotrauma is managed surgically in rural Australia as dictated by distance. However, neurotrauma training of rural surgeons has occurred on an ad hoc basis, with those most exposed and most distant developing some confidence. Evidence for specific adequate training is lacking, but this study suggests that it is necessary.	Royal Melbourne Hosp, Dept Neurosurg, Melbourne, Vic, Australia; Univ Melbourne, Dept Surg, Melbourne, Vic, Australia	Drummond, KJ (corresponding author), Royal Melbourne Hosp, Dept Neurosurg, Parkville, Vic 3050, Australia.	kjd@unimelb.edu.au					Atkinson L, 2001, WORLD J SURG, V25, P1224, DOI 10.1007/s00268-001-0086-4; *AUSTR MED WORKF A, 2000, NEUR WORKF AUSTR SUP; Cooper DJ, 1998, J TRAUMA, V45, P772, DOI 10.1097/00005373-199810000-00027; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; Cowan JA, 2003, NEUROSURGERY, V52, P48, DOI 10.1097/00006123-200301000-00005; Green A, 2003, ANZ J SURG, V73, P232, DOI 10.1046/j.1445-1433.2003.02565.x; Kiroff G, 2003, ANZ J SURG, V73, P172, DOI 10.1046/j.1445-1433.2003.02593.x; Long DM, 2003, NEUROSURGERY, V52, P1056, DOI 10.1227/01.NEU.0000057745.48813.93; *NEUR SOC AUSTR, 2000, MAN AC NEUR RUR REM; Newcombe R, 1999, J CLIN NEUROSCI, V6, P85, DOI 10.1016/S0967-5868(99)90619-7; Pasquale MD, 2001, J TRAUMA, V50, P465, DOI 10.1097/00005373-200103000-00010; RING IT, 1986, AUST NZ J SURG, V56, P557, DOI 10.1111/j.1445-2197.1986.tb07099.x; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Rosenfeld JV, 2000, J CLIN NEUROSCI, V7, P507, DOI 10.1054/jocn.1999.0694; *ROYAL AUSTR COLL, 2004, SURG ED TRAIN HDB, P67; SCHECTER WP, 1985, ARCH SURG-CHICAGO, V120, P1163; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SELECKI BR, 1982, AUST NZ J SURG, V52, P111, DOI 10.1111/j.1445-2197.1982.tb06081.x; SELECKI BR, 1982, AUST NZ J SURG, V52, P93, DOI 10.1111/j.1445-2197.1982.tb05297.x; SIMPSON D, 1984, AUST NZ J SURG, V54, P29, DOI 10.1111/j.1445-2197.1984.tb06681.x; Tulloh B, 2001, AUST NZ J SURG, V71, P215, DOI 10.1046/j.1440-1622.2001.02075.x; VANE DW, 1995, J TRAUMA, V38, P867, DOI 10.1097/00005373-199506000-00006; Wong K, 2004, ANZ J SURG, V74, P760, DOI 10.1111/j.1445-1433.2004.03138.x; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	24	12	12	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	JAN-FEB	2006	76	1-2					53	59		10.1111/j.1445-2197.2006.03642.x			7	Surgery	Surgery	011HI	WOS:000235258500012	16483297				2021-06-18	
J	Ross, SR; Putnam, SH; Adams, KM				Ross, SR; Putnam, SH; Adams, KM			Psychological disturbance, incomplete effort, and compensation-seeking status as predictors of neuropsychological test performance in head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RECOGNITION MEMORY TEST; TRAUMATIC BRAIN-INJURY; ADULT INTELLIGENCE SCALE; SYMPTOM VALIDITY TESTS; CROSS-VALIDATION; TEST-SCORES; BASE RATES; MMPI-2; VARIABLES; DEFICITS	Indices from the Minnesota Multiphasic Personality Inventory-2 (MMPI-2; Butcher, Dahlstrom, Graham, Tellegen, & Kaemmer, 1989) representing cognitive and emotional disturbance as well as incomplete effort on the Recognition Memory Test (RMT; Warrington, 1984) were examined as predictors of performance on the Halstead-Reitan Neuropsychological Test Battery (HRB; Reitan & Wolfson, 1993). In the current study, which included a large sample (N = 369) of patients referred for neuropsychological (NP) evaluation after presumptive head injury, MMPI-2 measures of psychological disturbance accounted for as much as 25% of the variance in HRB test scores, resulting in a moderate overall effect size (median Adj. R-2 = .16; R = .40). When demographic variables, head injury severity, and compensation-seeking status were entered in previous steps, incomplete effort as defined by chance performance on the RMT accounted for between 2% and 13% of the variance in HRB test scores, with modest overall effect size (median R-2 Delta = .07; R = .26) in multiple regression equations. Additionally, when MMPI-2 indices of psychological disturbance were included in the last step, they accounted for 2% to 11% of additional variance, retaining a modest overall effect (median R-2 Delta = .03; R = .17). Compensation-seeking status and injury severity as measured by duration of post-traumatic amnesia were, at best, modestly related to NP test performance. Findings confirm the reliable relationship between test performance and psychological disturbance as well as incomplete effort when assessing dysfunction following head injury. In contrast to previous studies, incomplete effort was unrelated to compensation-seeking status.	Depauw Univ, Dept Psychol, Greencastle, IN 46135 USA; Wayne State Univ, Sch Med, Detroit, MI USA; Ann Arbor VAMC, Ann Arbor, MI USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA	Ross, SR (corresponding author), Depauw Univ, Dept Psychol, Greencastle, IN 46135 USA.	srross@depauw.edu					Ackerman PL, 1997, PSYCHOL BULL, V121, P219, DOI 10.1037/0033-2909.121.2.219; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Butcher, 1989, MINNESOTA MULTIPHASI; Butcher JN, 1995, PSYCHOL ASSESSMENT, V7, P320, DOI 10.1037/1040-3590.7.3.320; Demakis GJ, 2001, PSYCHOL ASSESSMENT, V13, P240, DOI 10.1037//1040-3590.13.2.240; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Ganey H.C.N., 2003, J HUM PERFORM EXTREM, V7, P5, DOI [10.7771/2327-2937.1023, DOI 10.7771/2327-2937.1023, 10.7771/2327-2937.1023.]; GASS CS, 1994, J CLIN PSYCHOL, V50, P586, DOI 10.1002/1097-4679(199407)50:4<586::AID-JCLP2270500414>3.0.CO;2-Z; Gass CS, 1996, PSYCHOL ASSESSMENT, V8, P135, DOI 10.1037/1040-3590.8.2.135; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; HEATON RK, 1996, NEUROPSYCHOLOGICAL A; IVERSON GI, 1996, ASSESSMENT, V1, P323; KlOve H, 1963, MED CLIN N AM; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lees-Haley PR, 2003, ARCH CLIN NEUROPSYCH, V18, P585; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEZAK MD, 1995, NEUROPSYCHOL ASSESSM; McKinzey RK, 1997, ARCH CLIN NEUROPSYCH, V12, P585, DOI 10.1016/S0887-6177(97)00005-X; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; MILLER HG, 1961, BMJ-BRIT MED J, V1, P9; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Putnam S. H., 1996, NEUROPSYCHOLOGICAL A, P529; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; Putzke JD, 1997, ASSESSMENT, V4, P365, DOI 10.1177/107319119700400407; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Ross SR, 2003, CLIN NEUROPSYCHOL, V17, P581, DOI 10.1076/clin.17.4.581.27940; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Ross SR, 2003, ARCH CLIN NEUROPSYCH, V18, P905, DOI 10.1016/S0887-6177(02)00169-5; Ross SR, 1999, CLIN NEUROPSYCHOL, V13, P112, DOI 10.1076/clin.13.1.112.1973; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Tabachnik BG, 1996, USING MULTIVARIATE S; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS MJ, 1991, MEMORY ASSESSMENT SC; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Wolfson D., 1993, HALSTEAD REITAN NEUR; Wrobel NH, 1996, ARCH CLIN NEUROPSYCH, V11, P625; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	63	12	12	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	2006	28	1					111	125		10.1080/13803390590929270			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	014XX	WOS:000235515100009	16448980				2021-06-18	
J	Aydin, S; Ulusoy, H; Usul, H; Yulug, E; Cobanoglu, U; Aydin, K; Yenilmez, E; Kutun, S				Aydin, S; Ulusoy, H; Usul, H; Yulug, E; Cobanoglu, U; Aydin, K; Yenilmez, E; Kutun, S			Effects of early versus delayed nutrition on intestinal mucosal apoptosis and atrophy after traumatic brain injury	SURGERY TODAY			English	Article						traumatic brain injury; enteral nutrition; apoptosis; rat	EARLY ENTERAL NUTRITION; BACTERIAL TRANSLOCATION; CELL-DEATH; PERMEABILITY; GUT; STARVATION; DEFENSE; RATS; ISCHEMIA; BLUNT	Purpose. To determine the optimal time to start nutritional support after traumatic brain injury (TBI). Methods. Rats were divided into six groups of seven. All but one of these groups were subjected to moderate closed head trauma under general anesthesia. Groups Ia and Ib were commenced on immunonutrition and standard enteral nutrition, respectively, 8 h later; groups IIa and IIb were commenced on immunonutrition and standard enteral nutrition, respectively, 72 h later; and group III was commenced on a parenteral saline infusion 8 h later. Group IV was a control group fed a laboratory diet and not subjected to trauma. The rats were killed 7 days later, and ileal segments were examined using light and electron microscopy. We used the deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) technique to detect intestinal mucosal apoptosis. Results. Group III had a lower body weight than the other groups (P < 0.005). The mean villous height was highest in groups Ia and IV and lowest in group III. The villi count was lower in groups Ib, IIa, IIb, and III than in group IV (P < 0.005). The apoptotic index counts were higher in groups IIa, IIb, and III than in group IV (P < 0.005). Conclusions. The addition of enriching immunonutrients to early enteral feeding helps preserve an almost normal gut mucosa.	Karadeniz Tech Univ, Farabi Hosp, Anabilim Dali, Dept Histol & Embryol, TR-61080 Trabzon, Turkey; Karadeniz Tech Univ, Farabi Hosp, Anabilim Dali, Dept Anesthesiol & Reanimat, TR-61080 Trabzon, Turkey; Karadeniz Tech Univ, Farabi Hosp, Anabilim Dali, Dept Neurosurg, TR-61080 Trabzon, Turkey; Karadeniz Tech Univ, Farabi Hosp, Anabilim Dali, Dept Pathol, TR-61080 Trabzon, Turkey; Karadeniz Tech Univ, Farabi Hosp, Anabilim Dali, Dept Infect Dis & Clin Microbiol, TR-61080 Trabzon, Turkey; Ankara Oncol Hosp, Dept Gen Surg 1, Ankara, Turkey	Aydin, S (corresponding author), Karadeniz Tech Univ, Farabi Hosp, Anabilim Dali, Dept Histol & Embryol, TR-61080 Trabzon, Turkey.		Yulug, Esin/AAK-2077-2021; ulusoy, hulya/A-6223-2019; Yulug, Esin/AAK-5597-2021; Yenilmez, Engin/AAU-4690-2020; AYDIN, Sevim/AAO-5670-2020	Yulug, Esin/0000-0002-8857-9234; ulusoy, hulya/0000-0001-6645-6316; Yenilmez, Engin/0000-0002-0755-4394; AYDIN, Sevim/0000-0003-2445-2346; Cobanoglu, Umit/0000-0001-6429-427X			BABINEAU TJ, 1994, CRIT CARE MED, V22, P191, DOI 10.1097/00003246-199402000-00004; Braga M, 1996, EUR J SURG, V162, P105; CALBAN C, 2000, CRIT CARE MED, V28, P643; CHRISOULA DS, 2000, J AM COLL SURGEONS, V190, P423; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FRY DE, 1979, SURGERY, V85, P652; GAAL T, 1993, RES VET SCI, V55, P104, DOI 10.1016/0034-5288(93)90042-E; GARRISON RN, 1982, SURGERY, V92, P713; GIANOTTI L, 1994, CRIT CARE MED, V22, P265, DOI 10.1097/00003246-199402000-00018; GIANOTTI L, 1999, J PARENTER ENTERAL N, V23, P214; GLAVIN GB, 1992, ACTA PHYSIOL HUNG, V80, P107; GREER GG, 1975, CAN J MICROBIOL, V21, P877, DOI 10.1139/m75-130; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; INOUE S, 1989, JPEN-PARENTER ENTER, V13, P565, DOI 10.1177/0148607189013006565; Inoue S, 1989, J Burn Care Rehabil, V10, P300, DOI 10.1097/00004630-198907000-00003; Kantrow SP, 1997, ARCH BIOCHEM BIOPHYS, V345, P278, DOI 10.1006/abbi.1997.0264; Kompan L, 1999, INTENS CARE MED, V25, P157, DOI 10.1007/s001340050809; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; KUDSK KA, 1982, J TRAUMA, V22, P904, DOI 10.1097/00005373-198211000-00003; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LEE FD, 1993, J CLIN PATHOL, V46, P118, DOI 10.1136/jcp.46.2.118; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Minard G, 1994, New Horiz, V2, P156; Moss SF, 1996, GASTROENTEROLOGY, V111, P567, DOI 10.1053/gast.1996.v111.agast961110567; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270; OLeary MJ, 1996, BRIT J ANAESTH, V77, P118; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; PREMARATNE S, 1994, SHOCK, V2, P262, DOI 10.1097/00024382-199410000-00005; PURANDARE S, 1989, SCAND J GASTROENTERO, V24, P678, DOI 10.3109/00365528909093108; Saluja SS, 2002, SURG TODAY, V32, P672, DOI 10.1007/s005950200125; Shanahan F, 1999, Semin Gastrointest Dis, V10, P8; SIMONSON SG, 1994, CIRC SHOCK, V43, P34; STEINER M, 1968, AM J PHYSIOL, V215, P75; Ulusoy H, 2003, J CLIN NEUROSCI, V10, P596, DOI 10.1016/S0967-5868(03)00142-5; Wang XD, 1996, EUR SURG RES, V28, P402, DOI 10.1159/000129484; WOHAIEB SA, 1987, DIABETES, V36, P169, DOI 10.2337/diabetes.36.2.169	41	12	12	1	9	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2005	35	9					751	759		10.1007/s00595-005-3034-3			9	Surgery	Surgery	957CI	WOS:000231346600009	16133670				2021-06-18	
J	Lim, D; Robinovitch, S; Goodman, D				Lim, D; Robinovitch, S; Goodman, D			Effect of mouthguards on the transmission of force across the human jaw	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mouthguard; boil and bite; concussion; free vibration; spring-damper	HEAD-INJURY; ICE HOCKEY; CONCUSSION; MOUTH; SPORTS	Objective: To determine if impact responses (stiffness and damping values) of the jaw and neck are significantly different between mouth-guards of varying material and manufacturing properties, in controlled conditions involving specified upper limb orientation and applied loading. Design: Quasi-experimental design. Setting: Simon Fraser University biomechanical laboratory. Participants: Twelve male subjects between the ages of 19 to 28 participated in this study. All subjects were healthy, had no missing teeth, and had no mechanical (orthodontic) appliances. Main Outcome Measurements: For each condition, the system stiffness and damping values were estimated using the free vibration technique. Stiffness and damping values are relevant because they are the major determinants of impact force and, potentially, injury risk. It is the first study to show experimentally the quantitative effects of mouthguard in situ. Results: All the mouthguards lowered the system stiffness as compared with the no mouthguard condition (P < 0.001). There was no observed effect on stiffness between the 2 limb orientation positions. Excitation weight had an unexpected effect on system stiffness (P = 0.041), with increasing weight leading to increased stiffness. Conclusions: The findings suggest that wearing any mouthguard is better than wearing none at all due to their ability to reduce system stiffness and damping values after a blow to the chin.	Simon Fraser Univ, Dept Kinesiol, Burnaby, BC V5A 1S6, Canada	Goodman, D (corresponding author), Simon Fraser Univ, Dept Kinesiol, Burnaby, BC V5A 1S6, Canada.	goodman@sfu.ca		Robinovitch, Stephen/0000-0003-3881-6227			Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Bemelmanns P, 2001, INT J SPORTS MED, V22, P149, DOI 10.1055/s-2001-11342; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; Gardiner D M, 2000, Dent Clin North Am, V44, P53; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Hoffmann J, 1999, ENDOD DENT TRAUMATOL, V15, P157; JAGGER RG, 1995, BRIT DENT J, V178, P31, DOI 10.1038/sj.bdj.4808640; Maestrello Christopher L., 1999, Pediatric Dentistry, V21, P340; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; Milward P J, 1997, J Prosthodont, V6, P292, DOI 10.1111/j.1532-849X.1997.tb00110.x; Newsome P R, 2001, Int J Paediatr Dent, V11, P396, DOI 10.1046/j.0960-7439.2001.00304.x; PARK JB, 1994, J PROSTHET DENT, V72, P373, DOI 10.1016/0022-3913(94)90556-8; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 2001, J ATHL TRAINING, V36, P307; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tran D, 2001, DENT TRAUMATOL, V17, P260, DOI 10.1034/j.1600-9657.2001.170604.x	22	12	12	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2005	15	5					313	319		10.1097/01.jsm.0000180019.22018.3c			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	975OR	WOS:000232672300006	16162989				2021-06-18	
J	Turkstra, LS; Bourgeois, M				Turkstra, LS; Bourgeois, M			Intervention for a modern day HM: Errorless learning of practical goals	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ORGANIC AMNESIA; IMPLICIT MEMORY; EXPRESSIONS; STRATEGIES; EXPLICIT; DOMAIN	Impairments in declarative learning are a common consequence of traumatic brain injury (TBI), and limit participation in daily life for many survivors. Procedural learning and memory, however, typically are spared. In this article, we describe a memory therapy technique, Spaced Retrieval (SR), which is designed to capitalize on preserved procedural memory processes. SR is an errorless learning procedure previously reported to be effective for teaching practical goals to individuals with dementia. To illustrate the potential use of SR in TBI, we present the case of an individual with profound anterograde amnesia who received SR therapy via telephone. The positive results support future studies in TBI and suggest consideration of the role of errors in speech and language therapy.	Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA; Florida State Univ, Tallahassee, FL 32306 USA	Turkstra, LS (corresponding author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu	Bourgeois, Michelle/F-9397-2015	Bourgeois, Michelle/0000-0003-1458-6842			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BOURGEOIS M, 2003, AM SPEECH LANG HEAR; Bourgeois MS, 2003, J COMMUN DISORD, V36, P361, DOI 10.1016/S0021-9924(03)00051-0; Brush JA, 1998, THERAPY TECHNIQUE IM; CAMP CJ, 1997, PROSPECTIVE MEMORY T, P311; CAMP CJ, 2000, COGNITIVE REHABILITA, P224; Critchley H, 2000, HUM BRAIN MAPP, V9, P93, DOI 10.1002/(SICI)1097-0193(200002)9:2<93::AID-HBM4>3.0.CO;2-Z; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GUGER S, 2001, 29 ANN M INT NEUR SO; HOMBERG V, 1993, NEUROSCI LETT, V150, P187, DOI 10.1016/0304-3940(93)90532-P; LLOYD LF, 1994, BRAIN INJURY, V8, P529, DOI 10.3109/02699059409151005; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; Oberg L, 1998, J HEAD TRAUMA REHAB, V13, P44, DOI 10.1097/00001199-199806000-00005; SCHACTER DL, 1987, HUM NEUROBIOL, V6, P107; Stark C, 2005, NEUROPSYCHOLOGY, V19, P139, DOI 10.1037/0894-4105.19.2.139; TURKSTRA LS, 1995, BRAIN INJURY, V9, P61, DOI 10.3109/02699059509004573; Turkstra Lyn S., 2001, Seminars in Speech and Language, V22, P147; VERFAELLIE M, 1991, BRAIN COGNITION, V15, P10, DOI 10.1016/0278-2626(91)90012-W; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILKINSON GS, 1973, WIDE RANGE ACHIEVEME; Wilson B, 1999, COGNITIVE NEUROREHAB, P333; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	27	12	12	0	11	DELMAR LEARNING	CLIFTON PARK	EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	SEP	2005	13	3					205	212					8	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	963GO	WOS:000231792200005					2021-06-18	
J	Alexander, AI; Mayfield, J				Alexander, AI; Mayfield, J			Latent factor structure of the Test of Memory and Learning in a pediatric traumatic brain injured sample: Support for a general memory construct	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						factor structure; memory; neuropsychology; pediatric; structural equation modeling; traumatic brain injury	WIDE-RANGE ASSESSMENT; EQUATION ANALYSIS	The Test of Memory and Learning (TOMAL; Reynolds, C. R., & Bigler, E. D. (1994a). Test of Memory and Learning (TOMAL). Austin, Texas: Pro-Ed; Reynolds, C. R., & Bigler, E. D. (1994b). Test of Memory and Learning (TOMAL): Examiner's manual. Austin, Texas: Pro-Ed) was published to ameliorate the paucity of developmentally appropriate instruments for the assessment of memory in children and adolescents. No studies have confirmed the latent factor structure of the TOMAL. Two structural models were subjected to confirmatory factor analysis using the TOMAL performances of 140 subjects, age 5-19, with traumatic brain injury (TBI). Model 1 was a four-factor model with a large "Complex Memory" factor and three smaller factors. Model 2 was a two-factor model with Verbal and Nonverbal Memory factors, both of which loaded on a second-order "General" memory factor. Results indicated that the model with a higher order structure demonstrated better fit than the four-factor model. Further analysis suggested that the TOMAL factor structure is characterized by a large Complex Memory and smaller, Sustained Attention factor. The study provides tentative support for a "general memory" construct. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Texas Womans Univ, Denton, TX 76204 USA; Our Childrens House Baylor, Dallas, TX USA	Alexander, AI (corresponding author), Texas Womans Univ, Denton, TX 76204 USA.	alexanderai@lisd.net					Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Baddeley A., 1993, ATTENTION SELECTION, P152; Barbas H, 1995, HIPPOCAMPUS, V5, P511, DOI 10.1002/hipo.450050604; Bollen K.A., 1989, STRUCTURAL EQUATIONS, P514, DOI 10.1002/9781118619179; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Burton DB, 1999, CHILD NEUROPSYCHOL, V5, P34, DOI 10.1076/chin.5.1.34.7077; Burton DB, 1996, CHILD NEUROPSYCHOL, V2, P39, DOI 10.1080/09297049608401349; Cohen M.J., 1997, CHILDRENS MEMORY SCA; GERBING DW, 1984, J CONSUM RES, V11, P572, DOI 10.1086/208993; GIOIA GA, 1991, M INT NEUR SOC SAN A; Gorsuch R. L., 1983, FACTOR ANAL; Hale JB, 2002, J PSYCHOEDUC ASSESS, V20, P128, DOI 10.1177/073428290202000202; Hatcher L, 1994, STEP STEP APPROACH U; Haut M W, 2000, Appl Neuropsychol, V7, P237, DOI 10.1207/S15324826AN0704_5; Joreskog KG., 1993, LISREL 8 USERS REFER; KAMPHAUS RW, 1993, CLIN ASSESSMENT CHIL; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Lawley D. N., 1971, FACTOR ANAL STAT MET; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; *NAT INF CTR CHILD, 2004, TRAUM BRAIN INJ FACT; Phelps LA, 1995, J PSYCHOEDUC ASSESS, V13, P384, DOI 10.1177/073428299501300405; Ramsay MC, 1995, NEUROPSYCHOL REV, V5, P151, DOI 10.1007/BF02214760; Reynolds C.R., 1994, TEST MEMORY LEARNING; Reynolds CR, 1996, ARCH CLIN NEUROPSYCH, V11, P29, DOI 10.1016/0887-6177(95)00027-5; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Stevens J.P., 2002, APPL MULTIVARIATE ST, V4th ed; TABACHNICK BG, 1996, APPL MULTIVARIATE ST; THOMPSON B, 1992, EDUC PSYCHOL MEAS, V52, P69, DOI 10.1177/001316449205200107; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	32	12	12	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2005	20	5					587	598		10.1016/j.acn.2004.12.005			12	Psychology, Clinical; Psychology	Psychology	942EY	WOS:000230266900003	15939184	Bronze			2021-06-18	
J	Prigatano, GP; Borgaro, S; Baker, J; Wethe, J				Prigatano, GP; Borgaro, S; Baker, J; Wethe, J			Awareness and distress after traumatic brain injury - A relative's perspective	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						impaired awareness; relative's distress; TBI	CLOSED-HEAD-INJURY; BEHAVIORAL LIMITATIONS; ALZHEIMERS-DISEASE; SELF-AWARENESS; REHABILITATION; INSIGHT	Objective: To examine the relationship between relatives' distress level and their ratings of impaired awareness for persons with traumatic brain injury (TBI). Design and outcome Measures: Participants were 25 patients with TBI, 16 with probably dementia, and 15 with memory complaints but no dementia. Participants completed the Barrow Neurological Institute Screen for Higher Cerebral Functions. Relatives of all patients completed the Patient Competency Rating Scale (Relative Form). Relatives also rated their distress level on a scale from 0 (no distress) to 10 (severe distress) and then rated the patient's level of awareness of their difficulties, also on a scale from 0 (not aware) to 10 (completely aware). Setting: Clinical neuropsychology outpatient service of a neurological institute and medical center. Results: For relatives of patients with TBI, a significant correlation of -0.52 (P =.006) was found. Correlations for the dementia and memory complaint groups were -0.62 (P =.03) and -0-39 (P =.20), respectively. Conclusions: The presence of brain dysfunction associated with neuropsychological disturbances appears to influence the magnitude of the relationship between the distress level of family members and their ratings of impaired awareness in persons with TBI.	St Josephs Hosp, Barrow Neurol Inst, Clin Neuropsychol, Div Neurol, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Clin Neuropsychol, Div Neurol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	gprigat@chw.edu					Attix DK, 2003, NEURO S B C, P201; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DEBETTIGNIES BH, 1990, J CLIN EXP NEUROPSYC, V12, P355, DOI 10.1080/01688639008400980; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 2004, BNI Q, V20, P21; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1995, ADM SCORING MAN BNI; Sherer M, 2003, NEURO S B C, P39; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	31	12	13	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					359	367		10.1097/00001199-200507000-00007			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800007	16030442				2021-06-18	
J	Falk, AC; Cederfjall, C; von Wendt, L; Soderkvist, BK				Falk, AC; Cederfjall, C; von Wendt, L; Soderkvist, BK			Management and classification of children with head injury	CHILDS NERVOUS SYSTEM			English	Article						classification; paediatric; symptoms; traumatic brain injury	BRAIN INJURY	Background: Traumatic brain injury is the most common cause of morbidity and mortality during childhood. Aim: This study was conducted to describe the primary management and classification of children admitted to the emergency department for head trauma. Series: All children (0-15 years) with a history of head injury who were admitted to the outpatient emergency department at a single paediatric trauma centre in the Stockholm region during 1 month were included. Results: There were 242 children (137 girls and 105 boys; mean age 5.3 +/- 4.4 years) who fulfilled the inclusion criteria. Based on the Scandinavian Head Injury Classification, 73% were classified as minimal, 17% mild and 2% moderate head injury. This classification seemed to be more accurately reflective than the ICD-10-based classification in the management of the children with head trauma.	Karolinska Hosp, Astrid Lindgren Childrens Hosp, Pediat ICU, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Women & Child Hlth, Stockholm, Sweden; Univ Helsinki, Cent Hosp, Dept Child Neurol, Helsinki, Finland; Karolinska Inst, Dept Nursing, Stockholm, Sweden	Falk, AC (corresponding author), Karolinska Hosp, Astrid Lindgren Childrens Hosp, Pediat ICU, S-17176 Stockholm, Sweden.	ann-charlotte.falk@karolinska.se	Falk, Ann-Charlotte/ABA-1730-2020	Falk, Ann-Charlotte/0000-0003-2246-7894			Adelson D, 1997, J CHILD NEUROL, V13, P1; *EM NURS ASS, 1995, PROV MAN PED COM SCA, P313; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; KOURTOPOULOS H, 1994, BRAIN INJURY S1, V17, P7; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P165; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization , 1992, ICD10 WHO; 2000, 153 SBU	11	12	13	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	JUN	2005	21	6					430	436		10.1007/s00381-005-1142-4			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	935SE	WOS:000229802900002	15800789				2021-06-18	
J	Maeda, M; Ampo, KI; Kiryu-Seo, S; Konishi, H; Ohba, N; Kadono, C; Kiyama, H				Maeda, M; Ampo, KI; Kiryu-Seo, S; Konishi, H; Ohba, N; Kadono, C; Kiyama, H			The p53-independent nuclear translocation of cyclin G1 in degenerating neurons by ischemic and traumatic insults	EXPERIMENTAL NEUROLOGY			English	Article						cell cycle arrest; ischemia; trauma; MCA; p53; cyclin-G; degeneration; NMDA	GENE-TRANSFER; FLUORO-JADE; CELL-DEATH; EXPRESSION; DNA; P53; INJURY; DAMAGE; BRAIN; P21(WAF1/CIP1)	Cyclin G1 (CG1) was identified as a p53-transactivated target gene, and yet its physiological and pathological roles have been unclear. Here, we demonstrate that CG1 is translocated from cytoplasm to the nuclei of neurons in response to variety of injuries. In the normal matured rodent brain, CG1 immunoreactivity was hardly observed; however, some brain injuries exhibited intense CG1 immunoreactivity in the nuclei of the damaged neurons. Transient common carotid artery occlusion (CCAO) in the gerbil showed strong CG1-like immunoreactivity in the hippocampal CA1 neurons, and permanent middle cerebral artery occlusion (MCAO) in the mouse showed strong CG1-like immunoreactivity in the nuclei of neurons located in the ischemic brain regions. TUNEL staining did not exactly overlap with the CG1-positive cells, but overlapped highly with Fluoro-Jade B staining, a degeneration marker. Brain trauma caused by knife cut, cold injury, and kinate injection also showed CG1 accumulation in the neuronal nuclei located near the injury site. These observations were obtained in p53-deficient mice as well, suggesting that the accumulation of CG1 in the injured neurons is p53-independent. A similar nuclear translocation of endogenous CG1 was confirmed in a primary Culture of cortical neurons when a toxic level of N-methyl-D-aspartate (NMDA) was applied. These results demonstrate that nuclear translocation of CG1 from cytoplasmic region occurs in damaged and degenerating neurons in a p53-independent manner, and the CG1 nuclear staining could be a good marker for the neurons received fatal damages. (c) 2005 Elsevier Inc. All rights reserved.	Osaka City Univ, Grad Sch Med, Dept Anat, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Neurobiol, Abeno Ku, Osaka 5458585, Japan	Kiyama, H (corresponding author), Osaka City Univ, Grad Sch Med, Dept Anat, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	kiyama@med.osaka-cu.ac.jp	Kiyama, Hiroshi/M-8867-2014; KONISHI, Hiroyuki/M-8871-2014; Kiryu-Seo, Sumiko/M-8865-2014	Kiyama, Hiroshi/0000-0001-5963-046X; Kiryu-Seo, Sumiko/0000-0001-6213-1258; Konishi, Hiroyuki/0000-0002-4321-8339	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15082205] Funding Source: KAKEN		Bates S, 1996, ONCOGENE, V13, P1103; Campagne MV, 1998, J NEUROSCI RES, V53, P279; Campagne MV, 1998, NEUROSCIENCE, V84, P1097, DOI 10.1016/S0306-4522(97)00580-0; Campagne MV, 1999, MOL BRAIN RES, V64, P1; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Fujikawa DG, 2000, NEUROSCIENCE, V98, P41, DOI 10.1016/S0306-4522(00)00085-3; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; Jensen MR, 1998, HEPATOLOGY, V28, P537, DOI 10.1002/hep.510280235; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kiryu S, 1995, J NEUROSCI, V15, P7872; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Kurtkaya-Yapicier O, 2002, NEUROSURGERY, V51, P1246, DOI 10.1227/01.NEU.0000032035.74395.12; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Lipton P, 1999, PHYSIOL REV, V79, P1431; Lurton D, 1996, NEUROSCI LETT, V213, P181; Maeda M, 1997, ACTA NEUROPATHOL, V94, P116, DOI 10.1007/s004010050682; Morita N, 1996, J NEUROSCI, V16, P5961; Ohba N, 2003, MOL BRAIN RES, V115, P147, DOI 10.1016/S0169-328X(03)00181-5; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; TAMURA K, 1993, ONCOGENE, V8, P2113; Yagi T, 2000, BRAIN RES, V885, P273, DOI 10.1016/S0006-8993(00)02956-5; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao L, 2003, MOL CANCER RES, V1, P195	35	12	17	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2005	193	2					350	360		10.1016/j.expneurol.2005.01.018			11	Neurosciences	Neurosciences & Neurology	926PK	WOS:000229134900008	15869937				2021-06-18	
J	Steiner, LA; Balestreri, M; Johnston, AJ; Coles, JP; Smielewski, P; Pickard, JD; Menon, DK; Czosnyka, M				Steiner, LA; Balestreri, M; Johnston, AJ; Coles, JP; Smielewski, P; Pickard, JD; Menon, DK; Czosnyka, M			Predicting the response of intracranial pressure to moderate hyperventilation	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; hyperventilation; intracranial compliance; intracranial pressure	VOLUME INDEX; HEAD-INJURY; DYNAMICS; MONITOR	Background. Hyperventilation may cause brain ischaemia after traumatic brain injury. However, moderate reductions in PaCO2 are still an option in the management of raised intracranial pressure (ICP) under some circumstances. Being able to predict the ICP-response to such an intervention would be advantageous. We investigated the ability of pre-hyperventilation ICP and cerebrospinal compensatory reserve to predict the reduction in ICP achievable with moderate hyperventilation in head injured patients. Methods. Thirty head injured patients requiring sedation and mechanical ventilation were investigated. ICP was monitored via an intraparenchymal probe and intracranial cerebrospinal compensatory reserve was assessed using an index (R-ap) based on the relationship between mean ICP and its pulse amplitude. Measurements were made at a constant level of PaCO2 during a 20-minute baseline period. The patients were then subjected to an acute decrease in PaCO2 of approximately 1 kPa and, after an equilibration period of 10 minutes, measurements were again made at a constant level of PaCO2 for a further 20 minutes. A multiple linear regression model, incorporating baseline PaCO2, ICP, and R-ap was used to identify the relevant predictors of ICP reduction. Findings. Baseline ICP and R-ap were both significant predictors of ICP-reduction (p=0.02 and 0.001 respectively) with R-ap being the more powerful parameter. Conclusions. A model based on cerebrospinal compensatory reserve and ICP can predict the achievable ICP-reduction and may potentially be used to optimise patient selection and intensity of hyperventilation.	Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge, England; Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, England	Steiner, LA (corresponding author), Univ Basel Hosp, Dept Anaesthesia, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; Gray WP, 1996, NEUROSURGERY, V39, P927, DOI 10.1097/00006123-199611000-00008; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Kiening KL, 2002, ACT NEUR S, V81, P177; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; SHAPIRO K, 1980, ANN NEUROL, V7, P508, DOI 10.1002/ana.410070603; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Werner CKE, 1997, TXB NEUROANESTHESIA, P21; Yau Y, 2002, ACTA NEUROCHIR SUPPL, V81, P167; Yau YH, 2002, ACT NEUR S, V81, P181; YOSHIHARA M, 1995, J NEUROSURG, V82, P386, DOI 10.3171/jns.1995.82.3.0386; ZABLOTNY W, 1994, INTRACRANIAL PRESSUR, V9, P439	28	12	12	0	7	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2005	147	5					477	483		10.1007/s00701-005-0510-x			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	918MK	WOS:000228545700005	15770347				2021-06-18	
J	Tudor, M; Tudor, L; Tudor, KI				Tudor, M; Tudor, L; Tudor, KI			Complications of missile craniocerebral injuries during the Croatian Homeland War	MILITARY MEDICINE			English	Article							INTRACRANIAL BONE FRAGMENTS; TRAUMATIC EPILEPSY; LEBANESE CONFLICT; PRACTICAL SCALE; BRAIN; WOUNDS; HEAD; VIETNAM	Objective: Complications of penetrating craniocerebral injuries in war can be early (during the first week after wounding) or late (after that period). Postoperative hematomas, infections, seizures, and cerebrospinal fluid fistulas (CSFFs) are counted among the early complications, whereas foreign bodies migrating intracranially, seizures, infections, and posttraumatic hydrocephalus represent late complications. A total of 176 patients with well-defined head injuries from missiles, sustained during the Croatian Homeland War (1991-1995), developed a total of 61 (34.5%) complications. Methods: A retrospective statistical analysis of the medical records of the patients in our series was performed to determine the risk factors for the onset of complications, which have unfavorable effects on outcomes. Results: There were a total of 28 (15.9%) infections (deep or superficial), 21 (11.9%) cases of CSFFs, 9 (5.11%) cases of early epilepsy, and 3 cases of post-traumatic hydrocephalus. A total of 47.6% of patients with CSFFs developed intracranial infections. Of eight patients with meningoencephalitis, five had CSFFs and four had intracranially retained foreign bodies. Only one patient developed a cerebral abscess. Two patients died because of infectious complications (13.3%). Post-traumatic hydrocephalus (1.7%) required shunt placement. For 60% of patients with deep-seated intracranial infectious complications and 76% of patients with CSFFs, reoperations had to be performed, whereas this was the case for only 8% of patients without infections (chi(2) = 43.6, p = 0.00001). Conclusions: Intracranially retained foreign bodies, wound age, wound site, and operations performed outside the neurosurgical services were the main risk factors for the development of complications. Complications themselves exerted a very unfavorable influence on outcomes. The development of complications reflects very reliably the neurosurgical technique applied.	Clin Hosp Split, Dept Neurosurg, Split 21000, Croatia	Tudor, M (corresponding author), Clin Hosp Split, Dept Neurosurg, Vjekoslava Spineica 1, Split 21000, Croatia.		Car, Lorainne Tudor/E-1205-2017	Car, Lorainne Tudor/0000-0001-8414-7664			AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; AWASTHI D, 1991, SURG NEUROL, V36, P441, DOI 10.1016/0090-3019(91)90157-5; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; CAREY M, 1989, J NEUROSURG, V71, P572; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; Dillon J D Jr, 1975, Surg Neurol, V4, P515; FREYTAG E, 1963, ARCH PATHOL, V76, P215; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; IVEKOVIC V, 1992, ACTA MED CROAT S, V46, P13; JENNETT B, 1975, LANCET, V1, P480; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; ROSENWASSER RH, 1991, SURG CLIN N AM, V71, P305; SANDE JJ, 1978, J NEUROSURG, V94, P357; SEKULIC A, 1992, ACTA MED CROAT S, V46, P47; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; TEASDALE G, 1974, LANCET, V2, P81; Tudor M, 1998, MIL MED, V163, P486; TUDOR M, 1996, THESIS ZAGREB CROATI; Wagstaffe WW, 1928, LANCET, V2, P861; WANNAMAKER GT, 1958, J NEUROSURG, V15, P512, DOI 10.3171/jns.1958.15.5.0512; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	28	12	12	0	1	ASSN MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAY	2005	170	5					422	426		10.7205/MILMED.170.5.422			5	Medicine, General & Internal	General & Internal Medicine	019JL	WOS:000235831300017	15974211	Bronze			2021-06-18	
J	Wei, WH; Sambamoorthi, U; Crystal, S; Findley, PA				Wei, WH; Sambamoorthi, U; Crystal, S; Findley, PA			Mental illness, traumatic brain injury, and Medicaid expenditures	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; comorbidity; Medicaid; Mental Health; rehabilitation	HEAD-INJURY; PSYCHIATRIC-DISORDERS; REHABILITATION; HEALTH; SCHIZOPHRENIA; INDIVIDUALS; DISABILITY; DEPRESSION; SERVICES	Objective: To estimate the rates of mental illness among Medicaid beneficiaries with traumatic brain injury (TBI) and associated Medicaid-paid expenditures. Design: Retrospective claims-based calendar year data. Setting: Claims data. Participants: Medicaid recipients with diagnosed TBI and mental illness who received Medicaid services in 4 states in 1995. Interventions: Not applicable. Main Outcome Measures: Annual expenditures for total, inpatient, and noninpatient services, as derived from Medicaid personal summary files. Mental illness and TBI were identified by using International Classification of Diseases, 9th Revision, Clinical Modification codes recorded in Medicaid claims. Results: Of a total of 493,663 Medicaid recipients, 3641 (0.7%) were diagnosed with TBI in the 4 states. Significant demographic and racial differences were found in the rates of TBI; 18% of patients with TBI were diagnosed with serious mental illness. People with TBI in the age group 40 to 49 years were more likely to have a mental disorder. There were significant differences in estimated total, inpatient, and noninpatient expenditures between those with and without mental illness. In general, those with serious mental illness had higher Medicaid-paid expenditures than those without any mental illness. Conclusions: Psychiatric comorbidity in TBI increases the overall expenditures in this population. This increased cost is an important consideration in programming for those with TBI.	Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08901 USA; Rutgers State Univ, Program Disabil Res, New Brunswick, NJ 08901 USA	Wei, WH (corresponding author), Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08901 USA.	wwh@rci.rutgers.edu	Findley, Patricia/AAC-7539-2019	Findley, Patricia/0000-0001-6924-8248; Sambamoorthi, Usha/0000-0001-8311-1360	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD040779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH043450, R01MH060831] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD040779] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH 60831, P20 MH 11825, R01 MH060831, P-30 MH 43450] Funding Source: Medline		Appelbaum PS, 2003, HEALTH AFFAIR, V22, P110, DOI 10.1377/hlthaff.22.5.110; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONNORS S, 2003, GUIDE STAT GOVERNMEN; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Frank RG, 2003, HEALTH AFFAIR, V22, P101, DOI 10.1377/hlthaff.22.1.101; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; *KAIS COMM MED UN, 2002, MED ROL WOM; Kessler R.C., 1998, MENTAL HLTH US 1998, P99; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Mayer NH, 2003, ARCH PHYS MED REHAB, V84, P242, DOI 10.1053/apmr.2003.50101; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; PRIGATANO G, 1986, NEUROPSYCHOLOICAL RE; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Reynolds WE, 2001, J HEAD TRAUMA REHAB, V16, P34, DOI 10.1097/00001199-200102000-00006; ROSENTHAL M, 1998, REHABILITATION ADULT; Rowland D, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.5.73; Sambamoorthi U, 2001, J Health Soc Policy, V14, P19, DOI 10.1300/J045v14n01_02; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; SORENSON SB, 1991, J HEAD TRAUMA REHAB, P1; *TRAUM BRAIN INJ M, 2004, TBI RES REV POL PRAC, V1, P1; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vaughn SL, 2001, J HEAD TRAUMA REHAB, V16, P20, DOI 10.1097/00001199-200102000-00005; Yanos PT, 2001, PSYCHIATR SERV, V52, P1644, DOI 10.1176/appi.ps.52.12.1644	39	12	12	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					905	911		10.1016/j.apmr.2004.09.026			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	928NM	WOS:000229278500009	15895335	Green Accepted			2021-06-18	
J	Bodo, M; Pearce, FJ; Baranyi, L; Armonda, RA				Bodo, M; Pearce, FJ; Baranyi, L; Armonda, RA			Changes in the intracranial rheoencephalogram at lower limit of cerebral blood flow autoregulation	PHYSIOLOGICAL MEASUREMENT			English	Article; Proceedings Paper	12th International Conference on Electrical Bio-Impedance/5th Electrical Impedance Tomography Conference	JUN 20-24, 2004	Gdansk, POLAND				TRAUMATIC BRAIN-INJURY; ELECTRICAL-IMPEDANCE; PRESSURE AUTOREGULATION; HEMORRHAGIC HYPOTENSION; CLINICAL-APPLICATIONS; PERFUSION-PRESSURE; BIOPHYSICAL BASIS; ELECTRODE SIZE; HEAD-INJURY; TISSUE	Cerebral blood flow (CBF) reactivity monitoring is an appropriate primary parameter to evaluate cerebral resuscitation due to a systemic or regional cerebral injury leading to possible irreversible brain injury. Use of the electrical impedance method to estimate CBF is rare, as the method's anatomical background is not well understood. Use of intracranial rheoencephalography (iREG) during hemorrhage and comparison of iREG to other CBF measurements have not been previously reported. Our hypothesis was that iREG would reflect early cerebrovascular alteration (CBF autoregulation). Studies comparing iREG, laser Doppler flowmetry and ultrasound were undertaken on anesthetized rats to define CBF changes during hemorrhage. Blood was removed at a rate required to achieve a mean arterial blood pressure (MABP) of 40 mm Hg over 15 min. Estimation of CBF was taken with intracranial, bipolar REG (REG I; n = 14), laser Doppler flowmetry (LDF; n = 3) and carotid flow by ultrasound (n = 11). Data were processed off-line. During the initial phase of hemorrhage, when MABP was close to 40 mm Hg, intracranial REG amplitude transiently increased (80.94%); LDF (77.92%) and carotid flow (52.04%) decreased and changed with systemic arterial pressure. Intracranial REG amplitude change suggests classical CBF autoregulation, demonstrating its close relationship to arteriolar changes. The studies indicate that iREG might reflect cerebrovascular responses more accurately than changes in local CBF measured by LDF and carotid flow. REG may indicate promise as a continuous, non-invasive life-sign monitoring tool with potential advantages over ultrasound, the CBF measurement technique normally applied in clinical practice. REG has particular advantages in non-hospital settings such as military and emergency medicine.	Walter Reed Army Inst Res, Dept Resuscitat Med, Silver Spring, MD 20910 USA; Walter Reed Army Inst Res, Dept Membrane Biochem, Silver Spring, MD 20910 USA; Walter Reed Army Med Ctr, Div Neurosurg, Natl Capital Consortium, Sect Cerebrovasc Surg & Intervent Neuroradiol, Washington, DC 20307 USA	Bodo, M (corresponding author), Walter Reed Army Inst Res, Dept Resuscitat Med, Silver Spring, MD 20910 USA.	michael.bodo@us.army.mil					Aaslid R, 1999, ACT NEUR S, V72, P47; Aaslid Rune, 2002, Eur J Ultrasound, V16, P3, DOI 10.1016/S0929-8266(02)00045-9; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Bakay L, 1965, CEREBRAL EDEMA; Basano L, 2001, PHYSIOL MEAS, V22, P341, DOI 10.1088/0967-3334/22/2/306; Beaumont A, 2002, ACT NEUR S, V81, P193; Bellamy R, 1996, CRIT CARE MED, V24, pS24; BENABID AL, 1978, J LIFE SCI, V8, P59; Bertemes P, 2003, PHYSIOL MEAS, V24, P517, DOI 10.1088/0967-3334/24/2/362; Bodo M, 2004, PHYSIOL MEAS, V25, P1371, DOI 10.1088/0967-3334/25/6/003; Bodo M, 2003, AVIAT SPACE ENVIR MD, V74, P506; BODO M, 1995, MED PROG TECHNOL, V21, P53; BODO M, 1986, PHARM CEREBRAL ISCHE, P265; BODO M, 1998, ANTIAGING MED THERAP, V2, P86; BODO M, 2004, ADV TECHNOLOGY APPL; Borisenko V. V., 1993, Fiziologicheskii Zhurnal Imeni I M Sechenova, V79, P103; Bouma G J, 1995, New Horiz, V3, P384; CARTHEUSER CF, 1988, CAN J PHYSIOL PHARM, V66, P1398, DOI 10.1139/y88-228; CHILLON JM, 2002, CEREBRAL BLOOD FLOW, P395; COOPER R, 1980, EEG TECHNOLOGY; Czosnyka M, 2000, ACT NEUR S, V76, P483; Demchenko I T, 1971, Fiziol Zh SSSR Im I M Sechenova, V57, P1553; Edvinsson L, 2002, CEREBRAL BLOOD FLOW, P384; Ganong W., 2001, REV MED PHYSL; GEDDES LA, 1989, PRINCIPLES APPL BIOM; GRISWOLD WR, 1981, CRIT CARE MED, V9, P573, DOI 10.1097/00003246-198108000-00003; Gupta A K, 2002, J Postgrad Med, V48, P218; GUR AY, 2001, NEUR J NEUROCHIR P S, V3, P51; Guyton A C, 2000, TXB MED PHYSL; Hadjiev D, 1968, Brain Res, V8, P213, DOI 10.1016/0006-8993(68)90186-8; HATSELL CP, 1991, IEEE T BIO-MED ENG, V38, P665, DOI 10.1109/10.83566; HEILIG J, 1998, REDIREC US COPYRIGHT; HEROLD S, 1988, NEUROL NEUROSURG PSY, V151, P1045; Hlatky Roman, 2003, Neurosurg Focus, V14, pe2; JACQUY J, 1980, NEUROPSYCHOBIOLOGY, V6, P341, DOI 10.1159/000117780; JACQUY J, 1974, ELECTROENCEPHALOGR C, V37, P501; Jenkner FL, 1986, CLIN RHEOENCEPHALOGR; JOHNSON KB, 1995, SHOCK, V3, P343; JONES WP, 1989, COMBUST SCI TECHNOL, V63, P13, DOI 10.1080/00102208908947115; KAVEC M, 2001, MAGMA, V2, P32; Kim SG, 2002, CURR OPIN NEUROBIOL, V12, P607, DOI 10.1016/S0959-4388(02)00355-0; King JC, 1996, MUSCLE NERVE, V19, P1310, DOI 10.1002/(SICI)1097-4598(199610)19:10<1310::AID-MUS8>3.0.CO;2-H; Kirsch JR, 1996, INT ANESTHESIOL CLIN, V34, P73, DOI 10.1097/00004311-199603440-00007; Komjati K, 1996, Acta Physiol Hung, V84, P229; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Kovach A G, 1988, Prog Clin Biol Res, V264, P147; LAITINEN L, 1968, SCAND J CLIN LAB I S, V102, pDR11; Landmesser U, 2004, CIRCULATION, V109, P27, DOI 10.1161/01.CIR.0000129501.88485.1f; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Lechner H, 1968, Elektromed Biomed Tech, V13, P30; LEVY MM, 2004, HIGHLIGHTS COMPUTERS; LIFSHITZ K, 1963, J NERV MENT DIS, V137, P285, DOI 10.1097/00005053-196309000-00010; LIFSHITZ K, 1963, J NERV MENT DIS, V136, P388, DOI 10.1097/00005053-196304000-00010; Lingwood BE, 2002, BRAIN RES, V945, P97, DOI 10.1016/S0006-8993(02)02744-0; Livshitz LM, 2001, IEEE T NEUR SYS REH, V9, P355, DOI 10.1109/7333.1000115; Malmivuo J.A., 1992, P 8 ICEBI KUOP, P18; Manno EM, 2004, NEUROL CLIN, V22, P347, DOI 10.1016/j.ncl.2003.12.002; Manz H J, 1979, Pathobiol Annu, V9, P359; MARKOVICH S, 1967, J NEUROL SCI, V5, P267, DOI 10.1016/0022-510X(67)90135-9; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615; MCHENRY LC, 1965, NEUROLOGY, V15, P507, DOI 10.1212/WNL.15.6.507; MONTGOMERY LD, 1989, AVIAT SPACE ENVIR MD, V60, P1116; Moskalenko Iu E, 1996, Fiziol Zh Im I M Sechenova, V82, P36; MOSKALENKO YE, 1980, BIOPHYS ASPECTS CERE; Nilsson Holger, 2003, Mol Interv, V3, P79, DOI 10.1124/mi.3.2.79; NYBOER J, 1970, ANN NY ACAD SCI, V170, P410, DOI 10.1111/j.1749-6632.1970.tb17711.x; NYBOER J, 1960, AMA ARCH INT MED, V105, P64; Oostendorp TF, 2000, IEEE T BIO-MED ENG, V47, P1487, DOI 10.1109/TBME.2000.880100; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Patterson R, 1995, BIOMEDICAL ENG HDB, P1223; PEARCE WJ, 1980, STROKE, V11, P190, DOI 10.1161/01.STR.11.2.190; Perez JJ, 2000, CLIN NEUROPHYSIOL, V111, P1306, DOI 10.1016/S1388-2457(00)00304-7; PRALL JA, 1995, J TRAUMA, V38, P776, DOI 10.1097/00005373-199505000-00017; PRONK RAF, 1986, HDB ELECTROENCEPHALO, V2, P93; REIVICH M, 1980, CEREBROVASCULAR SURV; Roberts I, 2000, COCHRANE DATABASE SY, V2; ROFFEY P, 1999, CRIT CARE MED, V27, P2147; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUSH S, 1968, ANESTH ANAL CURR RES, V47, P717; SAFAR P, 1998, ANTIAGING MED THERAP, V2, P37; Sandor P, 2003, BRAIN RES BULL, V59, P433, DOI 10.1016/S0361-9230(02)00947-4; Schmidt EA, 2002, ACT NEUR S, V81, P133; SCHUHFRIED F, 1974, WIEN KLIN WOCHENSCHR, V86, P228; SEIPEL JH, 1967, NEUROLOGY, V17, P443, DOI 10.1212/WNL.17.5.443; Shoemaker WC, 1996, CRIT CARE MED, V24, pS12; Shulman RG, 2002, Q REV BIOPHYS, V35, P287, DOI 10.1017/S0033583502003803; SOKOLOVA IV, 1982, KOSM BIOL AVIAK MED+, V16, P81; Steiner LA, 2002, BRIT J NEUROSURG, V16, P429, DOI 10.1080/0268869021000030221; STRANDGAARD S, 1989, AM J HYPERTENS, V2, P486, DOI 10.1093/ajh/2.6.486; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; Strandgaard S, 1995, J Cardiovasc Risk, V2, P34, DOI 10.1097/00043798-199502000-00005; SYMON L, 1986, PHARM CEREBRAL ISCHE, P31; SZABO L, 1983, ACTA PHYSIOL HUNG, V62, P113; VAINRUB A, 2004, BIOMEDICAL TECHNOLOG; VAINSHTEIN G B, 1980, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V66, P777; VAINSHTEIN G B, 1978, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V64, P564; Vainshtein G. B., 1992, Fiziologicheskii Zhurnal Imeni I M Sechenova, V78, P44; VESPA P, 2003, NEUROSURG FOCUS, V15, pE15; Waschke KF, 2004, J TRAUMA, V56, P591, DOI 10.1097/01.TA.0000075335.35705.E2; WEINDLING AM, 1982, MED BIOL ENG COMPUT, V20, P545, DOI 10.1007/BF02443401; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002; WIGGERS CJ, 1950, PHYSL SHOCK, P121; Wilson M, 2003, J EMERG MED, V24, P413, DOI 10.1016/S0736-4679(03)00042-8; WOOD JH, 1987, CEREBRAL BLOOD FLOW; YONAS H, 1994, CEREBROVAS BRAIN MET, V6, P325; 1997, CODE FEDERAL REGULAT, V8; 2004, PHYS SYMPTOMS EPONYM	112	12	13	0	6	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0967-3334	1361-6579		PHYSIOL MEAS	Physiol. Meas.	APR	2005	26	2			SI		S1	S17		10.1088/0967-3334/26/2/001			17	Biophysics; Engineering, Biomedical; Physiology	Biophysics; Engineering; Physiology	918QW	WOS:000228563700002	15798222				2021-06-18	
J	De Guise, E; Leblanc, J; Feyz, M; Thomas, H; Gosselin, N				De Guise, E; Leblanc, J; Feyz, M; Thomas, H; Gosselin, N			Effect of an integrated reality orientation programme in acute care on post-traumatic amnesia in patients with traumatic brain injury	BRAIN INJURY			English	Article						orientation; amnesia; traumatic brain injury; acute care; rehabilitation	HEAD-INJURY; ALCOHOL	Primary objective: To assess the effect of an integrated reality orientation programme (North Star Project) in acute care on the duration of post-traumatic amnesia (PTA) of patients suffering from traumatic brain injury (TBI). It was hypothesized that those patients having participated in this programme would show a shorter PTA than those patients that did not. Method: Duration of PTA for 12 patients with TBI who were part of the North Star Project was compared with that of 26 patients matched for initial GCS and age for whom this approach was not available (control group). Results: Length of PTA was shorter by 5 days for the North Star patients. This result was not statistically significant (p=0.19) but is clinically relevant. No between-group difference was found for Glasgow Coma Scale. Conclusions: Consequences of shorter PTA would include increased and more appropriate patient interaction and earlier transfer to rehabilitation. The North Star project also allows the family to become more actively involved in the treatment of their loved one. Further study is required to evaluate this intervention strategy to improve orientation for the patient with TBI.	McGill Univ, Ctr Hlth, Montreal Gen Hosp, Traumat Brain Injury Program,N Star Project, Montreal, PQ H3G 1A4, Canada	Thomas, H (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Traumat Brain Injury Program,N Star Project, Montreal Gen Hosp Site,Room D13-124,1650 Cedar Av, Montreal, PQ H3G 1A4, Canada.	harle.thomas@muhc.mcgill.ca					BARNES J, 1974, GERONTOLOGIST, P138; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CERNY J, 1983, REHABILITATION HEAD, pCH24; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; DEGUISE E, UNPUB PREDICTION LEV; Folsom J C, 1967, Curr Psychiatr Ther, V7, P209; Grainger K, 1998, J AGING STUD, V12, P39, DOI 10.1016/S0890-4065(98)90019-6; JONES A, 1993, BR J NURS, V4, P519; KASCHEL R, 1995, BRAIN INJURY, V9, P619, DOI 10.3109/02699059509008220; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAC M, 1995, NEUROPSYCHOLOGICAL A; MCNENY R, 1990, REHABILITATION ADULT, pCH25; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Spector A, 2000, GERONTOLOGIST, V40, P206, DOI 10.1093/geront/40.2.206; TAULBEE LR, 1966, HOSP COMMUNITY PSYCH, V17, P133; TEASDALE G, 1974, LANCET, V2, P81; Thomas H, 2003, J HEAD TRAUMA REHAB, V18, P292, DOI 10.1097/00001199-200305000-00007; Watanabe TK, 1998, BRAIN INJURY, V12, P81; Woodrow P, 1998, Br J Nurs, V7, P1018; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Zencius AH, 1998, BRAIN INJURY, V12, P53, DOI 10.1080/026990598122854	26	12	14	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					263	269		10.1080/02699050400004971			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400004	15832872				2021-06-18	
J	Xin, WK; Zhao, XH; Xu, J; Lei, G; Kwan, CL; Zhu, KM; Cho, JS; Duff, M; Ellen, RP; McCulloch, CAG; Yu, XM				Xin, WK; Zhao, XH; Xu, J; Lei, G; Kwan, CL; Zhu, KM; Cho, JS; Duff, M; Ellen, RP; McCulloch, CAG; Yu, XM			The removal of extracellular calcium: a novel mechanism underlying the recruitment of N-methyl-D-aspartate (NMDA) receptors in neurotoxicity	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						channel gating; extracellular calcium; intracellular sodium; neuronal injury; NMDA; toxicity	RAT HIPPOCAMPAL-NEURONS; FLUOROCHROME-LABELED INHIBITORS; TRAUMATIC BRAIN INJURY; ACUTE ISCHEMIC-STROKE; CELL-DEATH; INTRACEREBRAL MICRODIALYSIS; INTRACELLULAR SODIUM; GLUTAMATE RECEPTORS; CASPASE ACTIVATION; CEREBRAL-ISCHEMIA	The involvement of NMDA-type glutamate receptor in neuronal injury established in experimental stroke and neurotrauma models has been recently challenged by failures in treatment of stroke/neurotrauma patients with NMDA receptor antagonists. NMDA receptor activity is known to be essential for mediating a multitude of physiological functions. However, how NMDA receptors are recruited to cause neuronal injury remains unclear. Here we report that the time period during which initial NMDA receptor up-regulation occurs is critical for the recruitment of NMDA receptors causing neuronal injury during extracellular calcium (Ca2+) reperfusion in cultured hippocampal neurons, and represents the key period for neuronal protection by NMDA receptor antagonists. Furthermore, we identified that via intracellular sodium (Na+), extracellular Ca2+ depletion induces the up-regulation of NMDA receptor gating. Taken together, our study provides direct experimental evidence suggesting that determination of when and how NMDA receptors are recruited to cause neurotoxicity is essential for guiding treatment via antagonism of NMDA receptor functions.	Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA; Univ Toronto, Fac Dent, Toronto, ON, Canada; Ctr Addict & Mental Hlth, Toronto, ON, Canada; Univ Toronto, CIHR Grp Matrix Dynam, Toronto, ON, Canada	Yu, XM (corresponding author), Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA.	xianmin.yu@utoronto.ca					Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Albers GW, 1999, STROKE, V30, P508, DOI 10.1161/01.STR.30.3.508; Amstad PA, 2001, BIOTECHNIQUES, V31, P608, DOI 10.2144/01313pf01; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baskin DS, 2003, TOXICOL SCI, V74, P361, DOI 10.1093/toxsci/kfg126; Bedner E, 2000, EXP CELL RES, V259, P308, DOI 10.1006/excr.2000.4955; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BIBBY KJ, 1994, AM J PHYSIOL, V266, pC1639; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Birmingham K, 2002, NAT MED, V8, P5, DOI 10.1038/nm0102-5a; Brewer GJ, 1999, EXP NEUROL, V159, P237, DOI 10.1006/exnr.1999.7123; Burgo A, 2003, J PHYSIOL-LONDON, V549, P537, DOI 10.1113/jphysiol.2003.041871; CHOI DW, 1993, PROG BRAIN RES, V96, P137; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLQUHOUN D, 1990, PROC R SOC SER B-BIO, V240, P453, DOI 10.1098/rspb.1990.0048; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; EKHOLM A, 1995, EXP BRAIN RES, V104, P462; Giardina SF, 2002, BRIT J PHARMACOL, V135, P1733, DOI 10.1038/sj.bjp.0704636; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; HARRIS RJ, 1981, J CEREBR BLOOD F MET, V1, P203, DOI 10.1038/jcbfm.1981.21; HEINEMANN U, 1986, EXP BRAIN RES, V65, P1; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B., 1992, IONIC CHANNELS EXCIT; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kyrozis A, 1996, J PHYSIOL-LONDON, V495, P449, DOI 10.1113/jphysiol.1996.sp021606; Lei G, 1999, J CELL BIOCHEM, V75, P160, DOI 10.1002/(SICI)1097-4644(19991001)75:1<160::AID-JCB16>3.3.CO;2-2; Lei G, 2002, EMBO J, V21, P2977, DOI 10.1093/emboj/cdf292; Lipton P, 1999, PHYSIOL REV, V79, P1431; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; NICHOLSON C, 1977, P NATL ACAD SCI USA, V74, P1287, DOI 10.1073/pnas.74.3.1287; Ohyashiki T, 2002, TOXICOLOGY, V176, P195, DOI 10.1016/S0300-483X(02)00139-7; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Rusakov DA, 2003, NEURON, V37, P287, DOI 10.1016/S0896-6273(03)00025-4; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; SAWYER TW, 1995, CLIN EXP PHARMACOL P, V22, P295, DOI 10.1111/j.1440-1681.1995.tb02000.x; Smolewski P, 2001, CYTOMETRY, V44, P73, DOI 10.1002/1097-0320(20010501)44:1<73::AID-CYTO1084>3.0.CO;2-S; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; Tang YP, 1999, NATURE, V401, P63; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2; Verkhratsky AJ, 1998, CELL CALCIUM, V24, P333, DOI 10.1016/S0143-4160(98)90057-4; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282; Westbrook GL, 1997, SOC GEN PHY, V52, P163; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xin WK, 2005, J NEUROSCI, V25, P139, DOI 10.1523/JNEUROSCI.3791-04.2005; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yu XM, 1998, NATURE, V396, P469; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang L, 1997, J NEUROCHEM, V69, P1983; ZIMMERMAN AN, 1966, NATURE, V211, P646, DOI 10.1038/211646a0	57	12	13	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2005	21	3					622	636		10.1111/j.1460-9568.2005.03888.x			15	Neurosciences	Neurosciences & Neurology	906OU	WOS:000227652300003	15733081				2021-06-18	
J	Cahill, LM; Murdoch, BE; Theodoros, DG				Cahill, LM; Murdoch, BE; Theodoros, DG			Articulatory function following traumatic brain injury in childhood: A perceptual and instrumental analysis	BRAIN INJURY			English	Article							TONGUE STRENGTH; SPEECH; DYSARTHRIA; FORCE	Primary objective: To investigate the articulatory function of a group of children with traumatic brain injury (TBI), using both perceptual and instrumental techniques. Research design: The performance of 24 children with TBI was assessed on a battery of perceptual (Frenchay Dysarthria Assessment, Assessment of Intelligibility of Dysarthric Speech and speech sample analysis) and instrumental ( lip and tongue pressure transduction systems) assessments and compared with that of 24 non-neurologically impaired children matched for age and sex. Main outcomes: Perceptual assessment identified consonant and vowel imprecision, increased length of phonemes and overall reduction in speech intelligibility, while instrumental assessment revealed significant impairment in lip and tongue function in the TBI group, with rate and pressure in repetitive lip and tongue tasks particularly impaired. Significant negative correlations were identified between the degree of deviance of perceptual articulatory features and decreased function on many non-speech measures of lip function, as well as maximum tongue pressure and fine force tongue control at 20% of maximum tongue pressure. Additionally, sub-clinical articulatory deficits were identified in the children with TBI who were non-dysarthric. Conclusion: The results of the instrumental assessment of lip and tongue function support the finding of substantial articulatory dysfunction in this group of children following TBI. Hence, remediation of articulatory function should be a therapeutic priority in these children.	Univ Queensland, Brisbane, Qld, Australia	Cahill, LM (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, St Lucia, Qld 4072, Australia.	l.cahill@uq.edu.au	Cahill, Louise/C-7919-2012	Cahill, Louise/0000-0003-3662-896X			Abbs J. H., 1986, INVARIANCE VARIABILI, P202; Abbs J. H., 1983, CLIN DYSARTHRIA, P21; ABBS JH, 1973, PHONETICA, V28, P65, DOI 10.1159/000259446; Barlow S. W., 1989, NEURAL BASES SPEECH, P146; BARLOW SM, 1983, J SPEECH HEAR RES, V26, P616, DOI 10.1044/jshr.2604.616; BARLOW SM, 1986, EXP NEUROL, V94, P699, DOI 10.1016/0014-4886(86)90248-7; BARLOW SM, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P53; BARLOW SM, 1990, J SPEECH HEAR RES, V33, P660, DOI 10.1044/jshr.3304.660; BARLOW SM, 1988, ASS RES OT ABSTR, V11, P218; Cahill LM, 2002, BRAIN INJURY, V16, P415, DOI 10.1080/02699050110119871; Cahill LM, 2000, J MED SPEECH-LANG PA, V8, P347; CAHILL LM, 2001, ASIA PAC J SPEECH LA, V6, P33; Darley F., 1975, MOTOR SPEECH DISORDE; DWORKIN JP, 1986, J COMMUN DISORD, V19, P115, DOI 10.1016/0021-9924(86)90015-8; ENDERBY P, 1986, BRIT J DISORD COMMUN, V21, P189; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; Goozee J V, 2001, Logoped Phoniatr Vocol, V26, P51; Goozee JV, 2002, FOLIA PHONIATR LOGO, V54, P177, DOI 10.1159/000063191; Hartelius L, 1993, SCANDINAVIAN J LOGOP, V18, P131, DOI DOI 10.3109/14015439309101359; HINTON VA, 1992, J SPEECH HEAR RES, V35, P245, DOI 10.1044/jshr.3502.245; HIROSE H, 1978, J SPEECH HEAR DISORD, V43, P96, DOI 10.1044/jshd.4301.96; HUGHES OM, 1976, PHONETICA, V33, P199; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; KENNEDY JG, 1989, NEURAL BASES SPEECH, P111; LANGMORE SE, 1994, J SPEECH HEAR RES, V37, P28, DOI 10.1044/jshr.3701.28; LUBKER JF, 1970, J ACOUST SOC AM, V42, P625; Ludlow C. L., 1984, DYSARTHRIAS PHYSL AC, P163; LUSCHEI ES, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P3; Muller E. M., 1985, Mathematics and computers in biomedical applications, P363; Murdoch B E, 1998, Motor Control, V2, P148; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; Murdoch BE, 1998, DYSARTHRIA PHYSL APP, P176; MURDOCH BE, 1998, DYSARTHRIA PHYSL APP, P373; Netsell R., 1982, SPEECH MOTOR CONTROL, P247, DOI [10.1016/B978-0-08-028892-5.50024-4, DOI 10.1016/B978-0-08-028892-5.50024-4]; ORSTRY DJ, 1997, J SPEECH LANG HEAR R, V40, P1341; ROBIN DA, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P173; ROBIN DA, 1992, J SPEECH HEAR RES, V35, P1239, DOI 10.1044/jshr.3506.1239; ROSENBEK JC, 1978, CLIN MANAGEMENT NEUR, P251; Stierwalt JAG, 1996, DISORDERS MOTOR SPEE, P241; TEASDALE G, 1974, LANCET, V2, P81; Theodoros D G, 1998, Pediatr Rehabil, V2, P107; Theodoros D. G., 2001, TRAUMATIC BRAIN INJU, p[53, 75]; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; Thompson EC, 1995, EUR J DISORDER COMM, V30, P451; THOMPSON EC, 1997, J MED SPEECH-LANG PA, V5, P191; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173	47	12	12	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2005	19	1					41	58		10.1080/02699050410001719961			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600005	15762100				2021-06-18	
J	Hoofien, D; Barak, O; Vakil, E; Gilboa, A				Hoofien, D; Barak, O; Vakil, E; Gilboa, A			Symptom checklist-90 revised scores in persons with traumatic brain injury: Affective reactions or neurobehavioral outcomes of the injury?	APPLIED NEUROPSYCHOLOGY			English	Article						affective-disorders; psychological-assessment; symptom-checklists; traumatic-brain-injury	BECK DEPRESSION INVENTORY; PSYCHIATRIC-DISORDERS; SCL 90-R; HEAD-INJURY; INDIVIDUALS; SCL-90-R; TUMOR; MMPI	The goal of this study was to examine the concurrent validity of the Symptom Checklist-90 Revised (SCL-90-R) as a measure of emotional distress among persons with traumatic brain injuries (TBI). Following previous studies, the scale was divided into a "Brain Injury Subscale " (BIS), composed of items that are confounded with the neurobehavioral outcomes of TBI, and a "Non Brain Injury Subscale" (NBIS), composed of items unrelated to the neurobehavioral outcomes. The scores of 94 persons with TBI were analyzed on the two subscales. Although more frequently endorsed, the BIS items were equally related to the cognitive and behavioral outcomes of the injury and to the respondents' affective dispositions. The same pattern of correlations was evident with the NBIS items. In addition, both scales were predicted by measures of emotional reactions to the injury. These results were interpreted as supporting the validity of the SCL-90-R as a measure of emotional distress among persons with brain injuries.	Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Natl Inst Rehabil Persons Brain Injury, Dept Psychol, Tel Aviv, Israel; Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; Univ Toronto, Dept Psychol, Toronto, ON, Canada	Hoofien, D (corresponding author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.	mshoofi@msec.huji.ac.il		Gilboa, Asaf/0000-0002-4530-7490			ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; ALMAGOR M, 1978, J ABNORM PSYCHOL, V3, P377; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Brooks D N, 1979, Int Rehabil Med, V1, P160; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; COREY MR, 1987, COGNITIVE REHABILITA, V5, P28; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Derogatis LR, 1994, SCL 90 R SYMPTOM CHE; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kaplan CP, 1998, J HEAD TRAUMA REHAB, V13, P94, DOI 10.1097/00001199-199806000-00009; Kaplan CP, 1998, BRAIN INJURY, V12, P977, DOI 10.1080/026990598122025; Kaplan CP, 1998, BRAIN INJURY, V12, P199, DOI 10.1080/026990598122674; Langer KG, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P75; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LINKOWSKI DC, 1971, REHABIL COUNS BULL, V14, P236; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muir C.A., 1984, BEHAV ASSESSMENT REH, P247; NADLER A, 1982, SERIES CLIN COMMUNIT, V8, P375; Newburn G, 1998, CNS DRUGS, V9, P441, DOI 10.2165/00023210-199809060-00003; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; ODONNELL WE, 1984, J CLIN PSYCHOL, V40, P241, DOI 10.1002/1097-4679(198401)40:1<241::AID-JCLP2270400147>3.0.CO;2-6; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; ROSKIN M, 1984, ISRAEL J PSYCHIAT, V21, P73; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SILBERG S, 1983, THESIS TEL AVIV U IS; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SOLOMON Z, 1989, SOC PSYCH PSYCH EPID, V24, P41, DOI 10.1007/BF01788199; SOLOMON Z, 1992, FAM PROCESS, V31, P289, DOI 10.1111/j.1545-5300.1992.00289.x; Spreen O., 1998, COMPENDIUM NEUROPSYC; TIFFIN J, 1968, PURDUE PEG BOARD EXA; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009	44	12	12	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2005	12	1					30	39		10.1207/s15324826an1201_6			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	916UT	WOS:000228412400006	15788221				2021-06-18	
J	LaChapelle, DL; Alfano, DP				LaChapelle, DL; Alfano, DP			Revised neurobehavioral scales of the MMPI: Sensitivity and specificity in traumatic brain injury	APPLIED NEUROPSYCHOLOGY			English	Article						MMPI; MMPI-2; neuropsychological assessment; traumatic brain injury	CLOSED-HEAD-INJURY; SPINAL-CORD INJURY; VALIDITY; PATTERNS	The ability of 23 previously identified Minnesota Multiphasic Personality Inventory (MMPI) "neurologic content" items to distinguish between individuals with traumatic brain injury (TBI; n = 32) or spinal cord injury (SCI; n = 17) was examined. Principal-components analysis of the 23 items revealed three conceptually coherent, nonoverlapping, and uncorrelated factors (Cognitive, Somatic, Inactivity) that together accounted for 44% of the total variance. Coefficients of internal consistency for the,factors were in the moderate to high range. Together, the factors were named the Revised Neurobehavioral Scales of the MMPI. The group with TBI scored significantly higher on the Cognitive scale and significantly lower on the Inactivity scale than the group with SCI (with or without depression as a covariate). The Glasgow Coma Scale correlated significantly and negatively with the Cognitive scale in the group with TBI. Discriminant function analysis revealed that together the scales correctly classified individuals with sensitivity and a positive predictive value (with respect to TBI) of 87% and 81%, respectively. Specificity and a negative predictive value (with respect to SCI) were 68% and 76%, respectively. The overall rate of correct classification of individual cases was 80% (with or without depression in the analysis). The Cognitive scale alone correctly classified individuals in the group with TBI with a positive predictive value of 84%. Findings are discussed in terms of the discriminative validity and potential utility of TBI-related MMPI items, as well as the issue of "neurocorrection" of the MMPI (or MMPI-2) in verified cases of TBI.	Univ Regina, Dept Psychol, Regina, SK S4S 0A2, Canada; Univ New Brunswick, Dept Psychol, Fredericton, NB, Canada	Alfano, DP (corresponding author), Univ Regina, Dept Psychol, Regina, SK S4S 0A2, Canada.	dennis.alfano@uregina.ca					Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; ARTZY G, 1994, THESIS U VICTORIA BR; BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; Brulot MM, 1997, CLIN NEUROPSYCHOL, V11, P391, DOI 10.1080/13854049708400468; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Cripe LI, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P291; FARR SP, 1988, MMPI USE SPECIFIC PO, P214; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GUADAGNOLI E, 1988, PSYCHOL BULL, V103, P265, DOI 10.1037/0033-2909.103.2.265; HATHAWAY SR, 1989, MINNESOTA MULTIPHASI, V2; HENRYSSON S, 1962, PSYCHOMETRIKA, V27, P41; Jackson D. N., 1970, CURRENT TOPICS CLIN, V2, P61, DOI DOI 10.1016/B978-0-12-153502-5.50008-4; LUBIN B, 1985, AM PSYCHOL, V40, P857, DOI 10.1037/0003-066X.40.7.857; McCaffrey RJ, 1996, ARCH CLIN NEUROPSYCH, V11, P11; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MEYERINK LH, 1988, J CLIN PSYCHOL, V44, P764, DOI 10.1002/1097-4679(198809)44:5<764::AID-JCLP2270440517>3.0.CO;2-Y; Radloff LS, 1977, J APPL PSYCHOL MEASU, V1, P385, DOI DOI 10.1177/014662167700100306; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Tabachnick BG, 2013, USING MULTIVARIATE S	24	12	13	0	2	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2005	12	3					143	150		10.1207/S15324826AN1203_4			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	965OR	WOS:000231960500004	16131341				2021-06-18	
J	Logan, MP; Parker, S; Shi, RY				Logan, MP; Parker, S; Shi, RY			Glutathione and ascorbic acid enhance recovery of guinea pig spinal cord white matter following ischemia and acrolein exposure	PATHOBIOLOGY			English	Article						neurotrauma; oxygen glucose deprivation; reperfusion; membrane; antioxidants	AXONAL MEMBRANE DISRUPTION; LIPID-PEROXIDATION; MYELINATED AXONS; CONDUCTION LOSS; PROTEIN DAMAGE; INJURY; AUGMENTATION; IMPAIRMENT; MECHANISMS; RESISTANCE	Objective:We have shown that acrolein, a lipid peroxidation byproduct, can inflict significant damage in isolated spinal cord white matter following oxygen glucose deprivation (OGD). The mechanism of such acrolein-induced damage is unclear. The aim of this study was to examine whether glutathione (GSH) and ascorbic acid, two reactive oxygen species (ROS) scavengers, can alleviate functional and anatomical damage due to acrolein. Methods: We used an OGD injury model with isolated guinea pig spinal cord white matter. Sucrose gap recording was used to monitor axonal impulse conduction, and a horseradish peroxidase exclusion test was employed to determine membrane integrity. The functional and anatomical parameters were compared in three groups: acrolein, acrolein/GSH and acrolein/ascorbic acid. Results:We found that while GSH resulted in an 87% recovery of compound action potential conductance, ascorbic acid produced a 97% recovery, compared with a 69% recovery in an injured group without treatment. It is noted that GSH, and to a lesser extent ascorbic acid, preferentially enhanced functional recovery in smaller axons. Conclusion: Acrolein-induced neuronal damage is likely mediated by ROS. Furthermore, GSH and ascorbic acid are effective in suppressing acrolein and free radical-induced injury in spinal cord white matter. Copyright (C) 2005 S. Karger AG, Basel.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Lafayette Ctr Med Educ, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	riyi@purdue.edu					ALLEN BT, 1995, VASCULAR SURG THEORY, P1402; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BEMENT SL, 1969, EXP NEUROL, V24, P147, DOI 10.1016/0014-4886(69)90012-0; BLIGHT AR, 1985, NEUROSCIENCE, V15, P13, DOI 10.1016/0306-4522(85)90119-8; Chakraborty H, 2001, NEUROCHEM INT, V39, P311, DOI 10.1016/S0197-0186(00)00117-0; CHAN PH, 1993, PROG BRAIN RES, V96, P97; CHAN WCW, 2000, P SOC PHOTO-OPT INS, V1, P2; HAENEN GRMM, 1988, BIOCHEM PHARMACOL, V37, P1933, DOI 10.1016/0006-2952(88)90539-4; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1989, CRIT CARE CLIN, V5, P793; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hall ED, 1991, J NEUROTRAUM, V8, pS1; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Heales SJR, 2002, NEUROCHEM INT, V40, P469, DOI 10.1016/S0197-0186(01)00117-6; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lucas JH, 2003, J NEUROTRAUM, V20, P1067; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; LUO J, 2003, NEUROBIOL LIPIDS, V2; LUO J, 2003, NEUROBIOL LIPIDS, V3; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Pocernich CB, 2001, NEUROCHEM INT, V39, P141, DOI 10.1016/S0197-0186(01)00012-2; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RICE ME, 1994, J NEUROPHYSIOL, V71, P1591; ROSE RC, 1993, FASEB J, V7, P1135; SATRAN R, 1988, Stroke, V19, P529; Shi R., 1996, Society for Neuroscience Abstracts, V22, P1185; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Stys PK, 1998, NEUROSCIENCE, V82, P21; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; WEST DC, 1983, J PHYSIOL-LONDON, V337, P37, DOI 10.1113/jphysiol.1983.sp014610; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5	42	12	17	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-2008	1423-0291		PATHOBIOLOGY	Pathobiology		2005	72	4					171	178		10.1159/000086786			8	Cell Biology; Pathology	Cell Biology; Pathology	961ZE	WOS:000231700000001	16127292				2021-06-18	
S	Pillay, NS; Kellaway, LA; Kotwal, GJ		Kotwal, GJ; Lahiri, DK		Pillay, NS; Kellaway, LA; Kotwal, GJ			Administration of vaccinia virus complement control protein shows significant cognitive improvement in a mild injury model	NATURAL PRODUCTS AND MOLECULAR THERAPY	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	1st International Conference on Natural Products and Molecular Medicine	JAN 13-15, 2005	Univ Cape Town, Cape Town, SOUTH AFRICA		Univ Cape Town	complement control; cognition; mild injury; vaccinia virus; VCP; Morris water maze (MWM); fluid percussion injury (FPI); traumatic brain injury (TBI)	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; FLUID; RAT; EXTRAVASATION; EXPRESSION	Previous studies have shown that traumatic mild brain injury in a rat model is accompanied by breakdown of the blood brain barrier and the accumulation of inflammatory cells. A therapeutic agent, vaccinia virus complement control protein (VCP), inhibits both the classic and the alternative pathways of the complement system and, in so doing, prevents cell death and inflammation. With the use of a rat mild injury model, the effects of VCP on spatial learning and memory were tested. Training in a Morris water maze consisted of a total of 16 trials over a 2-day period before rats were anesthetized and subjected to mild (1.0-1.1 atm) lateral fluid percussion injury (FPI) 3.0 mm lateral to the sagittal suture and 4.5 mm posterior to bregma. Ten mu l of VCP (1.7 mg/ml) was injected into the injury site immediately after FPI. Two weeks post-FPI the rats were assessed in the Morris water maze for spatial learning and memory. Neurologic motor function tests were carried out after FPI for 14 consecutive days and again after 28 days. The Morris water maze data show that FPI plus saline-injected rats spent a significantly (P < 0.05) larger amount of time in one of the incorrect quadrants than did the FPI plus VCP-injected group. Neurologic evaluations 24 hours postinjury revealed differences in sensorimotor function between groups. The results suggest that in a mild injury model, VCP influences neurologic outcome and offers some enhancement in spatial memory and learning.	Univ Cape Town, Sch Med, Div Med Virol, Observ, ZA-7925 Cape Town, South Africa; Univ Cape Town, Div Neurosci, ZA-7925 Cape Town, South Africa	Kotwal, GJ (corresponding author), Univ Cape Town, Sch Med, Div Med Virol, Observ, Anzio Rd, ZA-7925 Cape Town, South Africa.	gjkotw01@yahoo.corn			Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pillay Nirvana S., 2004, Current Alzheimer Research, V1, P295, DOI 10.2174/1567205043331965; Power AE, 2002, BEHAV BRAIN RES, V134, P307, DOI 10.1016/S0166-4328(02)00046-3; PRINS ML, 1996, DEV BRAIN RES, V95, P115; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; vanderStaay FJ, 1996, BRAIN RES, V735, P271; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	25	12	12	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-595-8; 1-57331-594-X	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1056						450	461		10.1196/annals.1352.021			12	Biochemistry & Molecular Biology; Integrative & Complementary Medicine; Medicine, Research & Experimental; Multidisciplinary Sciences	Biochemistry & Molecular Biology; Integrative & Complementary Medicine; Research & Experimental Medicine; Science & Technology - Other Topics	BDU43	WOS:000235433100037	16387708				2021-06-18	
J	Ryan, JJ; Carruthers, CA; Miller, LJ; Souheaver, GT; Gontkovsky, ST; Zehr, MD				Ryan, JJ; Carruthers, CA; Miller, LJ; Souheaver, GT; Gontkovsky, ST; Zehr, MD			Brief communication - the WASI matrix reasoning subtest: Performance in traumatic brain injury, stroke, and dementia	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						dementia; matrix reasoning; sensitivity; stroke; traumatic brain injury		Previous research reported that the WAIS-III Matrix Reasoning (MR) subtest was insensitive to the effects of traumatic brain injury (TBI), learning disability, and attention deficit hyperactivity disorder. This study was conducted to determine whether these findings generalize to the Wechsler Abbreviated Scale of Intelligence (WASI) MR subtest and to explore the subtest's sensitivity to other brain disorders. When 81 brain-damaged patients completed the WASI, the MR subtest was the highest score in the profile. For subgroups of TBI and Dementia, MR yielded the highest mean T-score. For patients with stroke, MR was the second highest mean. Subtest comparisons with estimated premorbid IQ suggested MR might show selective sensitivity. Results indicated no predictive validity for TBI, whereas MR was sensitive to the cognitive sequelae of stroke and dementia.	Cent Missouri State Univ, Dept Psychol, Warrensburg, MO 64093 USA; McClellan VAMC, Little Rock, AR USA; Methodist Rehabil Ctr, Jackson, MS USA; Med Res Ctr, Kansas City, MO USA	Ryan, JJ (corresponding author), Cent Missouri State Univ, Dept Psychol, Warrensburg, MO 64093 USA.	ryan@cmsu1.emsu.edu					BRODY N, 1992, INTELLIGENCE, P18; CATTELL RB, 1963, J EDUC PSYCHOL, V54, P1, DOI 10.1037/h0046743; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Kaufman A. S., 1990, ASSESSING ADOLESCENT; KEEDY S, 1999, 107 ANN CONV AM PSYC; Psychological Corporation, 2001, WECHSL TEST AD READ; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Wechsler D., 1997, WAIS 3 ADM SCORING M	8	12	13	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0020-7454			INT J NEUROSCI	Int. J. Neurosci.	JAN	2005	115	1					129	136		10.1080/00207450490512704			8	Neurosciences	Neurosciences & Neurology	885ED	WOS:000226139000011	15768857				2021-06-18	
J	Seki, Y; Kimura, M; Mizutani, N; Fujita, M; Aimi, Y; Suzuki, Y				Seki, Y; Kimura, M; Mizutani, N; Fujita, M; Aimi, Y; Suzuki, Y			Cerebrospinal fluid taurine after traumatic brain injury	NEUROCHEMICAL RESEARCH			English	Article						cytotoxic edema; regulatory volume decrease; taurine; traumatic brain injury	AMINO-ACIDS; GLUTAMATE; RELEASE; ANION; POTASSIUM; INCREASES; VOLUME	In the experimental setting, taurine is known to be released from swollen cells to reestablish their normal volume. However, its clinical relevance has not been fully understood. This study was undertaken to reveal changes in cerebrospinal fluid (CSF) amino acids concentration in patients with severe traumatic brain injury (TBI). The study included eight patients, in whom a ventricular catheter was inserted to measure intracranial pressure and obtain CSF samples for 5 days. CSF obtained from patients with normal pressure hydrocephalus served as a control. CSF taurine concentration increased 1.8 times control (P < 0.05) after TBI and returned to control value approximately 67 h after injury. Taurine decreased further and remained lower than control thereafter. Phosphoethanolamine showed similar increase, whereas glutamine decreased transiently and arginine remained close to control value. The present data support the period of astrocytic swelling observed after TBI in other morphological studies. The mechanism and consequences of CSF taurine decrease in the subacute stage of TBI need to be elucidated.	Chubu Rousai Hosp, Dept Neurosurg, Minato Ku, Nagoya, Aichi 4558530, Japan; Daini Red Cross Hosp, Dept Neurosurg, Nagoya, Aichi, Japan	Seki, Y (corresponding author), Chubu Rousai Hosp, Dept Neurosurg, Minato Ku, 1-10-6 Komei, Nagoya, Aichi 4558530, Japan.	seki.nes@chubuh.rofuku.go.jp	Fujita, Mitsugu/A-6690-2009	Fujita, Mitsugu/0000-0002-0000-9879			Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Birdsall T C, 1998, Altern Med Rev, V3, P128; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Estevez AY, 1999, NEUROCHEM RES, V24, P447, DOI 10.1023/A:1020902104056; HAYES KC, 1985, NUTR REV, V43, P65, DOI 10.1111/j.1753-4887.1985.tb06862.x; JACKSON PS, 1994, AM J PHYSIOL-CELL PH, V267, pC1203; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; LEE PLY, 1988, CLIN CHEM, V34, P719; Liu Y, 1998, MOL BRAIN RES, V59, P189, DOI 10.1016/S0169-328X(98)00145-4; MCGALE EHF, 1977, J NEUROCHEM, V29, P291, DOI 10.1111/j.1471-4159.1977.tb09621.x; PAAUW JD, 1990, AM J CLIN NUTR, V52, P657; Park E, 1998, ADV EXP MED BIOL, V442, P177; Pasantes-Morales H, 1998, ADV EXP MED BIOL, V442, P209; PASANTESMORALES H, 1989, GLIA, V2, P45, DOI 10.1002/glia.440020105; POMARA N, 1992, AM J PSYCHIAT, V149, P251; Redmond HP, 1998, NUTRITION, V14, P599, DOI 10.1016/S0899-9007(98)00097-5; ROSENBERG GA, 1980, AM J PHYSIOL, V238, pF42; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; SOLIS JM, 1988, NEUROSCI LETT, V91, P53, DOI 10.1016/0304-3940(88)90248-0; Stapleton PP, 1998, JPEN-PARENTER ENTER, V22, P42, DOI 10.1177/014860719802200142; STAUB F, 1990, J CEREBR BLOOD F MET, V10, P866, DOI 10.1038/jcbfm.1990.143; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135	25	12	12	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JAN	2005	30	1					123	128		10.1007/s11064-004-9693-4			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	896OQ	WOS:000226943800015	15756940				2021-06-18	
J	Powell, EC; Tanz, RR				Powell, EC; Tanz, RR			Incidence and description of scooter-related injuries among children	AMBULATORY PEDIATRICS			English	Article						child injury; in-line skates; scooters; skateboards		Objective.-To describe trends in scooter-related injuries among US youth and compare scooter injuries to those related to in-line skates and skateboards. Design.-Retrospective review of data for children 1-19 years old from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission for 1997-2002. Results.-There were an estimated 190 878 scooter-related injuries (95% confidence interval: 145984-235773) among children treated in US emergency departments; 90% were in those 15 years old or younger. There was a marked increase in scooter-related injuries in 2000, injuries peaked in 2001, and declined. In 2002, the number of scooter-related injuries was similar to in-line skates and lower than skateboard-related injuries. Scooter- and in-fine skate-associated injuries primarily involved children 5-12 years old: rates of scooter-related injuries were higher than rates of in-line skate-associated injuries among those 1-9 years old. Skateboard-related injuries more often involved teens. Forearm fractures accounted for 56% of fractures related to scooters (vs 74% in-line skates and 49% skateboards, chi-square, P < .01). Five percent of children injured using scooters had a closed head injury or skull fracture, similar to in-line skates and skateboards. Conclusions.-The annual number of injuries related to scooters, which peaked in 2001, is now similar to the number of injuries related to in-line skates. Injuries related to scooters primarily involve children 5-12 years old, and forearm fractures are common. These data suggest helmets should be used, and protective equipment should be developed to reduce forearm fractures.	Childrens Mem Hosp, Div Pediat Emergency Med, Chicago, IL 60614 USA; Childrens Mem Hosp, Div Gen Acad Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL USA	Powell, EC (corresponding author), Childrens Mem Hosp, Div Pediat Emergency Med, Box 62,2300 Childrens Plaza, Chicago, IL 60614 USA.	epowell@northwestern.edu		Powell, Elizabeth/0000-0003-3147-9889			Bull MJ, 2002, PEDIATRICS, V109, P542; Chapman S, 2001, J PAEDIATR CHILD H, V37, P567, DOI 10.1046/j.1440-1754.2001.00763.x; *CONS PROD SAF COM, SCOOT SAL SKYR INJ S; Forjuoh SN, 2002, ARCH PEDIAT ADOL MED, V156, P656, DOI 10.1001/archpedi.156.7.656; HANNON B, 2004, TAIPEI TIMES; Kubiak R, 2003, ACTA PAEDIATR, V92, P50; Levine DA, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e64; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; *US BUR CENS, 2000 CENS POP HOUS; *US CONS PROD SAF, 1993, EXPL SHEET NEISS EST; *US CONS PROD SAF, 1996, CONSUMER PROD SAFETY, V1, P4; *US CONS PROD SAF, 1986, US CONS PROD SAF COM; US Consumer Product Safety Commission, TOY REL DEATHS INJ C; *USDHHS, NAT EL INJ SURV SYST; Weir E, 2002, CAN MED ASSOC J, V167, P55; 2000, MMWR, V49, P1108	17	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1530-1567			AMBUL PEDIATR	Ambul. Pediatr.	NOV-DEC	2004	4	6					495	499		10.1367/A04-074R1.1			5	Pediatrics	Pediatrics	873JI	WOS:000225275400006	15548100				2021-06-18	
J	Esselman, PC; Dikmen, SS; Bell, K; Temkin, NR				Esselman, PC; Dikmen, SS; Bell, K; Temkin, NR			Access to inpatient rehabilitation after violence-related traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; violence	MODEL SYSTEMS; OUTCOMES	Objectives: To examine injury characteristics, demographics, and discharge disposition after traumatic brain injury of violent or nonviolent cause. Design: Cohort study. Setting: Level I trauma center. Participants: Patients (N = 1807) admitted with a Head Abbreviated Injury Score (AIS) of 2 or more over a 2-year period. Interventions: Not applicable. Main Outcome Measures: Injury cause was classified as violent or nonviolent. Discharge disposition was classified as home, inpatient rehabilitation, skilled nursing facility (SNF), and other. Results: The violence group was more likely to be male, to include individuals from diverse racial groups, to have an alcohol level above the legal limit, to have a more severe Head AIS, and to have Medicaid funding and equal access to inpatient rehabilitation compared with the nonviolence group. The violence group, though, was more likely to be discharged to home than to inpatient rehabilitation and more likely to be discharged to inpatient rehabilitation than to an SNF. The nonviolence group had a longer acute care length of stay and a higher rate of injuries to other body systems. Conclusions: People with violence-related injuries often present unique rehabilitation challenges. After accounting for injury severity and demographics, there was no evidence of bias against the violently injured in gaining access to inpatient rehabilitation services.	Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98104 USA	Esselman, PC (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, 325 9Th Ave, Seattle, WA 98104 USA.	esselman@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046			*AM MED ASS, 1997, INT CLASS DIS; *ASS ADV AUT MED, 1990, ABBR INJ SC; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Machamer JE, 2003, J HEAD TRAUMA REHAB, V18, P387, DOI 10.1097/00001199-200309000-00001; TEASDALE G, 1974, LANCET, V2, P81; *US DHHS CDC NAT C, 1999, TRAUM BRAIN INJ US	12	12	12	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1445	1449		10.1016/j.apmr.2003.10.018			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	852DW	WOS:000223736400009	15375814				2021-06-18	
J	Dong, K; Li, B; Guan, QL; Huang, T				Dong, Ke; Li, Bo; Guan, Quan-Lin; Huang, Tao			Analysis of multiple factors of postsurgical gastroparesis syndrome after pancreaticoduodenectomy and cryotherapy for pancreatic cancer	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article								AIM: To explore the etiology, pathogenesis, diagnosis, and treatment of postsurgical gastroparesis syndrome (PGS) after pancreatic cancer cryotherapy (PCC) or pancreatico-duodenectomy (PD), and to analyze the correlation between the multiple factors and PGS caused by the operations. METHODS: Clinical data of 210 patients undergoing PD and 46 undergoing PCC were analyzed retrospectively. RESULTS: There were 31 (67%, 31/46) patients suffering PGS in PCC group, including 29 with pancreatic head and uncinate tumors and 2 with pancreatic body and tail tumors. Ten patients (4.8%, 10/210) developed PGS in PD group, which had a significantly lower incidence of PGS than PCC group (chi = 145, P<0.001). In PCC group, 9 patients with PGS were managed with non-operative treatment (drugs, diet, nasogastric suction, etc.), and one received reoperation at the 16th day, but the symptoms were not relieved. In PD group, all the patients with PGS were managed with non-operative treatment. The PGS in patients undergoing PCC had close association with PCC, tumor location, but not with age, gender, obstructive jaundice, hypoproteinemia, preoperative gastric outlet obstruction and the type and number of gastric biliary tract operations. The mechanisms of PGS caused by PD were similar to those of PGS following gastrectomy. The damage to interstitial cells of Cajal might play a role in the pathogenesis of PGS after PCC, for which multiple factors were possibly responsible, including ischemic and neural injury to the antropyloric muscle and the duodenum after freezing of the pancreatico-duodenal regions or reduced circulating levels of motilin. CONCLUSION: PGS after PCC or PD is induced by multiple factors and the exact mechanisms, which might differ between these two operations, remain unknown. Radiography of the upper gastrointestinal tract and gastroscopy are main diagnostic modalities for PGS. Non-operative treatments are effective for PGS, and reoperation should be avoided in patients with PGS caused by PCC. Dong K, Li B, Guan QL, Huang T. Analysis of multiple factors of postsurgical gastroparesis syndrome after pancreaticodu-odenectomy and cryotherapy for pancreatic cancer. World J Gastroenterol 2004; 10(16): 2434-2438 http://www.wjgnet.com/1007-9327/10/2434.asp	[Dong, Ke; Li, Bo; Guan, Quan-Lin; Huang, Tao] Sichuan Univ, W China Hosp, Dept Gen Surg, Chengdu 610041, Sichuan Provinc, Peoples R China	Li, B (corresponding author), Sichuan Univ, W China Hosp, Dept Gen Surg, Chengdu 610041, Sichuan Provinc, Peoples R China.	cdlibo@medmail.com	Li, Bo/AAA-8968-2020	Li, Bo/0000-0002-7294-6888	Research Foundation of Department of Health of Sichuan Province [000050]	Supported by the Research Foundation of Department of Health of Sichuan Province, No. 000050	Abell T, 2003, JPEN-PARENTER ENTER, V27, P277, DOI 10.1177/0148607103027004277; B Li, 2000, ZHONGGUO PUWAI JICHU, V7, P390; Cai YT, 1999, ZHONGGUO SHIYONG WAI, V19, P338; Chen XL, 1998, ZHONGGUO PUWAI JICHU, V5, P324; DONAHUE PE, 1984, SURGERY, V96, P585; HOROWITZ M, 1994, DIGEST DIS SCI, V39, pS7, DOI 10.1007/BF02300360; Jones MP, 2003, AM J GASTROENTEROL, V98, P2122, DOI 10.1016/S0002-9270(03)00754-8; Koch K L, 2001, Diabetes Technol Ther, V3, P51; Kovach SJ, 2002, SURGERY, V131, P463, DOI 10.1067/msy.2002.121231; Lawlor PM, 2001, IRISH J MED SCI, V170, P126, DOI 10.1007/BF03168826; Lehmann R, 2003, EXP CLIN ENDOCR DIAB, V111, P255, DOI 10.1055/s-2003-41283; Lin ZY, 2003, DIGEST DIS SCI, V48, P837, DOI 10.1023/A:1023099206939; Liu FL, 2002, ZHONGHUA WEICHANG WA, V5, P245; MALFERTHEINER P, 1989, GASTROENTEROLOGY, V96, P200, DOI 10.1016/0016-5085(89)90781-6; Matsunaga H, 2000, WORLD J SURG, V24, P1236, DOI 10.1007/s002680010244; Naritomi G, 1996, SURGERY, V120, P831, DOI 10.1016/S0039-6060(96)80091-2; Ordog T, 2000, DIABETES, V49, P1731, DOI 10.2337/diabetes.49.10.1731; Patiutko Iu I, 1991, Vopr Onkol, V37, P695; Qin XY, 2000, ZHONGGUO WEICHANG WA, V3, P7; SCHIRMER BD, 1994, GASTROENTEROL CLIN N, V23, P327; Stanciu G O, 2001, Rev Med Chir Soc Med Nat Iasi, V105, P451; Toyota N, 1998, HEPATO-GASTROENTEROL, V45, P1005; Watkins PJ, 2003, DIABETIC MED, V20, P58, DOI 10.1046/j.1464-5491.2003.00872.x; Zarate N, 2003, GUT, V52, P966, DOI 10.1136/gut.52.7.966	24	12	15	0	2	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	AUG 15	2004	10	16					2434	2438					5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	V23BF	WOS:000208317600029	15285038				2021-06-18	
J	Chan, RCK; Chen, EYH; Cheung, ERC; Chen, RYL; Cheung, HK				Chan, RCK; Chen, EYH; Cheung, ERC; Chen, RYL; Cheung, HK			Problem-solving ability in chronic schizophrenia - A comparison study of patients with traumatic brain injury	EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE			English	Article						problem-solving; schizophrenia; brain injury	SPATIAL WORKING-MEMORY; TEMPORAL-LOBE LESIONS; FRONTAL-LOBE; ATTENTIONAL DEFICITS; PLANNING ABILITY; HANOI; PERFORMANCE; TOWER	We tested the hypothesis that patients with schizophrenia are more prone to impairment in planning and problem-solving as compared with normal controls and patients with traumatic brain injury (TBI) by administering the Tower of Hanoi (TOH) task. A total of one hundred and fifty-three participants (51 in each group) were recruited. The performance of the patient groups was markedly worse than normal controls in terms of profile score, number of rule-breaking behaviour, and mean execution time. Two-way 3 (group) x 6 (complexity) ANOVAs indicated that significant main effects of group and complexity were observed in the number of moves, planning time to initiate the first move and subsequent execution time. The general performance of TOH in the schizophrenia group was very similar to that of the TBI group. Subsequent comparison of sub-groups of frontal and posterior lobe damage indicated the pattern of performance in schizophrenia patients lie between them. Taken together, these findings suggest that neither focal frontal nor temporal lobe damage is a sufficient explanation for the problem-solving deficits in patients with schizophrenia.	Sun Yat Sen Univ, Dept Psychol, Guangzhou 510275, Peoples R China; Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; Castle Peak Hosp, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Sun Yat Sen Univ, Dept Psychol, Guangzhou 510275, Peoples R China.	rckchan@hkucc.hku.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X; Chen, Eric/0000-0002-5247-3593			American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; Bustini M, 1999, J PSYCHIATR RES, V33, P285, DOI 10.1016/S0022-3956(98)00063-6; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2002, J INT NEUROPSYCH SOC, V8, P771, DOI 10.1017/S1355617702860052; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; Falkai P, 2003, EUR ARCH PSY CLIN N, V253, P92, DOI 10.1007/s00406-003-0414-9; GATTAZ WF, 1990, SEARCH CAUSES SCHIZO, V2, P242; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; Goldberg T E, 1990, J Neuropsychiatry Clin Neurosci, V2, P165; GoldmanRakic PS, 1997, SCHIZOPHRENIA BULL, V23, P437, DOI 10.1093/schbul/23.3.437; GOLDMANRAKIC PS, 1990, PSYCHOPATHOLOGY BRAI, P1; Humes GE, 1997, ASSESSMENT, V4, P249, DOI 10.1177/107319119700400305; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Marczewski P., 2001, COGNITIVE NEUROPSYCH, V6, P175, DOI DOI 10.1080/13546800042000115; Morris RG, 1997, COGN NEUROPSYCHOL, V14, P1007, DOI 10.1080/026432997381330; MORRIS RG, 1995, SCHIZOPHR RES, V14, P235, DOI 10.1016/0920-9964(94)00044-9; Newell A, 1972, HUMAN PROBLEM SOLVIN, V104; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Pantelis C, 1999, SCHIZOPHR RES, V37, P251, DOI 10.1016/S0920-9964(98)00156-X; Rushe TM, 1999, SCHIZOPHR RES, V37, P21, DOI 10.1016/S0920-9964(98)00129-7; SCHMAND B, 1992, SCHIZOPHR RES, V8, P157, DOI 10.1016/0920-9964(92)90032-Z; SHARPIRO RM, 1993, SCHIZOPHR RES, V10, P187; Tiryaki A, 2003, EUR ARCH PSY CLIN N, V253, P221, DOI 10.1007/s00406-003-0434-5; WEINBERGER DR, 1988, TRENDS NEUROSCI, V11, P367, DOI 10.1016/0166-2236(88)90060-4	26	12	12	0	4	DR DIETRICH STEINKOPFF VERLAG	DARMSTADT	PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY	0940-1334			EUR ARCH PSY CLIN N	Eur. Arch. Psych. Clin. Neurosci.	AUG	2004	254	4					236	241		10.1007/s00406-004-0486-1			6	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	846JA	WOS:000223310600007	15309393				2021-06-18	
J	Marshall, RC; Karow, CM; Morelli, CA; Iden, KK; Dixon, J; Cranfill, TB				Marshall, RC; Karow, CM; Morelli, CA; Iden, KK; Dixon, J; Cranfill, TB			Effects of interactive strategy modelling training on problem-solving by persons with traumatic brain injury	APHASIOLOGY			English	Article							FRONTAL-LOBE DAMAGE; QUESTIONING STRATEGIES; DEFICITS; CHILDREN	Background : Problem-solving skills may be affected by traumatic brain injury (TBI). Because the ability to solve problems is integral to the social, educational, and vocational reintegration of persons who have sustained a TBI, interventions to improve this executive function have become an important part of rehabilitation. Aims : This Phase I study examined the effects of a behavioural intervention, interactive strategy modelling training (ISMT), on problem solving by individuals who had incurred a TBI. Methods & Procedures : Study participants were 20 individuals recruited from TBI support groups. All lived at home and were several months post-injury. Participants received a period of ISMT intended to train them to use meta-cognitive strategies to solve 20-questions problems. RAPS (Rapid Assessment of Problem Solving), a clinical test of problem solving was used to assess the effects of ISMT (Marshall, Karow, Morelli, Iden, & Dixon, 2003a). RAPS was administered before (Pre-training), after (Post-training), and 1-month after training (Follow-up). Outcomes & Results : Participants improved in problem solving significantly on RAPS from the Pre- to the Post-training tests. Specifically, they (a) solved problems with fewer questions, (b) asked more constraint-seeking questions, and (c) increased their question-asking efficiency scores. These improvements were maintained on the Follow-up test. Conclusions : Improved problem solving on RAPS was associated with better planning and strategy use, less impulsivity, and strategy shifting. Results suggest that IMST had a therapeutic effect and indicate a need to develop further hypotheses for testing ISMT in functional contexts.	Univ Kentucky, Dept Rehabil Sci, Lexington, KY 40536 USA; Univ Kentucky, Div Commun Disorders, Lexington, KY 40536 USA; Univ Rhode Isl, Kingston, RI 02881 USA; Univ Florida, Gainesville, FL USA; Vet Adm Med Ctr, Providence, RI 02908 USA; Massachusetts Hosp Sick Children, Boston, MA USA	Marshall, RC (corresponding author), Univ Kentucky, Dept Rehabil Sci, Room 124-F,900 S Limestone, Lexington, KY 40536 USA.						ADAMOVICH B, 1985, CCOGNITIVE REHABILIT; AITKEN S, 1993, ARCH CLIN NEUROPSYCH, V8, P212; ALLEN G, 1976, COMMUNITY PSYCHOL SC; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BARTON JA, 1988, J EDUC PSYCHOL, V80, P184, DOI 10.1037/0022-0663.80.2.184; Ben-Yishay Y, 1983, REHABILITATION HEAD, P367; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; DENNEY DR, 1975, J EXP CHILD PSYCHOL, V19, P476, DOI 10.1016/0022-0965(75)90077-6; DENNEY DR, 1973, DEV PSYCHOL, V8, P202, DOI 10.1037/h0034144; DENNEY DR, 1972, CHILD DEV, V43, P810, DOI 10.2307/1127633; DENNEY NW, 1974, DEV PSYCHOL, V10, P458, DOI 10.1037/h0036444; DENNEY NW, 1985, INT J AGING HUM DEV, V21, P161, DOI 10.2190/A3J2-75L4-01C3-W81W; DENNEY NW, 1974, CHILD DEV, V45, P1108; Dimitrov M, 1996, CORTEX, V32, P357, DOI 10.1016/S0010-9452(96)80057-8; GILLIS R, 1996, TRAUMATIC BRAIN INJU; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; GOLDSTEIN FC, 1991, BRAIN COGNITION, V17, P23, DOI 10.1016/0278-2626(91)90063-E; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Kaplan E., 1983, BOSTON NAMING TEST; KING A, 1991, J EDUC PSYCHOL, V83, P307, DOI 10.1037/0022-0663.83.3.307; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria, 1973, WORKING BRAIN INTRO; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Marshall RC, 2003, AM J SPEECH-LANG PAT, V12, P333, DOI 10.1044/1058-0360(2003/079); Marshall RC, 2003, BRAIN INJURY, V17, P589, DOI 10.1080/0269905031000088496; MERTZGARCIA J, 1986, J COMMUN DISORD, V19, P395; Mosher F.A., 1966, STUDIES COGNITIVE GR, P86; MURRAY L, 2001, LANGUAGE INTERVENTIO, P85; NEZU CM, 1991, RES DEV DISABIL, V12, P371, DOI 10.1016/0891-4222(91)90033-O; O'Reilly MF, 2000, J VOCAT REHABIL, V14, P187; ODDY M, 1984, CLOSED HEAD INJURY P, P285; PURDY M, 2000, APHASIOLOGY, V16, P549; Raven JC., 1984, COLOURED PROGR MATRI; Rende Barbara, 2000, Seminars in Speech and Language, V21, P121, DOI 10.1055/s-2000-7560; SAARNIO P, 1993, ALCOHOL ALCOHOLISM, V28, P585; SELINGER M, 1993, APHASIOLOGY, V7, P165, DOI 10.1080/02687039308249504; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SOHBERG MM, 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; TWOMBLY CA, 1998, AM J OCCUPATIONAL TH, V52, P810; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; Wilson BA, 1996, BEHAV ASSESSMENT DYS; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, 1987, COMMUNITY REENTRY HE	51	12	12	1	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	AUG	2004	18	8					659	673		10.1080/02687030444000237			15	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	835ZK	WOS:000222524300001					2021-06-18	
J	Shafe, M; Blaivas, M; Hooker, E; Straus, L				Shafe, M; Blaivas, M; Hooker, E; Straus, L			Noninvasive intracranial cerebral flow velocity evaluation in the emergency department by emergency physicians	ACADEMIC EMERGENCY MEDICINE			English	Article						emergency ultrasound; transcranial Doppler; head injury; elevated intracranial pressure; intubation; emergency medicine	TRANSCRANIAL DOPPLER; ULTRASONOGRAPHY; ULTRASOUND; PRESSURE	Transcranial Doppler (TCD) is an accepted modality for the evaluation of cerebral blood flow velocities. Objectives: The purpose of this study was to test the feasibility of bedside TCD measurement in the emergency department (ED) with critically ill, intubated patients. Methods: A prospective convenience sample of patients presenting to a university hospital over a two-month period underwent TCD evaluation of the middle cerebral artery. Intubated patients with head trauma and any patient requiring tracheal intubation were eligible. A 2-MHz Doppler probe was positioned over the temporal bone to acquire blood flow velocities. An emergency medicine resident and research assistant obtained measurements. Continuous TCD tracings were recorded on a video cassette recorder tape for quality assurance review and data collection. Vital signs and therapeutic interventions were also recorded. Flow velocities were measured in cm/s; the peak Resistance Index (RI) was calculated for each patient. Results: A total of 30 patients were enrolled in the study. Adequate tracings were obtained in 25 patients (83%) without a disruption of resuscitation. Tracings could not be obtained in five patients; they were listed as TCD failures. However, in two of these patients, adequate flow velocity tracings were obtained after resuscitation. Four patients were evaluated during tracheal intubation. One patient was monitored successfully during cardiopulmonary resuscitation. The median time required for data acquisition was 1.9 minutes. The mean highest RI for those who expired was 0.84. For those who survived, the mean highest RI was 0.52. The difference of 0.32 was statistically significant (p = 0.04). Conclusions: Noninvasive blood flow velocity monitoring of the middle cerebral artery using TCD is feasible in the ED when performed at the bedside on intubated patients with traumatic brain injury and others during tracheal intubation and resuscitation.	Med Coll Georgia, Dept Emergency Med, Augusta, GA 30912 USA; Univ Louisville, Dept Emergency Med, Louisville, KY USA	Blaivas, M (corresponding author), Med Coll Georgia, Dept Emergency Med, 1120 15th St,AF-2056, Augusta, GA 30912 USA.	blaivas@pyro.net					AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Blaivas M, 2000, ACAD EMERG MED, V7, P120, DOI 10.1111/j.1553-2712.2000.tb00512.x; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1197/aemj.9.8.791; CHADDUCK WM, 1989, SURG NEUROL, V31, P122, DOI 10.1016/0090-3019(89)90324-8; Heller MB, 2002, ACAD EMERG MED, V9, P835, DOI 10.1111/j.1553-2712.2002.tb02174.x; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; LEWIS LM, 1994, J CRIT CARE, V9, P169, DOI 10.1016/0883-9441(94)90013-2; LUNDAR T, 1990, ACTA NEUROCHIR, V102, P85, DOI 10.1007/BF01405419; NAKATANI S, 1989, INTRACRANIAL PRESSUR, V7	10	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUL	2004	11	7					774	777		10.1197/j.aem.2004.02.518			4	Emergency Medicine	Emergency Medicine	835EM	WOS:000222463300013	15231470	Bronze			2021-06-18	
J	Caner, H; Can, A; Atalay, B; Erdogan, B; Albayrak, AH; Kilinc, K; Bavbek, M; Altinors, N				Caner, H; Can, A; Atalay, B; Erdogan, B; Albayrak, AH; Kilinc, K; Bavbek, M; Altinors, N			Early effects of mild brain trauma on the cytoskeletal proteins neurofilament(160) and MAP(2), and the preventive effects of mexilitine	ACTA NEUROCHIRURGICA			English	Article						mild head injury; neurofilament protein (NF160); microtubule-associated protein-2 (MAP2); lipid peroxidation mexilitine	MICROTUBULE-ASSOCIATED PROTEINS; LIPID-PEROXIDATION; SPECTRIN PROTEOLYSIS; AXONAL INJURY; CALPAIN; MEXILETINE; EXPRESSION; ALPHA; PHASE; RISK	Objective. The aims were to investigate the early effects of graded, closed, mild head injury on neurofilament protein (NF160) and microtubule-associated protein-2 (MAP(2)) and to examine the levels of lipid peroxidation and the impact of mexilitine, inhibitor of lipid peroxidation, pretreatment on tissue damage. Material and method. One hundred and twenty-six rats were divided into groups as follows: Group 1 (n=14) were controls; group 2 (n=56) sustained trauma alone; and group 3 (n=56) were pretreated with mexilitine (50 mg/kg). Groups 2 and 3 were subdivided into subgroups (n=14 each), which were subjected to 100 g/cm(2), 125 g/cm(2), 150 g/cm(2), and 175 g/cm(2) trauma forces, respectively. Two hours after trauma, the frontal lobes from all groups were removed and processed for lipid peroxidation H&E staining, immunofluorescent labelling of neurofilaments and microtubules with anti-NF160 and anti-MAP(2) antibodies. Results. Compared to control findings, all the trauma-only animals showed increased lipid peroxidation levels and the elevations paralleled the amount of force applied. Administration of mexilitine significantly reduced the level of lipid peroxidation. In NF160 stainings, in group 2, the degree of impairment in axonal organization paralleled the different levels of force that were applied. Groups 3C and 3D (mexilitine pretreated) showed well-preserved axons and intact perikarya. In MAP(2) stainings group 2 animals showed remarkably less MAP(2) staining throughout the sections. There were no significant differences in MAP(2) staining intensity or pattern among the group 2 subgroups. In contrast, in the sections from the group 3 animals, the level of MAP(2) positivity was markedly preserved. Conclusion. In conclusion, our results show that the cytoskeletal proteins we investigated have different capacities for resisting injury, and that MAP(2) is more vulnerable to injury than NF160. One of the reason for this cytoskeletal disruption may be increased lipid peroxidation. Inhibition of lipid peroxidation by pre-treatment with 50-mg/kg mexilitine significantly reduces the level of lipid peroxidation and may protect MAP(2) and NF160 integrity in closed mild head injury. This protection is inversely proportional to the magnitude of the applied force.	Baskent Univ, Fac Med, Dept Neurosurg, TR-06490 Ankara, Turkey; Ankara Univ, Sch Med, Dept Histol Embryol, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, Ankara, Turkey	Caner, H (corresponding author), Baskent Univ, Fac Med, Dept Neurosurg, TR-06490 Ankara, Turkey.	hakanc@baskent-ank.edu.tr	Can, Alp/AAO-5734-2020				Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Baldwin SA, 1996, GLIA, V16, P266; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Can A, 1997, MUTAT RES-FUND MOL M, V373, P139, DOI 10.1016/S0027-5107(96)00184-4; Can A, 2000, MOL HUM REPROD, V6, P154, DOI 10.1093/molehr/6.2.154; Caner H, 2000, ACTA NEUROCHIR, V142, P455, DOI 10.1007/s007010050457; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Demirpence E, 1999, JPN J PHARMACOL, V81, P7, DOI 10.1254/jjp.81.7; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; MATHEWS CK, 2000, BIOCHEMISTRY-US, P724; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Paroczai M, 1997, PHARMACOL RES, V35, P279, DOI 10.1006/phrs.1997.0128; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SLATER TF, 1984, BIOCHEM J, V222, P1; Tymianski M, 1996, NEUROSURGERY, V38, P1176; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082	41	12	12	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUN	2004	146	6					611	621		10.1007/s00701-003-0209-9			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	824GN	WOS:000221674600021	15168230				2021-06-18	
J	Mokhosi, MT; Grieve, KW				Mokhosi, MT; Grieve, KW			African, families' perceptions of traumatic brain injury	SOUTH AFRICAN JOURNAL OF PSYCHOLOGY			English	Article							QUALITATIVE RESEARCH; HEAD-INJURY	Using semi-structured interviews, this study explored the perceptions of traumatic brain injury (TBI) held by a group of 22 brain-injured individuals and their caregivers living in rural African communities. While there are similarities between these findings and those in other parts of the world regarding the cognitive, emotional, personality and behavioural changes experienced by brain-injured individuals, the perceived aetiology of brain injury differed according to the individuals' worldview. Most of the participants believed that the accidents considered in this study as well as the injuries they gave rise to were the result of witchcraft, ancestral anger, God's will or thwasa. The reactions of family members to caring for, and living with, a brain-injured person appeared to be influenced by specific social practices and local cultural beliefs. It is important to incorporate these beliefs into the rehabilitation process. Suggestions for rehabilitation are discussed.	Univ North, Psychol Unit, Sch Social Sci, ZA-9866 Phuthaditjhaba, South Africa; Univ S Africa, Dept Psychol, ZA-0001 Pretoria, South Africa	Mokhosi, MT (corresponding author), Univ North, Psychol Unit, Sch Social Sci, QwaQwa Campus,Private Bag X13, ZA-9866 Phuthaditjhaba, South Africa.						Airhihenbuwa C O, 1989, AIDS Educ Prev, V1, P57; Brown R., 1999, HOMOL HOMOTOPY APPL, V1, P1, DOI DOI 10.4310/HHA.1999.V1.N1.A1; HAMMONDTOOKE WD, 1975, PSYCHOL AFR, V16, P25; HAMMONDTOOKE WD, 1989, RITUALS MED; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; HENWOOD K, 1996, HDB QUALITATIVE RES, P86; Hickson J., 1992, J MULTICULT COUNS D, V20, P11; HUBERT J, 1995, LIFE HEAD INJURY; Judd J, 2001, HEALTH PROMOT INT, V16, P367, DOI 10.1093/heapro/16.4.367; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Kosciulek JF, 1997, REHABIL COUNS BULL, V41, P43; KVALE S, 1994, J PHENOMENOL PSYCHOL, V25, P147, DOI 10.1163/156916294X00016; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; Massarik F., 1981, HUMAN INQUIRY SOURCE, P201; Mbiti J. S., 1969, AFRICAN RELIGION PHI; MOKHOSI MT, 2000, THESIS U S AFRICA PR; MOON SM, 1990, J MARITAL FAM THER, V16, P357, DOI 10.1111/j.1752-0606.1990.tb00056.x; Nell V, 1999, S AFR J PSYCHOL, V29, P128, DOI 10.1177/008124639902900305; NELL V, 1990, 901 UN HLTH PSYCH UN; ORTO AE, 1994, COMMUNITY INTEGRATIO, P225; Pidgeon N., 1996, HDB QUALITATIVE RES, P86; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Selby M. J., 2000, NEUROPSYCHOLOGICAL A, P48; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tyerman A., 1996, BRAIN INJURY IMPROVE, P97; UZZELL B, 1997, NEUROPSYCHOL REHABIL, P41; Vanderploeg RD, 2000, CLIN GUIDE NEUROPSYC; Williams J.M., 1991, HEAD INJURY FAMILY M, P81; Workman Jr J., 1995, STUDYING ELITES USIN, P65; World Health Organisation Collaborating Centers for Neurotrauma, 1995, PREV CRIT CAR REH NE	33	12	12	0	3	PSYCHOLOGICAL SOC SOUTH AFRICA	BROADWAY	PO BOX 66083, BROADWAY 2020, SOUTH AFRICA	0081-2463			S AFR J PSYCHOL	South Afr. J. Psychol.	JUN	2004	34	2					301	317		10.1177/008124630403400208			17	Psychology, Multidisciplinary	Psychology	997ST	WOS:000234268800008					2021-06-18	
J	Boivin, DB; Caliyurt, O; James, FO; Chalk, C				Boivin, DB; Caliyurt, O; James, FO; Chalk, C			Association between delayed sleep phase and hypernyctohemeral syndromes: A case study	SLEEP			English	Article						delayed sleep phase syndrome; non-24-hour sleep-wake disorder; brain injury	TRAUMATIC BRAIN INJURY; WAKE SYNDROME; CIRCADIAN-RHYTHMS; BLIND MAN; MELATONIN TREATMENT; TEMPERATURE; DISORDER; CYCLE; LIGHT; ENTRAINMENT	Study Objective: We investigated whether the hypernyetohemeral syndrome (non-24-hour sleep-wake syndrome) may show a clinical association with the delayed sleep phase syndrome (DSPS) in a 39-year-old woman who developed sleep disturbances following a traumatic brain injury. Measurements and Results: Sleep-wake log documentation and wrist-activity recordings for more than 6 consecutive months confirmed the patient's tendency to live on longer-than-24-hour "days." Episodes of relative coordination to the 24-hour day were also noted, suggesting that the patient was transiently in and out of phase with environmental synchronizers too weak to fully entrain her to the geophysical environment. Interestingly, we noted a tendency to initiate sleep between 3:00 am and 5:00 am and wake up from sleep between noon and 1:00 pm. Conclusions: These results support an association between the hypernyctohemeral syndrome and the DSPS. This association may carry implications for the treatment of circadian rhythms disorders.	Douglas Hosp, Res Ctr, Ctr Study & Treatment Circadian Rhythms, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Psychiat, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada	Boivin, DB (corresponding author), Douglas Hosp, Res Ctr, Ctr Study & Treatment Circadian Rhythms, 6875 LaSalle Blvd,Suite F-1127, Verdun, PQ H4H 1R3, Canada.	boidia@douglas.mcgill.ca	Caliyurt, Okan/ABE-7339-2020	Caliyurt, Okan/0000-0002-0513-0619			Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Boivin DB, 1996, NATURE, V379, P540, DOI 10.1038/379540a0; COHEN RA, 1991, NEUROLOGY, V41, P726, DOI 10.1212/WNL.41.5.726; CZEISLER CA, 1981, PHOTOCHEM PHOTOBIOL, V34, P239; EASTMAN CI, 1988, SLEEP RES, V17, P372; ELIOTT AL, 1971, J PHYSIOL-LONDON, V212, pP30; FERBER R, 1983, SLEEP RES, V12, P364; FOLKARD S, 1990, NEUROSCI LETT, V113, P193, DOI 10.1016/0304-3940(90)90302-P; GIEDKE H, 1983, SLEEP RES, V12, P365; Hebert M, 1998, CHRONOBIOL INT, V15, P59; KAMGARPARSI B, 1983, SLEEP, V6, P257, DOI 10.1093/sleep/6.3.257; KLEIN T, 1993, SLEEP, V16, P333, DOI 10.1093/sleep/16.4.333; Klerman EB, 1996, AM J PHYSIOL-REG I, V270, pR271; KOKKORIS CP, 1978, SLEEP, V1, P177, DOI 10.1093/sleep/1.2.177; LAPIERRE O, 1995, BIOL PSYCHIAT, V38, P119, DOI 10.1016/0006-3223(95)00072-O; McArthur AJ, 1996, SLEEP, V19, P544, DOI 10.1093/sleep/19.7.544; MILES LEM, 1977, SCIENCE, V198, P421, DOI 10.1126/science.910139; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; NAKAGAWA H, 1992, SLEEP, V15, P330, DOI 10.1093/sleep/15.4.330; OKAWA M, 1987, SLEEP, V10, P101, DOI 10.1093/sleep/10.2.101; OKAWA M, 1986, J NEUROL, V233, P274, DOI 10.1007/BF00314159; OKAWA M, 1981, J NEUROL, V266, P63; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; OREN DA, 1992, NEW ENGL J MED, V327, P1762; PALM L, 1991, ANN NEUROL, V29, P336, DOI 10.1002/ana.410290318; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P223, DOI 10.1007/BF01417856; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Smits MG, 2000, NEUROLOGY, V55, P902, DOI 10.1212/WNL.55.6.902; STROGATZ SH, 1986, LECT NOTES BIOMATH, V69, P1; Uchiyama M, 2000, NEUROSCI LETT, V294, P101, DOI 10.1016/S0304-3940(00)01551-2; Uchiyama M, 2002, SLEEP, V25, P83, DOI 10.1093/sleep/25.1.83; Watanabe T, 2003, SLEEP, V26, P657; WEITZMAN ED, 1981, ARCH GEN PSYCHIAT, V38, P737; WOLLMAN M, 1986, SLEEP, V9, P324, DOI 10.1093/sleep/9.2.324; WRIGHT KPJ, P NATL ACAD SCI US, V98, P14027	36	12	12	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1550-9109			SLEEP	Sleep	MAY 1	2004	27	3					417	421		10.1093/sleep/27.3.417			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	844OU	WOS:000223169000010	15164893	Bronze			2021-06-18	
J	Burke, R; Beukelman, DR; Hux, K				Burke, R; Beukelman, DR; Hux, K			Accuracy, efficiency and preferences of survivors of traumatic brain injury when using three organization strategies to retrieve words	BRAIN INJURY			English	Article								The primary objective was to compare the accuracy and preferences of adult survivors of traumatic brain injury (TBI) when using three organization strategies--semantic topic, geographic place and a word's first letter (alphabet)--to retrieve words using augmentative and alternative communication (AAC) technology. A repeated measures research design was employed. Twelve adult survivors of TBI ranging in age from 18-50 years participated in the study. These participants retrieved words using an AAC system organized using the three experimental conditions. In addition, they rank-ordered their preferences for each of the three strategies. Results showed that adults with TBI retrieve words more accurately and more efficiently when using the alphabet organization strategy than when using the topic or place strategies. Despite this, participants expressed a preference for using the topic strategy. Explanations for the findings and implications for AAC use are provided.	Univ Nebraska, Barkley Mem Ctr 318E, Lincoln, NE 68583 USA; Univ Nebraska, Med Ctr, Lincoln, NE 68583 USA; Inst Rehabil Sci & Engn, Lincoln, NE USA	Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr 318E, Lincoln, NE 68583 USA.	khux1@unl.edu	Hux, Karen/AAQ-2078-2020				Beukelman D. R., 1991, AUGMENTATIVE ALTERNA, V7, P171, DOI [10.1080/07434619112331275883, DOI 10.1080/07434619112331275883]; Beukelman D.R., 1998, AUGMENTATIVE ALTERNA; Blockberger S., 1995, J SPEECH LANGUAGE PA, V19, P221; BURKE R, UNPUB OLDER ADULTS A; CHERNEY LR, 1991, CLIN MANAGEMENT COMM, P9; DeRuyter F., 1987, AUGMENTATIVE ALTERNA, V3, P18, DOI DOI 10.1080/07434618712331274209; DERUYTER F, 1989, AUGMENTATIVE ALTERNA, V5, P49, DOI DOI 10.1080/07434618912331274966; DeRuyter F, 1991, COMMUNICATION DISORD, P317; Dongilli P, 1992, J HEAD TRAUMA REHAB, V7, P91; GARRY F, 1989, VET CLIN N AM-FOOD A, V5, P55, DOI 10.1016/S0749-0720(15)31003-3; HAGEN C, 1979, ANN M AM SPEECH LANG; Hagen C, 2000, TBI REH MAN CAR ENV; HUX K, 1993, J MED SPEECH-LANG PA, V1, P121; Kertesz A., 1982, W APHASIA BATTERY; Ladtkow M, 1992, AUGMENTATIVE COMMUNI, P139; Ladtkow Margaret, 1993, Seminars in Speech and Language, V14, P61, DOI 10.1055/s-2008-1064159; MALKMUS D, 1974, RANCHO LOS AMIGOS LE; WOODCOCK RW, 1990, WOODCOCKJOHNSON TEST	18	12	12	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					497	507		10.1080/02699050310001645784			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600007	15195796				2021-06-18	
J	Cahill, LM; Turner, AB; Stabler, PA; Addis, PE; Theodoros, DG; Murdoch, BE				Cahill, LM; Turner, AB; Stabler, PA; Addis, PE; Theodoros, DG; Murdoch, BE			An evaluation of continuous positive airway pressure (CPAP) therapy in the treatment of hypernasality following traumatic brain injury - A report of 3 cases	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						continuous positive airway pressure (CPAP); dysarthria; hypernasality; traumatic brain injury (TBI); velopharyngeal dysfunction (VPD)	CLOSED-HEAD-INJURY; NASALITY	Objective: To evaluate the effectiveness of continuous positive airway pressure (CPAP) therapy in the treatment of hypernasality following traumatic brain injury (17111). Design: An A-B-A experimental research design. Assessments were conducted prior to commencement of the program, midway, immediately posttreatment, and 1 month after completion of the CPAP therapy program. Participants: Three adults with dysarthria and moderate to severe hypernasality subsequent to TBI. Outcome Measures: Perceptual evaluation using the Frenchay Dysarthria Assessment, the Assessment of Intelligibility of Dysarthric Speech, and a speech sample analysis, and instrumental evaluation using the Nasometer. Results: Between assessment periods, varying degrees of improvement in hypernasality and sentence intelligibility were noted. At the 1-month post-CPAP assessment, all 3 participants demonstrated reduced nasalance values, and 2 exhibited increased sentence intelligibility. Conclusions: CPAP may be a valuable treatment of impaired velopharyngeal function in the TBI population.	Univ Queensland, Div Speech Pathol, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia	Cahill, LM (corresponding author), Univ Queensland, Div Speech Pathol, Brisbane, Qld 4072, Australia.	L.Cahill@uq.edu.au	Cahill, Louise/C-7919-2012; Theodoros, Deborah/F-1362-2010; Murdoch, Bruce E/C-1397-2012	Cahill, Louise/0000-0003-3662-896X			Cahill LM, 2002, BRAIN INJURY, V16, P415, DOI 10.1080/02699050110119871; CAHILL LM, 2001, ASIA PAC J SPEECH LA, V6, P33; Darley F., 1975, MOTOR SPEECH DISORDE; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; FLETCHER SG, 1972, J SPEECH HEAR DISORD, V37, P329, DOI 10.1044/jshd.3703.329; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KEARNS KP, 1988, HDB SPEECH LANGUAGE, P592; KUEHN DP, 1991, PLAST RECONSTR SURG, V88, P959, DOI 10.1097/00006534-199112000-00003; Kuehn DP, 1994, MOTOR SPEECH DISORDE, P207; Massengill R Jr, 1968, Cleft Palate J, V5, P44; McHenry MA, 1998, ARCH PHYS MED REHAB, V79, P545, DOI 10.1016/S0003-9993(98)90071-5; McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; MCWILLIAMS BJ, 1965, CLEFT PALATE J, V2, P46; MOLLER KT, 1991, PLAST RECONSTR SURG, V88, P967; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; POWERS GL, 1974, CLEFT PALATE J, V11, P28; Ramig L., 1994, J MED SPEECH LANG PA, V2, P191; Sharma RK, 2002, INDIAN J ANIM SCI, V72, P31; TEASDALE G, 1974, LANCET, V2, P81; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; Theodoros DG, 2001, TRAUMATIC BRAIN INJU, P75; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; Yorkston KM., 1999, MANAGEMENT MOTOR SPE	24	12	13	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					241	253		10.1097/00001199-200405000-00005			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300005	15247846				2021-06-18	
J	Kennedy, MRT				Kennedy, MRT			Self-monitoring traumatic brain recall during two tasks after injury: A preliminary study	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article; Proceedings Paper	32nd Annual Clinical Aphasiology Conference	JUN, 2002	RIDGEDALE, MO			self-monitoring; memory; metamemory; brain injury; learning	LEARNING JOLS; PREDICTING PERFORMANCE; METAMEMORY; MEMORY; AWARENESS; ACCURACY; JUDGMENTS; CALIBRATION; ABSOLUTE; TEXT	Impaired recall is a common consequence of traumatic brain injury (TBI). Predicting recall during learning is a critical part of self-monitoring. Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and implied). For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate. Both groups were more confident making predictions of stated information than implied information. Neither predictive accuracy nor confidence generalized across tasks. Working memory load across tasks and individual differences are proposed explanations. The lack of generalization highlights the need to train domain or task-specific self-monitoring.	Univ Minnesota, Dept Commun Disorders, Minneapolis, MN 55455 USA	Kennedy, MRT (corresponding author), Univ Minnesota, Dept Commun Disorders, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenne047@umn.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; AMMONS RB, 1979, PSYCHOL REP, V45, P943, DOI 10.2466/pr0.1979.45.3.943; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Brookshire RH, 1993, DISCOURSE COMPREHENS; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Connor LT, 1997, PSYCHOL AGING, V12, P50, DOI 10.1037/0882-7974.12.1.50; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Damasio AR, 1989, NEURAL COMPUT, V1, P123, DOI 10.1162/neco.1989.1.1.123; Detterman D.K., 1993, TRANSFER TRIAL INTEL, P1; DUNLOSKY J, 1994, J MEM LANG, V33, P545, DOI 10.1006/jmla.1994.1026; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; HERTZOG C, 1990, PSYCHOL AGING, V5, P215, DOI 10.1037/0882-7974.5.2.215; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; Johnson-Laird P. N., 1991, DEDUCTION; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelemen WL, 2000, MEM COGNITION, V28, P92, DOI 10.3758/BF03211579; Kennedy MRT, 2003, J SPEECH LANG HEAR R, V46, P98, DOI 10.1044/1092-4388(2003/008); Kennedy MRT, 2003, BRAIN INJURY, V17, P1043, DOI 10.1080/0269905031000110436; Kennedy MRT, 2001, BRAIN INJURY, V15, P469, DOI 10.1080/02699050120517; Kennedy MRT, 2000, J SPEECH LANG HEAR R, V43, P1072, DOI 10.1044/jslhr.4305.1072; KENNEDY MRT, IN PRESS NEUROPSYCHO, V13; Kertesz A., 1982, W APHASIA BATTERY; LEONESIO RJ, 1990, J EXP PSYCHOL LEARN, V16, P464, DOI 10.1037/0278-7393.16.3.464; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MAKI RH, 1990, J EXP PSYCHOL LEARN, V16, P609, DOI 10.1037/0278-7393.16.4.609; MAKI RH, 1987, MEM COGNITION, V15, P72, DOI 10.3758/BF03197713; Maki RH, 1998, MEM COGNITION, V26, P959, DOI 10.3758/BF03201176; Maki RH, 1999, J EXP PSYCHOL LEARN, V25, P1011, DOI 10.1037/0278-7393.25.4.1011; Maki RH, 1998, EDUC PSYCHO, P117; Matvey G, 2001, MEM COGNITION, V29, P222, DOI 10.3758/BF03194916; McGuire MJ, 2001, J EXP PSYCHOL LEARN, V27, P1172, DOI 10.1037//0278-7393.27.5.1172; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Nelson T. O., 1990, PSYCHOL LEARN MOTIV, V26, P125, DOI DOI 10.1016/S0079-7421(08)60053-5; Nelson TO, 1996, APPL COGNITIVE PSYCH, V10, P257, DOI 10.1002/(SICI)1099-0720(199606)10:3<257::AID-ACP400>3.0.CO;2-9; NELSON TO, 1991, PSYCHOL SCI, V2, P267, DOI 10.1111/j.1467-9280.1991.tb00147.x; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; Newman AC, 2000, BRAIN INJURY, V14, P333; Nicholas L.E., 1995, AM J SPEECH LANGUAGE, V4, P69, DOI [10.1044/1058-0360.0403.69, DOI 10.1044/1058-0360.0403.69]; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; REITAN RM, 1985, HALSTAD REITAN NEURO; Schlund MW, 1999, BRAIN INJURY, V13, P375, DOI 10.1080/026990599121566; SCHRAW G, 1995, J EDUC PSYCHOL, V87, P433, DOI 10.1037/0022-0663.87.3.433; SHIMAMURA AP, 1986, J EXP PSYCHOL LEARN, V12, P452, DOI 10.1037/0278-7393.12.3.452; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; STUSS DT, 1991, SELF : INTERDISCIPLINARY APPROACHES, P255; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Thiede KW, 2003, J EDUC PSYCHOL, V95, P66, DOI 10.1037/0022-0663.95.1.66; Thiede KW, 1999, J EXP PSYCHOL LEARN, V25, P1024, DOI 10.1037/0278-7393.25.4.1024; Thiede KW, 1999, PSYCHON B REV, V6, P662, DOI 10.3758/BF03212976; Thorndike EL, 1906, PRINCIPLES TEACHING; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; WEAVER CA, 1990, J EXP PSYCHOL LEARN, V16, P214, DOI 10.1037/0278-7393.16.2.214; WEAVER CA, 1995, MEM COGNITION, V23, P12, DOI 10.3758/BF03210553; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Yates J. F., 1990, JUDGMENT DECISION MA	67	12	12	0	3	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2004	13	2					142	154		10.1044/1058-0360(2004/015)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	970CR	WOS:000232283300005	15198633				2021-06-18	
J	Arce, FI; Katz, N; Sugarman, H				Arce, FI; Katz, N; Sugarman, H			The scaling of postural adjustments during bimanual load-lifting in traumatic brain-injured adults	HUMAN MOVEMENT SCIENCE			English	Article						traumatic brain injury; postural control; coordination; center of pressure	CENTRAL SET; RESPONSES; MOVEMENTS; BALANCE; SWAY; TASK; HUMANS	Previous postural studies of traumatic brain injury (TBI) patients have been limited to identifying deficits in static and quasi-dynamic postural control tasks such as weight shifting. In this study, we examined whether or not patients with TBI are able to scale adequately their postural adjustments during the performance of the dynamic task of bimanual load-lifting. An age matched group of healthy adults served as controls. We used the Tetrax posturography system that calculates a stability score (ST) based on fluctuations in vertical ground reaction forces, normalized for body weight. During quiet standing, the ST scores of the TBI group were significantly higher than the control group. Forward weight shift and percentage change in the vertical ground reaction forces (lift postural adjustment (LPA) and post-lift postural adjustment (PLPA) scores) linearly increased with increasing load weight in both healthy and TBI subjects. Group differences were found in the magnitude of forward weight shift but not in the relative increase of the LPA and PLPA scores during the lifting and post-lifting phases respectively. The forward weight shift of the TBI group was lower-than-normal and asymmetrical - there was significantly less forward weight shift on the more affected than on the less affected limb. In addition, a significant amplitude coupling was found between the scaling of the weight shift of the heel and forefoot of each limb. However, no coupling was found between the weight shift amplitudes of homologous parts of both limbs in the TBI group. The results showed that scaling based on prior experience was preserved in the TBI group, though some TBI subjects demonstrated absent scaling in either the more affected or less affected heel or forefoot. The differences between the normal and TBI groups in postural adjustments are not necessarily a sign of pathology; rather they may represent a deliberate choice of the central nervous system to counteract predictable disturbances. (C) 2004 Elsevier B.V. All rights reserved.	Hebrew Univ Jerusalem, Sch Occupat Therapy, IL-91120 Jerusalem, Israel; Int Ctr Enhancement Learning Potential, Jerusalem, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Aly Larson Motor Control Lab, IL-84105 Beer Sheva, Israel	Arce, FI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lab Higher Brain Funct Physiol, POB 12272, IL-91120 Jerusalem, Israel.	arcef@mscc.huji.ac.il		Arce-McShane, Fritzie/0000-0001-6616-3564			BOUISSET S, 1987, J BIOMECH, V20, P735, DOI 10.1016/0021-9290(87)90052-2; Caldwell C., 1986, PHYSIOTHER THEOR PR, V2, P109; Commissaris DACM, 1997, HUM MOVEMENT SCI, V16, P407, DOI 10.1016/S0167-9457(97)00007-9; DIENER HC, 1991, EXP BRAIN RES, V84, P219; ENG JJ, 1992, NEUROSCI RES COMMUN, V11, P73; Forssberg H, 1999, NEUROSCI LETT, V273, P9, DOI 10.1016/S0304-3940(99)00619-9; Gentile A. M., 1987, MOVEMENT SCI FDN PHY; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369; Horak FB, 1996, J NEUROPHYSIOL, V75, P2380; HORAK FB, 1994, J NEUROPHYSIOL, V72, P479; HORAK FB, 1989, J NEUROPHYSIOL, V62, P841; KARLSSON A, 2000, CLIN BIOMECH, V15, P193; KOHENRAZ R, 1991, PERCEPT MOTOR SKILL, V73, P635, DOI 10.2466/PMS.73.5.635-656; Kusoffsky A, 2001, ARCH PHYS MED REHAB, V82, P650, DOI 10.1053/apmr.2001.22611; LATASH ML, 1995, ELECTROMYOGR MOTOR C, V97, P77, DOI 10.1016/0924-980X(94)00272-9; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; MIZRAHI J, 1989, CLIN PHYS PHYSIOL M, V10, P25, DOI 10.1088/0143-0815/10/1/003; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; SCHMIDT RA, 1975, PSYCHOL REV, V82, P225, DOI 10.1037/h0076770; Timmann D, 1998, EXP BRAIN RES, V119, P73, DOI 10.1007/s002210050321; Timmann D, 1997, BRAIN, V120, P327, DOI 10.1093/brain/120.2.327; Toussaint HM, 1998, EXP BRAIN RES, V120, P85, DOI 10.1007/s002210050380; TURNER DM, 1998, THESIS U SOUTHAMPTON; Vernazza-Martin S, 1999, BRAIN RES, V846, P12, DOI 10.1016/S0006-8993(99)01846-6; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	28	12	14	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-9457			HUM MOVEMENT SCI	Hum. Mov. Sci.	APR	2004	22	6					749	768		10.1016/j.humov.2003.12.002			20	Neurosciences; Psychology; Psychology, Experimental; Sport Sciences	Neurosciences & Neurology; Psychology; Sport Sciences	814BD	WOS:000220949300010	15063052				2021-06-18	
J	Leahy, B; Suchy, Y; Sweet, JJ; Lam, CS				Leahy, B; Suchy, Y; Sweet, JJ; Lam, CS			Behavioral dyscontrol scale deficits among traumatic brain injury patients, part I: Validation with nongeriatric patients	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; MEMORY COMPLAINTS; 15-ITEM TEST; REHABILITATION; VALIDITY; PERFORMANCE; TASK; INDIVIDUALS; PREDICTION; INPATIENTS	The Behavioral Dyscontrol Scale is a measure of executive abilities initially designed to predict functional independence in geriatric populations. The current study examined the utility of two Behavioral Dyscontrol Scale (BDS) scoring systems in a nongeriatric sample. The BDS was administered to 49 TBI patients undergoing inpatient and outpatient rehabilitation. The results demonstrate slightly greater utility of the BDS-II scoring system, and support clinical utility of the instrument with nongeriatric patients. Specifically, the Motor Programming Factor and Environmental Independence Factor were more impaired among patients with severe, as compared to mild to moderate, TBIs. In contrast, the Fluid Intelligence Factor was more impaired among patients with frontal, as compared to nonfrontal, injuries. However, when patients were categorized by severity, lesion location differences on the BDS total score and factors were found only for patients with mild to moderate injuries. Similarly, when patients were categorized by lesion location, severity effects were only present among the nonfrontal group. Receiver Operating Characteristic curves demonstrated sensitivity and specificity rates that ranged from 60% to 100% for clinically meaningful cutting scores.	Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA; IIT, Chicago, IL 60616 USA; Evanston NW Healthcare, Evanston, IL USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Suchy, Y (corresponding author), Univ Utah, Dept Psychol, 380 S 1530 E,Rm 502, Salt Lake City, UT 84112 USA.	yana.suchy@psych.utah.edu		Suchy, Yana/0000-0001-6513-565X			ACKER MB, 1989, NEUROPSYCHOLOGY, V3, P1; ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bokura H, 2001, CLIN NEUROPHYSIOL, V112, P2224, DOI 10.1016/S1388-2457(01)00691-5; Bond M. R., 1990, REHABILITATION ADULT, P179; BOND MR, 1986, NEUROPSYCHOLOGICAL A; *CDCP, 1999, EP TRAUM BRAIN INJ U; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EISENBERG HM, 1985, CENTRAL NERVOUS SYST, P271; Eslinger Paul J., 1996, P415; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Griffin GAE, 1996, PSYCHOL ASSESSMENT, V8, P383; GRIGSBY J, 1992, PERCEPT MOTOR SKILL, V74, P883, DOI 10.2466/PMS.74.3.883-892; Grigsby J., 1996, BEHAV DYSCONTROL SCA; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KAYE K, 1990, J AM GERIATR SOC, V38, P1304, DOI 10.1111/j.1532-5415.1990.tb03452.x; Kibby MY, 1998, ARCH CLIN NEUROPSYCH, V13, P523, DOI 10.1016/S0887-6177(97)00038-3; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; MATEER CA, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P277; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Schoenbaum G, 2000, J NEUROSCI, V20, P5179; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1996, PSYCHOL AGING, V11, P387, DOI 10.1037/0882-7974.11.3.387; Suchy Y, 1997, CLIN NEUROPSYCHOL, V11, P258, DOI 10.1080/13854049708400454; Suchy Y, 1999, CLIN NEUROPSYCHOL, V13, P487, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT487; Tombaugh TN, 1996, TEST MEMORY MALINGER; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	44	12	12	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV	2003	17	4					474	491		10.1076/clin.17.4.474.27941			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	776XV	WOS:000189145400005	15168913				2021-06-18	
J	Lucas, SK; Carstairs, JR; Shores, EA				Lucas, SK; Carstairs, JR; Shores, EA			A comparison of methods to estimate premorbid intelligence in an Australian sample: Data from the Macquarie University Neuropsychological Normative Study (MUNNS)	AUSTRALIAN PSYCHOLOGIST			English	Article							CONTEXTUAL-READING-TEST; CLOSED-HEAD INJURY; SPOT-THE-WORD; WAIS-R IQ; VERBAL INTELLIGENCE; DEMOGRAPHIC-VARIABLES; OLDER PERSONS; PERFORMANCE; VALIDATION; EQUATIONS	A variety of methods for estimating premorbid intelligence were compared in an Australian sample participating in the Macquarie University Neuropsychological Normative Study (MUNNS). Predictors included a contextual version of the AUSNART, the WRAT-3 Reading subtest, Spot-the-Word Test and sub-tests from the WAIS-R. The study involved 244 healthy participants aged between 18 and 34 years, with half of them serving as a cross-validation sample. Multiple regression was used for all analyses. When taking into account both the statistical results and clinical utility of the methods, the Sydney Premorbid Intelligence Estimate (SPIE), consisting of Vocabulary and Picture Completion subtests from the WAIS-R, was considered to be the best predictor. Combining all measures into one regression did not substantially increase the amount of variance explained. Base rate tables for predicted IQ versus obtained IQ, and the discrepancy between predicted IQ and Delayed Recall Index of the WMS-R are provided for each of the prediction methods. Further research to examine the clinical utility of these methods is required.	Macquarie Univ, N Ryde, NSW 2113, Australia	Lucas, SK (corresponding author), Westmead Hosp, Dept Psychol Med, Westmead, NSW 2145, Australia.	sara_lucas@wsahs.nsw.gov.au		Shores, Edwin A/0000-0003-1553-5131			ALEKOUMBIDES A, 1987, INT J CLIN NEUROPSYC, V9, P11; Axelrod BN, 1999, J CLIN EXP NEUROPSYC, V21, P368, DOI 10.1076/jcen.21.3.368.916; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bassett R, 2000, POWER ENG J, V14, P3; Beardsall L, 1998, BRIT J CLIN PSYCHOL, V37, P229, DOI 10.1111/j.2044-8260.1998.tb01297.x; BEARDSALL L, 1994, J CLIN EXP NEUROPSYC, V16, P232, DOI 10.1080/01688639408402634; BEARDSALL L, 1990, BRIT J CLIN PSYCHOL, V29, P217; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOONE DE, 1992, J CLIN PSYCHOL, V48, P72, DOI 10.1002/1097-4679(199201)48:1<72::AID-JCLP2270480111>3.0.CO;2-0; BORNSTEIN RA, 1989, PSYCHOL ASSESSMENT J, V1, P203; CARSTAIRS JR, 2000, AUSTR PSYCHOL, V35, P1; Cohen J., 1983, APPL MULTIPLE REGRES; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC, P21; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; CRAWFORD JR, 1989, PERS INDIV DIFFER, V10, P585, DOI 10.1016/0191-8869(89)90043-3; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1990, THESIS U ABERDEEN; DELBRIDGE A, 1998, MACQUARIE CONCISE DI; DELEMOS M, 1981, WAIS R AUSTR S; Gladsjo JA, 1999, J INT NEUROPSYCH SOC, V5, P247, DOI 10.1017/S1355617799533079; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; Grove WM, 2001, PSYCHOL ASSESSMENT, V13, P396, DOI 10.1037/1040-3590.13.3.396; Hennessy M, 1995, TREATMENT ISSUES LON, P183; Jastak S, 1984, WIDE RANGE ACHIEVEME; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; Nelson H., 1991, REVISED NATL ADULT R; Nelson HE, 1982, NATL ADULT READING T; REYNOLDS CR, 1986, J COUNS DEV, V64, P540, DOI 10.1002/j.1556-6676.1986.tb01196.x; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; Shores EA, 2000, AUST PSYCHOL, V35, P41, DOI 10.1080/00050060008257467; Stevens K B, 1999, Appl Neuropsychol, V6, P68, DOI 10.1207/s15324826an0602_2; TELLEGEN A, 1967, J CONSULT PSYCHOL, V31, P499, DOI 10.1037/h0024963; Tremont G, 1997, ARCH CLIN NEUROPSYCH, V12, P757, DOI 10.1016/S0887-6177(97)00049-8; Vanderploeg RD, 1996, PSYCHOL ASSESSMENT, V8, P404, DOI 10.1037/1040-3590.8.4.404; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; WARD AW, 1995, 12 MENTAL MEASUREMEN, P1106; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WECHSLER D, 1987, WECHSLER MEMORY SALE; WECHSLER D, 1952, MANUAL WECHSLER ADUL; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038; Yuspeh RL, 2000, ARCH CLIN NEUROPSYCH, V15, P319, DOI 10.1016/S0887-6177(99)00020-7	45	12	12	0	2	AUSTRALIAN PSYCHOLOGICAL SOC	CARLTON	1 GRATTAN STREET, CARLTON, VICTORIA 3053, AUSTRALIA	0005-0067			AUST PSYCHOL	Aust. Psychol.	NOV	2003	38	3					227	237		10.1080/00050060310001707257			11	Psychology, Multidisciplinary	Psychology	771PD	WOS:000188794400010					2021-06-18	
J	Samuelsson, C; Kumlien, E; Elfving, A; Lindholm, D; Ronne-Engstrom, E				Samuelsson, C; Kumlien, E; Elfving, A; Lindholm, D; Ronne-Engstrom, E			The effects of PBN (phenyl-butyl-nitrone) on GLT-1 levels and on the extracellular levels of amino acids and energy metabolites in a model of iron-induced posttraumatic epilepsy	EPILEPSY RESEARCH			English	Article						iron; epilepsy; traumatic brain injury; amino acids; glutamate uptake; nitrones	GLUTAMATE TRANSPORTER GLT-1; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; INTRACEREBRAL MICRODIALYSIS; EPILEPTIFORM DISCHARGES; ANTISENSE KNOCKDOWN; NEURONAL DAMAGE; HEAD-INJURY; FOCUS; PEROXYNITRITE	This study investigates astrocytic glutamate uptake in the iron-induced animal model of posttraumatic epilepsy. Since formation of free radicals may be involved in epileptogenesis after brain trauma and hemorrhage the effects of the nitrone radical scavenger alpha-phenyl-tert-N-butyl nitrone (PBN) were also studied. Animals received an intracortical iron injection, or were sham-operated. They were given PBN intraperitoneally or saline as control. Twenty-four hours after lesion, brain tissue was collected and the level of glial glutamate transporter (GLT-1) was analyzed using immunoblotting. The extracellular concentrations of amino acids and energy metabolites were measured using microdialysis. The results showed significantly decreased levels of GLT-1 (70 kDa), higher basal levels of glutamate, and lower levels of glutamine as well as low arginine/citrulline ratios at the lesion compared to controls. PBN significantly attenuated the decrease of 70 kDa GLT-1 in the lesioned animals and attenuated the alterations in amino acid levels but not to a significant level. PBN also increased the arginine/citrulline ratios indicating reduced nitric oxide synthase activity. Our results suggest that astrocytic uptake of glutamate is oxidatively impaired in iron-induced epileptogenesis and that the administration of a radical scavenger can attenuate this process. (C) 2003 Elsevier B.V. All rights reserved.	Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Neurol Sect, Dept Neurosci, S-75185 Uppsala, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Univ Uppsala Hosp, Neurobiol Sect, Dept Neurosci, BMC, S-75123 Uppsala, Sweden	Samuelsson, C (corresponding author), Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden.	carolina.samuelsson@neurokir.uu.se	Lindholm, Dan/B-3777-2014	Kumlien, Eva/0000-0002-1952-8791			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHEN GM, 1990, FREE RADICAL BIO MED, V9, P93, DOI 10.1016/0891-5849(90)90110-5; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Dabrosin C, 1997, CLIN SCI, V92, P493, DOI 10.1042/cs0920493; De Micheli E, 2000, ADV EXP MED BIOL, V483, P595; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Kabuto H, 1998, EPILEPSIA, V39, P237, DOI 10.1111/j.1528-1157.1998.tb01367.x; Kabuto H, 1996, EPILEPSY RES, V25, P65, DOI 10.1016/0920-1211(96)00063-0; Kotake Y, 1998, BBA-MOL CELL RES, V1448, P77, DOI 10.1016/S0167-4889(98)00126-8; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MORIWAKI A, 1992, ELECTROEN CLIN NEURO, V83, P281, DOI 10.1016/0013-4694(92)90087-X; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Petroff OAC, 2002, EPILEPSIA, V43, P703, DOI 10.1046/j.1528-1157.2002.38901.x; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; Samuelsson C, 2000, NEUROSCI LETT, V289, P185, DOI 10.1016/S0304-3940(00)01284-2; Shibuki H, 2000, INVEST OPHTH VIS SCI, V41, P3607; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; Xu GY, 1998, NEUROSCIENCE, V86, P1011, DOI 10.1016/S0306-4522(98)00063-3; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	37	12	15	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	OCT	2003	56	2-3					165	173		10.1016/j.eplepsyres.2003.09.004			9	Clinical Neurology	Neurosciences & Neurology	753TZ	WOS:000187247800010	14643001				2021-06-18	
J	Wells, RG; Sty, JR				Wells, RG; Sty, JR			Traumatic low attenuation subdural fluid collections in children younger than 3 years	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							CLINICAL-SIGNIFICANCE; BRAIN INJURY; HEAD-INJURY; HYGROMA; HEMATOMA; AGE	Objective: To determine the time course for the development of posttraumatic nonhemic subdural fluid collections in infants and young children. Design: Retrospective consecutive case series during 16 years. Patients: Fifty-five head trauma patients younger than 3 years with low attenuation subdural fluid on computed tomography. Main Outcome Measure: Time after head trauma when low attenuation fluid first becomes visible. Setting: Regional pediatric medical center. Results: The initial visualization of low attenuation sub dural fluid was within 4 days of the trauma for 44 of the patients. The mean +/-SD size of the subdural fluid collections when first identified was 4.6 2.0 mm (range, 2-12 mm), and the maximum observed size was 7.7 +/- 3.5 mm (range, 3-21 mm). The mean +/-SD time after injury until the maximum observed size was 16 +/- 18 days (range, 0-87 days). Low attenuation subdural fluid and high attenuation intracranial hemorrhage coexisted on at least 1 computed tomographic study during the first week after the trauma in 42 (81%) of the 52 patients with hemorrhage. Conclusion: Low attenuation subdural fluid collections (distinct from clotted blood) in infants and young children with head injuries most often develop during the first week after the traumatic event.	Childrens Hosp Wisconsin, Dept Radiol, Milwaukee, WI 53201 USA	Wells, RG (corresponding author), Childrens Hosp Wisconsin, Dept Radiol, Mail Stop 721,900 W Wisconsin Ave,POB 1997, Milwaukee, WI 53201 USA.						Barnes PD, 2000, PEDIATR RADIOL, V30, P74, DOI 10.1007/s002470050018; Borzone M, 1983, J Neurosurg Sci, V27, P161; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; FRENCH BN, 1978, SURG NEUROL, V9, P145; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; Hwang SK, 2000, CHILD NERV SYST, V16, P590, DOI 10.1007/s003810000312; Lee KS, 2000, J KOREAN MED SCI, V15, P560, DOI 10.3346/jkms.2000.15.5.560; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Sargent S, 1996, J FORENSIC SCI, V41, P314; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; Wells RG, 2002, ARCH PEDIAT ADOL MED, V156, P252, DOI 10.1001/archpedi.156.3.252	16	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	OCT	2003	157	10					1005	1010		10.1001/archpedi.157.10.1005			6	Pediatrics	Pediatrics	730DZ	WOS:000185815100011	14557162	Bronze			2021-06-18	
J	Gil, AM				Gil, AM			Neurocognitive outcomes following pediatric brain injury: A developmental approach	JOURNAL OF SCHOOL PSYCHOLOGY			English	Article						brain injury; cognition; achievement; development; assessment	CLOSED-HEAD INJURY; CHILDREN; CHILDHOOD; PLASTICITY; ATTENTION; RECOVERY; AGE; HEMISPHERECTOMY; REORGANIZATION; ADOLESCENTS	Developmental neuropsychologists postulate that "immaturity" of the cerebral cortex should no longer be perceived as a protective factor. They argue that injury to the young brain may affect new learning by disrupting the skills in the midst of being acquired and skills that are yet to be developed. Cognitive deficits or weaknesses that are not detectable in the acute phase following a traumatic brain injury (TBI) may emerge over development as more complex skills are needed, thereby creating a developmental lag between children who sustained a pediatric TBI and typical age peers. This literature review was conducted to evaluate the developmental perspective on neurocognitive recovery/development following a TBI Overall, the described findings support a developmental view and suggest that predictions of prognosis should be based on the child's remaining ability to learn. (C) 2003 Society for the Study of School Psychology. Published by Elsevier Science Ltd. All rights reserved.	Univ Georgia, Dept Educ Psychol, Athens, GA 30602 USA	Gil, AM (corresponding author), Univ Georgia, Dept Educ Psychol, 325 Aderhold Hall, Athens, GA 30602 USA.	armande@arches.uga.edu					Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2000, BRAIN INJURY, V14, P679; Bakker K, 1999, Pediatr Rehabil, V3, P149; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BJORKLUND DF, 2000, CHILDRENS THINKING; BROWN JW, 1975, NEUROPSYCHOLOGIA, V13, P107, DOI 10.1016/0028-3932(75)90054-8; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chiron C, 1997, BRAIN, V120, P1057, DOI 10.1093/brain/120.6.1057; CHUGANI HT, 1993, EPILEPSIA, V34, P764, DOI 10.1111/j.1528-1157.1993.tb00459.x; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Dennis M, 1999, CHANGING NERVOUS SYSTEM, P172; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1999, COGNITIVE ASPECTS OF CHRONIC ILLNESS IN CHILDREN, P262; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GLAUB VE, 1994, J PSYCHOEDUC ASSESS, V12, P270, DOI 10.1177/073428299401200306; Guthrie E, 1999, CHILD ADOL PSYCH CL, V8, P807; Holmes CS, 1999, SCHOOL PSYCHOL REV, V28, P215; Kay JB, 1999, J CLIN EXP NEUROPSYC, V21, P186, DOI 10.1076/jcen.21.2.186.927; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; KOLB B, 1989, PROG NEUROBIOL, V32, P235, DOI 10.1016/0301-0082(89)90023-3; Kolb B., 1995, BRAIN PLASTICITY BEH; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Mash Eric J., 1996, P3; McArdle J.J, 2003, HDB PSYCHOL RES METH, P447, DOI [10.1002/0471264385.wei0218, DOI 10.1002/0471264385.WEI0218]; MULLER F, 1991, NEUROPSYCHOLOGIA, V29, P125, DOI 10.1016/0028-3932(91)90016-2; NORMAN MG, 1998, TXB PEDIAT NEUROPSYC, P43; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Plante E, 2000, J COMMUN DISORD, V33, P271, DOI 10.1016/S0021-9924(00)00024-1; Rakic Pasko, 1995, P127; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Rosenberg S., 1987, ADV APPLIED PSYCHOLI, V1, P1, DOI 10.1017/cbo9780511571374.002; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sowell ER, 1999, NEUROIMAGE, V9, P587, DOI 10.1006/nimg.1999.0436; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; TINUPER P, 1988, ANN NEUROL, V24, P27, DOI 10.1002/ana.410240107; VARGHAKHADEM F, 1991, BRAIN, V114, P473, DOI 10.1093/brain/114.1.473; Verger K, 2000, BRAIN INJURY, V14, P495; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; VOELLER KKS, 1998, TXB PEDIAT NEUROPSYC, P769	50	12	12	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4405	1873-3506		J SCHOOL PSYCHOL	J. Sch. Psychol.	SEP-OCT	2003	41	5					337	353		10.1016/S0022-4405(03)00085-2			17	Psychology, Educational	Psychology	723FD	WOS:000185421000003					2021-06-18	
J	Ulusoy, H; Usul, H; Aydin, S; Kaklikkaya, N; Cobanoglu, U; Reis, A; Akyol, A; Ozen, I				Ulusoy, H; Usul, H; Aydin, S; Kaklikkaya, N; Cobanoglu, U; Reis, A; Akyol, A; Ozen, I			Effects of immunonutrition on intestinal mucosal apoptosis, mucosal atrophy, and bacterial translocation in head injured rats	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						head injury; immunonutrition; intestinal atrophy; apoptosis; bacterial translocation	TOTAL PARENTERAL-NUTRITION; IMMUNE-ENHANCING DIET; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; EPITHELIAL-CELLS; CRITICALLY ILL; SEPTIC COMPLICATIONS; ENTERAL DIETS; GLUTAMINE; GUT	Background: Immunonutrition has been demonstrated to modulate gut function, reduce infectious complications, hospital stay, and ventilator days in the critical patients. Aim of the study: We assessed the effect of immunonutrition for the prevention of intestinal mucosal atrophy, apoptosis, and bacterial translocation in head injured rats. Methods: Thirty five rats were randomised into 5 groups. Following moderate closed head injury, in Group 1; Standard Enteral Nutrition, Group 2; Immunonutrition, Group 3; TPN, Group 4; pe. saline were applied. Group 5 was control group (chow-fed). The rats were sacrificed and segments of the ileum were removed for histologic examination, and samples of tissues taken for microbiologic evaluation. Results: Both intestinal apoptosis and mucosal atrophy were significantly lower in Group 2 and Group 5 (p < 0.008). Bacterial translocation was significantly lower in Group 2 than Group 1 (p < 0.008). Conclusion: The enteral immunonutrition prevents intestinal barrier function in brain injured rats. (C) 2003 Elsevier Science Ltd. All rights reserved.	Black Sea Tech Univ, Farabi Hosp, Dept Anesthesiol & Reanimat, Trabzon, Turkey; Black Sea Tech Univ, Farabi Hosp, Dept Neurosurg, Trabzon, Turkey; Black Sea Tech Univ, Farabi Hosp, Dept Histol & Embriol, Trabzon, Turkey; Black Sea Tech Univ, Farabi Hosp, Dept Microbiol, Trabzon, Turkey; Black Sea Tech Univ, Farabi Hosp, Dept Pathol, Trabzon, Turkey	Ulusoy, H (corresponding author), Black Sea Tech Univ, Farabi Hosp, Dept Anesthesiol & Reanimat, Trabzon, Turkey.		KAKLIKKAYA, NESE/AAL-9100-2021; AYDIN, Sevim/AAO-5670-2020; ulusoy, hulya/A-6223-2019	AYDIN, Sevim/0000-0003-2445-2346; ulusoy, hulya/0000-0001-6645-6316; Cobanoglu, Umit/0000-0001-6429-427X			ALVERDY J, 1985, ANN SURG, V202, P681, DOI 10.1097/00000658-198512000-00003; ALVERDY JC, 1990, JPEN-PARENTER ENTER, V14, pS109, DOI 10.1177/014860719001400415; ALVERDY JC, 1988, SURGERY, V104, P185; Archer S B, 1996, Adv Surg, V29, P165; Atkinson S, 1998, CRIT CARE MED, V26, P1164, DOI 10.1097/00003246-199807000-00013; Barton R G, 1997, Nutr Clin Pract, V12, P51, DOI 10.1177/011542659701200251; Bastian L, 1999, Anaesthesiol Reanim, V24, P95; Beale RJ, 1999, CRIT CARE MED, V27, P2799, DOI 10.1097/00003246-199912000-00032; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Boza JJ, 1999, J NUTR, V129, P1340; *BRAIN TRAUMA FDN, 2000, NUTR J NEUROTRAUMA, V17, P539; CUMMINGS MC, 1997, APOPTOSIS HISTOLOGY, P3; Deitch EA, 1994, GUT               S1, V35, pS23; DIETCH EA, 1990, GASTROENTEROLOGY, V98, P243; DIETCH EA, 1989, ARCH SURG-CHICAGO, V124, P699; Ersin S, 2000, J SURG RES, V89, P121, DOI 10.1006/jsre.1999.5808; GALHAN C, 1998, JPEN J PARENTER ENTE, V22, pS13; Gentilini O, 2000, Minerva Anestesiol, V66, P362; Gu Y, 2001, CLIN NUTR, V20, P159, DOI 10.1054/clnu.2000.0379; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Iwakiri R, 2001, SCAND J GASTROENTERO, V36, P39, DOI 10.1080/00365520150218048; Jeschke MG, 2000, DIGEST DIS SCI, V45, P415, DOI 10.1023/A:1005445501016; KING BK, 1998, ADV SURG, V31, P53; Kudsk K A, 1994, Nutr Clin Pract, V9, P165, DOI 10.1177/0115426594009005165; KUDSK KA, 1983, J TRAUMA, V23, P605, DOI 10.1097/00005373-198307000-00010; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; Marino PL, 1996, CRIT CARE CLIN, V12, P667, DOI 10.1016/S0749-0704(05)70270-0; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATES JM, 2000, CELL BIOL, V34, P439; Mendez C, 1997, J TRAUMA, V42, P933, DOI 10.1097/00005373-199705000-00026; Militsa B, 2001, Neurol India, V49 Suppl 1, pS75; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; Noda T, 1998, AM J PHYSIOL, V274, P270; OLeary MJ, 1996, BRIT J ANAESTH, V77, P118; Papaconstantinou HT, 2000, J GASTROINTEST SURG, V4, P416, DOI 10.1016/S1091-255X(00)80022-0; Papaconstantinou HT, 1998, SURGERY, V124, P152, DOI 10.1067/msy.1998.90562; Redmond HP, 1998, NUTRITION, V14, P599, DOI 10.1016/S0899-9007(98)00097-5; SAITO H, 1987, JPEN-PARENTER ENTER, V11, P1, DOI 10.1177/014860718701100101; SHEIFTER E, 1978, SURGERY, V84, P224; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TAMION F, 1997, AM J PHYSIOL, V273, P314; Thomas S, 1998, ACT NEUR S, V71, P135; WILMORE DW, 1988, SURGERY, V104, P917; Wilson RF, 1998, J HEAD TRAUMA REHAB, V13, P11, DOI 10.1097/00001199-199802000-00005; Wyncoll D, 2001, Curr Opin Crit Care, V7, P128, DOI 10.1097/00075198-200104000-00012; YANGAWA T, 2002, COCHRANE DATABASE SY, V3, DOI UNSP CD001530; Young B, 1991, Neurosurg Clin N Am, V2, P301; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; ZALOGA GP, 1991, CRIT CARE MED, V19, P54, DOI 10.1097/00003246-199101000-00015; Zaloga GP, 1998, CRIT CARE MED, V26, P1143, DOI 10.1097/00003246-199807000-00001; Zaloga GP, 1990, J CRIT ILLNESS, V5, P1180	55	12	14	1	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	SEP	2003	10	5					596	601		10.1016/S0967-5868(03)00142-5			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	727ZT	WOS:000185691300015	12948467				2021-06-18	
J	Vinchon, M; Defoort-Dhellemmes, S; Nzeyimana, C; Vallee, L; Dhellemmes, P				Vinchon, M; Defoort-Dhellemmes, S; Nzeyimana, C; Vallee, L; Dhellemmes, P			Infantile traumatic subdural hematomas: Outcome after five years	PEDIATRIC NEUROSURGERY			English	Article						infantile head injury; subdural hematoma; outcome	BRAIN-INJURY; CHILDREN	Objective: Although subdural hematomas (SDH) are common in infants, their long-term outcome is poorly documented in the literature. Methods: Infants operated for SDH were followed prospectively and evaluated during their sixth year with systematic neurological evaluation and standard neuropsychological testing. Results: We studied 48 infants operated for SIDH. At the last checkup, 39 were normal, 5 had mild deficits, 3 had severe deficits and 1 was in a vegetative state. IQ measurements did not differ significantly from normal values, but did not accurately reflect the outcome. The only independent factor significantly affecting the final outcome was initial clinical severity. Age at surgery, surgical complications and the nature of the trauma (inflicted or accidental) did not independently influence the outcome. Conclusion: Long-term follow-up is required after treatment of SIDH, to evaluate the child's changing needs in terms of medical and educational care. Copyright (C) 2003 S. Karger AG, Basel.	Hop Roger Salengro, Dept Pediat Neurosurg, FR-59037 Lille, France; Hop Roger Salengro, Dept Neuroophthalmol, FR-59037 Lille, France; Hop Roger Salengro, Dept Neuropediat, FR-59037 Lille, France	Vinchon, M (corresponding author), Hop Roger Salengro, Dept Pediat Neurosurg, FR-59037 Lille, France.	m-vinchon@chru-lille.fr		Vinchon, Matthieu/0000-0002-9122-6165			Adelson PD, 1999, TRAUMATIC BRAIN INJU, P283; DESCHAMPS G, 1982, NEUROPSYCHIAT ENFAN, V30, P671; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUNCAN CC, 1989, CONCEPTS PEDIAT NEUR, V9, P211; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; LEVIN HS, 2001, PEDIAT NEUROSURGERY, P654; MORSE CW, 1970, AM J DIS CHILD, V120, P439, DOI 10.1001/archpedi.1970.02100100103011; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; PARENT AD, 1999, PEDIATR NEUROSURG, V18, P266; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; Vinchon M, 2001, J NEUROSURG, V95, P249, DOI 10.3171/jns.2001.95.2.0249; Wechsler D., 1967, MANUAL WECHSLER PRES	18	12	12	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	SEP	2003	39	3					122	128		10.1159/000071648			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	712BF	WOS:000184775000002	12876390				2021-06-18	
J	Gray, C; Nukada, H; Jackson, DM; McMorran, PD; Wu, A; Ma, F				Gray, C; Nukada, H; Jackson, DM; McMorran, PD; Wu, A; Ma, F			Neuroprotective effects of nitrone radical scavenger S-PBN on reperfusion nerve injury in rats	BRAIN RESEARCH			English	Article						ischemic neuropathy; reperfusion; peripheral nerve; S-PBN; rat; pathology	FOCAL CEREBRAL-ISCHEMIA; CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN INJURY; SCIATIC-NERVE; FIBER DEGENERATION; OXIDATIVE DAMAGE; PERIPHERAL-NERVE; DIABETIC NERVE; BLOOD-FLOW; SPIN TRAP	The nitrone-based free radical scavengers have potent neuroprotective activities in models of stroke in which oxidative stress plays a key role in its development. We examined the effects of S-PBN (sodium 4-[(tert-butylimino) methyl]benzene-3-sulfonate N-oxide), a spin trap nitrone, on reperfusion injury in rat peripheral nerves. Immediately after the onset of 4-h ischaemia in rat right hindlimb, S-PBN was administered via mini-osmotic pumps, containing 2 ml of S-PBN (1.2 M), inserted subcutaneously. S-PBN, in addition, was given by a single injection (50 mg/kg BW, i.p.). Mean plasma concentrations of S-PBN were significantly greater in S-PBN-treated rats than in controls after 24, 48 and 72 h of reperfusion. Pump and dosing solution analysis indicated that the rats received between 82 and 99% of the target S-PBN concentration. Morphology in sciatic, tibial and peroneal nerves was assessed after 4 It of ischaemia followed by 72 It and 7 days of reperfusion. After 72 h of reperfusion, saline-treated control rats showed endoneurial oedema at the thigh level and diffuse axonal degeneration of myelinated nerve fibres distally. S-PBN-treated nerves were normal or revealed less severe abnormalities in myelinated fibres after 72 h and 7days of reperfusion, when compared with those in saline-treated control nerves. Morphometrically, the frequency of abnormal myelinated fibres at calf levels was significantly less in S-PBN-treated nerves than in controls. In conclusion, post-ischaemic administration of S-PBN exhibits substantial neuroprotective properties in ischemia/reperfusion nerve injury. (C) 2003 Elsevier B.V. All rights reserved.	Univ Otago, Sch Med, Dept Med, Dunedin 9015, New Zealand; Univ Otago, Sch Med, Dept Pharmacol & Toxicol, Dunedin 9015, New Zealand; Cent Pharmaceut Inc, Los Angeles, CA USA	Nukada, H (corresponding author), Univ Otago, Sch Med, Dept Med, POB 913,201 Great King St, Dunedin 9015, New Zealand.						Anderson GM, 1997, BRAIN RES, V772, P156, DOI 10.1016/S0006-8993(97)00800-7; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; DAY TJ, 1989, EXP NEUROL, V103, P173, DOI 10.1016/0014-4886(89)90079-4; Dehouck MP, 2002, BRAIN RES, V955, P229, DOI 10.1016/S0006-8993(02)03469-8; Fallon J, 1997, EXP NEUROL, V144, P193, DOI 10.1006/exnr.1997.6416; Floyd RA, 2002, MECH AGEING DEV, V123, P1021, DOI 10.1016/S0047-6374(01)00385-2; Floyd RA, 2002, ANN NY ACAD SCI, V959, P321, DOI 10.1111/j.1749-6632.2002.tb02103.x; Floyd RA, 2000, ANN NY ACAD SCI, V899, P222; He K, 1999, NEUROSCIENCE, V94, P909, DOI 10.1016/S0306-4522(99)00350-4; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Mitsui Y, 1999, J NEUROL SCI, V163, P11, DOI 10.1016/S0022-510X(99)00017-9; Mitsui Y, 1999, BRAIN RES, V844, P192, DOI 10.1016/S0006-8993(99)01830-2; Myhre O, 2001, J NEUROSCI RES, V66, P992, DOI 10.1002/jnr.10049; Nagamatsu M, 1996, MUSCLE NERVE, V19, P37, DOI 10.1002/mus.880190103; NUKADA H, 1992, MUSCLE NERVE, V15, P1116, DOI 10.1002/mus.880151010; Nukada H, 2002, J PERIPHER NERV SYST, V7, P37, DOI 10.1046/j.1529-8027.2002.02004.x; Nukada H, 1997, J Peripher Nerv Syst, V2, P60; Nukada H, 2000, ANN NEUROL, V47, P71, DOI 10.1002/1531-8249(200001)47:1<71::AID-ANA12>3.3.CO;2-G; NUKADA H, 1984, AM J PATHOL, V115, P275; NUKADA H, 1994, J ANAT, V185, P259; SCHMELZER JD, 1989, P NATL ACAD SCI USA, V86, P1639, DOI 10.1073/pnas.86.5.1639; Schulz JB, 1996, NEUROSCIENCE, V71, P1043, DOI 10.1016/0306-4522(95)00527-7; SCHULZ JB, 1995, J CEREBR BLOOD F MET, V15, P948, DOI 10.1038/jcbfm.1995.120; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Sturgess NC, 2000, ARCH TOXICOL, V74, P153, DOI 10.1007/s002040050668; WRIGHT A, 1994, ACTA NEUROPATHOL, V88, P571; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; Yoshimoto T, 2002, BRAIN RES, V947, P191, DOI 10.1016/S0006-8993(02)02922-0; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; Zhao ZG, 2001, BRAIN RES, V909, P46, DOI 10.1016/S0006-8993(01)02618-X	34	12	12	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 29	2003	982	2					179	185		10.1016/S0006-8993(03)03006-3			7	Neurosciences	Neurosciences & Neurology	721KR	WOS:000185316000005	12915253				2021-06-18	
J	Swaine, BR; Dutil, T; Demers, L; Gervais, M				Swaine, BR; Dutil, T; Demers, L; Gervais, M			Evaluating clients' perceptions of the quality of head injury rehabilitation services: development and validation of a questionnaire	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; PATIENT SATISFACTION; FAMILY NEEDS; CARE; PARENTS; SYSTEM	Objective: The objective of this research was to develop a tool to assess clients' perception of the quality of head injury rehabilitation services. Methods and results: A questionnaire PQRS-Montreal 1.0 was developed in Montreal, Quebec using a standardized methodology that incorporated a new technique to reach consensus regarding the tool's contents. Five dimensions of care (i.e. ecological approach, client-centred approach, accessibility, quality of the service providers and continuity) and their corresponding standards were identified as pertinent to include in the tool and were subsequently validated by experts. A phase of item generation followed that led to the development of an 87-item prototype of the questionnaire. The questionnaire is to be administered during an interview and employs a 5-point rating scale. Discussion and conclusion: The implications for the use of PQRS-Montreal 1.0 in the accreditation process of head injury rehabilitation services are discussed, as well as plans for future quantitative research in the development of the tool.	Univ Montreal, Fac Med, Sch Rehabil, Montreal, PQ H3C 3J7, Canada; Inst Readaptat Montreal, Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; Inst Univ Geriatrie Montreal, Montreal, PQ, Canada; Univ Laval, Dept Readaptat, Montreal, PQ, Canada	Swaine, BR (corresponding author), Univ Montreal, Fac Med, Sch Rehabil, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.						CHARRON L, 1992, ANAL DIRECTION ETUDE; *COAORF, 1993, STAND MAN ORG SERV P; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Crocker L., 1986, INTRO CLASSICAL MODE; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; DUTIL E, 1998, PROGRAMME CONJOINT F; Dutil E, 1998, CANADIAN J REHABILIT, V11, P268; Eldar R, 2000, DISABIL REHABIL, V22, P163, DOI 10.1080/096382800296854; Elliott-Burke TL., 1997, J REHABIL OUTCOMES M, V1, P18; Gerbing DW, 1996, STRUCT EQU MODELING, V3, P62, DOI 10.1080/10705519609540030; GERVAIS M, 1999, ETUDE EXPLORATOIRE B, P1; GERVAIS M, 2000, REV QUEBECOISE ERGOT, V9, P11; Haddad S, 1998, SOC SCI MED, V47, P381, DOI 10.1016/S0277-9536(98)00075-6; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Heinemann A, 1997, J REHABIL OUTCOMES M, V1, P52; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; *INT ORG STAND, 1990, QUAL MAN QUAL SYST 2; Johnston MV, 1997, ARCH PHYS MED REHAB, V78, pS1, DOI 10.1016/S0003-9993(97)90148-9; Keith RA, 1998, ARCH PHYS MED REHAB, V79, P1122, DOI 10.1016/S0003-9993(98)90182-4; King GA, 1997, CHILD CARE HLTH DEV, V23, P47, DOI 10.1046/j.1365-2214.1997.840840.x; KOSCIULEK J, 1997, J REHABILITATION APR; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCCOMAS J, 1995, AM J OCCUP THER, V49, P980, DOI 10.5014/ajot.49.10.980; MCNEIL R, 1999, 1994 1997 SATISFACTI; Pound P, 1999, STROKE, V30, P49, DOI 10.1161/01.STR.30.1.49; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; *QUEB LSDAAD, 1996, ENT AGR TYP SOC ASS, P1; Rossi P. H., 1993, EVALUATION SYSTEMATI; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Streiner DL, 1989, HLTH MEASUREMENT SCA; SWAINE B, 2002, 6 WORLD C INJ PREV C; Swaine BR, 1999, AM J PHYS MED REHAB, V78, P323, DOI 10.1097/00002060-199907000-00006; *SYST INF CLIENT T, 2000, INT JOINT C EBIS EMN; VANCAMPEN C, 1995, MED CARE RES REV, V52, P109, DOI 10.1177/107755879505200107; WAREING PF, 1978, BOT MAG TOKYO SPECIA, V1, P3	38	12	12	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2003	17	7					575	587		10.1080/0269905031000088568			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	690HG	WOS:000183541900004	12775270				2021-06-18	
J	Iglesias-Pais, M; Gelabert-Gonzalez, M; Lopez-Garcia, E; Allut, AG; Fernandez-Villa, JM; Gonzalez-Garcia, J; Rumbo, RM				Iglesias-Pais, M; Gelabert-Gonzalez, M; Lopez-Garcia, E; Allut, AG; Fernandez-Villa, JM; Gonzalez-Garcia, J; Rumbo, RM			De novo Arachnoid cyst treated with a cystoperitoneal shunt	REVISTA DE NEUROLOGIA			Spanish	Article						Arachnoid cyst; bypass valve; computerised tomography; transfontanellar echography	CHILDREN	Introduction. Arachnoid cysts (A Q are benign pathological structures that are typically found during childhood, and represent approximately 1% of all intracranial lesions. Unlike cases of secondary cysts with a known causation, which can be attributed to inflammatory processes or traumatic brain injuries, the causation of the primary cysts is unknown. In the cases reported to date, the cysts present from the first imaging study conducted, which is why they are considered to be of a prenatal origin. Case report. A boy who, at the age of 5 months, is found to have an AC of considerable dimensions that did not appear in a transfontanellar echographic study carried out for other reasons at the age of 2 months. Conclusion. The importance of this case lies in the fact that it has been possible to show the appearance of a cyst after birth in a sequence of images in the case of a pathology which, according to all the theories and tests, is considered to have a congenital causation. [REVNEVROL 2003; 36:1149-52].	Univ Santiago de Compostela, Hosp Clin, Serv Neurochirurg, Santiago De Compostela, Spain				Gelabert-Gonzalez, Miguel/0000-0002-9462-0045			Ballerini M, 1990, Riv Neurol, V60, P171; BASAURI L, 1992, CHILD NERV SYST, V8, P101, DOI 10.1007/BF00298451; Daneyemez M, 1999, J Neurosurg Sci, V43, P115; DIROCCO C, 1981, CHILD BRAIN, V8, P119; Galarza M, 2002, PEDIATR NEUROL, V27, P180, DOI 10.1016/S0887-8994(02)00414-9; GelabertGonzalez M, 1997, REV NEUROLOGIA, V25, P1095; GO KG, 1984, J NEUROSURG, V60, P803, DOI 10.3171/jns.1984.60.4.0803; Gomez-Escalonilla CI, 2001, REV NEUROLOGIA, V33, P305, DOI 10.33588/rn.3304.2000633; HORCAJADAS A, 1996, NEUROCIRUGIA 21, V2, P131; KUMAGAI M, 1986, CHILD NERV SYST, V2, P211, DOI 10.1007/BF00706815; Martinez-Lage JF, 1999, CHILD NERV SYST, V15, P94, DOI 10.1007/s003810050340; OKUMURA Y, 1995, J NEUROSURG, V82, P1075, DOI 10.3171/jns.1995.82.6.1075; ROBINSON RG, 1964, BRAIN, V88, P87; Santamarta D, 1995, MINIM INVAS NEUROSUR, V38, P133, DOI 10.1055/s-2008-1053473; Shibata T, 2001, SPINAL CORD, V39, P599, DOI 10.1038/sj.sc.3101217; Yanaka K, 1998, CHILD NERV SYST, V4, P302, DOI 10.1007/BF00271930	16	12	12	0	2	REVISTA DE NEUROLOGIA	BARCELONA	C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN	0210-0010			REV NEUROLOGIA	Rev. Neurologia	JUN 16	2003	36	12					1149	1152		10.33588/rn.3612.2003084			4	Clinical Neurology	Neurosciences & Neurology	699MX	WOS:000184061500010	12833234				2021-06-18	
J	Burger, R; Zuechner, M; Bendszus, M; Vince, GH; Roosen, K				Burger, R; Zuechner, M; Bendszus, M; Vince, GH; Roosen, K			Moderate hypothermia improves neurobehavioral deficits after an epidural focal mass lesion in rodents	JOURNAL OF NEUROTRAUMA			English	Article						behavior; focal mass lesion; hypothermia, ischemia; magnetic resonance imaging, outcome; trauma	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; GLOBAL FOREBRAIN ISCHEMIA; TERM BEHAVIORAL DEFICITS; HISTOPATHOLOGICAL CONSEQUENCES; REPRODUCIBLE MODEL; BLOOD-FLOW; DAMAGE; HIPPOCAMPAL; SENSORIMOTOR	The objective of this study was to evaluate the effects of a moderate, intraischemic hypothermia on the behavorial deficits up to 4 weeks after induction of a focal mass lesion. A focal epidural mass lesion was induced by an epidural balloon. The severity of the trauma was defined by the balloon volume and flattening of electroencephalography. Hypothermia (32degreesC) was induced as soon as maximum balloon inflation was reached. Ischemia was extended over 30 min. After reperfusion, normothermic (n = 24) and hypothermic animals (n = 25) were monitored for 3 h followed by a rewarming of the cooled animals. Results were compared to sham-operated animals (n = 10). Behavioral deficits were assessed by postural reflex (PR), open field (OF), beam balance (BB), beam walking (BW), and water maze tests (WMT). MRI follow-up and histology was evaluated. Sham-operated rats showed normal test results. Rats with normothermia showed worsening of test performance (PR, p < 0.05; OF, p < 0.05; BB, p < 0.05; BW, p < 0.05; WMT, p < 0.05) compared to controls over the whole observation period. A significantly better behavioral outcome was observed in animals treated with hypothermia which showed no differences from controls 3-4 days after injury (PR, OF, BB, BW, WMT, p > 0.05). Lesion induced mortality was reduced in cooled animals but overall mortality rates were not influenced by this therapeutic measure. Neuronal cell loss in the CA1-CA4 region (p < 0.05) was reduced and the lesion size smaller (21 %/p > 0.05) in hypothermic animals. Magnetic resonance imaging revealed that the lesion was more pronounced in the cortical grey matter after normothermia, whereas hypothermic animals showed more subcortical brain lacerations. In conclusion, intraischemic hypothermia significantly improved the behavioral outcome, and decreased lesion-induced mortality and the size of the lesion after an epidural focal mass lesion.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany; Univ Wurzburg, Dept Neuroradiol, Wurzburg, Germany; Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany	Burger, R (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	RBurger@t-online.de		Vince, Giles/0000-0002-0222-8733			ALEXIS NE, 1995, STROKE, V26, P2338, DOI 10.1161/01.STR.26.12.2338; Avitsur R, 1997, NEUROIMMUNOMODULAT, V4, P258, DOI 10.1159/000097345; BALDWIN WA, 1991, AM J PHYSIOL, V261, pH774; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Beilin B, 1998, ANESTHESIOLOGY, V89, P1133, DOI 10.1097/00000542-199811000-00013; Bendszus M, 2002, J NEUROSURG, V97, P1419, DOI 10.3171/jns.2002.97.6.1419; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Burger R, 2002, J NEUROSURG, V97, P1410, DOI 10.3171/jns.2002.97.6.1410; Burger R, 1998, NEUROL RES, V20, pS52; Burger R, 1999, J NEUROTRAUM, V16, P1149, DOI 10.1089/neu.1999.16.1149; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1998, STROKE, V29, P1967, DOI 10.1161/01.STR.29.9.1967; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Ebmeyer U, 1998, J NEUROTRAUM, V15, P323, DOI 10.1089/neu.1998.15.323; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GERMANO IM, 1987, J NEUROSURG, V67, P81, DOI 10.3171/jns.1987.67.1.0081; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayasaki K, 1997, ACT NEUR S, V70, P75; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hill AG, 1996, AM J PHYSIOL-REG I, V271, pR1142; Hoffman WE, 1996, NEUROL RES, V18, P185; JARRARD LE, 1973, PSYCHOL BULL, V79, P1, DOI 10.1037/h0033792; JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V; Jiang JY, 2000, J NEUROSURG, V93, P718; KIMBLE DP, 1963, J COMP PHYSIOL PSYCH, V56, P273, DOI 10.1037/h0048903; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MILESON BE, 1991, NEUROSCI LETT, V128, P71, DOI 10.1016/0304-3940(91)90762-I; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nelson A, 1997, BEHAV BRAIN RES, V85, P93, DOI 10.1016/S0166-4328(96)00167-2; PACKARD MG, 1989, J NEUROSCI, V9, P1465; PERSSON L, 1989, STROKE, V20, P641, DOI 10.1161/01.STR.20.5.641; ROBINSON RG, 1980, BRAIN RES, V188, P63, DOI 10.1016/0006-8993(80)90557-0; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; WINOCUR G, 1990, BEHAV NEUROSCI, V104, P544, DOI 10.1037/0735-7044.104.4.544	71	12	13	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					543	558		10.1089/089771503767168474			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900003	12906739				2021-06-18	
J	Thomas, H; Feyz, M; LeBlanc, J; Brosseau, J; Champoux, MC; Christopher, A; Desormeaux, N; Dorais, L; Lin, H				Thomas, H; Feyz, M; LeBlanc, J; Brosseau, J; Champoux, MC; Christopher, A; Desormeaux, N; Dorais, L; Lin, H			North Star Project - Reality orientation in an acute care setting for patients with traumatic brain injuries	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute care rehabilitation; brain injury; reality orientation	LOG	Objective: The North Star Project is an acute care rehabilitation approach for patients with moderate and severe traumatic brain injuries. This patient-centered project uses the concepts of Reality Orientation Therapy to develop a unique approach that focuses "environment," "consistency" and "standardization" to promote a total team effort. Patients, treatment staff and members of the patient's family collaborate in a unified bedside protocol that stimulates orientation, encourages patients' appropriate interactions and aims to decrease the length of post-traumatic amnesia. Development of materials, protocols, training and outcome measurement initiatives are described.	McGill Univ, Ctr Hlth, Traumat Brain Injury Program, Montreal, PQ H3G 1A4, Canada	Thomas, H (corresponding author), McGill Univ, Ctr Hlth, Traumat Brain Injury Program, Montreal Gen Hosp Site,1650 Cedar Ave,Room D13-124, Montreal, PQ H3G 1A4, Canada.						BARNES J, 1974, GERONTOLOGIST, P138; CERNY J, 1983, REHABILITATION HEAD; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Folsom J C, 1967, Curr Psychiatr Ther, V7, P209; HAGEN C, 1972, COMMUNICATION DISORD; HOLDEN P, 1995, POSITIVE APPROACHES; HOWIE P, 1997, INT J GERIATR PSYCH, V12, P718; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1975, LANCET, V1, P480; JONES A, 1993, BR J NURS, V4, P519; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LEVIN H, 1975, J NERV MENT DIS, V167, P675; MANZI DB, 1987, HEAD INJURY ACUTE CA; MCNENY R, 1990, REHABILITATION ADULT; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Spector A, 2000, GERONTOLOGIST, V40, P206, DOI 10.1093/geront/40.2.206; TAULBEE LR, 1966, HOSP COMMUNITY PSYCH, V17, P133; TEASDALE G, 1974, LANCET, V2, P81; Woodrow P, 1998, Br J Nurs, V7, P1018; Woodrow P, 1998, Br J Nurs, V7, P1247; Zencius AH, 1998, BRAIN INJURY, V12, P53, DOI 10.1080/026990598122854	21	12	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2003	18	3					292	302		10.1097/00001199-200305000-00007			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	682HM	WOS:000183085700007	12802171				2021-06-18	
J	Liu, Y; Ishida, Y; Shinoda, K; Nakamura, S				Liu, Y; Ishida, Y; Shinoda, K; Nakamura, S			Effects of repeated stress on regeneration of serotonergic and noradrenergic axons in the cerebral cortex of adult rats	NEUROSCIENCE LETTERS			English	Article						noradrenaline; serotonin; restraint stress; regeneration; degeneration; denervation area	LOCUS-CERULEUS NEURONS; TRAUMATIC BRAIN INJURY; DEPRESSION; PROJECTIONS; COERULEUS	We examined whether regeneration of serotonergic (5-HT) and noradrenergic (NA) axons might be affected by stress. Neurotoxins to 5-HT or NA axons were injected into the frontal cortex to cause partial denervation. Mild restraint stress (40 min/day) was started 16 days later and given for 14 consecutive days (30-day stressed group). Non-stressed animals were divided into two groups, animals sacrificed at 14 days (14-day control group) and those sacrificed at 30 days (30-day control group) after the toxin injection. In immunohistochemical study, the denervation area of 5-HT axons but not that of NA axons was significantly smaller in the 30-day control group than in the 14-day control group. However, there was no significant difference between the 14-day control and 30-day stressed groups. These findings suggested that regeneration of 5-HT axons occurred earlier than that of NA axons, and that stress exerted inhibitory influence on regeneration of 5-HT axons. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.	Yamaguchi Univ, Sch Med, Dept Neurosci, Ube, Yamaguchi 7558505, Japan	Nakamura, S (corresponding author), Yamaguchi Univ, Sch Med, Dept Neurosci, Ube, Yamaguchi 7558505, Japan.						Altar CA, 1999, TRENDS PHARMACOL SCI, V20, P59, DOI 10.1016/S0165-6147(99)01309-7; Belzung C, 2001, NEUROPHARMACOLOGY, V41, P400, DOI 10.1016/S0028-3908(01)00072-7; BJORKLUND A, 1980, BRAIN RES, V191, P109, DOI 10.1016/0006-8993(80)90318-2; FRANKFURT M, 1984, BRAIN RES, V298, P273, DOI 10.1016/0006-8993(84)91426-4; FRITSCHY JM, 1990, J CHEM NEUROANAT, V3, P309; FRITSCHY JM, 1992, J COMP NEUROL, V321, P421, DOI 10.1002/cne.903210309; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Huether G, 1996, PROG NEUROBIOL, V48, P569, DOI 10.1016/0301-0082(96)00003-2; Maes M, 1999, NEUROPSYCHOPHARMACOL, V20, P188, DOI 10.1016/S0893-133X(98)00058-X; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; NAKAMURA S, 1989, NEUROSCI LETT, V100, P147, DOI 10.1016/0304-3940(89)90675-7; NAKAMURA S, 1991, NEUROREPORT, V2, P525, DOI 10.1097/00001756-199109000-00007; NAKAMURA S, 1991, PROG BRAIN RES, V88, P587; Nowakowska E, 2001, POL J PHARMACOL, V53, P227; PLAZNIK A, 1989, PROG NEURO-PSYCHOPH, V13, P623, DOI 10.1016/0278-5846(89)90050-X; RODE J, 1983, HUM PATHOL, V14, P464, DOI 10.1016/S0046-8177(83)80294-9; SAKAGUCHI T, 1990, NEUROSCI LETT, V118, P193, DOI 10.1016/0304-3940(90)90624-I; VERTES RP, 1991, J COMP NEUROL, V313, P643, DOI 10.1002/cne.903130409; WATERHOUSE BD, 1983, J COMP NEUROL, V217, P418, DOI 10.1002/cne.902170406	19	12	12	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAR 27	2003	339	3					227	230		10.1016/S0304-3940(03)00014-4			4	Neurosciences	Neurosciences & Neurology	656ZU	WOS:000181641600014	12633894				2021-06-18	
J	Golding, EA; Robertson, CS; Fitch, JCK; Goodman, JC; Bryan, RM				Golding, EA; Robertson, CS; Fitch, JCK; Goodman, JC; Bryan, RM			Segmental vascular resistance after mild controlled cortical impact injury in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; pial arteriole; rat; servo-nulling pressure system; traumatic brain injury	CEREBRAL-BLOOD-FLOW; PERCUSSION BRAIN INJURY; ARTERIAL-PRESSURE; MICROCIRCULATION; REACTIVITY; ISCHEMIA; STIMULATION; OCCLUSION; RESPONSES; PERFUSION	In an effort to localize the site at which increased resistance occurs after brain trauma, pial arteriole diameter and pressure were assessed after mild controlled cortical impact (CCI) injury in rats using an open cranial window technique. The authors tested the hypothesis that an increase in resistance accompanied by vasoconstriction occurs at the level of the pial arterioles within the injured cortex of the brain. At I hour after mild CCI injury, ipsilateral cerebral blood flow was significantly reduced by 42% compared with sham injury (n = 4; P < 0.05). Pial arteriole diameter and pressure remained unchanged. Resistance in the larger arteries (proximal resistance), however, was significantly greater after CCI injury (1.87 +/- 0.26 mm Hg/[mL . 100 g . min]) compared with sham injury (0.91 +/- 0.21 mm Hg/[mL . 100 g . min]; P < 0.0001). Resistance in small vessels, arterioles, and venules (distal resistance) was also significantly greater after CCI injury (1.13 +/- 0.05 mm Hg/[mL . 100 g . min]) compared with sham injury (0.74 +/- 0.13 rum Hg/[mL . 100 g . min]; P = 0.0001). The authors conclude that, at I hour after mild CCI injury, changes in vascular resistance comprise a 53% increase in the resistance distal to the area of injury and, surprisingly, a 105% increase in resistance in the arteries proximal to the injury site.	Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Univ Oklahoma, Dept Anesthesiol, Oklahoma City, OK USA	Golding, EA (corresponding author), Baylor Coll Med, Dept Anesthesiol, 1 Baylor Plaza,Suite 434D, Houston, TX 77030 USA.	egolding@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BAUMBACH GL, 1989, J PHYSIOL-LONDON, V416, P123, DOI 10.1113/jphysiol.1989.sp017753; BAUMBACH GL, 1983, CIRC RES, V52, P527, DOI 10.1161/01.RES.52.5.527; BERNE RM, 1988, PHYSIOLOGY, P472; BRYAN RM, 1988, AM J PHYSIOL, V255, pR295; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1984, J NEUROPATH EXP NEUR, V43, P72, DOI 10.1097/00005072-198401000-00006; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; GOBEL U, 1990, CIRC RES, V66, P271, DOI 10.1161/01.RES.66.2.271; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Golding EM, 1998, BRAIN RES, V785, P293, DOI 10.1016/S0006-8993(97)01419-4; HAJDU MA, 1993, AM J PHYSIOL, V264, pH2136; HARPER SL, 1984, HYPERTENSION, V6, P408, DOI 10.1161/01.HYP.6.3.408; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LANGFITT TW, 1977, ANN SURG, V186, P411, DOI 10.1097/00000658-197710000-00002; Li PA, 1998, NEUROSCI LETT, V253, P191, DOI 10.1016/S0304-3940(98)00643-0; LIPOWSKY HH, 1980, MICROVASC RES, V19, P297, DOI 10.1016/0026-2862(80)90050-3; SCHMIDTKASTNER R, 1987, J CEREBR BLOOD F MET, V7, P109, DOI 10.1038/jcbfm.1987.16; SHAPIRO HM, 1971, AM J PHYSIOL, V221, P279; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; THEILEN H, 1994, J CEREBR BLOOD F MET, V14, P1055, DOI 10.1038/jcbfm.1994.138; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Thomale UW, 2001, J NEUROSCI METH, V108, P85, DOI 10.1016/S0165-0270(01)00375-2; Tompkins P., 1999, Society for Neuroscience Abstracts, V25, P312; Uhl E, 2000, PROG APPL MICROCIR, V24, P72; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	35	12	12	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2003	23	2					210	218		10.1097/01.WCB.0000044739.64940.B5			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	643ZQ	WOS:000180893800008	12571452	Bronze			2021-06-18	
J	Kaptanoglu, E; Palaoglu, S; Demirpence, E; Akbiyik, F; Solaroglu, I; Kilinc, A				Kaptanoglu, E; Palaoglu, S; Demirpence, E; Akbiyik, F; Solaroglu, I; Kilinc, A			Different responsiveness of central nervous system tissues to oxidative conditions and to the antioxidant effect of melatonin	JOURNAL OF PINEAL RESEARCH			English	Article						antioxidant; brain; melatonin; optic nerve; spinal cord; white matter	SPINAL-CORD INJURY; LIPID-PEROXIDATION; FREE-RADICALS; DAMAGE; PROTECTION; MODEL; EXCITOTOXICITY; ISCHEMIA; NEURONS; ACID	Melatonin, a product of the pineal gland, is an effective free-radical scavenger both in vitro and in vivo. Free-radical-mediated lipid peroxidation has been increasingly considered as an important factor in post-traumatic neuronal degeneration. The aim of the present study was (i) to examine the responses of different regions of central nervous system (CNS) to free-radical generation induced in vitro and (ii) to test the efficacy of melatonin in reducing oxidative damage in different regions of the CNS. Rat brain, total spinal cord, spinal cord white matter and optic nerves were dissected with the rats under general anesthesia and immediately frozen at -20degreesC. Thiobarbituric acid reactive substances were measured as an index of lipid peroxidation. Peroxidation was induced with ferrous iron (0.02 mm), ascorbate (1 mm), and hydrogen peroxide (H-2 O-2 ) (0.5 mm). All tissue samples showed increased lipid peroxidation levels after treatment with free-radical generating agents. The highest amount of damage was observed in the presence of ferrous iron, ascorbate, and H-2 O-2 . Melatonin showed antioxidant effects in the brain, total spinal cord, optic nerve, and spinal cord white matter. The results show that melatonin has differential protective effects on CNS tissues in vitro and the most potent effect is observed in the spinal cord white matter.	Hacettepe Univ, Dept Neurosurg, Sch Med, Spinal Res Lab,Inst Neurol Sci & Psychiat,Fac Med, TR-06100 Ankara, Turkey; Hacettepe Univ, Dept Neurosurg, Spinal Res Lab, Inst Neurol Sci & Psychiat,Ankara Numune Educ & R, TR-06100 Ankara, Turkey; Hacettepe Univ, Dept Biochem, Fac Med, TR-06100 Ankara, Turkey	Palaoglu, S (corresponding author), Hacettepe Univ, Dept Neurosurg, Sch Med, Spinal Res Lab,Inst Neurol Sci & Psychiat,Fac Med, TR-06100 Ankara, Turkey.	palaoglu@hacettepe.edu.tr	Solaroglu, Ihsan/ABE-8816-2020; Solaroglu, Ihsan/ABF-7606-2020; Demirpence, Ediz/P-6050-2015	Solaroglu, Ihsan/0000-0002-9472-1735; Demirpence, Ediz/0000-0002-8922-7329			ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; ANDERSON DK, 1985, ANN EMERG MED, V14, P816, DOI 10.1016/S0196-0644(85)80064-0; Blask DE, 1999, CANCER RES, V59, P4693; Carneiro RCG, 1998, NEUROSCIENCE, V82, P293; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Cuzzocrea S, 2000, J PINEAL RES, V28, P52, DOI 10.1034/j.1600-079x.2000.280108.x; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; Hardeland R, 1997, INT J BIOMETEOROL, V41, P47, DOI 10.1007/s004840050053; IANAS O, 1991, ROM J ENDOCR, V29, P117; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kaptanoglu E, 2002, J NEUROSURG, V97, P49, DOI 10.3171/spi.2002.97.1.0049; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; Karbownik M, 2000, P SOC EXP BIOL MED, V225, P9, DOI 10.1046/j.1525-1373.2000.22502.x; MELCHIORRI D, 1995, FASEB J, V9, P1205; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Pablos MI, 1997, J APPL PHYSIOL, V83, P354; Pappolla MA, 1997, J NEUROSCI, V17, P1683; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; REITER RJ, 1999, MOL CELL ENDOCRINOL, V79, pC53; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Sewerynek E, 1996, HEPATO-GASTROENTEROL, V43, P898; Tan DX, 1998, J PINEAL RES, V25, P184, DOI 10.1111/j.1600-079X.1998.tb00558.x; WAN Q, 1994, NEUROSCI LETT, V180, P253, DOI 10.1016/0304-3940(94)90532-0	33	12	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	JAN	2003	34	1					32	35		10.1034/j.1600-079X.2003.02934.x			4	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	627CD	WOS:000179910500005	12485369				2021-06-18	
J	Turkstra, LS; Flora, TL				Turkstra, LS; Flora, TL			Compensating for executive function impairments after TBI: a single case study of functional intervention	JOURNAL OF COMMUNICATION DISORDERS			English	Article						executive; strategy; employment; brain injury	CLOSED-HEAD INJURY; MEMORY PERFORMANCE; CHILDREN	The purpose of this study was to demonstrate the effectiveness of compensatory strategies for impairments in executive function. The strategies were designed to enable a client with traumatic brain injury (TBI) to obtain professional employment, In a series of individual speech-language therapy sessions, compensatory strategies were developed, refined, and trained in mock-interview situations. Significant improvements were noted in report-writing accuracy and self-reported stress during report-writing. The client was able to obtain and maintain competitive employment in his chosen profession. The results support the use of strategies aimed at supporting executive function to improve performance on verbal tasks, and were informative regarding the effects of self-perceived efficacy and stress on performance after TBI. They illustrate that intervention based oil real-life supports may be effective even many years post-TBI. Learning outcomes: At the conclusion of this article, readers will: ( 1) identify aspects of executive function that relate to communication in the work-place, (2) describe the steps in considering intervention within a single subject research design framework, and (3) consider the effects of stress and perceived self-efficacy on performance of communication tasks. (C) 2002 Elsevier Science Inc. All rights reserved.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA	Turkstra, LS (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.	lst2@po.cwru.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-00163] Funding Source: Medline		Armor DA, 1998, ADV EXP SOC PSYCHOL, V30, P309, DOI 10.1016/S0065-2601(08)60386-X; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GROSS TF, 1980, J EDUC PSYCHOL, V72, P605; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hoffman KB, 2000, J ABNORM PSYCHOL, V109, P651, DOI 10.1037//0021-843X.109.4.651; Isaki E, 2000, BRAIN INJURY, V14, P441; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; KRATOCHWILL TR, 1984, RES METHODS CLIN PSY, P55; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; LLOYD LF, 1994, BRAIN INJURY, V8, P529, DOI 10.3109/02699059409151005; MacDonald S, 1998, FUNCTIONAL ASSESSMEN; MALEC EA, 1991, NEUROPSYCHOLOGY, V5, P29, DOI DOI 10.1037/0894-4105.5.1.29; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Newcomer JW, 1999, ARCH GEN PSYCHIAT, V56, P527, DOI 10.1001/archpsyc.56.6.527; Oberg L, 1998, J HEAD TRAUMA REHAB, V13, P44, DOI 10.1097/00001199-199806000-00005; Prigatano G.P, 1988, BNI Q, V4, P40; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Scott C. M., 1988, LATER LANGUAGE DEV A, P49; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spitzer R. L., 1994, DSM 4 CASEBOOK LEARN; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; TAYLOR SE, 1988, PSYCHOL BULL, V103, P193, DOI 10.1037/0033-2909.103.2.193; WEBSTER, 1996, WEBSTERS COLL DICT; Ylvisaker M., 1998, COLLABORATIVE BRAIN	31	12	12	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	NOV-DEC	2002	35	6					467	482	PII S0021-9924(02)00118-1	10.1016/S0021-9924(02)00118-1			16	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	615YB	WOS:000179274000001	12443048				2021-06-18	
J	Alaca, R; Yilmaz, B; Gunduz, S				Alaca, R; Yilmaz, B; Gunduz, S			Anterior hypopituitarism with unusual delayed onset of diabetes insipidus after penetrating head injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; neuroendocrine dysfunctions; diabetes insipidus; anterior hypopituitarism	LESIONS	Neuroendocrine dysfunctions are among the various complications that occur after traumatic brain injury. We report a case of onset of diabetes insipidus during acute rehabilitation of a 20-yr-old patient with a traumatic brain injury caused by a gunshot wound. Our case is the latest onset of diabetes insipidus after traumatic brain injury that has been reported in the literature.	Gulhane Mil Med Acad, Dept Phys Med & Rehabil, Ankara, Turkey; Gulhane Mil Med Acad, Rehabil & Care Ctr, Ankara, Turkey	Alaca, R (corresponding author), TSK Rehabil Bakim Merkezi, TR-06530 Bilkent, Turkey.		YILMAZ, Bilge/W-6481-2019; YILMAZ, Bilge/A-7428-2013	YILMAZ, Bilge/0000-0003-1173-9399; YILMAZ, Bilge/0000-0003-1173-9399			BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; BARZILAY Z, 1988, J MED, V19, P47; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; HADANI M, 1985, J NEUROSURG, V63, P456, DOI 10.3171/jns.1985.63.3.0456; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; KAWAI K, 1995, J NEUROSURG, V83, P368, DOI 10.3171/jns.1995.83.2.0368; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LEE SC, 1994, BRAIN INJURY, V8, P571; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; TATOIAN JA, 1975, J ORAL SURG, V33, P548; ZACHARIADES N, 1982, ORAL SURG ORAL MED O, V53, P141, DOI 10.1016/0030-4220(82)90278-X	13	12	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2002	81	10					788	791		10.1097/00002060-200210000-00013			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	599KA	WOS:000178332500011	12362120				2021-06-18	
J	Das-Gupta, R; Turner-Stokes, L				Das-Gupta, R; Turner-Stokes, L			Traumatic brain injury	DISABILITY AND REHABILITATION			English	Article							DISABILITY RATING-SCALE; HETEROTOPIC OSSIFICATION; HEAD-INJURY; REHABILITATION; ADULTS	Purpose: Traumatic brain injury (TBI) leading to severe disability is fortunately rare. but when it occurs, the effect on patients and their families can be devastating. Issue: In the UK at the current time, there are insufficient specialist rehabilitation services to cater for the case-load and many patients receive their care in general wards. Conclusion: This educational article outlines the principles of management of severe TBI from a practical clinical viewpoint, reviews briefly the evidence for effectiveness of rehabilitation and offers an approach to consistent outcome measurement.	Northwick Pk Hosp & Clin Res Ctr, Harrow HA1 3UJ, Middx, England	Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Watford Rd, Harrow HA1 3UJ, Middx, England.	lynne.turner-stokes@kcl.ac.uk	Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Banovac K, 2000, J Spinal Cord Med, V23, P40; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Creedon SD, 1997, INT J REHABIL HLTH, V3, P171; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P59; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P133; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRONWALL D, 1975, LANCET, V2, P995; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HARVEY RF, 1983, ARCH PHYSICAL MED RE, V64, P868; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Keenan MAE, 1996, J HEAD TRAUMA REHAB, V11, P8, DOI 10.1097/00001199-199608000-00004; Ko C K, 1997, Br J Hosp Med, V58, P400; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MAHONEY F I, 1965, Md State Med J, V14, P61; MARTIN J, 1 OFF POP CONS SURV; MCLELLAN DL, 1998, REHABILITATION TRAUM; MCQUEEN JD, 1974, SURG NEUROL, V2, P271; Medical Research Council, 1976, AIDS EX PER NERV SYS; Nyein K, 1999, CLIN REHABIL, V13, P56, DOI 10.1191/026921599701532135; Pistarini Caterina, 1995, Recenti Progressi in Medicina, V86, P483; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rice-Oxley M, 2000, CLIN REHABIL, V14, P548, DOI 10.1191/0269215500cr359oa; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHIERHOUT G, 2000, COCHRANE LIB, V4; Schurch B, 1997, ARCH PHYS MED REHAB, V78, P687, DOI 10.1016/S0003-9993(97)90074-5; SHEIL A, 2000, CLIN REHABIL, V14, P408; SHIEL A, 1998, CLIN REHABIL, V13, P76; SLADE A, 1998, CLIN REHABIL, V13, P80; Sosnowski C, 1994, J Neurosci Nurs, V26, P336; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; TENNANT A, 1995, TRAUMATIC BRAIN INJU; Thomas B J, 1987, Hip, P59; TRUDELLE JL, 1990, BRAIN INJURY, V4, P305; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; TurnerStokes L, 1997, CLIN REHABIL, V11, P306, DOI 10.1177/026921559701100407; TURNERSTOKES L, 1999, CLIN REHABILITATIO S, V13; Wade DT, 1992, MEASUREMENT NEUROLOG; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; Young B, 1991, Neurosurg Clin N Am, V2, P301; 1995, SEVERE HEAD INJURIES	54	12	12	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	SEP 10	2002	24	13					654	665		10.1080/09638280110109282			12	Rehabilitation	Rehabilitation	594CE	WOS:000178030500002	12296981				2021-06-18	
J	Nathoo, N; Chite, SH; Edwards, PJ; van Dellen, JR				Nathoo, N; Chite, SH; Edwards, PJ; van Dellen, JR			Civilian infratentorial gunshot injuries: Outcome analysis of 26 patients	SURGICAL NEUROLOGY			English	Article						civilian; infratentorial missile; outcome; hydrocephalus; treatment	PENETRATING CRANIOCEREBRAL INJURIES; CEREBRAL MISSILE INJURY; PRACTICAL SCALE; WOUNDS; BRAIN; HEAD; PROGNOSIS; MORTALITY; SERIES; MODEL	BACKGROUND Craniocerebral missile injuries have steadily increased to become the most common form of penetrating neurotrauma in our environment resulting in continued morbidity and neuropsychological sequelae. Civilian infratentorial gunshot injuries are uncommon but generally regarded as fatal injuries, with many patients dying before reaching hospital. METHODS A retrospective analysis of 1,069 patients with civilian gunshot wounds (GSW), admitted to our unit over a 14-year period (1986-2000), identified 26 patients with infratentorial gunshot injuries (2.4%). A detailed analysis of these patients was carried out, which included demographic factors, clinical and anatomic correlation, computed tomography scans, surgical management, and outcome. RESULTS All patients were male. The mean age was 26.5 +/- 11.5 years and the mean admission Glasgow Coma Score 11.8 +/- 2.7. Twenty-four of 26 patients required cerebrospinal fluid (CSF) diversion to control secondary hydrocephalus. The second commonest surgical procedure was posterior fossa decompression. Five of 26 patients died (19.2%). Severe morbidity was noted in 9 of 21 surviving patients (42.8%). Significant predictors: good outcome was associated with primary missile entry of the infratentorial compartment (p = 0.005), while patients with supratentorial to infratentorial missile trajectory were noted to have a poorer outcome (p = 0.041). Location of cerebellar injury (lateral or medial) and missile caliber had no significant influence on patient outcome. CONCLUSION Early control of incipient or established hydrocephalus and aggressive surgical management where appropriate, with careful postoperative monitoring, is necessary for good outcome in patients with civilian infratentorial missile injuries. (C) 2002 by Elsevier Science Inc.	Wentworth Provincial Hosp, Dept Neurosurg, ZA-4026 Durban, South Africa; Univ KwaZulu Natal, Nelson R Mandela Sch Med, Durban, South Africa; UCL, Inst Child Hlth, London, England; Charing Cross Hosp, W London Neurosci Ctr, London, England; Charing Cross Hosp, Imperial Coll, Sch Med, London, England	Nathoo, N (corresponding author), Wentworth Provincial Hosp, Dept Neurosurg, Private Bag Jacobs, ZA-4026 Durban, South Africa.			Edwards, Phil/0000-0003-4431-8822			AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; CROCKARD HA, 1975, J TRAUMA, V15, P339, DOI 10.1097/00005373-197504000-00011; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; Cushing H, 1918, BRIT J SURG, V5, P558; GERBER AM, 1972, J NEUROSURG, V36, P43, DOI 10.3171/jns.1972.36.1.0043; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; Nadvi SS, 1997, NEUROSURGERY, V41, P61, DOI 10.1097/00006123-199707000-00013; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; NAROTAM PK, 1995, J NEUROSURG, V82, P406, DOI 10.3171/jns.1995.82.3.0406; Nathoo N, 2000, NEUROSURGERY, V47, P1117, DOI 10.1097/00006123-200011000-00018; Nathoo N, 1997, NEUROSURGERY, V41, P1263, DOI 10.1097/00006123-199712000-00005; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, NEUROTRAUMA, V9, pS279; SHOUNG HM, 1985, ACTA NEUROCHIR, V74, P27, DOI 10.1007/BF01413272; STONE JL, 1991, NEUROSURGERY, V128, P603; TEASDALE G, 1974, LANCET, V2, P81	29	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	SEP-OCT	2002	58	3-4					225	233	PII S0090-3019(02)00828-5	10.1016/S0090-3019(02)00828-5			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	625RE	WOS:000179828700009	12480225				2021-06-18	
J	Glass, TF; Reeves, B; Sharp, FR				Glass, TF; Reeves, B; Sharp, FR			Modeling both the mechanical and hypoxic features of traumatic brain injury in vitro in rats	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; hypoxia; ischemia; model; neuron; axon; death	QUANTITATIVE-DETERMINATION; INDUCIBLE FACTOR-1; NEURONAL INJURY; CELL-CULTURE; ASSAY	In traumatic brain injury, the brain is subjected to mechanical shear and varying degrees of hypoxia/ischemia. To compare effects of stretch injury, hypoxia, and the combination of both insults on neurons, mixed neuronal and astrocytic cultures were established from day 17 fetal rat brains. On days 17-19 in vitro, cultures were subjected to stretch injury or hypoxia of varying degrees, alone and in combination. Cultures were assayed for lactate dehydrogenase release and Trypan Blue uptake. Hypoxia or Stretch injury alone induced a graded response (P < 0.05) on both assays. Stretch + Hypoxia (4 or 6 h) resulted in significantly greater injury as compared with controls (P < 0.05), and as compared with either isolated Stretch or Hypoxia (1, 2, 4 or 6 h) alone (P < 0.05). (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Childrens Hosp, Med Ctr, Dept Pediat Emergency Med, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Neurosci Program, Cincinnati, OH 45267 USA	Glass, TF (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat Emergency Med, Locat C 2008,3333 Burnet Ave, Cincinnati, OH 45229 USA.	glast0@chmcc.org					Allen JW, 1999, FASEB J, V13, P1875; Boswell WC, 1996, SOUTHERN MED J, V89, P218, DOI 10.1097/00007611-199602000-00012; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Uliasz TF, 2000, J NEUROSCI METH, V100, P157, DOI 10.1016/S0165-0270(00)00248-X	14	12	13	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 9	2002	328	2					133	136	PII S0304-3940(02)00510-4	10.1016/S0304-3940(02)00510-4			4	Neurosciences	Neurosciences & Neurology	585JA	WOS:000177520600015	12133573				2021-06-18	
J	Wedekind, C; Hesselmann, V; Klug, N				Wedekind, C; Hesselmann, V; Klug, N			Comparison of MRI and electrophysiological studies for detecting brainstem lesions in traumatic brain injury	MUSCLE & NERVE			English	Article						brainstem auditory evoked potential (BAEP); brainstern reflexes; magnetic resonance imaging (MRI); traumatic brain injury		The yield of magnetic resonance imaging (MRI) and electrophysiological studies in detecting brainstem lesions was assessed in 35 patients suffering from traumatic brain injury (Glasgow Coma Scale, 3-10). As an inclusion criterion, all patients had brainstem trauma as revealed by early MRI or electrophysiological studies. Of the 35 cases, 7 (20%) had brainstem lesions detected by MRI only, whereas in 10 patients (29%), electrophysiological examination disclosed impairment of brainstem function with normal MRI. In 18 (51%) subjects, both diagnostic techniques revealed brainstem lesions. The midbrain was the most common location of lesions. Masseter reflex recording had the highest yield (93%) of abnormal findings. No mismatch with respect to site and side of abnormality occurred between MRI and electrophysiological studies. Outcome analysis indicated an unfavorable course for the vast majority (83%) of patients, regardless of the diagnostic means disclosing traumatic brainstem injury. Therefore, both techniques are effective in disclosing traumatic brainstem injury, with diagnostic overlap in about 50% of cases. In contrast to MRI, electrophysiological investigation is easily performed and repeated at low cost in the setting of an intensive care unit, where such patients are typically hospitalized after trauma. In addition to electrophysiological assessment of brainstem function, MRI is recommended in each case having normal electrophysiological findings when brainstem injury is suspected. (C) 2002 Wiley Periodicals, Inc.	Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany; Univ Cologne, Dept Radiol, D-50924 Cologne, Germany	Wedekind, C (corresponding author), Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany.	drchrwedekind@web.de					Chiappa K.H., 1997, EVOKED POTENTIALS CL; COMI G, 1993, EUR NEUROL, V33, P232, DOI 10.1159/000116943; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; HOPF HC, 1994, MUSCLE NERVE, V17, P475, DOI 10.1002/mus.880170502; JENNETT B, 1975, LANCET, V1, P480; Kimura J., 1989, ELECTRODIAGNOSIS DIS, V2nd ed.; SACHS L, 1997, ANGEWNADTE STAT; SALCMAN M, 1992, NEUROCHIRURGIE, V38, P329; THOEMKE F, 1994, Z EEG EMG, V25, P259; Thomke F, 1999, J NEUROL NEUROSUR PS, V66, P340, DOI 10.1136/jnnp.66.3.340; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010	12	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve	AUG	2002	26	2					270	273		10.1002/mus.10187			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	580LR	WOS:000177236500014	12210392				2021-06-18	
J	Rollins, S; Perkins, E; Mandybur, G; Zhang, JH				Rollins, S; Perkins, E; Mandybur, G; Zhang, JH			Oxyhemoglobin produces necrosis, not apoptosis, in astrocytes	BRAIN RESEARCH			English	Article						apoptosis; OxyHb; astrocyte; necrosis	SMOOTH-MUSCLE CELLS; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL ENDOTHELIAL-CELLS; RAT-BRAIN; DNA FRAGMENTATION; HEME OXYGENASE-1; LYSED BLOOD; HEMOGLOBIN; VASOSPASM	Objective: Subarachnoid blood, resulting from traumatic brain injury or subarachnoid hemorrhage, has been linked with cell injury and stress gene induction. We investigated whether oxyhemoglobin (OxyHb), a major component in blood clots, exerts a cytotoxic effect on cultured astrocyte cells, and the pattern of cell death. Methods: A murine astrocyte cell line was used (passages 28-35). Cell growth studies were performed 24, 48, and 72 h after exposure to OxyHb (1, 10, and 30 muM). Western blot analysis of poly adenosine diphosphate [ADP]-ribose polymerase (PARP) cleavage and TUNEL stain analysis were performed to determine the presence of apoptosis. Cells treated with OxyHb were also evaluated with transmission electron microscopy to determine changes that may have occurred at the ultra-structural level. Results: OxyHb (10-30 muM), after 72-h incubation, inhibited cell growth. Western blot analysis of PARP and TUNEL staining for the presence of apoptosis were essentially negative in all groups. Ultrastructural analysis revealed an abundance of necrosis and random occurrences of apoptosis in a few cells. Conclusion: Cultured astrocytes exposed to OxyHb causing cell growth inhibition could possibly be a result of cellular cytotoxicity and necrosis. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA	Zhang, JH (corresponding author), LSU Hlth Sci Ctr, Dept Neurosurg, 1501 Kings Highway, Shreveport, LA 71130 USA.						Chen JW, 2000, J BIOMED SCI, V7, P459, DOI 10.1007/BF02253361; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Findlay JM, 1997, CAN J NEUROL SCI, V24, P161; FOLEY PL, 1994, J NEUROSURG, V81, P87, DOI 10.3171/jns.1994.81.1.0087; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Kwan Aij Lie, 1997, Kaohsiung Journal of Medical Sciences, V13, P67; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; MACDONALD RL, 1991, J NEUROSURG, V75, P415, DOI 10.3171/jns.1991.75.3.0415; Maiese K, 1997, ANN NY ACAD SCI, V835, P255, DOI 10.1111/j.1749-6632.1997.tb48636.x; Maiese K, 2000, CELL MOL NEUROBIOL, V20, P383, DOI 10.1023/A:1007070311203; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Matz PG, 1996, J NEUROSURG, V85, P892, DOI 10.3171/jns.1996.85.5.0892; Matz PG, 2000, STROKE, V31, P2450, DOI 10.1161/01.STR.31.10.2450; Matz PG, 2000, BRAIN RES, V858, P312, DOI 10.1016/S0006-8993(99)02454-3; Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615; Meguro T, 2001, STROKE, V32, P561, DOI 10.1161/01.STR.32.2.561; Meguro T, 2000, J NEUROSURG, V93, P640, DOI 10.3171/jns.2000.93.4.0640; Meguro T, 2001, J NEUROCHEM, V77, P1128, DOI 10.1046/j.1471-4159.2001.00313.x; MISRA HP, 1972, J BIOL CHEM, V247, P6960; Mori T, 2001, STROKE, V32, P636, DOI 10.1161/01.STR.32.3.636; Ogihara K, 2000, ACT NEUR S, V76, P507; Ogihara K, 2001, BRAIN RES, V889, P89, DOI 10.1016/S0006-8993(00)03120-6; Ogihara K, 1999, J NEUROSURG, V91, P459, DOI 10.3171/jns.1999.91.3.0459; PETERSON JW, 1990, J NEUROSURG, V72, P775, DOI 10.3171/jns.1990.72.5.0775; Pluta RM, 1998, J NEUROSURG, V88, P557, DOI 10.3171/jns.1998.88.3.0557; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Stoodley M, 2000, J NEUROSURG, V93, P463, DOI 10.3171/jns.2000.93.3.0463; TAKENAKA K, 1993, STROKE, V24, P839, DOI 10.1161/01.STR.24.6.839; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VOLLRATH BAM, 1994, J NEUROSURG, V80, P261, DOI 10.3171/jns.1994.80.2.0261; Wang XY, 1999, NEUROSCI LETT, V274, P79, DOI 10.1016/S0304-3940(99)00682-5; Weir B, 1999, ACT NEUR S, V72, P27; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Yip S, 2000, BRAIN RES, V864, P1, DOI 10.1016/S0006-8993(00)02067-9; Zhang H, 1996, J PHARMACOL EXP THER, V277, P1501; Zhang H, 1995, AM J PHYSIOL-HEART C, V269, pH1874; Zubkov AY, 2000, SURG NEUROL, V53, P260, DOI 10.1016/S0090-3019(99)00187-1	42	12	13	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 26	2002	945	1					41	49	PII S0006-8993(02)02562-3	10.1016/S0006-8993(02)02562-3			9	Neurosciences	Neurosciences & Neurology	580FK	WOS:000177224300006	12113950				2021-06-18	
J	Hawkins, KA; Plehn, K; Borgaro, S				Hawkins, KA; Plehn, K; Borgaro, S			Verbal IQ-performance IQ differentials in traumatic brain injury samples	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						verbal IQ; performance IQ; traumatic brain injury	ADULT INTELLIGENCE SCALE; HEAD-INJURY; WAIS-R; MILD; DYSFUNCTION	Several studies of head trauma utilizing the Wechsler Adult Intelligence Scale (WAIS) reported large sample differentials between verbal IQ (VIQ) and performance IQ (PIQ), leading some writers to claim that the VIQ is largely unaffected by traumatic brain injury (TBI), and that a superiority of VIQ over PIQ should be expected. In contrast, our review of Wechsler Adult Intelligence Scale-Revised (WAIS-R) studies indicates that although TBI sample PIQ means are often depressed relative to VIQ means, the differences are small and sometimes in the opposite direction. Possible reasons for the discrepancy between our WAIS-R review and those of an earlier review of WAIS studies are discussed. Clinically, the lack of a VIQ-PIQ difference should never be used to infer that a TBI has not occurred. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA	Hawkins, KA (corresponding author), CMHC, Room 530,34 Pk St, New Haven, CT 06519 USA.	keith.hawkins@yale.edu		Hawkins, Keith/0000-0003-3494-2103			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BORNSTEIN RA, 1983, J CONSULT CLIN PSYCH, V51, P779, DOI 10.1037/0022-006X.51.5.779; BORNSTEIN RA, 1982, J CLIN NEUROPSYCHOL, V4, P319, DOI 10.1080/01688638208401140; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P345, DOI 10.1080/13854049708400463; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FARR SP, 1986, HDB CLIN NEUROPSYCHO, P213; Gazzaniga M.S., 1998, COGNITIVE NEUROSCIEN; Guilmette TJ, 1999, ASSESSMENT, V6, P33, DOI 10.1177/107319119900600104; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; HAWKINS KA, 1994, CLIN NEUROPSYCHOL, V8, P394, DOI 10.1080/13854049408402042; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kaufman A. S., 1990, ASSESSING ADOLESCENT; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kraiuhin C, 1996, BRAIN INJURY, V10, P677, DOI 10.1080/026990596124098; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Matarazzo JD, 1972, WECHSLERS MEASUREMEN; MATTIS PJ, 1994, J CLIN PSYCHOL, V50, P605, DOI 10.1002/1097-4679(199407)50:4<605::AID-JCLP2270500418>3.0.CO;2-V; MOORE AD, 1993, CAN J BEHAV SCI, V25, P605, DOI 10.1037/h0078849; PANIAK CE, 1992, J CLIN PSYCHOL, V48, P219, DOI 10.1002/1097-4679(199203)48:2<219::AID-JCLP2270480212>3.0.CO;2-K; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; *PSYCH CORP, 1997, WAIS 2 WMS 3 TECHN M; WARRINGTON EK, 1986, NEUROPSYCHOLOGIA, V24, P223, DOI 10.1016/0028-3932(86)90055-2; Wechsler D., 1958, MEASUREMENT APPRAISA	24	12	12	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2002	17	1					49	56		10.1016/S0887-6177(00)00099-8			8	Psychology, Clinical; Psychology	Psychology	504XD	WOS:000172880700004	14589752	Bronze			2021-06-18	
J	Berthier, ML; Posada, A; Puentes, C				Berthier, ML; Posada, A; Puentes, C			Dissociative flashbacks after right frontal injury in a Vietnam veteran with combat-related posttraumatic stress disorder	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; POSITRON EMISSION TOMOGRAPHY; CHILDHOOD SEXUAL ABUSE; SCRIPT-DRIVEN IMAGERY; CEREBRAL BLOOD-FLOW; ANXIETY DISORDERS; MEMORIES; SPECT; CORTEX; RECALL	A Vietnam veteran with a combat-related post-traumatic stress disorder developed recurrent dissociative flashbacks (related to the atrocities of a specific war incident) several months after suffering a traumatic brain injury. CT disclosed a small lesion in the right dorsolateral prefrontal cortex. SPECT demonstrated more extensive functional changes in prefrontal and anterior paralimbic brain regions, mainly in the right hemisphere. This case further implicates the provocative effect of physical stimuli (brain damage) in reawakening old dormant memories and the preferential role of the right hemisphere for the storage of traumatic memories.	Univ Malaga, Dept Med & Dermatol, Fac Med, E-29071 Malaga, Spain; Carlos Haya Univ Hosp, Dept Radiol, Nucl Med Serv, Malaga, Spain	Berthier, ML (corresponding author), Univ Malaga, Dept Med & Dermatol, Fac Med, Campus Univ Teatinos, E-29071 Malaga, Spain.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1995, AM J PSYCHIAT, V152, P963; BAUER RM, 1993, CLIN NEUROPSYCHOLOGY, P523; Berthier M L, 1998, Depress Anxiety, V8, P43, DOI 10.1002/(SICI)1520-6394(1998)8:1<43::AID-DA9>3.0.CO;2-6; Berthier ML, 1997, EUR J NEUROL, V4, P551, DOI 10.1111/j.1468-1331.1997.tb00405.x; Bremner JD, 1997, ARCH GEN PSYCHIAT, V54, P246; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; BREMNER JD, 1993, AM J PSYCHIAT, V150, P235; BRIGGS AC, 1993, BRIT J PSYCHIAT, V163, P828, DOI 10.1192/bjp.163.6.828; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; CASSIDAY KL, 1992, J TRAUMA STRESS, V5, P627, DOI 10.1007/BF00979230; DAVIDOFF DA, 1988, COGNITIVE REHABI MAR, P8; DECRISTOFARO MTR, 1993, BIOL PSYCHIAT, V33, P505, DOI 10.1016/0006-3223(93)90004-W; DOERFLER LA, 1994, GEN HOSP PSYCHIAT, V16, P193, DOI 10.1016/0163-8343(94)90101-5; Epstein Richard S., 1994, P285; Fink GR, 1996, J NEUROSCI, V16, P4275; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FREEMAN TW, 2000, J NEUROPSYCHIATRY CL, V13, P99; GOENJIAN AK, 1994, ACTA PSYCHIAT SCAND, V90, P214, DOI 10.1111/j.1600-0447.1994.tb01580.x; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Krikorian R, 1998, J NEUROPSYCH CLIN N, V10, P359, DOI 10.1176/jnp.10.3.359; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; MAYBERG HS, 1994, J NUCL MED, V35, P929; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; O'Brien M, 1998, BRIT J PSYCHIAT, V173, P102, DOI 10.1192/bjp.173.2.102; Rauch SL, 1996, ARCH GEN PSYCHIAT, V53, P380; SAIGH PA, 1992, BRIT J PSYCHIAT, V161, P704, DOI 10.1192/bjp.161.5.704; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHIFFER F, 1995, J NEUROPSYCH CLIN N, V7, P169; Shin LM, 1999, AM J PSYCHIAT, V156, P575; SOUTHWICK SM, 1994, PSYCHIAT CLIN N AM, V17, P251; Spitzer RL, 1990, STRUCTURED CLIN INTE; TOMB DA, 1994, PSYCHIAT CLIN N AM, V17, P237; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; WOODS SW, 1992, J CLIN PSYCHIAT, V53, P20	40	12	13	0	1	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2001	13	1					101	105		10.1176/appi.neuropsych.13.1.101			5	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	401TR	WOS:000166944800014	11207336				2021-06-18	
J	Dumas, HM; Haley, SM; Rabin, JP				Dumas, HM; Haley, SM; Rabin, JP			Short-term durability and improvement of function in traumatic brain injury: a pilot study using the Paediatric Evaluation of Disability Inventory (PEDI) classification levels	BRAIN INJURY			English	Article							CHILDREN; ADOLESCENTS; PERFORMANCE; RECOVERY; COHORT	Primary objective: To describe the short-term durability and improvement of functional outcomes for children and adolescents with traumatic brain injury (TBI) up to 6 months after discharge from inpatient rehabilitation. Research design: Retrospective, descriptive. Methods and procedures: Twenty-five (28.1%) of 89 children discharged from inpatient rehabilitation were available for outpatient follow-up within 6 months. The Paediatric Evaluation of Disability Inventory (PEDI) functional skill classification levels in the domains of self-care, mobility, and social function, recorded at discharge and follow-up, were examined using the Wilcoxon matched pairs signed rank test (two-tailed). Main outcomes and results: Most (64-80%) of the children sustained the outcome level achieved at hospital discharge in one or more of the three domains. Significant differences (p<0.05) from discharge to follow-up were detected in mobility and social function levels. Differences between children with and without follow-up were non-significant in all but one variable (social function level at hospital discharge). Conclusions : The results of this study suggest that children after TBI sustain outcomes achieved during inpatient rehabilitation and make significant gains in mobility and social function skills within 6 months of returning home. More research is needed to predict those children who will continue to recover and to identify factors that facilitate recovery in the community setting.	Franciscan Childrens Hosp & Rehabil Ctr, Boston, MA 02135 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA	Dumas, HM (corresponding author), Franciscan Childrens Hosp & Rehabil Ctr, 30 Warren St, Boston, MA 02135 USA.	fchcenter@tiac.net					BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; CARNEY J, 1994, PEDIATR ANN, V23, P47, DOI 10.3928/0090-4481-19940101-10; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Cockrell J. L., 1990, COMMUNITY INTEGRATIO, P287; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Haley S. M., 1993, PHYS MED REH CLIN N, V4, P529; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; HALEY SM, 1992, PEDIAT PHYS THERAPY, V4, P24; Haley SM, 1992, PAEDIAT EVALUATION D; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; Ottenbacher KJ, 1999, DEV MED CHILD NEUROL, V41, P186, DOI 10.1017/S0012162299000377; Proctor EK, 1995, SOC WORK HEALTH CARE, V22, P1, DOI 10.1300/J010v22n01_01; SILVER BV, 1994, ARCH PHYS MED REHAB, V75, P742; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; *TRAC, 2000, MED REH STAND MAN; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wright FV, 1993, CAN J REHABIL, V7, P41; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447	26	12	12	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2001	15	10					891	902		10.1080/02699050110065691			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483HF	WOS:000171627000005	11595085				2021-06-18	
J	Williams, G; Goldie, P				Williams, G; Goldie, P			Validity of motor tasks for predicting running ability in acquired brain injury	BRAIN INJURY			English	Article							PROFILE	Introduction: Rehabilitation of running following traumatic brain injury (TBI) has the potential to enhance quality of life. Retraining of running following TBI has not been previously reported in the literature. In response to a lack of information about which motor tasks should be included in a retraining programme, this study aimed to investigate performance predictors of running ability. Method: Forty TBI subjects (20 runners and 20 non-runners) performed four specific motor tasks which were selected on the basis of theory and clinical experience with TBI subjects. The four tasks included bounding onto a leg, walking on toes, stepping backwards up a step, and balancing on one leg. Subjects were generally extremely severely brain damaged (median post-traumatic amnesia > 28 days), had suffered multiple leg fractures and had received greater than 8 months rehabilitation. Results: The four motor tasks differentiated significantly between the two groups (p < 0.001) and were all strong predictors of running ability. The presence of a non-support phase (NSP) during the bounding task was the strongest predictor of running ability. Logistic regression indicated that TBI subjects who could execute a NSP into a single bound were 24.6 times more likely to be able to run than subjects who could not. When the four tasks were used in combination, two tasks were identified by logistic regression: (1) ability to execute a free-float phase during a bound, and (2) balancing on one leg. All four motor tasks had high retest reliability, with proportional indices of reliability ranging from 0.92-0.97. No statistically significant difference was found between runners and non-runners for group charateristics such as age, severity of injury (length of PTA), orthopaedic leg injuries and time post-injury (p > 0.05). These characteristics were not shown to influence the ability to run following TBI. Clinical implications: The four motor tasks were strong predictors of running ability. Severity and type of injury were not factors influencing ability to run. This study provides preliminary evidence about the motor tasks which have the potential to be used in a running programme. No casual relationship has been identified. The next step is to investigate whether training in these tasks is effective in the rehabilitation of running following TBI.	Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; La Trobe Univ, Fac Hlth Sci, Sch Physiotherapy, Bundoora, Vic, Australia	Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 29 Erin St, Richmond, Vic 3121, Australia.			Williams, Gavin/0000-0003-2758-7473			BAYLEY N, 1919, MANUAL BAYLEY SALES; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BRUININKS RH, 1978, BRUININKSOSERETSKY T; BURDON B, 1993, AUSTR DEV SCREENING; Folio M. R., 1983, PEABODY DEV MOTOR SC; FRANKENBURG WK, 1975, REVISED DENVER DEV S; GALLAGHUE DL, 1982, UNDERSTANDING MOTOR; Guttman L., 1950, MEASUREMENT PREDICTI; Hillier SL, 1997, BRAIN INJURY, V11, P661; Lincoln N, 1979, Physiotherapy, V65, P48; LUKE C, THESIS LA TROBE U ME; Miller L. J., 1994, TIME TODDLER INFANT; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Roberton M.A, 1984, DEV CHILDREN THEIR C; Russell D., 1993, GROSS MOTOR FUNCTION; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Wickstrom R., 1983, FUNDAMENTAL MOTOR PA; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003	19	12	12	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					831	841					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400008	11516351				2021-06-18	
J	Arenth, PM; Bogner, JA; Corrigan, JD; Schmidt, L				Arenth, PM; Bogner, JA; Corrigan, JD; Schmidt, L			The utility of the Substance Abuse Subtle Screening Inventory-3 for use with individuals with brain injury	BRAIN INJURY			English	Article							ALCOHOL-ABUSE; SETTINGS	The utility of the Substance Abuse Subtle Screening Inventory (SASSI-3) for the use with individuals with traumatic brain injuries (TBI) was investigated. The SASSI-3 was administered to 78 subjects prior to discharge from inpatient rehabilitation. The SASSI-3 diagnosis of chemical dependency was compared with the diagnosis of staff psychologists. Lower accuracy, sensitivity, and specificity were found in SASSI-3 diagnosis for the subjects with brain injury, as compared to a normative sample of persons with disabilities participating in a vocational rehabilitation programme. When a diagnosis of 'dependence or abuse' was used, accuracy of the SASSI-3 increased. Comparison of diagnosis based on SASSI-3 versus Blood Alcohol Level (BAL) at the time of injury showed comparable accuracy; however, BAL was found to have higher specificity. For dependence or abuse, BAL continued to be more specific than the SASSI-3; however, the SASSI-3 was more sensitive. Based on these findings, a clinical approach to screening using both BAL and the SASSI-3 is discussed.	Ohio State Univ, Columbus, OH 43210 USA	Bogner, JA (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BABOR TF, 1989, ADDICT BEHAV, V14, P139, DOI 10.1016/0306-4603(89)90043-9; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1999, TRAUM BRAIN INJ PUBL; EWING J, 1970, 29 INT C ALC DRUG DE; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Horrigan T J, 1996, J Perinatol, V16, P326; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Lazowski LE, 1998, J PERS ASSESS, V71, P114, DOI 10.1207/s15327752jpa7101_8; MAGRUDERHABIB K, 1991, J FAM PRACTICE, V32, P406; MILLER FG, 1997, SASSI 3 USERS GUIDE; Miller G.A., 1985, SUBSTANCE ABUSE SUBT, V2nd; Selzer M. L., 1971, AM J PSYCHIAT, V127, P89; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004	18	12	12	0	7	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2001	15	6					499	510		10.1080/02699050010006002			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439VE	WOS:000169137600003	11394969				2021-06-18	
J	Gaudet, L; Crethar, HC; Burger, S; Pulos, S				Gaudet, L; Crethar, HC; Burger, S; Pulos, S			Self-reported consequences of traumatic brain injury: A study of contrasting TBI and non-TBI participants	SEXUALITY AND DISABILITY			English	Article						traumatic brain injury; cognition; ego adaptability; sexuality	DAMAGE	This study examined the affective and behavioral concerns of male and female adults in the areas of cognition, ego adaptability, and sexuality Participants were given two Likert-type questionnaires: affective and behavioral. Three two-way analyses of covariance (ANCOVA) compared the independent variables of gender and injury status to the dependent variables of cognition, ego adaptability, and sexuality. Results suggest that non-Traumatic Brain Injured (TBI) participants have more positive feelings about their cognition, ego adaptability, and sexuality than TBI participants. It was found that although female participants without TBI have more positive feelings about their sexuality than male participants without TBI, the opposite is true for TBI participants. Male participants with TBI had the most concerns about their sexuality of all four groups.	Chadron State Coll, Dept Psychol, Chadron, NE 69337 USA; PREL, Honolulu, HI USA; Univ No Colorado, Dept Educ Psychol, Greeley, CO 80639 USA	Gaudet, L (corresponding author), Chadron State Coll, Dept Psychol, 1000 Main St, Chadron, NE 69337 USA.						Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; GAUDET L, 1995, THESIS U NO COLORADO; KREUTZER SJ, 1989, BRAIN INJURY, V3, P177; Levin HS, 1989, MILD HEAD INJURY; LEVIN HS, 1989, MILD HEAD INJURY, P189; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P164; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; PARKER R, 1990, TRAUMATIC BRAIN INJU; Reitan RM., 1985, HALSTEAD REITAN NEUR; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WRIGHTSON P, 1989, MILD HEAD INJURY, P245	18	12	12	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0146-1044	1573-6717		SEX DISABIL	Sex. Disabil.	SUM	2001	19	2					111	119		10.1023/A:1010673722429			9	Rehabilitation	Rehabilitation	479VM	WOS:000171424300003					2021-06-18	
J	Swaine, BR; Friedman, DS				Swaine, BR; Friedman, DS			Activity restrictions as part of the discharge management for children with a traumatic head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; concussion; emergency department; head injury; intervention; trauma center	BRAIN-INJURY; MILD; CONCUSSION; ADOLESCENTS; SEIZURES; TRENDS	This article describes a proactive management strategy that is currently part of the discharge protocol for children seeking care for a head injury (HI) at a pediatric and adolescent trauma center. The strategy consists of setting activity restrictions for children hospitalized and those seen in the emergency department after a HI that may or not have been sports related. It was developed based on extensive clinical experiments with families of children with a HI and existing guidelines for returning athletes to sports. Possible merits and pitfalls of the strategy are discussed.	Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Ctr Interdisciplinary Res Rehabil, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Pediat Program, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Adolescent Neurotrauma & Trauma Program, Montreal, PQ, Canada	Swaine, BR (corresponding author), Univ Montreal, Fac Med, Ecole Readaptat, CP 6128,Succurasale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	bonnie.swaine@umontreal.ca					*AM MED ASS, 1990, OFF QUAL INS HLTH CA; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CASEY R, 1986, PEDIATRICS, V78, P497; CERNAN J, 1966, HEAD INJURY POSTCONC; *COL MED SOC, 1991, REP SPORTS MED COMM; DAVIES RL, 1995, PEDIATRICS, V95, P345; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; GREENSPAN A, 1996, CURR PROB PEDIAT MAY, P170; GRONWALL D, 1975, LANCET, V2, P995; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Kelly JP, 1997, NEUROLOGY, V48, P581; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; MOSS NEG, 1994, CLIN REHABIL, V8, P149; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parker APJ, 1997, SEIZURE-EUR J EPILEP, V6, P499, DOI 10.1016/S1059-1311(97)80028-3; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; RIVARA FP, 1994, PEDIATR ANN, V23, P12, DOI 10.3928/0090-4481-19940101-06; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SWAINE B, 2000, ARCH PHYS MED REHAB, V81, P1617; WALLER J, 1980, PUBLIC HLTH PREVENTA; 1999, HEADLINE NEWS, V1; 1999, P 3 WORLD C BRAIN IN, P230	40	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2001	16	3					292	301		10.1097/00001199-200106000-00008			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	442YY	WOS:000169313600008	11346451				2021-06-18	
J	Yanagawa, Y; Marcillo, A; Garcia-Rojas, R; Loor, KE; Dietrich, WD				Yanagawa, Y; Marcillo, A; Garcia-Rojas, R; Loor, KE; Dietrich, WD			Influence of posttraumatic hypoxia on behavioral recovery and histopathological outcome following moderate spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						behavior; hypoxia; secondary insults; spinal cord injury	PERCUSSION BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; BLOOD-FLOW; AMINO-ACIDS; ULTRASTRUCTURAL EVIDENCE; SECONDARY DAMAGE; IMPACT INJURY; ANOXIC INJURY; HEAD-INJURY; TRAUMA	Pulmonary dysfunction leading to secondary hypoxia is a common complication of spinal cord injury (SCI). The purpose of this study was to clarify the behavioral and histopathological consequences of posttraumatic hypoxia in an established model of traumatic SCI. Forty-five female Sprague-Dawley rats were randomly assigned to one of four groups, including (1) laminectomy and normoxia (n = 10), (2) laminectomy and hypoxia (n = 11), (3) NYU weight-drop and normoxia (n 12), and (4) NYU weight-drop and hypoxia (n = 11). For these studies, a moderate injury was induced by adjusting the height of the weight drop (10 g) to 12.5 mm above the exposed spinal cord (T10). Immediately after injury, PaO2 in the hypoxic rats was kept between 30 and 35 mm Hg for 30 min. PaO2 in the normoxic group was maintained over 100 mm Hg, while PaCO2 in all rats was maintained at 35-40 mm Hg. The behavior of the rats was checked every 7 days using the Basso, Beattie, and Bresnahan (BBB) locomotor rating scale. Rats were sacrificed at 8 weeks for quantitative histopathological analysis of lesion areas. During the hypoxic insults, the mean arterial blood pressure dropped in both sham control and weight-drop rats (p < 0.01). At the end of the 8-week monitoring period, BBB scores were 12.5 +/- 3.1 (mean +/- SEM) and 14.2 +/- 3.4 in the normoxic and hypoxic traumatized rats, respectively. No significant difference between the traumatized groups was documented with BBB monitoring. In contrast, the percent of gray matter necrosis at the impact epicenter was significantly increased in hypoxic versus normoxic SCI rats (p < 0.01). These data demonstrate that posttraumatic hypoxia complicated by mild hypotension aggravates the histopathological consequences of SCI and further emphasize the need to control for secondary hypoxic insults after experimental and clinical SCI. Potential explanations for the lack of a correlation between the behavioral and histopathological findings are discussed.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, 1600 NW 10 Ave R-49, Miami, FL 33136 USA.	ddietrich@miami.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [38665] Funding Source: Medline		Agrawal SK, 1997, J NEUROSCI, V17, P1055; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1980, J NEUROSURG, V52, P387, DOI 10.3171/jns.1980.52.3.0387; Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; Atkinson PP, 1996, MAYO CLIN PROC, V71, P384, DOI 10.4065/71.4.384; BALENTINE JD, 1978, LAB INVEST, V39, P236; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; CAWTHON DF, 1980, J NEUROSURG, V52, P801, DOI 10.3171/jns.1980.52.6.0801; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CLANCY RR, 1989, ANN NEUROL, V25, P185, DOI 10.1002/ana.410250213; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COLES JC, 1986, ANN THORAC SURG, V41, P551, DOI 10.1016/S0003-4975(10)63040-8; CURZ J, 1998, CRIT CARE MED, V26, P344; DANIELISOVA V, 1990, NEUROLOGY, V40, P1125, DOI 10.1212/WNL.40.7.1125; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DeWitt D S, 1995, New Horiz, V3, P376; DOLAN EJ, 1982, J NEUROSURG, V56, P350, DOI 10.3171/jns.1982.56.3.0350; DUCKER TB, 1971, CURRENT TOP SURG RES, V3, P163; FADEN AI, 1982, NEUROLOGY, V32, P677, DOI 10.1212/WNL.32.6.677; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Feldman Z, 1997, J TRAUMA, V43, P667, DOI 10.1097/00005373-199710000-00017; Galley HF, 1999, CRIT REV CL LAB SCI, V36, P35, DOI 10.1080/10408369991239178; GEISLER FH, 1996, PRINCIPLES SPINAL SU, P769; Goldstein B, 1998, ARCH PHYS MED REHAB, V79, P107, DOI 10.1016/S0003-9993(98)90217-9; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALAT G, 1989, NEUROCHEM RES, V14, P1089, DOI 10.1007/BF00965615; Hall ED, 1991, J NEUROTRAUM, V8, P86; HUKUDA S, 1980, NEUROSURGERY, V6, P644, DOI 10.1227/00006123-198006000-00005; Kanellopoulos GK, 1997, STROKE, V28, P2532, DOI 10.1161/01.STR.28.12.2532; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LEMAY DR, 1987, J VASC SURG, V6, P383, DOI 10.1067/mva.1987.avs0060383; LEVY DE, 1975, ARCH NEUROL-CHICAGO, V32, P450, DOI 10.1001/archneur.1975.00490490054004; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P526, DOI 10.1038/jcbfm.1994.65; McAdoo DJ, 1997, J NEUROTRAUM, V14, P507, DOI 10.1089/neu.1997.14.507; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; PALLESKE H, 1969, Acta Neurochirurgica, V21, P319, DOI 10.1007/BF01402965; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; POE RH, 1978, J TRAUMA, V18, P71, DOI 10.1097/00005373-197801000-00016; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SANDLER AN, 1976, J NEUROSURG, V45, P660, DOI 10.3171/jns.1976.45.6.0660; SENTER HJ, 1978, J NEUROSURG, V49, P569, DOI 10.3171/jns.1978.49.4.0569; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SLACK RS, 1994, CLIN CHEST MED, V15, P739; SMITH AJK, 1978, J NEUROSURG, V48, P239, DOI 10.3171/jns.1978.48.2.0239; STYS PK, 1992, J NEUROSCI, V12, P430; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Taylor DL, 1999, BRAIN PATHOL, V9, P93; Tyroch AH, 1997, ARCH SURG-CHICAGO, V132, P778; Vannucci RC, 1998, J NEUROCHEM, V71, P1215; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; YOUNG W, 1993, RES P ARNMD, V71, P191; ZIVIN JA, 1980, STROKE, V11, P200, DOI 10.1161/01.STR.11.2.200	73	12	12	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					635	644		10.1089/089771501750291873			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800007	11437086				2021-06-18	
J	Bareyre, FM; Raghupathi, R; Saatman, KE; McIntosh, TK				Bareyre, FM; Raghupathi, R; Saatman, KE; McIntosh, TK			DNase I disinhibition is predominantly associated with actin hyperpolymerization after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; caspase; DNA fragmentation; head injury; rats	CELL-DEATH; DEOXYRIBONUCLEASE-I; TEMPORAL PROFILE; APOPTOSIS; RAT; FRAGMENTATION; CASPASE-3; CLEAVAGE; POLYMERIZATION; BINDING	To elucidate a role for the cytoskeletal protein actin in posttraumatic apoptotic cell death, the ability of actin-containing tissue extracts to inhibit exogenous DNase I was evaluated. In addition, cortical, hippocampal and thalamic extracts were examined for caspase-mediated actin cleavage and changes in actin polymerization state. Rats were anesthetized, subjected to lateral fluid percussion brain injury of moderate severity, and euthanized at 1 h, 6 h, 24 h, 1 week or 3 weeks post-injury (n = 3 per time-point). Tissue extracts from all brain regions of sham (uninjured) animals inhibited exogenous DNase I activity to a significant extent. However, inhibition of DNase I was significantly reduced at 1 h and 6 h in the injured hippocampus, and at 1, h, 6 h and 3 weeks in the thalamus. DNase I in cortical extracts of all injured animals was inhibited to a similar extent as that in uninjured animals. Actin fragments consistent with caspase-mediated proteolysis were observed in immunoblots of the injured hippocampus and thalamus at 1 h and 24 h, respectively, and were present up to 3 weeks post-injury. Transient actin hyperpolymerization was observed at 1 and 6 h post-injury in the thalamus and hippocampus, while actin depolymerization was observed at 1 and 3 weeks in the cortex and thalamus. Collectively our data suggest that DNase I disinhibition following brain trauma is associated predominantly with actin hyperpolymerization but also with actin depolymerization and concomitant caspase-mediated actin proteolysis.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-N540978] Funding Source: Medline		Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Enari M, 1998, NATURE, V391, P43; Friedman JE, 1998, NEUROSCIENCE, V82, P421; Guenal I, 1997, J CELL SCI, V110, P489; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVEE MG, 1996, AM J PHYSIOL-CELL PH, V40, pC1981; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; National Research Council, 1996, GUIDE CARE USE LAB A, P1; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; PEITSCH MC, 1992, BIOCHEM BIOPH RES CO, V186, P739, DOI 10.1016/0006-291X(92)90808-X; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RINK A, 1995, AM J PATHOL, V147, P1575; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P1942, DOI 10.1021/bi00304a009; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Villa PG, 1998, J CELL SCI, V111, P713; Wyllie A H, 1992, Semin Immunol, V4, P389; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang GY, 1998, J CEREBR BLOOD F MET, V18, P840, DOI 10.1097/00004647-199808000-00004; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x	37	12	13	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	APR	2001	77	1					173	181		10.1046/j.1471-4159.2001.t01-1-00215.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	417KY	WOS:000167835200018	11279273				2021-06-18	
J	Murgio, A; Patrick, PD; Andrade, FA; Boetto, S; Leung, KM; Sanchez, MAM				Murgio, A; Patrick, PD; Andrade, FA; Boetto, S; Leung, KM; Sanchez, MAM			International study of emergency department care for pediatric traumatic brain injury and the role of CT scanning	CHILDS NERVOUS SYSTEM			English	Article; Proceedings Paper	ICRAN 99 Conference	NOV 20-23, 1999	TAIPEI, TAIWAN			head injury; children; CT scan; emergency department	HEAD-INJURY; CHILDREN	Objects: Our objective was to investigate the use of CT and its relationship to head injury severi ty and age. Method: The multi-center group International Study of Head Injury Project (ISHIP) serves as the administrative body for research design, data collection and analysis. This is a nonrandomized prospective study of longitudinal outcomes following examination and care in emergency department in five different countries. The subjects of our study were 4,690 children from birth to 15 years of age, all of whom were systematically evaluated. Each child was medically evaluated and categorized as to injury severity, mechanism of injury and findings on X-ray and CT scan. Follow-up interview and assessment was completed for comparison with the presenting clinical state. Results: CT scans were performed for 674 (14.3%) of the children: 438 scans were normal and 236 were abnormal(P <0.001). Of the children with abnormal CT scans, 23.3% had mild head injuries, 42.7% had moderate injuries, and 33.8% had severe injuries, as determined by the GCS. By age, 10.5% of the positive CTs were in children aged 0-2 years, 56.3% in 3- to 9-year-olds, and 33% in 10- to 15-year-olds; only in 2% of cases were both CT and X-ray positive. Conclusions: The majority of children did not need significant medical intervention. Physicians ordered X-ray investigations more frequently than CT scanning. The use of X-ray to decide whether or not CT is necessary is not warranted. The implications of positive CTs in mild or moderate injuries were most noteworthy, as were age-related interactions with positive CT findings.	Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; Hosp Virgen Rocio, Emergency Dept, Seville, Spain	Murgio, A (corresponding author), Quintana 1256,B7602GDZ, Mar Del Plata, Argentina.						ALLISON M, 1992, EFFECTS NEUROLOGIC I; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BUTCHART A, 1991, S AFR MED J, V79, P472; CAMPANA MB, 1994, CIENCIA MED, V3, P32; DAVIES RL, 1995, PEDIATRICS, V95, P345; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DISCALA C, 1996, CHILDREN ADOLESCENTS; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; OSHANICK G, 1998, 4 ANN ASP NEUR C 5 9; QUAYLE KS, 1997, PEDIATRICS, V99, P11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; ZAFONTE RD, 1996, MED REHAEBILITATION, P267	16	12	12	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2001	17	4-5					257	262		10.1007/s003810000403			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	434AX	WOS:000168793900012	11398946				2021-06-18	
J	Bruder, N; Bonnet, M				Bruder, N; Bonnet, M			Epileptogenic pharmacologic properties in anaesthesia	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article; Proceedings Paper	22nd Conference of the Association-de-Neuroanesthesie-et-Reanimation-de-Langue-Francaise	NOV 23-24, 2000	DIJON, FRANCE	Assoc Neuroanesthes & Reanimat Langue Francaise		anaesthetics; epilepsy	REFRACTORY STATUS EPILEPTICUS; FENTANYL-INDUCED SEIZURES; TRAUMATIC BRAIN INJURY; SEVOFLURANE ANESTHESIA; PROPOFOL SEDATION; PARTIAL EPILEPSY; POSTOPERATIVE SEIZURES; ISOFLURANE ANESTHESIA; MIDAZOLAM; ELECTROENCEPHALOGRAM	Most anaesthetics and analgesics have both pro- and anticonvulsant activity. The data in the literature should be analysed with respect to the patient population, the recording of epileptic activity and the method of EEG analysis. Among inhaled anaesthetics, isoflurane has strong anticonvulsant properties. In some circumstances, sevoflurane may induce an epileptic activity. With the exception of ketamine and etomidate, all intravenous hypnotics may be used for anesthesia of the epileptic patient. Midazolam is a potent anticonvulsant. Among narcotics, fentanyl and alfentanil may induce clinical or electroencephalographic seizures. Considering the large number of patients treated with these agents without any neurological adverse effect, the clinical relevance of these data is unclear. Neuromuscular blocking agents do not possess pro- or anticonvulsant properties. (C) 2001 Editions scientifiques et medicales Elsevier SAS.	CHU Timone, Dept Anesthesie Reanimat, F-13385 Marseille, France	Bruder, N (corresponding author), CHU Timone, Dept Anesthesie Reanimat, F-13385 Marseille, France.	nbruder@ap-hm.fr					Abouleish EI, 1998, BRIT J ANAESTH, V80, P843, DOI 10.1093/bja/80.6.843; ADACHI M, 1992, BRIT J ANAESTH, V68, P214, DOI 10.1093/bja/68.2.214; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; AVRAMOV MN, 1995, ANESTH ANALG, V81, P596, DOI 10.1097/00000539-199509000-00031; Bausch SB, 1998, J PHARMACOL EXP THER, V284, P1147; BEEMER GH, 1989, ANAESTH INTENS CARE, V17, P504, DOI 10.1177/0310057X8901700421; Beenen LFM, 1999, J NEUROL NEUROSUR PS, V67, P474, DOI 10.1136/jnnp.67.4.474; Begemann M, 2000, EPILEPSIA, V41, P105, DOI 10.1111/j.1528-1157.2000.tb01513.x; BENARI Y, 1980, BRAIN RES, V191, P79, DOI 10.1016/0006-8993(80)90316-9; BEVAN JC, 1993, CAN J ANAESTH, V40, P805, DOI 10.1007/BF03009247; Bosenberg AT, 1997, PAEDIATR ANAESTH, V7, P477; BRUDER N, 1997, REANIM URGENCES, V6, P773; CASCINO GD, 1993, J CLIN NEUROPHYSIOL, V10, P520, DOI 10.1097/00004691-199310000-00010; COLLIER C, 1991, ANAESTH INTENS CARE, V19, P573, DOI 10.1177/0310057X9101900416; Constant I, 1999, ANESTHESIOLOGY, V91, P1604, DOI 10.1097/00000542-199912000-00010; EBRAHIM ZY, 1994, ANESTH ANALG, V78, P275, DOI 10.1213/00000539-199402000-00013; EBRAHIM ZY, 1986, ANESTH ANALG, V65, P1004; FERRERALLADO T, 1973, ANESTHESIOLOGY, V38, P333, DOI 10.1097/00000542-197304000-00006; FISHER MMD, 1974, ANAESTH INTENS CARE, V2, P266, DOI 10.1177/0310057X7400200313; Fountain NB, 1999, CLIN NEUROPHARMACOL, V22, P261; Fukuda H, 1996, ANESTH ANALG, V83, P570, DOI 10.1097/00000539-199609000-00023; GANCHER S, 1984, ANESTHESIOLOGY, V61, P616, DOI 10.1097/00000542-198411000-00029; Gilbert DL, 1999, J CHILD NEUROL, V14, P602, DOI 10.1177/088307389901400909; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Harrigan PWJ, 1996, ANAESTH INTENS CARE, V24, P261; HARRISON JL, 1986, ANESTH ANALG, V65, P1235; Herrick IA, 1997, ANESTH ANALG, V84, P1280, DOI 10.1097/00000539-199706000-00020; HIRSHMAN CA, 1982, ANESTHESIOLOGY, V56, P464, DOI 10.1097/00000542-198206000-00012; Holmes GL, 1999, PEDIATR NEUROL, V20, P259, DOI 10.1016/S0887-8994(98)00155-6; Huggins NJ, 1999, BRIT J ANAESTH, V82, P952; HUTCHISON GL, 1993, ANAESTHESIA, V48, P824, DOI 10.1111/j.1365-2044.1993.tb07610.x; HYMES JA, 1985, ANESTH ANALG, V64, P367; Igartua J, 1999, CRIT CARE MED, V27, P1982, DOI 10.1097/00003246-199909000-00043; INGVAR M, 1981, EUR NEUROL, V20, P219, DOI 10.1159/000115237; INGVAR M, 1981, ANESTHESIOLOGY, V54, P33, DOI 10.1097/00000542-198101000-00007; Islander G, 2000, ACTA ANAESTH SCAND, V44, P144, DOI 10.1034/j.1399-6576.2000.440203.x; JONES GW, 1988, ANAESTHESIA, V43, P905; Kaisti KK, 1999, ANESTHESIOLOGY, V91, P1952, DOI 10.1097/00000542-199912000-00052; KAYAMA Y, 1972, ANESTHESIOLOGY, V36, P316, DOI 10.1097/00000542-197204000-00004; Keene DL, 1997, CAN J NEUROL SCI, V24, P37; Koepp MJ, 1998, LANCET, V352, P952, DOI 10.1016/S0140-6736(97)09077-6; Kofke WA, 1997, J NEUROSURG ANESTH, V9, P269, DOI 10.1097/00008506-199707000-00012; KOFKE WA, 1989, ANESTHESIOLOGY, V71, P653, DOI 10.1097/00000542-198911000-00005; KOFKE WA, 1993, ANESTH ANALG, V77, P330; KOMATSU H, 1994, ANESTHESIOLOGY, V81, P1535, DOI 10.1097/00000542-199412000-00030; Kronenberg MF, 1998, PAIN, V75, P383, DOI 10.1016/S0304-3959(97)00173-5; LANIER WL, 1988, BRIT J ANAESTH, V60, P74, DOI 10.1093/bja/60.1.74; Lee VC, 1998, ANESTH ANALG, V86, P652, DOI 10.1097/00000539-199803000-00040; LOWSON S, 1990, BRIT J ANAESTH, V64, P59, DOI 10.1093/bja/64.1.59; MACKENZIE SJ, 1990, ANAESTHESIA, V45, P1043, DOI 10.1111/j.1365-2044.1990.tb14884.x; MAEKAWA T, 1984, J CEREBR BLOOD F MET, V4, P88, DOI 10.1038/jcbfm.1984.11; MAKELA JP, 1993, EPILEPSIA, V34, P832, DOI 10.1111/j.1528-1157.1993.tb02098.x; Manninen PH, 1999, ANESTH ANALG, V88, P1101, DOI 10.1097/00000539-199905000-00025; MCMANUS KF, 1992, ANAESTH INTENS CARE, V20, P245; MICHENFELDER JD, 1990, J NEUROSURG, V72, P703, DOI 10.3171/jns.1990.72.5.0703; MODICA PA, 1990, ANESTH ANALG, V70, P433; MODICA PA, 1990, ANESTH ANALG, V70, P303; Momota YH, 1998, ANESTH ANALG, V87, P900, DOI 10.1097/00000539-199810000-00029; NOWACK WJ, 1994, CLIN ELECTROENCEPHAL, V25, P110, DOI 10.1177/155005949402500308; Ohmura S, 1999, ANESTH ANALG, V88, P155, DOI 10.1097/00000539-199901000-00029; OSAWA M, 1994, ANESTH ANALG, V79, P52; PAECH MJ, 1990, ANAESTH INTENS CARE, V18, P585; PITTMILLER PL, 1994, ANESTH ANALG, V78, P1193; Polc P, 1996, EPILEPSIA, V37, P1007, DOI 10.1111/j.1528-1157.1996.tb00540.x; POULTON TJ, 1984, ANESTHESIOLOGY, V61, P471, DOI 10.1097/00000542-198410000-00022; Raeder JC, 1999, ACTA ANAESTH SCAND, V43, P794, DOI 10.1034/j.1399-6576.1999.430802.x; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P434, DOI 10.1097/00000542-199103000-00008; RAMPIL IJ, 1993, ANESTH ANALG, V77, P1071; SAMRA SK, 1995, ANESTHESIOLOGY, V82, P843; SCHELLER MS, 1990, BRIT J ANAESTH, V65, P388, DOI 10.1093/bja/65.3.388; Schultz A, 2000, ANAESTH INTENS CARE, V28, P205, DOI 10.1177/0310057X0002800216; SCHULZE BA, 2000, EPILEPSIA, V41, P186; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P812, DOI 10.1097/00000542-198506000-00024; Scott RC, 1999, LANCET, V353, P623, DOI 10.1016/S0140-6736(98)06425-3; SLATER BL, 1995, ANAESTH INTENS CARE, V23, P517; Sneyd JR, 1999, BRIT J ANAESTH, V82, P168, DOI 10.1093/bja/82.2.168; Stecker MM, 1998, EPILEPSIA, V39, P18, DOI 10.1111/j.1528-1157.1998.tb01269.x; TATEISHI A, 1989, BRIT J ANAESTH, V62, P548, DOI 10.1093/bja/62.5.548; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Terasako K, 1996, ACTA ANAESTH SCAND, V40, P953, DOI 10.1111/j.1399-6576.1996.tb04566.x; Tobias JD, 1998, PEDIATR EMERG CARE, V14, P248, DOI 10.1097/00006565-199806000-00022; TOMMASINO C, 1984, ANESTHESIOLOGY, V60, P283, DOI 10.1097/00000542-198404000-00003; Towne AR, 1999, J EMERG MED, V17, P323, DOI 10.1016/S0736-4679(98)00170-X; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wang BG, 1997, J NEUROSURG ANESTH, V9, P335, DOI 10.1097/00008506-199710000-00008; Watanabe S, 1998, ANESTH ANALG, V86, P677, DOI 10.1097/00000539-199803000-00052; WIKINSKI JA, 1970, ANESTH ANAL CURR RES, V49, P504; Woodforth IJ, 1997, ANESTHESIOLOGY, V87, P1579, DOI 10.1097/00000542-199712000-00041; Yli-Hankala A, 1999, ANESTHESIOLOGY, V91, P1596, DOI 10.1097/00000542-199912000-00009	90	12	18	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	FEB	2001	20	2					171	179					9	Anesthesiology	Anesthesiology	411LC	WOS:000167500700009	11270238				2021-06-18	
J	Jenkins, LW; DeWitt, DS; Johnston, WE; Davis, KL; Prough, DS				Jenkins, LW; DeWitt, DS; Johnston, WE; Davis, KL; Prough, DS			Intraischemic mild hypothermia increases hippocampal CA1 blood flow during forebrain ischemia	BRAIN RESEARCH			English	Article						hypothermia; brain; blood flow; forebrain ischemia; hippocampus; rat	GLOBAL CEREBRAL-ISCHEMIA; LASER-DOPPLER FLOWMETRY; TRAUMATIC BRAIN-INJURY; NEURONAL DAMAGE; POSTISCHEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; ENERGY-METABOLISM; RAT HIPPOCAMPUS; TEMPERATURE; NIMODIPINE	The hippocampal CA1 sector is selectively vulnerable to forebrain ischemia but protected by mild hypothermia. However, the consequence of intraischemic hypothermia on CA1 blood flow during the insult has not been adequately characterized. The effects of mild intraischemic hypothermia on relative changes in regional hippocampal CA1 blood how were recorded continuously using laser Doppler flowmetry (LDF) during and 30 min after 6 min of forebrain ischemia. Six experimental groups (n=6/group) of fasted male Wistar rats were compared. Groups 1, 3 and 5 consisted of normothermic rats that underwent either 6 (for CBF measurements) and 6 or 10 (for 7 day survival-CA1 neuronal death measurements) min of transient forebrain ischemia using bilateral carotid clamping and hemorrhagic hypotension. Groups 2, 4 and 6 rats were subjected to mild hypothermia (34 degreesC) before, during, and 30 min after 6 (for CBF measurements) and 6 or 10 (for 7 day survival-CA1 neuronal death measurements) min of transient forebrain ischemia. CA1 blood Row and electroencephalogram (EEG) were continuously recorded. During the ischemic insult there were intergroup differences in the magnitude of CBF decreases in the CA1 region. In both groups 1 and 2, CBF returned to preischemic values within 1 min of reperfusion but hypothermic rats had more sustained hyperemia. Hypothermic rats had a quicker recovery of EEG activity and less delayed CA1 neuronal death (group 2 versus 4). These data suggest ischemic blood Row to the CA1 sector was altered by intraischemic mild hypothermia which may contribute to the greater benefit of intraischemic hypothermic neuroprotection. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Jenkins, LW (corresponding author), Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA.	ljenkins@pitt.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [N535365] Funding Source: Medline		ALLEN KL, 1993, NMR BIOMED, V6, P181, DOI 10.1002/nbm.1940060303; BECK T, 1988, EUR J PHARMACOL, V158, P271, DOI 10.1016/0014-2999(88)90078-7; BIELENBERG GW, 1987, J CEREBR BLOOD F MET, V7, P480, DOI 10.1038/jcbfm.1987.91; BIELENBERG GW, 1989, N-S ARCH PHARMACOL, V339, P230; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Davis KL, 1998, J NEUROTRAUM, V15, P615, DOI 10.1089/neu.1998.15.615; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FUJIKURA H, 1994, BRAIN RES, V636, P103, DOI 10.1016/0006-8993(94)90181-3; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GIONET TX, 1992, BRAIN RES, V586, P188, DOI 10.1016/0006-8993(92)91626-P; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Hoffman WE, 1996, NEUROL RES, V18, P185; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; HOSSMANN KA, 1990, PROTECTION BRAIN ISC, P21; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; JONES SB, 1984, J APPL PHYSIOL, V57, P808; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KIKKAWA K, 1994, STROKE, V25, P474, DOI 10.1161/01.STR.25.2.474; KLOIBER O, 1993, NMR BIOMED, V6, P144, DOI 10.1002/nbm.1940060207; KRIEGLSTEIN J, 1989, EUR NEUROL, V29, P224, DOI 10.1159/000116416; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824; KUROIWA T, 1992, STROKE, V23, P1349, DOI 10.1161/01.STR.23.9.1349; KURZ A, 1995, ANESTHESIOLOGY, V82, P870, DOI 10.1097/00000542-199504000-00008; KURZ A, 1995, ANESTHESIOLOGY, V83, P491, DOI 10.1097/00000542-199509000-00007; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P488; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; NUGLISCH J, 1990, J CEREBR BLOOD F MET, V10, P654, DOI 10.1038/jcbfm.1990.118; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; Sagher O, 1997, J NEUROSURG, V87, P431, DOI 10.3171/jns.1997.87.3.0431; SAUER D, 1988, NEUROSCI LETT, V91, P327, DOI 10.1016/0304-3940(88)90701-X; Schwab M, 1997, EXP TOXICOL PATHOL, V49, P105; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.iy.02.040184.001535; SMITH ML, 1983, J CEREBR BLOOD F MET, V3, P543, DOI 10.1038/jcbfm.1983.83; SZABO L, 1989, ARZNEIMITTELFORSCH, V39-1, P314; Toung TJK, 1996, CRIT CARE MED, V24, P103, DOI 10.1097/00003246-199601000-00018; VERHAEGEN M, 1995, ANESTHESIOLOGY, V82, P1209, DOI 10.1097/00000542-199505000-00016; VERHAEGEN MJ, 1992, ANESTHESIOLOGY, V76, P743, DOI 10.1097/00000542-199205000-00013; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; WELSCH M, 1990, STROKE, V21, P105; Werner C, 1997, ANASTH INTENSIV NOTF, V32, P210, DOI 10.1055/s-2007-995040; YOUNG WL, 1987, ANESTHESIOLOGY, V67, P54, DOI 10.1097/00000542-198707000-00010	53	12	12	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 26	2001	890	1					1	10		10.1016/S0006-8993(00)03011-0			10	Neurosciences	Neurosciences & Neurology	397CU	WOS:000166676400001	11164763				2021-06-18	
J	Gomez, JF; Thatcher, RW				Gomez, JF; Thatcher, RW			Frequency domain equivalence between potentials and currents using Loreta	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						source location; EEG/MEG inverse problem; low resolution electromagnetic tomography current density	RESOLUTION ELECTROMAGNETIC TOMOGRAPHY; CLOSED-HEAD INJURY; BIOPHYSICAL LINKAGE; BRAIN; MRI	Analyzing the preferences of brain regions to oscillate at specific frequencies gives important functional information. Application of discrete inverse solutions for the EEG/MEG inverse problem in the frequency domain usually involves the use of many current sources (sometimes 10(4) or more) restricted to gray matter points, as the solution space for the possible generators. This number can progressively increase with the level of detail of the MRI when it is used in co-registration with EEG/MEG. However, the computation of the Fourier transform to all these sources is computationally intensive. We illustrate with a simple example how this procedure can be simplified by applying the Fourier transform to the signals in the sensors using a popular inverse method (LORETA). We also suggest how the search space of current sources at specific frequencies of oscillation can be limited to some regions constrained by other technologies such as fMRI, PET and SPECT.	Vet Adm Med Ctr, Bay Pines Fdn, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Def & Vet Head Injury Program, Washington, DC USA	Gomez, JF (corresponding author), Vet Adm Med Ctr, Bay Pines Fdn, Res & Dev Serv 151, Bay Pines, FL 33744 USA.						Anderer P, 1998, EVOKED POTENTIAL, V108, P160, DOI 10.1016/S0168-5597(97)00080-4; Anderer P, 1998, NEUROPSYCHOBIOLOGY, V37, P20, DOI 10.1159/000026472; Baillet S, 1997, IEEE T BIO-MED ENG, V44, P374, DOI 10.1109/10.568913; Gomez JF, 1999, MED HYPOTHESES, V53, P263, DOI 10.1054/mehy.1999.0769; HANDERSON E, 1975, ELECTROEN CLIN NEURO, V79, P119; JOHN ER, 1998, BRAIN TOPOGRAPHY, V11; LAGERLUND TD, 1993, ELECTROEN CLIN NEURO, V86, P7, DOI 10.1016/0013-4694(93)90062-Z; Lantz G, 1997, ELECTROEN CLIN NEURO, V102, P414, DOI 10.1016/S0921-884X(96)96551-0; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Malmivuo J., 1995, BIOELECTROMAGNETISM; MARQUI RP, 1994, BRAIN TOPOGRAPHY, V7, P180; MENKE W, GEPHYSICAL DATA ANAL; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; SALETU B, 1998, BRAIN TOPOGRAPHY, V11, P71; STERIADE M, 1990, ELECTROEN CLIN NEURO, V76, P481, DOI 10.1016/0013-4694(90)90001-Z; STRIK WK, 1998, 3 DIMENSIONAL TOMOGR; Thatcher R W, 1995, J Neuroimaging, V5, P35; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; THATCHER RW, 1999, NEUROIMAGE, V9, pS110; THATCHER RW, 1977, FUNCTIONAL NEUROSCIE, V1; THATCHER RW, 1994, FUNCTIONAL NEUROIMAG, V1; TORO C, 1994, FUNCTOINAL NEUROIMAG, V1; TOWLE VL, 1993, ELECTROEN CLIN NEURO, V86, P1, DOI 10.1016/0013-4694(93)90061-Y; VALDES P, 1998, NEUROIMAGE, pS636; VALDESSOSA P, 1997, ELECTROENCEPHALOGR C, V103, P19	26	12	12	0	3	GORDON BREACH PUBLISHING, TAYLOR & FRANCIS GROUP	PHILADELPHIA	325 CHESTNUT ST, 8TH FL, PHILADELPHIA, PA 19106 USA	0020-7454			INT J NEUROSCI	Int. J. Neurosci.		2001	107	3-4					161	171		10.3109/00207450109150683			11	Neurosciences	Neurosciences & Neurology	428DA	WOS:000168444800002	11328689				2021-06-18	
J	Iwasaki, M; Nakasato, N; Kanno, A; Hatanaka, K; Nagamatsu, K; Nagamine, Y; Yoshimoto, T				Iwasaki, M; Nakasato, N; Kanno, A; Hatanaka, K; Nagamatsu, K; Nagamine, Y; Yoshimoto, T			Somatosensory evoked fields in comatose survivors after severe traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						somatosensory evoked potentials; magnetoencephalography; traumatic brain injury; diffuse axonal injury; consciousness disturbance	HEAD-INJURY; POTENTIALS; DISSOCIATION; STIMULATION; RESPONSES; RECOVERY; HUMANS; CORTEX; SLEEP	Objective: To evaluate the cortical function quantitatively in patients in the chronic phase of severe traumatic brain injury. Methods: Thirteen patients with severe traumatic brain injury due to traffic accident followed by persistent consciousness disturbance and disability were studied. Somatosensory evoked magnetic fields (SEFs) for unilateral median nerve stimulation were measured using a whole-head magnetoencephalography system. The latency and electrical current dipole (ECD) moment for the N20m, P30m, N45m and P60m components were calculated and compared with those of 14 age-matched healthy adults. Results: The peak latency of N20m was longer (P < 0.05) and those of P30m and N45m were shorter (P < 0.01) in the patients than in normal adults. The ECD moment of N20m and P30m was smaller and that of N45m and P60m was larger in the patients than in normal adults (P < 0.01). Conclusions: These results can be explained by the hypothesis that diffuse brain injury induces decreased and delayed input of the somatosensory afferent and compensational amplification of the response in the primary somatosensory cortex. Middle-latency SEFs may be applicable as a cortical functional measure for patients with severe traumatic brain injury. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Tohoku Univ, Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi 9808574, Japan; Kohnan Hosp, Ryogo Ctr, Sendai, Miyagi, Japan; ELEKTA KK, Tokyo, Japan	Iwasaki, M (corresponding author), Tohoku Univ, Sch Med, Dept Neurosurg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	iwa@nsg.med.tohoku.ac.jp	Iwasaki, Masaki/AAH-4985-2020; Nakasato, Nobukazu/AAC-3650-2019	Iwasaki, Masaki/0000-0002-4204-7144; 			ADDY RO, 1989, ELECTROEN CLIN NEURO, V74, P105, DOI 10.1016/0168-5597(89)90015-4; AHONEN AI, 1993, PHYS SCRIPTA, VT49A, P198, DOI 10.1088/0031-8949/1993/T49A/033; BORAH NC, 1985, ACTA NEUROL SCAND, V71, P331; CARENINI L, 1988, EPILEPSIA, V29, P145, DOI 10.1111/j.1528-1157.1988.tb04410.x; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; COBB WA, 1979, ELECTROEN CLIN NEURO, V47, P251, DOI 10.1016/0013-4694(79)90278-5; DEWEERD AW, 1985, ELECTROEN CLIN NEURO, V62, P45, DOI 10.1016/0168-5597(85)90034-6; FACCO E, 1991, ELECTROEN CLIN NEURO, V80, P469, DOI 10.1016/0168-5597(91)90128-K; FUJIWARA S, 1993, SOC TREATMENT COMA, V2, P89; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; Huttunen J, 1999, BRAIN RES, V818, P196, DOI 10.1016/S0006-8993(98)01215-3; KAKIGI R, 1991, ELECTROEN CLIN NEURO, V80, P364, DOI 10.1016/0168-5597(91)90083-A; KAKIGI R, 1991, J CLIN NEUROPHYSIOL, V8, P320, DOI 10.1097/00004691-199107010-00008; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KARHU J, 1992, ELECTROEN CLIN NEURO, V83, P192, DOI 10.1016/0013-4694(92)90144-7; Kawamura T, 1996, EVOKED POTENTIAL, V100, P44, DOI 10.1016/0168-5597(95)00217-0; KEREN O, 1991, Brain Injury, V5, P233, DOI 10.3109/02699059109008094; Kitamura Y, 1996, COGNITIVE BRAIN RES, V4, P275, DOI 10.1016/S0926-6410(96)00066-3; LUDERS H, 1970, ELECTROEN CLIN NEURO, V29, P450, DOI 10.1016/0013-4694(70)90062-3; Mauguiere F, 1996, Electroencephalogr Clin Neurophysiol Suppl, V46, P27; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; NAKANO S, 1995, EVOKED POTENTIAL, V96, P385, DOI 10.1016/0168-5597(95)00023-L; NAKASHIMA K, 1985, J NEUROL SCI, V70, P117, DOI 10.1016/0022-510X(85)90081-4; Pierantozzi M, 1999, CLIN NEUROPHYSIOL, V110, P1700, DOI 10.1016/S1388-2457(99)00113-3; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; SHIBASAKI H, 1985, BRAIN, V108, P225, DOI 10.1093/brain/108.1.225; SKINNER JE, 1971, ELECTROEN CLIN NEURO, V31, P1, DOI 10.1016/0013-4694(71)90284-7; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Srisaan P, 1996, J CLIN NEUROPHYSIOL, V13, P156, DOI 10.1097/00004691-199603000-00006; Tinazzi M, 1998, BRAIN, V121, P1785, DOI 10.1093/brain/121.9.1785; Tinazzi M, 1997, NEUROSCI LETT, V223, P21, DOI 10.1016/S0304-3940(97)13382-1; Wikstrom H, 1996, EVOKED POTENTIAL, V100, P479	34	12	13	2	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2001	112	1					205	211		10.1016/S1388-2457(00)00506-X			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	396TE	WOS:000166652000026	11137679				2021-06-18	
J	Toms, AD; Williams, S; White, SH				Toms, AD; Williams, S; White, SH			Obturator dislocation of the hip	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article								We describe two patients with obturator dislocation of the hip which was irreducible by described techniques of closed reduction. The first required open reduction using the iliofemoral approach with release of rectus femoris, The second was treated on a traction table which allowed disengagement of the head and, when combined with simultaneous lateral traction, adduction and gradual release of the longitudinal traction, facilitated a smooth reduction, Since the hip is stable in flexion, early mobilisation in an extension-limiting brace avoids the prolonged bed rest traditionally recommended for this injury.	Royal Shrewsbury Hosp, Shrewsbury, Salop, England	Toms, AD (corresponding author), Robert Jones & Agnes Hunt Orthopaed Hosp NHS Trus, Inst Orthopaed, Oswestry SY10 7AG, Shrops, England.						AMIHOOD S, 1975, INJURY, V7, P107, DOI 10.1016/0020-1383(75)90007-8; Bigelow HJ., 1878, LANCET, V1, P860, DOI DOI 10.1016/S0140-6736(02)43952-9; CAMPBELL WC, CAMPBELLS OPERATIVE, V3, P2232; DAWSON I, 1989, ARCH ORTHOP TRAUM SU, V108, P55, DOI 10.1007/BF00934160; EPSTEIN HC, 1972, J BONE JOINT SURG AM, VA 54, P1561; Epstein HC, 1985, ORTHOPEDICS, V8, P132; HENDERSON RS, 1951, J BONE JOINT SURG BR, V33, P602; MOWERY C, 1986, J TRAUMA, V26, P1041, DOI 10.1097/00005373-198611000-00014; POLESKY RE, 1972, J BONE JOINT SURG AM, VA 54, P1097, DOI 10.2106/00004623-197254050-00020; ROCKWOOD, FRACTURES ADULTS, V2, P1756; SCHLICKEWWI W, 1993, INJURY, V1, P27; SIMPSON L, 1986, TECH ORTHOP, V1, P23; Stewart WJ, 1933, J BONE JOINT SURG, V15, P413	13	12	12	0	0	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X			J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	JAN	2001	83B	1					113	115		10.1302/0301-620X.83B1.10289			3	Orthopedics; Surgery	Orthopedics; Surgery	408BU	WOS:000167307300024	11245517				2021-06-18	
J	Ameh, EA				Ameh, EA			Major injuries from "domestic" animals in children	PEDIATRIC SURGERY INTERNATIONAL			English	Article						domestic animals; children; injury; evaluation; prevention	DOG	Domestic animals are a potential cause of serious injury to handlers and children. In developed countries dogs are the most common cause of such injuries, but in developing countries childhood injuries from domestic animals have not been given much attention. A retrospective analysis of major injuries from domestic animal attacks in children aged 12 years or less in a developing country showed 17 injuries in 16 children. The locations were the abdomen (6), head and neck (4), extremities (3), external genitalia (3), and back (1). A big-horned cow was the cause of injury in 11 patients, a donkey in 4 and a ram in 1. Children under 10 years were injured by provoked animals, mostly as bystanders, while older children were handlers. Four abdominal injuries were penetrating with evisceration and contusion of bowel and required a laparotomy. One blunt splenic injury was managed non operatively and one by partial splenectomy. Two head injuries were managed non operatively. All other injuries were examined and explored with the child under general anaesthesia. These injuries were debrided and closed primarily or closure was delayed when contamination was heavy or adequate debridement was limited by vital neighbouring structures. Broad-spectrum antibiotics and tetanus prophylaxis were given for all open wounds. The average duration of hospital stay was 7.3 days. Three patients had wound infections resulting in long hospitalizations. Two patients died (12.5%), 1 from a severe head injury and 1 from an overwhelming infection. The management of major injuries from domestic animals in children requires meticulous evaluation and examination during general anaesthesia to establish the extent of injury and avoid missed injuries. Prevention of these injuries requires public education about the proper and compassionate handling of domestic animals.	Ahmadu Bello Univ, Teaching Hosp, Dept Surg, Paediat Surg Unit, Zaria, Nigeria	Ameh, EA (corresponding author), Ahmadu Bello Univ, Teaching Hosp, Dept Surg, Paediat Surg Unit, Zaria, Nigeria.			Ameh, Emmanuel/0000-0003-2386-3039			GEDLU E, 1994, E AFR MED J, V71, P807; JANJUA KJ, 1994, TROP DOCT, V24, P84, DOI 10.1177/004947559402400220; NWAURA LN, 1994, E AFR MED J, V71, P506; REDMAN JF, 1995, CLIN PEDIATR, V34, P331, DOI 10.1177/000992289503400607; TAHGIB F, 1984, TROP DOCT, V14, P187; WISEMAN NE, 1983, J PEDIATR SURG, V18, P533, DOI 10.1016/S0022-3468(83)80353-4	6	12	12	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0179-0358			PEDIATR SURG INT	Pediatr. Surg. Int.	NOV	2000	16	8					589	591		10.1007/s003830000419			3	Pediatrics; Surgery	Pediatrics; Surgery	378XY	WOS:000165611700014	11149402				2021-06-18	
J	Devlin, JW; Coplin, WM; Murry, KR; Rengachary, SS; Wilson, RF				Devlin, JW; Coplin, WM; Murry, KR; Rengachary, SS; Wilson, RF			Nimodipine-induced acute hypoxemia: Case report	NEUROSURGERY			English	Article						calcium channel blockers; dihydropyridines; hypoxemia; nimodipine; subarachnoid hemorrhage; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; CONTROLLED TRIAL; PREVENTION	OBJECTIVE AND IMPORTANCE: Nimodipine is commonly used to improve neurological outcomes after subarachnoid hemorrhage. Although nimodipine reportedly has high specificity for the cerebral vasculature, adverse systemic effects such as hypotension have been described. This case report describes a patient with traumatic subarachnoid hemorrhage who experienced two episodes of previously undescribed, life-threatening hypoxemia that was directly related to nimodipine therapy. CLINICAL PRESENTATION: The patient experienced acute hypoxemia (partial pressures of oxygen of 32.9 and 58.7 mm Hg), on two separate occasions (3 d apart), that was temporally related to single doses of nimodipine therapy for traumatic subarachnoid hemorrhage. Other disease- and medication-related causes did not explain these episodes. INTERVENTION: After the inspired oxygen concentration was increased to 100% (both episodes) and the positive end expiratory pressure was increased to 7.5 mm Hg (first episode), the arterial oxygen saturation of the patient returned to baseline levels (>99%) within 40 minutes in each instance. Nimodipine therapy was discontinued after each episode. CONCLUSION: It is hypothesized that, in the presence of concomitant adult respiratory distress syndrome, nimodipine increased ventilation/perfusion ratio mismatch, through its direct vasodilatory effects on the pulmonary artery, and possibly interfered with the reflex hypoxic pulmonary vasoconstriction necessary to maintain adequate oxygenation for this patient. Clinicians should carefully monitor the oxygenation status of patients when nimodipine therapy is initiated.	Wayne State Univ, Detroit Receiving Hosp, Dept Pharm, Detroit, MI USA; Wayne State Univ, Detroit Receiving Hosp, Dept Neurol, Detroit, MI USA; Wayne State Univ, Detroit Receiving Hosp, Dept Neurol Surg, Detroit, MI USA; Wayne State Univ, Detroit Receiving Hosp, Dept Surg, Detroit, MI USA	Devlin, JW (corresponding author), Detroit Receiving Hosp, Dept Pharm Serv, 4201 St Antoine, Detroit, MI 48201 USA.						ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BOLDT J, 1987, INTENS CARE MED, V13, P52, DOI 10.1007/BF00263558; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GORE JM, 1984, HDB HEMODYNAMIC MONI, P83; HAN DH, J NEUROSURG, V78, pA346; LANGLEY MS, 1989, DRUGS, V37, P669, DOI 10.2165/00003495-198937050-00004; LOVELL AT, 1992, ANAESTHESIA, V47, P409, DOI 10.1111/j.1365-2044.1992.tb02223.x; MESSETER K, 1987, NEUROSURGERY, V20, P548, DOI 10.1227/00006123-198704000-00007; Muller H, 1988, Acta Neurochir Suppl (Wien), V45, P29; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NEIL-DWYER G, 1987, European Heart Journal, V8, P41; OHMAN J, 1988, J NEUROSURG, V69, P683, DOI 10.3171/jns.1988.69.5.0683; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; PHILIPPON J, 1986, ACTA NEUROCHIR, V82, P110, DOI 10.1007/BF01456369; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Rhoney DH, 1999, NEUROLOGY, V52, pA60; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TETTENBORN D, 1985, NEUROCHIRURGIA ST S1, V28, pS84	24	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	NOV	2000	47	5					1243	1246		10.1097/00006123-200011000-00048			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	368YE	WOS:000090144400115	11063120				2021-06-18	
J	Elangovan, V; Kohen, R; Shohami, E				Elangovan, V; Kohen, R; Shohami, E			Neurological recovery from closed head injury is impaired in diabetic rats	JOURNAL OF NEUROTRAUMA			English	Article						diabetes; closed head injury; reactive oxygen species; oxidative stress; low molecular weight antioxidants	OXIDATIVE STRESS; LIPID-PEROXIDATION; CYCLIC VOLTAMMETRY; PERIPHERAL-NERVE; SPINAL-CORD; ALPHA-TOCOPHEROL; BRAIN-DAMAGE; ANTIOXIDANT; NEUROPATHY; TISSUE	Diabetes mellitus is a metabolic disorder associated with central nervous system impairments. Recent studies implicate oxidative stress mediated by reactive oxygen species (ROS) in the pathogenesis of diabetic complications. ROS have been shown to play role in the pathophysiology of brain injury. In the present study, closed head injury (CHI) was induced in diabetic rats to test the hypothesis that chronic oxidative stress exacerbates brain damage following CHI. Neurological recovery, edema, levels of low molecular weight antioxidants (LMWA), and markers of lipid peroxidation were determined at different intervals after injury. Diabetic rats (4 weeks after induction with streptozotocin) were subjected to CHI. Brain edema (percent water) and clinical status (neurological severity score) were assessed during 7 days. Brain LMWA were determined using cyclic voltammetry (CV) and HPLC-EC. In addition, conjugated dienes and thiobarbituric acid reactive substances (TBARS) were measured. Diabetic-CHI rats exhibited a lower rate of recovery and greater and more sustained edema (p < 0.01), as compared with the controls. At all times diabetic rats had higher levels of TEARS and conjugated dienes and lower concentrations of LMWA, and of vitamins C and E, suggesting chronic oxidative stress. At 5 min of CHI, the amounts of LMWA in control-CHI brains decreased (<similar to>50%,p < 0.01) and returned to normal by 48 h and 7 days. In the diabetic-CHI brain only one class of LMWA slightly declined but remained low for 7 days. The present results support the hypothesis that diabetic rats are under chronic oxidative stress, and suffer greater neurological dysfunction, associated with further lipid peroxidation following CHI.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il					BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Buege J A, 1978, Methods Enzymol, V52, P302; CAMERON NE, 1994, DIABETES METAB REV, V10, P189, DOI 10.1002/dmr.5610100302; CHAN PH, 1989, CELLULAR ANTIOXIDANT, P89; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; CIUFFI M, 1991, NEUROCHEM RES, V16, P43, DOI 10.1007/BF00965826; COTTER MA, 1995, DIABETOLOGIA, V38, P1285; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DYCK PJ, 1989, NEUROLOGY, V39, P111, DOI 10.1212/WNL.39.1.111; EKSTROM PAR, 1990, EXP NEUROL, V109, P200, DOI 10.1016/0014-4886(90)90074-3; Elangovan V, 2000, FREE RADICAL RES, V32, P125, DOI 10.1080/10715760000300131; Gohshi A, 1998, BIOL PHARM BULL, V21, P795; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1994, NUTR REV, V52, P253; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; Hounsom L, 1998, DIABETOLOGIA, V41, P839, DOI 10.1007/s001250050996; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; Li C, 1998, NEUROBIOL DIS, V5, P117, DOI 10.1006/nbdi.1998.0189; Li WY, 1999, CELL MOL BIOL, V45, P59; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; Lin BW, 2000, NEUROSCI LETT, V278, P1, DOI 10.1016/S0304-3940(99)00889-7; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOW PA, 1991, DIABETES, V40, P873, DOI 10.2337/diabetes.40.7.873; McIntosh TK, 1996, LAB INVEST, V74, P315; NICKANDER KK, 1994, J NEUROL SCI, V126, P6, DOI 10.1016/0022-510X(94)90088-4; NUKADA H, 1986, DIABETES, V35, P1058, DOI 10.2337/diabetes.35.9.1058; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SUZUKI E, 1994, J LAB CLIN MED, V124, P627; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; TOMLINSON DR, 1992, DIABETES METAB REV, V8, P67, DOI 10.1002/dmr.5610080107; VANDAM PS, 1995, DIABETES METAB REV, V11, P181, DOI 10.1002/dmr.5610110303; WATSON BD, 1993, PROG BRAIN RES, V96, P69; WOHAIEB SA, 1987, DIABETES, V36, P1014, DOI 10.2337/diabetes.36.9.1014; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Yukido I, 1990, NEUROSURGERY, V27, P1	53	12	12	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2000	17	11					1013	1027		10.1089/neu.2000.17.1013			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	374KY	WOS:000165345400002	11101205				2021-06-18	
J	Calvanio, R; Burke, DT; Kim, HJ; Cheng, J; Lepak, P; Leonard, J; Dwyer, MA; Gavande, V				Calvanio, R; Burke, DT; Kim, HJ; Cheng, J; Lepak, P; Leonard, J; Dwyer, MA; Gavande, V			Naltrexone: effects on motor function, speech, and activities of daily living in a patient with traumatic brain injury	BRAIN INJURY			English	Article							ENDOGENOUS OPIOIDS; AMANTADINE; ANTAGONISTS; NALOXONE; AGONIST; THERAPY; STATE	Evidence from many studies has suggested that endogenous opioid peptides participate in a number of pathophysiological responses to brain injury. This provides the rationale for the use of opioid antagonists for the enhancement of neural recovery after brain injury. A case is presented of an 18-year-old male who had loss of consciousness for 1 month after a severe brain injury. Three months of intensive rehabilitative therapies did not change his functional status. A trial of naltrexone was given while his performance in mobility, speech and overall Functional Independence Measure (FIM) scores were monitored. Results indicate an accelerated improvement in functional status and statistically improved FIM score.	Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; Univ Texas, SW Med Sch, Dallas, TX 75230 USA	Burke, DT (corresponding author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	daverir@aol.com					ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; Backman CL, 1999, AM J PHYS MED REHAB, V78, P170, DOI 10.1097/00002060-199903000-00022; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; EDBY K, 1995, CHILD NERV SYST, V11, P607, DOI 10.1007/BF00301001; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCNICHOLAS LF, 1984, DRUGS, V27, P81, DOI 10.2165/00003495-198427010-00004; MELEGER A, 1999, AM J PHYSICAL MED RE, V78, P190; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Seliger GM, 1998, J NEUROL REHABIL, V12, P29; TENNANT FS, 1987, AM J PSYCHIAT, V144, P813; VINK R, 1990, J NEUROSCI, V10, P3524; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Zafonte RD, 1998, BRAIN INJURY, V12, P617	22	12	15	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2000	14	10					933	942					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900007	11076138				2021-06-18	
J	Hux, K; Manasse, N; Wright, S; Snell, J				Hux, K; Manasse, N; Wright, S; Snell, J			Effect of training frequency on face-name recall by adults with traumatic brain injury	BRAIN INJURY			English	Article							IMAGERY; PERFORMANCE	Many TBI survivors have difficulty recalling the names of people with whom they frequently interact. Researchers have established that mnemonics and visual imagery strategies are often effective in facilitating encoding and recall of such information; however, no research exists pertaining to the frequency that such training should occur. The purpose of this study was to assess the relative effectiveness of three frequencies of intervention sessions-once per day, two times per week, and five times per day-on TBI survivors' ability to recall face-name associations. Results showed that sessions held daily and twice a week were more effective than sessions held five times per day. Mnemonics and visual imagery strategies were effective for four of the seven participants, regardless of frequency of intervention sessions. Implications for treatment and future research are discussed.	Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders 3, Lincoln, NE 68583 USA; Qual Living Inc, Omaha, NE USA	Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders 3, Lincoln, NE 68583 USA.		Hux, Karen/AAQ-2078-2020				DELLAROSA D, 1985, MEM COGNITION, V13, P529, DOI 10.3758/BF03198324; DEMPSTER FN, 1988, AM PSYCHOL, V43, P627, DOI 10.1037/0003-066X.43.8.627; Downes JJ, 1997, NEUROPSYCHOL REHABIL, V7, P195, DOI 10.1080/713755535; GOLDSTEIN G, 1988, CLIN NEUROPSYCHOL, V2, P251; Kertesz A., 1982, W APHASIA BATTERY; LEE TD, 1988, RES Q EXERCISE SPORT, V59, P277, DOI 10.1080/02701367.1988.10609373; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; MADIGAN SA, 1969, J VERB LEARN VERB BE, V8, P828, DOI 10.1016/S0022-5371(69)80050-2; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; REYNOLDS JH, 1964, J EDUC PSYCHOL, V55, P297, DOI 10.1037/h0040734; RICHARDSON JTE, 1995, NEUROPSYCHOLOGIA, V33, P1345, DOI 10.1016/0028-3932(95)00068-E; Rustad RA, 1993, COGNITIVE ASSESSMENT; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674	16	12	15	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2000	14	10					907	920					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900005	11076136				2021-06-18	
J	Galvin, JE; Nakamura, M; McIntosh, TK; Saatman, KE; Sampathu, D; Raghupathi, R; Lee, VMY; Trojanowski, JQ				Galvin, JE; Nakamura, M; McIntosh, TK; Saatman, KE; Sampathu, D; Raghupathi, R; Lee, VMY; Trojanowski, JQ			Neurofilament-rich intraneuronal inclusions exacerbate neurodegenerative sequelae of brain trauma in NFH/LacZ transgenic mice	EXPERIMENTAL NEUROLOGY			English	Article						neuronal cytoplasmic inclusions; Lewy bodies; neurofilament; apoptosis; traumatic brain injury; transgenic mice; Parkinson's disease; neurodegeneration	AMYLOID PRECURSOR PROTEIN; AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRAMMED CELL-DEATH; MOTOR-NEURON DISEASE; PARKINSONS-DISEASE; LEWY BODIES; MONOCLONAL-ANTIBODIES; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; NERVOUS-SYSTEM	Several neurodegenerative disorders are characterized by filamentous inclusions in neurons that selectively degenerate. The role these inclusions play in neuron degeneration is unclear, but this issue can, be investigated experimentally in relevant animal models. The NFH/LacZ transgenic (TG) mice overexpress the high-molecular-weight neurofilament (NF) subunit (NFH) fused to beta-galactosidase, and these hybrid proteins aggregate into NF-rich, filamentous neuronal cytoplasmic inclusions (NCIs) that have been implicated in the progressive, age-dependent degeneration in subsets of affected neurons. Thus, these TG mice recapitulate some of the key pathology of neurodegenerative disorders with intraneuronal inclusions. To determine if the NCIs compromise neuron survival following traumatic brain injury (TBI), 3- to 6-month old TG and wild-type (WT) mice were subjected to TBI or sham injury. At 2 weeks post-TBI, the TG group showed increased TUNEL staining and activated caspase-3 immunoreactivity in cells of cerebral cortex, adjacent white matter, and hippocampus underlying the injury site, relative to control mice, but this labeling decreased at 4 weeks and was minimal thereafter. Compared to control mice, by 8 weeks postinjury, the TG mice showed a marked decrease in neuron density and increased gliosis in the hippocampal dentate gyrus and CA3 region as well as in the lateral thalamus, while the few remaining CA3 neurons exhibited cytoskeletal alterations, decreased synaptic protein immunoreactivity, and dissolution of NCIs. The more profound long-term neurodegenerative sequelae of TBI in the NFH/LacZ mice compared to WT mice suggest that the presence of intraneuronal inclusions may impair the recovery and long-term viability of injured neurons. (C) 2000 Academic Press.	Med Coll Penn & Hahnemann Univ, Dept Neurol, Philadelphia, PA 19102 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Galvin, JE (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Neurol, Philadelphia, PA 19102 USA.		Galvin, James/AAM-7492-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09215, AG10124] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803] Funding Source: Medline		ARAI H, 1991, ANN NEUROL, V30, P686, DOI 10.1002/ana.410300509; Baba M, 1998, AM J PATHOL, V152, P879; BANKIEWICZ K, 1993, EXP NEUROL, V124, P140, DOI 10.1006/exnr.1993.1185; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; Brinkley B R, 1980, Int Rev Cytol, V63, P59, DOI 10.1016/S0074-7696(08)61757-X; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; Chen J, 1998, J NEUROSCI, V18, P4914; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; Conti AC, 1998, J NEUROSCI, V18, P5663; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Cronford M.E., 1995, BRAIN COGNITION, V28, P321; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; DICKSON DW, 2000, NEURODEGENERATIVE DE, P247; DIXON CE, 1991, J NEUROSCI METH, V39, P1; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Frautschy SA, 1998, AM J PATHOL, V152, P307; Galvin J E, 1999, Adv Neurol, V80, P313; Galvin JE, 1997, ANN NEUROL, V42, P595, DOI 10.1002/ana.410420410; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIASSON BI, 2000, NEURODEGENERATIVE DE, P219; GINSBERG SD, 1999, CEREB CORTEX, V14, P603; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HILL WD, 1993, J COMP NEUROL, V329, P328, DOI 10.1002/cne.903290304; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEE VMY, 1986, J NEUROSCI, V6, P2179; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1984, J NEUROCHEM, V42, P25, DOI 10.1111/j.1471-4159.1984.tb09692.x; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakajo S, 1996, BRAIN RES, V741, P180, DOI 10.1016/S0006-8993(96)00914-6; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Namura S, 1998, J NEUROSCI, V18, P3659; Pierce JES, 1996, J NEUROSCI, V16, P1083; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SCHMIDT ML, 1994, EXP NEUROL, V130, P311, DOI 10.1006/exnr.1994.1209; SCHMIDT ML, 1991, AM J PATHOL, V139, P53; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; SHAW G, 1988, P NATL ACAD SCI USA, V85, P2854, DOI 10.1073/pnas.85.8.2854; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SMITH DH, 1997, J NEUROTRAUM, V14, P215; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tompkins MM, 1997, AM J PATHOL, V150, P119; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Tu PH, 1997, LAB INVEST, V76, P441; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; Tu PH, 1997, J NEUROSCI, V17, P1064; VANGROEN T, 1992, J COMP NEUROL, V324, P427, DOI 10.1002/cne.903240310; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307	75	12	12	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2000	165	1					77	89		10.1006/exnr.2000.7461			13	Neurosciences	Neurosciences & Neurology	353VC	WOS:000089295300008	10964487				2021-06-18	
J	Sbordone, RJ; Seyranian, GD; Ruff, RM				Sbordone, RJ; Seyranian, GD; Ruff, RM			The use of significant others to enhance the detection of malingerers from traumatically brain-injured patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	8th Annual Meeting of the American-Neuropsychiatric-Association	FEB 02-04, 1997	ORLANDO, FL	Amer Neuropsychiat Assoc			SIMULATED MEMORY IMPAIRMENT; MMPI-2 VALIDITY SCALES; FORCED-CHOICE METHOD; FAKE BAD SCALE; BELIEVABLE DEFICITS; SYMPTOM VALIDITY; COMPLAINTS; PERFORMANCE; INDIVIDUALS; CLAIMANTS	Cognitive and neurobehavioral symptoms are common following traumatic brain injuries (TBIs). Because malingerers are likely to complain of such symptoms and perform poorly on neuropsychological tests, clinicians may have considerable difficulty distinguishing malingerers from TBI patients. In this study, we compared the subjective complaints of malingerers to TBI patients and then compared both groups to the problems observed by their respective significant others. We rested the assumption whether significant others could add one more piece to the challenging puzzle of diagnosing malingering. Our results demonstrated that the malingerers complained of more problems than patients who had sustained moderate or severe TBI. However, the significant others of the malingerers observed fewer cognitive, emotional-behavioral, and total problems than did the significant others of patients with severe, moderate and even mild TBI. These findings suggest that the detection of malingering can be enhanced by interviews with significant others. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Calif Irvine, Irvine, CA USA	Sbordone, RJ (corresponding author), 7700 Ctr Dr,Suite 750, Irvine, CA 92618 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; BERRY DTR, 1991, CLIN PSYCHOL REV, V11, P585, DOI 10.1016/0272-7358(91)90005-F; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; Butcher JN, 1995, PSYCHOL ASSESSMENT, V7, P320, DOI 10.1037/1040-3590.7.3.320; Cercy S. P., 1997, CLIN ASSESSMENT MALI, P85; DAVIDSON H, 1991, ANN M INT NEUR SOC S; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; FRANZEN MD, 1998, CLIN NEUROPSYCHOLOGY, P88; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; Gough H.G, 1950, J CONSULT PSYCHOL, V14, P408; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEZAK MD, 1983, NEUROPSYCHOLGICAL AS; Pankratz, 1997, CLIN ASSESSMENT MALI, P223; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; Pankratz L., 1988, CLIN ASSESSMENT MALI, P169; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; PURISCH AD, 2000, LURIA NEBRASKA NEURO, V1, P165; Reitan RM, 1998, CRIT ISS NE, P163; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Salekin R. T., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sbordone RJ, 1996, NEUROREHABILITATION, V7, P15, DOI 10.3233/NRE-1996-7103; SBORDONE RJ, 1991, NEUROPSYCHOLOGY ATTO; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; WONG TH, 1994, INT POLYM PROC, V9, P3, DOI 10.3139/217.940003; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	45	12	12	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2000	15	6					465	477					13	Psychology, Clinical; Psychology	Psychology	343AB	WOS:000088678600001	14590202				2021-06-18	
J	Bara, BG; Bucciarelli, M; Geminiani, GC				Bara, BG; Bucciarelli, M; Geminiani, GC			Development and decay of extra-linguistic communication	BRAIN AND COGNITION			English	Article; Proceedings Paper	10th Annual Meeting on Tennet - Theoretical and Experimental Neuropsychology	JUN 17-19, 1999	MONTREAL, CANADA	Univ Quebec				Cognitive Pragmatics theory is concerned with analyzing the cognitive processes underlying communication. In previous works we have explained the emergence of communication in context, as revealed by very young children, and the communicative deficits shown by closed head injury patients. The aim of the present work is an extension of Cognitive Pragmatics to the emergence and the decay of extra-linguistic communication. In I,articular, we investigate the performance of 2- to 7 year-old children and that of Alzheimer's patients in standard and nonstandard (irony and deceit) pragmatic tusks. The predictions derived by Cognitive Pragmatics are confirmed. Comprehension of pragmatic phenomena which are more complex according to the theory emerges later in the development (Experiment 1), and their decay is most severe in Alzheimer's patients (Experiment 2). We conclude that the framework provided by Cognitive Pragmatics can accommodate both the development and the decay of extra-linguistic communication. (C) 2000 Academic Press.	Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy; Univ Turin, Ctr Cognit Sci, I-10124 Turin, Italy	Bara, BG (corresponding author), Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy.						AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; AIRENTI G, 1984, COMPUTATIONAL MODELS; Bara B. G., 1998, COGNITION CONTEXT, P317; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BRAZZELLI M, 1994, J NEUROL NEUROSUR PS, V57, P1510, DOI 10.1136/jnnp.57.12.1510; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P661	7	12	13	0	0	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	JUN-AUG	2000	43	1-3					21	27					7	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	316FU	WOS:000087157600034	10857656				2021-06-18	
J	Haroun, RI; Li, KW; Rigamonti, D				Haroun, RI; Li, KW; Rigamonti, D			Surgical resection of a cerebral arteriovenous malformation for treatment of superficial siderosis: Case report	SURGICAL NEUROLOGY			English	Article						arteriovenous malformation; subarachnoid hemorrhage; superficial siderosis	CENTRAL-NERVOUS-SYSTEM; MRI	BACKGROUND To our knowledge, there are only two reported cases of cerebral arteriovenous malformation associated with superficial siderosis. In both cases, the patients were asymptomatic and were discovered on retrospective review of magnetic resonance imaging. CASE DESCRIPTION We describe a case of superficial siderosis in a 47-year-old male with a remote history of closed head injury that presented with progressive hearing loss, cerebellar ataxia, and urinary incontinence. Lumbar puncture was indicative of active subarachnoid bleeding. Cerebral angiography revealed a small vascular malformation that was resected. RESULTS: Pathological examination confirmed the diagnosis of the arteriovenous malformation. Six months after surgery the patient is neurologically stable with no further progression of clinical signs or symptoms. CONCLUSIONS We report the first case of surgical resection of an intracranial arteriovenous malformation for the treatment of superficial siderosis. We emphasize the necessity of a detailed evaluation when superficial siderosis is suspected to localize and resect potential bleeding sources, because the disease is progressive and often irreversible. (C) 2000 by Elsevier Science Inc.	Johns Hopkins Hosp, Dept Neurol Surg, Baltimore, MD 21287 USA	Rigamonti, D (corresponding author), Dept Neurol Surg, Meyer 5-181,600 N Wolfe St, Baltimore, MD 21287 USA.						Arnaud A, 1998, REV NEUROL, V154, P243; BONITO V, 1994, J NEUROSURG, V80, P931, DOI 10.3171/jns.1994.80.5.0931; CAMMERMEYER J, 1947, J NEUROPATH EXP NEUR, V6, P111, DOI 10.1097/00005072-194704000-00001; FEARNLEY JM, 1995, BRAIN, V118, P1051, DOI 10.1093/brain/118.4.1051; FONCIN JF, 1967, REV NEUROL, V116, P685; Hashimoto M, 1996, J NEURO-OPHTHALMOL, V16, P277; HUGHES JT, 1969, ACTA NEUROPATHOL, V13, P56; KOEPPEN AH, 1988, J NEUROPATH EXP NEUR, V47, P249, DOI 10.1097/00005072-198805000-00005; Matsumoto S, 1998, J NEUROSURG, V88, P890, DOI 10.3171/jns.1998.88.5.0890; MCGEE DA, 1962, NEUROLOGY, V12, P108, DOI 10.1212/WNL.12.2.108; OFFENBACHER H, 1991, NEUROLOGY, V41, P1987, DOI 10.1212/WNL.41.12.1987; Offenbacher H, 1996, NEURORADIOLOGY, V38, pS51, DOI 10.1007/BF02278119; PARNES SM, 1992, OTOLARYNG HEAD NECK, V107, P69, DOI 10.1177/019459989210700111; PINKSTON JW, 1983, J COMPUT ASSIST TOMO, V7, P1073, DOI 10.1097/00004728-198312000-00025; Schievink WI, 1998, J NEUROSURG, V89, P1029, DOI 10.3171/jns.1998.89.6.1029; STEVENS I, 1991, EUR ARCH PSY CLIN N, V241, P57, DOI 10.1007/BF02193756; Tapscott SJ, 1996, ANN NEUROL, V40, P936, DOI 10.1002/ana.410400620	17	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2000	53	6					554	558		10.1016/S0090-3019(00)00217-2			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	343UZ	WOS:000088722000011	10940422				2021-06-18	
J	Lomnitski, L; Nyska, A; Shohami, E; Chen, Y; Michaelson, DM				Lomnitski, L; Nyska, A; Shohami, E; Chen, Y; Michaelson, DM			Increased levels of intracellular iron in the brains of ApoE-deficient mice with closed head injury	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article						apolipoprotein E; head injury, iron, intracellular; brain, intracellular iron; oxidation-stress	CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E; DISEASE; EXPRESSION; METABOLISM; RADICALS; MODEL	Previous studies have revealed that apolipoprotein E (apoE)-deficient mice have distinct memory deficits and neurochemical derangements and are oxidatively stressed prior to and following closed head injury. The objective of this study was to evaluate the possibility that the enhanced susceptibility of apoE-deficient mice to closed head injury is related to impairments in their antioxidative iron-chelating mechanisms. ApoE-deficient and control mice were subjected to closed had injury, after which the extent of brain-damage and the level of iron-containing cells were assessed. Examination of the brain-damaged areas in the injured mice revealed that, by Day 3 post injury, animals of both groups were maximally and similarly affected. While the size of the damaged area of the injured control mice diminished significantly by Day 7, however recovery was not observed in injured apoE-deficient mice up to at least 14 days post-injury. Histopathologically, the decrease in the damaged areas in the control mice was interpreted as related to decreased edema. Numbers of iron-containing cells at Days 3 and 7 after injury were greater in the brains of control mice than in the apoE-deficient mice. Whereas the number of iron-containing cells in injured control mice decreased at days 9 and 14-post injury, that of the injured apoE-deficient mice plateaued by Day 9 at a level more than two-fold higher than the maximal level seen for controls. The size of the damaged areas and the number of iron-containing cells were correlated (P < 0.03) for both mouse groups at days 9 and 14 after injury. The data suggest that the increased susceptibility of apoE-deficient mice to closed head injury may be due, at least in part, to impaired iron scavenging and sustained oxidative stress.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; NIEHS, Res Triangle Pk, NC 27709 USA; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel	Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.						BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BOCHICCHIO M, 1990, INTENS CARE MED, V16, P444, DOI 10.1007/BF01711223; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CIUFFI M, 1991, NEUROCHEM RES, V16, P43, DOI 10.1007/BF00965826; CLINTON SK, 1992, AM J PATHOL, V140, P301; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; GRISHAM MB, 1990, NATO ADV SCI I A-LIF, V189, P81; GUTTERIDGE JMC, 1992, ANN NEUROL, V32, pS16, DOI 10.1002/ana.410320705; HALL ED, 1994, FREE RADICAL DAMAGE, P217; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; ISHIBASHI S, 1993, HORM METAB RES, V25, P82, DOI 10.1055/s-2007-1002048; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; LMONITSKI L, 1999, BIOCHIM BIOPHYS ACTA, V1453, P359; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NYSKA A, 1989, HUM VET TOXICOL, V31, P218; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; TOMIMOTO H, 1995, ACTA NEUROPATHOL, V90, P608; *US DEP HHS, 1996, GUID CAR US LAB AN	35	12	15	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0940-2993			EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	MAY	2000	52	2					177	183					7	Pathology; Toxicology	Pathology; Toxicology	319KY	WOS:000087341100014	10965994				2021-06-18	
J	Bauer, R; Fritz, H; Walter, B; Schlonski, O; Jochum, T; Hoyer, D; Zwiener, U; Reinhart, K				Bauer, R; Fritz, H; Walter, B; Schlonski, O; Jochum, T; Hoyer, D; Zwiener, U; Reinhart, K			Effect of mild hypothermia on cerebral oxygen uptake during gradual cerebral perfusion pressure decrease in piglets	CRITICAL CARE MEDICINE			English	Article						cerebral blood flow; cerebral oxygen consumption; intracranial pressure; epidural balloon inflation; extracorporeal arterial blood pressure controller; piglets; hypothermia; colored microspheres; neurologic emergencies; brain	TRAUMATIC BRAIN INJURY; REGIONAL BLOOD-FLOW; COMA DATA-BANK; HEAD-INJURY; MODERATE HYPOTHERMIA; CIRCULATORY ARREST; NEWBORN PIGLETS; METABOLIC-RATE; CHILDREN; PROTECTION	Objective: To study the effect of mild hypothermia on cerebral oxygen metabolism and brain function in piglets during reduced cerebral blood flow because of gradual reduction of the effective cerebral perfusion pressure (CPP). Design: Comparison of two randomized treatment groups: normothermic group (NT; n = 7) and hypothermic group (HT; n = 7). Setting: Work was conducted in the research laboratory of the Institute for Pathophysiology, Friedrich Schiller University, Jena, Germany. Subjects: Fourteen piglets (14 days old) of mixed German domestic breed. Intervention: Animals were anesthetized and mechanically ventilated. An epidural balloon was gradually inflated to increase intracranial pressure to 25 mm Hg, 35 mm Hg, and 45 mm Hg every 30 mins at adjusted mean arterial blood pressures. After determination of baseline CPP (NT, 79 +/- 14 mm Hg; HT, 84 +/- 9 mm Hg), CPP was reduced to similar to 70%, 50%, and 30% of baseline (NT, 38.1 +/- 0.5 degrees C; HT, 31.7 +/- 0.5 degrees C). Measurements and Main Results: Every 25 mins after the gradual CPP reductions. Mild hypothermia induced a reduction of the cerebral metabolic rate of oxygen (CMRO2) to 50% +/- 15% of baseline values (baseline values, 352 +/- 99 mu mol.100 g(-1).min(-1)) (p < .05). Moreover, the electrocorticogram was altered to a pattern of reduced delta activity (p < .05) but unchanged higher frequency activity. The cerebral oxygen balance in HT animals remained improved until CPP reduction to 50%, indicated by a reduced cerebral arteriovenous difference of oxygen but elevated brain tissue PO2 (p < .05). Further CPP reduction gave rise to a strong CMRO2 reduction (NT, 19 +/- 21%; HT, 15 +/- 15%; p < .05). However, the high-frequency band of electrocorticogram was less reduced in hypothermic animals (p < .05). Conclusions: Mild whole body hypothermia improves cerebral oxygen balance by reduction of brain energy demand in juvenile piglets. The improvement of brain oxygen availability continues during a mild to moderate CPP decrease. A loss of the difference in CMRO2 between the hypothermic and normothermic piglets together with the fact that brain electrical activity was less suppressed under hypothermia during severe cerebral blood flow reduction indicates that hypothermic protection may involve some other mechanisms than reduction of brain oxidative metabolism.	Univ Jena, Inst Pathophysiol, Traumat Brain Injury & Perinatal Res Grp, D-07740 Jena, Germany; Univ Jena, Clin Anesthesiol & Intens Care, D-07740 Jena, Germany	Bauer, R (corresponding author), Univ Jena, Inst Pathophysiol, Traumat Brain Injury & Perinatal Res Grp, D-07740 Jena, Germany.						ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bauer R, 1997, EXP TOXICOL PATHOL, V49, P469, DOI 10.1016/S0940-2993(97)80139-X; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BUSIJA DW, 1987, AM J PHYSIOL, V253, pH869; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COYLE MG, 1993, AM J PHYSIOL, V264, pH141; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, NEUROTRAUMA, P1491; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HIRAMATSU T, 1995, J THORAC CARDIOV SUR, V109, P948, DOI 10.1016/S0022-5223(95)70321-7; Hoyer D, 1997, BIOMED TECH, V42, P284, DOI 10.1515/bmte.1997.42.10.284; INGVAR DH, 1958, ACTA PHYSIOL SCAND, V42, P130, DOI 10.1111/j.1748-1716.1958.tb01547.x; JONAS RA, 1993, J THORAC CARDIOV SUR, V106, P362; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KOWALLIK P, 1991, CIRCULATION, V83, P974, DOI 10.1161/01.CIR.83.3.974; Kurth CD, 1997, CIRCULATION, V96, P358; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MAKOWSKI EL, 1968, CIRC RES, V23, P623, DOI 10.1161/01.RES.23.5.623; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MEYER JS, 1969, ELECTROEN CLIN NEURO, V26, P125, DOI 10.1016/0013-4694(69)90203-X; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; NEMOTO EM, 1995, CRIT CARE MED, V23, pA246; POWNALL R, 1973, BRIT VET J, V129, P583, DOI 10.1016/S0007-1935(17)36340-6; RUPP SM, 1986, ANESTHESIA, P1195; Satas S, 1996, ACTA ANAESTH SCAND, V40, P452, DOI 10.1111/j.1399-6576.1996.tb04468.x; SCHRADER H, 1985, ACTA NEUROL SCAND, V72, P283; STEEN PA, 1983, ANESTHESIOLOGY, V58, P527, DOI 10.1097/00000542-198306000-00009; STERIADE M, 1990, ELECTROEN CLIN NEURO, V76, P481, DOI 10.1016/0013-4694(90)90001-Z; USIJA DW, 1988, AM J PHYSIOL, V255, pH343; Walter B, 1997, BASIC RES CARDIOL, V92, P191, DOI 10.1007/s003950050037; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; Wass CT, 1996, INT ANESTHESIOL CLIN, V34, P95, DOI 10.1097/00004311-199603440-00008	35	12	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2000	28	4					1128	1135		10.1097/00003246-200004000-00036			8	Critical Care Medicine	General & Internal Medicine	311AV	WOS:000086862800036	10809294				2021-06-18	
J	Numan, B; Sweet, JJ; Ranganath, C				Numan, B; Sweet, JJ; Ranganath, C			Use of the California Verbal Learning Test to detect proactive interference in the traumatically brain injured	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						proactive interference; CVLT; traumatic brain injury	DISEASE; MEMORY	Recent studies using the California Verbal Learning Test (CVLT) to investigate the learning and memory capacities of traumatically-brain injured (TBI) individuals have suggested that this population does not show the expected buildup of proactive interference (PI). The purpose of this study was to investigate whether PI could be detected on the CVLT. in a TBI sample, if PI were calculated using alternative methods. CVLT data from 25 TBI individuals with varying degrees of brain injury and 21 healthy controls were compared. Results from the various analyses suggested that TBI individuals show buildup and release from PI when learning and attempting to recall competing forms of information if appropriate methods of analysis are used. Although the CVLT differs considerably from traditional PI paradigms (e.g.. Wickens. 1970), our results suggest it can be used to detect PI in TBI individuals. (C) 2000 John Wiley & Sons, Inc.	Northwestern Univ, Dept Psychiat, Evanston Hosp, Evanston, IL 60201 USA	Sweet, JJ (corresponding author), Northwestern Univ, Dept Psychiat, Evanston Hosp, 2650 Ridge Ave, Evanston, IL 60201 USA.						CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CUSHMAN LA, 1988, J CLIN EXP NEUROPSYC, V10, P685, DOI 10.1080/01688638808402807; DELIS D, 1990, ADV PSYCHOL ASSESSME, V7; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; DELIS DC, 1991, PSYCHOL ASSESSMENT, V3, P19, DOI DOI 10.1037/1040-3590.3.1.19; DUPONT RM, 1990, ARCH GEN PSYCHIAT, V47, P55; Fridlund A, 1987, CVLT RES EDITION ADM; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; HERMANN BP, 1988, CORTEX, V24, P245, DOI 10.1016/S0010-9452(88)80033-9; Jennett B., 1983, REHABILITATION HEAD, P3; KARAKEN DA, 1996, J INT NEUROPSYCH SOC, V2, P486; Kramer J. H., 1991, PSYCHOL ASSESSMENT J, V3, P299; KRAMER JH, 1989, J CONSULT CLIN PSYCH, V57, P257, DOI 10.1037/0022-006X.57.2.257; LOESS H, 1967, J EXP PSYCHOL, V74, P556, DOI 10.1037/h0024787; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PETERSON LR, 1959, J EXP PSYCHOL, V54, P157; POSTMAN L, 1971, EXPT PSYCHOL; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Thorndike EL., 1944, TEACHERS WORD BOOK 3; VANDERPLOEG RD, 1990, ANN M AM PSYCH ASS B; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569	23	12	13	0	2	JOHN WILEY & SONS INC	NEW YORK	605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	APR	2000	56	4					553	562		10.1002/(SICI)1097-4679(200004)56:4<553::AID-JCLP8>3.0.CO;2-Q			10	Psychology, Clinical	Psychology	301WD	WOS:000086332600008	10775047				2021-06-18	
J	Simpson, A; Schmitter-Edgecombe, M				Simpson, A; Schmitter-Edgecombe, M			Intactness of inhibitory attentional mechanisms following severe closed-head injury	NEUROPSYCHOLOGY			English	Article							SELECTIVE ATTENTION; OLD ADULTS; INTERFERENCE; TASK	Attentional problems are a common sequelae of closed-head injury (CHI). Research in the area of selective attention has pointed to the role of inhibitory mechanisms in the suppression of irrelevant information. In the current study, a negative priming paradigm was used to assess the inhibitory mechanisms of individuals suffering from a severe CHI. Twenty participants with severe CHIs (greater than 1 year postinjury) and 20 matched controls completed a negative priming task, as well as several other standardized tests of cognitive functioning. Within the negative priming task, 2 conditions were used to elicit information regarding facilitation by attended and ignored information and 1 condition was used to elicit inhibition of ignored information, as compared with a neutral control condition. Despite poorer performances on several tests of attention, there were no significant differences in the amount of inhibition displayed by the CHI participants as compared with the controls. Findings suggest that inhibitory processing deficits may not underlie the selective attention difficulties commonly seen following a severe CHI.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 RO3 HD35838-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD035838] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Allport D. A., 1985, ATTENTION PERFORM, P107; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Broadbent D. E., 1970, ATTENTION CONT THEOR, P51; Bruning JL., 1997, COMPUTATIONAL HDB ST, V4th ed.; DRIVER J, 1993, B PSYCHONOMIC SOC, V31, P45; DULANEY CL, 1994, J EXP PSYCHOL LEARN, V20, P470, DOI 10.1037/0278-7393.20.2.470; FOX E, 1994, PERCEPT PSYCHOPHYS, V56, P565, DOI 10.3758/BF03206952; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; HASHER L, 1991, J EXP PSYCHOL LEARN, V17, P163, DOI 10.1037/0278-7393.17.1.163; Heaton R., 1981, MANUAL WISCONSIN CAR; Kane MJ, 1997, J EXP PSYCHOL HUMAN, V23, P632, DOI 10.1037/0096-1523.23.3.632; KANE MJ, 1994, PSYCHOL AGING, V9, P103, DOI 10.1037/0882-7974.9.1.103; Kaplan E., 1987, MANUAL CALIFORNIA VE; KUCERA H, 1967, COMPUTTIONAL ANAL PR; LOGAN GD, 1988, PSYCHOL REV, V95, P492, DOI 10.1037/0033-295X.95.4.492; LOWE DG, 1979, MEM COGNITION, V7, P382, DOI 10.3758/BF03196943; MAY CP, 1995, PSYCHOL BULL, V118, P35, DOI 10.1037/0033-2909.118.1.35; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEILL WT, 1992, J EXP PSYCHOL LEARN, V18, P565, DOI 10.1037/0278-7393.18.3.565; NEILL WT, 1977, J EXP PSYCHOL HUMAN, V3, P444, DOI 10.1037/0096-1523.3.3.444; NEILL WT, 1978, PERCEPT PSYCHOPHYS, V23, P80, DOI 10.3758/BF03214299; NEUMANN E, 1991, J EXP PSYCHOL LEARN, V17, P1136, DOI 10.1037/0278-7393.17.6.1136; *PAT BEH CHECKL, 1991, S MAT; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sattler J. M., 1992, ASSESSMENT CHILDREN; Schmitter-Edgecombe M, 1998, J INT NEUROPSYCH SOC, V4, P144, DOI 10.1017/S1355617798001441; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Spreen O, 1969, NEUROSENSORY CTR COM; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SULLIVAN MP, 1993, PSYCHOL AGING, V8, P589, DOI 10.1037/0882-7974.8.4.589; SULLIVAN MP, 1995, NEUROPSYCHOLOGY, V9, P537, DOI 10.1037/0894-4105.9.4.537; TEASDALE G, 1974, LANCET, V2, P81; TIPPER SP, 1988, MEM COGNITION, V16, P64, DOI 10.3758/BF03197746; TIPPER SP, 1989, J EXP CHILD PSYCHOL, V48, P353, DOI 10.1016/0022-0965(89)90047-7; TIPPER SP, 1991, B PSYCHONOMIC SOC, V29, P45; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P591, DOI 10.1080/14640748508400921; TIPPER SP, 1992, B PSYCHONOMIC SOC, V30, P77; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P571, DOI 10.1080/14640748508400920; Trenerry MR., 1990, VISUAL SEARCH ATTENT; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wechsler D., 1981, WAIS R MANUAL WECHSL; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; WILLIAMS LM, 1995, BRIT J CLIN PSYCHOL, V34, P193, DOI 10.1111/j.2044-8260.1995.tb01454.x	48	12	12	0	0	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	APR	2000	14	2					310	319		10.1037//0894-4105.14.2.310			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	321XM	WOS:000087480700014	10791870				2021-06-18	
J	Carstairs, JR; Shores, EA				Carstairs, JR; Shores, EA			The Macquarie University Neuropsychological Normative Study (MUNNS): Rationale and methodology	AUSTRALIAN PSYCHOLOGIST			English	Article							MINOR HEAD-INJURY; READING TEST	The Macquarie University Neuropsychological Normative Study (MUNNS) was conducted during the period January 1996 to March 1998, and involved the assessment of a sample of 399 healthy 18- to 34-year-olds in Sydney, Australia. The primary aim of the MUNNS was to establish normative data on neuropsychological measures commonly used in the rehabilitation and medico-regal assessments of patients with traumatic brain injuries. These norms provide local standards on tests of intelligence, memory, and higher neuropsychological function against which brain-injured patients can be compared. The present paper provides the rationale underpinning the MUNNS as well as an overview of the methodology used and an assessment of the representativeness of the MUNNS sample.	Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	Carstairs, JR (corresponding author), Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia.	jane.carstairs@mq.edu.au		Shores, Edwin A/0000-0003-1553-5131			ATKINSON L, 1991, BRIT J CLIN PSYCHOL, V30, P87, DOI 10.1111/j.2044-8260.1991.tb00923.x; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BEARDSALL L, 1994, J CLIN EXP NEUROPSYC, V16, P232, DOI 10.1080/01688639408402634; Bowden SC, 1999, PSYCHOL ASSESSMENT, V11, P339, DOI 10.1037/1040-3590.11.3.339; *CAMBR COGN, 1995, CAMBR NEUR TEST AUT; COCHA J, 1994, CAT COMPUTER CATEGOR; Crawford JR, 1995, J INT NEUROPSYCH SOC, V1, P321; *DEP ED TRAIN YOUT, 1998, SEL HIGH ED STUD STA; Hennessy M, 1995, TREATMENT ISSUES LON, P183; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1996, NEUROPSYCHOLOGICAL A; Lovibond S.H., 1995, MANUAL DEPRESSION AN; MILLER EN, 1996, CALIFORNIA COMPUTERI; MITTENBERG W, 1992, PSYCHOL ASSESSMENT, V4, P3363; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	19	12	12	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0005-0067			AUST PSYCHOL	Aust. Psychol.	MAR	2000	35	1					36	40		10.1080/00050060008257466			5	Psychology, Multidisciplinary	Psychology	301VM	WOS:000086331000006					2021-06-18	
J	Mills, WJ; Chapman, JR; Robinson, LR; Slimp, JC				Mills, WJ; Chapman, JR; Robinson, LR; Slimp, JC			Somatosensory evoked potential monitoring during closed humeral nailing: A preliminary report	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						humerus; nailing; radial nerve; SSEP; somatosensory evoked potential	FRACTURES; SHAFT	Objectives: To assess the role of intraoperative somatosensory evoked potential (SSEP) monitoring of the radial and median nerves in preventing iatrogenic nerve injury during closed, locked intramedullary (IM) nailing of the humerus. Design: Prospective clinical study. Setting: Pacific Northwest Level One trauma center and Southern California military medical center. Patients: Thirteen patients with indications for surgical stabilization of fractures of the humeral diaphysis and either unknown neurologic status of the affected Limb or anticipated difficult reduction maneuvers due to fracture complexity or displacement. Intervention: Closed, antegrade or retrograde locked IM nailing: of the humerus was attempted while intraoperative monitoring of the radial and median nerves with SSEP was performed. Main Outcome Measurements: Intraoperative radial and median nerve SSEP changes during closed fracture manipulation, guide rod insertion, reaming, and humeral nail placement. Results: Baseline recordings were obtained in twelve of thirteen patients for both the radial and median nerves. An absence of radial nerve signal in one patient with a closed head injury prompted an open procedure, revealing entrapment of the radial nerve in the fracture. Intraoperative SSEP changes were observed in two of the twelve remaining patients during fracture manipulation and distal interlocking. The signal amplitude returned after discontinuation of manipulation and traction, and alteration of the interlocking maneuver. No neurologic deficits were noted in these two patients. Conclusions: Intraoperative radial nerve SSEP monitoring appears to reliably reflect the status of the radial nerve in those patients with a humerus fracture. Ln three of eleven patients, intraoperative signal changes prompted a change in surgical plan. In no patient did there appear to be evidence of iatrogenic nerve injury.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Orthopaed Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA	Mills, WJ (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Orthopaed Surg, 325 9Th Ave,Box 359798, Seattle, WA 98104 USA.		Robinson, Lawrence/D-8455-2013	Robinson, Lawrence/0000-0002-9590-8745			BALFOUR GW, 1982, J BONE JOINT SURG AM, V64, P11, DOI 10.2106/00004623-198264010-00002; BLASIER RB, 1996, AM J ORTHOP S, V25, P31; BRUMBACK RJ, 1986, J BONE JOINT SURG AM, V68A, P960, DOI 10.2106/00004623-198668070-00002; CHAPMAN JR, 1988, TECH ORTHOP, V3, P88; FOSTER RJ, 1983, ORTHOP T, V7, P69; HELFET DL, 1994, CLIN ORTHOP RELAT R, V301, P213; Henley M B, 1991, J Orthop Trauma, V5, P14, DOI 10.1097/00005131-199103000-00003; HOLSTEIN A, 1963, J BONE JOINT SURG AM, V45, P1382, DOI 10.2106/00004623-196345070-00004; MAST JW, 1975, CLIN ORTHOP RELAT R, V112, P254; Miller WR, 1996, PSYCHOL ADDICT BEHAV, V10, P81, DOI 10.1037/0893-164X.10.2.81; NASH CL, 1989, J BONE JOINT SURG AM, V71A, P627, DOI 10.2106/00004623-198971040-00019; RIEMER BL, 1991, ORTHOPEDICS, V14, P239; ROBINSON LR, 1993, SPINE, V18, P1793, DOI 10.1097/00007632-199310000-00013; RUEDI T, 1974, RECONS SURG, V14, P65; RUSSELL TA, 1992, ORTHOPAEDIC T, V16, P334; SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P596, DOI 10.2106/00004623-197759050-00004; STERN PJ, 1984, J BONE JOINT SURG AM, V66A, P639, DOI 10.2106/00004623-198466050-00001; Yang KH, 1997, J ORTHOP TRAUMA, V11, P224, DOI 10.1097/00005131-199704000-00015	19	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	MAR-APR	2000	14	3					167	170		10.1097/00005131-200003000-00003			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	305JJ	WOS:000086536100003	10791666				2021-06-18	
J	Orliaguet, C; Rakotoniaina, S; Meyer, P; Blanot, S; Carli, P				Orliaguet, C; Rakotoniaina, S; Meyer, P; Blanot, S; Carli, P			Effect of a pulmonary contusion on the outcome of severely head injured children.	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						head trauma; pulmonary contusion	TRAUMATIC BRAIN INJURY; COMPUTED-TOMOGRAPHY; CHEST INJURIES; SEVERITY; SCALE; PATHOPHYSIOLOGY; MANAGEMENT; PREDICTORS; CHILDHOOD; ADULT	Objectives: To assess the effects of a pulmonary contusion (PC) on the outcome of a severe head trauma (SHT) in children less than -15-year-old. Study design: Retrospective study. Patients: The study included 30 severely head injured children with a Glasgow Coma Scale score (GCS) less than or equal to 8, associated with a PC (PC+) diagnosed on a thoracic CT-scan and 30 severely head injured children without PC (PC-). Methods: Outcome was assessed using the Glasgow Outcome Scale (GOS), on discharge and six months later. Age, body weight, gender, GCS, PTS, ISS, hypoxaemia, arterial hypotension, the results of the cerebral CT-scan, the main treatment administered, complications, the duration of tracheal intubation as well as the duration of stay in the intensive care unit (ICU) and in the hospital were compared between groups. Results: GCS median was lower (6 vs 8, P = 0.001) and ISS median higher (25 vs 23, P = 0.0004) in the PC+ group. Hypoxaemia was more frequent in the PC+ group (n = 12 vs n = 0, P= 0.0001). There was no difference between groups regarding the results of cerebral CT scan. Blood transfusion was more frequently used in the PC+ group (n = 14 vs n = 5, P= 0.03). Median duration of tracheal intubation, and of stay in the ICU and in the hospital were shorter in the PC- group (respectively 8 vs 6 days, P= 0.03; 10 vs 7.5 days, P= 0.008; 13.5 vs 10.5 days, P= 0.01). No difference was observed regarding complications between groups. GOS on discharge was higher in the PC+ group (3 vs 2, P = 0.01). There was an increase in GOS at six months in the two groups, however GOS remained significantly higher in the PC+ group (median values 2 vs 1, P = 0.002). A favourable outcome occurred less frequently in the PC+ group on discharge and at six months (respectively n = 14 vs 25, P= 0.006; n = 20 vs 28, P= 0.02). Conclusion: The association of a PC to a severe head trauma is responsible for a poorer outcome in children, probably because, at least in part, a higher incidence of hypoxaemia. (C) 2000 Editions scientifiques et medicales Elsevier SAS.	Hop Necker Enfants Malad, Detp Anesthesie Reanimat Chirurg & Samu Paris, F-75743 Paris 15, France	Orliaguet, C (corresponding author), Hop Necker Enfants Malad, Detp Anesthesie Reanimat Chirurg & Samu Paris, 149 Rue Sevres, F-75743 Paris 15, France.		Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631; Orliaguet, Gilles/0000-0003-0930-2251			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Allen GS, 1998, SOUTHERN MED J, V91, P1099, DOI 10.1097/00007611-199812000-00002; Allen GS, 1997, J AM COLL SURGEONS, V185, P229, DOI 10.1016/S1072-7515(97)00022-7; Black TL, 1996, SOUTHERN MED J, V89, P494, DOI 10.1097/00007611-199605000-00009; BONADIO WA, 1989, ANN EMERG MED, V18, P1050, DOI 10.1016/S0196-0644(89)80929-1; BRUCE DA, 1979, CHILD BRAIN, V5, P174; DEBEUGNY P, 1991, ANN CHIR, V45, P549; EICHELBERGER MR, 1988, J TRAUMA, V28, P1109, DOI 10.1097/00005373-198808000-00002; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1987, PEDIATRICS, V79, P501; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Magu S, 1998, J Indian Med Assoc, V96, P13; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; MEYER P, 1993, REANIM SOINS INTENS, V9, P134; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NAKAYAMA DK, 1989, ANN SURG, V210, P770, DOI 10.1097/00000658-198912000-00013; OPPENHEIMER L, 1979, J APPL PHYSIOL, V47, P718; ORLIAGUET G, 1996, MED URGENCE, P87; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pinella J, 1982, J TRAUMA, V22, P221; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Task Force on Blood Pressure Control in Children, 1987, PEDIATRIC, V79, P1; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Tocino I, 1987, J Thorac Imaging, V2, P45, DOI 10.1097/00005382-198707000-00008; VENUS B, 1988, CRIT CARE MED, V16, P686, DOI 10.1097/00003246-198807000-00008; WAGNER RB, 1989, SURG CLIN N AM, V69, P31; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	37	12	12	0	0	EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS CEDEX 15	23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.	MAR	2000	19	3					164	170					7	Anesthesiology	Anesthesiology	301ZL	WOS:000086340400004	10782239				2021-06-18	
J	Milders, M				Milders, M			Naming famous faces and buildings	CORTEX			English	Article						dissociation; proper name retrieval; task difficulty	PROPER NAME ANOMIA; PEOPLES NAMES; ANEMIA	Reports of a dissociation between impaired retrieval of people's names and spared retrieval of other categories of proper names have led to the suggestion that there are separate brain mechanisms for processing different categories of proper names. An alternative explanation states that geographical proper names (e.g. cities, countries) may be spared in patients with proper name anemia because they are easier to retrieve than people's names. Unlike people's names, geographical names are also used as adjectives. However, this explanation can not explain why retrieval of proper names that are never used as adjectives (e.g. buildings) was spared in some patients. This study investigated whether retrieving people's names is equally difficult as retrieving the names of buildings. Results from normal subjects and closed-head injured patients revealed no differences between retrieval of people's names and buildings names, and suggested that both categories of proper names are equally vulnerable to brain injury.	Univ Aberdeen, Dept Psychol, Aberdeen AB24 2UB, Scotland	Milders, M (corresponding author), Univ Aberdeen, Dept Psychol, Aberdeen AB24 2UB, Scotland.		Milders, Maarten/C-5560-2008				BRENNEN T, 1990, MEM COGNITION, V18, P339, DOI 10.3758/BF03197123; CARNEY R, 1993, COGNITIVE NEUROPSYCH, V10, P185, DOI 10.1080/02643299308253460; COHEN L, 1994, J NEUROL NEUROSUR PS, V57, P1283, DOI 10.1136/jnnp.57.10.1283; FERY P, 1995, CORTEX, V31, P191, DOI 10.1016/S0010-9452(13)80117-7; Hanley JR, 1998, CORTEX, V34, P155, DOI 10.1016/S0010-9452(08)70745-7; HARRIS DM, 1995, CORTEX, V31, P575, DOI 10.1016/S0010-9452(13)80068-8; HARRIS DM, 1995, BRIT J PSYCHOL, V86, P345, DOI 10.1111/j.2044-8295.1995.tb02757.x; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HITTMAIRDELAZER M, 1994, NEUROPSYCHOLOGIA, V32, P465, DOI 10.1016/0028-3932(94)90091-4; Lucchelli F, 1997, COGNITIVE NEUROPSYCH, V14, P881, DOI 10.1080/026432997381385; LUCCHELLI F, 1992, CORTEX, V28, P221, DOI 10.1016/S0010-9452(13)80050-0; MCKENNA P, 1980, J NEUROL NEUROSUR PS, V43, P781, DOI 10.1136/jnnp.43.9.781; Milders M, 1999, J CLIN EXP NEUROPSYC, V21, P171, DOI 10.1076/jcen.21.2.171.932; Papagno C, 1998, NEUROPSYCHOLOGIA, V36, P669, DOI 10.1016/S0028-3932(97)00142-5; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SEMENZA C, 1988, COGNITIVE NEUROPSYCH, V5, P711, DOI 10.1080/02643298808253279; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3	18	12	12	0	4	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	FEB	2000	36	1					139	145		10.1016/S0010-9452(08)70842-6			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	291MN	WOS:000085740800011					2021-06-18	
J	Penn, C				Penn, C			Paying attention to conversation	BRAIN AND LANGUAGE			English	Article							TRAUMATIC BRAIN INJURY; FLUENT APHASIA; DOUBLE-BLIND; PIRACETAM; COMPREHENSION; INDIVIDUALS; DISORDERS; LANGUAGE; DEMENTIA; STROKE		Univ Witwatersrand, Dept Speech Pathol & Audiol, ZA-2050 Johannesburg, South Africa	Penn, C (corresponding author), Univ Witwatersrand, Dept Speech Pathol & Audiol, ZA-2050 Johannesburg, South Africa.						CROISILE B, 1993, NEUROLOGY, V43, P301, DOI 10.1212/WNL.43.2.301; Davis GA, 1997, BRAIN LANG, V56, P183; ENDERBY P, 1994, CLIN NEUROPHARMACOL, V17, P320, DOI 10.1097/00002826-199408000-00003; Ferguson A, 1998, APHASIOLOGY, V12, P1007, DOI 10.1080/02687039808249466; FRIEDLAND D, 1996, BRAIN INJURY, V12, P1; Haarmann HJ, 1997, BRAIN LANG, V59, P76, DOI 10.1006/brln.1997.1814; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Homma A, 1995, Int Psychogeriatr, V7, P363, DOI 10.1017/S1041610295002109; Huber W, 1997, ARCH PHYS MED REHAB, V78, P245, DOI 10.1016/S0003-9993(97)90028-9; Kagan A, 1998, APHASIOLOGY, V12, P816, DOI 10.1080/02687039808249575; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; KLIPPI A, 1996, CONVERSATION ACHIEVE; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; McNeil MR., 1991, CLIN APHASIOL, V20, P21; MIYAKE A, 1994, COGNITIVE NEUROPSYCH, V11, P671, DOI 10.1080/02643299408251989; Murray LL, 1998, J SPEECH LANG HEAR R, V41, P213, DOI 10.1044/jslhr.4101.213; Orange JB, 1996, J SPEECH HEAR RES, V39, P881, DOI 10.1044/jshr.3904.881; Perkins L, 1998, J NEUROLINGUIST, V11, P33, DOI 10.1016/S0911-6044(98)00004-9; PERKINS L, 1995, INT J PSYCHOLINGUIST, V11, P167; POSNER MI, 1990, ANNU REV NEUROSCI, V1, P25; RUDOLPH K, 1998, 8 INT APH REH C S AF; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SHERRATT SM, 1990, APHASIOLOGY, V4, P539, DOI 10.1080/02687039008248506; SMALL SL, 1994, STROKE, V25, P1282, DOI 10.1161/01.STR.25.6.1282; Tanaka Y, 1997, LANCET, V350, P116, DOI 10.1016/S0140-6736(05)61820-X; TSENG CH, 1993, BRAIN LANG, V45, P276, DOI 10.1006/brln.1993.1046	26	12	12	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JAN	2000	71	1					185	189		10.1006/brln.1999.2247			5	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	291GK	WOS:000085725600053	10716842				2021-06-18	
J	Potter, DD; Pickles, CD; Roberts, RC; Rugg, MD				Potter, DD; Pickles, CD; Roberts, RC; Rugg, MD			The effect of cholinergic receptor blockade by scopolamine on memory performance and the auditory P3	JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						ACh; N1; P2; N2; P300; P3a; P3b ERP; memory; attention; amnesia	EVENT-RELATED POTENTIALS; SINGLE-STIMULUS PARADIGM; MEDIAL TEMPORAL-LOBE; CLOSED HEAD-INJURY; BRAIN POTENTIALS; COGNITIVE POTENTIALS; RECOGNITION MEMORY; ODDBALL TASK; TOPOGRAPHY; LESIONS	previous research has suggested a possible link between the effects of scopolamine-induced muscarinic cholinergic receptor blockade on memory and its effect on auditory P3 amplitude and latency. A potential problem with this hypothesis is that, although scopolamine has been reported to increase P3 latency in both visual and auditory modalities, amplitude reductions have been reported only in the case of auditory P3 at Ct. In the present study, subjects were injected intravenously with 5.7 mu g/kg of scopolamine of saline in a double blind design. A significant reduction in verbal recognition memory performance was observed. This memory impairment was shown to be largely specific to the encoding of verbal material. The drug effect was of equal magnitude when words of either high or low word frequency were used. Auditory P3 was recorded from frontal central and parietal sites along the midline and over left and right hemispheres. In contrast to a number of earlier reports using a similar drug dose, only limited evidence was found of either latency increase or amplitude reduction of the auditory P3. Importantly, two potentially confounding drug-related ERP modulations were observed prior to and during the latency range of the P3. The first was a widespread increase in N2 amplitude and latency preceding the P3. The second was that ERPs became relatively more negative at frontal and central sites in the 200-450 ms latency range in both target and non-target conditions. Whether this effect is the result of an increase in negativity or a reduction in P3a amplitude remains to be determined. Interestingly, ERPs to target stimuli became significantly less positive at frontal sites in the drug condition in the latency range 400-900 ms. This is consistent with recent reports highlighting the importance of frontal regions in normal memory function. Previously hypothesized links between cholinergic receptor blockade, effects on P3 latency and amplitude, and drug-induced memory impairments are discussed in the light of these findings.	Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland; Univ St Andrews, Sch Psychol, St Andrews KY16 9AJ, Fife, Scotland; Univ Dundee, Dept Med, Dundee DD1 4HN, Scotland; Dundee Royal Infirm, Dept Neurol, Dundee, Scotland; Keele Univ, Dept Psychol, Keele, Staffs, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England; UCL, Dept Psychol, London WC1E 6BT, England	Potter, DD (corresponding author), Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland.	d.d.potter@dundee.ac.uk					Allan K, 1998, ACTA PSYCHOL, V98, P231, DOI 10.1016/S0001-6918(97)00044-9; ALTAFULLAH I, 1986, ELECTROEN CLIN NEURO, V63, P503, DOI 10.1016/0013-4694(86)90138-0; BRANDT D, 1992, WRIT COMMUN, V9, P315, DOI 10.1177/0741088392009003001; CALLAWAY E, 1985, PSYCHOPHARMACOLOGY, V85, P133, DOI 10.1007/BF00428401; CALLAWAY E, 1984, BIOL PSYCHIAT, V19, P649; CALLAWAY E, 1992, BIOL PSYCHOL, V33, P1, DOI 10.1016/0301-0511(92)90002-C; CRAIK F, 1993, 34 ANN M PSYCH SOC W; CURRAN HV, 1991, PSYCHOPHARMACOLOGY, V103, P83; Donaldson DI, 1999, COGNITIVE BRAIN RES, V8, P1, DOI 10.1016/S0926-6410(98)00051-2; Duzel E, 1999, P NATL ACAD SCI USA, V96, P1794, DOI 10.1073/pnas.96.4.1794; Duzel E, 1997, P NATL ACAD SCI USA, V94, P5973, DOI 10.1073/pnas.94.11.5973; Fletcher PC, 1998, BRAIN, V121, P1239, DOI 10.1093/brain/121.7.1239; FRITH CD, 1984, Q J EXP PSYCHOL-A, V36, P133, DOI 10.1080/14640748408401507; GRAHAM JDP, 1979, INTRO HUMAN PHARM; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; HAMMOND EJ, 1987, NEUROLOGY, V37, P346, DOI 10.1212/WNL.37.2.346; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P633, DOI 10.1111/j.1469-8986.1989.tb03165.x; Johnson R, 1998, COGNITIVE BRAIN RES, V7, P119, DOI 10.1016/S0926-6410(98)00017-2; JORY SH, IN PRESS J PSYCHOPHY; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; KNOPMAN D, 1991, J EXP PSYCHOL LEARN, V17, P1017, DOI 10.1037/0278-7393.17.5.1017; KOPELMAN MD, 1988, BRAIN, V111, P1079, DOI 10.1093/brain/111.5.1079; MCCARTHY G, 1989, J NEUROSCI, V9, P4253; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; MEADOR KJ, 1987, INT J NEUROSCI, V33, P199, DOI 10.3109/00207458708987404; MEADOR KJ, 1989, J CLIN EXP NEUROPSYC, V11, P252, DOI 10.1080/01688638908400887; MEADOR KJ, 1988, ARCH NEUROL-CHICAGO, V45, P465, DOI 10.1001/archneur.1988.00520280119029; MEADOR KJ, 1988, J GERONTOL, V43, pM158, DOI 10.1093/geronj/43.6.M158; MEADOR KJ, 1989, NEUROPSY NEUROPSY BE, V2, P161; Mertens R, 1997, EVOKED POTENTIAL, V104, P488, DOI 10.1016/S0168-5597(97)00041-5; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAUMANN E, 1992, ELECTROEN CLIN NEURO, V83, P254, DOI 10.1016/0013-4694(92)90119-3; Naveh-Benjamin M, 1998, J EXP PSYCHOL LEARN, V24, P1091, DOI 10.1037/0278-7393.24.5.1091; ONOFRJ M, 1992, NEUROLOGY, V42, P1762, DOI 10.1212/WNL.42.9.1762; ONOFRJ M, 1991, ELECTROEN CLIN NEURO, V78, P480, DOI 10.1016/0013-4694(91)90065-C; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PINEDA JA, 1992, BRAIN RES BULL, V28, P485, DOI 10.1016/0361-9230(92)90051-X; PINEDA JA, 1991, ELECTROEN CLIN NEURO, P165; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P747, DOI 10.1111/j.1469-8986.1996.tb02371.x; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; POLSTER MR, 1993, PSYCHOL BULL, V114, P477, DOI 10.1037/0033-2909.114.3.477; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; POTTER DD, 1993, NEW DEVELOPMENTS IN EVENT-RELATED POTENTIALS, P303; POTTER DD, 1992, PSYCHOPHYSIOLOGY, V29, P29, DOI 10.1111/j.1469-8986.1992.tb02007.x; POTTER DD, IN PRESS BIOL PSCHOL; ROBBINS TW, 1995, COGNITIVE NEUROSCIEN, P684; ROGERS RL, 1992, ELECTROEN CLIN NEURO, V83, P146, DOI 10.1016/0013-4694(92)90028-G; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1990, MEM COGNITION, V18, P367, DOI 10.3758/BF03197126; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; Rugg MD., 1994, COGNITIVE ELECTROPHY, P124, DOI 10.1007/978-1-4612-0283-7%5F5; RUGG MD, 1994, HDB NEUROPSYCHOLOGY, V9; RUSTED JM, 1989, NEUROPSYCHOBIOLOGY, V21, P31, DOI 10.1159/000118548; SAHAKIAN BJ, 1988, HDB PSYCHOPHARMACOLO, V20, P393; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; SMITH ME, 1990, ELECTROEN CLIN NEURO, V76, P235, DOI 10.1016/0013-4694(90)90018-F; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; Van Horn JD, 1998, BRAIN RES, V793, P29, DOI 10.1016/S0006-8993(98)00051-1; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANPETTEN C, 1991, J COGNITIVE NEUROSCI, V3, P129; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; VERLEGER R, 1994, COGNITIVE BRAIN RES, V2, P103, DOI 10.1016/0926-6410(94)90007-8; WARBURTON DM, 1987, COGNITIVE NEUROCHEMI, P135; Woods DL., 1990, EVENT RELATED BRAIN, P178	66	12	12	0	0	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY	0269-8803			J PSYCHOPHYSIOL	J. Psychophysiol.		2000	14	1					11	23		10.1027//0269-8803.14.1.11			13	Psychology, Biological; Neurosciences	Psychology; Neurosciences & Neurology	302LP	WOS:000086366800002					2021-06-18	
J	Smith, RV; Krevitt, L; Yi, SM; Beitler, JJ				Smith, RV; Krevitt, L; Yi, SM; Beitler, JJ			Early wound complications in advanced head and neck cancer treated with surgery and Ir-192 brachytherapy	LARYNGOSCOPE			English	Article; Proceedings Paper	Meeting of the Eastern Section of the American-Laryngological-Rhinological-and-Otological-Society Inc	JAN 29-31, 1999	PROVIDENCE, RHODE ISLAND	Amer Laryngol Rhinol & Otol Soc Inc, Eastern Sect		wound complications; brachytherapy; iridium 192; adjuvant therapy; head and neck cancer	FREE-FLAP RECONSTRUCTION; I-125 SEED IMPLANTATION; INTERSTITIAL RADIOTHERAPY; SALVAGE TREATMENT; RECURRENT HEAD; LOCAL-CONTROL; TUMORS	Objectives: Brachytherapy, either as primary or adjuvant therapy, is increasingly used to treat head and neck cancer. Reports of complications from, the use of brachytherapy as adjuvant therapy to surgical excision have been limited and primarily follow Iodine 125 (I-125) therapy, Early complications include wound breakdown, infection, flap failure, and sepsis, and late complications may include osteoradionecrosis, bone marrow suppression, or carotid injuries. The authors sought to identify the early wound complications that follow adjuvant interstitial brachytherapy with iridium 192 (Ir-192). Study Design: A retrospective chart review of all patients receiving adjuvant brachytherapy at a tertiary medical center over a 4-year period. Methods: Nine patients receiving Ir-192 brachytherapy via afterloading catheters placed during surgical resection for close or microscopically positive margin control were evaluated. It was used during primary therapy in six patients and at salvage surgery in three. Early complications were defined as those occurring within 6 weeks of surgical therapy. Results: The overall complication rate was 55% (5/9), and included significant wound breakdown in two patients, minor wound dehiscence in three, and wound infection, bacteremia, and local tissue erosion in one patient each. All complications occurred in patients receiving Bap reconstruction and one patient required further surgery to manage the complication. Complication rates were not associated with patient age, site, prior radiotherapy, timing of therapy, number of catheters, or dosimetry, Conclusions: The relatively high complication rate is acceptable, given the minor nature of most and the potential benefit of radiotherapy. Further study should be undertaken to identify those patients who will achieve maximum therapeutic benefit without prohibitive local complications.	Montefiore Med Ctr, Albert Einstein Coll Med, Dept Otolaryngol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiat Therapy, Bronx, NY 10467 USA; Univ Iowa, Dept Otolaryngol, Iowa City, IA USA	Smith, RV (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Otolaryngol, 111 E 210th St, Bronx, NY 10467 USA.						Beitler JJ, 1998, INT J RADIAT ONCOL, V40, P313, DOI 10.1016/S0360-3016(97)00717-7; BILLER HF, 1981, ARCH OTOLARYNGOL, V107, P23; CLOSE LG, 1993, LARYNGOSCOPE, V103, P231; Cornes PGS, 1996, BRIT J SURG, V83, P1620, DOI 10.1002/bjs.1800831141; FEE WE, 1983, ARCH OTOLARYNGOL, V109, P727; FONTANESI J, 1989, INT J RADIAT ONCOL, V17, P365, DOI 10.1016/0360-3016(89)90452-5; LANGLOIS D, 1988, INT J RADIAT ONCOL, V14, P849, DOI 10.1016/0360-3016(88)90004-1; LEE DJ, 1991, RADIOLOGY, V178, P879, DOI 10.1148/radiology.178.3.1994436; MEHRHOF AI, 1983, AM J SURG, V146, P478, DOI 10.1016/0002-9610(83)90235-0; MOSCOSO JF, 1994, ARCH OTOLARYNGOL, V120, P965; PANCHAL JI, 1993, BRIT J PLAST SURG, V46, P511, DOI 10.1016/0007-1226(93)90227-3; PARK RI, 1991, LARYNGOSCOPE, V101, P405; Righi PD, 1997, LARYNGOSCOPE, V107, P1464, DOI 10.1097/00005537-199711000-00008; STAFFORD N, 1988, BRIT J SURG, V75, P62, DOI 10.1002/bjs.1800750123; SYED AMN, 1978, BRIT J RADIOL, V51, P814, DOI 10.1259/0007-1285-51-610-814	15	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0023-852X			LARYNGOSCOPE	Laryngoscope	JAN	2000	110	1					8	12		10.1097/00005537-200001000-00002			5	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	275DY	WOS:000084805200002	10646707	Bronze			2021-06-18	
J	Docking, K; Jordan, FM; Murdoch, BE				Docking, K; Jordan, FM; Murdoch, BE			Interpretation and comprehension of linguistic humour by adolescents with head injury: a case-by-case analysis	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; LANGUAGE PERFORMANCE; CHILDREN; CHILDHOOD; SKILLS	The aim of the present study was to examine the Linguistic humour abilities of a group of adolescents with head injury on a case-by-case basis. Nine adolescents with head injury ag;ed between 12 years 1 month and 15 years 4 months, and nine individually matched adolescents aged between 12 years 1 month and 16 years 1 month were administered a humour test, a standard language battery, the CELF-3, and the Self-Esteem Index. The test of humour abilities required each subject to recognize and select an explanation from a group of three, as to what made each item funny. Items were based on morphological, semantic and syntactic humour elements. Examination of the individual profiles of each subject with head injury illustrated the existence of variability between subjects representing three main trends: reduced humour abilities together with below average language skills; intact humour and language abilities in the presence of mild head injury; and impaired humour ability with concurrent language skills that are within normal limits. This third pattern supports previous studies, which have documented the occurrence of high-level language impairment while language abilities are intact. The present study emphasized the importance of investigating the abilities of individuals who have had a head injury in childhood, within a developmental framework. This perspective serves to highlight the context of contributing aspects that impact on future language development and recovery of injury, such as the time that the injury occurred in a child's development, in addition to injury severity and the time that has elapsed post-injury.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia; Royal Childrens Hosp, Brisbane, Qld 4029, Australia	Murdoch, BE (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.		Murdoch, Bruce E/C-1397-2012				BERNSTEIN DK, 1986, TOP LANG DISORD, V6, P65, DOI 10.1097/00011363-198609000-00008; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Brown L., 1991, SELF ESTEEM INDEX; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; DENNIS M, 1992, TOP LANG DISORD, V13, P66, DOI 10.1097/00011363-199211000-00008; DENNIS M, 1987, ENCY NEUROSCIENCE, P559; Dennis Maureen, 1988, CLIN NEUROPSYCHOLOGY, P89; DOCKING K, IN PRESS BRAIN INJUR; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; HAMERSKY J, 1995, CARTOON CUT UPS TEAC; JORDAN F M, 1990, Brain Injury, V4, P27; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; JORDAN FM, 1995, APHASIOLOGY, V9, P23, DOI 10.1080/02687039508248686; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; JORDAN FM, 1990, ACQUIRED NEUROLOGICA, P124; JORDAN FM, 1989, INT J NEUROSCI, V46, P12; LEES JA, 1993, CHILDREN ACQUIRED AP; Lehr E, 1990, PSYCHOL MANAGEMENT T; Nelson C., 1991, PRACTICAL PROCEDURES; Nippold M., 1983, LANG SPEECH HEAR SER, V14, P171, DOI DOI 10.1044/0161-1461.1403.171; NIPPOLD MA, 1985, TOP LANG DISORD, V5, P1, DOI 10.1097/00011363-198506000-00004; SEMEL E, 1995, CLIN EVALUATION LANG, V3; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	29	12	12	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1999	13	12					953	972					20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600002	10628501				2021-06-18	
J	Hendler, T; Goshen, E; Tadmor, R; Lustig, M; Zwas, ST; Zohar, J				Hendler, T; Goshen, E; Tadmor, R; Lustig, M; Zwas, ST; Zohar, J			Evidence for striatal modulation in the presence of fixed cortical injury in obsessive-compulsive disorder (OCD)	EUROPEAN NEUROPSYCHOPHARMACOLOGY			English	Article						head injury; cortical lesions; single photon emission computerised tomography (SPECT); computerized tomography (CT); magnetic resonance imaging (MRI); neural circuit	TRAUMATIC BRAIN INJURY; BASAL GANGLIA; BEHAVIORAL-CHANGES; SPECT; TOMOGRAPHY; PERFUSION; THERAPY; LESIONS; DRUG	A patient with obsessive-compulsive disorder (OCD) onset resulting from a traumatic head injury underwent longitudinal brain imaging evaluation. Structural and functional brain imaging studies were repeatedly performed before and after treatment. Computerized tomography (CT) demonstrated bilateral prefrontal contusions immediately following the trauma and prior to the onset of OCD. Magnetic resonance imaging (MRI) demonstrated bilateral cortical abnormalities in the prefrontal and anterior-temporal regions a few months following the onset of OCD. Almost concurrently, single photon emission computerised tomography (SPECT) demonstrated bilateral perfusion deficits in fronto-temporal regions, and asymmetric increased perfusion in the anterior striatum. Six months later, after clinical improvement, a second SPECT study demonstrated improvement of brain perfusion, mostly in the striatum. The reflection of these results on a possible model of brain pathogenesis in OCD, and the role of brain imaging in neuropsychiatric evaluation, are demonstrated. (C) 1999 Elsevier Science B.V./ECNP. All rights reserved.	Chaim Sheba Med Ctr, Dept Psychiat, IL-52621 Tel Hashomer, Israel; Sackler Sch Med, Dept Nucl Med, Tel Aviv, Israel; Tel Aviv Univ, Dept Imaging, IL-69978 Tel Aviv, Israel	Hendler, T (corresponding author), Chaim Sheba Med Ctr, Dept Psychiat, IL-52621 Tel Hashomer, Israel.	talma@tasmc.health.gov.il	hendler, talma/C-7677-2012				ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; AMES D, 1994, J NEUROPSYCH CLIN N, V6, P100; BAXTER LR, 1992, PSYCHIAT CLIN N AM, V15, P871; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BAXTER LR, 1987, ARCH GEN PSYCHIAT, V44, P211; DICHIARA G, 1994, TRENDS NEUROSCI, V17, P228, DOI 10.1016/0166-2236(94)90005-1; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; EBLEN F, 1995, J NEUROSCI, V15, P5999; GOSHEN E, 1994, EUR J NUCL MED, V21, pS70; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; HOEHNSARIC R, 1994, CURRENT INSIGHTS OCD; HOLMAN BL, 1992, J NUCL MED, V33, P1888; ICHISE M, 1994, J NUCL MED, V35, P217; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KIM JS, 1977, BRAIN RES, V132, P370, DOI 10.1016/0006-8993(77)90430-9; LAPLANE D, 1989, BRAIN, V112, P699, DOI 10.1093/brain/112.3.699; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LUXENBERG JS, 1988, AM J PSYCHIAT, V145, P1089; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; MOLINA V, 1995, J NUCL MED, V36, P2234; PARENT A, 1990, TRENDS NEUROSCI, V13, P254, DOI 10.1016/0166-2236(90)90105-J; RAPOPORT JL, 1988, PSYCHOPHARMACOL BULL, V24, P380; ROGERS MP, 1994, PSYCHOSOMATICS, V35, P402, DOI 10.1016/S0033-3182(94)71763-1; SCARONE S, 1994, PSYCHIAT RES, V45, P115; SCATTON B, 1982, BRAIN RES, V232, P331, DOI 10.1016/0006-8993(82)90277-3; SIMPSON S, 1995, BRIT J PSYCHIAT, V166, P390, DOI 10.1192/bjp.166.3.390; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P518; TIKOFSKY RS, 1994, J NUCL MED, V35, P227; VILLABLANCA JR, 1976, EXP NEUROL, V52, P389, DOI 10.1016/0014-4886(76)90213-2; VOLKOW ND, 1991, AM J PSYCHIAT, V148, P439	31	12	12	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0924-977X	1873-7862		EUR NEUROPSYCHOPHARM	Eur. Neuropsychopharmacol.	SEP	1999	9	5					371	376					6	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	244RK	WOS:000083064400001	10523043				2021-06-18	
J	McNair, ND				McNair, ND			Traumatic brain injury	NURSING CLINICS OF NORTH AMERICA			English	Article							CEREBRAL BLOOD-FLOW; ARTERIOVENOUS OXYGEN DIFFERENCE; CLOSED HEAD-INJURY; COMATOSE PATIENTS; INTRACRANIAL HYPERTENSION; PRACTICAL SCALE; METABOLISM; AGITATION; ALCOHOL	Every year, approximately 7 million people sustain some type of traumatic brain injury (TBI) in the United States. Of these, approximately 500,000 require hospitalization.(24) Another 100,000 are permanently disabled and approximately 2000 remain in a persistent vegetative state.(16) The societal cost of care for the survivors of TBI is estimated to be between $48 and $83.5 billion annually. Of patients admitted to the emergency room, more than 50% have high alcohol or drug levels. Most individuals are men younger than 30 years of age.(24) TBIs can change the lives of patients and their families significantly. Motor vehicle accidents, falls, assault, or sports injury can result in TBI. Injury may be classified based on severity, location, mechanism, Glasgow Coma Scale (GCS) score, or the results of neuroimaging studies.(16,24) The purpose of this article is to describe TBIs, treatment options, multidisciplinary management, and expected outcomes. Severity of injury is based on the postresuscitation GCS.(33) A GCS Of 13 to 15 is considered a mild injury, 8 to 12 is a moderate injury, and less than 8 is a severe brain injury (Fig. 1). A mild head. injury may include transient signs and symptoms such as unsteady gait or mild confusion. Most patients seen in the emergency room have mild head injuries.(24) Most patients make a full recovery, but others may have postinjury sequelae such as a postconcussion syndrome for a few weeks to a few months. In postconcussion syndrome, patients complain of headache, difficulty concentrating, short-term memory deficits, depression, anxiety, irritability, and fatigue. These symptoms are often not appreciated initially until difficulty with work or school is encountered and medical attention is sought.	Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Liver Transplant & Surg Subspecialties Intens Car, Los Angeles, CA 90024 USA	McNair, ND (corresponding author), 2307 Ocean Ave,215, Los Angeles, CA 90045 USA.						ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 1995, GUID MAN SEV HEAD IN; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; *COMM TRAUM AM COL, 1993, ADV TRAUM LIF SUPP C; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; GOTOH F, 1965, ARCH NEUROL-CHICAGO, V12, P410, DOI 10.1001/archneur.1965.00460280080008; HAYEK DA, 1992, CRITICAL CARE, P1449; HICKEY JV, 1997, CLIN PRACTICE NEUROL, P385; JENNETT B, 1976, LANCET, V1, P1031; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PETERSON PL, 1998, NEUROLOGICAL NEUROSU, P1; *RANCH LOS AM HOSP, 1980, REH HEAD INJ AD; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SANDEL ME, 1998, NEUROLOGICAL NEUROSU, P503; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; TEASDALE G, 1974, LANCET, V2, P81; *UN DAT SYST MED R, 1989, FUNCT IND MEAS FIM G; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581	35	12	15	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0029-6465			NURS CLIN N AM	Nurs. Clin. North Am.	SEP	1999	34	3					637	+					25	Nursing	Nursing	235BM	WOS:000082519100008	10433652				2021-06-18	
J	Cossa, FM; Fabiani, M; Farinato, A; Laiacona, M; Capitani, E				Cossa, FM; Fabiani, M; Farinato, A; Laiacona, M; Capitani, E			The 'preliminary neuropsychological battery'. An instrument to grade the cognitive level of minimally responsive patients	BRAIN INJURY			English	Article							HEAD-INJURED PATIENTS; TRAUMATIC BRAIN INJURY; ATTENTIONAL DEFICITS; COMA; IMPAIRMENT; SCORES; SCALE; TOOL	An early, formalized cognitive evaluation of 'minimally responsive' patients could be important in the planning of their care and rehabilitation as well as in providing a realistic prognosis and studying the modality of the cognitive recovery. A shea, bedside, neuropsychologically-oriented test-battery, the Preliminary Neuropsychological Battery, a psychometric tool which enables the cognitive evaluation of these patients and of patients unable to give verbal or complex motor answers, has been devised. The BNP was administered to a sample of 40 head-injured patients and to a sample of 34 healthy subjects. The aim was (i) to evaluate its usefulness, and (ii) to study its correlation with cortical functions as assessed by a more extensive battery. The findings suggest that the BNP is useful for assessing the general cognitive level of head-injured post-comatose patients. It was able to detect patients deserving a wider, analytic, neuropsychological assessment. Attentional defects emerged as an important variable determining the BNP score.	Rehabil Inst Veruno, Salvatore Maugeri Fdn IRCCS, Dept Neurol, Neuropsychol Unit, I-28010 Veruno, NO, Italy; Rehabil Inst Veruno, Salvatore Maugeri Fdn IRCCS, Psychol Serv, I-28010 Veruno, NO, Italy; Univ Milan, San Paolo Hosp, Clin Nervous Dis, Milan, Italy	Cossa, FM (corresponding author), Rehabil Inst Veruno, Salvatore Maugeri Fdn IRCCS, Dept Neurol, Neuropsychol Unit, I-28010 Veruno, NO, Italy.	fcossa@fsm.it		Fabiani, Monica/0000-0002-7579-2773			ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; BARBAROTTO R, 1999, ASSISTENZA CLIN RICE, P29; Basso A, 1987, Funct Neurol, V2, P189; Benton AL., 1983, CONTRIBUTION NEUROPS; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; Capitani E, 1997, J CLIN EXP NEUROPSYC, V19, P795, DOI 10.1080/01688639708403761; CAPITANI E, 1988, DEV NEUROPSYCHOL, V4, P325, DOI 10.1080/87565648809540416; DELLASALA S, 1992, PSYCHOL MED, V22, P885, DOI 10.1017/S0033291700038460; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Flannery J, 1993, West J Nurs Res, V15, P465, DOI 10.1177/019394599301500406; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Guilford J. P., 1965, FUNDAMENTAL STAT PSY; HAJEK VE, 1989, ARCH PHYS MED REHAB, V70, P114; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; MALKMUS D, 1980, COGNITIVE ASSESSMENT, P1; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MATEKOLE CC, 1994, ARCH PHYS MED REHAB, V75, P867; Novelli G., 1986, ARCH PSICOL NEUROL P, V2, P278; ORSINI A, 1987, ITAL J NEUROL SCI, V8, P539; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prigatano GP, 1997, ARCH PHYS MED REHAB, V78, P621, DOI 10.1016/S0003-9993(97)90428-7; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Walker WC, 1996, BRAIN INJURY, V10, P65; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5	34	12	12	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					583	592					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200003	10901687				2021-06-18	
J	Prasad, MR; Ewing-Cobbs, L; Baumgartner, J				Prasad, MR; Ewing-Cobbs, L; Baumgartner, J			Crush head injuries in infants and young children: Neurologic and neuropsychologic sequelae	JOURNAL OF CHILD NEUROLOGY			English	Article; Proceedings Paper	26th Annual Meeting of the International-Neuropsychological-Society	FEB 04-05, 1998	HONOLULU, HI	Int Neuropsychol Soc			SKULL FRACTURES; AGE; SCALE; COMA	Neurologic and neuropsychologic sequelae of crush head injury, which is produced by static forces occurring when the head is stationary and pinned against a rigid structure, were studied prospectively in a series of eight children ranging in age from 13 to 32 months. Hospital course, computed tomographic findings, and neurologic and developmental outcomes were examined. All children sustained pronounced cerebral trauma characterized by multiple fractures throughout the calvaria, extra-axial hemorrhages, and parenchymal contusions. Cranial nerve injuries were noted in three and hemiparesis in two of the cases. Two months after the injury, 63% of the children displayed deficits in either IQ or motor functioning. One year after the injury, five of the six children reevaluated had a good recovery. Motor scores were significantly lower than cognitive scores at baseline and showed the greatest degree of improvement over time. Neuropsychologic outcome after brain injury produced by static loading of the head is more favorable than from traumatic brain injury associated with dynamic loading.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Div Dev Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, Div Dev Pediat, 7000 Fannin,Ste 2431, Houston, TX 77030 USA.	lewing@ped1.med.uth.tmc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [29462, 21889, 27597] Funding Source: Medline		Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BAYLEY N, 1984, MANUAL BAYLEY SCALES; Bayley N., 1993, MANUAL BAYLEY SCALES, V2nd; BERNARD PA, 1998, PEDIATRICS, P102; BERNEY J, 1994, CHILD NERV SYST, V10, P517, DOI 10.1007/BF00335074; Choux M., 1986, HEAD INJURIES NEWBOR, P163; CORRADINO G, 1990, NEUROSURGERY, V27, P592, DOI 10.1227/00006123-199010000-00015; DUHAIME AC, 1995, NEUROSURGERY, V37, P401, DOI 10.1227/00006123-199509000-00005; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; HARWOODNASH DC, 1971, RADIOLOGY, V101, P151, DOI 10.1148/101.1.151; HISS J, 1995, J TRAUMA, V38, P32, DOI 10.1097/00005373-199501000-00010; JENNETT B, 1975, LANCET, V1, P480; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; MANN KS, 1986, CHILD NERV SYST, V2, P258; McCarthy D., 1972, MCCARTHY SCALES CHIL; MINER ME, 1986, NEUROTRAUMA, V1, P233; POSNICK JC, 1994, ANN PLAS SURG, V33, P442, DOI 10.1097/00000637-199410000-00017; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RUSSELL WR, 1949, J NEUROL NEUROSUR PS, V12, P52, DOI 10.1136/jnnp.12.1.52; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; THORNDIKE RL, 1986, STANFORDBINET INTELL	25	12	12	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	AUG	1999	14	8					496	501		10.1177/088307389901400803			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	223KX	WOS:000081841200003	10456758				2021-06-18	
J	Beaumont, A; Marmarou, A				Beaumont, A; Marmarou, A			Treatment of raised intracranial pressure following traumatic brain injury	CRITICAL REVIEWS IN NEUROSURGERY			English	Article						refractory intracranial pressure (ICP) management; vasopressors; mannitol; glycerol; hypertonic saline; bifrontal craniectomy	EDEMA; THERAPY; SALINE	Appropriate treatment of raised intracranial pressure (ICP) after traumatic brain injury (TBI) remains a controversial topic in neurotraumatology. Several techniques are employed clinically, which include vasopressors, osmotically active substances, hyperventilation, and decompressive surgery. This article reviews six recent papers that have examined alternative methods of treating elevated ICP. The first two papers consider a new and controversial alternative to cerebral perfusion pressure (CPP) management, which involves mild hypotension coupled with pre-capillary vasoconstriction using dihydroergotamine. The authors claim success with this treatment, and although the patient numbers are small, there is no evidence that they fare any less well than patients treated with conventional techniques. The third and fourth papers consider hypertonic saline (HTS) as a possible osmotic treatment for raised ICP. The third examines HTS given as a 23.4% bolus and found beneficial effects. The fourth examines HTS as a 1.6% constant infusion for fluid replacement and found that patients fared less well. The reason for this difference between the results for the two administration methods is unknown, although it may relate to the triggering of body homeostatic mechanisms in the case of constant infusion. The fifth paper compares glycerol and mannitol as osmotic ICP agents and found no significant differences between them. The final study reports for the first time a series of patients treated for refractory elevations in ICP with bifrontal craniectomy. They report good results, and suggest that this therapy should be formalized as a treatment option for severely elevated ICP. The pathophysiological mechanisms underlying the generation of a raised ICP belie the use of one therapy to treat all cases. Analysis of these studies demonstrates how problematic heterogeneity in the injury population can be for the assessment of possible treatments. It is clear, therefore, that effective analysis of treatments for raised ICP requires appropriate subdivision of the injured population into common pathophysiological processes and, furthermore, that the future of clinical TBI management may well require a similar stratification in order to tailor treatments for the individual patient.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA			Beaumont, Andrew/AAJ-7457-2020				ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Biestro A, 1997, ACTA NEUROCHIR, V139, P725, DOI 10.1007/BF01420045; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038	6	12	12	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0939-0146			CRIT REV NEUROSURG	Crit. Rev. Neurosurg.	JUL	1999	9	4					207	216		10.1007/s003290050135			10	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	223PK	WOS:000081849300002	10436209				2021-06-18	
J	Schwab, S; Schwarz, S; Bertram, M; Spranger, M; Hacke, W				Schwab, S; Schwarz, S; Bertram, M; Spranger, M; Hacke, W			Benefit and side effects of moderate hypothermia in the therapy of malignant MCA infarction	NERVENARZT			German	Article						brain edema; hypothermia; therapy	TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; CEREBRAL-ISCHEMIA; INTRACRANIAL-PRESSURE; RATS; COAGULATION; ARREST; STROKE; EDEMA	Moderate hypothermia was induced in 30 patients with malignant middle cerebral artery (MCA) territory infarction. Patients were kept at 33 degrees C body-core temperature for 48 to 72 h, and ICP, CPP, and brain temperature were monitored. Outcome at 4 weeks and at 3 months after the stroke as well as side effects of moderate hypothermia were analysed. Mortality of malignant MCA infarction could be reduced from 80% in historical controls, to 43% (13/30) under hypothermia. During hypothermia elevated ICP values could be significantly reduced. Herniation due to a secondary rise of ICP after rewarming was the cause of death in all 13 patients. The most frequent complication of moderate hypothermia was pneumonia in 12 of the 30 patients (40%). Other severe side effects of hypothermia could not be detected. Moderate hypothermia may improve clinical outcome in patients with malignant MCA infarction.	Heidelberg Univ, Neurol Klin, D-69120 Heidelberg, Germany	Schwab, S (corresponding author), Heidelberg Univ, Neurol Klin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Hacke, Werner/ABE-8661-2020				[Anonymous], 1985, Stroke, V16, P885; AOYAGI M, 1975, CIRCULATION, V52, P52; AUSMAN JI, 1993, J NEUROSURG, V79, P810, DOI 10.3171/jns.1993.79.6.0810; BERRY RG, 1957, NEUROLOGY, V7, P223, DOI 10.1212/WNL.7.4.223; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BOUNDS JV, 1981, STROKE, V12, P474, DOI 10.1161/01.STR.12.4.474; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CHIARA O, 1987, CRIT CARE MED, V15, P995, DOI 10.1097/00003246-198711000-00001; CLIFTON GL, 1995, J NEUROSURG ANESTH, V7, P152, DOI 10.1097/00008506-199504000-00023; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DUGUID H, 1961, LANCET, V2, P1213; FOULIS AK, 1982, J CLIN PATHOL, V35, P1244, DOI 10.1136/jcp.35.11.1244; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HAYASHI N, 1994, ACTA NEUROCHIR, P541; HERVEY GR, 1973, P ROY SOC MED, V66, P1053, DOI 10.1177/003591577306601034; HIRANO T, 1992, BRIT J SURG, V79, P803, DOI 10.1002/bjs.1800790832; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; MAHONEY F I, 1965, Md State Med J, V14, P61; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MICHENFELDER JD, 1977, STROKE, V8, P87, DOI 10.1161/01.STR.8.1.87; MORALES P, 1957, ANN SURG, V145, P488, DOI 10.1097/00000658-195704000-00005; RANKIN J, 1957, Scott Med J, V2, P200; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; RUIZSANTANA S, 1987, CRIT CARE MED, V15, P930, DOI 10.1097/00003246-198710000-00007; Safar P, 1996, CRIT CARE MED, V24, P911, DOI 10.1097/00003246-199606000-00004; Schwab S, 1996, AKTUEL NEUROL, V23, P155, DOI 10.1055/s-2007-1017853; SCHWAB S, 1994, NERVENARZT, V65, P828; Schwab S, 1998, ACT NEUR S, V71, P131; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; TEASDALE G, 1976, LANCET, V1, P484; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; WHITE OB, 1979, STROKE, V10, P743, DOI 10.1161/01.STR.10.6.743; YOSHIHARA H, 1985, THROMB RES, V37, P503, DOI 10.1016/0049-3848(85)90096-9	47	12	12	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-2804	1433-0407		NERVENARZT	Nervenarzt	JUN	1999	70	6					539	+		10.1007/s001150050477			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	206ZJ	WOS:000080910500009	10412699				2021-06-18	
J	Andersen, G; Stylsvig, M; Sunde, N				Andersen, G; Stylsvig, M; Sunde, N			Citalopram treatment of traumatic brain damage in a 6-year-old boy	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; child; citalopram; crying; motor paresis; serotonin; sleep	INJURY; DEPRESSION	Traumatic brain damage may cause acute emotional symptoms such as uncontrolled crying, apathy, and sleep problems. Rehabilitation may be less effective in patients afflicted by these symptoms. Citalopram, a selective serotonin reuptake inhibitor (SSRI), has a documented immediate and dramatic effect on pathological crying in stroke patients. The present case history of a 6-year-old boy with a traumatic right-sided hemorrhage in the basal ganglia indicates that early SSRI treatment has a dramatic effect on pathological crying and in addition may have a concomitant beneficial effect on motor paresis, sleep disturbance, and neurobehavioral problems.	Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Neuropsychol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Neurosurg, DK-8000 Aarhus, Denmark	Andersen, G (corresponding author), Aarhus Univ Hosp, Dept Neurol F, Norrebrogade 44, DK-8000 Aarhus, Denmark.			Andersen, Grethe/0000-0001-6807-2500			ANDERSEN G, 1994, STROKE, V25, P1099, DOI 10.1161/01.STR.25.6.1099; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; HYTTEL J, 1994, INT CLIN PSYCHOPHARM, V9, P19, DOI 10.1097/00004850-199403001-00004; KORKMAN M, 1993, NEPSY NEUROPSYCHOLOG; Meltzer H. Y., 1987, PSYCHOPHARMACOLOGY 3, P513; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Noble S, 1997, CNS DRUGS, V8, P410, DOI 10.2165/00023210-199708050-00009; Poeck K, 1985, HDB CLIN NEUROLOGY, P219; *PSYCH CORP, 1949, WECHSL INT SCAL CHIL; REIS DJ, 1973, BRAIN RES, V57, P307, DOI 10.1016/0006-8993(73)90139-X; ROLE LW, 1991, PRINCIPLES NEURAL SC, P683; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; WELCH KMA, 1977, STROKE, V8, P341, DOI 10.1161/01.STR.8.3.341	16	12	14	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1999	16	4					341	344		10.1089/neu.1999.16.341			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	190AM	WOS:000079939400007	10225220				2021-06-18	
J	Guan, DW; Ohshima, T; Jia, JT; Kondo, T; Li, DX				Guan, DW; Ohshima, T; Jia, JT; Kondo, T; Li, DX			Morphological findings of 'cardiac concussion' due to experimental blunt impact to the precordial region	FORENSIC SCIENCE INTERNATIONAL			English	Article						non-penetrating cardiac trauma; cardiac concussion; immunohistochemistry; myoglobin; lanthanum; creatine kinase	MYOCARDIAL CONTUSION; COMMOTIO-CORDIS; SPORTS ACTIVITIES; CHEST; TRAUMA; DEATH; ARREST	The dog's precordial region at the sternum was impacted with a mechanical elastic-cord propelled impactor at the velocity of 8.0 m/s. The left and right intraventricular pressures and electrocardiogram (ECG) were monitored continuously for 60 min after the impact. The micro- and ultra-structure of myocardium were examined. Localization of myocardial myoglobin (Mb), creatine kinase BE (CK-BB) and creatine kinase MM (CK-MM) as well as plasma membrane permeability were studied by immunohistochemical and lanthanum probe techniques. Upon the impact, abrupt over-pressures within both ventricles were recorded with transient depression of the left ventricular systolic pressure. In all the dogs, some rhythm- and conduction-disorders were noted, which lasted transiently and resumed to normal sinus rhythm. At autopsy, no gross injuries of the heart were detected, and microscopic examination showed no visible myocardial lesions. However, immunohistochemically, focal patchy loss of myocardial Mb, CK-BB and CK-MM was identified with scattered deposition of these substances between myocardial fibers elsewhere. Such changes as relaxed myofibrils with widened I band, contracted myofibrils and broken cristae of the mitochondria were observed in myocardial ultrastructure. Lanthanum particles deposited inside the mitochondria. These results indicate that increase in cardiac cell membrane permeability and ultrastructural damage in myocardium may be involved even in cardiac concussion. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.	Kanazawa Univ, Fac Med, Sch Med, Dept Legal Med, Kanazawa, Ishikawa 9208640, Japan; China Med Univ, Fac Forens Med, Dept Forens Pathol, Shenyang 110001, Peoples R China	Ohshima, T (corresponding author), Kanazawa Univ, Fac Med, Sch Med, Dept Legal Med, Takara-machi 13-1, Kanazawa, Ishikawa 9208640, Japan.			Kondo, Toshikazu/0000-0002-5059-8309			ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; AKENSIDE M, 1983, JAMA-J AM MED ASSOC, V250, P2189; ANDERSON AE, 1975, J TRAUMA, V15, P237, DOI 10.1097/00005373-197503000-00011; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FABIAN TC, 1988, J TRAUMA, V28, P50, DOI 10.1097/00005373-198801000-00007; FRAZEE RC, 1986, J TRAUMA, V26, P510, DOI 10.1097/00005373-198606000-00004; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FROEDE RC, 1979, J FORENSIC SCI, V24, P752; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; HOFFSTEIN S, 1975, AM J PATHOL, V79, P207; JANSSEN W, 1984, FORENSIC HISTOPATHOL, P192; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KAROFSKY PS, 1990, PHYSICIAN SPORTSMED, V18, P99, DOI 10.1080/00913847.1990.11709976; Kissane RW, 1937, ANN INTERN MED, V11, P907, DOI 10.7326/0003-4819-11-6-907; KULBS H, 1908, VERH DTSCH PATH GES, V12, P172; LIEDTKE AJ, 1974, AM J PHYSIOL, V226, P377; LINDSEY D, 1978, CHEST, V74, P15, DOI 10.1378/chest.74.1.15; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; Moritz AR, 1938, ARCH PATHOL, V25, P445; PARMLEY LF, 1958, CIRCULATION, V18, P371, DOI 10.1161/01.CIR.18.3.371; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; Viano DC, 1992, CLIN J SPORT MED, V2, P166; VIANO DC, 1992, CLIN J SPORT MED, V2, P161	25	12	13	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAR 29	1999	100	3					211	220		10.1016/S0379-0738(99)00002-X			10	Medicine, Legal	Legal Medicine	194MW	WOS:000080199000005	10423847				2021-06-18	
J	Audouy, S; Mallet, J; Privat, A; Ribotta, MGY				Audouy, S; Mallet, J; Privat, A; Ribotta, MGY			Adenovirus-mediated suicide gene therapy in an in vitro model of reactive gliosis	GLIA			English	Article						gene therapy; adenovirus; herpes simplex thymidine kinase; astrocytes; reactive gliosis	HERPES-SIMPLEX VIRUS; FIBRILLARY ACIDIC PROTEIN; THYMIDINE KINASE GENE; EXPERIMENTAL BRAIN-TUMORS; SPINAL-CORD; RECOMBINANT RETROVIRUS; SIALOSYL CHOLESTEROL; EXPERIMENTAL GLIOMAS; ASTROGLIAL RESPONSE; MESSENGER-RNA	Adenovirus-mediated herpes simplex thymidine kinase/ganciclovir (HSV-tk/GCV) system has been demonstrated to be efficient for the treatment of experimental brain tumors. However, no study has been directed to the elimination of proliferating cellular populations in other pathological conditions. In this study we used this suicide gene approach in a primary culture of astrocytes, as a model of reactive gliosis, in order to evaluate its efficiency as a therapeutic strategy for post-traumatic astrogliosis in vivo. First, we evaluated the peak of astrocytic proliferation to characterize our model. Second, the efficiency of adenovirus-mediated lacZ gene transfer is shown to be dependent on vector multiplicity of infection (MOI). As expected, the cells transfected with the HSV-tk gene showed an increase in sensibility to GCV compared with cells transfected with lacZ gene. Finally, an unexpected interaction between the adenoviral vector and bromodeoxyuridine (BrdU) or [H-3]-Thymidine ([H-3]-Thy) was evidenced in transfected cultures, whose interpretation is discussed. The present study demonstrates that a recombinant adenoviral vector carrying the th gene confers to in vitro cultured astrocytes a cytotoxic sensibility to GCV, and that this system constitutes a potentially efficient tool to eliminate the hyperplasia of astrocytes following injury to the central nervous system in vivo. (C) 1999 Wiley-Liss, Inc.	Univ Montpellier 2, INSERM U336, DPVSN, F-34095 Montpellier, France; CNRS C 9923, Lab Mixte Rhone Poulenc Rorer, Paris, France	Privat, A (corresponding author), Univ Montpellier 2, INSERM U336, DPVSN, Pl E Bataillon,BP 106, F-34095 Montpellier, France.	u336@univ-montp2.fr					ABEDOHMAE S, 1990, NEUROCHEM INT, V17, P93, DOI 10.1016/0197-0186(90)90072-2; AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BALZARINI J, 1993, J BIOL CHEM, V268, P6332; BALZARINI J, 1995, GENE THER, V2, P317; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; BIGNAMI A, 1989, INT J DEV NEUROSCI, V7, P343, DOI 10.1016/0736-5748(89)90056-7; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; Bignami Amico, 1995, P843; BOHMAN C, 1994, J BIOL CHEM, V269, P8036; BOVIATSIS EJ, 1994, HUM GENE THER, V5, P183, DOI 10.1089/hum.1994.5.2-183; BROWN JO, 1947, J COMP NEUROL, V87, P131, DOI 10.1002/cne.900870204; CARLSTEDT T, 1985, NEUROSCIENCE, V15, P507, DOI 10.1016/0306-4522(85)90229-5; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; CHEN CY, 1995, HUM GENE THER, V6, P1467, DOI 10.1089/hum.1995.6.11-1467; Chen HH, 1997, P NATL ACAD SCI USA, V94, P1645, DOI 10.1073/pnas.94.5.1645; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; COLAK A, 1995, HUM GENE THER, V6, P1317, DOI 10.1089/hum.1995.6.10-1317; COLAK A, 1995, BRAIN RES, V691, P76, DOI 10.1016/0006-8993(95)00616-X; COLOMBO BM, 1995, HUM GENE THER, V6, P763, DOI 10.1089/hum.1995.6.6-763; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; CULVER KW, 1995, BRIT MED BULL, V51, P192, DOI 10.1093/oxfordjournals.bmb.a072946; CULVER KW, 1994, COLD SPRING HARB SYM, V59, P685, DOI 10.1101/SQB.1994.059.01.079; Elion G B, 1980, Adv Enzyme Regul, V18, P53, DOI 10.1016/0065-2571(80)90008-4; FREEMAN SM, 1993, CANCER INVEST, V11, P676, DOI 10.3109/07357909309046941; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; GOLDMAN JE, 1984, J NEUROCHEM, V42, P175, DOI 10.1111/j.1471-4159.1984.tb09714.x; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; HANCOCK MB, 1982, J HISTOCHEM CYTOCHEM, V30, P578; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HORELLOU P, 1995, RESTOR NEUROL NEUROS, V8, P63, DOI 10.3233/RNN-1995-81214; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; ISACSON O, 1987, NEUROSCIENCE, V20, P1043, DOI 10.1016/0306-4522(87)90262-4; IshiiMorita H, 1997, GENE THER, V4, P244, DOI 10.1038/sj.gt.3300379; ITO J, 1994, J NEUROCHEM, V62, P235; ITO J, 1993, J NEUROCHEM, V61, P80, DOI 10.1111/j.1471-4159.1993.tb03539.x; Izquierdo M, 1996, GENE THER, V3, P491; IZQUIERDO M, 1995, GENE THER, V2, P66; KRAMM CM, 1995, BRAIN PATHOL, V5, P345, DOI 10.1111/j.1750-3639.1995.tb00615.x; KREMER EJ, 1995, BRIT MED BULL, V51, P31, DOI 10.1093/oxfordjournals.bmb.a072951; LE GLS, 1993, SCIENCE, V259, P988; LINDSAY RM, 1986, ASTROCYTES, P231; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; LOWENSTEIN PR, 1995, GENETIC MANIPULATION, P1; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; Maron A, 1996, GENE THER, V3, P315; Maron A, 1997, GENE THER, V4, P25, DOI 10.1038/sj.gt.3300353; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; Nathaniel EJ., 1981, ADV CELLULAR NEUROBI, P249, DOI [10.1016/B978-0-12-008302-2.50012-2, DOI 10.1016/B978-0-12-008302-2.50012-2]; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; NOETZEL MJ, 1990, J NEUROSCI RES, V27, P184, DOI 10.1002/jnr.490270208; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; PEREZCRUET MJ, 1994, J NEUROSCI RES, V39, P506, DOI 10.1002/jnr.490390417; PRIVAT A, 1986, ASTROCYTES, P105; Privat Alain, 1995, P3; QIAN C, 1995, HEPATOLOGY, V22, P118, DOI 10.1016/0270-9139(95)90362-3; Ramon y Cajal S, 1913, ESTUDIOS DEGENERACIO; RATABOUL P, 1988, J NEUROSCI RES, V20, P165, DOI 10.1002/jnr.490200204; REIER PJ, 1989, ASTROCYTES, P263; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; REIER PJ, 1989, FRONTIERS CLIN NEURO, P183; RIBOTTA MGY, 1995, J NEUROSCI RES, V41, P79, DOI 10.1002/jnr.490410110; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHINE HD, 1995, GENETIC MANIPULATION, P53; Stensaas LJ, 1987, PROG BRAIN RES <D>, V71, P457; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TAKAMIYA Y, 1992, J NEUROSCI RES, V33, P493, DOI 10.1002/jnr.490330316; TERAMOTO S, 1995, HUM GENE THER, V6, P1045, DOI 10.1089/hum.1995.6.8-1045; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; VIOLA JJ, 1995, J NEUROSURG, V82, P70, DOI 10.3171/jns.1995.82.1.0070; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; YU ACH, 1991, J NEUROSCI RES, V30, P72, DOI 10.1002/jnr.490300109	78	12	12	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB 1	1999	25	3					293	303		10.1002/(SICI)1098-1136(19990201)25:3<293::AID-GLIA9>3.0.CO;2-G			11	Neurosciences	Neurosciences & Neurology	160UX	WOS:000078250600009	9932875				2021-06-18	
J	Doppenberg, EMR; Rice, MR; Alessandri, B; Qian, Y; Di, X; Bullock, R				Doppenberg, EMR; Rice, MR; Alessandri, B; Qian, Y; Di, X; Bullock, R			Reducing hemoglobin oxygen affinity does not increase hydroxyl radicals after acute subdural hematoma in the rat	JOURNAL OF NEUROTRAUMA			English	Article						free radicals; normoxic and hyperoxic conditions; subdural hematoma; traumatic brain injury	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; ALLOSTERIC MODIFIERS; SUBSTRATE DELIVERY; INITIAL EXPERIENCE; GLOBAL-ISCHEMIA; FOCAL ISCHEMIA	Extensive evidence is available to show the importance of ischemia after severe human head injury. We have previously shown that pharmacologically increasing the release of oxygen in brain tissue where the local oxygen pressure is low reduces infarct size in animal models. To study the possible negative effects of this strategy, we tested the effect of an allosteric modifier of hemoglobin (RSR13) on free radical production in the rat acute subdural hematoma (ASDH) model, both under normoxic as well as under hyperoxic, normobaric conditions. When compared to baseline, induction of ASDH resulted in a significant increase (p < 0.05) in 2,3-DHBA (2,3 dihydroxybenzoic acid, produced from salicylate after attack by hydroxyl radicals) at 30 and 60 min postinduction, both for the control group (39% and 91%) as well as the RSR13-treated group (41% and 62%). The 2,5-DHBA also increased significantly (p < 0.05) in the drug-treated animals at the 30- and 60-min time points when compared to baseline (49% and 77%). At all time points, except the 30-min, the increase in 2,3-DHBA was less marked in the RSR13 animals than in the control group. Similarly, the 2,5-DHBA increase after ASDH was lower at all time points except for the 30-min time point in the RSR13-treated group. These results indicate that enhanced tissue oxygen release by the allosteric modifier of hemoglobin RSR13 does not increase hydroxyl radical production after ASDH. Clinical trials are needed to test this compound in humans after severe head injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Doppenberg, EMR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ABRAHAM DJ, 1992, BIOCHEMISTRY-US, V31, P9141, DOI 10.1021/bi00153a005; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOISVERT DP, 1991, J CEREB BLOOD FLOW M, V11, pS637; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P241, DOI 10.1111/j.1749-6632.1997.tb48435.x; Doppenberg EMR, 1997, J NEUROSURG, V87, P809, DOI 10.3171/jns.1997.87.6.0809; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FLOYD RA, 1984, J BIOCHEM BIOPH METH, V10, P221, DOI 10.1016/0165-022X(84)90042-3; FLOYD RA, 1990, P NATL ACAD SCI USA, V87, P5144; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; Greenburg A G, 1997, Adv Surg, V31, P149; Habler OP, 1998, TRANSFUSION, V38, P145, DOI 10.1046/j.1537-2995.1998.38298193096.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; INGLIS FM, 1990, ACT NEUR S, V51, P277; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KHANDELWAL SR, 1993, AM J PHYSIOL, V265, pH1450; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Kuroda S, 1997, CLIN NEUROSCI, V4, P199; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; KURODA Y, 1992, NEUROSURGERY, V30, P687; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; MOON S, 1991, STROKE, V22, P915; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; OLIVER CN, 1990, J NEUROSCI, V10, P1035; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PERUTZ MF, 1983, LANCET, V2, P881; RANDAD RS, 1991, J MED CHEM, V34, P752, DOI 10.1021/jm00106a041; ROCKSWOLD GL, 1991, BRAIN RES, V554, P186; Sakas DE, 1996, CEREBROVAS BRAIN MET, V8, P209; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; Watson JC, 1997, STROKE, V28, P1624, DOI 10.1161/01.STR.28.8.1624; WEI EP, 1993, AM J PHYSIOL, V265, pH1439; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	57	12	12	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1999	16	2					123	133		10.1089/neu.1999.16.123			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	173BA	WOS:000078960000002	10098957				2021-06-18	
J	Blanken, G; Schafer, C; Tucha, O; Lange, KW				Blanken, G; Schafer, C; Tucha, O; Lange, KW			Serial processing in graphemic encoding: evidence from letter exchange errors in a multilingual patient	JOURNAL OF NEUROLINGUISTICS			English	Article							ACQUIRED DYSGRAPHIA; SELECTIVE DEFICIT; BUFFER; REPRESENTATIONS	We report on the spelling performance of a multilingual patient who developed symptoms of pure dysgraphia after concussion. In all languages studied (German, English, Finnish) her main error type consisted of adjacent letter exchanges (e,g. and --> adn). Closer examinations showed that LM's spelling impairment could be attributed to a relatively selective disorder of the Graphemic Buffer. It is suggested that her exchange errors result from anticipations and complementary perseverations during graphemic selection and can be located between the activation of graphemic strings coded in parallel and serial conversion into subgraphemic units. (C) 1999 Elsevier Science Ltd. All rights reserved.	Univ Freiburg, Inst German Language, D-79085 Freiburg, Germany; Univ Freiburg, Inst Psychol, D-79085 Freiburg, Germany; Univ Regensburg, Dept Neuropsychol, D-93040 Regensburg, Germany	Blanken, G (corresponding author), Univ Freiburg, Inst German Language, Hugstetter Str 55, D-79085 Freiburg, Germany.		Tucha, Oliver/AAD-1403-2019				BASSO A, 1978, J NEUROL NEUROSUR PS, V41, P556, DOI 10.1136/jnnp.41.6.556; BLANKEN G, 1994, GRUPPENSTUDIE NEUROL, V8, P59; CARAMAZZA A, 1987, COGNITION, V26, P59, DOI 10.1016/0010-0277(87)90014-X; CARAMAZZA A, 1990, COGNITION, V37, P243, DOI 10.1016/0010-0277(90)90047-N; CLEMENTS GN, 1983, CV PHONOLOGY GENERAT; CUBELLI R, 1991, NATURE, V353, P258, DOI 10.1038/353258a0; DELL GS, 1988, J MEM LANG, V27, P124, DOI 10.1016/0749-596X(88)90070-8; Ellis A. W., 1982, NORMALITY PATHOLOGY; Ellis A. W., 1988, LANG COGNITIVE PROC, V3, P99, DOI [10.1080/01690968808402084, DOI 10.1080/01690968808402084]; ELLIS AW, 1979, VISIBLE LANG, V13, P265; ELLIS AW, 1987, COGNITIVE NEUROPSYCH, V4, P465, DOI 10.1080/02643298708252048; Garrett M.F., 1975, PSYCHOL LEARNING MOT, V9; HILLIS AE, 1989, BRAIN LANG, V36, P208, DOI 10.1016/0093-934X(89)90062-X; HOTOPF N, 1980, COGNITIVE PROCESSES; Huber W., 1983, AACHENER APHASIE TES; Jonsdottir MK, 1996, COGNITION, V59, P169, DOI 10.1016/0010-0277(95)00693-1; KATZ RB, 1991, CORTEX, V27, P111, DOI 10.1016/S0010-9452(13)80274-2; KAY J, 1994, HDB SPELLING THEORY; MAI N, 1993, NEUROPSYCHOLOGISCHE; MAI N, 1992, CS COMPUTER ASSISTED; Margolin D. I., 1992, COGNITIVE NEUROPSYCH; MARGOLIN DI, 1984, Q J EXP PSYCHOL-A, V36, P459, DOI 10.1080/14640748408402172; MCCLOSKEY M, 1994, COGNITIVE NEUROPSYCH, V11, P341, DOI 10.1080/02643299408251979; MEIER H, 1967, DTSCH SPRACHSTATISTI; MICELI G, 1985, BRAIN LANG, V25, P187, DOI 10.1016/0093-934X(85)90080-X; MICELI G, 1995, CORTEX, V31, P161, DOI 10.1016/S0010-9452(13)80114-1; MORTON J, 1980, COGNITIVE PROCESSES; POSTERARO L, 1988, BRAIN LANG, V35, P274, DOI 10.1016/0093-934X(88)90112-5; RAPCSAK SZ, 1997, APRAXIA NEUROPSYCHOL; ROELTGEN DP, 1993, LINGUISTIC DISORDERS; Ruoff Arno., 1981, HAUFIGKEITSWORTERBUC; SGARAMELLA TM, 1991, CORTEX, V27, P29, DOI 10.1016/S0010-9452(13)80266-3; SHALLICE T, 1995, LANG COGNITIVE PROC, V10, P25; SHATTUCKHUFNAGEL S, 1992, COGNITION, V42, P213, DOI 10.1016/0010-0277(92)90044-I; Tainturier MJ, 1996, J MEM LANG, V35, P53, DOI 10.1006/jmla.1996.0003; WING AM, 1980, COGNITIVE PROCESSES	36	12	12	1	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0911-6044			J NEUROLINGUIST	J. Neurolinguist.	JAN	1999	12	1					13	39		10.1016/S0911-6044(99)00002-0			27	Linguistics; Neurosciences; Psychology, Experimental	Linguistics; Neurosciences & Neurology; Psychology	221KV	WOS:000081727000002					2021-06-18	
J	Finnie, J; Lewis, S; Manavis, J; Blumbergs, P; Van den Heuvel, C; Jones, N				Finnie, J; Lewis, S; Manavis, J; Blumbergs, P; Van den Heuvel, C; Jones, N			Traumatic axonal injury in lambs: a model for paediatric axonal damage	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						multifocal axonal injury; amyloid precursor protein; cerebellar granular layer necrosis; paediatric head injury model; lambs	AMYLOID PRECURSOR PROTEIN; CEREBRAL BLOOD-FLOW; CLOSED-HEAD-INJURY; CHILDREN; IMMATURE; BRAIN; MATURE; SHEEP; MICE; RATS	Axonal injury (Al), an important determinant of clinical outcome after traumatic head injury in adults, has been little studied in child neurotrauma. In this experimental model, 10 anaesthetised, ventilated and physiologically monitored 4-5 week old lambs sustained a temporal impact to an unconstrained head. Examination of the brain 2 hours post-impact using amyloid precursor protein immunostaining, a sensitive marker of axonal damage, revealed widespread multifocal Al in the ipsilateral and contralateral hemispheres, brain stem and cerebellum in all cases. Impact contusions (predominantly microscopic) (8/10), contralateral contusions (2/10), parenchymal haemorrhage (10/10) and focal subarachnoid haemorrhage (10/10) were also present. Unusual multifocal cerebellar granular layer necrosis occurred in all impacted lambs. The pattern of Al in these lamb brains 2 hours post-impact was similar to that found in adult sheep using the same experimental paradigm.	Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Vet Serv Div, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA 5000, Australia	Blumbergs, P (corresponding author), Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia.			, Corinna/0000-0003-0664-8935			Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; AUER RN, 1997, GREENFIELDS NEUROPAT, P263; BENDOTTI C, 1988, P NATL ACAD SCI USA, V85, P3628, DOI 10.1073/pnas.85.10.3628; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; DOBBING J, 1981, SCI FDN PAEDIAT, P747; Fearnside MR, 1997, HEAD INJURY PATHOPHY, P3; FINNIE JW, 1988, ACTA NEUROPATHOL, V75, P411, DOI 10.1007/BF00687795; Finnie JW, 1997, AUST VET J, V75, P204, DOI 10.1111/j.1751-0813.1997.tb10067.x; FINNIE JW, 1993, PATHOLOGY, V25, P99, DOI 10.3109/00313029309068912; FINNIE JW, 1984, J COMP PATHOL, V94, P363, DOI 10.1016/0021-9975(84)90024-0; FRANKOWSKI RF, 1985, DESCRIPTIVE EPIDEMIO, P33; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; LINDENBERG R, 1982, HISTOL HISTOPATHOL, P1018; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MENDELOW AD, 1997, HEAD INJURY PATHOPHY, P71; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SIMPSON DA, 1992, WORLD J SURG, V16, P403, DOI 10.1007/BF02104439; SMITH ML, 1995, J NEUROTRAUM, V12, P143; UPTON R, 1994, J CEREBR BLOOD F MET, V14, P680, DOI 10.1038/jcbfm.1994.85; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Ward JD, 1996, NEUROTRAUMA, P859; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95	36	12	12	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	JAN	1999	6	1					38	42		10.1016/S0967-5868(99)90601-X			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	169QZ	WOS:000078761200009	18639121				2021-06-18	
J	Gidday, JM; Beetsch, JW; Park, TS				Gidday, JM; Beetsch, JW; Park, TS			Endogenous glutathione protects cerebral endothelial cells from traumatic injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; edema; endothelium; glutathione peroxidase; oxygen free radicals; oxypurinol; traumatic brain injury	CONJUGATED SUPEROXIDE-DISMUTASE; EXPERIMENTAL BRAIN INJURY; STRETCH-INDUCED INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; BARRIER DISRUPTION; ISCHEMIC-INJURY; NITRIC-OXIDE; RATS; FLUID	Blood-brain barrier breakdown and edema, indicative of cerebrovascular injury, are characteristic pathophysiologic outcomes following head trauma. These injuries result from both primary mechanical damage and from secondary events initiated by the traumatic insult. Free radicals are recognized as mediators of secondary injury in a number of trauma models. In this study, we used a navel in vitro model of traumatic microvascular injury to test the hypothesis that endogenous glutathione protects cerebral endothelial cells from secondary autooxidative injury following mechanical trauma. Porcine brain cerebral endothelial cells were grown in tissue culture wells with Silastic membrane bottoms, and cellular injury was induced by displacing the membrane different distances with user-defined pressure pulses from a customized device. The resultant endothelial cell injury 2 h following stretch was determined by measuring lactate dehydrogenase in the culture media. Significant stretch-dependent increases in endothelial injury were elicited that depended in a nonlinear fashion on the degree of membrane displacement. Depletion of intracellular glutathione with buthionine sulfoximine (1 mM) increased the extent of traumatic endothelial cell injury by 17-56%, particularly at low to moderate levels of traumatic injury (30-40% of total endothelial cell LDH release). Conversely, traumatic injury was reduced by 22-45% when endothelial cell glutathione levels were augmented threefold (to 140 +/- 8 nmol/mg protein) by preincubating cells with 2 mM glutathione; the extent of protection was inversely proportional to the extent of the traumatic stretch. Traumatic endothelial cell injury was also significantly and dose-dependently attenuated (up to 40%) by treatment with the xanthine oxidase inhibitor oxypurinol (50 and 100 mu M). These results demonstrate that cerebral endothelial cells are the targets of hydrogen peroxide-mediated injury secondary to trauma-induced superoxide radical formation via the xanthine oxidase pathway. The neutralization of peroxides by the endogenous glutathione redox cycle provides endothelial cells a finite capacity to reduce free radical-mediated traumatic injury; this cycle may be amenable to therapeutic manipulation to mitigate posttraumatic edema and other manifestations of vascular dysfunction.	St Louis Childrens Hosp, Dept Neurosurg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Park, TS (corresponding author), St Louis Childrens Hosp, Dept Neurosurg, 1 Childrens Pl, St Louis, MO 63110 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [21045] Funding Source: Medline		Barker JE, 1996, DEV NEUROSCI-BASEL, V18, P391, DOI 10.1159/000111432; Beckman JS, 1996, ADV NEUROL, V71, P339; Beetsch JW, 1998, BRAIN RES, V786, P89, DOI 10.1016/S0006-8993(97)01407-8; Betz A. Lorris, 1993, P303; BETZ AL, 1985, J NEUROCHEM, V44, P574, DOI 10.1111/j.1471-4159.1985.tb05451.x; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHEN SH, 1992, PROSTAG LEUKOTR ESS, V45, P299, DOI 10.1016/0952-3278(92)90087-Y; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; ELLIOTT SJ, 1995, AM J PHYSIOL-HEART C, V268, pH278; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gobbel GT, 1997, J PHARMACOL EXP THER, V282, P1600; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Gourin CG, 1996, J TRAUMA, V41, P129, DOI 10.1097/00005373-199607000-00021; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUMA, V9, P425; HALL ED, 1996, NEUROTRAUMA, P1405; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hsu CY, 1996, NEUROTRAUMA, P1433; HSU P, 1993, AM J PHYSIOL, V264, pH1485; KALARIA RN, 1986, J NEUROCHEM, V47, P1849, DOI 10.1111/j.1471-4159.1986.tb13098.x; KINNULA VL, 1992, AM J RESP CELL MOL, V6, P175, DOI 10.1165/ajrcmb/6.2.175; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MIZUI T, 1992, AM J PHYSIOL, V262, pH313; MOORHOUSE CP, 1987, FEBS LETT, V213, P23; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PLATEEL M, 1995, J NEUROCHEM, V65, P2138; SEN S, 1993, NEUROSCI LETT, V162, P117, DOI 10.1016/0304-3940(93)90574-5; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; SIFLINGERBIRNBOIM A, 1993, J CELL PHYSIOL, V155, P234, DOI 10.1002/jcp.1041550203; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Weisbrot-Lefkowitz M, 1998, MOL BRAIN RES, V53, P333, DOI 10.1016/S0169-328X(97)00313-6; Wolin Michael S., 1996, Microcirculation (Philadelphia), V3, P1, DOI 10.3109/10739689609146778; Xu J, 1991, J NEUROTRAUM, V8, P11, DOI 10.1089/neu.1991.8.11; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; ZIMMERMAN BJ, 1988, AM J PHYSIOL, V255, pH202	54	12	12	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1999	16	1					27	36		10.1089/neu.1999.16.27			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	162BL	WOS:000078325300003	9989464				2021-06-18	
J	Kanelos, SK; McDeavitt, JT				Kanelos, SK; McDeavitt, JT			Neural transplantation: Potential role in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fetal tissue; Huntington's disease; neural tissue transplantation; Parkinson's disease; spinal cord injury; traumatic brain injury	PARKINSONS-DISEASE; FETAL TISSUE; SPINAL-CORD; ADULT-RATS; GRAFTS; CELLS; LESION; AXONS	Neuroscientists have been transplanting neurological tissue into humans and animals for more than a century. Recently, a number of animal studies have demonstrated a degree of central nervous system protection after brain injury using transplanted tissue. This article reviews the history of neural tissue transplantation. Clinical efficacy in Huntington's disease, Parkinson's disease, and spinal cord injury is discussed. In addition, possible implications for the treatment of traumatic brain injury are reviewed. Ethical issues in the use of fetal tissue are also discussed.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA	Kanelos, SK (corresponding author), Charlotte Inst Rehabil, Dept Phys Med & Rehabil, 1100 Blythe Blvd, Charlotte, NC 28203 USA.						AHLSKOG JE, 1993, MAYO CLIN PROC, V68, P578, DOI 10.1016/S0025-6196(12)60373-5; BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; BJORKLUND A, 1985, FERNSTROM FDN SERIES, P5; BOER GJ, 1994, J NEUROL, V242, P1, DOI 10.1007/BF00920568; BOYER KL, 1995, NEUROSURG CLIN N AM, V6, P113; Clark WELG, 1940, J NEUROL PSYCHIATRY, V3, P263, DOI 10.1136/jnnp.3.3.263; Defer GL, 1996, BRAIN, V119, P41, DOI 10.1093/brain/119.1.41; Dunn EH, 1917, J COMP NEUROL, V27, P565, DOI 10.1002/cne.900270403; ESCOBAR M, 1989, BRAIN RES, V478, P368, DOI 10.1016/0006-8993(89)91519-9; FINE A, 1994, CAN MED ASSOC J, V151, P1261; FREED WJ, 1981, NATURE, V292, P351, DOI 10.1038/292351a0; GONZALEZ MF, 1988, EXP NEUROL, V99, P154, DOI 10.1016/0014-4886(88)90135-5; GOPAL DD, 1980, AM J ANAT, V158, P135; HAINLINE BE, 1995, OBSTET GYNECOL, V85, P619, DOI 10.1016/0029-7844(95)00003-A; HAUN F, 1984, DEV BRAIN RES, V15, P290, DOI 10.1016/0165-3806(84)90108-1; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krauss JK, 1996, AM FAM PHYSICIAN, V54, P1621; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LINDVALL O, 1995, CELL TRANSPLANT, V4, P393, DOI 10.1016/0963-6897(95)00022-P; MADRAZO I, 1991, Society for Neuroscience Abstracts, V17, P902; MARTIN D, 1991, NEUROSCI LETT, V124, P44, DOI 10.1016/0304-3940(91)90818-E; Newman-Gage H, 1996, J Hematother, V5, P189, DOI 10.1089/scd.1.1996.5.189; NORNES H, 1984, NEURAL TRANSPLANTS D; PERLOW MJ, 1979, SCIENCE, V204, P643, DOI 10.1126/science.571147; Quinn N, 1996, MOVEMENT DISORD, V11, P143; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; REIER PJ, 1986, J COMP NEUROL, V247, P275, DOI 10.1002/cne.902470302; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; RICHARDSON PM, 1984, J NEUROCYTOL, V13, P165, DOI 10.1007/BF01148324; Saltykow S, 1905, ARCH PSYCHIAT NERVEN, V40, P329, DOI 10.1007/BF02071085; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; THOMPSON WG, 1890, NY MED J, V51, P107; TURNER DA, 1993, NEUROSURGERY, V33, P1031; WANG JJ, 1995, NEUROSCIENCE, V65, P973, DOI 10.1016/0306-4522(94)00519-B	35	12	12	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					1	9		10.1097/00001199-199812000-00003			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300003	9885314				2021-06-18	
J	Keller, TM; Holland, MC				Keller, TM; Holland, MC			Chronic subdural haematoma, an unusual injury from playing basketball	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						subdural haematoma; basketball injury; computed tomography	HEMATOMA	Although the literature records instances of acute epidural haematoma and acute subdural haematoma related to playing basketball, there has not been a report of chronic subdural haematoma as a basketball injury. With the burgeoning interest in this sport in the United Kingdom and Europe, the possibility of this particular neurotrauma increases. Such an injury, along with the diagnosis and management of this often insidious lesion, is documented in this case report.	Pacific Neurosci Inst, Orinda, CA 94563 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	Keller, TM (corresponding author), Pacific Neurosci Inst, 15 Altarinda Rd,Suite 102, Orinda, CA 94563 USA.						ALARCON RD, 1983, AM J PSYCHIAT, V140, P1360; Allen AM, 1940, NEW ENGL J MED, V223, P324, DOI 10.1056/NEJM194008292230903; AMBROSE J, 1974, J NEUROSURG, V40, P679, DOI 10.3171/jns.1974.40.6.0679; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; DATTI R, 1995, BRIT J SPORT MED, V29, P95, DOI 10.1136/bjsm.29.2.95; HENRY JH, 1982, AM J SPORT MED, V10, P16, DOI 10.1177/036354658201000104; LEHMAN LB, 1987, AM J SPORT MED, V15, P494, DOI 10.1177/036354658701500512; OSLER W, 1907, MODERN MED, V3, P436; THOMAS LM, 1973, NEUROLOGICAL SUG, P960; TSAI FY, 1979, J NEUROSURG, V50, P64, DOI 10.3171/jns.1979.50.1.0064; Tudor R B, 1979, Am J Sports Med, V7, P136, DOI 10.1177/036354657900700211; VIRCHOW R, 1863, KRANKHAFTEN GESCHWUL, P128; WELSH JE, 1979, STROKE, V10, P564, DOI 10.1161/01.STR.10.5.564; WEPFER JJ, 1658, OBSERVATIONES ANATOM, P1	15	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC	1998	32	4					338	339		10.1136/bjsm.32.4.338			2	Sport Sciences	Sport Sciences	143PD	WOS:000077263800029	9865409	Bronze, Green Published			2021-06-18	
J	Paniak, C; MacDonald, J; Toller-Lobe, G; Durand, A; Nagy, J				Paniak, C; MacDonald, J; Toller-Lobe, G; Durand, A; Nagy, J			A preliminary normative profile of mild traumatic brain injury diagnostic criteria	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							AMNESIA	This study investigated how mild traumatic brain injury (MTBI) diagnostic and related variables present in a large, nonreferred MTBI sample. Participants were 119 adults with MTBI, drawn from consecutive admissions to two hospital emergency wards. Within 3 weeks of injury, they were asked how the 1993 American Congress of Rehabilitation Medicine MTBI diagnostic criteria and related phenomena presented in their particular cases. Results showed that retrograde amnesia was not reported or was generally very brief; retrograde amnesia was not reported unless posttraumatic amnesia was also reported; and the median ratio of posttraumatic amnesia to retrograde amnesia duration, when both were reported, was 300:1. These and other data provide a preliminary normative profile of such MTBI phenomena, and can help with differential diagnosis of MTBI in individual cases.	Glenrose Rehabil Hosp, Psychol Serv, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, Psychol Serv, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY, P8; OMMAYA AK, 1969, LANCET, V2, P237; PANIAK C, IN PRESS BRAIN INJUR; Parkin AJ, 1996, ACTA NEUROL BELG, V96, P43; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; WOLPAW JR, 1971, LANCET, V2, P356	11	12	12	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1998	20	6					852	855		10.1076/jcen.20.6.852.1108			4	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	204RQ	WOS:000080778300008	10484696				2021-06-18	
J	Sharma, AC; Misra, M; Prat, R; Alden, K; Sam, AD; Markiv, VZ; Dujovny, M; Ferguson, JL				Sharma, AC; Misra, M; Prat, R; Alden, K; Sam, AD; Markiv, VZ; Dujovny, M; Ferguson, JL			A differential response of diffuse brain injury on the concentrations of endothelin and nitric oxide in the plasma and brain regions in rats	NEUROLOGICAL RESEARCH			English	Article						diffuse brain injury; cerebral blood flow; mean arterial pressure; endothelin-1; nitric oxide; anesthetized rats	CEREBRAL BLOOD-FLOW; CLOSED-HEAD-INJURY; SUBARACHNOID HEMORRHAGE; MODEL; CIRCULATION; REVERSAL	In the present study, we hypothesized that acute diffuse brain injury (DBI) in rats would produce an increase in endothelin-1 (ET-1), a potent vasoconstrictor, and/or nitric oxide (NO), a potent vasodilator, in plasma and brain areas in rats. DBI was induced in anesthetized male Sprague-Dawley rats (350-400 g) using a 350 g weight dropped from 1 meter height impact through a device designed by Marmarou et at., 1994. Blood plasma and brain tissue (cerebral cortex, diencephalon and brain stem) samples were collected for estimation of ET-1 and NO at zero or 6 h from rats (n = 6) subjected to DBI as well as control rats (n = 6), i.e., not subjected to DBI. In a separate group of animals, cerebral blood flow (CBF) was recorded at 0, 5, 10, 15, 30, 60, 120, 240 and 360 min after induction of DBI or sham-DBI. Acute DBI produced a significant decrease in CBF at 120 min after induction of DBI. Plasma levels of ET-1 was found to be significantly increased (from 0.89 +/- 0.09 to 2.09 +/- 0.29 pg ml(-1)), at 6 h following DBI. DBI produced a significant decrease in the levels of ET-1 in diencephalon (from 70.97 +/- 9.47 to 51.64 +/- 2.65 pg g(-1)). In contrast to ET-1, DBI produced a significant increase in the concentrations of NO in the diencephalon, cerebral cortex and brain stem at 6 h Post DBI. II appears that DBI-induced increase in the levels of NO in brain regions Which might De down regulating the synthesis of ET-1 in diencephalon. It is concluded that ET and NO homeostatic mechanisms may play a role in the regional and vascular responses associated with acute DBI.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Neurosurg, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Surg, Chicago, IL 60612 USA	Sharma, AC (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, M-C 901,835 S Wolcott Ave, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007692] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL07692] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 48219] Funding Source: Medline		BARONE FC, 1995, J CARDIOVASC PHARM, V26, pS404; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; EKELUND L, 1974, NEURORADIOLOGY, V7, P209, DOI 10.1007/BF00342700; FIESCHI C, 1972, EUR NEUROL, V8, P192, DOI 10.1159/000114577; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gennarelli TA, 1993, HEAD INJURY, P137; Gulati A, 1997, AM J PHYSIOL-HEART C, V273, pH827; HARBEL RL, 1993, ACTA NEUROCHIR WIE S, V59, P64; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Kwan AL, 1997, J NEUROSURG, V87, P281, DOI 10.3171/jns.1997.87.2.0281; Lang E W, 1995, New Horiz, V3, P400; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MASAKI T, 1995, ANNU REV PHARMACOL, V35, P235, DOI 10.1146/annurev.pharmtox.35.1.235; MCCULLOUGH D, 1971, J TRAUM, V11, P422, DOI 10.1097/00005373-197105000-00007; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Sharma AC, 1997, J MOL CELL CARDIOL, V29, P1469, DOI 10.1006/jmcc.1997.0386; SHARMA AC, 1995, ENDOTHELIN ROLE HLTH, P215; Thomas JE, 1997, NEUROSURGERY, V40, P1245, DOI 10.1097/00006123-199706000-00026; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; Wijdicks EFM, 1997, J NEUROSURG, V87, P275, DOI 10.3171/jns.1997.87.2.0275; YAMADA G, 1995, J CARDIOVASC PHARM, V26, pS486; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	26	12	16	0	2	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	OCT	1998	20	7					632	636					5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	124LQ	WOS:000076184200010	9785592				2021-06-18	
J	Demirhan, M; Akpinar, S; Atalar, AC; Akman, S; Akalin, Y				Demirhan, M; Akpinar, S; Atalar, AC; Akman, S; Akalin, Y			Primary replacement of the humeral head in iatrogenically displaced fracture-dislocations of the shoulder: a report about six cases	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article								Dislocation of the shoulder is a common injury and may be associated with a variety of complications. We report six cases of primary replacement of the humeral head where closed reduction of a shoulder dislocation associated with an undisplaced fracture of the humeral neck led to displacement of the neck fracture. All dislocations examined were anterior with a displaced greater tubercle fracture. The patients had undergone closed reduction at of her medical centres and were referred to us because of iatrogenically displaced fracture-dislocations of the shoulder. Three were women and three were men with a mean age of 52.8 years (range 38-72). Primary replacement of the humeral head was done in an average of 9.3 days (range 2-30 days) following the injury. The average follow-up period was 30.2 months (range 12-55 months). Postoperative pain, active range of motion and function were evaluated with the American Shoulder and Elbow Surgeons Criteria. The forward flexion averaged 124 degrees, active external rotation averaged 29 degrees and internal rotation (achieved movement) to the second lumbar vertebra. Because of the high risk of avascular necrosis and severe collapse of the humeral head, we conclude that the primary replacement of the humeral head is the superior treatment option in iatrogenically displaced fracture dislocations of the shoulder. (C) 1998 Elsevier Science Ltd. All rights reserved.	Istanbul Univ, Istanbul Sch Med, Dept Orthopaed & Traumatol, TR-34390 Istanbul, Turkey	Demirhan, M (corresponding author), Istanbul Univ, Istanbul Sch Med, Dept Orthopaed & Traumatol, TR-34390 Istanbul, Turkey.						DEMOURGUES G, 1965, REV CHIR ORTHOP, V51, P151; FERKEL RD, 1984, J TRAUMA, V24, P363, DOI 10.1097/00005373-198404000-00016; FOURRIER P, 1977, INT ORTHOP, V1, P187, DOI 10.1007/BF00266336; Goldman R T, 1995, J Shoulder Elbow Surg, V4, P81, DOI 10.1016/S1058-2746(05)80059-X; HERSCHE O, 1994, J BONE JOINT SURG BR, V76B, P30; KRAULIS J, 1976, INJURY, V8, P129, DOI 10.1016/0020-1383(76)90048-6; KRISTIANSEN B, 1987, ACTA ORTHOP SCAND, V58, P124, DOI 10.3109/17453678709146455; MAROTTE JH, 1978, CHIRURGIE, V104, P816; NEER CS, 1988, REV CHIR ORTHOP, V74, P31; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; Neer CS, 1986, ORTHOP T, V10, P475; Norris T R, 1995, J Shoulder Elbow Surg, V4, P271, DOI 10.1016/S1058-2746(05)80020-5; Schai P, 1995, J Shoulder Elbow Surg, V4, P319, DOI 10.1016/S1058-2746(95)80015-8; STABLEFORTH PG, 1984, J BONE JOINT SURG BR, V66, P104; TANNER MW, 1983, CLIN ORTHOP RELAT R, P116; WILLEMS WJ, 1985, ACTA ORTHOP SCAND, V56, P394, DOI 10.3109/17453678508994355; Zyto K, 1995, J Shoulder Elbow Surg, V4, P331, DOI 10.1016/S1058-2746(95)80016-6	17	12	14	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	1998	29	7					525	528		10.1016/S0020-1383(98)00124-7			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	115GK	WOS:000075655100008	10193495				2021-06-18	
J	Garnier, C; Enot-Joyeux, F; Jokic, C; Le Thiec, F; Desgranges, B; Eustache, F				Garnier, C; Enot-Joyeux, F; Jokic, C; Le Thiec, F; Desgranges, B; Eustache, F			Evaluation of executive functions in head-injured patients: a French adaptation of the Six Element Task	REVUE DE NEUROPSYCHOLOGIE			French	Article						head injury; frontal syndrome; assessment; executive function	FRONTAL-LOBE DAMAGE; PERFORMANCE; COGNITION; DEFICITS	An impairment of executive functions is frequently observed after a severe head injury and often compromises the patient autonomy. If there are numerous tests to detect such a dysfunction in a post-traumatic period, they are often insufficient in case of minor disorders as observed in long delay post onset. To improve evaluation of executive functions, Shallice and Burgess (1991) have elaborated the sir element task, which requires the patient to organize himself a situation close to every day activities. We have adapted this test and we suggested an original scoring. Classical tests to assess executive functions and the six element task have been proposed to three head injured patients and to thirty controls. We observed a dissociation between normal or subnormal performance in classical tests and disorders in the six element task. These results demonstrate the higher sensitivity of this test as compared to the results obtained in classical tests assessing executive functions. The disorders are interpreted within the Norman and Shallice (1980) model.	CHU Cote Nacre, INSERM, U320, F-14033 Caen, France; Ctr Hosp, Serv Reeduc Neurol, F-14260 Aunay Sur Odon, France; CHU Cote Nacre, Serv Neurol, F-14033 Caen, France; Univ Caen, F-14032 Caen, France			DESGRANGES, BEATRICE/AAK-4756-2021; Desgranges, Beatrice/L-7739-2015; Eustache, Francis/J-9465-2015	DESGRANGES, BEATRICE/0000-0002-3657-9996; Eustache, Francis/0000-0003-4460-8686			BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; Damasio A., 2005, ERREUR DESCARTES RAI; Dimitrov M, 1996, CORTEX, V32, P357, DOI 10.1016/S0010-9452(96)80057-8; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fuster J, 1989, PREFRONTAL CORTEX; Godefroy O, 1997, NEUROLOGY, V49, P695, DOI 10.1212/WNL.49.3.695; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; JOKIC C, 1997, REEDUCATIONS NEUROPS, P237; LETHIEC F, IN PRESS ANN READAPT; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A. R., 1969, HDB CLINICAL NEUROLO, V2, P725; Luria A. R., 1978, FONCTIONS CORTICALES; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; Milner B, 1964, FRONTAL GRANULAR COR, P313; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NORMAN DA, 1980, 99 CTR HUM INF PROC; PORTEUS SD, 1965, TEST LABYRINTHES SD; Raven J. C., 1947, PROGR MATRICES STAND; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REY A, 1959, TEST COPIE UNE FIGUR; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D.T., 1986, FRONTAL LOBES; Wechsler D, 1989, ECHELLE INTELLIGENCE	32	12	15	0	3	ADRSC-ASSOC DIFFUSION RECHERCHES SCIENCES COGNITIVES	MARSEILLE CEDEX 20	C N R S-C R N C, 31, CHEMIN JOSEPH ALGUIER, 13402 MARSEILLE CEDEX 20, FRANCE	1155-4452			REV NEUROPSYCHOL	Rev. Neuropsychol.	SEP	1998	8	3					385	414					30	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	131EB	WOS:000076561800003					2021-06-18	
J	Gutentag, SS; Naglieri, JA; Yeates, KO				Gutentag, SS; Naglieri, JA; Yeates, KO			Performance of children with traumatic brain injury on the cognitive assessment system	ASSESSMENT			English	Article						TBI; children; assessment; cognitive processing; PASS theory	CLOSED-HEAD-INJURY; RECOVERY; MEMORY	Children End adolescents with traumatic brain injury (TBI) were compared to a matched sample of neurologically normal children and adolescents on several measures of cognitive processing. Each of the children in the TBI group had experienced a closed head injury of moderate to severe magnitude. Participants in both the TBI (n = 22) and control (n = 22) groups ranged in age from 9 to 17 years and lived in the midwestern United States. They were all administered the Cognitive Assessment System (Naglieri & Das, 1997a). Children with TBI earned significantly lower scores in the domains of Planning and Attention than the matched control group. Within-group comparisons showed that the TBI group's Planning and Attention scores were significantly lower than their Simultaneous and Successive scores. The results are consistent with previous literature demonstrating poor performance on measures of attention and executive functions among children who have experienced TBI.	Univ N Carolina, Chapel Hill, NC 27515 USA; Ohio State Univ, Columbus, OH 43210 USA; Childrens Hosp, Columbus, OH 43205 USA	Gutentag, SS (corresponding author), New Hope Elementary Sch, 1900 New Hope Church Rd, Chapel Hill, NC 27514 USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAXTER R, 1985, HEAD INJURY REHABILI, P247; BEGALI V, 1992, HEAD INJURY CHILDREN; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Das JP, 1994, ASSESSMENT COGNITIVE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KREUTZER JS, 1991, COGNITIVE REHABILITA, P55; LEHR E, 1990, PSYCHOL MANAGEMENT T, P99; LEHR E, 1990, PSYCHOL MANAGEMENT T, P1; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Luria, 1973, WORKING BRAIN INTRO; Naglieri J, 1997, COGNITIVE ASSESSMENT; NAGLIERI JA, 1989, J SCHOOL PSYCHOL, V27, P347, DOI 10.1016/0022-4405(89)90012-5; PANIAK CE, 1989, J CLIN EXP NEUROPSYC, V11, P631, DOI 10.1080/01688638908400921; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Sattler J., 1990, ASSESSMENT CHILDREN; Savage R. C., 1994, ED DIMENSIONS ACQUIR, P3; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TELZROW CF, 1991, J HEAD TRAUMA REHAB, V6, P23; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Ylvisaker M., 1994, ED DIMENSIONS ACQUIR, P69	31	12	12	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	SEP	1998	5	3					263	272		10.1177/107319119800500306			10	Psychology, Clinical	Psychology	118WT	WOS:000075864500006	9728033				2021-06-18	
J	Gurevich, B; Artru, AA; Lam, AM; Mueller, AL; Merkind, V; Talmor, D; Katchko, L; Shapira, Y				Gurevich, B; Artru, AA; Lam, AM; Mueller, AL; Merkind, V; Talmor, D; Katchko, L; Shapira, Y			Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats	JOURNAL OF NEUROSURGERY			English	Article						brain injury; edema; excitotoxicity; ion; neuroprotection; N-methyl-D-aspartate; rat	EXPERIMENTAL BRAIN INJURY; EXCITATORY AMINO-ACIDS; CEREBRAL EDEMA; 5-PERCENT DEXTROSE; GLUTAMATE RELEASE; ISCHEMIC-INJURY; RAPID INFUSION; NMDA RECEPTOR; MAGNESIUM; KETAMINE	Object. The authors sought to determine whether 3,3-bis (3-fluorophenyl) propylamine (NPS 846), a novel noncompetitive N-methyl-D-aspartate receptor antagonist, alters outcome after closed head trauma in rats. Methods. The experimental variables were: presence or absence of closed head trauma, treatment with NPS 846 or no treatment, and time at which the rats were killed (24 or 48 hours). The NPS 846 (1 mg/kg) was administered intraperitoneally at 1 and 3 hours after closed head trauma or sham operation. Outcome measures were the neurological severity score (NSS), ischemic tissue volume, hemorrhagic necrosis volume, and specific gravity, water content, and concentrations of calcium, sodium, potassium, and magnesium in brain tissue. The following closed head trauma-induced changes in the injured hemisphere (expressed as the mean +/- the standard deviation) were reversed by NPS 846: decreased specific gravity of 1.035 +/- 0.006 at 24 hours was increased to 1.042 +/- 0.004; the decreased potassium level of 0.583 +/- 0.231 mg/L at 48 hours and at 24 hours was increased to 2.442 +/- 0.860 mg/L; the increased water content of 84.7 +/- 2.6% at 24 hours was decreased to 79.8 +/- 2%; the increased calcium level of 0.592 +/- 0.210 mg/L at 24 hours was decreased to 0.048 +/- 0.029 mg/L; and the increased sodium level of 2.035 +/- 0.649 mg/L was decreased to 0.631 +/- 0.102 mg/L. Administration of NPS 846 also lowered the NSS (improved neurological status) at 48 hours (7 +/- 3) and caused no significant changes in ischemic tissue or hemorrhagic necrosis volumes in the injured hemisphere at 24 or 48 hours. Conclusions. In this model of closed head trauma, NPS 846 improved neurological outcome, delayed the onset of brain edema, and improved brain tissue ion homeostasis.	Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Kaplan Hosp, Dept Anesthesiol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anesthesiol, IL-91010 Jerusalem, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Dept Neurosurg, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol, IL-84105 Beer Sheva, Israel; NPS Pharmaceut Inc, Salt Lake City, UT USA	Artru, AA (corresponding author), Univ Washington, Sch Med, Dept Anesthesiol, Box 356540, Seattle, WA 98195 USA.						ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; Artman L. D., 1996, Society for Neuroscience Abstracts, V22, P1282; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bullock R, 1995, ANN NY ACAD SCI, V765, P272, DOI 10.1111/j.1749-6632.1995.tb16584.x; BULLOCK R, 1992, J NEUROTRAUMA S2, V9, P443; Chien Y., 1996, Society for Neuroscience Abstracts, V22, P1282; CHOI DW, 1990, J NEUROSCI, V10, P2493; DIEMER NH, 1990, STROKE, V21, P39; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FELDMAN Z, 1995, J NEUROSURG, V83, P1060, DOI 10.3171/jns.1995.83.6.1060; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; Koroshetz WJ, 1996, TRENDS PHARMACOL SCI, V17, P227, DOI 10.1016/0165-6147(96)10020-1; LEVY DI, 1990, NEUROLOGY, V40, P852, DOI 10.1212/WNL.40.5.852; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MATSUMIYA N, 1991, STROKE, V22, P1193, DOI 10.1161/01.STR.22.9.1193; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; MORLEY P, 1994, BRAIN PATHOL, V4, P37; Mueller A. L., 1996, Society for Neuroscience Abstracts, V22, P1282; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P51, DOI 10.1097/00008506-199701000-00012; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SMITH DH, 1993, J NEUROSCI, V13, P5383; VANWAGENEN BC, 1996, 212 NAT M AM CHEM SO; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	46	12	12	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	1998	88	6					1066	1074		10.3171/jns.1998.88.6.1066			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZP267	WOS:000073735200018	9609302				2021-06-18	
J	Cypser, DA; Davis, SD				Cypser, DA; Davis, SD			Induced seismicity and the potential for liability under US law	TECTONOPHYSICS			English	Article; Proceedings Paper	IASPEI Symposium on New Trends in Seismological Research - Studies of Seismicity Induced by Mining, Petroleum and Geothermal Activities at the IUGG Meeting	JUL, 1995	BOULDER, COLORADO	IASPEI, Gen Assembly Int Union Geodesy & Geophys		triggered induced seismicity; earthquakes; liability; legal	RESERVOIR-INDUCED SEISMICITY; TRIGGERED EARTHQUAKES; CALIFORNIA; FIELD; TEXAS; STATE	Research by seismologists over the past 30+ years has firmly established that some human activities induce seismicity. Sometimes induced seismicity causes injuries to people or property. The activities which induce seismicity generally involve extraction of energy, or natural resources, or the disposal of wastes. As the human population increases these extraction and disposal activities will increase in number of sites and intensity of effort as the demands became greater and the resources scarcer. With these increases the number and severity of damaging induced earthquakes is likely to increase. Induced seismicity may cause injuries by vibrations or by seismically induced ground failure. In either case compensation for injuries caused by induced seismicity should be paid for by the inducer. In the United States the inducer of damaging seismicity can be made to pay for the harm caused. Liability for damage caused by vibrations can be based on several legal theories: trespass, strict liability, negligence and nuisance. Our research revealed no cases in which an appellate court has upheld or rejected the application of tort liability to an induced earthquake situation. However, there are numerous analogous cases that support the application of these legal theories to induced seismicity. Vibrations or concussions due to blasting or heavy machinery are sometimes viewed as a 'trespass' analogous to a physical invasion. In some states activities which induce earthquakes might be considered 'abnormally dangerous' activities that require companies engaged in them to pay for injuries the quakes cause regardless of how careful the inducers were. In some circumstances, a court may find that an inducer was negligent in its site selection or in maintenance of the project. If induced seismicity interferes with the use or enjoyment of another's land, then the inducing activity may be a legal nuisance, even if the seismicity causes little physical damage. In most states of the United States owners of land owe a duty of lateral support to adjacent landowners, and, in some states, mineral estate owners and lessees owe a duty of subjacent support to the surface owners. Failure to meet those duties of support can result in liability. Seismicity induced by one source might accelerate failure of support originating from another source, leaving both of the parties at fault proportionally liable to the injured parties. Geoscientists can use their roles as investigators, educators and advisors to help companies in the petroleum, mining and geothermal fields avoid liability. (C) 1998 Elsevier Science B.V. All rights reserved.	NOAA, Natl Geophys Data Ctr, Cooperat Inst Res Environm Sci, Boulder, CO 80303 USA	Cypser, DA (corresponding author), POB 2187, Boulder, CO 80306 USA.	dcypser@nyx.net					AKE J, 1992, SEISMOL RES LETT, V63, P19; ALLEN C. R., 1982, CALIF GEOL, V35, P248; American Law Institute, 1979, REST 2 TORTS; BECK JL, 1976, B SEISMOL SOC AM, V66, P1121; BELL ML, 1978, J GEOPHYS RES, V83, P4469, DOI 10.1029/JB083iB09p04469; BUFE CG, 1976, SCIENCE, V192, P72, DOI 10.1126/science.192.4234.72; CARDER D, 1970, ENG GEOL CASE HIST, V8, P51; COOK NGW, 1976, ENG GEOL, V10, P99, DOI 10.1016/0013-7952(76)90015-6; Cox R. T., 1991, Seismological Research Letters, V62, P113; Cypser DA, 1994, J ENV LAW LITIG, V9, P551; Davis S. D., 1993, Seismological Research Letters, V64, P207; Davis SD, 1995, B SEISMOL SOC AM, V85, P1888; DAVIS SD, 1989, B SEISMOL SOC AM, V79, P1477; EBERHARTPHILLIPS D, 1984, J GEOPHYS RES, V89, P1191, DOI 10.1029/JB089iB02p01191; FLETCHER JB, 1977, J GEOPHYS RES, V82, P3767, DOI 10.1029/JB082i026p03767; GRASSO JR, 1992, PURE APPL GEOPHYS, V139, P507, DOI 10.1007/BF00879949; Gupta H.K., 1992, RESERVOIR INDUCED EA; GUPTA HK, 1985, TECTONOPHYSICS, V118, P257, DOI 10.1016/0040-1951(85)90125-8; Gupta HK, 1976, DEV GEOTECHNICAL ENG; HASEGAWA HS, 1989, PURE APPL GEOPHYS, V129, P423, DOI 10.1007/BF00874518; HEALY JH, 1968, SCIENCE, V161, P1301, DOI 10.1126/science.161.3848.1301; JANSEN RB, 1967, J SOIL MECH, V4, P551; KANAMORI H, 1992, B SEISMOL SOC AM, V82, P2087; LONG LT, 1989, PURE APPL GEOPHYS, V129, P415, DOI 10.1007/BF00874517; MCGARR A, 1991, B SEISMOL SOC AM, V81, P948; NICHOLSON C, 1992, PURE APPL GEOPHYS, V139, P561, DOI 10.1007/BF00879951; NICHOLSON C, 1990, US GEOL SURV B, V1951; PENNINGTON WD, 1986, B SEISMOL SOC AM, V76, P939; POMEROY PW, 1976, B SEISMOL SOC AM, V66, P685; RALEIGH CB, 1976, SCIENCE, V191, P1230, DOI 10.1126/science.191.4233.1230; RASTOGI BK, 1995, IUGG 21 GEN ASS BOUL, pA367; REDMAYNE DW, 1988, GEOLOGICAL SOC ENG G, V5, P405; SEEBER L, 1988, RECENT HIST SEISMICI; SEGALL P, 1989, GEOLOGY, V17, P942, DOI 10.1130/0091-7613(1989)017<0942:ETBFE>2.3.CO;2; SEGALL P, 1994, J GEOPHYS RES-SOL EA, V99, P15423, DOI 10.1029/94JB00989; SIMPSON DW, 1988, B SEISMOL SOC AM, V78, P2025; SIMPSON DW, 1986, ANNU REV EARTH PL SC, V14, P21, DOI 10.1146/annurev.ea.14.050186.000321; SWANSON PL, 1995, 8695 US BUR MIN; VONHAKE CA, 1969, US EARTHQUAKES 1967; WONG IG, 1992, ROCK MECHANICS : PROCEEDINGS OF THE 33RD U S SYMPOSIUM, P1103; ZOBACK ML, 1980, J GEOPHYS RES, V85, P6113, DOI 10.1029/JB085iB11p06113; 1980, PACIFIC REPORTER, V612, P889; 1987, FEDERAL REPORTER, V814, P258; 1909, FEDERAL REPORTER, V172, P792; 1920, SE REPORTER, V105, P425; 1928, PACIFIC REPORTER, V270, P952; 1972, PACIFIC REPORTER, V497, P340; 1993, SUPREME COURT REPORT, V113, P2786; 1979, NW REPORTER, V281, P520; 1961, NE REPORTER, V173, P292; 1986, FEDERAL S, V647, P303; 1968, SO REPORTER, V229, P524; 1920, NW REPORTER, V175, P45; 1947, FEDERAL REPORTER, V159, P169; 1892, SE REPORTER, V16, P12; 1942, SW REPORTER, V158, P134; 1960, ATLANTIC REPORTER, V157, P740; 1945, PACIFIC REPORTER, V154, P428; 1971, AM JURISPRUDENCE, V54, P376; 1984, FEDERAL REPORTER, V732, P1375; 1985, SO REPORTER, V482, P662; 1988, FEDERAL REPORTER, V845, P1307; 1934, PACIFIC REPORTER, V28, P862; 1992, PACIFIC REPORTER, V824, P783; 1944, NE REPORTER, V58, P517; 1986, PACIFIC REPORTER, V720, P152; 1923, FEDERAL REPORTER, V293, P1013; 1963, NE REPORTER, V188, P406; 1961, SW REPORTER, V344, P411; 1927, SW REPORTER, V298, P554; 1983, SW REPORTER, V644, P339; 1916, NW REPORTER, V156, P188; 1972, SW REPORTER, V487, P651; 1931, FEDERAL REPORTER, V54, P510; 1982, PACIFIC REPORTER, V772, P640	75	12	12	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0040-1951			TECTONOPHYSICS	Tectonophysics	APR 15	1998	289	1-3					239	255		10.1016/S0040-1951(97)00318-1			17	Geochemistry & Geophysics	Geochemistry & Geophysics	ZR956	WOS:000074033200017					2021-06-18	
J	McHugh, GJ				McHugh, GJ			Anaphylactoid reaction to pentastarch	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							HYDROXYETHYL STARCH; PLASMA SUBSTITUTES	Purpose: To report a probable anaphylactoid reaction to pentastarch, a low molecular weight hydroxyethyl starch (HES) colloid solution. Clinical features: Following a closed head injury, an 18-yr-old male was admitted to the Intensive Care Unit. Therapy was directed towards control of intracranial pressure (ICP) and maintenance of cerebral perfusion pressure (CPP), In the first 12 hr after admission, he had received 2500 ml polygeline (Haemaccel(R), Hoechst Marion Roussel Ltd.) and a dopamine infusion (up to 10 mu g.kg(-1).min(-1)) titrated to achieve a mean arterial pressure (MAP) of greater than or equal to 80 mmHg. Subsequent failure to achieve the target MAP resulted in commencement of a noradrenaline infusion (2.67 mu g.min(-1)), and rapid administration of 500ml pentastarch (Pentaspan(R), duPont Pharmaceuticals). During the HES infusion, marked hypotension (MAP < 60 mmHg) developed associated with marked truncal urticaria. The hypotension was resistant to escalation of noradrenaline to 36 mu g.min(-1). Haemodynamic stability was rapidly restored and maintained with adrenaline boluses (total 450 mu g) and infusion (1.67 mu g.min(-1)). The remainder of the patient's ICU and hospital stay was unremarkable. A serum tryptase drawn in the first 40 min of the reaction was not elevated. Other biochemical markers were not assayed, Skin testing has not been carried out. Conclusion: The temporal relationship and clinical manifestations observed in this case, together with the resistance to inotropes/vasopressors other than adrenaline is highly suggestive of an anaphylactoid reaction to pentastarch. The diagnostic value of serum tryptase may be compromised when blood samples are drawn too early.	Palmerston N Hosp, Dept Anaesthesia & Intens Care, Palmerston North, New Zealand	McHugh, GJ (corresponding author), Palmerston N Hosp, Dept Anaesthesia & Intens Care, Private Bag 11036, Palmerston North, New Zealand.						CULLEN MJ, 1990, ANAESTHESIA, V45, P1041, DOI 10.1111/j.1365-2044.1990.tb14883.x; FISHER M, 1994, EUR J ANAESTH, V11, P263; KRAFT D, 1992, EUR SURG RES, V24, P138, DOI 10.1159/000129200; KREIMEIER U, 1995, LANCET, V346, P49, DOI 10.1016/S0140-6736(95)92677-1; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; LAXENAIRE MC, 1994, ANN FR ANESTH, V13, P301, DOI 10.1016/S0750-7658(94)80038-3; LORENZ W, 1975, ANAESTHESIST, V24, P228; MAURER PH, 1968, TRANSFUSION, V8, P265, DOI 10.1111/j.1537-2995.1968.tb02422.x; PORTER SS, 1986, CAN J ANAESTH, V33, P394, DOI 10.1007/BF03010756; RING J, 1977, LANCET, V1, P466; RING J, 1976, EUR SURG RES, V8, P389, DOI 10.1159/000127883; RING J, 1985, INT ANESTHESIOL CLIN, V23, P67	12	12	12	0	0	CANADIAN ANAESTHETISTS SOC INC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	1998	45	3					270	272		10.1007/BF03012915			3	Anesthesiology	Anesthesiology	ZK214	WOS:000073296800015	9579268	Bronze			2021-06-18	
J	Al Moutaery, K; Arshaduddin, M; Tariq, M; Al Deeb, S				Al Moutaery, K; Arshaduddin, M; Tariq, M; Al Deeb, S			Functional recovery and vitamin E level following sciatic nerve crush injury in normal and diabetic rats	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						vitamin E; sciatic nerve; diabetes; crush injury; neuropathy	SPINAL-CORD INJURY; ALPHA-TOCOPHEROL; LIPID-PEROXIDATION; BLOOD-FLOW; CONDUCTION-VELOCITY; OXIDATIVE STRESS; TIBIAL NERVE; E-DEFICIENCY; ANTIOXIDANT; BRAIN	Extensive biochemical data document the involvement of oxygen derived free radicals (ODFR) in recovery following neurotrauma as well as diabetic neuropathy. Vitamin E is considered as one of the principle protective mechanism against oxidative damage in neuronal tissue. The present study was undertaken to determine the association between functional recovery and vitamin E levels following sciatic nerve crush injury in normal and diabetic rats. The sciatic nerve of normal and streptozotocin (STZ) induced diabetic rats was crushed using a haemostat. The walking track analysis and vitamin E levels were recorded on 10, 20 and 30th day. Maximum functional deficiency and depletion of vitamin E in sciatic nerve was observed on 10th day following crush injury in both normal and diabetic animals. A progressive motor recovery and repletion of vitamin E was observed on day 20 and 30 following injury in both diabetic and normal rats. The functional recovery was slower whereas vitamin E level was higher in diabetic animals as compared to normal injured rats during healing phase suggesting that vitamin E alone may not be an efficient indicator of oxidative stress during regeneration of axons following trauma in diabetic rats.	Armed Forces Hosp, Dept Neurosurg, Riyadh 11159, Saudi Arabia; Armed Forces Hosp, Res Ctr, Riyadh 11159, Saudi Arabia	Tariq, M (corresponding author), Armed Forces Hosp, Dept Neurosurg, W-912 POB 7897, Riyadh 11159, Saudi Arabia.						ANDERSON DK, 1980, J NEUROSURG, V53, P575; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; BOWE CM, 1987, DEV BRAIN RES, V34, P123, DOI 10.1016/0165-3806(87)90201-X; BRIN MF, 1986, NEUROLOGY, V36, P669, DOI 10.1212/WNL.36.5.669; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; CARSTEN RE, 1989, DIABETES, V38, P730, DOI 10.2337/diabetes.38.6.730; Ceriello A, 1997, DIABETES CARE, V20, P1589, DOI 10.2337/diacare.20.10.1589; CLENDENON NR, 1978, J NEUROSURG, V49, P563, DOI 10.3171/jns.1978.49.4.0563; CUPPINI R, 1993, J NEUROL SCI, V117, P61, DOI 10.1016/0022-510X(93)90155-R; DEKONING P, 1986, J NEUROL SCI, V74, P237, DOI 10.1016/0022-510X(86)90109-7; DELAMARTER RB, 1995, J BONE JOINT SURG AM, V77A, P1042, DOI 10.2106/00004623-199507000-00010; DEXTER DT, 1992, ANN NEUROL, V32, P591, DOI 10.1002/ana.410320420; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; HALL ED, 1987, BRAIN RES, V413, P175, DOI 10.1016/0006-8993(87)90166-1; HALLIWELL B, 1984, LANCET, V1, P1396; HELLWEG R, 1994, EXP NEUROL, V130, P24, DOI 10.1006/exnr.1994.1181; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; JAMES AK, 1991, PAIN, V47, P31; LONGO FM, 1986, MUSCLE NERVE, V9, P385, DOI 10.1002/mus.880090502; LOW PA, 1991, DIABETES, V40, P873, DOI 10.2337/diabetes.40.7.873; MARKLUND SL, 1985, J NEUROL SCI, V67, P319, DOI 10.1016/0022-510X(85)90156-X; MARTINOLI L, 1993, INT J VITAM NUTR RES, V63, P87; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MEISTER A, 1988, J BIOL CHEM, V263, P17207; NAVARRO X, 1988, BRAIN RES, V447, P133, DOI 10.1016/0006-8993(88)90973-0; NICKANDER KK, 1994, J NEUROL SCI, V126, P6, DOI 10.1016/0022-510X(94)90088-4; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; NUKADA H, 1993, J NEUROL SCI, V119, P162, DOI 10.1016/0022-510X(93)90129-M; NUKADA H, 1986, DIABETES, V35, P1058, DOI 10.2337/diabetes.35.9.1058; PERUMAL AS, 1989, BRAIN RES, V504, P139, DOI 10.1016/0006-8993(89)91611-9; ROMERO FJ, 1991, NEUROCHEM RES, V16, P157, DOI 10.1007/BF00965704; SATYAMURTI S, 1986, NEUROLOGY, V36, P917, DOI 10.1212/WNL.36.7.917; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Tariq M, 1995, INT J NEUROSCI, V83, P165, DOI 10.3109/00207459508986336; THURSTON JH, 1995, DIABETES, V44, P190, DOI 10.2337/diabetes.44.2.190; WALLACE MC, 1986, NEUROSURGERY, V18, P433; YOUNG IS, 1995, FREE RADICAL BIO MED, V18, P833, DOI 10.1016/0891-5849(94)00202-U	38	12	12	0	0	GORDON BREACH SCI PUBL LTD	READING	C/O STBS LTD, PO BOX 90, READING RG1 8JL, BERKS, ENGLAND	0020-7454			INT J NEUROSCI	Int. J. Neurosci.		1998	96	3-4					245	254					10	Neurosciences	Neurosciences & Neurology	155EL	WOS:000077933300010	10069624				2021-06-18	
J	Fertl, E; Steinhoff, N; Schofl, R; Potzi, R; Doppelbauer, A; Muller, C; Auff, E				Fertl, E; Steinhoff, N; Schofl, R; Potzi, R; Doppelbauer, A; Muller, C; Auff, E			Transient and long-term feeding by means of percutaneous endoscopic gastrostomy in neurological rehabilitation	EUROPEAN NEUROLOGY			English	Article						percutaneous endoscopic gastrostomy; neurological rehabilitation; long-term PEG feeding; transient PEG feeding; traumatic brain injury; posthypoxic encephalopathy	ENTERAL NUTRITION; ACUTE STROKE; HEAD-INJURY; DYSPHAGIA; SUPPORT	In 28 patients of a neurological rehabilitation unit of a hospital the use of enteral nutrition via percutaneous endoscopic gastrostomy (PEG) tubes was reviewed. During a total observation period of 5,172 days no life-threatening complications occurred. Minor complications were observed in 12 patients (43%) in the first 2 weeks after the insertion and in 5 patients (18%) afterwards. The nutritional status stabilized in all subjects. Transient PEG feeding was performed in 11 patients (39%) with a mean duration of 150 days. We conclude that hesitation in the application of PEG feeding in neurological rehabilitation should be abandoned. The timing and monitoring of PEG feeding in patients undergoing neurological rehabilitation for acute remitting neurological disorders is discussed.	Univ Clin Vienna, Dept Neurol Rehabil, A-1090 Vienna, Austria; Univ Clin Vienna, Dept Gastroenterol & Hepatol, Vienna, Austria	Fertl, E (corresponding author), Univ Clin Vienna, Dept Neurol Rehabil, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.						BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BIESALSKI HK, 1995, ERNAHRUNGSMEDIZIN; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Britton JER, 1997, J NEUROL, V244, P431, DOI 10.1007/s004150050117; BRUNELLI E, 1993, LANCET, V341, P1534, DOI 10.1016/0140-6736(93)90668-7; DEUTSCH E, 1990, LEHRBUCH INTERNISTIS; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; Gossner L, 1995, DEUT MED WOCHENSCHR, V120, P1768, DOI 10.1055/s-2008-1055540; Grimble GK, 1996, CURR OPIN GASTROEN, V12, P174, DOI 10.1097/00001574-199603000-00012; HULL MA, 1993, LANCET, V341, P869, DOI 10.1016/0140-6736(93)93072-9; KEYMLING M, 1985, MED WELT, V36, P1297; MCWIRTHER JP, 1994, BRIT MED J, V308, P945; MEIER R, 1994, SCHWEIZ MED WSCHR, V124, P655; PARK RHR, 1992, BRIT MED J, V304, P1406, DOI 10.1136/bmj.304.6839.1406; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; UNOSSON M, 1994, STROKE, V25, P366, DOI 10.1161/01.STR.25.2.366; Wade DT, 1992, MEASUREMENT NEUROLOG; WAXMANN I, 1992, DIGEST DIS SCI, V36, P251; WEEKES E, 1992, CLIN NUTR, V11, P18, DOI 10.1016/0261-5614(92)90058-X; WILLIG TN, 1995, SEMIN NEUROL, V15, P18, DOI 10.1055/s-2008-1041002; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	22	12	14	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022			EUR NEUROL	Eur. Neurol.		1998	40	1					27	30		10.1159/000007952			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	105MZ	WOS:000075078500006	9693229				2021-06-18	
J	Wang, HD; Duan, GS; Zhang, J; Zhu, DB				Wang, HD; Duan, GS; Zhang, J; Zhu, DB			Clinical studies on diffuse axonal injury in patients with severe closed head injury	CHINESE MEDICAL JOURNAL			English	Article							COMPUTED-TOMOGRAPHY; HUMANS; TRAUMA	Objective To discuss the clinical criteria for diagnosing diffuse axonal injury (DAI). Methods Clinical and computed tomographic features of 117 patients with severe closed head injury were analyzed. The authors preliminarily put forward CT diagnostic criteria of DAI, that is, 1) single or multiple small intraparenchymal hemorrhages in the cerebral hemispheres (< 2 cm in diameter); 2) intraventricular hemorrhage; 3) hemorrhage in the corpus callosum; 4) small focal areas of hemorrhage adjacent to the third ventricle (< 2 cm in diameter); and 5) brain stem hemorrhage. All patients were divided into two groups, DAI and non-DAI group, according to the criteria. There were 42 patients in the DAI group and 75 patients in the non-DAI group. The injury causes, Glasgow coma scale (GCS) scores on admission, coexisting injuries and outcomes were compared between the two groups. The relationship between DAI and the outcomes in the patients with severe head injury was analyzed. Results Traffic accident was the main injury cause in the cases of DAI. GCS scores on admission in patients with DAI were significantly lower than those in patients without DAI. The incidence of diffuse brain swelling (DBS) in the DAI group was significantly higher than that in the non-DAI group, whereas the incidences of both skull fracture and epidural hematoma (EDH) in the DAI group were significantly lower than those in non-DAI group. There was no significant difference between the incidence of subarachnoid hemorrhage (SAH) and subdural hematoma (SDH) in the two groups. The incidence of poor outcome in the DAI group was significantly higher than that in the non-DAI group, although there was no significant difference between the mortalities in the two groups. Conclusions Because DAI is a very important factor worsening the outcome of patients with head injury, it is essential to make a diagnosis as soon as possible. The clinical manifestations of DAI, however, are not specific and DAI does not show directly on CT scans, so it is difficult to make a definite diagnosis. The CT diagnostic criteria of DAI put forward in this article are practicable, though they are by no means perfect.	Nanjing Univ, Sch Clin Med, Nanjing Gen Hosp PLA, Dept Neurosurg, Nanjing 210002, Peoples R China; Gen Hosp PLA, Dept Neurosurg, Beijing 100853, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Clin Med, Nanjing Gen Hosp PLA, Dept Neurosurg, Nanjing 210002, Peoples R China.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MITCHELL DE, 1973, LANCET, V2, P215; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	14	12	14	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0366-6999			CHINESE MED J-PEKING	Chin. Med. J.	JAN	1998	111	1					59	62					4	Medicine, General & Internal	General & Internal Medicine	YV690	WOS:000071853000020	10322656				2021-06-18	
J	Watanabe, TK; Black, KL; Zafonte, RD; Millis, SR; Mann, NR				Watanabe, TK; Black, KL; Zafonte, RD; Millis, SR; Mann, NR			Do calendars enhance posttraumatic temporal orientation? a pilot study	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; REALITY ORIENTATION; PSYCHOGERIATRIC PATIENTS; RECOVERY	The purpose of this study was to determine the effectiveness of an in-room calendar to correct temporal disorientation in a brain-injured population. Thirty consecutive brain injured patients (16 traumatic, 14 non-traumatic) admitted to a brain injury rehabilitation unit were randomly assigned to either a group with in-room calendars (n = 14) or a group without calendars (n = 16). A baseline Temporal Orientation Test (TOT) score was obtained. Daily TOT scores were obtained for patients throughout their rehabilitation stay or until two consecutive normal scores were obtained. When orientation errors were made, they were corrected and the attention of the patient was drawn to the calendar. There were no statistically significant associations between group and age, gender or mean GCS (for patients with traumatic etiology). Only baseline length of post-traumatic amnesia (PTA) had a significant association with eventual emergence from PTA (as defined by a normal score on the TOT). Age and presence of calendar were not significant. In-room calendars have been espoused as orientation aides. The data from this pilot study suggest that calendars do not hasten re-orientation. This finding suggests that other widely held but not rigorously tested beliefs regarding cognitive rehabilitation may need to be examined.	Wayne State Univ, Rehabil Inst Michigan, Detroit, MI 48201 USA	Black, KL (corresponding author), Wayne State Univ, Rehabil Inst Michigan, 261 Mack Blvd, Detroit, MI 48201 USA.						Benton A.L., 1983, CONTRIBUTIONS NEUROP; BROOK P, 1975, BRIT J PSYCHIAT, V127, P42, DOI 10.1192/bjp.127.1.42; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; GREENE JG, 1979, BEHAV RES THER, V17, P615, DOI 10.1016/0005-7967(79)90106-2; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; KASCHEL R, 1995, BRAIN INJURY, V9, P619, DOI 10.3109/02699059509008220; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LINCOLN NB, 1988, BRIT J OCCUPATIONAL, V51, P195; MCNENY R, 1989, REHABILITATION ADULT, P366; NEVILLE A, 1980, AM J OCCUP THER, V34, P328, DOI 10.5014/ajot.34.5.328; ZAFONTE RD, IN PRESS ARCH PHYSIC	14	12	14	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					81	85					5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500009	9483341				2021-06-18	
J	Zencius, AH; Wesolowski, MD; Rodriguez, IM				Zencius, AH; Wesolowski, MD; Rodriguez, IM			Improving orientation in head injured adults by repeated practice, multi-sensory input and peer participation	BRAIN INJURY			English	Article							CONFABULATION	The efficacy of using antecedent control procedures (practice, multi-sensory input and peer participation) in facilitating orientation to person, place and time with two survivors of traumatic brain injuries were tested in two studies. In the first investigation, a 23-year-old male was treated by presenting the orientation questions orally while being shown questions on written flashcards. Results suggest that correct responses to orientation questions only occurred when flashcards were coupled with oral questioning. The participant responded correctly to nearly 100% of all orientation questions within 2 weeks of initiating flashcards. In the second study, a 19-year-old male was asked to respond in writing to 20 orientation questions in a small group. The group had a leader and 4 TBI patients. Following this, group members who correctly answered the orientation questions, took turns reading orientation questions and providing the correct responses.	Premier Chicago Rehabil Ctr, Downer Grove, IL USA; Florida Dept Children & Families, Miami, FL USA; Florida Int Univ, Miami, FL 33199 USA	Wesolowski, MD (corresponding author), 401 NW 2 Ave,Room N826, Miami, FL 33128 USA.						Arnie Zencius, 1991, BEHAV RESIDENTIAL TR, V6, P1, DOI DOI 10.1002/BIN.2360060102; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; KAPUR N, 1980, J NEUROL NEUROSUR PS, V43, P461, DOI 10.1136/jnnp.43.5.461; KLEMENT JJ, 1973, LEARNING ED TECHNOLO, V10, P65; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIN CS, 1979, B ED PSYCHOL, V12, P115; LUCHOW JP, 1981, LEARN DISABILITY Q, V4, P38, DOI 10.2307/1510711; MAGOON RA, 1977, CONTEMP EDUC PSYCHOL, V12, P55; MERCER B, 1977, ARCH NEUROL-CHICAGO, V34, P429, DOI 10.1001/archneur.1977.00500190063009; SHAPIRO BE, 1981, NEUROLOGY, V31, P1070, DOI 10.1212/WNL.31.9.1070; SISLER G, 1975, CAN PSYCHIAT ASSOC J, V20, P333, DOI 10.1177/070674377502000502; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; Wesolowski M.D., 1993, PRACTICAL GUIDE HEAD; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146; Zencius A H, 1989, Brain Inj, V3, P199, DOI 10.3109/02699058909004553; ZENCIUS AH, 1991, BRAIN INJURY, V5, P288	19	12	12	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					53	61		10.1080/026990598122854			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500005	9483337				2021-06-18	
J	Takami, H; Takahashi, S; Ando, M				Takami, H; Takahashi, S; Ando, M			Irreducible isolated dislocation of the radial head	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							ANTERIOR DISLOCATION	Isolated dislocation of the radial head in adults is a rare injury, A 20-year-old man received a direct blow to his elbow and sustained an isolated anterior dislocation of the radial head, Open reduction was required because soft tissue interposition prevented reduction by closed manipulation. At operation the annular ligament was found to be ruptured and interposed between the articular surfaces, preventing reduction, A satisfactory result was obtained 1 year after surgery.	Kanto Rosai Hosp, Sect Orthopaed Surg, Nakahara Ku, Kawasaki, Kanagawa, Japan	Takami, H (corresponding author), Kanto Rosai Hosp, Sect Orthopaed Surg, Nakahara Ku, Kawasaki, Kanagawa, Japan.						BENJAMIN A, 1976, WATSON JONES FRACT J, P666; BONATUS T, 1995, J ORTHOP TRAUMA, V9, P441, DOI 10.1097/00005131-199505000-00014; HAMILTON W, 1973, CLIN ORTHOP RELAT R, V97, P94; HEIDT RS, 1982, CLIN ORTHOPAEDICS, V168, P136; HUME AC, 1957, J BONE JOINT SURG BR, V39, P508; KONG KC, 1993, ARCH ORTHOP TRAUM SU, V112, P304, DOI 10.1007/BF00452972; LLOYDROBERTS GC, 1977, J BONE JOINT SURG BR, V59, P402; RYU J, 1984, CLIN ORTHOP RELAT R, V183, P169; SALAMA R, 1977, CLIN ORTHOPAEDICS, V125, P156; WILEY JJ, 1974, J BONE JOINT SURG BR, VB 56, P501	10	12	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	DEC	1997		345					168	170					3	Orthopedics; Surgery	Orthopedics; Surgery	YL426	WOS:000070953800023	9418635				2021-06-18	
J	Karger, B; Banaschak, S				Karger, B; Banaschak, S			Two cases of exenteration of the brain from Brenneke shotgun slugs	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Brenneke shotgun slug; gunshot; exenteration of the brain; incomplete Kronlein shot	INJURIES	A case of extended suicide resulted in two fatalities due to craniocerebral gunshots from a 12-gauge shotgun firing Brenneke shotgun slugs. In each case, the gunshot shattered the skull and the brain and in one case, large parts of the brain including a complete hemisphere were ejected similar to a ''Kronlein shot''. The location of the trajectory close to the base of the skull, the muzzle gases and the ballistic characteristics of the missile contributed to this rare form of head injury. The high mass and the large diameter of the lead missile do not necessitate a high muzzle velocity to crush large amounts of tissue or to produce an explosive type of head injury. The wadding material and the metal screw attached to the Brenneke slug can be of forensic significance.		Karger, B (corresponding author), UNIV MUNSTER,INST LEGAL MED,VON ESMARCH STR 62,D-48129 MUNSTER,GERMANY.		Banaschak, Sibylle/AAE-2104-2020	Banaschak, Sibylle/0000-0002-1413-1250			Bohnert M, 1995, Arch Kriminol, V195, P85; DAVIS GJ, 1993, AM J FOREN MED PATH, V14, P162, DOI 10.1097/00000433-199306000-00013; DIMAIO, 1985, GUNSHOT WOUNDS, P179; FACKLER ML, 1985, J TRAUMA, V25, P522, DOI 10.1097/00005373-198506000-00009; FRANZ C, 1910, ARCH KLIN CHIR, V93, P497; Gestring ML, 1996, J TRAUMA, V40, P650, DOI 10.1097/00005373-199604000-00025; IKEDA N, 1989, MED SCI LAW, V29, P156, DOI 10.1177/002580248902900211; Karger B, 1996, INT J LEGAL MED, V108, P252, DOI 10.1007/BF01369820; KILLAM EW, 1991, CRIME LAB DIGEST, V18, P36; KNEUBUEHL BP, 1994, GESCHOSSE, P169; Kronlein RU, 1899, ARCH KLIN CHIR, V59, P67; MERTENS, 1917, BEITR KLIN CHIR, V108, P371; PANKRATZ H, 1985, Z RECHTSMED, V95, P213; Petty C S, 1968, J Forensic Sci, V13, P114; PIVA C, 1988, J MED LEG DROIT MED, V31, P423; Pollak S, 1990, Beitr Gerichtl Med, V48, P507; RAO VJ, 1987, J FORENSIC SCI, V32, P1435; Risse M, 1988, Arch Kriminol, V182, P75; SELLIER K, 1982, SCHUSSWAFFEN SCHUSSW, P148; Strauch Hansjuerg, 1995, Archiv fuer Kriminologie, V195, P27	20	12	13	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	NOV	1997	110	6					323	325		10.1007/s004140050096			3	Medicine, Legal	Legal Medicine	YF831	WOS:A1997YF83100006	9387015				2021-06-18	
J	Henry, JM; Talukder, NK; Lee, AB; Walker, ML				Henry, JM; Talukder, NK; Lee, AB; Walker, ML			Cerebral trauma-induced changes in corpus striatal dopamine receptor subtypes	JOURNAL OF INVESTIGATIVE SURGERY			English	Article						cerebral trauma; corpus striatum; dopamine receptors; Wistar rat	ISCHEMIC BRAIN INJURY; UPTAKE SITES; RAT; BINDING; LIGAND; D-2	A device designed specifically for mild to severe concussions was used to produce quantitative experimental blunt brain injury in male Wistar rats. We have examined the effects of varying magnitudes of cerebral trauma on the maximal binding capacity (B-max) of D1 and D2 dopamine (DA) receptors. The B-max for each receptor subtype was obtained from Scatchard analyses of [H-3]-SCH 23390 and [H-3]Spiperone binding to striatal membrane. Anesthetized rats were injured-one, two, or three times-once every 24 h, with either a 68- or 268-g rubber-headed reflex hammer accelerated from a predetermined distance. Uninjured nonanesthetized (NA) and anesthetized (A) rats served as controls. No significant difference in receptor density was observed between NA and A rats for each receptor subtype. Immediately (0 h) following injury from the 68-g hammer weight, the density of D1 receptors decreased (50%), then increased (30%) above control levels by 24 h. The same pattern was observed with the 268-g hammer weight. Analysis of variance (ANOVA) showed that there was no overall effect of number of injuries or treatment on the density of D1 and D2 receptor subtypes. However, there was an interaction of both variables on the DI, but not D2, receptor subtype. Partial ANOVA for receptor densities after rats were injured either one, two, or three times showed that receptor density was altered only after the rats were injured one time. These results suggest that striatal DA D1 receptors are downregulated and then upregulated following isolated injury to the cerebral cortex.	MOREHOUSE SCH MED,DEPT SURG,ATLANTA,GA 30310; CLARK ATLANTA UNIV,DEPT PHYS,ATLANTA,GA 30314					NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR003034] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12-RR03034] Funding Source: Medline		BILLARD W, 1984, LIFE SCI, V35, P1885, DOI 10.1016/0024-3205(84)90540-X; BLAKE MJ, 1990, NEUROBIOL AGING, V12, P193; GRABOW JD, 1970, AM J PUBLIC HEALTH, V74, P710; HAMBLIN MW, 1984, BIOCHEM PHARMACOL, V33, P877, DOI 10.1016/0006-2952(84)90441-6; HYTELL J, 1982, ADV DOPAMINE RES; JENNETT B, 1972, LANCET, V1, P734; KOSTIC V, 1991, J NEUROCHEM, V57, P1962, DOI 10.1111/j.1471-4159.1991.tb06410.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OBOYLE KM, 1984, EUR J PHARMACOL, V105, P171, DOI 10.1016/0014-2999(84)90663-0; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; PRZEDBORSKI S, 1991, J NEUROCHEM, V57, P1951, DOI 10.1111/j.1471-4159.1991.tb06409.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x	14	12	12	0	0	TAYLOR & FRANCIS	BRISTOL	1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598	0894-1939			J INVEST SURG	J. Invest. Surg.	SEP-OCT	1997	10	5					281	286		10.3109/08941939709032167			6	Surgery	Surgery	YD803	WOS:A1997YD80300006	9361992				2021-06-18	
J	Young, CC; Jacobs, BA; Clavette, K; Mark, DH; Guse, CE				Young, CC; Jacobs, BA; Clavette, K; Mark, DH; Guse, CE			Serial sevens: Not the most effective test of mental status in high school athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mental status testing; concussion evaluation; high school athletes	CONCUSSION	Objective: To evaluate the ability of uninjured high school athletes to pass three mental status tests that are commonly used on the sidelines for the evaluation of concussions: the serial sevens test, the serial threes test, and recitation of months of year in reverse order (MOYR). Participants: High school student athletes in grades 9, 10, 11, and 12 having sports preparticipation physical examinations. The initial study tested 522 consecutive athletes. The follow-up study tested 109 consecutive athletes. Intervention: The athletes of the initial group were asked to perform a serial sevens test, followed by a serial threes test, and finally to recite the MOYR. The second group was asked to perform the same tests in a random order. Main Outcome Measures: Participants were given 1-min time limits for each test, with passing defined as either 7 consecutive correct iterations or 11 correct with one mistake. Results: For the initial group, 51.3% successfully performed serial sevens, 78.7% successfully performed serial threes, and 89.5% successfully recited the MOYR. For the second group, 52.7% successfully performed serial sevens, 78.1% success fully performed serial threes, and 88.9% successfully recited the MOYR. The pass rates were significantly different for both groups. The pass rates were similar for both sexes, all grade levels, and all sports in both test groups. Participants, both overall and in all subgroups, failed serial sevens more often than serial threes and MOYR (p < 0.001 for the initial group. p < 0.0001 for the second group,. They failed serial threes more often than MOYR (p < 0.001 for the initial group; p < 0.01 for the second group). Conclusions: The percentage of uninjured high school athletes successfully completing serial sevens is too low to make the test useful for evaluation of concussion: the test lacks specificity. The percentage of athletes passing the MOYR was great est, perhaps making this a better sideline test than the traditional serial sevens test. However, resting needs to be done in injured athletes before clinical application can be recommended.	MED COLL WISCONSIN,DEPT COMMUNITY & FAMILY MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV BIOSTAT,MILWAUKEE,WI 53226	Young, CC (corresponding author), MED COLL WISCONSIN,DEPT ORTHOPAED SURG,9200 W WISCONSIN AVE,POB 26099,MILWAUKEE,WI 53226, USA.						BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1988, CLIN SPORT MED, V7, P459; *COL MED SOC SCH S, 1990, GUID MAN CONC SPORTS; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; IRRGNAG J, 1994, SPORTS INJURIES MECH, P349; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MANNING RT, 1982, ARCH INTERN MED, V142, P1192; MILSTEIN V, 1972, ARCH GEN PSYCHIAT, V26, P439; SMITH A, 1967, ARCH NEUROL-CHICAGO, V17, P78, DOI 10.1001/archneur.1967.00470250082008; TORG JS, 1994, ORTHOPAEDIC SPORTS M, P417	12	12	12	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	1997	7	3					196	198		10.1097/00042752-199707000-00008			3	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	XP440	WOS:A1997XP44000008	9262887				2021-06-18	
J	Karakucuk, EI; Pasaoglu, H; Pasaoglu, A; Oktem, S				Karakucuk, EI; Pasaoglu, H; Pasaoglu, A; Oktem, S			Endogenous neuropeptides in patients with acute traumatic head injury .2. Changes in the levels of cerebrospinal fluid substance P, serotonin and lipid peroxidation products in patients with head trauma	NEUROPEPTIDES			English	Article; Proceedings Paper	International Congress on Free Radicals in Health and Disease	SEP 06-10, 1995	ISTANBUL, TURKEY				BIOGENIC-AMINE CONTENT; NERVOUS-SYSTEM INJURY; BRAIN INJURY; SPINAL-CORD; CEREBRAL METABOLISM; FREE-RADICALS; RATS; RESPONSES	The cerebrospinal fluid (CSF) levels of substance P (SP), serotonin (5-HT) and lipid peroxidation (LPx) products were measured in patients with traumatic head injury and then compared to the levels obtained from control subjects. CSF samples were collected from 45 patients (31 male, 14 female, aged 19.2 +/- 17.79) within 24 h of the head trauma and the control CSF samples were obtained from 25 healthy subjects (23 male, 2 female, aged 51.44 +/- 17.6 years) having minor surgical operations under spinal anaesthesia. CSF SP and 5-HT levels in patients with head trauma were significantly lower than the levels in controls (P < 0.005, P < 0.001, respectively). On the other hand, the CSF Lpx products were significantly increased in patients with head trauma (P < 0.001). No significant correlation was found between the CSF changes and the admission Glasgow Coma Scale scores of the patients. This study constitutes the second part of our work on endogenous neuropeptides in patients with traumatic head injury and it emphasizes the role of SP, 5-HT and lipid peroxidation as additional endogenous factors in traumatic head injuries.	ERCIYES UNIV, DEPT BIOCHEM, FAC MED, TR-38039 KAYSERI, TURKEY; ERCIYES UNIV, DEPT NEUROSURG, FAC MED, TR-38039 KAYSERI, TURKEY	Karakucuk, EI (corresponding author), ERCIYES UNIV, DEPT CLIN BIOCHEM, FAC MED, TR-38039 KAYSERI, TURKEY.						BOCHICCHIO M, 1990, INTENS CARE MED, V16, P444, DOI 10.1007/BF01711223; Caron M J, 1991, Neurosurg Clin N Am, V2, P483; Choi Byung Ho, 1993, Yonsei Medical Journal, V34, P1; COOPER JR, 1986, BIOCH BASIS NEUROPHA, P352; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; EGHWRUDJAKPOR PO, 1991, SURG NEUROL, V35, P273, DOI 10.1016/0090-3019(91)90004-S; Faden A I, 1988, Adv Neurol, V47, P531; FADEN AI, 1984, JAMA-J AM MED ASSOC, V252, P1452, DOI 10.1001/jama.252.11.1452; FADEN AI, 1985, NEUROPEPTIDES, V6, P215, DOI 10.1016/0143-4179(85)90092-7; FADEN AI, 1988, BRAIN RES, V450, P94, DOI 10.1016/0006-8993(88)91548-X; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GADE GF, 1990, NEUROLOGICAL SURG, V3, P1965; GENNARELLI TA, 1990, NEUROLOGICAL SURG VA, V3, P1953; GUOLIANG W, 1991, CHIN MED J, V104, P764; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HUNTER MIS, 1985, NEUROCHEM RES, V10, P1645, DOI 10.1007/BF00988606; IKEDA Y, 1990, NEUROSURGERY, V27, P1; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; MANTYH PW, 1991, ANN NY ACAD SCI, V632, P263, DOI 10.1111/j.1749-6632.1991.tb33114.x; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; MIONE MC, 1990, PHARMACOL THERAPEUT, V46, P429, DOI 10.1016/0163-7258(90)90027-Y; NAFTCHI NE, 1978, BRAIN RES, V153, P507, DOI 10.1016/0006-8993(78)90335-9; NAFTCHI NE, 1990, ANN NY ACAD SCI, V579, P168; OSTERHOLM JL, 1972, J NEUROSURG, V36, P386, DOI 10.3171/jns.1972.36.4.0386; PAPPIUS HM, 1989, PROG NEURO-PSYCHOPH, V13, P353, DOI 10.1016/0278-5846(89)90124-3; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; Pasaoglu H, 1996, NEUROPEPTIDES, V30, P47; SALZMAN SK, 1987, J NEUROSURG, V66, P431, DOI 10.3171/jns.1987.66.3.0431; SEN S, 1993, NEUROSCI LETT, V162, P117, DOI 10.1016/0304-3940(93)90574-5; SINGH S, 1986, INDIAN J EXP BIOL, V24, P505; VITA G, 1990, NEUROPEPTIDES, V17, P147, DOI 10.1016/0143-4179(90)90078-D; Wills E.D., 1987, BIOCH TOXICOLOGY PRA, P127	37	12	12	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179	1532-2785		NEUROPEPTIDES	Neuropeptides	JUN	1997	31	3					259	263		10.1016/S0143-4179(97)90057-3			5	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	XJ769	WOS:A1997XJ76900009	9243523				2021-06-18	
J	Lowenstein, SR; KoziolMcLain, J; Glazner, J				Lowenstein, SR; KoziolMcLain, J; Glazner, J			The Colorado Motorcycle Safety Survey: Public attitudes and beliefs	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						legislation; head protective devices; motorcycles; polling	HELMET-USE-LAW; INJURY PREVENTION; HEAD-INJURIES; FATALITIES	Background: Motorcycle riders have a high risk of traumatic brain injury, disability, and death, Epidemiologic studies have proven that helmets reduce the severity of brain injuries and the cost of care. Yet, Colorado remains one of three states with no helmet law for riders. Objectives: This study measured public support for (1) a mandatory motorcycle helmet use law and (2) mandatory motorcycle operator safety training. We also sought to ascertain citizens' attitudes toward traffic safety mandates from the federal government. Methods: Structured telephone interviews were conducted with 407 Colorado adults selected by random-digit dialing. Results: Sixty-five percent of respondents believed that motorcycle riders of all ages should be required to wear helmets. An additional 18% believed that only riders under age 21 should be required to wear helmets, Only 17% of respondents opposed all helmet laws, Even among motorcyclists, most supported helmet laws for all riders (47%) or for those <21 years of age (26%), In a multiple logistic regression, there were three significant independent predictors of a pro-helmet law stance: older age, female gender, and not possessing a motorcycle operator's license, Most respondents also supported mandatory motorcycle operator safety training, Despite supporting state helmet use regulations, a large proportion (41%) opposed mandatory Federal mandates to enact them. Conclusion: Even in Colorado, a state with no helmet use requirements, there is strong public support for a regulatory strategy of motorcycle helmet use laws.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA	Lowenstein, SR (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV EMERGENCY MED, COLORADO EMERGENCY MED RES CTR, 4200 E 9TH AVE, DENVER, CO 80262 USA.						BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; BAKER SP, 1980, AM J PUBLIC HEALTH, V70, P573, DOI 10.2105/AJPH.70.6.573; BRIED JM, 1987, CLIN ORTHOP RELAT R, P252; *CO DEP HLTH HLTH, 1992, COL VIT STAT 1990; COBLE YD, 1994, JAMA-J AM MED ASSOC, V272, P1535, DOI 10.1001/jama.1994.03520190081039; DARE CE, 1979, I TRANSPORTATIO 1009; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; GABELLA B, 1995, ACCIDENT ANAL PREV, V27, P363, DOI 10.1016/0001-4575(94)00079-2; Krane S. W., 1980, IMPACT MOTORCYCLE HE; KRAUS JF, 1995, AM J PUBLIC HEALTH, V85, P96, DOI 10.2105/AJPH.85.1.96; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LOWENSTEIN SR, 1993, J TRAUMA, V35, P786, DOI 10.1097/00005373-199311000-00023; MCKNIGHT AJ, 1995, ACCIDENT ANAL PREV, V27, P493, DOI 10.1016/0001-4575(95)00008-N; MOCK CN, 1995, J TRAUMA, V39, P29, DOI 10.1097/00005373-199507000-00004; *NAT HIGHW TRAFF S, 1997, ANN EMERG MED, V29, P282; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; POLEN MR, 1988, JAMA-J AM MED ASSOC, V259, P76, DOI 10.1001/jama.259.1.76; RUTLEDGE R, 1993, ACCIDENT ANAL PREV, V25, P347, DOI 10.1016/0001-4575(93)90028-U; SALZBERG P, 1991, MOTORCYCLE HELMET US; SHANKAR BS, 1992, ACCIDENT ANAL PREV, V24, P385, DOI 10.1016/0001-4575(92)90051-J; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V267, P1649, DOI 10.1001/jama.267.12.1649; THORNBERRY OT, 1988, WILEY S PRO, P25; *US BUR CENS, 1990, 1990 CENS POP HOUS S; *US DEP TRANSP, 1994, TRAFF SAF FACTS 1994; US General Accounting Office, 1991, GAORCED91170 US GEN; VERNICK JS, 1993, HEALTH AFFAIR, V12, P198, DOI 10.1377/hlthaff.12.4.198; WILSON D, 1989, 807416 HS US DEP TRA	27	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1997	42	6					1124	1128		10.1097/00005373-199706000-00024			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XH700	WOS:A1997XH70000031	9210553				2021-06-18	
J	Hollis, GJ				Hollis, GJ			Sixth cranial nerve palsy following closed head injury in a child	JOURNAL OF ACCIDENT & EMERGENCY MEDICINE			English	Article						abducens nerve palsy; closed head injury; child	INTERNAL CAROTID-ARTERY; DISSECTION; ANEURYSM	A five year old female had an isolated abducens nerve palsy following closed head injury, There was no associated skull fracture, haematoma, or other cranial nerve injury, The significance, frequency, and differential diagnosis of traumatic sixth cranial nerve injury is discussed, particularly in paediatric patients, Management is symptomatic; occlusion with an eye pad may be used if diplopia is significant, In young children alternate day occlusion of each eye will help prevent amblyopia. Most cases improve within three months and many resolve by six months. Residual palsy at six months is likely to be permanent and surgical treatment may be needed.		Hollis, GJ (corresponding author), ST GEORGE HOSP, DEPT EMERGENCY MED, KOGARAH, NSW 2217, AUSTRALIA.						ARIAS MJ, 1985, NEUROSURGERY, V16, P232, DOI 10.1227/00006123-198502000-00020; BERLIT P, 1989, FORTSCHR NEUROL PSYC, V57, P32, DOI 10.1055/s-2007-1000743; DEPPER MH, 1993, AM J ROENTGENOL, V160, P837, DOI 10.2214/ajr.160.4.8456676; GLASTER JS, 1994, DUANES CLIN OPHTHALM, V2, P3; HARLEY RD, 1980, OPHTHALMOLOGY, V87, P24; HIPWELL G, 1992, MODERN MED AUSTR OCT, P141; INSEL TR, 1980, NEW ENGL J MED, V303, P703; LAL V, 1994, COMPUT MED IMAG GRAP, V18, P381, DOI 10.1016/0895-6111(94)90009-4; LIMNAIOS EE, 1980, OPHTHALMOLOGICA, V181, P326, DOI 10.1159/000309071; MAITLAND CG, 1983, ARCH NEUROL-CHICAGO, V40, P448, DOI 10.1001/archneur.1983.04050070078022; Marconi F, 1994, J Neurosurg Sci, V38, P177; MILLER EA, 1982, ARCH OPHTHALMOL-CHIC, V100, P603, DOI 10.1001/archopht.1982.01030030605012; MORIOKA T, 1992, J CLIN NEURO-OPHTHAL, V12, P263; MOSTER ML, 1984, ARCH OPHTHALMOL-CHIC, V102, P1328; ODELL KB, 1990, ANN EMERG MED, V19, P1063, DOI 10.1016/S0196-0644(05)82574-0; PARKS MM, 1994, DUANES CLIN OPHTHALM, V1, P12; RENZI ED, 1977, EUR NEUROL, V15, P227, DOI 10.1159/000114837; ROBERTSON DM, 1970, ARCH OPHTHALMOL-CHIC, V83, P574; RUSH JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P76, DOI 10.1001/archopht.1981.03930010078006; SHIFRIN LZ, 1991, SPINE, V16, P374, DOI 10.1097/00007632-199103000-00024; STRACCIARI A, 1988, ACTA NEUROL BELG, V88, P148; Takagi H, 1976, No Shinkei Geka, V4, P963; Yamashita K, 1995, No To Shinkei, V47, P286	23	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0622			J ACCID EMERG MED	J. Accid. Emerg. Med.	MAY	1997	14	3					172	175					4	Emergency Medicine	Emergency Medicine	XF573	WOS:A1997XF57300014	9193985				2021-06-18	
J	Patterson, DE; Braverman, SE; Belandres, PV				Patterson, DE; Braverman, SE; Belandres, PV			Speech dysfunction due to trazodone-fluoxetine combination in traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	1995 Association-of-Academic-Psychiatrists Meeting	MAR, 1995	SCOTTSDALE, AZ	Assoc Acad Physiatrists			DRUG-DRUG INTERACTIONS; MOTOR RECOVERY; ANTIDEPRESSANTS; DEPRESSION; PATIENT	New serotonin reuptake inhibitors are available for the treatment of affective disorders and sleep dysfunction in traumatic brain injury (TBI) patients. Commonly reported serotonergic side-effects include nausea, headache, dizziness, nervousness, and orthostatic hypotension. Trazodone, a nonselective serotonin reuptake inhibitor, is often used in conjunction with fluoxetine, a selective serotonin reuptake inhibitor, in order to combat the insomnia associated with fluoxetine. Successful use of this combination is generally limited by the cumulative serotonergic side-effects of the two medications. This paper describes the first reported case of speech dysfunction as a complication of combined trazodone and fluoxetine use. A 43-year-old male suffered bilateral wrist fractures and a moderate TBI during a fall. Within 1 week of adding fluoxetine to trazodone the patient developed new-onset dysarthria and speech blocking. Upon discontinuation of fluoxetine, speech returned to normal. Possible mechanisms include inhibition of hepatic metabolism, unmasking of caudate nucleus injury, increased noradrenergic activity or previously unreported serotonergic effects. This case illustrates the importance of monitoring drug combinations for unexpected side-effects in the TBI population.	WALTER REED ARMY MED CTR,DEPT PHYS MED & REHABIL,RES TRAINING PROGRAM,WASHINGTON,DC 20307							ALBERT ML, 1988, JAMA-J AM MED ASSOC, V259, P1043, DOI 10.1001/jama.259.7.1043; ARANOW RB, 1989, AM J PSYCHIAT, V146, P911; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; CIRAULO DA, 1990, J CLIN PSYCHOPHARM, V10, P213; CIRAULO DA, 1990, J CLIN PSYCHOPHARM, V10, P48, DOI 10.1097/00004714-199002000-00009; COLE JO, 1990, J CLIN PSYCHIAT, V51, P21; FEIGHNER JP, 1988, PSYCHOPHARMACOLOGY, V95, pS50; FISHER S, 1993, J CLIN PSYCHOPHARM, V13, P235; LEVINSON ML, 1991, DICP ANN PHARMAC, V25, P657; METZ A, 1990, INT CLIN PSYCHOPHARM, V5, P191, DOI 10.1097/00004850-199007000-00004; NIERENBERG AA, 1992, J CLIN PSYCHIAT, V53, P83; SAUNDERS M, 1977, BRIT MED J, V275, P317; SCHATZBERG AF, 1987, J CLIN PSYCHOPHARM, V7, P445; SHATZBERG AF, 1978, AM J PSYCHIAT, V135, P600; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; SMALL SL, 1994, STROKE, V25, P1282, DOI 10.1161/01.STR.25.6.1282; VAUGHAN DA, 1988, AM J PSYCHIAT, V145, P1478; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273	19	12	12	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1997	11	4					287	291		10.1080/026990597123593			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WQ736	WOS:A1997WQ73600006	9134203				2021-06-18	
J	Harrington, C; Salloway, S; Malloy, P				Harrington, C; Salloway, S; Malloy, P			Dramatic neurobehavioral disorder in two cases following bilateral anteromedial frontal lobe injury: Delayed psychosis and marked change in personality	NEUROCASE			English	Article						closed head injury; frontal lobe deficits; psychosis; mood lability	TRAUMATIC BRAIN INJURY; REDUPLICATIVE PARAMNESIA; HEAD TRAUMA; INTERICTAL BEHAVIOR; HUMAN AUTONOMY; EPILEPSY; DYSFUNCTION; DELUSIONS; DEPRESSION; DIAGNOSIS	This paper describes two cases of closed head injury causing bilateral frontal lobe contusions that resulted in enduring changes in self-control, perception, mood and cognition. In the first case the primary feature was delayed-onset psychosis. In the second case the patient developed mood lability, poor impulse control, a dramatic change in personality and impaired cognition. Midline, anterior frontal regions were most severely affected in both cases. The diagnostic evaluation and the clinical course are described. The neuropsychiatric syndromes are discussed with reference to lesion location and the literature on the neurobehavioral sequelae of closed head injury.	BROWN UNIV, SCH MED, DEPT CLIN NEUROSCI & PSYCHIAT & HUMAN BEHAV, PROVIDENCE, RI 02912 USA			Malloy, Paul F/A-8581-2009				ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BANCAUD J, 1994, BRAIN, V117, P71, DOI 10.1093/brain/117.1.71; BARNHILL LJ, 1989, NEUROPSY NEUROPSY BE, V2, P211; BEAR DM, 1977, ARCH NEUROL-CHICAGO, V34, P454, DOI 10.1001/archneur.1977.00500200014003; BENSON DF, 1976, NEUROLOGY, V26, P147, DOI 10.1212/WNL.26.2.147; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CAMPBELL JJ, 1994, J NEUROPSYCH CLIN N, V6, P411; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; DONGIER S, 1959, EPILEPSIA, V1, P117; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEINBERG TE, 1989, NEUROPSY NEUROPSY BE, V2, P39; FILLEY CM, 1987, NEUROLOGY, V37, P701, DOI 10.1212/WNL.37.4.701; FORSTL H, 1991, PSYCHOL MED, V21, P905, DOI 10.1017/S0033291700029895; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; HAKIM H, 1988, J NEUROL NEUROSUR PS, V51, P839, DOI 10.1136/jnnp.51.6.839; Hillbom E., 1960, ACTA PSYCHIATRICA S, VS142, P1; KAPUR N, 1988, J NEUROL NEUROSUR PS, V51, P579, DOI 10.1136/jnnp.51.4.579; KOUFEN P, 1987, EUROPEAN ARCH PSYCHI, V237, P2; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LEVINE DN, 1982, NEUROLOGY, V32, P267, DOI 10.1212/WNL.32.3.267; LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404; LHERMITTE F, 1986, ANN NEUROL, V19, P335, DOI 10.1002/ana.410190405; MALLOY P, 1992, NEUROPSY NEUROPSY BE, V5, P83; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P399; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P455; MALLOY PF, 1985, INT J CLIN NEUROPSYC, V7, P88; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; PRITCHARD PB, 1980, NEUROLOGY, V30, P227, DOI 10.1212/WNL.30.3.227; Rabins P V, 1991, J Neuropsychiatry Clin Neurosci, V3, P6; Richardson E D, 1991, J Geriatr Psychiatry Neurol, V4, P160, DOI 10.1177/089198879100400307; Robinson R G, 1990, J Neuropsychiatry Clin Neurosci, V2, P1; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1994, NEUROPSYCHIATRY TRAU; RUFF RL, 1981, J NEUROL NEUROSUR PS, V44, P382, DOI 10.1136/jnnp.44.5.382; SALLOWAY SP, 1994, J NEUROPSYCH CLIN N, V6, P388; SHEPHERD M, 1961, J MENT SCI, V107, P687; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SILVER JM, 1992, APA TXB NEUROPSYCHIA; STARKSTEIN SE, 1989, BRIT J PSYCHIAT, V155, P79, DOI 10.1192/bjp.155.1.79; STATON RD, 1982, CORTEX, V18, P23, DOI 10.1016/S0010-9452(82)80016-6; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TUCKER GJ, 1986, J NERV MENT DIS, V174, P348, DOI 10.1097/00005053-198606000-00007; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; WAXMAN SG, 1975, ARCH GEN PSYCHIAT, V32, P1580; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; Zald DH, 1996, J NEUROPSYCH CLIN N, V8, P125; Zald DH, 1996, J NEUROPSYCH CLIN N, V8, P249	55	12	12	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase		1997	3	2					137	149		10.1093/neucas/3.2.137			13	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	XL491	WOS:A1997XL49100007					2021-06-18	
J	Lundberg, F; Tegenfeldt, JO; Montelius, L; Ransjo, U; Appelgren, P; Siesjo, P; Ljungh, A				Lundberg, F; Tegenfeldt, JO; Montelius, L; Ransjo, U; Appelgren, P; Siesjo, P; Ljungh, A			Protein depositions on one hydrocephalus shunt and on fifteen temporary ventricular catheters	ACTA NEUROCHIRURGICA			English	Article						shunt; protein; ventricular catheter	COAGULASE-NEGATIVE STAPHYLOCOCCI; ACUTE INFLAMMATORY RESPONSES; HUMAN-PLASMA; AFFINITY-CHROMATOGRAPHY; SURFACE HEPARINIZATION; POLYMER SURFACES; BINDING-SITES; FIBRONECTIN; FIBRINOGEN; VITRONECTIN	Biomaterials are commonly used in modem medicine. Proteins are adsorbed to the surface of the biomaterial immediately after insertion. This report demonstrates the presence of adsorbed proteins in one infected cerebrospinal shunt from a child with hydrocephalus and on fifteen temporary ventricular catheters from adult patients with spontaneous or traumatic brain injuries. Depositions of vitronectin, fibrinogen and thrombospondin-fibronectin to some extent - on the shunt surface was imaged by field-emission scanning electron microscopy. Vitronectin, fibronectin, fibrinogen, and thrombospondin on the ventricular catheters were shown with radio-actively labelled antibodies. Furthermore, protein adsorption from human cerebrospinal fluid to heparinized and unheparinized polymers was studied under flowing conditions in vitro. On heparinized polymer, significantly reduced levels of vitronectin, fibronectin, and thrombospondin were exposed, as measured after 4 hours in vitro perfusion. After 24 hours perfusion, the differences in protein exposition between heparinized and unheparinized polymers were substantially reduced.	LUND UNIV, DEPT MED MICROBIOL, S-22362 LUND, SWEDEN; LUND INST TECHNOL, DEPT SOLID STATE PHYS, LUND, SWEDEN; KAROLINSKA HOSP, DEPT LAB MED, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT MED, S-10401 STOCKHOLM, SWEDEN; UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN			Montelius, Lars/B-9071-2008; Tegenfeldt, Jonas/B-9506-2008	Montelius, Lars/0000-0001-9563-2307; Tegenfeldt, Jonas/0000-0002-3695-6886; Siesjo, Peter/0000-0002-5848-690X			AMMIRATI M, 1987, CHILD NERV SYST, V3, P106, DOI 10.1007/BF00271135; Appelgren P, 1996, CRIT CARE MED, V24, P1482, DOI 10.1097/00003246-199609000-00009; APPLEYARD ME, 1991, BRIT J OPHTHALMOL, V75, P276, DOI 10.1136/bjo.75.5.276; BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2; BAYSTON R, 1989, HYDROCEPHALUS SHUNT; CHEUNG AL, 1990, J INFECT DIS, V161, P1177, DOI 10.1093/infdis/161.6.1177; CLERI DJ, 1980, J INFECT DIS, V141, P781, DOI 10.1093/infdis/141.6.781; FABRIZIUSHOMAN DJ, 1991, J BIOMAT SCI-POLYM E, V3, P27, DOI 10.1163/156856292X00060; FROMAN G, 1987, J BIOL CHEM, V262, P6564; Gardner P, 1988, Curr Clin Top Infect Dis, V9, P185; GEBB C, 1986, J BIOL CHEM, V261, P6698; GEORGE R, 1979, J NEUROSURG, V51, P804, DOI 10.3171/jns.1979.51.6.0804; GYRING J, 1989, ALFRED BENZON SYMP S, V27, P80; HERRMANN M, 1991, INFECT IMMUN, V59, P279, DOI 10.1128/IAI.59.1.279-288.1991; HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693; Hook M, 1989, FIBRONECTIN, P295; HWANG RQ, 1991, PHYS REV LETT, V67, P3279, DOI 10.1103/PhysRevLett.67.3279; Hynes R. O., 1990, FIBRONECTINS; JACOBSEN RJ, 1983, J BIOMED MATER RES, V16, P199; KOST C, 1992, J BIOL CHEM, V267, P12098; LARM O, 1987, THROMB HAEMOSTASIS, V58, P84; LINDON JN, 1986, BLOOD, V68, P355; LJUNGH A, 1995, METHOD ENZYMOL, V253, P501; Lundberg F, 1997, J MED MICROBIOL, V46, P285, DOI 10.1099/00222615-46-4-285; Lundberg F, 1997, INFECT IMMUN, V65, P897, DOI 10.1128/IAI.65.3.897-902.1997; LUNDBERG N, 1960, ACTA PSYCHIATR S149, V36, P7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; PARISE LV, 1993, BIOCHEM J, V289, P445, DOI 10.1042/bj2890445; PAULSSON M, 1992, J CLIN MICROBIOL, V30, P2006, DOI 10.1128/JCM.30.8.2006-2012.1992; PEKNA M, 1993, BIOMATERIALS, V14, P189, DOI 10.1016/0142-9612(93)90022-T; PITT WG, 1986, BIOMATERIALS, V7, P340, DOI 10.1016/0142-9612(86)90004-9; PODACK ER, 1979, J BIOL CHEM, V254, P9908; RAPOZA R, 1990, J BIOMED MATER RES, P1263; RENIER D, 1984, J NEUROSURG, V61, P1072, DOI 10.3171/jns.1984.61.6.1072; ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1016/0928-8244(95)00039-A; RUGE JR, 1993, BRAIN SURGERY COMPLI, P1463; SANTERRE JP, 1992, J BIOMED MATER RES, V26, P39, DOI 10.1002/jbm.820260105; STEELE JG, 1991, BIOMATERIALS, V12, P531, DOI 10.1016/0142-9612(91)90046-D; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549; VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633; VROMAN L, 1986, J COLLOID INTERF SCI, V111, P391, DOI 10.1016/0021-9797(86)90042-1; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WOOD JM, 1985, NEUROSURGERY, V1, P161; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3; YU JL, 1995, J SURG RES, V59, P596, DOI 10.1006/jsre.1995.1210; Yu JL, 1997, BIOMATERIALS, V18, P421, DOI 10.1016/S0142-9612(96)00154-8; ZARDI L, 1980, J IMMUNOL METHODS, V34, P155, DOI 10.1016/0022-1759(80)90169-6	50	12	13	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1997	139	8					734	742		10.1007/BF01420046			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XT967	WOS:A1997XT96700015	9309288				2021-06-18	
J	Di, X; Lyeth, BG; Hamm, RJ; Bullock, MR				Di, X; Lyeth, BG; Hamm, RJ; Bullock, MR			Voltage-dependent Na+/K+ ion channel blockade fails to ameliorate behavioral deficits after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						tetrodotoxin (TTX); microdialysis; neurotrauma; fluid percussion; voltage-gated channel; behavioral performance; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; COMPLETE ISCHEMIA; FOCAL ISCHEMIA; EDEMA; SODIUM; GERBIL; MK-801; MODEL; TETRODOTOXIN; ANTAGONISTS	Traumatic brain injury (TBI) induces massive, transient ion flux, after impact. This may be via agonist gated channels, such as the muscarinic, cholinergic or NMDA receptor, or via voltage-dependent channels. Pharmacological blockade of the former, is neuroprotective in most TBI models, but the role of voltage-dependent Na+/K+ channels has not been tested. We have therefore tested the hypothesis that intraventricular tetrodotoxin (TTX) (20 mu l, 5 mM) induced blockade of post-TBI ion flux will prevent cytotoxic cell swelling, Na+ and K+ flux, and behavioral deficit. Microdialysis demonstrated blockade of [K+]d flux in the TTX group compared to controls. Behavioral evaluation of motor (days 1-5) and memory function (days 11-15) after TBI revealed no beneficial effect in the TTX group compared to controls. Thus, although evidence of reduced ionic flux was demonstrated in the TTX group, memory and behavior were unaffected, suggesting that agonist-operated channel-mediated ion flux is more important after TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ANDINE P, 1992, J CEREBR BLOOD F MET, V12, P773, DOI 10.1038/jcbfm.1992.108; BETA AL, 1989, STROKE, V20, P1253; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1993, KLINISCHE ERNAHRUNG, V36, P113; DELUGA KS, 1991, STROKE, V22, P1259, DOI 10.1161/01.STR.22.10.1259; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELEFF SM, 1991, STROKE, V22, P233, DOI 10.1161/01.STR.22.2.233; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; GUELDRY S, 1990, STROKE, V21, P1458, DOI 10.1161/01.STR.21.10.1458; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HATASHITA S, 1990, STROKE, V21, P582, DOI 10.1161/01.STR.21.4.582; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1992, J NEUROTRAUMA, V9, P547; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYSKO PG, 1994, STROKE, V25, P2476, DOI 10.1161/01.STR.25.12.2476; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NELLGARD B, 1992, J CEREB BLOOD FLOW M, V12, P8; NISHI H, 1989, STROKE, V20, P1236, DOI 10.1161/01.STR.20.9.1236; NOZAKI K, 1992, J CEREBR BLOOD F MET, V12, P400, DOI 10.1038/jcbfm.1992.57; SYMON L, 1979, STROKE, V10, P184, DOI 10.1161/01.STR.10.2.184; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; UEMATSU D, 1991, J CEREBR BLOOD F MET, V11, P779, DOI 10.1038/jcbfm.1991.135; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; YOUNG W, 1987, STROKE, V18, P751, DOI 10.1161/01.STR.18.4.751	31	12	12	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					497	504		10.1089/neu.1996.13.497			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600002	8913966				2021-06-18	
J	DiTrapani, G; Carnevale, A; Scerrati, M; Colosimo, C; Vaccario, ML; Mei, D				DiTrapani, G; Carnevale, A; Scerrati, M; Colosimo, C; Vaccario, ML; Mei, D			Post-traumatic malignant glioma. Report of a case	ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article						brain tumor; head injury; oligodendroglioma	EXPLORATORY CASE-CONTROL; BRAIN-TUMORS	Only a few cases reported in the literature fulfil the currently established criteria for accepting the traumatic origin of some intracranial tumors. A case of post-traumatic glioma is presented. Several years after sustaining a commotive left parietal trauma, our patient developed symptoms of intracranial tumor. Neuroimaging (CT and MRI) show,ed a large neoplasia in the left temporo-parietal-occipital region, and stereotactic biopsy revealed a mixed glioma in continuity with the scar resulting from the trauma.	UNIV CATTOLICA SACRO CUORE,IST NEUROSURG,I-00168 ROME,ITALY; UNIV CATTOLICA SACRO CUORE,IST RADIOL,I-00168 ROME,ITALY							ANNEGERS JF, 1979, NEUROSURGERY, V4, P203, DOI 10.1227/00006123-197903000-00001; BOKER DK, 1991, FORTSCHR NEUROL PSYC, V59, P488, DOI 10.1055/s-2007-1000724; BURCH JD, 1987, J NATL CANCER I, V78, P601; CHOI NW, 1970, AM J EPIDEMIOL, V91, P467, DOI 10.1093/oxfordjournals.aje.a121158; HOCHBERG F, 1984, NEUROLOGY, V34, P1511, DOI 10.1212/WNL.34.11.1511; HOWE GR, 1989, CANCER RES, V49, P4349; Manuelidis EE., 1972, PATHOLOGY NERVOUS SY, V2, P2237; MORANTZ RA, 1978, NEUROSURGERY, V3, P181, DOI 10.1227/00006123-197809000-00009; PEREZDIAZ C, 1985, SURG NEUROL, V24, P581, DOI 10.1016/0090-3019(85)90278-2; POVLISHOCK J, 1980, ADV EXPT MED BIOL, V31, P227; SCHIFFER D, 1991, ACTA NEUROPATHOL, V83, P30, DOI 10.1007/BF00294427; TROOST D, 1984, CLIN NEUROPATHOL, V3, P139; ZULCH KJ, 1953, AERZTL FORSCH, V7, P535	13	12	12	0	2	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0392-0461			ITAL J NEUROL SCI	Ital. J. Neurol. Sci.	AUG	1996	17	4					283	286		10.1007/BF01997787			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	VN369	WOS:A1996VN36900004	8915759				2021-06-18	
J	Kirkby, BS; VanHorn, JD; Ostrem, JL; Weinberger, DR; Berman, KF				Kirkby, BS; VanHorn, JD; Ostrem, JL; Weinberger, DR; Berman, KF			Cognitive activation during PET: A case study of monozygotic twins discordant for closed head injury	NEUROPSYCHOLOGIA			English	Article						regional cerebral blood flow; frontal lobe; recovery of function; hippocampus; working memory; Wisconsin Card Sorting Test	CEREBRAL BLOOD-FLOW; CONTUSION INDEX; DYSFUNCTION; TOMOGRAPHY; RECOVERY; CORTEX; BRAIN	Using positron emission tomography (PET), we studied physiological changes in a patient with frontal lobe damage resulting from closed head injury by assessing his regional cerebral blood flow (rCBF) pattern relative to that of his uninjured monozygotic (MZ) cotwin and against normal variability between cotwins in 10 comparably-aged, uninjured MZ twin pairs. rCBF was measured during the Wisconsin Card Sorting Test (WCST) and a sensorimotor control task. Differences between the index twins in rCBF activation (WCST-control) in regions determined on coplanar MRIs were compared to within pair differences in the control group using the Z-statistic. Activation differences between the index twins extending beyond normal variability were found in two regions-relative to his uninjured cotwin, the injured twin showed less activation in the inferior portion of the left inferior frontal gyrus while showing greater activation in the left hippocampus (P < 0.04). This pattern contrasts with that of normal subjects during WCST performance of augmented rCBF in the prefrontal cortex and not in the hippocampus. These rCBF differences appear to reflect the utilization of different neural systems when performing a frontal-lobe task. The use of the hippocampus by the injured twin might reflect an attempt to compensate for compromised frontal lobe functioning.	NIMH,CLIN BRAIN DISORDERS BRANCH,INTRAMURAL RES PROGRAM,NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032				Van Horn, John/0000-0003-1537-0816			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; BERMAN KF, 1994, NEUROLOGY, V44, pA376; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; DELIS D, 1987, CALIFORNIA VERBAL LE; DUARA R, 1987, J CEREBR BLOOD F MET, V7, P266, DOI 10.1038/jcbfm.1987.62; FORD I, 1991, J CEREBR BLOOD F MET, V11, pA89, DOI 10.1038/jcbfm.1991.43; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V5, P362; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R., 1993, WISCONSIN CARD SORTI; ICHISE M, 1994, J NUCL MED, V35, P217; JENNETT B, 1975, LANCET, V1, P480; KETY SS, 1951, PHARMACOL REV, V3, P1; KOEPPE RA, 1985, J CEREBR BLOOD F MET, V5, P224, DOI 10.1038/jcbfm.1985.29; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SABATINI U, 1994, STROKE, V25, P514, DOI 10.1161/01.STR.25.2.514; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Weinberger D. R., 1993, Society for Neuroscience Abstracts, V19, P7; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267	31	12	12	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUL	1996	34	7					689	697					9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	UQ417	WOS:A1996UQ41700007	8783220				2021-06-18	
J	Sall, JM; Morehead, M; Murphy, S; Goldman, H; Walker, PD				Sall, JM; Morehead, M; Murphy, S; Goldman, H; Walker, PD			Alterations in CNS gene expression in a rodent model of moderate traumatic brain injury complicated by acute alcohol intoxication	EXPERIMENTAL NEUROLOGY			English	Article							IMMEDIATE EARLY GENES; PREPROENKEPHALIN MESSENGER-RNA; PROTEIN-LIKE IMMUNOREACTIVITY; CENTRAL NERVOUS-SYSTEM; C-FOS PROTEIN(S); RAT-BRAIN; INSITU HYBRIDIZATION; FOREBRAIN ISCHEMIA; CELL-DEATH; INDUCTION	The combined effects of acute alcoholic intoxication and moderate traumatic brain injury (TBI) on zif/268, glial fibrillary acidic protein (GFAP), and preproenkephalin (PPE) mRNA expression were examined. Adult male Wistar rats received ip injections of a 5% alcohol solution (2.4 g/kg in a final volume of 20 ml isotonic saline) 10 min prior to fixed-head, mechanical injury. Using Northern analysis, a transient three- to fourfold induction of zif/268 mRNA levels was observed 45 min after injury in both TBI and alcohol-treated rats. This induction occurred in regions close to the impact site, namely, the olfactory bulb (OB) and frontal cortex (FTCTX) but not in the more distal piriform/amygdala cortex (P/A). No PPE mRNA changes were observed at 45 min for any experimental group. By 6 h, zif/268 transcript levels returned to or fell below basal levels in the OB and FTCTX while GFAP mRNA levels began to increase in TBI rats. At 24 h, GFAP mRNA levels were greatly increased in all three brain regions of TBI rats. However, alcohol inhibited the temporal induction of GFAP mRNA in the FTCTX and P/A triggered by TBI at 6 and 24 h. These results suggest that although acute alcohol intoxication prior to TBI does not influence gene expression patterns immediately after injury, it may minimize the transcriptional activation of astrocytes particularly in more distant brain regions that were influenced by the impact in nonintoxicated rats. (C) 1996 Academic Press, Inc.	WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201	Sall, JM (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,540 E CANFIELD AVE,DETROIT,MI 48201, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030550] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30550] Funding Source: Medline		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; CULLINAN WE, 1995, NEUROSCIENCE, V64, P477, DOI 10.1016/0306-4522(94)00355-9; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DRAGUNOW M, 1993, INT J DEV NEUROSCI, V11, P249, DOI 10.1016/0736-5748(93)90083-P; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; FALLON JH, 1986, J COMP NEUROL, V249, P293, DOI 10.1002/cne.902490302; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GASS P, 1993, NEUROSCIENCE, V53, P749, DOI 10.1016/0306-4522(93)90621-L; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRAZZIZUCCONI G, 1993, EUR J NEUROSCI, V5, P1071; HARLAN RE, 1987, J COMP NEUROL, V258, P159, DOI 10.1002/cne.902580202; HAYES RL, CENTRAL NERVOUS SYST, P173; HERDEGEN T, 1993, J COMP NEUROL, V333, P271, DOI 10.1002/cne.903330212; HONKANIEMI J, 1995, MOL BRAIN RES, V28, P157, DOI 10.1016/0169-328X(94)00200-X; HUGHES P, 1995, PHARMACOL REV, V47, P133; JORGENSEN MB, 1989, BRAIN RES, V484, P393, DOI 10.1016/0006-8993(89)90388-0; Klatzo I, 1980, Adv Neurol, V28, P359; KOISTINAHO J, 1990, HISTOCHEMISTRY, V95, P73, DOI 10.1007/BF00737230; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; MENEGAZZI M, 1994, NEUROSCI LETT, V182, P295, DOI 10.1016/0304-3940(94)90820-6; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MUCKE L, 1991, NEW BIOL, V3, P465; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; NOWAK TS, 1990, STROKE, V21, P107; ONODERA H, 1989, NEUROSCI LETT, V98, P101, DOI 10.1016/0304-3940(89)90381-9; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PYYKONEN I, 1991, ACTA NEUROPATHOL, V82, P66, DOI 10.1007/BF00310925; RUZDIJIC S, 1993, BRAIN RES, V60, P230; SAITOH T, 1991, LAB INVEST, V64, P596; SHARP FR, 1991, J NEUROSCI, V11, P2321, DOI 10.1523/jneurosci.11-08-02321.1991; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; TAKEUCHI J, 1993, NEURON, V11, P825, DOI 10.1016/0896-6273(93)90112-5; VACCARINO FM, 1992, MOL BRAIN RES, V12, P233, DOI 10.1016/0169-328X(92)90089-T; WALKER PD, 1993, J NEUROSCI RES, V36, P588, DOI 10.1002/jnr.490360511; WESSEL TC, 1991, BRAIN RES, V567, P231, DOI 10.1016/0006-8993(91)90800-B; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301	53	12	12	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	1996	139	2					257	268		10.1006/exnr.1996.0099			12	Neurosciences	Neurosciences & Neurology	UP253	WOS:A1996UP25300008	8654528				2021-06-18	
J	Girard, J; Panizzon, K; Wallis, RA				Girard, J; Panizzon, K; Wallis, RA			Azelastine protects against CA1 traumatic neuronal injury in the hippocampal slice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						azelastine; traumatic brain injury; leukotriene; NMDA (N-methyl-D-aspartate); hippocampus; (in vitro)	LONG-TERM POTENTIATION; BRAIN-BARRIER PERMEABILITY; LEUKOTRIENE PRODUCTION; ARACHIDONIC-ACID; HEAD-INJURY; ISCHEMIA; RAT; INDUCTION	Activation of NMDA receptors appears to play a important role in traumatic neuronal injury. Additionally, N-methyl-D-aspartate (NMDA) excitotoxicity may involve leukotriene production. Therefore, we investigated whether azelastine, an anti-allergic agent inhibiting the synthesis and release of leukotrienes, could protect against CA1 traumatic neuronal injury in the hippocampal slice. Fluid percussion trauma produced evidence of severe neuronal injury with CA1 antidromic population spike amplitude recovering after 95 min to only a mean 16 +/- 1% S.E. of initial amplitude. With 15 mu M azelastine treatment given after trauma for 35 min this recovery improved to 112 +/- 17%. The azelastine EC(50) for this protection was 10 mu M Significant protection was also seen with azelastine application begun 15 min after trauma. Azelastine also protected the ability to induce long-term potentiation after trauma. The specific leukotriene inhibitors, MK-571 and MK-886, similarly provided significant neuroprotection. These findings suggest that CAI traumatic neuronal injury may be mediated by leukotriene production.	VET ADM MED CTR,NEURONAL INJURY LAB IIINI,SEPULVEDA,CA 91343							ACHTERRATHTUCKERMANN U, 1988, AGENTS ACTIONS, V24, P217, DOI 10.1007/BF02028274; AKTAN S, 1991, PROSTAG LEUKOTR ESS, V43, P247, DOI 10.1016/0952-3278(91)90037-6; AKTAN S, 1991, PROSTAG LEUKOTR ESS, V42, P67, DOI 10.1016/0952-3278(91)90069-H; AUER RN, 1989, J NEUROSCI, V9, P1641; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BLACK KL, 1985, ANN NEUROL, V18, P349, DOI 10.1002/ana.410180313; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CASALE TB, 1989, J ALLERGY CLIN IMMUN, V83, P771, DOI 10.1016/0091-6749(89)90013-4; COLLINGRIDGE GL, 1992, EXP PHYSIOL, V77, P771, DOI 10.1113/expphysiol.1992.sp003645; DUMMUIS A, 1988, NATURE, V336, P68; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRONWALL D, 1974, LANCET, V2, P605; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NISHIHIRA J, 1989, INT ARCH ALLER A IMM, V90, P285, DOI 10.1159/000235039; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SCHURR A, 1984, BRAIN RES, V297, P357, DOI 10.1016/0006-8993(84)90576-6; UMEKI S, 1992, BIOCHEM PHARMACOL, V43, P1109, DOI 10.1016/0006-2952(92)90619-T; WALLIS RA, 1993, EUR J PHARMACOL, V238, P165, DOI 10.1016/0014-2999(93)90844-8; WALLIS RA, 1992, STROKE, V23, P546; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5; YAVIN E, 1992, ADV EXP MED BIOL, V318, P314; YOUNG RN, 1991, AGENT ACTION SUPPL, V34, P179; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	29	12	12	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	APR 4	1996	300	1-2					43	49		10.1016/0014-2999(95)00804-7			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	UG949	WOS:A1996UG94900006	8741163				2021-06-18	
J	Goldstein, FC; Levin, HS; Roberts, VJ; Goldman, WP; Kalechstein, AS; Winslow, M; Goldstein, SJ				Goldstein, FC; Levin, HS; Roberts, VJ; Goldman, WP; Kalechstein, AS; Winslow, M; Goldstein, SJ			Neuropsychological effects of closed head injury in older adults: A comparison with Alzheimer's disease	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	International-Neuropsychological-Society Meeting	JAN, 1995	SEATTLE, WA	Int Neuropsychol Soc			SEMANTIC MEMORY; PRACTICAL SCALE; RISK FACTOR; IMPAIRMENT; DEMENTIA	In this study, neuropsychological profiles of 14 older adult patients with mild or moderate closed head injury (CHI), 14 patients with probable Alzheimer's disease (AD), and 14 community residing elderly controls were compared. The groups were similar in demographic features, and the CHI and AD patients had comparable Mini-Mental State Examination scores. Tests of verbal learning and memory, letter and category fluency, and naming were administered. Relative to the CHI group, AD patients exhibited more devastated memory and did not show a normal facilitation on the category retrieval task. The patient groups exhibited similar levels of categorical clustering and naming accuracy for both high- and low-frequency words. These results suggest that neuropsychological markers of memory and semantic processing may be useful in differentiating the cognitive effects from AD versus early recovery from CHI.	UNIV MARYLAND, SCH MED, DIV NEUROL SURG, BALTIMORE, MD 21201 USA	Goldstein, FC (corresponding author), EMORY UNIV, SCH MED,WESLEY WOODS HLTH CTR,DEPT NEUROL, NEUROBEHAV PROGRAM, 1841 CLIFTON RD NE, ATLANTA, GA 30329 USA.						Benton A, 1989, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; COHEN BH, 1954, 10 U CONN; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CRUMMINGS JL, 1992, DEMENTIA CLIN APPROA; DELIS D, 1986, CALIFORNIA VERBAL LE; DELIS DC, 1991, PSYCHOL ASSESSMENT, V3, P19, DOI DOI 10.1037/1040-3590.3.1.19; Delis DC, 1988, CALIFORNIA VERBAL LE; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDSTEIN FC, 1992, BRAIN LANG, V43, P308, DOI 10.1016/0093-934X(92)90132-X; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Gollomp S, 1993, NEUROPSYCHOLOGY, V7, P182, DOI DOI 10.1037/0894-4105.7.2.182; Haut MW, 1991, NEUROPSYCHOLOGY, V5, P81, DOI 10.1037/0894-4105.5.2.81; HODGES JR, 1990, J NEUROL NEUROSUR PS, V53, P1089, DOI 10.1136/jnnp.53.12.1089; HUFF FJ, 1986, BRAIN LANG, V28, P235, DOI 10.1016/0093-934X(86)90103-3; Kaplan E., 1983, BOSTON NAMING TEST; KRAUS JF, 1987, HEAD INJURY, P1; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARTIN A, 1983, BRAIN LANG, V19, P124, DOI 10.1016/0093-934X(83)90059-7; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Monsch AU, 1994, NEUROPSYCHOLOGY, V8, P25, DOI 10.1037/0894-4105.8.1.25; MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NEBES RD, 1989, PSYCHOL BULL, V106, P377, DOI 10.1037/0033-2909.106.3.377; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V51, P65; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SHUTTLEWORTH EC, 1988, BRAIN LANG, V34, P222, DOI 10.1016/0093-934X(88)90134-4; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; Thorndike EL., 1944, TEACHERS WORD BOOK 3; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; ZEC RF, 1993, NEUROPSYCHOLOGY ALZH, P1	46	12	12	0	0	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	1996	10	2					147	154					8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	UD704	WOS:A1996UD70400001					2021-06-18	
J	Kossmann, T; Hans, V; Stocker, R; Imhof, HG; Joos, B; Trentz, O; MorgantiKossmann, MC				Kossmann, T; Hans, V; Stocker, R; Imhof, HG; Joos, B; Trentz, O; MorgantiKossmann, MC			Penetration of cefuroxime into the cerebrospinal fluid of patients with traumatic brain injury	JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY			English	Article							HEAD-INJURY	Cefuroxime levels were measured in cerebrospinal fluid (CSF) and serum of four patients with traumatic brain injury following the implantation of intraventricular catheters. The levels ranged from 0.15 to 2.03 mu g/mL in CSF and from 1.8 to 66.9 mu g/mL in serum. No ventriculostomy related infections were detected.	UNIV ZURICH,SCH MED,DEPT SURG,DIV TRAUMA SURG,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,SCH MED,DEPT INTERNAL MED,DIV INFECT DIS,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,SCH MED,DEPT NEUROSURG,CH-8091 ZURICH,SWITZERLAND			Joos, Beda/D-5547-2009	Joos, Beda/0000-0002-3082-8875; Morganti-Kossmann, Cristina/0000-0002-0807-2063			CLARK WC, 1989, NEUROSURGERY, V25, P20; Daikos G K, 1977, Proc R Soc Med, V70, P38; JENNETT B, 1976, LANCET, V1, P1031; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Ristuccia A M, 1992, Antibiot Chemother (1971), V45, P118; Rosner M J, 1976, Clin Neurosurg, V23, P494; SIRINAVIN S, 1984, ANTIMICROB AGENTS CH, V25, P273, DOI 10.1128/AAC.25.2.273; STOCKER R, 1995, UPD INT CAR, V22, P196; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862	10	12	12	0	4	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON, ENGLAND NW1 7DX	0305-7453			J ANTIMICROB CHEMOTH	J. Antimicrob. Chemother.	JAN	1996	37	1					161	167		10.1093/jac/37.1.161			7	Infectious Diseases; Microbiology; Pharmacology & Pharmacy	Infectious Diseases; Microbiology; Pharmacology & Pharmacy	TT399	WOS:A1996TT39900019	8647759	Green Accepted, Bronze, Green Published			2021-06-18	
J	Warschausky, S; Kewman, DG; Selim, A				Warschausky, S; Kewman, DG; Selim, A			Attentional performance of children with traumatic brain injury: A quantitative and qualitative analysis of digit span	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; MEMORY	Previous studies have indicated that digit span performance is not particularly sensitive to the effects of traumatic brain injury (Baddeley & Warrington, 1970; Brooks, 1975; Sterne, 1969). However clinical lore posits poorer backward vs. forward performance compared to normals due to the greater attentional demands of the backward task. This study examined qualitative aspects of Digit Span performance including forward/backward span discrepancies and error patterns in children with traumatic brain injury (n = 20) and normals (n = 19). The hypothesis of greater forward/backward discrepancy with traumatic brain injury was not supported Children with traumatic brain injury make a significantly greater number of preceiling errors than normals, consistent with other findings of increased performance variability. Preceiling errors are errors that occur in trials prior to the two failed trials resulting in discontinuation of the task In addition, cognitive correlates of error types, such as WISC-R factor scores, were significantly different between groups. The results of this study suggest that a more detailed analysis of performance on attentional tasks previously described as resilient to brain injury may shed further light on the nature of acquired attentional deficits.	UNIV MICHIGAN,SCH MED,DEPT PHYS MED & REHABIL,ANN ARBOR,MI 48109							BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BLACK FW, 1983, J CLIN PSYCHOL, V39, P263, DOI 10.1002/1097-4679(198303)39:2<263::AID-JCLP2270390223>3.0.CO;2-R; BLEIBERG J, 1994, ANN M INT NEUROPSYCH; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO, P372; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; DAS JP, 1975, J EDUC PSYCHOL, V67, P213, DOI 10.1037/h0076929; FRANKEL F, 1974, AM J MENT DEF, V79, P311; GARDNER RA, 1981, J CLIN CHILD PSY SUM, P131; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Kaplan E, 1983, HOLISTIC DEV PSYCHOL, P143; KAUFMAN AS, 1975, J CONSULT CLIN PSYCH, V43, P135, DOI 10.1037/h0076502; MACK JL, 1986, J HEAD TRAUMA REHAB, V1, P22; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; ROBERTSON IH, 1990, NEUROPSYCHOLOGIA, V28, P217, DOI 10.1016/0028-3932(90)90103-U; RUDEL RG, 1974, NEUROPSYCHOLOGIA, V12, P109, DOI 10.1016/0028-3932(74)90032-3; STERNE DM, 1969, J CLIN PSYCHOL, V25, P173, DOI 10.1002/1097-4679(196904)25:2<173::AID-JCLP2270250216>3.0.CO;2-9; WEINBERG J, 1972, J CLIN PSYCHOL, V28, P361, DOI 10.1002/1097-4679(197207)28:3+<361::AID-JCLP2270280315>3.0.CO;2-5; Werner H, 1937, HARVARD EDUC REV, V7, P353	20	12	12	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	2					147	153		10.1016/0887-6177(95)00004-6			7	Psychology, Clinical; Psychology	Psychology	TT914	WOS:A1996TT91400006	14588915	Bronze, Green Published			2021-06-18	
J	Donahue, DJ; Sanford, RA; Muhlbauer, MS; Chadduck, WM				Donahue, DJ; Sanford, RA; Muhlbauer, MS; Chadduck, WM			Cranial burst fracture in infants: Acute recognition and management	CHILDS NERVOUS SYSTEM			English	Article						head injury; children; diastatic fracture; burst fracture; skull fracture	EROSION GROWING FRACTURE; SKULL; TOMOGRAPHY; CHILDREN	In the past, the diagnosis of ''growing skull fracture'' or ''diastatic fracture'' has included a subset of injuries better referred to as ''cranial burst fracture.'' Cranial burst fracture, typically associated with severe injury in infants less than 1 year of age, is a closed, widely diastatic skull fracture accompanied by acute cerebral extrusion outside the calvarium. We treated 11 such infants at the LeBonheur Children's Medical Center and 2 at the Children's National Medical Center from January 1986 through December 1994. Infants ranged in age from 1 to 17 months, with an average age of 5.7 months. All presented with marked scalp swelling and a Glasgow Coma Scale score of 10 or less. Twelve had a history consistent with severe injury (motor vehicle accident, 7, abuse 5). The cause of injury in one patient remains unproven. Surgery (reduction of herniated cerebral tissue, repair of large dural laceration, and cranioplasty) was usually performed within 10 days of injury, a time period long enough to assure hemodynamic stability and resolution of acute cerebral swelling, yet sufficiently brief to avoid the chronic changes (scarring, parasitization of scalp vessels by damaged cortex) associated with a ''growing skull fracture.'' Prompt repair of cranial burst. fracture may prevent ongoing brain injury such as has been neuropathologically demonstrated in patients with ''growing skull fracture.'' Magnetic resonance imaging establishes the diagnosis of cranial burst fracture in equivocal cases, rendering unnecessary a ''waiting period'' to see if scalp swelling resolves. Our experience, together with information in the neuropathological and neurosurgical literature, suggests that cranial burst fracture is associated with severe trauma, requires expeditious treatment, and has been underdiagnosed in the past, leading to ''growing skull fracture,'' a condition requiring more extensive surgery.	UNIV TENNESSEE,LE BONHEUR CHILDRENS MED CTR,COLL MED,MEMPHIS,TN	Donahue, DJ (corresponding author), GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.						ARSENI C, 1981, CHILD BRAIN, V8, P161; Ben Jelloun R, 1992, Ann Pediatr (Paris), V39, P49; DIMINGO Z, 1994, PEDIATR NEUROSURG, V21, P45; EISENBERG HM, 1989, PEDIATRIC NEUROSURGE, P290; EPSTEIN JA, 1961, J PEDIATR-US, V59, P562, DOI 10.1016/S0022-3476(61)80240-0; GOLDSTEIN F, 1967, J NEUROSURG, V27, P541, DOI 10.3171/jns.1967.27.6.0541; HOFFMAN HJ, 1995, CHILD NERV SYST, V11, P268, DOI 10.1007/BF00301757; JOHNSON DL, 1995, CHILD NERV SYST, V11, P265, DOI 10.1007/BF00301756; KINGSLEY D, 1978, J NEUROL NEUROSUR PS, V41, P312, DOI 10.1136/jnnp.41.4.312; LEESTMA JE, 1988, FORENSIC NEUROPATHOL, P333; LENDE RA, 1961, J NEUROSURG, V18, P479, DOI 10.3171/jns.1961.18.4.0479; LYE RH, 1981, J NEUROSURG, V55, P470, DOI 10.3171/jns.1981.55.3.0470; MATSON DD, 1969, NEUROSURGERY INFANCY, P304; NALLS G, 1990, AM J EMERG MED, V8, P34, DOI 10.1016/0735-6757(90)90291-7; RAMAMURTHI B, 1970, J NEUROSURG, V32, P427, DOI 10.3171/jns.1970.32.4.0427; ROSENTHAL SA, 1970, J NEUROSURG, V32, P431, DOI 10.3171/jns.1970.32.4.0431; ROY S, 1987, ACTA NEUROCHIR, V87, P112, DOI 10.1007/BF01476061; SEKHAR LN, 1980, NEUROSURGERY, V6, P285, DOI 10.1227/00006123-198003000-00011; STEIN BM, 1972, ARCH NEUROL-CHICAGO, V26, P137, DOI 10.1001/archneur.1972.00490080055005; TANDON PN, 1987, ACTA NEUROCHIR, V88, P1, DOI 10.1007/BF01400508; TAVERAS JM, 1953, J NEUROSURG, V10, P233, DOI 10.3171/jns.1953.10.3.0233; TENNER MS, 1970, RADIOLOGY, V94, P351, DOI 10.1148/94.2.351; THOMPSON JB, 1973, J NEUROSURG, V39, P493, DOI 10.3171/jns.1973.39.4.0493; WINSTON K, 1983, J NEUROSURG, V59, P839, DOI 10.3171/jns.1983.59.5.0839	24	12	12	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	DEC	1995	11	12					692	697		10.1007/BF00262233			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	TM909	WOS:A1995TM90900006	8750951				2021-06-18	
J	Olver, JH				Olver, JH			Brain injury: The need to assess outcome	CURRENT OPINION IN NEUROLOGY			English	Article								After traumatic brain injury, outcome measures can be used to monitor the effectiveness of preventative programmes and of therapy in acute management and rehabilitation. Early prediction of outcome can help with the planning of intervention in terms of cost and improving function. Outcome studies have determined that problems with psychosocial adjustment and quality of life are the most important in the long term.	UNIV MELBOURNE,DEPT REHABIL,MELBOURNE,VIC,AUSTRALIA; BETHESDA HOSP,MELBOURNE,VIC,AUSTRALIA				Olver, John/0000-0001-7069-1191			BANJA J, 1994, ARCH PHYS MED REHABI, V75; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; Hall KM, 1994, ARCH PHYS MED REHABI, V75, pSC; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JOHNSTON MV, 1994, ARCH PHYS MED REHABI, V75; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCMILLAN TM, 1993, CLIN REHABIL, V7, P248; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1995, BRAIN INJURY, V9, P49; STRATTON M, 1995, BRAIN INJURY, V8, P631; The European Study Group on Nimodipine in Severe Head Injury, 1994, J NEUROSURG, V80, P797	27	12	12	0	0	CURRENT SCIENCE	PHILADELPHIA	400 MARKET STREET,SUITE 750 ATTN:SARAH WHEALEN/SUB MGR, PHILADELPHIA, PA 19106	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1995	8	6					443	446		10.1097/00019052-199512000-00008			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	TR416	WOS:A1995TR41600008	8845928				2021-06-18	
J	HESTAD, K; UPDIKE, M; SELNES, OA; ROYAL, W				HESTAD, K; UPDIKE, M; SELNES, OA; ROYAL, W			COGNITIVE SEQUELAE OF REPEATED HEAD-INJURY IN A POPULATION OF INTRAVENOUS-DRUG-USERS	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						HEAD INJURY; SEVERITY; REPEATED; NEUROPSYCHOLOGY; DRUG USE	SOCCER INJURIES; NEUROPSYCHOLOGICAL DEFICITS; FOOTBALL PLAYERS; BRAIN-DAMAGE; COCAINE USE; ALCOHOL; ETHANOL; ABUSERS; TRAUMA	The relationship between closed head injury acid performance on neuropsychological (NP) tests was investigated in a group of intravenous drug users (IVDUs). Subjects with repeated head traumas involving loss of consciousness (LOC) performed worse than both a control group without LOC and reference group with only a single episode of LOG. There were no significant differences between the last two groups. Performance on tests of memory, attention, and motor performance was significantly worse in the group with repeated head injury. The average time since the last episode of LOC was more than 11 years. We conclude from these findings that a single episode of LOC does not result in significant cognitive impairment in this population. Two or more episodes, however, are more likely to produce chronic cognitive impairment.	JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21218	HESTAD, K (corresponding author), UNIV BERGEN,DEPT CLIN PSYCHOL,CLIN NEUROPSYCHOL SECT,SYDNESPLASS 13,N-5007 BERGEN,NORWAY.						ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348; BRUHN P, 1975, AM J PSYCHIAT, V138, P397; DeCrescito V, 1974, Surg Forum, V25, P438; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; FIELDS FJJ, 1974, NEWS NEWSLETTER RES; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRANT I, 1978, ARCH GEN PSYCHIAT, V35, P1063; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1975, LANCET, V22, P995; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Ingraham L J, 1990, J Neuropsychiatry Clin Neurosci, V2, P174; KELLY J P, 1990, Neurology, V40, P252; KLONOFF DC, 1989, ARCH NEUROL-CHICAGO, V46, P989, DOI 10.1001/archneur.1989.00520450059019; Klove H, 1972, Scand J Rehabil Med, V4, P55; KlOve H, 1963, MED CLIN N AM; LEONE AP, 1990, NEUROLOGY, V40, P404; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LINNOILA M, 1983, ACTA PSYCHIAT SCAND, V68, P175, DOI 10.1111/j.1600-0447.1983.tb11121.x; LOBERG T, 1986, NEUROPSYCHOLOGICAL A, P415; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MALLOY P, 1990, ADDICT BEHAV, V15, P431, DOI 10.1016/0306-4603(90)90029-W; MATSER E, 1992, PSYCHOLOOG, V27, P515; MATTHEWS CG, 1964, INSTRUCTION MANUAL A; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; OSCARBERMAN M, 1987, NEUROBEHAVIORAL RECO, P178; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1979, MANUAL ADM NEUROPSYC; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROYAL W, 1991, NEUROLOGY, V41, P1905, DOI 10.1212/WNL.41.12.1905; RUTHERFORD WH, 1977, LANCET, V1, P1; SELNES OA, 1989, 5 P INT C AIDS MONTR; Smith A., 1982, SYMBOL DIGIT MODALIT; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; STRICKLAND TL, 1993, J NEUROPSYCH CLIN N, V5, P419; TEASDALE G, 1984, CLOSED HEAD INJURY P, P4; TYSVAER A T, 1992, Tidsskrift for den Norske Laegeforening, V112, P1268; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; VLAHOV D, 1991, LONGITUDINAL STUDIES; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; 1990, STATISTIX MANUAL VER	48	12	12	0	1	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5564			SCAND J PSYCHOL	Scand. J. Psychol.	SEP	1995	36	3					246	255		10.1111/j.1467-9450.1995.tb00984.x			10	Psychology, Multidisciplinary	Psychology	RW615	WOS:A1995RW61500002	7481597				2021-06-18	
J	MADDOCKS, DL; SALING, M; DICKER, GD				MADDOCKS, DL; SALING, M; DICKER, GD			NOTE ON NORMATIVE DATA FOR A TEST SENSITIVE TO CONCUSSION IN AUSTRALIAN RULES FOOTBALLERS	AUSTRALIAN PSYCHOLOGIST			English	Article							MILD CONCUSSION	The medical diagnosis of concussion and assessment of recovery in athletes has traditionally been subjectively based on clinical symptoms such as headache, nausea, and dizziness. Recently, there has been increasing interest in the use of neuropsychological tests as objective measures of recovery from concussion. In particular, performance on tests of speed of information processing, such as the Digit-Symbol subtest (DS) from the Wechsler Adult Intelligence Scale-Revised (WAIS-R), has been found to be reduced in the first weeks after concussion. In the present study, baseline DS data were obtained from Australian Rules footballers. DS was administered to a sample of 200 professional Australian Rules football players according to standard WAIS-R procedures. Players were then grouped according to concussive history. No player had been concussed within six months of the study. No significant differences were found between the groups. Therefore, while previous research suggests that performance on DS may be affected in the first few weeks following concussive injury, the present results demonstrated that DS performance does not differentiate concussed and nonconcussed players by the sixth month posttrauma. These data constitute normative values against which the DS can be interpreted in concussed footballers in the early stages of recovery.	MONASH UNIV,CLAYTON,VIC,AUSTRALIA	MADDOCKS, DL (corresponding author), UNIV MELBOURNE,FAC MED,SCH BEHAV SCI,DEPT PSYCHOL,PARKVILLE,VIC 3052,AUSTRALIA.						*AUSTR NAT FOOTB C, 1992, STAT NAT AUSTR RUL F; Barth JT., 1989, MILD HEAD INJURY, P257; Dicker G, 1993, Aust Fam Physician, V22, P750; DICKER G, 1986, AUSTR FAMILY PHYSICI, V145, P455; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1974, LANCET, P605; GRONWALL D, 1975, LANCET          1122, P995; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; NORUSIS MJ, 1988, STATISTICAL PACKAGES; Smith A., 1973, SYMBOL DIGIT MODALIT; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	16	12	12	0	2	AUSTRALIAN PSYCHOL SOC	CARLTON	1 GRATTAN STREET, CARLTON VICTORIA 3053, AUSTRALIA	0005-0067			AUST PSYCHOL	Aust. Psychol.	JUL	1995	30	2					125	127		10.1080/00050069508258916			3	Psychology, Multidisciplinary	Psychology	RT403	WOS:A1995RT40300012					2021-06-18	
J	BURG, JS; BURRIGHT, RG; DONOVICK, PJ				BURG, JS; BURRIGHT, RG; DONOVICK, PJ			PERFORMANCE DATA FOR TRAUMATIC BRAIN-INJURED SUBJECTS ON THE GORDON DIAGNOSTIC SYSTEM (GDS) TESTS OF ATTENTION	BRAIN INJURY			English	Article								Thirty adults with traumatic brain injury (TBI) (20 males and 10 females, mean age 40 years) and a non-injured control soup (12 males and 13 females, mean age 41 years) were tested on 16 tests of attention including three tasks of the Gordon Diagnostic System (GDS), a relatively new set of attention tasks. No differences between groups were found on age or education. Both groups had estimated IQs in the average range. Performance data for the GDS are presented for the TBI and CON groups. Mild to moderate deficits of attention were seen in the TBI soup relative to controls on the Vigilance and Distractibility tasks. No differences between groups were seen on the Standard Delay groups. Pearson product moment correlations suggested different patterns of relationships between the GDS tasks and other tests of attention for the TBI and CON groups. These results support the utility of the Vigilance and Distractibility tasks for assessment of attention in a mild to moderately injured population.	SUNY BINGHAMTON,DEPT PSYCHOL,ENVIRONM NEUROPSYCHOL LAB,BINGHAMTON,NY 13902; UNITED HLTH SERV,DEPT PSYCHIAT & NEUROSCI,BINGHAMTON,NY							BURG JS, UNPUB CLOSED HEAD IN; Gordon M, 1988, INSTRUCTION MANUAL G; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; Kaufman A., 1990, KBIT KAUFMAN BRIEF I; POSNER MI, 1984, J NEUROSCI, V4, P1863; RASILE DA, IN PRESS INT J PSYCH; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; VANZOMEREN AH, 1990, TRAUMATIC BRAIN INJU, P33; WECHSLER D, 1987, WMSR WECHSLER MEMORY; WECHSLER D, 1981, WAISR MANUAL WECHSLE	13	12	12	0	1	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					395	403		10.3109/02699059509005779			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000007	7640685				2021-06-18	
J	VUILLEUMIER, P				VUILLEUMIER, P			CALLOSAL LESIONS AND INTERHEMISPHERIC DISCONNECTION SYNDROMES AFTER HEAD-INJURY	NEUROCHIRURGIE			French	Article						HEAD INJURY; CORPUS CALLOSUM; INTERHEMISPHERIC DISCONNECTION; FORNIX; AMNESIA; DIFFUSE AXONAL INJURY	DIFFUSE AXONAL INJURY; PERSISTENT VEGETATIVE STATE; CORPUS-CALLOSUM; MULTIPLE-SCLEROSIS; TRAUMATIC LESIONS; MEMORY; FEATURES; BRAIN; IMPAIRMENT; TOMOGRAPHY	We review the different kinds of injury to the corpus callosum in closed head trauma, as well as their different mechanisms. Most frequent lesions are either diffuse and at the microscopic level, secondary to disruption of axons at the time of the trauma, or focal and at macroscopic level, also due to torsion or shearing strains on the corpus callosum. They are associated with diffuse axonal injury of hemispheric and brainstem white matter. Focal macroscopic lesions, sometimes extensive, are encountered in 16-40% of autopsies after fatal head injury. Likewise, MRI allows nowadays to show them in 22-49% of nonfatal head injuries. Such lesions can produce an interhemispheric disconnection syndrome. However, clinical observation of an interhemispheric disconnection after head trauma has been only rarely reported in the literature, as it is showed by a brief overview of those cases, which suggests that this pathology is probably often overlooked. Focal damage to the corpus callosum seems to be a marker of severe injury, with often long-lasting coma and sometimes tansitory vegetative state or mutism. Extension of posterior callosal lesions towards adjacent midline structures, such as the fornix, could contribute to the important memory impairment which is particularly frequently associated with posttraumatic interhemispheric disconnection syndromes.	CHU VAUDOIS, DIV AUTONOME NEUROPSYCHOL, CH-1011 LAUSANNE, SWITZERLAND	VUILLEUMIER, P (corresponding author), CHU VAUDOIS, SERV NEUROL, CH-1011 LAUSANNE, SWITZERLAND.			Vuilleumier, Patrik/0000-0002-8198-9214			Adams J.H., 1990, HDB CLIN NEUROLOGY, V13, P43; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; ARNE J, 1975, HDB CLIN NEUROLOGY, V23, P459; Bakay L, 1980, HEAD INJURY; BARNARD RO, 1974, J NEUROL NEUROSUR PS, V37, P1259, DOI 10.1136/jnnp.37.11.1259; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Blinkov SM, 1971, BRAIN DISPLACEMENTS; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bogen J.E., 1993, CLIN NEUROPSYCHOLOGY, P337; BOLDRINI P, 1992, CORTEX, V28, P135, DOI 10.1016/S0010-9452(13)80172-4; BRION S, 1975, TROUBLES TRANSFERT I; CECCALDI M, 1994, REV NEUROL-FRANCE, V150, P229; CHESTER CS, 1987, ANN NEUROL, V22, P77; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; DAMASIO H, 1979, NEUROLOGY, V29, P644, DOI 10.1212/WNL.29.5.644; DEGE A, 1920, NEUE DTSCH CHIRURG, V18, P1; DEGOS JD, 1988, ENCY MED CHIR NEUROL; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; Gordon HW, 1990, HDB NEUROPSYCHOLOGY, P85; GRAFMAN J, 1985, ARCH NEUROL-CHICAGO, V42, P1162, DOI 10.1001/archneur.1985.04060110044014; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; HUBER SJ, 1987, ARCH NEUROL-CHICAGO, V44, P732, DOI 10.1001/archneur.1987.00520190040015; JUNET W, 1938, HELV MED ACTA, V42, P375; KOMATSU S, 1979, NEUROSURGERY, V5, P32, DOI 10.1227/00006123-197907010-00005; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LINDENBERG R, 1955, AM J PATHOL, V31, P297; LONG CG, 1992, HDB HEAD TRAUMA; MCCORMICK WF, 1985, NEUROSURGERY, V2, P1544; MCCORMICK WF, 1983, CLIN NEUROSCIENCES, V3, P241; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Nakagawa Y, 1991, Rinsho Shinkeigaku, V31, P6; RAO SM, 1989, ARCH NEUROL-CHICAGO, V46, P918, DOI 10.1001/archneur.1989.00520440114028; RAPOPORT AM, 1980, HEADACHE, V20, P279, DOI 10.1111/j.1526-4610.1980.hed2005279.x; REINARZ SJ, 1988, AM J ROENTGENOL, V151, P791, DOI 10.2214/ajr.151.4.791; RISSE GL, 1989, ARCH NEUROL-CHICAGO, V46, P437, DOI 10.1001/archneur.1989.00520400097026; ROWBOTHAM GF, 1949, ACUTE INJURIES HEAD, P1; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; RUBENS AB, 1985, ANN NEUROL, V18, P459, DOI 10.1002/ana.410180408; RUDGE P, 1991, BRAIN, V114, P349, DOI 10.1093/brain/114.1.349; SCHNIDER A, 1993, NEUROLOGY, V43, P1243, DOI 10.1212/WNL.43.6.1243; SCHOTT B, 1969, REV NEUROL-FRANCE, V120, P359; SHIGEMORI M, 1986, ACTA NEUROCHIR, V81, P36, DOI 10.1007/BF01456262; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SUSSMAN NM, 1983, J NEUROSURG, V59, P514, DOI 10.3171/jns.1983.59.3.0514; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; TUCKER DM, 1988, CORTEX, V24, P465, DOI 10.1016/S0010-9452(88)80010-8; Yamadori A, 1988, Behav Neurol, V1, P11, DOI 10.3233/BEN-1988-1103; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; 1991, JAMA-J AM MED ASSOC, V263, P420	64	12	12	0	2	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0028-3770	1773-0619		NEUROCHIRURGIE	Neurochirurgie		1995	41	2					98	107					10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RG171	WOS:A1995RG17100004	7630468				2021-06-18	
J	GOLDING, EM; VINK, R				GOLDING, EM; VINK, R			INHIBITION OF PHOSPHOLIPASE-C WITH NEOMYCIN IMPROVES METABOLIC AND NEUROLOGIC OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						MAGNESIUM; NUCLEAR MAGNETIC RESONANCE; TRAUMA; BIOENERGETICS; TREATMENT	NUCLEAR-MAGNETIC-RESONANCE; INTRACELLULAR FREE MG-2+; EXCITATORY AMINO-ACIDS; P-31 NMR-SPECTROSCOPY; FREE MAGNESIUM; SPINAL-CORD; RAT; ANTAGONIST; RELEASE; SYSTEM	Activation of phospholipase C has been implicated as a factor in the development of irreversible tissue damage following injury to the central nervous system. We have used phosphorus magnetic resonance spectroscopy and a battery of postinjury motor function tests to characterize the role that phospholipase C activity may play in determining biochemical and neurologic outcome following traumatic brain injury in rats. Moderate (2.7 atmospheres) fluid percussion induced lateral brain injury caused a decline in free magnesium concentration, phosphorylation potential, and increased mitochondrial rate of oxidative phosphorylation. Neurologic motor score at 24 h and 1 week posttrauma in these animals was consistent with moderate injury. In contrast, treatment with the phospholipase C inhibitor neomycin B (15 mg/kg i.v.) immediately prior to injury significantly improved free magnesium status, bioenergetic state and neurological outcome (P < 0.01) after injury. We propose that phospholipase C activated second messenger pathways affecting magnesium homeostasis are involved in determining outcome after brain injury.	JAMES COOK UNIV N QUEENSLAND,DIV BIOCHEM & HUMAN PHYSIOL,TOWNSVILLE,QLD 4811,AUSTRALIA			AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			Aikawa J., 1981, MAGNESIUM ITS BIOL S; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHN M, 1962, J BIOL CHEM, V237, P176; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CUNNINGHAM CC, 1986, BIOCHIM BIOPHYS ACTA, V885, P12, DOI 10.1016/0167-4889(86)90033-9; DIAMANT S, 1988, J NEUROCHEM, V51, P795, DOI 10.1111/j.1471-4159.1988.tb01814.x; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAYES RL, 1992, CENTRAL NERVOUS SYST, P173; HEADRICK JP, 1991, J MOL CELL CARDIOL, V23, P991, DOI 10.1016/0022-2828(91)91635-5; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; JANE JA, 1992, 1991 CTR NERV SYST T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KEITH RA, 1992, J MOL NEUROSCI, V3, P147, DOI 10.1007/BF02919406; KENDALL DA, 1993, BIOCHEM SOC T, V21, P1120, DOI 10.1042/bst0211120; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NIOKA S, 1990, J APPL PHYSIOL, V68, P2527; PEARSON HA, 1993, NEUROPHARMACOLOGY, V32, P1171, DOI 10.1016/0028-3908(93)90011-Q; PETITTI N, 1991, J NEUROCHEM, V56, P628, DOI 10.1111/j.1471-4159.1991.tb08196.x; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; RECASENS M, 1991, CURRENT ASPECTS NEUR, V3, P103; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; STREB H, 1985, J BIOL CHEM, V260, P7309; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; UMEMURA A, 1992, J NEUROSURG, V76, P648, DOI 10.3171/jns.1992.76.4.0648; UMEMURA A, 1992, STROKE, V23, P1163, DOI 10.1161/01.STR.23.8.1163; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1989, ANN NEUROL, V25, P26, DOI 10.1002/ana.410250105; VINK R, 1988, J NEUROTRAUMA, V5, P365; VINK R, 1991, MAGNESIUM EXCITABLE, P695; WADE A, 1977, BOOK MARTINDALE EXTR; WALLACE MA, 1993, NEUROCHEM RES, V18, P139, DOI 10.1007/BF01474676; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YOUNG W, 1992, 1991 CTR NERV SYST T, P9; ZHENG LX, 1994, ENDOCRINOLOGY, V134, P1446, DOI 10.1210/en.134.3.1446	61	12	12	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 30	1994	668	1-2					46	53		10.1016/0006-8993(94)90509-6			8	Neurosciences	Neurosciences & Neurology	QB354	WOS:A1994QB35400006	7704617				2021-06-18	
J	YANG, KY; TAFT, WC; DIXON, CE; YU, RK; HAYES, RL				YANG, KY; TAFT, WC; DIXON, CE; YU, RK; HAYES, RL			ENDOGENOUS PHOSPHORYLATION OF A 61,000-DALTON HIPPOCAMPAL PROTEIN INCREASES FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							MR 60,000 PROTEIN; KINASE-C ACTIVITY; FOREBRAIN ISCHEMIA; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; NMDA RECEPTORS; CELL-DEATH; RAT; GLUTAMATE; NEUROTOXICITY	Acute biochemical consequences of moderate traumatic brain injury (TBI) include activation of kinases, including protein kinase C (PKC). To determine the possible consequences of PKC activation at the substrate level, we have examined protein phosphorylation patterns 1 h following injury. Although the phosphorylation of most proteins remained unchanged following injury, we observed a significant increase in the phosphorylation of a 61,000 dalton protein (TBI61) in injured rat hippocampus (121% higher than sham control) in vitro. TBI61 phosphorylation could be enhanced by phosphatidyl serine and diacylglycerol or by addition of exogenous PKC. In addition, TBI61 phosphorylation was inhibited by the PKC inhibitor, staurosporine, suggesting further that this protein may be a PKC substrate. These data suggest that TBI increases the phosphorylation of a 61 kD hippocampal protein in vitro. Increases in the protein level and activity of PKC could contribute to this increased phosphorylation.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,DIV NEUROSURG,HOUSTON,TX 77030; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM,RICHMOND,VA 23298					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, NS31998] Funding Source: Medline		AHMED Z, 1990, BRAIN RES, V516, P165, DOI 10.1016/0006-8993(90)90914-W; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHURN SB, 1992, J NEUROCHEM, V59, P1221, DOI 10.1111/j.1471-4159.1992.tb08431.x; CRUMRINE RC, 1990, J NEUROCHEM, V55, P2001, DOI 10.1111/j.1471-4159.1990.tb05788.x; DELORENZO RJ, 1978, BIOCHEM BIOPH RES CO, V80, P183, DOI 10.1016/0006-291X(78)91121-X; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; FLOREZ JC, 1991, EXP NEUROL, V112, P264, DOI 10.1016/0014-4886(91)90126-W; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOCHHAR A, 1989, J NEUROCHEM, V53, P946, DOI 10.1111/j.1471-4159.1989.tb11797.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASLIAH E, 1991, J NEUROSCI, V11, P2759; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MERRILL CR, 1981, SCIENCE, V211, P67; NELSON RB, 1985, EXP NEUROL, V89, P213, DOI 10.1016/0014-4886(85)90277-8; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PRASAD MR, 1993, J NEUROCHEM, V63, P1; SAITOH T, 1988, J NEUROPATH EXP NEUR, V47, P1, DOI 10.1097/00005072-198801000-00001; SAITOH T, 1991, LAB INVEST, V64, P596; SAITOH T, 1986, P NATL ACAD SCI USA, V83, P9764, DOI 10.1073/pnas.83.24.9764; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAFT WC, 1988, BRAIN RES, V447, P159, DOI 10.1016/0006-8993(88)90978-X; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WIELOCH T, 1991, J NEUROCHEM, V56, P1227, DOI 10.1111/j.1471-4159.1991.tb11415.x; Yang K., 1994, Society for Neuroscience Abstracts, V20, P424; YANG K, 1993, SOC NEUR ABSTR, V767, P13; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	41	12	12	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					523	532		10.1089/neu.1994.11.523			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700006	7861445				2021-06-18	
J	LLOYD, LF; CUVO, AJ				LLOYD, LF; CUVO, AJ			MAINTENANCE AND GENERALIZATION OF BEHAVIORS AFTER TREATMENT OF PERSONS WITH TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							SKILLS; ADULTS	This review of behavioural research literature was conducted to determine if persons who have experienced a traumatic brain injury are able to maintain and generalize behaviours after training, and to identify formal programming strategies that might have been utilized to enhance maintenance and generalization. Studies reviewed included those that employed behavioural procedures to increase adaptive behaviours or reduce maladaptive behaviours and collected maintenance and generalization data. Results of the review indicate that persons who have experienced a traumatic brain injury have experienced successful response maintenance and generalization of community-referenced tasks. It is suggested that impaired memory does not keep persons from maintaining and generalizing such tasks, and that strategies to promote maintenance and generalization need to be included in behavioural programming.		LLOYD, LF (corresponding author), SO ILLINOIS UNIV,INST REHABIL,CARBONDALE,IL 62901, USA.						Arnie Zencius, 1991, BEHAV RESIDENTIAL TR, V6, P1, DOI DOI 10.1002/BIN.2360060102; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; COOPER JO, 1987, APPLIED BEHAVIOR ANA, P585; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; GARCIA J G, 1990, Brain Injury, V4, P203, DOI 10.3109/02699059009026167; KAY T, 1986, MINOR HEAD INJURY IN, P1; KENTUDOLF L, 1984, BEHAVIORAL ASSESSMEN, P23; LANE IM, 1989, J BEHAV THER EXP PSY, V20, P79, DOI 10.1016/0005-7916(89)90011-6; LEWIS FD, 1990, BEHAVIORAL RESIDENTI, V1, P61; O'Reilly M. F., 1989, BEHAV RESIDENTIAL TR, V4, P359, DOI 10. 1002/bin. 2360040406; OREILLY MF, 1990, J APPL BEHAV ANAL, V23, P431, DOI 10.1901/jaba.1990.23-431; REIDY TJ, 1979, ARCH PHYS MED REHAB, V60, P226; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; STOKES TF, 1977, J APPL BEHAV ANAL, V10, P349, DOI 10.1901/jaba.1977.10-349; SULZERAZAROFF B, 1991, BEHAVIOR ANAL LASTIN, P522; TURNER JM, 1990, BEHAVIORAL RESIDENTI, V5, P1; ZAHARA DJ, 1984, CLIN PSYCHOL REV, V4, P477, DOI 10.1016/0272-7358(84)90022-9; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163; Zencius A. H., 1991, BEHAV INTERVENT, V6, P155, DOI DOI 10.1002/BIN.236006; ZENCUIUS AH, 1990, BEHAVIORAL RESIDENTI, V5, P61; 1982, BRINGING RES EFFECTI, V5, P1; 1989, INTERAGENCY HEAD INJ, P1; 1985, INJURY AM CONTINUING	25	12	12	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					529	540		10.3109/02699059409151005			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200005	7987289				2021-06-18	
J	WONG, PP; DORNAN, J; KEATING, AM; SCHENTAG, CT; IP, RY				WONG, PP; DORNAN, J; KEATING, AM; SCHENTAG, CT; IP, RY			RE-EXAMING THE CONCEPT OF SEVERITY IN TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							HEAD	This paper re-examines the theoretical concept of severe brain injury focusing on the duration of coma as a precise indicator of the clinical profile. A retrospective hospital chart study of 361 traumatic brain-injured patients was undertaken to determine the homogeneity of the subsample of the severely brain-injured (defined as 2 or more days of coma) with respect to the probability of four types of impairment: ataxia, contractures, paralysis and speech impairment. The current concept of severity assumes homogeneity among the 'severely brain-injured'. However, our results indicate significant differences in impairment within this population. The authors feel strongly that future studies must describe coma duration in finer gradations, and test for homogeneity within samples before inferences are made. Improvements in life-sustaining technologies have resulted in longer coma durations. The need to use coma days as an indicator of impairment rather than a broad category of severity is emphasized.		WONG, PP (corresponding author), COLUMBIA HLTH CARE INC,NEUROREHABIL SERV,180 DUNDAS ST W,4TH FLOOR,TORONTO M5G 1Z8,ON,CANADA.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Annoni J M, 1992, Disabil Rehabil, V14, P23; COHADON F, 1991, J NEUROL SCI, V103, P27; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; MacPherson Valerie, 1992, Brain Injury, V6, P489, DOI 10.3109/02699059209008146; MILLER JD, 1990, REHABILITATION ADULT, P236; MINDERHOUD JM, 1990, TRAUMATIC BRAIN INJU, P23; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; VILKKI J, 1988, J NEUROL NEUROSUR PS, V51, P1452, DOI 10.1136/jnnp.51.11.1452; WONG P, BRAIN INJURY, V7, P283; Wong P P, 1993, Leadersh Health Serv, V2, P25	18	12	13	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					509	518		10.3109/02699059409151003			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200003	7527268				2021-06-18	
J	GURNS, S; KAPPENBERG, R; MCKENNA, A; WOOD, C				GURNS, S; KAPPENBERG, R; MCKENNA, A; WOOD, C			BRAIN INJURY - PERSONALITY, PSYCHOPATHOLOGY AND NEUROPSYCHOLOGY	BRAIN INJURY			English	Article							LESION LOCATION; MOOD DISORDERS; STROKE; DYSFUNCTION; DEPRESSION; DISEASE; INJURY	This study investigated the relationship between brain injury and personality, using the Luria-Nebraska Neuropsychological Battery and the Clinical Analysis Questionnaire as measurement tools. Psychopathological factors, as opposed to normal personality traits, were highly correlated with measures of brain injury. Depression, in particular, was found to be substantially involved in the sequelae of brain injury for this sample. A trend in the data revealed that suicidal depression and anxious depression were differentially related to deficits on two scales of the LNNB. Patients with evidence of suicidal depression were also more sensitive to emotional dysfunction in other areas. Few differences were found between patients with traumatic brain injury and those with other types of brain injuries. Results suggest that measures of psychopathology can provide important supplementary information to neuropsychological assessment, above that obtained from measures of brain functioning alone. Controlled studies should investigate the relationship between psychopathology and neuropsychology more thoroughly to provide clearer determinations of its involvement in the rehabilitation of the brain-injured person.	PACIFIC INST BEHAV MED,HONOLULU,HI; KANSAS REHABIL HOSP,TOPEKA,KS							Bigler E D, 1989, Brain Inj, V3, P73, DOI 10.3109/02699058909008077; BOYAR J J, 1981, Clinical Neuropsychology, V3, P15; BUROS OK, 1978, 5TH MENTAL MEASUREME; CATTELL RB, 1973, J MULTIVARIATE EXPT, V1, P34; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; DAM H, 1989, ACTA PSYCHIAT SCAND, V80, P118, DOI 10.1111/j.1600-0447.1989.tb01312.x; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; FILSKOV S, 1981, HDB CLIN NEUROPSYCHO; FLOR-HENRY P, 1990, Neuropsychology Review, V1, P103, DOI 10.1007/BF01108713; FOLSTEIN MF, 1977, J NEUROL NEUROSUR PS, V40, P1018, DOI 10.1136/jnnp.40.10.1018; Franzen M. D., 1989, RELIABILITY VALIDITY; Golden C. J., 1980, LURIA NEBRASKA NEURO; Goldstein G, 1987, Arch Clin Neuropsychol, V2, P215; GRACA J, 1983, DISSERT ABSTR INT, V43, P2707; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; HATHAWAY SR, 1970, MINNESOTA MULTIPHASI; HEILMAN KM, 1983, NEUROPSYCHOLOGY HUMA; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; Jennett B, 1981, MANAGEMENT HEAD INJU; KAMEOKA VA, 1986, MULTIVAR BEHAV RES, V21, P105, DOI 10.1207/s15327906mbr2101_6; KOLB B, 1989, AM PSYCHOL, V44, P1203, DOI 10.1037/0003-066X.44.9.1203; Krug S. E., 1980, CLIN ANAL QUESTIONNA; Krug S. E., 1976, HDB IPAT ANXIETY SCA; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; LEWIS GP, 1979, J CONSULT CLIN PSYCH, V47, P1003, DOI 10.1037/0022-006X.47.6.1003; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Luria A. R, 1973, WORKING BRAIN; Luria A. R., 1963, RESTORATION FUNCTION; LURIA AR, 1980, CLIN NEUROPSYCHOLOGY, V2, P1; LURIA AR, 1969, SOVIET STUDIES PSYCH, V1; MAGNI G, 1984, J NEUROL NEUROSUR PS, V47, P567, DOI 10.1136/jnnp.47.5.567; MORRIS PLP, 1992, NEUROPSY NEUROPSY BE, V5, P75; Newman P J, 1987, Arch Clin Neuropsychol, V2, P115, DOI 10.1016/0887-6177(87)90039-4; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1987, NEUROBEHAVIORAL RECO; ROBINSON RG, 1987, STROKE, V18, P837, DOI 10.1161/01.STR.18.5.837; Sacks O., 1985, MAN WHO MISTOOK HIS; SHARPE M, 1990, PSYCHOL MED, V20, P815, DOI 10.1017/S0033291700036503; STARKSTEIN S, 1989, BRIT J PSYCHIAT, V133, P79; STERN Y, 1983, J NEUROL NEUROSUR PS, V46, P145, DOI 10.1136/jnnp.46.2.145; Strub R. L., 1981, ORGANIC BRAIN SYNDRO; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TSUSHIMA WT, 1987, INT J CLIN NEUROPSYC, V9, P120; WATSON CG, 1984, J CLIN PSYCHOL, V40, P1008, DOI 10.1002/1097-4679(198407)40:4<1008::AID-JCLP2270400425>3.0.CO;2-9; WIEBE J, 1988, JUL BRAIN INJ OUTC C	46	12	12	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1994	8	5					413	427		10.3109/02699059409150993			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NW122	WOS:A1994NW12200003	7951204				2021-06-18	
J	KOTANI, M; MASAMOTO, Y; WATANABE, M				KOTANI, M; MASAMOTO, Y; WATANABE, M			AN ALTERNATIVE STUDY OF THE SKIN IRRITANT EFFECT OF AN HOMOLOGOUS SERIES OF SURFACTANTS	TOXICOLOGY IN VITRO			English	Article								An attempt has been made to differentiate between in vivo and in vitro skin reactions to a homologous series of surfactants (sodium alkyl sulfate, R-OSO3 Na) and to determine the usefulness of percutaneous absorption in vitro as an alternative test system. Sodium alkyl sulfate showed considerable biological activity by virtue of its polar head groups. The length of the lipophilic chain in the surfactants was an important factor in their overall activity. The following in vivo tests were performed: a primary skin irritation test in guinea pigs, a primary eye irritation test in rabbits and a closed patch test in humans. Peak skin irritation occurred with C-10-C-16 sodium alkyl sulfate, which had lipophilic groups of different alkyl chain lengths. Cell injury was also evaluated by the neutral red dye uptake assay in rabbit corneal (RC) cells. C-4 and C-6 compounds had no effect, while maximal effects occurred with C-18. Protein denaturation and haemolysis occurred with C-10-C-16 compounds. In the percutaneous absorption test in guinea pig skin, permeation was low for the C-18 compound and high for the C-4 compound. The results with the C-18 compound suggest that differences between cell injury and skin irritation result from skin permeation. Although the C-18 compound caused cell injury, membrane destruction and protein denaturation were more severely with the C-10-C-16 compounds, owing to their strong haemolytic and protein-denaturation action.	NAGASAKI UNIV,SCH PHARM,DIV RADIAT BIOL,NAGASAKI 852,JAPAN	KOTANI, M (corresponding author), SUNSTAR INC,CTR SAFETY ANAL,TECH HQ,MFG,R&D,3-1 ASAHI MACHI,TAKATSUKI,OSAKA 569,JAPAN.						DAWEKE H, 1959, Arch Klin Exp Dermatol, V209, P520, DOI 10.1007/BF00492397; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; DUGARD PH, 1973, J INVEST DERMATOL, V60, P263, DOI 10.1111/1523-1747.ep12722895; FIKER S, 1972, Acta Facultatis Medicae Universitatis Brunensis, V41, P177; GLOXHUBER C, 1975, DETERGENCY THEORY TE, P695; IMOKAWA G, 1975, J AM OIL CHEM SOC, V52, P484, DOI 10.1007/BF02640737; KONDO T, 1968, J PHARM SCI, V57, P1246, DOI 10.1002/jps.2600570740; OKAMOTO K, 1976, SHINSHU IGAKU ZASSHI, V24, P243; PAPE W J W, 1987, Molecular Toxicology, V1, P525; PROTTEY C, 1975, J SOC COSMET CHEM, V26, P29; SCHULZ K H, 1957, Arch Klin Exp Dermatol, V205, P254, DOI 10.1007/BF00482575; SUGAI T, 1978, J COSMETIC SCI SOC, V2, P19	12	12	12	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-2333			TOXICOL IN VITRO	Toxicol. Vitro	APR	1994	8	2					229	233		10.1016/0887-2333(94)90187-2			5	Toxicology	Toxicology	NK547	WOS:A1994NK54700012	20692910				2021-06-18	
J	LITOFSKY, NS; CHIN, LS; TANG, G; BAKER, S; GIANNOTTA, SL; APUZZO, MLJ				LITOFSKY, NS; CHIN, LS; TANG, G; BAKER, S; GIANNOTTA, SL; APUZZO, MLJ			THE USE OF LOBECTOMY IN THE MANAGEMENT OF SEVERE CLOSED-HEAD TRAUMA	NEUROSURGERY			English	Article						GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HEAD INJURY; LOBECTOMY; SEVERE BRAIN INJURY; TRANSTENTORIAL HERNIATION	DECOMPRESSIVE CRANIECTOMY; PROGNOSTIC FEATURES; CEREBRAL EDEMA; INJURY	A RETROSPECTIVE REVIEW is presented of 20 patients with traumatic brain injury who were treated during the course of their illness by lobectomies either after a herniation or other significant deterioration or to reduce elevated intracranial pressure. All the patients suffered from blunt head trauma. Patient ages ranged from 19 to 59 years (average, 34 yr). The initial Glasgow Coma Scale score ranged from 3 to 15 (average, 8.2). There were 14 frontal lobectomies, 2 temporal, 3 frontal and temporal, and 1 occipital. Surgery was performed between 0 and 8 days after injury (average, 2.8). Outcome was favorable (good or moderately disabled) in 11 patients and unfavorable (severely disabled, persistently vegetative, or dead) in 9. No patients survived in a persistently vegetative state. A higher initial Glasgow Coma Scale score was positively correlated with a more favorable outcome (P < 0.03). Younger patients also showed a significant positive relationship to outcome (P < 0.0005). Better pupillary reactivity showed a significant trend toward a more favorable outcome (P < 0.04). The type of lesions identified on computed tomographic scans had no association with outcome. A lobectomy can be a useful adjuvant in the management of severe brain injury, especially in younger patients with relatively higher initial Glasgow Coma Scale scores who subsequently deteriorate or develop elevated intracranial pressure.	UNIV MASSACHUSETTS, GRAD SCH BIOMED SCI, WORCESTER, MA 01655 USA; UNIV SO CALIF, SCH MED, DEPT NEUROSURG, LOS ANGELES, CA 90033 USA	LITOFSKY, NS (corresponding author), UNIV MASSACHUSETTS, MED CTR, SCH MED, DIV NEUROSURG, 55 LAKE AVE N, WORCESTER, MA 01655 USA.		Baker, Stephen P/B-8562-2008				ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CUSHING HW, 1908, J HOPKINS HOSP B, V19, P48; EVANS J P, 1951, U S Armed Forces Med J, V2, P1001; FREEDMAN H, 1952, J NEUROSURG, V9, P52, DOI 10.3171/jns.1952.9.1.0052; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; Heiden J.S., 1979, NEURAL TRAUMA, P181; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MEHTA CR, 1986, COMMUN STAT THEORY, V15, P387, DOI 10.1080/03610928608829128; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NUSSBAUM ES, 1991, NEUROSURGERY, V29, P62, DOI 10.1227/00006123-199107000-00010; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Reid WL, 1940, SURGERY, V8, P756; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SCOVILLE WB, 1979, ACTA NEUROCHIR, V47, P149, DOI 10.1007/BF01406400; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WALKER AE, 1960, J NEUROSURG, V26, P184; 1992, STATXACT TURBO; 1988, SAS STAT USERS GUIDE	34	12	14	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	1994	34	4					628	632		10.1227/00006123-199404000-00009			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NC633	WOS:A1994NC63300025	8008159				2021-06-18	
J	TODD, MM; WU, B; WARNER, DS				TODD, MM; WU, B; WARNER, DS			THE HEMISPHERIC CEREBROVASCULAR RESPONSE TO HEMODILUTION IS ATTENUATED BY A FOCAL CRYOGENIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; NITRIC-OXIDE SYNTHESIS; SPREADING DEPRESSION; RAT-BRAIN; OXYGEN-CONSUMPTION; NMDA-RECEPTOR; ISOVOLEMIC HEMODILUTION; HEMATOCRIT VARIATIONS; HYPOXIC HYPOXIA	Experimental brain injury attenuates the normal increase in cerebral blood flow (CBF) that accompanies a fall in PaO2, and this may contribute to the well-known detrimental effects of hypoxia following closed head injury. Anemia is also known to adversely affect posttraumatic survival, and it is reasonable to hypothesize that this too may be related to an altered cerebrovascular response. Therefore, to examine this possibility, pentobarbital-anesthetized rabbits were subjected to a left posterior parietal cryogenic cortical injury, followed 90 min later by isovolemic hemodilution with hetastarch. Unlesioned control animals underwent an identical degree of hemodilution. CBF was measured using radioactive microspheres. In control animals, hemodilution was accompanied by a marked increase in CBF in all brain regions. For example, in the left posterior cortex, CBF increased from 30 +/- 14 mL/100 g/min (baseline Hct = 42 +/- 2%, mean +/- SD) to 100 +/- 20 mL/100 g/min at Hct = 12 +/- 1%. By contrast, there was a markedly attenuated response throughout the left (ipsilateral) hemisphere of injured animals, even in cortical regions distant from the injury. For example, in the left posterior cortex, CBF changed from a baseline of 32 +/- 21 mL/100 g/min (baseline) to 40 +/- 14 mL/100 g/min at the lowest Hct. CBF responses to hemodilution were unaltered in the contralateral hemisphere and in the hindbrain. These data indicate that a localized brain lesion can produce widespread ipsilateral alterations in the CBF response to hemodilution, with resultant compromise in cerebral O-2 delivery. These data support the argument that the CBF increase produced by hemodilution is an active vasodilatory process rather than a passive response to changing blood viscosity.		TODD, MM (corresponding author), UNIV IOWA, COLL MED, DEPT ANESTHESIA, NEUROANESTHESIA RES LAB, IOWA CITY, IA 52242 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS24517] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024517] Funding Source: NIH RePORTER		ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BENVENISTE H, 1987, J NEUROCHEM, V49, P729, DOI 10.1111/j.1471-4159.1987.tb00954.x; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P423, DOI 10.1111/j.1748-1716.1975.tb05832.x; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROWN MM, 1985, BRAIN, V108, P81, DOI 10.1093/brain/108.1.81; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLASEN RA, 1957, SURG GYNECOL OBSTET, V104, P591; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAN FC, 1980, AM J PHYSIOL, V238, pH545; FEUSTEL PJ, 1987, J SURG RES, V43, P86, DOI 10.1016/0022-4804(87)90051-5; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GENTLEMAN D, 1992, INT SURG, V77, P297; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; HUDAK ML, 1986, AM J PHYSIOL, V251, pH63; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JOHANNSSON H, 1975, ACTA PHYSIOL SCAND, V93, P269, DOI 10.1111/j.1748-1716.1975.tb05815.x; JONES MD, 1981, AM J PHYSIOL, V240, pH209; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KONTOS HA, 1993, STROKE, V24, P427, DOI 10.1161/01.STR.24.3.427; KOROSUE K, 1992, STROKE, V23, P1487, DOI 10.1161/01.STR.23.10.1487; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; LAURITZEN M, 1984, J CEREBR BLOOD F MET, V4, P546, DOI 10.1038/jcbfm.1984.79; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MARSHALL WH, 1959, PHYSIOL REV, V39, P239; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1992, AM J PHYSIOL, V262, pH949; NELLGARD B, 1992, ACTA PHYSIOL SCAND, V146, P497, DOI 10.1111/j.1748-1716.1992.tb09451.x; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; RAMANI R, 1991, J CEREBR BLOOD F MET, V11, P388, DOI 10.1038/jcbfm.1991.79; REILLY PL, 1977, J NEUROL NEUROSUR PS, V40, P1092, DOI 10.1136/jnnp.40.11.1092; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SHINOZUKA T, 1989, J CEREBR BLOOD F MET, V9, P187, DOI 10.1038/jcbfm.1989.28; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TOMIDA S, 1989, J CEREBR BLOOD F MET, V9, P79, DOI 10.1038/jcbfm.1989.11; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; TRAYSTMAN RJ, 1981, AM J PHYSIOL, V241, pH724; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; TSUDA Y, 1987, J NEUROL SCI, V82, P171, DOI 10.1016/0022-510X(87)90016-5; VERHAEGEN MJ, 1992, J CEREBR BLOOD F MET, V12, P230, DOI 10.1038/jcbfm.1992.33; WOOD JH, 1985, STROKE, V16, P765, DOI 10.1161/01.STR.16.5.765; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	54	12	12	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1994	11	2					149	160		10.1089/neu.1994.11.149			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	NR684	WOS:A1994NR68400002	7932795				2021-06-18	
J	PACKARD, RC; HAM, LP				PACKARD, RC; HAM, LP			PROMISING TECHNIQUES IN THE ASSESSMENT OF MILD HEAD-INJURY	SEMINARS IN NEUROLOGY			English	Article							POSITRON EMISSION TOMOGRAPHY; EVENT-RELATED POTENTIALS; TRANSCRANIAL DOPPLER EVALUATION; CEREBRAL BLOOD-FLOW; EVOKED-POTENTIALS; COMPUTERIZED-TOMOGRAPHY; ULTRASONIC FEATURES; SELECTIVE ATTENTION; GLUCOSE-METABOLISM; ALZHEIMERS-DISEASE	Closed head injury may result in varying degrees of brain injury, from slight to severe and irreversible. Severe or even moderate head injuries often result in obvious structural damage, which is usually easily detected by imaging or neurophysiologic assessment. Mild head injuries (MHI; defined by Rimel et al1 as a period of unconsciousness less than 20 minutes, a Glasgow Coma Scale of 13 or greater, a negative neurologic examination, and a duration of posttraumatic amnesia less than 48 hours) are typically more subtle. In spite of persisting symptomatology, there is typically no anatomic evidence of injury as traditionally assessed.2,3 (See Young and Silberstein in this issue of Seminars). A variety of distressing symptoms often follow MHI or neck injury. The most common are headache, dizziness, impaired concentration, memory difficulties, fatigue, irritability, depression, and anxiety.2-5 Paradoxically, individuals sustaining MHI often have more intense posttraumatic symptoms than those who sustain more severe head injuries.3 The persistence of these symptoms often results in feelings of distrust from the public, the legal profession, insurance companies, and even other physicians.4,6 Even in the face of legitimate posttraumatic symptoms, patients may still be labeled as ''accident neurosis,'' ''personality disorder,'' or ''malingering in order to receive compensation.'' New technologic advances in experimental head injury and neuroimaging techniques have revealed that even MHIs result in subtle changes in the structure and physiology of the brain.7,8 Such cerebral alterations may explain the persistence of memory difficulties, depression, distractibility, dizziness, and headache. Traditional studies, however, including radiographs, electroencephalography (EEG), computerized tomography (CT), and magnetic resonance imaging (MRI) are often normal in MHI. Transcranial Doppler (TCD), positron emission tomography (PET), single photon emission computerized tomography (SPECT), and quantitative analysis of EEG and evoked potentials (brain mapping) have only recently become available for clinical use. These new and promising techniques will be reviewed in detail in this article.	UNIV W FLORIDA, DEPT PSYCHOL, PENSACOLA, FL 32514 USA	PACKARD, RC (corresponding author), HEADACHE MANAGEMENT & NEUROL, 5500 N DAVIS HIGHWAY, PENSACOLA, FL 32503 USA.						AASLID R, 1902, TRANSCRANIAL DOPPLER, P1; ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; [Anonymous], 1989, Neurology, V39, P1100; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BARON JC, 1983, POSITRON EMISSION TO, P212; BENNETT TL, 1988, COGN REHABIL, P34; BENSON DF, 1983, ARCH NEUROL-CHICAGO, V40, P711, DOI 10.1001/archneur.1983.04050110029003; BROOKS DJ, 1984, J CEREBR BLOOD F MET, V4, P458, DOI 10.1038/jcbfm.1984.65; BUCHSBAUM MS, 1986, J AFFECT DISORDERS, V10, P137, DOI 10.1016/0165-0327(86)90036-4; DEVOUS MD, 1989, BRAIN IMAGING APPLIC, P147; DOPPLER CA, 1992, TRANSCRANIAL DOPPLER, P1; EMERSON RG, 1992, 27TH ANN COURS CLIN; ENGEL J, 1982, ANN NEUROL, V12, P518, DOI 10.1002/ana.410120604; EPSTEIN C, 1992, 27TH AM EL SOC ANN C; FARKAS T, 1984, ARCH GEN PSYCHIAT, V41, P293; FERROMILONE D, 1984, JUN INT S EV POT ASS, P79; FRACKOWIAK RSJ, 1983, FUNCTIONAL RADIONUCL, P305; GAWEL MJ, 1990, HEADACHE REV, V3, P3; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; GERARD G, 1992, HEADACHE Q-CURR TREA, V3, P217; GOODIN DS, 1992, AAN BREAKFAST S, V211; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GRAY BG, 1992, J NUCL MED, V33, P52; GREEN J, 1992, CLIN ELECTROENCEPHAL, V23, P79, DOI 10.1177/155005949202300207; GROLIMUND P, 1987, STROKE, V18, P1018, DOI 10.1161/01.STR.18.6.1018; GRONWALL D, 1974, LANCET, V2, P605; GROSS MM, 1965, ELECTROEN CLIN NEURO, V18, P451, DOI 10.1016/0013-4694(65)90125-2; GRUBB RL, 1978, ANN NEUROL, V4, P322, DOI 10.1002/ana.410040407; GUR RC, 1983, NEUROPSYCHOLOGIA, V21, P601, DOI 10.1016/0028-3932(83)90057-X; Hayes RL, 1989, MILD HEAD INJURY, P54; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; HOLCOMB HH, 1989, BRAIN IMAGING APPLIC, P235; JAMIESON D, 1988, RADIOL CLIN N AM, V26, P1075; JOLLES PR, 1989, J NUCL MED, V30, P1589; JONES SC, 1985, J CEREBR BLOOD F MET, V5, P566, DOI 10.1038/jcbfm.1985.85; KRELINA M, 1989, CAN J NEUROL SCI, V2, P279; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; McCarthy G, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P331; MCGEER PL, 1986, CAN MED ASSOC J, V134, P597; MEADOR KJ, 1992, AAN BREAKFAST S, V211; MITGUY J, 1992, HEADLINES        MAY, P6; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; NAATANEN R, 1982, PSYCHOL BULL, V92, P605; NAATANEN R, 1975, BIOL PSYCHOL, V2, P237, DOI 10.1016/0301-0511(75)90038-1; NEWELL DW, 1992, TRANSCRANIAL DOPPLER, P109; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; NIMMON C C, 1989, European Journal of Nuclear Medicine, V15, P507; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OLBRICH HM, 1986, ACTA NEUROCHIR, V80, P116, DOI 10.1007/BF01812285; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PATTERSON JV, 1988, ELECTROEN CLIN NEURO, V71, P450, DOI 10.1016/0168-5597(88)90049-4; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; PODOSHIN L, 1990, J LARYNGOL OTOL, V104, P191, DOI 10.1017/S0022215100112241; POOICH J, 1991, AM J EEG TECHNOL, V1, P201; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; PRATT H, 1981, ELECTROEN CLIN NEURO, V51, P80, DOI 10.1016/0013-4694(81)91511-X; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; PRITCHARD WS, 1986, PSYCHOL BULL, V100, P43, DOI 10.1037/0033-2909.100.1.43; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; RASKIN NH, 1988, HEADACHE, P289; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; REIVICH M, 1982, J CEREBR BLOOD F MET, V2, P307, DOI 10.1038/jcbfm.1982.32; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUTH RA, 1982, AM SPEECH HEARING AS; SCHLAKE HP, 1989, HEADACHE, V29, P344, DOI 10.1111/j.1526-4610.1989.hed2906344.x; SCHLAKE HP, 1990, HEADACHE Q-CURR TREA, V1, P303; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1987, ARCH NEUROL-CHICAGO, V44, P1181, DOI 10.1001/archneur.1987.00520230061015; SKYHOJ OT, 1989, HEADACHE, V29, P15; SMITH ME, 1989, J EXP PSYCHOL LEARN, V15, P50, DOI 10.1037/0278-7393.15.1.50; STOCKARD JJ, 1980, ELECTRODIAGNOSIS CLI, P503; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; TEBANO RW, 1989, ELECTROENCEPHALOGR C, V73, P94; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; THIE A, 1990, HEADACHE, V30, P209, DOI 10.1111/j.1526-4610.1990.hed3004209.x; THIE A, 1990, HEADACHE, V30, P201, DOI 10.1111/j.1526-4610.1990.hed3004201.x; THIVIERGE J, 1988, CAN J PSYCHIAT, V33, P552, DOI 10.1177/070674378803300619; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WILKINSON RT, 1967, ELECTROEN CLIN NEURO, V23, P50, DOI 10.1016/0013-4694(67)90140-X; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495; ZWETSLOOT CP, 1991, HEADACHE, V31, P593, DOI 10.1111/j.1526-4610.1991.hed3109593.x; 1991, NEUROLOGY, V41, pA13	92	12	12	0	0	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					74	83		10.1055/s-2008-1041062			10	Clinical Neurology	Neurosciences & Neurology	NE151	WOS:A1994NE15100013	8029563				2021-06-18	
J	MESTDAGH, H; MAYNOU, C; DELOBELLE, JM; URVOY, P; BUTIN, E				MESTDAGH, H; MAYNOU, C; DELOBELLE, JM; URVOY, P; BUTIN, E			TRAUMATIC POSTERIOR DISLOCATION OF THE SHOULDER IN ADULTS - REVIEW OF 25 CASES	ANNALES DE CHIRURGIE			French	Article						SHOULDER; POSTERIOR DISLOCATION; LOCKED DISLOCATION; CLOSED REDUCTION; SURGICAL TREATMENT		In a series of 25 traumatic posterior dislocations of the shoulder treated from 1960 to 1985, 16 were overlooked and the time from injury to treatment ranged from 3 weeks to 14 months. 11 cases were secondary to motor vehicle accident and 14 occurred after a convulsive fit. Early closed reduction was effective in only 4 cases ; in 2 cases, reduction was unstable and further screwing of an associated fracture of the tuberculum majus was performed to prevent redislocation; 3 locked dislocations necessitated open reduction and stabilization by subscapularis transposition into the defect of the humeral head. Most of the 16 chronic unreduced dislocations were treated by the same procedure. Overall, 21 cases were reviewed with a mean follow-up of 14 years. Functional outcome was more often satisfactory in acute (5/7) than in old unreduced dislocations (6/14). Mc Laughlin or Neer's procedures yielded good results in 9 out of 14 cases ; they are indicated irrespective of the patient's age whenever Mc Laughlin's notch does not involve more than one third of the articular surface of the humeral head.		MESTDAGH, H (corresponding author), CHRU LILLE,SERV ORTHOPED TRAUMATOL D,PL VERDUN,F-59037 LILLE,FRANCE.							0	12	12	0	1	EXPANSION SCI FRANCAISE	PARIS	31 BLVD LATOUR MAUBOURG, 75007 PARIS, FRANCE	0003-3944			ANN CHIR	Ann. Chir.		1994	48	4					355	363					9	Surgery	Surgery	NK132	WOS:A1994NK13200011	8085761				2021-06-18	
J	WOOLLEY, SM; RUBIN, AM; KANTNER, RM; ARMSTRONG, CW				WOOLLEY, SM; RUBIN, AM; KANTNER, RM; ARMSTRONG, CW			DIFFERENTIATION OF BALANCE DEFICITS THROUGH EXAMINATION OF SELECTED COMPONENTS OF STATIC STABILOMETRY	JOURNAL OF OTOLARYNGOLOGY			English	Article								Stabilometry, which measures the body's center of pressure (COP) movements, during relaxed standing, has been used to distinguish individuals with vestibular and neurologic dysfunctions from normal subjects. The purpose of this study was to determine whether mathematical differences in the magnitudes of the COP obtained from six somatosensory testing conditions could be used to discriminate between different types of balance deficits. Stabilometry measures, using a fixed force platform, were obtained from normal (N = 52) and dizzy (N = 149), peripheral vestibular dysfunction (PVD), post-concussion syndrome (PCS), psychogenic (PSG), and unknown/undetermined etiology (UNK). The data significantly differentiated CVD, PVD and PSG patients from normals and between some of the dizzy groups: CVD versus PVD, PCS; and PSG versus CVD, PVD, PCS and UNK. The measures of anterior-posterior COP movements provided the greatest discrimination.		WOOLLEY, SM (corresponding author), MED COLL OHIO,DEPT REHABIL MED,POB 10008,TOLEDO,OH 43699, USA.							0	12	13	0	0	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0381-6605			J OTOLARYNGOL	J. Otolaryngol.	OCT	1993	22	5					368	375					8	Otorhinolaryngology	Otorhinolaryngology	MH125	WOS:A1993MH12500008	8283507				2021-06-18	
J	MYSIW, WJ; TAN, J; JACKSON, RD				MYSIW, WJ; TAN, J; JACKSON, RD			HETEROTOPIC OSSIFICATION - THE UTILITY OF OSTEOCALCIN IN DIAGNOSIS AND MANAGEMENT	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						HETEROTOPIC OSSIFICATION; OSTEOCALCIN; TRAUMATIC BRAIN INJURY	BONE GLA-PROTEIN; ALKALINE-PHOSPHATASE; SERUM OSTEOCALCIN; PAGETS-DISEASE; OSTEOPOROSIS	The status of 12 patients after severe traumatic brain injury was investigated to determine the clinical significance of serum osteocalcin levels during the active phase of neurogenic heterotopic ossification. The diagnosis of heterotopic ossification was confirmed on the basis of radiologic, findings. The mean interval between the initial injury and diagnosis of heterotopic ossification was 29 weeks. At the time of diagnosis, serum osteocalcin and total alkaline phosphatase levels were determined along with 24-hour urinary calcium and hydroxyproline excretion. The mean serum osteocalcin level was normal at 4.3 ng/ml (normal range 1.6-6.6 ng/ml) in contrast to the elevated mean values for serum alkaline phosphatase (mean = 173 units/liter; normal range 0-105 units/liter) and urinary hydroxyproline concentration (mean = 39.6 mg/24 h; normal range 7-25 mg/24 hr). Only 17% of the subjects demonstrated an elevated serum osteocalcin level, whereas 58% of the patients had an elevated serum alkaline phosphatase level. Urinary calcium excretion and hydroxyproline excretion were elevated in 33% and 70% of subjects, respectively. These data did not reveal a significant correlation between serum osteocalcin and serum alkaline phosphatase, urinary calcium excretion or urinary hydroxyproline at the time of diagnosis or in serial measurements. Therefore, serum osteocalcin is not a valuable adjunct in confirming the diagnosis of neurogenic heterotopic ossification once the diagnosis has been suggested on the basis of clinical findings and it does not appear to play a role in assessing the maturation of heterotopic ossification.	OHIO STATE UNIV,DIV ENDOCRINOL & METAB INTERNAL MED,COLUMBUS,OH 43210	MYSIW, WJ (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,1048 DODD HALL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.		Mysiw, Walter/E-3724-2011				BUSCHBACHER R, 1992, CRIT REV PHYS MED RE, V4, P199; DELMAS PD, 1986, CALCIFIED TISSUE INT, V38, P60, DOI 10.1007/BF02556596; DIAMOND T, 1989, AM J MED, V86, P282, DOI 10.1016/0002-9343(89)90297-0; DUDA RJ, 1988, J CLIN ENDOCR METAB, V66, P951, DOI 10.1210/jcem-66-5-951; EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem-67-4-741; FORTUNE CL, 1989, ENDOCRINOLOGY, V124, P2785, DOI 10.1210/endo-124-6-2785; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; HYLDSTRUP L, 1988, SCAND J CLIN LAB INV, V48, P611, DOI 10.3109/00365518809085780; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; JENSEN LL, 1988, AM J PHYS MED, V66, P351; JOHNSON JS, 1990, METABOLISM, V39, P1122; LIAN JB, 1988, CLIN ORTHOP RELAT R, V226, P267; NIELSEN HK, 1991, J BONE MINER RES, V6, P435; NIELSEN HK, 1990, CALCIFIED TISSUE INT, V46, P173, DOI 10.1007/BF02555040; ORZEL JA, 1985, J NUCL MED, V26, P125; PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954; TORRES R, 1989, SCAND J CLIN LAB INV, V49, P279, DOI 10.3109/00365518909089096; WEINREB M, 1990, J BONE MINER RES, V5, P831	18	12	13	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	1993	72	4					184	187		10.1097/00002060-199308000-00002			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LU176	WOS:A1993LU17600002	8363811				2021-06-18	
J	KLONOFF, PS; LAGE, GA; CHIAPELLO, DA				KLONOFF, PS; LAGE, GA; CHIAPELLO, DA			VARIETIES OF THE CATASTROPHIC REACTION TO BRAIN INJURY - A SELF PSYCHOLOGY PERSPECTIVE	BULLETIN OF THE MENNINGER CLINIC			English	Article							HEAD-INJURY	Patients with traumatic brain injury sometimes manifest varieties of what Goldstein (1952) called the ''catastrophic reaction.'' Recognizing the particular form of catastrophic reaction is important both to determine proper behavioral management and to help patients accept the effects of the brain injury. Applying Kohutian theory and self psychology constructs, the authors present several case studies to show bow the patients shared the same underlying experience of shame and anxiety over their injury-related impairments. These patients participated in an outpatient, milieu-oriented rehabilitation program intended to increase their independence at borne and to facilitate their return to productive work. The rehabilitation therapist's role was to help patients move from a state of being unable to accept their deficits to one of setting and pursuing attainable goals. The authors discuss ways of managing these catastrophic reactions.		KLONOFF, PS (corresponding author), ST JOSEPHS HOSP, BARROW NEUROL INST, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.						*AM PSYCH ASS, 1989, TREATM PSYCH DIS TA, V3; BAKER HS, 1987, AM J PSYCHIAT, V144, P1; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; Klonoff P.S., 1991, J HEAD TRAUMA REHAB, V6, P11, DOI DOI 10.1097/00001199-199112000-00005; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KOHUT H, 1978, INT J PSYCHOANAL, V59, P413; Kohut H., 1972, PSYCHOANAL STUD C, V27, P360, DOI DOI 10.1080/00797308.1972.11822721; Kohut H., 1977, RESTORATION SELF; LAGE GA, 1991, PSYCHOTHERAPY ADOLES; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Ornstein P.H., 1991, SEARCH SELF SELECTED, V4; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; SANDLER J, 1962, PSYCHOANAL STUD CHIL, V17, P107; SANDLER J, 1973, PATIENT ANAL BASIS P; SCHWABER EA, 1979, STAFF PSYCHIATRY C C; TERMAN DM, 1975, ANNU PSYCHOANAL, V3, P239; Wolf ES, 1988, TREATING SELF ELEMEN	19	12	12	0	0	GUILFORD PUBLICATIONS INC	NEW YORK	370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA	0025-9284	1943-2828		B MENNINGER CLIN	Bull. Menninger Clin.	SPR	1993	57	2					227	241					15	Psychiatry; Psychology, Psychoanalysis	Psychiatry; Psychology	LC530	WOS:A1993LC53000008	8508158				2021-06-18	
J	MATTEUCCI, MJ; WISNER, DH; GUNTHER, RA; WOOLLEY, DE				MATTEUCCI, MJ; WISNER, DH; GUNTHER, RA; WOOLLEY, DE			EFFECTS OF HYPERTONIC AND ISOTONIC FLUID INFUSION ON THE FLASH EVOKED-POTENTIAL IN RATS - HEMORRHAGE, RESUSCITATION, AND HYPERNATREMIA	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SMALL-VOLUME RESUSCITATION; LACTATED RINGERS SOLUTION; CEREBRAL WATER-CONTENT; SALINE-DEXTRAN; INTRACRANIAL-PRESSURE; TRAUMATIC SHOCK; BRAIN-INJURY; HEAD-INJURY	In resuscitation from hemorrhagic shock, very small volumes of hypertonic saline (HS) improve blood pressure while reducing intracranial pressure and edema formation. The effects of hypertonic resuscitation fluids and hypernatremia on electrophysiologic brain function have not been studied. The present study was done in two parts. First we examined the effects of hemorrhagic shock and resuscitation with either 7.5% HS or lactated Ringer's (LR) solution on the flash evoked potential (FEP). Rats were bled to a mean arterial pressure (MAP) of 35 mm Hg for 1 hour, then resuscitated with HS (n = 10) or LR (n = 10) to a MAP of 80 mm Hg for another hour. Resuscitation required 3.8 +/- 0.5 mL/kg HS and 42.9 +/- 7.5 mL/kg LR (p < 0.05). During hemorrhage, FEP latencies increased and amplitudes decreased. During resuscitation, these variables returned toward baseline values. There were no significant differences between groups, although HS tended to restore the FEP better than LR. We next examined the effects on the FEP of hypernatremia and hyperosmolarity produced by two different hyperosmotic fluids. Over a 1-hour period, 16 mL/kg HS (n = 8), 16 mL/kg IsoSal (4.5% saline, 5.9% glucose, 6.4% mixed amino acids; n = 8), or 40 mL/kg LR (n = 8) was infused into normovolemic rats. Plasma sodium levels increased in both hyperosmotic groups (baseline = 145.2 +/- 0.7 mEq/L; after infusion, HS = 202.4 +/- 9.8 mEq/L, IsoSal = 163.3 +/- 4.2 mEq/L; p < 0.05). Plasma osmolarity also increased in these two groups (baseline = 303.1 +/- 1.6 mOsm/L; after infusion, HS = 404.6 +/- 17.6 mOsm/L, IsoSal = 357.9 +/- 6.7 mOsm/L; p < 0.05). Brain tissue water content was slightly decreased in both hyperosmotic groups compared with the LR group (HS = 77.4% +/- 0.7%; IsoSal = 77.5% +/- 0.6%; LR = 78.2% +/- 0.4%) although the differences were not significant. Some deterioration was seen in the FEP at very high levels of serum sodium and osmolarity. Neural tissue dehydration as a result of hypertonic saline infusion in hemorrhaged and normovolemic rats has no apparent deleterious effects on acute brain function as measured by the FEP until very high levels of sodium and osmolarity are reached.	UNIV CALIF DAVIS,SACRAMENTO MED CTR,MED CTR,DEPT SURG,4301 X ST,ROOM 2310,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,DEPT ANIM PHYSIOL,DAVIS,CA 95616							BATTISTELLA F D, 1989, Surgical Forum (Chicago), V40, P40; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; DUCEY JP, 1990, CRIT CARE MED, V18, P744, DOI 10.1097/00003246-199007000-00013; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; HAGHIGHI SS, 1989, NEUROSURGERY, V24, P246, DOI 10.1227/00006123-198902000-00015; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; KRAMER GC, 1986, SURGERY, V100, P239; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MATTSSON JL, 1988, NEUROTOXICOL TERATOL, V10, P435, DOI 10.1016/0892-0362(88)90005-0; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; SMITH GJ, 1985, J SURG RES, V39, P517, DOI 10.1016/0022-4804(85)90120-9; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; Wisner D H, 1983, Curr Surg, V40, P32; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WISNER DH, 1992, J TRAUMA, V32, P351, DOI 10.1097/00005373-199203000-00013; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	19	12	17	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1993	34	1					1	7		10.1097/00005373-199301000-00001			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	KP908	WOS:A1993KP90800001	8437174				2021-06-18	
J	DAILEY, SW; BARSAN, WG				DAILEY, SW; BARSAN, WG			HEAD-INJURIES IN SOCCER - A CASE FOR PROTECTIVE HEADGEAR	PHYSICIAN AND SPORTSMEDICINE			English	Article								Two soccer goalies, a 20-year-old woman and a 28-year-old man, sustained head injuries as they fielded shots on goal. One was kicked, the other kneed by another player. The female goalie suffered a mild concussion. The male goalie lost consciousness and was transported to a hospital where he scored a 7 of 15 on the Glasgow Coma Scale. Three months after the injury, he still suffered from decreased concentration and hearing loss and had not returned to work.		DAILEY, SW (corresponding author), UNIV CINCINNATI,COLL MED,DEPT EMERGENCY MED,CINCINNATI,OH 45221, USA.							0	12	12	1	7	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000	0091-3847			PHYSICIAN SPORTSMED	Physician Sportsmed.	AUG	1992	20	8					79	&					0	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	JH413	WOS:A1992JH41300013	29272675				2021-06-18	
J	COLOHAN, ART; OYESIKU, NM				COLOHAN, ART; OYESIKU, NM			MODERATE HEAD-INJURY - AN OVERVIEW	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE; RAT; SEQUELAE; RECOVERY; DEFICIT; COMA; PH	This review summarizes currently available epidemiologic, clinical, pathologic, and outcome data in patients with moderate head injury (MHI, GCS 9-12). This important subset comprises about 20% of head injuries in the United States. Affected patients usually are young, and most injuries are due to vehicular accidents. Current evidence (mortality rate and outcome) from various studies suggests an apparent dichotomy within the MHI category (9-10 vs 11-12). The former is more in keeping with the favorable subgroup of severe head injuries, and the latter is more appropriate to the mild head injury group. Should there be a reclassification based on this dichotomy? This is obviously important for clinical management and prognostication in these patients. The experimental evidence for a pathologic and biochemical substrate of MHI is reviewed. It is becoming increasing evident that biochemical mediators of secondary neuronal injury in MHI are at least as important as those attributed to severe head injury, but MHI may be more amenable to therapy. It may be prudent, therefore, to direct further effort to this subgroup of patients. Although additional study is required, the pattern of recovery in MHI as determined by extant neurobehavioral studies is analyzed.	EMORY UNIV,SCH MED,ATLANTA,GA 30322	COLOHAN, ART (corresponding author), GRADY MEM HOSP,DIV NEUROL SURG,80 BUTLER ST NE,ATLANTA,GA 30335, USA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; DICKMAN S, 1986, ARCH PHYS MED REHAB, V67, P507; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRONWALL D, 1975, LANCET, V2, P995; HAYES R, 1987, IEEE T SOFTWARE ENG, V13, P1254, DOI 10.1109/TSE.1987.232879; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SIESJO BK, 1985, CENTRLA NERVOUS SYST; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105	26	12	12	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S259	S264					6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600024	1588614				2021-06-18	
J	YAMAKI, T; MURAKAMI, N; IWAMOTO, Y; NAKAGAWA, Y; UEDA, S; IRIZAWA, Y; KOMURA, S; MATSUURA, T				YAMAKI, T; MURAKAMI, N; IWAMOTO, Y; NAKAGAWA, Y; UEDA, S; IRIZAWA, Y; KOMURA, S; MATSUURA, T			PATHOLOGICAL-STUDY OF DIFFUSE AXONAL INJURY PATIENTS WHO DIED SHORTLY AFTER IMPACT	ACTA NEUROCHIRURGICA			English	Article						HEAD INJURY; EARLY DEATH; DIFFUSE AXONAL INJURY; PATHOLOGICAL STUDY	NONMISSILE HEAD-INJURY; BRAIN INJURY; DAMAGE; HUMANS; NERVE	It is generally considered that axonal injury is apparent only on electron microscopy in the very early stage after a closed head injury. To clarify the pathological findings in head injury patients dying very shortly after the impact, we analyzed 8 fatal cases of diffuse axonal injury (DAI) who underwent medicolegal autopsy at the Department of Forensic Medicine of Kyoto Prefectural University of Medicine. Seven cases died within one hour after injury and another one case died 3 days after injury. We studied these cases macroscopically, microscopically, and electron microscopically. Macroscopically all cases showed the typical findings of diffuse axonal injury. Microscopical study of the cases who died within one hour revealed no characteristic findings of DAI such as appearance of retraction balls or microglia. On the other hand, in the case who died only 3 days after injury it showed the typical retraction balls. Electron microscopic study showed the remarkable destruction of cytoskeletal structure of axons in all cases. From our results, it is reasonable to speculate that DAI may be common among head injury patients who die very soon after the impact.	KYOTO PREFECTURAL UNIV MED, DEPT FORENS MED, KYOTO 602, JAPAN; MEIJI COLL ORIENTAL MED, DEPT ANAT, KYOTO, JAPAN	YAMAKI, T (corresponding author), KYOTO PREFECTURAL UNIV MED, DEPT NEUROSURG, KAWARAMACHI HIROKOJI, KAMIGYO KU, KYOTO 602, JAPAN.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CROMPTON MR, 1971, LANCET, V1, P669; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; GRAHAM DI, 1985, NEUROPATH APPL NEURO, V11, P319; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	18	12	16	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1992	119	1-4					153	158		10.1007/BF01541800			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KD133	WOS:A1992KD13300028	1481741				2021-06-18	
J	THOMPSON, NM; EWINGCOBBS, L; FLETCHER, JM; MINER, ME; LEVIN, HS				THOMPSON, NM; EWINGCOBBS, L; FLETCHER, JM; MINER, ME; LEVIN, HS			LEFT UNILATERAL NEGLECT IN A PRESCHOOL-CHILD	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article								The authors present a case of transient left hemispatial inattention following traumatic brain injury in a three-year-old child. Computed tomographic scan revealed a small right frontal and a right temporo-parietal contusion. Stimuli were developed to quantify the response difference between hemifields in this pre-literate child. Hemispatial inattention showed resolution at 19 days post-trauma and had completely resolved six months later. These findings suggest that right hemisphere systems subserve visually guided attention before six years of age.	UNIV TEXAS,SCH MED,DEPT PSYCHIAT,SAN ANTONIO,TX 78285; UNIV TEXAS,SCH MED,DEPT PEDIAT,SAN ANTONIO,TX 78285; OHIO STATE UNIV,SCH MED,DEPT NEUROSURG,COLUMBUS,OH 43210; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550	THOMPSON, NM (corresponding author), UNIV TEXAS,SCH MED,SW NEUROPSYCHIAT INST,8535 TOM SLICK DR,SAN ANTONIO,TX 78229, USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Brain WR, 1941, BRAIN, V64, P244, DOI 10.1093/brain/64.4.244; CARROLL JB, 1973, J VERB LEARN VERB BE, V12, P556; FERRO JM, 1984, ANN NEUROL, V15, P281, DOI 10.1002/ana.410150314; FERRO JM, 1982, DEV MED CHILD NEUROL, V24, P173; HEILMAN KM, 1985, CLIN NEUROPSYCHOLOGY; HELLER W, 1989, J CLIN EXP NEUROPSYC, V11, P79; JOHNSTON CW, 1986, CORTEX, V22, P279, DOI 10.1016/S0010-9452(86)80052-1; McCarthy D., 1972, MCCARTHY SCALES CHIL; TEASDALE G, 1974, LANCET, V2, P81; TERMAN LM, 1973, STANFORDBINET INTELL	10	12	12	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUL	1991	33	7					640	644					5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	FR944	WOS:A1991FR94400011	1879627				2021-06-18	
J	HALL, S; BORNSTEIN, RA				HALL, S; BORNSTEIN, RA			SERIAL-POSITION EFFECTS IN PARAGRAPH RECALL FOLLOWING MILD CLOSED-HEAD INJURY	PERCEPTUAL AND MOTOR SKILLS			English	Article							PERFORMANCE; EDUCATION; DISEASE		OHIO STATE UNIV,COLL MED,NEUROPSYCHOL LAB,COLUMBUS,OH 43210							BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECKER DP, 1979, ARCH NEUROL-CHICAGO, V36, P750, DOI 10.1001/archneur.1979.00500480024005; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; BORNSTEIN RA, 1983, J CLIN PSYCHOL, V39, P470, DOI 10.1002/1097-4679(198307)39:4<470::AID-JCLP2270390403>3.0.CO;2-F; FINLAYSON MAJ, 1977, J CONSULT CLIN PSYCH, V45, P536, DOI 10.1037/0022-006X.45.4.536; HALL S, IN PRESS J NEUROSURG; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P414; VALLAR G, 1986, BRAIN COGNITION, V5, P428, DOI 10.1016/0278-2626(86)90044-8; Wechsler D., 1987, WECHSLER MEMORY SCAL	10	12	12	0	1	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	JUN	1991	72	3	2				1295	1298		10.2466/PMS.72.4.1295-1298			4	Psychology, Experimental	Psychology	GA987	WOS:A1991GA98700048	1961678				2021-06-18	
J	MOORE, TJ; ANDERSON, RB				MOORE, TJ; ANDERSON, RB			THE USE OF OPEN PHENOL BLOCKS TO THE MOTOR BRANCHES OF THE TIBIAL NERVE IN ADULT ACQUIRED SPASTICITY	FOOT & ANKLE			English	Article								Spasticity of the posterior calf muscles often occurs following head injury or spinal cord injury. If left untreated, equinovarus contractures of the foot and ankle may occur in a relatively short time period. This paper retrospectively reviews nine patients with either closed head injury (six patients) or spinal cord injury (three patients) who underwent open phenol injections into the motor branches of the tibial nerve in 16 limbs. Spasticity was decreased in all patients. No significant equinus contractures had occurred at final follow-up. Five of the patients were subsequently able to ambulate. One patient had recurrence of spasticity requiring a second surgical procedure (split anterior tibial tendon transfer), and two patients had significant toe clawing at final follow-up. Open phenol injections to the motor branches of the tibial nerve safely and effectively prevent foot and ankle contractures following spinal cord injury or head injury.		MOORE, TJ (corresponding author), MILLER ORTHOPAED CLIN,1001 BLYTHE BLVD,SUITE 200,CHARLOTTE,NC 28203, USA.							0	12	13	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0198-0211			FOOT ANKLE		FEB	1991	11	4					219	221		10.1177/107110079101100406			3	Orthopedics	Orthopedics	FA272	WOS:A1991FA27200006	1855707				2021-06-18	
J	STAMBROOK, M; MOORE, AD; KOWALCHUK, S; KASSUM, DA; PETERS, LC; MCCLARTY, BM; HAWRYLUK, GA				STAMBROOK, M; MOORE, AD; KOWALCHUK, S; KASSUM, DA; PETERS, LC; MCCLARTY, BM; HAWRYLUK, GA			EARLY METABOLIC AND NEUROLOGIC PREDICTORS OF LONG-TERM QUALITY OF LIFE AFTER CLOSED HEAD-INJURY	CANADIAN JOURNAL OF SURGERY			English	Article									UNIV MANITOBA,FAC MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,NEUROPSYCHOL RES UNIT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT PSYCHOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; ST BONIFACE GEN HOSP,SURG INTENS CARE UNIT,WINNIPEG R2H 2A6,MANITOBA,CANADA; UNIV MANITOBA,DEPT PSYCHIAT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT RADIOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; HLTH SCI CTR,WINNIPEG R3E 0W1,MANITOBA,CANADA	STAMBROOK, M (corresponding author), SOC MANITOBANS DISABIL,825 SHERBROOK ST,WINNIPEG R3A 1M5,MANITOBA,CANADA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; EISENBERG HM, 1987, HEAD INJURY, P20; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; KASSUM DA, 1984, CAN J SURG, V27, P64; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KRAUS JF, 1987, HEAD INJURY, P1; McNair DM, 1971, EITS MANUAL PROFILE; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; PARKINSON D, 1985, CAN J SURG, V28, P79; SMITH JS, 1978, SURG GYNECOL OBSTET, V147, P18; STAMBROOK M, 1988, CANADIAN J REHABI S4, V1, P74	15	12	12	0	0	CANADIAN MEDICAL ASSOCIATION	OTTAWA	1867 ALTA VISTA DR, OTTAWA ON K1G 3Y6, CANADA	0008-428X			CAN J SURG	Can. J. Surg.	APR	1990	33	2					115	118					4	Surgery	Surgery	DA996	WOS:A1990DA99600009	2268809				2021-06-18	
J	ADAMOVICH, BB				ADAMOVICH, BB			INFORMATION-PROCESSING, COGNITION, ATTENTION, AND COMMUNICATION FOLLOWING CLOSED-HEAD INJURY	FOLIA PHONIATRICA			English	Article										ADAMOVICH, BB (corresponding author), MERCY HOSP,WELDON CTR REHABIL,271 CAREW ST,SPRINGFIELD,MA 01102, USA.						ADAMOVICH BB, 1985, COGNITIVE REHABILITA; ADAMOVICH BB, 1984, CLIN APHASIOLOGY C P; ADAMOVICH BB, 1983, AM SPEECH LANG HEAR; ADAMOVICH BB, 1982, AM SPEECH LANG HEAR; ADAMOVICH BB, 1978, CLIN APHASIOLOGY C P, P327; ADAMOVICH BL, 1981, CLIN APHASIOLOGY C P, P244; BATES E, 1976, J CHILD LANG, V6, P29; BELLUGI U, 1980, DAHLEM WORKSHOP BERL; BENYISHAY Y, 1978, WORKING APPROACHES R; BEVER TG, 1975, ANN NY ACAD SCI, V265, P252; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; GALIN D, 1974, ARCH GEN PSYCHIAT, V31, P572; GAZZANIGA M, 1978, DISORDERS ATTENTION; GESCHWIND N, 1982, PHILOS T ROY SOC B, V298, P173, DOI 10.1098/rstb.1982.0080; GREENFIELD PM, 1978, INFORMATIVENESS PRES; Guilford J.P., 1971, ANAL INTELLIGENCE; HAGEN C, 1983, LANGUAGE DISABILITIE; HAGEN C, 1981, C MODELS TECHNIQUES; KIRBY JR, 1980, COGNITION DEV INSTRU; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; MANN L, 1985, F COGNITIVE PROCESS; MARSHALL J, 1980, SIGNED SPOKEN LANGUA; MAYER R, 1981, PROMISE COGNITIVE PS; *MED, PROV B 217; MUMA JR, 1978, LANGUAGE HDB CONCEPT; Neisser U., 1976, COGNITION REALITY; NORMAN DA, 1979, COGNITIVE PSYCHOL, V11, P107, DOI 10.1016/0010-0285(79)90006-9; PARRILLBURNSTEI.M, 1981, PROBLEM SOLVING LEAR; PATTEN BM, 1982, MODALITY SPECIFIC ME; PEA RD, 1979, J CHILD LANG, V6, P397, DOI 10.1017/S0305000900002440; PRIBRAM KH, 1975, PSYCHOL REV, V82, P116, DOI 10.1037/h0076780; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SHAW RE, 1980, DAHLEM WORKSHOP BERL; WETZEL CD, 1982, BRAIN LANG, V15, P70, DOI 10.1016/0093-934X(82)90047-5	34	12	12	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0015-5705			FOLIA PHONIATR	Folia Phoniatr.	JAN-FEB	1990	42	1					11	23		10.1159/000266015			13	Linguistics	Linguistics	CM922	WOS:A1990CM92200002	2307386				2021-06-18	
J	LEHRER, PM; GROVEMAN, A; RANDOLPH, C; MILLER, MH; POLLACK, I				LEHRER, PM; GROVEMAN, A; RANDOLPH, C; MILLER, MH; POLLACK, I			PHYSIOLOGICAL-RESPONSE PATTERNS TO COGNITIVE TESTING IN ADULTS WITH CLOSED HEAD-INJURIES	PSYCHOPHYSIOLOGY			English	Article										LEHRER, PM (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PSYCHIAT, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.		Lehrer, Paul/AAE-8257-2020	Lehrer, Paul/0000-0002-9010-6129			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; DROHOCKI Z, 1948, REV NEUROL, V80, P619; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FOWLES DC, 1981, PSYCHOPHYSIOLOGY, V18, P232, DOI 10.1111/j.1469-8986.1981.tb03024.x; FRANZ SI, 1920, HDB MENTAL EXAMINATI; GARDEUR D, 1979, J RADIOL ELEC MED N, V60, P79; GOLDSTEIN HS, 1985, J PSYCHOSOM RES, V29, P419, DOI 10.1016/0022-3999(85)90028-5; Goldstein L, 1965, Int Rev Neurobiol, V8, P265, DOI 10.1016/S0074-7742(08)60760-6; Groveman AM, 1987, NEUROPSYCHOLOGY, V1, P19, DOI 10.1037//0894-4105.1.1.19; HOLLOWAY FA, 1969, PSYCHOPHYSIOLOGY, V6, P138, DOI 10.1111/j.1469-8986.1969.tb02893.x; HOLLOWAY FA, 1971, PSYCHOPHYSIOLOGY, V8, P623, DOI 10.1111/j.1469-8986.1971.tb00498.x; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KLOVE H, 1987, J CLIN EXP NEUROPSYC, V9, P297, DOI 10.1080/01688638708402792; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIPPOLD OCJ, 1967, MANUAL PSYCHOPHYSIOL, P245; LISHMAN WA, 1973, PSYCHOL CONSEQUENCES; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; OBRIST PA, 1982, PERSPECTIVES CARDIOV, P644; PARSONS OA, 1969, PSYCHOPHYSIOLOGY, V5, P644, DOI 10.1111/j.1469-8986.1969.tb02867.x; Pollack I W, 1984, J Med Soc N J, V81, P311; REITAN R M, 1955, AMA Arch Neurol Psychiatry, V73, P28; Spielberger CD, 1970, STAI MANUAL; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TAHMOUSH AJ, 1976, PSYCHOPHYSIOLOGY, V13, P357, DOI 10.1111/j.1469-8986.1976.tb03090.x; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120; ZAHN TP, 1982, OCT ANN M SOC PSYCH	34	12	12	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	NOV	1989	26	6					668	675		10.1111/j.1469-8986.1989.tb03169.x			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	CQ553	WOS:A1989CQ55300004	2629014				2021-06-18	
J	SELECKI, BR; BERRY, G; DAN, NG; KWOK, B; MANDRYK, JA; NORTH, JB; RING, IT; SEWELL, MF; SIMPSON, DA; STENING, WA; VANDERFIELD, GK				SELECKI, BR; BERRY, G; DAN, NG; KWOK, B; MANDRYK, JA; NORTH, JB; RING, IT; SEWELL, MF; SIMPSON, DA; STENING, WA; VANDERFIELD, GK			PREVENTABLE CAUSES OF DEATH AND DISABILITY FROM NEUROTRAUMA	AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY			English	Article																	0	12	12	0	0	BLACKWELL SCIENCE	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON VICTORIA 3053, AUSTRALIA	0004-8682			AUST NZ J SURG	Aust. N. Z. J. Surg.	JUL	1986	56	7					529	534		10.1111/j.1445-2197.1986.tb07095.x			6	Surgery	Surgery	D5284	WOS:A1986D528400002	2943259				2021-06-18	
J	GEETS, W; DEZEGHER, F				GEETS, W; DEZEGHER, F			EEG AND BRAIN-STEM ABNORMALITIES AFTER CEREBRAL CONCUSSION - SHORT-TERM OBSERVATIONS	ACTA NEUROLOGICA BELGICA			English	Article										GEETS, W (corresponding author), ST ELIZABETH HOSP,DEPT NEUROL,AVE DEFRE 206,B-1180 BRUSSELS,BELGIUM.						FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Geets W, 1983, Rev Electroencephalogr Neurophysiol Clin, V13, P253, DOI 10.1016/S0370-4475(83)80036-7; GEETS W, 1961, Acta Neurol Psychiatr Belg, V61, P460; GEETS W, 1983, ACTA NEUROL BELG, V83, P126; GEETS W, 1984, REV EEG NEUROPHYSIOL, V14, P333; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; JENNETT WB, 1962, EPILEPSY BLUNT HEAD; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P511, DOI 10.1016/0013-4694(55)90077-8; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PENFIELD W, 1956, Acta Neurol Psychiatr Belg, V56, P75; Shetter A G, 1979, Adv Neurol, V22, P5; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2	13	12	12	0	2	ACTA MEDICA BELGICA	BRUSSELS	AVENUE CIRCULAIRE 138-A, B-1180 BRUSSELS, BELGIUM	0300-9009			ACTA NEUROL BELG	Acta Neurol. Belg.		1985	85	5					277	283					7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AUC38	WOS:A1985AUC3800002	3934918				2021-06-18	
J	GOETHE, KE; LEVIN, HS				GOETHE, KE; LEVIN, HS			BEHAVIORAL MANIFESTATIONS DURING THE EARLY AND LONG-TERM STAGES OF RECOVERY AFTER CLOSED HEAD-INJURY	PSYCHIATRIC ANNALS			English	Article									UNIV TEXAS, MED BRANCH, DIV NEUROSURG E17, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT NEUROL, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, NEUROPSYCHOL LAB, GALVESTON, TX 77550 USA							BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OVERALL JE, 1962, PSYCHOL REP, V10, P799; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SANO K, 1983, J NEUROSURG, V58, P223, DOI 10.3171/jns.1983.58.2.0223; SISLER GC, 1978, PSYCHIATR CLIN N AM, V1, P137; Symonds C P, 1937, Proc R Soc Med, V30, P1081; TEASDALE G, 1974, LANCET, P45; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEINSTEIN EA, 1968, ARCH GEN PSYCHIAT, V18, P348	33	12	12	0	4	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0048-5713	1938-2456		PSYCHIAT ANN	Psychiatr. Ann.		1984	14	7					540	546		10.3928/0048-5713-19840701-11			7	Psychiatry	Psychiatry	SY923	WOS:A1984SY92300007					2021-06-18	
J	WOOD, F; NOVACK, TA; LONG, CJ				WOOD, F; NOVACK, TA; LONG, CJ			POST-CONCUSSION SYMPTOMS - COGNITIVE, EMOTIONAL, AND ENVIRONMENTAL ASPECTS	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article									UNIV TENNESSEE MEMPHIS STATE UNIV,NEUROPSYCHOL LAB,MEMPHIS,TN; VANDERBILT UNIV,MED CTR,SCH MED,NASHVILLE,TN 37232							LEWIN H, 1982, NEUROSURGERY, V11, P668; LIDVALL H, 1974, ACTA NEUROLOGICA S S, V50; LONG CJ, 1982, NEUROPSYCHOLOGY COGN, V2; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; OMMAYA A, 1968, BRAIN, V97, P633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501	9	12	12	0	0	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1984	14	4					277	283					7	Psychiatry	Psychiatry	ABA68	WOS:A1984ABA6800001					2021-06-18	
J	PARKINSON, D; DELBIGIO, M; JELL, RM				PARKINSON, D; DELBIGIO, M; JELL, RM			SPINAL-CORD CONCUSSION	SURGICAL NEUROLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA	PARKINSON, D (corresponding author), UNIV MANITOBA,FAC MED,NEUROSURG SECT,WINNIPEG R3E 0W3,MANITOBA,CANADA.			Del Bigio, Marc/0000-0001-8366-0394			CROFT TJ, 1972, J NEUROSURG, V36, P402, DOI 10.3171/jns.1972.36.4.0402; Denny-Brown D, 1944, J NEUROL NEUROSUR PS, V7, P76, DOI 10.1136/jnnp.7.3-4.76; DOHRMANN GJ, 1978, J NEUROSURG, V48, P993, DOI 10.3171/jns.1978.48.6.0993; GRAY JAB, 1954, J PHYSIOL-LONDON, V124, P84, DOI 10.1113/jphysiol.1954.sp005087; KANDEL E, 1979, SCI AM, V241, P67; KREMS A. D., 1942, PROC SOC EXP BIOL AND MED, V49, P73; LLOYD DPC, 1942, J NEUROPHYSIOL, V6, P435; PARKINSON D, 1977, MAYO CLIN PROC, V52, P492; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; RICHARDSON PM, 1979, J NEUROSURG, V51, P178, DOI 10.3171/jns.1979.51.2.0178; Shetter A G, 1979, Adv Neurol, V22, P5	11	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.		1981	16	5					347	349		10.1016/0090-3019(81)90272-X			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MS212	WOS:A1981MS21200008	6977881				2021-06-18	
J	ROBINSON, RG; GWYNNE, JF				ROBINSON, RG; GWYNNE, JF			BILATERAL INTERNAL CAROTID-ARTERY THROMBOSIS AFTER CLOSED HEAD-INJURY	ACTA NEUROCHIRURGICA			English	Article									UNIV OTAGO,SCH MED,DEPT PATHOL,DUNEDIN,NEW ZEALAND	ROBINSON, RG (corresponding author), UNIV OTAGO,SCH MED,DEPT SURG,NEUROSURG UNIT,DUNEDIN,NEW ZEALAND.						ADAMS WE, 1958, COMP MORPHOLOGY CARO; BAUER RB, 1969, J AMER MED ASSOC, V208, P509, DOI 10.1001/jama.208.3.509; BERGAN F, 1963, J CARDIOVASC SURG, V4, P300; BLAAUW G, 1976, HDB CLIN NEUROLOGY 2, V26, P43; BLAISDELL WF, 1969, J AMER MED ASSOC, V209, P1889, DOI 10.1001/jama.209.12.1889; BOLDREY E, 1956, J NEUROSURG, V13, P127, DOI 10.3171/jns.1956.13.2.0127; Boyd JD., 1937, ANAT ANZEIGER, V84, P386; DINNING TAR, 1976, I NEUROL MADRAS P, V6, P239; FLEMING JFR, 1968, CAN J SURG, V11, P166; GARG AG, 1968, BRIT J SURG, V55, P4, DOI 10.1002/bjs.1800550103; MURATORI D, 1966, ANAT ANZEIGER, V119, P466; SCHOTER I, 1975, ADV NEUROSURGERY, V3, P401; TOWNE JB, 1972, ARCH SURG-CHICAGO, V104, P565; YAMADA S, 1967, J TRAUM, V7, P333, DOI 10.1097/00005373-196705000-00001; YASHON D, 1964, J NEUROL NEUROSUR PS, V27, P547, DOI 10.1136/jnnp.27.6.547; YATES PO, 1961, 300 MED RES COUN SPE	16	12	12	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1978	44	1-2					137	142		10.1007/BF01401637			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FY825	WOS:A1978FY82500010	726960				2021-06-18	
J	EDVINSSON, L; OWMAN, C; ROSENGREN, E; WEST, KA				EDVINSSON, L; OWMAN, C; ROSENGREN, E; WEST, KA			BRAIN CONCENTRATIONS OF DOPAMINE, NORADRENALINE, 5-HYDROXYTRYPTAMINE, AND HOMOVANILLIC ACID DURING INTRACRANIAL HYPERTENSION FOLLOWING TRAUMATIC BRAIN INJURY IN RABBIT	ACTA NEUROLOGICA SCANDINAVICA			English	Article													Edvinsson, Lars/0000-0002-1805-1346			ANDEN NE, 1966, ACTA PHYSIOL SCAND, V67, P313, DOI 10.1111/j.1748-1716.1966.tb03318.x; ANDEN NE, 1963, LIFE SCI, P448; BERTLER A, 1961, ACTA PHYSIOL SCAND, V51, P75, DOI 10.1111/j.1748-1716.1961.tb02115.x; BERTLER AKE, 1958, K FYSIOGR SALLSKAPETS I LUND FORHANDL, V28, P121; BOGDANSKI DF, 1956, J PHARMACOL EXP THER, V117, P82; EDVINSSON L, IN PRESS; HAGGENDAL J, 1963, ACTA PHYSIOL SCAND, V59, P242, DOI 10.1111/j.1748-1716.1963.tb02739.x; OWMAN C, 1970, BRAIN RES, V18, P469, DOI 10.1016/0006-8993(70)90130-7; OWMAN C, IN PRESS	9	12	12	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.		1971	47	4					458	+		10.1111/j.1600-0404.1971.tb07500.x			1	Clinical Neurology	Neurosciences & Neurology	K2750	WOS:A1971K275000007	5123487				2021-06-18	
J	OLSSON, Y; RINDER, L; LINDGREN, S; STALHAMMAR, D				OLSSON, Y; RINDER, L; LINDGREN, S; STALHAMMAR, D			STUDIES ON VASCULAR PERMEABILITY CHANGES IN EXPERIMENTAL BRAIN CONCUSSION .3. COMPARISON BETWEEN EFFECTS OF SINGLE AND REPEATED SUDDEN MECHANICAL LOADING OF BRAIN	ACTA NEUROPATHOLOGICA			English	Article																COURVILLE CB, 1953, COMMOTIO CEREBRI; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GUTH L, 1968, EXP NEUROL, V22, P590, DOI 10.1016/0014-4886(68)90151-9; HAMBERGER A, 1966, Z ZELLFORSCH MIK ANA, V70, P386, DOI 10.1007/BF00336504; HOGDSON VR, 1968, THESIS WAYNE STATE U; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; RINDER L, 1969, ACTA PHYSIOL SCAND, V76, P352, DOI 10.1111/j.1748-1716.1969.tb04478.x; RINDER L, 1968, ACTA NEUROPATHOL, V11, P201; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; SPILLANE JD, 1962, BRIT MED J, P1205; STEINWALL O, 1965, ACTA NEUROL SCAN S13, pR31; UNTERHARNSCHEIDT F, 1971, FORTSCHR NEUROL P I, V39, P109; Unterharnscheidt F, 1963, GEDECKTEN SCHADEN GE; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561	17	12	12	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.		1971	19	3					225	+		10.1007/BF00684599			1	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	L1513	WOS:A1971L151300005	5134158				2021-06-18	
J	MASTAGLIA, FL; SAVAS, S; KAKULAS, BA				MASTAGLIA, FL; SAVAS, S; KAKULAS, BA			INTRACRANIAL THROMBOSIS OF INTERNAL CAROTID ARTERY AFTER CLOSED HEAD INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article												Bozbas, Serife Savas/AAI-8064-2021	Bozbas, Serife Savas/0000-0002-7230-202X			BERAUD R, 1966, CAN MED ASSOC J, V94, P537; CALDWELL HW, 1948, ANN INTERN MED, V28, P1132, DOI 10.7326/0003-4819-28-6-1132; CLARKE PRR, 1955, BRIT J SURG, V43, P215, DOI 10.1002/bjs.18004317816; Colledge L, 1917, LANCET, V1, P57; FISHER CM, 1951, ARCH NEUROL PSYCHIAT, V65, P346; FISHER M, 1954, AMA ARCH NEUROL PSY, V72, P187, DOI 10.1001/archneurpsyc.1954.02330020055006; FISHER RG, 1959, JAMA-J AM MED ASSOC, V170, P1918, DOI 10.1001/jama.1959.63010160001010; FRANTZEN E, 1961, NEUROLOGY, V11, P695, DOI 10.1212/WNL.11.8.695; GURDJIAN ES, 1963, J NEUROSURG, V20, P418, DOI 10.3171/jns.1963.20.5.0418; HOCKADAY TDR, 1959, J NEUROL NEUROSUR PS, V22, P229, DOI 10.1136/jnnp.22.3.229; HOUCK WS, 1964, ANN SURG, V159, P219, DOI 10.1097/00000658-196402000-00006; HUGHES JT, 1968, J NEUROL NEUROSUR PS, V31, P307, DOI 10.1136/jnnp.31.4.307; HUMPHREY JG, 1960, BRAIN, V83, P565, DOI 10.1093/brain/83.4.565; LAWRENCE KB, 1948, AM J SURG, V76, P29, DOI 10.1016/S0002-9610(48)90181-0; LUESSENHOP AJ, 1959, J NEUROSURG, V16, P705, DOI 10.3171/jns.1959.16.6.0705; Makins GH, 1916, LANCET, V2, P543; MILLER JDR, 1967, RADIOLOGY, V89, P95, DOI 10.1148/89.1.95; MURPHEY F, 1959, J NEUROSURG, V16, P1, DOI 10.3171/jns.1959.16.1.0001; MURRAY DS, 1957, BRIT J SURG, V44, P556, DOI 10.1002/bjs.18004418803; PAILLAS JE, 1955, THROMBOSES CAROTIDE; PEARCE GW, 1969, PERSONAL COMMUNICATI; PEERLESS SJ, 1967, CAN MED ASSOC J, V97, P247; PITNER SE, 1966, NEW ENGL J MED, V274, P764, DOI 10.1056/NEJM196604072741403; RALPH LL, 1954, J FAC RADIOL-LONDON, V5, P210, DOI 10.1016/S0368-2242(54)80032-7; RANEY AA, 1948, ARCH NEURO PSYCHIATR, V60, P425, DOI 10.1001/archneurpsyc.1948.02310050002001; SCHNEIDER RC, 1952, J NEUROSURG, V9, P495, DOI 10.3171/jns.1952.9.5.0495; SEDZIMIR CB, 1955, J NEUROL NEUROSUR PS, V18, P293, DOI 10.1136/jnnp.18.4.293; THERKELSEN J, 1963, CIRCULATION, V28, P101, DOI 10.1161/01.CIR.28.1.101; THOMSON JLG, 1963, BRIT J RADIOL, V36, P840, DOI 10.1259/0007-1285-36-431-840; TOAKLEY G, 1965, Aust N Z J Surg, V34, P261, DOI 10.1111/j.1445-2197.1965.tb04371.x; VERBIEST H, 1969, FOLIA PSYCHIAT NEERL, V62, P371	31	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1969	32	5					383	+		10.1136/jnnp.32.5.383			1	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	E6019	WOS:A1969E601900003	5360046	Bronze, Green Published			2021-06-18	
J	YARNELL, P; OMMAYA, AK				YARNELL, P; OMMAYA, AK			EXPERIMENTAL CEREBRAL CONCUSSION IN RHESUS MONKEY	BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE			English	Article																Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1956, PERSONAL COMMUNICATI; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; Ommaya A, 1966, 10 P STAPP CAR CRASH, P197; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211	8	12	12	0	1	NEW YORK ACAD MEDICINE	NEW YORK	1216 FIFTH AVE, NEW YORK, NY 10029	0028-7091			B NEW YORK ACAD MED	Bull. N. Y. Acad. med.		1969	45	1					39	&					0	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	C3685	WOS:A1969C368500004	4977441				2021-06-18	
J	Schaller, WF; Tamaki, K; Newman, HW				Schaller, WF; Tamaki, K; Newman, HW			Petechial hemorrhages of the brain - Experimentally produced in rats by concussion	ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article									Stanford Univ, Sch Med, Dept Neuropsychiat, San Francisco, CA USA							DURET H, 1877, GAZ MED PARIS, V6, P598; DURET H, 1877, GAZ MED PARIS, V6, P624; DURET H, 1877, GAZ MED PARIS, V6, P612; JAKOB A, 1913, HISTOLOGISCHE HISTOP, V5, P182; Ricker G, 1919, VIRCHOWS ARCH A, V226, P180, DOI 10.1007/BF02039959; Schaller WF, 1939, J AMER MED ASSOC, V113, P1779; Schaller WT, 1937, ARCH NEURO PSYCHIATR, V37, P1048, DOI 10.1001/archneurpsyc.1937.02260170076004; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470	8	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0096-6754			ARCH NEURO PSYCHIATR		JAN	1941	45	1					1	23					23	Psychiatry	Psychiatry	V23XK	WOS:000201615600001					2021-06-18	
J	Dixon, KC				Dixon, KC			Mechanism of cerebral concussion	LANCET			English	Article																Dixon KC, 1940, BRAIN, V63, P191, DOI 10.1093/brain/63.2.191; Greenfield J G, 1938, Proc R Soc Med, V32, P43; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Trotter W, 1925, LANCET, V2, P953	4	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1940	2						360	360					1	Medicine, General & Internal	General & Internal Medicine	V9610	WOS:000188728700263					2021-06-18	
J	Ferraro, A				Ferraro, A			Experimental medullary concussion of the spinal cord in rabbits - Histologic study of the early stages	ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article									St Elizabeths Hosp, Washington, DC USA							CLAUDE, 1915, AM MED, V11, P479; CORNIL L, 1921, THESIS PARIS; DABUNDO G, 1916, RIV ITAL NEUROPAT, V9, P145; DELISI L, 1915, RIV SPER FRENIATR, V41, P249; DUMENIL, 1885, ARCH NEUROL, V9, P149; FERRARO A, 1922, CERVELLO ANNO, V1, P361; FRAZIER CH, 1921, SURG SPINAL CORD NEW; GUILLAIN G, 1921, TRAUVAUX NEUROLOGIQU; HARTMANN, 1900, JB PSYCHIAT, V19, P380; Hassin GB, 1925, ARCH NEURO PSYCHIATR, V13, P369, DOI 10.1001/archneurpsyc.1925.02200090083003; JAKOB A, 1919, Z GES NEUROL PSYCH, V51, P297; KIRCHGASSER G, 1897, DTSCH Z NERVENH, V2, P400; LAQUER, 1915, MONATSCHR PSYCHIAT N, V29, P35; LAX, 1898, DTSCH Z NERVENHEILKU, V12, P333; MAIRET, 1918, REV NEUROL, V35, P97; MAIRET, 1918, REV NEUROL, V35, P228; MAIRET, 1918, REV NEUROL, V35, P110; MARBURG, 1921, DTSCH Z NERVENHEILK, V70, P10; Mussen A, 1916, REV NEUROL PSYCHIAT, V14, P417; ROSSI O, 1921, TIPOGRAFIA SASSARESE; SCHMAUS H, 1901, VORLESUNGEN PATHOLOG; Schterbach H., 1907, ENCEPHALE V, V2, P521; SOUQUES, 1916, REV NEUROL, V29, P101; Spatz H, 1920, Z GESAMTE NEUROL PSY, V58, P327, DOI 10.1007/BF02902040; SPILLER WG, 1903, M B, V15, P483; TODDE G, 1907, RIV SPER FRENIATR, V33, P751; TROMMER, 1915, NEUROL CENTRALBL, V34, P617; WARRINGTON, 1910, REV NEUROL PSYCHIAT, V8, P271	28	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0096-6754			ARCH NEURO PSYCHIATR		SEP	1927	18	3					357	373		10.1001/archneurpsyc.1927.02210030037003			17	Psychiatry	Psychiatry	V23UG	WOS:000201607400003					2021-06-18	
J	Lara-Reyna, J; Yaeger, KA; Rossitto, CP; Camara, D; Wedderburn, R; Ghatan, S; Bederson, JB; Margetis, K				Lara-Reyna, Jacques; Yaeger, Kurt A.; Rossitto, Christina P.; Camara, Divaldo; Wedderburn, Raymond; Ghatan, Saadi; Bederson, Joshua B.; Margetis, Konstantinos			"Staying Home"-Early Changes in Patterns of Neurotrauma in New York City During the COVID-19 Pandemic	WORLD NEUROSURGERY			English	Article						Coronavirus; COVID-19; Trauma; Traumatic brain injury		OBJECTIVE: New York City is the epicenter of the novel coronavirus disease 2019 (COVID-19) pandemic in the United States. Traumatic brain injury accounts for a significant proportion of admissions to our trauma center. We sought to characterize the effect of the pandemic on neurotraumas, given the cancellation of nonessential activities during the crisis. METHODS: Retrospective and prospective reviews were performed from November 2019 to April 2020. General demographics, clinical status, mechanism of trauma, diagnosis, and treatment instituted were recorded. We dichotomized the data between pre-COVID-19 (before 1 March) and COVID-19 periods and compared the differences between the 2 groups. We present the timeline of events since the beginning of the crisis in relation to the number of neurotraumas. RESULTS: A total of 150 patients composed our cohort with a mean age of 66.2 years (standard deviation 18.9), and 66% were male. More males sustained neurotrauma in the COVID-19 period compared with the pre-COVID-19 (60.4% vs. 77.6%, P = 0.03). The most common mechanism of trauma was mechanical fall, but it was observed less frequently compared with the pre-COVID-19 period (61.4% vs. 40.8; P = 0.03). Subdural hematoma, traumatic subarachnoid hemorrhage, and intracerebral contusion accounted for the most common pathologies in both periods. Nonoperative management was selected for most patients (79.2 vs. 87.8%, P = 0.201) in both periods. CONCLUSIONS: A decrease in the frequency of neurotraumas was observed during the COVID-19 crisis concomitant with the increase in COVID-19 patients in the city. This trend began after the cancellation of nonessential activities and implementation of social distancing recommendations.	[Lara-Reyna, Jacques; Yaeger, Kurt A.; Rossitto, Christina P.; Camara, Divaldo; Ghatan, Saadi; Bederson, Joshua B.; Margetis, Konstantinos] Icahn Sch Med Mt Sinai, Dept Neurol Surg, New York, NY 10029 USA; [Wedderburn, Raymond] Mt Sinai Morningside, Dept Surg, New York, NY USA	Lara-Reyna, J (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol Surg, New York, NY 10029 USA.	jacques.lara.r@gmail.com		Lara-Reyna, Jacques/0000-0003-2762-6460			Ahmed F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5446-1; [Anonymous], 2020, LANCET INFECT DIS, V20, P383, DOI 10.1016/S1473-3099(20)30180-8; [Anonymous], 2019, TRAUM BRAIN INJ US E; [Anonymous], PAND VIOL WOM CHILDR; [Anonymous], MOT VEH FAT RAT 14 P; Bradbury-Jones C, 2020, J CLIN NURS, V29, P2047, DOI 10.1111/jocn.15296; Burke JF, 2020, NEUROSURGERY, V87, pE50, DOI 10.1093/neuros/nyaa116; Calvert S, 2020, WSJ ONLINE; Chadra K, MOTOR VEHICLE FATALI; Christey G, 2020, NEW ZEAL MED J, V133, P81; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; DeBlasio Mayor, 2020, NYC HLTH THORN HOSP; Ducharme J, 2020, TIME; DYER O, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1846; Farrell TW, 2020, J AM GERIATR SOC, V68, P1143, DOI 10.1111/jgs.16539; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Goldstein Joseph, 2020, NY TIMES; Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0; Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1; Mazza M, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113046; Richards C, 2017, AM J PHYS MED REHAB, V96, pS124, DOI 10.1097/PHM.0000000000000620; Sen-Crowe B, 2020, AM J EMERG MED, V38, P1519, DOI 10.1016/j.ajem.2020.03.063; Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889; Tan YT, 2020, CURR MED SCI, V40, P281, DOI 10.1007/s11596-020-2173-5; Usher K, 2020, INT J MENT HEALTH NU, V29, P549, DOI 10.1111/inm.12735; Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383; Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020; Zoia C, 2020, ACTA NEUROCHIR, V162, P1221, DOI 10.1007/s00701-020-04305-w	29	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	NOV	2020	143						E344	E350		10.1016/j.wneu.2020.07.155			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	OS2GK	WOS:000589984400038	32730975	Bronze, Green Published			2021-06-18	
J	Baksaas-Aasen, K; Gall, LS; Stensballe, J; Juffermans, NP; Curry, N; Maegele, M; Brooks, A; Rourke, C; Gillespie, S; Murphy, J; Maroni, R; Vulliamy, P; Henriksen, HH; Pedersen, KH; Kolstadbraaten, KM; Wirtz, MR; Kleinveld, DJB; Schafer, N; Chinna, S; Davenport, RA; Naess, PA; Goslings, JC; Eaglestone, S; Stanworth, S; Johansson, PI; Gaarder, C; Brohi, K				Baksaas-Aasen, K.; Gall, L. S.; Stensballe, J.; Juffermans, N. P.; Curry, N.; Maegele, M.; Brooks, A.; Rourke, C.; Gillespie, S.; Murphy, J.; Maroni, R.; Vulliamy, P.; Henriksen, H. H.; Pedersen, K. Holst; Kolstadbraaten, K. M.; Wirtz, M. R.; Kleinveld, D. J. B.; Schaefer, N.; Chinna, S.; Davenport, R. A.; Naess, P. A.; Goslings, J. C.; Eaglestone, S.; Stanworth, S.; Johansson, P. I.; Gaarder, C.; Brohi, K.			Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial	INTENSIVE CARE MEDICINE			English	Article						Trauma; Haemorrhage; Coagulopathy; Thrombelastography; Thromboelastometry	BRAIN-INJURY; RAPID THROMBELASTOGRAPHY; RESUSCITATION; COAGULOPATHY; TRANSFUSION; MORTALITY; DEFINITION; MANAGEMENT; PLASMA	Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs). Methods This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI). Results Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34). Conclusion There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.	[Baksaas-Aasen, K.; Kolstadbraaten, K. M.; Naess, P. A.; Gaarder, C.] Oslo Univ Hosp, Oslo, Norway; [Baksaas-Aasen, K.; Kolstadbraaten, K. M.; Naess, P. A.; Gaarder, C.] Univ Oslo, Oslo, Norway; [Gall, L. S.; Rourke, C.; Gillespie, S.; Vulliamy, P.; Davenport, R. A.; Eaglestone, S.; Brohi, K.] Queen Mary Univ London, Blizard Inst, Ctr Trauma Sci, 4 Newark St, London E1 2AT, England; [Stensballe, J.; Henriksen, H. H.; Pedersen, K. Holst; Johansson, P. I.] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark; [Juffermans, N. P.; Wirtz, M. R.; Kleinveld, D. J. B.; Goslings, J. C.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Curry, N.; Stanworth, S.] Oxford Univ Hosp NHS Trust, Oxford, England; [Maegele, M.; Schaefer, N.] Univ Witten Herdecke, Cologne Merheim Med Ctr, Cologne, Germany; [Brooks, A.; Chinna, S.] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Murphy, J.; Maroni, R.] Queen Mary Univ London, London, England; [Stanworth, S.] NHS Blood & Transplant, Bristol, Avon, England	Brohi, K (corresponding author), Queen Mary Univ London, Blizard Inst, Ctr Trauma Sci, 4 Newark St, London E1 2AT, England.	k.brohi@qmul.ac.uk	Baksaas-Aasen, Kjersti/AAP-4957-2021; Maroni, Roberta/K-7044-2019	Baksaas-Aasen, Kjersti/0000-0002-1140-8939; Maroni, Roberta/0000-0001-6420-2881; Johansson, Par Ingemar/0000-0001-9778-5964; Hee Henriksen, Hanne/0000-0003-1323-9718	European Commission under the FP7 framework [F3-2013-602771]	The study was part of the "Targeted Action for Curing Trauma-Induced Coagulopathy" (TACTIC) program, funded by the European Commission under the FP7 framework (Grant No. F3-2013-602771). Both TEM (R) International GmbH and Haemonetics (R) Corporation were collaborating organizations in the TACTIC program. For this ITACTIC study, they provided the ROTEM Sigma and TEG 6S analyzers and all reagents to the relevant participating institutions. Neither these organizations nor any of their representatives had any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afshari A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007871.pub2; [Anonymous], 2011, LANCET, V377; [Anonymous], 2016, NICE RECOMMENDATIONS; Asehnoune K, 2017, INTENS CARE MED, V43, P1340, DOI 10.1007/s00134-017-4895-9; Baksaas-Aasen K, 2019, ANN SURG, V270, P1178, DOI 10.1097/SLA.0000000000002825; Baksaas-Aasen K, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2224-9; Balvers K, 2017, BRIT J SURG, V104, P222, DOI 10.1002/bjs.10330; Brohi K, 2019, INTENS CARE MED, V45, P709, DOI 10.1007/s00134-019-05560-x; Chesnut R, 2020, INTENS CARE MED, V46, P919, DOI 10.1007/s00134-019-05900-x; Cole Elaine, 2021, Ann Surg, V273, P1215, DOI 10.1097/SLA.0000000000003657; Da Luz LT, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0518-9; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Einersen PM, 2017, J TRAUMA ACUTE CARE, V82, P114, DOI 10.1097/TA.0000000000001270; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Hagemo JS, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0823-y; Hawryluk GWJ, 2019, INTENS CARE MED, V45, DOI 10.1007/s00134-019-05805-9; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Hunt H, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010438.pub2; Johansson PI, 2013, TRANSFUSION, V53, P3088, DOI 10.1111/trf.12214; Khan S, 2015, INTENS CARE MED, V41, P239, DOI 10.1007/s00134-014-3584-1; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Roberts I, 2019, LANCET, V394, P1713, DOI 10.1016/S0140-6736(19)32233-0; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Veigas PV, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0308-2; Winearls J, 2016, ANESTH ANALG, V123, P910, DOI 10.1213/ANE.0000000000001516	31	11	11	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JAN	2021	47	1					49	59		10.1007/s00134-020-06266-1		OCT 2020	11	Critical Care Medicine	General & Internal Medicine	PO2FJ	WOS:000578323800001	33048195	Green Published, Other Gold			2021-06-18	
J	Gauvin-Lepage, J; Friedman, D; Grilli, L; Sufrategui, M; De Matteo, C; Iverson, GL; Gagnon, I				Gauvin-Lepage, Jerome; Friedman, Debbie; Grilli, Lisa; Sufrategui, Maria; De Matteo, Carol; Iverson, Grant L.; Gagnon, Isabelle			Effectiveness of an Exercise-Based Active Rehabilitation Intervention for Youth Who Are Slow to Recover After Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						children and adolescent; post-concussion; trauma; active rehabilitation; exercise-based approach	TRAUMATIC BRAIN-INJURY; GENERIC CORE SCALES; MILD HEAD-INJURY; PHYSICAL-ACTIVITY; POSTCONCUSSION SYNDROME; MISERABLE MINORITY; RANDOMIZED-TRIAL; RISK-FACTORS; CHILDREN; SPORT	Objective: (1) To determine the impact of providing participants aged 8 to 17 years who are slow to recover after a concussion with a well-developed active rehabilitation intervention (ARI), compared with receiving standard care alone, on postconcussion symptoms (PCS) at 2 and 6 weeks after the initiation of ARI; and (2) to investigate functional recovery 6 weeks after initiation of ARI. Design: A multicenter prospective quasi-experimental control group design. Setting: Tertiary care pediatric trauma center and community health care providers. Participants: Forty-nine youth were enrolled (experimental n = 36; control n = 13). Procedures: Participants were assessed on 3 different occasions: (1) initial visit (baseline); (2) 2 weeks; and (3) 6 weeks after enrollment. Main Outcome Measures: Child- and parent-reported PCS were obtained by the PCS Inventory Scale (primary outcome). Secondary outcomes included: (1) mood and anxiety; (2) quality of life; (3) energy level; (4) coordination and balance; (5) neurocognition; (6) parental anxiety; and (7) satisfaction with intervention. Results: Both groups reported decrease of PCS over time (child:P= 0.01; parent:P= 0.03). Children in the experimental group presented higher quality of life (P= 0.04) and less anger (P= 0.02). A trend toward significance was observed for better tandem gait (P= 0.07) and for less general fatigue on self-reported PCS (P= 0.09) in the experimental group. Conclusions: Active rehabilitation intervention does not affect the PCS beyond the usual management, but it increases their quality of life, decreases anger, and potentially increases energy level and balance.	[Gauvin-Lepage, Jerome] Univ Montreal, Fac Nursing, Montreal, PQ, Canada; [Gauvin-Lepage, Jerome] St Justine Univ Hosp, Res Ctr, Montreal, PQ, Canada; [Friedman, Debbie] McGill Univ, Montreal Childrens Hosp Trauma Ctr, Hlth Ctr, Montreal, PQ, Canada; [Friedman, Debbie] Hlth Canada, Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada; [Friedman, Debbie] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; [Friedman, Debbie] McGill Univ, Fac Med, Dept Pediat Surg, Montreal, PQ, Canada; [Friedman, Debbie] McGill Univ, Fac Med, Student Affairs, Montreal, PQ, Canada; [Grilli, Lisa; Sufrategui, Maria] McGill Univ, Montreal Childrens Hosp Trauma Ctr, Hlth Ctr, MTBI Program & Concuss Clin, Montreal, PQ, Canada; [De Matteo, Carol] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [De Matteo, Carol; Iverson, Grant L.] CanChild Ctr Childhood Disabil Res, Hamilton, ON, Canada; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] MassGen Hosp Children Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Gagnon, Isabelle] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp Trauma Ctr, Kids & Teens Concuss Res Lab, Hlth Ctr, Montreal, PQ, Canada	Gauvin-Lepage, J (corresponding author), Univ Montreal, Montreal, PQ H1T 1C9, Canada.	jerome.gauvin-lepage@umontreal.ca			Fonds de recherche du Quebec-SanteFonds de la Recherche en Sante du Quebec; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Research Institute of the McGill University Health Centre	The authors thank the cooperation of the Montreal Children's Hospital Trauma Centre, McGill University Health Centre's MTBI Program and Concussion Clinic, and the CanChild Research Center at McMaster University. They also thank the "Fonds de recherche du Quebec-Sante," the Canadian Institutes for Health Research, as well as the Research Institute of the McGill University Health Centre for their financial support of this work.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Bruininks BD, 2006, BRUININKS OSERETSKY; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Crocker PRE, 1997, MED SCI SPORT EXER, V29, P1344, DOI 10.1097/00005768-199710000-00011; Gadoury M, 2001, CADRE REFERENCE CLIN; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Imhoff S, 2016, J SPORTS MED, V2016, P5127374, DOI DOI 10.1155/2016/5127374; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Ministere de la Sante et des Services Sociaux, 1999, CONT SERV PERS AYANT; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mrazik M, 2016, ARCH CLIN NEUROPSYCH, V31, P297, DOI 10.1093/arclin/acw013; Novak Z, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.2900; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Pardini D., 2004, BR J SPORTS MED, V38, P661; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Salum GA, 2017, J CHILD PSYCHOL PSYC, V58, P595, DOI 10.1111/jcpp.12659; Sariaslan A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002103; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Spielberger C, 2010, CORSINI ENCY PSYCHOL, V1; Steer, 2005, BECK YOUTH INVENTORI; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2004, J DEV BEHAV PEDIATR, V25, P10, DOI 10.1097/00004703-200402000-00002; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2010, INT STAT CLASS DIS R; Zemek R., 2014, GUIDELINES DIAGNOSIN	56	11	11	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2020	30	5					423	432		10.1097/JSM.0000000000000634			10	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	NX9CH	WOS:000575999300018	30095507				2021-06-18	
J	Nasution, RA; Islam, AA; Hatta, M; Prihantono; Turchan, A; Nasrullah; Faruk, M				Nasution, Rizha Anshori; Islam, Andi Asadul; Hatta, Mochammad; Prihantono; Turchan, Agus; Nasrullah; Faruk, Muhammad			Role of CAPE in reducing oxidative stress in animal models with traumatic brain injury	ANNALS OF MEDICINE AND SURGERY			English	Article						Traumatic brain injury; F2-isoprostane; Oxidative stress	ACID PHENETHYL ESTER; ANTIOXIDANT ACTIVITY; F-2-ISOPROSTANES; F-4-NEUROPROSTANES; NEUROPROSTANES; ISOPROSTANES; INFLAMMATION; TISSUE	Introduction: The central nervous system (CNS) is the most metabolically active organ characterized by high oxygen demand and relatively low anti-oxidative activity, which makes neurons and glia highly susceptible to damage by reactive oxygen and nitrogen byproducts as well as neurodegeneration. Free radicals are associated with secondary injuries that occur after a primary brain injury. Some of these free radical products include F2Isoprostane (F2-IsoPs), malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) and acrolein. Methods: In this study we measured serum F2-IsoPs levels as markers of free radical activity in 10-12 week-old male Sprague-Dawley rats weighing 200-300 g, all rats (n = 10) subjected with a head injury according to the modified marmourou model, then divided into 2 groups, one group treated with CAPE (Caffeic Acid Phenethyl Ester) (n = 5) and the other not treated with CAPE (n = 5), serum levels in the two groups were compared starting from day-0 (before brain injury), day-4 and day-7. Results: We found lower F2-IsoPs levels in the group that received the CAPE treatment compared to the group that did not receive the CAPE treatment. Conclusion: CAPE is capable of significantly reducing oxidative stress in brain injury.	[Nasution, Rizha Anshori] Pelamonia Hosp, Dept Neurosurg, Jalan Jend Sudirman 27, Makassar 90157, Indonesia; [Nasution, Rizha Anshori] Hasanuddin Univ, Fac Med, Doctoral Program Biomed Sci, Makassar, Indonesia; [Islam, Andi Asadul; Nasrullah] Hasanuddin Univ, Fac Med, Dept Neurosurg, Makassar, Indonesia; [Hatta, Mochammad] Hasanuddin Univ, Fac Med, Clin Microbiologist Program, Makassar, Indonesia; [Prihantono; Faruk, Muhammad] Hasanuddin Univ, Dept Surg, Fac Med, Makassar, Indonesia; [Turchan, Agus] Airlangga Univ, Fac Med, Dept Neurosurg, Surabaya, Indonesia	Nasution, RA (corresponding author), Pelamonia Hosp, Dept Neurosurg, Jalan Jend Sudirman 27, Makassar 90157, Indonesia.	rizha_nst@yahoo.com; andiasadul@yahoo.com; hattaram@yahoo.com; prihantono.md@gmail.com; agusturchan@gmail.com; nasrullah.makassar@gmail.com; faroex8283@gmail.com	Hatta, Mochammad/D-3742-2019	Hatta, Mochammad/0000-0002-8456-4203; Prihantono, Prihantono/0000-0002-8247-0457; Faruk, Muhammad/0000-0002-7079-4585			Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Garcia-Flores LA, 2016, FREE RADICAL RES, V50, P485, DOI 10.3109/10715762.2015.1111514; Aloutaibi G. T., 2017, African Journal of Traditional, Complementary and Alternative Medicines, V14, P138, DOI 10.21010/ajtcam.v14i5.17; Ayla S, 2018, ACTA HISTOCHEM, V120, P117, DOI 10.1016/j.acthis.2018.01.001; Branton A., 2017, INT J CLIN DEV ANATO, V3, P9; Cetin A, 2019, FOLIA MORPHOL, V78, P221, DOI 10.5603/FM.a2018.0085; Chu JJ, 2015, ENVIRON TOXICOL PHAR, V39, P683, DOI 10.1016/j.etap.2015.01.020; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dunn JD, 2015, REDOX BIOL, V6, P472, DOI 10.1016/j.redox.2015.09.005; Foret MK, 2019, FREE RADICAL BIO MED, V130, P471, DOI 10.1016/j.freeradbiomed.2018.11.019; Galano JM, 2017, PROG LIPID RES, V68, P83, DOI 10.1016/j.plipres.2017.09.004; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Khoubnasabjafari M, 2015, BIOIMPACTS, V5, P123, DOI 10.15171/bi.2015.20; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; McCullough PA, 2016, THROMB RES, V148, P85, DOI 10.1016/j.thromres.2016.10.022; Melton CD, 2017, ANN EPIDEMIOL, V27, P391, DOI 10.1016/j.annepidem.2017.05.005; Moosavi F, 2017, BIOORGAN MED CHEM, V25, P3233, DOI 10.1016/j.bmc.2017.04.026; Nasution RA, 2020, ANN MED SURG, V54, P89, DOI 10.1016/j.amsu.2020.04.015; Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5; Nikolaidis MG, 2011, PROG LIPID RES, V50, P89, DOI 10.1016/j.plipres.2010.10.002; Proudfoot JM, 2018, FREE RADICAL BIO MED, V126, P142, DOI 10.1016/j.freeradbiomed.2018.08.007; Proudfoot JM, 2016, FREE RADICAL RES, V50, P1374, DOI 10.1080/10715762.2016.1250262; Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012; Salmas RE, 2017, CELL BIOCHEM FUNCT, V35, P304, DOI 10.1002/cbf.3277; Schoneich C, 2017, FREE RADICAL BIO MED, V108, pS100, DOI 10.1016/j.freeradbiomed.2017.04.321; Signorini C, 2018, FREE RADICAL BIO MED, V115, P261, DOI 10.1016/j.freeradbiomed.2017.12.009; Stoiber W, 2015, BIOMOLECULES, V5, P702, DOI 10.3390/biom5020702; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Tolba MF, 2016, CRIT REV FOOD SCI, V56, P2183, DOI 10.1080/10408398.2013.821967; Wisniewski K, 2018, NEUROL NEUROCHIR POL, V52, P643, DOI 10.1016/j.pjnns.2018.09.009; Yen HC, 2015, FREE RADICAL RES, V49, P1419, DOI 10.3109/10715762.2015.1080363; Yen HC, 2015, FREE RADICAL RES, V49, P861, DOI 10.3109/10715762.2015.1014812	32	11	11	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2049-0801			ANN MED SURG	Ann. Med. Surg.	SEP	2020	57						118	122		10.1016/j.amsu.2020.07.036			5	Medicine, General & Internal	General & Internal Medicine	NO4BQ	WOS:000569430900027	32760580	Other Gold, Green Published			2021-06-18	
J	Neufeld, KJ; Leoutsakos, JMS; Yan, HJ; Lin, SH; Zabinski, JS; Dinglas, VD; Hosey, MM; Parker, AM; Hopkins, RO; Needham, DM				Neufeld, Karin J.; Leoutsakos, Jeannie-Marie S.; Yan, Haijuan; Lin, Shihong; Zabinski, Jeffrey S.; Dinglas, Victor D.; Hosey, Megan M.; Parker, Ann M.; Hopkins, Ramona O.; Needham, Dale M.			Fatigue Symptoms During the First Year Following ARDS	CHEST			English	Article						acute lung injury; cognitive function; depression; disability; rehabilitation	RESPIRATORY-DISTRESS-SYNDROME; CANCER-RELATED FATIGUE; POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; FUNCTIONAL PERFORMANCE INVENTORY; MINI-MENTAL-STATE; ACUTE LUNG INJURY; CRITICAL ILLNESS; HOSPITAL ANXIETY; SURVIVORS	BACKGROUND: Fatigue is commonly reported by ARDS survivors, but empirical data are scarce. RESEARCH QUESTION: This study evaluated fatigue prevalence and associated variables in a prospective study of ARDS survivors. STUDY DESIGN AND METHODS: This analysis is part of the ARDSNet Long-Term Outcomes Study (ALTOS) conducted at 38 US hospitals. Using ageand sex-adjusted, time-averaged random effects regression models, we evaluated associations between the validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale with patient and critical illness variables, and with physical, cognitive, and mental health status at 6 and 12 months following ARDS. RESULTS: Among ARDS survivors, 501 of 711 (70%) and 436 of 659 (66%) reported clinically significant symptoms of fatigue at 6 and 12 months, respectively, with 41% and 28% reporting clinically important improvement and worsening (n 1/4 638). At 6 months, the prevalence of fatigue (70%) was greater than that of impaired physical functioning (50%), anxiety (42%), and depression (36%); 46% reported both impaired physical function and fatigue, and 27% reported co-existing anxiety, depression, and fatigue. Fatigue was less severe in men and in those employed prior to ARDS. Critical illness variables (eg, illness severity, length of stay) had little association with fatigue symptoms. Worse physical, cognitive, and mental health symptoms were associated with greater fatigue at both the 6and 12-month follow-up. INTERPRETATION: During the first year following ARDS, more than two-thirds of survivors reported clinically significant fatigue symptoms. Due to frequent co-occurrence, clinicians should evaluate and manage survivors' physical, cognitive, and mental health status when fatigue is endorsed.	[Neufeld, Karin J.; Leoutsakos, Jeannie-Marie S.; Yan, Haijuan; Lin, Shihong; Zabinski, Jeffrey S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Dinglas, Victor D.; Parker, Ann M.; Needham, Dale M.] Johns Hopkins Univ, Sch Med, Div Pulm & Pulm & Crit Care Med, Baltimore, MD USA; [Hosey, Megan M.; Needham, Dale M.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Neufeld, Karin J.; Leoutsakos, Jeannie-Marie S.; Hosey, Megan M.; Parker, Ann M.; Needham, Dale M.] Johns Hopkins Univ, Sch Med, Outcomes Crit Illness & Surg OACIS Grp, Baltimore, MD USA; [Hopkins, Ramona O.] Brigham Young Univ, Neurosci Ctr, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Intermt Healthcare, Pulm & Crit Care Med, Murray, KY USA; [Hopkins, Ramona O.] Intermt Med Ctr, Ctr Humanizing Crit Care, Murray, KY USA	Neufeld, KJ (corresponding author), Johns Hopkins Bayview Med Ctr, A4Ctr,Ste 457,4940 Eastern Ave, Baltimore, MD 21224 USA.	kneufel2@jh.edu	Zabinski, Jeffrey/AAC-6415-2021		National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R24 HL111895, R01HL091760, R01HL091760-02S1]; Johns Hopkins Institute for Clinical and Translational Research [UL1 TR 000424-06]; Albuterol for Treatment of Acute Lung Injury Trial (ALTA); Omega Nutrition Supplement Trial (OMEGA); Statins for Acutely Injured Lungs from Sepsis Trial (SAILS) [National Heart, Lung, and Blood Institute] [HHSN268200536165C, HHSN268200536166C, HHSN268200536167C, HHSN268200536168C, HHSN268200536169C, HHSN268200536170C, HHSN268200536171C, HHSN268200536172C, HHSN268200536173C, HHSN268200536174C, HHSN268200536175C, HHSN268200536176C, HHSN268200536179C]; Early Versus Delayed Enteral Nutrition Trial (EDEN)	This research was supported by the National Heart, Lung, and Blood Institute [Grants R24 HL111895, R01HL091760, and R01HL091760-02S1], the Johns Hopkins Institute for Clinical and Translational Research [Grant UL1 TR 000424-06], and the Albuterol for Treatment of Acute Lung Injury Trial (ALTA), Early Versus Delayed Enteral Nutrition Trial (EDEN), Omega Nutrition Supplement Trial (OMEGA), and Statins for Acutely Injured Lungs from Sepsis Trial (SAILS) [National Heart, Lung, and Blood Institute contracts HHSN268200536165C to HHSN268200536176C and HHSN268200536179C].	Acaster S, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0257-x; Azoulay E, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1887-7; Barroso J, 2020, J PAIN SYMPTOM MANAG, V59, P242, DOI 10.1016/j.jpainsymman.2019.09.009; Berger AM, 2015, CA-CANCER J CLIN, V65, P190, DOI 10.3322/caac.21268; Bienvenu OJ, 2013, CHEST, V144, P24, DOI 10.1378/chest.12-0908; Cella D, 2005, J RHEUMATOL, V32, P811; Cella D, 2002, J PAIN SYMPTOM MANAG, V24, P547, DOI 10.1016/S0885-3924(02)00529-8; Cella D, 2002, CANCER-AM CANCER SOC, V94, P528, DOI 10.1002/cncr.10245; Chaboyer Wendy, 2003, Nurs Crit Care, V8, P149, DOI 10.1046/j.1478-5153.2003.00020.x; Chan KS, 2016, GEN HOSP PSYCHIAT, V42, P32, DOI 10.1016/j.genhosppsych.2016.07.004; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Davydow DS, 2008, PSYCHOSOM MED, V70, P512, DOI 10.1097/PSY.0b013e31816aa0dd; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Dinglas VD, 2016, THORAX, V71, P401, DOI 10.1136/thoraxjnl-2015-208017; Ebede CC, 2017, MED CLIN N AM, V101, P1085, DOI 10.1016/j.mcna.2017.06.007; Escalante CP, 2009, J GEN INTERN MED, V24, P412, DOI 10.1007/s11606-009-1056-z; Finlayson M, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1367-6; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goertz YMJ, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619878128; Hamilton L.C, 2017, STAT STATA 15; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Khan F, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00177; Latronico N, 2017, INTENS CARE MED, V43, P1270, DOI 10.1007/s00134-017-4757-5; Leidy NK, 2012, INT J CHRONIC OBSTR, V7, P543, DOI 10.2147/COPD.S32032; Leidy NK, 1999, NURS RES, V48, P20, DOI 10.1097/00006199-199901000-00004; Lequerica AH, 2017, NEUROPSYCHOL REHABIL, V27, P1019, DOI 10.1080/09602011.2016.1231120; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; Mohandas H, 2017, J CANCER RES THER, V13, P916, DOI 10.4103/jcrt.JCRT_50_17; Needham DM, 2016, LANCET RESP MED, V4, P203, DOI 10.1016/S2213-2600(16)00005-9; Needham DM, 2013, BMJ, V346, pf1532, DOI DOI 10.1136/BMJ.F1532; Nguyen S, 2017, ARCH PHYS MED REHAB, V98, P1508, DOI 10.1016/j.apmr.2017.02.031; Nikayin S, 2016, GEN HOSP PSYCHIAT, V43, P23, DOI 10.1016/j.genhosppsych.2016.08.005; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Parker AM, 2015, CRIT CARE MED, V43, P1121, DOI 10.1097/CCM.0000000000000882; Pearson EJM, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2415-9; Perazzo JD, 2017, J HOSP PALLIAT NURS, V19, P124, DOI 10.1097/NJH.0000000000000329; Rabiee A, 2016, CRIT CARE MED, V44, P1744, DOI 10.1097/CCM.0000000000001811; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Spadaro S, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0554-z; Steenbergen S, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0121-x; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Tur C, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-016-0411-8; Ware JE., 2000, SCORE VERSION 2 SF 3; Wintermann GB, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0295-7; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	51	11	11	2	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0012-3692	1931-3543		CHEST	Chest	SEP	2020	158	3					999	1007		10.1016/j.chest.2020.03.059			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	NQ3ZD	WOS:000570802000011	32304774				2021-06-18	
J	Sasaki, Y; Engber, TM; Hughes, RO; Figley, MD; Wu, T; Bosanac, T; Devraj, R; Milbrandt, J; Krauss, R; DiAntonio, A				Sasaki, Yo; Engber, Thomas M.; Hughes, Robert O.; Figley, Matthew D.; Wu, Tong; Bosanac, Todd; Devraj, Rajesh; Milbrandt, Jeffrey; Krauss, Raul; DiAntonio, Aaron			cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons	EXPERIMENTAL NEUROLOGY			English	Article							SERUM NEUROFILAMENT LIGHT; TIR DOMAINS; CELL-DEATH; ACTIVATION; PROTEIN; INJURY; MICE; PREVENTION; PROTECTION; TRIGGERS	SARM1 is the central executioner of pathological axon degeneration, promoting axonal demise in response to axotomy, traumatic brain injury, and neurotoxic chemotherapeutics that induce peripheral neuropathy. SARM1 is an injury-activated NAD+ cleavage enzyme, and this NADase activity is required for the pro-degenerative function of SARM1. At present, SARM1 function is assayed by either analysis of axonal loss, which is far downstream of SARM1 enzymatic activity, or via NAD(+) levels, which are regulated by many competing pathways. Here we explored the utility of measuring cADPR, a product of SARM1-dependent cleavage of NAD(+), as an in cell and in vivo biomarker of SARM1 enzymatic activity. We find that SARM1 is a major producer of cADPR in cultured dorsal root ganglion (DRG) neurons, sciatic nerve, and brain, demonstrating that SARM1 has basal activity in the absence of injury. Following injury, there is a dramatic SARM1-dependent increase in the levels of axonal cADPR that precedes morphological axon degeneration. In vivo, there is also a rapid and large injury-stimulated increase in cADPR in sciatic and optic nerves. The increase in cADPR after injury is proportional to SARM1 gene dosage, suggesting that SARM1 activity is the prime regulator of cADPR levels. The role of cADPR as an important calcium mobilizing agent prompted exploration of its functional contribution to axon degeneration. We used multiple bacterial and mammalian engineered enzymes to manipulate cADPR levels in neurons but found no changes in the time course of axonal degeneration, suggesting that cADPR is unlikely to be an important contributor to the degenerative mechanism. Using cADPR as a SARM1 biomarker, we find that SARM1 can be partially activated by a diverse array of mitochondrial toxins administered at doses that do not induce axon degeneration. Hence, the subcritical activation of SARM1 induced by mitochondrial dysfunction may contribute to the axonal vulnerability common to many neurodegenerative diseases. Finally, we assay levels of both nerve cADPR and plasma neurofilament light chain (NfL) following nerve injury in vivo, and demonstrate that both biomarkers are excellent readouts of SARM1 activity, with cADPR reporting the early molecular changes in the nerve and NfL reporting subsequent axonal breakdown. The identification and characterization of cADPR as a SARM1 biomarker will help identify neurodegenerative diseases in which SARM1 contributes to axonal loss and expedite target validation studies of SARM1-directed therapeutics.	[Sasaki, Yo; Wu, Tong; Milbrandt, Jeffrey] Washington Univ, Genet, St Louis, MO 63110 USA; [Engber, Thomas M.; Hughes, Robert O.; Bosanac, Todd; Devraj, Rajesh; Krauss, Raul] Disarm Therapeut, Cambridge, MA 02142 USA; [Figley, Matthew D.; DiAntonio, Aaron] Washington Univ, Dev Biol, St Louis, MO 63110 USA; [Milbrandt, Jeffrey; DiAntonio, Aaron] Needleman Ctr Neurometab & Axonal Therapeut, St Louis, MO USA	Sasaki, Y; Milbrandt, J (corresponding author), Washington Univ, Genet, St Louis, MO 63110 USA.; Krauss, R (corresponding author), Disarm Therapeut, Cambridge, MA 02142 USA.; DiAntonio, A (corresponding author), Washington Univ, Dev Biol, St Louis, MO 63110 USA.	sasaki@wustl.edu; jmilbrandt@wustl.edu; rkrauss@disarmtx.com; diantonio@wustl.edu		Figley, Matthew/0000-0003-2125-829X; DiAntonio, Aaron/0000-0002-7262-0968	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG013730, NS087632, CA219866]	This work was supported by funds from the National Institutes of Health (AG013730 to J.M. and NS087632 & CA219866 to A.D. and J.M.).	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Benatar M, 2018, ANN NEUROL, V84, P130, DOI 10.1002/ana.25276; Cheng YL, 2019, DIABETES, V68, P2120, DOI 10.2337/db18-1233; DiAntonio A, 2019, PAIN, V160, pS17, DOI 10.1097/j.pain.0000000000001528; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Essuman K, 2018, CURR BIOL, V28, P421, DOI 10.1016/j.cub.2017.12.024; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Fliegert R, 2007, BIOCHEM SOC T, V35, P109, DOI 10.1042/BST0350109; Geisler S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129920; Geisler S, 2019, J EXP MED, V216, P294, DOI 10.1084/jem.20181040; Geisler S, 2016, BRAIN, V139, P3092, DOI 10.1093/brain/aww251; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Guse AH, 2015, BBA-PROTEINS PROTEOM, V1854, P1132, DOI 10.1016/j.bbapap.2014.12.015; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hikosaka K, 2014, J BIOL CHEM, V289, P14796, DOI 10.1074/jbc.M114.554378; Horsefield S, 2019, SCIENCE, V365, P793, DOI 10.1126/science.aax1911; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Liu HW, 2018, P NATL ACAD SCI USA, V115, P10654, DOI 10.1073/pnas.1809392115; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Loreto A, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104678; Marion CM, 2019, EXP NEUROL, V321, DOI 10.1016/j.expneurol.2019.113040; Ribeiro JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18393-9; Millecamps S, 2007, J NEUROSCI, V27, P4947, DOI 10.1523/JNEUROSCI.5299-06.2007; Neukomm LJ, 2017, NEURON, V95, P78, DOI 10.1016/j.neuron.2017.06.031; Olsson B, 2019, JAMA NEUROL, V76, P318, DOI 10.1001/jamaneurol.2018.3746; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Sako W, 2015, J NEUROL SCI, V352, P84, DOI 10.1016/j.jns.2015.03.041; Sandelius A, 2018, NEUROLOGY, V90, pE518, DOI 10.1212/WNL.0000000000004932; Sasaki Y, 2016, ELIFE, V5, DOI 10.7554/eLife.19749; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Sasaki Y, 2009, J NEUROSCI, V29, P5525, DOI 10.1523/JNEUROSCI.5469-08.2009; Summers DW, 2020, MOL NEUROBIOL, V57, P1146, DOI 10.1007/s12035-019-01796-2; Summers DW, 2014, J NEUROSCI, V34, P9338, DOI 10.1523/JNEUROSCI.0877-14.2014; Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09; Turkiew E, 2017, J PERIPHER NERV SYST, V22, P162, DOI 10.1111/jns.12219; Vargas ME, 2015, J NEUROSCI, V35, P15026, DOI 10.1523/JNEUROSCI.2484-15.2015; Wan L, 2019, SCIENCE, V365, P799, DOI 10.1126/science.aax1771; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Weston PSJ, 2017, NEUROLOGY, V89, P2167, DOI 10.1212/WNL.0000000000004667; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Zhao YJ, 2011, J BIOL CHEM, V286, P22170, DOI 10.1074/jbc.M111.228379; Zhao ZY, 2019, ISCIENCE, V15, P452, DOI 10.1016/j.isci.2019.05.001; Zhu XH, 2018, J MAGN RESON, V292, P155, DOI 10.1016/j.jmr.2018.05.005; Ziogas NK, 2018, J NEUROSCI, V38, P4031, DOI 10.1523/JNEUROSCI.2343-17.2018	48	11	11	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2020	329								113252	10.1016/j.expneurol.2020.113252			12	Neurosciences	Neurosciences & Neurology	LT0MX	WOS:000536772200005	32087251				2021-06-18	
J	Ashina, H; Iljazi, A; Al-Khazali, HM; Eigenbrodt, AK; Larsen, EL; Andersen, AM; Hansen, KJ; Brauner, KB; Morch-Jessen, T; Chaudhry, B; Antic, S; Christensen, CE; Ashina, M; Amin, FM; Schytz, HW				Ashina, Hakan; Iljazi, Afrim; Al-Khazali, Haidar Muhsen; Eigenbrodt, Anna Kristina; Larsen, Eigil Lindekilde; Andersen, Amalie Middelboe; Hansen, Kevin John; Brauner, Karoline Bendix; Morch-Jessen, Thomas; Chaudhry, Basit; Antic, Sonja; Christensen, Casper Emil; Ashina, Messoud; Amin, Faisal Mohammad; Schytz, Henrik Winther			Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study	JOURNAL OF HEADACHE AND PAIN			English	Article						Concussion; Secondary headache; Head trauma; Head injury; Clinical management	PAIN	Background Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and safety of erenumab for prevention of persistent PTH attributed to mild traumatic brain injury. Methods A single-center, non-randomized, single-arm, open-label study of erenumab for adults aged 18-65 years with persistent PTH. Patients were assigned to receive 140-mg erenumab monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks. The primary outcome measure was the mean change in number of monthly headache days of moderate to severe intensity from baseline (4-week pretreatment period) to week 9 through 12. Tolerability and safety endpoints were adverse events (i.e. number and type). Results Eighty-nine of 100 patients completed the open-label trial. At baseline, the mean monthly number of headache days of moderate to severe intensity was 15.7. By week 9 through 12, the number was reduced by 2.8 days. The most common adverse events were constipation (n = 30) and injection-site reactions (n = 15). Of 100 patients who received at least one dose of erenumab, two patients discontinued the treatment regimen due to adverse events. Conclusions Among patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in patients with persistent PTH.	[Ashina, Hakan; Iljazi, Afrim; Al-Khazali, Haidar Muhsen; Eigenbrodt, Anna Kristina; Larsen, Eigil Lindekilde; Andersen, Amalie Middelboe; Hansen, Kevin John; Brauner, Karoline Bendix; Morch-Jessen, Thomas; Chaudhry, Basit; Christensen, Casper Emil; Ashina, Messoud; Amin, Faisal Mohammad; Schytz, Henrik Winther] Univ Copenhagen, Fac Hlth & Med Sci, Rigshosp Glostrup, Danish Headache,Ctr Dept Neurol, Valdemar Hansens Vej 5, DK-2600 Glostrup, Denmark; [Antic, Sonja] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark	Schytz, HW (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Rigshosp Glostrup, Danish Headache,Ctr Dept Neurol, Valdemar Hansens Vej 5, DK-2600 Glostrup, Denmark.	henrik.winther.schytz.01@regionh.dk		Amin, Faisal Mohammad/0000-0003-3803-3599; Ashina, Hakan/0000-0002-6268-727X; Ashina, Messoud/0000-0003-0951-5804; Schytz, Henrik Winther/0000-0002-6262-2986; Christensen, Casper Emil/0000-0003-4906-9204	Novartis Healthcare A/S	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this Article: The study was supported by an investigator-initiated research grant from Novartis Healthcare A/S who also provided the study drug.	[Anonymous], 2018, Cephalalgia, V38, P1, DOI 10.1177/0333102417738202; Ashina H, 2020, CEPHALALGIA, V40, P554, DOI 10.1177/0333102420909865; Ashina H, 2019, NAT REV NEUROL, V15, P607, DOI 10.1038/s41582-019-0243-8; Ashina M, 2020, CEPHALALGIA, V40, P241, DOI 10.1177/0333102420905132; Ashina M, 2018, CEPHALALGIA, V38, P1611, DOI 10.1177/0333102418788347; Bree D, 2018, CEPHALALGIA, V38, P246, DOI 10.1177/0333102416681571; Charles A, 2019, LANCET, V394, P1765, DOI 10.1016/S0140-6736(19)32504-8; Cushman DM, 2019, HEADACHE, V59, P371, DOI 10.1111/head.13451; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Goadsby PJ, 2019, CEPHALALGIA, V39, P817, DOI 10.1177/0333102419835459; Goadsby PJ, 2017, NEW ENGL J MED, V377, P2123, DOI 10.1056/NEJMoa1705848; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Larsen EL, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1051-7; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Navratilova E, 2019, CEPHALALGIA, V39, P1762, DOI 10.1177/0333102419877662; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; Reuter U, 2018, LANCET, V392, P2280, DOI 10.1016/S0140-6736(18)32534-0; Silberstein SD, 2017, NEW ENGL J MED, V377, P2113, DOI 10.1056/NEJMoa1709038; Stauffer VL, 2018, JAMA NEUROL, V75, P1080, DOI 10.1001/jamaneurol.2018.1212; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053	21	11	11	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1129-2369	1129-2377		J HEADACHE PAIN	J. Headache Pain	JUN 3	2020	21	1							62	10.1186/s10194-020-01136-z			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	LY1XA	WOS:000540313500001	32493206	DOAJ Gold, Green Published			2021-06-18	
J	Keret, O; Hoang, TD; Xia, F; Rosen, HJ; Yaffe, K				Keret, Ophir; Hoang, Tina D.; Xia, Feng; Rosen, Howard J.; Yaffe, Kristine			Association of Late-Onset Unprovoked Seizures of Unknown Etiology With the Risk of Developing Dementia in Older Veterans	JAMA NEUROLOGY			English	Article							DIAGNOSED EPILEPTIC SEIZURES; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; EEG ALTERATIONS; POPULATION; MODEL	Importance The incidence of unprovoked seizures and epilepsy increases considerably in late life, with approximately one-third of seizures being of unknown etiology. While individuals with dementia have a high risk of developing unprovoked seizures, it is unknown whether older adults with late-onset unprovoked seizures of unknown etiology (LOSU) are at risk of developing dementia. Objective To determine whether incident LOSU is associated with a higher risk of dementia among older US veterans. Design, Setting, and Participants This retrospective multicenter cohort study was conducted using data from US Veterans Health Administration medical centers from October 2001 to September 2015. Data were generated from all veteran inpatient and outpatient encounters that occurred within Veterans Health Administration facilities. A random sample of 941 524 veterans 55 years and older was generated. A total of 649 262 veterans previously diagnosed (using International Classification of Diseases, Ninth Revision, Clinical Modification codes) with dementia, unprovoked seizures, epilepsy, and conditions that could lead to seizures (brain tumors, trauma, infections, stroke, and neurotoxin exposure) as well as veterans without follow-up data were excluded. Data were analyzed from October 2018 to July 2019. Exposures Late-onset unprovoked seizures of unknown etiology were defined as a new diagnosis of epilepsy or unprovoked seizures without a diagnosis of a secondary cause for seizures. Incident LOSU was assessed during a 5-year baseline period. Main Outcomes and Measures Veterans were assessed for incident dementia diagnosis during an outcome period. Fine-Gray proportional hazards models were used to determine whether LOSU was associated with greater risk of incident dementia. Models were adjusted for demographic variables, cardiovascular risk factors, depression, and traumatic brain injury. Results Of the 292 262 included veterans, 282 628 (96.7%) were male, and the mean (SD) age was 73.0 [8.8] years. During the baseline period, 2166 veterans developed LOSU. The mean (SD) follow-up after LOSU was 6.1 (2.9) years. After multivariable adjustment, veterans with LOSU had greater risk of dementia compared with veterans without seizures (hazard ratio, 1.89; 95% CI, 1.62-2.20). A sensitivity analysis imposing a 2-year lag between incident LOSU and dementia diagnosis led to similar results. Conclusions and Relevance These findings suggest LOSU in older veterans is associated with a 2-fold risk of developing dementia. While seizures are commonly thought to occur in late stages of dementia, these findings suggest unexplained seizures in older adults may be a first sign of neurodegenerative disease.	[Keret, Ophir; Rosen, Howard J.; Yaffe, Kristine] Univ Calif San Francisco, Global Brain Hlth Inst, San Francisco, CA 94158 USA; [Hoang, Tina D.; Xia, Feng; Yaffe, Kristine] San Francisco Vet Affairs Hlth Care Syst, San Francisco, CA USA; [Hoang, Tina D.; Xia, Feng; Yaffe, Kristine] Vet Hlth Res Inst, Northern Calif Inst Res & Educ, San Francisco, CA USA; [Rosen, Howard J.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94158 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA	Keret, O (corresponding author), Univ Calif San Francisco, Global Brain Hlth Inst, Sandler Neurosci Ctr, 675 Nelson Rising Ln,Ste 190, San Francisco, CA 94158 USA.	ophir.keret@gbhi.org			US Department of DefenseUnited States Department of Defense [W81XWH-12-PHTBI-CENC]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24 AG031155]; Sierra Pacific VISN Mental Illness Research, Education, and Clinical Centers	This research was supported by grant W81XWH-12-PHTBI-CENC from the US Department of Defense (Dr Yaffe), grant K24 AG031155 from the National Institute on Aging (Dr Yaffe), and the Sierra Pacific VISN Mental Illness Research, Education, and Clinical Centers (Dr Yaffe).	Acharya JN, 2014, ANN INDIAN ACAD NEUR, V17, pS18, DOI 10.4103/0972-2327.128645; Appel S, 2015, ACTA NEUROL SCAND, V131, P152, DOI 10.1111/ane.12304; Beghi E, 2019, LANCET NEUROL, V18, P357, DOI 10.1016/S1474-4422(18)30454-X; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Carter MD, 2007, J NEUROL SCI, V252, P169, DOI 10.1016/j.jns.2006.11.004; Chang TE, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003056; Cheng CH, 2015, EPILEPSY RES, V115, P63, DOI 10.1016/j.eplepsyres.2015.05.009; Costa C, 2019, NEUROBIOL AGING, V73, P61, DOI 10.1016/j.neurobiolaging.2018.09.006; Cretin B, 2016, J ALZHEIMERS DIS, V52, P1125, DOI 10.3233/JAD-150096; DiFrancesco JC, 2017, J ALZHEIMERS DIS, V60, P1267, DOI 10.3233/JAD-170392; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Giussani G, 2016, EPILEPSY BEHAV, V55, P30, DOI 10.1016/j.yebeh.2015.11.021; Giussani G, 2014, EPILEPSIA, V55, P1526, DOI 10.1111/epi.12748; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; Imfeld P, 2013, EPILEPSIA, V54, P700, DOI 10.1111/epi.12045; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; Kim HT, 2007, CLIN CANCER RES, V13, P559, DOI 10.1158/1078-0432.CCR-06-1210; KOKMEN E, 1991, NEUROLOGY, V41, P1393, DOI 10.1212/WNL.41.9.1393; LOISEAU J, 1990, ANN NEUROL, V27, P232, DOI 10.1002/ana.410270304; MACKENZIE IRA, 1994, ACTA NEUROPATHOL, V87, P504; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Pitkanen A, 2016, LANCET NEUROL, V15, P185, DOI 10.1016/S1474-4422(15)00248-3; Ponomareva NV, 2008, NEUROBIOL AGING, V29, P819, DOI 10.1016/j.neurobiolaging.2006.12.019; Ponomareva NV, 2003, NEUROPSYCHOBIOLOGY, V48, P152, DOI 10.1159/000073633; Ramsay RE, 2004, NEUROLOGY, V62, pS24, DOI 10.1212/WNL.62.5_suppl_2.S24; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; Sarkis RA, 2016, J NEUROPSYCH CLIN N, V28, P56, DOI 10.1176/appi.neuropsych.15060143; Scarmeas N, 2009, ARCH NEUROL-CHICAGO, V66, P992, DOI 10.1001/archneurol.2009.130; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Sohn Min-Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478-7954-4-2; Stefanidou M, 2017, SEIZURE-EUR J EPILEP, V47, P105, DOI 10.1016/j.seizure.2017.03.009; Stephen LJ, 2000, LANCET, V355, P1441, DOI 10.1016/S0140-6736(00)02149-8; Tai XY, 2016, BRAIN, V139, P2441, DOI 10.1093/brain/aww187; Tarlov E, ASCERTAINING VETERAN; Tchalla AE, 2011, EPILEPSIA, V52, P2203, DOI 10.1111/j.1528-1167.2011.03320.x; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; US Department of Veterans Affairs, 2016, VHA DEM STEER COMM R; VOLICER L, 1995, DEMENTIA, V6, P258, DOI 10.1159/000106956; Vossel KA, 2013, JAMA NEUROL, V70, P1158, DOI 10.1001/jamaneurol.2013.136	46	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUN	2020	77	6					710	715		10.1001/jamaneurol.2020.0187			6	Clinical Neurology	Neurosciences & Neurology	MA8CR	WOS:000542138800009	32150220	Green Published			2021-06-18	
J	Wang, JY; Deng, JH; Li, YB; Yuan, H; Xu, M				Wang, Jiayu; Deng, Jiahao; Li, Yunbo; Yuan, Huan; Xu, Ming			ZnO nanocrystal-coated MoS2 nanosheets with enhanced ultraviolet light gas sensitive activity studied by surface photovoltage technique	CERAMICS INTERNATIONAL			English	Article						ZnO; MoS2; Surface photovoltage; Gas sensors	NANOWIRE HETEROJUNCTIONS; NO2; PHOTOLUMINESCENCE; HETEROSTRUCTURES; PERFORMANCE; OXIDE; BULK	In this paper, ZnO nanocrystals and MoS2/ZnO composites were fabricated by a simple sol-gel method and ultrasonic concussion. Several characterization techniques including XRD, TEM, XPS, Raman spectroscopy and surface photovoltage were employed to explore the samples. The doping of MoS2 nanosheet into the ZnO nanocrystal composites was studied for its effect on NO2 gas-sensitivity under UV irradiation at room temperature. Compared to gas sensors developed from pure ZnO, those developed from ZnO/MoS2 exhibited higher sensitivity with a reversible response. Surface photovoltage results suggest that these desirable sensing features can be attributed to MoS2/ZnO heterojunctions and an abundance of diffusion channels which reduce the energy barrier to promote ready transference and target gas adsorption/desorption. These results offer new opportunities to fabricate composite materials for gas sensors.	[Wang, Jiayu; Deng, Jiahao; Li, Yunbo; Yuan, Huan; Xu, Ming] Southwest Minzu Univ, Sch Elect & Informat Engn, Key Lab Informat Mat Sichuan Prov, Chengdu 610041, Peoples R China	Yuan, H; Xu, M (corresponding author), Southwest Minzu Univ, Sch Elect & Informat Engn, Key Lab Informat Mat Sichuan Prov, Chengdu 610041, Peoples R China.	yuanhuanwill@126.com; hsuming_2001@aliyun.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61901401, 61701050]; Training Program of Innovation and Entrepreneurship for Undergraduates, Southwest Minzu University [S201910656171]	This work is supported by the National Natural Science Foundation of China (Grant No. 61901401, 61701050) and Training Program of Innovation and Entrepreneurship for Undergraduates, Southwest Minzu University (Grant No. S201910656171).	Bae SH, 2019, NAT MATER, V18, P550, DOI 10.1038/s41563-019-0335-2; Cho SY, 2015, ACS NANO, V9, P9314, DOI 10.1021/acsnano.5b04504; Cui SM, 2015, SMALL, V11, P2305, DOI 10.1002/smll.201402923; Donarelli M, 2013, CHEM PHYS LETT, V588, P198, DOI 10.1016/j.cplett.2013.10.034; Gribchenkova NA, 2019, J ALLOY COMPD, V778, P77, DOI 10.1016/j.jallcom.2018.11.136; Kasipandi S, 2019, ADV MATER, V31, DOI 10.1002/adma.201803390; Late DJ, 2012, ADV FUNCT MATER, V22, P1894, DOI 10.1002/adfm.201102913; Li H, 2012, ADV FUNCT MATER, V22, P1385, DOI 10.1002/adfm.201102111; Li X, 2020, MATER LETT, V262, DOI 10.1016/j.matlet.2019.127148; Liu S, 2014, SENSOR ACTUAT B-CHEM, V202, P272, DOI 10.1016/j.snb.2014.05.086; Mak KF, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.136805; Manjon FJ, 2005, J APPL PHYS, V97, DOI 10.1063/1.1856222; Radisavljevic B, 2011, NAT NANOTECHNOL, V6, P147, DOI [10.1038/nnano.2010.279, 10.1038/NNANO.2010.279]; Rudakova AV, 2019, J PHYS CHEM C, V123, P8884, DOI 10.1021/acs.jpcc.8b12125; Saravanan A, 2019, SENSOR ACTUAT B-CHEM, V292, P70, DOI 10.1016/j.snb.2019.04.108; Splendiani A, 2010, NANO LETT, V10, P1271, DOI 10.1021/nl903868w; Tong ZF, 2018, MATER LETT, V217, P296, DOI 10.1016/j.matlet.2018.01.083; Xu M, 2020, J PHYS D APPL PHYS, V53, DOI 10.1088/1361-6463/ab4bfd; Yan HH, 2016, J ALLOY COMPD, V662, P118, DOI 10.1016/j.jallcom.2015.12.066; Yang XL, 2019, SENSOR ACTUAT B-CHEM, V281, P415, DOI 10.1016/j.snb.2018.10.138; Yuan HY, 2019, ADV MATER, V31, DOI 10.1002/adma.201807161; Yuan H, 2019, APPL SURF SCI, V496, DOI 10.1016/j.apsusc.2019.07.253; Yuan H, 2019, CERAM INT, V45, P16694, DOI 10.1016/j.ceramint.2019.05.136; Zhao SF, 2018, APPL SURF SCI, V456, P808, DOI 10.1016/j.apsusc.2018.06.103; Zhao SF, 2018, RSC ADV, V8, P11070, DOI 10.1039/c7ra13484c; Zhou Y, 2018, APPL PHYS LETT, V113, DOI 10.1063/1.5042061; Zhou Y, 2018, J MATER CHEM A, V6, P10286, DOI 10.1039/c8ta02679c	27	11	12	8	47	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0272-8842	1873-3956		CERAM INT	Ceram. Int.	JUN 1	2020	46	8	A				11427	11431		10.1016/j.ceramint.2020.01.157			5	Materials Science, Ceramics	Materials Science	LH0LS	WOS:000528481900177					2021-06-18	
J	Hamer, J; Churchill, NW; Hutchison, MG; Graham, SJ; Schweizer, TA				Hamer, Julia; Churchill, Nathan W.; Hutchison, Michael G.; Graham, Simon J.; Schweizer, Tom A.			Sex Differences in Cerebral Blood Flow Associated with a History of Concussion	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; concussion; neuroimaging; sex differences; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; IMPACT EXPOSURE; WORKING-MEMORY; FEMALE; MILD; RECOVERY	Growing evidence suggests that a history of sport concussion may lead to long-term changes in brain physiology, with cerebral blood flow (CBF) being particularly sensitive to injury. However, it is unknown whether these changes are sex specific. The goal of this study was to evaluate sex differences in CBF of asymptomatic athletes, with and without a history of concussion (HOC) using arterial spin labeling (ASL). Scans were acquired for 122 athletes, including those without HOC (33 male, 33 female) and those with HOC (28 male, 28 female). Males with HOC had lower CBF bilaterally than males without HOC, seen predominantly in the temporal lobes. In contrast, females with HOC showed no significant differences relative to females without HOC, although they had significantly higher variability in temporal CBF values compared with males with HOC. Additional analyses within the HOC groups found that females with multiple concussion had lower CBF posteriorly compared with those with a single concussion, whereas males showed no significant effects. This study provides the first evidence of sex differences in CBF associated with HOC.	[Hamer, Julia; Churchill, Nathan W.; Hutchison, Michael G.; Schweizer, Tom A.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Hamer, Julia] Univ Sydney, Sydney, NSW, Australia; [Churchill, Nathan W.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Graham, Simon J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn IBBME, Toronto, ON, Canada	Schweizer, TA (corresponding author), St Michaels Hosp, Keenan Res Ctr, 209 Victoria St, Toronto, ON M5B 1M8, Canada.	Tom.Schweizer@unityhealth.to			CIHRCanadian Institutes of Health Research (CIHR) [RN294001-367456] Funding Source: Medline		Armstead William M, 2016, Anesthesiol Clin, V34, P465, DOI 10.1016/j.anclin.2016.04.002; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Black AM, 2017, CLIN J SPORT MED, V27, P52, DOI 10.1097/JSM.0000000000000308; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bretzin AC, 2018, AM J SPORT MED, V46, P2263, DOI 10.1177/0363546518778251; Cable RG, 2012, TRANSFUSION, V52, P1031, DOI 10.1111/j.1537-2995.2011.03389.x; Churchill N, 2017, J NEUROTRAUM, V34, P765, DOI 10.1089/neu.2016.4531; Churchill NW, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00390; Churchill NW, 2017, NEUROIMAGE-CLIN, V16, P234, DOI 10.1016/j.nicl.2017.07.019; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hsu HL, 2015, RADIOLOGY, V276, P828, DOI 10.1148/radiol.2015142549; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kimberly WT, 2013, NEUROLOGY, V80, P719, DOI 10.1212/WNL.0b013e31828250ff; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; MacIntosh BJ, 2010, MAGN RESON MED, V63, P641, DOI 10.1002/mrm.22256; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McGlade E, 2015, BRAIN IMAGING BEHAV, V9, P535, DOI 10.1007/s11682-015-9379-3; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Morton SM, 2004, NEUROSCIENTIST, V10, P247, DOI 10.1177/1073858404263517; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Sicard V, 2018, INT J PSYCHOPHYSIOL, V132, P3, DOI 10.1016/j.ijpsycho.2018.03.011; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Tan H, 2009, J MAGN RESON IMAGING, V29, P1134, DOI 10.1002/jmri.21721; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Wilcox BJ, 2015, J BIOMECH, V48, P2201, DOI 10.1016/j.jbiomech.2015.04.005; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006	52	11	11	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2020	37	10					1197	1203		10.1089/neu.2019.6800			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LL3VP	WOS:000531484000003	31650894	Bronze			2021-06-18	
J	Hartings, JA; Andaluz, N; Bullock, MR; Hinzman, JM; Mathern, B; Pahl, C; Puccio, A; Shutter, LA; Strong, AJ; Vagal, A; Wilson, JA; Dreier, JP; Ngwenya, LB; Foreman, B; Pahren, L; Lingsma, H; Okonkwo, DO				Hartings, Jed A.; Andaluz, Norberto; Bullock, M. Ross; Hinzman, Jason M.; Mathern, Bruce; Pahl, Clemens; Puccio, Ava; Shutter, Lori A.; Strong, Anthony J.; Vagal, Achala; Wilson, J. Adam; Dreier, Jens P.; Ngwenya, Laura B.; Foreman, Brandon; Pahren, Laura; Lingsma, Hester; Okonkwo, David O.			Prognostic Value of Spreading Depolarizations in Patients With Severe Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							ISCHEMIC NEUROLOGICAL DEFICITS; DEPRESSION; CARE; EXCITOTOXICITY; HEMORRHAGE; MANAGEMENT; MODEL	This multicenter cohort study assesses the association between spreading depolarizations in the brains of individuals who have undergone surgery for traumatic brain injury and neurologic outcomes. Question Does the measurement of spreading depolarizations provide clinically meaningful information that is independent of other assessments? Findings In this cohort study of 138 patients who underwent surgery for traumatic brain injury, the occurrence of repetitive spreading depolarizations (clusters) in 51 patients (37.0%) was associated with poor neurologic recovery during intensive care and was a factor independently associated with worse 6-month functional outcomes. Meaning Spreading depolarizations are a common mechanism of secondary injury that should be considered for monitoring and treatment targeting in traumatic brain injury. Importance Advances in treatment of traumatic brain injury are hindered by the inability to monitor pathological mechanisms in individual patients for targeted neuroprotective treatment. Spreading depolarizations, a mechanism of lesion development in animal models, are a novel candidate for clinical monitoring in patients with brain trauma who need surgery. Objective To test the null hypothesis that spreading depolarizations are not associated with worse neurologic outcomes. Design, Setting, and Participants This prospective, observational, multicenter cohort study was conducted from February 2009 to August 2013 in 5 level 1 trauma centers. Consecutive patients who required neurological surgery for treatment of acute brain trauma and for whom research consent could be obtained were enrolled; participants were excluded because of technical problems in data quality, patient withdrawal, or loss to follow-up. Primary statistical analysis took place from April to December 2018. Evaluators of outcome assessments were blinded to other measures. Interventions A 6-contact electrode strip was placed on the brain surface during surgery for continuous electrocorticography during intensive care. Main Outcomes and Measures Electrocorticography was scored for depolarizations, following international consensus procedures. Six-month outcomes were assessed by the Glasgow Outcome Scale-Extended score. Results A total of 157 patients were initially enrolled; 19 were subsequently excluded. The 138 remaining patients (104 men [75%]; median [interquartile range] age, 45 [29-64] years) underwent a median (interquartile range) of 75.5 (42.2-117.1) hours of electrocorticography. A total of 2837 spreading depolarizations occurred in 83 of 138 patients (60.1% incidence) who, compared with patients who did not have spreading depolarizations, had lower prehospital systolic blood pressure levels (mean [SD], 133 [31] mm Hg vs 146 [33] mm Hg; P = .03), more traumatic subarachnoid hemorrhage (depolarization incidences of 17 of 37 [46%], 18 of 32 [56%], 22 of 33 [67%], and 23 of 30 patients [77%] for Morris-Marshall Grades 0, 1, 2, and 3/4, respectively; P = .047), and worse radiographic pathology (in 38 of 73 patients [52%] and 42 of 60 patients [70%] for Rotterdam Scores 2-4 vs 5-6, respectively; P = .04). Of patients with depolarizations, 32 of 83 (39%) had only sporadic events that induced cortical spreading depression of spontaneous electrical activity, whereas 51 of 83 patients (61%) exhibited temporal clusters of depolarizations (>= 3 in a 2-hour span). Nearly half of those with clusters (23 of 51 [45%]) also had depolarizations in an electrically silent area of the cortex (isoelectric spreading depolarization). Patients with clusters did not improve in motor neurologic examinations from presurgery to postelectrocorticography, while other patients did improve. In multivariate ordinal regression adjusting for baseline prognostic variables, the occurrence of depolarization clusters had an odds ratio of 2.29 (95% CI, 1.13-4.65; P = .02) for worse outcomes. Conclusions and Relevance In this cohort study of patients with acute brain trauma, spreading depolarizations were predominant but heterogeneous and independently associated with poor neurologic recovery. Monitoring the occurrence of spreading depolarizations may identify patients most likely to benefit from targeted management strategies.	[Hartings, Jed A.; Andaluz, Norberto; Hinzman, Jason M.; Shutter, Lori A.; Wilson, J. Adam; Ngwenya, Laura B.; Foreman, Brandon] Univ Cincinnati, Dept Neurosurg, Coll Med, Cincinnati, OH 45267 USA; [Bullock, M. Ross] Univ Miami, Dept Neurol Surg, Miami, FL USA; [Mathern, Bruce] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA; [Pahl, Clemens] Kings Coll London, Dept Crit Care Med, London, England; [Puccio, Ava; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; [Strong, Anthony J.] Kings Coll London, Dept Basic & Clin Neurosci, London, England; [Vagal, Achala] Univ Cincinnati, Dept Radiol, Coll Med, Cincinnati, OH 45267 USA; [Dreier, Jens P.] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Dreier, Jens P.] Charite Univ Med Berlin, Dept Expt Neurol, Berlin, Germany; [Dreier, Jens P.] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany; [Dreier, Jens P.] Charite Univ Med Berlin, Ctr Stroke Res, Berlin, Germany; [Lingsma, Hester] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Andaluz, Norberto] Univ Louisville, Sch Med, Dept Neurosurg, Louisville, KY 40292 USA; [Shutter, Lori A.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Pahren, Laura] Univ Cincinnati, Dept Mech Engn, Cincinnati, OH 45267 USA; [Hartings, Jed A.; Ngwenya, Laura B.; Foreman, Brandon] Univ Cincinnati, Dept Neurol & Rehabil Med, Coll Med, Cincinnati, OH USA	Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jed.hartings@uc.edu		Shutter, Lori/0000-0002-1390-0628; Ngwenya, Laura/0000-0001-7103-971X	US Army Congressionally Directed Medical Research Program Psychological Health/Traumatic Brain Injury Research Program [W81XWH-08-2-0016]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DR 323/5-1, DR 323/10-1]; 7th Framework Programme for Research and Technological Development [602150]	This study was funded by the US Army Congressionally Directed Medical Research Program Psychological Health/Traumatic Brain Injury Research Program (contract W81XWH-08-2-0016). Dr Dreier acknowledges support from Deutsche Forschungsgemeinschaft (grants DR 323/5-1 and DR 323/10-1). Drs Hartings, Lingsma, and Dreier acknowledge support from the 7th Framework Programme for Research and Technological Development (grant 602150 [Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury]).	Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BRANSTON NM, 1977, J NEUROL SCI, V32, P305, DOI 10.1016/0022-510X(77)90014-4; Carlson AP, 2019, J NEUROSURG, V131, P1773, DOI 10.3171/2018.7.JNS181478; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2018, ANN NEUROL, V83, P295, DOI 10.1002/ana.25147; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Eriksen N, 2019, NEUROCRIT CARE, V30, P557, DOI 10.1007/s12028-019-00692-w; Eriksen N, 2019, NEUROLOGY, V92, pE326, DOI 10.1212/WNL.0000000000006814; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Hartings JA, 2018, FRONT SYST NEUROSCI, V12, DOI 10.3389/fnsys.2018.00019; Hartings JA, 2017, BRAIN, V140, P2673, DOI 10.1093/brain/awx214; Hartings JA, 2017, CURR OPIN CRIT CARE, V23, P94, DOI 10.1097/MCC.0000000000000395; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2014, J NEUROSURG, V120, P434, DOI 10.3171/2013.9.JNS13581; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hawryluk GWJ, 2016, J NEUROSURG, V125, P1217, DOI 10.3171/2015.7.JNS15809; Helbok R, 2020, NEUROCRIT CARE, V32, P306, DOI 10.1007/s12028-019-00777-6; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Krenzlin H, 2019, J NEUROTRAUM, V36, P395, DOI 10.1089/neu.2018.5657; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Reinhart KM, 2018, EXP NEUROL, V305, P121, DOI 10.1016/j.expneurol.2018.04.007; Spaite DW, 2017, JAMA SURG, V152, P360, DOI 10.1001/jamasurg.2016.4686; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Vande Vyvere T, 2019, J NEUROTRAUM, V36, P1080, DOI 10.1089/neu.2018.6061; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	44	11	11	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	APR	2020	77	4					489	499		10.1001/jamaneurol.2019.4476			11	Clinical Neurology	Neurosciences & Neurology	LH2CS	WOS:000528595700013	31886870	Bronze, Green Published			2021-06-18	
J	Kiraz, M; Demir, E				Kiraz, Murat; Demir, Emre			A Bibliometric Analysis of Publications on Spinal Cord Injury During 1980-2018	WORLD NEUROSURGERY			English	Article						Bibliometric analysis; Spinal cord injury; Trends	INTERNATIONAL STANDARDS; FUNCTIONAL RECOVERY; METHYLPREDNISOLONE; REHABILITATION; CLASSIFICATION	BACKGROUND: Spinal cord injury (SCI) could cause motor, sensory loss, severe functional insufficiency, and social problems. This study aims to provide a holistic summary of the global scientific outputs about SCI through bibliometric analyses and reveal the trend topics. METHODS: All publications about SCI published between 1980 and 2018 in Web of Science (WoS) index were downloaded (Access date: 01.09.2019) and analyzed using bibliometric methods. In the Title search section in WoS, the documents with the words "spinal cord injury" were identified. Correlation analysis between SCI publication productivity and economic development indicators of the world countries were analyzed using the Spearman correlation coefficient. RESULTS: There were 20,322 publications, 13,662 of which were articles. The top 3 productive countries were the USA, China, and Canada. British Columbia (403; 2.9%), Toronto (401; 2.9%), and Miami (387; 2.8%) were the prominent cities. The top productive journals were Spinal Cord (1,399; 10.24%), Archives of Physical Medicine and Rehabilitation (835; 6.11%), and Journal of Neurotrauma (631; 4.61%). A statistically significant, high-level correlation was found between the number of publications about SCI and the countries' gross domestic product and gross domestic product per capita (r = 0.711, P < 0.001; r = 0.699, P < 0.001). CONCLUSIONS: This study provides a systematic analysis of SCI and could be a beneficial guide for clinicians and scientists.	[Kiraz, Murat] Hitit Univ, Fac Med, Dept Neurosurg, Corum, Turkey; [Demir, Emre] Hitit Univ, Fac Med, Dept Biostat, Corum, Turkey	Kiraz, M (corresponding author), Hitit Univ, Fac Med, Dept Neurosurg, Corum, Turkey.	kirazmurat@gmail.com	kiraz, murat/ABC-2965-2020; Demir, Emre/AAA-8193-2020	/0000-0001-6692-444X; Demir, Emre/0000-0002-3834-3864			Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Demir E, 2020, J FORENSIC LEG MED, V69, DOI 10.1016/j.jflm.2019.101885; Demir E, 2020, IRISH J MED SCI, V189, P267, DOI 10.1007/s11845-019-02080-x; Demir E, 2019, J RELIG HEALTH, V58, P1, DOI 10.1007/s10943-018-00739-w; Dogan G, 2019, EUR J PEDIATR SURG, DOI [10.1055/s-0039-3400514, DOI 10.1055/S-0039-]; Dogan G, 2020, J RELIG HEALTH, V59, P96, DOI 10.1007/s10943-019-00886-8; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fehlings MG, 2017, NEUROSURGERY, V80, P51, DOI 10.1093/neuros/nyw112; Jazayeri SB, 2017, EUR SPINE J, V24, P905; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Liu XX, 2019, THER CLIN RISK MANAG, V15, P1, DOI 10.2147/TCRM.S163881; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; Nas K, 2015, WORLD J ORTHOP, V6, P8, DOI 10.5312/wjo.v6.i1.8; Nori S, 2017, NEUROSURGERY, V64, P119, DOI 10.1093/neuros/nyx217; Nowrouzi B, 2017, EUR SPINE J, V26, P28, DOI 10.1007/s00586-016-4669-z; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3	26	11	11	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	APR	2020	136						E504	E513		10.1016/j.wneu.2020.01.064			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KW0BN	WOS:000520838600054	31954906				2021-06-18	
J	Xu, F; Huang, ZL; Yang, FF; Wang, D; Tsui, KL				Xu, Fan; Huang, Zhelin; Yang, Fangfang; Wang, Dong; Tsui, Kwok Leung			Constructing a health indicator for roller bearings by using a stacked auto-encoder with an exponential function to eliminate concussion	APPLIED SOFT COMPUTING			English	Article						Roller bearings; Deep learning; Stacked auto-encoder; Health indicator; Exponent function	ROTATING MACHINERY; FAULT-DIAGNOSIS; COULOMBIC EFFICIENCY; NEURAL-NETWORKS; LEARNING-METHOD; DEEP NETWORK; AUTOENCODER; DEGRADATION; PROGNOSIS; TOOL	Most deep-learning models, especially stacked auto-encoders (SAES), have been used in recent years for the diagnosis of faults in rotating machinery. However, very few studies have reported on health indicator (HI) construction by using SAES in deep learning. SAES have a good feature-extraction ability when several hidden layers are used to reconstruct the original input. In this study, we first introduce a method to reduce dependence on prior knowledge that is based on SAES and enables extraction of the preliminary degradation trend from the bearing's frequency domain directly. Second, to construct the final HI and improve the monotonicity of the indicators, an exponential function is used to eliminate global severe vibration after an SAE has extracted the preliminary degradation trend. To prove the effect of our presented method, some other HI construction models, such as root mean square, kurtosis, approximate entropy, permutations entropy, empirical mode decomposition-singular value decomposition, K-means/K-medoids, and various time-frequency fusion indicators are used for comparison. Moreover, to prove that the exponential-function effect exceeds other severe vibration-eliminating methods, examples of the latter methods such as exponentially weighted moving-average and outlier detection are used for comparative analysis. Finally, the results shows that our proposed model is better than the above-mentioned existing models. (C) 2020 Elsevier B.V. All rights reserved.	[Xu, Fan; Huang, Zhelin; Yang, Fangfang; Tsui, Kwok Leung] City Univ Hong Kong, Sch Data Sci, Kowloon, Tat Chee Ave, Hong Kong 990777, Peoples R China; [Huang, Zhelin] Shenzhen Univ, Sch Econ, Dept Stat, Shenzhen 518061, Peoples R China; [Wang, Dong] Shanghai Jiao Tong Univ, State Key Lab Mech Syst & Vibrat, Shanghai 200240, Peoples R China	Huang, ZL (corresponding author), City Univ Hong Kong, Sch Data Sci, Kowloon, Tat Chee Ave, Hong Kong 990777, Peoples R China.; Huang, ZL (corresponding author), Shenzhen Univ, Sch Econ, Dept Stat, Shenzhen 518061, Peoples R China.	fanxu8@cityu.edu.hk; zhuang44@cityu.edu.hk	Wang, Dong/K-8230-2018	Wang, Dong/0000-0003-4872-4860	Research Grants Council Theme-based Research Scheme [T32-101/15-R]; grant (RIF) from the Research Grants Council of the Hong Kong Special Administrative Region, China [R-5020-18]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [51975355];  [CityU 11206417]	This research work was partly supported by the General Research Fund (Project No. CityU 11206417), the Research Grants Council Theme-based Research Scheme under Project T32-101/15-R, the grant (RIF) from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. R-5020-18). The Natural Science Foundation of China under Grant No. 51975355.	Affonso C, 2017, EXPERT SYST APPL, V85, P114, DOI 10.1016/j.eswa.2017.05.039; Bandt C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174102; Chandar A. P. S., 2014, P 27 INT C NEUR INF, V2, P1853; Chandola V., 2007, ACM COMPUT SURV CSUR, P1; Guo L, 2017, NEUROCOMPUTING, V240, P98, DOI 10.1016/j.neucom.2017.02.045; Gupta M, 2014, IEEE T KNOWL DATA EN, V26, P2250, DOI 10.1109/TKDE.2013.184; He Zhengjia, 2014, Journal of Mechanical Engineering, V50, P171, DOI 10.3901/JME.2014.02.171; Heng A, 2009, MECH SYST SIGNAL PR, V23, P1600, DOI 10.1016/j.ymssp.2008.12.006; Hinton GE, 2006, SCIENCE, V313, P504, DOI 10.1126/science.1127647; Javed K, 2015, IEEE T IND ELECTRON, V62, P647, DOI 10.1109/TIE.2014.2327917; Jia F, 2016, MECH SYST SIGNAL PR, V72-73, P303, DOI 10.1016/j.ymssp.2015.10.025; Kong ZM, 2019, IEEE T INF FOREN SEC, V14, P3151, DOI 10.1109/TIFS.2019.2908481; Kosasih B, 2014, APPL MECH MATER, V493, P343, DOI 10.4028/www.scientific.net/AMM.493.343; Lai JG, 2020, IEEE T CIRCUITS-II, V67, P2094, DOI 10.1109/TCSII.2019.2950764; Lai JG, 2019, IEEE T IND INFORM, V15, P5906, DOI 10.1109/TII.2019.2908666; Lei YG, 2016, IEEE T INSTRUM MEAS, V65, P2671, DOI 10.1109/TIM.2016.2601004; Li XQ, 2019, MECH MACH THEORY, V133, P229, DOI 10.1016/j.mechmachtheory.2018.11.005; Lu C, 2017, SIGNAL PROCESS, V130, P377, DOI 10.1016/j.sigpro.2016.07.028; Mansouri M, 2018, SOL ENERGY, V167, P125, DOI 10.1016/j.solener.2018.03.073; Nectoux P., 2012, PRONOSTIA EXPT PLATF, P1; Qi YM, 2017, IEEE ACCESS, V5, P15066, DOI 10.1109/ACCESS.2017.2728010; Rai A, 2017, MECH SYST SIGNAL PR, V93, P16, DOI 10.1016/j.ymssp.2017.02.003; Ren L, 2017, J MANUF SYST, V43, P248, DOI 10.1016/j.jmsy.2017.02.013; Rumelhart David E, 2002, COGNITIVE MODELING, V1, P213; Saufi SR, 2018, MEAS SCI TECHNOL, V29, DOI 10.1088/1361-6501/aae5b2; Shao HD, 2017, MECH SYST SIGNAL PR, V95, P187, DOI 10.1016/j.ymssp.2017.03.034; Shen CQ, 2018, ENG APPL ARTIF INTEL, V76, P170, DOI 10.1016/j.engappai.2018.09.010; Shen Zhongjie, 2013, Journal of Mechanical Engineering, V49, P183, DOI 10.3901/JME.2013.02.183; Sun SN, 2017, NEUROCOMPUTING, V257, P79, DOI 10.1016/j.neucom.2016.11.063; Sun WJ, 2016, MEASUREMENT, V89, P171, DOI 10.1016/j.measurement.2016.04.007; Tang RL, 2020, APPL ENERG, V259, DOI 10.1016/j.apenergy.2019.114183; Tang RL, 2018, ENERGY, V162, P697, DOI 10.1016/j.energy.2018.08.048; Tian Y, 2019, MECH SYST SIGNAL PR, V114, P658, DOI 10.1016/j.ymssp.2016.04.028; Tse PW, 2017, J VIB CONTROL, V23, P1925, DOI 10.1177/1077546315604522; Tse YL, 2019, MEASUREMENT, V139, P140, DOI 10.1016/j.measurement.2019.02.079; Vincent P., 2008, P 25 INT C MACH LEAR, P1096, DOI [10.1145/1390156.1390294, DOI 10.1145/1390156.1390294]; Vincent P, 2010, J MACH LEARN RES, V11, P3371; Wang D, 2018, IEEE ACCESS, V6, DOI 10.1109/ACCESS.2017.2774261; Wang YR, 2019, KNOWL-BASED SYST, V163, P438, DOI 10.1016/j.knosys.2018.09.005; Williams T, 2001, MECH SYST SIGNAL PR, V15, P979, DOI 10.1006/mssp.2001.1418; Wu Z, 2020, IEEE T IND INFORM, V16, P4512, DOI 10.1109/TII.2019.2944627; Xu F, 2018, APPL SOFT COMPUT, V73, P898, DOI 10.1016/j.asoc.2018.09.037; Yan RQ, 2007, MECH SYST SIGNAL PR, V21, P824, DOI 10.1016/j.ymssp.2006.02.009; Yan RQ, 2012, MECH SYST SIGNAL PR, V29, P474, DOI 10.1016/j.ymssp.2011.11.022; Yang FF, 2019, ENERGY, V171, P1173, DOI 10.1016/j.energy.2019.01.083; Yang FF, 2018, ENERGY, V145, P486, DOI 10.1016/j.energy.2017.12.144	46	11	11	10	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1568-4946	1872-9681		APPL SOFT COMPUT	Appl. Soft. Comput.	APR	2020	89								106119	10.1016/j.asoc.2020.106119			15	Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications	Computer Science	KU9KA	WOS:000520042200024					2021-06-18	
J	Roumes, H; Dumont, U; Sanchez, S; Mazuel, L; Blanc, J; Raffard, G; Chateil, JF; Pellerin, L; Bouzier-Sore, AK				Roumes, Helene; Dumont, Ursule; Sanchez, Stephane; Mazuel, Leslie; Blanc, Jordy; Raffard, Gerard; Chateil, Jean-Francois; Pellerin, Luc; Bouzier-Sore, Anne-Karine			Neuroprotective role of lactate in rat neonatal hypoxia-ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Neonatal hypoxia-ischemia; lactate; neuroprotection; astrocyte to neuron lactate shuttle; MRI	TRAUMATIC BRAIN-INJURY; NEURONAL MONOCARBOXYLATE TRANSPORTER; PENTOSE-PHOSPHATE PATHWAY; CENTRAL-NERVOUS-SYSTEM; PYRUVATE CARBOXYLATION; GLUCOSE-UTILIZATION; CEREBRAL-ISCHEMIA; ENERGY-METABOLISM; GLUTAMATE UPTAKE; EXPRESSION	Hypoxic-ischemic (HI) encephalopathy remains a major cause of perinatal mortality and chronic disability in newborns worldwide (1-6 for 1000 births). The only current clinical treatment is hypothermia, which is efficient for less than 60% of babies. Mainly considered as a waste product in the past, lactate, in addition to glucose, is increasingly admitted as a supplementary fuel for neurons and, more recently, as a signaling molecule in the brain. Our aim was to investigate the neuroprotective effect of lactate in a neonatal (seven day old) rat model of hypoxia-ischemia. Pups received intra-peritoneal injection(s) of lactate (40 mu mol). Size and apparent diffusion coefficients of brain lesions were assessed by magnetic resonance diffusion-weighted imaging. Oxiblot analyses and long-term behavioral studies were also conducted. A single lactate injection induced a 30% reduction in brain lesion volume, indicating a rapid and efficient neuroprotective effect. When oxamate, a lactate dehydrogenase inhibitor, was co-injected with lactate, the neuroprotection was completely abolished, highlighting the role of lactate metabolism in this protection. After three lactate injections (one per day), pups presented the smallest brain lesion volume and a complete recovery of neurological reflexes, sensorimotor capacities and long-term memory, demonstrating that lactate administration is a promising therapy for neonatal HI insult.	[Roumes, Helene; Dumont, Ursule; Sanchez, Stephane; Mazuel, Leslie; Blanc, Jordy; Raffard, Gerard; Chateil, Jean-Francois; Pellerin, Luc; Bouzier-Sore, Anne-Karine] Univ Bordeaux, Ctr Resonance Magnet Syst Biol, CNRS, UMR5536, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Pellerin, Luc] Univ Lausanne, Dept Physiol, Lausanne, Switzerland	Bouzier-Sore, AK (corresponding author), Univ Bordeaux, Ctr Resonance Magnet Syst Biol, CNRS, UMR5536, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	akb@rmsb.u-bordeaux.fr	; Pellerin, Luc/A-8912-2017	CHATEIL, Jean-Francois/0000-0002-6143-7607; Pellerin, Luc/0000-0002-1016-1970; Roumes, Helene/0000-0002-0387-7823; Bouzier-Sore, Anne-Karine/0000-0002-3470-0940	TRAIL (Translational Research and Advanced Imaging Laboratory) cluster of excellence of Bordeaux University; program IdEx; LabEx TRAIL [ANR-10-IDEX, ANR-10-LABX-57]; international French (ANR)/Swiss (FNS)French National Research Agency (ANR) [ANR-15-CE37-0012]; FNSSwiss National Science Foundation (SNSF) [310030E164271]; program IdEx Bordeaux [ANR-10-IDEX-03-02]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the TRAIL (Translational Research and Advanced Imaging Laboratory) cluster of excellence of Bordeaux University. AKBS has received financial support from the program IdEx and the LabEx TRAIL, reference ANR-10-IDEX and ANR-10-LABX-57. AKBS and LP have received financial support from an international French (ANR)/Swiss (FNS) grant, references ANR-15-CE37-0012 and FNS no 310030E164271. LP received financial support from the program IdEx Bordeaux ANR-10-IDEX-03-02.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Allen KA, 2011, NEWBORN INFANT NURS, V11, P125, DOI 10.1053/j.nainr.2011.07.004; Arteaga O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142424; Bak LK, 2018, J PHYSIOL-LONDON, V596, P351, DOI 10.1113/JP274945; Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1; Barros LF, 2018, J PHYSIOL-LONDON, V596, P347, DOI 10.1113/JP274944; BENYOSEPH O, 1994, DEV NEUROSCI-BASEL, V16, P328, DOI 10.1159/000112127; Bergersen LH, 2007, NEUROSCIENCE, V145, P11, DOI 10.1016/j.neuroscience.2006.11.062; Bergersen Linda H, 2012, Front Neuroenergetics, V4, P5, DOI 10.3389/fnene.2012.00005; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Bolanos JP, 2016, J NEUROCHEM, V139, P115, DOI 10.1111/jnc.13486; Bouet V, 2010, BEHAV BRAIN RES, V212, P56, DOI 10.1016/j.bbr.2010.03.043; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bouzier AK, 2000, J NEUROCHEM, V75, P480, DOI 10.1046/j.1471-4159.2000.0750480.x; Bouzier-Sore AK, 2003, BIOCHIMIE, V85, P841, DOI 10.1016/j.biochi.2003.08.003; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Bouzier-Sore AK, 2002, J PHYSIOL-PARIS, V96, P273, DOI 10.1016/S0928-4257(02)00016-5; Bouzier-Sore AK, 2006, EUR J NEUROSCI, V24, P1687, DOI 10.1111/j.1460-9568.2006.05056.x; Bouzier-Sore AK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00179; Brekke E, 2015, NEUROCHEM INT, V82, P33, DOI 10.1016/j.neuint.2015.02.002; Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8; Brissaud O, 2010, PEDIATR RES, V68, P123, DOI 10.1203/00006450-201011001-00237; Camandola S, 2017, EMBO J, V36, P1474, DOI 10.15252/embj.201695810; Castillo X, 2015, J CEREBR BLOOD F MET, V35, P1561, DOI 10.1038/jcbfm.2015.115; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; CHEW W, 1991, AM J NEURORADIOL, V12, P603; Chouthai Nitin S, 2015, J Neonatal Perinatal Med, V8, P125, DOI 10.3233/NPM-15814075; Cotten C Michael, 2010, Expert Rev Obstet Gynecol, V5, P227, DOI 10.1586/eog.10.7; Cremillieux Y, 2018, NMR BIOMED, V31, DOI 10.1002/nbm.3861; Davidson JO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00198; FREEMAN R, 1981, J MAGN RESON, V42, P341, DOI 10.1016/0022-2364(81)90227-4; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Guggisberg N., 2016, MEMOIRE MAITRISE MED, V3394, P1; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Ikeda T, 2001, BEHAV BRAIN RES, V118, P17, DOI 10.1016/S0166-4328(00)00287-4; Iwata O, 2007, BRAIN RES, V1154, P173, DOI 10.1016/j.brainres.2007.03.083; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Juul SE, 2014, CLIN PERINATOL, V41, P119, DOI 10.1016/j.clp.2013.09.004; Karalis F, 2011, BRAIN RES, V1425, P98, DOI 10.1016/j.brainres.2011.09.044; Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; LEBLANC MH, 1994, STROKE, V25, P1443, DOI 10.1161/01.STR.25.7.1443; LEBLANC MH, 1993, STROKE, V24, P1055, DOI 10.1161/01.STR.24.7.1055; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; Mazuel L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174990; Morken TS, 2014, NEUROCHEM RES, V39, P556, DOI 10.1007/s11064-013-1014-3; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; Ohki S, 1999, PEDIATR NEUROL, V21, P543, DOI 10.1016/S0887-8994(99)00039-9; Pan YS, 2017, STROKE, V48, P3006, DOI 10.1161/STROKEAHA.117.019081; Patet C, 2015, J NEUROTRAUM, V32, P1560, DOI 10.1089/neu.2014.3781; Pellerin L, 1998, P NATL ACAD SCI USA, V95, P3990, DOI 10.1073/pnas.95.7.3990; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pierre K, 2002, J CEREBR BLOOD F MET, V22, P586, DOI 10.1097/00004647-200205000-00010; Pierre K, 2009, EUR J NEUROSCI, V29, P1951, DOI 10.1111/j.1460-9568.2009.06756.x; Quintard H, 2016, J NEUROTRAUM, V33, P681, DOI 10.1089/neu.2015.4057; Rafiki A, 2003, NEUROSCIENCE, V122, P677, DOI 10.1016/j.neuroscience.2003.08.040; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Rosafio K, 2014, GLIA, V62, P477, DOI 10.1002/glia.22618; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; Sada N, 2015, SCIENCE, V347, P1362, DOI 10.1126/science.aaa1299; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sampol Denys, 2013, Front Neuroenergetics, V5, P5, DOI 10.3389/fnene.2013.00005; Sanches EF, 2013, NEUROSCIENCE, V237, P208, DOI 10.1016/j.neuroscience.2013.01.066; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; Shah PS, 2010, SEMIN FETAL NEONAT M, V15, P238, DOI 10.1016/j.siny.2010.02.003; Shalak L, 2004, EARLY HUM DEV, V80, P125, DOI 10.1016/j.earlhumdev.2004.06.003; SUTHERLA.EW, 1969, DIABETES, V18, P797, DOI 10.2337/diab.18.12.797; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Taher M, 2016, EUR J PAEDIATR NEURO, V20, P3, DOI 10.1016/j.ejpn.2015.09.008; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015	82	11	11	2	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2021	41	2					342	358	0271678X20908355	10.1177/0271678X20908355		MAR 2020	17	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	PS9BL	WOS:000523907800001	32208801	Other Gold, Green Published			2021-06-18	
J	Tabibkhooei, A; Izadpanahi, M; Arab, A; Zare-Mirzaei, A; Minaeian, S; Rostami, A; Mohsenian, A				Tabibkhooei, Alireza; Izadpanahi, Maryam; Arab, Abolfazl; Zare-Mirzaei, Ali; Minaeian, Sara; Rostami, Ali; Mohsenian, Alireza			Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Circulating MicroRNAs; GBM; Biomarkers; Plasma exosomal-microRNAs; Prognosis; EGFR and MET signaling pathways	MESENCHYMAL STEM-CELLS; GLIOBLASTOMA-MULTIFORME; EXPRESSION; PROGNOSIS; GROWTH; TUMORS; CLASSIFICATION; TEMOZOLOMIDE; MECHANISMS; SIGNATURE	Objective: Glioblastoma (GBM) is the most common primary malignant neoplasm of the central nervous system (CNS). Despite the progress in therapeutic strategies such as surgical techniques, radiotherapy, chemotherapy, and targeted therapy, prognosis and therapeutically convenient monitoring tools in patients with GBM has not improved significantly up to now.Therefore, exosomal miRNAs as novel non-invasive biomarkers having high sensitivity and specificity are required to improve diagnosis and to develop new targeted therapy strategies for GBM patients. The aim of the present study was to investigate a novel miRNA signature as a predictive biomarker for diagnosis and measurement of response to therapeutic interventions in plasma of GBM patients versus traumatic brain injury and diffuse low-grade astrocytoma (LGA) patients. Patients and methods: Plasma exosomal-microRNAs were isolated from GBM (n = 25), LGA (n = 25), and head trauma patients (n = 15) as non-glioma control from March 2017 to June 2018 in Department of Neurosurgery at Rasoul-e-Akram Hospital. Through a bioinformatics analysis, we used Miranda, TargetScan, mirBase, DIANA-microT-CDS, and KEGG database as well as microarray data analysis from GEO for microRNA candidates. Finally, miR-210, miR-185, miR-5194, and miR-449 were selected among those miRNAs because they were recorded to target the maximum number of genes in EGFR and c-MET signaling pathways. Then, exosomal microRNAs were extracted from plasma of patients and quantitated by locked nucleic acid real-time PCR in GBM, LGA, and trauma patients. Results: This result is the first report on the role of circulating miR-185, miR-449, and miR-5194 in GBM compared to LGA and trauma. The plasma expression of miR-210 as an oncogenic miR was upregulated in GBM and LGA groups (P < 0.0001). Otherwise, miR-185, miR-5194, and miR-449 were significantly downregulated (P <= 0.05) in GBM and LGA compared to trauma patients. There was no significant downregulation in the expression of miR-185 between GBM and LGA, while the expression of miR-5194 (P <= 0.05) and miR-449 (P <= 0.05) was significantly decreased in GBM patients compared with LGA. Conclusions: These results indicate that the levels of miR-210, miR-449, and miR-5194 are a promising diagnostic and prognostic biomarker positively correlated with histopathological grade and invasiveness of GBM. These findings imply that circulating microRNA can be potentially used as novel biomarkers for glioma that might be beneficial in clinical management of glioma patients.	[Tabibkhooei, Alireza; Izadpanahi, Maryam; Rostami, Ali; Mohsenian, Alireza] Iran Univ Med Sci, Dept Neurosurg, Tehran, Iran; [Arab, Abolfazl] Univ Tehran, Fac New Sci & Technol, Tehran, Iran; [Zare-Mirzaei, Ali] Iran Univ Med Sci, Dept Pathol, Tehran, Iran; [Minaeian, Sara] Iran Univ Med Sci, Antimicrobial Resistance Res Ctr, Inst Immunol & Infect Dis, Tehran, Iran	Tabibkhooei, A; Izadpanahi, M (corresponding author), Hazrat Rasool Hosp, Neurosurg Ward, Niyayesh St,Sattarkhan Ave, Tehran, Iran.	Tabibkhooei.a@iums.ac.ir; science_izadpanahi@yahoo.com		arab, abolfazl/0000-0002-0024-2937	Department of Neurosurgery, Hazrat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran	This work was supported by Department of Neurosurgery, Hazrat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran. The authors confirm that there are no conflicts of interest, and take this opportunity to appreciate Exiqon, Dr. Daniel Kiani,Dr.Ehsan Arefian for their help during this project.	Abounader R., 2009, CNS CANC CANC DRUG D, P933; Agnihotri S, 2013, ARCH IMMUNOL THER EX, V61, P25, DOI 10.1007/s00005-012-0203-0; Agrahari V, 2019, TRENDS BIOTECHNOL; Akers JC, 2017, ONCOTARGET, V8, P68769, DOI 10.18632/oncotarget.18332; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Alexiou GA, 2019, EPILEPSY SURG INTRIN, P261; Alexiou GA, 2012, CURR RADIOPHARM, V5, P308, DOI 10.2174/1874471011205040308; Areeb Z, 2015, J NEURO-ONCOL, V125, P237, DOI 10.1007/s11060-015-1912-0; Awad AJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14520; Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bradshaw A.A., 2009, HDB CELL SIGNALING; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chakraborty S, 2019, INT CONF ADV COMMUN, P260, DOI 10.23919/ICACT.2019.8701983; Chakravarty D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08940-9; Chhabda S, 2016, QUANT IMAGING MED SU, V6, P486, DOI 10.21037/qims.2016.10.01; D'Urso PI, 2015, CURR GENOMICS, V16, P304, DOI 10.2174/1389202916666150707155610; Dai XJ, 2019, INT J ONCOL, V54, P261, DOI 10.3892/ijo.2018.4621; Damiani E, 2019, BIOCHEM J, V476, P245, DOI 10.1042/BCJ20180384; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; Di Somma A, 2019, WORLD NEUROSURG, V122, P441, DOI 10.1016/j.wneu.2018.11.057; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Ebrahimkhani S, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0071-0; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Garajova Ingrid, 2015, Transl Oncogenomics, V7, P13, DOI 10.4137/TOG.S30534; Graner MW, 2013, PROC SPIE, V8723, DOI 10.1117/12.2027435; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hanif Farina, 2017, Asian Pac J Cancer Prev, V18, P3; Hardee ME, 2012, AM J PATHOL, V181, P1126, DOI 10.1016/j.ajpath.2012.06.030; Hintenlang LL, 2018, J CLIN NEUROSCI, V48, P118, DOI 10.1016/j.jocn.2017.11.003; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; Hossain A, 2015, STEM CELLS, V33, P2400, DOI 10.1002/stem.2053; Hua Z, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0628-5; Hubbard SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI 10.1016/j.ceb.2007.02.010; Itakura H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7582; Katakowski M, 2010, CANCER RES, V70, P8259, DOI 10.1158/0008-5472.CAN-10-0604; Koochekpour S, 1997, CANCER RES, V57, P5391; Kudo-Saito C, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00023; Lai NS, 2015, BRIT J CANCER, V112, P1241, DOI 10.1038/bjc.2015.91; Lai NS, 2014, J CLIN NEUROSCI, V21, P755, DOI 10.1016/j.jocn.2013.06.024; Lai NS, 2014, FOLIA NEUROPATHOL, V52, P79, DOI 10.5114/fn.2014.41746; Li HY, 2016, EUR REV MED PHARMACO, V20, P3599; Li S, 2015, INT J CLIN EXP PATHO, V8, P11854; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Malara N., 2018, BLOOD BRAIN BARRIER; Massey S.C., 2019, BIORXIV; Mikaelian I, 2013, TOXICOL PATHOL, V41, P18, DOI 10.1177/0192623312448939; Minniti G, 2019, NEUROREHABILITATION, P53; Modrek AS, 2017, CELL REP, V21, P1267, DOI 10.1016/j.celrep.2017.10.009; Murray LMA, 2019, STEM CELLS, V37, P14, DOI 10.1002/stem.2922; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Osti D, 2019, CLIN CANCER RES, V25, P266, DOI 10.1158/1078-0432.CCR-18-1941; Otani R, 2018, CANCER SCI, V109, P2327, DOI 10.1111/cas.13635; Pelloski C.E., 2007, CURRENT TREATMENT OP; Pessina F, 2017, J NEURO-ONCOL, V131, P377, DOI 10.1007/s11060-016-2310-y; Qiu J, 2013, MOL MED REP, V7, P1955, DOI 10.3892/mmr.2013.1431; Qiu SW, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-10; Romano A, 2018, J NEURO-ONCOL, V139, P455, DOI 10.1007/s11060-018-2887-4; Saadatpour L, 2016, CANCER GENE THER, V23, P415, DOI 10.1038/cgt.2016.48; Sana J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20929-6; Santangelo A, 2018, J NEURO-ONCOL, V136, P51, DOI 10.1007/s11060-017-2639-x; Santangelo A, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.15; Schotte D, 2011, LEUKEMIA, V25, P1389, DOI 10.1038/leu.2011.105; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shahar T, 2017, NEURO-ONCOLOGY, V19, P660, DOI 10.1093/neuonc/now239; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Spinelli C, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5010001; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Szopa W, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8013575; Tang HL, 2015, J CANCER RES THER, V11, P630, DOI 10.4103/0973-1482.146121; Tang HL, 2012, CURR CANCER DRUG TAR, V12, P1032, DOI 10.2174/156800912803251180; Tiberio P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/731479; Tumilson CA, 2014, MOL NEUROBIOL, V50, P545, DOI 10.1007/s12035-014-8679-8; Unkelbach J., 2014, PHYS MED BIOL, V59; Vallabhaneni KC, 2015, ONCOTARGET, V6, P4953, DOI 10.18632/oncotarget.3211; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Visani M, 2014, MOL ONCOL, V8, P417, DOI 10.1016/j.molonc.2013.12.010; Wang Q, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-97; Westphal M, 2015, NAT REV NEUROL, V11, P556, DOI 10.1038/nrneurol.2015.171; Wu J, 2015, MOL NEUROBIOL, V52, P783, DOI 10.1007/s12035-014-8918-z; Wu ZF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047270; Xie Q, 2012, P NATL ACAD SCI USA, V109, P570, DOI 10.1073/pnas.1119059109; Xing W, 2017, TUMOR BIOL, V39, P5; Yano S, 2014, JPN J CLIN ONCOL, V44, P9, DOI 10.1093/jjco/hyt188; Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316; Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001; Zhang R, 2016, MOL NEUROBIOL, V53, P1452, DOI 10.1007/s12035-014-9079-9; Zhi F, 2015, NEURO-ONCOLOGY, V17, P383, DOI 10.1093/neuonc/nou169	92	11	11	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAR	2020	190								105652	10.1016/j.clineuro.2019.105652			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KW9PE	WOS:000521514800027	31896490				2021-06-18	
J	Corbett, JM; Ho, KM; Honeybul, S				Corbett, Jade-Marie; Ho, Kwok M.; Honeybul, Stephen			Prognostic significance of abnormal hematological parameters in severe traumatic brain injury requiring decompressive craniectomy	JOURNAL OF NEUROSURGERY			English	Article						head injury; hemorrhage; prognosis; surgery; trauma; traumatic brain injury	PLASMA TRANSFUSION; LYMPHOCYTE RATIO; COAGULOPATHY; PLATELET; CRASH; VALIDATION; NEUTROPHIL; MODELS	OBJECTIVE Hematological abnormalities after severe traumatic brain injury (TBI) are common, and are associated with a poor outcome. Whether these abnormalities offer additional prognostic significance over and beyond validated TBI prognostic models is uncertain. METHODS This retrospective cohort study compared the ability of admission hematological abnormalities to that of the IMPACT (International Mission for Prognosis and Analysis of Clinical Trials) prognostic model to predict 18-month neurological outcome of 388 patients who required a decompressive craniectomy after severe TBI, between 2004 and 2016, in Western Australia. Area under the receiver operating characteristic (AUROC) curve was used to assess predictors' ability to discriminate between patients with and without an unfavorable outcome of death, vegetative state, or severe disability. RESULTS Of the 388 patients included in the study, 151 (38.9%) had an unfavorable outcome at 18 months after decompressive craniectomy for severe TBI. Abnormalities in admission hemoglobin (AUROC 0.594, p = 0.002), plasma glucose (AUROC 0.592, p = 0.002), fibrinogen (AUROC 0.563, p = 0.036), international normalized ratio (INR; AUROC 0.645, p = 0.001), activated partial thromboplastin time (AUROC 0.564, p = 0.033), and disseminated intravascular coagulation score (AUROC 0.623, p = 0.001) were all associated with a higher risk of unfavorable outcome at 18 months after severe TBI. As a marker of inflammation, neutrophil to lymphocyte ratio was not significantly associated with the risk of unfavorable outcome (AUROC 0.500, p = 0.998). However, none of these parameters, in addition to the platelet count, were significantly associated with an unfavorable outcome after adjusting for the IMPACT predicted risk (odds ratio [OR] per 10% increment in risk 2.473, 95% confidence interval [CI] 2.061-2.967; p = 0.001). After excluding 8 patients (2.1%) who were treated with warfarin prior to the injury, there was a suggestion that INR was associated with some additional prognostic significance (OR 3.183, 95% CI 0.856-11.833; p = 0.084) after adjusting for the IMPACT predicted risk. CONCLUSIONS In isolation, INR was the best hematological prognostic parameter in severe TBI requiring decompressive craniectomy, especially when patients treated with warfarin were excluded. However, the prognostic significance of admission hematological abnormalities was mostly captured by the IMPACT prognostic model, such that they did not offer any additional prognostic information beyond the IMPACT predicted risk. These results suggest that new prognostic factors for TBI should be evaluated in conjunction with predicted risks of a comprehensive prognostic model that has been validated, such as the IMPACT prognostic model.	[Corbett, Jade-Marie; Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, Australia; [Ho, Kwok M.] Murdoch Univ, Sch Vet & Life Sci, Perth, WA, Australia; [Honeybul, Stephen] Royal Perth & Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia	Ho, KM (corresponding author), Royal Perth Hosp, Perth, WA, Australia.	kwok.ho@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004	Department of Intensive Care Medicine, Royal Perth Hospital	This study was solely supported by the Department of Intensive Care Medicine, Royal Perth Hospital. No external support was received for this study.	Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0; Bauer DF, 2011, J TRAUMA, V70, P1112, DOI 10.1097/TA.0b013e3181e7c2ae; Chang R, 2017, SURGERY, V161, P538, DOI 10.1016/j.surg.2016.08.023; Chen WQ, 2018, J HEAD TRAUMA REHAB, V33, pE53, DOI 10.1097/HTR.0000000000000320; Dekker SE, 2016, J SURG RES, V205, P147, DOI 10.1016/j.jss.2016.06.023; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Herbert JP, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070092; Honeybul S, 2016, INJURY, V47, P1886, DOI 10.1016/j.injury.2016.04.017; Honeybul S, 2014, J NEUROSURG, V120, P1131, DOI 10.3171/2014.1.JNS131559; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rowell SE, 2014, J TRAUMA ACUTE CARE, V77, P846, DOI 10.1097/TA.0000000000000459; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tao CY, 2017, NEUROCRIT CARE, V26, P393, DOI 10.1007/s12028-016-0332-0; Toh CH, 2007, J THROMB HAEMOST, V5, P604, DOI 10.1111/j.1538-7836.2007.02313.x; Wang F, 2018, CNS NEUROSCI THER; Yuan Q, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-017-0471-0; Yuan Q, 2016, J NEUROTRAUM, V33, P1279, DOI 10.1089/neu.2015.4205	21	11	11	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2020	132	2					545	551		10.3171/2018.10.JNS182293			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KS5YL	WOS:000518384200024	30738401				2021-06-18	
J	Killgore, WDS; Vanuk, JR; Shane, BR; Weber, M; Bajaj, S				Killgore, William D. S.; Vanuk, John R.; Shane, Bradley R.; Weber, Mareen; Bajaj, Sahil			A randomized, double-blind, placebo-controlled trial of blue wavelength light exposure on sleep and recovery of brain structure, function, and cognition following mild traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						mTBI; Concussion; Light therapy; Blue light; Sleep; Circadian rhythm; Neuroimaging; DTI; VBM; Connectivity	DELAYED SLEEP; BRIGHT LIGHT; MELATONIN; DEPRIVATION; DISTURBANCE; WAKE; CONNECTIVITY; SENSITIVITY; DIFFUSION; THALAMUS	Sleep and circadian rhythms are among the most powerful but least understood contributors to cognitive performance and brain health. Here we capitalize on the circadian resetting effect of blue-wavelength light to phase shift the sleep patterns of adult patients (aged 18-48 years) recovering from mild traumatic brain injury (mTBI), with the aim of facilitating recovery of brain structure, connectivity, and cognitive performance. During a randomized, double-blind, placebo-controlled trial of 32 adults with a recent mTBI, we compared 6-weeks of daily 30-min pulses of blue light (peak lambda = 469 nm) each morning versus amber placebo light (peak lambda= 578 nm) on neurocognitive and neuroimaging outcomes, including gray matter volume (GMV), resting-state functional connectivity, directed connectivity using Granger causality, and white matter integrity using diffusion tensor imaging (DTI). Relative to placebo, morning blue light led to phase-advanced sleep timing, reduced daytime sleepiness, and improved executive functioning, and was associated with increased volume of the posterior thalamus (i.e., pulvinar), greater thalamo-cortical functional connectivity, and increased axonal integrity of these pathways. These findings provide insight into the contributions of the circadian and sleep systems in brain repair and lay the groundwork for interventions targeting the retinohypothalamic system to facilitate injury recovery.	[Killgore, William D. S.; Vanuk, John R.; Shane, Bradley R.; Weber, Mareen; Bajaj, Sahil] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85721 USA	Killgore, WDS (corresponding author), Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85721 USA.	killgore@psychiatry.arizona.edu	; Bajaj, Sahil/C-6580-2016	Killgore, William/0000-0002-5328-0208; Bajaj, Sahil/0000-0003-0629-6036	U.S. Army Medical Research and Development Command [W81XWH-11-1-0056]	This study was funded by a grant from the U.S. Army Medical Research and Development Command (W81XWH-11-1-0056) to W. D. S.K.	Aoki Y, 2016, NEUROSCI BIOBEHAV R, V66, P119, DOI 10.1016/j.neubiorev.2016.04.021; Arendt J, 2006, CHRONOBIOL INT, V23, P21, DOI 10.1080/07420520500464361; Bajaj S, 2016, BRAIN CONNECT, V6, P652, DOI 10.1089/brain.2016.0422; Bajaj S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00616; Banks SD, 2016, ARCH PHYS MED REHAB, V97, P1254, DOI 10.1016/j.apmr.2016.03.013; Beck AT, 1996, BDI 2 BECK DEPRESSIO; Bellesi M, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy034; Bellesi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36804; Bellesi M, 2013, J NEUROSCI, V33, P14288, DOI 10.1523/JNEUROSCI.5102-12.2013; BLAIR RC, 1993, PSYCHOPHYSIOLOGY, V30, P518, DOI 10.1111/j.1469-8986.1993.tb02075.x; Bolzenius JD, 2018, J HEAD TRAUMA REHAB, V33, P113, DOI 10.1097/HTR.0000000000000379; Brovelli A, 2004, P NATL ACAD SCI USA, V101, P9849, DOI 10.1073/pnas.0308538101; Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x; Clark AL, 2018, J HEAD TRAUMA REHAB, V33, P382, DOI 10.1097/HTR.0000000000000377; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Dai XJ, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00266; de Vivo L, 2017, SCIENCE, V355, P507, DOI 10.1126/science.aah5982; Dhamala M., 2013, ENCY COMPUTATIONAL N; Dhamala M, 2008, NEUROIMAGE, V41, P354, DOI 10.1016/j.neuroimage.2008.02.020; Dhamala M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.018701; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Figueiro MG, 2014, CLIN INTERV AGING, V9, P1527, DOI 10.2147/CIA.S68557; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Geerdink M, 2016, J BIOL RHYTHM, V31, P483, DOI 10.1177/0748730416657462; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Grima NA, 2016, NEUROREHAB NEURAL RE, V30, P972, DOI 10.1177/1545968316650279; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; HERSCOVITCH J, 1981, SLEEP, V4, P83, DOI 10.1093/sleep/4.1.83; Honma S, 2018, J PHYSIOL SCI, V68, P207, DOI 10.1007/s12576-018-0597-5; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Killgore WDS, 2006, J SLEEP RES, V15, P7, DOI 10.1111/j.1365-2869.2006.00487.x; Killgore WDS, 2007, SLEEP, V30, P345, DOI 10.1093/sleep/30.3.345; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lavie P, 2001, ANNU REV PSYCHOL, V52, P277, DOI 10.1146/annurev.psych.52.1.277; Liu CL, 2014, NEUROREPORT, V25, P320, DOI 10.1097/WNR.0000000000000091; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142; Monk T.H., 2005, CLIN SPORTS MED, V24, pxi; Munivenkatappa A, 2016, BRAIN INJURY, V30, P388, DOI 10.3109/02699052.2015.1089599; Naess-Schmidt ET, 2017, BRAIN INJURY, V31, P230, DOI 10.1080/02699052.2016.1229034; Nordin LE, 2016, SCI REP-UK, V6, DOI 10.1038/srep21183; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Qiu XD, 2005, NATURE, V433, P745, DOI 10.1038/nature03345; Raikes Adam C, 2018, Concussion, V3, pCNC57, DOI 10.2217/cnc-2018-0006; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Richardson C, 2018, SLEEP MED, V45, P114, DOI 10.1016/j.sleep.2018.02.001; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Rosa JPP, 2018, CHRONOBIOL INT, V35, P1095, DOI 10.1080/07420528.2018.1459660; Sapede D, 2013, CURR TOP DEV BIOL, V106, P171, DOI 10.1016/B978-0-12-416021-7.00005-5; Saxvig IW, 2014, CHRONOBIOL INT, V31, P72, DOI 10.3109/07420528.2013.823200; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Sinclair KL, 2014, NEUROREHAB NEURAL RE, V28, P303, DOI 10.1177/1545968313508472; Sullivan KA, 2016, APPL NEUROPSYCH-ADUL, V23, P426, DOI 10.1080/23279095.2016.1172229; Tahkamo L, 2018, CHRONOBIOL INT, V36, P1; Tononi G, 2014, NEURON, V81, P12, DOI 10.1016/j.neuron.2013.12.025; Tucker AM, 2010, SLEEP, V33, P47, DOI 10.1093/sleep/33.1.47; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058; Wu LM, 2018, J CLIN SLEEP MED, V14, P31, DOI 10.5664/jcsm.6874; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yeh E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060439; Yeh FC, 2016, NEUROIMAGE, V125, P162, DOI 10.1016/j.neuroimage.2015.10.053; Yeh FC, 2011, NEUROIMAGE, V58, P91, DOI 10.1016/j.neuroimage.2011.06.021; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	72	11	11	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2020	134								104679	10.1016/j.nbd.2019.104679			16	Neurosciences	Neurosciences & Neurology	KG3BV	WOS:000509818400045	31751607	Other Gold, Green Published			2021-06-18	
J	Svaldi, DO; Joshi, C; McCuen, EC; Music, JP; Hannemann, R; Leverenz, LJ; Nauman, EA; Talavage, TM				Svaldi, Diana O.; Joshi, Chetas; McCuen, Emily C.; Music, Jacob P.; Hannemann, Robert; Leverenz, Larry J.; Nauman, Eric A.; Talavage, Thomas M.			Accumulation of high magnitude acceleration events predicts cerebrovascular reactivity changes in female high school soccer athletes	BRAIN IMAGING AND BEHAVIOR			English	Article						Cerebrovascular Reactivity; Functional magnetic resonance imaging; Concussion; Mild traumatic brain injury; Subconcussive injury; Soccer	DEFAULT MODE NETWORK; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; 1ST EXPOSURE; FOOTBALL; CONCUSSION; SEASON; FMRI; PATHOPHYSIOLOGY	Mitigating the effects of repetitive exposure to head trauma has become a major concern for the general population, given the growing body of evidence that even asymptomatic exposure to head accelerations is linked with increased risk for negative life outcomes and that risk increases as exposure is prolonged over many years. Among women's sports, soccer currently exhibits the highest growth in participation and reports the largest number of mild traumatic brain injuries annually, making female soccer athletes a relevant population in assessing the effects of repetitive exposure to head trauma. Cerebrovascular biomarkers may be useful in assessing the effects of repetitive head trauma, as these are thought to contribute directly to neurocognitive symptoms associated with mild traumatic brain injury. Here we use fMRI paired with a hypercapnic breath hold task along with monitoring of head acceleration events, to assess the relationship between cerebrovascular brain changes and exposure to repetitive head trauma over a season of play in female high school soccer athletes. We identified longitudinal changes in cerebrovascular reactivity that were significantly associated with prolonged accumulation to high magnitude (> 75th percentile) head acceleration events. Findings argue for active monitoring of athletes during periods of exposure to head acceleration events, illustrate the importance of collecting baseline (i.e., pre-exposure) measurements, and suggest modeling as a means of guiding policy to mitigate the effects of repetitive head trauma.	[Svaldi, Diana O.; McCuen, Emily C.; Hannemann, Robert; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 4907 USA; [Svaldi, Diana O.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [Joshi, Chetas; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Music, Jacob P.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Hannemann, Robert] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA; [Hannemann, Robert] Purdue Univ, Dept Child Psychol, W Lafayette, IN 47907 USA; [Hannemann, Robert] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA	Svaldi, DO (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 4907 USA.; Svaldi, DO (corresponding author), Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.	dianaotero7@gmail.com		Svaldi, Diana/0000-0001-6265-1931	Indiana Clinical and Translational Sciences Institute Spinal Cord and Brain Injury Research Fund [SCBI 207-32]; BrainScope Company (GE-NFL Head Health Initiative)	This study was funded in part by the Indiana Clinical and Translational Sciences Institute Spinal Cord and Brain Injury Research Fund (Grant #SCBI 207-32), and the BrainScope Company (as part of a grant from the GE-NFL Head Health Initiative).	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bari S, 2019, BRAIN IMAGING BEHAV, V13, P735, DOI 10.1007/s11682-018-9861-9; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Bright MG, 2013, NEUROIMAGE, V83, P559, DOI 10.1016/j.neuroimage.2013.07.007; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chan ST, 2015, BRAIN INJURY, V29, P403, DOI 10.3109/02699052.2014.974209; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cummiskey B, 2017, P I MECH ENG P-J SPO, V231, P144, DOI 10.1177/1754337116658395; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ellis Michael J, 2016, Front Neurol, V7, P61, DOI 10.3389/fneur.2016.00061; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Lewis PM, 2014, VASCULAR MECH CNS TR; Lipp I, 2015, NEUROIMAGE, V113, P387, DOI 10.1016/j.neuroimage.2015.03.004; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Morris B, 2015, WHY IS US SO GOOD WO; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; Slobounov SM, 2017, NEUROIMAGE-CLIN, V14, P708, DOI 10.1016/j.nicl.2017.03.006; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stewart WF, 2017, NEUROLOGY, V88, P901, DOI 10.1212/WNL.0000000000003657; Svaldi DO, 2017, BRAIN IMAGING BEHAV, V11, P98, DOI 10.1007/s11682-016-9509-6; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Talavage TM, 2016, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00273; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072	56	11	11	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	FEB	2020	14	1					164	174		10.1007/s11682-018-9983-0			11	Neuroimaging	Neurosciences & Neurology	KJ1DP	WOS:000511797100017	30377933				2021-06-18	
J	Teymoori, A; Real, R; Gorbunova, A; Haghish, EF; Andelic, N; Wilson, L; Asendorf, T; Menon, D; von Steinbuchel, N				Teymoori, Ali; Real, Ruben; Gorbunova, Anastasia; Haghish, E. F.; Andelic, Nada; Wilson, Lindsay; Asendorf, Thomas; Menon, David; von Steinbuechel, Nicole			Measurement invariance of assessments of depression (PHQ-9) and anxiety (GAD-7) across sex, strata and linguistic backgrounds in a European-wide sample of patients after Traumatic Brain Injury	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Depression; Anxiety; Measurement invariance; Differential Item Functioning (DIF)	ITEM RESPONSE THEORY; GLASGOW COMA SCALE; MAJOR DEPRESSION; DISORDERS; ASSOCIATION; VALIDITY; SEQUELAE; PACKAGE; IMPACT; CARE	Background: The Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) are two widely used instruments to screen patients for depression and anxiety. Comparable psychometric properties across different demographic and linguistic groups are necessary for multiple group comparison and international research on depression and anxiety. Objectives and Method: We examine measurement invariance for the PHQ-9 and GAD-7 by: (a) the sex of the participants, (b) recruitment stratum, and (c) linguistic background. This study is based on non-randomized observational data six months after Traumatic Brain Injury (TBI) that were collected in 18 countries. We used multiple methods to detect Differential Item Functioning (DIF) including Item Response Theory, logistic regression, and the Mantel-Haenszel method. Results: At the 6-month post-injury, 2137 (738 [34.5%] women) participants completed the PHQ-9 and GAD-7 questionnaires: 885 [41.4%] patients were primarily admitted to the Intensive Care Unit (ICU), 805 [37.7%] were admitted to hospital ward, and 447 [20.9%] were evaluated in the Emergency Room and discharged. Results supported the invariance of PHQ-9 and GAD-7 across sex, patient strata and linguistic background. For different strata three PHQ-9 items and one GAD-7 item and for different linguistic groups only two GAD-7 items were flagged as showing differences in two out of four DIF tests. However, the magnitude of the DIF effect was negligible. Limitation: Despite high number of participants from ICU, patients have mostly mild TBI. Conclusion: The findings demonstrate adequate psychometric properties for PHQ-9 and GAD-7, allowing direct multigroup comparison across sex, strata, and linguistic background.	[Teymoori, Ali; Real, Ruben; Gorbunova, Anastasia; Haghish, E. F.; Asendorf, Thomas; von Steinbuechel, Nicole] Georg August Univ, Univ Med Ctr, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany; [Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Andelic, Nada] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, Oslo, Norway; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling, Scotland; [Asendorf, Thomas] Georg August Univ Gottingen, Med Ctr, Inst Med Stat, Gottingen, Germany; [Menon, David] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge, England	Teymoori, A (corresponding author), Georg August Univ, Univ Med Ctr, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	ali.teymoori@uqconnect.edu.au	Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328; Teymoori, Ali/0000-0003-2227-7361; Andelic, Nada/0000-0002-3719-4406	European UnionEuropean Commission [602150]	The research leading to these results was supported by the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement no 602150 (CENTER-TBI).	Arthurs E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052028; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chalmers RP, 2012, J STAT SOFTW, V48, P1; Clauser B.E., 1998, ED MEASUREMENT ISSUE, V17, P31, DOI [10.1111/j.1745-3992.1998.tb00619.x, DOI 10.1111/J.1745-3992.1998.TB00619.X]; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Galenkamp H, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1506-9; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Hambleton RK, 2006, MED CARE, V44, pS182, DOI 10.1097/01.mlr.0000245443.86671.c4; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Keum B.T, 2018, PSYCHOL ASSESS; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Magis D, 2010, BEHAV RES METHODS, V42, P847, DOI 10.3758/BRM.42.3.847; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005; Putnick DL, 2016, DEV REV, V41, P71, DOI 10.1016/j.dr.2016.06.004; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; REISE SP, 1993, PSYCHOL BULL, V114, P552, DOI 10.1037/0033-2909.114.3.552; Rutter LA, 2017, J PSYCHOPATHOL BEHAV, V39, P140, DOI 10.1007/s10862-016-9571-9; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Tay L, 2015, ORGAN RES METHODS, V18, P3, DOI 10.1177/1094428114553062; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zumbo BD., 2007, LANG ASSESS Q, V4, P223, DOI [10.1080/15434300701375832, DOI 10.1080/15434300701375832]	40	11	11	1	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	FEB 1	2020	262						278	285		10.1016/j.jad.2019.10.035			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	JU3RS	WOS:000501596400037	31732280	Green Accepted			2021-06-18	
J	Sen, T; Saha, P; Gupta, R; Foley, LM; Jiang, T; Abakumova, OS; Hitchens, TK; Sen, N				Sen, Tanusree; Saha, Pampa; Gupta, Rajaneesh; Foley, Lesley M.; Jiang, Tong; Abakumova, Olena S.; Hitchens, T. Kevin; Sen, Nilkantha			Aberrant ER Stress Induced Neuronal-IFN beta Elicits White Matter Injury Due to Microglial Activation and T-Cell Infiltration after TBI	JOURNAL OF NEUROSCIENCE			English	Article						IFN; microglia; neuroinflammation; traumatic brain injury; white matter injury	TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM STRESS; INTRACEREBRAL INFLAMMATORY RESPONSE; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; ANXIETY-LIKE BEHAVIOR; DIFFUSION TENSOR; POLARIZATION DYNAMICS; MICE; DEGENERATION	Persistent endoplasmic reticulum (ER) stress in neurons is associated with activation of inflammatory cells and subsequent neuroinflammation following traumatic brain injury (TBI); however, the underlying mechanism remains elusive. We found that induction of neuronal-ER stress, which was mostly characterized by an increase in phosphorylation of a protein kinase R-like ER kinase (PERK) leads to release of excess interferon (IFN)beta due to atypical activation of the neuronal-STING signaling pathway. IFN beta enforced activation and polarization of the primary microglial cells to inflammatory M1 phenotype with the secretion of a proinflammatory chemokine CXCL10 due to activation of STAT1 signaling. The secreted CXCL10, in turn, stimulated the T-cell infiltration by serving as the ligand and chemoattractant for CXCR3(+)T-helper 1 (Th1) cells. The activation of microglial cells and infiltration of Th1 cells resulted in white matter injury, characterized by impaired myelin basic protein and neurofilament NF200, the reduced thickness of corpus callosum and external capsule, and decline of mature oligodendrocytes and oligodendrocyte precursor cells. Intranasal delivery of CXCL10 siRNA blocked Th1 infiltration but did not fully rescue microglial activation and white matter injury after TBI. However, impeding PERK-phosphorylation through the administration of GSK2656157 abrogated neuronal induction of IFN beta, switched microglial polarization to M2 phenotype, prevented Th1 infiltration, and increased Th2 and Treg levels. These events ultimately attenuated the white matter injury and improved anxiety and depressive-like behavior following TBI.	[Sen, Tanusree; Saha, Pampa; Gupta, Rajaneesh; Jiang, Tong; Abakumova, Olena S.; Sen, Nilkantha] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin] Univ Pittsburgh, Anim Imaging Ctr, Sch Med, Pittsburgh, PA 15044 USA	Sen, T; Sen, N (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA.	tas215@pitt.edu; senn@pitt.edu	Gupta, Rajaneesh/AAD-5893-2019; Sen, Nilkantha/AAW-9788-2020	Gupta, Rajaneesh/0000-0003-0212-6478; Sen, Nilkantha/0000-0002-8383-8209	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS094516, R01EY025622]; University of PittsburghUniversity of Pittsburgh; Copeland Foundation	This work was partly supported by the National Institutes of Health (Grants R01NS094516 and R01EY025622 to N.S.), and the University of Pittsburgh and Copeland Foundation to T.S. and N.S.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abdullah A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1354-7; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Aroniadou-Anderjaska V, 2012, NEUROSCIENCE, V221, P157, DOI 10.1016/j.neuroscience.2012.07.006; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Berl S, 2017, J NEUROSCI METH, V283, P15, DOI 10.1016/j.jneumeth.2017.03.015; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bitko Vira, 2008, V442, P75, DOI 10.1007/978-1-59745-191-8_6; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Broussard JI, 2018, BRAIN INJURY, V32, P113, DOI 10.1080/02699052.2017.1380228; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CASH E, 1993, CELL IMMUNOL, V147, P129, DOI 10.1006/cimm.1993.1053; Cheeran MCJ, 2003, J VIROL, V77, P4502, DOI 10.1128/JVI.77.8.4502-4515.2003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen YX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08227-z; Chhatbar C, 2018, CELL REP, V25, P118, DOI 10.1016/j.celrep.2018.09.003; Cui YY, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00182; Dai PH, 2011, J VIROL, V85, P10814, DOI 10.1128/JVI.00104-11; Dash PK, 2015, J NEUROTRAUM, V32, P1608, DOI 10.1089/neu.2014.3772; Deczkowska A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00769-0; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; do Amaral JF, 2013, FUND CLIN PHARMACOL, V27, P471, DOI 10.1111/j.1472-8206.2012.01058.x; Donlin LT, 2014, J IMMUNOL, V193, P2373, DOI 10.4049/jimmunol.1400486; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Einat H, 2001, BEHAV BRAIN RES, V118, P77, DOI 10.1016/S0166-4328(00)00314-4; Ejlerskov P, 2015, CELL, V163, P324, DOI 10.1016/j.cell.2015.08.069; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fenwick PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128757; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fu HJ, 2019, NAT NEUROSCI, V22, P47, DOI 10.1038/s41593-018-0298-7; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Guida F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00095; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hernandez-Rabaza V, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0420-7; Hilgenberg Lutz G W, 2007, J Vis Exp, P562, DOI 10.3791/562; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hood KN, 2018, J NEUROSCI, V38, P2372, DOI 10.1523/JNEUROSCI.1756-17.2018; Jin XM, 2016, J BIOCHEM, V159, P491, DOI 10.1093/jb/mvw009; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones KJ, 2015, J NEUROIMMUNE PHARM, V10, P587, DOI 10.1007/s11481-015-9625-x; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Lian Hong, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1989; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu YP, 2012, J IMMUNOL, V189, P4630, DOI 10.4049/jimmunol.1102737; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Lopez-Fabuel I, 2016, P NATL ACAD SCI USA, V113, P13063, DOI 10.1073/pnas.1613701113; Matveeva V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113453; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Michlmayr D., 2014, INT J INTERFER CYT M, V6, P1; Mills CD, 2014, J INNATE IMMUN, V6, P716, DOI 10.1159/000364945; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moore SM, 2014, P NATL ACAD SCI USA, V111, P18061, DOI 10.1073/pnas.1411294111; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Narayana Ponnada A, 2017, Concussion, V2, pCNC35, DOI 10.2217/cnc-2016-0028; Ndode-Ekane XE, 2018, RESTOR NEUROL NEUROS, V36, P485, DOI 10.3233/RNN-170811; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Petrasek J, 2013, P NATL ACAD SCI USA, V110, P16544, DOI 10.1073/pnas.1308331110; Pino Paula A, 2011, J Vis Exp, DOI 10.3791/2348; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Qin C, 2017, STROKE, V48, P3336, DOI 10.1161/STROKEAHA.117.018505; Qu WR, 2016, NEURAL REGEN RES, V11, P248, DOI 10.4103/1673-5374.177732; Rodgers KM, 2014, J NEUROTRAUM, V31, P487, DOI [10.1089/NEU.2013.3090, 10.1089/neu.2013.3090]; Rodriguez M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01819-9; Rojas-Rivera D, 2017, CELL DEATH DIFFER, V24, P1100, DOI 10.1038/cdd.2017.58; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Saha P, 2018, NEUROBIOL DIS, V118, P108, DOI 10.1016/j.nbd.2018.07.010; Schafer DP, 2016, ELIFE, V5, DOI 10.7554/eLife.15224; Sen T, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6765; Sen T, 2017, J NEUROSCI, V37, P5900, DOI 10.1523/JNEUROSCI.2343-16.2017; Sen T, 2016, NEUROPHARMACOLOGY, V107, P79, DOI 10.1016/j.neuropharm.2016.03.009; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Tan HP, 2018, NEURAL REGEN RES, V13, P827, DOI 10.4103/1673-5374.232477; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Xia YG, 2018, P NATL ACAD SCI USA, V115, pE9230, DOI 10.1073/pnas.1810693115; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xu ZH, 2015, J NEUROCHEM, V133, P233, DOI 10.1111/jnc.13064; Yi Y, 2018, MOL NEUROBIOL, V55, P2454, DOI 10.1007/s12035-017-0504-8; Yu F, 2015, NAT IMMUNOL, V16, P197, DOI 10.1038/ni.3053; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015; Zhu CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12184-y; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	107	11	11	2	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JAN 8	2020	40	2					424	446		10.1523/JNEUROSCI.0718-19.2019			23	Neurosciences	Neurosciences & Neurology	KB0QB	WOS:000506203800013	31694961	Bronze, Green Published			2021-06-18	
J	Jodra, P; Lago-Rodriguez, A; Sanchez-Oliver, AJ; Lopez-Samanes, A; Perez-Lopez, A; Veiga-Herreros, P; San Juan, AF; Dominguez, R				Jodra, P.; Lago-Rodriguez, A.; Sanchez-Oliver, A. J.; Lopez-Samanes, A.; Perez-Lopez, A.; Veiga-Herreros, P.; San Juan, A. F.; Dominguez, R.			Effects of caffeine supplementation on physical performance and mood dimensions in elite and trained-recreational athletes	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION			English	Article						Caffeine; Sport supplementation; Athletes; Boxing; Ergogenic aid	REPEATED-SPRINT PERFORMANCE; SPORTS-RELATED CONCUSSION; NUTRITIONAL SUPPLEMENTS; ERGOGENIC AIDS; MUSCLE PAIN; INGESTION; DEPRESSION; INCREASES; RESPONSES; ENDURANCE	Background: Caffeine supplementation (CAFF) has an established ergogenic effect on physical performance and the psychological response to exercise. However, few studies have compared the response to CAFF intake among athletes of different competition level. This study compares the acute effects of CAFF on anaerobic performance, mood and perceived effort in elite and moderately-trained recreational athletes. Methods: Participants for this randomized, controlled, crossover study were 8 elite athletes (in the senior boxing national team) and 10 trained-recreational athletes. Under two experimental conditions, CAFF supplementation (6 mg/kg) or placebo (PLAC), the athletes completed a Wingate test. Subjective exertion during the test was recorded as the rating of perceived exertion (RPE) both at the general level (RPEgeneral) and at the levels muscular (RPEmuscular) and cardiorespiratory (RPEcardio). Before the Wingate test, participants completed the questionnaires Profiles of Moods States (POMS) and Subjective Vitality Scale (SVS). Results: In response to CAFF intake, improvements were noted in W-peak (11.22 +/- 0.65 vs 10.70 +/- 0.84; p = 0.003; eta(2)(p) =0.44), W-avg (8.75 +/- 0.55 vs 8.41 0.46; p = 0.001; eta(2)(p) =0.53) and time taken to reach Wpeak (7.56 +/- 1.58 vs 9.11 +/- 1.53; p < 0.001; eta(2)(p) =0.57) both in the elite and trained-recreational athletes. However, only the elite athletes showed significant increases in tension (+ 325%), vigor (+ 31%) and SVS (+ 28%) scores after the intake of CAFF compared to levels recorded under the condition PLAC ( p < 0.05). Similarly, levels of vigor after consuming CAFF were significantly higher in the elite than the trained- recreational athletes (+ 5.8%). Conclusions: CAFF supplementation improved anaerobic performance in both the elite and recreational athletes. However, the ergogenic effect of CAFF on several mood dimensions and subjective vitality was greater in the elite athletes.	[Jodra, P.; Veiga-Herreros, P.] Univ Alfonso X Sabio, Fac Hlth Sci, Madrid, Spain; [Jodra, P.] Univ Alcala De Henares, Madrid, Spain; [Lago-Rodriguez, A.; Dominguez, R.] Univ Isabel I, Fac Hlth Sci, Burgos, Spain; [Sanchez-Oliver, A. J.] Univ Seville, Fac Educ Sci, Dept Human Motric & Sports Performance, Seville, Spain; [Lopez-Samanes, A.] Univ Francisco de Vitoria, Fac Hlth Sci, Sch Physiotherapy, Madrid, Spain; [Perez-Lopez, A.] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Biomed Sci, Madrid, Spain; [San Juan, A. F.] Univ Politecn Madrid, Sports Biomech Lab, Dept Hlth & Human Performance, Fac Phys Act & Sport Sci,INEF, Madrid, Spain	Lago-Rodriguez, A (corresponding author), Univ Isabel I, Fac Hlth Sci, Burgos, Spain.	angel.lago@ui1.es	Sanchez-Oliver, Antonio J/AAD-6640-2019; Rodriguez, Angel Lago/M-4351-2018; Jodra, Pablo/U-8322-2017; San Juan, Alejandro/AAN-9136-2020; Perez-Lopez, Alberto/I-7559-2015	Sanchez-Oliver, Antonio J/0000-0001-9022-6043; Rodriguez, Angel Lago/0000-0002-2942-5462; Jodra, Pablo/0000-0003-3331-8464; San Juan, Alejandro/0000-0002-7083-7610; Perez-Lopez, Alberto/0000-0003-0220-6240; Veiga Herreros, Pablo/0000-0002-5054-2815; Dominguez, Raul/0000-0002-6891-391X; Lopez Samanes, Alvaro/0000-0003-0721-0150	UAX; Banco Santander	This study was financed (supplementation, translation and publication costs) by a grant for the project Effects of caffeine supplementation on psychophysiological responses of performance and fatigue in the Olympic boxing team of the X Call for Research Projects of the UAX and Banco Santander.	Abidin MAH, 2018, SPORT SCI HLTH, V14, P673, DOI [10.1007/s11332-018-0492-8, DOI 10.1007/S11332-018-0492-8]; Abo-Salem OM, 2004, J PHARMACOL EXP THER, V308, P358, DOI 10.1124/jpet.103.056036; Aguilar-Navarro M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020286; Ali A, 2016, J SPORT SCI, V34, P330, DOI 10.1080/02640414.2015.1052746; ALLEN DG, 1995, J PHYSIOL-LONDON, V487, P331, DOI 10.1113/jphysiol.1995.sp020883; Astorino TA, 2010, MED SCI SPORT EXER, V42, P2205, DOI 10.1249/MSS.0b013e3181e3a11d; Balaguer E, 2005, CAPLLETRA, P9; BAROR O, 1987, SPORTS MED, V4, P381, DOI 10.2165/00007256-198704060-00001; Boyett JC, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100639; Brosse AL, 2002, SPORT MED, V32, P741; Casado A, 2019, EUR J SPORT SCI, V19, P1045, DOI 10.1080/17461391.2019.1593510; Chtourou H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11050992; COLLOMP K, 1992, EUR J APPL PHYSIOL O, V64, P377, DOI 10.1007/BF00636227; Cuenca E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091222; Davis JK, 2009, SPORTS MED, V39, P813, DOI 10.2165/11317770-000000000-00000; Davis JM, 2003, AM J PHYSIOL-REG I, V284, pR399, DOI 10.1152/ajpregu.00386.2002; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; Demirkan E, 2015, J STRENGTH COND RES, V29, P1876, DOI 10.1519/JSC.0000000000000833; Desbrow B, 2012, J SPORT SCI, V30, P115, DOI 10.1080/02640414.2011.632431; Doherty M, 2004, J SPORT SCI, V22, P637, DOI 10.1080/02640410310001655741; Dominguez R, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121360; Duncan MJ, 2019, EUR J SPORT SCI, V19, P103, DOI 10.1080/17461391.2018.1508505; Duncan MJ, 2013, EUR J SPORT SCI, V13, P392, DOI 10.1080/17461391.2011.635811; Duncan MJ, 2011, J STRENGTH COND RES, V25, P178, DOI 10.1519/JSC.0b013e318201bddb; Duncan MJ, 2011, J STRENGTH COND RES, V25, P178; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Ferreira LHB, 2018, MED SCI SPORT EXER, V50, P599; Fuentes I., 1995, 5 C NAC PSIC ACT FIS; Pallares JG, 2012, J STRENGTH COND RES, V26, P794, DOI 10.1519/JSC.0b013e31824741e7; Garcia-Pallares J, 2011, EUR J APPL PHYSIOL, V111, P1747, DOI 10.1007/s00421-010-1809-8; Glaister M, 2018, INT J SPORT PHYSIOL, V13, P402, DOI 10.1123/ijspp.2017-0312; Goods PSR, 2017, J SPORT SCI MED, V16, P93; Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002; Graham-Paulson T, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070393; Grgic J, 2018, J INT SOC SPORT NUTR, V15, DOI 10.1186/s12970-018-0216-0; Grgic J, 2018, EUR J SPORT SCI, V18, P219, DOI 10.1080/17461391.2017.1394371; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; HANIN YL, 1978, SPORT PSYCHOL ANAL A, P236; Hanin YL, 2007, EMOTIONS ATHLETIC PE; Jacobson B H, 1992, Br J Sports Med, V26, P276; Jodra P, 2020, INT J SPORT PHYSIOL, V15, P243, DOI 10.1123/ijspp.2019-0149; Jonvik KL, 2018, EUR J SPORT SCI, V18, P524, DOI 10.1080/17461391.2018.1433722; Salinero JJ, 2019, RES SPORTS MED, V27, P238, DOI 10.1080/15438627.2018.1552146; Kalmar JM, 2006, J APPL PHYSIOL, V100, P1757, DOI 10.1152/japplphysiol.01347.2005; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Killen LG, 2013, EUR J APPL PHYSIOL, V113, P721, DOI 10.1007/s00421-012-2480-z; Kristiansen M, 2005, INT J SPORT NUTR EXE, V15, P195, DOI 10.1123/ijsnem.15.2.195; Kumar N, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00009; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lane AM, 2005, J SPORT SCI MED, V4, P47; Lane AM, 2005, J SPORTS SCI MED, V4, P195; Laurence G, 2012, J SPORT SCI, V30, P1235, DOI 10.1080/02640414.2012.693620; Lieberman HR, 2001, NUTR REV, V59, P91, DOI 10.1111/j.1753-4887.2001.tb06995.x; Lopez-Dominguez R, 2018, RETOS-NUEV TEND EDUC, P272; Lopez-Gonzalez LM, 2018, J INT SOC SPORT NUTR, V15, DOI 10.1186/s12970-018-0267-2; Lopez-Samanes A, 2017, NUTR HOSP, V34, P1463, DOI 10.20960/nh.1404; Lopez-Samanes A, 2015, STRENGTH COND J, V37, P1; Makdissi M, 2014, AUST FAM PHYSICIAN, V43, P94; Marcora SM, 2010, EUR J APPL PHYSIOL, V109, P763, DOI 10.1007/s00421-010-1418-6; Maughan RJ, 2018, INT J SPORT NUTR EXE, V28, P104, DOI 10.1123/ijsnem.2018-0020; McLellan TM, 2016, NEUROSCI BIOBEHAV R, V71, P294, DOI 10.1016/j.neubiorev.2016.09.001; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; McNair D.M., 1992, MANUAL PROFILE MOOD; Medicine GB, 1978, SCAND J REHABIL, V6, P197; Meeusen R, 2014, SPORTS MED, V44, P47, DOI 10.1007/s40279-014-0150-5; *MIN SAN CONS, 2005, REAL FARM ESP; Moore RD, 2016, BRAIN IMAGING BEHAV, V10, P1108, DOI 10.1007/s11682-015-9473-6; Motl RW, 2003, J PAIN, V4, P316, DOI 10.1016/S1526-5900(03)00635-7; Muller K, 1989, TECHNOMETRICS, V31, DOI [DOI 10.2307/1270020, https://doi.org/10.2307/1270020]; Negaresh R, 2019, EUR J SPORT SCI, V19, P499, DOI 10.1080/17461391.2018.1534990; Nehlig A, 2010, J ALZHEIMERS DIS, V20, pS85, DOI 10.3233/JAD-2010-091315; Pallares JG, 2013, MED SCI SPORT EXER, V45, P2184, DOI 10.1249/MSS.0b013e31829a6672; Paton CD, 2010, EUR J APPL PHYSIOL, V110, P1243, DOI 10.1007/s00421-010-1620-6; Petroczi A, 2008, J INT SOC SPORT NUTR, V5, DOI 10.1186/1550-2783-5-2; Plaskett CJ, 2001, J APPL PHYSIOL, V91, P1535; Potach D, 2002, NSCA FUNDAM ENTREN P, P515; Richardson JTE, 2011, EDUC RES REV-NETH, V6, P135, DOI 10.1016/j.edurev.2010.12.001; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; Ryan RM, 1997, J PERS, V65, P529, DOI 10.1111/j.1467-6494.1997.tb00326.x; Sanchez-Oliver A, 2008, ARCH LATINOAM NUTR, V58, P221; Skinner TL, 2014, J SCI MED SPORT, V17, P516, DOI 10.1016/j.jsams.2013.07.006; Smith A, 2002, FOOD CHEM TOXICOL, V40, P1243, DOI 10.1016/S0278-6915(02)00096-0; Sokmen B, 2008, J STRENGTH COND RES, V22, P978, DOI 10.1519/JSC.0b013e3181660cec; Solomon GS, 2016, PHYSICIAN SPORTSMED, V44, P14, DOI 10.1080/00913847.2016.1121091; Souissi M, 2015, BIOL RHYTHM RES, V46, P291, DOI 10.1080/09291016.2014.994857; Souissi M, 2013, BIOL RHYTHM RES, V44, P897, DOI 10.1080/09291016.2013.780700; Souissi Makram, 2012, Asian J Sports Med, V3, P161; Stevens MJ, 2006, J SPORT SCI MED, V5, P143; Stojanovic E, 2019, APPL PHYSIOL NUTR ME, V44, P849, DOI 10.1139/apnm-2018-0671; Teychenne M, 2010, HEALTH EDUC RES, V25, P632, DOI 10.1093/her/cyq008; Tsitsimpikou C, 2011, INT J SPORT NUTR EXE, V21, P377, DOI 10.1123/ijsnem.21.5.377; Vargas G, 2015, J ATHL TRAINING, V50, P250, DOI 10.4085/1062-6050-50.3.02; Wiles JD, 2006, J SPORT SCI, V24, P1165, DOI 10.1080/02640410500457687; Woolf K, 2008, INT J SPORT NUTR EXE, V18, P412, DOI 10.1123/ijsnem.18.4.412; Yang JZ, 2015, DEV NEUROPSYCHOL, V40, P18, DOI 10.1080/87565641.2014.973499; Yrondi A, 2017, PRESSE MED, V46, P890, DOI 10.1016/j.lpm.2017.08.013	96	11	11	7	19	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1550-2783		J INT SOC SPORT NUTR	J. Int. Soc. Sport Nutr.	JAN 3	2020	17	1							2	10.1186/s12970-019-0332-5			11	Nutrition & Dietetics; Sport Sciences	Nutrition & Dietetics; Sport Sciences	KK2UH	WOS:000512602800001	31900166	DOAJ Gold, Green Published			2021-06-18	
J	Chiaravalloti, ND; Weber, E; Wylie, G; Dyson-Hudson, T; Wecht, JM				Chiaravalloti, Nancy D.; Weber, Erica; Wylie, Glenn; Dyson-Hudson, Trevor; Wecht, Jill M.			Patterns of cognitive deficits in persons with spinal cord injury as compared with both age-matched and older individuals without spinal cord injury	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injury; Cognitive deficits; Memory; Processing speed; Executive functioning	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; TREAT LEARNING IMPAIRMENT; MULTIPLE-SCLEROSIS; DYSFUNCTION; MEMORY; REHABILITATION; PERFORMANCE; EXPOSURE; FLUENCY	Context/Objective: Cognitive deficits can impact as many as 60% of individuals with spinal cord injury (SCI). In an effort to identify the nature of cognitive deficits in SCI, we examined neuropsychological test performance in individuals with SCI, age matched healthy controls and older healthy controls. Design: Participants completed a motor-free neuropsychological test battery assessing attention, working memory, information processing speed, new learning /memory and executive control. Setting: Outpatient rehabilitation research facility. Participants: Participants included 60 individuals with chronic spinal cord injury [SCI; 32 with paraplegia (T2-T12) and 28 with tetraplegia (C3-T1)], 30 age-matched healthy controls (AMHC; 30-40 years old) and 20 older healthy controls (OHC; 50-60 years old). Outcome Measures: Wechsler Intelligence Scale - 3(rd) edition (WAIS-III) Digit Span and Letter-Number Sequencing; Symbol Digit Modalities Test (SDMT) - oral version; California Verbal Learning Test-II; Paced Auditory Serial Addition Test (PASAT); Wechsler Abbreviated Scale of Intelligence (WASI); Delis-Kaplan Executive Function System; Verbal Fluency subtest. Results: Significant differences were noted between the SCI and AMHC groups on measures of information processing speed, new learning and memory, and verbal fluency. No significant differences were noted between the groups on tests of attention or working memory. Conclusion: The current study documented differences in specific realms of cognitive functioning between a chronic SCI sample and AMHC. Implications for cognitive rehabilitation and overall quality of life are discussed. Additional research is needed utilizing a more comprehensive battery of motor-free neuropsychological tests that avoid the confound of upper limb motor limitations on cognitive performance.	[Chiaravalloti, Nancy D.; Weber, Erica] Kessler Fdn, Traumat Brain Injury Res, W Orange, NJ USA; [Chiaravalloti, Nancy D.; Wylie, Glenn] Kessler Fdn, Neuropsychol & Neurosci Res, W Orange, NJ USA; [Chiaravalloti, Nancy D.; Weber, Erica; Wylie, Glenn; Dyson-Hudson, Trevor] Rutgers NJ, Dept Phys Med & Rehabil, Med Sch, Newark, NJ USA; [Wylie, Glenn] VA War Related Illness & Injury Study Ctr, E Orange, NJ USA; [Dyson-Hudson, Trevor] Kessler Fdn, Spinal Cord Injury Res, W Orange, NJ USA; [Wecht, Jill M.] VA RR&D Natl Ctr Med Consequences SCI, James J Peters VAMC, Bronx, NY USA; [Wecht, Jill M.] Icahn Sch Med Mt Sinai, Dept Med & Rehabil Med, New York, NY 10029 USA	Chiaravalloti, ND (corresponding author), Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA.	nchiaravalloti@kesslerfoundation.org		Chiaravalloti, Nancy/0000-0003-2943-7567; Dyson-Hudson, Trevor/0000-0002-0252-2764	New Jersey Commission on Spinal Cord Research [CSCR13IRG018]; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B9212-C]	This work was supported by New Jersey Commission on Spinal Cord Research: [Grant Number CSCR13IRG018]; Rehabilitation Research and Development Service: [Grant Number B2020-C]; Rehabilitation Research and Development Service: [Grant Number B9212-C].	[Anonymous], 2015, J SPINAL CORD MED, V38, P812; Bombardier CH, 2016, ARCH PHYS MED REHAB, V97, P1628, DOI 10.1016/j.apmr.2016.03.008; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS77, DOI 10.1016/j.apmr.2008.07.008; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Capitani E, 2009, NEUROPSYCHOLOGIA, V47, P423, DOI 10.1016/j.neuropsychologia.2008.09.016; Carlozzi NE, 2017, ARCH CLIN NEUROPSYCH, V32, P555, DOI 10.1093/arclin/acx020; Chiaravalloti ND, 2016, NEUROREHAB NEURAL RE, V30, P539, DOI 10.1177/1545968315604395; Chiaravalloti ND, 2015, MULT SCLER J, V21, P1575, DOI 10.1177/1352458514567726; Chiaravalloti ND, 2013, NEUROLOGY, V81, P2066, DOI 10.1212/01.wnl.0000437295.97946.a8; Chiaravalloti ND, 2005, MULT SCLER, V11, P58, DOI 10.1191/1352458505ms1118oa; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Craig A, 2017, J NEUROTRAUM, V34, P1156, DOI 10.1089/neu.2016.4632; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1990, ARCH PHYS MED REHAB, V71, P121; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; Davidoff G, 1990, Arch Clin Neuropsychol, V5, P77, DOI 10.1016/0887-6177(90)90009-E; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Delis D, 2000, DELIS KAPLAN EXECUTI; Delis DC, 1987, CALIFORNIA VERBAL LE; Dowler R N, 1995, Appl Neuropsychol, V2, P124, DOI 10.1207/s15324826an0203&4_4; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; DUBO H, 1984, P AM SPINAL INJURY A, P35; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; Engelberts NHJ, 2002, EPILEPSY BEHAV, V3, P316, DOI 10.1016/S1525-5050(02)00036-7; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Guggenmos M, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/s41398-017-0037-y; Handrakis JP, 2017, J NEUROTRAUM, V34, P3372, DOI 10.1089/neu.2016.4850; Handrakis JP, 2015, J NEUROTRAUM, V32, P1168, DOI 10.1089/neu.2014.3719; Inzitari D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2477; Jefferson AL, 2010, CIRCULATION, V122, P690, DOI 10.1161/CIRCULATIONAHA.109.905091; Jegede AB, 2010, CLIN AUTON RES, V20, P3, DOI 10.1007/s10286-009-0036-z; Jones S, 2006, CORTEX, V42, P347, DOI 10.1016/S0010-9452(08)70361-7; KESSLER HR, 1992, INT J NEUROSCI, V62, P17, DOI 10.3109/00207459108999754; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Koutsouleris N, 2014, SCHIZOPHRENIA BULL, V40, P1140, DOI 10.1093/schbul/sbt142; Krch D, 2011, J INT NEUROPSYCH SOC, V17, P557, DOI 10.1017/S1355617711000336; Krebs J, 2018, SPINAL CORD, V56, P22, DOI 10.1038/sc.2017.94; Krystal JH, 2005, ARCH GEN PSYCHIAT, V62, P985, DOI 10.1001/archpsyc.62.9.985; Ladavass E, 2011, EUR J PHYS REHAB MED, V47, P91; Lu PH, 2011, J CLIN EXP NEUROPSYC, V33, P1059, DOI 10.1080/13803395.2011.595397; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Molina B, 2018, SPINAL CORD, V56, P796, DOI 10.1038/s41393-018-0076-0; Murray RF, 2007, SPINAL CORD, V45, P429, DOI 10.1038/sj.sc.3102022; Postal KS., 2013, FEEDBACK STICKS ART; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Salthouse TA, 2010, J INT NEUROPSYCH SOC, V16, P754, DOI 10.1017/S1355617710000706; Salthouse TA, 2009, J INT NEUROPSYCH SOC, V15, P650, DOI 10.1017/S1355617709990385; Schembri R, 2017, SLEEP, V40, P1, DOI DOI 10.1093/sleep/zsw037; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schueneman AL, 1982, SCI DIG, V4, P64; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tzourio C, 2014, HYPERTENSION, V63, P894, DOI 10.1161/HYPERTENSIONAHA.113.00147; WAGNER H, 1984, INT J RADIAT ONCOL, V10, P1575, DOI 10.1016/0360-3016(84)90506-6; Weber E, 2018, LEARNING MEMORY PROF; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wecht JM, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12683; Wecht JM, 2012, CLIN AUTON RES, V22, P25, DOI 10.1007/s10286-011-0139-1; Wecht JM, J NEUROTRAUMA UNPUB; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; Wood RL, 2017, BRAIN INJURY, V31, P1270, DOI 10.1080/02699052.2017.1332387	75	11	11	1	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JAN 2	2020	43	1					88	97		10.1080/10790268.2018.1543103			10	Clinical Neurology	Neurosciences & Neurology	KD1IS	WOS:000507626000011	30508409	Green Published			2021-06-18	
J	Miller, LE; Pinkerton, EK; Fabian, KC; Wu, LC; Espeland, MA; Lamond, LC; Miles, CM; Camarillo, DB; Stitzel, JD; Urban, JE				Miller, Logan E.; Pinkerton, Elizabeth K.; Fabian, Katie C.; Wu, Lyndia C.; Espeland, Mark A.; Lamond, Lindsey C.; Miles, Christopher M.; Camarillo, David B.; Stitzel, Joel D.; Urban, Jillian E.			Characterizing head impact exposure in youth female soccer with a custom-instrumented mouthpiece	RESEARCH IN SPORTS MEDICINE			English	Article						Subconcussive head impacts; head impact exposure; mouthpiece; instrumentation; women's soccer	STATES HIGH-SCHOOL; CONCUSSION INCIDENCE; BRAIN; EPIDEMIOLOGY; INJURIES; ACCELERATION; SPORTS	While many research efforts have focused on head impact exposure in professional soccer, there have been few studies characterizing exposure at the youth level. The aim of this study is to evaluate a new instrumentation approach and collect some of the first head impact exposure data for youth female soccer players. Athletes were instrumented with custom-fit mouthpieces that measure head impacts. Detailed video analysis was conducted to identify characteristics describing impact source (e.g., kick, header, throw). A total of 763 verified head impacts were collected over 23 practices and 8 games from 7 athletes. The median peak linear accelerations, rotational velocities, and rotational accelerations of all impacts were 9.4 g, 4.1 rad/s, and 689 rad/s(2), respectively. Pairwise comparisons resulted in statistically significant differences in kinematics by impact source. Headers following a kicked ball had the highest accelerations and velocity when compared to headers from thrown or another header.	[Miller, Logan E.; Pinkerton, Elizabeth K.; Fabian, Katie C.; Miles, Christopher M.; Stitzel, Joel D.; Urban, Jillian E.] Wake Forest Sch Med, Dept Biomed Engn, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27106 USA; [Miller, Logan E.; Stitzel, Joel D.; Urban, Jillian E.] Wake Forest Univ, Sch Biomed Engn & Sci, Virginia Tech, Winston Salem, NC 27101 USA; [Wu, Lyndia C.; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC 27106 USA; [Lamond, Lindsey C.] Wake Forest Sch Med, Dept Family & Community Med, Winston Salem, NC 27106 USA	Urban, JE (corresponding author), Wake Forest Sch Med, Dept Biomed Engn, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27106 USA.	jurban@wakehealth.edu	Wu, Lyndia/AAQ-1106-2020	Wu, Lyndia/0000-0002-8236-032X			Abramowitz M, 1965, HDB MATH FUNCTIONS F, V55; [Anonymous], 2016, IMPLEMENTATION GUIDE; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Caccese JB, 2018, SPORT BIOMECH, V17, P462, DOI 10.1080/14763141.2017.1360385; Caccese JB, 2018, RES SPORTS MED, V26, P64, DOI 10.1080/15438627.2017.1393756; Caccese JB, 2016, RES SPORTS MED, V24, P407, DOI 10.1080/15438627.2016.1230549; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chrisman SPD, 2019, CLIN J SPORT MED, V29, P3, DOI 10.1097/JSM.0000000000000497; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Cuff SC, 2019, RES SPORTS MED, V27, P11, DOI 10.1080/15438627.2018.1502186; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; FIFA Communications Division, 2007, FIFA DAT BIG COUNT 2, DOI 10.1177/0883073816634857; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harriss A, 2018, RES SPORTS MED, V26, P191, DOI 10.1080/15438627.2018.1431534; Hood E. A., 2018, RES SPORTS MED, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hunter LE, 2018, RES SPORTS MED, V26, P390, DOI 10.1080/15438627.2018.1492396; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Langhorst P., 2016, ENGAGE SPORTS; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Miller LE, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4039165; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Press J. N, 2016, CLIN J SPORT MED; Rowson S., 2012, HEAD ACCELERATION ME; Salinas CM, 2009, J CLIN SPORT PSYCHOL, V3, P15, DOI 10.1123/jcsp.3.1.15; Self BP, 2006, ENG SPORT 6, V6, P81; Society of Automotive Engineers, 2007, J2111 SAE; Tyson A., 2017, LAB EVALUATION LOW C; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; U.S. Soccer Announces Recognize to Recover Player Health and Safety Program, 2015, US SOCCER ANNOUNCES; U.S. Soccer Provides Additional Information About Upcoming Player Safety Campaign, 2015, US SOCCER PROVIDES A; Walker L. B., 1973, SAE TECHNICAL PAPER; Wu L., 2016, ABS160107255 CORR, P1; Wu LC, 2016, J BIOMECH, V49, P2918, DOI 10.1016/j.jbiomech.2016.07.004; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153	46	11	11	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1543-8627	1543-8635		RES SPORTS MED	Res. Sports Med.	JAN 2	2020	28	1					55	71		10.1080/15438627.2019.1590833			17	Sport Sciences	Sport Sciences	KE9PZ	WOS:000508883700005	30880469				2021-06-18	
J	Wu, JC; He, JC; Tian, XC; Zhong, JJ; Li, H; Sun, XC				Wu, Jingchuan; He, Junchi; Tian, Xiaocui; Zhong, Jianjun; Li, Hui; Sun, Xiaochuan			Activation of the Hedgehog Pathway Promotes Recovery of Neurological Function After Traumatic Brain Injury by Protecting the Neurovascular Unit	TRANSLATIONAL STROKE RESEARCH			English	Article						Hedgehog pathway; Traumatic brain injury; Neurovascular unit; Blood-brain barrier; Oxygen-glucose deprivation; Inflammation	SONIC-HEDGEHOG; RESVERATROL; STROKE; PROLIFERATION; ANGIOGENESIS; IMPROVES; EDEMA; CELLS; MODEL	The homeostasis of the neurovascular unit (NVU) is disrupted after traumatic brain injury (TBI), and therapeutic strategies targeting the NVU would likely improve neurological outcomes after TBI. Sonic Hedgehog (Shh), which is an endogenous activator of the Hedgehog pathway, promotes brain repair in various injuries. In this study, the controlled cortical impact (CCI) was used to establish a moderate TBI model in adult male Sprague-Dawley rats (250-300 g), and the NVU was reconstructed in vitro from the blood-brain barrier (BBB) and neurons to investigate the effects of exogenous Shh protein on TBI. The modified neurological severity scores (mNSS) and Morris water maze tests were used to evaluate the effect of Shh on neurological function after TBI. The effect of Shh on the NVU in vivo was evaluated by detecting the degrees of cerebral edema and neuronal apoptosis. The integrity and permeability of the BBB, the level of inflammatory factors, and the expression of apoptotic proteins were detected to explore the effect of exogenous Shh on the NVU in vitro. The results showed that exogenous Shh reduced cerebral edema and neuronal apoptosis and promoted neurological recovery after TBI in rats. In vitro experiments showed that Shh-induced activation of the Hedgehog pathway promoted stability of the NVU by reducing damage to the tight junction structure and inhibiting the release of inflammatory factors and neuron apoptosis. Based on these results, the Shh-induced activation of the Hedgehog pathway might be a new promising treatment for TBI.	[Wu, Jingchuan] Wuhan Brain Hosp, Dept Neurosurg, Gen Hosp YangTze River Shipping, Wuhan 430014, Hubei, Peoples R China; [Wu, Jingchuan; He, Junchi; Zhong, Jianjun; Li, Hui; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Tian, Xiaocui] Chongqing Med Univ, Coll Pharm, Chongqing Key Lab Biochem & Mol Pharmacol, Chongqing 400016, Peoples R China	Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	sunxch1445@qq.com	Wu, Jingchuan/AAV-7799-2020; 风, 张/AAR-1410-2020	Wu, Jingchuan/0000-0002-1213-4888; 	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159]; National Natural Science Foundation for Youth of ChinaNational Natural Science Foundation of China (NSFC) [81801230]; Health Commission of Wuhan Municipality scientific research Funding [WX19Q17]; Health Commission of Hubei Province scientific research project [WJ2019H364]	This work was supported by grants from the National Natural Science Foundation of China (No. 81571159), and National Natural Science Foundation for Youth of China (No. 81801230), and Health Commission of Wuhan Municipality scientific research Funding (No. WX19Q17), and Health Commission of Hubei Province scientific research project (No. WJ2019H364).	Anthonymuthu TS, 2018, FREE RADICAL BIO MED, V124, P493, DOI 10.1016/j.freeradbiomed.2018.06.031; Badaut J, 2014, TRANSL STROKE RES, V5, P394, DOI 10.1007/s12975-013-0304-z; Brilha S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16250-3; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Chai C, 2018, CNS NEUROSCI THER, V24, P369, DOI 10.1111/cns.12785; Chen J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.490; Cheng W, 2015, CELL PHYSIOL BIOCHEM, V35, P2019, DOI 10.1159/000374009; Darwazeh R, 2018, WORLD NEUROSURG, V116, pE329, DOI 10.1016/j.wneu.2018.04.202; Ferent J, 2015, NEUROSCIENTIST, V21, P356, DOI 10.1177/1073858414531457; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; He QW, 2013, MOL NEUROBIOL, V47, P976, DOI 10.1007/s12035-013-8396-8; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Huang ZJ, 2016, J NEUROCHEM, V136, P1017, DOI 10.1111/jnc.13491; Hui Z, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1579-5; Hung YH, 2016, MOL NEUROBIOL, V53, P793, DOI 10.1007/s12035-014-9046-5; Jin YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124657; Kinoshita K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0138-3; Liang M, 2018, EUR REV MED PHARMACO, V22, P6809, DOI 10.26355/eurrev_201810_16148; Liu S, 2019, BASIC CLIN PHARMACOL, V124, P660, DOI 10.1111/bcpt.13186; Liu Z, 2012, CELL MOL NEUROBIOL, V32, P191, DOI 10.1007/s10571-011-9746-6; Ma XX, 2017, NEUROREPORT, V28, P141, DOI 10.1097/WNR.0000000000000725; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Papatriantafyllou M, 2012, NAT REV IMMUNOL, V12, DOI 10.1038/nri3143; Placzek M, 2018, INT J DEV BIOL, V62, P225, DOI 10.1387/ijdb.170293jb; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Powers SA, 2019, J SEX MED, V16, P27, DOI 10.1016/j.jsxm.2018.11.010; Rong HT, 2018, BRAIN RES, V1694, P104, DOI 10.1016/j.brainres.2018.05.015; Salvador E, 2018, METHODS MOL BIOL, V1717, P219, DOI 10.1007/978-1-4939-7526-6_17; Schwedt TJ, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00615; Shao S, 2017, MOL MED REP, V16, P1269, DOI 10.3892/mmr.2017.6751; Tang FR, 2017, CELL PHYSIOL BIOCHEM, V43, P852, DOI 10.1159/000481611; Tian XC, 2016, J NEUROCHEM, V139, P757, DOI 10.1111/jnc.13833; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wang NY, 2018, MOL MED REP, V17, P3891, DOI 10.3892/mmr.2017.8341; Wang YJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0110024, 10.1371/journal.pone.0085234]; Xia YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068891; Yu PP, 2017, MOL NEUROBIOL, V54, P212, DOI 10.1007/s12035-015-9639-7; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210; Zhang L, 2013, STROKE, V44, P1965, DOI 10.1161/STROKEAHA.111.000831; Zhang YP, 2014, TRANSL STROKE RES, V5, P454, DOI 10.1007/s12975-014-0327-0; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033	41	11	12	2	11	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	AUG	2020	11	4					720	733		10.1007/s12975-019-00771-2		JAN 2020	14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	MG9XF	WOS:000505374600001	31898187				2021-06-18	
J	Herr, DR; Chew, WS; Satish, RL; Ong, WY				Herr, Deron R.; Chew, Wee Siong; Satish, R. L.; Ong, Wei-Yi			Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases	MOLECULAR NEUROBIOLOGY			English	Article						Autotaxin; Lysophospholipase D; Inflammatory neuropathic pain; Glioblastoma multiforme; Hemorrhagic hydrocephalus; Schizophrenia; Multiple sclerosis; Alzheimer's disease; Metabolic syndrome-induced brain damage; Traumatic brain injury; Hepatic encephalopathy induced cerebral edema; Macular edema; Major depressive disorder; Stress-induced psychiatric disorder; Alcohol-induced brain damage; HIV-induced brain injury; Pruritus; Peripheral nerve injury	LYSOPHOSPHATIDIC ACID RECEPTOR; OBVIOUS PHENOTYPIC ABNORMALITY; PROTEIN-COUPLED RECEPTOR; NF-KAPPA-B; LYSOPHOSPHOLIPASE-D; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; I-ALPHA/AUTOTAXIN; NEUROPATHIC PAIN; PHARMACOLOGICAL CHARACTERIZATION	Autotaxin (ATX) is a soluble extracellular enzyme that is abundant in mammalian plasma and cerebrospinal fluid (CSF). It has two known enzymatic activities, acting as both a phosphodiesterase and a phospholipase. The majority of its biological effects have been associated with its ability to liberate lysophosphatidic acid (LPA) from its substrate, lysophosphatidylcholine (LPC). LPA has diverse pleiotropic effects in the central nervous system (CNS) and other tissues via the activation of a family of six cognate G protein-coupled receptors. These LPA receptors (LPARs) are expressed in some combination in all known cell types in the CNS where they mediate such fundamental cellular processes as proliferation, differentiation, migration, chronic inflammation, and cytoskeletal organization. As a result, dysregulation of LPA content may contribute to many CNS and PNS disorders such as chronic inflammatory or neuropathic pain, glioblastoma multiforme (GBM), hemorrhagic hydrocephalus, schizophrenia, multiple sclerosis, Alzheimer's disease, metabolic syndrome-induced brain damage, traumatic brain injury, hepatic encephalopathy-induced cerebral edema, macular edema, major depressive disorder, stress-induced psychiatric disorder, alcohol-induced brain damage, HIV-induced brain injury, pruritus, and peripheral nerve injury. ATX activity is now known to be the primary biological source of this bioactive signaling lipid, and as such, represents a potentially high-value drug target. There is currently one ATX inhibitor entering phase III clinical trials, with several additional preclinical compounds under investigation. This review discusses the physiological and pathological significance of the ATX-LPA-LPA receptor signaling axis and summarizes the evidence for targeting this pathway for the treatment of CNS diseases.	[Herr, Deron R.; Chew, Wee Siong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore; [Herr, Deron R.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Satish, R. L.; Ong, Wei-Yi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 119260, Singapore; [Ong, Wei-Yi] Natl Univ Singapore, Inst Life Sci, Neurobiol Programme, Singapore 119260, Singapore	Herr, DR (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore.; Herr, DR (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.; Ong, WY (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 119260, Singapore.; Ong, WY (corresponding author), Natl Univ Singapore, Inst Life Sci, Neurobiol Programme, Singapore 119260, Singapore.	phcdrh@nus.edu.sg; wei_yi_ong@nuhs.edu.eg		Ong, Wei-Yi/0000-0001-9756-7772			Abers HMHG, 2011, J MED CHEM, V54, P4619, DOI 10.1021/jm200310q; Aikawa S, 2017, BIOCHEM BIOPH RES CO, V484, P202, DOI 10.1016/j.bbrc.2016.12.154; Annabi B, 2009, MOL CARCINOGEN, V48, P910, DOI 10.1002/mc.20541; Aston C, 2005, MOL PSYCHIATR, V10, P309, DOI 10.1038/sj.mp.4001565; Awada R, 2014, J CELL BIOCHEM, V115, P2123, DOI 10.1002/jcb.24889; Awada R, 2012, FREE RADICAL BIO MED, V52, P516, DOI 10.1016/j.freeradbiomed.2011.11.014; Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Benesch MGK, 2015, FASEB J, V29, P3990, DOI 10.1096/fj.15-274480; Benesch MGK, 2015, ENDOCR-RELAT CANCER, V22, P593, DOI 10.1530/ERC-15-0045; Benesch MGK, 2014, FEBS LETT, V588, P2712, DOI 10.1016/j.febslet.2014.02.009; Benesch MGK, 2014, FASEB J, V28, P2655, DOI 10.1096/fj.13-248641; Beuers U, 2006, HEPATOLOGY, V44, P280, DOI 10.1002/hep.21271; Bhave SR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00236; Bolisetty S, 2014, PEDIATRICS, V133, P55, DOI 10.1542/peds.2013-0372; Bouchareb R, 2015, CIRCULATION, V132, P677, DOI 10.1161/CIRCULATIONAHA.115.016757; Brindley DN, 2013, BBA-MOL CELL BIOL L, V1831, P74, DOI 10.1016/j.bbalip.2012.08.015; Castagna D, 2016, J MED CHEM, V59, P5604, DOI 10.1021/acs.jmedchem.5b01599; Chew WS, 2016, PHARMACOL RES, V113, P521, DOI 10.1016/j.phrs.2016.09.025; Choi JW, 2013, BBA-MOL CELL BIOL L, V1831, P20, DOI 10.1016/j.bbalip.2012.07.015; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Clair T, 2003, CANCER RES, V63, P5446; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Contos JJA, 2001, GENE, V267, P243, DOI 10.1016/S0378-1119(01)00410-3; Crack PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-37; Cui QL, 2014, GLIA, V62, P1361, DOI 10.1002/glia.22688; Dacheva I, 2016, RETINA-J RET VIT DIS, V36, P2311, DOI 10.1097/IAE.0000000000001112; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; Dennis J, 2008, MOL CELL NEUROSCI, V37, P412, DOI 10.1016/j.mcn.2007.10.018; Desroy N, 2017, J MED CHEM, V60, P3580, DOI 10.1021/acs.jmedchem.7b00032; Elferink RPJO, 2015, BBA-MOL CELL BIOL L, V1851, P61, DOI 10.1016/j.bbalip.2014.09.004; Elferink RPJO, 2011, CURR OPIN GASTROEN, V27, P289, DOI 10.1097/MOG.0b013e32834575e8; Fagard L, A103 IPF MORE THERAP, pA2701, DOI [10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A2701, DOI 10.1164/AJRCCM-C0NFERENCE.2016.193.1_MEETINGABSTRACTS.A2701]; Farooqui AA, 2007, GLYCEROPHOSPHOLIPIDS; Farooqui AA, 2006, NEUROSCIENTIST, V12, P245, DOI 10.1177/1073858405285923; Federico L, 2012, MOL ENDOCRINOL, V26, P786, DOI 10.1210/me.2011-1229; Ferry G, 2008, J PHARMACOL EXP THER, V327, P809, DOI 10.1124/jpet.108.141911; Fotopoulou S, 2010, DEV BIOL, V339, P451, DOI 10.1016/j.ydbio.2010.01.007; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Fox MA, 2003, MOL CELL NEUROSCI, V23, P507, DOI 10.1016/S1044-7431(03)00073-3; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Fujita R, 2007, NEUROCHEM INT, V50, P351, DOI 10.1016/j.neuint.2006.09.003; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Fulkerson Z, 2011, J BIOL CHEM, V286, P34654, DOI 10.1074/jbc.M111.276725; Garcia-Diaz B, 2015, BRAIN STRUCT FUNCT, V220, P3701, DOI 10.1007/s00429-014-0885-7; Gierse J, 2010, J PHARMACOL EXP THER, V334, P310, DOI 10.1124/jpet.110.165845; Goldshmit Y, 2012, AM J PATHOL, V181, P978, DOI 10.1016/j.ajpath.2012.06.007; Greenman R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00053; Gupte R, 2011, CHEMMEDCHEM, V6, P922, DOI 10.1002/cmdc.201000425; Hammack BN, 2004, MULT SCLER, V10, P245, DOI 10.1191/1352458504ms1023oa; Hata E, 2016, INT IMMUNOL, V28, P283, DOI 10.1093/intimm/dxv072; Hausmann J, 2011, NAT STRUCT MOL BIOL, V18, P198, DOI 10.1038/nsmb.1980; Herr DR, 2018, ACS CHEM NEUROSCI, V9, P398, DOI 10.1021/acschemneuro.8b00057; Herr KJ, 2011, P NATL ACAD SCI USA, V108, P15444, DOI 10.1073/pnas.1106129108; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Hoelzinger DB, 2008, J NEURO-ONCOL, V86, P297, DOI 10.1007/s11060-007-9480-6; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; ILLINGWORTH DR, 1971, J NEUROCHEM, V18, P769, DOI 10.1111/j.1471-4159.1971.tb12006.x; Im E, 2010, MOL CELL BIOL, V30, P2401, DOI 10.1128/MCB.01275-09; Inoue M, 2008, NEUROSCIENCE, V152, P296, DOI 10.1016/j.neuroscience.2007.12.041; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Inoue M, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-6; Inoue M, 2008, J NEUROCHEM, V107, P1556, DOI 10.1111/j.1471-4159.2008.05725.x; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Itagaki K, 2019, INT J NEUROPSYCHOPH, V22, P261, DOI 10.1093/ijnp/pyz005; Iyer P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042627; Jones SB, 2016, ACS MED CHEM LETT, V7, P857, DOI 10.1021/acsmedchemlett.6b00207; Jung CG, 2007, GLIA, V55, P1656, DOI 10.1002/glia.20576; Kakiuchi Y, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-33; Katakai T, 2014, J IMMUNOL, V193, P617, DOI 10.4049/jimmunol.1400565; Kato K, 2016, NAT STRUCT MOL BIOL, V23, P395, DOI 10.1038/nsmb.3200; Katsifa A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143083; Kawagoe H, 1997, CANCER RES, V57, P2516; Kim SE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171664; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Koike S, 2011, DEV DYNAM, V240, P413, DOI 10.1002/dvdy.22543; Kremer AE, 2016, J PEDIATR GASTR NUTR, V62, P530, DOI 10.1097/MPG.0000000000001044; Kremer AE, 2015, J HEPATOL, V62, P897, DOI 10.1016/j.jhep.2014.10.041; Kremer AE, 2012, HEPATOLOGY, V56, P1391, DOI 10.1002/hep.25748; Kremer AE, 2010, GASTROENTEROLOGY, V139, P1008, DOI 10.1053/j.gastro.2010.05.009; Kuwajima K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207310; Leblanc R, 2015, EXP CELL RES, V333, P183, DOI 10.1016/j.yexcr.2014.11.010; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Li HY, 2017, KIDNEY INT, V91, P1362, DOI 10.1016/j.kint.2016.11.010; Li S, 2012, FEBS LETT, V586, P792, DOI 10.1016/j.febslet.2012.01.044; Li S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-18; Li S, 2009, BIOCHEM BIOPH RES CO, V378, P264, DOI 10.1016/j.bbrc.2008.11.047; Lin ME, 2012, J BIOL CHEM, V287, P17608, DOI 10.1074/jbc.M111.330183; Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Ma L, 2010, J PHARMACOL EXP THER, V333, P540, DOI 10.1124/jpet.109.164830; Ma L, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-64; Maher TM, 2018, LANCET RESP MED, V6, P627, DOI 10.1016/S2213-2600(18)30181-4; Manzardo AM, 2013, GENE, V526, P356, DOI 10.1016/j.gene.2013.05.052; Manzardo AM, 2014, ALCOHOL CLIN EXP RES, V38, P1594, DOI 10.1111/acer.12429; Masago K, 2018, BIOCHEM BIOPH RES CO, V501, P1048, DOI 10.1016/j.bbrc.2018.05.106; McArthur S, 2015, J IMMUNOL, V195, P1139, DOI 10.4049/jimmunol.1500733; McLimans KE, 2017, J ALZHEIMERS DIS, V56, P403, DOI 10.3233/JAD-160891; Mirendil H, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.33; Mirzoyan K, 2017, INFLAMMATION, V40, P1707, DOI 10.1007/s10753-017-0612-7; Moolenaar WH, 2013, BBA-MOL CELL BIOL L, V1831, P13, DOI 10.1016/j.bbalip.2012.09.013; Motiejunaite R, 2014, MICROVASC RES, V93, P62, DOI 10.1016/j.mvr.2014.03.003; Mouratis MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133619; Mulder C, 2003, J NEURAL TRANSM, V110, P949, DOI 10.1007/s00702-003-0007-9; Nagai J, 2011, J NEUROCHEM, V118, P256, DOI 10.1111/j.1471-4159.2011.07297.x; Nagai J, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-78; Nahum S, 2011, CLIN EXP DERMATOL, V36, P188, DOI 10.1111/j.1365-2230.2010.03944.x; Nakao A, 2014, J INVEST DERMATOL, V134, P1745, DOI 10.1038/jid.2014.24; Nakasaki T, 2008, AM J PATHOL, V173, P1566, DOI 10.2353/ajpath.2008.071153; Nam SW, 2001, CANCER RES, V61, P6938; Navab M, 2015, J LIPID RES, V56, P871, DOI 10.1194/jlr.M056614; Ng W, 2014, J CLIN NEUROSCI, V21, P893, DOI 10.1016/j.jocn.2014.02.013; Nishimura S, 2014, DIABETES, V63, P4154, DOI 10.2337/db13-1694; Nogaroli L, 2009, NEUROCHEM RES, V34, P182, DOI 10.1007/s11064-008-9772-z; Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06-7420com; Ohuchi H, 2007, DEV DYNAM, V236, P1134, DOI 10.1002/dvdy.21119; Parimisetty A, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0530-x; Park GY, 2013, AM J RESP CRIT CARE, V188, P928, DOI 10.1164/rccm.201306-1014OC; Park R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10329; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Ptaszynska MM, 2010, MOL CANCER RES, V8, P309, DOI 10.1158/1541-7786.MCR-09-0288; Quehenberger O, 2010, J LIPID RES, V51, P3299, DOI 10.1194/jlr.M009449; Ramesh S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071827; Ray R, 2017, BLOOD, V129, P1177, DOI 10.1182/blood-2016-10-743757; Reeves VL, 2015, OBESITY, V23, P2371, DOI 10.1002/oby.21232; Renback K, 2000, MOL BRAIN RES, V75, P350, DOI 10.1016/S0169-328X(99)00333-2; Robering JW, 2019, GLIA, V67, P999, DOI 10.1002/glia.23585; Saga H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093230; Salous AK, 2013, J LIPID RES, V54, P2775, DOI 10.1194/jlr.M039685; Sato K, 2005, J NEUROCHEM, V92, P904, DOI 10.1111/j.1471-4159.2004.02933.x; Savaskan NE, 2007, CELL MOL LIFE SCI, V64, P230, DOI 10.1007/s00018-006-6412-0; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schleicher SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022182; Schmitz K, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0446-4; Shi J, 2013, BBA-MOL BASIS DIS, V1832, P29, DOI 10.1016/j.bbadis.2012.09.010; Shimizu Y, 2014, AM J PATHOL, V184, P1593, DOI 10.1016/j.ajpath.2014.01.029; Shimomura Y, 2009, EXP DERMATOL, V18, P218, DOI 10.1111/j.1600-0625.2008.00788.x; Shimura T, 2019, ANN CLIN BIOCHEM, V56, P240, DOI 10.1177/0004563218818197; Shinkuma S, 2010, HUM MUTAT, V31, P602, DOI 10.1002/humu.21235; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Spohr TCDSE, 2008, J BIOL CHEM, V283, P7470, DOI 10.1074/jbc.M707758200; Srikanth M, 2018, EUR J PHARMACOL, V841, P49, DOI 10.1016/j.ejphar.2018.10.005; St-Coeur PD, 2013, ARCH PHARM, V346, P91, DOI 10.1002/ardp.201200395; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Su J, 2017, Scand J Pain, V8, P53, DOI 10.1016/j.sjpain.2015.04.021; Sun YX, 2003, DEMENT GERIATR COGN, V16, P136, DOI 10.1159/000071001; Swaney JS, 2010, BRIT J PHARMACOL, V160, P1699, DOI 10.1111/j.1476-5381.2010.00828.x; Szepanowski F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0612-9; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; Tabuchi S, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0059-5; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; Thalman C, 2018, MOL PSYCHIATR, V23, P1699, DOI 10.1038/s41380-018-0053-1; Thirunavukkarasu K, 2017, OSTEOARTHR CARTILAGE, V25, P935, DOI 10.1016/j.joca.2016.09.006; Thirunavukkarasu K, 2016, J PHARMACOL EXP THER, V359, P207, DOI 10.1124/jpet.116.234013; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tokumura A, 2002, J LIPID RES, V43, P307; Tsukahara R, 2016, J PHARMACOL SCI, V132, P162, DOI 10.1016/j.jphs.2016.07.010; Ueda H, 2006, PHARMACOL THERAPEUT, V109, P57, DOI 10.1016/j.pharmthera.2005.06.003; Ueda H, 2013, BBA-MOL CELL BIOL L, V1831, P61, DOI 10.1016/j.bbalip.2012.08.014; Umemura K, 2006, NEUROSCI LETT, V400, P97, DOI 10.1016/j.neulet.2006.02.008; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; van Meeteren LA, 2008, CANCER LETT, V266, P203, DOI 10.1016/j.canlet.2008.02.052; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Velasco M, 2017, NEUROPHARMACOLOGY, V113, P608, DOI 10.1016/j.neuropharm.2016.04.002; Venkatraman G, 2015, FASEB J, V29, P772, DOI 10.1096/fj.14-262659; Vogt J, 2016, EMBO MOL MED, V8, P25, DOI 10.15252/emmm.201505677; Wang HYJ, 2010, RAPID COMMUN MASS SP, V24, P2057, DOI 10.1002/rcm.4620; Watanabe N, 2007, J CLIN GASTROENTEROL, V41, P616, DOI 10.1097/01.mcg.0000225642.90898.0e; Weiner JA, 1998, J COMP NEUROL, V398, P587; Wheeler NA, 2016, ASN NEURO, V8, DOI 10.1177/1759091416669618; Wheeler NA, 2015, J NEUROSCI, V35, P11399, DOI 10.1523/JNEUROSCI.0345-15.2015; Woodcock JM, 2015, ONCOTARGET, V6, P14522, DOI 10.18632/oncotarget.3995; Wu JM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-71; Yao MJ, 2018, CELL MOL IMMUNOL, V15, P737, DOI 10.1038/cmi.2017.159; Ye XQ, 2012, FERTIL STERIL, V97, P757, DOI 10.1016/j.fertnstert.2011.12.004; Ye XQ, 2011, FERTIL STERIL, V95, P2107, DOI 10.1016/j.fertnstert.2011.02.024; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Yeo JF, 2004, PAIN, V112, P148, DOI 10.1016/j.pain.2004.08.009; Yuelling LM, 2008, BBA-MOL CELL BIOL L, V1781, P525, DOI 10.1016/j.bbalip.2008.04.009; Yuelling LW, 2012, GLIA, V60, P1605, DOI 10.1002/glia.22381; Yukiura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126734; Yung YC, 2014, J LIPID RES, V55, P1192, DOI 10.1194/jlr.R046458; Yung YC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002095; Zahednasab H, 2014, J NEUROIMMUNOL, V273, P120, DOI 10.1016/j.jneuroim.2014.06.006; Zheng HY, 2017, CARCINOGENESIS, V38, P1196, DOI 10.1093/carcin/bgx100	189	11	11	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2020	57	1			SI		372	392		10.1007/s12035-019-01719-1			21	Neurosciences	Neurosciences & Neurology	KV1HZ	WOS:000520176200033	31364025				2021-06-18	
J	Chen, W; Zheng, P; Hong, T; Wang, Y; Liu, N; He, B; Zou, SF; Ren, DB; Duan, J; Zhao, L; Feng, JG				Chen, Wei; Zheng, Ping; Hong, Tao; Wang, Yang; Liu, Ning; He, Bin; Zou, Shufeng; Ren, Dabin; Duan, Jian; Zhao, Lin; Feng, Jiugeng			Astrocytes-derived exosomes induce neuronal recovery after traumatic brain injury via delivering gap junction alpha 1-20 k	JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE			English	Article						apoptosis; astrocytes; exosome; GJA1-20 k mitochondria; TBI	TRANSLATION; MOUSE	Astrocytes are more resistant to ischemia and hypoxia in the acute phase of brain injury after traumatic brain injury (TBI). Previous study showed that gap junction alpha 1 (GJA1) phosphorylation can increase the survival of damaged astrocytes. The GJA1-20 k expression in neurons co-culture with astrocytes was positively correlated with exosomes uptake. This study aims to explore the effect of exogenous GJA1-20 k carried by astrocyte-derived exosomes on neurons apoptosis and mitochondrial function after TBI. Astrocytes were co-cultured with the neuron with/without damage from air pressure. Exosomes were isolated, extracted from the culture medium by differential ultra-centrifugation, and verified by electron microscopy. Immunofluorescence staining, tunnel, western blot were employed to detect exosomes marker CD60, apoptosis, and mitochondrial function related protein expression and GJA1-20 k in cell culture. A rat model of hydraulic injury TBI was built, and exosomes was transferred. 2,3,5-Triphenyltetrazolium chloride (TTC) staining and immunohistochemistry staining of Nissl and microtubule associated protein 2 were used to detect the brain damage. A transwell stereo culture model of astrocytes and TBI-like injured neuron was constructed. The exosomes derived from astrocytes promoted the recovery of damaged neuron by in vitro exosome treatment. Compared with GJA1-20 k knockout exosome control group, GJA1-20 k exosomes were uptaken by neuron and downregulated the apoptosis rate and upregulated mitochondrial function to promote neuronal recovery. Finally, the results were validated by TTC staining and damaged tissue sections of rat TBI model. This study contributes to a better understanding of the astrocyte-neuron protection mechanism in TBI and provides a potential new target for the treatment of TBI.	[Chen, Wei; Hong, Tao; Wang, Yang; Zou, Shufeng; Duan, Jian; Feng, Jiugeng] Nanchang Univ, Emergency Trauma Ctr, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Zheng, Ping; He, Bin; Ren, Dabin] Shanghai Univ Med & Hlth Sci, Dept Neurosurg, Peoples Hosp Shanghai Pudong New Area, Shanghai, Peoples R China; [Liu, Ning; Zhao, Lin] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing 330008, Jiangsu, Peoples R China	Feng, JG (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang 330008, Jiangxi, Peoples R China.	fengjg_1979@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81960236, 81701231, 81872058]; Livelihood Project of Pudong new area Science and Technology Commission [PKJ2016-Y31]; Key Research Project of Science and Technology Agency [20192BBGL70022]; Shanghai Nature Science Foundation [19ZR1447400]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81960236, 81701231, 81872058]	National Natural Science Foundation of China, Grant/Award Number: 81960236, 81701231, 81872058; the Livelihood Project of Pudong new area Science and Technology Commission, Grant/Award Number: PKJ2016-Y31; Livelihood Project of Pudong New Area Science and Technology Commission, Grant/Award Number: PKJ2016-Y31; Key Research Project of Science and Technology Agency, Grant/Award Number: 20192BBGL70022; Shanghai Nature Science Foundation, Grant/Award Number: 19ZR1447400; Natural Science Foundation of China, Grant/Award Numbers: 81872058, 81701231, 81960236	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Barman A, 2016, INDIAN J PSYCHOL MED, V38, P172, DOI 10.4103/0253-7176.183086; Basheer W, 2016, BBA-MOL CELL RES, V1863, P1848, DOI 10.1016/j.bbamcr.2015.10.015; Basheer WA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121900; Basheer WA, 2017, CIRC RES, V121, P1069, DOI 10.1161/CIRCRESAHA.117.311955; Bell CL., 2018, INT J MOL SCI, V20, pE44; Chen W. P., 2017, SCI REP, V7, P1, DOI DOI 10.1038/S41598-017-09923-6; Chen W, 2018, J NEUROPHYSIOL, V119, P305, DOI 10.1152/jn.00654.2017; Chen W, 2017, RESTOR NEUROL NEUROS, V35, P217, DOI 10.3233/RNN-160705; Chen W, 2016, 2016 IEEE INTERNATIONAL CONFERENCE ON COMPUTATIONAL ELECTROMAGNETICS (ICCEM), P40, DOI 10.1109/COMPEM.2016.7588630; Chen W, 2015, EXP BRAIN RES, V233, P2823, DOI 10.1007/s00221-015-4352-3; Fu Y., 2017, FRONT PHYSIOL, V8, P1; Kim SN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07658-y; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Marcus ME, 2013, PHARMACEUTICALS-BASE, V6, P659, DOI 10.3390/ph6050659; Mutschelknaus L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152213; Pecoraro M, 2018, TOXICOL IN VITRO, V47, P120, DOI 10.1016/j.tiv.2017.11.004; Popp A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004764; Salat-Canela C, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-31; Sancho M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084666; Slavi N, 2018, P NATL ACAD SCI USA, V115, pE5934, DOI 10.1073/pnas.1803907115; Wang L, 2018, CELL PHYSIOL BIOCHEM, V50, P1535, DOI 10.1159/000494652; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yin X, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1127-3; Zuo R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1121-9	25	11	11	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-6254	1932-7005		J TISSUE ENG REGEN M	J. Tissue Eng. Regen. Med.	MAR	2020	14	3					412	423		10.1002/term.3002		DEC 2019	12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Engineering, Biomedical	Cell Biology; Biotechnology & Applied Microbiology; Engineering	KW1ME	WOS:000503701800001	31826322				2021-06-18	
J	Wang, ZY; Wilson, CM; Mendelev, N; Ge, YC; Galfalvy, H; Elder, G; Ahlers, S; Yarnell, AM; LoPresti, ML; Kamimori, GH; Carr, W; Haghighi, F				Wang, Zhaoyu; Wilson, Caroline M.; Mendelev, Natalia; Ge, Yongchao; Galfalvy, Hanga; Elder, Gregory; Ahlers, Stephen; Yarnell, Angela M.; LoPresti, Matthew L.; Kamimori, Gary H.; Carr, Walter; Haghighi, Fatemeh			Acute and Chronic Molecular Signatures and Associated Symptoms of Blast Exposure in Military Breachers	JOURNAL OF NEUROTRAUMA			English	Article						blast overpressure; epigenetics; sleep; tinnitus; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LOW-LEVEL BLAST; NF-KAPPA-B; FACTOR 1A EXPRESSION; SLEEP DURATION; INNER-EAR; GENE; MILD; ACTIVATION; NEUROTRAUMA	Injuries from exposure to explosions rose dramatically during the Iraq and Afghanistan wars, which motivated investigations of blast-related neurotrauma and operational breaching. In this study, military "breachers" were exposed to controlled, low-level blast during a 10-day explosive breaching course. Using an omics approach, we assessed epigenetic, transcriptional, and inflammatory profile changes in blood from operational breaching trainees, with varying levels of lifetime blast exposure, along with daily self-reported symptoms (with tinnitus, headaches, and sleep disturbances as the most frequently reported). Although acute exposure to blast did not confer epigenetic changes, specifically in DNA methylation, differentially methylated regions (DMRs) with coordinated gene expression changes associated with lifetime cumulative blast exposures were identified. The accumulative effect of blast showed increased methylation of PAX8 antisense transcript with coordinated repression of gene expression, which has been associated with sleep disturbance. DNA methylation analyses conducted in conjunction with reported symptoms of tinnitus in the low versus high blast incidents groups identified DMRS in KCNE1 and CYP2E1 genes. KCNE1 and CYP2E1 showed the expected inverse correlation between DNA methylation and gene expression, which have been previously implicated in noise-related hearing loss. Although no significant transcriptional changes were observed in samples obtained at the onset of the training course relative to chronic cumulative blast, we identified a large number of transcriptional perturbations acutely pre- versus post-blast exposure. Acutely, 67 robustly differentially expressed genes (fold change >= 1.5), including UFC1 and YOD1 ubiquitin-related proteins, were identified. Inflammatory analyses of cytokines and chemokines revealed dysregulation of MCP-1, GCSF, HGF, MCSF, and RANTES acutely after blast exposure. These data show the importance of an omics approach, revealing that transcriptional and inflammatory biomarkers capture acute low-level blast overpressure exposure, whereas DNA methylation marks encapsulate chronic long-term symptoms.	[Wilson, Caroline M.; Mendelev, Natalia; Galfalvy, Hanga; Haghighi, Fatemeh] James J Peters VA Med Ctr, Med Epigenet, Bronx, NY USA; [Elder, Gregory] James J Peters VA Med Ctr, Neurol Serv, Bronx, NY USA; [Wang, Zhaoyu; Wilson, Caroline M.; Mendelev, Natalia; Haghighi, Fatemeh] Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, 1425 Madison Ave,Room 9-20D, New York, NY 10029 USA; [Ge, Yongchao; Elder, Gregory] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Elder, Gregory] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Galfalvy, Hanga] Columbia Univ, Dept Biostat Psychiat, New York, NY USA; [Yarnell, Angela M.; LoPresti, Matthew L.; Kamimori, Gary H.; Carr, Walter] Walter Reed Army Inst Res, Silver Spring, MD USA; [Ahlers, Stephen] Naval Med Res Ctr, Silver Spring, MD USA; [Carr, Walter] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA	Haghighi, F (corresponding author), Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, 1425 Madison Ave,Room 9-20D, New York, NY 10029 USA.	fatemeh.haghighi@mssm.edu	Ge, Yongchao/AAG-9317-2021; Galfalvy, Hanga/AAI-5492-2020	Ge, Yongchao/0000-0001-6448-5703; Galfalvy, Hanga/0000-0001-7156-6106; Mendelev, Natalia/0000-0001-8596-2986	U.S. Army Medical Research and Development Command/USAMRDC; Veterans Affairs Office of Research and Development; WRAIR; NMRCNational Medical Research Council, Singapore; United States Department of Veterans AffairsUS Department of Veterans Affairs [1IK6CX002074]; Veterans Affairs Merit Grants [RX001705, CX001395, BX003794, CX001728]; Veterans AffairsUS Department of Veterans Affairs [I01RX001705] Funding Source: NIH RePORTER	This work was supported by the U.S. Army Medical Research and Development Command/USAMRDC and the Veterans Affairs Office of Research and Development. This research was supported, in part, by an appointment to the Research Participation Program at the Walter Reed Army Institute of Research (WRAIR) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and Medical Research and Development Command/USAMRDC. The WRAIR and NMRC support further derives from Joint Program Committee Five intramural awards, The Development of Blast Exposure Standards, Evaluation of the Effects of High Level Overpressure (8+ psi) on Cognitive Performance, Brain Blood Biomarkers and Symptom Reporting, and Environmental Sensors in Training (ESiT). Dr. Haghighi is the recipient of a Research Career Scientist Award (#1IK6CX002074) from the United States Department of Veterans Affairs. Dr. Haghighi's research is supported by Veterans Affairs Merit Grants RX001705, CX001395, BX003794, and CX001728.	Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Beckelman BC, 2016, J ALZHEIMERS DIS, V54, P669, DOI 10.3233/JAD-160036; Beckelman BC, 2016, NEURODEGENER DIS, V16, P39, DOI 10.1159/000438925; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Bukowska-Damska A, 2017, CHRONOBIOL INT, V34, P1211, DOI 10.1080/07420528.2017.1358176; Carr W, 2017, SHOCK WAVES, V27, P829, DOI 10.1007/s00193-017-0766-0; Carr W., 2018, 25 ANN M MIL ASP BAL; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Carr W, 2015, J HEAD TRAUMA REHAB, V30, P47, DOI 10.1097/HTR.0000000000000064; Cathomas F, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.8; Cedernaes J, 2015, J CLIN ENDOCR METAB, V100, pE1255, DOI [10.1210/jc.2015-2284, 10.1210/JC.2015-2284]; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Doig J, 2013, FEBS J, V280, P6528, DOI 10.1111/febs.12554; Drake C, 2010, SLEEP, V33, P745, DOI 10.1093/sleep/33.6.745; Dubash AD, 2011, CURR BIOL, V21, pR529, DOI 10.1016/j.cub.2011.04.035; Edwards DS, 2016, INJURY, V47, P646, DOI 10.1016/j.injury.2015.12.021; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Fechter LD, 2004, JARO-J ASSOC RES OTO, V5, P90, DOI 10.1007/s10162-003-4028-8; Forstner P, 2018, J NEUROTRAUM, V35, P2317, DOI 10.1089/neu.2017.5593; Frederic MY, 2009, HUM MUTAT, V30, P181, DOI 10.1002/humu.20794; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gill J, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000186; Gottlieb DJ, 2015, MOL PSYCHIATR, V20, P1232, DOI 10.1038/mp.2014.133; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Groh J, 2010, HUM MOL GENET, V19, P3530, DOI 10.1093/hmg/ddq269; Himes BE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099625; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Jones SE, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006125; Kamnaksh A., 2014, TRANSL PROTEOM, V3, P22, DOI [10.1016/j.trprot.2013.11.001, DOI 10.1016/J.TRPROT.2013.11.001]; Kim YH, 2013, J GEN PHYSIOL, V142, P207, DOI 10.1085/jgp.201311019; Kuriakose M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26813-7; Kwon MJ, 2015, J NEUROSCI, V35, P15934, DOI 10.1523/JNEUROSCI.1924-15.2015; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mathews ZR, 2015, J EMERG MED, V49, P573, DOI 10.1016/j.jemermed.2015.03.013; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Miller GE, 2008, BIOL PSYCHIAT, V64, P266, DOI 10.1016/j.biopsych.2008.03.017; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Newbery HJ, 2005, J NEUROPATH EXP NEUR, V64, P295, DOI 10.1093/jnen/64.4.295; Nieswandt B, 2007, J EXP MED, V204, P3113, DOI 10.1084/jem.20071827; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Orman MA, 2011, CYTOKINE, V56, P494, DOI 10.1016/j.cyto.2011.07.001; Pawelczyk M, 2012, INT J OCCUP MED ENV, V25, P356, DOI 10.2478/S13382-012-0061-3; Pedersen BS, 2012, BIOINFORMATICS, V28, P2986, DOI 10.1093/bioinformatics/bts545; Peirson SN, 2018, J NEUROSCI METH, V300, P26, DOI 10.1016/j.jneumeth.2017.04.007; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; R DEVELOPMENT CORE TEAM, 2014, R LANG ENV STAT COMP; Ramakrishnan NA, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.375832; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Ruiz-Llorente S, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-147; Sand PG, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00041; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Schwenk J, 2010, NATURE, V465, P231, DOI 10.1038/nature08964; Seddik R, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.412767; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Shanker T, 2007, NY TIMES; Shen HT, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00353; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsao Jack W, 2013, Neurol Clin Pract, V3, P30, DOI 10.1212/CPJ.0b013e318283ffa2; U.S. DIST. COURT W. DIST. OF N.Y, 2019, ANN BEN REP FISC YEA, P1; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; Valiyaveettil M, 2012, J REHABIL RES DEV, V49, P1153, DOI 10.1682/JRRD.2011.09.0182; Van Laer L, 2006, HUM MUTAT, V27, P786, DOI 10.1002/humu.20360; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wangemann P, 2002, HEARING RES, V165, P1, DOI 10.1016/S0378-5955(02)00279-4; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wu YJ, 2005, CELL RES, V15, P483, DOI 10.1038/sj.cr.7290318	80	11	11	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2020	37	10					1221	1232		10.1089/neu.2019.6742		DEC 2019	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LL3VP	WOS:000506163700001	31621494	Green Published, Other Gold			2021-06-18	
J	Das, M; Mayilsamy, K; Mohapatra, SS; Mohapatra, S				Das, Mahasweta; Mayilsamy, Karthick; Mohapatra, Shyam S.; Mohapatra, Subhra			Mesenchymal stem cell therapy for the treatment of traumatic brain injury: progress and prospects	REVIEWS IN THE NEUROSCIENCES			English	Article						exosomes; mesenchymal stem cell (MSC); regenerative medicine; traumatic brain injury (TBI)	MARROW STROMAL CELLS; T-LYMPHOCYTE PROLIFERATION; MURINE BONE-MARROW; FUNCTIONAL RECOVERY; SPINAL-CORD; NEUROVASCULAR PLASTICITY; EXTRACELLULAR VESICLES; INTERNATIONAL-SOCIETY; INTRANASAL DELIVERY; COMPUTED-TOMOGRAPHY	Traumatic brain injury (TBI) is a major cause of injury-related mortality and morbidity in the USA and around the world. The survivors may suffer from cognitive and memory deficits, vision and hearing loss, movement disorders, and different psychological problems. The primary insult causes neuronal damage and activates astrocytes and microglia which evokes immune responses causing further damage to the brain. Clinical trials of drugs to recover the neuronal loss are not very successful. Regenerative approaches for TBI using mesenchymal stem cells (MSCs) seem promising. Results of preclinical research have shown that transplantation of MSCs reduced secondary neurodegeneration and neuroinflammation, promoted neurogenesis and angiogenesis, and improved functional outcome in the experimental animals. The functional improvement is not necessarily related to cell engraftment; rather, immunomodulation by molecular factors secreted by MSCs is responsible for the beneficial effects of this therapy. However, MSC therapy has a few drawbacks including tumor formation, which can be avoided by the use of MSC-derived exosomes. This review has focused on the research works published in the field of regenerative therapy using MSCs after TBI and its future direction.	[Das, Mahasweta; Mayilsamy, Karthick; Mohapatra, Shyam S.; Mohapatra, Subhra] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Das, Mahasweta; Mayilsamy, Karthick; Mohapatra, Subhra] Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Mohapatra, Shyam S.] Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA	Mohapatra, S (corresponding author), James A Haley Vet Hosp, Tampa, FL 33612 USA.; Mohapatra, S (corresponding author), Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA.	smohapa2@health.usf.edu		Das, Mahasweta/0000-0003-3809-5861	Veterans Affairs Merit Review grantUS Department of Veterans Affairs [BX002668, IK6BX004212, IK6 BX003778]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs	This work is supported by Veterans Affairs Merit Review grant (BX002668, Funder Id: http://dx.doi.org/10.13039/100006364) to Subhra Mohapatra, and Research Career Scientist Awards to Dr. Subhra Mohapatra (IK6BX004212) and Dr. Shyam Mohapatra (IK6 BX003778). Though this report is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, the contents of this report do not represent the views of the Department of Veterans Affairs or the United States Government.	Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Alexanian AR, 2011, NEUROREHAB NEURAL RE, V25, P873, DOI 10.1177/1545968311416823; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Alves H, 2010, J CELL MOL MED, V14, P2729, DOI 10.1111/j.1582-4934.2009.00931.x; [Anonymous], 2012, Drug Discov Today Technol, V9, pe71, DOI 10.1016/j.ddtec.2011.12.002; Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Badiavas EV, 2003, ARCH DERMATOL, V139, P510, DOI 10.1001/archderm.139.4.510; Baustian C, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0139-5; Belting M, 2015, J INTERN MED, V278, P251, DOI 10.1111/joim.12393; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Boltze J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00155; Boltze J, 2014, J CEREBR BLOOD F MET, V34, P1420, DOI 10.1038/jcbfm.2014.94; Brait VH, 2012, J CEREBR BLOOD F MET, V32, P598, DOI 10.1038/jcbfm.2012.6; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Carbonara M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00885; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Chamberlain G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025663; Chau MJ, 2014, STEM CELLS, V32, P3075, DOI 10.1002/stem.1802; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251; Choi MS, 2008, CELL TRANSPLANT, V17, P899, DOI 10.3727/096368908786576471; Choo KB, 2014, INT J MED SCI, V11, P1201, DOI 10.7150/ijms.8356; Cui LL, 2017, STROKE, V48, P2895, DOI 10.1161/STROKEAHA.117.017809; Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z; Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076; Di Lanni M, 2008, EXP HEMATOL, V36, P309, DOI 10.1016/j.exphem.2007.11.007; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193; Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Donega V, 2017, NEUROSCIENTIST, V23, P605, DOI 10.1177/1073858417697036; El Bassit G, 2017, ENDOCRINOLOGY, V158, P183, DOI 10.1210/en.2016-1819; Engela AU, 2013, CELL TRANSPLANT, V22, P41, DOI 10.3727/096368912X636984; Eslaminejad MB, 2006, DEV GROWTH DIFFER, V48, P361, DOI 10.1111/j.1440-169x.2006.00874.x; Eslaminejad MB, 2009, IN VITRO CELL DEV-AN, V45, P451, DOI 10.1007/s11626-009-9198-1; Feng Y, 2017, MOL MED REP, V16, P654, DOI 10.3892/mmr.2017.6619; Galeano C, 2018, CELL TRANSPLANT, V27, P501, DOI 10.1177/0963689718754561; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-005-0052-6; Geesala R, 2017, CYTOTHERAPY, V19, P756, DOI 10.1016/j.jcyt.2017.03.072; Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959; Greco SJ, 2007, STEM CELLS DEV, V16, P811, DOI 10.1089/scd.2007.0011; Han EY, 2013, CURR STEM CELL RES T, V8, P172; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hasan A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00028; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; Herberts CA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-29; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125; Huat TJ, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-91; Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006-0686; ITOH K, 1989, EXP HEMATOL, V17, P145; Jang SH, 2015, J NEURO-OPHTHALMOL, V35, P270, DOI 10.1097/WNO.0000000000000249; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kainer MA, 2004, NEW ENGL J MED, V350, P2564, DOI 10.1056/NEJMoa023222; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; King A, 2014, ADV WOUND CARE, V3, P614, DOI 10.1089/wound.2013.0497; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37; Ko E, 2012, STEM CELLS DEV, V21, P1877, DOI 10.1089/scd.2011.0284; Kobayashi CI, 2012, J CELL PHYSIOL, V227, P421, DOI 10.1002/jcp.22764; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Kwon HM, 2014, VASC PHARMACOL, V63, P19, DOI 10.1016/j.vph.2014.06.004; Lai RC, 2011, REGEN MED, V6, P481, DOI [10.2217/RME.11.35, 10.2217/rme.11.35]; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Landgraf K, 2011, TRANSPL IMMUNOL, V25, P167, DOI 10.1016/j.trim.2011.06.007; Lee Bruce, 2005, NeuroRx, V2, P372; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Li G, 2018, EXPERT OPIN DRUG DEL, V15, P163, DOI 10.1080/17425247.2018.1378642; Lin CH, 2019, J FORMOS MED ASSOC, V118, P1661, DOI 10.1016/j.jfma.2019.01.008; Lin WP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063444; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Maerz JK, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-015-0243-6; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Mancini OK, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0127-9; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Mastro-Martinez I, 2015, BRAIN INJURY, V29, P1497, DOI 10.3109/02699052.2015.1053525; Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122; Meirelles LD, 2016, FRONT BIOSCI-LANDMRK, V21, P130, DOI 10.2741/4380; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Meirelles LD, 2009, TISSUE ENG PT A, V15, P221, DOI 10.1089/ten.tea.2008.0103; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mettang M, 2018, FASEB J, V32, P1916, DOI 10.1096/fj.201700826R; Minnich JE, 2010, RESTOR NEUROL NEUROS, V28, P293, DOI 10.3233/RNN-2010-0528; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Moreau F, 2013, CEREBROVASC DIS EXTR, V3, P130, DOI 10.1159/000355024; Narva E, 2010, NAT BIOTECHNOL, V28, P371, DOI 10.1038/nbt.1615; Nasef A, 2008, REGEN MED, V3, P531, DOI 10.2217/17460751.3.4.531; Nasef A, 2007, GENE EXPRESSION, V13, P217; Navaratna D, 2009, CELL ADHES MIGR, V3, P216, DOI 10.4161/cam.3.2.8396; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Ni HQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00014; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichols JE, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt151; Niwa A, 2009, J CELL PHYSIOL, V221, P367, DOI 10.1002/jcp.21864; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Okouchi M, 2007, ANTIOXID REDOX SIGN, V9, P1059, DOI 10.1089/ars.2007.1511; Omori Y, 2008, BRAIN RES, V1236, P30, DOI 10.1016/j.brainres.2008.07.116; Orciani M, 2010, FREE RADICAL BIO MED, V49, P830, DOI 10.1016/j.freeradbiomed.2010.06.007; Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Patel NA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1240-3; Pati S, 2016, CURR STEM CELL RES T, V11, P149, DOI 10.2174/1574888X10666151019120050; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Peruzzaro ST, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-018-1383-2; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Pischiutta F, 2016, CRIT CARE MED, V44, pE1118, DOI 10.1097/CCM.0000000000001864; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Qu J, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5251313; Redondo-Castro E, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0531-4; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Ren JQ, 2013, STEM CELL RES, V11, P1060, DOI 10.1016/j.scr.2013.07.005; Rizzo R, 2008, CYTOTHERAPY, V10, P364, DOI 10.1080/14653240802105299; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rojewski MT, 2008, TRANSFUS MED HEMOTH, V35, P168, DOI 10.1159/000129013; Ruster B, 2006, BLOOD, V108, P3938, DOI 10.1182/blood-2006-05-025098; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246; Schizas N, 2018, CELL TISSUE RES, V372, P493, DOI 10.1007/s00441-018-2808-z; Schmidt A, 2006, EUR J CELL BIOL, V85, P1179, DOI 10.1016/j.ejcb.2006.05.015; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Segers VFM, 2006, AM J PHYSIOL-HEART C, V290, pH1370, DOI 10.1152/ajpheart.00523.2005; Sheikh AM, 2011, NEUROBIOL DIS, V41, P717, DOI 10.1016/j.nbd.2010.12.009; Shen Q, 2016, CELL PHYSIOL BIOCHEM, V38, P748, DOI 10.1159/000443031; Siegel G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-146; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; Sordi V, 2009, TRANSPLANTATION, V87, pS42, DOI 10.1097/TP.0b013e3181a28533; Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004-0359; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; Steingen C, 2008, J MOL CELL CARDIOL, V44, P1072, DOI 10.1016/j.yjmcc.2008.03.010; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sun JM, 2015, EXP NEUROL, V272, P78, DOI 10.1016/j.expneurol.2015.03.011; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tian CL, 2013, EXP CLIN TRANSPLANT, V11, P176, DOI 10.6002/ect.2012.0053; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Tugwell BD, 2005, ANN INTERN MED, V143, P648, DOI 10.7326/0003-4819-143-9-200511010-00008; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; VANVLASSELAER P, 1994, BLOOD, V84, P753, DOI 10.1182/blood.V84.3.753.bloodjournal843753; Vasandan AB, 2016, SCI REP-UK, V6, DOI 10.1038/srep38308; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Wang ZG, 2017, EXP THER MED, V13, P3613, DOI 10.3892/etm.2017.4423; Wang ZT, 2013, J MOL NEUROSCI, V49, P409, DOI 10.1007/s12031-012-9908-0; Wei L, 2017, PROG NEUROBIOL, V157, P49, DOI 10.1016/j.pneurobio.2017.03.003; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Wu LW, 2014, TRANSPL IMMUNOL, V30, P122, DOI 10.1016/j.trim.2014.03.001; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Zaim M, 2012, ANN HEMATOL, V91, P1175, DOI 10.1007/s00277-012-1438-x; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhao Q., 2016, J CELLULAR IMMUNOTHE, V2, P3, DOI DOI 10.1016/J.JOCIT.2014.12.001; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	189	11	11	4	17	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	DEC	2019	30	8					839	855		10.1515/revneuro-2019-0002			17	Neurosciences	Neurosciences & Neurology	JQ0ST	WOS:000498665600004	31203262				2021-06-18	
J	Ebert, SE; Jensen, P; Ozenne, B; Armand, S; Svarer, C; Stenbaek, DS; Moeller, K; Dyssegaard, A; Thomsen, G; Steinmetz, J; Forchhammer, BH; Knudsen, GM; Pinborg, LH				Ebert, S. E.; Jensen, P.; Ozenne, B.; Armand, S.; Svarer, C.; Stenbaek, D. S.; Moeller, K.; Dyssegaard, A.; Thomsen, G.; Steinmetz, J.; Forchhammer, B. H.; Knudsen, G. M.; Pinborg, L. H.			Molecular imaging of neuroinflammation in patients after mild traumatic brain injury: a longitudinal I-123-CLINDE single photon emission computed tomography study	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						concussion; inflammation; microglia; mild traumatic brain injury; neuroinflammation; post-concussion symptoms; post-concussion syndrome; translocator protein	ACTIVATION	Background and purpose Neuroinflammation has been proposed as part of the pathogenesis of post-concussion symptoms (PCS), but the inflammatory response of the human brain to mild traumatic brain injury (mTBI) remains unknown. We hypothesized that a neuroinflammatory response is present in mTBI at 1-2 weeks post-injury and persists in patients with PCS. Methods We scanned 14 patients with mTBI without signs of structural damage at 1-2 weeks and 3-4 months post-injury and 22 healthy controls once using the single photon emission computed tomography tracer I-123-CLINDE, which visualizes translocator protein (TSPO), a protein upregulated in active immune cells. PCS was defined as three or more persisting symptoms from the Rivermead Post Concussion Symptoms Questionnaire at 3 months post-injury. Results Across brain regions, patients had significantly higher I-123-CLINDE binding to TSPO than healthy controls, both at 1-2 weeks after the injury in all patients (P = 0.011) and at 3-4 months in the seven patients with PCS (P = 0.006) and in the six patients with good recovery (P = 0.018). When the nine brain regions were tested separately and results were corrected for multiple comparisons, no individual region differed significantly, but all estimated parameters indicated increased I-123-CLINDE binding to TSPO, ranging from 2% to 19% in all patients at 1-2 weeks, 13% to 27% in patients with PCS at 3-4 months and -9% to 17% in patients with good recovery at 3-4 months. Conclusions Neuroinflammation was present in mTBI at 1-2 weeks post-injury and persisted at 3-4 months post-injury with a tendency to be most pronounced in patients with PCS.	[Ebert, S. E.; Jensen, P.; Ozenne, B.; Armand, S.; Svarer, C.; Stenbaek, D. S.; Dyssegaard, A.; Thomsen, G.; Knudsen, G. M.; Pinborg, L. H.] Rigshosp, Neurobiol Res Unit, 28 Juliane Mules Vej,3rd Floor,Bldg 6931, DK-2100 Copenhagen, Denmark; [Ebert, S. E.; Ozenne, B.; Moeller, K.; Forchhammer, B. H.; Knudsen, G. M.; Pinborg, L. H.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark; [Moeller, K.] Rigshosp, Dept Neuroanaesthesiol, Copenhagen, Denmark; [Steinmetz, J.] Rigshosp, Trauma Ctr, Copenhagen, Denmark; [Pinborg, L. H.] Rigshosp, Dept Neurol, Copenhagen, Denmark	Pinborg, LH (corresponding author), Rigshosp, Neurobiol Res Unit, 28 Juliane Mules Vej,3rd Floor,Bldg 6931, DK-2100 Copenhagen, Denmark.	lars.pinborg@nru.dk	Knudsen, Gitte Moos/C-1368-2013; Steinmetz, Jacob/AAY-6076-2020; Moller, Kirsten/A-4751-2009	Knudsen, Gitte Moos/0000-0003-1508-6866; Steinmetz, Jacob/0000-0001-9620-8911; Pinborg, Lars Hageman/0000-0001-9024-7936; Moller, Kirsten/0000-0003-3058-1072; Stenbaek, Dea/0000-0002-5439-4637; Elgaard Ebert, Sebastian/0000-0001-6626-0276; Svarer, Claus/0000-0001-7811-1825			Albrecht DS, 2016, ACS CHEM NEUROSCI, V7, P470, DOI 10.1021/acschemneuro.6b00056; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Dmitrienko A, 2013, STAT MED, V32, P5172, DOI 10.1002/sim.5990; Feng L, 2017, J NUCL MED, V58, P989, DOI 10.2967/jnumed.116.183202; Feng L, 2014, J NUCL MED, V55, P1966, DOI 10.2967/jnumed.114.143727; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Holst KK, 2013, COMPUTATION STAT, V28, P1385, DOI 10.1007/s00180-012-0344-y; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Khong E, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00156; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Knudsen GM, 2016, NEUROIMAGE, V124, P1213, DOI 10.1016/j.neuroimage.2015.04.025; Kraus JF, 2014, BRAIN INJURY, V28, P1248, DOI 10.3109/02699052.2014.916420; Laksari K, 2018, PHYS REV LETT, V120, DOI 10.1103/PhysRevLett.120.138101; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Mountney A, 2017, J NEUROTRAUM, V34, P2768, DOI 10.1089/neu.2016.4679; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Skrondal A., 2004, GEN LATENT VARIABLE; Svarer C, 2005, NEUROIMAGE, V24, P969, DOI 10.1016/j.neuroimage.2004.10.017; Vallez Garcia D, 2016, J NEUROTRAUM, V33, P1855, DOI 10.1089/neu.2015.4230	24	11	11	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	DEC	2019	26	12					1426	1432		10.1111/ene.13971			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JJ0XV	WOS:000493885800005	31002206				2021-06-18	
J	Honig, MG; Del Mar, NA; Henderson, DL; Ragsdale, TD; Doty, JB; Driver, JH; Li, CY; Fortugno, AP; Mitchell, WM; Perry, AM; Moore, BM; Reiner, A				Honig, Marcia G.; Del Mar, Nobel A.; Henderson, Desmond L.; Ragsdale, Tyler D.; Doty, John B.; Driver, Jake H.; Li, Chunyan; Fortugno, Andrew P.; Mitchell, William M.; Perry, Aaron M.; Moore, Bob M.; Reiner, Anton			Amelioration of visual deficits and visual system pathology after mild TBI via the cannabinoid Type-2 receptor inverse agonism of raloxifene	EXPERIMENTAL NEUROLOGY			English	Article						TBI; Visual deficits; Microglia; CB2 receptors; Therapy	TRAUMATIC BRAIN-INJURY; RETINAL GANGLION-CELLS; MOUSE MODEL; CB2 RECEPTOR; BLAST; MICROGLIA; NEUROINFLAMMATION; POLARIZATION; THRESHOLDS; RESPONSES	Visual deficits after traumatic brain injury (TBI) are common, but interventions that limit the post-trauma impairments have not been identified. We have found that treatment with the cannabinoid type-2 receptor (C82) inverse agonist SMM-189 for 2 weeks after closed-head blast TBI greatly attenuates the visual deficits and retinal pathology this otherwise produces in mice, by modulating the deleterious role of microglia in the injury process after trauma. SMM-189, however, has not yet been approved for human use. Raloxifene is an FDA-approved estrogen receptor drug that is used to treat osteoporosis, but it was recently found to also show noteworthy CB2 inverse agonism. In the current studies, we found that a high pressure air blast in the absence of raloxifene treatment yields deficits in visual acuity and contrast sensitivity, reductions in the A-wave and B-wave of the scotopic electroretinogram (ERG), light aversion, and increased pupil constriction to light. Raloxifene delivered daily for two weeks after blast at 5-10 mg/kg mitigates or eliminates these abnormalities (with the higher dose generally more effective). This functional rescue with raloxifene is accompanied by a biasing of microglia from the harmful M1 to the helpful M2 state, and reductions in retinal, optic nerve, and oculomotor nucleus pathology. We also found that raloxifene treatment is still effective even when delayed until 48 h after TBI, and that raloxifene benefit appears attributable to its CB2 inverse agonism rather than its estrogenic actions. Our studies show raloxifene is effective in treating visual injury after brain and/or eye trauma, and they provide basis for phase-2 efficacy testing in human clinical trials.	[Honig, Marcia G.; Del Mar, Nobel A.; Henderson, Desmond L.; Ragsdale, Tyler D.; Doty, John B.; Driver, Jake H.; Li, Chunyan; Fortugno, Andrew P.; Mitchell, William M.; Perry, Aaron M.; Reiner, Anton] Univ Tennessee, Dept Anat & Neurobiol, Hlth Sci Ctr, 855 Monroe Ave, Memphis, TN 38163 USA; [Reiner, Anton] Univ Tennessee, Dept Pharmaceut Sci, Hlth Sci Ctr, Memphis, TN 38163 USA; [Moore, Bob M.] Univ Tennessee, Dept Ophthalmol, Hlth Sci Ctr, Memphis, TN 38163 USA	Reiner, A (corresponding author), Univ Tennessee, Dept Anat & Neurobiol, Hlth Sci Ctr, 855 Monroe Ave, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	Methodist Hospitals Endowed Professorship in Neuroscience; UTHSC Neuroscience Institute; NIH Medical Student Research Fellowship Program at UTHSCUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; DoDUnited States Department of Defense [W81XWH-16-1-0076]	Special thanks to Marion Joni, Conor Dorian, and Dr. Natalie Guley for technical assistance. The research was supported by The Methodist Hospitals Endowed Professorship in Neuroscience (AR), UTHSC Neuroscience Institute (CL), NIH Medical Student Research Fellowship Program at UTHSC (JBD & JHD), and DoD grant W81XWH-16-1-0076 (AR, MGH).	Armstrong RA, 2018, CLIN EXP OPTOM, V101, P716, DOI 10.1111/cxo.12670; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Atwood BK, 2012, PROG NEURO-PSYCHOPH, V38, P16, DOI 10.1016/j.pnpbp.2011.12.001; Baver SB, 2008, EUR J NEUROSCI, V27, P1763, DOI 10.1111/j.1460-9568.2008.06149.x; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Benedetto MM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00417; Berson DM, 2010, J COMP NEUROL, V518, P2405, DOI 10.1002/cne.22381; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boudard DL, 2009, EUR J NEUROSCI, V30, P1527, DOI 10.1111/j.1460-9568.2009.06935.x; Bricker-Anthony C, 2017, OPTOMETRY VISION SCI, V94, P20, DOI 10.1097/OPX.0000000000000898; Bricker-Anthony C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131921; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Bruce BB, 2006, J NEUROL NEUROSUR PS, V77, P986, DOI 10.1136/jnnp.2006.088799; Bu W, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00449; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Capo-Aponte JE, 2017, OPTOMETRY VISION SCI, V94, P7, DOI 10.1097/OPX.0000000000000825; Collison FT, 2015, INVEST OPHTH VIS SCI, V56, P7130, DOI 10.1167/iovs.15-17467; Deng YP, 2016, J COMP NEUROL, V524, P3518, DOI 10.1002/cne.24013; Dimaraki EV, 2004, EUR J ENDOCRINOL, V150, P481, DOI 10.1530/eje.0.1500481; Dobolyi A, 2012, INT J MOL SCI, V13, P8219, DOI 10.3390/ijms13078219; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Donat CK, 2014, ACTA NEUROBIOL EXP, V74, P197; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Draper MW, 1996, J BONE MINER RES, V11, P835; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Fernandez-Arjona MD, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00235; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Frick KM, 2015, LEARN MEMORY, V22, P472, DOI 10.1101/lm.037267.114; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Guley NM, 2019, EXP EYE RES, V182, P109, DOI 10.1016/j.exer.2019.03.013; Habib P., 2015, J STEROID BIOCH MOL, V146; Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Hughes S, 2013, CURR BIOL, V23, P1696, DOI 10.1016/j.cub.2013.07.010; Jacobs SM, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0389-5; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kumar P, 2013, BIOCHEM BIOPH RES CO, V435, P76, DOI 10.1016/j.bbrc.2013.04.040; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li XM, 2017, METAB BRAIN DIS, V32, P259, DOI 10.1007/s11011-016-9913-z; Liebelhart B., 2009, CLIN CASES MINER BON, V6, P163; Lin B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068084; Liu Y, 2017, BMC BIOCHEM, V18, DOI 10.1186/s12858-017-0079-z; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Lunn CA, 2006, J PHARMACOL EXP THER, V316, P780, DOI 10.1124/JPET.105.093500; Madathil SK, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00964; Magid L, 2019, J NEUROTRAUM, V36, P1836, DOI 10.1089/neu.2018.6063; Matynia A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00060; Matynia A, 2015, EXP EYE RES, V137, P57, DOI 10.1016/j.exer.2015.05.025; Matynia A, 2012, EXP EYE RES, V105, P60, DOI 10.1016/j.exer.2012.09.012; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Ouk K, 2016, HUM MOL GENET, V25, P5418, DOI 10.1093/hmg/ddw359; Pisani SL, 2016, ENDOCRINOLOGY, V157, P292, DOI 10.1210/en.2015-1616; Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Schmidt TM, 2011, TRENDS NEUROSCI, V34, P572, DOI 10.1016/j.tins.2011.07.001; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003-032058; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Vest V, 2019, J NEUROTRAUM, V36, P1646, DOI 10.1089/neu.2018.6046; Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090	67	11	11	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2019	322								113063	10.1016/j.expneurol.2019.113063			19	Neurosciences	Neurosciences & Neurology	JU1CS	WOS:000501416100011	31518568	Other Gold			2021-06-18	
J	Juengst, SB; Nabasny, A; Terhorst, L				Juengst, Shannon B.; Nabasny, Andrew; Terhorst, Lauren			Neurobehavioral Symptoms in Community-Dwelling Adults With and Without Chronic Traumatic Brain Injury: Differences by Age, Gender, Education, and Health Condition	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; behavior; emotion; gender; age; education	ETHNIC DISPARITIES; MENTAL-HEALTH; CHALLENGING BEHAVIOR; SEX-DIFFERENCES; DEPRESSION; OUTCOMES; WOMEN; PTSD; TBI; IMPULSIVITY	Neurobehavioral symptoms after Traumatic Brain Injury (TBI) are prevalent, persist for many years, and negatively affect long-term health, function, and quality of life. Symptoms may differ based on age, gender, education, race, ethnicity, and injury severity. To better understand neurobehavioral functioning after TBI, we need a comprehensive picture of emotional, cognitive, and behavioral symptoms in the context of personal factors that may affect these symptoms. We also need to understand the extent to which these symptoms are specific to TBI, shared across other neurological conditions, or attributable to factors outside of the injury itself. We collected neurobehavioral symptoms via the self-reported Behavioral Assessment Screening Tool (BAST) in a National Cohort of English (n = 2,511) and Spanish speaking (n = 350) community-dwelling adults with and without chronic TBI and other neurological and mental health conditions. The primary focus of the present study was to comprehensively describe neurobehavioral symptoms in adults with and without TBI, broken down by gender and health conditions and then further by age group or educational attainment. As expected, participants with TBI reported more symptoms than Healthy Controls. Regardless of condition, women reported more fatigue, while men reported more substance abuse and impulsivity. Hispanic participants reported more neurobehavioral symptoms than non-Hispanic participants did across health conditions, though primarily Spanish-speakers reported fewer symptoms than English-speakers, suggesting that level of acculturation may contribute to symptom reporting. These data provide a comprehensive characterization of neurobehavioral symptoms in adults with TBI and adults without TBI (healthy controls, adults with other neurological conditions, and adults with mental health conditions).	[Juengst, Shannon B.; Nabasny, Andrew] Univ Texas Southwestern Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; [Terhorst, Lauren] Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA USA	Juengst, SB (corresponding author), Univ Texas Southwestern Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA.	shannon.juengst@utsouthwestern.edu			National Institutes for Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD) [R03HD09445]	This work was funded by the National Institutes for Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD). Grant no:R03HD09445 (PI: Juengst).	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P814, DOI 10.3109/02699052.2012.655360; Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P801, DOI 10.3109/02699052.2012.655368; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Arcia E, 2001, SOC SCI MED, V53, P41, DOI 10.1016/S0277-9536(00)00310-5; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Bauldry S, 2015, SOC MENT HEALTH, V5, P145, DOI 10.1177/2156869314564399; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brannlund A, 2017, J MENT HEALTH, V26, P318, DOI 10.1080/09638237.2017.1294739; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Cianelli R, 2008, CULT HEALTH SEX, V10, P297, DOI 10.1080/13691050701861439; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; Cooper KD., 1983, NEUROEPIDEMIOLOGY, V2, P79, DOI [10.1159/000110513, DOI 10.1159/000110513]; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cross CP, 2011, PSYCHOL BULL, V137, P97, DOI 10.1037/a0021591; Cruz-Flores S, 2011, STROKE, V42, P2091, DOI 10.1161/STR.0b013e3182213e24; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Diamantopoulou S, 2007, DEV NEUROPSYCHOL, V32, P521, DOI 10.1080/87565640701360981; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fuentes A, 2019, REHABIL PSYCHOL, V64, P229, DOI 10.1037/rep0000260; Gao SY, 2018, J HEAD TRAUMA REHAB, V33, pE40, DOI 10.1097/HTR.0000000000000338; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Gil R.M., 2014, MARIA PARADOX LATINA; Guerra-Carrillo B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182276; Gum Amber M, 2009, Am J Geriatr Psychiatry, V17, P769, DOI 10.1097/JGP.0b013e3181ad4f5a; Halbreich U, 2007, J AFFECT DISORDERS, V102, P245, DOI 10.1016/j.jad.2006.09.023; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Higashi Robin T, 2019, Health Lit Res Pract, V3, pe243, DOI 10.3928/24748307-20190925-01; Hiott Ann, 2006, Fam Syst Health, V24, P137, DOI 10.1037/1091-7527.24.2.137; Holzer KJ, 2019, J PSYCHIATR RES, V114, P149, DOI 10.1016/j.jpsychires.2019.05.002; Iverson GL, 2019, J NEUROPSYCHIATRY CL, DOI [10.1176/appi.neuropsych.1901002131587629, DOI 10.1176/APPI.NEUROPSYCH.1901002131587629]; James LM, 2014, MIL MED, V179, P357, DOI 10.7205/MILMED-D-13-00241; Juengst S, 2014, ARCH PHYS MED REHAB, V95, pE71, DOI [10.1016/j.apmr.2014.07.227, DOI 10.1016/J.APMR.2014.07.227]; Juengst SB, 2014, BRAIN BEHAV IMMUN, V41, P134, DOI 10.1016/j.bbi.2014.05.020; Juengst SB, 2018, DISABIL REHABIL, DOI [10.1080/09638288.2018.149648730451025, DOI 10.1080/09638288.2018.149648730451025]; Juengst SB, 2019, DISABIL REHABIL, V41, P1200, DOI 10.1080/09638288.2017.1423403; Juengst SB, 2017, J CLIN EXP NEUROPSYC, V39, P513, DOI 10.1080/13803395.2016.1240758; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Lequerica AH, 2018, ARCH PHYS MED REHAB, V99, P1811, DOI 10.1016/j.apmr.2018.03.023; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; McGuive TG, 2008, HEALTH AFFAIR, V27, P393, DOI 10.1377/hlthaff.27.2.393; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Myers CE, 2012, PSYCHIAT RES, V196, P271, DOI 10.1016/j.psychres.2011.11.015; Myrga JM, 2016, NEUROREHAB NEURAL RE, V30, P920, DOI 10.1177/1545968316648409; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nunnari D, 2014, NEUROL SCI, V35, P1513, DOI 10.1007/s10072-014-1897-z; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Perrin PB, 2014, ARCH PHYS MED REHAB, V95, P2288, DOI 10.1016/j.apmr.2014.07.409; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Reynolds K, 2015, WORLD PSYCHIATRY, V14, P74, DOI 10.1002/wps.20193; Riggio S, 2010, PSYCHIAT CLIN N AM, V33, P807, DOI 10.1016/j.psc.2010.08.004; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; ten Kate J, 2017, SOCIOL SPECTRUM, V37, P63, DOI 10.1080/02732173.2016.1274248; Todd M, 2018, AM J ORTHOPSYCHIAT, DOI [10.1037/ort000037030382727, DOI 10.1037/ORT000037030382727]; Weafer J, 2014, ADDICT BEHAV, V39, P1573, DOI 10.1016/j.addbeh.2013.10.033; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900	62	11	11	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	NOV 20	2019	10								1210	10.3389/fneur.2019.01210			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JV0YS	WOS:000502094600001	31849805	DOAJ Gold, Green Published			2021-06-18	
J	Liebert, A; Bicknell, B; Johnstone, DM; Gordon, LC; Kiat, H; Hamblin, MR				Liebert, Ann; Bicknell, Brian; Johnstone, Daniel M.; Gordon, Luke C.; Kiat, Hosen; Hamblin, Michael R.			"Photobiomics": Can Light, Including Photobiomodulation, Alter the Microbiome?	PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY			English	Article						photobiomodulation; microbiome; bacteria; metabolome	LEVEL LASER THERAPY; BIPHASIC DOSE-RESPONSE; DORSAL-ROOT GANGLION; CHAIN FATTY-ACIDS; GUT-BRAIN AXIS; MOUSE MODEL; STEM-CELLS; DISEASE PROGRESSION; PARKINSON DISEASE; NERVOUS-SYSTEM	Objective: The objective of this review is to consider the dual effects of microbiome and photobiomodulation (PBM) on human health and to suggest a relationship between these two as a novel mechanism. Background: PBM describes the use of low levels of visible or near-infrared (NIR) light to heal and stimulate tissue, and to relieve pain and inflammation. In recent years, PBM has been applied to the head as an investigative approach to treat diverse brain diseases such as stroke, traumatic brain injury (TBI), Alzheimer's and Parkinson's diseases, and psychiatric disorders. Also, in recent years, increasing attention has been paid to the total microbial population that colonizes the human body, chiefly in the gut and the mouth, called the microbiome. It is known that the composition and health of the gut microbiome affects many diseases related to metabolism, obesity, cardiovascular disorders, autoimmunity, and even brain disorders. Materials and methods: A literature search was conducted for published reports on the effect of light on the microbiome. Results: Recent work by our research group has demonstrated that PBM (red and NIR light) delivered to the abdomen in mice, can alter the gut microbiome in a potentially beneficial way. This has also now been demonstrated in human subjects. Conclusions: In consideration of the known effects of PBM on metabolomics, and the now demonstrated effects of PBM on the microbiome, as well as other effects of light on the microbiome, including modulating circadian rhythms, the present perspective introduces a new term "photobiomics" and looks forward to the application of PBM to influence the microbiome in humans. Some mechanisms by which this phenomenon might occur are considered.	[Liebert, Ann] Australasian Res Inst, 185 Fox Valley Rd, Wahroonga, NSW 2076, Australia; [Liebert, Ann] Univ Sydney, Dept Med, Camperdown, NSW, Australia; [Bicknell, Brian] Australian Catholic Univ, Fac Hlth Sci, Sydney, NSW, Australia; [Johnstone, Daniel M.; Gordon, Luke C.] Univ Sydney, Discipline Physiol, Camperdown, NSW, Australia; [Kiat, Hosen] Macquarie Univ, Fac Med & Hlth Sci, Marsfield, Australia; [Kiat, Hosen] Univ New South Wales, Fac Med, Kensington, NSW, Australia; [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA; [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA	Liebert, A (corresponding author), Australasian Res Inst, 185 Fox Valley Rd, Wahroonga, NSW 2076, Australia.	ann.liebert@sah.org.au	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Kiat, Hosen/0000-0002-2899-118X			Abrahamse H, 2012, PHOTOMED LASER SURG, V30, P681, DOI 10.1089/pho.2012.9881; Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; de Sousa NTA, 2016, LASER MED SCI, V31, P549, DOI 10.1007/s10103-016-1907-x; Anderson George, 2017, BioMolecular Concepts, V8, P185, DOI 10.1515/bmc-2017-0009; Arora HC, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.32; Auboyer L, 2019, SPIE PHOTONICS W; Bagheri M, 2018, PHOTOMED LASER SURG, V36, P415, DOI 10.1089/pho.2018.4453; Basha A. Ahamed, 2018, Indian Journal of Physiology and Pharmacology, V62, P187; Baxter NT, 2019, MSPHERE, V4, DOI [10.1128/mSphere.00528-18, 10.1128/msphere.00528-18]; Beauchemin KM, 1998, J ROY SOC MED, V91, P352, DOI 10.1177/014107689809100703; Bicknell B, 2019, LASER MED SCI, V34, P317, DOI 10.1007/s10103-018-2594-6; Bien J, 2013, THER ADV GASTROENTER, V6, P53, DOI 10.1177/1756283X12454590; Blivet Guillaume, 2018, Alzheimers Dement (N Y), V4, P54, DOI 10.1016/j.trci.2017.12.003; Boswell M, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040271; Boulange CL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0303-2; Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108; Brial F, 2018, CELL MOL LIFE SCI, V75, P3977, DOI 10.1007/s00018-018-2901-1; Chen M, 1993, LASER LIFE SCI, V5, P237; Chen SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep34477; Chow RT, 2007, J PERIPHER NERV SYST, V12, P28, DOI 10.1111/j.1529-8027.2007.00114.x; Cui M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111786; de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201; de la Fuente-Nunez C, 2018, ACS CHEM NEUROSCI, V9, P141, DOI 10.1021/acschemneuro.7b00373; Deaver JA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00737; Derkinderen P, 2011, NEUROLOGY, V77, P1761, DOI 10.1212/WNL.0b013e318236ef60; Disanto G, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-69; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Emanuel AJ, 2015, NEURON, V85, P1043, DOI 10.1016/j.neuron.2015.02.011; Farfara D, 2015, J MOL NEUROSCI, V55, P430, DOI 10.1007/s12031-014-0354-z; Fekrazad R, 2016, PHOTOMED LASER SURG, V34, P533, DOI 10.1089/pho.2015.4029; Ferraresi C, 2016, J BIOPHOTONICS, V9, P1273, DOI 10.1002/jbio.201600176; Figueiro MG, 2012, INT J ENDOCRINOL, V2012, P6; Flyktman A, 2015, J EXP BIOL, V218, P1521, DOI 10.1242/jeb.111864; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Fu JY, 2015, CIRC RES, V117, P817, DOI 10.1161/CIRCRESAHA.115.306807; Fukuda TY, 2013, LASER MED SCI, V28, P1305, DOI 10.1007/s10103-012-1231-z; Ganeshan V, 2019, NEUROSCIENCE, V400, P85, DOI 10.1016/j.neuroscience.2018.12.050; Gao J, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00013; Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Gonzalez A, 2016, MSYSTEMS, V1; Gooley JJ, 2011, J CLIN ENDOCR METAB, V96, pE463, DOI 10.1210/jc.2010-2098; Grosicki GJ, 2018, CALCIFIED TISSUE INT, V102, P433, DOI 10.1007/s00223-017-0345-5; Grzybowski A, 2012, CLIN DERMATOL, V30, P451, DOI 10.1016/j.clindermatol.2011.11.019; Gubatan J, 2018, CURR OPIN GASTROEN, V34, P217, DOI 10.1097/MOG.0000000000000449; Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864; Hamblin Michael R, 2017, Adv Exp Med Biol, V996, P295, DOI 10.1007/978-3-319-56017-5_25; Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337; Hamblin MR, 2016, J BIOPHOTONICS, V9, P1122, DOI 10.1002/jbio.201670113; Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V95, P126; Heiman ML, 2016, MOL METAB, V5, P317, DOI 10.1016/j.molmet.2016.02.005; Ho M. D., 2016, J INT NEUROPSYCH SOC, V22, P229; Holanda VM, 2017, LASER SURG MED, V49, P516, DOI 10.1002/lsm.22628; Holanda VM, 2016, LASER SURG MED, V48, P653, DOI 10.1002/lsm.22522; Horta-Baas G, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4835189; Huang C, 2016, PHOTOMED LASER SURG, V34, P313, DOI 10.1089/pho.2015.4077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Imhann F, 2018, GUT, V67, P108, DOI 10.1136/gutjnl-2016-312135; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132; Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787; Jenkins TA, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010056; Jiang CM, 2017, J ALZHEIMERS DIS, V58, P1, DOI 10.3233/JAD-161141; Jie ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00900-1; Johnstone DM, 2014, NEUROSCIENCE, V274, P93, DOI 10.1016/j.neuroscience.2014.05.023; Johnstone DM, 2016, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fninc.2015.00500, 10.3389/fnins.2015.00500]; Johnstone DM, 2015, NEURAL REGEN RES, V10, P349, DOI 10.4103/1673-5374.153673; Kaelberer MM, 2018, SCIENCE, V361, P1219, DOI 10.1126/science.aat5236; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; KARU TJ, 1983, NUOVO CIMENTO D, V2, P1138, DOI 10.1007/BF02457148; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Kelly JR, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00392; Kennedy PJ, 2017, NEUROPHARMACOLOGY, V112, P399, DOI 10.1016/j.neuropharm.2016.07.002; Kent A, 2018, J PAEDIATR CHILD H, V54, P27; Khan I, 2015, ADV WOUND CARE, V4, P724, DOI 10.1089/wound.2014.0623; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim B, 2018, IBRO REP, V4, P14, DOI 10.1016/j.ibror.2018.01.001; Kim B, 2017, AGEING RES REV, V37, P69, DOI 10.1016/j.arr.2017.05.005; Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108; Kitai Takeshi, 2016, Curr Heart Fail Rep, V13, P103, DOI 10.1007/s11897-016-0285-9; Klingelhoefer L, 2017, INT REV NEUROBIOL, V134, P787, DOI 10.1016/bs.irn.2017.05.027; Klingelhoefer L, 2015, NAT REV NEUROL, V11, P625, DOI 10.1038/nrneurol.2015.197; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Koliada A, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1027-1; Komaroff AL, 2018, JAMA-J AM MED ASSOC, V319, P2381, DOI 10.1001/jama.2018.5240; Leone V, 2015, CELL HOST MICROBE, V17, P681, DOI 10.1016/j.chom.2015.03.006; Liang X, 2017, J BIOL RHYTHM, V32, P505, DOI 10.1177/0748730417729066; Liebert A, 2018, PHOTOMED LASER SURG, V36, P515, DOI 10.1089/pho.2018.4527; Liebert AD, 2016, J EXP NEUROSCI, V10, P1, DOI 10.4137/JEN.S33444; Liebert AD, 2014, MED HYPOTHESES, V82, P275, DOI 10.1016/j.mehy.2013.12.009; Lim CK, 2017, PROG NEUROBIOL, V155, P76, DOI 10.1016/j.pneurobio.2015.12.009; Lima PLV, 2019, J PHOTOCH PHOTOBIO B, V194, P71, DOI 10.1016/j.jphotobiol.2019.03.015; Lovelace MD, 2017, NEUROPHARMACOLOGY, V112, P373, DOI 10.1016/j.neuropharm.2016.03.024; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Luczynski P, 2017, ELIFE, V6, DOI 10.7554/eLife.25887; Luthold RV, 2017, METABOLISM, V69, P76, DOI 10.1016/j.metabol.2017.01.007; Mahony SMO, 2017, PAIN, V158, pS19, DOI 10.1097/j.pain.0000000000000779; Maier L, 2018, NATURE, V555, P623, DOI 10.1038/nature25979; Mariat D, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-123; Marsland BJ, 2015, ANN AM THORAC SOC, V12, pS150, DOI 10.1513/AnnalsATS.201503-133AW; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Mazidi M, 2016, DIABETES METAB SYND, V10, pS150, DOI 10.1016/j.dsx.2016.01.024; Meckel K, 2016, AM J CLIN NUTR, V104, P113, DOI 10.3945/ajcn.115.123786; Mester E., 1968, LASER REV, V1, P3; Milani C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25945; Montagner A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20127; Muili KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030655; Nakamura K, 2016, BIOSCI MICROB FOOD H, V35, P57, DOI 10.12938/bmfh.2015-019; Natoli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072135; Neish AS, 2013, FREE RADICAL RES, V47, P950, DOI 10.3109/10715762.2013.833331; Nissila JS, 2017, CHRONOBIOL INT, V34, P37, DOI 10.1080/07420528.2016.1232269; Noseda R, 2017, P NATL ACAD SCI USA, V114, pE5683, DOI 10.1073/pnas.1708361114; Oldham MA, 2014, CHRONOBIOL INT, V31, P305, DOI 10.3109/07420528.2013.833935; Olsen I, 2016, J ORAL MICROBIOL, V8, DOI 10.3402/jom.v8.33029; Ondrusova K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16689-4; Ooi JH, 2013, J NUTR, V143, P1679, DOI 10.3945/jn.113.180794; Oron A, 2016, PHOTOMED LASER SURG, V34, P627, DOI 10.1089/pho.2015.4072; Oron U, 2001, CIRCULATION, V103, P296; Ottman N, 2017, BEST PRACT RES CL GA, V31, P637, DOI 10.1016/j.bpg.2017.10.001; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Parashar A, 2017, PARKINSONISM RELAT D, V38, P1, DOI 10.1016/j.parkreldis.2017.02.002; Parekh PJ, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00047; Patra V, 2018, FRONT MED-LAUSANNE, V5, DOI [10.3339/fmed.2013.00166, 10.3389/fmed.2018.00166]; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Perez-Pardo P, 2017, EUR J PHARMACOL, V817, P86, DOI 10.1016/j.ejphar.2017.05.042; Oliveira DAAP, 2009, PHOTOMED LASER SURG, V27, P461, DOI 10.1089/pho.2008.2290; Pistollato F, 2016, NUTR REV, V74, P624, DOI 10.1093/nutrit/nuw023; Purkayastha S, 2013, MOL METAB, V2, P356, DOI 10.1016/j.molmet.2013.09.005; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Raza GS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05259-3; Ricci R, 2009, J PHOTOCH PHOTOBIO B, V95, P6, DOI 10.1016/j.jphotobiol.2008.11.007; Roager HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05470-4; Rodriguez-Santana E, 2014, PHOTOMED LASER SURG, V32, P240, DOI 10.1089/pho.2013.3682; Rutten S, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/767105; Salem I, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01459; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Santana-Blank L, 2010, PHOTOMED LASER SURG, V28, pS173, DOI 10.1089/pho.2009.2745; Fernandes KPS, 2015, J PHOTOCH PHOTOBIO B, V153, P344, DOI 10.1016/j.jphotobiol.2015.10.015; Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009; Sherwin E, 2017, ANN NY ACAD SCI, V30, P1019; Sibley CH, 2016, OCUL IMMUNOL INFLAMM, V24, P460, DOI 10.1080/09273948.2016.1175641; Sikka G, 2014, P NATL ACAD SCI USA, V111, P17977, DOI 10.1073/pnas.1420258111; Singh MM, 2017, INTEGRATIVE ENV MED, P115; Song JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00553-6; Song P, 2017, CELL MOL LIFE SCI, V74, P2899, DOI 10.1007/s00018-017-2504-2; Stone J, 2013, 9 WALT C GOLD COAST; Sun MF, 2018, BRAIN BEHAV IMMUN, V70, P48, DOI 10.1016/j.bbi.2018.02.005; Tang WHW, 2017, CIRC RES, V120, P1183, DOI 10.1161/CIRCRESAHA.117.309715; Taylor RC, 2014, NAT REV MOL CELL BIO, V15, P211, DOI 10.1038/nrm3752; Tetel MJ, 2018, J NEUROENDOCRINOL, V30, DOI 10.1111/jne.12548; Thaiss CA, 2016, CELL, V167, P1495, DOI 10.1016/j.cell.2016.11.003; Tilg H, 2011, J CLIN INVEST, V121, P2126, DOI 10.1172/JCI58109; Tremlett H, 2017, ANN NEUROL, V81, P369, DOI 10.1002/ana.24901; Tsimakouridze Elena V, 2015, Front Pharmacol, V6, P77, DOI 10.3389/fphar.2015.00077; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; Turnbaugh PJ, 2009, J PHYSIOL-LONDON, V587, P4153, DOI 10.1113/jphysiol.2009.174136; Vandeputte D, 2017, GUT, V66, P1968, DOI 10.1136/gutjnl-2016-313271; Vandewalle G, 2010, P NATL ACAD SCI USA, V107, P19549, DOI 10.1073/pnas.1010180107; Vandewalle G, 2009, TRENDS COGN SCI, V13, P429, DOI 10.1016/j.tics.2009.07.004; Wang Y, 2017, SCI REP, V7, P415; Wang YG, 2017, BBA-GEN SUBJECTS, V1861, P441, DOI 10.1016/j.bbagen.2016.10.008; Wang YG, 2016, SCI REP-UK, V6, DOI 10.1038/srep33719; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Willis GL, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00741; Woting A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040202; Wu H, 2017, NAT MED, V23, P850, DOI 10.1038/nm.4345; Wu XM, 2016, J PHOTOCH PHOTOBIO B, V157, P89, DOI 10.1016/j.jphotobiol.2016.02.007; Wu ZH, 2010, LASER SURG MED, V42, P503, DOI 10.1002/lsm.20924; Yin K, 2017, STEM CELLS DEV, V26, P762, DOI 10.1089/scd.2016.0332; Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367; ZOMORRODI R, 2019, BRAIN STIMUL, V12, P457; Zomorrodi R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42693-x	174	11	11	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA		2578-5478		PHOTOBIOMOD PHOTOMED	Photobiomodulation Photomed. Laser Surg.	NOV 1	2019	37	11					681	693		10.1089/photob.2019.4628			13	Surgery	Surgery	JL5CN	WOS:000495548100003	31596658	Green Published, Other Gold			2021-06-18	
J	Maggio, MG; Torrisi, M; Buda, A; De Luca, R; Piazzitta, D; Cannavo, A; Leo, A; Milardi, D; Manuli, A; Calabro, RS				Maggio, Maria Grazia; Torrisi, Michele; Buda, Antonio; De Luca, Rosaria; Piazzitta, Denise; Cannavo, Antonio; Leo, Antonio; Milardi, Demetrio; Manuli, Alfredo; Calabro, Rocco Salvatore			Effects of robotic neurorehabilitation through lokomat plus virtual reality on cognitive function in patients with traumatic brain injury: A retrospective case-control study	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						Cognitive rehabilitation; Lokomat; traumatic brain injury; virtual reality	REHABILITATION; RECOVERY; STROKE; TREADMILL; PEOPLE	Background: Traumatic brain injury (TBI) is a clinical condition characterized by damage due to a mechanical physical event, which has a devastating impact on both the patient and his/her family. The purpose of this study is to evaluate the effects of robotic neurorehabilitation using Lokomat with virtual reality (VR) on attention processes and executive functions in patients with TBI. Materials and Methods: This is a retrospective case-control study. Fifty-six TBI patients have been included in the analysis, using an electronic recovery data system. The enrolled patients were divided into two groups: the experimental group (LPG) underwent rehabilitation training with Lokomat Pro, equipped with a VR screen, whereas the control group (LNG) performed rehabilitation training using Lokomat Nanos, without VR. The two groups matched for age, sex, education, brain lesions, interval from TBI. The rehabilitation protocol consisted of a total of 40 training sessions. Results: LPG and LNG had a significant improvement in mood and in the perception of physical well-being. However, only the LPG had a significant improvement in global cognitive, executive and attention functions. Furthermore, LPG presented a significant enhancement of the quality of life, with regard to the perception of the mental and physical state. Conclusion: Our study supports the idea that Lokomat is a useful tool in the rehabilitation of patients with TBI; in particular, the integration of the VR device can implement the cognitive and behavioral functions of TBI patients, enhancing also their physical and mental well-being.	[Maggio, Maria Grazia; Torrisi, Michele; Buda, Antonio; De Luca, Rosaria; Piazzitta, Denise; Cannavo, Antonio; Leo, Antonio; Milardi, Demetrio; Manuli, Alfredo; Calabro, Rocco Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, SS 113, I-98124 Messina, Italy; [Milardi, Demetrio] Univ Messina, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy	Calabro, RS (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo, SS 113, I-98124 Messina, Italy.	salbro77@tiscali.it	Milardi, Demetrio/J-6587-2016; Leo, Antonino/K-7529-2016; Manuli, Alfredo/ABF-3128-2020; Calabro, Rocco S/K-7520-2016; MILARDI, DEMETRIO/AAD-7793-2019; Leo, Antonino/ABI-7198-2020; Maggio, Maria Grazia/ABA-1852-2020	Milardi, Demetrio/0000-0001-7311-2757; Leo, Antonino/0000-0003-4163-5830; Manuli, Alfredo/0000-0002-4030-1399; MILARDI, DEMETRIO/0000-0001-7311-2757; Leo, Antonino/0000-0003-4163-5830; /0000-0003-0757-2389			Aida J, 2018, NEUROREHABILITATION, V42, P441, DOI 10.3233/NRE-172361; Banz R, 2008, PHYS THER, V88, P1135, DOI 10.2522/ptj.20070203; Bergmann J, 2018, EUR J PHYS REHAB MED, V54, P397, DOI 10.23736/S1973-9087.17.04735-9; Calabro RS, 2015, INT J REHABIL RES, V38, P219, DOI 10.1097/MRR.0000000000000114; Calabro RS, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0268-4; Calabro RS, 2017, J NEUROL SCI, V377, P25, DOI 10.1016/j.jns.2017.03.047; Calabro RS, 2016, NEUROL SCI, V37, P503, DOI 10.1007/s10072-016-2474-4; Calabro RS, 2015, AGING CLIN EXP RES, V27, P935, DOI 10.1007/s40520-015-0343-2; Calabro RS, 2014, FUNCT NEUROL, V29, P139, DOI 10.11138/FNeur/2014.29.2.139; D'Arcy RCN, 2016, J HEAD TRAUMA REHAB, V31, pE50, DOI 10.1097/HTR.0000000000000185; De Luca R, 2017, INT J NEUROSCI, V17, p20171403915, DOI 10.1080/00207454; Duschau-Wicke A, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-43; Esquenazi A, 2017, PM&R, V9, P839, DOI 10.1016/j.pmrj.2016.12.010; Furnari A, 2017, INT J NEUROSCI, V127, P996, DOI 10.1080/00207454.2017.1288623; Hussain S, 2012, MED ENG PHYS, V34, P1448, DOI 10.1016/j.medengphy.2012.02.003; Latella D, 2018, J CLIN NEUROSCI, V58, P1, DOI 10.1016/j.jocn.2018.09.030; Lopez-Samaniego L, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121176; Maggio MG, 2019, J NATL MED ASSOC, V111, P457, DOI 10.1016/j.jnma.2019.01.003; Maggio MG, 2019, J NEUROSCI NURS, V51, P101, DOI 10.1097/JNN.0000000000000423; Maggio MG, 2019, J CLIN NEUROSCI, V61, P1, DOI 10.1016/j.jocn.2018.12.020; Maggio MG, 2018, J GERIATR PSYCH NEUR, V31, P312, DOI 10.1177/0891988718807973; Maggio MG, 2018, APPL NURS RES, V41, P11, DOI 10.1016/j.apnr.2018.03.005; Morone G, 2012, STROKE, V43, P1140, DOI 10.1161/STROKEAHA.111.638148; Rizzo A, 2011, STUD HEALTH TECHNOL, V163, P510, DOI 10.3233/978-1-60750-706-2-510; Rizzolatti G, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0420; Robitaille N, 2017, DISABIL REHABIL-ASSI, V12, P758, DOI 10.1080/17483107.2016.1229048; Saatian Mohamadreza, 2018, Bull Emerg Trauma, V6, P45, DOI 10.29252/beat-060107; Sale A, 2009, TRENDS NEUROSCI, V32, P233, DOI 10.1016/j.tins.2008.12.004; See J, 2013, NEUROREHAB NEURAL RE, V27, P732, DOI 10.1177/1545968313491000; Ucar DE, 2014, NEUROREHABILITATION, V34, P447, DOI 10.3233/NRE-141054; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Wang YX, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.719; Wilson BA, 2013, S AFR J PSYCHOL, V43, P267, DOI 10.1177/0081246313494156; Zanier ER, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00345; Zengin-Metli D, 2018, J BACK MUSCULOSKELET, V31, P1059, DOI 10.3233/BMR-171015	35	11	12	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	FEB 1	2020	130	2					117	123		10.1080/00207454.2019.1664519		OCT 2019	7	Neurosciences	Neurosciences & Neurology	KA6CS	WOS:000490726100001	31590592				2021-06-18	
J	Clacy, A; Goode, N; Sharman, R; Lovell, GP; Salmon, P				Clacy, Amanda; Goode, Natassia; Sharman, Rachael; Lovell, Geoff P.; Salmon, Paul			A systems approach to understanding the identification and treatment of sport-related concussion in community rugby union	APPLIED ERGONOMICS			English	Article						Systems thinking; Concussion; Injury management; Sport-related injury; Rugby union	RISK-FACTORS; MANAGEMENT; INJURY; IMPLEMENTATION; PREVENTION; STRATEGIES; STATEMENT; PLAYERS; DESIGN; RETURN	Aim: The aim of the present study was to utilise a systems thinking approach to explore the perceived responsibilities for identifying and treating concussion held by different actors across the community rugby system (e.g., players, coaches, parents, medics, referees, and management), as well as their role specific concussion management strategies. Methods: A systems approach was taken to assess what different stakeholders within rugby systems perceive their roles to be regarding concussion identification and treatment. Through an online survey, 118 members of the amateur (community) rugby union system were asked about their role-specific concussion management responsibilities and strategies. Respondents included players, parents, medics, coaches, club managers, administrators, and volunteers. Results: The majority of respondents indicated that they were able to identify the symptoms of rugby related concussion, however, only medics stated their responsibility to use formal concussion assessments (e.g., SCAT2). A smaller number of the respondents indicated that they were involved in treating concussion within their current role/s (majority of which were medics). Conclusions: This study illustrated that the current challenges in the identification and treatment of rugby-related concussion in community sport may be due to role/responsibility confusion and possible overreliance on field-side medics. These findings offer insight into the possible limitations of the current concussion management guidelines and may offer empirically based direction for future revisions. (C) 2017 Elsevier Ltd. All rights reserved.	[Clacy, Amanda; Goode, Natassia; Salmon, Paul] Univ Sunshine Coast, Ctr Human Factors & Sociotech Syst, Sunshine Coast, Australia; [Sharman, Rachael; Lovell, Geoff P.] Univ Sunshine Coast, Fac Arts & Business Psychol, Sunshine Coast, Australia	Clacy, A (corresponding author), Univ Sunshine Coast, Ctr Human Factors & Sociotech Syst, Sunshine Coast, Australia.	aclacy@usc.edu.au		Salmon, Paul/0000-0001-7403-0286			Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Borich MR, 2013, J NEUROL PHYS THER, V37, P133, DOI 10.1097/NPT.0b013e31829f7460; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Chalmers DJ, 2012, BRIT J SPORT MED, V46, P95, DOI 10.1136/bjsports-2011-090272; Clacy A, 2017, J SPORT SCI, V35, P2232, DOI 10.1080/02640414.2016.1265140; Clacy A, 2015, PROCEDIA MANUF, V3, P1173, DOI 10.1016/j.promfg.2015.07.195; Clacy A, 2013, J BIOETHIC INQ, V10, P127, DOI 10.1007/s11673-012-9421-8; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Dallat C, 2015, PROCEDIA MANUF, V3, P1157, DOI 10.1016/j.promfg.2015.07.193; Donaldson A, 2012, BRIT J SPORT MED, V46, P306, DOI 10.1136/bjsports-2011-090461; Donaldson A, 2016, AM J LIFESTYLE MED, V10, P120, DOI 10.1177/1559827614538751; Finch CF, 2010, BRIT J SPORT MED, V44, P973, DOI 10.1136/bjsm.2008.056069; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87; Goode N., 2015, P 6 APPL HUM FACT ER; Gourley MM., 2010, ATHL TRAIN SPORTS HL, V2, P208, DOI DOI 10.3928/19425864-20100524-03; Helps Y., 2008, INJURY RES STAT SERI, V45; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Kerr HA, 2014, PEDIATR ANN, V43, pE309, DOI 10.3928/00904481-20141124-10; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Leveson N, 2004, SAFETY SCI, V42, P237, DOI 10.1016/S0925-7535(03)00047-X; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Marras WS, 2014, APPL ERGON, V45, P55, DOI 10.1016/j.apergo.2013.03.025; McCrory P., 2009, S AFR J SPORTS MED, V21, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Perrow Charles., 1984, NORMAL ACCIDENTS LIV; Rasmussen J, 1997, SAFETY SCI, V27, P183, DOI 10.1016/S0925-7535(97)00052-0; Rasmussen J, 2000, PROACTIVE RISK MANAG; Salmon PM, 2016, APPL ERGON, V53, P312, DOI 10.1016/j.apergo.2015.06.021; Svedung I, 2002, SAFETY SCI, V40, P397, DOI 10.1016/S0925-7535(00)00036-9; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tibbert SJ, 2015, PSYCHOL SPORT EXERC, V17, P68, DOI 10.1016/j.psychsport.2014.10.007; World Rugby, 2015, PLAYER WELF IRB CONC	40	11	11	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0003-6870	1872-9126		APPL ERGON	Appl. Ergon.	OCT	2019	80						256	264		10.1016/j.apergo.2017.06.010			9	Engineering, Industrial; Ergonomics; Psychology, Applied	Engineering; Psychology	IM0OD	WOS:000477687200030	28687400				2021-06-18	
J	Kang, JH; Sherill, GC; Sinha, SR; Swisher, CB				Kang, Jennifer H.; Sherill, G. Clay; Sinha, Saurabh R.; Swisher, Christa B.			A Trial of Real-Time Electrographic Seizure Detection by Neuro-ICU Nurses Using a Panel of Quantitative EEG Trends	NEUROCRITICAL CARE			English	Article						Quantitative EEG; qEEG; Seizures; ICU; EEG; Non-convulsive seizures	NONCONVULSIVE STATUS EPILEPTICUS; AMPLITUDE INTEGRATED EEG; TRAUMATIC BRAIN-INJURY; IDENTIFICATION; SENSITIVITY; ELECTROENCEPHALOGRAPHY; NEUROPHYSIOLOGISTS; ACCURACY; BURDEN	Background Non-convulsive seizures (NCS) are a common occurrence in the neurologic intensive care unit (Neuro-ICU) and are associated with worse outcomes. Continuous electroencephalogram (cEEG) monitoring is necessary for the detection of NCS; however, delays in interpretation are a barrier to early treatment. Quantitative EEG (qEEG) calculates a time-compressed simplified visual display from raw EEG data. This study aims to evaluate the performance of Neuro-ICU nurses utilizing bedside, real-time qEEG interpretation for detecting recurrent NCS. Methods This is a prospective, single-institution study of patients admitted to the Duke Neuro-ICU between 2016 and 2018 who had NCS identified on traditional cEEG review. The accuracy of recurrent seizure detection on hourly qEEG review by bedside Neuro-ICU nurses was compared to the gold standard of cEEG interpretation by two board-certified neurophysiologists. The nurses first received brief qEEG training, individualized for their specific patient. The bedside qEEG display consisted of rhythmicity spectrogram (left and right hemispheres) and amplitude-integrated EEG (left and right hemispheres) in 1-h epochs. Results Twenty patients were included and 174 1-h qEEG blocks were analyzed. Forty-seven blocks contained seizures (27%). The sensitivity was 85.1% (95% CI 71.1-93.1%), and the specificity was 89.8% (82.8-94.2%) for the detection of seizures for each 1-h block when compared to interpretation of conventional cEEG by two neurophysiologists. The false positive rate was 0.1/h. Hemispheric seizures (> 4 unilateral EEG electrodes) were more likely to be correctly identified by nurses on qEEG than focal seizures (<= 4 unilateral electrodes) (p = 0.03). Conclusions After tailored training sessions, Neuro-ICU nurses demonstrated a good sensitivity for the interpretation of bedside real-time qEEG for the detection of recurrent NCS with a low false positive rate. qEEG is a promising tool that may be used by non-neurophysiologists and may lead to earlier detection of NCS.	[Kang, Jennifer H.; Sherill, G. Clay; Sinha, Saurabh R.; Swisher, Christa B.] Duke Univ, Dept Neurol, Med Ctr, DUMC 2905, Durham, NC 27710 USA; [Sinha, Saurabh R.] Vet Affairs Med Ctr, Neurodiagnost Ctr, Durham, NC USA	Kang, JH (corresponding author), Duke Univ, Dept Neurol, Med Ctr, DUMC 2905, Durham, NC 27710 USA.	Jennifer.kang@duke.edu		Kang, Jennifer/0000-0002-0859-3942; Swisher, Christa/0000-0001-7753-7023	Donald B. Sanders Neurology Fellows Research Grant (Duke University)	This study was funded by the Donald B. Sanders Neurology Fellows Research Grant (Internal grant within Duke University).	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Akman CI, 2011, EPILEPSY RES, V93, P66, DOI 10.1016/j.eplepsyres.2010.10.018; Amorim E, 2017, J CLIN NEUROPHYSIOL, V34, P359, DOI 10.1097/WNP.0000000000000368; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Cheng JY, 2016, J NEUROL SCI, V370, P290, DOI 10.1016/j.jns.2016.10.004; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; De Marchis GM, 2016, NEUROLOGY, V86, P253, DOI 10.1212/WNL.0000000000002281; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dhiman V, 2013, EPILEPSIA, V54, P109; Evans E, 2010, ARCH DIS CHILD-FETAL, V95, pF169, DOI 10.1136/adc.2009.165969; Fernandez IS, 2018, NEUROLOGY, V90, pE1692, DOI 10.1212/WNL.0000000000005488; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Ganesan SL, 2018, CRIT CARE MED, V46, pE1105, DOI 10.1097/CCM.0000000000003385; Gavvala J, 2014, EPILEPSIA, V55, P1864, DOI 10.1111/epi.12809; Glauser T, 2016, EPILEPSY CURR, V16, P48, DOI 10.5698/1535-7597-16.1.48; Gutierrez-Viedma A, 2018, EPILEPSY BEHAV, V82, P11, DOI 10.1016/j.yebeh.2018.02.029; Haider HA, 2016, NEUROLOGY, V87, P935, DOI 10.1212/WNL.0000000000003034; Hill CE, 2017, ANN NEUROL, V82, P155, DOI 10.1002/ana.24986; Leitinger M, 2015, EPILEPSY BEHAV, V49, P158, DOI 10.1016/j.yebeh.2015.05.007; Mazarati AM, 1998, BRAIN RES, V814, P179, DOI 10.1016/S0006-8993(98)01080-4; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; Nitzschke R, 2011, J CLIN MONIT COMPUT, V25, P329, DOI 10.1007/s10877-011-9312-2; Payne ET, 2014, BRAIN, V137, P1429, DOI 10.1093/brain/awu042; Pisani F, 2008, J CHILD NEUROL, V23, P394, DOI 10.1177/0883073807309253; Rao SK, 2018, EPILEPTIC DISORD, V20, P265, DOI 10.1684/epd.2018.0987; Rennie JM, 2004, ARCH DIS CHILD-FETAL, V89, pF37, DOI 10.1136/fn.89.1.F37; Shellhaas RA, 2007, PEDIATRICS, V120, P770, DOI 10.1542/peds.2007-0514; Sinha SR, 2013, HANDBOOK OF ICU EEG MONITORING, P221; Swisher CB, 2016, J CLIN NEUROPHYSIOL, V33, P538, DOI 10.1097/WNP.0000000000000287; Swisher CB, 2015, J CLIN NEUROPHYSIOL, V32, P324, DOI 10.1097/WNP.0000000000000144; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Westover MB, 2015, CLIN NEUROPHYSIOL, V126, P463, DOI 10.1016/j.clinph.2014.05.037; Williamson CA, 2014, NEUROCRIT CARE, V20, P32, DOI 10.1007/s12028-013-9912-4	35	11	11	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2019	31	2					312	320		10.1007/s12028-019-00673-z			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	JA0OX	WOS:000487511700013	30788707				2021-06-18	
J	Takahata, K; Kimura, Y; Sahara, N; Koga, S; Shimada, H; Ichise, M; Saito, F; Moriguchi, S; Kitamura, S; Kubota, M; Umeda, S; Niwa, F; Mizushima, J; Morimoto, Y; Funayama, M; Tabuchi, H; Bieniek, KF; Kawamura, K; Zhang, MR; Dickson, DW; Mimura, M; Kato, M; Suhara, T; Higuchi, M				Takahata, Keisuke; Kimura, Yasuyuki; Sahara, Naruhiko; Koga, Shunsuke; Shimada, Hitoshi; Ichise, Masanori; Saito, Fumie; Moriguchi, Sho; Kitamura, Soichiro; Kubota, Manabu; Umeda, Satoshi; Niwa, Fumitoshi; Mizushima, Jin; Morimoto, Yoko; Funayama, Michitaka; Tabuchi, Hajime; Bieniek, Kevin F.; Kawamura, Kazunori; Zhang, Ming-Rong; Dickson, Dennis W.; Mimura, Masaru; Kato, Motoichiro; Suhara, Tetsuya; Higuchi, Makoto			PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury	BRAIN			English	Article						tau; traumatic brain injury (TBI); chronic traumatic encephalopathy (CTE); PET; post-traumatic psychosis	AMYLOID PROTEIN DEPOSITION; HEAD-INJURY; DISEASE; ENCEPHALOPATHY; DISORDERS; TAUOPATHY; PATHOGENESIS; PLAYERS; BINDING; MATTER	Tau deposits is a core feature of neurodegenerative disorder following traumatic brain injury (TBI). Despite ample evidence from post-mortem studies demonstrating exposure to both mild-repetitive and severe TBIs are linked to tau depositions, associations of topology of tau lesions with late-onset psychiatric symptoms due to TBI have not been explored. To address this issue, we assessed tau deposits in long-term survivors of TBI by PET with C-11-PBB3, and evaluated those associations with late-life neuropsychiatric outcomes. PET data were acquired from 27 subjects in the chronic stage following mild-repetitive or severe TBI and 15 healthy control subjects. Among the TBI patients, 14 were diagnosed as having late-onset symptoms based on the criteria of traumatic encephalopathy syndrome. For quantification of tau burden in TBI brains, we calculated C-11-PBB3 binding capacity (cm(3)), which is a summed voxel value of binding potentials (BP*ND) multiplied by voxel volume. Main outcomes of the present study were differences in C-11-PBB3 binding capacity between groups, and the association of regional C-11-PBB3 binding capacity with neuropsychiatric symptoms. To confirm C-11-PBB3 binding to tau deposits in TBI brains, we conducted in vitro PBB3 fluorescence and phospho-tau antibody immunofluorescence labelling of brain sections of chronic traumatic encephalopathy obtained from the Brain Bank. Our results showed that patients with TBI had higher C-11-PBB3 binding capacities in the neocortical grey and white matter segments than healthy control subjects. Furthermore, TBI patients with traumatic encephalopathy syndrome showed higher C-11-PBB3 binding capacity in the white matter segment than those without traumatic encephalopathy syndrome, and regional assessments revealed that subgroup difference was also significant in the frontal white matter. C-11-PBB3 binding capacity in the white matter segment correlated with the severity of psychosis. In vitro assays demonstrated PBB3-positive tau inclusions at the depth of neocortical sulci, confirming C-11-PBB3 binding to tau lesions. In conclusion, increased C-11-PBB3 binding capacity is associated with late-onset neuropsychiatric symptoms following TBI, and a close correlation was found between psychosis and C-11-PBB3 binding capacity in the white matter.	[Takahata, Keisuke; Kimura, Yasuyuki; Sahara, Naruhiko; Shimada, Hitoshi; Ichise, Masanori; Moriguchi, Sho; Kitamura, Soichiro; Kubota, Manabu; Suhara, Tetsuya; Higuchi, Makoto] Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Dept Funct Brain Imaging Res, Chiba, Japan; [Takahata, Keisuke; Saito, Fumie; Mizushima, Jin; Morimoto, Yoko; Tabuchi, Hajime; Mimura, Masaru; Kato, Motoichiro] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Kimura, Yasuyuki] Natl Ctr Geriatr & Gerontol, Obu, Aichi, Japan; [Koga, Shunsuke; Bieniek, Kevin F.; Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Moriguchi, Sho] Ctr Addict & Mental Hlth, Res Imaging Ctr, Toronto, ON, Canada; [Kitamura, Soichiro; Kawamura, Kazunori] Nara Med Univ, Dept Psychiat, Nara, Japan; [Umeda, Satoshi] Keio Univ, Dept Psychol, Tokyo, Japan; [Niwa, Fumitoshi] Kyoto Prefectural Univ Med, Dept Neurol, Kyoto, Kyoto, Japan; [Funayama, Michitaka] Japanese Red Cross Ashikaga Hosp, Dept Psychiat, Ashikaga, Tochigi, Japan; [Zhang, Ming-Rong] Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Dept Radiopharmaceut Dev, Chiba, Japan	Takahata, K (corresponding author), Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Dept Funct Brain Imaging Res, Inage Ku, 4-9-1 Anagawa, Chiba, Chiba 2638555, Japan.	takahata.keisuke@qst.go.jp	Koga, Shunsuke/ABE-7206-2020; Kimura, Yasuyuki/ABC-5158-2020	Koga, Shunsuke/0000-0001-8868-9700; Kimura, Yasuyuki/0000-0002-7927-9483; Niwa, Fumitoshi/0000-0001-5431-5559; Bieniek, Kevin/0000-0003-4922-864X	Japan Agency for Medical Research and DevelopmentJapan Agency for Medical Research and Development (AMED) [JP18dm0207007, JP18dm0207018, JP18dk0207026]; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP16K19789]	This study was supported by grants from Grants-in-Aid for Brain Mapping by Integrated Neurotechnologies for Disease Studies (JP18dm0207007 and JP18dm0207018), Research and Development Grants for Dementia (JP18dk0207026) from the Japan Agency for Medical Research and Development. This study was also supported by JSPS KAKENHI Grand Number JP16K19789. H.S., M.R.Z., T.S., and M.H. hold a patent on compounds related to the present report (JP 5422782/EP 12 884 742.3).	ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ALAVI A, 1993, J NUCL MED, V34, P1681; Albano D, 2018, ANN NUCL MED, V32, P532, DOI 10.1007/s12149-018-1274-8; Barrio JR, 2015, P NATL ACAD SCI USA; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bohorquez SS, 2017, ANN M SOC NUCL MED M; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Bural G, 2015, NUCL MED COMMUN, V36, P1249, DOI 10.1097/MNM.0000000000000394; Deighton S, 2016, SCHIZOPHR RES, P1; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Endo H, 2019, MOVEMENT DISORD, V10, P333; Filley CM, 2016, J NEUROPHYSIOL, V116, P2093, DOI 10.1152/jn.00221.2016; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Garcia-Sierra F, 2000, ACTA NEUROPATHOL, V100, P29, DOI 10.1007/s004010051189; Goland R, 2009, J NUCL MED, V50, P382, DOI 10.2967/jnumed.108.054866; Hashimoto H, 2014, J NUCL MED, V55, P1532, DOI 10.2967/jnumed.114.139550; Hostetler ED, 2016, J NUCL MED, V57, P1599, DOI 10.2967/jnumed.115.171678; Ichise M, 2014, United States Patent, Patent No. [8,652,440 B2, 8652440B2]; Johnson VE, 2014, NATURE, V11, P128; Johnson VE, 2017, ADV NEUROBIOL, V15, P383, DOI 10.1007/978-3-319-57193-5_15; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Khalil MM, 2016, BASIC SCI PET IMAGIN, P303; KIMURA Y, 2015, J NUCL MED, V56, P1; Kimura Y, 2016, EJNMMI RES, V6, DOI 10.1186/s13550-016-0182-y; Koga S, 2017, MOVEMENT DISORD, V32, P884, DOI 10.1002/mds.27013; Larson Steven M., 1999, Clin Positron Imaging, V2, P159, DOI 10.1016/S1095-0397(99)00016-3; Lee P, 2007, INT J RADIAT ONCOL, V69, P328, DOI 10.1016/j.ijrobp.2007.04.036; LoBue C, 2018, J NEUROPSYCH CLIN N, V30, P7, DOI 10.1176/appi.neuropsych.17070145; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Montenigro PH, 2015, BRAIN PATHOL, V25, P304, DOI 10.1111/bpa.12250; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; NG KP, 2017, ALZHEIMERS RES THER, V9, P1; Ni RQ, 2018, J NUCL MED, V59, P960, DOI 10.2967/jnumed.117.201632; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ono M, 2017, BRAIN, V140, P764, DOI 10.1093/brain/aww339; Perez-Soriano A, 2017, MOVEMENT DISORD, V32, P1016, DOI 10.1002/mds.27029; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Shimada Hitoshi, 2017, Alzheimers Dement (Amst), V6, P11, DOI 10.1016/j.dadm.2016.12.009; Shinotoh H, 2019, NEUROLOGY, V92, pE136, DOI 10.1212/WNL.0000000000006736; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Southekal S, 2018, J NUCL MED, V59, P944, DOI 10.2967/jnumed.117.200006; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2019, NEW ENGL J MED, V380, P1716, DOI 10.1056/NEJMoa1900757; Vanhove Karolien, 2018, Cancer Treat Res Commun, V15, P7, DOI 10.1016/j.ctarc.2017.11.005; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038	65	11	11	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2019	142		10				3265	3279		10.1093/brain/awz238			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JY3MJ	WOS:000504322300034	31504227				2021-06-18	
J	Liu, SF; Utriainen, D; Chai, C; Chen, YS; Wang, L; Sethi, SK; Xia, S; Haacke, EM				Liu, Saifeng; Utriainen, David; Chai, Chao; Chen, Yongsheng; Wang, Lin; Sethi, Sean K.; Xia, Shuang; Haacke, E. Mark			Cerebral microbleed detection using Susceptibility Weighted Imaging and deep learning	NEUROIMAGE			English	Article						Cerebral microbleeds; Computer aided detection; Deep learning; Convolutional neural networks; Susceptibility weighted imaging; Quantitative susceptibility mapping	TRAUMATIC BRAIN-INJURY; COMPUTER-AIDED DETECTION; IDENTIFICATION; CALCIFICATION	Detecting cerebral microbleeds (CMBs) is important in diagnosing a variety of diseases including dementia, stroke and traumatic brain injury. However, manual detection of CMBs can be time-consuming and prone to errors, whereas the current automatic algorithms for CMB detection are usually limited by large number of false positives. In this study, we present a two-stage CMB detection framework which contains a candidate detection stage based on a 3D fast radial symmetry transform of the composite images from Susceptibility Weighted Imaging (SWI), and a false positive reduction stage based on deep residual neural networks using both the SWI and the high-pass filtered phase images. While the SWI images provide exquisite sensitivity to the presence of blood products, the high-pass filtered phase images enable the differentiation of diamagnetic calcifications from paramagnetic microbleeds. The deep learning model was trained using 154 data sets, and the best models were selected using 25 validation data sets. Finally, the models were tested using 41 cases, including 13 hemodialysis cases, 9 traumatic brain injury cases, 9 stroke cases and 10 healthy controls. Using 3D SWI and high-pass filtered phase images as input, the best model led to a sensitivity of 95.8%, a precision of 70.9%, and 1.6 false positives per case. This model achieved similar performance to the most experienced human rater and outperformed recently reported CMB detection methods. This study demonstrates the potential of applying deep learning techniques to medical imaging for improving efficiency and accuracy in diagnosis.	[Liu, Saifeng; Utriainen, David; Chen, Yongsheng; Wang, Lin; Sethi, Sean K.; Haacke, E. Mark] MRI Inst Biomed Res, Bingham Farms, MI USA; [Utriainen, David; Sethi, Sean K.; Haacke, E. Mark] Magnet Resonance Innovat, Bingham Farms, MI USA; [Chai, Chao; Xia, Shuang] Tianjin First Cent Hosp, Dept Radiol, Tianjin, Peoples R China; [Chen, Yongsheng; Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA	Liu, SF (corresponding author), 30200 Telegraph Rd,Ste 104, Bingham Farms, MI 48025 USA.	liusaifeng@gmail.com	Chen, Yongsheng/U-9800-2019	Chen, Yongsheng/0000-0001-7114-5731	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871342]	This work was supported in part by the National Natural Science Foundation of China (grant number 81871342 to Shuang Xia).	Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Barnes SRS, 2011, MAGN RESON IMAGING, V29, P844, DOI 10.1016/j.mri.2011.02.028; Bian W, 2013, NEUROIMAGE-CLIN, V2, P282, DOI 10.1016/j.nicl.2013.01.012; BLAIR RC, 1993, PSYCHOPHYSIOLOGY, V30, P518, DOI 10.1111/j.1469-8986.1993.tb02075.x; Chen YC, 2019, J DIGIT IMAGING, V32, P766, DOI 10.1007/s10278-018-0146-z; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dou Q, 2016, IEEE T MED IMAGING, V35, P1182, DOI 10.1109/TMI.2016.2528129; Fan YH, 2003, STROKE, V34, P2459, DOI 10.1161/01.STR.0000090841.90286.81; Fatemi-Ardekani A, 2009, MED PHYS, V36, P5429, DOI 10.1118/1.3250860; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Faziollahi A, 2014, I S BIOMED IMAGING, P113, DOI 10.1109/ISBI.2014.6867822; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Groppe DM, 2011, PSYCHOPHYSIOLOGY, V48, P1711, DOI 10.1111/j.1469-8986.2011.01273.x; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Krizhevsky A, 2012, NEURAL INFORM PROCES, P1097, DOI DOI 10.1145/3065386; Kuijf HJ, 2012, NEUROIMAGE, V59, P2266, DOI 10.1016/j.neuroimage.2011.09.061; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu SF, 2017, PROC SPIE, V10134, DOI 10.1117/12.2277121; Liu SF, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3552; Loshchilov Ilya, 2017, ARXIV171105101; Loy G, 2002, LECT NOTES COMPUT SC, V2350, P358; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Pacurar EE, 2016, NEUROIMAGE, V124, P1220, DOI 10.1016/j.neuroimage.2015.04.066; Poels MMF, 2012, NEUROLOGY, V78, P326, DOI 10.1212/WNL.0b013e3182452928; Poels MMF, 2010, STROKE, V41, pS103, DOI 10.1161/STROKEAHA.110.595181; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trifan G, 2017, MAGN RESON IMAGING, V37, P243, DOI 10.1016/j.mri.2016.12.009; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; van den Heuvel TLA, 2016, NEUROIMAGE-CLIN, V12, P241, DOI 10.1016/j.nicl.2016.07.002; Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617; Yates PA, 2014, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00205; ZHAO ZJ, 2019, IEEE T NEUR NET LEAR, DOI DOI 10.1080/24699322.2018.1560097	42	11	11	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	SEP	2019	198						271	282		10.1016/j.neuroimage.2019.05.046			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	IE6OI	WOS:000472495100023	31121296				2021-06-18	
J	Malec, JF; Ketchum, JM; Hammond, FM; Corrigan, JD; Dams-O'Connor, K; Hart, T; Novack, T; Dahdah, M; Whiteneck, GG; Bogner, J				Malec, James F.; Ketchum, Jessica M.; Hammond, Flora M.; Corrigan, John D.; Dams-O'Connor, Kristen; Hart, Tessa; Novack, Thomas; Dahdah, Marie; Whiteneck, Gale G.; Bogner, Jennifer			Longitudinal Effects of Medical Comorbidities on Functional Outcome and Life Satisfaction After Traumatic Brain Injury: An Individual Growth Curve Analysis of NIDILRR Traumatic Brain Injury Model System Data	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						comorbidities; function; life satisfaction; medical conditions; outcomes; prevalence; rehabilitation; traumatic brain injury	DISABILITY; PREDICTORS	Objective: To explore associations of specific physical and neuropsychiatric medical conditions to motor and cognitive functioning and life satisfaction over the first 10 years following traumatic brain injury (TBI). Setting: Telephone follow-up through 6 TBI Model System centers. Participants: In total, 404 individuals or proxies with TBI enrolled in the TBI Model System longitudinal study participating in 10-year follow-up. Design: Individual growth curve analysis. Main Measures: FIM Motor and Cognitive subscales, Satisfaction With Life Scales, and Medical and Mental Health Comorbidities Interview. Results: Hypertension, diabetes, cancers, rheumatoid arthritis, and anxiety negatively affected the trajectory of motor functioning over time. Diabetes, cancers, chronic bronchitis, anxiety, and depression negatively impacted cognitive functioning. Numerous neuropsychiatric conditions (sleep disorder, alcoholism, drug addiction, anxiety, panic attacks, posttraumatic stress disorder, depression, and bipolar disorder), as well as hypertension, liver disease, and cancers, diminished life satisfaction. Other medical conditions had a negative effect on functioning and satisfaction at specific follow-up periods. Conclusion: Natural recovery after TBI may include delayed onset of functional decline or early recovery, followed by progressive deterioration, and is negatively affected by medical comorbidities. Results contribute to the growing evidence that TBI is most appropriately treated as a chronic medical condition complicated by a variety of comorbid conditions.	[Malec, James F.; Hammond, Flora M.] Indiana Univ Sch Med, 4141 Shore Dr, Indianapolis, IN 46254 USA; [Ketchum, Jessica M.; Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Columbus, OH 43210 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Novack, Thomas] Univ Alabama Birmingham, Birmingham, AL USA; [Dahdah, Marie] Baylor Scott & White Med Ctr Plano, Plano, TX USA	Hammond, FM (corresponding author), Indiana Univ Sch Med, 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.hammond@rhin.com	Ketchum, Jessica/AAE-8200-2020		Statistical Center [90DP0013, 90DP0084]; Moss TBI Model System [90DP0037]; North Texas TBI Model System [90DP0045]; National Institutes of Health National Center for Medical Rehabilitation Research(NICHD) [K01HD074651]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	Statistical Center (Grant #90DP0013 and #90DP0084), Moss TBI Model System (Grant #90DP0037), North Texas TBI Model System (Grant #90DP0045), and from the National Institutes of Health National Center for Medical Rehabilitation Research(NICHD; K01HD074651). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this publication do not necessarily represent the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government.	Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Centers for Disease Control and Prevention, 2017, NAT HLTH NUTR EX SUR; Corrigan J, 1999, TBI 21 CENT LEARN MO; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Hammond FM, 2019, J HEAD TRAUMA REHAB, V34, pE1, DOI 10.1097/HTR.0000000000000465; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Institute of Medicine, 2009, GULF WAR HLTH, V7; Kessler RC, 2004, INT J METH PSYCH RES, V13, P60, DOI 10.1002/mpr.166; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Malec JF, 2013, J HEAD TRAUMA REHAB, V28, P476, DOI 10.1097/HTR.0000000000000003; Malec JF, 2013, BRAIN INJURY PROFESS, P10; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; *SAS I INC, 2002, SAS; World Health Organization, 2002, INN CAR CHRON COND B	18	11	11	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2019	34	5			SI		E24	E35		10.1097/HTR.0000000000000459			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IZ7NI	WOS:000487281100004	30829813	Green Accepted, Green Published			2021-06-18	
J	Saboori, P; Walker, G				Saboori, Parisa; Walker, Graham			Brain Injury and Impact Characteristics	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Jerk; Impact energy; Trapezoidal profile; TBI	HEAD; DEFORMATION	Almost all studies of traumatic brain injuries have only focused on the maximum acceleration associated with the impact. However, it has been noted that other impact characteristics should also be considered. This study has examined the effect on brain deformation [maximum principal strain (MPS)] associated with changing three characteristics of an isosceles trapezoid acceleration profile: initial slope (jerk), maximum acceleration, and impact energy (maximum velocity squared). This involved using a preexisting finite element model of the brain and applying the trapezoidal acceleration impact to the center of the forehead. The results showed the largest values of MPS were found along a line between the coup and contrecoup positions, and that a strong direct relationship existed between maximum acceleration and brain deformation as measured using MPS. In addition, a strong direct relationship was found to exist between impact energy and brain deformation as measured using MPS. However, it was found that there was almost no observable change in MPS with respect to different jerk values, and in fact there was a slight decrease in MPS as jerk values increased. This comported with a shock spectrum analysis of a simple one dimensional multiple degree of freedom system exposed to similar trapezoidal impulses.	[Saboori, Parisa; Walker, Graham] Manhattan Coll, Dept Mech Engn, Bronx, NY 10471 USA	Saboori, P (corresponding author), Manhattan Coll, Dept Mech Engn, Bronx, NY 10471 USA.	parisa.saboori@manhattan.edu		Saboori, Parisa/0000-0003-2355-9387			Alvarez V., 2017, THESIS; An YH, 2014, SMART MATER STRUCT, V23, DOI 10.1088/0964-1726/23/2/025020; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bayly PV, 2004, J BIOMECH ENG-T ASME, V126, P523, DOI 10.1115/1.1785811; Chen YL, 2011, THESIS; Clark J. M., 2015, IRC1526 IRCOBI; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Farid M. H., 2017, IMECHE2017, P70356; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fernandes FAO, 2018, ENG COMPUTATION, V35, P477, DOI 10.1108/EC-09-2016-0321; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W. N., 1997, CRASHWORTHINESS OCCU; Hoshizaki B., 2013, J NEUROL NEUROPHYSIO, V5, P1, DOI [DOI 10.4172/2155-9562.1000181, 10.4172/2155-9562.1000181]; King AI, 2003, INT RES COUNC BIOM I; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; Mackerle J, 1999, SHOCK VIB, V6, P321, DOI 10.1155/1999/802580; Mao HJ, 2018, BASIC FINITE ELEMENT METHOD AS APPLIED TO INJURY BIOMECHANICS, P469, DOI 10.1016/B978-0-12-809831-8.00012-X; McLean A. J., 1997, HEAD INJURY, P25; Meaney D, 2015, ACCIDENTAL INJURY BI, P247; Melvin J. W., 2015, ACCIDENTAL INJURY BI, P221; MILLER RT, 1998, 42 STAPP CAR CRASH C; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Saboori P, 2014, ADV BIOMECH APPL, V1, P253, DOI DOI 10.12989/aba.2014.1.4.253; Saboori P, 2011, THESIS; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tse Kwong Ming, 2014, AM J ENG TECHNOLOGY, V1, P28; Wang F, 2018, BIOMECH MODEL MECHAN, V17, P1165, DOI 10.1007/s10237-018-1021-z; Yang B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/408278	31	11	11	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2019	47	9			SI		1982	1992		10.1007/s10439-019-02199-z			11	Engineering, Biomedical	Engineering	JD1MH	WOS:000489738300011	30673954				2021-06-18	
J	Elder, GA; Ehrlich, ME; Gandy, S				Elder, Gregory A.; Ehrlich, Michelle E.; Gandy, Sam			Relationship of traumatic brain injury to chronic mental health problems and dementia in military veterans	NEUROSCIENCE LETTERS			English	Article						Alzheimer's disease; Blast; Chronic traumatic encephalopathy; Dementia; Inflammation; Microglia; Post-traumatic stress disorder; Traumatic brain injury; TYROBP/DAP12; TREM2	DISORDER-RELATED TRAITS; ALZHEIMERS-DISEASE; BLAST EXPOSURE; TREM2 DEFICIENCY; AMYLOID-BETA; MOUSE MODEL; MICROGLIAL RESPONSE; APOLIPOPROTEIN-E; SERVICE MEMBERS; HEAD-INJURY	Traumatic brain injury (TBI) is an unfortunately common event in military life. The conflicts in Iraq and Afghanistan have increased public awareness of TBI in the military. Certain injury mechanisms are relatively unique to the military, the most prominent being blast exposure. Blast-related mild TBI (mTBI) has been of particular concern in the most recent veterans although controversy remains concerning separation of the postconcussion syndrome associated with mTBI from post-traumatic stress disorder. TBI is also a risk factor for the development of neurodegenerative diseases including chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD). AD, TBI, and CTE are all associated with chronic inflammation. Genome wide association studies (GWAS) have identified multiple genetic loci associated with AD that implicate inflammation and - in particular microglia - as key modulators of the AD- and TBI-related degenerative processes. At the molecular level, recent studies have identified TREM2 and TYROBP/DAP12 as components of a key molecular hub linking inflammation and microglia to the pathophysiology of AD and possibly TBI. Evidence concerning the relationship of TBI to chronic mental health problems and dementia is reviewed in the context of its relevance to military veterans.	[Elder, Gregory A.] Vet Affairs Med Ctr, Neurol Serv, James J Peters Dept, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Elder, Gregory A.; Ehrlich, Michelle E.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA; [Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA; [Elder, Gregory A.; Ehrlich, Michelle E.; Gandy, Sam] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Elder, Gregory A.; Ehrlich, Michelle E.; Gandy, Sam] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Gandy, Sam] Vet Affairs Med Ctr, Res & Dev Serv, James J Peters Dept, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Pediat, One Gustave Levy Pl, New York, NY 10029 USA; [Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA	Elder, GA (corresponding author), James J Peters VA Med Ctr, Neurol Serv 3E16, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.	gregory.elder@va.gov		Elder, Gregory/0000-0001-7035-8380	United States Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1IO1RX000179, 1I01RX000996, 1I01RX000684, 1I01RX001705, 1I21RX002876, 1I01RX002660, 1I01BX004067, 1I21RX003019]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG005138]; Alzheimer's Drug Discovery Foundation	The authors have received research support from the United States Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1IO1RX000179, 1I01RX000996, 1I01RX000684, 1I01RX001705, 1I21RX002876, 1I01RX002660, 1I01BX004067, 1I21RX003019 and by NIH grant P50 AG005138. SG has received support from the Alzheimer's Drug Discovery Foundation.	Audrain M, 2018, MOL PSYCHIAT; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bochicchio GV, 2008, AM SURGEON, V74, P267; Brenner LA, 2013, J HEAD TRAUMA REHAB, V28, P21, DOI 10.1097/HTR.0b013e31827df0b5; Brickell TA, 2014, MIL MED, V179, P839, DOI 10.7205/MILMED-D-14-00016; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Castranio EL, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0569-2; Castranio EL, 2017, NEUROBIOL DIS, V105, P1, DOI 10.1016/j.nbd.2017.05.006; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Cheng QW, 2018, J BIOL CHEM, V293, P12620, DOI 10.1074/jbc.RA118.001848; Colonna M, 2016, NAT REV NEUROSCI, V17, P201, DOI 10.1038/nrn.2016.7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Defense and Veterans Brain Injury Center, 2018, DOD WORLDW NUMB TBI; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DePalma R.G., 2015, BRAIN NEUROTRAUMA MO, P5; Dreer LE, 2018, CURR OPIN PSYCHOL, V22, P73, DOI 10.1016/j.copsyc.2017.08.030; Effgen GB, 2016, J NEUROTRAUM, V33, P1901, DOI 10.1089/neu.2015.4327; Elali A, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00072; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Engel C., 2019, P FIND EXP REC 7 DEP; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Falcon B, 2019, NATURE, V568, P420, DOI 10.1038/s41586-019-1026-5; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Gardner R. C., 2015, MOL CELL NEUROSCI; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gill J, 2018, BRAIN INJURY, V32, P1277, DOI 10.1080/02699052.2018.1471738; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich JA, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0395-3; Gubata ME, 2014, J HEAD TRAUMA REHAB, V29, P65, DOI 10.1097/HTR.0b013e318295f590; Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069; HaureMirande J. V., 2018, MOL PSYCHIAT; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jay TR, 2017, J NEUROSCI, V37, P637, DOI [10.1523/JNEUROSCI.2110-16.2016, 10.1523/JNEUROSCI.2110-16.2017]; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Jiang T, 2015, NEUROBIOL AGING, V36, P3176, DOI 10.1016/j.neurobiolaging.2015.08.019; Jiang T, 2014, NEUROPSYCHOPHARMACOL, V39, P2949, DOI 10.1038/npp.2014.164; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Kallakuri S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169239; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kokiko-Cochran ON, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00672; Korvatska O, 2015, JAMA NEUROL, V72, P920, DOI 10.1001/jamaneurol.2015.0979; Kraus A, 2019, ACTA NEUROPATHOL, V137, P585, DOI 10.1007/s00401-018-1947-3; Kucherov Y, 2012, J APPL PHYS, V112, DOI 10.1063/1.4765727; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lawrence D. W., 2015, BRAIN INJURY, P1; Lenz KM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00698; Leyns CEG, 2017, P NATL ACAD SCI USA, V114, P11524, DOI 10.1073/pnas.1710311114; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu YJ, 2015, NEUROL SCI, V36, P1881, DOI 10.1007/s10072-015-2274-2; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McKee AC, 2018, HAND CLINIC, V158, P297, DOI 10.1016/B978-0-444-63954-7.00028-8; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mohamed AZ, 2019, EUR J NUCL MED MOL I, V46, P1139, DOI 10.1007/s00259-018-4241-7; Muller N, 2014, NEUROIMMUNOMODULAT, V21, P123, DOI 10.1159/000356540; National Research Council, 2008, GULF WAR HLTH, V7; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newcombe EA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1313-3; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perez-Garcia G, 2019, NEUROPHARMACOLOGY, V145, P220, DOI 10.1016/j.neuropharm.2018.09.023; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Puntambekar SS, 2018, BRAIN BEHAV IMMUN, V71, P9, DOI 10.1016/j.bbi.2018.03.033; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reisman Miriam, 2016, P T, V41, P623; Saber M, 2017, J NEUROTRAUM, V34, P423, DOI 10.1089/neu.2016.4401; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Serrano-Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189; Sharrock AE, 2018, INJURY; Sibener L, 2014, ALZHEIMERS DEMENT, V10, pS105, DOI 10.1016/j.jalz.2014.04.011; Sosa MAG, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-018-0647-5; Sosa MAG, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0483-z; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Toklu HZ, 2018, BEHAV BRAIN RES, V340, P14, DOI 10.1016/j.bbr.2017.04.025; Ulrich JD, 2017, NEURON, V94, P237, DOI 10.1016/j.neuron.2017.02.042; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Vincent AS, 2014, ALZHEIMERS DEMENT, V10, pS174, DOI 10.1016/j.jalz.2014.04.006; Wang YM, 2016, J EXP MED, V213, P667, DOI 10.1084/jem.20151948; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Wieck A, 2014, NEUROIMMUNOMODULAT, V21, P145, DOI 10.1159/000356552; Williams WH, 2018, LANCET PSYCHIAT, V5, P836, DOI 10.1016/S2215-0366(18)30062-2; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V277, P268, DOI 10.1016/j.expneurol.2016.01.010; Yeh FL, 2016, NEURON, V91, P328, DOI 10.1016/j.neuron.2016.06.015; Younger D., 2018, MOL NEUROBIOL; Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030; Zhao YJ, 2018, NEURON, V97, P1023, DOI 10.1016/j.neuron.2018.01.031; Zheng HH, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00395	124	11	11	1	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 10	2019	707								134294	10.1016/j.neulet.2019.134294			8	Neurosciences	Neurosciences & Neurology	IY0PG	WOS:000486094600033	31141716				2021-06-18	
J	Kulkarni, P; Morrison, TR; Cai, XZ; Iriah, S; Simon, N; Sabrick, J; Neuroth, L; Ferris, CF				Kulkarni, Praveen; Morrison, Thomas R.; Cai, Xuezhu; Iriah, Sade; Simon, Neal; Sabrick, Julia; Neuroth, Lucas; Ferris, Craig F.			Neuroradiological Changes Following Single or Repetitive Mild TBI	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						Parkinson's disease; dopamine; dementia; hyperconnectivity; microglia activation; cerebellum; suprachiasmatic nucleus (SCN); olfactory system diseases	TRAUMATIC BRAIN-INJURY; STATE FUNCTIONAL CONNECTIVITY; COLLEGIATE FOOTBALL PLAYERS; CEREBRAL GLUCOSE-METABOLISM; DORSAL COLUMN NUCLEI; RESTING-STATE; HEAD-INJURY; CEREBELLAR MODULATION; OLFACTORY DYSFUNCTION; RECOVERY-TIME	Objectives: To test the hypothesis that there are differences in neuroradiological measures between single and repeated mild traumatic brain injury using multimodal MRI. Methods: A closed-head momentum exchange model was used to produce one or three mild head injuries in young adult male rats compared to non-injured, age and weight-matched controls. Six-seven weeks post-injury, rats were studied for deficits in cognitive and motor function. Seven-eight weeks post-injury changes in brain anatomy and function were evaluated through analysis of high resolution T2 weighted images, resting-state BOLD functional connectivity, and diffusion weighted imaging with quantitative anisotropy. Results: Head injuries occurred without skull fracture or signs of intracranial bleeding or contusion. There were no significant differences in cognitive or motors behaviors between experimental groups. With a single mild hit, the affected areas were limited to the caudate/putamen and central amygdala. Rats hit three times showed altered diffusivity in white matter tracts, basal ganglia, central amygdala, brainstem, and cerebellum. Comparing three hits to one hit showed a similar pattern of change underscoring a dose effect of repeated head injury on the brainstem and cerebellum. Disruption of functional connectivity was pronounced with three mild hits. The midbrain dopamine system, hippocampus, and brainstem/cerebellum showed hypoconnectivity. Interestingly, rats exposed to one hit showed enhanced functional connectivity (or hyperconnectivity) across brain sites, particularly between the olfactory system and the cerebellum. Interpretation: Neuroradiological evidence of altered brain structure and function, particularly in striatel and midbrain dopaminergic areas, persists long after mild repetitive head injury. These changes may serve as biomarkers of neurodegeneration and risk for dementia later in life.	[Kulkarni, Praveen; Morrison, Thomas R.; Cai, Xuezhu; Iriah, Sade; Sabrick, Julia; Neuroth, Lucas; Ferris, Craig F.] Northeastern Univ, Ctr Translat NeuroImaging, Boston, MA 02115 USA; [Simon, Neal] Azevan Pharmaceut, Bethlehem, PA USA; [Simon, Neal] Lehigh Univ, Dept Biol Sci, Coll Arts & Sci, Bethlehem, PA 18015 USA	Ferris, CF (corresponding author), Northeastern Univ, Ctr Translat NeuroImaging, Boston, MA 02115 USA.	c.ferris@northeastern.edu		Kulkarni, Praveen/0000-0002-8876-4544	Program Consortium BUILD Award [UL1MD009605/RL5MD009590/TL4MD009635]	This work was funded by the Program Consortium BUILD Award (UL1MD009605/RL5MD009590/TL4MD009635) to CF. This work appeared as a preprint in BioRxiv.	Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; ALLEN GI, 1974, PHYSIOL REV, V54, P957; Allen G, 2007, ARCH NEUROL-CHICAGO, V64, P1482, DOI 10.1001/archneur.64.10.1482; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Astafiev SV, 2016, NEUROIMAGE-CLIN, V11, P10, DOI 10.1016/j.nicl.2016.01.004; Aumann TD, 1996, J COMP NEUROL, V376, P420; Aumann TD, 1996, J COMP NEUROL, V368, P608, DOI 10.1002/(SICI)1096-9861(19960513)368:4<608::AID-CNE11>3.0.CO;2-D; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bai F, 2009, BIOL PSYCHIAT, V65, P951, DOI 10.1016/j.biopsych.2008.10.017; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bostan AC, 2010, P NATL ACAD SCI USA, V107, P8452, DOI 10.1073/pnas.1000496107; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chen CH, 2014, NAT NEUROSCI, V17, P1767, DOI 10.1038/nn.3868; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; DOTY RL, 1992, J NEUROL NEUROSUR PS, V55, P138, DOI 10.1136/jnnp.55.2.138; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; FARZANEH F, 1990, MAGNET RESON MED, V14, P123, DOI 10.1002/mrm.1910140112; Fazio L, 2011, NEUROIMAGE, V54, P2915, DOI 10.1016/j.neuroimage.2010.11.034; Fidan E, 2018, ASN NEURO, V10, DOI 10.1177/1759091418770543; Fidan E, 2016, J NEUROTRAUM, V33, P641, DOI 10.1089/neu.2015.3958; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Gorges M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00200; Guilfoyle DN, 2013, J NEUROSCI METH, V214, P144, DOI 10.1016/j.jneumeth.2013.01.019; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hacker CD, 2012, BRAIN, V135, P3699, DOI 10.1093/brain/aws281; HAINES DE, 1984, BRAIN BEHAV EVOLUT, V24, P198, DOI 10.1159/000121317; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Harrison FE, 2009, BEHAV BRAIN RES, V198, P247, DOI 10.1016/j.bbr.2008.10.015; HEATH RG, 1978, BIOL PSYCHIAT, V13, P501; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoogenraad FGC, 2000, MAGN RESON IMAGING, V18, P405, DOI 10.1016/S0730-725X(00)00127-2; Hoshi E, 2005, NAT NEUROSCI, V8, P1491, DOI 10.1038/nn1544; Hu X, 2015, MOVEMENT DISORD, V30, P238, DOI 10.1002/mds.26087; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Iannilli E, 2011, RHINOLOGY, V49, P458, DOI 10.4193/Rhino11.110; Impellizzeri D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00458; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jenkins PO, 2018, BRAIN, V141, P797, DOI 10.1093/brain/awx357; Jesmanowicz A, 1998, MAGNET RESON MED, V40, P754, DOI 10.1002/mrm.1910400517; Jonckers E, 2014, MAGN RESON MED, V72, P1103, DOI 10.1002/mrm.24990; KALIL K, 1981, J COMP NEUROL, V195, P25, DOI 10.1002/cne.901950105; Kang D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/394213; Katzenschlager R, 2004, CURR OPIN NEUROL, V17, P417, DOI 10.1097/01.wco.0000137531.76491.c2; Koch W, 2012, NEUROBIOL AGING, V33, P466, DOI 10.1016/j.neurobiolaging.2010.04.013; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kulkarni P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125748; Lanteaume L, 2007, CEREB CORTEX, V17, P1307, DOI 10.1093/cercor/bhl041; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Liu M, 2017, J NEUROTRAUM, V34, P414, DOI 10.1089/neu.2015.4361; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainland JD, 2005, J NEUROSCI, V25, P6362, DOI 10.1523/JNEUROSCI.0920-05.2005; Manktelow AE, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00058; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Meconi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197187; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Menon RS, 1997, NMR BIOMED, V10, P179, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<179::AID-NBM463>3.0.CO;2-X; Mesholam RI, 1998, ARCH NEUROL-CHICAGO, V55, P84, DOI 10.1001/archneur.55.1.84; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Onuki Y, 2015, CEREB CORTEX, V25, P313, DOI 10.1093/cercor/bht221; Ordek G, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00197; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Pellegrino R, 2017, NEUROSCIENCE, V363, P43, DOI 10.1016/j.neuroscience.2017.07.030; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Poser BA, 2009, NEUROIMAGE, V45, P1162, DOI 10.1016/j.neuroimage.2009.01.007; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Qin Y, 2018, BEHAV BRAIN RES, V340, P41, DOI 10.1016/j.bbr.2016.08.008; Rajesh A, 2017, J NEUROTRAUM, V34, P3280, DOI 10.1089/neu.2017.5047; Richardson JS, 2018, J TELEMED TELECARE, V24, P282, DOI 10.1177/1357633X17696586; Rogers TD, 2011, SYNAPSE, V65, P1204, DOI 10.1002/syn.20960; Rowe RK, 2016, DEV NEUROSCI-BASEL, V38, P195, DOI 10.1159/000446773; Roy A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170541; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sacchetti B, 2002, P NATL ACAD SCI USA, V99, P8406, DOI 10.1073/pnas.112660399; Sackheim AM, 2017, J SURG RES, V213, P100, DOI 10.1016/j.jss.2017.02.016; Schofield PW, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00005; Schroeter ML, 2015, J NEUROTRAUM, V32, P1380, DOI 10.1089/neu.2013.3163; Schutter DJL, 2006, NEUROIMAGE, V33, P1227, DOI 10.1016/j.neuroimage.2006.06.055; Selwyn RG, 2016, J NEUROTRAUM, V33, P1479, DOI 10.1089/neu.2015.4129; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith R, 2015, NEUROSCI BIOBEHAV R, V57, P1, DOI 10.1016/j.neubiorev.2015.08.003; SNIDER RS, 1976, J NEUROSCI RES, V2, P133, DOI 10.1002/jnr.490020204; Swisher JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034626; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor KM, 2016, PARKINSONISM RELAT D, V23, P57, DOI 10.1016/j.parkreldis.2015.12.005; Teipel SJ, 2013, MED CLIN N AM, V97, P399, DOI 10.1016/j.mcna.2012.12.013; Teune TM, 2000, PROG BRAIN RES, V124, P141; Vergara VM, 2017, J NEUROTRAUM, V34, P1045, DOI 10.1089/neu.2016.4526; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Witter L, 2015, CURR OPIN NEUROBIOL, V33, P150, DOI 10.1016/j.conb.2015.03.017; Wortman RC, 2018, ANN CLIN TRANSL NEUR, V5, P1588, DOI 10.1002/acn3.667; Wright DK, 2017, ANN CLIN TRANSL NEUR, V4, P640, DOI 10.1002/acn3.441; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Wu T, 2009, NEUROSCI LETT, V460, P6, DOI 10.1016/j.neulet.2009.05.046; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang Y, 2015, MOVEMENT DISORD, V30, P1229, DOI 10.1002/mds.26251	132	11	12	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	AUG 2	2019	13								34	10.3389/fnsys.2019.00034			16	Neurosciences	Neurosciences & Neurology	IN8CR	WOS:000478908700001	31427931	DOAJ Gold, Green Published			2021-06-18	
J	Bales, JW; Bonow, RH; Buckley, RT; Barber, J; Temkin, N; Chesnut, RM				Bales, James William; Bonow, Robert H.; Buckley, Robert T.; Barber, Jason; Temkin, Nancy; Chesnut, Randall M.			Primary External Ventricular Drainage Catheter Versus Intraparenchymal ICP Monitoring: Outcome Analysis	NEUROCRITICAL CARE			English	Article						External ventricular drain; Mortality; Outcomes; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROPENSITY SCORE; MANAGEMENT; THERAPY; TRIAL	BackgroundIntracranial pressure (ICP) monitoring is central to the care of severe traumatic brain injury (TBI). External ventricular drains (EVD) allow ICP control via cerebrospinal fluid drainage, whereas intraparenchymal monitors (IPM) for ICP do not, but it is unclear whether EVD placement improves outcomes. To evaluate whether there exists a difference in patient outcomes with the use of EVD versus IPM in severe TBI patients, we conducted a retrospective cohort study using data from the Citicoline Brain Injury Treatment trial.MethodsAdults with Glasgow Coma Score <9 who had either an EVD or IPM placed within 6h of study center arrival were included. We compared patients with EVD placement to those without on Glasgow Outcome Scale-Extended (GOS-E) and neuropsychological performance at 180days, mortality, and intensive care unit length of stay. We used regression models with propensity score weighting for probability of EVD placement to test for association between EVD use and outcomes. Of 224 patients included, 45% received an EVD.ResultsEVD patients had lower GOS-E at 180days [3.82.2 vs 4.9 +/- 2.2, p=0.002; weighted difference -0.97, 95% CI (-1.58, -0.37)], higher in-hospital mortality [23% vs 10%, p=0.014; weighted OR 2.46, 95% CI (1.20, 5.05)], and did significantly worse on all 8 neuropsychological measures. Additional sensitivity analysis was performed to minimize confounding effects supported our initial results.Conclusions Our retrospective data analysis suggests that early placement of EVDs in severe TBI is associated with worse functional and neuropsychological outcomes and higher mortality than IPMs and future prospective trials are needed to determine whether these results represent an important consideration for clinicians.	[Bales, James William; Bonow, Robert H.; Buckley, Robert T.; Barber, Jason; Temkin, Nancy; Chesnut, Randall M.] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, 325 Ninth Ave, Seattle, WA 98104 USA	Bales, JW (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, 325 Ninth Ave, Seattle, WA 98104 USA.	Balesj@uw.edu		Chesnut, Randall/0000-0001-6377-3666			Agoritsas T, 2017, JAMA-J AM MED ASSOC, V317, P748, DOI 10.1001/jama.2016.20029; Aiolfi A, 2018, J NEUROSURG, V128, P828, DOI 10.3171/2016.11.JNS162198; Alice P, 2017, INJURY, V48, P1944, DOI 10.1016/j.injury.2017.04.033; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Brookhart M.A., 2007, INT J BIOSTAT, V3, P14; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cnossen MC, 2018, CLIN EPIDEMIOL, V10, P841, DOI 10.2147/CLEP.S154500; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Dams-O'Connor K, 2017, J HEAD TRAUMA REHAB, V32, P147, DOI 10.1097/HTR.0000000000000263; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Hernan MA, 2006, J EPIDEMIOL COMMUN H, V60, P578, DOI 10.1136/jech.2004.029496; HOLM S, 1979, SCAND J STAT, V6, P65; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; Khan SH, 1998, ACT NEUR S, V71, P50; Liu H, 2015, WORLD NEUROSURG, V83, P794, DOI 10.1016/j.wneu.2014.12.040; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Nwachuku EL, 2014, NEUROCRIT CARE, V20, P49, DOI 10.1007/s12028-013-9885-3; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Petkus V, 2017, J CRIT CARE, V41, P49, DOI 10.1016/j.jcrc.2017.04.029; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tsioutis C, 2017, J CLIN NEUROSCI, V42, P54, DOI 10.1016/j.jocn.2017.03.023; Volovici V, 2019, J NEUROTRAUM, V36, P988, DOI 10.1089/neu.2018.6086; Xie Q, 2017, WORLD NEUROSURG, V100, P118, DOI 10.1016/j.wneu.2016.12.097; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	30	11	11	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2019	31	1					11	21		10.1007/s12028-019-00712-9			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	IH0YF	WOS:000474217800003	31037639				2021-06-18	
J	Caldwell, JA; Knapik, JJ; Shing, TL; Kardouni, JR; Lieberman, HR				Caldwell, John A.; Knapik, Joseph J.; Shing, Tracie L.; Kardouni, Joseph R.; Lieberman, Harris R.			The association of insomnia and sleep apnea with deployment and combat exposure in the entire population of US army soldiers from 1997 to 2011: a retrospective cohort investigation	SLEEP			English	Article						posttraumatic stress disorder; traumatic brain injury; depression; anxiety; stress; mediation analysis; comorbidities	POSTTRAUMATIC-STRESS-DISORDER; GULF-WAR VETERANS; MEDIATION ANALYSIS; PSYCHIATRIC-DISORDERS; VIETNAM VETERANS; HEALTH-STATUS; PREVALENCE; IRAQ; COMORBIDITY; AFGHANISTAN	Since 2001, the United States has been engaged in the longest and most expensive overseas conflict in its history. Sleep disorders, especially insomnia and obstructive sleep apnea (OSA), are common in service members and appear related to deployment and combat exposure, but this has not been systematically examined. Therefore, the incidence of clinically diagnosed insomnia and OSA from 1997 to 2011 in the entire population of US Army soldiers was determined and associations of these disorders with deployment and combat exposure examined. This observational retrospective cohort study linked medical, demographic, deployment, and combat casualty data from all active duty US Army soldiers serving from 1997 to 2011 (n = 1 357 150). The mediating effects of multiple known comorbid conditions were considered. From 2003 to 2011, there were extraordinary increases in incidence of insomnia (652%) and OSA (600%). Factors increasing insomnia risk were deployment (risk ratio [RR] [deployed/not deployed] = 2.06; 95% confidence interval [CI], 2.04-2.08) and combat exposure (RR [exposed/not exposed] = 1.20; 95% CI, 1.19-1.22). Risk of OSA was increased by deployment (RR [deployed/not deployed] = 2.14; 95% CI, 2.11-2.17), but not combat exposure (RR [exposed/not exposed] = 1.00; 95% CI, 0.98-1.02). These relationships remained after accounting for other factors in multivariable analyses. A number of comorbid medical conditions such as posttraumatic stress disorder and traumatic brain injury mediated a portion of the association between the sleep disorders and deployment. It is essential to determine underlying mechanisms responsible for these very large increases in insomnia and OSA and introduce effective preventive measures.	[Caldwell, John A.; Shing, Tracie L.] Oak Ridge Inst Sci & Educ, Belcamp, MD USA; [Caldwell, John A.; Knapik, Joseph J.; Lieberman, Harris R.] US Army Res Inst Environm Med, Mil Nutr Div, 10 Gen Greene Ave,Bldg 42, Natick, MA 01760 USA; [Knapik, Joseph J.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Shing, Tracie L.; Kardouni, Joseph R.] US Army Res Inst Environm Med, Mil Performance Div, Natick, MA USA	Lieberman, HR (corresponding author), US Army Res Inst Environm Med, Mil Nutr Div, 10 Gen Greene Ave,Bldg 42, Natick, MA 01760 USA.	harris.r.lieberman.civ@mail.mil			US Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC)	The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as official Department of the Army position, policy, or decision, unless so designated by other official documentation. Approved for public release; distribution is unlimited. This work was supported by the US Army Medical Research and Materiel Command (USAMRMC).	Armed Forces Health Surveillance Branch, 2010, MSMR, V17, P12; Armed Forces Health Surveillance Branch, 2010, MSMR, V17, P8; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Caldwell JA, 2017, J SLEEP RES, V26, P665, DOI 10.1111/jsr.12543; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Clark Leslie L, 2016, MSMR, V23, P9; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Dean A.G., 2014, OPEN SOURCE EPIDEMIO; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Epidemiology Program Post-Deployment Health Group Office of Patient Care Services Veterans Health Administration Department of Veterans Affairs, 2017, ANAL VA HLTH CAR UT; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Foster SN, 2016, CURR PULMONOL REP, V5, P101, DOI 10.1007/s13665-016-0147-7; Harrison E, 2017, MIL MED, V182, P189, DOI 10.7205/MILMED-D-16-00078; Helfer Thomas M, 2011, MSMR, V18, P7; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hunt EJ, 2016, OCCUP MED; Institue of Medicine of the National Academies, 2006, SLEEP DISORDERS SLEE; Institute of Medicine, 2010, RET HOM IR AFGH PREL; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kapur VK, 2017, J CLIN SLEEP MED, V13, P479, DOI 10.5664/jcsm.6506; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Knapik JJ, 2012, PUBLIC HEALTH, V126, P498, DOI 10.1016/j.puhe.2012.01.031; Krakow BJ, 2015, SLEEP MED REV, V24, P37, DOI 10.1016/j.smrv.2014.11.001; Lee-Chiong T., 2008, SLEEP MED ESSENTIALS; Lewis Paul E, 2014, MSMR, V21, P6; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Parish JM, 2009, CHEST, V135, P563, DOI 10.1378/chest.08-0934; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Plumb TR, 2014, PSYCHOL SERV, V11, P209, DOI 10.1037/a0034958; Prigerson HG, 2002, AM J PUBLIC HEALTH, V92, P59, DOI 10.2105/AJPH.92.1.59; Prigerson HG, 2001, J NERV MENT DIS, V189, P99, DOI 10.1097/00005053-200102000-00005; Sateia MJ, 2009, CHEST, V135, P1370, DOI 10.1378/chest.08-1834; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238; Scofield DE, 2017, J NEUROTRAUM, V34, P3249, DOI 10.1089/neu.2017.5101; Seelig AD, 2016, SLEEP, V39, P1111, DOI 10.5665/sleep.5766; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Shattuck NL, 2013, SLEEP, V36, P159, DOI 10.5665/sleep.2356; Spiegelhalder K, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0364-5; Swinkels CM, 2013, SLEEP, V36, P1019, DOI 10.5665/sleep.2800; Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213; Taylor MK, 2014, MIL MED, V179, P744, DOI 10.7205/MILMED-D-13-00551; Thorpy MJ, 2012, NEUROTHERAPEUTICS, V9, P687, DOI 10.1007/s13311-012-0145-6; Troxel W.M., 2015, SLEEP MILITARY PROMO; Valeri L, 2013, PSYCHOL METHODS, V18, P137, DOI 10.1037/a0031034; VanderWeele TJ, 2016, ANNU REV PUBL HEALTH, V37, P17, DOI 10.1146/annurev-publhealth-032315-021402; VanderWeele TJ, 2010, AM J EPIDEMIOL, V172, P1339, DOI 10.1093/aje/kwq332; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845	51	11	11	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	AUG	2019	42	8							zsz112	10.1093/sleep/zsz112			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JI3QV	WOS:000493383600014	31106808	Green Published, Other Gold			2021-06-18	
J	Chakroun-Walha, O; Samet, A; Jerbi, M; Nasri, A; Talbi, A; Kanoun, H; Souissi, B; Chtara, K; Bouaziz, M; Ksibi, H; Rekik, N				Chakroun-Walha, Olfa; Samet, Amal; Jerbi, Mouna; Nasri, Abdennour; Talbi, Aziza; Kanoun, Hassen; Souissi, Basma; Chtara, Kamilia; Bouaziz, Mounir; Ksibi, Hichem; Rekik, Noureddine			Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients	EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY			English	Article						Tranexamic acid; Traumatic brain injury; Management; Prognosis; Emergency department; Pulmonary embolism	VASCULAR OCCLUSIVE EVENTS; BRAIN-INJURY; HEMORRHAGE; CRASH-2; COAGULATION; TRANSFUSION; DEATH	Introduction Tranexamic acid (TXA) is one of the debated therapies in the management of traumatic brain injury (TBI). We conducted this study to evaluate the benefits of TXA in TBI on the mortality and its safety in these patients. Methods This was a prospective randomized open-label trial including all patients, aged at 18 years or older, hospitalized in the emergency room during a 13-month period, for TBI. After the realization of the body CT scan, the patients were included if they had intracranial bleeding, and were then randomized according to their medical file number to receive or not the TXA. The eligibility criteria were based on the uncertainty principle, patients with significant extracranial bleeding were excluded since there was evidence that TXA improve their outcome. Results We enrolled 180 patients aged at 42 +/- 20 years, with an 88% men-proportion. Subarachnoid haemorrhage was the most frequent lesion in the brain CT-scan (67.5%). After randomization, 96 patients were in the TXA group (53%). Demographic data, clinical, biological and radiological features were statistically comparable in the two groups of patients ('TXA' and 'noTXA'). The needs of transfusion or neurosurgery, the mortality rate, the in-hospital length of stay and the dependency at 28-post-traumatic day were similar in the two groups of patients. However, pulmonary embolism was statistically more frequent in 'TXA' group (11.5 versus 2.4%, p = 0.02). Conclusion TXA is an interesting treatment in haemorrhagic shock. Its efficiency in head trauma is still debated and controversial. Its impact on the mortality and the needs of transfusion or surgery were not demonstrated in this study. Nevertheless, its safety worth to be studied in larger samples as we found a higher rate of pulmonary embolism in the treated group.	[Chakroun-Walha, Olfa; Samet, Amal; Jerbi, Mouna; Nasri, Abdennour; Talbi, Aziza; Kanoun, Hassen; Ksibi, Hichem; Rekik, Noureddine] Univ Hosp Habib Bourguiba, Serv Urgences & SAMU04 SFAX, Emergency Dept, Route EL Ain Km 0,5, Sfax 3029, Tunisia; [Souissi, Basma] Univ Hosp Habib Bourguiba, Radiol Dept, Sfax, Tunisia; [Chtara, Kamilia; Bouaziz, Mounir] Univ Hosp Habib Bourguiba, Intens Care Unit, Sfax, Tunisia	Chakroun-Walha, O (corresponding author), Univ Hosp Habib Bourguiba, Serv Urgences & SAMU04 SFAX, Emergency Dept, Route EL Ain Km 0,5, Sfax 3029, Tunisia.	chakroun_olfa@medecinesfax.org		chakroun-walha, olfa/0000-0002-9224-7080			[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Boudreau RM, 2017, J SURG RES, V215, P47, DOI 10.1016/j.jss.2017.03.031; Chelly H, 2017, EUR J TRAUMA EMERG S; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Fakharian E, 2018, WORLD NEUROSURG, V109, pE748, DOI 10.1016/j.wneu.2017.10.075; French KF, 2012, NEUROCRIT CARE, V17, P107, DOI 10.1007/s12028-012-9681-5; Gayet-Ageron A, 2018, LANCET, V391, P125, DOI 10.1016/S0140-6736(17)32455-8; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Jackisch J., 2015, EUROPEAN FACTS GLOBA; JENNETT B, 1975, LANCET, V1, P480; Jokar A, 2017, CHIN J TRAUMATOL, V20, P49, DOI 10.1016/j.cjtee.2016.02.005; Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162; KER K, 2015, COCHRANE DB SYST REV, V9; Mahmood A, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2073-6; Mahmood A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4814; Majima Nozomi, 2013, Masui, V62, P410; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039; Napolitano LM, 2013, J TRAUMA ACUTE CARE, V74, P1575, DOI 10.1097/TA.0b013e318292cc54; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Roberts I, 2015, J THROMB HAEMOST, V13, pS195, DOI 10.1111/jth.12878; Roberts I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI [10.3310/HTA17100, 10.3310/hta17100]; Roberts I, 2017, TRIALS, V18, DOI 10.1186/s13063-016-1750-1; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Schochl H, 2014, SHOCK, V41, P44, DOI 10.1097/SHK.0000000000000093; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Valle EJ, 2014, J TRAUMA ACUTE CARE, V76, P1373, DOI 10.1097/TA.0000000000000242; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023	32	11	12	1	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-9933	1863-9941		EUR J TRAUMA EMERG S	Eur. J. Trauma Emerg. Surg.	AUG	2019	45	4					719	726		10.1007/s00068-018-0974-z			8	Emergency Medicine	Emergency Medicine	IQ1JQ	WOS:000480506500016	29922895				2021-06-18	
J	Mahan, MY; Thorpe, M; Ahmadi, A; Abdallah, T; Casey, H; Sturtevant, D; Judge-Yoakam, S; Hoover, C; Rafter, D; Miner, J; Richardson, C; Samadani, U				Mahan, Margaret Y.; Thorpe, Maxwell; Ahmadi, Aliya; Abdallah, Tessneem; Casey, Hannah; Sturtevant, Dylan; Judge-Yoakam, Senait; Hoover, Caleb; Rafter, Daniel; Miner, James; Richardson, Chad; Samadani, Uzma			Glial Fibrillary Acidic Protein (GFAP) Outperforms S100 Calcium-Binding Protein B (S100B) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) as Predictor for Positive Computed Tomography of the Head in Trauma Subjects	WORLD NEUROSURGERY			English	Article						Calcium-binding protein B (S100 beta); Computed tomography (CT); Glial fibrillary acidic protein (GFAP); S100 ubiquitin carboxy-terminal hydrolase isozyme L1 (UCHL1); Traumatic brain injury (TBI)	GLASGOW COMA SCALE; BRAIN-INJURY; SERUM S100B; OUTCOME PREDICTION; DIAGNOSTIC MARKER; BLOOD BIOMARKERS; MILD; MODERATE; MANAGEMENT; CRITERIA	OBJECTIVE: Traumatic brain injuries (TBIs) are largely underdiagnosed and may have persistent refractory consequences. Current assessments for acute TBI are limited to physical examination and imaging. Biomarkers such as glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), and S100 calcium-binding protein B (S100B) have shown predictive value as indicators of TBI and potential screening tools. METHODS: In total, 37 controls and 118 unique trauma subjects who received a clinically ordered head computed tomography (CT) in the emergency department of a level 1 trauma center were evaluated. Blood samples collected at 0-8 hours (initial) and 12-32 hours (delayed) postinjury were analyzed for GFAP, UCH-L1, and S100B concentrations. These were then compared in CT-negative and CT-positive subjects. RESULTS: Median GFAP, UCH-L1, and S100B concentrations were greater in CT-positive subjects at both timepoints compared with CT-negative subjects. In addition, median UCH-L1 and S100B concentrations were lower at the delayed timepoint, whereas median GFAP concentrations were increased. As predictors of a positive CT of the head, GFAP outperformed UCH-L1 and S100B at both timepoints (initial: 0.89 sensitivity, 0.62 specificity; delayed: 0.94 sensitivity, 0.67 specificity). GFAP alone also outperformed all possible combinations of biomarkers. CONCLUSIONS: GFAP, UCH-L1, and S100B demonstrated utility for rapid prediction of a CT-positive TBI within 0-8 hours of injury. GFAP exhibited the greatest predictive power at 12-32 hours. Furthermore, these results suggest that GFAP alone has greater utility for predicting a positive CT of the head than UCH-L1, S100B, or any combination of the 3.	[Mahan, Margaret Y.; Thorpe, Maxwell; Ahmadi, Aliya; Abdallah, Tessneem; Casey, Hannah; Sturtevant, Dylan; Judge-Yoakam, Senait; Hoover, Caleb; Rafter, Daniel; Samadani, Uzma] Hennepin Healthcare, Dept Neurosurg, Minneapolis, MN 55415 USA; [Miner, James] Hennepin Healthcare, Dept Emergency Med, Minneapolis, MN USA; [Richardson, Chad] Hennepin Healthcare, Dept Gen Surg, Minneapolis, MN USA; [Mahan, Margaret Y.; Samadani, Uzma] Univ Minnesota, Dept Biomed Informat & Computat Biol, Minneapolis, MN 55455 USA; [Samadani, Uzma] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA	Samadani, U (corresponding author), Hennepin Healthcare, Dept Neurosurg, Minneapolis, MN 55415 USA.; Samadani, U (corresponding author), Univ Minnesota, Dept Biomed Informat & Computat Biol, Minneapolis, MN 55455 USA.; Samadani, U (corresponding author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.	uzma@samadani.com		Casey, Hannah/0000-0002-6562-4020; Mahan, Margaret/0000-0002-7332-9523; Abdallah, Tessneem/0000-0002-1604-9621	Minnesota Spinal Cord and Traumatic Brain Injury Research Fund; Rockswold Kaplan Endowed Chair; Abbott LaboratoriesAbbott Laboratories	This research was supported by funding from the Minnesota Spinal Cord and Traumatic Brain Injury Research Fund, Rockswold Kaplan Endowed Chair, and Abbott Laboratories. Dr. Uzma Samadani reports grant money to Hennepin Healthcare Research Institute to conduct research conceived and sponsored by Abbott Laboratories.	Abbasi Mohsen, 2014, Turk J Emerg Med, V14, P147, DOI 10.5505/1304.7361.2014.74317; Bishop P, 2016, BIOCHEM J, V473, P2453, DOI 10.1042/BCJ20160082; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Calcagnile O, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0723-z; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; DAGOSTIN.R, 1973, BIOMETRIKA, V60, P613, DOI 10.1093/biomet/60.3.613; DAGOSTINO RB, 1971, BIOMETRIKA, V58, P341, DOI 10.2307/2334522; Dams-O'Connor K, 2017, J HEAD TRAUMA REHAB, V32, P147, DOI 10.1097/HTR.0000000000000263; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dutton RP, 2011, J TRAUMA, V70, P554, DOI 10.1097/TA.0b013e31820d1062; Easter JS, 2013, ACAD EMERG MED, V20, P753, DOI 10.1111/acem.12184; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Gilquin B, 2010, MOL CELL BIOL, V30, P2724, DOI 10.1128/MCB.01468-09; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Heidari K, 2015, BRAIN INJURY, V29, P33, DOI 10.3109/02699052.2014.948068; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kellermann I, 2016, CLIN NEUROL NEUROSUR, V145, P79, DOI 10.1016/j.clineuro.2016.04.005; Kim DS, 2013, J KOREAN NEUROSURG S, V54, P100, DOI 10.3340/jkns.2013.54.2.100; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kreitzer N, 2017, AM J EMERG MED, V35, P875, DOI 10.1016/j.ajem.2017.01.051; KRUSKAL WH, 1953, J AM STAT ASSOC, V48, P907, DOI 10.2307/2281082; Lagerstedt L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175572; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mata-Mbemba D, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1781-9; McKinney W., 2010, P 9 PYTHON SCI C, P56, DOI 10.25080/majora-92bf1922-00a; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Moschnegootz S, 2010, NEURORADIOL J, V23, P296, DOI 10.1177/197140091002300306; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nayebaghayee Hossein, 2016, Asian J Neurosurg, V11, P46, DOI 10.4103/1793-5482.165780; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oliphant TE, 2007, COMPUT SCI ENG, V9, P10, DOI 10.1109/MCSE.2007.58; Owlia M, 2014, AM J MED, V127, P406, DOI 10.1016/j.amjmed.2014.01.023; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Peacock WF, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00641; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811; Sharma R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173798; Sieber M, 2018, J FORENSIC LEG MED, V55, P65, DOI 10.1016/j.jflm.2018.02.016; Steiner Emanuel, 2016, J Trauma Manag Outcomes, V10, P5, DOI 10.1186/s13032-016-0035-8; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Studer M, 2015, BRAIN INJURY, V29, P1667, DOI 10.3109/02699052.2015.1075250; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Zhou JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040403	71	11	11	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	AUG	2019	128						E434	E444		10.1016/j.wneu.2019.04.170			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	IJ4SX	WOS:000475895100050	31051301				2021-06-18	
J	Olldashi, F; Latifi, R; Parsikia, A; Boci, A; Qesteri, O; Dasho, E; Bakiu, E				Olldashi, Fatos; Latifi, Rifat; Parsikia, Afshin; Boci, Arian; Qesteri, Orland; Dasho, Erion; Bakiu, Elvis			Telemedicine for Neurotrauma Prevents Unnecessary Transfers: An Update from a Nationwide Program in Albania and Analysis of 590 Patients	WORLD NEUROSURGERY			English	Article						Albania; Low- and middle-income countries; Neurotrauma; Spinal cord injuries; Telemedicine; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; DIGITAL OBSERVATION CAMERA; DEVELOPING-COUNTRIES; MEDICAL SYSTEMS; MANAGEMENT; ARIZONA	BACKGROUND: The telemedicine program in Albania includes a specialized teleneurotrauma program. There is only 1 national trauma center with neurosurgery capability in the capital city of Tirana. Patients with isolated head or spine injury who require consultation with neurosurgeons located at the National Trauma Center receive telemedicine consultation. The aim of this follow-up study was to evaluate the effectiveness of a nationwide teleneurotrauma network in preventing unnecessary transfers for neurotrauma. METHODS: Retrospective analysis was performed of prospectively collected data on all telemedicine consultations for isolated neurotrauma from March 2014 to February 2018. All teleconsultations were coded using the International Classification of Diseases, Tenth Revision coding system (codes S00, S01-S010). RESULTS: Of 590 teleconsultations for neurotrauma, most patients (76%) were male (median age 46.5 years; range, 1-93 years); 403 (68.31%; mean age 45.12 years) did not require a transfer to the tertiary center, and 187 (mean age 42.47 years) were transferred. An average 12.5 (monthly average range, 8.5-16) patients were seen monthly with a steady increase to a mature telemedicine program at the present time. Most teleconsultations (70.67%) occurred during business hours (8:00 AM 4:30 PM); 173 (29.32%) occurred at night and on weekends. Analysis by diagnosis indicated that most cases of low severity were not transferred, whereas higher severity cases were twice as likely to be transferred (P < 0.05). CONCLUSIONS: Structured and coordinated telemedicine for neurotrauma increases access to care for neurosurgery patients in countries that do not have widespread neurosurgery services. Nearly 70% of patients may be treated locally by nonneurosurgeons.	[Olldashi, Fatos] Univ Hosp Trauma, Dept Neurosurg, Tirana, Albania; [Latifi, Rifat] New York Med Coll, Dept Surg, Sch Med, Valhalla, NY 10595 USA; [Latifi, Rifat] Westchester Med Ctr Hlth Network, Valhalla, NY 10595 USA; [Latifi, Rifat; Parsikia, Afshin; Boci, Arian; Dasho, Erion] Int Virtual E Hosp Fdn, Hope, ID 83836 USA; [Boci, Arian; Qesteri, Orland; Bakiu, Elvis] Integrated Telemed & E Hlth Program Albania, Tirana, Albania	Latifi, R (corresponding author), New York Med Coll, Dept Surg, Sch Med, Valhalla, NY 10595 USA.; Latifi, R (corresponding author), Westchester Med Ctr Hlth Network, Valhalla, NY 10595 USA.; Latifi, R (corresponding author), Int Virtual E Hosp Fdn, Hope, ID 83836 USA.	Rifat.Latifi@wmchealth.org		Latifi, Rifat/0000-0003-1091-3682			Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; Demaerschalk BM, 2012, TELEMED E-HEALTH, V18, P230, DOI 10.1089/tmj.2011.0116; Demaerschalk BM, 2010, STROKE, V41, P1251, DOI 10.1161/STROKEAHA.109.574509; El Khamlichi Abdeslam, 2005, Clin Neurosurg, V52, P214; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Joseph B, 2014, J TRAUMA ACUTE CARE, V77, P984, DOI 10.1097/TA.0000000000000428; Kahn EN, 2016, WORLD NEUROSURG, V89, P133, DOI 10.1016/j.wneu.2016.01.075; Latifi R., 2012, TELEMEDICINE TRAUMA; Latifi R, 2006, TELEMED J E-HEALTH, V12, P332, DOI 10.1089/tmj.2006.12.332; Latifi R, 2018, WORLD NEUROSURG, V112, pE747, DOI 10.1016/j.wneu.2018.01.146; Latifi R, 2016, TELEMED E-HEALTH, V22, P1024, DOI 10.1089/tmj.2016.0050; Latifi R, 2016, INT J EMERG MED, V9, DOI 10.1186/s12245-016-0124-5; Latifi R, 2015, TELEMED E-HEALTH, V21, P503, DOI 10.1089/tmj.2014.0138; Latifi R, 2014, TELEMED E-HEALTH, V20, P1027, DOI 10.1089/tmj.2014.0026; Latifi R, 2014, WORLD J SURG, V38, P1898, DOI 10.1007/s00268-014-2538-7; Latifi Rifat, 2014, Am J Disaster Med, V9, P25, DOI 10.5055/ajdm.2014.0139; Latifi Rifat, 2009, Am J Surg, V198, P905, DOI 10.1016/j.amjsurg.2009.08.011; Lewis ER, 2012, TELEMED E-HEALTH, V18, P434, DOI 10.1089/tmj.2011.0199; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Migliaretti G, 2013, J TELEMED TELECARE, V19, P33, DOI 10.1177/1357633X12474738; Puvanachandra P., 2009, PAK J NEUROL SCI, V4, P27; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206	23	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	AUG	2019	128						E340	E346		10.1016/j.wneu.2019.04.150			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	IJ4SX	WOS:000475895100039	31029813				2021-06-18	
J	Rafferty, J; Ranson, C; Oatley, G; Mostafa, M; Mathema, P; Crick, T; Moore, IS				Rafferty, James; Ranson, Craig; Oatley, Giles; Mostafa, Mohamed; Mathema, Prabhat; Crick, Tom; Moore, Isabel S.			On average, a professional rugby union player is more likely than not to sustain a concussion after 25 matches	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							EXTREMITY MUSCULOSKELETAL INJURY; RISK; INCREASES; EVENTS; RETURN	Objectives To investigate concussion injury rates, the likelihood of sustaining concussion relative to the number of rugby union matches and the risk of subsequent injury following concussion. Methods A four-season (2012/2013-2015/2016) prospective cohort study of injuries in professional level (club and international) rugby union. Incidence (injuries/1000 player-match-hours), severity (days lost per injury) and number of professional matches conferring a large risk of concussion were determined. The risk of injury following concussion was assessed using a survival model. Results Concussion incidence increased from 7.9 (95% CI 5.1 to 11.7) to 21.5 injuries/1000 player-match-hours (95% CI 16.4 to 27.6) over the four seasons for combined club and international rugby union. Concussion severity was unchanged over time (median: 9 days). Players were at a greater risk of sustaining a concussion than not after an exposure of 25 matches (95% CI 19 to 32). Injury risk (any injury) was 38% greater (HR 1.38; 95% CI 1.21 to 1.56) following concussion than after a non-concussive injury. Injuries to the head and neck (HR 1.34; 95% CI 1.06 to 1.70), upper limb (HR 1.59; 95% CI 1.19 to 2.12), pelvic region (HR 2.07; 95% CI 1.18 to 3.65) and the lower limb (HR 1.60; 95% CI 1.21 to 2.10) were more likely following concussion than after a non-concussive injury. Conclusion Concussion incidence increased, while severity remained unchanged, during the 4 years of this study. Playing more than 25 matches in the 2015/2016 season meant that sustaining concussion was more likely than not sustaining concussion. The 38% greater injury risk after concussive injury (compared with non-concussive injury) suggests return to play protocols warrant investigation.	[Rafferty, James] Swansea Univ, Med Sch, Swansea, W Glam, Wales; [Ranson, Craig] English Inst Sport, Manchester, Lancs, England; [Oatley, Giles] Murdoch Univ, Sch Engn & Informat Technol, Perth, WA, Australia; [Mostafa, Mohamed] Cardiff Univ, Sch Comp Sci & Informat, Social Data Sci Lab, Cardiff, S Glam, Wales; [Mathema, Prabhat] Welsh Rugby Union, Cardiff, S Glam, Wales; [Crick, Tom] Cardiff Metropolitan Univ, Dept Comp & Informat Syst, Cardiff, S Glam, Wales; [Moore, Isabel S.] Cardiff Metropolitan Univ, Cardiff Sch Sport & Hlth Sci, Cardiff CF23 6XD, S Glam, Wales	Moore, IS (corresponding author), Cardiff Metropolitan Univ, Cardiff Sch Sport & Hlth Sci, Cardiff CF23 6XD, S Glam, Wales.	imoore@cardiffmet.ac.uk	Crick, Tom/C-8481-2011; Ranson, Craig/AAQ-5452-2020	Crick, Tom/0000-0001-5196-9389; Mostafa, Mohamed/0000-0001-9870-8637; Ranson, Craig/0000-0002-3783-0505; Oatley, Giles/0000-0002-5034-5213; Rafferty, James/0000-0002-1667-7265; Moore, Isabel/0000-0002-4746-3390	World Rugby; Welsh Rugby Union	World Rugby and Welsh Rugby Union.	Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Efron B., 1982, SOC IND APPL MATH; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2017, BRIT J SPORT MED, V51, P51, DOI 10.1136/bjsports-2016-096275; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Gabbett TJ, 2016, BRIT J SPORT MED, V50, P273, DOI 10.1136/bjsports-2015-095788; Gabbett TJ, 2016, BR J SPORTS MED; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Holtzhausen LJ, 2006, SAMJ S AFR MED J, V96, P1260; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Mahmood A, 2014, BRIT J SPORT MED, V48, P630; McCrory P, 2017, BRIT J SPORT MED, V2017, P51; Moore IS, 2017, BR J SPORTS MED; Moore IS, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115596194; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Ranson C, J SPORTS SCI; RFU, 2017, ENGL PROF RUGB INJ S; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Therneau T., 2015, MIXED EFFECTS COX MO; Therneau TM, 2013, MODELING SURVIVAL DA; Tucker R, 2017, BRIT J SPORT MED, V51, P1152, DOI 10.1136/bjsports-2017-097895; Ullah S, 2014, BRIT J SPORT MED, V48, P1287, DOI 10.1136/bjsports-2011-090803; van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37; WorldRugby, CONC MAN REC REM	30	11	11	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2019	53	15					969	973		10.1136/bjsports-2017-098417			5	Sport Sciences	Sport Sciences	IM3ME	WOS:000477896500011	29530941	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Redelmeier, DA; Manzoor, F; Thiruchelvam, D				Redelmeier, Donald A.; Manzoor, Fizza; Thiruchelvam, Deva			Association Between Statin Use and Risk of Dementia After a Concussion	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CHRONIC SUBDURAL-HEMATOMA; ALZHEIMER-DISEASE; VASCULAR-DISEASE; ATORVASTATIN; POPULATION; HEALTH; THERAPY; CARE; DEPRESSION	Key PointsQuestionIs statin use associated with an increased or decreased risk of subsequent dementia after a concussion? FindingsIn this large extended population-based double cohort study following 28815 patients after a concussion, the 5-year incidence of dementia was substantial and statin use was associated with a significantly reduced risk of subsequent dementia. MeaningConcussions are associated with an increased long-term risk of dementia, which is modestly reduced for patients receiving a statin. This large extended population-based double cohort study tests whether statin use is associated with an increased or decreased risk of subsequent dementia after a concussion among older adults. ImportanceConcussions are an acute injury that may lead to chronic disability, while statin use might improve neurologic recovery. ObjectiveTo test whether statin use is associated with an increased or decreased risk of subsequent dementia after a concussion. Design, Setting, and ParticipantsLarge extended population-based double cohort study in Ontario, Canada, from April 1, 1993, to April 1, 2013 (enrollment), and continued until March 31, 2016 (follow-up). Dates of analysis were April 28, 2014, through March 21, 2019. Participants were older adults diagnosed as having a concussion, excluding severe cases resulting in hospitalization, individuals with a prior diagnosis of dementia or delirium, and those who died within 90 days. ExposureStatin prescription within 90 days after a concussion. Main Outcome and MeasureLong-term incidence of dementia. ResultsThis study identified 28815 patients diagnosed as having a concussion (median age, 76 years; 61.3% female), of whom 7058 (24.5%) received a statin, and 21757 (75.5%) did not receive a statin. A total of 4727 patients subsequently developed dementia over a mean follow-up of 3.9 years, equal to an incidence of 1 case per 6 patients. Patients who received a statin had a 13% reduced risk of dementia compared with patients who did not receive a statin (relative risk, 0.87; 95% CI, 0.81-0.93; P<.001). The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain. Conclusions and RelevanceIn this study, older adults had a substantial long-term risk of dementia after a concussion, which was associated with a modest reduction among patients receiving a statin.	[Redelmeier, Donald A.; Manzoor, Fizza] Univ Toronto, Dept Med, Toronto, ON, Canada; [Redelmeier, Donald A.; Manzoor, Fizza] Sunnybrook Res Inst, Evaluat Clin Sci Program, Toronto, ON, Canada; [Redelmeier, Donald A.; Manzoor, Fizza; Thiruchelvam, Deva] Inst Clin Evaluat Sci Ontario, Toronto, ON, Canada; [Redelmeier, Donald A.] Sunnybrook Hlth Sci Ctr, Div Gen Internal Med, 2075 Bayview Ave,Ste G-151, Toronto, ON M4N 3M5, Canada; [Redelmeier, Donald A.] Ctr Leading Injury Prevent Practice Educ & Res, Toronto, ON, Canada	Redelmeier, DA (corresponding author), Sunnybrook Hlth Sci Ctr, Div Gen Internal Med, 2075 Bayview Ave,Ste G-151, Toronto, ON M4N 3M5, Canada.	dar@ices.on.ca			Canada Research Chair in Medical Decision SciencesCanada Research Chairs; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); BrightFocus FoundationBrightFocus Foundation; Comprehensive Research Experience for Medical Students at the University of Toronto	This work was supported by a Canada Research Chair in Medical Decision Sciences, the Canadian Institutes of Health Research, the BrightFocus Foundation, and the Comprehensive Research Experience for Medical Students at the University of Toronto.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; [Anonymous], 2016, HLTH PROMOT CHRONIC, V36, P231, DOI DOI 10.24095/hpcdp.36.10.04; Bardach NS, 2013, JAMA-J AM MED ASSOC, V310, P1051, DOI 10.1001/jama.2013.277353; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barkow K, 2003, J AFFECT DISORDERS, V76, P157, DOI 10.1016/S0165-0327(02)00081-2; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brasure M, 2018, ANN INTERN MED, V168, P30, DOI 10.7326/M17-1528; Bronskill S, 2011, HLTH SYSTEM USE FRAI; Brookhart MA, 2007, AM J EPIDEMIOL, V166, P348, DOI 10.1093/aje/kwm070; Butterfield DA, 2011, PHARMACOL RES, V64, P180, DOI 10.1016/j.phrs.2011.04.007; Canadian Institute for Health Information, 2008, CIHI DAT QUAL STUD E; Carlsson CM, 2012, CURR ALZHEIMER RES, V9, P990; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Chan DYC, 2017, BRIT J NEUROSURG, V31, P72, DOI 10.1080/02688697.2016.1208806; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Daviglus ML, 2010, ANN INTERN MED, V153, P176, DOI 10.7326/0003-4819-153-3-201008030-00260; Davis DHJ, 2012, BRAIN, V135, P2809, DOI 10.1093/brain/aws190; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Downey A, 2017, PREVENTING COGNITIVE; Efron DT, 2008, J TRAUMA, V64, P66, DOI 10.1097/TA.0b013e31815b842a; Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8; Farzanegan GR, 2017, J CLIN NEUROSCI, V44, P143, DOI 10.1016/j.jocn.2017.06.010; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Feldman HH, 2010, NEUROLOGY, V74, P956, DOI 10.1212/WNL.0b013e3181d6476a; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fink HA, 2018, ANN INTERN MED, V168, P39, DOI 10.7326/M17-1529; Gardener H, 2015, NAT REV NEUROL, V11, P651, DOI 10.1038/nrneurol.2015.195; Gardner RC, 2018, J NEUROTRAUM, V35, P889, DOI 10.1089/neu.2017.5371; Giannopoulos S, 2014, J ALZHEIMERS DIS, V42, pS315, DOI 10.3233/JAD-132366; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Gurwitz JH, 2016, JAMA-J AM MED ASSOC, V316, P1971, DOI 10.1001/jama.2016.15212; Haag MDM, 2009, J NEUROL NEUROSUR PS, V80, P13, DOI 10.1136/jnnp.2008.150433; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iron K., 2008, LIVING DYING ONTARIO; Jaffee MS, 2015, BRAIN INJURY, V29, P221, DOI 10.3109/02699052.2014.983978; Juurlink D., 2006, Canadian Institute for Health Information Discharge Abstract Database: a validation study; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Khokhar B, 2018, J HEAD TRAUMA REHAB, V33, pE68, DOI 10.1097/HTR.0000000000000369; Khokhar B, 2017, J PHARM TECHNOL, V33, P225, DOI 10.1177/8755122517735656; Kinjo M, 2017, OPEN HEART, V4, DOI 10.1136/openhrt-2016-000417; Ko DT, 2013, CIRC-CARDIOVASC QUAL, V6, P315, DOI 10.1161/CIRCOUTCOMES.111.000015; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Levy AR, 1999, CAN J CARDIOL, V15, P1277; Lin FC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002143; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Macpherson A, 2005, INJURIES ONTARIO ICE; Maegele M, 2018, LANCET NEUROL, V17, P13, DOI 10.1016/S1474-4422(17)30419-2; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Master CL, 2018, ANN INTERN MED, V169, pITC1, DOI 10.7326/AITC201807030; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McFarland AJ, 2014, INT J MOL SCI, V15, P20607, DOI 10.3390/ijms151120607; McGuinness B, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003160.pub3; McInnes K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174847; Mendoza-Oliva A, 2014, CURR ALZHEIMER RES, V11, P817; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; Miron VE, 2009, AM J PATHOL, V174, P1880, DOI 10.2353/ajpath.2009.080947; Morrish J, 2013, CONCUSSIONS CANADA, P1; Muldoon MF, 2004, AM J MED, V117, P823, DOI 10.1016/j.amjmed.2004.07.041; Neilson SJ, 2016, BRAIN INJURY, V30, P993, DOI 10.3109/02699052.2016.1147599; Ng R, 2015, BRAIN DISORDERS ONTA; Nordstrom A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002496; Orlando A, 2017, INJURY, V48, P1040, DOI 10.1016/j.injury.2016.11.027; Orlando Alessandro, 2013, J Clin Med Res, V5, P168, DOI 10.4021/jocmr1333w; Paterson JM, 2008, J POPUL THER CLIN PH, V15, pE108; Peng WJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/261409; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Power MC, 2015, NAT REV NEUROL, V11, P220, DOI 10.1038/nrneurol.2015.35; Prince M., 2015, WORLD ALZHEIMER REPO; Proulx Jeff, 2015, Healthc Q, V18, P11; Public Health Agency of Canada, 2017, DEM CAN INCL ALZH DI; Radosevich JJ, 2013, BRAIN INJURY, V27, P1492, DOI 10.3109/02699052.2013.823658; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Redelmeier DA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002104; Redlich C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0348-y; Reed B, 2014, JAMA NEUROL, V71, P195, DOI 10.1001/jamaneurol.2013.5390; Robertson CS, 2017, J NEUROTRAUM, V34, P1394, DOI 10.1089/neu.2016.4717; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roy Satyajeet, 2017, J Clin Med Res, V9, P638, DOI 10.14740/jocmr3066w; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Sanchez-Aguilar M, 2013, J NEUROSURG, V118, P669, DOI 10.3171/2012.12.JNS121084; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schilling JM, 2014, BEHAV BRAIN RES, V267, P6, DOI 10.1016/j.bbr.2014.03.014; Schilling S, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002265; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sessions SY, 2010, JAMA-J AM MED ASSOC, V303, P2078, DOI 10.1001/jama.2010.654; Shrank WH, 2011, J GEN INTERN MED, V26, P546, DOI 10.1007/s11606-010-1609-1; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; St Germaine-Smith C, 2012, NEUROLOGY, V79, P1049, DOI 10.1212/WNL.0b013e3182684707; Statistics Canada, POP EST JUL 1 AG SEX; Strom BL, 2015, JAMA INTERN MED, V175, P1399, DOI 10.1001/jamainternmed.2015.2092; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5; Taylor WD, 2013, MOL PSYCHIATR, V18, P963, DOI 10.1038/mp.2013.20; Tuccori M, 2014, CNS DRUGS, V28, P249, DOI 10.1007/s40263-013-0135-1; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Wang D, 2014, J NEUROL SCI, V336, P237, DOI 10.1016/j.jns.2013.11.005; Wang HX, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002251; Wee HY, 2016, J CLIN PSYCHIAT, V77, P505, DOI 10.4088/JCP.14m09749; Wilchesky M, 2004, J CLIN EPIDEMIOL, V57, P131, DOI 10.1016/S0895-4356(03)00246-4; WILKINS R, 2004, AUTOMATED GEOGRAPHIC; Williams JI, 1996, PATTERNS HLTH CARE O, V2nd; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xie CC, 2015, BRAIN RES, V1602, P1, DOI 10.1016/j.brainres.2014.03.021; Xu M, 2016, WORLD NEUROSURG, V91, P23, DOI 10.1016/j.wneu.2016.03.067; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Yusuf S, 2016, LANCET, V388, P943, DOI 10.1016/S0140-6736(16)31532-X; Zhang HB, 2013, ANN INTERN MED, V158, P526, DOI 10.7326/0003-4819-158-7-201304020-00004	123	11	12	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	AUG	2019	76	8					887	896		10.1001/jamaneurol.2019.1148			10	Clinical Neurology	Neurosciences & Neurology	IS8ZF	WOS:000482437500005	31107515	Bronze, Green Published			2021-06-18	
J	Sun, MJ; Brady, RD; Casillas-Espinosa, PM; Wright, DK; Semple, BD; Kim, HA; Mychasiuk, R; Sobey, CG; O'Brien, TJ; Vinh, A; McDonald, SJ; Shultz, SR				Sun, Mujun; Brady, Rhys D.; Casillas-Espinosa, Pablo M.; Wright, David K.; Semple, Bridgette D.; Kim, Hyun Ah; Mychasiuk, Richelle; Sobey, Christopher G.; O'Brien, Terence J.; Vinh, Antony; McDonald, Stuart J.; Shultz, Sandy R.			Aged rats have an altered immune response and worse outcomes after traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Neuroinflammation; Aging; Immunosenescence; Immunology; MRI; DTI	TELOMERE LENGTH; JUVENILE RATS; ANIMAL-MODELS; TISSUE; NEUROINFLAMMATION; BIOMARKERS; INCREASES; RECOVERY; NEURONS; MICE	Initial studies suggest that increased age is associated with worse outcomes after traumatic brain injury (TBI), though the pathophysiological mechanisms responsible for this remain unclear. Immunosenescence (i.e., dysregulation of the immune system due to aging) may play a significant role in influencing TBI outcomes. This study therefore examined neurological outcomes and immune response in young-adult (i.e., 10 weeks old) compared to middle-aged (i.e., 1 year old) rats following a TBI (i.e., fluid percussion) or sham-injury. Rats were euthanized at either 24 h or one-week post-injury to analyze immune cell populations in the brain and periphery via flow cytometry, as well as telomere length (i.e., a biomarker of neurological health). Behavioral testing, as well as volumetric and diffusion-weighted MRI, were also performed in the one-week recovery rats to assess for functional deficits and brain damage. Middle-aged rats had worse sensorimotor deficits and shorter telomeres after TBI compared to young rats. Both aging and TBI independently worsened cognitive function and cortical volume. These changes occurred in the presence of fewer total leukocytes, fewer infiltrating myeloid cells, and fewer microglia in the brains of middle-aged TBI rats compared to young rats. These findings indicate that middle-aged rats have worse sensorimotor deficits and shorter telomeres after TBI than young rats, and this may be related to an altered neuroimmune response. Although further studies are required, these findings have important implications for understanding the pathophysiology and optimal treatment strategies in TBI patients across the life span.	[Sun, Mujun; Brady, Rhys D.; Casillas-Espinosa, Pablo M.; Wright, David K.; Semple, Bridgette D.; Mychasiuk, Richelle; O'Brien, Terence J.; McDonald, Stuart J.; Shultz, Sandy R.] Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Vic, Australia; [Sun, Mujun; Brady, Rhys D.; Casillas-Espinosa, Pablo M.; Semple, Bridgette D.; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia; [Kim, Hyun Ah; Sobey, Christopher G.; Vinh, Antony; McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic, Australia; [Mychasiuk, Richelle] Univ Calgary, Dept Psychol, Calgary, AB, Canada	Shultz, SR (corresponding author), Monash Univ, Dept Neurosci, Melbourne, Vic 3004, Australia.	sandy.shultz@monash.edu		O'Brien, Terence/0000-0002-7198-8621; Sun, Mujun/0000-0002-9923-9913; Wright, David/0000-0002-7535-8651	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This study was funded by grants and fellowship to SRS from the National Health and Medical Research Council.	Abdullah AI, 2012, MOL NEUROBIOL, V45, P586, DOI 10.1007/s12035-012-8277-6; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Brady RD, 2019, NEUROBIOL DIS, V123, P8, DOI 10.1016/j.nbd.2018.08.007; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Doran SJ, 2019, J NEUROTRAUM, V36, P1040, DOI 10.1089/neu.2018.6019; Forero DA, 2016, J GERONTOL A-BIOL, V71, P1069, DOI 10.1093/gerona/glw053; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gon Y, 1996, CLIN EXP IMMUNOL, V106, P120; Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588; Guan JZ, 2008, J GERONTOL A-BIOL, V63, P467, DOI 10.1093/gerona/63.5.467; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hefendehl JK, 2014, AGING CELL, V13, P60, DOI 10.1111/acel.12149; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim HA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00365; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Natrajan MS, 2015, BRAIN, V138, P3581, DOI 10.1093/brain/awv289; Ndode-Ekane XE, 2019, EPILEPSY RES, V151, P7, DOI 10.1016/j.eplepsyres.2019.01.006; Nissinen J, 2017, EPILEPSY RES, V136, P18, DOI 10.1016/j.eplepsyres.2017.07.005; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Ritzel RM, 2019, NEUROBIOL AGING, V77, P194, DOI 10.1016/j.neurobiolaging.2019.02.010; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shakur H, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-109; Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Sun MJ, 2018, BRAIN BEHAV IMMUN, V69, P618, DOI 10.1016/j.bbi.2018.01.007; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tucker AM, 2011, CURR ALZHEIMER RES, V8, P354; Tucker LB, 2018, NEUROSCI BIOBEHAV R, V88, P187, DOI 10.1016/j.neubiorev.2018.03.010; von Zglinicki T, 2005, CURR MOL MED, V5, P197; Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wortman RC, 2018, ANN CLIN TRANSL NEUR, V5, P1588, DOI 10.1002/acn3.667; Wright DK, 2018, NEUROIMAGE-CLIN, V18, P315, DOI 10.1016/j.nicl.2018.01.033; Wright DK, 2017, ANN CLIN TRANSL NEUR, V4, P640, DOI 10.1002/acn3.441; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yates MA, 2007, BRAIN RES, V1142, P13, DOI 10.1016/j.brainres.2007.01.043; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456; Zhao C, 2006, NEUROBIOL AGING, V27, P1298, DOI 10.1016/j.neurobiolaging.2005.06.008	58	11	12	1	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2019	80						536	550		10.1016/j.bbi.2019.04.038			15	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	IM6LX	WOS:000478105500052	31039431				2021-06-18	
J	Berke, DS; Kline, NK; Wachen, JS; McLean, CP; Yarvis, JS; Mintz, J; Young-McCaughan, S; Petersong, AL; Foa, E; Resick, PA; Litz, BT				Berke, Danielle S.; Kline, Nora K.; Wachen, Jennifer Schuster; McLean, Carmen P.; Yarvis, Jeffrey S.; Mintz, Jim; Young-McCaughan, Stacey; Petersong, Alan L.; Foa, Edna; Resick, Patricia A.; Litz, Brett T.		STRONG STAR Consortium	Predictors of attendance and dropout in three randomized controlled trials of PTSD treatment for active duty service members	BEHAVIOUR RESEARCH AND THERAPY			English	Article						PTSD; Clinical trial; Attendance; Dropout; Active duty service members	POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH-CARE; PROLONGED EXPOSURE; PSYCHOMETRIC PROPERTIES; CLINICAL-SIGNIFICANCE; IDENTIFICATION TEST; BEHAVIORAL THERAPY; SELF-REPORT	Dropout from first-line posttraumatic stress disorder (PTSD) treatments is a significant problem. We reported rates and predictors of attendance and dropout in three clinical trials of evidence-based PTSD treatments in military service members (N = 557). Service members attended 81.0% of treatment sessions and 30.7% dropped out. Individually delivered treatment was associated with greater attendance rates (beta = 0.23, p < .001) than group therapy; trauma-focused treatments were associated with higher dropout (beta = 0.19, p < .001) than Present-Centered Therapy. Age was a significant predictor of session attendance (beta = 0.17, p < .001) and drop out (beta = -0.23, p < .001). History of traumatic brain injury (TBI) predicted lower attendance rates (beta = -0.26, p < .001) and greater dropout (beta = 0.19, p < .001). Regardless of treatment type or format, patients who did not drop out were more likely to experience clinically significant gains (d = 0.49, p < .001). Results demonstrate that dropout from PTSD treatments in these trials was significantly associated with treatment outcome and suggest that strategies are needed to mitigate dropout, particularly in group and trauma-focused therapies, and among younger service members and those with TBI.	[Berke, Danielle S.; Kline, Nora K.; Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA; [Berke, Danielle S.; Wachen, Jennifer Schuster; Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Wachen, Jennifer Schuster] VA Boston Healthcare Syst, Natl Ctr, PTSD, Boston, MA USA; [McLean, Carmen P.] VA Palo Alto Healthcare Syst, PTSD, Natl Ctr, Menlo Pk, CA USA; [McLean, Carmen P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Yarvis, Jeffrey S.] Carl R Darnall Army Med Ctr, Ft Hood, TX USA; [Mintz, Jim; Young-McCaughan, Stacey; Petersong, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Petersong, Alan L.] South Texas Vet Hlth Care Syst, Res & Dev Serv, San Antonio, TX USA; [Petersong, Alan L.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA; [Foa, Edna] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; [Resick, Patricia A.] Duke Univ, Med Ctr, Durham, NC USA; [Litz, Brett T.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Berke, Danielle S.] CUNY Hunter Coll, New York, NY 10021 USA; [Kline, Nora K.] Clark Univ, Worcester, MA 01610 USA; [Yarvis, Jeffrey S.] 21st Combat Support Hosp, Ft Hood, TX USA	Berke, DS (corresponding author), VA Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA.	db2800@hunter.cuny.edu; nkline@clarku.edu; jennifer.wachen@va.gov; carmen.mclean4@va.gov; jeffrey.s.yarvis.mil@mail.mil; mintz@uthscsa.edu; youngs1@uthscsa.edu; petersona3@uthscsa.edu; foa@pennmedicine.upenn.edu; patricia.resick@duke.edu; brett.litz@va.gov		McLean, Carmen/0000-0003-4322-9318	U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-02-109, W81XWH-08-02-0111, W81XWH-08-02-0114, W81XWH-08-02-0116]	This work was supported by the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-02-109 (Alan Peterson), W81XWH-08-02-0111 (Edna Foa), W81XWH-08-02-0114 (Brett Litz), and W81XWH-08-02-0116 (Patricia Resick).	Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Barnes J. B, 2018, MIL MED, DOI [10.1093/milmed/usy226, DOI 10.1093/MILMED/USY226]; Bauer S, 2004, J PERS ASSESS, V82, P60, DOI 10.1207/s15327752jpa8201_11; Beck A., 1996, MANUAL BDI 2; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Cabin R.J., 2000, B ECOLOGICAL SOC AM, V81, P246, DOI DOI 10.2307/20168454; Chard KM, 2010, J TRAUMA STRESS, V23, P25, DOI 10.1002/jts.20500; Clinical Data Interchange Standards Consortium, 2011, CDISC IND COLL GROUP; Compas BE, 2015, J CONSULT CLIN PSYCH, V83, P541, DOI 10.1037/a0039053; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Department of Veterans Affairs, 2017, VA DOD CLIN PRACT GU; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; Ehlers A, 2013, BEHAV RES THER, V51, P742, DOI 10.1016/j.brat.2013.08.006; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; Foa EB, 2018, JAMA-J AM MED ASSOC, V319, P354, DOI 10.1001/jama.2017.21242; Galovski TE, 2012, J CONSULT CLIN PSYCH, V80, P968, DOI 10.1037/a0030600; Garcia HA, 2011, PSYCHOL SERV, V8, P1, DOI 10.1037/a0022705; Geiser C., 2013, DATA ANAL MPLUS; Gros DF, 2011, BEHAV THER, V42, P276, DOI 10.1016/j.beth.2010.07.005; Hembree EA, 2003, J TRAUMA STRESS, V16, P555, DOI 10.1023/B:JOTS.0000004078.93012.7d; Hoge CW, 2017, JAMA PSYCHIAT, V74, P13, DOI 10.1001/jamapsychiatry.2016.2740; Hoge CW, 2014, PSYCHIAT SERV, V65, P997, DOI 10.1176/appi.ps.201300307; Imel ZE, 2013, J CONSULT CLIN PSYCH, V81, P394, DOI 10.1037/a0031474; Interagency Taskforce on Military and Veterans Mental Health, 2013, NAT RES ACT PLAN RES; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jeffreys MD, 2014, J ANXIETY DISORD, V28, P108, DOI 10.1016/j.janxdis.2013.04.010; Kehle-Forbes SM, 2016, PSYCHOL TRAUMA-US, V8, P107, DOI 10.1037/tra0000065; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Kok BC, 2012, J NERV MENT DIS, V200, P444, DOI 10.1097/NMD.0b013e3182532312; Lambert M. J, 2011, PSYCHOTHERAPY RELATI; Luke D.A., 2004, MULTILEVEL MODELING; Martinovich Z, 1996, PSYCHOTHER RES, V6, P124, DOI 10.1080/10503309612331331648; Mott JM, 2014, J TRAUMA STRESS, V27, P265, DOI 10.1002/jts.21927; Najavits Lisa M, 2015, F1000Prime Rep, V7, P43, DOI 10.12703/P7-43; Palmer GA, 2014, MIL MED, V179, P879, DOI 10.7205/MILMED-D-14-00048; Price M, 2015, DEPRESS ANXIETY, V32, P392, DOI 10.1002/da.22354; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Resick PA, 2017, JAMA PSYCHIAT, V74, P28, DOI 10.1001/jamapsychiatry.2016.2729; Resick PA, 2015, J CONSULT CLIN PSYCH, V83, P1058, DOI 10.1037/ccp0000016; Rizvi SL, 2009, BEHAV RES THER, V47, P737, DOI 10.1016/j.brat.2009.06.003; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schnurr PP, 2003, ARCH GEN PSYCHIAT, V60, P481, DOI 10.1001/archpsyc.60.5.481; Scholten J, 2017, BRAIN INJURY, V31, P1246, DOI 10.1080/02699052.2016.1274780; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sloan DM, 2013, PSYCHOL TRAUMA-US, V5, P176, DOI 10.1037/a0026291; Society of Clinical Psychology, 2012, PRES CTR THER POSTTR; Steenkamp MM, 2015, JAMA-J AM MED ASSOC, V314, P489, DOI 10.1001/jama.2015.8370; Sterba SK, 2017, PSYCHOTHER RES, V27, P425, DOI 10.1080/10503307.2015.1114688; Szafranski DD, 2017, J ANXIETY DISORD, V47, P91, DOI 10.1016/j.janxdis.2017.01.002; Szafranski DD, 2014, PSYCHIATRY, V77, P263, DOI 10.1521/psyc.2014.77.3.263; Taylor S, 2003, J CONSULT CLIN PSYCH, V71, P330, DOI 10.1037/0022-006X.71.2.330; Tuerk PW, 2013, PSYCHOL SERV, V10, P401, DOI 10.1037/a0030549; van Minnen A, 2002, J TRAUMA STRESS, V15, P359, DOI 10.1023/A:1020177023209; van Minnen A, 2002, BEHAV RES THER, V40, P439, DOI 10.1016/S0005-7967(01)00024-9; van Minnen A, 2006, J TRAUMA STRESS, V19, P427, DOI 10.1002/jts.20146; Watts BV, 2013, J CLIN PSYCHIAT, V74, pE541, DOI 10.4088/JCP.12r08225; Weathers F. W., 1993, ANN M INT SOC TRAUMA; Wright KM, 2009, PSYCHOL SERV, V6, P108, DOI 10.1037/a0012620; Zandberg LJ, 2016, BEHAV RES THER, V80, P1, DOI 10.1016/j.brat.2016.02.005; Zayfert C, 2005, J TRAUMA STRESS, V18, P637, DOI 10.1002/jts.20072	66	11	13	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967	1873-622X		BEHAV RES THER	Behav. Res. Ther.	JUL	2019	118						7	17		10.1016/j.brat.2019.03.003			11	Psychology, Clinical	Psychology	ID5TJ	WOS:000471738600002	30933748				2021-06-18	
J	Hertelendy, P; Varga, DP; Menyhart, A; Bari, F; Farkas, E				Hertelendy, Peter; Varga, Daniel P.; Menyhart, Akos; Bari, Ferenc; Farkas, Eszter			Susceptibility of the cerebral cortex to spreading depolarization in neurological disease states: The impact of aging	NEUROCHEMISTRY INTERNATIONAL			English	Article						Aging; Brain injury; Ischemia; Migraine; Spreading depolarization; Spreading depression	EXTRACELLULAR POTASSIUM CONCENTRATION; NITRIC-OXIDE; NMDA RECEPTOR; SUBARACHNOID HEMORRHAGE; GLUTAMATE RELEASE; BLOOD-FLOW; TISSUE OXYGENATION; CALCIUM-CHANNELS; ARTERY OCCLUSION; ISCHEMIC BRAIN	Secondary injury following acute brain insults significantly contributes to poorer neurological outcome. The spontaneous, recurrent occurrence of spreading depolarization events (SD) has been recognized as a potent secondary injury mechanism in subarachnoid hemorrhage, malignant ischemic stroke and traumatic brain injury. In addition, SD is the underlying mechanism of the aura symptoms of migraineurs. The susceptibility of the nervous tissue to SD is subject to the metabolic status of the tissue, the ionic composition of the extracellular space, and the functional status of ion pumps, voltage-gated and other cation channels, glutamate receptors and excitatory amino acid transporters. All these mechanisms tune the excitability of the nervous tissue. Aging has also been found to alter SD susceptibility, which appears to be highest at young adulthood, and decline over the aging process. The lower susceptibility of the cerebral gray matter to SD in the old brain may be caused by the age-related impairment of mechanisms implicated in ion translocations between the intra- and extracellular compartments, glutamate signaling and surplus potassium and glutamate clearance. Even though the aging nervous tissue is thus less able to sustain SD, the consequences of SD recurrence in the old brain have proven to be graver, possibly leading to accelerated lesion maturation. Taken that recurrent SDs may pose an increased burden in the aging injured brain, the benefit of therapeutic approaches to restrict SD generation and propagation may be particularly relevant for elderly patients.	[Hertelendy, Peter; Varga, Daniel P.; Menyhart, Akos; Bari, Ferenc; Farkas, Eszter] Univ Szeged, Fac Med, Dept Med Phys & Informat, Koranyis Fasor 9, H-6720 Szeged, Hungary; [Hertelendy, Peter; Varga, Daniel P.; Menyhart, Akos; Bari, Ferenc; Farkas, Eszter] Univ Szeged, Fac Sci & Informat, Koranyis Fasor 9, H-6720 Szeged, Hungary; [Hertelendy, Peter] Univ Szeged, Fac Med, Dept Neurol, Semmelweis U 6, H-6725 Szeged, Hungary	Farkas, E (corresponding author), Univ Szeged, Fac Med, Dept Med Phys & Informat, Koranyis Fasor 9, H-6720 Szeged, Hungary.	hertelendy.peter@med.u-szeged.hu; vardan.bio@gmail.com; menyhartakos89@gmall.com; bari.ferenc@med.u-szeged.hu; farkas.eszter.1@med.u-szeged.hu		Farkas, Eszter/0000-0002-8478-9664; Menyhart, Akos/0000-0002-1355-3208; Varga, Daniel Peter/0000-0001-5797-9334	National Research, Development and Innovation Office of Hungary [K111923, K120358]; Economic Development and Innovation Operational Programme in Hungary; European Regional Development FundEuropean Commission [GINOP-2.3.2-15-2016-00006]; EUEuropean Commission [EFOP-3.6.1-16-2016-00008]; European UnionEuropean Commission	This work was supported by grants from the National Research, Development and Innovation Office of Hungary (Grant No. K111923 and K120358); the Economic Development and Innovation Operational Programme in Hungary co-financed by the European Union and the European Regional Development Fund (No. GINOP-2.3.2-15-2016-00006); and the EU-funded Hungarian grant No. EFOP-3.6.1-16-2016-00008.	AITKEN PG, 1991, BRAIN RES, V541, P7, DOI 10.1016/0006-8993(91)91067-B; Ayata C, 2000, NEUROSCIENCE, V95, P639; Ayata C, 2009, CEPHALALGIA, V29, P1095, DOI 10.1111/j.1468-2982.2009.01982.x; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Ayata C, 2010, HEADACHE, V50, P725, DOI 10.1111/j.1526-4610.2010.01647.x; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Benzi G, 1994, J Neural Transm Suppl, V44, P159; Bere Z, 2014, J CEREBR BLOOD F MET, V34, P1695, DOI 10.1038/jcbfm.2014.136; Bodhinathan K, 2010, J NEUROSCI, V30, P1914, DOI 10.1523/JNEUROSCI.5485-09.2010; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BURES J, 1957, ELECTROEN CLIN NEURO, V9, P121, DOI 10.1016/0013-4694(57)90116-5; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Capuani C, 2016, EMBO MOL MED, V8, P967, DOI 10.15252/emmm.201505944; Carlson AP, 2019, J NEUROSURG, V130, P1513, DOI 10.3171/2017.12.JNS171665; Cervetto C, 2013, J NEUROCHEM, V124, P821, DOI 10.1111/jnc.12143; Chakraborty H, 2003, EXP GERONTOL, V38, P705, DOI 10.1016/S0531-5565(03)00066-4; Charpentier C, 1999, STROKE, V30, P1402, DOI 10.1161/01.STR.30.7.1402; Chen G, 2005, J NEUROPHYSIOL, V94, P1287, DOI 10.1152/jn.00224.2005; Chen RL, 2010, NAT REV NEUROL, V6, P256, DOI 10.1038/nrneurol.2010.36; Chen SP, 2017, BRAIN, V140, P1643, DOI 10.1093/brain/awx085; Cholet N, 2002, CEREB CORTEX, V12, P515, DOI 10.1093/cercor/12.5.515; Clark D, 2014, NEUROBIOL AGING, V35, P2803, DOI 10.1016/j.neurobiolaging.2014.06.013; COHADON F, 1986, GERONTOLOGY, V32, P46; Cook N. S., 1990, POTASSIUM CHANNELS S; Costa C, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-62; Cotrina ML, 2001, BRAIN RES, V901, P55, DOI 10.1016/S0006-8993(01)02258-2; Crobeddu E, 2012, STROKE, V43, P697, DOI 10.1161/STROKEAHA.111.638403; CZEH G, 1992, NEUROREPORT, V3, P197, DOI 10.1097/00001756-199202000-00019; CZEH G, 1993, BRAIN RES, V632, P195, DOI 10.1016/0006-8993(93)91154-K; de Lores Arnaiz Georgina Rodriguez, 2014, Int J Biomed Sci, V10, P85; de Rooij NK, 2013, STROKE, V44, P1288, DOI 10.1161/STROKEAHA.113.001125; Dichgans M, 2005, LANCET, V366, P371, DOI 10.1016/S0140-6736(05)66786-4; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Durham PL, 2008, HEADACHE, V48, pS5, DOI 10.1111/j.1526-4610.2008.01262.x; Enyedi P, 2012, MOL CELL ENDOCRINOL, V353, P75, DOI 10.1016/j.mce.2011.11.009; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Farkas E, 2014, J GERONTOL A-BIOL, V69, P1363, DOI 10.1093/gerona/glu066; Farkas E, 2011, NEUROBIOL AGING, V32, P1707, DOI 10.1016/j.neurobiolaging.2009.10.002; Gagolewicz P. J. A., 2017, ELUSIVE CHANNEL DRIV; Goadsby PJ, 2009, CEPHALALGIA, V29, P7, DOI 10.1111/j.1468-2982.2008.01804.x; Goadsby PJ, 2017, PHYSIOL REV, V97, P553, DOI 10.1152/physrev.00034.2015; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154; Grinberg YY, 2013, J NEUROCHEM, V126, P662, DOI 10.1111/jnc.12267; Guedes RCA, 1996, BRAZ J MED BIOL RES, V29, P1407; Gupta RK, 2013, BIOGERONTOLOGY, V14, P531, DOI 10.1007/s10522-013-9459-y; Gupta RK, 2013, AGE, V35, P59, DOI 10.1007/s11357-011-9330-5; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hajek I, 1996, NEUROCHEM INT, V28, P335, DOI 10.1016/0197-0186(95)00081-X; HANSEN AJ, 1978, ACTA PHYSIOL SCAND, V102, P324, DOI 10.1111/j.1748-1716.1978.tb06079.x; HANSEN AJ, 1980, ACTA PHYSIOL SCAND, V108, P355, DOI 10.1111/j.1748-1716.1980.tb06544.x; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; HANSEN AJ, 1977, ACTA PHYSIOL SCAND, V99, P412, DOI 10.1111/j.1748-1716.1977.tb10394.x; Harada K, 2016, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00499; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hertelendy P, 2017, J CEREBR BLOOD F MET, V37, P1763, DOI 10.1177/0271678X16643735; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hille B., 1992, IONIC CHANNELS EXCIT; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hoffmann U, 2013, J CEREBR BLOOD F MET, V33, P191, DOI 10.1038/jcbfm.2012.132; Hoffmann U, 2010, J CEREBR BLOOD F MET, V30, P1588, DOI 10.1038/jcbfm.2010.92; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iwamoto M, 2004, NEUROSCI LETT, V366, P277, DOI 10.1016/j.neulet.2004.05.048; Kao YCJ, 2014, NEUROBIOL DIS, V71, P131, DOI 10.1016/j.nbd.2014.07.005; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; KATSURA K, 1991, J CEREBR BLOOD F MET, V11, P597, DOI 10.1038/jcbfm.1991.109; Kaufmann D, 2017, J CEREBR BLOOD F MET, V37, P1748, DOI 10.1177/0271678X16659496; Kilic K, 2018, ANN NEUROL, V83, P61, DOI 10.1002/ana.25122; Kim Y, 2017, NEUROTHERAPEUTICS, V14, P1148, DOI 10.1007/s13311-017-0536-9; Kocak H, 2002, GERONTOLOGY, V48, P279, DOI 10.1159/000065249; Kofuji P, 2004, NEUROSCIENCE, V129, P1045, DOI 10.1016/j.neurscience.2004.06.008; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Kudo C, 2008, EXP NEUROL, V212, P201, DOI 10.1016/j.expneurol.2008.03.026; Kumar A, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00473; Lalo U, 2011, AGING CELL, V10, P392, DOI 10.1111/j.1474-9726.2011.00682.x; LAURITZEN M, 1983, ANN NEUROL, V13, P633, DOI 10.1002/ana.410130609; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Leis JA, 2005, GLIA, V50, P407, DOI 10.1002/glia.20145; Leo L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002129; Liu FD, 2012, NEUROCHEM INT, V61, P1255, DOI 10.1016/j.neuint.2012.10.003; Liu P, 2013, J NEUROSCI, V33, P12810, DOI 10.1523/JNEUROSCI.1237-13.2013; Magge SN, 2010, J NEUROSURG, V112, P1208, DOI 10.3171/2009.9.JNS081670; Magnusson KR, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00011; Major S, 2017, J CEREBR BLOOD F MET, V37, P1687, DOI 10.1177/0271678X16639059; Makra P. M., 2018, FRONTIERS PHYS UNPUB; Malarkey EB, 2008, NEUROCHEM INT, V52, P142, DOI 10.1016/j.neuint.2007.06.005; Mannelli LD, 2015, NEUROPHARMACOLOGY, V97, P133, DOI 10.1016/j.neuropharm.2015.05.037; Mansour H., 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057038.e57038, DOI 10.1371/JOURNAL.PONE.0057038.E57038]; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Maslarova A, 2011, STROKE, V42, P2917, DOI 10.1161/STROKEAHA.111.621581; MATSUURA T, 1971, EXP BRAIN RES, V12, P238, DOI 10.1007/BF00237916; Mayevsky A, 1998, ACT NEUR S, V71, P78; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; Menyhart A, 2018, NEUROBIOL DIS, V119, P41, DOI 10.1016/j.nbd.2018.07.026; Menyhart A, 2017, AM J PHYSIOL-HEART C, V313, pH328, DOI 10.1152/ajpheart.00222.2017; Menyhart A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01284-4; Menyhart A, 2015, NEUROBIOL AGING, V36, P3269, DOI 10.1016/j.neurobiolaging.2015.08.014; MILNER PM, 1958, ELECTROEN CLIN NEURO, V10, P705, DOI 10.1016/0013-4694(58)90073-7; Misonou H, 2010, NEUROSCIENTIST, V16, P51, DOI 10.1177/1073858409341085; Murphy S, 2007, BIOCHEM SOC T, V35, P1133, DOI 10.1042/BST0351133; NEDERGAARD M, 1995, J NEUROBIOL, V28, P433, DOI 10.1002/neu.480280404; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Pannasch U, 2013, TRENDS NEUROSCI, V36, P405, DOI 10.1016/j.tins.2013.04.004; Petzold GC, 2008, STROKE, V39, P1292, DOI 10.1161/STROKEAHA.107.500710; PHILLIPS JM, 1979, BRAIN RES, V173, P567, DOI 10.1016/0006-8993(79)90254-3; Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770; Pinczolits A, 2017, J CEREBR BLOOD F MET, V37, P1896, DOI 10.1177/0271678X17699629; Pusic KM, 2014, GLIA, V62, P1176, DOI 10.1002/glia.22672; RABB CH, 1994, ACTA NEUROCHIR, V127, P27, DOI 10.1007/BF01808542; Reinhart KM, 2018, EXP NEUROL, V305, P121, DOI 10.1016/j.expneurol.2018.04.007; Richter F, 1998, DEV BRAIN RES, V106, P217, DOI 10.1016/S0165-3806(98)00018-2; Richter F, 2002, NEUROSCI LETT, V334, P123, DOI 10.1016/S0304-3940(02)01120-5; Richter F, 2017, J CEREBR BLOOD F MET, V37, P1791, DOI 10.1177/0271678X16641127; Richter F, 2014, ANN NEUROL, V76, P43, DOI 10.1002/ana.24176; Rimmele TS, 2016, NEUROCHEM INT, V98, P19, DOI 10.1016/j.neuint.2016.04.010; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Rovegno M, 2018, BBA-BIOMEMBRANES, V1860, P216, DOI 10.1016/j.bbamem.2017.08.014; Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Sanchez-Porras Renan, 2015, Acta Neurochir Suppl, V120, P153, DOI 10.1007/978-3-319-04981-6_26; Satoh M, 1999, BRAIN RES, V822, P142, DOI 10.1016/S0006-8993(99)01141-5; SCHADE JP, 1959, J NEUROPHYSIOL, V22, P243; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Sesti F, 2016, AGING DIS, V7, P130, DOI 10.14336/AD.2015.0901; Shatillo A, 2015, NEUROPHARMACOLOGY, V93, P164, DOI 10.1016/j.neuropharm.2015.01.028; Shibata M, 2017, J CEREBR BLOOD F MET, V37, P1182, DOI 10.1177/0271678X17690537; Simpson JE, 2010, NEUROBIOL AGING, V31, P578, DOI 10.1016/j.neurobiolaging.2008.05.015; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Spong KE, 2016, J NEUROPHYSIOL, V116, P1117, DOI 10.1152/jn.00352.2016; Steffensen AB, 2015, J NEUROSCI, V35, P12172, DOI 10.1523/JNEUROSCI.0400-15.2015; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Sukhotinsky I, 2010, J CEREBR BLOOD F MET, V30, P1168, DOI 10.1038/jcbfm.2009.285; Sun XL, 2010, CLIN EXP PHARMACOL P, V37, P243, DOI 10.1111/j.1440-1681.2009.05190.x; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; Tang YT, 2014, J NEUROPHYSIOL, V112, P2572, DOI 10.1152/jn.00205.2014; Theis M, 2003, J NEUROSCI, V23, P766; Tombaugh GC, 1996, J PHYSIOL-LONDON, V493, P719, DOI 10.1113/jphysiol.1996.sp021417; Tong CK, 2000, J NEUROPHYSIOL, V84, P2449; Tottene A, 2009, NEURON, V61, P762, DOI 10.1016/j.neuron.2009.01.027; Urenjak J, 2000, N-S ARCH PHARMACOL, V362, P137, DOI 10.1007/s002100000273; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; Verkhratsky A, 2016, CURR OPIN PHARMACOL, V26, P74, DOI 10.1016/j.coph.2015.09.011; Victor TW, 2010, CEPHALALGIA, V30, P1065, DOI 10.1177/0333102409355601; Villa RF, 2002, NEUROCHEM RES, V27, P861, DOI 10.1023/A:1020381829107; Vinogradova LV, 2018, CEPHALALGIA, V38, P1177, DOI 10.1177/0333102417724151; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Wang MY, 2012, BRIT J PHARMACOL, V165, P235, DOI 10.1111/j.1476-5381.2011.01553.x; Willmot M, 2005, NITRIC OXIDE-BIOL CH, V12, P141, DOI 10.1016/j.niox.2005.01.003; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169; Wu YJ, 2003, J MED CHEM, V46, P3197, DOI 10.1021/jm034073f; Wulff H, 2008, CHEM REV, V108, P1744, DOI 10.1021/cr078234p; Yao XM, 2015, GLIA, V63, P1860, DOI 10.1002/glia.22853; Zhao X, 2009, NEUROSCIENCE, V162, P933, DOI 10.1016/j.neuroscience.2009.05.018; Zhao XR, 2000, BRAIN RES, V872, P215, DOI 10.1016/S0006-8993(00)02459-8; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113	175	11	11	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUL	2019	127						125	136		10.1016/j.neuint.2018.10.010			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	IH2LY	WOS:000474327500015	30336178	Green Accepted			2021-06-18	
J	Kotagama, P; Phadnis, A; Manning, KC; Rykaczewski, K				Kotagama, Praveen; Phadnis, Akshay; Manning, Kenneth C.; Rykaczewski, Konrad			Rational Design of Soft, Thermally Conductive Composite Liquid-Cooled Tubes for Enhanced Personal, Robotics, and Wearable Electronics Cooling	ADVANCED MATERIALS TECHNOLOGIES			English	Article						contact resistance; soft composites; soft heat exchangers; thermal conductivity; thermoregulation; wearable cooling; wearable electronics	TRAUMATIC BRAIN-INJURY; HEAT-STRESS; HUMAN SKIN; GARMENTS; DEVICES; SYSTEM; PERFORMANCE; MANAGEMENT	Thermoregulatory garments composed of liquid-cooled plastic tubes have users ranging from astronauts to multiple sclerosis patients and are emerging as a flexible cooling solution for wearable electronics and high-power robotics. Despite the plethora of applications, the current cooling systems are cumbersome to use due to their excessive size. In this work this issue is resolved by developing soft, thermally conductive silicone-aluminum composite tubes. To achieve optimal device performance, the material must be designed to balance the decrease in bulk thermal resistance and the increase in interfacial tube-substrate resistance due to composite stiffening. Thus, to enable the rational design of such tubes, a closed form thermomechanical model that predicts cooling performance as a function of tube geometry and filler fraction is developed and experimentally validated. Predictions via this model and experiments are used to reveal how the tube's geometrical and material design can be adjusted to minimize the required length of tubing and maximize the heat extracted from a metallic surface and skin. Lastly, through a holistic analysis, this work demonstrates that besides significantly increasing overall cooling capability, the use of low-resistance tubing can provide a multifold reduction in the cooling system size and enable novel operating modes.	[Kotagama, Praveen; Phadnis, Akshay; Manning, Kenneth C.; Rykaczewski, Konrad] Arizona State Univ, Sch Engn Matter Transport & Energy, Tempe, AZ 85287 USA	Rykaczewski, K (corresponding author), Arizona State Univ, Sch Engn Matter Transport & Energy, Tempe, AZ 85287 USA.	konradr@asu.edu			National Science FoundationNational Science Foundation (NSF) [1724452]	The authors gratefully acknowledge funding from the National Science Foundation through award number CBET #1724452. The authors would like to thank Hooman Daghooghi Mobarakeh and Ahmad Bamasag from ASU, who helped in the initial stages of this work in their Advanced Heat Transfer graduate class project. The authors would also like to thank Matt Ralphs from ASU for his assistance with SEM imaging. The authors gratefully acknowledge the use of facilities within the Center for Solid State Science at Arizona State University.	Bartlett MD, 2017, P NATL ACAD SCI USA, V114, P2143, DOI 10.1073/pnas.1616377114; Bejan A., 2003, HEAT TRANSFER HDB, V1, P261; Bejan A., 2008, DESIGN CONSTRUCTAL T; Bergman TL, 2011, FUNDAMENTALS HEAT MA; BUDIANSK.B, 1965, J MECH PHYS SOLIDS, V13, P223, DOI 10.1016/0022-5096(65)90011-6; Cadarette BS, 2006, ERGONOMICS, V49, P209, DOI 10.1080/00140130500436106; Cadogan DP, 2015, AM SCI, V103, P36, DOI 10.1511/2015.116.338; Cao H., 2005, J ASTM INT, V2, P12100; Cao HT, 2006, TEXT RES J, V76, P587, DOI 10.1177/0040517506067375; Cevallos JG, 2012, HEAT TRANSFER ENG, V33, P1075, DOI 10.1080/01457632.2012.663654; Chambers A., 1972, 2ND C PORT LIF SUPP, P283; Chen HY, 2016, PROG POLYM SCI, V59, P41, DOI 10.1016/j.progpolymsci.2016.03.001; Chen XJ, 2016, RENEW SUST ENERG REV, V60, P1367, DOI 10.1016/j.rser.2016.03.024; Christensen R.M., 2012, MECH COMPOSITE MAT; Conger B., 2019, 46 INT C ENV SYST HO, P1; COOPER MG, 1969, INT J HEAT MASS TRAN, V12, P279, DOI 10.1016/0017-9310(69)90011-8; Davis SL, 2010, J APPL PHYSIOL, V109, P1531, DOI 10.1152/japplphysiol.00460.2010; Denton M., 1972, TEXTILES, V3, P12; Dignicap, CLIN PROV RED HAIR L; Dionne J. P., 2003, THERMAL MANIKIN EVAL; Ernst TC, 2013, APPL THERM ENG, V60, P316, DOI 10.1016/j.applthermaleng.2013.06.019; Flouris AD, 2006, ANN BIOMED ENG, V34, P359, DOI 10.1007/s10439-005-9061-9; Fornasiero F, 2017, CURR OPIN CHEM ENG, V16, P1, DOI 10.1016/j.coche.2017.02.001; Fu SY, 2008, COMPOS PART B-ENG, V39, P933, DOI 10.1016/j.compositesb.2008.01.002; Gao TT, 2017, ACS NANO, V11, P11513, DOI 10.1021/acsnano.7b06295; Greenemeier L, 2008, SCI AM, V298, P34, DOI 10.1038/scientificamerican0408-34c; GUTHRIE TC, 1995, J NEUROL SCI, V129, P1, DOI 10.1016/0022-510X(94)00248-M; Hill D, 2017, INT J TECHNOL ASSESS, V33, P160, DOI 10.1017/S0266462317000460; Holt B, 2008, J BIOMECH, V41, P2689, DOI 10.1016/j.jbiomech.2008.06.008; Hwang DG, 2018, ACS APPL MATER INTER, V10, P6747, DOI 10.1021/acsami.7b18594; Jeong SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep18257; Johnston NJ, 2006, RESUSCITATION, V70, P254, DOI 10.1016/j.resuscitation.2006.02.010; Katrycz C. W., 2018, BIOINSPIRED ENG THER, P129; Kendrick J. T., 2018, THESIS; KERNER EH, 1956, P PHYS SOC LOND B, V69, P808, DOI 10.1088/0370-1301/69/8/305; Kim D, 2017, 2017 IEEE-RAS 17TH INTERNATIONAL CONFERENCE ON HUMANOID ROBOTICS (HUMANOIDS), P710, DOI 10.1109/HUMANOIDS.2017.8246950; Kim JH, 2011, J OCCUP ENVIRON HYG, V8, P409, DOI 10.1080/15459624.2011.584840; Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843; KUZNETZ LH, 1980, J BIOMECH ENG-T ASME, V102, P155, DOI 10.1115/1.3138213; Li YH, 2016, THEOR APPL MECH LETT, V6, P32, DOI 10.1016/j.taml.2015.12.001; Li YH, 2013, P ROY SOC A-MATH PHY, V469, DOI 10.1098/rspa.2013.0142; Midwest Research Institute, 1975, LIQ COOL GARM; Norton BA, 2015, LANDSCAPE URBAN PLAN, V134, P127, DOI 10.1016/j.landurbplan.2014.10.018; NUNNELEY SA, 1970, SPACE LIFE SCI, V2, P335, DOI 10.1007/BF00929293; Paxman, PION SCALP COOL; Polar Products, LEAD US MAN BOD COOL; Prasher R., 2017, MAT ADV PACKAGING, P511; Prasher RS, 2004, IEEE T COMPON PACK T, V27, P702, DOI 10.1109/TCAPT.2004.838883; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Ralphs MI, 2018, ACS APPL MATER INTER, V10, P2083, DOI 10.1021/acsami.7b15814; Ridderheim M, 2003, SUPPORT CARE CANCER, V11, P371, DOI 10.1007/s00520-003-0451-y; Rini D. P., 2006, USA, Patent No. [US12495279, 12495279]; Rothmaier M, 2008, MED BIOL ENG COMPUT, V46, P825, DOI 10.1007/s11517-008-0363-6; Rykaczewski Konrad, 2019, Temperature (Austin), V6, P97, DOI 10.1080/23328940.2019.1574201; Rykaczewski Konrad, 2019, Temperature (Austin), V6, P85, DOI 10.1080/23328940.2018.1551706; Sentis L., 2017, USA, Patent No. [US20170341227A1, 20170341227]; Style RW, 2015, NAT PHYS, V11, P82, DOI 10.1038/nphys3181; Sun Y, 2015, BUILD ENVIRON, V93, P50, DOI 10.1016/j.buildenv.2015.06.008; T'Joen C, 2009, INT J REFRIG, V32, P763, DOI 10.1016/j.ijrefrig.2008.11.008; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Tong JK, 2015, ACS PHOTONICS, V2, P769, DOI 10.1021/acsphotonics.5b00140; Tutika R, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804336; Wang FM, 2017, J THERM BIOL, V70, P37, DOI 10.1016/j.jtherbio.2017.05.007; Wang H, 2015, TRANSL NEUROSCI, V6, P20, DOI 10.1515/tnsci-2015-0004; Webb P., 1967, BIOTHERMAL RESPONSE; Webb RC, 2013, NAT MATER, V12, P938, DOI [10.1038/NMAT3755, 10.1038/nmat3755]; Welkins LLC, WELK PROV INN PROD E; Yang YF, 2012, APPL THERM ENG, V47, P18, DOI 10.1016/j.applthermaleng.2012.04.012; Yang Y, 2016, APL MATER, V4, DOI 10.1063/1.4944749; Yazdi MM, 2014, J TEXT I, V105, P1231, DOI 10.1080/00405000.2014.895088; Yin YF, 2018, APPL THERM ENG, V144, P504, DOI 10.1016/j.applthermaleng.2018.08.088; Zhang GZ, 2016, ADV MATER, V28, P4811, DOI 10.1002/adma.201506118; Zhao MM, 2013, INT J IND ERGONOM, V43, P232, DOI 10.1016/j.ergon.2013.01.001; Zhao RK, 2018, SOFT MATTER, V14, P2515, DOI 10.1039/c7sm02338c	74	11	11	4	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2365-709X			ADV MATER TECHNOL-US	Adv. Mater. Technol.	JUL	2019	4	7							1800690	10.1002/admt.201800690			12	Materials Science, Multidisciplinary	Materials Science	IH7FJ	WOS:000474669100013		Bronze			2021-06-18	
J	Oerter, S; Forster, C; Bohnert, M				Oerter, Sabrina; Foerster, Carola; Bohnert, Michael			Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Traumatic brain injury; Sodium-glucose transporters; SGLT; Biomarker; Human; Post-mortem	ACUTE-PHASE RESPONSE; GLUCOSE-TRANSPORTER; IN-VITRO; EXPRESSION; INJURY; TISSUE; SGLT1; GENE; RNA	In many forensic cases, the existence of a traumatic brain injury (TBI) is an essential factor, and the determination of the survival time is nearly as important as the determination of whether or not a trauma exists. Since it is known that glucose uptake increases in injured brain cells in order to perpetuate the neuronal integrity, this study focuses on the pathomechanism of brain glucose supply via sodium/glucose cotransporters 1 and 2 (SGLT1, SGLT2) following traumatization. Human cerebrum tissue of male and female individuals who died following TBI was taken from the contusional and contralateral regions, as well as from individuals deceased due to cardiac arrest (control group). Total SGLT1 and SGLT2 protein expression was analyzed by immunoblotting comparing injured and non-injured tissue. The immunoreactivity in contusional cerebral cortex region began to increase 3 to 7h following traumatization. We found that both SGLT1 and SGLT2 protein expression increased significantly 37h post-injury compared to the control group. SGLT1 rose significantly at 52h post-injury and peaked significantly at 72h, while SGLT2 rose significantly at 52 and 72h after injury. By compiling these data, we predict a standard operator via SGLT expression as a comparative expression assertion to determine post-injury survival time for unknown cases. Our result suggests that SGLT1 and SGLT2 protein expression may be useful in forensic practice as an effective target to analyze the existence of a TBI and to determine the time of the traumatization.	[Oerter, Sabrina; Bohnert, Michael] Julius Maximilian Univ Wuerzburg, Inst Legal Med, Versbacher Str 3, D-97078 Wurzburg, Germany; [Foerster, Carola] Univ Hosp Wuerzburg, Ctr Operat Med, Dept Anesthesia & Crit Care, D-97080 Wurzburg, Germany	Oerter, S (corresponding author), Julius Maximilian Univ Wuerzburg, Inst Legal Med, Versbacher Str 3, D-97078 Wurzburg, Germany.	sabrina.oerter@uuni-wuerzburg.de					BARTON AJL, 1993, J NEUROCHEM, V61, P1, DOI 10.1111/j.1471-4159.1993.tb03532.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Blair JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151615; Davidsson P, 2001, PROTEOMICS, V1, P444; De Paepe ME, 2002, DIAGN MOL PATHOL, V11, P170, DOI 10.1097/00019606-200209000-00008; Destatis, 2017, GES TOD DEUTSCHL; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Elfeber K, 2004, HISTOCHEM CELL BIOL, V121, P201, DOI 10.1007/s00418-004-0633-9; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Harada S, 2013, BRAIN RES, V1541, P61, DOI 10.1016/j.brainres.2013.09.041; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Huang ZG, 1999, CAN J NEUROL SCI, V26, P298, DOI 10.1017/S0317167100000421; Huth A, 2013, INT J LEGAL MED, V127, P335, DOI 10.1007/s00414-012-0787-2; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; KUMAGAI AK, 1994, BBA-BIOMEMBRANES, V1193, P24, DOI 10.1016/0005-2736(94)90328-X; Li DR, 2012, LEGAL MED-TOKYO, V14, P84, DOI 10.1016/j.legalmed.2011.12.007; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nagatsu T, 2005, CURR PHARM DESIGN, V11, P999, DOI 10.2174/1381612053381620; Ondruschka B, 2018, INT J LEGAL MED, V132, P531, DOI 10.1007/s00414-017-1768-2; Orihara Y, 2002, INT J LEGAL MED, V116, P92, DOI 10.1007/s00414-001-0265-8; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; Pandey GN, 2018, SCHIZOPHR RES, V192, P247, DOI 10.1016/j.schres.2017.04.043; PERRETT CW, 1988, J NEUROL NEUROSUR PS, V51, P325, DOI 10.1136/jnnp.51.3.325; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Sajja RK, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-8; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; Sasseville LJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154589; Schrag B, 2012, INT J LEGAL MED, V126, P505, DOI 10.1007/s00414-011-0596-z; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tyagi NK, 2005, BIOCHEMISTRY-US, V44, P15514, DOI 10.1021/bi051377q; Vemula S, 2009, J PHARMACOL EXP THER, V328, P487, DOI 10.1124/jpet.108.146589; Wais Sebastian, 2012, THESIS; Wang XY, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00025; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	39	11	11	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JUL	2019	133	4					1107	1114		10.1007/s00414-018-1893-6			8	Medicine, Legal	Legal Medicine	IG3EQ	WOS:000473685700018	30073510				2021-06-18	
J	Erdodi, LA; Taylor, B; Sabelli, AG; Malleck, M; Kirsch, NL; Abeare, CA				Erdodi, Laszlo A.; Taylor, Brian; Sabelli, Alana G.; Malleck, Malayna; Kirsch, Ned L.; Abeare, Christopher A.			Demographically Adjusted Validity Cutoffs on the Finger Tapping Test Are Superior to Raw Score Cutoffs in Adults with TBI	PSYCHOLOGICAL INJURY & LAW			English	Article						Finger tapping test; Demographically adjusted cutoffs; Performance validity; Erdodi Index; Modality specificity	TRAUMATIC BRAIN-INJURY; EMBEDDED PERFORMANCE VALIDITY; VERBAL-LEARNING TEST; INTELLIGENCE SCALE-4TH EDITION; COMPLEX FIGURE TEST; WORD MEMORY TEST; CROSS-VALIDATION; RECOGNITION TRIAL; RESPONSE BIAS; TEST-II	This study was designed to develop validity cutoffs within the Finger Tapping Test (FTT) using demographically adjusted T-scores, and to compare their classification accuracy to existing cutoffs based on raw scores. Given that FTT performance is known to vary with age, sex, and level of education, failure to correct for these demographic variables poses the risk of elevated false positive rates in examinees who, at the level of raw scores, have inherently lower FTT performance (women, older, and less educated individuals). Data were collected from an archival sample of 100 adult outpatients (M-Age=38.8years, M-Education=13.7years, 56% men) consecutively referred for neuropsychological assessment at an academic medical center in the Midwestern USA after sustaining a traumatic brain injury (TBI). Performance validity was psychometrically defined using the Word Memory Test and two validity composites based on five embedded performance validity indicators. Previously published raw score-based validity cutoffs disproportionately sacrificed sensitivity (.13-.33) for specificity (.98-1.00). Worse yet, they were confounded by sex and education. Newly introduced demographically adjusted cutoffs (T33 for the dominant hand, T37 for both hands) produced high levels of specificity (.89-.98) and acceptable sensitivity (.36-.55) across criterion measures. Equally importantly, they were robust to injury severity and demographic variables. The present findings provide empirical support for a growing trend of demographically adjusted performance validity cutoffs. They provide a practical and epistemologically superior alternative to raw score cutoffs, while also reducing the potential bias against examinees inherently vulnerable to lower raw score level FTT performance.	[Erdodi, Laszlo A.; Malleck, Malayna; Abeare, Christopher A.] Univ Windsor, Dept Psychol, Neuropsychol Track, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Taylor, Brian; Sabelli, Alana G.] Univ Windsor, Behav Cognit Neurosci Program, Windsor, ON, Canada; [Kirsch, Ned L.] Univ Michigan, Dept Phys Med & Rehabil, Adult Outpatient Neurehabil Program, Ann Arbor, MI 48109 USA	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, Neuropsychol Track, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434	Faculty of Arts, Humanities, and Social Sciences at the University of Windsor	This research was supported by a Collaborative Research Grant from the Faculty of Arts, Humanities, and Social Sciences at the University of Windsor.	Abeare C, 2019, J HEAD TRAUMA REHAB, V34, pE20, DOI 10.1097/HTR.0000000000000451; Abeare CA, 2018, JAMA NEUROL, V75, P697, DOI 10.1001/jamaneurol.2018.0031; Allen L, 1999, ARCH CLIN NEUROPSYCH, V14, P789, DOI 10.1016/S0887-6177(99)80328-X; An KY, 2019, J CLIN EXP NEUROPSYC, V41, P15, DOI 10.1080/13803395.2018.1483488; An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; Armistead-Jehle P, 2015, APPL NEUROPSYCH-ADUL, V22, P147, DOI 10.1080/23279095.2014.880842; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Baker DA, 2014, CLIN NEUROPSYCHOL, V28, P116, DOI 10.1080/13854046.2013.858184; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Brooks BL, 2015, ARCH CLIN NEUROPSYCH, V30, P200, DOI 10.1093/arclin/acv017; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Committee on Psychological Testing IVT Populations B on the H of S Medicine I of, 2015, COGN TESTS PERF VAL; Conners K. C., 2004, CONNERS CONTINUOUS P; Costabile T, 2018, PSYCHIAT CLIN NEUROS, V72, P189, DOI 10.1111/pcn.12630; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Critchfield E, 2019, CLIN NEUROPSYCHOL, V33, P1083, DOI 10.1080/13854046.2018.1508615; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC, 2000, CALIFORNIA VERBAL LE; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Donders J, 2013, J CLIN EXP NEUROPSYC, V35, P827, DOI 10.1080/13803395.2013.824557; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; Erdodi L. A., 2019, ASSESSMENT FEIGNED C; Erdodi LA., 2019, PSYCHOL NEUROSCI, V12, P451, DOI [10.1037/pne0000175., DOI 10.1037/PNE0000175, 10.1037/pne0000175]; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P307, DOI 10.1007/s12207-018-9337-7; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P1082, DOI 10.1037/pas0000561; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2018, ARCH CLIN NEUROPSYCH, V33, P845, DOI 10.1093/acn/acx110; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Guilmette T. J., 2013, MILD TRAUMATIC BRAIN, P31; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2018, J INT NEUROPSYCH SOC, V24, P735, DOI 10.1017/S1355617718000218; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Homann CN, 2003, J NEURAL TRANSM, V110, P885, DOI 10.1007/s00702-003-0009-7; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kalfon TBO, 2016, J PSYCHOSOM RES, V87, P30, DOI 10.1016/j.jpsychores.2016.06.004; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Lichtenstein J. D., 2019, PSYCHOL INJURY LAW, DOI [10.1007/s12207-019-0935, DOI 10.1007/S12207-019-0935]; Lichtenstein JD., 2018, J PEDIATR NEUROPSYCH, V4, P94, DOI [10.1007/s40817-018-0057-4, DOI 10.1007/S40817-018-0057-4]; Lichtenstein JD, 2019, DEV NEUROPSYCHOL, V44, P159, DOI 10.1080/87565641.2019.1565535; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lippa SM, 2014, REHABIL PSYCHOL, V59, P306, DOI 10.1037/a0037217; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Matthews C, 1964, INSTRUCTION MANUAL A, P36; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Newcombe F., 1969, MISSILE WOUNDS BRAIN; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOLUTIONS W; Persinger VC, 2018, CLIN NEUROPSYCHOL, V32, P1039, DOI 10.1080/13854046.2017.1419507; Prigatano GP, 2003, J INT NEUROPSYCH SOC, V9, P128, DOI 10.1017/S1355617703000134; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rai J., 2019, APPL NEUROPSYCHOL, DOI [10.1080/23279095.2019.161.1613994, DOI 10.1080/23279095.2019.161.1613994]; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Reitan RM., 1969, MANUAL ADM NEUROPSYC; Reitan RM., 1985, HALSTEAD REITAN NEUR; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; Schatz P, 2011, ENCY NEUROPSYCHOLOGY; Schutte C, 2015, PSYCHOL INJ LAW, V8, P100, DOI 10.1007/s12207-015-9225-3; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Shimoyama I, 2012, INT MED J, V19, P138; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Suhr J, 2012, CLIN NEUROPSYCHOL, V26, P1128, DOI 10.1080/13854046.2012.713121; Sussman ZW, 2019, APPL NEUROPSYCH-CHIL, V8, P70, DOI 10.1080/21622965.2017.1382359; Sweet JJ, 2013, BEHAV SCI LAW, V31, P756, DOI 10.1002/bsl.2088; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Tyson BT, 2018, EPILEPSY BEHAV, V87, P39, DOI 10.1016/j.yebeh.2018.08.010; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Williamson DJ, 2012, CLIN NEUROPSYCHOL, V26, P588, DOI 10.1080/13854046.2012.670266; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	137	11	11	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	JUN	2019	12	2					113	126		10.1007/s12207-019-09352-y			14	Psychology, Clinical	Psychology	IF6ZK	WOS:000473231100002					2021-06-18	
J	Erdodi, LA; Green, P; Sirianni, CD; Abeare, CA				Erdodi, Laszlo A.; Green, Paul; Sirianni, Christina D.; Abeare, Christopher A.			The Myth of High False-Positive Rates on the Word Memory Test in Mild TBI	PSYCHOLOGICAL INJURY & LAW			English	Article						Word Memory Test; False-positive rate; Performance validity; Mild TBI	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; CARD SORTING TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; PERFORMANCE VALIDITY TESTS; FEIGNED COGNITIVE IMPAIRMENT; TEST-SCORES; CROSS-VALIDATION; SUBOPTIMAL PERFORMANCE; TEST INDICATORS	This study was designed to replicate previous reports of elevated false-positive rates (FPR) on the Word Memory Test (WMT) in patients with mild traumatic brain injury (TBI) and to evaluate previous claims that genuine memory deficits and non-credible responding are conflated on the WMT. Data from a consecutive case sequence of 170 patients with mild TBI referred for neuropsychological assessment were collected. Failure rate on the WMT was compared to that on other performance validity tests (PVTs). The clinical characteristics and neuropsychological profiles of patients who passed and those who failed the WMT and other PVTs were compared. Base rate of failure was the highest on the WMT (44.7%), but comparable to that on other established PVTs (39.4-41.8%). The vast majority of patients (94.7%) who failed the WMT had independent evidence of invalid performance, refuting previous estimates of 20-30% FPR. Failing the WMT was associated with globally lower scores on tests measuring various cognitive domains. The neurocognitive profile of individuals with invalid performance was remarkably consistent across various PVTs. Previously reported FPR of the WMT were not replicated. Failing the WMT typically occurred in the context of failing other PVTs too. Results suggest a common factor behind non-credible responding that is invariant of the psychometric definition of invalid performance. Failure on the WMT should not be discounted based on rational arguments unsubstantiated by objective data. Inferring elevated FPR from high failure rate alone is a fundamental epistemological error.	[Erdodi, Laszlo A.; Sirianni, Christina D.; Abeare, Christopher A.] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Green, Paul] Greens Publishing, Kelowna, BC, Canada	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434	Faculty of Arts, Humanities, and Social Sciences at the University of Windsor	This research was supported by a Collaborative Research Grant from the Faculty of Arts, Humanities, and Social Sciences at the University of Windsor.	Abeare C., 2018, J HEAD TRAUMA REHABI; Abeare C., 2019, PSYCHOL INJURY LAW, DOI [10.1007/s12207-019-09353, DOI 10.1007/S12207-019-09353]; Abeare CA, 2018, JAMA NEUROL, V75, P697, DOI 10.1001/jamaneurol.2018.0031; Allen LM, 1999, SEVERE TBI SAMPLE PE; An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone K. B., 2013, CLIN PRACTICE FORENS; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Brockhaus R., 2003, J INT NEUROPSYCH SOC, V9, P503; Carone DA, 2014, APPL NEUROPSYCH-ADUL, V21, P155, DOI 10.1080/09084282.2012.755533; Carone DA, 2014, CLIN NEUROPSYCHOL, V28, P146, DOI 10.1080/13854046.2013.861019; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; CONDER R, 1992, COMPUTERIZED ASSESSM; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; DeFlippis N. A., 1997, PSYCHOL ASSESSMENT R; DeFlippis N. A., 1991, PSYCHOL ASSESSMENT R; DeFlippis N. A., 1979, PSYCHOL ASSESSMENT R; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; DiCarlo MA, 2000, ARCH CLIN NEUROPSYCH, V15, P399, DOI 10.1016/S0887-6177(99)00031-1; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Elbaum T, 2020, APPL NEUROPSYCH-ADUL, V27, P403, DOI 10.1080/23279095.2018.1555161; Erdodi L. A., 2019, ASSESSMENT FEIGNED C; Erdodi LA., 2019, PSYCHOL NEUROSCI, V12, P451, DOI [10.1037/pne0000175., DOI 10.1037/PNE0000175, 10.1037/pne0000175]; Erdodi LA, 2017, APPL NEUROPSYCHOL, V6, P335, DOI [10.1080/21622965.2016.1197126, DOI 10.1080/21622965.2016.1197126]; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P307, DOI 10.1007/s12207-018-9337-7; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P1082, DOI 10.1037/pas0000561; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P755, DOI 10.1037/pas0000525; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2018, ARCH CLIN NEUROPSYCH, V33, P845, DOI 10.1093/acn/acx110; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, PSYCHOL INJ LAW, V10, P96, DOI 10.1007/s12207-017-9282-x; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fritze E, 2003, THESIS; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gilchrist GS, 1999, THROMB HAEMOSTASIS, P97; Gligorovic M, 2013, J INTELLECT DEV DIS, V38, P134, DOI 10.3109/13668250.2013.772956; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green, 2004, GREENS MED SYMPTOM V; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P., 2012, PERFORMANCE WMT MSVT; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P, 2013, MILD TRAUMATIC BRAIN; Green P., 1995, MANUAL ORAL WORD MEM; Green P, 2016, APPL NEUROPSYCH-CHIL, V5, P25, DOI 10.1080/21622965.2014.935378; Green P, 2015, APPL NEUROPSYCH-ADUL, V22, P293, DOI 10.1080/23279095.2014.925903; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hall VL, 2014, J NEUROPSYCHOL, V8, P216, DOI 10.1111/jnp.12021; Heaton RK, 2004, REVISED COMPREHENSIV; Henry GK, 2018, J INT NEUROPSYCH SOC, V24, P735, DOI 10.1017/S1355617718000218; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hurtubise JL, 2017, PSYCHOL INJ LAW, V10, P121, DOI 10.1007/s12207-017-9287-5; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Larochette AC, 2012, APPL NEUROPSYCH-CHIL, V1, P38, DOI 10.1080/21622965.2012.665777; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Lichtenstein JD., 2018, J PEDIATR NEUROPSYCH, V4, P94, DOI [10.1007/s40817-018-0057-4, DOI 10.1007/S40817-018-0057-4]; Lichtenstein JD, 2019, DEV NEUROPSYCHOL, V44, P159, DOI 10.1080/87565641.2019.1565535; Lupu T, 2018, APPL NEUROPSYCH-ADUL, V25, P532, DOI 10.1080/23279095.2017.1341410; Macciocchi SN, 2017, ARCH CLIN NEUROPSYCH, V32, P339, DOI 10.1093/arclin/acw112; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pearson, 2009, ADV CLIN SOLUTIONS W; Persinger VC, 2018, CLIN NEUROPSYCHOL, V32, P1039, DOI 10.1080/13854046.2017.1419507; Rabin LA, 2014, PROF PSYCHOL-RES PR, V45, P368, DOI 10.1037/a0037987; Rai J., 2019, APPL NEUROPSYCHOL, DOI [10.1080/23279095.2019.161.1613994, DOI 10.1080/23279095.2019.161.1613994]; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; Shelley-Tremblay JE, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9050109; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Soble, 2019, CLIN NEUROPSYCHOL, V21, P209, DOI [10.1080/13825580601025932, DOI 10.1080/13825580601025932]; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tomer E, 2020, APPL NEUROPSYCH-ADUL, V27, P49, DOI 10.1080/23279095.2018.1480483; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TYDECKS S, 2006, INT J FORENSIC PSYCH, V1, P29; Tyson BT, 2018, EPILEPSY BEHAV, V87, P39, DOI 10.1016/j.yebeh.2018.08.010; Warrington EK., 1984, RECOGNITION MEMORY T; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Williamson DJ, 2012, CLIN NEUROPSYCHOL, V26, P588, DOI 10.1080/13854046.2012.670266; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	119	11	11	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	JUN	2019	12	2					155	169		10.1007/s12207-019-09356-8			15	Psychology, Clinical	Psychology	IF6ZK	WOS:000473231100005					2021-06-18	
J	Huang, WT; Shao, MJ; Liu, H; Chen, J; Hu, J; Zhu, LY; Liu, F; Wang, DX; Zou, YC; Xiong, Y; Wang, X				Huang, Wenting; Shao, Mingjie; Liu, Huan; Chen, Jun; Hu, Jian; Zhu, Liyun; Liu, Fei; Wang, Dongxue; Zou, Yuchi; Xiong, Ye; Wang, Xue			Fibroblast growth factor 21 enhances angiogenesis and wound healing of human brain microvascular endothelial cells by activating PPAR gamma	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						Angiogenesis; Wound healing; FGF21; FGF21/FGFR1/beta-klotho complex; PPAR gamma	IN-VITRO; MECHANISMS; PATHWAY; DISEASE	Angiogenesis of brain microvascular endothelial cells (BMECs) is required in the functional restoration of brain injury, such as traumatic brain injury (TBI) and ischemic stroke. Fibroblast growth factor 21 (FGF21) is an angiogenic molecule that functions through the formation of the FGF21/FGFR1/beta-klotho complex but does not cause carcinogenic events. The current study was to determine whether recombinant human FGF21 (rhFGF21) could promote angiogenesis and scratch wound healing of human brain microvascular endothelial cells (HBMECs) and the possible underlying mechanism. rhFGF21 promoted angiogenesis and migration of HBMECs. The FGFR1 inhibitor PD173074 was applied to demonstrate that rhFGF21 functions through the formation of FGF21/FGFR1/beta-klotho complexes. In addition, the specific PPAR gamma inhibitor GW9662 and PPAR gamma activator rosiglitazone were applied to determine that the role of rhFGF21 in increasing angiogenesis is through the PPAR gamma pathway. In addition, we revealed that the effect of rhFGF21 acts partially through upregulating eNOS expression. In conclusion, our study provides novel evidence that rhFGF21 can enhance the angiogenesis and migration of HBMECs through the formation of the FGF21/FGFR1/beta-klotho complex via PPAR gamma activation and eNOS upregulation, indicating that FGF21 is a potential therapeutic angiogenic agent for the treatment of human brain injury. (C) 2019 The Authors. Production and hosting by Elsevier B. V. on behalf of Japanese Pharmacological Society.	[Huang, Wenting; Shao, Mingjie; Wang, Xue] Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou 325035, Zhejiang, Peoples R China; [Liu, Huan; Chen, Jun; Hu, Jian; Zhu, Liyun; Liu, Fei; Wang, Dongxue; Wang, Xue] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Zou, Yuchi; Xiong, Ye] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 315020, Zhejiang, Peoples R China	Wang, X (corresponding author), Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou 325035, Zhejiang, Peoples R China.; Xiong, Y (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 315020, Zhejiang, Peoples R China.	xiongye2310@163.com; xinyuw001@163.com			National Undergraduate Training Programs for Innovation and Entrepreneurship [201710343011]; Public Welfare Technology Application Research Foundation of Zhejiang Province [2017C33080]; Wenzhou Municipal Science and Technology Bureau [Y20170686, Y20170224]	This study was supported by the National Undergraduate Training Programs for Innovation and Entrepreneurship (201710343011), the Public Welfare Technology Application Research Foundation of Zhejiang Province (2017C33080), and the Wenzhou Municipal Science and Technology Bureau (Y20170686, Y20170224).	Cao W, 2016, J PHARMACOL SCI, V132, P131, DOI 10.1016/j.jphs.2016.09.003; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen J, 2018, J NEUROTRAUM, V35, P2091, DOI 10.1089/neu.2017.5271; Domouzoglou EM, 2015, AM J PHYSIOL-HEART C, V309, pH1029, DOI 10.1152/ajpheart.00527.2015; Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062; Iizuka N, 2018, J PHARMACOL SCI, V138, P203, DOI 10.1016/j.jphs.2018.10.004; Jiang F, 2018, J PHARMACOL SCI, V137, P265, DOI 10.1016/j.jphs.2018.07.004; Kim KH, 2015, J ENDOCRINOL, V226, pR1, DOI 10.1530/JOE-15-0160; Kobayashi N, 2008, AM J HYPERTENS, V21, P576, DOI 10.1038/ajh.2008.27; Liu R, 2018, INT IMMUNOPHARMACOL, V57, P72, DOI 10.1016/j.intimp.2018.02.014; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Norton KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep36992; Ouk T, 2013, CURR DRUG TARGETS, V14, P752, DOI 10.2174/1389450111314070005; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Presta M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02327; Semenza GL, 2007, J CELL BIOCHEM, V102, P840, DOI 10.1002/jcb.21523; Villapol S, 2018, CELL MOL NEUROBIOL, V38, P121, DOI 10.1007/s10571-017-0554-5; Wang BT, 2018, J PHARMACOL SCI, V137, P290, DOI 10.1016/j.jphs.2018.07.007; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xu C, 2017, J DIABETES COMPLICAT, V31, P4, DOI 10.1016/j.jdiacomp.2016.10.010; Xu L, 2015, J CELL MOL MED, V19, P92, DOI 10.1111/jcmm.12463; Yang XX, 2018, BIOCONJUGATE CHEM, V29, P287, DOI 10.1021/acs.bioconjchem.7b00588; Yaqoob U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098130; Yu ZY, 2019, MOL NEUROBIOL, V56, P2314, DOI 10.1007/s12035-018-1234-2; Yuan Falei, 2013, Front Biosci (Elite Ed), V5, P517; Zhao YZ, 2015, J PHARMACOL SCI, V129, P83, DOI 10.1016/j.jphs.2015.09.002; Zhu WH, 2014, CAN J PHYSIOL PHARM, V92, P927, DOI 10.1139/cjpp-2014-0227; Zhuang SF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050968	28	11	11	0	4	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	JUN	2019	140	2					120	127		10.1016/j.jphs.2019.03.010			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IM5JO	WOS:000478030400002	31255518	DOAJ Gold			2021-06-18	
J	Jha, RM; Desai, SM; Zusman, BE; Koleck, TA; Puccio, AM; Okonkwo, DO; Park, SY; Shutter, LA; Kochanek, PM; Conley, YP				Jha, Ruchira M.; Desai, Shashvat M.; Zusman, Benjamin E.; Koleck, Theresa A.; Puccio, Ava M.; Okonkwo, David O.; Park, Seo-Young; Shutter, Lori A.; Kochanek, Patrick M.; Conley, Yvette P.			Downstream TRPM4 Polymorphisms Are Associated with Intracranial Hypertension and Statistically Interact with ABCC8 Polymorphisms in a Prospective Cohort of Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ABCC8; SUR1; cerebral edema; SNPs; TBI; TRPM4	SINGLE NUCLEOTIDE POLYMORPHISMS; SULFONYLUREA RECEPTOR 1; CEREBRAL EDEMA; DOUBLE-BLIND; GLIBENCLAMIDE; PRESSURE; VISUALIZATION; DISABILITY; GLYBURIDE; MORTALITY	Sulfonylurea-receptor-1(SUR1) and its associated transient-receptor-potential cation channel subfamily-M (TRPM4) channel are key contributors to cerebral edema and intracranial hypertension in traumatic brain injury (TBI) and other neurological disorders. Channel inhibition by glyburide is clinically promising. ABCC8 (encoding SUR1) single-nucleotide polymorphisms (SNPs) are reported as predictors of raised intracranial pressure (ICP). This project evaluated whether TRPM4 SNPs predicted ICP and TBI outcome. DNA was extracted from 435 consecutively enrolled severe TBI patients. Without a priori selection, all 11 TRPM4 SNPs available on the multiplex platform (Illumina:Human-Core-Exome v1.0) were genotyped spanning the 25 exon gene. A total of 385 patients were analyzed after quality control. Outcomes included ICP and 6 month Glasgow Outcome Scale (GOS) score. Proxy SNPs, spatial modeling, and functional predictions were determined using established software programs. rs8104571 (intron-20) and rs150391806 (exon-24) were predictors of ICP. rs8104571 heterozygotes predicted higher average ICP (beta = 10.3 mm Hg, p = 0.00000029), peak ICP (beta = 19.6 mm Hg, p = 0.0007), and proportion ICP >25 mm Hg (beta = 0.16 p = 0.004). rs150391806 heterozygotes had higher mean (beta = 7.2 mm Hg, p = 0.042) and peak (beta = 28.9 mm Hg, p = 0.0015) ICPs. rs8104571, rs150391806, and 34 associated proxy SNPs in linkage-disequilibrium clustered downstream. This region encodes TRPM4's channel pore and a region postulated to juxtapose SUR1 sequences encoded by an ABCC8 DNA segment containing previously identified relevant SNPs. There was an interaction effect on ICP between rs8104571 and a cluster of predictive ABCC8 SNPs (rs2237982, rs2283261, rs11024286). Although not significant in univariable or a basic multivariable model, in an expanded model additionally accounting for injury pattern, computed tomographic (CT) appearance, and intracranial hypertension, heterozygous rs8104571 was associated with favorable 6 month GOS (odds ratio [OR] = 16.7, p = 0.007951). This trend persisted in a survivor-only subcohort (OR = 20.67, p = 0.0168). In this cohort, two TRPM4 SNPs predicted increased ICP with large effect sizes. Both clustered downstream, spanning a region encoding the channel pore and interacting with SUR1. If validated, this may guide risk stratification and eventually inform treatment-responder classification for SUR1-TRPM4 inhibition in TBI. Larger studies are warranted.	[Jha, Ruchira M.; Shutter, Lori A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Desai, Shashvat M.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Zusman, Benjamin E.; Puccio, Ava M.; Okonkwo, David O.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Park, Seo-Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesia, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Kochanek, Patrick M.; Conley, Yvette P.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA; [Park, Seo-Young] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15261 USA; [Koleck, Theresa A.] Columbia Univ, Sch Nursing, New York, NY USA; [Kochanek, Patrick M.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA 15261 USA	Jha, RM (corresponding author), Univ Pittsburgh, 3550 Terrace St,Scaife Hall, Pittsburgh, PA 15261 USA.	jharm3@upmc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628; Conley, Yvette/0000-0002-1784-6067	National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS101036]; NIH/NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R00 NR013176, T32NR007969, R01NR013342]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 NS30318]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS087978-01]; University of Pittsburgh Physicians Foundation Award; University of Pittsburgh School of Medicine Dean's Faculty Advancement Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS087978, K23NS101036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R00NR013176, T32NR007969] Funding Source: NIH RePORTER	The authors are grateful to funding from following grants: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) K23NS101036 (R.M.J.), NIH/NINR R00 NR013176 (A.M.P.), NIH P50 NS30318 (D.O.O.), NIH/NINR T32NR007969 (T.A.K.), NIH/NINDS 1R01NS087978-01 (P.M.K.), NIH/NINR R01NR013342 (Y.P.C.), University of Pittsburgh Physicians Foundation Award (R.M.J.), and University of Pittsburgh School of Medicine Dean's Faculty Advancement Award (R.M.J.).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Autzen HE, 2018, SCIENCE, V359, P228, DOI 10.1126/science.aar4510; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bomba L, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1212-4; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Castro L, 2019, J NEUROTRAUM, V36, P165, DOI 10.1089/neu.2017.5619; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Earley S, 2013, PFLUG ARCH EUR J PHY, V465, P1223, DOI 10.1007/s00424-013-1250-z; Gorse KM, 2018, J NEUROTRAUM, V35, P1694, DOI 10.1089/neu.2017.5275; Jha R, 2015, J NEUROTRAUM, V32, pA119; Jha RM, 2018, J NEUROTRAUM, V35, P2125, DOI 10.1089/neu.2016.4696; Jha RM, 2018, CRIT CARE MED, V46, P1792, DOI 10.1097/CCM.0000000000003361; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Jha RM, 2017, NEUROCRIT CARE, V26, P213, DOI 10.1007/s12028-016-0309-z; Jha Ruchira M, 2017, Crit Care Med, V45, pe255, DOI 10.1097/CCM.0000000000002079; Jha RM, 2018, J NEUROL NEUROSUR PS, V89, P1152, DOI 10.1136/jnnp-2017-317741; Khalili H, 2017, WORLD NEUROSURG, V101, P130, DOI 10.1016/j.wneu.2017.01.103; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Li NN, 2017, CELL, V168, P101, DOI 10.1016/j.cell.2016.12.028; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Lin ZZ, 2017, NEUROPHARMACOLOGY, V121, P1, DOI 10.1016/j.neuropharm.2017.04.016; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Lu YC, 2010, ATHEROSCLEROSIS, V213, P200, DOI 10.1016/j.atherosclerosis.2010.08.053; Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402; Mall T, 2016, BIOINFORMATICS, V32, P2499, DOI 10.1093/bioinformatics/btw068; Martinez-Valverde T, 2015, J NEUROTRAUM, V32, P1478, DOI 10.1089/neu.2014.3706; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Narum SR, 2006, CONSERV GENET, V7, P783, DOI 10.1007/s10592-005-9056-y; Nishimura J, 2014, NEW ENGL J MED, V370, P632, DOI 10.1056/NEJMoa1311084; Nissen SE, 2018, JAMA CARDIOL, V3, P401, DOI 10.1001/jamacardio.2018.0569; Omasits U, 2014, BIOINFORMATICS, V30, P884, DOI 10.1093/bioinformatics/btt607; Osier ND, 2017, J NEUROTRAUM, V34, P86, DOI 10.1089/neu.2015.4343; Parolo S, 2017, GENES NUTR, V12, DOI 10.1186/s12263-017-0579-x; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Schwamm LH, 2014, NEW ENGL J MED, V371, P2522, DOI 10.1056/NEJMe1412951; Shah S, 2016, SEMIN NEUROL, V36, P502, DOI 10.1055/s-0036-1592109; Sheth KN, 2016, LANCET NEUROL, V15, P1160, DOI 10.1016/S1474-4422(16)30196-X; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Stallmeyer B, 2012, HUM MUTAT, V33, P109, DOI 10.1002/humu.21599; Stenson PD, 2017, HUM GENET, V136, P665, DOI 10.1007/s00439-017-1779-6; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Winkler EA, 2017, J CLIN NEUROSCI, V35, P109, DOI 10.1016/j.jocn.2016.09.017; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157; Yue JK, 2017, NEUROGENETICS, V18, P29, DOI 10.1007/s10048-016-0500-6; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue ZC, 2015, AM J PHYSIOL-HEART C, V308, pH157, DOI 10.1152/ajpheart.00457.2014; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	67	11	11	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2019	36	11					1804	1817		10.1089/neu.2018.6124			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IB1EQ	WOS:000470007600011	30484364	Green Published			2021-06-18	
J	Shahror, RA; Ali, AAA; Wu, CC; Chiang, YH; Chen, KY				Shahror, Rami Ahmad; Ali, Ahmed Atef Ahmed; Wu, Chung-Che; Chiang, Yung-Hsiao; Chen, Kai-Yun			Enhanced Homing of Mesenchymal Stem Cells Overexpressing Fibroblast Growth Factor 21 to Injury Site in a Mouse Model of Traumatic Brain Injury	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						regenerative medicine; mesenchymal stems cells; fibroblast growth factor 21; traumatic brain injury; cell tracking; cell homing; cell therapy; gene therapy	STROMAL CELLS; VALPROIC ACID; MIGRATION; FGF21; TRACKING; NANOPARTICLES; OPTIMIZATION; EXPRESSION; CONTRAST; RECOVERY	Mesenchymal stem cells (MSCs) are emerging as a potential therapeutic intervention for brain injury due to their neuroprotective effects and safe profile. However, the homing ability of MSCs to injury sites still needs to be improved. Fibroblast Growth Factor 21 (FGF21) was recently reported to enhance cells migration in different cells type. In this study, we investigated whether MSCs that overexpressing FGF21 (MSC-FGF21) could exhibit enhanced homing efficacy in brain injury. We used novel Molday IONEverGreen (MIEG) as cell labeling probe that enables a non-invasive, high-sensitive and real-time MRI tracking. Using a mouse model of traumatic brain injury (TBI), MIEG labeled MSCs were transplanted into the contralateral lateral ventricle followed by real-time MRI tracking. FGF21 retained MSC abilities of proliferation and morphology. MSC-FGF21 showed significantly greater migration in transwell assay compared to control MSC. MIEG labeling showed no effects on MSCs' viability, proliferation and differentiation. Magnetic resonance imaging (MRI) revealed that FGF21 significantly enhances the homing of MSC toward injury site. Histological analysis further confirmed the MRI findings. Taken together, these results show that FGF21 overexpression and MIEG labeling of MSC enhances their homing abilities and enables non-invasive real time tracking of the transplanted cells, provides a promising approach for MSC based therapy and tracking in TBI.	[Shahror, Rami Ahmad; Chiang, Yung-Hsiao; Chen, Kai-Yun] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Neural Regenerat Med, Taipei 110, Taiwan; [Shahror, Rami Ahmad; Chiang, Yung-Hsiao; Chen, Kai-Yun] Natl Hlth Res Inst, Taipei 110, Taiwan; [Shahror, Rami Ahmad; Wu, Chung-Che; Chiang, Yung-Hsiao; Chen, Kai-Yun] Taipei Med Univ, Ctr Neurotrauma & Neuroregenerat, Taipei 110, Taiwan; [Shahror, Rami Ahmad; Ali, Ahmed Atef Ahmed; Wu, Chung-Che; Chiang, Yung-Hsiao; Chen, Kai-Yun] Taipei Med Univ, TMU Neurosci Res Ctr, Taipei 110, Taiwan; [Ali, Ahmed Atef Ahmed] Taipei Med Univ Hosp, Dept Med Res, Translat Lab, Taipei 110, Taiwan; [Wu, Chung-Che; Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Neurosurg, Taipei 110, Taiwan; [Wu, Chung-Che; Chiang, Yung-Hsiao] Taipei Med Univ, Coll Med, Sch Med, Dept Surg, Taipei 110, Taiwan	Chen, KY (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Neural Regenerat Med, Taipei 110, Taiwan.; Chen, KY (corresponding author), Natl Hlth Res Inst, Taipei 110, Taiwan.; Chen, KY (corresponding author), Taipei Med Univ, Ctr Neurotrauma & Neuroregenerat, Taipei 110, Taiwan.; Chen, KY (corresponding author), Taipei Med Univ, TMU Neurosci Res Ctr, Taipei 110, Taiwan.	rami.shahror@yahoo.com; ahmed.atef@tmu.edu.tw; johnwu@tmu.edu.tw; ychiang@tmu.edu.tw; kychen08@tmu.edu.tw		Ali, Ahmed/0000-0002-0375-6511; Shahror, Rami/0000-0001-6403-9404	Ministry of Science and Technology Grants, Taiwan [MOST 104-2923-B-038-004 -MY2, MOST 107-2314-B-038-063, MOST 107-2314-B-038-042]; Taipei Medical University [TMU 105-AE1-B03, TMU 106-5400-004-400, TMU 106-5310-001-400, DP2-107-21121-01-N-05, DP2-108-21121-01-N-05-01]	This study was supported by the Ministry of Science and Technology Grants, Taiwan (MOST 104-2923-B-038-004 -MY2, MOST 107-2314-B-038-063, and MOST 107-2314-B-038-042) and Taipei Medical University (TMU 105-AE1-B03, TMU 106-5400-004-400, TMU 106-5310-001-400, DP2-107-21121-01-N-05 and DP2-108-21121-01-N-05-01).	Aertker BM, 2016, EXP NEUROL, V275, P411, DOI 10.1016/j.expneurol.2015.01.008; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Berman SC, 2011, MAGN RESON MED, V65, P564, DOI 10.1002/mrm.22613; Berman SMC, 2013, MAGN RESON MED, V69, P255, DOI 10.1002/mrm.24216; Betzer O, 2015, SCI REP-UK, V5, DOI 10.1038/srep15400; Billotey C, 2003, MAGN RESON MED, V49, P646, DOI 10.1002/mrm.10418; Chen J, 2018, J NEUROTRAUM, V35, P2091, DOI 10.1089/neu.2017.5271; Cox CS, 2017, STEM CELLS, V35, P1065, DOI 10.1002/stem.2538; De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Guzman R, 2007, P NATL ACAD SCI USA, V104, P10211, DOI 10.1073/pnas.0608519104; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Himmelreich U, 2008, MINIM INVASIV THER, V17, P132, DOI 10.1080/13645700801969873; Hu SQ, 2017, EXP THER MED, V14, P771, DOI 10.3892/etm.2017.4564; Huang L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt519; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kim SJ, 2016, CONTRAST MEDIA MOL I, V11, P55, DOI 10.1002/cmmi.1658; Kuroda M, 2017, J CLIN INVEST, V127, P3502, DOI 10.1172/JCI94337; Leng Y, 2015, MOL PSYCHIATR, V20, P215, DOI 10.1038/mp.2013.192; Lewin M, 2000, NAT BIOTECHNOL, V18, P410; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Li YM, 2017, AM J TRANSL RES, V9, P5299; Linares GR, 2016, EXP NEUROL, V281, P81, DOI 10.1016/j.expneurol.2016.04.003; Ma L, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4837503; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mishra SK, 2015, EXP CELL RES, V339, P427, DOI 10.1016/j.yexcr.2015.11.010; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood-2010-10-311464; Song YH, 2016, MOL MED REP, V13, P3619, DOI 10.3892/mmr.2016.4942; TAYLOR A, 2014, J RURAL COMMUNITY DE, V9, DOI DOI 10.1371/journal.pone.0100259; Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang X, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00032; Xu J, 2009, AM J PHYSIOL-ENDOC M, V297, pE1105, DOI 10.1152/ajpendo.00348.2009; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	42	11	12	0	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	JUN 1	2019	20	11							2624	10.3390/ijms20112624			19	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	IE8OX	WOS:000472634100018	31142002	DOAJ Gold, Green Published			2021-06-18	
J	Suarez, JI; Sheikh, MK; Macdonald, RL; Amin-Hanjani, S; Brown, RD; Manoel, ALD; Derdeyn, CP; Etminan, N; Keller, E; Leroux, PD; Mayer, SA; Morita, A; Rinkel, G; Rufennacht, D; Stienen, MN; Torner, J; Vergouwen, MDI; Wong, GKC; Bijlenga, P; Ko, N; McDougall, CG; Mocco, J; Murayama, Y; Werner, MJH; Damani, R; Broderick, J; Dhar, R; Jauch, EC; Kirkpatrick, PJ; Martin, RH; Mocco, J; Muehlschlegel, S; Mutoh, T; Nyquist, P; Olson, D; Mejia-Mantilla, JH; Manoel, ALDO; van der Jagt, M; Bambakidis, NC; Brophy, G; Bulsara, K; Claassen, J; Connolly, ES; Hoffer, SA; Hoh, BL; Holloway, RG; Kelly, A; Mayer, S; Nakaji, P; Rabinstein, A; Suarez, JI; Vajkoczy, P; Vergouwen, MDI; Woo, H; Zipfel, GJ; Keller, E; Chou, S; Dore, S; Dumont, AS; Gunel, M; Kasuya, H; Roederer, A; Ruigrok, Y; Vespa, PM; Sarrafzadeh-Khorrasani, AS; Huston, J; Krings, T; Lanzino, G; Meyers, PM; Rinkel, G; Rufennacht, D; Wintermark, M; Torner, J; Wong, GKC; Broderick, J; Daly, J; Ogilvy, C; Rhoney, DH; Roos, YB; Siddiqui, A; Etminan, N; Rinkel, G; Hackenberg, K; Algra, A; Frosen, J; Hasan, D; Juvela, S; Langer, DJ; Meyers, PM; Morita, A; Salman, RA; Stienen, MN; Vergouwen, MDI; Hanggi, D; Schweizer, T; Visser-Meily, J; Amos, L; Ludet, C; Moy, C; Odenkirchen, J; Ala'i, S; Esterlitz, J; Joseph, K; Sheikh, M				Suarez, Jose I.; Sheikh, Muniza K.; Macdonald, R. Loch; Amin-Hanjani, Sepideh; Brown, Robert D., Jr.; Manoel, Airton Leonardo de Oliveira; Derdeyn, Colin P.; Etminan, Nima; Keller, Emanuela; Leroux, Peter D.; Mayer, Stephan A.; Morita, Akio; Rinkel, Gabriel; Rufennacht, Daniel; Stienen, Martin N.; Torner, James; Vergouwen, Mervyn D. I.; Wong, George K. C.; Bijlenga, Philippe; Ko, Nerissa; McDougall, Cameron G.; Mocco, J.; Murayama, Yuuichi; Werner, Marieke J. H.; Damani, Rahul; Broderick, Joseph; Dhar, Raj; Jauch, Edward C.; Kirkpatrick, Peter J.; Martin, Renee H.; Mocco, J.; Muehlschlegel, Susanne; Mutoh, Tatsushi; Nyquist, Paul; Olson, Daiwai; Mejia-Mantilla, Jorge H.; Manoel, Airton Leonardo de Oliveira; van der Jagt, Mathieu; Bambakidis, Nicholas C.; Brophy, Gretchen; Bulsara, Ketan; Claassen, Jan; Connolly, E. Sander; Hoffer, S. Alan; Hoh, Brian L.; Holloway, Robert G.; Kelly, Adam; Mayer, Stephan; Nakaji, Peter; Rabinstein, Alejandro; Suarez, Jose I.; Vajkoczy, Peter; Vergouwen, Mervyn D. I.; Woo, Henry; Zipfel, Gregory J.; Keller, Emanuela; Chou, Sherry; Dore, Sylvain; Dumont, Aaron S.; Gunel, Murat; Kasuya, Hidetoshi; Roederer, Alexander; Ruigrok, Ynte; Vespa, Paul M.; Sarrafzadeh-Khorrasani, Asita Simone; Huston, John, III; Krings, Timo; Lanzino, Giuseppe; Meyers, Philip M.; Rinkel, Gabriel; Rufennacht, Daniel; Wintermark, Max; Torner, James; Wong, George K. C.; Broderick, Joseph; Daly, Janis; Ogilvy, Christopher; Rhoney, Denise H.; Roos, Y. B.; Siddiqui, Adnan; Etminan, Nima; Rinkel, Gabriel; Hackenberg, Katharina; Algra, Ale; Frosen, Juhanna; Hasan, David; Juvela, Seppo; Langer, David J.; Meyers, Philip M.; Morita, Akio; Salman, Rustam Al-Shahi; Stienen, Martin N.; Vergouwen, Mervyn D. I.; Hanggi, Daniel; Schweizer, Tom; Visser-Meily, Johanna; Amos, Liz; Ludet, Christophe; Moy, Claudia; Odenkirchen, Joanne; Ala'i, Sherita; Esterlitz, Joy; Joseph, Kristen; Sheikh, Muniza		Unruptured Intracranial Aneurysms	Common Data Elements for Unruptured Intracranial Aneurysms and Subarachnoid Hemorrhage Clinical Research: A National Institute for Neurological Disorders and Stroke and National Library of Medicine Project	NEUROCRITICAL CARE			English	Article						Subarachnoid hemorrhage; Unruptured intracranial aneurysms; Common data elements; Clinical trials; Observational studies; Outcomes	TRAUMATIC BRAIN-INJURY; GRADING SCALES; RECOMMENDATIONS; IMPLEMENTATION; PREVALENCE	ObjectivesThe goal for this project was to develop a comprehensive set of common data elements (CDEs), data definitions, case report forms and guidelines for use in unruptured intracranial aneurysm (UIA) and subarachnoid hemorrhage (SAH) clinical research, as part of a new joint effort between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Library of Medicine of the US National Institutes of Health. These UIA and SAH CDEs will join several other neurological disease-specific CDEs that have already been developed and are available for use by research investigators.MethodsA Working Group (WG) divided into eight sub-groups and a Steering Committee comprised of international UIA and SAH experts reviewed existing NINDS CDEs and instruments, created new elements when needed and provided recommendations for UIA and SAH clinical research. The recommendations were compiled, internally reviewed by the entire UIA and SAH WG and posted online for 6weeks for external public comments. The UIA and SAH WG and the NINDS CDE team reviewed the final version before posting the SAH Version 1.0 CDE recommendations.ResultsThe NINDS UIA and SAH CDEs and supporting documents are publicly available on the NINDS CDE (https://www.commondataelements.ninds.nih.gov/#page=Default) and NIH Repository (https://cde.nlm.nih.gov/home) websites. The recommendations are organized into domains including Participant Characteristics and Outcomes and Endpoints.ConclusionDissemination and widespread use of CDEs can facilitate UIA and SAH clinical research and clinical trial design, data sharing, and analyses of observational retrospective and prospective data. It is vital to maintain an international and multidisciplinary collaboration to ensure that these CDEs are implemented and updated when new information becomes available.	[Suarez, Jose I.] Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, 1800 Orleans St,Sheikh Zayed Bldg,3014C, Baltimore, MD 21287 USA; [Sheikh, Muniza K.] Emmes Corp, Rockville, MD USA; [Macdonald, R. Loch; Manoel, Airton Leonardo de Oliveira] Univ Toronto, Toronto, ON, Canada; [Amin-Hanjani, Sepideh] Univ Illinois, Chicago, IL USA; [Brown, Robert D., Jr.] Mayo Clin, Rochester, MN USA; [Derdeyn, Colin P.; Torner, James] Univ Iowa, Iowa City, IA USA; [Etminan, Nima] Univ Duesseldorf, Dusseldorf, Germany; [Keller, Emanuela; Stienen, Martin N.] Univ Zurich, Zurich, Switzerland; [Leroux, Peter D.] Main Line Hlth Care, Wynnewood, PA USA; [Mayer, Stephan A.] Henry Ford Hosp, Detroit, MI 48202 USA; [Morita, Akio] Nippon Med Sch, Tokyo, Japan; [Rinkel, Gabriel; Vergouwen, Mervyn D. I.] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht, Netherlands; [Rufennacht, Daniel] Klin Hirslanden, Zurich, Switzerland; [Wong, George K. C.] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Suarez, Jose I.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Macdonald, R. Loch] Univ Toronto, Toronto, ON, Canada; [Amin-Hanjani, Sepideh] Univ Illinois, Chicago, IL USA; [Brown, Robert D., Jr.] Mayo Clin, Rochester, MN USA; [Manoel, Airton Leonardo de Oliveira] Univ Toronto, Toronto, ON, Canada; [Derdeyn, Colin P.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Etminan, Nima] Univ Hosp Mannheim, Mannheim, Germany; [Keller, Emanuela] Univ Zurich, Zurich, Switzerland; [Leroux, Peter D.] Main Line Hlth, Wynnewood, PA USA; [Mayer, Stephan] Henry Ford Hosp, Detroit, MI 48202 USA; [Morita, Akio] Nippon Med Sch, Tokyo, Japan; [Rinkel, Gabriel] Univ Med Ctr, Utrecht, Netherlands; [Rufennacht, Daniel] Klin Hirslanden, Zurich, Switzerland; [Stienen, Martin N.] Univ Zurich, Zurich, Switzerland; [Torner, James] Univ Iowa, Iowa City, IA USA; [Vergouwen, Mervyn D. I.] Univ Med Ctr, Utrecht, Netherlands; [Wong, George K. C.] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Brown, Robert D., Jr.] Mayo Clin, Rochester, MN USA; [Morita, Akio] Nippon Med Sch, Tokyo, Japan; [Bijlenga, Philippe] Geneva Univ Hosp, Geneva, Switzerland; [Mayer, Stephan] Henry Ford Hosp, Detroit, MI USA; [Suarez, Jose I.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Damani, Rahul] Baylor Coll Med, Houston, TX 77030 USA; [Amin-Hanjani, Sepideh] Univ Illinois, Chicago, IL USA; [Manoel, Airton Leonardo de Oliveira] Univ Toronto, Toronto, ON, Canada; [van der Jagt, Mathieu] Erasmus MC, Rotterdam, Netherlands; [Keller, Emanuela] Univ Zurich, Zurich, Switzerland; [Macdonald, R. Loch] Univ Toronto, Toronto, ON, Canada; [Derdeyn, Colin P.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Etminan, Nima] Univ Hosp Mannheim, Mannheim, Germany; [Hackenberg, Katharina] Univ Hosp Mannheim, Mannheim, Germany; [Torner, James] Univ Iowa, Iowa City, IA USA; [Wong, George K. C.] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Etminan, Nima] Univ Hosp Mannheim, Mannheim, Germany; [Rinkel, Gabriel] Univ Med Ctr, Utrecht, Netherlands; [Hackenberg, Katharina] Univ Hosp Mannheim, Mannheim, Germany; [Stienen, Martin N.] Univ Zurich, FEBNS, Zurich, Switzerland; [Vergouwen, Mervyn D. I.] Univ Med Ctr, Utrecht, Netherlands; [Amos, Liz] Natl Lib Med, Natl Informat Ctr Hlth Serv Res & Hlth Care Techn, Bethesda, MD USA; [Ludet, Christophe] Natl Lib Med, Bethesda, MD USA; [Moy, Claudia; Odenkirchen, Joanne] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Ala'i, Sherita; Esterlitz, Joy; Joseph, Kristen; Sheikh, Muniza] Emmes Corp, Rockville, MD USA	Suarez, JI (corresponding author), Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, 1800 Orleans St,Sheikh Zayed Bldg,3014C, Baltimore, MD 21287 USA.	jsuarez5@jhmi.edu	Claassen, Jan/AAA-5451-2020; Wong, George Kwok Chu/L-4344-2016; Dore, Sylvain/AAG-1470-2020; Olson, DaiWai/I-5932-2019; de Oliveira Manoel, Airton Leonardo/C-4724-2018	Olson, DaiWai/0000-0002-9280-078X; de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013; Derdeyn, Colin/0000-0002-5932-2683; Keller, Emanuela, Elisabeth, Sophia/0000-0002-7560-7574	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HHSN271201200034C]	Logistical support for this project was provided in part through NIH Contract HHSN271201200034C, the Intramural Research Program of the NIH, NLM, The Neurocritical Care Society and the CHI Baylor St Luke's Medical Center in Houston, TX.	Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Biering-Sorensen F, 2015, SPINAL CORD, V53, P265, DOI 10.1038/sc.2014.246; Bijlenga P, 2019, NEUROCRIT CARE; Chou SH-Y, 2019, NEUROCRIT CARE; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Damani R, 2019, NEUROCRIT CARE; de Oliveira Manoel AL, 2019, NEUROCRIT CARE; Degen LAR, 2011, STROKE, V42, P1546, DOI 10.1161/STROKEAHA.110.601211; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980; Hackenberg KAM, 2019, NEUROCRIT CARE; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Jaja BNR, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5745; Jaja BNR, 2013, NEUROCRIT CARE, V18, P143, DOI 10.1007/s12028-012-9792-z; Johnston SC, 1998, NEUROLOGY, V50, P1413, DOI 10.1212/WNL.50.5.1413; Kirkpatrick PJ, 2014, LANCET NEUROL, V13, P666, DOI 10.1016/S1474-4422(14)70084-5; Loring DW, 2011, EPILEPSIA, V52, P1186, DOI 10.1111/j.1528-1167.2011.03018.x; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Mees SMD, 2012, LANCET, V380, P44, DOI 10.1016/S0140-6736(12)60724-7; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; National Institute of Neurological Disorders and Stroke, 2018, NINDS COMM DAT EL; National Library of Medicine, 2019, NIH CDE REP; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Roos YBWEM, 2002, STROKE, V33, P1595, DOI 10.1161/01.STR.0000016401.49688.2F; Rosen DS, 2005, NEUROCRIT CARE, V2, P110, DOI 10.1385/NCC:2:2:110; Saver JL, 2012, STROKE, V43, P967, DOI 10.1161/STROKEAHA.111.634352; Sheehan J, 2016, CLIN TRIALS, V13, P671, DOI 10.1177/1740774516653238; Siironen J, 2003, J NEUROSURG, V99, P953, DOI 10.3171/jns.2003.99.6.0953; Stienen MN, 2019, NEUROCRIT CARE; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Wong GKC, 2019, NEUROCRIT CARE; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	36	11	11	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2019	30			1			4	19		10.1007/s12028-019-00723-6			16	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	IF3IS	WOS:000472974700002	31087257				2021-06-18	
J	Xia, DY; Zhai, XF; Wang, HL; Chen, ZY; Fu, CJ; Zhu, MH				Xia, Dayong; Zhai, Xiaofu; Wang, Honglian; Chen, Zhiyong; Fu, Chuanjing; Zhu, Meihua			Alpha lipoic acid inhibits oxidative stress-induced apoptosis by modulating of Nrf2 signalling pathway after traumatic brain injury	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						ALA; neuronal apoptosis; Nrf2; traumatic brain injury	GENE-EXPRESSION; MICE; SUPPLEMENTATION; BREVISCAPINE; RATS	Alpha lipoic acid (ALA) is a powerful antioxidant which has been widely used in the treatment of different system diseases, such as cardiovascular and cerebrovascular diseases. But, there are few studies that refer to protective effects and potential mechanisms on traumatic brain injury (TBI). This study was carried out to investigate the neuroprotective effect following TBI and illuminate the underlying mechanism. Weight drop-injured model in rats was induced by weight-drop. ALA was administrated via intraperitoneal injection after TBI. Neurologic scores were examined following several tests. Neurological score was performed to measure behavioural outcomes. Nissl staining and TUNEL were performed to evaluate the neuronal apoptosis. Western blotting was engaged to analyse the protein content of the Nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream protein factors, including hemeoxygenase-1 (HO-1) and quinine oxidoreductase-1 (NQO1). ALA treatment alleviated TBI-induced neuron cell apoptosis and improved neurobehavioural function by up-regulation of Nrf2 expression and its downstream protein factors after TBI. This study presents new perspective of the mechanisms responsible for the neuronal apoptosis of ALA, with possible involvement of Nrf2 pathway.	[Xia, Dayong] Wannan Med Coll, Affiliated Hosp 1, Dept Neurosurg, Wuhu, Anhui, Peoples R China; [Zhai, Xiaofu] Xuzhou Med Coll, Huaian Peoples Hosp 2, Dept Neurosurg, Huaian, Jiangsu, Peoples R China; [Wang, Honglian] Huaian Fourth Peoples Hosp, Dept Radiol, Huaian, Jiangsu, Peoples R China; [Chen, Zhiyong; Zhu, Meihua] Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Anesthesiol, Nanjing 210017, Jiangsu, Peoples R China; [Fu, Chuanjing] Jiangsu Hosp Tradit Chinese Med, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China	Zhu, MH (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Anesthesiol, Nanjing 210017, Jiangsu, Peoples R China.; Fu, CJ (corresponding author), Jiangsu Hosp Tradit Chinese Med, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.	zhu_zmh@yeah.net; fcj_5150@163.com		Xia, Dayong/0000-0002-3777-7038	Natural Science Research Project in Higher Education of Anhui Province [KJ2018A0253]	The Natural Science Research Project in Higher Education of Anhui Province, Grant/Award Number: No. KJ2018A0253	Ambrosi N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010102; Bi W, 2018, FOOD FUNCT, V9, P2809, DOI 10.1039/c8fo00054a; El-Beshbishy HA, 2011, EUR J PHARMACOL, V668, P278, DOI 10.1016/j.ejphar.2011.06.051; El-Senousey HK, 2018, POULTRY SCI, V97, P30, DOI 10.3382/ps/pex298; Gao F, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00357; Gao JL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00289; Giammattei L, 2018, WORLD NEUROSURG, V116, P322, DOI 10.1016/j.wneu.2018.05.176; Gumus S, 2010, ARCH MED SCI, V6, P848, DOI 10.5114/aoms.2010.19290; Guven A, 2008, SURG TODAY, V38, P1029, DOI 10.1007/s00595-007-3752-9; Hu Y, 2018, ENVIRON TOXICOL PHAR, V62, P79, DOI 10.1016/j.etap.2018.05.012; Huerta AE, 2017, BIOFACTORS, V43, P117, DOI 10.1002/biof.1317; Jiang CS, 2018, J ENZYM INHIB MED CH, V33, P833, DOI 10.1080/14756366.2018.1461856; Jiang L, 2017, NEURAL REGEN RES, V12, P90, DOI 10.4103/1673-5374.198990; Kinoshita T, 2018, WORLD NEUROSURG, V118, pE792, DOI 10.1016/j.wneu.2018.07.053; Lin YZ, 2016, J SURG RES, V203, P268, DOI 10.1016/j.jss.2016.02.013; Ozbal S, 2015, BIOTECH HISTOCHEM, V90, P206, DOI 10.3109/10520295.2014.977950; Ozbeyli D, 2017, CLIN EXP PHARMACOL P, V44, P62, DOI 10.1111/1440-1681.12682; Piechota-Polanczyk A, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2028936; Ren F, 2018, CRYOBIOLOGY; Silva MD, 2018, MOLECULES, V23, DOI 10.3390/molecules23071803; Sun X, 2018, ENVIRON TOXICOL PHAR, V60, P110, DOI 10.1016/j.etap.2018.04.016; Uchendu C, 2018, ENVIRON SCI POLLUT R, V25, P19605, DOI 10.1007/s11356-018-2185-x; Vidovic B, 2017, J MED FOOD, V20, P79, DOI 10.1089/jmf.2016.0070; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Xia XM, 2014, INT IMMUNOPHARMACOL, V22, P293, DOI 10.1016/j.intimp.2014.07.008; Zhang DF, 2016, PAK J PHARM SCI, V29, P1365; Zhang L, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00190; Zhao XJ, 2018, REDOX BIOL, V18, P124, DOI 10.1016/j.redox.2018.07.002	28	11	11	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		1582-4934		J CELL MOL MED	J. Cell. Mol. Med.	JUN	2019	23	6					4088	4096		10.1111/jcmm.14296			9	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	IC0OL	WOS:000470659500028	30989783	DOAJ Gold, Green Published			2021-06-18	
J	Vest, V; Bernardo-Colon, A; Watkins, D; Kim, B; Rex, TS				Vest, Victoria; Bernardo-Colon, Alexandra; Watkins, Dexter; Kim, Bohan; Rex, Tonia S.			Rapid Repeat Exposure to Subthreshold Trauma Causes Synergistic Axonal Damage and Functional Deficits in the Visual Pathway in a Mouse Model	JOURNAL OF NEUROTRAUMA			English	Article						axon degeneration; blast injury; CNS; neurotrauma; interinjury interval; optic nerve; repeat injury	CLOSED-HEAD MODEL; BRAIN-INJURY; OPTIC-NERVE; RETINAL DAMAGE; BLAST INJURY; EYE TRAUMA; TIME; NEUROINFLAMMATION; ENCEPHALOPATHY; CONCUSSION	We examined the effect of repeat exposure to a non-damaging insult on central nervous system axons using the optic projection as a model. The optic projection is attractive because its axons are spatially separated from the cell bodies, it is easily accessible, it is composed of long axons, and its function can be measured. We performed closed-system ocular neurotrauma in C57Bl/6 mice using bursts of 15 or 26-psi (pounds per square inch) overpressure air that caused no gross damage. We quantified the visual evoked potential (VEP) and total and degenerative axons in the optic nerve. Repeat exposure to a 15-psi air blast caused more axon damage and vision loss than a single exposure to a 26-psi air blast. However, an increased VEP latency was detected in both groups. Exposure to three 15-psi air blasts separated by 0.5 sec caused 15% axon degeneration at 2 weeks. In contrast, no axon degeneration above sham levels was detected when the interinjury interval was increased to 10 min. Exposure to 15-psi air blasts once a day for 6 consecutive days caused 3% axon degeneration. Therefore, repeat mild trauma within an interinjury interval of 1 min or less causes synergistic axon damage, whereas mild trauma repeated at a longer interinjury interval causes additive, cumulative damage. The synergistic damage may underlie the high incidence of traumatic brain injury and traumatic optic neuropathy in blast-injured service members given that explosive blasts are multiple injury events that occur in a very short time span. This study also supports the use of the VEP as a biomarker for traumatic optic neuropathy.	[Vest, Victoria; Bernardo-Colon, Alexandra; Rex, Tonia S.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 11435 Med Res Bldg 4,2213 Garland Ave, Nashville, TN 37232 USA; [Kim, Bohan; Rex, Tonia S.] Vanderbilt Univ, Sch Med, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA; [Watkins, Dexter] Vanderbilt Univ, Dept Mech Engn, Nashville, TN 37232 USA	Rex, TS (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 11435 Med Res Bldg 4,2213 Garland Ave, Nashville, TN 37232 USA.	tonia.rex@vanderbilt.edu		Kim, Bohan/0000-0001-9277-3040	DoDUnited States Department of Defense [W81XWH-15-1-0096, W81XWH-17-2-0055]; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY022349]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 NS094595]; Potocsnak Discovery Grant in Regenerative Medicine; Ayers Foundation Regenerative Visual Neuroscience Pilot Grant; Jones Gift; Research Prevent Blindness, Inc.;  [P30EY008126]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022349, P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094595] Funding Source: NIH RePORTER	The authors thank Dr. Robert Webster for helpful discussions. Support was provided by: DoD W81XWH-15-1-0096 and W81XWH-17-2-0055, NEI R01 EY022349, NIA R01 NS094595, Potocsnak Discovery Grant in Regenerative Medicine, Ayers Foundation Regenerative Visual Neuroscience Pilot Grant, Jones Gift, and P30EY008126, and Research Prevent Blindness, Inc.	Abbott CJ, 2013, BIOMED OPT EXPRESS, V4, P364, DOI 10.1364/BOE.4.000364; Bernardo-Colon A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1061-4; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bond WS, 2016, MOL THER, V24, P230, DOI 10.1038/mt.2015.198; Bricker-Anthony C, 2017, OPTOMETRY VISION SCI, V94, P20, DOI 10.1097/OPX.0000000000000898; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.01146.x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Curreri AG, 2009, CLIN SPORT MED, V28, P591, DOI 10.1016/j.csm.2009.07.004; Daniel S, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0069-y; Defense & Veterans Brain Injury Center, 2017, DOD WORLDW NUMB TBI; Doig RLO, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0380-1; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fehily B, 2017, CELL TRANSPLANT, V26, P1131, DOI 10.1177/0963689717714092; Frati A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122600; Gaetz M, 2000, BRAIN INJURY, V14, P815; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Hilber David J, 2011, MSMR, V18, P2; Hines-Beard J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0499-5; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Jamnia N, 2017, J NEUROTRAUM, V34, P1351, DOI 10.1089/neu.2016.4517; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Leong D, 2018, J NEURO-OPHTHALMOL, V38, P285, DOI 10.1097/WNO.0000000000000572; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; MAHAPATRA A K, 1991, Indian Journal of Ophthalmology, V39, P20; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MCGWIN G, 2001, INVEST OPHTH VIS SCI, V47, P521; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Phillips BN, 2013, RETINA-J RET VIT DIS, V33, P371, DOI 10.1097/IAE.0b013e318261a726; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Sarno S, 2000, VISION RES, V40, P3029, DOI 10.1016/S0042-6989(00)00137-1; Selwyn RG, 2016, J NEUROTRAUM, V33, P1479, DOI 10.1089/neu.2015.4129; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Solomon G, 2018, DEV NEUROPSYCHOL, V43, P279, DOI 10.1080/87565641.2018.1447575; Sosa MAG, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0483-z; Swanson TM, 2017, PUBLIC HEALTH REP, V132, P251, DOI 10.1177/0033354916687748; Tabatabaei SA, 2011, CLIN OPHTHALMOL, V5, P1021, DOI 10.2147/OPTH.S21409; Thomsen G., 2016, J TRAUMA ACUTE CARE, V82, P1039; Thomsen GM, 2016, J TRAUMA ACUTE CARE, V81, P1070, DOI 10.1097/TA.0000000000001248; Turner RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00222; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Urosevich TG, 2018, MIL MED, V183, pE564, DOI 10.1093/milmed/usy102; Vlasov A, 2015, J TRAUMA ACUTE CARE, V79, pS210; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yuan AD, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a018309	65	11	11	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2019	36	10					1646	1654		10.1089/neu.2018.6046			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HX7CZ	WOS:000467562900015	30451083	Green Published			2021-06-18	
J	Juengst, SB; Terhorst, L; Dicianno, BE; Niemeier, JP; Wagner, AK				Juengst, Shannon B.; Terhorst, Lauren; Dicianno, Brad E.; Niemeier, Janet P.; Wagner, Amy K.			Development and content validity of the behavioral assessment screening tool (BAST(beta))	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; measurement; psychometrics; behavior; emotions	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; CHALLENGING BEHAVIOR; SUICIDAL-BEHAVIOR; CLUSTER-ANALYSIS; SYMPTOMS; DEPRESSION; ADULTS; IMPULSIVITY; VETERANS	Purpose: Develop and establish the content validity of the Behavioral Assessment Screening Tool (BAST(beta)), a self-reported measure of behavioral and emotional symptoms after traumatic brain injury. Methods: This was an assessment development study, including two focus groups of individuals with traumatic brain injury (n = 11) and their family members (n = 10) and an expert panel evaluation of content validity by experts in traumatic brain injury rehabilitation (n = 7). We developed and assessed the Content Validity Index of the BAST(beta). Results: The BAST(beta) initial items (n = 77) corresponded with an established conceptual model of behavioral dysregulation after traumatic brain injury. After expert panel evaluation and focus group feedback, the final BAST(beta) included 66 items (60 primary, 6 branching logic) rated on a three-level ordinal scale (Never, Sometimes, Always) with reference to the past two weeks, and an Environmental Context checklist including recent major life events (n = 23) and four open-ended questions about environmental factors. The BAST(beta) had a high Content Validity Index of 89.3%. Conclusion: The BAST(beta) is a theoretically grounded, multidimensional self-reported assessment of behavioral dysregulation after traumatic brain injury, with good content validity. Future translation into mobile health modalities could improve effectiveness and efficiency of long-term symptom monitoring post-traumatic brain injury. Future work will establish and validate the factor structure, internal consistency reliabilities and other validities of the BAST.	[Juengst, Shannon B.] Univ Texas Southwestern, Dept Phys Med & Rehabil, Dallas, TX USA; [Juengst, Shannon B.] Univ Texas Southwestern, Dept Rehabil Counseling, Dallas, TX USA; [Terhorst, Lauren] Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA USA; [Terhorst, Lauren] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Dicianno, Brad E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Dicianno, Brad E.; Wagner, Amy K.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA; [Niemeier, Janet P.] Carolinas Med Ctr, Dept Phys Med & Rehabil, Charlotte, SC USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat, Pittsburgh, PA USA	Juengst, SB (corresponding author), Univ Texas Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd C56-202, Dallas, TX 75390 USA.	shannon.juengst@utsouthwestern.edu	Juengst, Shannon B/AAC-5891-2019; Terhorst, Lauren/H-7942-2018; Dicanno, Brad/AAC-5918-2019	Dicanno, Brad/0000-0003-0738-0192; Juengst, Shannon/0000-0003-4709-545X	University of Pittsburgh Medical Center Rehabilitation Institute Pilot Program(University of Pittsburgh) [01140]; National Institutes of Health Clinical Loan Repayment ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH L30NS089099]; Clinical and Translational Science Institute, University of Pittsburgh(University of Pittsburgh); Clinical and Translational Science Institute, University of Pittsburgh (NIH) [UL1-TR-001857]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001857] Funding Source: NIH RePORTER	This work was supported in part by the University of Pittsburgh Medical Center Rehabilitation Institute Pilot Program(University of Pittsburgh, 10.13039/100007921,#01140), National Institutes of Health Clinical Loan Repayment Program (NIH L30NS089099), and the Clinical and Translational Science Institute, University of Pittsburgh(University of Pittsburgh, 10.13039/100010554, NIH UL1-TR-001857).	Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Armistead-Jehle P, 2018, ARCH CLIN NEUROPSYCH, V33, P120, DOI 10.1093/arclin/acx031; Armistead-Jehle P, 2016, APPL NEUROPSYCH-ADUL, V23, P264, DOI 10.1080/23279095.2015.1055564; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brands IMH, 2014, PSYCHOL ASSESSMENT, V26, P848, DOI 10.1037/a0036275; Brenner LA, 2015, ARCH PHYS MED REHAB, V96, P1411, DOI 10.1016/j.apmr.2015.04.010; Bryan CJ, 2014, JAMA PSYCHIAT, V71, P95, DOI 10.1001/jamapsychiatry.2013.2991; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Carvalho JO, 2013, ASSESSMENT, V20, P632, DOI 10.1177/1073191113492845; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Monsalve BC, 2014, NEUROREHABILITATION, V35, P67, DOI 10.3233/NRE-141103; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Currier D, 2008, PSYCHIAT CLIN N AM, V31, P247, DOI 10.1016/j.psc.2008.01.005; Davis LL., 1992, APPL NURS RES, V5, P194, DOI DOI 10.1016/S0897-1897(05)80008-4; Denning JH, 2019, APPL NEUROPSYCH-ADUL, V26, P1, DOI 10.1080/23279095.2017.1350684; Dombrovski AY, 2013, JAMA PSYCHIAT, V70, P1020, DOI 10.1001/jamapsychiatry.2013.75; Donker T, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2791; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Homaifar BY, 2012, REHABIL PSYCHOL, V57, P337, DOI 10.1037/a0030480; James LM, 2014, MIL MED, V179, P357, DOI 10.7205/MILMED-D-13-00241; Juengst S, 2014, ARCH PHYS MED REHAB, V95, pE71, DOI [10.1016/j.apmr.2014.07.227, DOI 10.1016/J.APMR.2014.07.227]; Juengst SB, 2014, BRAIN BEHAV IMMUN, V41, P134, DOI 10.1016/j.bbi.2014.05.020; Juengst SB, 2017, J NEUROPSYCH CLIN N, V29, P260, DOI 10.1176/appi.neuropsych.16100217; Juengst SB, 2017, J CLIN EXP NEUROPSYC, V39, P513, DOI 10.1080/13803395.2016.1240758; Juengst SB, 2015, BRAIN INJURY, V29, P1351, DOI 10.3109/02699052.2015.1045031; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kocka A, 2014, BEHAV SCI, V4, P352, DOI 10.3390/bs4040352; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; Krueger RA, 2014, FOCUS GROUPS PRACTIC, V5th; Lopez-Larson Melissa, 2013, Front Psychiatry, V4, P83, DOI 10.3389/fpsyt.2013.00083; LYNN MR, 1986, NURS RES, V35, P382; Machamer J, 2013, J NEUROTRAUM, V30, P1845, DOI 10.1089/neu.2013.2920; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Matthews S, 2012, PSYCHOSOM MED, V74, P471, DOI 10.1097/PSY.0b013e31824f888f; Myers CE, 2012, PSYCHIAT RES, V196, P271, DOI 10.1016/j.psychres.2011.11.015; Myrga JM, 2016, NEUROREHAB NEURAL RE, V30, P920, DOI 10.1177/1545968316648409; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Pett M., 2003, MAKING SENSE FACTOR; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549	54	11	11	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	MAY 8	2019	41	10					1200	1206		10.1080/09638288.2017.1423403			7	Rehabilitation	Rehabilitation	HU3XK	WOS:000465208200008	29303003	Green Accepted			2021-06-18	
J	Cryan, MT; Ross, AE				Cryan, Michael T.; Ross, Ashley E.			Scalene Waveform for Codetection of Guanosine and Adenosine Using Fast-Scan Cyclic Voltammetry	ANALYTICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; DOPAMINE RELEASE; SENSITIVITY; NUCLEOSIDES; INCREASES; SLICES; PURINE	Guanosine and adenosine are important neuromodulators in the brain and work in cooperation to mitigate the effects of stroke, traumatic injury, and other neurological events. Both purines can act on slow (minutes to hours) and rapid (milliseconds to seconds) time scales. A guanosine-adenosine interaction has been proposed in which guanosine modulates adenosine levels, and the two work together to control glutamate neurotransmission. Traditional methods to codetect purines, such as HPLC with microdialysis, are robust but lack the temporal resolution necessary to quantify release in real time. Fast-scan cyclic voltammetry (FSCV) has been used to detect guanosine and adenosine independently, but codetection has not been possible. Here, we developed a novel "scalene waveform" to codetect guanosine and adenosine with nanomolar limits of detection in real time with FSCV. The scalene waveform uses a slow rate (100 V/s) on the forward scan and the conventional rate (400 V/s) on the back scan; potentials go from -0.4 to 1.45 V and back to -0.4 V. The scan rates were optimized to increase the separation of the oxidative peaks for guanosine and adenosine. The temporal separation of the primary peaks was increased (4.6 +/- 0.1)-fold at the scalene waveform compared to the traditional waveform. Both exogenously applied guanosine and adenosine and endogenous transient release were detected at the scalene waveform in rat-brain slices. We show the first method for codetecting guanosine and adenosine using FSCV, which can be used to study the guanosine adenosine interaction and better understand their cooperative therapeutic effects.	[Cryan, Michael T.; Ross, Ashley E.] Univ Cincinnati, Dept Chem, 312 Coll Dr,404 Crosley Tower, Cincinnati, OH 45221 USA	Ross, AE (corresponding author), Univ Cincinnati, Dept Chem, 312 Coll Dr,404 Crosley Tower, Cincinnati, OH 45221 USA.	ashley.ross@uc.edu		Ross, Ashley/0000-0003-2456-3636; Cryan, Michael/0000-0002-0635-8105			Bath BD, 2000, ANAL CHEM, V72, P5994, DOI 10.1021/ac000849y; Bettio LEB, 2016, PURINERG SIGNAL, V12, P411, DOI 10.1007/s11302-016-9509-4; Cryan MT, 2019, ANALYST, V144, P249, DOI 10.1039/c8an01547c; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Di Liberto V, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00158; Dobolyi A, 1998, NEUROCHEM INT, V32, P247, DOI 10.1016/S0197-0186(97)00090-9; Dobolyi A, 2000, NEUROCHEM INT, V37, P71, DOI 10.1016/S0197-0186(99)00162-X; DRAGUNOW M, 1988, TRENDS PHARMACOL SCI, V9, P193, DOI 10.1016/0165-6147(88)90079-X; Feng JDZ, 2000, THER DRUG MONIT, V22, P177, DOI 10.1097/00007691-200004000-00007; Hashemi P, 2009, ANAL CHEM, V81, P9462, DOI 10.1021/ac9018846; Hensley AL, 2018, ANAL CHEM, V90, P8642, DOI 10.1021/acs.analchem.8b01976; JACKSON BP, 1995, ANAL CHEM, V67, P1115, DOI 10.1021/ac00102a015; Jackson EK, 2014, J PHARMACOL EXP THER, V350, P719, DOI 10.1124/jpet.114.216978; John CE, 2007, FRONT NEUROENG, V1, P49; Keithley RB, 2011, ANAL CHEM, V83, P3563, DOI 10.1021/ac200143v; Lanznaster D, 2016, AGING DIS, V7, P657, DOI 10.14336/AD.2016.0208; Lee ST, 2018, ACS CHEM NEUROSCI, V9, P505, DOI 10.1021/acschemneuro.7b00280; Lim GN, 2019, ACS SENSORS, V4, P479, DOI 10.1021/acssensors.8b01504; Nguyen MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087165; Pajski ML, 2013, PURINERG SIGNAL, V9, P167, DOI 10.1007/s11302-012-9343-2; Pajski ML, 2010, ACS CHEM NEUROSCI, V1, P775, DOI 10.1021/cn100037d; Pyakurel P, 2016, ACS CHEM NEUROSCI, V7, P1112, DOI 10.1021/acschemneuro.6b00070; RATHBONE MP, 1991, NEUROREPORT, V2, P661, DOI 10.1097/00001756-199111000-00007; Robinson DL, 2003, CLIN CHEM, V49, P1763, DOI 10.1373/49.10.1763; Ross AE, 2015, J NEUROCHEM, V132, P51, DOI 10.1111/jnc.12946; Ross AE, 2014, ANAL CHEM, V86, P7486, DOI 10.1021/ac501229c; Ross AE, 2014, J NEUROCHEM, V130, P50, DOI 10.1111/jnc.12711; Ross AE, 2012, ANALYST, V137, P3045, DOI 10.1039/c2an35297d; Sanford AL, 2010, ANAL CHEM, V82, P5205, DOI 10.1021/ac100536s; Schmidt AC, 2014, ANAL CHEM, V86, P7806, DOI 10.1021/ac501725u; Spanos M, 2013, ACS CHEM NEUROSCI, V4, P782, DOI 10.1021/cn4000499; Strand AM, 2008, ANAL CHEM, V80, P3708, DOI 10.1021/ac8001275; Swamy BEK, 2007, ANAL CHEM, V79, P744, DOI 10.1021/ac061820i; WALLMANJOHANSSON A, 1994, LIFE SCI, V55, P721, DOI 10.1016/0024-3205(94)00680-6; Wang YX, 2012, J NEUROSCI METH, V208, P34, DOI 10.1016/j.jneumeth.2012.04.009; ZIMMERMAN JB, 1991, ANAL CHEM, V63, P24, DOI 10.1021/ac00001a005; 1988, TALANTA, V35, P911; 2008, NEUROSCI LETT, V431, P101, DOI DOI 10.1016/J.NEUTET.2007.11.072; 2002, CELL MOL NEUROBIOL, V22, P353	39	11	11	2	10	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	MAY 7	2019	91	9					5987	5993		10.1021/acs.analchem.9b00450			7	Chemistry, Analytical	Chemistry	HX8FQ	WOS:000467642100072	30938508				2021-06-18	
J	Santo, CCD; Fiorin, FD; Ilha, J; Duarte, MMMF; Duarte, T; Santos, ARS				do Espirito Santo, Caroline Cunha; Fiorin, Fernando da Silva; Ilha, Jocemar; Medeiros Frescura Duarte, Marta Maria; Duarte, Tiago; Soares Santos, Adair Roberto			Spinal cord injury by clip-compression induces anxiety and depression-like behaviours in female rats: The role of the inflammatory response	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Spinal cord injury; Behaviour; Anxiety; Depression; Inflammation; Cytokines	ELEVATED-PLUS-MAZE; SEX-DIFFERENCES; EXPRESSION; STRESS; CYTOKINES; MODEL; BRAIN; ELECTROACUPUNCTURE; AUTOANTIBODIES; METAANALYSIS	Traumatic spinal cord injury (SCI) promotes long-term disability that affects mobility and functional independence. The spinal cord inflammatory response after the initial mechanical insult substantially impacts locomotor impairment and development of neuropsychiatric disorders, including anxiety and depression. However, these psychiatric events are scarcely investigated in females. This study investigated the anxiety/depression-like behaviours and inflammatory responses related to the production/release of pro- and anti-inflammatory cytokines in female adult Wistar rats submitted to severe clip-compression SCI. Data showed that SCI impaired the locomotor performance assessment by the BBB scale, but did not alter exploratory activity in open-field test. Animals' locomotor impairment was associated with anxious and depressive-like behaviours characterised by a decreased amount of time in the open arms of the elevated plus-maze test, and the motivational reduction of social interaction and anhedonia assessed by social exploration and sucrose preference tests. By contrast, SCI decreased the immobility time in the forced swimming test. Moreover, SCI caused a significant increase in local and systemic proinflammatory cytokines (TNF-alpha, INF-gamma, IL-1 beta, and IL-6) and a reduction in the anti-inflammatory cytokine IL-10. Finally, there were significant negative correlations between depression-like behaviour, but not anxiety, and increased plasma concentrations of TNF-alpha, IL-1 beta, IL-6, and INF-gamma. Additionally, the laminectomy procedure provoked the inflammatory response associated with reduced sucrose intake in Sham animals, although less expressively than in the SCI group. Collectively, these results indicate that SCI by clip-compression in female rats promotes a neuropsychiatric-like profile associated with an imbalance in the production/release of pro- and anti-inflammatory cytokines.	[do Espirito Santo, Caroline Cunha; Fiorin, Fernando da Silva; Soares Santos, Adair Roberto] Univ Fed Santa Catarina, Ctr Ciencias Biol, Programa Posgrad Neurociencias, Florianopolis, SC, Brazil; [do Espirito Santo, Caroline Cunha; Fiorin, Fernando da Silva; Soares Santos, Adair Roberto] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Ciencias Fisiol, Lab Neurobiol Dor & Inflamacao, Florianopolis, SC, Brazil; [Ilha, Jocemar] Univ Estado Santa Catarina, Dept Fisioterapia Nucleo Pesquisa Lesao Medula Es, Florianopolis, SC, Brazil; [Medeiros Frescura Duarte, Marta Maria] Univ Luterana Brasil, Programa Posgrad Farmacol, Canoas, RS, Brazil; [Medeiros Frescura Duarte, Marta Maria] Univ Luterana Brasil, Ctr Ciencias Saude, Canoas, RS, Brazil; [Duarte, Tiago] Univ Fed Santa Maria, Programa Posgrad Farmacol, Santa Maria, RS, Brazil	Santo, CCD; Santos, ARS (corresponding author), Univ Fed Santa Catarina, BR-88040900 Florianopolis, SC, Brazil.	karolces@hotmail.com; adair.santos@ufsc.br	da Silva Fiorin, Fernando/AAQ-9472-2021; Ilha, Jocemar/I-4247-2012; Santos, Adair/C-5565-2013	Ilha, Jocemar/0000-0002-6300-4696; Santos, Adair/0000-0002-6435-4698; do Espirito Santo, Caroline/0000-0001-8657-9532; da Silva Fiorin, Fernando/0000-0002-6517-7160	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC)Fundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Programa INCT-INOVAMED [465430/2014-7]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	We are thankful to Angela P. Franca, Nicolas Alexsander M. M. M. Pereira, Kelly O. Coelho, Nathana T. M. Loebens, and Amabile A. Weber for their advice in experiments and assistance in animal care. This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Programa INCT-INOVAMED (465430/2014-7). Caroline Cunha do Espirito Santo, Fernando da Silva Fiorin, and Tiago Duarte are recipients of CAPES fellowships. Adair RS Santos is recipient of a productivity fellowship from CNPq.	Allison DJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0425-2; Amsen Derk, 2009, V511, P107, DOI 10.1007/978-1-59745-447-6_5; Anyan J, 2018, NEUROPSYCHOPHARMACOL, V43, P931, DOI 10.1038/npp.2017.260; Baastrup C, 2011, BRAIN RES, V1370, P129, DOI 10.1016/j.brainres.2010.11.008; BANKS WA, 1994, J PHYSIOL-LONDON, V479, P257, DOI 10.1113/jphysiol.1994.sp020293; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bateman E., 2017, THESIS; Beedie A, 2002, J CLIN PSYCHOL MED S, V9, P227, DOI 10.1023/A:1016003428370; Boadas-Vaello P, 2018, NEUROSCI LETT, V664, P98, DOI 10.1016/j.neulet.2017.11.007; Bombardier CH, 2012, ARCH PHYS MED REHAB, V93, P775, DOI 10.1016/j.apmr.2011.12.020; Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825; Cheng ZJ, 2017, CELL TRANSPLANT, V26, P469, DOI 10.3727/096368916X693473; Cheriyan T, 2014, SPINAL CORD, V52, P588, DOI 10.1038/sc.2014.91; Christianson JP, 2008, BEHAV BRAIN RES, V193, P87, DOI 10.1016/j.bbr.2008.04.024; Chung MC, 2006, J AFFECT DISORDERS, V93, P229, DOI 10.1016/j.jad.2006.02.021; Davies AL, 2007, ARCH PHYS MED REHAB, V88, P1384, DOI 10.1016/j.apmr.2007.08.004; Derry HM, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0618-5; Ferguson SA, 2005, PHYSIOL BEHAV, V85, P621, DOI 10.1016/j.physbeh.2005.06.009; Frenois F, 2007, PSYCHONEUROENDOCRINO, V32, P516, DOI 10.1016/j.psyneuen.2007.03.005; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P255; Geng X, 2015, NEURAL REGEN RES, V10, P394, DOI 10.4103/1673-5374.153687; Goldkuhl R, 2008, EUR SURG RES, V41, P272, DOI 10.1159/000142372; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Haapakoski R, 2015, BRAIN BEHAV IMMUN, V49, P206, DOI 10.1016/j.bbi.2015.06.001; Hayes KC, 2002, J NEUROTRAUM, V19, P753, DOI 10.1089/08977150260139129; Heshmati Mitra, 2015, Curr Behav Neurosci Rep, V2, P146; Hoge EA, 2009, DEPRESS ANXIETY, V26, P447, DOI 10.1002/da.20564; Jalan D, 2017, J NEUROSURG-SPINE, V26, P62, DOI 10.3171/2016.6.SPINE16343; JOHNSTON AL, 1991, PHYSIOL BEHAV, V49, P245, DOI 10.1016/0031-9384(91)90039-Q; Khazaeipour Zahra, 2015, Top Spinal Cord Inj Rehabil, V21, P149, DOI 10.1310/sci2102-149; Kohler CA, 2017, ACTA PSYCHIAT SCAND, V135, P373, DOI 10.1111/acps.12698; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Le J, 2016, SPINAL CORD, V54, P570, DOI 10.1038/sc.2016.15; Luedtke K, 2014, J NEUROTRAUM, V31, P1107, DOI 10.1089/neu.2013.3204; Maldonado-Bouchard S, 2016, BRAIN BEHAV IMMUN, V51, P176, DOI 10.1016/j.bbi.2015.08.009; Mehta S, 2018, TOP SPINAL CORD INJ, V24, P37, DOI 10.1310/sci16-00027; Mezadri TJ, 2011, J NEUROSCI METH, V195, P200, DOI 10.1016/j.jneumeth.2010.12.015; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Mitchell MC, 2008, SPINAL CORD, V46, P547, DOI 10.1038/sj.sc.3102154; Moieni M, 2015, NEUROPSYCHOPHARMACOL, V40, P1709, DOI 10.1038/npp.2015.17; NSCISC, 2017, ANN STAT REP SPIN CO; O'Donovan A, 2010, BRAIN BEHAV IMMUN, V24, P1074, DOI 10.1016/j.bbi.2010.03.003; Otte C, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.65; Pan WH, 1997, J NEUROIMMUNOL, V76, P105, DOI 10.1016/S0165-5728(97)00034-9; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pacheco-Unguetti AP, 2010, PSYCHOL SCI, V21, P298, DOI 10.1177/0956797609359624; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Pitsavos C, 2006, ATHEROSCLEROSIS, V185, P320, DOI 10.1016/j.atherosclerosis.2005.06.001; Popovich PG, 2001, J NEUROTRAUM, V18, P957, DOI 10.1089/089771501750451866; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Pruss H, 2011, BRAIN PATHOL, V21, P652, DOI 10.1111/j.1750-3639.2011.00488.x; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; Reis JSS, 2014, PHYTOMEDICINE, V21, P1466, DOI 10.1016/j.phymed.2014.06.001; Riaz MS, 2015, PHYSIOL BEHAV, V152, P128, DOI 10.1016/j.physbeh.2015.09.005; Sandi C, 2009, TRENDS NEUROSCI, V32, P312, DOI 10.1016/j.tins.2009.02.004; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Skurlova M, 2011, NEUROSCI LETT, V487, P250, DOI 10.1016/j.neulet.2010.10.032; Song C, 2009, PHARMACOPSYCHIATRY, V42, P182, DOI 10.1055/s-0029-1202263; Vinkers CH, 2008, EUR J PHARMACOL, V585, P407, DOI 10.1016/j.ejphar.2008.02.097; Vogelzangs N, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.27; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Williams R, 2015, ARCH PHYS MED REHAB, V96, P133, DOI 10.1016/j.apmr.2014.08.016; World Health Organization, 2017, DEPR OTH COMM MENT D; Wu JF, 2016, J NEUROTRAUM, V33, P1919, DOI 10.1089/neu.2015.4348; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Xiang XJ, 2011, BEHAV BRAIN RES, V222, P326, DOI 10.1016/j.bbr.2011.03.068; Yee JR, 2010, BRAIN BEHAV IMMUN, V24, P942, DOI 10.1016/j.bbi.2010.03.006; Zhang C, 2014, BIOCHEM BIOPH RES CO, V444, P395, DOI 10.1016/j.bbrc.2014.01.070; 2017, NAT NEUROSCI, V20, P1549, DOI DOI 10.1038/NN.4643; 2018, NEUROCHEM RES, V43, P1258, DOI DOI 10.1007/S11064-018-2543-6; 2016, PSYCHONEUROENDOCRINO, V65, P109, DOI DOI 10.1016/J.PSYNEUEN.2015.12.004	74	11	11	4	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2019	78						91	104		10.1016/j.bbi.2019.01.012			14	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	HY6RH	WOS:000468256900012	30659938				2021-06-18	
J	Dobrachinski, F; Gerbatin, RR; Sartori, G; Golombieski, RM; Antoniazzi, A; Nogueira, CW; Royes, LF; Fighera, MR; Porciuncula, LO; Cunha, RA; Soares, FAA				Dobrachinski, Fernando; Gerbatin, Rogerio R.; Sartori, Glaubia; Golombieski, Ronaldo M.; Antoniazzi, Alfredo; Nogueira, Cristina W.; Royes, Luiz F.; Fighera, Michele R.; Porciuncula, Lisiane O.; Cunha, Rodrigo A.; Soares, Felix A. A.			Guanosine Attenuates Behavioral Deficits After Traumatic Brain Injury by Modulation of Adenosinergic Receptors	MOLECULAR NEUROBIOLOGY			English	Article						Purinergic nucleoside; Fluid percussion injury; Memory; Anxiety; Adenosine A(1) receptor; Adenosine A(2A) receptor	FLUID PERCUSSION INJURY; A(2A) RECEPTORS; RAT-BRAIN; CAFFEINE; DYSFUNCTION; MECHANISMS; A(1); DEPRIVATION; PROTECTS; MEMORY	Traumatic brain injury (TBI) is a leading cause of disability worldwide, triggering chronic neurodegeneration underlying cognitive and mood disorder still without therapeutic prospects. Based on our previous observations that guanosine (GUO) attenuates short-term neurochemical alterations caused by TBI, this study investigated the effects of chronical GUO treatment in behavioral, molecular, and morphological disturbances 21days after trauma. Rats subject to TBI displayed mood (anxiety-like) and memory dysfunction. This was accompanied by a decreased expression of both synaptic (synaptophysin) and plasticity proteins (BDNF and CREB), a loss of cresyl violet-stained neurons, and increased astrogliosis and microgliosis in the hippocampus. Notably, chronic GUO treatment (7.5mg/kgi.p. daily starting 1h after TBI) prevented all these TBI-induced long-term behavioral, neurochemical, and morphological modifications. This neuroprotective effect of GUO was abrogated in the presence of the adenosine A(1) receptor antagonist DPCPX (1mg/kg) but unaltered by the adenosine A(2A) receptor antagonist SCH58261 (0.05mg/kg). These findings show that a chronic GUO treatment prevents the long-term mood and memory dysfunction triggered by TBI, which involves adenosinergic receptors.	[Dobrachinski, Fernando; Golombieski, Ronaldo M.; Fighera, Michele R.; Soares, Felix A. A.] Univ Fed Santa Maria, Dept Biochem & Mol Biol, Ctr Nat & Exact Sci, UFSM, BR-97105900 Santa Maria, RS, Brazil; [Dobrachinski, Fernando; Cunha, Rodrigo A.] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal; [Gerbatin, Rogerio R.; Royes, Luiz F.] Univ Fed Santa Maria, Lab Exercise Biochem, Santa Maria, RS, Brazil; [Sartori, Glaubia; Nogueira, Cristina W.] Univ Fed Santa Maria, Dept Biochem & Mol Biol, Lab Synth React & Pharmacol Evaluating & Toxicol, Santa Maria, RS, Brazil; [Antoniazzi, Alfredo] Univ Fed Santa Maria, Lab Biotechnol & Anim Reprod, BioRep Vet Hosp, Santa Maria, RS, Brazil; [Fighera, Michele R.] Univ Fed Santa Maria, Dept Neuropsychiat, Hlth Sci Ctr, Santa Maria, RS, Brazil; [Porciuncula, Lisiane O.] Univ Fed Rio Grande do Sul, ICBS, Dept Biochem, Lab Studies Purinerg Syst, Porto Alegre, RS, Brazil; [Cunha, Rodrigo A.] Univ Coimbra, Fac Med, P-3004504 Coimbra, Portugal	Soares, FAA (corresponding author), Univ Fed Santa Maria, Dept Biochem & Mol Biol, Ctr Nat & Exact Sci, UFSM, BR-97105900 Santa Maria, RS, Brazil.	felix@ufsm.br	Soares, Felix/AAE-6251-2020; Golombieski, Ronaldo M/D-3342-2014; SARTORI, GLAUBIA/J-3435-2014; Dobrachinski, Fernando/C-4316-2014; Cunha, Rodrigo A/E-7475-2015; Fighera, Michele R/J-9576-2014	Soares, Felix/0000-0002-6453-7902; Golombieski, Ronaldo M/0000-0002-1153-4396; SARTORI, GLAUBIA/0000-0002-1088-8731; Dobrachinski, Fernando/0000-0002-3948-1273; Cunha, Rodrigo A/0000-0003-2550-6422; 	INCT for excitotoxicity and neuroprotection-MCT/CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Maratona da Saude; GAI-FMUC; Banco Santander-Totta; ERDF through Centro 2020 [CENTRO-01-0145-FEDER-000008: BrainHealth 2020]; ERDF through FCT [POCI-01-0145-FEDER-007440, PTDC/NEU-NMC/4154/2016]; FAPERGS/PRONEMFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [11/2029-1]; CNPq Brasil (Programa Ciencia sem Fronteiras)	This study was supported by INCT for excitotoxicity and neuroprotection-MCT/CNPq. C.W.N., L.F.R., M.R.F., L.O.P., and F.A.A.S. received a fellowship by CNPq; F.D., R.R.G., and G.S. received a fellowship by CAPES. RAC received funding from Maratona da Saude, GAI-FMUC and Banco Santander-Totta, ERDF, through Centro 2020 (project CENTRO-01-0145-FEDER-000008: BrainHealth 2020), and through FCT (projects POCI-01-0145-FEDER-007440 and PTDC/NEU-NMC/4154/2016). Additional support was given by FAPERGS/PRONEM 11/2029-1. F.D. received a fellowship from CNPq Brasil (Programa Ciencia sem Fronteiras).	Almeida RF, 2017, MOL NEUROBIOL, V54, P423, DOI 10.1007/s12035-015-9660-x; Araque A, 2014, NEURON, V81, P728, DOI 10.1016/j.neuron.2014.02.007; Ballerini R, 2006, INT J IMMUNOPATH PH, V19, P293; Benito E, 2010, TRENDS NEUROSCI, V33, P230, DOI 10.1016/j.tins.2010.02.001; Bettio LEB, 2016, PURINERG SIGNAL, V12, P411, DOI 10.1007/s11302-016-9509-4; Bettio LEB, 2016, EUR J NEUROSCI, V43, P1006, DOI 10.1111/ejn.13172; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chen ZC, 2014, J NEUROSCI, V34, P9621, DOI 10.1523/JNEUROSCI.3991-13.2014; Ciccarelli R, 2000, GLIA, V29, P202, DOI 10.1002/(SICI)1098-1136(20000201)29:3<202::AID-GLIA2>3.0.CO;2-C; Ciruela F, 2006, J NEUROSCI, V26, P2080, DOI 10.1523/JNEUROSCI.3574-05.2006; Cunha GMA, 2006, NEUROSCIENCE, V141, P1775, DOI 10.1016/j.neuroscience.2006.05.024; Cunha RA, 2016, J NEUROCHEM, V139, P1019, DOI 10.1111/jnc.13724; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dal-Cim T, 2013, J NEUROCHEM, V126, P437, DOI 10.1111/jnc.12324; Dall'Igna OP, 2007, EXP NEUROL, V203, P241, DOI 10.1016/j.expneurol.2006.08.008; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Denny JB, 2006, CURR NEUROPHARMACOL, V4, P293, DOI 10.2174/157015906778520782; Di Liberto V, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00158; Dobrachinski F, 2017, J NEUROTRAUM, V34, P1318, DOI 10.1089/neu.2016.4563; El Yacoubi M, 2000, BRIT J PHARMACOL, V129, P1465; Forner S, 2017, TRENDS NEUROSCI, V40, P347, DOI 10.1016/j.tins.2017.04.002; Ganzella M, 2012, NEUROL SCI, V33, P985, DOI 10.1007/s10072-011-0872-1; Gerbatin RD, 2017, MOL NEUROBIOL, V54, P7585, DOI 10.1007/s12035-016-0238-z; Gerrikagoitia I, 2009, ANAT REC, V292, P1968, DOI 10.1002/ar.20999; Giuliani P, 2015, ADV EXP MED BIOL, V837, P23, DOI 10.1007/5584_2014_73; Guo D, 2014, BRIT J PHARMACOL, V171, P5295, DOI 10.1111/bph.12836; Gysbers JW, 1996, INT J DEV NEUROSCI, V14, P19, DOI 10.1016/0736-5748(95)00083-6; Halldner L, 2004, NEUROPHARMACOLOGY, V46, P1008, DOI 10.1016/j.neuropharm.2004.01.014; Hansel G, 2015, MOL NEUROBIOL, V52, P1791, DOI 10.1007/s12035-014-8978-0; Jackson EK, 2013, AM J PHYSIOL-CELL PH, V304, pC406, DOI 10.1152/ajpcell.00212.2012; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kaster MP, 2015, P NATL ACAD SCI USA, V112, P7833, DOI 10.1073/pnas.1423088112; Lanznaster D, 2017, MOL NEUROBIOL, V54, P5482, DOI 10.1007/s12035-016-0082-1; Lepeta K, 2016, J NEUROCHEM, V138, P785, DOI 10.1111/jnc.13713; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MASLIAH E, 1993, BRAIN PATHOL, V3, P77, DOI 10.1111/j.1750-3639.1993.tb00728.x; Matos M, 2013, J NEUROSCI, V33, P18492, DOI 10.1523/JNEUROSCI.1828-13.2013; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Muller C E, 1993, Pharm Acta Helv, V68, P77, DOI 10.1016/0031-6865(93)90012-U; Oliveira KA, 2017, PURINERG SIGNAL, V13, P305, DOI 10.1007/s11302-017-9562-7; Paniz LG, 2014, METAB BRAIN DIS, V29, P645, DOI 10.1007/s11011-014-9548-x; Petronilho F, 2012, BRAIN BEHAV IMMUN, V26, P904, DOI 10.1016/j.bbi.2012.03.007; Prediger RDS, 2005, NEUROBIOL AGING, V26, P957, DOI 10.1016/j.neurobiolaging.2004.08.012; Quincozes-Santos A, 2013, PURINERG SIGNAL, V9, P643, DOI 10.1007/s11302-013-9377-0; Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x; Rial D, 2016, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00521; Rodrigues RJ, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00148; Sajja VSSS, 2016, FRONT INTEGR NEUROSC, V10, DOI [10.3389/fnint.2016.00007, 10.3389/fnint.7016.00007]; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt AP, 2010, BRIT J PHARMACOL, V159, P1247, DOI 10.1111/j.1476-5381.2009.00597.x; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Serchov T, 2015, NEURON, V87, P549, DOI 10.1016/j.neuron.2015.07.010; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Simoes AP, 2016, NEUROPSYCHOPHARMACOL, V41, P2862, DOI 10.1038/npp.2016.98; Su C, 2013, J BIOL REG HOMEOS AG, V27, P673; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Traversa U, 2003, BIOORGAN MED CHEM, V11, P5417, DOI 10.1016/j.bmc.2003.09.043; Tay TL, 2017, J PHYSIOL-LONDON, V595, P1929, DOI 10.1113/JP272134; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wu XF, 2010, BIOCHEM BIOPH RES CO, V393, P514, DOI 10.1016/j.bbrc.2010.02.038; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098; Zorec R, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00056	67	11	11	4	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAY	2019	56	5					3145	3158		10.1007/s12035-018-1296-1			14	Neurosciences	Neurosciences & Neurology	HZ0MQ	WOS:000468535100006	30105669				2021-06-18	
J	Kelly, KM; Kiderman, A; Akhavan, S; Quigley, MR; Snell, ED; Happ, E; Synowiec, AS; Miller, ER; Bauer, MA; Oakes, LP; Eydelman, Y; Gallagher, CW; Dinehart, T; Schroeder, JH; Ashmore, RC				Kelly, Kevin M.; Kiderman, Alex; Akhavan, Sam; Quigley, Matthew R.; Snell, Edward D.; Happ, Erik; Synowiec, Andrea S.; Miller, Eric R.; Bauer, Melissa A.; Oakes, Liza P.; Eydelman, Yakov; Gallagher, Charles W.; Dinehart, Thomas; Schroeder, John Howison; Ashmore, Robin C.			Oculomotor, Vestibular, and Reaction Time Effects of Sports-Related Concussion: Video-Oculography in Assessing Sports-Related Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; oculomotor; optokinetic; OVRT; reaction time; smooth pursuit; vestibular; video-oculography	TRAUMATIC BRAIN-INJURY; EYE-MOVEMENTS; SMOOTH-PURSUIT; HEAD-INJURY; MILD; DEFICITS; RECOVERY; IMPACT; RELIABILITY; PERFORMANCE	Objective: The purpose of the study was to test the ability of oculomotor, vestibular, and reaction time (OVRT) metrics to serve as a concussion assessment or diagnostic tool for general clinical use. Setting and Participants: Patients with concussion were high school-aged athletes clinically diagnosed in a hospital setting with a sports-related concussion (n = 50). Control subjects were previously recruited male and female high school student athletes from 3 local high schools (n = 170). Design: Video-oculography was used to acquire eye movement metrics during OVRT tasks, combined with other measures. Measures were compared between groups, and a subset was incorporated into linear regression models that could serve as indicators of concussion. Measures: The OVRT test battery included multiple metrics of saccades, smooth pursuit tracking, nystagmoid movements, vestibular function, and reaction time latencies. Results: Some OVRT metrics were significantly different between groups. Linear regression models distinguished control subjects from concussion subjects with high accuracy. Metrics included changes in smooth pursuit tracking, increased reaction time and reduced saccade velocity in a complex motor task, and decreased optokinetic nystagmus (OKN) gain. In addition, optokinetic gain was reduced and more variable in subjects assessed 22 or more days after injury. Conclusion: These results indicate that OVRT tests can be used as a reliable adjunctive tool in the assessment of concussion and that OKN results appear to be associated with a prolonged expression of concussion symptoms.	[Kelly, Kevin M.; Synowiec, Andrea S.; Miller, Eric R.] Allegheny Gen Hosp, Dept Neurol, 940 South Tower,320 E North Ave, Pittsburgh, PA 15212 USA; [Akhavan, Sam; Snell, Edward D.; Bauer, Melissa A.] Allegheny Gen Hosp, Dept Orthopaed Surg, Pittsburgh, PA 15212 USA; [Happ, Erik] Allegheny Gen Hosp, Dept Ophthalmol, Pittsburgh, PA 15212 USA; [Quigley, Matthew R.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Erie, PA USA; [Kiderman, Alex; Oakes, Liza P.; Eydelman, Yakov; Gallagher, Charles W.; Dinehart, Thomas; Schroeder, John Howison; Ashmore, Robin C.] Neuro Kinet Inc, Pittsburgh, PA USA	Kelly, KM (corresponding author), Allegheny Gen Hosp, Dept Neurol, 940 South Tower,320 E North Ave, Pittsburgh, PA 15212 USA.	kevin.kelly@ahn.org			Department of DefenseUnited States Department of Defense [81XWH-12-C-0205]; US Department of the Treasury, Internal Revenue Service Qualifying Therapeutic Discovery Project [21.013]	A.K., Y.E., J.H.S., and R.C.A. are employees of and financial stakeholders in Neuro Kinetics, Inc (NKI), a for-profit, privately held company, and manufacturer of the equipment used in this study. C.W.G. and L.P.O. were former employees of NKI, and T.D. was temporarily employed by NKI for this project. K.M.K. and M.R.Q. received salary support from Department of Defense Rapid Innovation Fund Contract 81XWH-12-C-0205 by a subcontract to Allegheny General Hospital from NKI. K.M.K., S.A., M.R.Q., E.D.S., E.H., A.S.S., E.R.M., and M.A.B. used the equipment lent by NKI, for the conduct of the study, which was supported in part by US Department of the Treasury, Internal Revenue Service Qualifying Therapeutic Discovery Project Credit Grant 21.013 to NKI, and by the Department of Defense Rapid Innovation Fund Contract 81XWH-12-C-0205 awarded to NKI under which Allegheny General Hospital was subcontracted.	BAHILL A T, 1975, Mathematical Biosciences, V24, P191, DOI 10.1016/0025-5564(75)90075-9; Balaban C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162168; Casto KL, 2012, AUDITORY VESTIBULAR; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Contreras R, 2008, J BIOL PHYS, V34, P381, DOI 10.1007/s10867-008-9092-1; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; DiCesare CA, 2017, BEHAV RES METHODS, V49, P258, DOI 10.3758/s13428-015-0693-x; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; GLASS I, 1995, BRAIN INJURY, V9, P769, DOI 10.3109/02699059509008233; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Hoffer ME, 2017, LARYNGOSCOPE INVEST, V2, P157, DOI 10.1002/lio2.74; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Jacobson GP, 2008, BALANCE FUNCTION ASS; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Johnson B, 2015, NEUROLOGY, V85, P1163, DOI 10.1212/WNL.0000000000001968; Johnson B, 2015, BRAIN IMAGING BEHAV, V9, P564, DOI 10.1007/s11682-014-9316-x; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Krauzlis RJ, 2004, J NEUROPHYSIOL, V91, P591, DOI 10.1152/jn.00801.2003; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; LYNCH JC, 1994, EXP BRAIN RES, V100, P181; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Samadani U, 2015, J NEUROTRAUM, V32, P548, DOI 10.1089/neu.2014.3687; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Shepard NT, 1996, PRACTICAL MANAGEMENT; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Tyler CW, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00282; Wright WG, 2017, J VESTIBUL RES-EQUIL, V27, P27, DOI 10.3233/VES-170607	43	11	11	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2019	34	3			SI		176	188		10.1097/HTR.0000000000000437			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IH1KG	WOS:000474249100014	30234848	Green Published, Other Gold			2021-06-18	
J	Voormolen, DC; Cnossen, MC; Polinder, S; Gravesteijn, BY; Von Steinbuechel, N; Real, RGL; Haagsma, JA				Voormolen, Daphne C.; Cnossen, Maryse C.; Polinder, Suzanne; Gravesteijn, Benjamin Y.; Von Steinbuechel, Nicole; Real, Ruben G. L.; Haagsma, Juanita A.			Prevalence of post-concussion-like symptoms in the general population in Italy, The Netherlands and the United Kingdom	BRAIN INJURY			English	Article						Post-concussion symptoms; traumatic brain injury; post-concussion syndrome; quality of life; rivermead post-concussion symptoms questionnaire	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; MILD HEAD-INJURY; BASE RATES; STRESS; LIFE	Objectives: To evaluate the frequency of post-concussion symptoms and prevalence and risk factors of post-concussion syndrome (PCS) in the general population, investigate the association between the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and self-perceived health, and evaluate differences between three European countries. Methods: A web-based survey including the RPQ and EQ-5D was conducted among representative samples in three European countries. Results: A total of 11,759 respondents completed the questionnaire. The most frequently reported symptom was fatigue (49.9%). Almost half (45.1%) of the respondents were classified as having PCS considering rating score 2 (three RPQ items with score >= 2) as a cut-off. Chronic health complaints were found as a significant risk factor for PCS. All items of the RPQ were positively correlated with the EQ-5D and the strongest positive correlation (0.633, p<0.001) was between RPQ item 'feeling depressed or tearful' and EQ-5D domain 'anxiety/depression'. Conclusions: We found a high frequency of post-concussion-like symptoms and PCS in the general population, indicating that these symptoms are not specific for patients with traumatic brain injury (TBI), and PCS is not a unique syndrome after TBI. Therefore, the use of post-concussion symptoms and PCS as outcome following mild TBI should be interpreted with caution.	[Voormolen, Daphne C.; Cnossen, Maryse C.; Polinder, Suzanne; Gravesteijn, Benjamin Y.; Haagsma, Juanita A.] Erasmus Univ, Dept Publ Hlth, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Von Steinbuechel, Nicole; Real, Ruben G. L.] Georg August Univ, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Haagsma, Juanita A.] Erasmus Univ, Dept Emergency Med, Med Ctr, Rotterdam, Netherlands	Voormolen, DC (corresponding author), Erasmus Univ, Dept Publ Hlth, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.voormolen@erasmusmc.nl	Gravesteijn, Benjamin/AAN-9524-2020	Gravesteijn, Benjamin/0000-0001-8096-5803	European UnionEuropean Commission [602150]; National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086090]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	The paper has been written in the context of the CENTER-TBI project. CENTER-TBI has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602150. TRACK-TBI has received funding from the National Institutes of Neurologic Disorders and Stroke, grant no U01 NS086090. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; FP7 Health [no 602150];	[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Clough M, 2018, J NEUROTRAUM, V35, P730, DOI 10.1089/neu.2017.5204; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; Edmed SL, 2014, BRAIN INJURY, V28, P1277, DOI 10.3109/02699052.2014.915988; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; EVANS RW, 1992, NEUROL CLIN, V10, P815; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Janssen B., 2014, SELF REPORTED POPULA, P19; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Subbian V, 2014, IEEE ENG MED BIO, P5353, DOI 10.1109/EMBC.2014.6944835; Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003; Voormolen DC, 2018, J NEUROTRAUM, V35, P1233, DOI 10.1089/neu.2017.5257; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Zakzanis KK, 2011, ARCH CLIN NEUROPSYCH, V26, P461, DOI 10.1093/arclin/acr021	33	11	11	1	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL 3	2019	33	8					1078	1086		10.1080/02699052.2019.1607557		APR 2019	9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IM6FW	WOS:000469575400001	31032649	Other Gold, Green Published			2021-06-18	
J	Elia, LP; Mason, AR; Alijagic, A; Finkbeiner, S				Elia, Lisa P.; Mason, Amanda R.; Alijagic, Amela; Finkbeiner, Steven			Genetic Regulation of Neuronal Progranulin Reveals a Critical Role for the Autophagy-Lysosome Pathway	JOURNAL OF NEUROSCIENCE			English	Article						AD; autophagy; FTD; lysosome; progranulin	PROTEIN 6 JMJD6; TRAUMATIC BRAIN-INJURY; MYOSIN VI; ACTIVATED MICROGLIA; ALZHEIMERS-DISEASE; CATHEPSIN-D; DYSFUNCTION; UBIQUITINATION; TRAFFICKING; BIOGENESIS	Deficient progranulin levels cause dose-dependent neurological syndromes: haploinsufficiency leads to frontotemporal lobar degeneration (FTLD) and nullizygosity produces adult-onset neuronal ceroid lipofuscinosis. Mechanisms controlling progranulin levels are largely unknown. To better understand progranulin regulation, we performed a genome-wide RNAi screen using an ELISA-based platform to discover genes that regulate progranulin levels in neurons. We identified 830 genes that raise or lower progranulin levels by at least 1.5-fold in Neuro2a cells. When inhibited by siRNA or some by submicromolar concentrations of small-molecule inhibitors, 33 genes of the druggable genome increased progranulin levels in mouse primary cortical neurons; several of these also raised progranulin levels in FTLD model mouse neurons. "Hit" genes regulated progranulin by transcriptional or posttranscriptional mechanisms. Pathway analysis revealed enrichment of hit genes from the autophagy-lysosome pathway (ALP), suggesting a key role for this pathway in regulating progranulin levels. Progranulin itself regulates lysosome function. We found progranulin deficiency in neurons increased autophagy and caused abnormally enlarged lysosomes and boosting progranulin levels restored autophagy and lysosome size to control levels. Our data link the ALP to neuronal progranulin: progranulin levels are regulated by autophagy and, in turn, progranulin regulates the ALP. Restoring progranulin levels by targeting genetic modifiers reversed FTLD functional deficits, opening up potential opportunities for future therapeutics development.	[Elia, Lisa P.; Finkbeiner, Steven] Koret Ctr Neurodegenerat Dis Res, Ctr Syst & Therapeut & Taube, San Francisco, CA 94117 USA; [Elia, Lisa P.; Alijagic, Amela; Finkbeiner, Steven] J David Gladstone Inst, San Francisco, CA 94158 USA; [Mason, Amanda R.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Finkbeiner, Steven] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Finkbeiner, Steven] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	Elia, LP; Finkbeiner, S (corresponding author), Koret Ctr Neurodegenerat Dis Res, Ctr Syst & Therapeut & Taube, San Francisco, CA 94117 USA.; Elia, LP; Finkbeiner, S (corresponding author), J David Gladstone Inst, San Francisco, CA 94158 USA.; Finkbeiner, S (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Finkbeiner, S (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA.	lisa.elia@gladstone.ucsf.edu; steve.finkbeiner@gladstone.ucsf.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS093236-01A1, 1P01AG054407, 1RF1AG058476]; Consortium for Frontotemporal Dementia Research; Taube/Koret Center for Neurodegenerative Disease Research; J. David Gladstone InstitutesUniversity of California System; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR18928]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083390, R21NS093236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG054407, RF1AG058476] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grants 1R21NS093236-01A1, 1P01AG054407, and 1RF1AG058476), the Consortium for Frontotemporal Dementia Research, the Taube/Koret Center for Neurodegenerative Disease Research, and the J. David Gladstone Institutes. The Gladstone Institutes received support from the National Center for Research Resources (Grant RR18928). We thank Robert V. Farese (Harvard Medical School), Andrew D. Nguyen (Harvard Medical School), and Ping Zhou (Gladstone Institute of Cardiovascular Disease) for kindly providing the GRN<SUP>+/-</SUP> and GRN<SUP>R493X/+</SUP> mice and the progranulin rabbit polyclonal antibody; Laura Mitic (UCSF) and members of the Finkbeiner lab for discussion and comments on these experiments; Megan Laurance (UCSF) for assistance with Ingenuity Pathway Analysis; Hui Wang for animal husbandry; Gary Howard for editorial assistance; and Kelley Nelson for administrative assistance. PSA was a gift from R.G. Kalb (Mojsilovic-Petrovic et al., 2009).	Ahmed Z, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-7; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Albanesi J, 2015, AUTOPHAGY, V11, P2127, DOI 10.1080/15548627.2015.1093718; Almeida S, 2016, NEUROBIOL AGING, V42, P35, DOI 10.1016/j.neurobiolaging.2016.03.001; Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Altieri DC, 2012, BBA-MOL CELL RES, V1823, P767, DOI 10.1016/j.bbamcr.2011.08.007; Amoroso MR, 2012, CELL DEATH DIFFER, V19, P592, DOI 10.1038/cdd.2011.128; Arrant AE, 2017, BRAIN, V140, P1447, DOI 10.1093/brain/awx060; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Baldo B, 2012, J BIOL CHEM, V287, P1406, DOI 10.1074/jbc.M111.294801; Barbosa IA, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12900; Barmada SJ, 2014, NAT CHEM BIOL, V10, P677, DOI 10.1038/nchembio.1563; Beel S, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0288-y; Beel S, 2017, HUM MOL GENET, V26, P2850, DOI 10.1093/hmg/ddx162; Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108; Bond LM, 2011, MOL BIOL CELL, V22, P54, DOI 10.1091/mbc.E10-06-0553; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Canuel M, 2008, BIOCHEM BIOPH RES CO, V373, P292, DOI 10.1016/j.bbrc.2008.06.021; Capell A, 2014, J BIOL CHEM, V289, P25879, DOI 10.1074/jbc.M114.560128; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Cenik B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193433; Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801; Chang MC, 2017, J EXP MED, V214, P2611, DOI 10.1084/jem.20160999; Chen YD, 2015, J NEUROL, V262, P814, DOI 10.1007/s00415-014-7630-2; Chitramuthu BP, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-41; Colombo M, 2013, J CELL SCI, V126, P5553, DOI 10.1242/jcs.128868; Elrick MJ, 2013, AUTOPHAGY, V9, P234, DOI 10.4161/auto.22501; Elrick MJ, 2012, HUM MOL GENET, V21, P4876, DOI 10.1093/hmg/dds324; Evers BM, 2017, CELL REP, V20, P2565, DOI 10.1016/j.celrep.2017.08.056; Gass J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-33; Gross C, 2008, ONCOGENE, V27, P1333, DOI 10.1038/sj.onc.1210736; Heim A, 2014, NUCLEIC ACIDS RES, V42, P7833, DOI 10.1093/nar/gku488; Heo SH, 2014, INT J BIOL SCI, V10, P438, DOI 10.7150/ijbs.8095; Hong DS, 2013, CANCER TREAT REV, V39, P375, DOI 10.1016/j.ctrv.2012.10.001; Hosokawa M, 2015, J NEUROPATH EXP NEUR, V74, P158, DOI 10.1097/NEN.0000000000000158; Hsiung GYR, 2011, J NEUROL SCI, V300, P28, DOI 10.1016/j.jns.2010.10.009; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jenzer C, 2014, AUTOPHAGY, V10, P1868, DOI 10.4161/auto.29745; Liu JL, 2015, MOL ENDOCRINOL, V29, P528, DOI 10.1210/me.2014-1266; Liu Y, 2019, ONCOGENE, V38, P980, DOI 10.1038/s41388-018-0466-y; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Luo L, 2014, MOL MED REP, V9, P1675, DOI 10.3892/mmr.2014.2016; Mantri M, 2011, CHEMBIOCHEM, V12, P531, DOI 10.1002/cbic.201000641; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Martens S, 2016, J CELL BIOL, V215, P761, DOI 10.1083/jcb.201611116; Matassa DS, 2012, AM J CANCER RES, V2, P235; McEwan DG, 2015, MOL CELL, V57, P39, DOI 10.1016/j.molcel.2014.11.006; Minami SS, 2014, NAT MED, V20, P1157, DOI 10.1038/nm.3672; Mojsilovic-Petrovic J, 2009, J NEUROSCI, V29, P8236, DOI 10.1523/JNEUROSCI.1805-09.2009; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Nguyen AD, 2018, P NATL ACAD SCI USA, V115, pE2849, DOI 10.1073/pnas.1722344115; Osaka M, 2015, HUM MOL GENET, V24, P1617, DOI 10.1093/hmg/ddu575; Pacheco CD, 2007, HUM MOL GENET, V16, P1495, DOI 10.1093/hmg/ddm100; Pacheco CD, 2007, AUTOPHAGY, V3, P487, DOI 10.4161/auto.4586; Park JH, 2016, BIOCHEM BIOPH RES CO, V477, P277, DOI 10.1016/j.bbrc.2016.06.057; Pereson S, 2009, J PATHOL, V219, P173, DOI 10.1002/path.2580; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Petkau TL, 2014, TRENDS NEUROSCI, V37, P388, DOI 10.1016/j.tins.2014.04.003; Petkau TL, 2012, NEUROBIOL DIS, V45, P711, DOI 10.1016/j.nbd.2011.10.016; Petoukhov E, 2013, J CELL SCI, V126, P5412, DOI 10.1242/jcs.132076; Picher-Martel V, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0162-6; Piscopo P, 2010, NEUROCHEM INT, V57, P893, DOI 10.1016/j.neuint.2010.09.008; Poulard C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087982; Putcha P, 2010, J PHARMACOL EXP THER, V332, P849, DOI 10.1124/jpet.109.158436; Rabinovici GD, 2010, CNS DRUGS, V24, P375, DOI 10.2165/11533100-000000000-00000; Rademakers R, 2012, NAT REV NEUROL, V8, P423, DOI 10.1038/nrneurol.2012.117; Riedl L, 2014, NEUROPSYCH DIS TREAT, V10, P297, DOI 10.2147/NDT.S38706; Ryan TA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01024; Semenchenko K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159531; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Suh HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035115; Takemoto K, 2011, NEUROCHEM INT, V58, P880, DOI 10.1016/j.neuint.2011.02.015; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tanaka Y, 2017, HUM MOL GENET, V26, P969, DOI 10.1093/hmg/ddx011; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tanimoto R, 2017, MATRIX BIOL, V64, P27, DOI 10.1016/j.matbio.2017.04.001; Nguyen TN, 2016, J CELL BIOL, V215, P857, DOI 10.1083/jcb.201607039; Tsai WC, 2017, J BIOL CHEM, V292, P18886, DOI 10.1074/jbc.M117.800706; Tsvetkov AS, 2013, NAT CHEM BIOL, V9, P586, DOI [10.1038/NCHEMBIO.1308, 10.1038/nchembio.1308]; Tsvetkov AS, 2010, P NATL ACAD SCI USA, V107, P16982, DOI 10.1073/pnas.1004498107; Tumbarello DA, 2013, J CELL SCI, V126, P2561, DOI 10.1242/jcs.095554; Tumbarello DA, 2012, NAT CELL BIOL, V14, P1024, DOI 10.1038/ncb2589; Unoki M, 2013, J BIOL CHEM, V288, P6053, DOI 10.1074/jbc.M112.433284; Walport LJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11974; Wang HZ, 2015, P NATL ACAD SCI USA, V112, P7015, DOI 10.1073/pnas.1507263112; Wang TL, 2010, TRAFFIC, V11, P1119, DOI 10.1111/j.1600-0854.2010.01098.x; Ward ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5642; Wasylyk C, 2008, CANCER RES, V68, P1275, DOI 10.1158/0008-5472.CAN-07-2674; Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865; Xu HM, 2017, MOL NEUROBIOL, V54, P1187, DOI 10.1007/s12035-016-9698-4; Zhang MS, 2012, NAT METHODS, V9, P727, DOI [10.1038/NMETH.2021, 10.1038/nmeth.2021]; Zhang XN, 2015, J BIOL CHEM, V290, P20273, DOI 10.1074/jbc.M115.646554; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069; Zheng YQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021023; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029; 2011, J NEUROSCI, V31, P1885, DOI DOI 10.1523/JNEUROSCI.5757-10.2011; 2013, J ALZHEIMERS DIS, V33, P23, DOI DOI 10.3233/JAD-2012-120946; 2014, ACTA NEUROPATHOL, V127, P845, DOI DOI 10.1007/S00401-014-1262-6	100	11	11	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 24	2019	39	17					3332	3344		10.1523/JNEUROSCI.3498-17.2019			13	Neurosciences	Neurosciences & Neurology	HU7VT	WOS:000465492300014	30696728	Green Published, Bronze			2021-06-18	
J	Carlozzi, NE; Kallen, MA; Sander, AM; Brickell, TA; Lange, RT; French, LM; Ianni, PA; Miner, JA; Hanks, R				Carlozzi, Noelle E.; Kallen, Michael A.; Sander, Angelle M.; Brickell, Tracey A.; Lange, Rael T.; French, Louis M.; Ianni, Phillip A.; Miner, Jennifer A.; Hanks, Robin			The Development of a New Computer Adaptive Test to Evaluate Anxiety in Caregivers of Individuals With Traumatic Brain Injury: TBI-CareQOL Caregiver-Specific Anxiety	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Caregiver; Families of Veterans; Health-related quality of life; Patient reported outcome; Rehabilitation; Traumatic brain injury; Veterans	QUALITY-OF-LIFE; SOCIAL SUPPORT; FAMILY CAREGIVERS; TIME-COURSE; RECOVERY; OUTCOMES; PREDICTORS; REHABILITATION; BURDEN; SCALE	Objective: To design a new measure of caregiver-specific anxiety for use in caregivers of individuals with traumatic brain injury (TBI), the Traumatic Brain Injury Caregiver Quality of Life (TBI-CareQOL) Caregiver-Specific Anxiety item bank. Design: Cross-sectional survey study. Setting: Three TBI Model Systems rehabilitation hospitals, an academic medical center, and a military medical treatment facility. Participants: Three hundred forty-four caregivers of civilians with TBI and 216 caregivers of service members/veterans with TBI (N=560). Interventions: Not applicable. Main Outcome Measures: TBI-CareQOL Caregiver-Specific Anxiety item bank. Results: The retention of 40 Caregiver-Specific Anxiety items was supported by exploratory and confirmatory factor analyses. Graded response model (GRM) and differential item functioning analyses supported the retention of 33 items in the final measure. Expert review and GRM calibration data was used to select a 6-item static short form, and GRM calibration data was used to program the TBI-CareQOL Caregiver-Specific Anxiety computer adaptive test (CAT). Conclusions: Established, rigorous measurement development standards were used to develop the new TBI-CareQOL Caregiver-Specific Anxiety CAT and corresponding 6-item short form. This measure is the first patient-reported outcome measure designed to assess caregiver-specific anxiety in caregivers of individuals with TBI. The measure exhibits strong psychometric properties. (C) 2018 by the American Congress of Rehabilitation Medicine	[Carlozzi, Noelle E.; Ianni, Phillip A.; Miner, Jennifer A.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Kallen, Michael A.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Sander, Angelle M.] Baylor Coll Med, H Ben Taub Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] Harris Hlth Syst, Houston, TX USA; [Sander, Angelle M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada; [Hanks, Robin] Rehabil Inst Michigan, Dept Psychol & Neuropsychol, Detroit, MI USA; [Hanks, Robin] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR013658]; National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002240, UL1TR000433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	Supported by grant number R01NR013658 from the National Institutes of Health, National Institute of Nursing Research, the National Center for Advancing Translational Sciences (UL1TR000433), and the Defense and Veterans Brain Injury Center. We thank the investigators, coordinators, and research associates/assistants who worked on this study and organizations who supported recruitment efforts. The University of Michigan Research Team would also like to thank the Hearts of Valor and the Brain Injury Association of Michigan for assistance with community outreach for recruitment efforts at this site.	Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Burns Anthony S, 2012, Handb Clin Neurol, V109, P47, DOI 10.1016/B978-0-444-52137-8.00003-6; Cappelleri JC, 2014, CLIN THER, V36, P648, DOI 10.1016/j.clinthera.2014.04.006; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS1, DOI 10.1016/j.apmr.2018.08.175; Carlozzi NE, 2016, J REHABIL RES DEV, V53, P669, DOI 10.1682/JRRD.2015.07.0136; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Cook KF, 2009, QUAL LIFE RES, V18, P447, DOI 10.1007/s11136-009-9464-4; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Crane PK, 2006, MED CARE, V44, pS115, DOI 10.1097/01.mlr.0000245183.28384.ed; Degeneffe CE, 2011, REHABIL PSYCHOL, V56, P243, DOI 10.1037/a0024465; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dillahunt-Aspillaga C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082896; DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431; DVBIC, 2015, DOD WORLDW NUMB TBI; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Hanauer DA, 2015, J BIOMED INFORM, V55, P290, DOI 10.1016/j.jbi.2015.05.003; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hatcher L., 1994, STEP BY STEP APPROAC; Holland JN, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/902802; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kitter B, 2015, BRAIN INJURY, V29, P1082, DOI 10.3109/02699052.2015.1018323; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Kratz AL, 2017, NEUROPSYCHOL REHABIL, V27, P16, DOI 10.1080/09602011.2015.1051056; Kreutzer JS, 2010, J HEAD TRAUMA REHAB, V25, P113, DOI 10.1097/HTR.0b013e3181cf0712; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Manskow US, 2015, J HEAD TRAUMA REHAB, V30, P411, DOI 10.1097/HTR.0000000000000085; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mazlan M, 2016, DISABIL REHABIL, V38, P2198, DOI 10.3109/09638288.2015.1123307; McDonald R. P., 1999, TEST THEORY UNIFIED; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Ramkumar NA, 2010, NEUROREHABILITATION, V27, P105, DOI 10.3233/NRE-2010-0585; Reise SP, 2007, QUAL LIFE RES, V16, P19, DOI 10.1007/s11136-007-9183-7; Samejima F, 1996, HDB MODERN ITEM RESP, P85, DOI DOI 10.1007/978-1-4757-2691-6_5; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2013, BRAIN IMPAIR, V14, P113, DOI 10.1017/BrImp.2013.12; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P842, DOI 10.1016/j.apmr.2011.11.031; Schonberger M, 2010, NEUROPSYCHOL REHABIL, V20, P813, DOI 10.1080/09602011003620077; Smith A M, 1998, Rehabil Nurs, V23, P252; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Temple JL, 2016, BRAIN INJURY, V30, P1672, DOI 10.3109/02699052.2015.1113561; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Waters R L, 1998, J Spinal Cord Med, V21, P195; WATERS RL, 1993, ARCH PHYS MED REHAB, V74, P242; WATERS RL, 1992, ARCH PHYS MED REHAB, V73, P784; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P67; Zaider TI, 2003, PSYCHOL MED, V33, P611, DOI 10.1017/S0033291703007414	62	11	11	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2019	100	4		1			S22	S30		10.1016/j.apmr.2018.05.027			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HR2FV	WOS:000462951900003	29958902	Green Accepted			2021-06-18	
J	Hogg, FRA; Gallagher, MJ; Chen, SL; Zoumprouli, A; Papadopoulos, MC; Saadoun, S				Hogg, Florence R. A.; Gallagher, Mathew J.; Chen, Suliang; Zoumprouli, Argyro; Papadopoulos, Marios C.; Saadoun, Samira			Predictors of Intraspinal Pressure and Optimal Cord Perfusion Pressure After Traumatic Spinal Cord Injury	NEUROCRITICAL CARE			English	Article						Blood pressure; Perfusion pressure; Spinal cord injury; Trauma	OPTIMAL RADIOLOGIC METHOD; INTRACRANIAL-PRESSURE; REACTIVITY INDEX; CANAL COMPROMISE; PART II; BRAIN; COMPRESSION; AGE; DUROPLASTY	Background/ObjectivesWe recently developed techniques to monitor intraspinal pressure (ISP) and spinal cord perfusion pressure (SCPP) from the injury site to compute the optimum SCPP (SCPPopt) in patients with acute traumatic spinal cord injury (TSCI). We hypothesized that ISP and SCPPopt can be predicted using clinical factors instead of ISP monitoring.MethodsSixty-four TSCI patients, grades A-C (American spinal injuries association Impairment Scale, AIS), were analyzed. For 24h after surgery, we monitored ISP and SCPP and computed SCPPopt (SCPP that optimizes pressure reactivity). We studied how well 28 factors correlate with mean ISP or SCPPopt including 7 patient-related, 3 injury-related, 6 management-related, and 12 preoperative MRI-related factors.ResultsAll patients underwent surgery to restore normal spinal alignment within 72h of injury. Fifty-one percentage had U-shaped sPRx versus SCPP curves, thus allowing SCPPopt to be computed. Thirteen percentage, all AIS grade A or B, had no U-shaped sPRx versus SCPP curves. Thirty-six percentage (22/64) had U-shaped sPRx versus SCPP curves, but the SCPP did not reach the minimum of the curve, and thus, an exact SCPPopt could not be calculated. In total 5/28 factors were associated with lower ISP: older age, excess alcohol consumption, nonconus medullaris injury, expansion duroplasty, and less intraoperative bleeding. In a multivariate logistic regression model, these 5 factors predicted ISP as normal or high with 73% accuracy. Only 2/28 factors correlated with lower SCPPopt: higher mean ISP and conus medullaris injury. In an ordinal multivariate logistic regression model, these 2 factors predicted SCPPopt as low, medium-low, medium-high, or high with only 42% accuracy. No MRI factors correlated with ISP or SCPPopt.ConclusionsElevated ISP can be predicted by clinical factors. Modifiable factors that may lower ISP are: reducing surgical bleeding and performing expansion duroplasty. No factors accurately predict SCPPopt; thus, invasive monitoring remains the only way to estimate SCPPopt.	[Hogg, Florence R. A.; Gallagher, Mathew J.; Chen, Suliang; Papadopoulos, Marios C.; Saadoun, Samira] St Georges Univ London, Acad Neurosurgery Unit, Mol & Clin Sci Inst, London SW17 0RE, England; [Zoumprouli, Argyro] St George Hosp, Neurointens Care Units, London, England	Saadoun, S (corresponding author), St Georges Univ London, Acad Neurosurgery Unit, Mol & Clin Sci Inst, London SW17 0RE, England.	ssaadoun@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Saadoun, Samira/0000-0002-5480-5678; Zoumprouli, Argyro/0000-0003-0890-690X	Wings for Life Spinal Cord Research Foundation; Neurosciences Research Foundation (Fletcher Fund); London Deanery; Fletcher Fund; Neurosciences Research Foundation	This work was supported by grants awarded to MCP and SS from the Wings for Life Spinal Cord Research Foundation and to MCP from the Neurosciences Research Foundation (Fletcher Fund). FRAH is a UK Stem Cell Foundation and Royal College of Surgeons of England research fellow. MJG is supported by the Neurosciences Research Foundation (Fletcher Fund) and the London Deanery. Supported by the Wings for Life Spinal Cord Research Foundation, the Fletcher Fund, the Neurosciences Research Foundation and the London Deanery.	[Anonymous], 2014, J Spinal Cord Med, V37, P659, DOI 10.1179/1079026814Z.000000000341; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Biering-Sorensen F, 2015, SPINAL CORD, V53, P265, DOI 10.1038/sc.2014.246; BONDURANT FJ, 1990, SPINE, V15, P161, DOI 10.1097/00007632-199003000-00002; Chen SL, 2017, J NEUROTRAUM, V34, P2941, DOI 10.1089/neu.2017.4982; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Fehlings MG, 1999, SPINE, V24, P605, DOI 10.1097/00007632-199903150-00023; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Gallagher MJ, J NEUROTRAUMA; Garcia-Valdecasas-Campelo E, 2007, ALCOHOL ALCOHOLISM, V42, P533, DOI 10.1093/alcalc/agm065; HARPER C, 1985, J NEUROL NEUROSUR PS, V48, P211, DOI 10.1136/jnnp.48.3.211; Huber E, 2017, ANN NEUROL, V81, P740, DOI 10.1002/ana.24932; Kato F, 2012, EUR SPINE J, V21, P1499, DOI 10.1007/s00586-012-2176-4; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Papadopoulos MC, 2015, NEUROSURGERY, V77, pE500, DOI 10.1227/NEU.0000000000000862; Park JW, 2016, J INT MED RES, V44, P950, DOI 10.1177/0300060516652751; Phang I, 2016, ANN NEUROL, V80, P522, DOI 10.1002/ana.24750; Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Rao SC, 1999, SPINE, V24, P598, DOI 10.1097/00007632-199903150-00022; Ruegg TB, 2015, J NEUROSURG-SPINE, V22, P230, DOI 10.3171/2014.10.SPINE14346; Saadoun S, 2016, BRIT J NEUROSURG, V30, P582, DOI 10.3109/02688697.2016.1173191; Skeers P, 2018, J BONE JOINT SURG AM, V100, P305, DOI 10.2106/JBJS.16.00995; Squair JW, 2017, NEUROLOGY, V89, P1660, DOI 10.1212/WNL.0000000000004519; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Talbott JF, 2015, J NEUROSURG-SPINE, V23, P495, DOI 10.3171/2015.1.SPINE141033; Tykocki T, 2017, WORLD NEUROSURG, V105, P145, DOI 10.1016/j.wneu.2017.05.138; van Middendorp JJ, 2011, GLOB SPINE J, V1, P1, DOI 10.1055/s-0031-1296049; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870; Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f; Werndle MC, 2016, ACTA NEUROCHIR SUPPL, V122, P323, DOI 10.1007/978-3-319-22533-3_64; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	39	11	12	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2019	30	2					421	428		10.1007/s12028-018-0616-7			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	HP0UB	WOS:000461380900026	30328047	Green Published, Green Accepted, Other Gold			2021-06-18	
J	Howell, DR; Myer, GD; Grooms, D; Diekfuss, J; Yuan, WH; Meehan, WP				Howell, David R.; Myer, Gregory D.; Grooms, Dustin; Diekfuss, Jed; Yuan, Weihong; Meehan, William P., III			Examining Motor Tasks of Differing Complexity After Concussion in Adolescents	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Attention; Locomotion; Postural balance; Rehabilitation	TRAUMATIC BRAIN-INJURY; GAIT BALANCE CONTROL; DUAL-TASK; PERFORMANCE; ABNORMALITIES; STABILITY; RECOVERY; WALKING; SPEED; RISK	Objectives: (1) To determine the effects of concussion-related motor impairments at different task complexities in isolation and with a cognitive dual-task and (2) to determine if self-reported balance deficits after concussion are associated with gait, quiet stance, or cognitive dual-task impairments. Design: Cross-sectional study. Setting: Sports medicine clinic. Participants: Adolescent athletes clinically diagnosed with a sport-related concussion and those without concussion. Forty-nine patients with concussion (mean age = 14.9 +/- 1.9y; 51% female; tested 7.0 +/- 3.0d postinjury) and 65 control participants (mean age= -14.9 +/- 1.6y; 52% female) completed the study (N =114). Interventions: Athletes with concussion completed a single-task and dual-task standing and walking protocol within 14 days of injury and were compared to those without concussion. Main Outcome Measures: Outcome measures included gait speed, quiet stance (root mean square [RMS] coronal/sagittal plane sway), and cognitive performance (accuracy). Dual-task costs were calculated as the percentage change between single-task and dual-task conditions. Participants with concussion were then stratified by those who did and did not report subjective balance problems at the time of testing and compared using objective balance and gait metrics. Results: The concussion group walked slower during dual-task gait than controls (0.83 +/- 0.17 m/s vs 0.92 +/- 0.15 m/s; Cohen's d=0.53). Dual-task quiet stance RMS sway values were similar for concussion and control groups in coronal (1.20 +/- 0.52 m/s(-2) vs 1.26 +/- 0.65 m/s(-2); d=0.09) and sagittal (0.56 +/- 0.24 m/s(-2) vs 0.73 +/- 0.44 m/s(-2); d = 0.20) movement planes. The concussion participants with subjectively-reported balance problems had significantly greater walking speed dual-task costs than concussion participants without self-reported balance problems (-25 +/- 10% vs -19 +/- 9%; P = .02). Conclusions: Following concussion, adolescents demonstrate slower gait speeds, but similar quiet stance values relative to those without concussion. The study results indicate that tasks requiring greater motor coordination may elicit greater alterations following a concussion. (C) 2018 by the American Congress of Rehabilitation Medicine	[Howell, David R.] Childrens Hosp Colorado, Sports Med Ctr, 13123 E 16th Ave,B060, Aurora, CO 80045 USA; [Howell, David R.] Univ Colorado, Sch Med, Dept Orthoped, Aurora, CO USA; [Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Myer, Gregory D.; Diekfuss, Jed] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, SPORT Ctr, Cincinnati, OH 45229 USA; [Grooms, Dustin] Ohio Univ, Coll Hlth Sci & Profess, Sch Appl Hlth Sci & Wellness, Ohio Musculoskeletal & Neurol Inst, Athens, OH 45701 USA; [Grooms, Dustin] Ohio Univ, Coll Hlth Sci & Profess, Sch Appl Hlth Sci & Wellness, Div Athlet Training, Athens, OH 45701 USA; [Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Radiol, Cincinnati, OH 45229 USA; [Yuan, Weihong] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthoped Surg, Boston, MA 02115 USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA	Howell, DR (corresponding author), Childrens Hosp Colorado, Sports Med Ctr, 13123 E 16th Ave,B060, Aurora, CO 80045 USA.	David.Howell@ucdenver.edu	Grooms, Dustin/AAO-8917-2021; Diekfuss, Jed/ABD-7372-2020; Myer, Gregory/H-6572-2016	Grooms, Dustin/0000-0001-6102-8224; Diekfuss, Jed/0000-0003-3835-363X; Howell, David/0000-0002-2955-0191; Myer, Gregory/0000-0002-9983-8422	Eunice Kennedy Shriver National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Boston Children's Hospital; Cincinnati Children's Hospital Medical Center; ElMindA Ltd.; National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament	Unrelated to this study, Dr. Howell has received research support from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, the National Institute of Neurological Disorders and Stroke, and a research contract between Boston Children's Hospital, Cincinnati Children's Hospital Medical Center, and ElMindA Ltd. Dr. Meehan receives royalties from ABC-Clio publishing for the sale of his books, Kids, Sports, and Concussion: A Guide for Coaches and Parents and Concussions; Springer International for the book Head and Neck Injuries in Young Athlete; and Wolters Kluwer for working as an author for UpToDate. His research is funded, in part, by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.	Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Berkner J, 2017, J ATHL TRAINING, V52, P1089, DOI 10.4085/1062-6050-52.11.23; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Cossette I, 2016, BRAIN INJURY, V30, P1648, DOI 10.1080/02699052.2016.1200143; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fino PC, 2018, GAIT POSTURE, V62, P157, DOI 10.1016/j.gaitpost.2018.03.021; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell DR, 2018, J NEUROTRAUM, V35, P1630, DOI 10.1089/neu.2017.5570; Howell DR, 2018, CLIN J SPORT MED, V28, P262, DOI 10.1097/JSM.0000000000000439; Howell DR, 2018, SPORTS MED, V48, P1097, DOI 10.1007/s40279-018-0871-y; Howell DR, 2018, J SCI MED SPORT, V21, P358, DOI 10.1016/j.jsams.2017.08.004; Howell DR, 2017, J NEUROTRAUM, V34, P3288, DOI 10.1089/neu.2017.5191; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kelly VE, 2010, EXP BRAIN RES, V207, P65, DOI 10.1007/s00221-010-2429-6; King LA, 2017, ANN BIOMED ENG, V45, P2135, DOI 10.1007/s10439-017-1856-y; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Moreau NG, 2016, PHYS THER, V96, P1938, DOI 10.2522/ptj.20150401; Oldham JR, 2018, MED SCI SPORT EXER, V50, P1162, DOI 10.1249/MSS.0000000000001540; Paker N, 2015, J PHYS THER SCI, V27, P3675, DOI 10.1589/jpts.27.3675; Plummer P, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00225; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Rochefort C, 2017, J SCI MED SPORT, V20, P970, DOI 10.1016/j.jsams.2017.04.008; Rochefort C, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117695507; Ruffieux J, 2015, SPORTS MED, V45, P1739, DOI 10.1007/s40279-015-0369-9; Stephens J, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.025361; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Teel E, 2016, NEUROPSYCHOLOGY, V30, P474, DOI 10.1037/neu0000261; Wilkerson GB, 2017, CURR SPORT MED REP, V16, P419, DOI 10.1249/JSR.0000000000000430; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; Zhang AL, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116662458	38	11	11	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2019	100	4					613	619		10.1016/j.apmr.2018.07.441			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HR2FU	WOS:000462951800004	30193950				2021-06-18	
J	Kosari-Nasab, M; Shokouhi, G; Ghorbanihaghjo, A; Mesgari-Abbasi, M; Salari, AA				Kosari-Nasab, Morteza; Shokouhi, Ghaffar; Ghorbanihaghjo, Amir; Mesgari-Abbasi, Mehran; Salari, Ali-Akbar			Quercetin mitigates anxiety-like behavior and normalizes hypothalamus-pituitary-adrenal axis function in a mouse model of mild traumatic brain injury	BEHAVIOURAL PHARMACOLOGY			English	Article						adrenocorticotropic hormone; anxiety; brain injury; depression; hypothalamus-pituitary-adrenal axis; mouse; quercetin	DEPRESSION-LIKE BEHAVIORS; ANXIOGENIC-LIKE BEHAVIOR; OXIDATIVE STRESS; HPA AXIS; MAJOR DEPRESSION; RAT MODEL; PROTECTS; DYSFUNCTION; MEMORY; ACETYLCHOLINESTERASE	Mild traumatic brain injury (mTBI) is a major public health risk for developing anxiety-related disorders and hypothalamus-pituitary-adrenal (HPA) axis dysregulation in humans. Extensive research has shown that dietary intake or supplementation of the natural flavonoid quercetin might be useful for treating anxiety-related symptoms. The objectives of this study were to determine whether quercetin treatment can attenuate anxiogenic-like behaviors and normalize HPA axis function in mice with mTBI. Animals subjected to mTBI were treated daily with quercetin (50mg/kg) or diazepam (positive control, 3mg/kg) for 14 days. Four behavioral tests (open field, plus maze, light-dark box, and zero maze) were used to assess anxiety-related behaviors in mice. To evaluate HPA axis function, adrenocorticotropic hormone and corticosterone were measured in the serum of mice after the anxiety tests. Quercetin treatment was found to significantly reduce anxiety-like behaviors in mTBI-induced mice. A strength of this study is the consistency of results among anxiety tests. The dysregulation of the HPA axis in mTBI-induced mice treated with quercetin was also attenuated, with decreased levels of adrenocorticotropic hormone and corticosterone. The effects of quercetin were comparable with those of diazepam treatment. Taken together, these results suggest that quercetin might be useful for treating anxiety-related symptoms and HPA axis hyperreactivity in patients with mTBI.	[Kosari-Nasab, Morteza; Shokouhi, Ghaffar; Ghorbanihaghjo, Amir; Mesgari-Abbasi, Mehran; Salari, Ali-Akbar] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Shokouhi, Ghaffar] Tabriz Univ Med Sci, Dept Neurosurg, Tabriz, Iran; [Shokouhi, Ghaffar] Tabriz Univ Med Sci, Neurosci Res Ctr, Tabriz, Iran; [Ghorbanihaghjo, Amir] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran; [Salari, Ali-Akbar] SICBD, Alborz, Iran	Shokouhi, G (corresponding author), Tabriz Univ Med Sci, Drug Appl Res Ctr, Alborz, Iran.	shokouhigh@yahoo.com	Salari, Ali-Akbar/I-7843-2013	Salari, Ali-Akbar/0000-0002-4970-0337; Kosari-Nasab, Morteza/0000-0001-8454-5873	Drug Applied Research Center at Tabriz University of Medical Sciences [GN94/77]	This study was supported by the Drug Applied Research Center at Tabriz University of Medical Sciences (GN94/77).	Abdalla FH, 2014, PHYSIOL BEHAV, V135, P152, DOI 10.1016/j.physbeh.2014.06.008; Abelson JL, 2007, DEPRESS ANXIETY, V24, P66, DOI 10.1002/da.20220; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Ayatollahi AM, 2017, NEUROL RES, V39, P1056, DOI 10.1080/01616412.2017.1376789; Babri S, 2014, BRAIN BEHAV IMMUN, V37, P164, DOI 10.1016/j.bbi.2013.12.003; Bhutada P, 2010, PROG NEURO-PSYCHOPH, V34, P955, DOI 10.1016/j.pnpbp.2010.04.025; Chakraborty J, 2014, CNS NEUROSCI THER, V20, P10, DOI 10.1111/cns.12189; Davis JM, 2008, AM J PHYSIOL-REG I, V295, pR505, DOI 10.1152/ajpregu.90319.2008; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Du GL, 2018, MOL MED REP, V17, P7859, DOI 10.3892/mmr.2018.8801; Du GL, 2016, NEUROL RES, V38, P1012, DOI 10.1080/01616412.2016.1240393; Esmaeili MH, 2018, BRAIN RES BULL, V137, P265, DOI 10.1016/j.brainresbull.2018.01.001; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Gibellini L., 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1093/ECAM/NEQ053; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Haleagrahara N, 2009, EUR J PHARMACOL, V621, P46, DOI 10.1016/j.ejphar.2009.08.030; Jung CH, 2013, PHYTOTHER RES, V27, P139, DOI 10.1002/ptr.4687; Kawabata K, 2010, J NUTR BIOCHEM, V21, P374, DOI 10.1016/j.jnutbio.2009.01.008; Kim JH, 2011, NUTR RES PRACT, V5, P107, DOI 10.4162/nrp.2011.5.2.107; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kosari-Nasab M, 2018, BEHAV PHARM; Kosari-Nasab M, 2019, METAB BRAIN DIS; Kosari-Nasab M, 2018, LIFE SCI, V213, P198, DOI 10.1016/j.lfs.2018.10.040; Kosari-Nasab M, 2018, TOXICOL APPL PHARM, V338, P159, DOI 10.1016/j.taap.2017.11.012; Kosari-Nasab M, 2014, BEHAV PHARMACOL, V25, P325, DOI 10.1097/FBP.0000000000000051; Kumar A, 2008, J MED FOOD, V11, P469, DOI 10.1089/jmf.2006.0207; Maciel RM, 2016, BIOMED PHARMACOTHER, V84, P559, DOI 10.1016/j.biopha.2016.09.069; Sabogal-Guaqueta AM, 2015, NEUROPHARMACOLOGY, V93, P134, DOI 10.1016/j.neuropharm.2015.01.027; Marina M, 2010, J PHARM PHARM SCI, V13, P311, DOI 10.18433/J3VS3S; Mehta V, 2017, PHYSIOL BEHAV, V171, P69, DOI 10.1016/j.physbeh.2017.01.006; Merzoug S, 2014, N-S ARCH PHARMACOL, V387, P921, DOI 10.1007/s00210-014-1008-y; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Pariante CM, 2008, TRENDS NEUROSCI, V31, P464, DOI 10.1016/j.tins.2008.06.006; Pei B, 2016, BIOCHEM BIOPH RES CO, V478, P199, DOI 10.1016/j.bbrc.2016.07.068; Ravindran LN, 2010, J CLIN PSYCHIAT, V71, P839, DOI 10.4088/JCP.10r06218blu; Reul JMHM, 2002, CURR OPIN PHARMACOL, V2, P23, DOI 10.1016/S1471-4892(01)00117-5; Rinwa P, 2013, NEUROSCIENCE, V255, P86, DOI 10.1016/j.neuroscience.2013.09.044; Rogerio AP, 2010, PHARMACOL RES, V61, P288, DOI 10.1016/j.phrs.2009.10.005; Sah SP, 2011, INDIAN J PHARMACOL, V43, P192, DOI 10.4103/0253-7613.77365; Salari AA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29595-0; Salari AA, 2017, INT J DEV NEUROSCI, V57, P62, DOI 10.1016/j.ijdevneu.2017.01.007; Samad N, 2018, PHYSIOL RES, V67, P795, DOI 10.33549/physiolres.933776; Selvakumar K, 2013, TOXICOL LETT, V222, P45, DOI 10.1016/j.toxlet.2013.06.237; Toumi ML, 2013, PHARMACOL BIOCHEM BE, V107, P1, DOI 10.1016/j.pbb.2013.03.009; Unsal C, 2015, TOXICOL IND HEALTH, V31, P1106, DOI 10.1177/0748233713486960; Yang T, 2014, CELL MOL NEUROBIOL, V34, P797, DOI 10.1007/s10571-014-0070-9; Youdim KA, 2004, FREE RADICAL BIO MED, V36, P592, DOI 10.1016/j.freeradbiomed.2003.11.023	51	11	12	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0955-8810	1473-5849		BEHAV PHARMACOL	Behav. Pharmacol.	APR	2019	30	2-3			SI		282	289		10.1097/FBP.0000000000000480			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	HR2SZ	WOS:000462988600017	30882424				2021-06-18	
J	Yu, ST; Liu, HX; Li, K; Qin, ZG; Qin, XM; Zhu, P; Li, ZY				Yu, Shuting; Liu, Haixia; Li, Kun; Qin, Zhengguo; Qin, Xuemei; Zhu, Ping; Li, Zhenyu			Rapid characterization of the absorbed constituents in rat serum after oral administration and action mechanism of Naozhenning granule using LC-MS and network pharmacology	JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS			English	Article						Naozhenning granule; UHPLC-Qexactive quadrupole-orbitrap MS; Metabolites; Prototype components; Network pharmacology	MAJOR BIOACTIVE COMPONENTS; REHMANNIA-GLUTINOSA; CEREBRAL-ISCHEMIA; MAPK PATHWAY; IDENTIFICATION; METABOLITES; INJURY; ACTIVATION; DECOCTION; DANSHEN	Naozhenning granule is a Chinese herbal formula, which is mainly used in the treatment of concussion, cerebral post-traumatic syndrome. Although its effectiveness has been certified in the clinical use, the mechanism of action and bioactive components of Naozhenning remain unknown. In this study, the ultrahigh performance liquid chromatography coupled with hybrid quadrupole-orbitrap mass spectrometry was applied to identify the absorbed constituents of Naozhenning in the rat serum. A total of 60 compounds, including 30 prototype components and 30 metabolites were identified. Then the absorbed constituents were subjected to the network pharmacology analysis. The compound-target-disease (CTD) and KEGG pathway analysis revealed that 40 absorbed constituents, 56 target genes and three key pathways such as RAS, PI3K/Akt, MAPK, TGF beta were probably related with the efficacy of Naozhenning against cerebral trauma and cerebral concussion. The results provided a scientific basis for understanding the bioactive compounds and the pharmacological mechanism of Naozhenning granule. (C) 2019 Elsevier B.V. All rights reserved.	[Yu, Shuting; Qin, Xuemei; Li, Zhenyu] Shanxi Univ, Modern Res Ctr Tradit Chinese Med, Taiyuan 030006, Shanxi, Peoples R China; [Liu, Haixia; Li, Kun; Qin, Zhengguo; Zhu, Ping] Shanxi Zhendong Ante Biol Pharmaceut Co Ltd, Jinzhong 030600, Peoples R China; [Yu, Shuting] Shanxi Univ, Coll Chem & Chem Engn, Taiyuan 030006, Shanxi, Peoples R China	Li, ZY (corresponding author), Shanxi Univ, Modern Res Ctr Tradit Chinese Med, Taiyuan 030006, Shanxi, Peoples R China.; Zhu, P (corresponding author), Shanxi Zhendong Ante Biol Pharmaceut Co Ltd, Jinzhong 030600, Peoples R China.	zp8236@sohu.com; lizhenyu@sxu.edu.cn			Program of Science and Technology of Shanxi Province [201603D3113003, 2106ZD0404]; Shanxi Provincial Education Department [2018JD05]; Key Laboratory of Effective Substances Research and Utilization in TCM of Shanxi Province [201605D111004]	This study was financially supported by the Program of Science and Technology of Shanxi Province (Nos. 201603D3113003, 2106ZD0404), Shanxi Provincial Education Department (2018JD05), Key Laboratory of Effective Substances Research and Utilization in TCM of Shanxi Province (201605D111004). We also thank Scientific Instrument Center of Shanxi University for the LC-MS analysis.	Bai YJ, 2014, J PHARMACEUT BIOMED, V94, P77, DOI 10.1016/j.jpba.2014.01.036; Bi J, 2009, NEUROCHEM INT, V54, P264, DOI 10.1016/j.neuint.2008.12.003; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Comstock K., GENE EISERBERG RAPID; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Guo C, 2015, PHYTOMEDICINE, V22, P283, DOI 10.1016/j.phymed.2014.12.001; Han D. D., 2016, EVID-BASED COMPL ALT, V2016, P1; He HF, 2018, DRUG DES DEV THER, V12, P629, DOI 10.2147/DDDT.S158313; Hong M., 2017, MOLECULES, V22, P1; Huang JH, 2017, MOL MED REP, V16, P4583, DOI 10.3892/mmr.2017.7149; Huang T., 2018, FRONT PHARMACOL, V270, P1; Kovalska M, 2012, NEUROCHEM RES, V37, P1568, DOI 10.1007/s11064-012-0752-y; Lee Y, 2018, EUR J OBSTET GYN R B, V221, P151, DOI 10.1016/j.ejogrb.2017.12.047; Li JA, 2018, NEURAL REGEN RES, V13, P298, DOI 10.4103/1673-5374.226400; Lin ZT, 2014, PHYTOCHEM ANALYSIS, V25, P485, DOI 10.1002/pca.2517; Liu CF, 2013, J ETHNOPHARMACOL, V145, P509, DOI 10.1016/j.jep.2012.11.021; Luo XQ, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0173-1; Ortuno-Sahagun D, 2014, J MOL NEUROSCI, V52, P366, DOI 10.1007/s12031-013-0157-7; Pang HH, 2018, J ZHEJIANG UNIV-SC B, V19, P227, DOI 10.1631/jzus.B1700105; Qian YY, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-42; Shi P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092937; Tao JH, 2017, CHIN HERB MED, V9, P147, DOI [10.1016/s1674-6384(17)60088-1, 10.1016/S1674-6384(17)60088-1]; Tao JH, 2015, J CHROMATOGR B, V1001, P98, DOI 10.1016/j.jchromb.2015.07.035; Wang X. J., 2017, CHIN J NEUROTRAUMA S, V3, P292; Wen XD, 2012, J PHARMACEUT BIOMED, V67-68, P114, DOI 10.1016/j.jpba.2012.04.026; Willems JL, 2016, ANAL CHIM ACTA, V933, P164, DOI 10.1016/j.aca.2016.05.041; Xiao S, 2005, J MOD MED HLTH, V21, P1711; Xu DD, 2016, NEUROCHEM RES, V41, P2086, DOI 10.1007/s11064-016-1921-1; Yu GH, 2017, INT J CHRONIC OBSTR, V12, P85, DOI 10.2147/COPD.S121079; Yu J, 2015, BIOL PHARM BULL, V38, P1564, DOI 10.1248/bpb.b15-00352; Yu Shu-ting, 2018, Yaoxue Xuebao, V53, P609, DOI 10.16438/j.0513-4870.2017-1190; Zhang FY, 2009, EXP BRAIN RES, V193, P109, DOI 10.1007/s00221-008-1600-9; Zhang FX, 2016, J PHARMACEUT BIOMED, V122, P59, DOI 10.1016/j.jpba.2016.01.047; Zhang JL, 2005, BIOMED CHROMATOGR, V19, P51, DOI 10.1002/bmc.415; Zhang MS, 1997, CHIN TRADIT PAT MED, V19, P33; Zhang P, 2018, CELL BIOL INT, V42, P1041, DOI 10.1002/cbin.10980; Zhang XJ, 2018, J CHROMATOGR B, V1076, P70, DOI 10.1016/j.jchromb.2018.01.023; Zhang Y, 2017, J CHROMATOGR B, V1061, P474, DOI 10.1016/j.jchromb.2017.07.021	38	11	14	3	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0731-7085	1873-264X		J PHARMACEUT BIOMED	J. Pharm. Biomed. Anal.	MAR 20	2019	166						281	290		10.1016/j.jpba.2019.01.020			10	Chemistry, Analytical; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	HO2AL	WOS:000460713700033	30682694				2021-06-18	
J	Mu, J; Li, MY; Wang, TT; Li, XJ; Bai, ML; Zhang, GH; Kong, JM				Mu, Jiao; Li, Meiyu; Wang, Tingting; Li, Xiujuan; Bai, Meiling; Zhang, Guohui; Kong, Jiming			Myelin Damage in Diffuse Axonal Injury	FRONTIERS IN NEUROSCIENCE			English	Article						diffuse axonal injury; demyelination; oligodendrocyte; axon-myelin unite; corpus callosum; brain stem	TRAUMATIC BRAIN-INJURY; SUBVENTRICULAR ZONE; PROGENITOR CELLS; MULTIPLE-SCLEROSIS; PROLIFERATION; DIFFERENTIATION; DEGENERATION; DIAGNOSIS	Diffuse axonal injury (DAI) is characterized by delayed axonal disconnection. Although the effect of DAI on axonal pathology has been well documented, there is limited information regarding the role of myelin in the pathogenesis of DAI. We used a modified Marmarou method to create a moderate DAI model in adult rat and examined the corpus callosum and brain stem for myelin pathology and dynamic glial responses to DAI. During the first week following DAI, Luxol Fast Blue staining and western blot analysis for MBP showed significant loss of myelin in the corpus callosum and the brain stem. Increased apoptosis of mature oligodendrocyte, as depicted by its marker CC-1, was observed. Conversely, there was an increased number of Olig2-positive cells accompanied by hypertrophic microglia/macrophage and mild reactive astrocytes. Electron microscopy revealed degenerating axons in the corpus callosum and marked myelin abnormalities in the brain stem in the early stage of DAI. Brain stem regions exhibited myelin intrusions or external protrusions with widespread delamination and myelin collapse, leading to degeneration of accompanying axons. Our results show distinct pathologic processes involving axon and myelin between the corpus callosum and the brain stem in DAI. Oligodendrocyte selective vulnerability and subsequent demyelination may contribute to axonal degeneration in the brain stem. Defining the cause of ongoing oligodendrocyte death and promoting myelin regeneration may provide important targets for therapeutic interventions of DAI.	[Mu, Jiao; Li, Meiyu; Wang, Tingting; Li, Xiujuan; Bai, Meiling; Zhang, Guohui; Kong, Jiming] Hebei North Univ, Dept Forens Med, Zhangjiakou, Peoples R China; [Kong, Jiming] Univ Manitoba, Dept Human Anat & Cell Sci, Coll Med, Winnipeg, MB, Canada	Zhang, GH; Kong, JM (corresponding author), Hebei North Univ, Dept Forens Med, Zhangjiakou, Peoples R China.; Kong, JM (corresponding author), Univ Manitoba, Dept Human Anat & Cell Sci, Coll Med, Winnipeg, MB, Canada.	m18931315882_1@163.com; jiming.kong@umanitoba.ca	wang, tingting/AAK-2640-2020		Hebei Natural Science FoundationNatural Science Foundation of Hebei Province [H2017405021]	This study was supported by Hebei Natural Science Foundation (Grant No. H2017405021).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aggarwal S, 2011, TRENDS CELL BIOL, V21, P585, DOI 10.1016/j.tcb.2011.06.004; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Chen Ge, 2002, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V19, P500; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Deoni SCL, 2011, J NEUROSCI, V31, P784, DOI 10.1523/JNEUROSCI.2106-10.2011; Flygt J, 2017, RESTOR NEUROL NEUROS, V35, P251, DOI 10.3233/RNN-160675; Gallo V, 2008, CURR OPIN NEUROL, V21, P278, DOI 10.1097/WCO.0b013e3282fd1875; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Jang SH, 2016, BRAIN INJURY, V30, P1026, DOI 10.3109/02699052.2016.1146961; Jankovski A, 1998, EUR J NEUROSCI, V10, P3853, DOI 10.1046/j.1460-9568.1998.00397.x; Jia XX, 2012, J TRAUMA ACUTE CARE, V73, P1168, DOI 10.1097/TA.0b013e318246eaf4; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kiray H, 2016, EXP NEUROL, V283, P541, DOI 10.1016/j.expneurol.2016.03.009; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Ma JW, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9746313; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; Montanino A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00643; Mu J, 2015, INT J CLIN EXP PATHO, V8, P4388; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Simons M, 2014, J CELL BIOL, V206, P335, DOI 10.1083/jcb.201404154; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Waxman SG, 2004, TRENDS PHARMACOL SCI, V25, P584, DOI 10.1016/j.tips.2004.09.001; Xu LY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0087-0; Zhang J, 2015, J FORENSIC SCI, V60, P759, DOI 10.1111/1556-4029.12743; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhou P, 2017, CNS NEUROSCI THER, V24, P126, DOI [10.1111/cns.12728, DOI 10.1111/CNS.12728]	30	11	11	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAR 19	2019	13								217	10.3389/fnins.2019.00217			11	Neurosciences	Neurosciences & Neurology	HP4EI	WOS:000461628800001	30941005	DOAJ Gold, Green Published			2021-06-18	
J	Forslund, MV; Perrin, PB; Roe, C; Sigurdardottir, S; Hellstrom, T; Berntsen, SA; Lu, J; Arango-Lasprilla, JC; Andelic, N				Forslund, Marit, V; Perrin, Paul B.; Roe, Cecilie; Sigurdardottir, Solrun; Hellstrom, Torgeir; Berntsen, Svein A.; Lu, Juan; Carlos Arango-Lasprilla, Juan; Andelic, Nada			Global Outcome Trajectories up to 10 Years After Moderate to Severe Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						brain injury; outcome assessment; GOSE; prospective studies; rehabilitation	QUALITY-OF-LIFE; 1ST 5 YEARS; FOLLOW-UP; HEAD-INJURY; GENDER-DIFFERENCES; PHYSICAL HEALTH; MODEL SYSTEMS; YOUNG-PEOPLE; DISABILITY; STABILITY	Aims: Based on important predictors, global functional outcome after traumatic brain injury (TBI) may vary significantly over time. This study sought to: (1) describe changes in the Glasgow Outcome Scale-Extended (GOSE) score in survivors of moderate to severe TBI, (2) examine longitudinal GOSE trajectories up to 10 years after injury, and (3) investigate predictors of these trajectories based on socio-demographic and injury characteristics. Methods: Socio-demographic and injury characteristics of 97 TBI survivors aged 16-55 years were recorded at baseline. GOSE was used as a measure of TBI-related global outcome and assessed at 1-, 2-, 5-, and 10-year follow-ups. Hierarchical linear models were used to examine global outcomes over time and whether those outcomes could be predicted by: time, time*time, sex, age, partner relationship status, education, employment pre-injury, occupation, cause of injury, acute Glasgow Coma Scale score, length of post-traumatic amnesia (PTA), CT findings, and Injury Severity Score (ISS), as well as the interactions between each of the significant predictors and time*time. Results: Between 5- and 10-year follow-ups, 37% had deteriorated, 7% had improved, and 56% showed no change in global outcome. Better GOSE trajectories were predicted by male gender (p = 0.013), younger age (p = 0.012), employment at admission (p = 0.012), white collar occupation (p = 0.014), and shorter PTA length (p = 0.001). The time*time*occupation type interaction effect (p = 0.001) identified different trajectory slopes between survivors in white and blue collar occupations. The time*time*PTA interaction effect (p = 0.023) identified a more marked increase and subsequent decrease in functional level among survivors with longer PTA duration. Conclusion: A larger proportion of survivors experienced deterioration in GOSE scores over time, supporting the concept of TBI as a chronic health condition. Younger age, pre-injury employment, and shorter PTA duration are important prognostic factors for better long-term global outcomes, supporting the existing literature, whereas male gender and white collar occupation are vaguer as prognostic factors. This information suggests that more intensive and tailored rehabilitation programs may be required to counteract a negative global outcome development in survivors with predicted worse outcome and to meet their long-term changing needs.	[Forslund, Marit, V; Roe, Cecilie; Hellstrom, Torgeir; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USA; [Roe, Cecilie] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Berntsen, Svein A.] Sorlandet Hosp, Dept Phys Med & Rehabil, Kristiansand, Norway; [Lu, Juan] Virginia Commonwealth Univ, Div Epidemiobgy, Dept Family Med & Populat Hlth, Richmond, VA USA; [Lu, Juan; Andelic, Nada] Univ Oslo, Fac Med, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Oslo, Norway; [Carlos Arango-Lasprilla, Juan] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Carlos Arango-Lasprilla, Juan] Cruces Univ Hosp Barakaldo, BioCruces Hlth Res Inst, Baracaldo, Spain	Forslund, MV (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway.	mavfor@ous-hf.no		Andelic, Nada/0000-0002-3719-4406; Lu, Juan/0000-0002-5389-7603	Department of Physical Medicine and Rehabilitation, Oslo University Hospital; The Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo; Research Council of NorwayResearch Council of Norway	The authors would like to thank the patients for their participation. Special thanks to Nini Hammergren for assistance with patient registration, and Tone Jerstad, neuroradiologist, for the CT assessments. This study was funded by the Department of Physical Medicine and Rehabilitation, Oslo University Hospital, The Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo and The Research Council of Norway.	Andelic N, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.1018; Andelic N, 2016, J NEUROTRAUM, V33, P95, DOI 10.1089/neu.2014.3844; Andelic N, 2015, J NEUROL, V262, P523, DOI 10.1007/s00415-014-7595-1; Andelic N, 2014, PM&R, V6, P1013, DOI 10.1016/j.pmrj.2014.05.005; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andersson E, 2017, ACTA ANAESTH SCAND, V61, P502, DOI 10.1111/aas.12880; Anke A, 2015, J HEAD TRAUMA REHAB, V30, pE38, DOI 10.1097/HTR.0000000000000080; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Azouvi P, 2016, BRAIN INJURY, V30, P1665, DOI 10.1080/02699052.2016.1201593; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bonow RH, 2018, WORLD NEUROSURG, V111, pE82, DOI 10.1016/j.wneu.2017.11.171; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Dams-O'Connor K, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000073; Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Einarsen CE, 2018, WORLD NEUROSURG, V114, pE1199, DOI 10.1016/j.wneu.2018.03.176; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Forslund MV, 2017, BRAIN INJURY, V31, P329, DOI 10.1080/02699052.2016.1255778; Forslund MV, 2014, NEUROREHABILITATION, V34, P781, DOI 10.3233/NRE-141084; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Gautschi OP, 2013, CLIN NEUROL NEUROSUR, V115, P2482, DOI 10.1016/j.clineuro.2013.09.038; Grauwmeijer E, 2017, J NEUROTRAUM, V34, P2575, DOI 10.1089/neu.2016.4846; Haller CS, 2017, BRAIN INJURY, V31, P319, DOI 10.1080/02699052.2016.1255777; Hammond FM, 2010, EUR J PHYS REHAB MED, V46, P545; Howe EI, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01051; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2017, J HEAD TRAUMA REHAB, V32, pE26, DOI 10.1097/HTR.0000000000000276; Kosty JA, 2013, NEUROL RES, V35, P277, DOI 10.1179/1743132813Y.0000000168; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lu J, 2018, J NEUROTRAUM, V35, P1596, DOI 10.1089/neu.2017.5299; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2486, DOI 10.1016/j.apmr.2013.06.021; Roe C, 2012, J NEUROL RES, V2, P134, DOI DOI 10.4021/JNR133W; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Wright DW, 2014, ACAD EMERG MED, V21, P1414, DOI 10.1111/acem.12532; Zelnick LR, 2014, J NEUROTRAUM, V31, P1029, DOI 10.1089/neu.2013.3122	59	11	11	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 14	2019	10								219	10.3389/fneur.2019.00219			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HP5DZ	WOS:000461698400001	30923511	DOAJ Gold, Green Published			2021-06-18	
J	Bliven, E; Rouhier, A; Tsai, S; Willinger, R; Bourdet, N; Deck, C; Madey, SM; Bottlang, M				Bliven, Emily; Rouhier, Alexandra; Tsai, Stanley; Willinger, Remy; Bourdet, Nicolas; Deck, Caroline; Madey, Steven M.; Bottlang, Michael			Evaluation of a novel bicycle helmet concept in oblique impact testing	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Bicycle helmet; Brain injury; Concussion; Impact testing; Impact mitigation; Rotational acceleration	BRAIN-INJURY; HEAD; BIOMECHANICS; ACCELERATION; PERFORMANCE; CONCUSSION; SYSTEM	Background A novel bicycle helmet concept has been developed to mitigate rotational head acceleration, which is a predominant mechanism of traumatic brain injury (TBI). This WAVECEL concept employs a collapsible cellular structure that is recessed within the helmet to provide a rotational suspension. This cellular concept differs from other bicycle helmet technologies for mitigation of rotational head acceleration, such as the commercially available Multi-Directional Impact Protection System (MIPS) technology which employs a slip liner to permit sliding between the helmet and the head during impact. This study quantified the efficacy of both, the WAVECEL cellular concept, and a MIPS helmet, in direct comparison to a traditional bicycle helmet made of rigid expanded polystyrene (EPS). Methods: Three bicycle helmet types were subjected to oblique impacts in guided vertical drop tests onto an angled anvil: traditional EPS helmets (CONTROL group); helmets with a MIPS slip liner (SLIP group); and helmets with a WAVECEL cellular structure (CELL group). Helmet performance was evaluated using 4.8 m/s impacts onto anvils angled at 30 degrees, 45 degrees, and 60 degrees from the horizontal plane. In addition, helmet performance was tested at a faster speed of 6.2 m/s onto the 45 degrees anvil. Five helmets were tested under each of the four impact conditions for each of the three groups, requiring a total of 60 helmets. Headform kinematics were acquired and used to calculate an injury risk criterion for Abbreviated Injury Score (AIS) 2 brain injury. Results: Linear acceleration of the headform remained below 90 g and was not associated with the risk of skull fracture in any impact scenario and helmet type. Headform rotational acceleration in the CONTROL group was highest for 6.2 m/s impacts onto the 45 degrees anvil (7.2 +/- 0.6 krad/s(2)). In this impact scenario, SLIP helmets and CELL helmets reduced rotational acceleration by 22% (p = 0003) and 73% (p < 0.001), respectively, compared to CONTROL helmets. The CONTROL group had the highest AIS 2 brain injury risk of 59 +/- 8% for 6.2 m/s impacts onto the 45 degrees anvil. In this impact scenario, SLIP helmets and CELL helmets reduced the AIS 2 brain injury risk to 34.2% (p = 0.001) and 1.2% (p < 0.001), respectively, compared to CONTROL helmets. Discussion: Results of this study are limited to a narrow range of impact conditions, but demonstrated the potential that rotational acceleration and the associated brain injury risk can be significantly reduced by the cellular WAVECEL concept or a MIPS slip liner. Results obtained under specific impact angles and impact velocities indicated performance differences between these mechanisms. These differences emphasize the need for continued research and development efforts toward helmet technologies that further improve protection from brain injury over a wide range a realistic impact parameters.	[Bliven, Emily; Rouhier, Alexandra; Tsai, Stanley; Madey, Steven M.; Bottlang, Michael] Legacy Res Inst, Biomech Lab, Portland, OR 97232 USA; [Willinger, Remy; Bourdet, Nicolas; Deck, Caroline] Univ Strasbourg, Inst Mecan Fluides & Solides, Strasbourg, France	Bottlang, M (corresponding author), Legacy Biomech Lab, 1225 NE 2nd Ave, Portland, OR 97215 USA.	mbottlan@lhs.org	Bliven, Emily/AAP-8732-2021	Bourdet, Nicolas/0000-0002-1087-6829; DECK, Caroline/0000-0003-2289-1222; Rouhier, Alexandra/0000-0001-7644-516X	National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [SB1NS074734]; Research Foundation of the Legacy Health System; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [SB1NS074734] Funding Source: NIH RePORTER	This research was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) under Award Number SB1NS074734. Additional support was provided by the Research Foundation of the Legacy Health System.	AAAM, 2008, ABBR INJ SCAL 2005; Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; [Anonymous], J21101 SAE; [Anonymous], 2016, CONSUMER REPORTS; Bartsch A, 2012, ACCIDENT ANAL PREV, V48, P285, DOI 10.1016/j.aap.2012.01.032; Bland ML, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4040019; Bourdet N, 2014, INT J CRASHWORTHINES, V19, P222, DOI 10.1080/13588265.2013.805293; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Caccese V, 2013, COMPOS STRUCT, V100, P404, DOI 10.1016/j.compstruct.2012.12.034; Caserta GD, 2011, COMPOS STRUCT, V93, P2748, DOI 10.1016/j.compstruct.2011.05.029; Ching RP, 1997, ACCIDENT ANAL PREV, V29, P555, DOI 10.1016/S0001-4575(97)00008-0; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; ECE, 1999, R2205 ECE; Fahlstedt M., 2014, INT CYCL SAF C; Finan JD, 2008, TRAFFIC INJ PREV, V9, P483, DOI 10.1080/15389580802272427; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Holbourn A. H, 2019, LANCET, V2, P438; Hoye A, 2018, ACCIDENT ANAL PREV, V117, P85, DOI 10.1016/j.aap.2018.03.026; Ivarsson J, 2003, J BIOMECH ENG-T ASME, V125, P523, DOI 10.1115/1.1590360; Jadischke R, 2016, J BIOMECH ENG-T ASME, V138, DOI 10.1115/1.4034306; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; Klug C., 2015, INT RES COUNC BIOM I; McIntosh AS, 2013, J AUSTRALAS COLL ROA, V24, P11; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mills NJ, 2008, INT J IMPACT ENG, V35, P1075, DOI 10.1016/j.ijimpeng.2007.05.005; Milne G., 2013, INT J CRASHWORTHINES, P1; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Otte D, 1989, SAE T, V98, P1606; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Sahoo D, 2016, ACCIDENT ANAL PREV, V92, P53, DOI 10.1016/j.aap.2016.03.013; Sances A, 2002, BIOMED SCI INSTRUM, V38, P459; Sone JY, 2017, J NEUROSURG, V126, P768, DOI 10.3171/2016.2.JNS151972; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Willinger R., 2014, P INT CYCL SAF C; YOGANANDAN N, 1989, Journal of Biomechanical Engineering, V111, P250	42	11	11	2	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR	2019	124						58	65		10.1016/j.aap.2018.12.017			8	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	HO3OB	WOS:000460831700007	30634159	Other Gold, Green Accepted			2021-06-18	
J	Chang, PP; Williams, AM; Bhatti, UF; Biesterveld, B; Liu, BL; Nikolian, VC; Dennahy, IS; Lee, J; Li, YQ; Alam, HB				Chang, Panpan; Williams, Aaron M.; Bhatti, Umar F.; Biesterveld, Ben E.; Liu, Baoling; Nikolian, Vahagn C.; Dennahy, Isabel S.; Lee, Jessica; Li, Yongqing; Alam, Hasan B.			Valproic Acid and Neural Apoptosis, Inflammation, and Degeneration 30 Days after Traumatic Brain Injury, Hemorrhagic Shock, and Polytrauma in a Swine Model	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							EMERGENCY-DEPARTMENT THORACOTOMY; LONG-TERM CONSEQUENCES; NEUROTROPHIC FACTOR; TRANSCRIPTOMIC CHANGES; INDUCED HYPOTHERMIA; ALZHEIMERS-DISEASE; HEAD-INJURY; CELL-DEATH; RESUSCITATION; ACTIVATION	BACKGROUND: A single-dose (150 mg/kg) of valproic acid (VPA) has been shown to decrease brain lesion size and improve neurologic recovery in preclinical models of traumatic brain injury (TBI). However, the longer-term (30 days) impact of single-dose VPA treatment after TBI has not been well evaluated. STUDY DESIGN: Yorkshire swine were subjected to TBI (cortical impact), hemorrhagic shock, and polytrauma. Animals remained in hypovolemic shock for 2 hours before resuscitation with normal saline (NS; volume = 3 x hemorrhaged volume) or NS thorn VPA (150 mg/kg) (n = 5/cohort). Brain samples were harvested 30 days after injuries. The cerebral cortex adjacent to the site of cortical impact was evaluated using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, immunohistochemistry, and Western blot analysis. Neural apoptosis, inflammation, degeneration, plasticity, and signaling pathways were evaluated. RESULTS: For apoptosis, VPA treatment significantly decreased (p < 0.05) the number of TUNEL (thorn) cells and expression of cleaved-caspase 3. For inflammation and degeneration, expression of ionized calcium binding adaptor molecule-1, glial fibrillary acid protein, amyloid-beta, and phosphorylated-Tau protein were significantly attenuated (p < 0.05) in the VPA-treated animals compared with the NS group. For, plasticity, VPA treatment also increased expression of brain-derived neurotrophic factor significantly (p < 0.05) compared with the NS group. For signaling pathways, nuclear factor-kappa B was decreased significantly (p < 0.05) and cytosolic I kappa B alpha expression was increased significantly (p < 0.05) in the VPA-treated animals compared with the NS group. CONCLUSIONS: Administration of a single dose of VPA (150 mg/kg) can decrease neural apoptosis, inflammation, and degenerative changes, and promote neural plasticity at 30 days after TBI. In addition, VPA acts, in part, via regulation of nuclear factor-kappa B and I kappa B alpha pathways. (C) 2019 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.	[Chang, Panpan] Peking Univ, Peoples Hosp, Trauma Med Ctr, Beijing, Peoples R China; [Chang, Panpan; Williams, Aaron M.; Bhatti, Umar F.; Biesterveld, Ben E.; Liu, Baoling; Nikolian, Vahagn C.; Dennahy, Isabel S.; Lee, Jessica; Li, Yongqing; Alam, Hasan B.] Univ Michigan Hlth Syst, Dept Surg, Ann Arbor, MI USA	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 5331 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Biesterveld, Ben/AAM-1087-2021		US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-1-0520]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [F32GM130010] Funding Source: NIH RePORTER	This work was supported by a grant from the US Army Medical Research and Materiel Command, Contract W81XWH-09-1-0520 (principal investigator: Hasan B Alam).	Acosta S.A., 2013, PLOS ONE, V8, P1; Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; Arai K, 2001, JPN J PHARMACOL, V87, P195, DOI 10.1254/jjp.87.195; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Butler FK, 2017, EMERG MED CLIN N AM, V35, P391, DOI 10.1016/j.emc.2016.12.005; Calabrese F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00430; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chan JP, 2008, MOL CELL NEUROSCI, V39, P372, DOI 10.1016/j.mcn.2008.07.017; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gentilello L, 2000, J TRAUMA, V48, P447; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Georgoff PE, 2018, J TRAUMA ACUTE CARE, V84, P642, DOI 10.1097/TA.0000000000001763; Georgoff PE, 2018, CLIN PHARMACOKINET, V57, P209, DOI 10.1007/s40262-017-0553-1; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guan ZW, 2006, BRAIN BEHAV IMMUN, V20, P64, DOI 10.1016/j.bbi.2005.04.005; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Hansson E, 2016, IBRO REP, V1, P1, DOI 10.1016/j.ibror.2016.06.001; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Irving EA, 1996, NEUROSCI LETT, V213, P189; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Korley FK, 2018, J NEUROTRAUM, V35, P1185, DOI 10.1089/neu.2017.5581; LAPCHAK PA, 1993, NEUROSCIENCE, V53, P297, DOI 10.1016/0306-4522(93)90196-M; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nikolian VC, 2018, J TRAUMA ACUTE CARE, V84, P459, DOI 10.1097/TA.0000000000001765; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Nolan Y, 2003, EXP NEUROL, V184, P794, DOI 10.1016/S0014-4886(03)00301-7; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pugh CR, 1998, BRAIN BEHAV IMMUN, V12, P212, DOI 10.1006/brbi.1998.0524; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rowell SE, 2016, J NEUROTRAUM, V33, P1054, DOI 10.1089/neu.2014.3478; Sairanen M, 2005, J NEUROSCI, V25, P1089, DOI 10.1523/JNEUROSCI.3741-04.2005; Schnydrig S, 2007, NEUROSCI LETT, V429, P69, DOI 10.1016/j.neulet.2007.09.067; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Shih RH, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00077; Sochocka M, 2017, MOL NEUROBIOL, V54, P8071, DOI 10.1007/s12035-016-0297-1; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; van Wyck D, 2017, J SPEC OPER MED, V17, P130; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Waterhouse EG, 2012, J NEUROSCI, V32, P14318, DOI 10.1523/JNEUROSCI.0709-12.2012; Weng S, 2018, WORLD NEUROSURG; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430; Zhao Bo, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P236; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	68	11	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2019	228	3					265	275		10.1016/j.jamcollsurg.2018.12.026			11	Surgery	Surgery	HM5EA	WOS:000459496700007	30639301	Green Accepted			2021-06-18	
J	Farell, M; Aherne, S; O'Riordan, S; O'Keeffe, E; Greene, C; Campbell, M				Farell, Michael; Aherne, Susan; O'Riordan, Sean; O'Keeffe, Eoin; Greene, Chris; Campbell, Matthew			Blood-brain barrier dysfunction in a boxer with chronic traumatic encephalopathy and schizophrenia	CLINICAL NEUROPATHOLOGY			English	Article						chronic traumatic encephalopathy (CTE); blood-brain barrier (BBB); schizophrenia; claudin-5	SERUM S100B; INJURY; DIAGNOSIS; TAUOPATHY; PATHOLOGY; IMPACT	Chronic traumatic encephalopathy (CTE) is a neurodegenerative condition characterized by the perivascular deposition of phosphorylated tau (p-tau) protein aggregates resulting from repetitive mild traumatic brain injury (rTB1). Advances in the field have revealed the significance of repetitive head trauma in the pathogenesis of CTE in contact sports as well as military veterans. In this study we provide evidence of blood-brain barrier (BBB) disruption in regions of intense perivascular p-tau deposition in a former professional boxer diagnosed with CTE and schizophrenia. P-tau deposition was associated with loss of the tight junction protein claudin-5 and enhanced extravasation of endogenous blood components such as fibrinogen and IgG. We also provide evidence of tight junction disruption in individuals with schizophrenia, with discontinuous claudin-5 immunoreactivity in the parietal cortex. This data highlights a common phenotype of a dysfunctional BBB in individuals with CTE and schizophrenia and may represent a novel correlate of neural dysfunction in individuals at risk of developing CTE and schizophrenia.	[Farell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin, Ireland; [Aherne, Susan] St Columcilles Hosp, Dept Pathol, Loughlinstown, Ireland; [O'Riordan, Sean] St Vincents Univ Hosp, Dept Neurol, Dublin, Ireland; [O'Riordan, Sean] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [O'Keeffe, Eoin; Greene, Chris; Campbell, Matthew] Trinity Coll Dublin, Smurfit Inst Genet, Trinity Pl Gate, Dublin 2, Ireland	Campbell, M (corresponding author), Trinity Coll Dublin, Smurfit Inst Genet, Trinity Pl Gate, Dublin 2, Ireland.	canpbem2@tcd.ie		Greene, Chris/0000-0003-4192-9433	Science Foundation Ireland (SFI)Science Foundation Ireland [12/YI/B2614, 08/IN.I/B2033]; SFIScience Foundation Ireland; Health Research Board of Ireland (HRB); Bright Focus FoundationBrightFocus Foundation; St James' Hospital Research Foundation	This work was supported by grants from Science Foundation Ireland (SFI), (12/YI/B2614; 08/IN.I/B2033), SFI funded centre FutureNeuro, The Health Research Board of Ireland (HRB), the Bright Focus Foundation and St James' Hospital Research Foundation.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Banks WA, 2017, J ALZHEIMERS DIS, V55, P411, DOI 10.3233/JAD-160542; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bechter K, 2010, J PSYCHIATR RES, V44, P321, DOI 10.1016/j.jpsychires.2009.08.008; Catafau AM, 2004, MOVEMENT DISORD, V19, P1175, DOI 10.1002/mds.20112; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Enwright JF, 2018, MOL PSYCHIATR, V23, P1606, DOI 10.1038/mp.2017.216; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greene C, 2017, MOL PSYCHIATR, DOI [10.1038/mp.2017, DOI 10.1038/MP.2017]; Lara DR, 2001, J PSYCHIATR RES, V35, P11, DOI 10.1016/S0022-3956(01)00003-6; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menard C, 2017, NAT NEUROSCI, V20, P1752, DOI 10.1038/s41593-017-0010-3; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Najjar S, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00083; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Nishiura K, 2017, ONCOTARGET, V8, P93382, DOI 10.18632/oncotarget.21850; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rothermundt M, 2001, MOL PSYCHIATR, V6, P445, DOI 10.1038/sj.mp.4000889; Schroeter ML, 2003, SCHIZOPHR RES, V62, P231, DOI 10.1016/S0920-9964(02)00383-3; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Sun ZY, 2004, EUR PSYCHIAT, V19, P354, DOI 10.1016/j.eurpsy.2004.06.007; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022	31	11	11	1	10	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	MAR-APR	2019	38	2					51	58		10.5414/NP301130			8	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	HM0GB	WOS:000459123800003	30574863				2021-06-18	
J	Kaushal, M; Espana, LY; Nencka, AS; Wang, Y; Nelson, LD; McCrea, MA; Meier, TB				Kaushal, Mayank; Espana, Lezlie Y.; Nencka, Andrew S.; Wang, Yang; Nelson, Lindsay D.; McCrea, Michael A.; Meier, Timothy B.			Resting-state functional connectivity after concussion is associated with clinical recovery	HUMAN BRAIN MAPPING			English	Article						athletes; functional MRI; mild traumatic brain injury; postconcussion symptoms	TRAUMATIC BRAIN-INJURY; NETWORK; IMPACT; FMRI; RELIABILITY; ACCURATE; HISTORY; ROBUST; SPORT	There has been a recent call for longitudinal imaging studies to better characterize the time course of physiological recovery following sport-related concussion (SRC) and its relationship with clinical recovery. To address this, we evaluated changes to resting-state functional connectivity (rs-FC) of the whole-brain network following SRC and explored associations between rs-FC and measures of clinical outcome. High school and collegiate football athletes were enrolled during preseason. Athletes that suffered SRC (N = 62) were assessed across the acute (within 48 hr) and sub-acute (days 8, 15, and 45) phases. Matched football athletes without concussion served as controls (N = 60) and participated in similar visits. Multi-band resting-state fMRI was used to assess whole-brain rs-FC at each visit using network-based statistic and average nodal strength from regions of interest defined using a common whole-brain parcellation. Concussed athletes had elevated symptoms, psychological distress, and oculomotor, balance, and memory deficits at 48 hr postconcussion relative to controls, with diminished yet significant elevations in symptoms and psychological distress at 8 days. Both rs-FC analyses showed that concussed athletes had a global increase in connectivity at 8 days postconcussion relative to controls, with no differences at the 48-hr, 15-day, or 45-day visits. Further analysis revealed the group effect at the 8-day visit was driven by the large minority of concussed athletes still symptomatic at their visit; asymptomatic concussed athletes did not differ from controls. Findings from this large-scale, prospective study suggest whole-brain rs-FC alterations following SRC are delayed in onset but associated with the presence of self-reported symptoms.	[Kaushal, Mayank; Espana, Lezlie Y.; Nelson, Lindsay D.; McCrea, Michael A.; Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nencka, Andrew S.; Wang, Yang] Med Coll Wisconsin, Dept Radiol, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Meier, TB (corresponding author), Med Coll Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	tmeier@mcw.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR001436]; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); Department of DefenseUnited States Department of Defense [W81XWH-14-1-0561]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001436] Funding Source: NIH RePORTER	National Institutes of Health, Grant/Award Number: UL1TR001436; National Center for Advancing Translational Sciences; Department of Defense, Grant/Award Number: W81XWH-14-1-0561	Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Birn RM, 2013, NEUROIMAGE, V83, P550, DOI 10.1016/j.neuroimage.2013.05.099; Churchill N, 2017, BRAIN INJURY, V31, P39, DOI 10.1080/02699052.2016.1221135; Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Craddock RC, 2012, HUM BRAIN MAPP, V33, P1914, DOI 10.1002/hbm.21333; Czerniak SM, 2015, BRAIN IMAGING BEHAV, V9, P323, DOI 10.1007/s11682-014-9312-1; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Hallquist M.N., 2018, 012041 BIORXIV; Hillary FG, 2017, TRENDS COGN SCI, V21, P385, DOI 10.1016/j.tics.2017.03.003; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Iraji A, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/4072402; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Manning KY, 2017, NEUROLOGY, V89, P2157, DOI 10.1212/WNL.0000000000004669; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2017, BRAIN IMAGING BEHAV, V11, P129, DOI 10.1007/s11682-016-9520-y; Meier TB, 2017, J NEUROTRAUM, V34, P824, DOI 10.1089/neu.2016.4599; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mijalkov M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178798; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P791, DOI 10.1093/arclin/act077; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Taylor PA, 2013, BRAIN CONNECT, V3, P523, DOI 10.1089/brain.2013.0154; van den Heuvel MP, 2017, NEUROIMAGE, V152, P437, DOI 10.1016/j.neuroimage.2017.02.005; van der Horn HJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171031; Wechsler D., 2001, WECHSLER TEST ADULT; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yan Y, 2017, J CLIN NEUROSCI, V44, P114, DOI 10.1016/j.jocn.2017.05.010; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	48	11	11	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2019	40	4					1211	1220		10.1002/hbm.24440			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	HM4UM	WOS:000459470400012	30451340	Green Accepted, Green Published, Bronze			2021-06-18	
J	Niu, X; Bai, LJ; Sun, YX; Wang, S; Cao, JL; Sun, CZ; Wang, ZN; Xu, H; Gan, SQ; Fan, G; Huang, WM; Gu, CH; Yin, B; Bai, GH; Xu, XL; Zhang, M				Niu, Xuan; Bai, Lijun; Sun, Yingxiang; Wang, Shan; Cao, Jieli; Sun, Chuanzhu; Wang, Zhuonan; Xu, Hui; Gan, Shuoqiu; Fan, Geng; Huang, Wenmin; Gu, Chenghui; Yin, Bo; Bai, Guanghui; Xu, Xiaoling; Zhang, Ming			Disruption of periaqueductal grey-default mode network functional connectivity predicts persistent post-traumatic headache in mild traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							PAIN MODULATORY SYSTEMS; SUSTAINED ATTENTION; STATE; IMPACT; GRAY; PREVALENCE; DISABILITY; COMPONENT; TRACKING; DEFICITS	Objective Post-traumatic headache (PTH) is one of the most frequent and persistent physical symptoms following mild traumatic brain injury (mTBI) and develop in more than 50% of this population. This study aimed to investigate the periaqueductal grey (PAG)-seeded functional connectivity (FC) in patients with mTBI with acute post-traumatic headache (APTH) and further examine whether the FC can be used as a neural biomarker to identify patients developing chronic pain 3 months postinjury. Methods 70 patients with mTBI underwent neuropsychological measurements and MRI scans within 7 days postinjury and 56 (80%) of patients were followed up at 3 months. 46 healthy controls completed the same protocol on recruitment to the study. PAG-seeded resting-state FC analysis was measured in 54 patients with mTBI with APTH, in comparison with 46 healthy volunteers. Results The mTBI+APTH group presented significantly reduced PAG-seeded FC within the default mode network (DMN), compared with healthy volunteers group. The connectivity strength can also predict patients' complaints on the impact of headache on their lives. Crucially, the initial FC strength between the PAG-right precuneus as well as the PAG-right inferior parietal lobule became the important predictor to identify patients with mTBI developing persistent PTH 3 months postinjury. Conclusions Patients with mTBI+APTH exhibited significant PAG-related FC differences mainly within the DMN. These regions extended beyond traditional pain processing areas and may reflect the diminished top-down attention regulation of pain perception through antinociceptive descending modulation network. The disrupted PAG-DMN FC may be used as an early imaging biomarker to identify patients at risk of developing persistent PTH.	[Niu, Xuan; Sun, Yingxiang; Wang, Zhuonan; Xu, Hui; Gan, Shuoqiu; Xu, Xiaoling; Zhang, Ming] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian 710049, Shaanxi, Peoples R China; [Bai, Lijun; Wang, Shan; Cao, Jieli; Sun, Chuanzhu; Xu, Hui; Gan, Shuoqiu; Fan, Geng; Huang, Wenmin] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Minist Educ,Dept Biomed Engn, Xian 710049, Shaanxi, Peoples R China; [Gu, Chenghui; Yin, Bo] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurosurg, Xian, Shaanxi, Peoples R China; [Gu, Chenghui; Yin, Bo; Bai, Guanghui] Wenzhou Med Univ, Yuying Childrens Hosp, Xian, Shaanxi, Peoples R China; [Bai, Guanghui] Wenzhou Med Univ, Affiliated Hosp 2, Dept Radiol, Xian, Shaanxi, Peoples R China	Zhang, M (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian 710049, Shaanxi, Peoples R China.; Bai, LJ (corresponding author), Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Minist Educ,Dept Biomed Engn, Xian 710049, Shaanxi, Peoples R China.	bailijun@xjtu.edu.cn; zhangming01@mail.xjtu.edu.cn	Wang, Zhuonan/E-3691-2017; Xu, Hui/AAB-9421-2020; Bai, Lijun/C-5119-2015	Xu, Hui/0000-0003-4514-0413; Niu, Xuan/0000-0002-1580-0209; Bai, Lijun/0000-0001-8790-5424; Wang, Zhuonan/0000-0002-5745-4340	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571752, 81771914, 81571640]; Shanxi Nova Program [2014KJXX-34]; National Key Research and Development Plan of China [2016YFC0100300]; Zhejiang Natural Science FoundationNatural Science Foundation of Zhejiang Province [LY15H090016]; Wenzhou Municipal Sci-Tech Bureau [Y20140577]	This research was supported by the National Natural Science Foundation of China under grant numbers 81571752, 81771914 and 81571640, Shanxi Nova Program (2014KJXX-34), the National Key Research and Development Plan of China (2016YFC0100300), the Zhejiang Natural Science Foundation (grant no LY15H090016), and Wenzhou Municipal Sci-Tech Bureau (Y20140577).	BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Dall'Acqua P, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00280; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; Flaherty S A, 1996, AANA J, V64, P133; Fortenbaugh FC, 2018, NEUROIMAGE, V171, P148, DOI 10.1016/j.neuroimage.2018.01.002; Gauriau C, 2002, EXP PHYSIOL, V87, P251, DOI 10.1113/eph8702357; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Jang SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004017; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Kucyi A, 2014, J NEUROSCI, V34, P3969, DOI 10.1523/JNEUROSCI.5055-13.2014; Kucyi A, 2013, P NATL ACAD SCI USA, V110, P18692, DOI 10.1073/pnas.1312902110; Kwong WJ, 2007, CEPHALALGIA, V27, P336, DOI 10.1111/j.1468-2982.2007.01283.x; La Cesa S, 2014, MAGN RESON IMAGING, V32, P236, DOI 10.1016/j.mri.2013.12.003; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Legrain V, 2009, PAIN, V144, P230, DOI 10.1016/j.pain.2009.03.020; Linnman C, 2012, NEUROIMAGE, V60, P505, DOI 10.1016/j.neuroimage.2011.11.095; Liu P, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13060; Loggia ML, 2013, PAIN, V154, P24, DOI 10.1016/j.pain.2012.07.029; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Miller M D, 1993, Fam Pract Res J, V13, P15; Nachit-Ouinekh F, 2005, EUR J NEUROL, V12, P189, DOI 10.1111/j.1468-1331.2004.00934.x; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; Parkes L, 2018, NEUROIMAGE, V171, P415, DOI 10.1016/j.neuroimage.2017.12.073; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Ruff RL, 2008, NEW ENGL J MED, V358, P2178; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Shin HE, 2008, J CLIN NEUROL, V4, P158, DOI 10.3988/jcn.2008.4.4.158; Stacey A, 2017, J NEUROTRAUM, V34, P1558, DOI 10.1089/neu.2016.4721; Strigo IA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.116; Varndell W, 2017, J CLIN NURS, V26, P7, DOI 10.1111/jocn.13594; Wei SY, 2016, PAIN, V157, P92, DOI 10.1097/j.pain.0000000000000340; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Yu RJ, 2014, NEUROIMAGE-CLIN, V6, P100, DOI 10.1016/j.nicl.2014.08.019; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	49	11	11	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2019	90	3					326	332		10.1136/jnnp-2018-318886			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	IC7UC	WOS:000471181900182	30554137				2021-06-18	
J	Zonner, SW; Ejima, K; Fulgar, CC; Charleston, CN; Huibregtse, ME; Bevilacqua, ZW; Kawata, K				Zonner, Steven W.; Ejima, Keisuke; Fulgar, Ciara C.; Charleston, Carmen N.; Huibregtse, Megan E.; Bevilacqua, Zachary W.; Kawata, Keisuke			Oculomotor Response to Cumulative Subconcussive Head Impacts in US High School Football Players A Pilot Longitudinal Study	JAMA OPHTHALMOLOGY			English	Article							CONVERGENCE; CONCUSSION; POINT	IMPORTANCE Repetitive subconcussive head impacts in sports have emerged as a complex public health issue. Most of these head impacts remain asymptomatic yet have the potential to cause insidious neurological deficit if sustained repetitively. Near point of convergence (NPC) values have shown to reflect subclinical neuronal damage; however, the longitudinal pattern of NPC changes in association with subconcussive head impacts remains unclear. OBJECTIVES To examine the NPC response to recurring subconcussive head impacts in a single high school football season through a series of repeated measurements. DESIGN, SETTING, AND PARTICIPANTS This prospective case-series study of US varsity high school football players included baseline measurements of NPC, measurements at pregame and postgame points from 6 in-season games, and postseason follow-up measurements (a total of 14 points). An accelerometer-embedded mouthguard measured head impact frequency and magnitude from all practices and games. During the 6 games, players wore chest-strap heart rate monitors to record heart rate and estimate their excess postexercise oxygen consumption, accounting for possible physical exertion effects on NPC values. EXPOSURES Players participated in practices and games with no restrict on. MAIN OUTCOMES AND MEASURES Near point of convergence. RESULTS The 12 included players were all boys, with a mean (SD) age of 16.4 (0.5) years. A total of 8009 head impacts, 177 907g of peak linear acceleration, and 16 123 371 rad/s(2) of peak rotational acceleration were recorded from the players in a single football season. There was a significant increase in NPC over time until the middle of the season (mean [SD] NPC: baseline, 5.25 [1.49] cm; pregame 3, 6.42 [1.93] cm; P = .01), which was significantly associated with subconcussiye head impact frequency and magnitude (0.02 cm per 100 g of peak linear acceleration [SE, 0.0108; 95% CI, [0.0436-0.004]; P = .01; 0.023 cm per 10 000 rad/s(2) of peak rotational acceleration [SE, 0.009; 95% [I, 0.041-0.0105]; P = .02). However, NPC values began to normalize toward baseline level from midseason (mean [SD] NPC: baseline, 5.25 [1.49] cm; pregame 6, 5.75 [2.23] cm; P = .32), as supported by a significant quadratic trend (beta [SE], -0.002 [0.001] cm/d; P = .003), while participants continued to incur subconcussive head impacts. CONCLUSIONS AND RELEVANCE This longitudinal case series study suggests that NPC can be perturbed over the longterm by subconcussive head impacts but may normalize over time. The oculomotor system may have an adaptational capacity to subclinical head impacts, yet the mechanism for such remains an open question and warrants further investigation.	[Zonner, Steven W.] Washington Township Med Fdn, Dept Sports Med, Union City, CA USA; [Ejima, Keisuke] Indiana Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Bloomington, IN USA; [Fulgar, Ciara C.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA; [Charleston, Carmen N.] Irvington High Sch, Div Washington Sports Med, Fremont, CA USA; [Huibregtse, Megan E.; Bevilacqua, Zachary W.; Kawata, Keisuke] Indiana Univ, Dept Kinesiol, Sch Publ Hlth, Bloomington, IN 47405 USA; [Kawata, Keisuke] Indiana Univ, Neurosci Program, Coll Arts & Sci, Bloomington, IN USA	Kawata, K (corresponding author), Indiana Univ, Sch Publ Hlth, 1025 E 7th St,C215, Bloomington, IN 47405 USA.	kkawata@indiana.edu			Indiana Spinal Cord & Brain Injury Research Fund from the Indiana State Department of Health [0019939]; Indiana University School of Public Health faculty research grant program [2246237]	This work was supported from the Indiana Spinal Cord & Brain Injury Research Fund from the Indiana State Department of Health (grant 0019939; Dr Kawata) and Indiana University School of Public Health faculty research grant program (grant 2246237; Dr Kawata).	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Capo-Aponte JE, 2018, MIL MED, V183, P9, DOI 10.1093/milmed/usx166; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Carmer S. G., 1985, J AGRON ED, V14, P19; Cheever KM, 2018, INT J SPORTS MED, V39, P141, DOI 10.1055/s-0043-118339; DuPrey KM, 2017, AM J SPORT MED, V45, P2388, DOI 10.1177/0363546517705640; Hedeker D., 2006, LONGITUDINAL DATA AN; HUNG GK, 1986, DOC OPHTHALMOL, V62, P165, DOI 10.1007/BF00229128; Johnson B, 2015, NEUROLOGY, V85, P1163, DOI 10.1212/WNL.0000000000001968; Kawata K, 2016, INT J SPORTS MED, V37, P405, DOI 10.1055/s-0035-1569290; Kawata K, 2017, J NEUROTRAUM, V34, P2254, DOI 10.1089/neu.2016.4786; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; NCAA-Research, EST PROB COMP COLL A; Rusko H. K., 2003, Medicine & Science in Sports & Exercise, V35, pS183, DOI 10.1097/00005768-200305001-01014; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Storey EP, 2018, J NEUROL PHYS THER, V42, P134, DOI 10.1097/NPT.0000000000000228; Storey EP, 2017, OPTOMETRY VISION SCI, V94, P96, DOI 10.1097/OPX.0000000000000910; Williams CS, 2016, UNDERSEA HYPERBAR M, V43, P511	23	11	11	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6165	2168-6173		JAMA OPHTHALMOL	JAMA Ophthalmol.	MAR	2019	137	3					265	270		10.1001/jamaophthalmol.2018.6193			6	Ophthalmology	Ophthalmology	HO8LL	WOS:000461203100011	30570665	Green Published, Bronze			2021-06-18	
J	Kimura, I; Dohgu, S; Takata, F; Matsumoto, J; Kawahara, Y; Nishihira, M; Sakada, S; Saisho, T; Yamauchi, A; Kataoka, Y				Kimura, Ikuya; Dohgu, Shinya; Takata, Fuyuko; Matsumoto, Junichi; Kawahara, Yohei; Nishihira, Megumi; Sakada, Shohei; Saisho, Takuya; Yamauchi, Atsushi; Kataoka, Yasufumi			Activation of the alpha 7 nicotinic acetylcholine receptor upregulates blood-brain barrier function through increased claudin-5 and occludin expression in rat brain endothelial cells	NEUROSCIENCE LETTERS			English	Article						Blood-brain barrier; Brain endothelial cells; Nicotinic acetylcholine receptor; Claudin-5; Occludin; Permeability	ALZHEIMERS-DISEASE; PERMEABILITY; SUBTYPES; NACHR	The blood-brain barrier (BBB) is formed by brain endothelial cells (BECs) and regulates brain homeostasis by restricting the entry of blood-borne substances into the brain. Recent in vivo studies have shown that administration of nicotinic acetylcholine receptor (nAChR) agonists protects against BBB disruption and neuroin-flammation induced by stroke and traumatic brain injury through the systemic cholinergic anti-inflammatory pathway. In the present study, we focused on the nAChRs expressed on BECs rather than those widely expressed in the central nervous system and peripheral tissues, and examined whether activation of the nAChRs on BECs facilitates BBB function. We used primary cultures of rat brain endothelial cells to evaluate brain endothelial permeability and tight junction (TJ)-related protein expression after a 24-h exposure to PHA543613 (a selective alpha 7 nAChR agonist) or 5-iodo-A-85380 (a selective alpha 4 beta 2 nAChR agonist). We found that PHA543613 decreased sodium fluorescein permeability and increased the expression levels of claudin-5 and occludin, key TJ components. In contrast, 5-iodo-A-85380 had no effect on brain endothelial permeability or TJ protein expression. These findings suggest that the selective activation of alpha 7 nAChRs on BECs has a specific role in upregulating BBB properties through increased claudin-5 and occludin expression.	[Kimura, Ikuya; Dohgu, Shinya; Takata, Fuyuko; Matsumoto, Junichi; Kawahara, Yohei; Nishihira, Megumi; Sakada, Shohei; Saisho, Takuya; Yamauchi, Atsushi; Kataoka, Yasufumi] Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka, Fukuoka, Japan	Kataoka, Y (corresponding author), Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Jonan Ku, 8-19-1 Nanakuma, Fukuoka, Fukuoka 8140180, Japan.	ikimura@fukuoka-u.ac.jp; dohgu@fukuoka-u.ac.jp; ftakata@fukuoka-u.ac.jp; jmatsumoto@fukuoka-u.ac.jp; pp100201@cis.fukuoka-u.ac.jp; pp130060@cis.fukuoka-u.ac.jp; pp130146@cis.fukuoka-u.ac.jp; pp130266@cis.fukuoka-u.ac.jp; atyama@fukuoka-u.ac.jp; ykataoka@fukuoka-u.ac.jp	Dohgu, Shinya/AAK-9992-2020		Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [16K08429, 26460113, 16K08566, 15K08255]; Fukuoka University Program for supporting research activities of female researchers; Central Research Institute of Fukuoka University [166003, 157007, 166005, 166006, 167111]	This work was supported in part by Grants-in-Aid for Scientific Research to Y.K. (C) 16K08429, to F.T. (C) 26460113, to S.D. (C) 16K08566 and to A.Y. (C) 15K08255 from the Japan Society for the Promotion of Science (http://www.jsps.go.jp/), funds (to F.T.) from Fukuoka University Program for supporting research activities of female researchers (http://www.suisin.fukuoka-u.ac.jp/jyosei/), and funds (to Y.K.) 166003, 157007, (to S.D.) 166005, (to A.Y.) 166006 and (to F.T. and S.D.) 167111, from the Central Research Institute of Fukuoka University (http://www.suisin.fukuoka-u.ac.jp/homel/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Melony Black, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.	Abbruscato TJ, 2002, J PHARM SCI-US, V91, P2525, DOI 10.1002/jps.10256; Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Buckingham SD, 2009, PHARMACOL REV, V61, P39, DOI 10.1124/pr.108.000562; Chan YJ, 2018, EXP CELL RES, V369, P266, DOI 10.1016/j.yexcr.2018.05.025; Colon-Saez JO, 2014, PFLUG ARCH EUR J PHY, V466, P1571, DOI 10.1007/s00424-013-1385-y; Cooke JP, 2008, TRENDS CARDIOVAS MED, V18, P247, DOI 10.1016/j.tcm.2008.11.007; Dash PK, 2016, J NEUROSCI, V36, P2809, DOI 10.1523/JNEUROSCI.3197-15.2016; del Barrio L, 2011, TOXICOL SCI, V123, P193, DOI 10.1093/toxsci/kfr163; Dohgu S, 2005, BRAIN RES, V1038, P208, DOI 10.1016/j.brainres.2005.01.027; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Gahring LC, 2005, AAPS J, V7, pE885, DOI 10.1208/aapsj070486; He Q, 2015, TRENDS PHARMACOL SCI, V33, P395, DOI [10.1038/nbt.3121.ChIP-nexus, DOI 10.1038/NBT.3121.CHIP-NEXUS]; Hutamekalin P, 2008, CELL BIOL INT, V32, P198, DOI 10.1016/j.cellbi.2007.08.026; Krafft PR, 2013, STROKE, V44, P1743, DOI 10.1161/STROKEAHA.111.000427; Lee H, 2014, FRONT BIOSCI-LANDMRK, V19, P272, DOI 10.2741/4206; Mao XB, 2016, ANIM NUTR, V2, P218, DOI 10.1016/j.aninu.2016.05.004; Matsumoto J, 2018, BRAIN RES, V1692, P34, DOI 10.1016/j.brainres.2018.04.023; Miner JJ, 2016, CURR OPIN IMMUNOL, V38, P18, DOI 10.1016/j.coi.2015.10.008; Montagne A, 2017, J EXP MED, V214, P3151, DOI 10.1084/jem.20171406; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Papke RL, 2010, J PHARMACOL EXP THER, V333, P501, DOI 10.1124/jpet.109.164566; Rakkar K, 2016, BBA-MOL BASIS DIS, V1862, P56, DOI 10.1016/j.bbadis.2015.10.016; Shaw S, 2002, J BIOL CHEM, V277, P44920, DOI 10.1074/jbc.M204610200; Stamatovic SM, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1154641; Takata F, 2008, NEUROSCI LETT, V441, P163, DOI 10.1016/j.neulet.2008.06.030; Thom MD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126755; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wooltorton JRA, 2003, J NEUROSCI, V23, P3176; Wu JCF, 2009, J CELL BIOCHEM, V108, P433, DOI 10.1002/jcb.22270; Yang TY, 2017, ACTA PHARM SIN B, V7, P611, DOI 10.1016/j.apsb.2017.09.001; Zhang N, 2018, ONCOL REP, V39, P1034, DOI 10.3892/or.2017.6159; Zoli M, 2015, NEUROPHARMACOLOGY, V96, P302, DOI 10.1016/j.neuropharm.2014.11.003; Zwart R, 2014, EUR J PHARMACOL, V726, P77, DOI 10.1016/j.ejphar.2014.01.031	33	11	11	1	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 16	2019	694						9	13		10.1016/j.neulet.2018.11.022			5	Neurosciences	Neurosciences & Neurology	HM7FS	WOS:000459643800002	30452951				2021-06-18	
J	Brandi, G; Stocchetti, N; Pagnamenta, A; Stretti, F; Steiger, P; Klinzing, S				Brandi, Giovanna; Stocchetti, Nino; Pagnamenta, Alberto; Stretti, Federica; Steiger, Peter; Klinzing, Stephanie			Cerebral metabolism is not affected by moderate hyperventilation in patients with traumatic brain injury	CRITICAL CARE			English	Article						Traumatic brain injury; Hyperventilation; Intracranial pressure; Brain metabolites; Brain oxygenation; Transcranial color-coded duplex sonography	TISSUE OXYGEN-TENSION; HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PROLONGED HYPERVENTILATION; COMATOSE PATIENTS; CHILDREN	Hyperventilation-induced hypocapnia (HV) reduces elevated intracranial pressure (ICP), a dangerous and potentially fatal complication of traumatic brain injury (TBI). HV decreases the arteriolar diameter of intracranial vessels, raising the risk of cerebral ischemia. The aim of this study was to characterize the effects of moderate short-term HV in patients with severe TBI by using concomitant monitoring of cerebral metabolism, brain tissue oxygen tension (PbrO(2)), and cerebral hemodynamics with transcranial color-coded duplex sonography (TCCD). This prospective trial was conducted between May 2014 and May 2017 in the surgical intensive care unit (ICU) at the University Hospital of Zurich. Patients with nonpenetrating TBI older than 18 years of age with a Glasgow Coma Scale (GCS) score < 9 at presentation and with ICP monitoring, PbrO(2), and/or microdialysis (MD) probes during ICU admission within 36 h after injury were included in our study. Data collection and TCCD measurements were performed at baseline (A), at the beginning of moderate HV (C), after 50 min of moderate HV (D), and after return to baseline (E). Moderate HV was defined as arterial partial pressure of carbon dioxide 4-4.7 kPa. Repeated measures analysis of variance was used to compare variables at the different time points, followed by post hoc analysis with Bonferroni adjustment as appropriate. Eleven patients (64% males, mean age 36 +/- 14 years) with an initial median GCS score of 7 (IQR 3-8) were enrolled. During HV, ICP and mean flow velocity (CBFV) in the middle cerebral artery decreased significantly. Glucose, lactate, and pyruvate in the brain extracellular fluid did not change significantly, whereas PbrO(2) showed a statistically significant reduction but remained within the normal range. Moderate short-term hyperventilation has a potent effect on the cerebral blood flow, as shown by TCCD, with a concomitant ICP reduction. Under the specific conditions of this study, this degree of hyperventilation did not induce pathological alterations of brain metabolites and oxygenation.	[Brandi, Giovanna; Stretti, Federica; Steiger, Peter; Klinzing, Stephanie] Univ Hosp Zurich, Inst Intens Care Med, Ramistr 100, CH-8091 Zurich, Switzerland; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] Neuro ICU Fdn IRCCSCa Granda Osped Maggiore Polic, Milan, Italy; [Pagnamenta, Alberto] Ente Osped Cantonale, Unit Clin Epidemiol, Bellinzona, Switzerland; [Stretti, Federica] Westmead Hosp, Dept Intens Care, Westmead, NSW 2145, Australia	Brandi, G (corresponding author), Univ Hosp Zurich, Inst Intens Care Med, Ramistr 100, CH-8091 Zurich, Switzerland.	giovanna.brandi@usz.ch					Ainslie PN, 2008, BRAIN RES, V1230, P115, DOI 10.1016/j.brainres.2008.07.048; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Chesnut RM, 2018, J NEUROTRAUM, V35, P54, DOI 10.1089/neu.2016.4472; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Eriksson EA, 2012, CLIN NEUROPHYSIOL, V123, P1255, DOI 10.1016/j.clinph.2011.08.035; Godoy DA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00250; Hawryluk GWJ, 2016, J NEUROSURG, V125, P1217, DOI 10.3171/2015.7.JNS15809; Klinzing S, 2015, MINERVA ANESTESIOL, V81, P298; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; McCarville MB, 2008, PEDIATR BLOOD CANCER, V50, P818, DOI 10.1002/pbc.21430; Minhas JS, 2018, PHYSIOL MEAS, V39, DOI 10.1088/1361-6579/aae469; Minhas JS, 2018, PHYSIOL MEAS, V39, DOI 10.1088/1361-6579/aac76b; Minhas JS, 2019, J CLIN ULTRASOUND, V47, P14, DOI 10.1002/jcu.22645; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rohlwink UK, 2012, NEUROSURGERY, V70, P1220, DOI 10.1227/NEU.0b013e318243fc59; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Willie CK, 2012, J PHYSIOL-LONDON, V590, P3261, DOI 10.1113/jphysiol.2012.228551; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	26	11	14	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	FEB 13	2019	23								45	10.1186/s13054-018-2304-6			7	Critical Care Medicine	General & Internal Medicine	HL7KJ	WOS:000458919400002	30760295	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Celikkaya, H; Cosacak, MI; Papadimitriou, C; Popova, S; Bhattarai, P; Biswas, SN; Siddiqui, T; Wistorf, S; Nevado-Alcalde, I; Naumann, L; Mashkaryan, V; Brandt, K; Freudenberg, U; Werner, C; Kizil, C				Celikkaya, Hilal; Cosacak, Mehmet Ilyas; Papadimitriou, Christos; Popova, Stanislava; Bhattarai, Prabesh; Biswas, Srijeeta Nag; Siddiqui, Tohid; Wistorf, Sabrina; Nevado-Alcalde, Isabel; Naumann, Lisa; Mashkaryan, Violeta; Brandt, Kerstin; Freudenberg, Uwe; Werner, Carsten; Kizil, Caghan			GATA3 Promotes the Neural Progenitor State but Not Neurogenesis in 3D Traumatic Injury Model of Primary Human Cortical Astrocytes	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						GATA3; neurogenic potential; neural progenitors; scratch injury; primary human astrocytes; SOX2	STEM-CELL PROLIFERATION; ADULT ZEBRAFISH BRAIN; IN-VIVO; REGENERATIVE NEUROGENESIS; ALZHEIMERS-DISEASE; NEURONAL REGENERATION; SUBVENTRICULAR ZONE; GENE DELIVERY; GLIAL-CELLS; IDENTIFICATION	Astrocytes are abundant cell types in the vertebrate central nervous system and can act as neural stem cells in specialized niches where they constitutively generate new neurons. Outside the stem cell niches, however, these glial cells are not neurogenic. Although injuries in the mammalian central nervous system lead to profound proliferation of astrocytes, which cluster at the lesion site to form a gliotic scar, neurogenesis does not take place. Therefore, a plausible regenerative therapeutic option is to coax the endogenous reactive astrocytes to a pre-neurogenic progenitor state and use them as an endogenous reservoir for repair. However, little is known on the mechanisms that promote the neural progenitor state after injuries in humans. Gata3 was previously found to be a mechanism that zebrafish brain uses to injury-dependent induction of neural progenitors. However, the effects of GATA3 in human astrocytes after injury are not known. Therefore, in this report, we investigated how overexpression of GATA3 in primary human astrocytes would affect the neurogenic potential before and after injury in 2D and 3D cultures. We found that primary human astrocytes are unable to induce GATA3 after injury. Lentivirus-mediated overexpression of GATA3 significantly increased the number of GFAP/SOX2 double positive astrocytes and expression of pro-neural factor ASCL1, but failed to induce neurogenesis, suggesting that GATA3 is required for enhancing the neurogenic potential of primary human astrocytes and is not sufficient to induce neurogenesis alone.	[Celikkaya, Hilal; Cosacak, Mehmet Ilyas; Papadimitriou, Christos; Popova, Stanislava; Bhattarai, Prabesh; Biswas, Srijeeta Nag; Siddiqui, Tohid; Wistorf, Sabrina; Nevado-Alcalde, Isabel; Naumann, Lisa; Mashkaryan, Violeta; Brandt, Kerstin; Kizil, Caghan] Helmholtz Assoc, German Ctr Neurodegenerat Dis, Dresden, Germany; [Celikkaya, Hilal; Popova, Stanislava; Biswas, Srijeeta Nag; Mashkaryan, Violeta; Freudenberg, Uwe; Werner, Carsten; Kizil, Caghan] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany; [Freudenberg, Uwe; Werner, Carsten] Leibniz Inst Polymer Res Dresden, Max Bergmann Ctr Biomat Dresden, Dresden, Germany; [Wistorf, Sabrina] Inst Bioengn Catalonia, Barcelona, Spain; [Nevado-Alcalde, Isabel] Vivia Biotech, Parque Cient Madrid, Madrid, Spain	Kizil, C (corresponding author), Helmholtz Assoc, German Ctr Neurodegenerat Dis, Dresden, Germany.; Kizil, C (corresponding author), Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany.	caghan.kizil@dzne.de	Cosacak, Mehmet Ilyas/V-3872-2019; Freudenberg, Uwe/C-3009-2019; Werner, Carsten/F-8127-2010; Werner, Carsten/AAF-1510-2019; Kizil, Caghan/J-6923-2015	Cosacak, Mehmet Ilyas/0000-0003-2978-3902; Freudenberg, Uwe/0000-0002-1359-1095; Werner, Carsten/0000-0003-0189-3448; Papadimitriou, Christos/0000-0002-1752-4711; Kizil, Caghan/0000-0002-8164-9762; Siddiqui, Tohid/0000-0003-0625-9710	German Center for Neurodegenerative Diseases (DZNE)Helmholtz Association; Helmholtz Association Young investigator ProgramHelmholtz Association [VH-NG-1021]; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [KI1524/6, KI1524/10, KI1524/11]; Graduate Academy scholarship [CRC-TR67, CRC SFB655, FOR/EXC999]; BMBFFederal Ministry of Education & Research (BMBF) [PRECIMATRIX-FKZ-03XP0083-310117]; DZNE I2A award; CRTD; TU DresdenEuropean Commission [FZ-111, 043_261518]	This work was supported by German Center for Neurodegenerative Diseases (DZNE) and Helmholtz Association Young investigator Program (VH-NG-1021 to CK), Deutsche Forschungsgemeinschaft (DFG) (KI1524/6, KI1524/10, and KI1524/11 to CK; DZNE I2A award to CK; CRTD, TU Dresden (FZ-111, 043_261518) to CK; Graduate Academy scholarship to SP; CRC-TR67, CRC SFB655, and FOR/EXC999 to CW) and BMBF (PRECIMATRIX-FKZ-03XP0083-310117 to CW).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Alunni A, 2016, DEVELOPMENT, V143, P741, DOI 10.1242/dev.122796; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Baumgart EV, 2012, GLIA, V60, P343, DOI 10.1002/glia.22269; Bhattarai P, 2017, JOVE-J VIS EXP, DOI 10.3791/56014; Bhattarai P, 2016, CELL REP, V17, P941, DOI 10.1016/j.celrep.2016.09.075; Bonfanti L, 2011, EUR J NEUROSCI, V34, P930, DOI 10.1111/j.1460-9568.2011.07832.x; Brill MS, 2009, NAT NEUROSCI, V12, P1524, DOI 10.1038/nn.2416; Brulet R, 2017, STEM CELL REP, V8, P1506, DOI 10.1016/j.stemcr.2017.04.013; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Chapouton P, 2010, METHOD CELL BIOL, V100, P73, DOI 10.1016/B978-0-12-384892-5.00004-9; Chen CH, 2019, CEREB CORTEX, V29, P54, DOI 10.1093/cercor/bhx303; Chen G., 2015, ENEURO, V2; Cherry ABC, 2012, CELL, V148, P1110, DOI 10.1016/j.cell.2012.02.031; Choi SH, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0139-7; Codega P, 2014, NEURON, V82, P545, DOI 10.1016/j.neuron.2014.02.039; Cory G, 2011, METHODS MOL BIOL, V769, P25, DOI 10.1007/978-1-61779-207-6_2; Cosacak MI, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/769763; Costa MR, 2010, BRAIN RES REV, V63, P47, DOI 10.1016/j.brainresrev.2010.01.002; Curto GG, 2014, STEM CELLS DEV, V23, P2813, DOI 10.1089/scd.2014.0058; Deemyad T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06338-3; Doetsch F, 2001, BRAIN BEHAV EVOLUT, V58, P306, DOI 10.1159/000057572; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Draberova E, 2008, J NEUROPATH EXP NEUR, V67, P341, DOI 10.1097/NEN.0b013e31816a686d; Espuny-Camacho I, 2017, NEURON, V93, P1066, DOI 10.1016/j.neuron.2017.02.001; Faiz M, 2015, CELL STEM CELL, V17, P624, DOI 10.1016/j.stem.2015.08.002; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fleisch VC, 2011, BBA-MOL BASIS DIS, V1812, P364, DOI 10.1016/j.bbadis.2010.10.012; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gao K, 2013, GLIA, V61, P2063, DOI 10.1002/glia.22577; Gascon S, 2016, CELL STEM CELL, V18, P396, DOI 10.1016/j.stem.2015.12.003; Gould T, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0607; Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040; Guo ZY, 2014, CELL STEM CELL, V14, P188, DOI 10.1016/j.stem.2013.12.001; Heinrich C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000373; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; Hong JY, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.588871; Jebelli J, 2015, ANN NY ACAD SCI, V1351, P1, DOI 10.1111/nyas.12711; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Jones EV, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/321209; Karl MO, 2010, TRENDS MOL MED, V16, P193, DOI 10.1016/j.molmed.2010.02.003; Karow M, 2012, CELL STEM CELL, V11, P471, DOI 10.1016/j.stem.2012.07.007; Katz S, 2016, CELL REP, V17, P1383, DOI 10.1016/j.celrep.2016.09.088; Kettenmann H., 2012, NEUROGLIA; Kishimoto N, 2012, DIS MODEL MECH, V5, P200, DOI 10.1242/dmm.007336; Kizil C, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00159; Kizil C, 2018, CURR PATHOBIOL REP, V6, P71, DOI 10.1007/s40139-018-0158-x; Kizil C, 2015, EMBO REP, V16, P416, DOI 10.15252/embr.201439702; Kizil C, 2012, DEV CELL, V23, P1230, DOI 10.1016/j.devcel.2012.10.014; Kizil C, 2012, DEV NEUROBIOL, V72, P429, DOI 10.1002/dneu.20918; Kotterman MA, 2015, DEVELOPMENT, V142, P1885, DOI 10.1242/dev.115253; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lujan E, 2012, P NATL ACAD SCI USA, V109, P2527, DOI 10.1073/pnas.1121003109; Marz M, 2011, DEV DYNAM, V240, P2221, DOI 10.1002/dvdy.22710; Magnusson JP, 2016, DEVELOPMENT, V143, P1075, DOI 10.1242/dev.133975; Masserdotti G, 2015, CELL STEM CELL, V17, P74, DOI 10.1016/j.stem.2015.05.014; Matsubayashi Y, 2011, J CELL SCI, V124, P1017, DOI 10.1242/jcs.080853; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; Murphy AR, 2017, ACTA BIOMATER, V54, P1, DOI 10.1016/j.actbio.2017.02.046; Niu WZ, 2015, STEM CELL REP, V4, P780, DOI 10.1016/j.stemcr.2015.03.006; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Papadimitriou C., 2017, BIORXIV, DOI [10.1101/227306, DOI 10.1101/227306]; Papadimitriou C., 2017, BIORXIV, DOI [10.1101/225243, DOI 10.1101/225243]; Papadimitriou C, 2018, DEV CELL, V46, P85, DOI 10.1016/j.devcel.2018.06.005; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Phillips W, 2006, STEM CELLS DEV, V15, P359, DOI 10.1089/scd.2006.15.359; Pietschmann T, 1999, J VIROL, V73, P2613, DOI 10.1128/JVI.73.4.2613-2621.1999; Pozniak CD, 2010, P NATL ACAD SCI USA, V107, P21795, DOI 10.1073/pnas.1016485107; Qiu J, 2016, ELIFE, V5, DOI 10.7554/eLife.20337; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Urban N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00396; Viales RR, 2015, STEM CELLS, V33, P892, DOI 10.1002/stem.1883; Vizuete AFK, 2019, NEUROCHEM RES, V44, P301, DOI 10.1007/s11064-018-2675-8; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zupanc GKH, 2008, J PHYSIOL-PARIS, V102, P357, DOI 10.1016/j.jphysparis.2008.10.007	89	11	11	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	FEB 11	2019	13								23	10.3389/fncel.2019.00023			13	Neurosciences	Neurosciences & Neurology	HK9DS	WOS:000458290100001	30809125	DOAJ Gold, Green Published			2021-06-18	
J	Batsaikhan, B; Wang, JY; Scerba, MT; Tweedie, D; Greig, NH; Miller, JP; Hoffer, BJ; Lin, CT; Wang, JY				Batsaikhan, Buyandelger; Wang, Jing-Ya; Scerba, Michael T.; Tweedie, David; Greig, Nigel H.; Miller, Jonathan P.; Hoffer, Barry J.; Lin, Chih-Tung; Wang, Jia-Yi			Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6-Dithiothalidomide on Traumatic Brain Injury	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; neurological deficits; 3; 6-dithiothalidomide; neurodegeneration; neuroinflammation; oxidative stress	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY CYTOKINES; PIFITHRIN-ALPHA; INHIBITION; EXPRESSION; 3,6'-DITHIOTHALIDOMIDE; NEUROINFLAMMATION	Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. Long-term deficits after TBI arise not only from the direct effects of the injury but also from ongoing processes such as neuronal excitotoxicity, inflammation, oxidative stress and apoptosis. Tumor necrosis factor- (TNF-) is known to contribute to these processes. We have previously shown that 3,6-dithiothalidomide (3,6-DT), a thalidomide analog that is more potent than thalidomide with similar brain penetration, selectively inhibits the synthesis of TNF- in cultured cells and reverses behavioral impairments induced by mild TBI in mice. In the present study, we further explored the therapeutic potential of 3,6-DT in an animal model of moderate TBI using Sprague-Dawley rats subjected to controlled cortical impact. A single dose of 3,6-DT (28 mg/kg, i.p.) at 5 h after TBI significantly reduced contusion volume, neuronal degeneration, neuronal apoptosis and neurological deficits at 24 h post-injury. Expression of pro-inflammatory cytokines in the contusion regions were also suppressed at the transcription and translation level by 3,6-DT. Notably, neuronal oxidative stress was also suppressed by 3,6-DT. We conclude that 3,6-DT may represent a potential therapy to ameliorate TBI-induced functional deficits.	[Batsaikhan, Buyandelger; Wang, Jing-Ya; Lin, Chih-Tung; Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 11031, Taiwan; [Scerba, Michael T.; Tweedie, David; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Miller, Jonathan P.; Hoffer, Barry J.] Case Western Reserve Univ, Dept Neurol Surg, Cleveland, OH 44106 USA; [Wang, Jia-Yi] Taipei Med Univ, Dept Physiol, Sch Med, Coll Med, Taipei 11031, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 11031, Taiwan.; Wang, JY (corresponding author), Taipei Med Univ, Dept Physiol, Sch Med, Coll Med, Taipei 11031, Taiwan.	buyndlgr@gmail.com; gaeajyw911real@hotmail.com.tw; mike.scerba@nih.gov; tweedieda@grc.nia.nih.gov; greign@grc.nia.nih.gov; Jonathan.Miller@uhhospitals.org; bjh82@case.edu; sss880205@gmail.com; jywang2010@tmu.edu.tw			Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST104-2923-B-038-001-MY3]; Taipei Medical University, Taipei, Taiwan [DP2-107-21121-01-N-05]; National Institutes of Health, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R56 AG057028]; Intramural Research Program, National Institute on Aging, National Institutes of Health, USA; Lincoln MC Funds; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000994, ZIAAG000469] Funding Source: NIH RePORTER	This research was supported in part by grants from (i) the Ministry of Science and Technology, Taiwan (MOST104-2923-B-038-001-MY3); and DP2-107-21121-01-N-05, Taipei Medical University, Taipei, Taiwan; (ii) National Institutes of Health R56 AG057028, USA; by (iii) the Intramural Research Program, National Institute on Aging, National Institutes of Health, USA; and (iv) Lincoln MC Funds.	Aaltonen KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030275; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Blach-Olszewska Zofia, 2007, Neuropsychiatr Dis Treat, V3, P365; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Choudhery MS, 2012, CELL BIOL INT, V36, P747, DOI 10.1042/CBI20110183; Decourt B, 2017, CURR ALZHEIMER RES, V14, P403, DOI 10.2174/1567205014666170117141330; EGER K, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1073; Ekici MA, 2014, EUR REV MED PHARMACO, V18, P10; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gabbita SP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-99; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Greig NH, 2004, ACTA NEUROBIOL EXP, V64, P1; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Hasturk Askin Esen, 2018, Asian J Neurosurg, V13, P1018, DOI 10.4103/ajns.AJNS_29_17; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Huang YN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19654-x; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ordas I, 2012, CLIN PHARMACOL THER, V91, P635, DOI 10.1038/clpt.2011.328; Qiu P, 2011, EXPERT OPIN INV DRUG, V20, P1555, DOI 10.1517/13543784.2011.623125; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rowland TL, 1998, IMMUNOPHARMACOLOGY, V40, P11, DOI 10.1016/S0162-3109(98)00010-1; Rowland TL, 1999, IMMUNOL LETT, V68, P325, DOI 10.1016/S0165-2478(99)00055-3; Ryu JK, 2009, NEUROSCIENCE, V163, P601, DOI 10.1016/j.neuroscience.2009.07.006; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Tansey MG, 2010, NEUROBIOL DIS, V37, P491, DOI 10.1016/j.nbd.2009.12.004; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tobinick E, 2018, EXPERT REV NEUROTHER, V18, P453, DOI 10.1080/14737175.2018.1468253; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Tweedie David, 2011, Open Biochem J, V5, P37, DOI 10.2174/1874091X01105010037; Tweedie D, 2009, J NEUROSCI METH, V183, P182, DOI 10.1016/j.jneumeth.2009.06.034; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang JY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0631-6; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yang LY, 2016, NEUROBIOL DIS, V96, P216, DOI 10.1016/j.nbd.2016.08.012; Yoon JS, 2013, J NEUROSCI RES, V91, P671, DOI 10.1002/jnr.23190; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhou S, 2013, CURR MED CHEM, V20, P4102; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f	61	11	11	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	FEB 1	2019	20	3							502	10.3390/ijms20030502			20	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	HQ4WR	WOS:000462412500046	30682785	DOAJ Gold, Green Published			2021-06-18	
J	Caglayan, B; Kilic, E; Dalay, A; Altunay, S; Tuzcu, M; Erten, F; Orhan, C; Gunal, MY; Yulug, B; Juturu, V; Sahin, K				Caglayan, Berrak; Kilic, Ertugrul; Dalay, Arman; Altunay, Serdar; Tuzcu, Mehmet; Erten, Fusun; Orhan, Cemal; Gunal, Mehmet Yalcin; Yulug, Burak; Juturu, Vijaya; Sahin, Kazim			Allyl isothiocyanate attenuates oxidative stress and inflammation by modulating Nrf2/HO-1 and NF-kappa B pathways in traumatic brain injury in mice	MOLECULAR BIOLOGY REPORTS			English	Article						Traumatic brain injury; Allyl isothiocyanate; NF-kappa B; Nrf2	INTERCELLULAR-ADHESION MOLECULE-1; INCREASED EXPRESSION; ACTIVATION; NRF2; PATHOPHYSIOLOGY; POPULATION; INDUCTION; MELATONIN; ANTIBODY; DAMAGE	Traumatic brain injury (TBI) is the leading cause of mortality and morbidity in young adults and children in the industrialized countries; however, there are presently no FDA approved therapies. TBI results in oxidative stress due to the overproduction of reactive oxygen species and overwhelming of the endogenous antioxidant mechanisms. Recently, it has been reported that antioxidants including phytochemicals have a protective role against oxidative damage and inflammation after TBI. To analyze the effects of a naturally occurring antioxidant molecule, allyl isothiocyanate (AITC), on the nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear factor kappa B (NF-kappa B) signaling pathways in TBI, a cryogenic injury model was induced in mice. Here, we showed that AITC administered immediately after the injury significantly decreased infarct volume and blood-brain barrier (BBB) permeability. Protein levels of proinflammatory cytokines interleukin-1 beta (IL1 beta) and interleukin-6 (IL6), glial fibrillary acidic protein (GFAP) and NF-kappa B were decreased, while Nrf2, growth-associated protein 43 (GAP43) and neural cell adhesion molecule levels were increased with AITC when compared with vehicle control. Our results demonstrated that the antioxidant molecule AITC, when applied immediately after TBI, provided beneficial effects on inflammatory processes while improving infarct volume and BBB permeability. Increased levels of plasticity markers, as well as an antioxidant gene regulator, Nrf2, by AITC, suggest that future studies are warranted to assess the protective activities of dietary or medicinal AITC in clinical studies.	[Caglayan, Berrak] Istanbul Medipol Univ, Dept Med Biol, Int Sch Med, Istanbul, Turkey; [Kilic, Ertugrul; Dalay, Arman; Altunay, Serdar] Istanbul Medipol Univ, Dept Physiol, Istanbul, Turkey; [Caglayan, Berrak; Kilic, Ertugrul; Dalay, Arman; Altunay, Serdar; Gunal, Mehmet Yalcin; Yulug, Burak] Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, Istanbul, Turkey; [Tuzcu, Mehmet; Erten, Fusun] Firat Univ, Div Biol, Fac Sci, Elazig, Turkey; [Orhan, Cemal; Sahin, Kazim] Firat Univ, Sch Vet Med, Dept Anim Nutr, Elazig, Turkey; [Gunal, Mehmet Yalcin; Yulug, Burak] Istanbul Medipol Univ, Sch Med, Dept Neurol, Istanbul, Turkey; [Juturu, Vijaya] OmniAct Hlth Technol Inc, Res & Dev, Morristown, NJ USA	Sahin, K (corresponding author), Firat Univ, Sch Vet Med, Dept Anim Nutr, Elazig, Turkey.	bcaglayan@medipol.edu.tr; ekilic@medipol.edu.tr; dalayarman@gmail.com; altnyserdar@gmail.com; mtuzcu@firat.edu.tr; fusun_87@yahoo.com; corhan@firat.edu.tr; yalcin.gunal@alanya.edu.tr; burakyulug@gmail.com; v.juturu@omniactives.com; nsahinkm@yahoo.com	Kilic, Ertugrul/W-4563-2018; Sahin, Kazim/D-5625-2009; Orhan, Cemal/Q-2086-2015; TUZCU, MEHMET/H-2953-2018; Gunal, Mehmet/AAT-2910-2020; Erten, Fusun/W-8563-2018	Kilic, Ertugrul/0000-0001-6494-8923; Sahin, Kazim/0000-0001-9542-5244; Orhan, Cemal/0000-0003-4138-7689; TUZCU, MEHMET/0000-0002-1329-3143; Gunal, Mehmet/0000-0001-7702-2441; ALTUNAY, SERDAR/0000-0002-4051-2559; , Burak/0000-0002-9704-6173; Caglayan, Berrak/0000-0002-5072-132X; Erten, Fusun/0000-0003-1657-7253	OmniActive Health Technologies Inc.; Turkish Academy of SciencesTurkish Academy of Sciences	This study was supported by OmniActive Health Technologies Inc. (NJ, USA). This work was also supported in part by the Turkish Academy of Sciences.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; [Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Bautista DM, 2013, ANNU REV PHYSIOL, V75, P181, DOI 10.1146/annurev-physiol-030212-183811; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Beker MC, 2015, ONCOTARGET, V6, P30604, DOI 10.18632/oncotarget.5773; Beker MC, 2018, MOL NEUROBIOL, V55, P2565, DOI 10.1007/s12035-017-0524-4; BEVILACQUA MP, 1985, AM J PATHOL, V121, P394; Boutin C, 2009, EUR J NEUROSCI, V30, P1209, DOI 10.1111/j.1460-9568.2009.06928.x; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; Bryant CD, 2008, J NEUROGENET, V22, P315, DOI 10.1080/01677060802357388; Caglayan B, 2017, EXP NEUROL, V296, P23, DOI 10.1016/j.expneurol.2017.06.024; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Conaway CC, 2002, CURR DRUG METAB, V3, P233, DOI 10.2174/1389200023337496; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; de Roos B, 2015, MOL NUTR FOOD RES, V59, P1229, DOI 10.1002/mnfr.201400568; Dixon KJ, 2017, PHYS MED REH CLIN N, V28, P215, DOI 10.1016/j.pmr.2016.12.001; Ernst IMA, 2011, PHARMACOL RES, V63, P233, DOI 10.1016/j.phrs.2010.11.005; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gorup D, 2015, NEUROSCI LETT, V597, P176, DOI 10.1016/j.neulet.2015.04.042; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jakubikova J, 2006, J AGR FOOD CHEM, V54, P1656, DOI 10.1021/jf052717h; Jennings M, 1998, LAB ANIM-UK, V32, P233, DOI 10.1258/002367798780559301; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kelestemur T, 2016, NEUROSCI LETT, V612, P92, DOI 10.1016/j.neulet.2015.11.043; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Liddell JR., 2017, J CLIN CELL IMMUNOL, V8, P489, DOI DOI 10.4172/2155-9899.1000489; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Peirson SN, 2018, J NEUROSCI METH, V300, P26, DOI 10.1016/j.jneumeth.2017.04.007; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Smith T, 1996, BIOCHEM SOC T, V24, pS381, DOI 10.1042/bst024381s; Smith TK, 2004, CARCINOGENESIS, V25, P1409, DOI 10.1093/carcin/bgh149; Sun J, 2008, AM J PHYSIOL-CELL PH, V294, pC1586, DOI 10.1152/ajpcell.00129.2008; Tang L, 2004, J NUTR, V134, P2004; Trevisan G, 2013, EUR J PHARMACOL, V714, P332, DOI 10.1016/j.ejphar.2013.07.029; Venegoni W, 2017, J ADV NURS, V73, P1331, DOI 10.1111/jan.13259; Vos Pieter E, 2011, Crit Care, V15, P183, DOI 10.1186/cc10290; Wagner AE, 2012, J CELL MOL MED, V16, P836, DOI 10.1111/j.1582-4934.2011.01367.x; Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiao D, 2003, CARCINOGENESIS, V24, P891, DOI 10.1093/carcin/bgg023; Xiao Guo-min, 2005, J Zhejiang Univ Sci B, V6, P28, DOI 10.1631/jzus.2005.B0028; Yehuda H, 2012, INFLAMM RES, V61, P735, DOI 10.1007/s00011-012-0465-3; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290	60	11	11	0	7	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-4851	1573-4978		MOL BIOL REP	Mol. Biol. Rep.	FEB	2019	46	1					241	250		10.1007/s11033-018-4465-4			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	HP9OI	WOS:000462022300026	30406889				2021-06-18	
J	Castelnovo, LF; Magnaghi, V; Thomas, P				Castelnovo, Luca F.; Magnaghi, Valerio; Thomas, Peter			Expression of membrane progesterone receptors (mPRs) in rat peripheral glial cell membranes and their potential role in the modulation of cell migration and protein expression	STEROIDS			English	Article; Proceedings Paper	10th International Meeting on Rapid Responses to Steroid Hormones	NOV 02-05, 2016	Richmond, VA			Membrane progesterone receptors; Schwann cells; Migration; Myelin associated glycoprotein; Cyclic AMP	SCHWANN-CELLS; SCIATIC-NERVE; MYELIN FORMATION; GENE-EXPRESSION; ESTROGEN; SYSTEM; MAINTENANCE; SIGNALS; ALPHA; BRAIN	The role played by progestogens in modulating Schwann cell pathophysiology is well established. Progestogens exert their effects in these cells through both classical genomic and non-genomic mechanisms, the latter mediated by the GABA-A receptor. However, there is evidence that other receptors may be involved. Membrane progesterone receptors (mPRs) are novel 7-transmembrane receptors coupled to G proteins that have been characterized in different tissues and cells, including the central nervous system (CNS). The mPRs were shown to mediate some of progestogens' neuroprotective effects in the CNS, and to be upregulated in glial cells after traumatic brain injury. Based on this evidence, this paper investigated the possible involvement of mPRs in mediating progestogen actions in S42 Schwann cells. All five mPR isoforms and progesterone receptor membrane component 1 (PGRMC1) were detected in Schwann cells, and were present on the cell membrane. Progesterone and the mPR-specific agonist, Org-OD-02-0 (02) bound to these membranes, indicating the presence of functional mPRs. The mPR agonist 02 rapidly increased cell migration in an in vitro assay, suggesting a putative role of mPRs in the nerve regeneration process. Treatment with pertussis toxin and 8-Br-cAMP blocked 02-induced cell migration, suggesting this progestogen action is mediated by activation of an inhibitory G protein, leading to a decrease in intracellular cAMP levels. In contrast, long-term mPR activation led to increased expression levels of myelin associated glycoprotein (MAG). Taken together, these findings show that mPRs are present and active in Schwann cells and have a role in modulating their physiological processes.	[Castelnovo, Luca F.; Magnaghi, Valerio] Univ Milan, Dept Pharmacol & Biomol Sci, Via G Balzaretti 9, I-20133 Milan, Italy; [Castelnovo, Luca F.; Thomas, Peter] Univ Texas Austin, Marine Sci Univ, 750 Channel View Dr, Port Aransas, TX 78373 USA	Castelnovo, LF (corresponding author), Univ Milan, Dept Pharmacol & Biomol Sci, Via G Balzaretti 9, I-20133 Milan, Italy.	luca.castelnovo@unimi.it	Castelnovo, Luca/AAB-7088-2019; Thomas, Peter/U-9908-2019; Castelnovo, Luca/E-6364-2016	Thomas, Peter/0000-0001-6656-4907; Castelnovo, Luca/0000-0003-4784-1221	H.E.B. endowment	This research was partially funded by an H.E.B. endowment to P.T. The authors would like to thank Dr. Yefei Pang for his advice and Jing Dong for her technical assistance.	Aizen J, 2015, J ENDOCRINOL, V225, P59, DOI 10.1530/JOE-14-0576; Arthur-Farraj PJ, 2012, NEURON, V75, P633, DOI 10.1016/j.neuron.2012.06.021; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Carver CM, 2013, PSYCHOPHARMACOLOGY, V230, P151, DOI 10.1007/s00213-013-3276-5; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; Ding YQ, 2016, TISSUE CELL, V48, P503, DOI 10.1016/j.tice.2016.07.002; Faroni A, 2015, ADV DRUG DELIVER REV, V82-83, P160, DOI 10.1016/j.addr.2014.11.010; Faroni Alessandro, 2011, Front Endocrinol (Lausanne), V2, P103, DOI 10.3389/fendo.2011.00103; Glenn TD, 2013, CURR OPIN NEUROBIOL, V23, P1041, DOI 10.1016/j.conb.2013.06.010; Gu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145185; Guennoun R, 2015, J STEROID BIOCHEM, V146, P48, DOI 10.1016/j.jsbmb.2014.09.001; Intlekofer KA, 2011, NEUROSCIENCE, V172, P55, DOI 10.1016/j.neuroscience.2010.10.051; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; JungTestas I, 1996, J STEROID BIOCHEM, V58, P77, DOI 10.1016/0960-0760(96)00009-X; Kelder J, 2010, STEROIDS, V75, P314, DOI 10.1016/j.steroids.2010.01.010; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Latasa MJ, 2016, BBA-MOL CELL RES, V1863, P1510, DOI 10.1016/j.bbamcr.2016.04.009; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lopez PHH, 2011, J NEUROCHEM, V116, P900, DOI 10.1111/j.1471-4159.2010.07069.x; Lv J., 2019, STEROIDS, V142, P6; Lv JW, 2015, BIOCHEM BIOPH RES CO, V464, P263, DOI 10.1016/j.bbrc.2015.06.140; Magnaghi V, 1999, MOL BRAIN RES, V70, P36, DOI 10.1016/S0169-328X(99)00124-2; Magnaghi V, 2006, J MOL NEUROSCI, V28, P89, DOI 10.1385/JMN:28:1:89; Magnaghi V, 2001, BRAIN RES REV, V37, P360, DOI 10.1016/S0165-0173(01)00140-0; Magnaghi V, 2010, J NEUROCHEM, V112, P980, DOI 10.1111/j.1471-4159.2009.06512.x; Magnaghi V, 2009, INT REV NEUROBIOL, V87, P295, DOI 10.1016/S0074-7742(09)87015-3; Mantuano E, 2015, J CELL SCI, V128, P3478, DOI 10.1242/jcs.173765; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Melcangi R C, 1992, Endocr Regul, V26, P119; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; MELCANGI RC, 1990, J STEROID BIOCHEM, V35, P145, DOI 10.1016/0022-4731(90)90159-P; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Mellon SH, 2001, BRAIN RES REV, V37, P3, DOI 10.1016/S0165-0173(01)00109-6; Monje PV, 2010, J BIOL CHEM, V285, P31024, DOI 10.1074/jbc.M110.116970; Pang YF, 2015, AM J PHYSIOL-ENDOC M, V308, pE899, DOI 10.1152/ajpendo.00527.2014; Pang YF, 2013, ENDOCRINOLOGY, V154, P283, DOI 10.1210/en.2012-1772; Pang YF, 2011, STEROIDS, V76, P921, DOI 10.1016/j.steroids.2011.01.008; Perego C, 2012, J CELL PHYSIOL, V227, P1740, DOI 10.1002/jcp.22898; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Quarles RH, 2002, CELL MOL LIFE SCI, V59, P1851, DOI 10.1007/PL00012510; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Selzer J.L., 2015, COLD SPRING HARB PER, V7, DOI [10.1101/cshperspect.a020529, DOI 10.1101/CSHPERSPECT.A020529]; Sleiter N, 2009, ENDOCRINOLOGY, V150, P3833, DOI 10.1210/en.2008-0774; Svenningsen AF, 1999, J NEUROSCI RES, V57, P124, DOI 10.1002/(SICI)1097-4547(19990701)57:1<124::AID-JNR13>3.3.CO;2-G; Tang YT, 2005, J MOL EVOL, V61, P372, DOI 10.1007/s00239-004-0375-2; Taveggia C, 2016, CURR OPIN NEUROBIOL, V39, P24, DOI 10.1016/j.conb.2016.03.006; Thi AD, 1998, J STEROID BIOCHEM, V67, P201; Thomas P., 2019, STEROIDS, V142, P6; Thomas P, 2007, ENDOCRINOLOGY, V148, P705, DOI 10.1210/en.2006-0974; Thomas P, 2014, ENDOCRINOLOGY, V155, P1107, DOI 10.1210/en.2013-1991; Thomas P, 2013, STEROIDS, V78, P583, DOI 10.1016/j.steroids.2013.01.003; Thomas P, 2012, NEUROENDOCRINOLOGY, V96, P162, DOI 10.1159/000339822; TODA K, 1994, J NEUROCHEM, V63, P1646; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; Zhang ZH, 2016, GLIA, V64, P374, DOI 10.1002/glia.22934; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100; Zuloaga DG, 2012, ENDOCRINOLOGY, V153, P4432, DOI 10.1210/en.2012-1469	61	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0039-128X	1878-5867		STEROIDS	Steroids	FEB	2019	142				SI		6	13		10.1016/j.steroids.2017.09.009			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	HO3ID	WOS:000460813500003	28962850				2021-06-18	
J	Daar, DA; Abdou, SA; Cohen, JM; Wilson, SC; Levine, JP				Daar, David A.; Abdou, Salma A.; Cohen, Joshua M.; Wilson, Stelios C.; Levine, Jamie P.			Is the Medial Sural Artery Perforator Flap a New Workhorse Flap? A Systematic Review and Meta-Analysis	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article; Proceedings Paper	Senior Resident's Conference of the American-Society-of-Plastic-Surgeons / Plastic Surgery The Meeting	SEP 28-OCT 01, 2018	Chicago, IL	Amer Soc Plast Surg			RADIAL FOREARM FLAP; ANTEROLATERAL THIGH FLAP; DONOR SITE MORBIDITY; INTRAORAL RECONSTRUCTION; LOWER-EXTREMITY; HEAD; COMPLICATIONS; EXPERIENCE; DEFECTS; ANATOMY	Background: The medial sural artery perforator flap offers thin, pliable tissue with a relatively long pedicle and low donor-site morbidity. This study explores the characteristics and uses of the medial sural artery perforator flap along with postoperative outcomes and complications. Methods: A systematic literature review was performed using PubMed, Embase, and Cochrane Central Register of Controlled Trials to identify all cases of medial sural artery perforator flap reconstruction. Descriptive and meta-analyses were performed on pooled outcomes. Multivariate logistic regression identified factors associated with increased complication rates. Results: Thirty-five studies encompassing 526 medial sural artery perforator flaps were included for analysis. The most common reasons for surgery were oncologic (47.6 percent) and traumatic injuries (31.8 percent). The oral cavity was the most common recipient location (45.5 percent). Average flap dimensions were 6.0 +/- 2.3 cm x 9.8 +/- 3.6 cm, with an average pedicle length of 10.1 +/- 6.6 cm. Meta-analysis revealed an overall complication rate of 14.3 percent (Q value = 22.16; p = 0.877; I-2= -39.9). Use of chimeric medial sural artery perforator flaps was associated with significantly higher rates of complications (OR, 3.92; p = 0.039; 95 percent CI, 1.10 to 13.89). The majority of flap donor sites were closed primarily (68 percent) versus 32 percent that were covered with split-thickness skin grafts. A flap width greater than 5.75 cm had an odds ratio of 5.3 (95 percent CI, 1.3 to 21.8; p = 0.014) of having a donor-site complication if closed primarily. Conclusions: The medial sural artery perforator flap offers thin, pliable tissue with a relatively long pedicle and has minimal donor-site morbidity when the donor site is managed appropriately. As such, it should be considered a workhorse flap for both head and neck and extremity reconstruction.	[Daar, David A.; Abdou, Salma A.; Cohen, Joshua M.; Wilson, Stelios C.; Levine, Jamie P.] NYU, Sch Med, Hansjorg Wyss Dept Plast Surg, 305 East 33rd St, New York, NY 10016 USA	Levine, JP (corresponding author), NYU, Sch Med, Hansjorg Wyss Dept Plast Surg, 305 East 33rd St, New York, NY 10016 USA.	jamie.levine@nyulangone.org	Cohen, Joshua/AAA-5910-2019	Cohen, Joshua/0000-0002-0845-5160			Achal KS, 2011, J CRANIO MAXILL SURG, V39, P111, DOI 10.1016/j.jcms.2010.05.007; Alkureishi LWT, 2003, BRIT J PLAST SURG, V56, P401, DOI 10.1016/S0007-1226(03)00125-5; Avery CME, 2001, INT J ORAL MAX SURG, V30, P37, DOI 10.1054/ijom.2000.0016; BAEK SM, 1983, PLAST RECONSTR SURG, V71, P354, DOI 10.1097/00006534-198303000-00012; BARDSLEY AF, 1990, PLAST RECONSTR SURG, V86, P287, DOI 10.1097/00006534-199008000-00014; Bekara F, 2018, MICROSURG, V38, P109, DOI 10.1002/micr.30047; Camaioni A, 2008, ACTA OTORHINOLARYNGO, V28, P7; Cavadas PC, 2001, PLAST RECONSTR SURG, V108, P1609, DOI 10.1097/00006534-200111000-00027; Chalmers RL, 2016, J PLAST RECONSTR AES, V69, P687, DOI 10.1016/j.bjps.2016.01.005; Chen CH, 2005, ORAL ONCOL, V41, P602, DOI 10.1016/j.oraloncology.2005.01.010; Chen SL, 2008, ANN PLAS SURG, V61, P274, DOI 10.1097/SAP.0b013e318157a1a0; Choi JW, 2013, J RECONSTR MICROSURG, V29, P437, DOI 10.1055/s-0033-1343959; Dusseldorp JR, 2014, J PLAST RECONSTR AES, V67, P1267, DOI [10.1016/j.bjps.2014.04.013, 10.1016/j.bjps.2014.05.016]; Foissac R, 2017, OTOLARYNG HEAD NECK, V156, P822, DOI 10.1177/0194599817691931; GOTTLIEB LJ, 1994, PLAST RECONSTR SURG, V93, P1503, DOI 10.1097/00006534-199406000-00027; Hallock GG, 2014, J RECONSTR MICROSURG, V30, P187, DOI 10.1055/s-0033-1357276; Haughey BH, 2002, ARCH OTOLARYNGOL, V128, P1388, DOI 10.1001/archotol.128.12.1388; He Y, 2014, J ORAL MAXIL SURG, V72, P2351, DOI 10.1016/j.joms.2014.05.019; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hoffmann J, 1998, J CRANIO MAXILL SURG, V26, P255, DOI 10.1016/S1010-5182(98)80022-X; Hung SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171570; Ives M, 2015, J PLAST RECONSTR AES, V68, P853, DOI 10.1016/j.bjps.2015.02.001; Kao HK, 2010, PLAST RECONSTR SURG, V125, P1135, DOI 10.1097/PRS.0b013e3181d180ac; Kao HK, 2009, PLAST RECONSTR SURG, V124, P1125, DOI 10.1097/PRS.0b013e3181b457cf; Kesting MR, 2011, ANN SURG ONCOL, V18, P1988, DOI 10.1245/s10434-011-1584-8; Kim H, 2015, CLIN EXP OTORHINOLAR, V8, P167, DOI 10.3342/ceo.2015.8.2.167; Knott PD, 2016, HEAD NECK-J SCI SPEC, V38, pE945, DOI 10.1002/hed.24131; KOSHIMA I, 1989, BRIT J PLAST SURG, V42, P645, DOI 10.1016/0007-1226(89)90075-1; Kosutic D, 2012, J PLAST RECONSTR AES, V65, P1530, DOI 10.1016/j.bjps.2012.04.045; Lin CH, 2011, J TRAUMA, V70, P736, DOI 10.1097/TA.0b013e318203179e; Lutz BS, 1999, PLAST RECONSTR SURG, V103, P132, DOI 10.1097/00006534-199901000-00021; Murray RC, 2011, MICROSURG, V31, P104, DOI 10.1002/micr.20833; Nugent M, 2015, BRIT J ORAL MAX SURG, V53, P461, DOI 10.1016/j.bjoms.2015.02.023; Richardson D, 1997, PLAST RECONSTR SURG, V99, P109, DOI 10.1097/00006534-199701000-00017; Ross GL, 2003, BRIT J PLAST SURG, V56, P409, DOI 10.1016/S0007-1226(03)00126-7; Sanati-Mehrizy P, 2016, J CRANIOFAC SURG, V27, P1956, DOI 10.1097/SCS.0000000000003026; Sharabi SE, 2010, ANN PLAS SURG, V65, P555, DOI 10.1097/SAP.0b013e3181cbfebc; Sims JR, 2018, AM J OTOLARYNG, V39, P116, DOI 10.1016/j.amjoto.2017.12.012; Song CT, 2018, J RECONSTR MICROSURG, V34, DOI 10.1055/s-0038-1636939; Song XM, 2015, J RECONSTR MICROSURG, V31, P319, DOI 10.1055/s-0035-1544180; SONG YG, 1984, BRIT J PLAST SURG, V37, P149, DOI 10.1016/0007-1226(84)90002-X; SOUTAR DS, 1986, PLAST RECONSTR SURG, V78, P1; Sullivan D, 2011, PLAST RECONSTR SURG, V128, P311, DOI 10.1097/PRS.0b013e3182195826; Taghinia A., 2017, FLAPS RECONSTRUCTIVE, V2nd edition, P525; TAYLOR GI, 1987, BRIT J PLAST SURG, V40, P113, DOI 10.1016/0007-1226(87)90185-8; Toyserkani NM, 2015, EUR J PLAST SURG, V38, P391, DOI 10.1007/s00238-015-1110-5; URKEN ML, 1994, ARCH OTOLARYNGOL, V120, P589; Wang X, 2013, PLAST RECONSTR SURG, V131, P95, DOI 10.1097/PRS.0b013e3182729e3c; Wolff KD, 2011, J RECONSTR MICROSURG, V27, P225, DOI 10.1055/s-0031-1275485; Wong AK, 2015, MICROSURG, V35, P6, DOI 10.1002/micr.22223; Wong MZ, 2012, J RECONSTR MICROSURG, V28, P555, DOI 10.1055/s-0032-1315778; Wu JCW, 2016, PLAST RECONSTR SURG, V137, P257, DOI 10.1097/PRS.0000000000001880; Xie RG, 2007, J HAND SURG-EUR VOL, V32E, P512, DOI 10.1016/j.jhse.2007.05.010; Xie XT, 2012, ANN PLAS SURG, V68, P105, DOI 10.1097/SAP.0b013e31821190e6; Xiong LY, 2016, MICROSURG, V36, P511, DOI 10.1002/micr.30020; Zhao WQ, 2016, J ORAL MAXIL SURG, V74, P1063, DOI 10.1016/j.joms.2015.11.011	56	11	11	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	FEB	2019	143	2					393E	403E		10.1097/PRS.0000000000005204			11	Surgery	Surgery	IH6AE	WOS:000474573800017	30531631				2021-06-18	
J	Fickling, SD; Smith, AM; Pawlowski, G; Hajra, SG; Liu, CC; Farrell, K; Jorgensen, J; Song, XW; Stuart, MJ; D'Arcy, RCN				Fickling, Shaun D.; Smith, Aynsley M.; Pawlowski, Gabriela; Hajra, Sujoy Ghosh; Liu, Careesa C.; Farrell, Kyle; Jorgensen, Janelle; Song, Xiaowei; Stuart, Michael J.; D'Arcy, Ryan C. N.			Brain vital signs detect concussion-related neurophysiological impairments in ice hockey	BRAIN			English	Article						quantified electroencephalography; cognitive evoked potentials; event-related potentials	WHITE-MATTER; IMPACTS	There is a growing demand for objective evaluations of concussion. We developed a portable evoked potential framework to extract brain vital signs' using electroencephalography. Brain vital signs were derived from well established evoked responses representing auditory sensation (N100), basic attention (P300), and cognitive processing (N400) amplitudes and latencies, converted to normative metrics (six total). The study evaluated whether concussion-related neurophysiological impairments were detected over the duration of ice hockey seasons using brain vital signs. Forty-seven Tier III, Junior A, male ice hockey players were monitored over two seasons. Twelve sustained concussions after baseline testing then completed post-injury and return-to-play assessments. Twenty-three were not diagnosed with a concussion during the season and completed both baseline and post-season testing. Scores were evaluated using a repeated-measures analysis of variance with post hoc two-tailed paired t-tests. Concussion resulted in significantly increased amplitude and delayed latency scores for all six brain vital signs (P < 0.0001). Importantly, significant changes at return-to-play were also detected in basic attention (P300) amplitude, indicating persistent subclinical impairment. In the non-concussed group, there was also a significant change between baseline and post-season (P = 0.0047), with specific decreases in cognitive processing (N400) speed (P = 0.011) and overall total score (P = 0.002).	[Fickling, Shaun D.; Pawlowski, Gabriela; Hajra, Sujoy Ghosh; Liu, Careesa C.; Song, Xiaowei; D'Arcy, Ryan C. N.] Simon Fraser Univ, Fac Sci Appl, Metro Vancouver, BC, Canada; [Fickling, Shaun D.; Pawlowski, Gabriela; Hajra, Sujoy Ghosh; Liu, Careesa C.; Song, Xiaowei; D'Arcy, Ryan C. N.] Surrey Mem Hosp, Fraser Hlth, Hlth Sci & Innovat, Metro Vancouver, BC, Canada; [Smith, Aynsley M.; Farrell, Kyle; Jorgensen, Janelle] Mayo Clin, Sports Med Ctr, Dept Orthoped Surg & Phys Med & Rehabil, Rochester, MN USA; [Stuart, Michael J.] Mayo Clin, Sports Med Ctr, Dept Orthoped Surg, Rochester, MN USA; [D'Arcy, Ryan C. N.] HealthTech Connex Inc, Surrey, BC, Canada	D'Arcy, RCN (corresponding author), Simon Fraser Univ, Fac Sci Appl, Metro Vancouver, BC, Canada.	rdarcy@sfu.ca			Mathematics of Information Technology and Complex Systems (MITACS) [IT03240]; Natural Sciences and Engineering Council Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Johannson-Gund Endowment; USA Hockey	Financial support was provided by Mathematics of Information Technology and Complex Systems (MITACS, Grant #IT03240), Natural Sciences and Engineering Council Canada (NSERC), and Canadian Institutes for Health Research (CIHR) for this study. The research study was designed and carried out by the Mayo Clinic Sports Medicine Ice Hockey Research team, partially funded by USA Hockey and the Johannson-Gund Endowment.	Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Cassidy SM, 2012, PSYCHOPHYSIOLOGY, V49, P659, DOI 10.1111/j.1469-8986.2011.01349.x; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V37, P31, DOI 10.1016/S0167-8760(00)00093-3; D'Arcy RCN, 2003, CLIN NEUROPHYSIOL, V114, P662, DOI 10.1016/S1388-2457(03)00007-5; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Davis PA, 1939, J NEUROPHYSIOL, V2, P494; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Gavett B, 2012, NEUROSURGERY, V30, P1; Gawryluk JR, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-11; Gawryluk JR, 2010, HDB PHYS MED BIOL, P548; Giza CC, 2015, NEUROSURGERY, V75, pS24, DOI DOI 10.1227/NEU.0000000000000505; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hajra SG, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00211; Hajra SG, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1527-2; He P, 2004, MED BIOL ENG COMPUT, V42, P407, DOI 10.1007/BF02344717; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ledwidge PS, 2016, J NEUROTRAUM, V33, P2081, DOI 10.1089/neu.2015.4251; Luck S.J, 2005, MONOGR SOC RES CHILD, V78, P388; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marchand Y, 2002, CLIN NEUROPHYSIOL, V113, P1715, DOI 10.1016/S1388-2457(02)00224-9; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Moore RD, 2017, INT J PSYCHOPHYSIOL, V112, P22, DOI 10.1016/j.ijpsycho.2016.11.011; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; Smith AM, 2017, CLIN J SPORT MED, V27, P503, DOI 10.1097/JSM.0000000000000412; SUTTON S, 1967, SCIENCE, V155, P1436, DOI 10.1126/science.155.3768.1436; Talavage TM, 2010, J NEUROTRAUM, V338, P1; Wilson MJ, 2015, SOUTH MED J, V108, P559, DOI 10.14423/SMJ.0000000000000342	30	11	11	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2019	142		2				255	262		10.1093/brain/awy317			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HQ7QT	WOS:000462616700012	30649205	Other Gold, Green Published			2021-06-18	
J	Okuma, Y; Wake, H; Teshigawara, K; Takahashi, Y; Hishikawa, T; Yasuhara, T; Mori, S; Takahashi, HK; Date, I; Nishibori, M				Okuma, Yu; Wake, Hidenori; Teshigawara, Kiyoshi; Takahashi, Yu; Hishikawa, Tomohito; Yasuhara, Takao; Mori, Shuji; Takahashi, Hideo K.; Date, Isao; Nishibori, Masahiro			Anti-High Mobility Group Box 1 Antibody Therapy May Prevent Cognitive Dysfunction After Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Cognitive dysfunction; Electroencephalography; High mobility group box 1; Traumatic brain injury	RECEPTOR; EPIDEMIOLOGY; INFLAMMATION; ISCHEMIA; MEDIATOR; PROFILE; CORTEX; BLOOD; HMG-1; RISK	BACKGROUND: High mobility group box 1 (HMGB1) protein plays a key role in triggering inflammatory responses in many diseases. Our previous study showed that HMGB1 is found upstream of secondary damage in traumatic brain injury (TBI). We found that anti-HMGB1 monoclonal antibody (mAb) effectively decreased acute brain damage, including the disruption of the blood-brain barrier, brain edema, and neurologic dysfunction. This effect of anti-HMGB1 mAb lasts for at least 1 week. In this study, we explored subacute effects of anti-HMGB1 mAb after TBI. METHODS: TBI was induced in rats by fluid percussion. Anti-HMGB1 mAb or control mAb was given intravenously after TBI. Histochemical staining, plasma levels of HMGB1, motor activity and memory, and video electroencephalography monitoring were evaluated 2 weeks after fluid percussion injury. RESULTS: Anti-HMGB1 mAb remarkably attenuated accumulation of activated microglia in the rat cortex in the ipsilateral hemisphere after TBI. Anti-HMGB1 mAb also prevented neuronal death in the hippocampus in the ipsilateral hemisphere after TBI. Treatment of rats with anti-HMGB1 mAb inhibited HMGB1 translocation and suppressed impairment of motor function. The beneficial effects of anti-HMGB1 mAb on motor and cognitive function persisted for 14 days after injury. Treatment with anti-HMGB1 mAb also had positive effects on electroencephalography activity. CONCLUSIONS: The beneficial effects of anti-HMGB1 mAb continued during the subacute postinjury phase, suggesting that anti-HMGB1 mAb may prevent cognitive dysfunction after TBI.	[Okuma, Yu; Wake, Hidenori; Teshigawara, Kiyoshi; Takahashi, Yu; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan; [Okuma, Yu; Takahashi, Yu; Hishikawa, Tomohito; Yasuhara, Takao; Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan; [Mori, Shuji] Shujitsu Univ, Sch Pharm, Dept Pharmacol, Okayama, Japan; [Takahashi, Hideo K.] Kinki Univ, Dept Pharmacol, Sch Med, Osaka, Japan; [Okuma, Yu] Hiroshima City Hiroshima Citizens Hosp, Dept Neurol Surg, Hiroshima, Japan	Nishibori, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan.	mbori@md.okayama-u.ac.jp		Okuma, Yu/0000-0003-4769-8111	Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18K08909]	This work was supported in part by the Japan Society for the Promotion of Science KAKENHI Grants-in-Aid for Scientific Research (C), Grant Number 18K08909.	Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Aneja RK, NEUROTRAUMA, DOI [10.1089/neu.2018.5664, DOI 10.1089/NEU.2018.5664]; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Eastman CL, 2011, J PHARMACOL EXP THER, V336, P779, DOI 10.1124/jpet.110.175133; Flores-Rio de la Loza LJ, 2005, REV NEUROLOGIA, V41, P22, DOI 10.33588/rn.4101.2004442; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Haruma J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37755; Hayashi K, 2011, EPILEPSIA, V52, P1010, DOI 10.1111/j.1528-1167.2011.03046.x; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kobayashi M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1168-7; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Nishibori M, 2009, ACTA MED OKAYAMA, V63, P65; Nosaka N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0983-9; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2013, NEUROSCI LETT, V554, P156, DOI 10.1016/j.neulet.2013.08.058; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Reid AY, 2016, EPILEPSIA, V57, P1558, DOI 10.1111/epi.13486; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sugihara M, 2016, AM J SURG, V211, P179, DOI 10.1016/j.amjsurg.2015.06.025; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang LY, 2016, NEUROBIOL DIS, V96, P216, DOI 10.1016/j.nbd.2016.08.012; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334	36	11	12	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	FEB	2019	122						E864	E871		10.1016/j.wneu.2018.10.164			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HJ6UM	WOS:000457328100104	30391757				2021-06-18	
J	Wirsching, A; Chen, ZX; Bevilacqua, ZW; Huibregtse, ME; Kawata, K				Wirsching, Angela; Chen, Zhongxue; Bevilacqua, Zachary W.; Huibregtse, Megan E.; Kawata, Keisuke			Association of Acute Increase in Plasma Neurofilament Light with Repetitive Subconcussive Head Impacts: A Pilot Randomized Control Trial	JOURNAL OF NEUROTRAUMA			English	Article						blood biomarker; concussion; neurofilament; soccer; subconcussion	TRAUMATIC BRAIN-INJURY; DEFAULT MODE NETWORK; EXPOSURE; DISEASE; PROTEIN; BLOOD; IMMUNOASSAY; BIOMARKERS; INTENSITY; MARKER	The purpose of the study was to examine an association of repetitive subconcussive head impacts with changes in plasma neurofilament light (NF-L) levels following 10 bouts of controlled soccer heading. In this randomized control trial, 37 healthy adult soccer players were randomly assigned into either a heading (n=19) or kicking-control group (n=18). The heading group executed 10 headers with soccer balls projected at a velocity of 25mph over 10min. Plasma samples were obtained at pre-heading baseline, 0h, 2h, and 24h post-heading. The kicking-control group followed the same protocol with 10 kicks. Plasma NF-L was measured using ultrasensitive single-molecule array technology. Data from 34 subjects were eligible for analysis (heading n=18 and kicking n=16). Ten subconcussive head impacts induced a gradual increase in plasma NF-L expression for the heading group (=0.0297, standard error [SE]=0.01, p=0.0049), whereas there was no significant time effect for the kicking-control group. A follow-up analysis revealed that a significant difference appeared at 24h post-heading (3.68 +/- 0.30pg/mL) compared with pre-heading (3.12 +/- 0.29pg/mL, p=0.0013; Cohen's d=1.898). At the 24h post-heading time-point, the plasma NF-L level for the heading group was significantly higher than that of the kicking-control group with an estimated mean difference of 0.66pg/mL (SE=0.22, p=0.0025). The data suggest that the increased level of plasma NF-L was driven by repetitive subconcussive head impacts and required longer than 2h after the head impacts for the increase to be detected. Plasma NF-L levels may serve as an objective marker to monitor acute axonal burden from subconcussive head impacts.	[Wirsching, Angela; Bevilacqua, Zachary W.; Huibregtse, Megan E.; Kawata, Keisuke] Indiana Univ, Dept Kinesiol, Sch Publ Hlth, Bloomington, IN 47405 USA; [Chen, Zhongxue] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN USA; [Kawata, Keisuke] Indiana Univ, Coll Arts & Sci, Neurosci Program, Bloomington, IN USA	Kawata, K (corresponding author), Indiana Univ, Sch Publ Hlth, 1025 E 7th St, Bloomington, IN 47405 USA.	kkawata@indiana.edu	Chen, Zhongxue/K-1372-2013	Chen, Zhongxue/0000-0003-2537-7843	Indiana Spinal Cord and Brain Injury Research Fund from the Indiana State Department of Health [ISCBIRF 0019939]; IU School of Public Health faculty research grant program [FRGP: 2246237]	The authors would like to thank Drs. Carrie Docherty and Jackie Kingma from Indiana University School of Public Health for their assistance in reviewing the study materials and the manuscript. This work was partly supported by the Indiana Spinal Cord and Brain Injury Research Fund from the Indiana State Department of Health (to K. Kawata: ISCBIRF 0019939) and the IU School of Public Health faculty research grant program (to K. Kawata: FRGP: 2246237). Sponsors had no role in the design or execution of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Bacioglu M, 2016, NEURON, V91, P494, DOI 10.1016/j.neuron.2016.07.007; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Bretzin AC, 2017, SPORTS HEALTH, V9, P168, DOI 10.1177/1941738116678615; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Federation Internationale de Football Association-FIFA, 2007, FIFA BIG COUNT 2006; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hall AA, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00104; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Hwang S, 2017, J NEUROTRAUM, V34, P8, DOI 10.1089/neu.2015.4238; Igarashi K, 2017, J GASTROEN HEPATOL, V32, P602, DOI 10.1111/jgh.13543; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kawata K, 2016, INT J SPORTS MED, V37, P405, DOI 10.1055/s-0035-1569290; Kawata K, 2017, J NEUROTRAUM, V34, P2254, DOI 10.1089/neu.2016.4786; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Weston PSJ, 2017, NEUROLOGY, V89, P2167, DOI 10.1212/WNL.0000000000004667; Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580; Yap YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176997; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143	39	11	11	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2019	36	4					548	553		10.1089/neu.2018.5836			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HM4MQ	WOS:000459448300004	30019617				2021-06-18	
J	Zhou, N; Liu, KL; Sun, Y; Cao, Y; Yang, J				Zhou, Nan; Liu, Kaili; Sun, Yue; Cao, Ying; Yang, Jing			Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition	PROTEIN & CELL			English	Article						microglia; 3D fluorescence imaging technique; neurodegeneration; IRF8; PU.1	CENTRAL-NERVOUS-SYSTEM; INNATE IMMUNE-RESPONSES; NF-KAPPA-B; MYELOID CELLS; BRAIN-DEVELOPMENT; INSIGHTS; ORIGIN; GENE; NEUROINFLAMMATION; INFLAMMATION	Microglial activation occurs in divergent neuropathological conditions. Such microglial event has the key involvement in the progression of CNS diseases. However, the transcriptional mechanism governing microglial activation remains poorly understood. Here, we investigate the microglial response to traumatic injury-induced neurodegeneration by the 3D fluorescence imaging technique. We show that transcription factors IRF8 and PU.1 are both indispensible for microglial activation, as their specific post-developmental deletion in microglia abolishes the process. Mechanistically, we reveal that IRF8 and PU.1 directly target the gene transcription of each other in a positive feedback to sustain their highly enhanced expression during microglial activation. Moreover, IRF8 and PU.1 dictate the microglial response by cooperatively acting through the composite IRF-ETS motifs that are specifically enriched on microglial activation-related genes. This action of cooperative transcription can be further verified biochemically by the synergetic binding of IRF8 and PU.1 proteins to the composite-motif DNA. Our study has therefore elucidated the central transcriptional mechanism of microglial activation in response to neurodegenerative condition.	[Sun, Yue; Cao, Ying; Yang, Jing] Peking Univ, State Key Lab Membrane Biol, Beijing 100871, Peoples R China; [Yang, Jing] Peking Univ, IDG McGovern Inst Brain Res, Beijing 100871, Peoples R China; [Liu, Kaili; Cao, Ying; Yang, Jing] Peking Univ, Ctr Life Sci, Beijing 100871, Peoples R China; [Sun, Yue; Yang, Jing] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; [Cao, Ying] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China; [Zhou, Nan] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China	Yang, J (corresponding author), Peking Univ, State Key Lab Membrane Biol, Beijing 100871, Peoples R China.; Yang, J (corresponding author), Peking Univ, IDG McGovern Inst Brain Res, Beijing 100871, Peoples R China.; Yang, J (corresponding author), Peking Univ, Ctr Life Sci, Beijing 100871, Peoples R China.; Yang, J (corresponding author), Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China.	jing.yang@pku.edu.cn	Yang, Jing/M-2831-2017	Yang, Jing/0000-0002-2048-735X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31522024, 31771111]; State Key Laboratory of Membrane Biology; IDG/McGovern Institute for Brain Research; Center for Life Sciences and School of Life Sciences at Peking University	This study has been supported by State Key Laboratory of Membrane Biology, IDG/McGovern Institute for Brain Research, Center for Life Sciences and School of Life Sciences at Peking University, and National Natural Science Foundation of China to J. Yang (Grant Nos. 31522024 and 31771111).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Biber K, 2016, NAT REV DRUG DISCOV, V15, P110, DOI 10.1038/nrd.2015.14; Colonna M, 2017, ANNU REV IMMUNOL, V35, P441, DOI 10.1146/annurev-immunol-051116-052358; Colonna M, 2016, NAT REV NEUROSCI, V17, P201, DOI 10.1038/nrn.2016.7; Finsen B, 2011, FEBS LETT, V585, P3806, DOI 10.1016/j.febslet.2011.05.030; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; Ginhoux F, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020537; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Herz J, 2017, IMMUNITY, V46, P943, DOI 10.1016/j.immuni.2017.06.007; Hollenhorst PC, 2011, ANNU REV BIOCHEM, V80, P437, DOI 10.1146/annurev.biochem.79.081507.103945; Hong S, 2016, CURR OPIN NEUROBIOL, V36, P128, DOI 10.1016/j.conb.2015.12.004; Horiuchi M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-227; Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2; Kalin S, 2015, NAT REV ENDOCRINOL, V11, P339, DOI 10.1038/nrendo.2015.48; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kierdorf K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00044; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Lall D, 2017, J CLIN INVEST, V127, P3250, DOI 10.1172/JCI90607; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Lum FM, 2017, CLIN INFECT DIS, V64, P914, DOI 10.1093/cid/ciw878; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045; Meyer-Luehmann M, 2015, TRENDS NEUROSCI, V38, P659, DOI 10.1016/j.tins.2015.08.011; Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066; Minten C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049851; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Prinz M, 2017, NAT IMMUNOL, V18, P385, DOI 10.1038/ni.3703; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schafer DP, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020545; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Tay TL, 2016, CURR OPIN NEUROBIOL, V39, P30, DOI 10.1016/j.conb.2016.04.003; Terry RL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-270; Thaler JP, 2010, FRONT NEUROENDOCRIN, V31, P79, DOI 10.1016/j.yfrne.2009.10.002; Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804; Tay TL, 2017, J PHYSIOL-LONDON, V595, P1929, DOI 10.1113/JP272134; Ulrich JD, 2017, NEURON, V94, P237, DOI 10.1016/j.neuron.2017.02.042; Valdearcos M, 2015, ANNU REV PHYSIOL, V77, P131, DOI 10.1146/annurev-physiol-021014-071656; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yoshida Y, 2014, IMMUNITY, V40, P187, DOI 10.1016/j.immuni.2013.11.022; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zuchero JB, 2015, DEVELOPMENT, V142, P3805, DOI 10.1242/dev.129304	63	11	12	2	4	SPRINGEROPEN	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	1674-800X	1674-8018		PROTEIN CELL	Protein Cell	FEB	2019	10	2					87	103		10.1007/s13238-018-0599-3			17	Cell Biology	Cell Biology	HK5QG	WOS:000458021200002	30484118	DOAJ Gold, Green Published			2021-06-18	
J	Shaji, CA; Robinson, BD; Yeager, A; Beeram, MHR; Davis, ML; Isbell, CL; Huang, JH; Tharakan, B				Shaji, Chinchusha Anasooya; Robinson, Bobby D.; Yeager, Antonia; Beeram, Mad Hava R.; Davis, Matthew L.; Isbell, Claire L.; Huang, Jason H.; Tharakan, Binu			The Tri-phasic Role of Hydrogen Peroxide in Blood-Brain Barrier Endothelial cells	SCIENTIFIC REPORTS			English	Article							REACTIVE OXYGEN; OXIDATIVE STRESS; TRAUMATIC BRAIN; BIPHASIC REGULATION; FREE-RADICALS; HYPERPERMEABILITY; ANGIOGENESIS; MECHANISMS; APOPTOSIS; H2O2	Hydrogen peroxide (H2O2) plays an important role physiologically as the second messenger and pathologically as an inducer of oxidative stress in injury, ischemia and other conditions. However, it is unclear how H2O2 influences various cellular functions in health and disease differentially, particularly in the blood-brain barrier (BBB). We hypothesized that the change in cellular concentrations of H2O2 is a major contributor in regulation of angiogenesis, barrier integrity/permeability and cell death/apoptosis in BBB endothelial cells. Rat brain microvascular endothelial cells were exposed to various concentrations of H2O2 (1 nM to 25 mM). BBB tight junction protein (zonula ocludens-1; ZO-1) localization and expression, cytoskeletal organization, monolayer permeability, angiogenesis, cell viability and apoptosis were evaluated. H2O2 at low concentrations (0.001 mu M to 1 mu M) increased endothelial cell tube formation indicating enhanced angiogenesis. H2O2 at 100 mu M and above induced monolayer hyperpermeability significantly (p < 0.05). H2O2 at 10 mM and above decreased cell viability and induced apoptosis (p < 0.05). There was a decrease of ZO-1 tight junction localization with 100 mu m H2O2, but had no effect on protein expression. Cytoskeletal disorganizations were observed starting at 1 mu m. In conclusion H2O2 influences angiogenesis, permeability, and cell death/apoptosis in a tri-phasic and concentration-dependent manner in microvascular endothelial cells of the blood-brain barrier.	[Shaji, Chinchusha Anasooya; Robinson, Bobby D.; Yeager, Antonia; Davis, Matthew L.; Isbell, Claire L.; Tharakan, Binu] Texas A&M Univ, Coll Med, Dept Surg, Hlth Sci Ctr, Temple, TX 76508 USA; [Shaji, Chinchusha Anasooya; Robinson, Bobby D.; Yeager, Antonia; Beeram, Mad Hava R.; Davis, Matthew L.; Isbell, Claire L.; Huang, Jason H.; Tharakan, Binu] Baylor Scott & White Hlth, Temple, TX 76508 USA; [Beeram, Mad Hava R.] Texas A&M Univ, Coll Med, Dept Pediat, Hlth Sci Ctr, Temple, TX 76508 USA; [Huang, Jason H.] Texas A&M Univ, Coll Med, Dept Neurosurg, Hlth Sci Ctr, Temple, TX 76508 USA	Tharakan, B (corresponding author), Texas A&M Univ, Coll Med, Dept Surg, Hlth Sci Ctr, Temple, TX 76508 USA.; Tharakan, B (corresponding author), Baylor Scott & White Hlth, Temple, TX 76508 USA.	Binu.Tharakan@BSWHealth.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168			Alluri H, 2016, J BIOL CHEM, V291, P26958, DOI 10.1074/jbc.M116.735365; Alluri H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154427; Alluri H, 2014, MICROCIRCULATION, V21, P187, DOI 10.1111/micc.12110; Apoptosis, 2010, NON TRADITIONAL REF, V2; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Chen X, 2012, NEUROSCIENCE, V226, P89, DOI 10.1016/j.neuroscience.2012.08.043; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; COHEN G, 1994, ANN NY ACAD SCI, V738, P8; Cruz-Haces M, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0088-2; Freeman LR, 2012, BBA-MOL BASIS DIS, V1822, P822, DOI 10.1016/j.bbadis.2011.12.009; Goldstein N, 2012, BIOCHEMISTRY-MOSCOW+, V77, P419, DOI 10.1134/S000629791205001X; Granger DN, 2015, REDOX BIOL, V6, P524, DOI 10.1016/j.redox.2015.08.020; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; Huang SS, 2006, PHARMAZIE, V61, P223; Kevil CG, 1998, FREE RADICAL BIO MED, V24, P1015, DOI 10.1016/S0891-5849(97)00433-4; Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749; Larochelle C, 2011, FEBS LETT, V585, P3770, DOI 10.1016/j.febslet.2011.04.066; Lee HS, 2009, FEBS J, V276, P4622, DOI 10.1111/j.1742-4658.2009.07174.x; Lennicke C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0118-6; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li JF, 2003, BRAIN RES BULL, V62, P101, DOI 10.1016/j.brainresbull.2003.08.011; Lochhead JJ, 2017, AAPS J, V19, P910, DOI 10.1208/s12248-017-0076-6; Lopez-Lazaro M, 2007, CANCER LETT, V252, P1, DOI 10.1016/j.canlet.2006.10.029; Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23; Maulik N, 2002, ANTIOXID REDOX SIGN, V4, P805, DOI 10.1089/152308602760598963; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; Mu P, 2010, CELL BIOL INT, V34, P1013, DOI 10.1042/CBI20090092; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Nizamutdinov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7010011; Park WH, 2013, INT J MOL MED, V31, P471, DOI 10.3892/ijmm.2012.1215; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Quillinan Nidia, 2016, Anesthesiol Clin, V34, P453, DOI 10.1016/j.anclin.2016.04.011; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Saito Y, 2006, FREE RADICAL RES, V40, P619, DOI 10.1080/10715760600632552; Siflinger-Birnboim A, 1996, New Horiz, V4, P87; SIFLINGERBIRNBOIM A, 1992, LAB INVEST, V67, P24; Stamatovic SM, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1154641; Teramoto S, 1999, JPN J PHARMACOL, V79, P33, DOI 10.1254/jjp.79.33; Tharakan B, 2010, SHOCK, V33, P56, DOI 10.1097/SHK.0b013e3181a7fb7c; Weidinger A, 2015, BIOMOLECULES, V5, P472, DOI 10.3390/biom5020472; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Yoo SY, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/127170; Yun J, 2009, ANTIOXID REDOX SIGN, V11, P1961, DOI [10.1089/ars.2009.2476, 10.1089/ARS.2009.2476]; Zahedi K, 2010, J NEUROTRAUM, V27, P515, DOI 10.1089/neu.2009.1097	45	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 15	2019	9								133	10.1038/s41598-018-36769-3			9	Multidisciplinary Sciences	Science & Technology - Other Topics	HH3BJ	WOS:000455593600018	30644421	DOAJ Gold, Green Published			2021-06-18	
J	Douglas, JM; Knox, L; De Maio, C; Bridge, H; Drummond, M; Whiteoak, J				Douglas, Jacinta M.; Knox, Lucy; De Maio, Carren; Bridge, Helen; Drummond, Melanie; Whiteoak, Joanne			Effectiveness of Communication-specific Coping Intervention for adults with traumatic brain injury: preliminary results	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injury; communication; coping; intervention	SOCIAL INTEGRATION; FACIAL EXPRESSION; FOLLOW-UP; QUESTIONNAIRE; ABILITY; DISCOURSE; VALIDITY; OUTCOMES; SKILLS; PERSPECTIVES	People with traumatic brain injury (TBI) describe everyday interactions as a long-term challenge frequently associated with ongoing stress. Communication-specific Coping Intervention (CommCope-I) is a new treatment developed to target coping in the context of communication breakdown. The intervention incorporates principles of cognitive behavioural therapy, self-coaching and context-sensitive social communication therapy. The purpose of this study was to examine the effectiveness of CommCope-I in a group of adults with severe TBI and ongoing functional communication difficulties. Participants were 13 adults with severe TBI (GCS = 3-8; mean age = 35.2 years; mean time post-injury = 7.6 years). The project involved three phases: (1) Control/pre-intervention wait phase (multiple assessments), (2) Treatment (6 weeks), and (3) Follow-up (12 weeks). Repeated measures ANOVA with planned pairwise comparisons were used to test the significance of change. Intervention elicited statistically significant improvements in communication-specific coping, functional communication and stress that were maintained for three months. Improved use of communication-specific coping strategies was evident in clinician blind ratings. Clients reported significant reduction in stress at the end of treatment and one and three months later. This intervention provides a promising means of improving communication-specific coping and reducing communication dysfunction and its negative consequences for people with TBI.	[Douglas, Jacinta M.; Knox, Lucy; De Maio, Carren; Bridge, Helen; Drummond, Melanie; Whiteoak, Joanne] La Trobe Univ, Sch Allied Hlth, Living Disabil Res Ctr, Bundoora, Vic, Australia; [Douglas, Jacinta M.; Knox, Lucy] Summer Fdn, Box Hill, Vic, Australia; [De Maio, Carren] Scope, Hawthorn, Vic, Australia; [Bridge, Helen] Beachside & South Eastern Suburbs Speech Pathol, Edithvale, Vic, Australia; [Drummond, Melanie] Epworth Monash Rehabil Med Unit, Melbourne, Vic, Australia; [Drummond, Melanie; Whiteoak, Joanne] Epworth HealthCare, Speech Pathol Dept, Epworth Rehabil, Richmond, Vic, Australia; [Whiteoak, Joanne] Caulfield Hosp, Alfred Hlth, Speech Pathol Dept, Caulfield, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Allied Hlth, Living Disabil Res Ctr, Bundoora, Vic, Australia.	J.Douglas@latrobe.edu.au	Knox, Lucy/E-8642-2013; Douglas, Jacinta M/C-2380-2009	Knox, Lucy/0000-0001-8331-6032; Douglas, Jacinta/0000-0003-0940-6624	Transport Accident Commission, Victorian Neurotrauma Initiative [DO71]	This work was supported by the Transport Accident Commission, Victorian Neurotrauma Initiative under [grant number DO71].	Access Economics, 2008, EC COST SPIN CORD IN; AIHW, 2007, AIHW B, V55; Behn N, 2012, BRAIN INJURY, V26, P1702, DOI 10.3109/02699052.2012.722258; Bootes K, 2010, WORK, V36, P207, DOI [10.3233/WOR-2010-1021, 10.3233/WOR-2010-01021]; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Douglas J., 2012, BRAIN IMPAIR, V13, P170; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2016, J SPEECH LANG HEAR R, V59, P511, DOI 10.1044/2015_JSLHR-L-15-0025; Douglas JM, 2014, BRAIN IMPAIR, V15, P190, DOI 10.1017/BrImp.2014.25; Douglas JM, 2010, BRAIN IMPAIR, V11, P171, DOI 10.1375/brim.11.2.171; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Friedman A., 2005, BRAIN INJURY S, V19, P50; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Manolov R, 2009, BEHAV RES METHODS, V41, P1262, DOI 10.3758/BRM.41.4.1262; Mellick D., 2000, CRAIG HANDICAP ASSES; Mitchell C., 2011, BRAIN IMPAIRMENT S, V12, P41; Muir A., 2007, BRAIN IMPAIR, V8, P83; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rietdijk R, 2013, BRAIN INJURY, V27, P812, DOI 10.3109/02699052.2013.775491; Scruggs TE, 1998, BEHAV MODIF, V22, P221, DOI 10.1177/01454455980223001; Shorland J, 2010, BRAIN INJURY, V24, P569, DOI 10.3109/02699051003610441; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P30, DOI 10.1097/HTR.0b013e3182048f7c; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Togher L, 2014, J HEAD TRAUMA REHAB, V29, P353, DOI 10.1097/HTR.0000000000000071; Togher L, 2013, J REHABIL MED, V45, P637, DOI 10.2340/16501977-1173; Tu LV, 2011, BRAIN INJURY, V25, P560, DOI 10.3109/02699052.2011.571655; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI DOI 10.1375/BRIM.7.3.246; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	47	11	11	1	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN 2	2019	29	1					73	91		10.1080/09602011.2016.1259114			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	GY1HI	WOS:000448276600004	27911168	Other Gold			2021-06-18	
J	Lim, LJH; Ho, RCM; Ho, CSH				Lim, Lucas J. H.; Ho, Roger C. M.; Ho, Cyrus S. H.			Dangers of Mixed Martial Arts in the Development of Chronic Traumatic Encephalopathy	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article						mixed martial arts; chronic traumatic encephalopathy; neuropsychiatric sequelae	BRAIN-INJURY; CONCUSSION; SEVERITY; RISK	Chronic traumatic encephalopathy (CTE) was first discovered in professional boxers after they exhibited memory impairments, mood and behavioral changes after years of boxing. However, there is now a growing acceptance that CTE can develop in athletes of other sports due to the repetitive head trauma they receive. We present a case of a middle-aged male who presented with worsening memory, poor concentration, and behavioral changes for a year. On further cognitive testing, it was revealed that he had difficulties with short-term memory and processing speed as well as difficulties in organizing and multitasking. He had been practicing mixed martial arts (MMA) for 10 years, and later was an instructor of the sport. Through a detailed examination of his history, it was discovered that he sustained recurrent minor head concussions due to his line of work. To date, there has been limited large-scale research on head trauma in MMA. There is thus an urgent need for more studies in this area as CTE can be a chronic and debilitating illness with incapacitating neuropsychiatric sequelae. This case highlights the importance of public awareness of the risks of MMA and the dangers it poses to the brain, especially with more young people being attracted to this sport.	[Lim, Lucas J. H.; Ho, Roger C. M.; Ho, Cyrus S. H.] Natl Univ Singapore, Dept Psychol Med, Yong Loo Lin Sch Med, Singapore 119074, Singapore; [Ho, Roger C. M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Biomed Global Inst Healthcare Res & Technol BIGHE, Singapore 117599, Singapore; [Ho, Roger C. M.] NTTU, Ctr Excellence Behav Med, Ho Chi Minh City 70000, Vietnam; [Ho, Roger C. M.] Huaibei Normal Univ, Fac Educ, 100 Dongshan Rd, Huaibei 235000, Peoples R China	Ho, CSH (corresponding author), Natl Univ Singapore, Dept Psychol Med, Yong Loo Lin Sch Med, Singapore 119074, Singapore.	lucas.lim@mohh.com.sg; pcmrhcm@nus.edu.sg; su_hui_ho@nuhs.edu.sg	Ho, Roger C/H-8714-2014; Ho, Cyrus SH/AAN-9344-2020	Ho, Roger C/0000-0001-9629-4493; Ho, Cyrus SH/0000-0002-7092-9566			Acabchuk Rebecca, 2016, Concussion, V1, DOI 10.2217/cnc-2015-0001; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belson K., 2017, NY TIMES; Buse GJ, 2006, BRIT J SPORT MED, V40, P169, DOI 10.1136/bjsm.2005.021295; Cantu R., 1995, BOXING AND MED; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Denk W., 1990, Z RECHTSMED, V103, P367; Frey A., 2004, J TRAUMATOLOGIE SPOR, V21, P100, DOI DOI 10.1016/S0762-915X(04)97390-1; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hutchison MG, 2014, AM J SPORT MED, V42, P1352, DOI 10.1177/0363546514526151; Jawaid MT, 2017, ANN INDIAN ACAD NEUR, V20, P106, DOI 10.4103/0972-2327.205773; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Lystad RP, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967113518492; Lystad RP, 2013, BRIT J SPORT MED, V47, P441, DOI 10.1136/bjsports-2012-091666; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Garcia RS, 2010, INT REV SOCIOL SPORT, V45, P39, DOI 10.1177/1012690209352392; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Zazryn T, 2007, SPORTS MED, V37, P467	32	11	11	0	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1660-4601		INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	JAN 2	2019	16	2							254	10.3390/ijerph16020254			8	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	HM0CF	WOS:000459112100089	30658408	DOAJ Gold, Green Published			2021-06-18	
J	Bittar, A; Bhatt, N; Hasan, TF; Montalbano, M; Puangmalai, N; McAllen, S; Ellsworth, A; Murillo, MC; Taglialatela, G; Lucke-Wold, B; Logsdon, A; Rosen, C; Turner, RC; Kayed, R				Bittar, Alice; Bhatt, Nemil; Hasan, Tasneem F.; Montalbano, Mauro; Puangmalai, Nicha; McAllen, Salome; Ellsworth, Anna; Murillo, Mariana Carretero; Taglialatela, Giulio; Lucke-Wold, Brandon; Logsdon, Aric; Rosen, Charles; Turner, Ryan C.; Kayed, Rakez			Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury	BRAIN COMMUNICATIONS			English	Article						traumatic brain injury; tau oligomers; tau polymorphisms; tau strains; neurodegeneration	PATHOLOGY; IMPAIRMENT; NEUROINFLAMMATION; NEURODEGENERATION; CONSCIOUSNESS; ACCUMULATION; OUTCOMES; STRAINS; DISEASE; BLAST	Mild traumatic brain injury accounts for the majority of head injuries and has been correlated with neurodegeneration and dementia. While repetitive mild traumatic brain injury is highly correlated to neurodegeneration, the correlation of a single mild traumatic brain injury with neurodegeneration is still unclear. Because tau aggregates are the main form of mild traumatic brain injury induced pathology, toxic forms of tau protein most likely play a role in the development of post-mild traumatic brain injury neurodegeneration. Therefore, it becomes crucial to characterize the properties of soluble tau aggregates in single versus repetitive mild traumatic brain injury. Herein, we isolated tau oligomers from wild-type mice exposed to single or repetitive mild traumatic brain injury and characterized the tau aggregates at functional, biochemical and biophysical levels. We demonstrated that single versus repetitive mild traumatic brain injuries frequencies lead to the formation of different tau oligomeric polymorphisms. These polymorphisms express different long-term potentiation impairment potencies, toxicity potentials, morphologies and strain indicating properties. To our knowledge, this is the first evidence that soluble tau oligomers derived from single versus repetitive mild traumatic brain injuries form distinct polymorphisms that possibly correlate with the risk of neurodegeneration after mild traumatic brain injury.	[Bittar, Alice; Bhatt, Nemil; Montalbano, Mauro; Puangmalai, Nicha; McAllen, Salome; Ellsworth, Anna; Taglialatela, Giulio; Kayed, Rakez] Univ Texas Med Branch, Mitchell Ctr Neurodegenerat Dis, Dept Neurol, 301 Univ Blvd,Route 0539,Med Res Bldg, Galveston, TX 77555 USA; [Hasan, Tasneem F.] Ochsner Louisiana State Univ, Dept Neurol, Hlth Sci Ctr, Shreveport, LA 71103 USA; [Murillo, Mariana Carretero] Baylor Coll Med, Houston, TX 77030 USA; [Lucke-Wold, Brandon] Univ Florida, Dept Neurosurg, Gainesville, FL 32608 USA; [Logsdon, Aric] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA; [Rosen, Charles] Cent Illinois Neural Hlth Sci, Bloomington, IL 61701 USA; [Turner, Ryan C.] West Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA	Kayed, R (corresponding author), Univ Texas Med Branch, Mitchell Ctr Neurodegenerat Dis, Dept Neurol, 301 Univ Blvd,Route 0539,Med Res Bldg, Galveston, TX 77555 USA.	rakayed@utmb.edu	Montalbano, Mauro/AAA-6833-2021; Puangmalai, Nicha/AAO-7521-2021	Montalbano, Mauro/0000-0002-0456-452X; Puangmalai, Nicha/0000-0002-1138-237X; Turner, Ryan/0000-0001-5523-0645	Gillson Longenbaugh foundation; Mitchel Center; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG054025, RFA1AG055771]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG052354] Funding Source: NIH RePORTER	This work was supported by the Gillson Longenbaugh foundation, the Mitchel Center, and the National Institutes of Health [Grant Nos. AG054025 and RFA1AG055771].	Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bandyopadhyay A, 2018, SPR SER POLYM COMPOS, P135, DOI 10.1007/978-981-10-6514-9_5; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bemiller SM, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0216-6; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Carron SF, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00047; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Comerota MM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15357-x; Cruz-Haces M, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0088-2; Fa M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19393; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Falcon B, 2019, NATURE, V568, P420, DOI 10.1038/s41586-019-1026-5; Furman JL, 2015, JOVE-J VIS EXP, DOI 10.3791/53205; Gerson J, 2016, J NEUROTRAUM, V33, P2034, DOI 10.1089/neu.2015.4262; Ghag G, 2018, PROTEIN SCI, V27, P1901, DOI 10.1002/pro.3499; Guo JL, 2016, J EXP MED, V213, P2635, DOI 10.1084/jem.20160833; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Holmes BB, 2014, P NATL ACAD SCI USA, V111, pE4376, DOI 10.1073/pnas.1411649111; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kaufman SK, 2016, NEURON, V92, P796, DOI 10.1016/j.neuron.2016.09.055; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Leyns CEG, 2017, P NATL ACAD SCI USA, V114, P11524, DOI 10.1073/pnas.1710311114; Little DM, 2014, ALZHEIMERS DEMENT, V10, pS188, DOI 10.1016/j.jalz.2014.04.002; Lo Cascio F, 2018, ACS CHEM NEUROSCI, V9, P1317, DOI 10.1021/acschemneuro.7b00501; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; Logsdon AF, 2017, ARCH NEUROSCI, V4, DOI 10.5812/archneurosci.44254; Luo YW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11458-9; Mayeux J, 2017, J NEUROTRAUM, V34, P436, DOI 10.1089/neu.2016.4452; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Narasimhan S, 2017, J NEUROSCI, V37, P11406, DOI 10.1523/JNEUROSCI.1230-17.2017; Narasimhan S, 2017, METHOD CELL BIOL, V141, P287, DOI 10.1016/bs.mcb.2017.06.009; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Spires-Jones TL, 2014, NEURON, V82, P756, DOI 10.1016/j.neuron.2014.05.004; TEASDALE G, 1974, LANCET, V2, P81; Turner RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00222; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Yin YL, 2016, P NATL ACAD SCI USA, V113, pE3773, DOI 10.1073/pnas.1604519113	52	11	11	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND		2632-1297		BRAIN COMMUN	Brain Commun.		2019	1	1							04	10.1093/braincomms/fcz004			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	NW3RF	WOS:000574927100004	31608324	DOAJ Gold, Green Published			2021-06-18	
J	Kleffelgaard, I; Soberg, HL; Tamber, AL; Bruusgaard, KA; Pripp, AH; Sandhaug, M; Langhammer, B				Kleffelgaard, Ingerid; Soberg, Helene Lundgaard; Tamber, Anne-Lise; Bruusgaard, Kari Anette; Pripp, Are Hugo; Sandhaug, Maria; Langhammer, Birgitta			The effects of vestibular rehabilitation on dizziness and balance problems in patients after traumatic brain injury: a randomized controlled trial	CLINICAL REHABILITATION			English	Article						Dizziness; neurological rehabilitation; physical therapy; postural balance; traumatic brain injury	MOBILITY ASSESSMENT-TOOL; HOSPITAL ANXIETY; HEAD-INJURY; CONCUSSION; DISORDERS; VALIDITY; VERTIGO; SYSTEM; SCALE	Objective: To investigate the effects of group-based vestibular rehabilitation in patients with traumatic brain injury. Design: A single-blind randomized controlled trial. Setting: University Hospital (recruitment and baseline assessments) and Metropolitan University (experimental intervention). Subjects: A total of 65 patients (45 women) with mild-to-moderate traumatic brain injury (mean age 39.4 +/- 13.0 years) were randomly assigned to intervention (n = 33) or control group (n = 32). Intervention: Group-based vestibular rehabilitation for eight weeks. Participants were tested at baseline (3.5 +/- 2.1 months after injury) and at two post-intervention follow-ups (2.7 +/- 0.8 and 4.4 +/- 1.0 months after baseline testing). Main measures: Primary outcome: Dizziness Handicap Inventory. Secondary outcome: High-Level Mobility Assessment Tool. Other outcomes: Vertigo Symptom Scale; Rivermead Post-concussion Symptoms Questionnaire; Hospital Anxiety and Depression Scale; and Balance Error Scoring System. Between-group differences were analyzed with a linear mixed-model analysis for repeated measurements. Results: At baseline, no group differences were revealed (personal factors, clinical characteristics and outcome measures). At the first follow-up, statistically significant mean differences in favor of the intervention were found in the primary (-8.7, 95% confidence interval (CI): -16.6 to -0.9) and secondary outcomes (3.7 points, 95% CI: 1.4-6.0). At the second follow-up, no significant between-group differences were found. No significant between-group differences in the other outcomes were found at the two follow-ups. Conclusion: The intervention appeared to speed up recovery for patients with dizziness and balance problems after traumatic brain injury. However, the benefits had dissipated two months after the end of the intervention.	[Kleffelgaard, Ingerid; Soberg, Helene Lundgaard] Oslo Univ Hosp, Dept Phys Med & Rehabil, Postboks 4950, N-0424 Oslo, Norway; [Kleffelgaard, Ingerid; Soberg, Helene Lundgaard; Tamber, Anne-Lise; Bruusgaard, Kari Anette; Pripp, Are Hugo; Langhammer, Birgitta] Oslo Metropolitan Univ, Fac Hlth Sci, Oslo, Norway; [Kleffelgaard, Ingerid] Univ Oslo, Fac Med, Oslo, Norway; [Pripp, Are Hugo] Oslo Univ Hosp, Res Support Serv, Oslo Ctr Biostat & Epidemiol, Oslo, Norway; [Sandhaug, Maria] Statped, Dept Res, Oslo, Norway; [Langhammer, Birgitta] Sunnaas Rehabil Hosp, Nesoddtangen, Norway	Kleffelgaard, I (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Postboks 4950, N-0424 Oslo, Norway.	ingerid.kleffelgard@ous-hf.no	Langhammer, Birgitta/P-1765-2019	Langhammer, Birgitta/0000-0002-9639-0570	Oslo Metropolitan University	We would like to thank all the participants who took part in the study. We thank the physiatrists Nada Andelic, Torgeir Hellstrom and Fredrik Walter Smith who took part in the recruitment of participants to this study. Furthermore, we are grateful to the multidisciplinary traumatic brain injury rehabilitation team at Oslo University Hospital and the colleagues at Oslo Metropolitan University for collaboration and support during the study. We would also like to thank Oslo Metropolitan University for the funding of the study and for providing necessary equipment and facilities for the intervention.	Akin FW, 2017, BRAIN INJURY, V31, P1188, DOI 10.1080/02699052.2017.1288928; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Arshad Q, 2017, CLIN NEUROL NEUROSUR, V155, P17, DOI 10.1016/j.clineuro.2017.01.021; Bandura A., 1997, SELF EFFICACY EXERCI; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fife TD, 2015, ANN NY ACAD SCI, V1343, P97, DOI 10.1111/nyas.12678; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Herdman SJ., 2014, VESTIBULAR REHABILIT, V4th edn; Hilton MP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003162.pub3; Iverson GL, 2013, REHABIL RES PRACT, V2013, DOI 10.1155/2013/846418; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleffelgaard I, 2018, EUR J PHYSIOTHER, V20, P25, DOI 10.1080/21679169.2017.1352020; Kleffelgaard I, 2016, PHYS THER, V96, P839, DOI 10.2522/ptj.20150095; Kleffelgaard I, 2013, PHYS THER, V93, P900, DOI 10.2522/ptj.20120381; Kurre A, 2010, BMC EAR NOSE THROAT, V10, DOI 10.1186/1472-6815-10-3; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; Murray DA, 2017, BRIT J SPORT MED, V51, P442, DOI 10.1136/bjsports-2016-096081; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Quatman-Yates C, 2016, PHYS THER, V96, P1753, DOI 10.2522/ptj.20150557; Reavenall S, 2010, INT J THER REHABIL, V17, P360, DOI 10.12968/ijtr.2010.17.7.48893; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Shumway-Cook A., 2017, MOTOR CONTROL TRANSL, V5; Tamber AL, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-101; Vikane E, 2017, BRAIN INJURY, V31, P475, DOI 10.1080/02699052.2017.1280852; Wilhelmsen K, 2008, BMC EAR NOSE THROAT, V8, DOI 10.1186/1472-6815-8-2; Williams G, 2005, BRAIN INJURY, V19, P925, DOI 10.1080/02699050500058687; Williams GP, 2009, INT J THER REHABIL, V16, P370, DOI 10.12968/ijtr.2009.16.7.43046; Yorker A., 2013, ARCH PHYS MED REHAB, V94, P2313, DOI [10.1016/j.apmr.2013.07.007, DOI 10.1016/J.APMR.2013.07.007]; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	11	12	0	14	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2019	33	1					74	84		10.1177/0269215518791274			11	Rehabilitation	Rehabilitation	HF8VW	WOS:000454521300009	30056743				2021-06-18	
J	Lee, JY; Acosta, S; Tuazon, JP; Xu, KY; Nguyen, H; Lippert, T; Liska, MG; Semechkin, A; Garitaonandia, I; Gonzalez, R; Kern, R; Borlongan, CV				Lee, Jea-Young; Acosta, Sandra; Tuazon, Julian P.; Xu, Kaya; Hung Nguyen; Lippert, Trenton; Liska, Michael G.; Semechkin, Andrey; Garitaonandia, Ibon; Gonzalez, Rodolfo; Kern, Russell; Borlongan, Cesario V.			Human parthenogenetic neural stem cell grafts promote multiple regenerative processes in a traumatic brain injury model	THERANOSTICS			English	Article						neuroprotection; traumatic brain injury; human parthenogenetic neural stem cells; inflammation; stem cell transplantation	TRANSPLANTATION; THERAPIES; NEURONS; SPLEEN; RATS	International Stem Cell Corporation human parthenogenetic neural stem cells (ISC-hpNSC) have potential therapeutic value for patients suffering from traumatic brain injury (TBI). Here, we demonstrate the behavioral and histological effects of transplanting ISC-hpNSC intracerebrally in an animal model of TBI. Methods: Sprague-Dawley rats underwent a moderate controlled cortical impact TBI surgery. Transplantation occurred at 72 h post-TBI with functional readouts of behavioral and histological deficits conducted during the subsequent 3-month period after TBI. We characterized locomotor, neurological, and cognitive performance at baseline (before TBI), then on days 0, 1, 7, 14, 30, 60, and 90 (locomotor and neurological), and on days 28-30, 58-60, and 88-90 (cognitive) after TBI. Following completion of behavioral testing at 3 months post-TBI, animals were euthanized by transcardial perfusion and brains harvested to histologically characterize the extent of brain damage. Neuronal survival was revealed by Nissl staining, and stem cell engraftment and host tissue repair mechanisms such as the anti-inflammatory response in peri-TBI lesion areas were examined by immunohistochemical analyses. Results: We observed that TBI groups given high and moderate doses of ISC-hpNSC had an improved swing bias on an elevated body swing test for motor function, increased scores on forelimb akinesia and paw grasp neurological tests, and committed significantly fewer errors on a radial arm water maze test for cognition. Furthermore, histological analyses indicated that high and moderate doses of stem cells increased the expression of phenotypic markers related to the neural lineage and myelination and decreased reactive gliosis and inflammation in the brain, increased neuronal survival in the peri-impact area of the cortex, and decreased inflammation in the spleen at 90 days post-TBI. Conclusion: These results provide evidence that high and moderate doses of ISC-hpNSC ameliorate TBI-associated histological alterations and motor, neurological, and cognitive deficits.	[Lee, Jea-Young; Acosta, Sandra; Tuazon, Julian P.; Xu, Kaya; Hung Nguyen; Lippert, Trenton; Liska, Michael G.; Borlongan, Cesario V.] USF Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; [Semechkin, Andrey; Garitaonandia, Ibon; Gonzalez, Rodolfo; Kern, Russell] Int Stem Cell Corp, Carlsbad, CA USA; [Kern, Russell] Cyto Therapeut, Melbourne, Vic, Australia	Borlongan, CV (corresponding author), USF Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA.	cborlong@health.usf.edu					Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Acosta SA, 2015, STROKE, V46, P2616, DOI 10.1161/STROKEAHA.115.009854; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Altumbabic M, 1998, STROKE, V29, P1917, DOI 10.1161/01.STR.29.9.1917; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Boutajangout A, 2017, CURR ALZHEIMER RES, V14, P104, DOI 10.2174/1567205013666161004151416; Carpenter MK, 2009, NAT BIOTECHNOL, V27, P606, DOI 10.1038/nbt0709-606; Chen BJ, 2004, BLOOD, V103, P4344, DOI 10.1182/blood-2003-07-2534; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Daughtry B, 2014, STEM CELL TRANSL MED, V3, P290, DOI 10.5966/sctm.2013-0127; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frey-Vasconcells J, 2012, STEM CELL TRANSL MED, V1, P353, DOI 10.5966/sctm.2012-0018; Garbuzova-Davis S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00993-0; Garitaonandia I, 2018, STEM CELLS DEV, V27, P951, DOI 10.1089/scd.2018.0001; Garitaonandia I, 2016, SCI REP-UK, V6, DOI 10.1038/srep34478; Gonzalez R, 2016, CELL TRANSPLANT, V25, P1945, DOI 10.3727/096368916X691682; Gonzalez R, 2015, CELL TRANSPLANT, V24, P681, DOI 10.3727/096368915X687769; Gonzalez R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01463; Isaev DA, 2012, REGEN MED, V7, P37, DOI [10.2217/RME.11.110, 10.2217/rme.11.110]; Johannesson B, 2014, CELL STEM CELL, V15, P634, DOI 10.1016/j.stem.2014.10.002; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lo B, 2009, ENDOCR REV, V30, P204, DOI 10.1210/er.2008-0031; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Quyyumi AA, 2011, AM HEART J, V161, DOI 10.1016/j.ahj.2010.09.025; Ratcliffe E, 2013, BRIT MED BULL, V108, P73, DOI 10.1093/bmb/ldt034; Revazova ES, 2008, CLONING STEM CELLS, V10, P11, DOI 10.1089/clo.2007.0063; Revazova ES, 2007, CLONING STEM CELLS, V9, P432, DOI 10.1089/clo.2007.0033; Robinson AM, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0540-3; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tajiri N, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00116; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0; Turovets N, 2012, CELL TRANSPLANT, V21, P217, DOI 10.3727/096368911X582723; Uchida H, 2017, STROKE, V48, P428, DOI 10.1161/STROKEAHA.116.014950; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wislet-Gendebien S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-33; Wood KJ, 2012, NAT REV IMMUNOL, V12, P417, DOI 10.1038/nri3227; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011	46	11	11	0	3	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2019	9	4					1029	1046		10.7150/thno.29868			18	Medicine, Research & Experimental	Research & Experimental Medicine	HJ5DV	WOS:000457199500009	30867814	DOAJ Gold, Green Published			2021-06-18	
J	Li, XG; Sandler, H; Kleiven, S				Li, Xiaogai; Sandler, Hakan; Kleiven, Svein			Infant skull fractures: Accident or abuse? Evidences from biomechanical analysis using finite element head models	FORENSIC SCIENCE INTERNATIONAL			English	Article						Abusive Head Trauma; Multiple skull fractures; Finite element head model; Ossification centers; Impact location	TRAUMATIC BRAIN-INJURIES; IMPACT; CHILDREN; TISSUE; FALL; PREDICTION; SUTURE	Abusive Head Trauma (AHT) is considered by some authors to be a leading cause of traumatic death in children less than two years of age and skull fractures are commonly seen in cases of suspected AHT. Today, diagnosing whether the observed fractures are caused by abuse or accidental fall is still a challenge within both the medical and the legal communities and the central question is a biomechanical question: can the described history explain the observed fractures? Finite element (FE) analysis has been shown a valuable tool for biomechanical analysis accounting for detailed head geometry, advanced material modelling, and case-specific factors (e.g. head impact location, impact surface properties). Here, we reconstructed two well-documented suspected abuse cases (a 3- and a 4-month-old) using subject-specific FE head models. The models incorporate the anatomical details and age-dependent anisotropic material properties of infant cranial bones that reflect the grainy fibres radiating from ossification centres. The impact locations are determined by combining multimodality images. The results show that the skull fracture patterns in both cases of suspected abuse could be explained by the described accidental fall history, demonstrating the inherent potential of FE analysis for providing biomechanical evidence to aid forensic investigations. Increased knowledge of injury mechanisms in children may have enormous medico-legal implications world-wide. (C) 2018 Published by Elsevier B.V.	[Li, Xiaogai; Kleiven, Svein] Royal Inst Technol KTH, Sch Technol & Hlth, Div Neuron Engn, S-14152 Huddinge, Sweden; [Sandler, Hakan] Uppsala Univ, Dept Surg Sci Forens Med, Uppsala, Sweden; [Sandler, Hakan] Natl Board Forens Med, Uppsala, Sweden	Li, XG (corresponding author), Royal Inst Technol KTH, Sch Technol & Hlth, Div Neuron Engn, S-14152 Huddinge, Sweden.	xiaogai@kth.se		Li, Xiaogai/0000-0001-8522-4705	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2016-04203]; Swedish National Board of Forensic Medicine [RMV 4155451]	This work was supported by the Swedish Research Council [grant number 2016-04203]; the Swedish National Board of Forensic Medicine [grant number RMV 4155451]. The funders had no role in study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.	American Academy of Pediatrics, 2017, STAT AB HEAD TRAUM S; Arnholz D, 1998, J TRAUMA, V45, P172, DOI 10.1097/00005373-199807000-00039; Baumer TG, 2010, J FORENSIC SCI, V55, P993, DOI 10.1111/j.1556-4029.2010.01391.x; Beillas P., 2016, 14 INT C PROT CHILDR, P19; Bilo RAC, 2010, FORENSIC ASPECTS OF PAEDIATRIC FRACTURES: DIFFERENTIATING ACCIDENTAL TRAUMA FROM CHILD ABUSE, P1, DOI 10.1007/978-3-540-78716-7; BYLSKI DI, 1986, J BIOMECH, V19, P19, DOI 10.1016/0021-9290(86)90105-3; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Colbourne M, 2015, B C MED J, V57, P331; Deland T.S., 2016, J FORENSIC SCI, V61; Ehsani JP, 2010, AM J FOREN MED PATH, V31, P287, DOI 10.1097/PAF.0b013e3181db7eb5; Fahlstedt M, 2015, J BIOMECH, V48, P1331, DOI 10.1016/j.jbiomech.2015.02.057; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; Flaherty EG, 2014, PEDIATRICS, V133, pE477, DOI 10.1542/peds.2013-3793; Giordano C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187916; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Gray H., 1918, ANATOMY HUMAN BODY; Hamel A, 2013, INT J LEGAL MED, V127, P111, DOI 10.1007/s00414-011-0627-9; Haut RC, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4034430; HELFER RE, 1977, PEDIATRICS, V60, P533; Hinds T, 2015, CURR PROB PEDIATR AD, V45, P71, DOI 10.1016/j.cppeds.2015.02.002; Ho J, 2017, J BIOMECH, V60, P243, DOI 10.1016/j.jbiomech.2017.06.023; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; HOBBS CJ, 1989, BRIT MED J, V298, P1015, DOI 10.1136/bmj.298.6679.1015; Holck P, 2005, FORENSIC SCI INT, V151, P187, DOI 10.1016/j.forsciint.2004.12.038; Hymel KP, 2013, PEDIATR CRIT CARE ME, V14, P210, DOI 10.1097/PCC.0b013e3182712b09; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2014, FORENSIC PATHOLOGY I, P435; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kleinman PK., 2015, DIAGNOSTIC IMAGING C; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; KRIEWALL TJ, 1982, AM J OBSTET GYNECOL, V143, P707, DOI 10.1016/0002-9378(82)90119-3; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Li XG, 2016, INT J IMPACT ENG, V91, P56, DOI 10.1016/j.ijimpeng.2015.12.010; Li XG, 2017, BIOMECH MODEL MECHAN, V16, P823, DOI 10.1007/s10237-016-0855-5; Li XG, 2013, J CLIN NEUROSCI, V20, P509, DOI 10.1016/j.jocn.2012.04.019; Li ZG, 2015, INT J LEGAL MED, V129, P1055, DOI 10.1007/s00414-015-1190-6; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; MESERVY CJ, 1987, AM J ROENTGENOL, V149, P173, DOI 10.2214/ajr.149.1.173; Parks S. E., 2012, PEDIAT ABUSIVE HEAD, P5; Peterson C, 2014, PEDIATRICS, V134, P91, DOI 10.1542/peds.2014-0117; Post A, 2015, NEUROSURGERY, V76, P81, DOI 10.1227/NEU.0000000000000554; Powell B.J., 2012, 2007DNBXK196 NAT I J; Powell BJ, 2013, J FORENSIC SCI, V58, P678, DOI 10.1111/1556-4029.12094; Ross AH, 2009, FORENSIC SCI INT, V188, P99, DOI 10.1016/j.forsciint.2009.03.021; Sullivan S, 2015, ACCIDENT ANAL PREV, V82, P143, DOI 10.1016/j.aap.2015.05.020; Thompson AK, 2011, ACCIDENT ANAL PREV, V43, P143, DOI 10.1016/j.aap.2010.07.020; Vaughan PE, 2016, J FORENSIC SCI, V61, P1190, DOI 10.1111/1556-4029.13111; von Holst H, 2013, J NEUROTRAUM, V30, P1192, DOI 10.1089/neu.2012.2730; von Holst H, 2012, ACTA NEUROCHIR, V154, P1583, DOI 10.1007/s00701-012-1393-2; WEBER W, 1985, Z RECHTSMED, V94, P93; WEBER W, 1984, Z RECHTSMED, V92, P87, DOI 10.1007/BF02116216	53	11	11	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JAN	2019	294						173	182		10.1016/j.forsciint.2018.11.008			10	Medicine, Legal	Legal Medicine	HG3GL	WOS:000454861200029	30529991				2021-06-18	
J	Nagakannan, P; Islam, MI; Karimi-Abdolrezaee, S; Eftekharpour, E				Nagakannan, Pandian; Islam, Md Imamul; Karimi-Abdolrezaee, Soheila; Eftekharpour, Eftekhar			Inhibition of VDAC1 Protects Against Glutamate-Induced Oxytosis and Mitochondrial Fragmentation in Hippocampal HT22 Cells	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Glutamate toxicity; Ferroptosis; Caspase-independent apoptosis; Oxidative stress; AIF; DIDS	OXIDATIVE STRESS; N-TERMINUS; DEATH; APOPTOSIS; RELEASE; AIF; OLIGOMERIZATION; DEGRADATION; NEUROTRANSMITTER; GLIOTRANSMISSION	The involvement of glutamate in neuronal cell death in neurodegenerative diseases and neurotrauma is mediated through excitotoxicity or oxytosis. The latter process induces oxidative stress via glutamate-mediated inhibition of cysteine transporter xCT, leading to depletion of the cellular glutathione pool. Mitochondrial damage, loss of mitochondrial membrane potential (MMP), and depletion of energy metabolites have been shown in this process. The Voltage-Dependent Anion Channel-1 (VDAC1) is one of the main components of the mitochondrial outer membrane and plays a gatekeeping role in mitochondria-cytoplasm transport of metabolites. In this study, we explored the possible participation of VDAC-1 in the pathophysiology of oxytosis. Administration of glutamate in HT22 cells that lack the glutamate ionotropic receptors induced an upregulation and oligomerization of VDAC1. This was associated with an increase in ROS and loss of cell survival. Glutamate-mediated oxytosis in this model also decreased MMP and promoted ATP depletion, resulting in translocation of cytochrome c (cyt C) and apoptosis inducing factor (AIF) from mitochondria into the cytosol. This was also accompanied by cleavage of AIF to form truncated AIF. Inhibition of VDAC1 oligomerization using 4,4-Diisothiocyanatostilbene-2,2-disulfonate (DIDS), significantly improved the cell survival, decreased the ROS levels, improved mitochondrial functions, and decreased the mitochondrial damage. Notably, DIDS also inhibited the mitochondrial fragmentation caused by glutamate, indicating the active role of VDAC1 oligomerization in the process of mitochondrial fragmentation in oxytosis. These results suggest a critical role for VDAC1 in mitochondrial fragmentation and its potential therapeutic value against glutamate-mediated oxidative neurotoxicity.	[Nagakannan, Pandian; Islam, Md Imamul; Karimi-Abdolrezaee, Soheila; Eftekharpour, Eftekhar] Univ Manitoba, Dept Physiol & Pathophysiol, Regenerat Med Program, Winnipeg, MB, Canada; [Nagakannan, Pandian; Islam, Md Imamul; Karimi-Abdolrezaee, Soheila; Eftekharpour, Eftekhar] Univ Manitoba, Spinal Cord Res Ctr, Winnipeg, MB, Canada	Eftekharpour, E (corresponding author), Univ Manitoba, Dept Physiol & Pathophysiol, Regenerat Med Program, Winnipeg, MB, Canada.; Eftekharpour, E (corresponding author), Univ Manitoba, Spinal Cord Res Ctr, Winnipeg, MB, Canada.	eftekhar@umanitoba.ca		Islam, Md Imamul/0000-0002-3126-5453; Pandian, Nagakannan/0000-0002-6791-0661; Eftekharpour, Eftekhar/0000-0002-2849-3754; Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663	Health Sciences Centre Foundation; Paralyzed Veterans of America	Funding was provided by Health Sciences Centre Foundation and Paralyzed Veterans of America.	Abu-Hamad S, 2009, J CELL SCI, V122, P1906, DOI 10.1242/jcs.040188; Ben-Hail D, 2016, BBA-MOL CELL RES, V1863, P1612, DOI 10.1016/j.bbamcr.2016.04.002; Chaanine AH, 2013, CIRC-HEART FAIL, V6, P572, DOI 10.1161/CIRCHEARTFAILURE.112.000200; Daugas E, 2000, FASEB J, V14, P729; De Pinto V, 2016, BBA-BIOENERGETICS, V1857, P1219, DOI 10.1016/j.bbabio.2016.02.020; DeHart DN, 2018, BIOCHEM PHARMACOL, V148, P155, DOI 10.1016/j.bcp.2017.12.022; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Edison N, 2017, CELL REP, V21, P442, DOI 10.1016/j.celrep.2017.09.052; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Fukui M, 2009, EUR J PHARMACOL, V617, P1, DOI 10.1016/j.ejphar.2009.06.059; Geula S, 2012, BIOCHEM J, V444, P475, DOI 10.1042/BJ20112079; Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006; Kang YY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4672; Keinan N, 2013, BBA-MOL CELL RES, V1833, P1745, DOI 10.1016/j.bbamcr.2013.03.017; Keinan N, 2010, MOL CELL BIOL, V30, P5698, DOI 10.1128/MCB.00165-10; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Lewerenz J, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00214; Lewerenz J, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00469; Liu ZY, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0188-y; Maher P, 2018, CELL CALCIUM, V70, P47, DOI 10.1016/j.ceca.2017.05.007; Malia TJ, 2007, BIOCHEMISTRY-US, V46, P514, DOI 10.1021/bi061577h; Manczak M, 2012, HUM MOL GENET, V21, P5131, DOI 10.1093/hmg/dds360; McCommis KS, 2012, BBA-BIOMEMBRANES, V1818, P1444, DOI 10.1016/j.bbamem.2011.10.025; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Nagakannan P, 2016, FREE RADICAL BIO MED, V101, P53, DOI 10.1016/j.freeradbiomed.2016.09.026; Neitemeier S, 2017, REDOX BIOL, V12, P558, DOI 10.1016/j.redox.2017.03.007; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Pamenter ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060804; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Reddy PH, 2013, BBA-MOL BASIS DIS, V1832, P67, DOI 10.1016/j.bbadis.2012.09.003; Sahlender DA, 2014, BIOL SCI, V369, DOI 10.1098/rstb.2013.0592; Sanderson TH, 2015, MOL CELL NEUROSCI, V64, P116, DOI 10.1016/j.mcn.2014.12.007; Santello M, 2012, ADV EXP MED BIOL, V970, P307, DOI 10.1007/978-3-7091-0932-8_14; Savtchouk I, 2018, J NEUROSCI, V38, P14, DOI 10.1523/JNEUROSCI.0017-17.2017; Shoshan-Barmatz V, 2018, PHARMACOL RES, V131, P87, DOI 10.1016/j.phrs.2018.03.010; Shoshan-Barmatz V, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00060; Shoshan-Barmatz V, 2010, BBA-BIOENERGETICS, V1797, P1281, DOI 10.1016/j.bbabio.2010.03.003; Shoshan-Barmatz V, 2009, BBA-BIOENERGETICS, V1787, P421, DOI 10.1016/j.bbabio.2008.11.009; Shoshan-Barmatzt V, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00164; Su B, 2010, BBA-MOL BASIS DIS, V1802, P135, DOI 10.1016/j.bbadis.2009.09.013; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779; van Leyen K, 2005, J NEUROCHEM, V92, P824, DOI 10.1111/j.1471-4159.2004.02915.x; Voronina SG, 2004, J BIOL CHEM, V279, P27327, DOI 10.1074/jbc.M311698200; Zhou Y, 2014, J NEURAL TRANSM, V121, P799, DOI 10.1007/s00702-014-1180-8	48	11	11	6	29	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2019	39	1					73	85		10.1007/s10571-018-0634-1			13	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	HG8CY	WOS:000455226200005	30421242				2021-06-18	
J	Singleton, Q; Vaibhav, K; Braun, M; Patel, C; Khayrullin, A; Mendhe, B; Lee, BR; Kolhe, R; Kaiser, H; Awad, ME; Fariyike, T; Elsayed, R; Elsalanty, M; Isales, CM; Liu, YT; Hamrick, MW; Dhandapani, KM; Fulzele, S				Singleton, Quante; Vaibhav, Kumar; Braun, Molly; Patel, Chandani; Khayrullin, Andrew; Mendhe, Bharati; Lee, Byung R.; Kolhe, Ravindra; Kaiser, Helen; Awad, Mohamed E.; Fariyike, Tunde; Elsayed, Ranya; Elsalanty, Mohammed; Isales, Carlos M.; Liu, Yutao; Hamrick, Mark W.; Dhandapani, Krishnan M.; Fulzele, Sadanand			Bone Marrow Derived Extracellular Vesicles Activate Osteoclast Differentiation in Traumatic Brain Injury Induced Bone Loss	CELLS			English	Article						traumatic brain injury; bone loss; traumatic brain injury; extracellular vesicles; extracellular vesicles	NECROSIS-FACTOR-ALPHA; MINERAL DENSITY; CONSEQUENCES; REHABILITATION; POLARIZATION; PREVALENCE; EXPRESSION; REDUCTION; IMPACT; ADULTS	Traumatic brain injury (TBI) is a major source of worldwide morbidity and mortality. Patients suffering from TBI exhibit a higher susceptibility to bone loss and an increased rate of bone fractures; however, the underlying mechanisms remain poorly defined. Herein, we observed significantly lower bone quality and elevated levels of inflammation in bone and bone marrow niche after controlled cortical impact-induced TBI in in vivo CD-1 mice. Further, we identified dysregulated NF-kappa B signaling, an established mediator of osteoclast differentiation and bone loss, within the bone marrow niche of TBI mice. Ex vivo studies revealed increased osteoclast differentiation in bone marrow-derived cells from TBI mice, as compared to sham injured mice. We also found bone marrow derived extracellular vesicles (EVs) from TBI mice enhanced the colony forming ability and osteoclast differentiation efficacy and activated NF-kappa B signaling genes in bone marrow-derived cells. Additionally, we showed that miRNA-1224 up-regulated in bone marrow-derived EVs cargo of TBI. Taken together, we provide evidence that TBI-induced inflammatory stress on bone and the bone marrow niche may activate NF-kappa B leading to accelerated bone loss. Targeted inhibition of these signaling pathways may reverse TBI-induced bone loss and reduce fracture rates.	[Singleton, Quante; Patel, Chandani; Lee, Byung R.; Isales, Carlos M.; Fulzele, Sadanand] Augusta Univ, Dept Orthoped Surg, Augusta, GA 30912 USA; [Vaibhav, Kumar; Braun, Molly; Fariyike, Tunde; Dhandapani, Krishnan M.] Augusta Univ, Dept Neurosurg, Augusta, GA 30912 USA; [Khayrullin, Andrew; Mendhe, Bharati; Kaiser, Helen; Liu, Yutao; Hamrick, Mark W.] Augusta Univ, Cell Biol & Anat, Augusta, GA 30912 USA; [Kolhe, Ravindra; Elsayed, Ranya; Elsalanty, Mohammed] Augusta Univ, Dept Pathol, Augusta, GA 30912 USA; [Awad, Mohamed E.] Augusta Univ, Dept Oral Biol, Augusta, GA 30912 USA; [Isales, Carlos M.; Hamrick, Mark W.; Fulzele, Sadanand] Georgia Regents Univ, Inst Regenerat & Reparat Med, Augusta, GA 30912 USA	Fulzele, S (corresponding author), Augusta Univ, Dept Orthoped Surg, Augusta, GA 30912 USA.; Dhandapani, KM (corresponding author), Augusta Univ, Dept Neurosurg, Augusta, GA 30912 USA.; Fulzele, S (corresponding author), Georgia Regents Univ, Inst Regenerat & Reparat Med, Augusta, GA 30912 USA.	qsingleton@augusta.edu; kvaibhav@augusta.edu; mobraun@augusta.edu; chapatel@augusta.edu; akhayrullin@augusta.edu; bmendhe@augusta.edu; blee@augusta.edu; rkolhe@augusta.edu; hkaiser@augusta.edu; moawad@augusta.edu; bfariyike@augusta.edu; relsayed@augusta.edu; melsalanty@augusta.edu; cisales@augusta.edu; yutliu@augusta.edu; mhamrick@augusta.edu; kdhandapani@augusta.edu; sfulzele@augusta.edu	Awad, Mohamed E./ABC-8407-2020; Awad, Mohamed/U-1799-2019; Vaibhav, Kumar/H-4120-2019	Singleton, Quante/0000-0002-2910-1353; Vaibhav, Kumar/0000-0002-4206-3830; Dhandapani, Krishnan/0000-0001-7044-1117; Awad, Mohamed E./0000-0001-7525-5364; KOLHE, RAVINDRA/0000-0002-8283-2403	National Institutes on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG 036675]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS097825, NS110378]; National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD094606]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG036675] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes on Aging P01 AG 036675 to SF, MWH, and CS; National Institute of Health NS097825; NS110378 to KMD; and National Institute of Child Health & Human Development HD094606 to KV. The authors declare no competing financial and non-financial interests.	Andelic N, 2014, J NEUROTRAUM, V31, P1313, DOI 10.1089/neu.2013.3292; Banham-Hall N, 2013, PHYSIOTHERAPY, V99, P328, DOI 10.1016/j.physio.2012.12.009; Brady RD, 2016, J MUSCULOSKEL NEURON, V16, P369; Brady RD, 2016, J NEUROTRAUM, V33, P2154, DOI 10.1089/neu.2014.3836; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Braun M, 2018, BRAIN BEHAV IMMUN, V68, P224, DOI 10.1016/j.bbi.2017.10.021; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Bretz NP, 2013, J BIOL CHEM, V288, P36691, DOI 10.1074/jbc.M113.512806; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Cefalu CA, 2004, CURR MED RES OPIN, V20, P341, DOI 10.1185/030079903125003062; Chao CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132685; Crescitelli R., 2013, J ORAL TISSUE ENG, V2, P20677; Davis C, 2017, TISSUE ENG PT A, V23, P1231, DOI [10.1089/ten.tea.2016.0525, 10.1089/ten.TEA.2016.0525]; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Dias C, 2015, NEUROCRIT CARE, V22, P192, DOI 10.1007/s12028-014-0045-1; Divittorio G, 2006, PHARMACOTHERAPY, V26, P104, DOI 10.1592/phco.2006.26.1.104; Ekstrom K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075227; Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742-4933-2-14; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helwa I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170628; Hilz MJ, 2017, J NEUROL, V264, P1956, DOI 10.1007/s00415-017-8581-1; Julien J, 2017, ANN PHYS REHABIL MED, V60, P347, DOI 10.1016/j.rehab.2017.03.009; Kagiya T, 2013, J PERIODONTAL RES, V48, P373, DOI 10.1111/jre.12017; Kanis JA, 2017, J CLIN DENSITOM, V20, P444, DOI 10.1016/j.jocd.2017.06.013; Kisser JE, 2016, J NEUROL SCI, V365, P9, DOI 10.1016/j.jns.2016.03.033; Kolhe R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01905-y; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JI, 2005, BRAIN INJURY, V19, P1207, DOI 10.1080/02699050500309338; Lee Young Joo, 2015, Obstet Gynecol Sci, V58, P46, DOI 10.5468/ogs.2015.58.1.46; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Marton N, 2017, CELL MOL LIFE SCI, V74, P3599, DOI 10.1007/s00018-017-2535-8; Niu YN, 2011, IMMUNOLOGY, V133, P8, DOI 10.1111/j.1365-2567.2010.03374.x; Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159; Rau CS, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121203; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sangani R, 2013, EXP MOL PATHOL, V95, P298, DOI 10.1016/j.yexmp.2013.08.007; Smith E, 2016, IRISH J MED SCI, V185, P473, DOI 10.1007/s11845-016-1399-5; Smith E, 2011, J CLIN DENSITOM, V14, P85, DOI 10.1016/j.jocd.2010.12.002; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; Villapol S, 2016, NEURAL REGEN RES, V11, P226, DOI 10.4103/1673-5374.177720; Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017; Xu JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114627; Yu HR, 2014, BRAIN INJURY, V28, P244, DOI 10.3109/02699052.2013.859735	49	11	12	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2073-4409		CELLS-BASEL	Cells	JAN	2019	8	1							63	10.3390/cells8010063			16	Cell Biology	Cell Biology	HM8PD	WOS:000459742400062	30658394	DOAJ Gold, Green Published			2021-06-18	
J	Chanda, A; Callaway, C; Clifton, C; Unnikrishnan, V				Chanda, Arnab; Callaway, Christian; Clifton, Cassie; Unnikrishnan, Vinu			Biofidelic human brain tissue surrogates	MECHANICS OF ADVANCED MATERIALS AND STRUCTURES			English	Article						Brain tissue; grey matter; surrogates; traumatic brain injury (TBI); white matter	WHITE-MATTER CHANGES; NORMAL ADULT BRAIN; TOTAL GRAY-MATTER; SILICONE-RUBBER; INJURY; DEMENTIA; BEHAVIOR; MODELS; DAMAGE; SKIN	Traumatic brain injury (TBI) due to blast exposure or head impacts in accidents or contact sports is one of the most critical and poorly understood areas of research in the 21st century. To date, the unavailability of human brain tissues (grey and white matter especially) due to ethical and biosafety issues has not allowed for much experimental research into the study of the mechanics of brain tissues under impact or dynamic loading. In the current work, for the first time, biofidelic brain tissue surrogates have been developed using a low cost, castable (to any shape or size), two-part silicone-based material system to precisely mimic the nonlinear mechanical properties of both the white and the grey matter. The fabrication methodology involves the iterative mixing of the two parts of silicone at certain mix ratios (by weight) to generate a biomechanical behavior similar to the white and the grey matter tissues, respectively, at two different strain rates (low and high). The nonlinear behavior of these novel brain tissue surrogates have been characterized using five hyperelastic material models. These brain tissue simulant materials would be indispensable not only for the study of TBI, but also to allow doctors to practice brain surgeries (for training purposes) in a clinical setting. Additionally, crucial brain tissue modifications in Alzheimer's disease and dementia can be studied in the future with such accessible biofidelic brain tissue surrogate materials.	[Chanda, Arnab; Unnikrishnan, Vinu] Univ Alabama, Dept Aerosp Engn & Mech, Box 870280, Tuscaloosa, AL USA; [Callaway, Christian; Clifton, Cassie] Univ Alabama, Dept Mech Engn, Tuscaloosa, AL USA	Unnikrishnan, V (corresponding author), Univ Alabama, Dept Aerosp Engn & Mech, Box 870280, Tuscaloosa, AL USA.	vunnikrishnan@ua.edu			University of Alabama	VU would like to acknowledge the faculty start-up funds and 2014 RGC grants from The University of Alabama.	Bigler E. D., 2009, TXB ALZHEIMER DIS OT, P229; BIRD TD, 1983, ANN NEUROL, V14, P284, DOI 10.1002/ana.410140306; Centers for Disease Control and Prevention, 1997, INT J TRAUMA NURS, V3, P88; Chafi MS, 2011, INT J APPL MECH, V3, P803, DOI 10.1142/S175882511100124X; Chanda A., 2015, U. S. Patent, Patent No. [62/189,504, 62189504, US 62/189,504]; Chanda A, 2015, AIMS MATER SCI, V2, P425, DOI 10.3934/matersci.2015.4.425; Chanda A, 2015, APPL MECH REV, V67, DOI 10.1115/1.4030967; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; CRUTCHER KA, 1993, J NEUROSCI, V13, P2540; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; de Leeuw FE, 2002, BRAIN, V125, P765, DOI 10.1093/brain/awf077; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; ENGLUND E, 1988, BRAIN, V111, P1425, DOI 10.1093/brain/111.6.1425; Estes MS, 1970, RESPONSE BRAIN TISSU; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Ganpule S., 2010, ASME 2010 INT MECH E, P181; Ganpule S., 2009, ASME INT MECH ENG C, P339; Ganpule S., 2013, ASME 2013 SUMM BIOEN; Ge YL, 2002, AM J NEURORADIOL, V23, P1327; Ge YL, 2002, AM J NEURORADIOL, V23, P1334; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gonzalez L.Y.S., 2005, HYPERELASTIC MAT MOD; Gu LX, 2012, COMPOS PART B-ENG, V43, P3160, DOI 10.1016/j.compositesb.2012.04.014; Gupta RS, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00217; Holzapfel G.A., 2000, NONLINEAR SOLID MECH, V24; Ikram MA, 2010, NEUROBIOL AGING, V31, P378, DOI 10.1016/j.neurobiolaging.2008.04.008; Jenson D., 2014, ASME 2014 INT MECH E; Jenson D, 2015, COMPOS STRUCT, V121, P211, DOI 10.1016/j.compstruct.2014.08.028; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Kangarlou K., 2013, NATIONALPARK FORSCHU, V12, P511; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Mai J. K., 1997, ATLAS HUMAN BRAIN; Martins PALS, 2006, STRAIN, V42, P135, DOI 10.1111/j.1475-1305.2006.00257.x; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; MIELKE R, 1992, ARCH NEUROL-CHICAGO, V49, P909, DOI 10.1001/archneur.1992.00530330031011; Miller K, 2005, J BIOMECH, V38, P153, DOI 10.1016/j.jbiomech.2004.03.004; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; NOVITZKY D, 1988, TRANSPLANTATION, V45, P32; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Shergold OA, 2006, INT J IMPACT ENG, V32, P1384, DOI 10.1016/j.ijimpeng.2004.11.010; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	50	11	12	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1537-6494	1537-6532		MECH ADV MATER STRUC	Mech. Adv. Mater. Struct.	DEC 10	2018	25	15-16			SI		1335	1341		10.1080/15376494.2016.1143749			7	Materials Science, Multidisciplinary; Mechanics; Materials Science, Characterization & Testing; Materials Science, Composites	Materials Science; Mechanics	HE5ES	WOS:000453396900009		Bronze			2021-06-18	
J	Guillotte, AR; Herbert, JP; Madsen, R; Hammer, RD; Litofsky, NS				Guillotte, Andrew R.; Herbert, Joseph P.; Madsen, Richard; Hammer, Richard D.; Litofsky, N. Scott			Effects of platelet dysfunction and platelet transfusion on outcomes in traumatic brain injury patients	BRAIN INJURY			English	Article						Coagulopathy; platelet dysfunction; thromboelastography; TEG; traumatic brain injury	ADENOSINE-DIPHOSPHATE; COAGULOPATHY; THROMBOELASTOGRAPHY; INHIBITION	Objective: Platelet inhibition in traumatic brain injury (TBI) may be due to injury or antiplatelet medication use pre-injury. This study aims to identify factors associated with increased platelet arachidonic acid (AA) and adenosine diphosphate (ADP) inhibition and determine if platelet transfusion reduces platelet dysfunction and affects outcome. Methods: Prospective thromboelastography (TEG) assays were collected on adult patients with TBI with intracranial injuries detected by computed tomography (CT). Outcomes included in-hospital mortality, and CT lesion expansion. Results: Of 153 patients, ADP inhibition was increased in moderate and severe TBI compared to mild TBI (p = 0.0011). P2Y12 inhibiting medications had increased ADP inhibition (p = 0.0077). Admission ADP inhibition was not associated with in-hospital mortality (p = 0.24) or CT lesion expansion (p = 0.94). Mean reduction of ADP inhibition from platelet transfusion (-15.1%) relative to no transfusion (+ 11.7%) was not statistically different (p = 0.0472). Conclusions: Mild TBI results in less ADP inhibition compared to moderate and severe TBI, suggesting a dose response relationship between TBI severity and degree of platelet dysfunction. Further, study is warranted to determine efficacy and parameters for platelet transfusion in patients with TBI.	[Guillotte, Andrew R.; Herbert, Joseph P.; Litofsky, N. Scott] Univ Missouri, Sch Med, Div Neurol Surg, One Hosp Dr,MC 321, Columbia, MO 65212 USA; [Madsen, Richard] Univ Missouri, Sch Med, Biostat & Res Design, Columbia, MO USA; [Hammer, Richard D.] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO USA	Litofsky, NS (corresponding author), Univ Missouri, Sch Med, Div Neurol Surg, One Hosp Dr,MC 321, Columbia, MO 65212 USA.	litofskyn@health.missouri.edu		Guillotte, Andrew/0000-0001-7222-5856	University of Missouri School of Medicine Office of Research; University of Missouri School of Medicine Department of Surgery; Division of Neurological Surgery of University of Missouri School of Medicine	Andrew R. Guillotte was funded through a Summer Medical Student Research Fellowship from University of Missouri School of Medicine Office of Research and Department of Surgery. Additional funding was from scholarship funds of the Division of Neurological Surgery of University of Missouri School of Medicine.	Abdelmalik PA, 2016, NEUROCRIT CARE, V24, P361, DOI 10.1007/s12028-015-0191-0; [Anonymous], 2017, SAMPLE SIZE ISSUES P; Bartels AN, 2016, US CAN AC PATH 105 A; Bartels AN, 2016, SURGERY, V160, P954, DOI 10.1016/j.surg.2016.07.012; Bolliger D, 2012, TRANSFUS MED REV, V26, P1, DOI 10.1016/j.tmrv.2011.07.005; Briggs A, 2015, J SURG RES, V193, P802, DOI 10.1016/j.jss.2014.08.016; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Chang R, 2016, BLOOD, V128, P1043, DOI 10.1182/blood-2016-01-636423; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; Curran PJ, 2010, J COGN DEV, V11, P121, DOI 10.1080/15248371003699969; Daley MJ, 2017, EUR J TRAUMA EMERG S, V43, P105, DOI 10.1007/s00068-016-0643-z; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029; Gozal Yair M, 2017, Surg Neurol Int, V8, P48, DOI 10.4103/sni.sni_265_16; Herbert JP, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070092; Hoffman M, 2009, STROKE, V40, P2882, DOI 10.1161/STROKEAHA.109.555433; Holzmacher JL, 2018, BRAIN INJURY, V32, P325, DOI 10.1080/02699052.2018.1425804; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591; Kreitzer NP, 2015, NEUROCRIT CARE, V23, P427, DOI 10.1007/s12028-015-0187-9; Kunio NR, 2012, AM J SURG, V203, P584, DOI 10.1016/j.amjsurg.2011.12.011; Lindblad C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00015; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Reddy GD, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-015-0379-9; Schochl H, 2011, J NEUROTRAUM, V28, P2033, DOI 10.1089/neu.2010.1744; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	31	11	12	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC 6	2018	32	13-14					1849	1857		10.1080/02699052.2018.1536805			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	HE5DS	WOS:000453393600031	30346865				2021-06-18	
J	Mizuma, A; Kim, JY; Kacimi, R; Stauderman, K; Dunn, M; Hebbar, S; Yenari, MA				Mizuma, Atsushi; Kim, Jong Youl; Kacimi, Rachid; Stauderman, Ken; Dunn, Michael; Hebbar, Sudarshan; Yenari, Midori A.			Microglial Calcium Release-Activated Calcium Channel Inhibition Improves Outcome from Experimental Traumatic Brain Injury and Microglia-Induced Neuronal Death	JOURNAL OF NEUROTRAUMA			English	Article						calcium release-activated calcium channel; microglia; store-operated calcium entry; traumatic brain injury	HEAT-SHOCK-PROTEIN; CYCLOSPORINE-A; MILD HYPOTHERMIA; CALCINEURIN INHIBITORS; NEUROPROTECTIVE ACTION; MOLECULAR-MECHANISMS; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; TACROLIMUS FK506; DOWN-REGULATION	Store-operated Ca2+ entry (SOCE) mediated by calcium release-activated calcium (CRAC) channels contributes to calcium signaling. The resulting intracellular calcium increases activate calcineurin, which in turn activates immune transcription factor nuclear factor of activated T cells (NFAT). Microglia contain CRAC channels, but little is known whether these channels play a role in acute brain insults. We studied a novel CRAC channel inhibitor to explore the therapeutic potential of this compound in microglia-mediated injury. Cultured microglial BV2 cells were activated by Toll-like receptor agonists or IFN gamma. Some cultures were treated with a novel CRAC channel inhibitor (CM-EX-137). Western blots revealed the presence of CRAC channel proteins STIM1 and Orai1 in BV2 cells. CM-EX-137 decreased nitric oxide (NO) release and inducible nitric oxide synthase (iNOS) expression in activated microglia and reduced agonist-induced intracellular calcium accumulation in microglia, while suppressing inflammatory transcription factors nuclear factor kappa B (NF-kappa B) and nuclear factor of activated T cells (NFAT). Male C57/BL6 mice exposed to experimental brain trauma and treated with CM-EX-137 had decreased lesion size, brain hemorrhage, and improved neurological deficits with decreased microglial activation, iNOS and Orai1 and STIM1 levels. We suggest a novel anti-inflammatory approach for managing acute brain injury. Our observations also shed light on new calcium signaling pathways not described previously in brain injury models.	[Mizuma, Atsushi; Kim, Jong Youl; Kacimi, Rachid; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mizuma, Atsushi; Kim, Jong Youl; Kacimi, Rachid; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA USA; [Mizuma, Atsushi] Tokai Univ, Sch Med, Dept Neurol, Isehara, Kanagawa, Japan; [Kim, Jong Youl] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea; [Stauderman, Ken; Dunn, Michael; Hebbar, Sudarshan] CalciMedica Inc, La Jolla, CA USA	Yenari, MA (corresponding author), Univ Calif San Francisco, San Francisco VAMC, Dept Neurol, 4150 Clement St,MS 127, San Francisco, CA 94121 USA.	yenari@alum.mit.edu		Yenari, Midori/0000-0003-3916-8006	Veterans Affairs Merit AwardUS Department of Veterans Affairs [I01 BX000589]; NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03 NS101246]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS101246] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000589] Funding Source: NIH RePORTER	This work was supported by grants from the Veterans Affairs Merit Award I01 BX000589 and NIH National Institute of Neurological Disorders and Stroke R03 NS101246, and gift funds from CalciMedica, Inc (to MY) and the SENSHIN Medical Research Foundation (to AM). Grants to MY were administered by the Northern California Institute for Research and Education, and supported by resources from the Veterans Affairs Medical Center, San Francisco, CA.	Bechstein WO, 2000, TRANSPL INT, V13, P313, DOI 10.1007/s001470050708; Beck A, 2008, J PHYSIOL-LONDON, V586, P427, DOI 10.1113/jphysiol.2007.145151; Berna-Erro A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000522; Cahalan MD, 2007, CELL CALCIUM, V42, P133, DOI 10.1016/j.ceca.2007.03.002; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Cho TH, 2013, INT J STROKE, V8, P669, DOI 10.1111/j.1747-4949.2012.00849.x; Christians U, 2004, BRIT J PHARMACOL, V143, P388, DOI 10.1038/sj.bjp.0705939; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Eylenstein A, 2012, J BIOL CHEM, V287, P2719, DOI 10.1074/jbc.M111.275925; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Furman JL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0158-7; Furuichi Y, 2004, BRAIN RES, V1014, P120, DOI 10.1016/j.brainres.2004.04.031; Furuichi Y, 2007, EXP NEUROL, V204, P138, DOI 10.1016/j.expneurol.2006.10.003; Gold BG, 2004, J NEUROSCI RES, V77, P367, DOI 10.1002/jnr.20165; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Heo DK, 2015, CELL SIGNAL, V27, P177, DOI 10.1016/j.cellsig.2014.11.003; Hoffmann A, 2003, J NEUROSCI, V23, P4410; Hou PF, 2015, CELL MOL NEUROBIOL, V35, P283, DOI 10.1007/s10571-014-0123-0; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Kacimi R, 2015, GLIA, V63, P1200, DOI 10.1002/glia.22811; Kacimi R, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-7; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Kim JY, 2013, J NEUROTRAUM, V30, P1170, DOI 10.1089/neu.2012.2691; Kim N, 2015, NEUROSCIENCE, V284, P912, DOI 10.1016/j.neuroscience.2014.11.010; Kraft R, 2015, CHANNELS, V9, P244, DOI 10.1080/19336950.2015.1071747; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Ma JA, 2010, EUR J IMMUNOL, V40, P3028, DOI 10.1002/eji.201040614; Macleod MR, 2005, J CEREBR BLOOD F MET, V25, P713, DOI 10.1038/sj.jcbfm.9600064; Malvezzi P, 2015, EXPERT OPIN DRUG SAF, V14, P1531, DOI 10.1517/14740338.2015.1083974; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Nighoghossian N, 2015, NEUROLOGY, V84, P2216, DOI 10.1212/WNL.0000000000001639; Ohana L, 2009, CHANNELS, V3, P129, DOI 10.4161/chan.3.2.8609; Osman MM, 2011, NEUROPEPTIDES, V45, P359, DOI 10.1016/j.npep.2011.04.002; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Prakriya M, 2015, PHYSIOL REV, V95, P1383, DOI 10.1152/physrev.00020.2014; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rao W, 2015, BBA-MOL BASIS DIS, V1852, P2402, DOI 10.1016/j.bbadis.2015.08.014; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Saganova K, 2012, LIFE SCI, V91, P77, DOI 10.1016/j.lfs.2012.06.022; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Servais H, 2008, APOPTOSIS, V13, P11, DOI 10.1007/s10495-007-0151-z; Shim AHR, 2015, J MOL BIOL, V427, P77, DOI 10.1016/j.jmb.2014.09.021; SIEKIERKA JJ, 1992, CURR OPIN IMMUNOL, V4, P548, DOI 10.1016/0952-7915(92)90024-9; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	53	11	13	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					996	1007		10.1089/neu.2018.5856		DEC 2018	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR6BY	WOS:000451965900003	30351197	Green Published			2021-06-18	
J	Maruta, J; Lumba-Brown, A; Ghajar, J				Maruta, Jun; Lumba-Brown, Angela; Ghajar, Jamshid			Concussion Subtype Identification With the Rivermead Post-concussion Symptoms Questionnaire	FRONTIERS IN NEUROLOGY			English	Article						mild traumatic brain injury (mTBI); epidemiology; cognitive; fatigue; vestibular; migraine; sleep	TRAUMATIC BRAIN-INJURY; ANXIETY DISORDERS; SPORTS; SLEEP	Classifying concussion in key subtypes according to presenting symptomatology at an early post-injury stage is an emerging approach that may allow prediction of clinical trajectories and delivery of targeted treatments. The Rivermead Post-concussion Symptoms Questionnaire (RPQ) is a simple, freely available, and widely used tool for assessment of the presence and severity of various post-concussion symptoms. We aimed to probe the prevalence among athletes of symptom classes associated with identified concussion phenotypes using the RPQ at baseline and acutely after a concussion. Participants of organized sports aged 12-30 years were baseline-assessed with the expectation that some would experience a concussion during the study period. Concussed athletes were re-assessed within 2 weeks of their injuries. The RPQ was supplemented with three specific questions and reworded for baseline assessment. A binomial test was used to contrast the prevalence of an attribute in the concussed cohort against the probability established by the baseline observation. Three thousand and eighty-eight athletes were baseline-assessed and eighty-nine were re-assessed post-concussion. All concussed athletes endorsed having some elevated symptoms in the RPQ, and such endorsements were more prevalent than those among normal athletes. Moderate-to-severe post-concussion symptoms of specific classes tended to be endorsed with few additional symptoms of other classes of similar intensities. Elevated symptoms detected with the RPQ within as short as 2 weeks after a concussion may help delineate patients' clinical subtypes and guide their treatment. Further refinement of symptom questionnaires and use of objective measures will be needed to properly populate the concussion subtype classification.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Maruta, Jun; Ghajar, Jamshid] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Maruta, Jun] Dept Rehabil & Human Performance, New York, NY 10029 USA; [Lumba-Brown, Angela] Stanford Univ, Sch Med, Dept Emergency Med, Stanford, CA USA	Maruta, J (corresponding author), Brain Trauma Fdn, New York, NY 10007 USA.; Maruta, J (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.; Maruta, J (corresponding author), Dept Rehabil & Human Performance, New York, NY 10029 USA.	jun.maruta@mssm.edu	Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	U.S. Department of DefenseUnited States Department of Defense [W911QY-12-C-0005, W911QY-14-C-0086]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM121312] Funding Source: NIH RePORTER	The authors thank Brain Trauma Foundation's clinical research staff for assistance with data collection and maintenance. This work was supported by U.S. Department of Defense contracts W911QY-12-C-0005 and W911QY-14-C-0086.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Beesdo K, 2009, PSYCHIAT CLIN N AM, V32, P483, DOI 10.1016/j.psc.2009.06.002; BELLDOLAN DJ, 1990, J AM ACAD CHILD PSY, V29, P759, DOI 10.1097/00004583-199009000-00014; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Capo-Aponte JE, 2017, OPTOMETRY VISION SCI, V94, P7, DOI 10.1097/OPX.0000000000000825; Ciuffreda KJ, 2014, MIL MED, V179, P1212, DOI 10.7205/MILMED-D-14-00059; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2003, J ATHL TRAINING, V38, P238; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kenzie ES, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00203; Kenzie ES, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00513; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos A.P., 2018, CONCUSSION CLIN PROF; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maruta J, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00611; Maruta J, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00640; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Panczykowski DM, 2014, PROG NEUROL SURG, V28, P195, DOI 10.1159/000358780; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Wickwire EM, 2016, NEUROTHERAPEUTICS, V13, P403, DOI 10.1007/s13311-016-0429-3	27	11	11	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	DEC 3	2018	9								1034	10.3389/fneur.2018.01034			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HC7AS	WOS:000451953400001	30559709	DOAJ Gold, Green Published			2021-06-18	
J	Estrup, S; Kjer, CKW; Vilhelmsen, F; Poulsen, LM; Gogenur, I; Mathiesen, O				Estrup, Stine; Kjer, Cilia K. W.; Vilhelmsen, Frederik; Poulsen, Lone M.; Gogenur, Ismail; Mathiesen, Ole			Cognitive Function 3 and 12 Months After ICU DischargeA Prospective Cohort Study	CRITICAL CARE MEDICINE			English	Article						aftercare; cognitive dysfunction; intensive care; postintensive care syndrome; rehabilitation	INTENSIVE-CARE-UNIT; CRITICAL ILLNESS; ECONOMIC-IMPLICATIONS; REPEATABLE BATTERY; IMPAIRMENT; SURVIVORS; REHABILITATION; DISABILITY; DELIRIUM; RBANS	Objectives: Studies have shown impaired cognitive function after ICU discharge. We aimed to describe long-term cognitive function in Danish ICU patients. Design: Prospective cohort study. Setting: Single-center ICU at Zealand University Hospital, KOge, Denmark. Patients: Adult patients admitted for over 24 hours. Intervention: Three and 12 months after discharge, the patients were visited at home and tested with the Repeatable Battery for the Assessment of Neuropsychological Status. Measurements and Main Results: We included 161 patients, 79 patients had a 3-month and 53 a 12-month follow-up visit. The primary reasons for not being visited at 3-month were death (44 patients), decline (26 patients), or transferal to another ICU (6 patients). Visited patients were median 67 years old (interquartile range, 59-73), had a median Acute Physiology and Chronic Health Evaluation score of 20 (interquartile range, 16-26), 58% were on a ventilator, and 30% were surgical patients. The mean Repeatable Battery for the Assessment of Neuropsychological Status score was 67 (sd, 21), compared with a normal value of 100 (15). A total of 57% had Repeatable Battery for the Assessment of Neuropsychological Status scores corresponding to moderate traumatic brain injury, 46% scored corresponding to light Alzheimer's disease, and 73% corresponding to mild cognitive impairment. After 12 months, the Repeatable Battery for the Assessment of Neuropsychological Status was still reduced (71 [25]). We examined protective and risk factors using multiple linear regression and found protective effects of being employed before admission (p = 0.0005) or being admitted from a surgical ward (p = 0.019). Conclusions: In this prospective cohort study of Danish ICU patients, we found significantly reduced cognitive function for intensive care patients 3 and 12 months after discharge.	[Estrup, Stine; Kjer, Cilia K. W.; Vilhelmsen, Frederik; Poulsen, Lone M.; Mathiesen, Ole] Zealand Univ Hosp, Ctr Anaesthesiol Res, Dept Anesthesiol, Koge, Denmark; [Gogenur, Ismail] Zealand Univ Hosp, Ctr Surg Sci, Dept Gastrointestinal Surg, Koge, Denmark	Estrup, S (corresponding author), Zealand Univ Hosp, Ctr Anaesthesiol Res, Dept Anesthesiol, Koge, Denmark.	sed@regionsjaelland.dk		Mathiesen, Ole/0000-0003-4544-0619; Estrup, Stine/0000-0002-1467-7085; Gogenur, Ismail/0000-0002-3753-268X; Poulsen, Lone Musaeus/0000-0002-7030-3395	Aase and Ejnar Danielsens Fund; Danish Society for Anaesthesiology and Intensive Care Medicine's research initiative; Intensive Care Symposium Hindsgavl; Aase og Ejnar Danielsens fund	Supported, in part, by Aase and Ejnar Danielsens Fund, The Danish Society for Anaesthesiology and Intensive Care Medicine's research initiative, and the Intensive Care Symposium Hindsgavl.; Drs. Estrup's, Kjer's, Vilhelmsen's, and Mathiesen's institution received funding from Aase og Ejnar Danielsens fund, The Danish Society for Anaesthesiology and Intensive Care Medicine's Research Initiative, and Intensive Care Symposium Hindsgavl. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Agard AS, 2014, INTENS CRIT CARE NUR, V30, P101, DOI 10.1016/j.iccn.2013.11.001; Aguero-Torres H, 2001, J CLIN EPIDEMIOL, V54, P795, DOI 10.1016/S0895-4356(00)00371-1; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Brummel NE, 2012, PHYS THER, V92, P1580, DOI 10.2522/ptj.20110414; Corner EJ, 2013, PHYSIOTHERAPY, V99, P33, DOI 10.1016/j.physio.2012.01.003; Davydow DS, 2008, PSYCHOSOM MED, V70, P512, DOI 10.1097/PSY.0b013e31816aa0dd; Duff K, 2008, ARCH CLIN NEUROPSYCH, V23, P603, DOI 10.1016/j.acn.2008.06.004; Duff K, 2010, ARCH CLIN NEUROPSYCH, V25, P429, DOI 10.1093/arclin/acq045; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Estrup S, 2018, ACTA ANAESTH SCAND, V62, P367, DOI 10.1111/aas.13037; Fonsmark L, 2015, DAN MED J, V62; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hobson VL, 2010, INT J GERIATR PSYCH, V25, P525, DOI 10.1002/gps.2382; Hopkins RO, 2012, SEMIN RESP CRIT CARE, V33, P348, DOI 10.1055/s-0032-1321984; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Iwashyna TJ, 2012, SEMIN RESP CRIT CARE, V33, P327, DOI 10.1055/s-0032-1321982; Iwashyna TJ, 2012, J AM GERIATR SOC, V60, P1070, DOI 10.1111/j.1532-5415.2012.03989.x; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Kress JP, 2012, SEMIN RESP CRIT CARE, V33, P339, DOI 10.1055/s-0032-1321983; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Mehlhorn J, 2014, CRIT CARE MED, V42, P1263, DOI 10.1097/CCM.0000000000000148; Misak C, 2009, CRIT CARE, V13, DOI 10.1186/cc7962; Mitchell ML, 2018, AUST CRIT CARE, V31, P204, DOI 10.1016/j.aucc.2017.07.002; Nedergaard HK, 2017, ACTA ANAESTH SCAND, V61, P135, DOI 10.1111/aas.12832; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Perna L, 2015, AGE AGEING, V44, P445, DOI 10.1093/ageing/afu188; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Svenningsen H, 2013, ACTA ANAESTH SCAND, V57, P288, DOI 10.1111/aas.12048; van Ewijk CE, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0186-9; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; Wilcox ME, 2013, CRIT CARE MED, V41, pS81, DOI 10.1097/CCM.0b013e3182a16946; Wolters A, 2015, J CLIN NURS, V24, P876, DOI 10.1111/jocn.12678; Wolters AE, 2014, CRIT CARE, V18, DOI 10.1186/cc13929; Wunsch H, 2011, AM J RESP CRIT CARE, V183, P1666, DOI 10.1164/rccm.201012-1961OC; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	11	11	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2018	46	12					E1121	E1127		10.1097/CCM.0000000000003391			7	Critical Care Medicine	General & Internal Medicine	HA6ZY	WOS:000450431600005	30188383				2021-06-18	
J	Mesotten, D; Joosten, K; van Kempen, A; Verbruggen, S; Braegger, C; Bronsky, J; Cai, W; Campoy, C; Carnielli, V; Darmaun, D; Decsi, T; Domellof, M; Embleton, N; Fewtrell, M; Fidler Mis, N; Franz, A; Goulet, O; Hartman, C; Hill, S; Hojsak, I; Iacobelli, S; Jochum, F; Joosten, K; Kolacek, S; Koletzko, B; Ksiazyk, J; Lapillonne, A; Lohner, S; Mesotten, D; Mihalyi, K; Mihatsch, WA; Mimouni, F; Molgaard, C; Moltu, SJ; Nomayo, A; Picaud, JC; Prell, C; Puntis, J; Riskin, A; De Pipaon, MS; Senterre, T; Shamir, R; Simchowitz, V; Szitanyi, P; Tabbers, MM; Van Den Akker, CHB; Van Goudoever, JB; Van Kempen, A; Verbruggen, S; Wu, J; Yan, WH				Mesotten, D.; Joosten, K.; van Kempen, A.; Verbruggen, S.; Braegger, Christian; Bronsky, Jiri; Cai, Wei; Campoy, Cristina; Carnielli, Virgilio; Darmaun, Dominique; Decsi, Tamas; Domellof, Magnus; Embleton, Nicholas; Fewtrell, Mary; Fidler Mis, Natasa; Franz, Axel; Goulet, Olivier; Hartman, Corina; Hill, Susan; Hojsak, Iva; Iacobelli, Silvia; Jochum, Frank; Joosten, Koen; Kolacek, Sanja; Koletzko, Berthold; Ksiazyk, Janusz; Lapillonne, Alexandre; Lohner, Szimonetta; Mesotten, Dieter; Mihalyi, Krisztina; Mihatsch, Walter A.; Mimouni, Francis; Molgaard, Christian; Moltu, Sissel J.; Nomayo, Antonia; Picaud, Jean Charles; Prell, Christine; Puntis, John; Riskin, Arieh; Saenz De Pipaon, Miguel; Senterre, Thibault; Shamir, Raanan; Simchowitz, Venetia; Szitanyi, Peter; Tabbers, Merit M.; Van Den Akker, Chris H. B.; Van Goudoever, Johannes B.; Van Kempen, Anne; Verbruggen, Sascha; Wu, Jiang; Yan Weihui		ESPGHAN ESPEN ESPR CSPEN Wor	ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Carbohydrates	CLINICAL NUTRITION			English	Article						children; parenteral nutrition; glucose; carbohydrate; energy-resource; insulin; critical illness	TIGHT GLYCEMIC CONTROL; INTENSIVE-CARE-UNIT; CRITICALLY-ILL CHILDREN; TRAUMATIC BRAIN-INJURY; BIRTH-WEIGHT INFANTS; GLUCOSE-PRODUCTION; CRITICAL ILLNESS; PRETERM INFANTS; BLOOD-GLUCOSE; NEONATAL HYPERGLYCEMIA		[Mesotten, D.] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium; [Joosten, K.; Verbruggen, S.] Erasmus MC, Subdivis Intens Care, Dept Pediat & Pediat Surg, Sophia Childrens Hosp, Rotterdam, Netherlands; [van Kempen, A.] OLVG, Dept Pediat & Neonatol, Amsterdam, Netherlands; [Braegger, Christian] Univ Childrens Hosp, Zurich, Switzerland; [Bronsky, Jiri] Univ Hosp Motol, Prague, Czech Republic; [Cai, Wei] Shanghai Jiao Tong Univ, Shanghai, Peoples R China; [Campoy, Cristina] Univ Granada, Sch Med, Dept Paediat, Granada, Spain; [Carnielli, Virgilio] Polytech Univ Marche, Ancona, Italy; [Darmaun, Dominique] Univ Nantes, Nantes, France; [Decsi, Tamas] Univ Pecs, Dept Pediat, Pecs, Hungary; [Domellof, Magnus] Umea Univ, Dept Clin Sci, Pediat, Umea, Sweden; [Embleton, Nicholas] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [Fewtrell, Mary] UCL Great Ormond St Inst Child Hlth, London, England; [Fidler Mis, Natasa] Univ Med Ctr Ljubljana, Ljubljana, Slovenia; [Franz, Axel] Univ Childrens Hosp, Tubingen, Germany; [Goulet, Olivier] Univ Sordonne Paris Cite, Paris Descartes Med Sch, Paris, France; [Hartman, Corina] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Hartman, Corina] Carmel Hosp, Haifa, Israel; [Hill, Susan] Great Ormond St Hosp Sick Children, NHS Fdn Trust, London, England; [Hill, Susan] UCL Inst Child Hlth, London, England; [Hojsak, Iva] Univ JJ Strossmayer, Univ Zagreb, Sch Med Osijek, Sch Med,Childrens Hosp Zagreb, Osijek, Croatia; [Iacobelli, Silvia] CHU Reunion, St Pierre, Reunion, France; [Jochum, Frank; Nomayo, Antonia] Ev Waldkrankenhaus Spandau, Berlin, Germany; [Joosten, Koen] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat & Pediat Surg, Intens Care, Rotterdam, Netherlands; [Kolacek, Sanja] Univ Zagreb, Sch Med, Childrens Hosp, Zagreb, Croatia; [Koletzko, Berthold; Prell, Christine] LMU Ludwig Maximilians Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Ksiazyk, Janusz] Childrens Mem Hlth Inst, Dept Pediat Nutr & Metab Dis, Warsaw, Poland; [Lapillonne, Alexandre] Paris Descartes Univ, Paris, France; [Lohner, Szimonetta] Univ Pecs, Dept Pediat, Pecs, Hungary; [Mesotten, Dieter] Katholieke Univ Leuven, Leuven, Belgium; [Mihalyi, Krisztina] Univ Pecs, Dept Pediat, Pecs, Hungary; [Mihatsch, Walter A.] Univ Ulm, Ulm, Germany; [Mihatsch, Walter A.] Helios Hosp, Pforzheim, Germany; [Mimouni, Francis] Wilf Childrens Hosp, Shaare Zedek Med Ctr, Div Neonatol, Dept Pediat, Jerusalem, Israel; [Mimouni, Francis] Tel Aviv Univ, Tel Aviv, Israel; [Molgaard, Christian] Univ Copenhagen, Dept Nutr Exercise & Sports, Copenhagen, Denmark; [Molgaard, Christian] Rigshosp, Paediat Nutr Unit, Copenhagen, Denmark; [Moltu, Sissel J.] Oslo Univ Hosp, Oslo, Norway; [Picaud, Jean Charles] Claude Bernard Univ Lyon 1, Hop Croix Rousse, Lab CarMEN, Lyon, France; [Puntis, John] Gen Infirm Leeds, Leeds, W Yorkshire, England; [Riskin, Arieh] Technion, Rappaport Fac Med, Bnai Zion Med Ctr, Haifa, Israel; [Saenz De Pipaon, Miguel] Univ Autonoma Madrid, Paz Univ Hosp, Red Salud Materno Infantil & Desarrollo SAMID, Dept Neonatol, Madrid, Spain; [Senterre, Thibault] Univ Liege, CHR Citadelle, CHU Liege, Liege, Belgium; [Shamir, Raanan] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Shamir, Raanan] Tel Aviv Univ, Tel Aviv, Israel; [Simchowitz, Venetia] Great Ormond St NHS Trust, London, England; [Szitanyi, Peter] Charles Univ Prague, Fac Med 1, Gen Univ Hosp, Prague, Czech Republic; [Tabbers, Merit M.; Van Den Akker, Chris H. B.; Van Goudoever, Johannes B.] Amsterdam UMC, Emma Childrens Hosp, Amsterdam, Netherlands; [Van Kempen, Anne] OLVG, Amsterdam, Netherlands; [Verbruggen, Sascha] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat & Pediat Surg, Intens Care, Rotterdam, Netherlands; [Wu, Jiang] Xin Hua Hosp, Shanghai, Peoples R China; [Yan Weihui] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Gastroenterol & Nutr, Shanghai, Peoples R China	Mesotten, D (corresponding author), Katholieke Univ Leuven, Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium.	walter.mihatsch@gmx.de	Mis, Natasa Fidler/L-7045-2014; Domellof, Magnus/AAP-9542-2021; van den Akker, Chris/V-3058-2018; Ksiazyk, Janusz/L-8752-2017; Hojsak, Iva/AAI-8937-2020; Mesotten, Dieter/ABE-4176-2020; Campoy, Cristina/F-4946-2017; Verbruggen, Sascha/ABB-7745-2020; Moltu, Sissel Jennifer/S-4683-2019; de Pipaon, Miguel Saenz/AAA-3851-2019; Lohner, Szimonetta/AAM-9339-2020; Molgaard, Christian/D-2052-2014	Mis, Natasa Fidler/0000-0003-3199-0484; van den Akker, Chris/0000-0002-5494-730X; Ksiazyk, Janusz/0000-0002-9136-2722; Hojsak, Iva/0000-0003-3262-5964; Mesotten, Dieter/0000-0002-3258-4720; Campoy, Cristina/0000-0002-9860-6785; Verbruggen, Sascha/0000-0003-4866-9865; Lohner, Szimonetta/0000-0002-6292-4802; Embleton, Nicholas/0000-0003-3750-5566; van Kempen, Anne/0000-0003-3959-7353; Molgaard, Christian/0000-0002-5311-9457; van Goudoever, Johannes (Hans)/0000-0003-3960-1703			Aarsland A, 1996, J CLIN INVEST, V98, P2008, DOI 10.1172/JCI119005; Agius L, 2013, BIOCHEM PHARMACOL, V85, P306, DOI 10.1016/j.bcp.2012.09.019; Agus MSD, 2012, NEW ENGL J MED, V367, P1208, DOI 10.1056/NEJMoa1206044; Alaedeen DI, 2006, J PEDIATR SURG, V41, P239, DOI 10.1016/j.jpedsurg.2005.10.045; Alsweiler JM, 2007, J PAEDIATR CHILD H, V43, P632, DOI 10.1111/j.1440-1754.2007.01158.x; Alsweiler JM, 2012, PEDIATRICS, V129, P639, DOI 10.1542/peds.2011-2470; ASKANAZI J, 1984, ANESTHESIOLOGY, V60, P106, DOI 10.1097/00000542-198402000-00005; Auerbach A, 2013, J PEDIATR-US, V163, P388, DOI 10.1016/j.jpeds.2013.01.051; Beardsall K, 2008, NEW ENGL J MED, V359, P1873, DOI 10.1056/NEJMoa0803725; Beardsall K, 2010, J PEDIATR-US, V157, P715, DOI 10.1016/j.jpeds.2010.04.032; Beardsall K, 2010, EARLY HUM DEV, V86, P263, DOI 10.1016/j.earlhumdev.2010.05.005; Boluyt N, 2006, PEDIATRICS, V117, P2231, DOI 10.1542/peds.2005-1919; BURKE JF, 1979, ANN SURG, V190, P274, DOI 10.1097/00000658-197909000-00002; Chacko SK, 2011, J PEDIATR-US, V158, P891, DOI 10.1016/j.jpeds.2010.12.040; Chacko SK, 2010, ARCH DIS CHILD-FETAL, V95, pF413, DOI 10.1136/adc.2009.178020; Chien JY, 2005, CRIT CARE MED, V33, P1688, DOI 10.1097/01.CCM.0000171183.79525.6B; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; COWETT RM, 1983, J CLIN INVEST, V71, P467, DOI 10.1172/JCI110791; de Betue CTI, 2012, CRIT CARE, V16, DOI 10.1186/cc11658; Dylewksi ML, 2013, PEDIATR CRIT CARE ME, V14, pE120, DOI 10.1097/PCC.0b013e3182712b2b; ELWYN DH, 1981, ACTA CHIR SCAND, P209; Faustino EVS, 2010, PEDIATR CRIT CARE ME, V11, P690, DOI 10.1097/PCC.0b013e3181e8f502; Finfer S, 2013, CRIT CARE, V17, DOI 10.1186/cc12537; Fivez T, 2016, NEW ENGL J MED, V374, P1111, DOI 10.1056/NEJMoa1514762; Fivez T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0728-8; FORSYTH JS, 1995, ARCH DIS CHILD-FETAL, V73, pF4, DOI 10.1136/fn.73.1.F4; Geukers VG, 2012, NUTRITION, V28, P644, DOI 10.1016/j.nut.2011.09.018; Hagvik J, 2008, CLIN CHEM LAB MED, V46, P729, DOI 10.1515/CCLM.2008.142; Hirshberg E, 2008, PEDIATR CRIT CARE ME, V9, P361, DOI 10.1097/PCC.0b013e318172d401; Hudgins LC, 1996, J CLIN INVEST, V97, P2081, DOI 10.1172/JCI118645; Inoue S, 2013, CRIT CARE, V17, DOI 10.1186/cc12567; Jain R, 1996, J CLIN LAB ANAL, V10, P13, DOI 10.1002/(SICI)1098-2825(1996)10:1<13::AID-JCLA3>3.0.CO;2-M; Jeschke MG, 2010, AM J RESP CRIT CARE, V182, P351, DOI 10.1164/rccm.201002-0190OC; JONES MO, 1993, J PEDIATR SURG, V28, P1121, DOI 10.1016/0022-3468(93)90144-A; Kalhan SC, 1999, EUR J CLIN NUTR, V53, pS94, DOI 10.1038/sj.ejcn.1600749; Kalhan SC, 2001, AM J PHYSIOL-ENDOC M, V281, pE991; Kanji S, 2005, CRIT CARE MED, V33, P2778, DOI 10.1097/01.CCM.0000189939.10881.60; KAPLAN M, 1989, CRIT CARE MED, V17, P279, DOI 10.1097/00003246-198903000-00016; Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200; Klein CJ, 1998, J AM DIET ASSOC, V98, P795, DOI 10.1016/S0002-8223(98)00179-5; Koletzko Berthold, 2005, J Pediatr Gastroenterol Nutr, V41 Suppl 2, pS1, DOI 10.1097/01.mpg.0000181841.07090.f4; Koretz RL, 2001, GASTROENTEROLOGY, V121, P970, DOI 10.1053/gast.2001.28031; Kyle UG, 2010, INTENS CARE MED, V36, P312, DOI 10.1007/s00134-009-1703-1; LAFEBER HN, 1990, PEDIATR RES, V28, P153, DOI 10.1203/00006450-199028020-00015; Lang CH, 2007, AM J PHYSIOL-ENDOC M, V293, pE453, DOI 10.1152/ajpendo.00204.2007; Leite HP, 2013, JPEN-PARENTER ENTER, V37, P335, DOI 10.1177/0148607112458124; LUCAS A, 1988, BRIT MED J, V297, P1304, DOI 10.1136/bmj.297.6659.1304; MACFIE J, 1981, GASTROENTEROLOGY, V80, P103; Macrae D, 2014, NEW ENGL J MED, V370, P107, DOI 10.1056/NEJMoa1302564; Magnoni S, 2012, CRIT CARE MED, V40, P1785, DOI 10.1097/CCM.0b013e318246bd45; McKinlay CJD, 2015, NEW ENGL J MED, V373, P1507, DOI 10.1056/NEJMoa1504909; Mesotten D, 2004, J CLIN ENDOCR METAB, V89, P219, DOI 10.1210/jc.2003-030760; Mesotten D, 2012, JAMA-J AM MED ASSOC, V308, P1641, DOI 10.1001/jama.2012.12424; Mitanchez D, 2007, HORM RES, V68, P265, DOI 10.1159/000104174; Nayak PP, 2013, INTENS CARE MED, V39, P123, DOI 10.1007/s00134-012-2738-2; Newman JD, 2002, ANN CLIN BIOCHEM, V39, P509, DOI 10.1258/000456302320314539; NOSE O, 1987, PEDIATR RES, V21, P538, DOI 10.1203/00006450-198706000-00006; Ogilvy-Stuart AL, 2010, ARCH DIS CHILD-FETAL, V95, pF126, DOI 10.1136/adc.2008.154716; Ognibene KL, 2011, PEDIATR CRIT CARE ME, V12, pE386, DOI 10.1097/PCC.0b013e3182192c53; Peet AC, 2002, ANN CLIN BIOCHEM, V39, P502, DOI 10.1258/000456302320314520; PINEAULT M, 1988, AM J CLIN NUTR, V47, P298; Preissig CM, 2010, CRIT CARE, V14, DOI 10.1186/cc8865; Preissig CM, 2009, CRIT CARE, V13, DOI 10.1186/cc7732; Ramel SE, 2013, J PERINATOL, V33, P882, DOI 10.1038/jp.2013.77; ROBIN AP, 1981, ACTA CHIR BELG, V80, P133; RODRIGUEZ JL, 1985, CHEST, V88, P512, DOI 10.1378/chest.88.4.512; SAUER PJJ, 1986, CLIN SCI, V70, P587, DOI 10.1042/cs0700587; Schwarz JM, 1995, J CLIN INVEST, V96, P2735, DOI 10.1172/JCI118342; Scott MG, 2009, CLIN CHEM, V55, P18, DOI 10.1373/clinchem.2008.117291; Sheridan RL, 1998, JPEN-PARENTER ENTER, V22, P212, DOI 10.1177/0148607198022004212; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Srinivasan V, 2014, PEDIATR DIABETES, V15, P75, DOI 10.1111/pedi.12134; Sunehag AL, 1999, DIABETES, V48, P791, DOI 10.2337/diabetes.48.4.791; Suresh D, 2010, PEDIATR DIABETES, V11, P70, DOI 10.1111/j.1399-5448.2009.00520.x; TALPERS SS, 1992, CHEST, V102, P551, DOI 10.1378/chest.102.2.551; Tang ZP, 2000, ARCH PATHOL LAB MED, V124, P1135; Tin W, 2014, SEMIN FETAL NEONAT M, V19, P27, DOI 10.1016/j.siny.2013.09.003; Tin W, 2012, PEDIATRICS, V130, pE1497, DOI 10.1542/peds.2012-0776; TULIKOURA I, 1982, SCAND J GASTROENTERO, V17, P177, DOI 10.3109/00365528209182037; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; van der Lugt NM, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-52; van Kempen AAMW, 2006, AM J PHYSIOL-ENDOC M, V290, pE723, DOI 10.1152/ajpendo.00303.2005; van Kempen AAMW, 2005, CLIN NUTR, V24, P727, DOI 10.1016/j.clnu.2005.02.004; van Kempen AAMW, 2003, METABOLISM, V52, P945, DOI 10.1016/S0026-0495(03)00148-3; Van Kempen AAMW, 2003, PEDIATR RES, V53, P628, DOI 10.1203/01.PDR.0000054733.13366.AF; van Puffelen E, 2018, LANCET CHILD ADOLESC, V2, P505, DOI 10.1016/S2352-4642(18)30131-7; van Puffelen E, 2018, CRIT CARE, V22, DOI 10.1186/s13054-017-1936-2; Vanhorebeek I, 2017, LANCET RESP MED, V5, P475, DOI 10.1016/S2213-2600(17)30186-8; Verbruggen SC, 2011, CLIN NUTR, V30, P469, DOI 10.1016/j.clnu.2011.02.001; Verbruggen SCAT, 2011, CLIN NUTR, V30, P786, DOI 10.1016/j.clnu.2011.05.011; Verbruggen SCAT, 2011, CRIT CARE MED, V39, P2518, DOI 10.1097/CCM.0b013e3182257410; Vermont CL, 2005, CRIT CARE MED, V33, P1610, DOI 10.1097/01.CCM.0000171272.50888.AD; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vlaardingerbroek H, 2013, J PEDIATR-US, V163, P638, DOI 10.1016/j.jpeds.2013.03.059; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Woo HC, 2014, ARCH DIS CHILD-FETAL, V99, pF153, DOI 10.1136/archdischild-2013-304682; Zhou W, 2015, J MATERN-FETAL NEO M, V28, P422, DOI 10.3109/14767058.2014.918599	98	11	14	0	8	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0261-5614	1532-1983		CLIN NUTR	Clin. Nutr.	DEC	2018	37	6	B				2337	2343		10.1016/j.clnu.2018.06.947			7	Nutrition & Dietetics	Nutrition & Dietetics	HF6VN	WOS:000454376500006	30037708				2021-06-18	
J	Russo, E; Citraro, R				Russo, Emilio; Citraro, Rita			Pharmacology of epileptogenesis and related comorbidities in the WAG/Rij rat model of genetic absence epilepsy	JOURNAL OF NEUROSCIENCE METHODS			English	Article; Proceedings Paper	Mediterranean Conference of Neuroscience	JUN, 2017	St Julians, MALTA			Epileptogenesis; Genetic animal model; Antiepileptic drugs; Comorbidities; Depression; Cognitive impairment	DEPRESSIVE-LIKE BEHAVIOR; MTOR SIGNALING PATHWAY; SPIKE-WAVE DISCHARGES; LONG-TERM TREATMENT; WHEY-PROTEIN RICH; ANIMAL-MODEL; RODENT MODELS; ANTIEPILEPTIC DRUGS; GENERALIZED ABSENCE; ALPHA-LACTOALBUMIN	Animal studies currently represent the best source of information also in the field of epileptogenesis research. Many animal models have been proposed and studied so far both from the pathophysiological and pharmacological point of view. Furthermore, they are widely used for the identification of potentially clinically valuable biomarkers. The WAG/Rij rat model, similarly to other genetic animal strains, represents a suitable animal model of absence epileptogenesis accompanied by depressive-like and cognitive comorbidities. Generally, animal models of epileptogenesis are characterized by an identifiable initial insult (e.g. traumatic brain injury), a latent phase lasting up to the appearance of the first spontaneous seizure and a chronic phase characterized by recurrent spontaneous seizures. In most of genetic models: the initial insult should be defined as the mutation causing epilepsy, which is not clearly defined in the WAG/Rij rat model; the latent phase ends at the appearance of the first spontaneous seizure, which is about 2-3 months of age in WAG/Rij rats and thereafter the chronic phase. WAG/Rij rats also display depressive-like comorbidity around the age of 4 months, which is apparently linked to the development of absence seizures considering both its ontogeny and the fact that drugs affecting absence seizures development also block the development of depressive-like behavior. Finally, WAG/Rij rats also display cognitive impairment in some memory tasks, however, this has not been yet definitively linked to absence seizures development and may represent an epiphenomenon. This review is focused on the effects of pharmacological treatments against epileptogenesis and their effects on comorbidities.	[Russo, Emilio; Citraro, Rita] Univ Catanzaro, Sch Med, Sci Hlth Dept, Viale Europa Germaneto, I-88100 Catanzaro, Italy	Russo, E (corresponding author), Univ Catanzaro, Sch Med, Sci Hlth Dept, Viale Europa Germaneto, I-88100 Catanzaro, Italy.	erusso@unicz.it	Russo, Emilio/G-5241-2010	Russo, Emilio/0000-0002-1279-8123	Italian Ministry of Health: Bando Ricerca Finalizzata 2013	This work was partially supported by a grant obtained from the Italian Ministry of Health: Bando Ricerca Finalizzata 2013.	Ates N, 2005, DEV BRAIN RES, V154, P137, DOI 10.1016/j.devbrainres.2004.10.001; Avanzini G, 2012, EPILEPSIA, V53, P771, DOI 10.1111/j.1528-1167.2012.03462.x; Bagdy G, 2007, J NEUROCHEM, V100, P857, DOI 10.1111/j.1471-4159.2006.04277.x; Berg AT, 2014, EPILEPSIA, V55, P551, DOI 10.1111/epi.12551; Birioukova LM, 2005, EPILEPSY RES, V63, P89, DOI 10.1016/j.eplepsyres.2004.12.001; Blumenfeld H, 2008, EPILEPSIA, V49, P400, DOI 10.1111/j.1528-1167.2007.01458.x; Brooks-Kayal AR, 2013, EPILEPSIA, V54, P44, DOI 10.1111/epi.12298; Caplan R, 2008, EPILEPSIA, V49, P1838, DOI 10.1111/j.1528-1167.2008.01680.x; Cardamone L, 2013, BRIT J PHARMACOL, V168, P1531, DOI 10.1111/bph.12052; Cardamone L, 2014, NEUROBIOL DIS, V63, P194, DOI 10.1016/j.nbd.2013.11.020; Citraro R, 2006, NEUROPHARMACOLOGY, V51, P1058, DOI 10.1016/j.neuropharm.2006.06.014; Citraro R, 2017, EPILEPSIA, V58, P231, DOI 10.1111/epi.13629; Citraro R, 2016, PHARMACOL RES, V107, P333, DOI 10.1016/j.phrs.2016.03.039; Citraro R, 2015, BRIT J PHARMACOL, V172, P3177, DOI 10.1111/bph.13121; Citraro R, 2015, BRAIN RES BULL, V113, P1, DOI 10.1016/j.brainresbull.2015.02.004; Citraro R, 2014, EPILEPSIA, V55, P1284, DOI 10.1111/epi.12686; Citraro R, 2014, EXPERT OPIN THER TAR, V18, P319, DOI 10.1517/14728222.2014.874416; Citraro R, 2011, EPILEPSY RES, V95, P60, DOI 10.1016/j.eplepsyres.2011.02.013; Coenen AML, 2003, BEHAV GENET, V33, P635, DOI 10.1023/A:1026179013847; de Bruin NMWJ, 2000, NEUROSCI RES, V38, P165, DOI 10.1016/S0168-0102(00)00154-1; de Vries EE, 2016, NEUROSCI BIOBEHAV R, V63, P177, DOI 10.1016/j.neubiorev.2016.02.007; Dezsi G, 2013, EPILEPSIA, V54, P635, DOI 10.1111/epi.12118; Epps SA, 2013, BIOCHEM PHARMACOL, V85, P135, DOI 10.1016/j.bcp.2012.08.016; Galanopoulou AS, 2012, EPILEPSIA, V53, P1119, DOI 10.1111/j.1528-1167.2012.03506.x; Gao F, 2012, PHARMACOL BIOCHEM BE, V103, P187, DOI 10.1016/j.pbb.2012.08.025; Gauguier D, 2004, EPILEPSIA, V45, P908, DOI 10.1111/j.0013-9580.2004.13104.x; Giblin KA, 2010, NEUROSCIENTIST, V16, P253, DOI 10.1177/1073858409354385; Gol M, 2017, EUR J PHARM SCI, V96, P72, DOI 10.1016/j.ejps.2016.09.016; Goldberg EM, 2013, NAT REV NEUROSCI, V14, P337, DOI 10.1038/nrn3482; Jafarian M, 2015, NEUROSCIENCE, V298, P161, DOI 10.1016/j.neuroscience.2015.04.033; Jarre G, 2017, CEREB CORTEX, V27, P4607, DOI 10.1093/cercor/bhx174; Kaminski RM, 2003, POL J PHARMACOL, V55, P741; Kanner AM, 2009, NEUROL CLIN, V27, P865, DOI 10.1016/j.ncl.2009.08.002; Karson A, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-51; Kovacs Z, 2012, BRAIN RES BULL, V89, P102, DOI 10.1016/j.brainresbull.2012.07.010; Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455; Landmark CJ, 2016, EPILEPSY BEHAV, V61, P287, DOI 10.1016/j.yebeh.2016.01.029; Leo A, 2016, MOL MED MTOR TRANSLA, P123, DOI [10.1016/B978-0-12-802733-2.00006-2, DOI 10.1016/B978-0-12-802733-2.00006-2]; Leo A, 2017, NEUROTHERAPEUTICS, V14, P1134, DOI 10.1007/s13311-017-0550-y; Leo A, 2017, CNS NEUROL DISORD-DR, V16, P311, DOI 10.2174/1871527315666161104163031; Mazarati A, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a022798; Midzianovskaia IS, 2001, BRAIN RES, V911, P62, DOI 10.1016/S0006-8993(01)02705-6; Midzyanovskaya IS, 2006, BRAIN RES BULL, V69, P631, DOI 10.1016/j.brainresbull.2006.03.008; Prager B, 2015, TRENDS MOL MED, V21, P354, DOI 10.1016/j.molmed.2015.03.006; Rudolf G, 2004, EPILEPSIA, V45, P301, DOI 10.1111/j.0013-9580.2004.50303.x; Russo E, 2012, NEUROSCIENCE, V226, P282, DOI 10.1016/j.neuroscience.2012.09.021; Russo E, 2008, INT J DEV NEUROSCI, V26, P739, DOI 10.1016/j.ijdevneu.2008.07.002; Russo E, 2008, EPILEPSY BEHAV, V13, P295, DOI 10.1016/j.yebeh.2008.04.018; Russo E, 2016, NEUROSCI BIOBEHAV R, V71, P388, DOI 10.1016/j.neubiorev.2016.09.017; Russo E, 2014, BRAIN BEHAV IMMUN, V42, P157, DOI 10.1016/j.bbi.2014.06.016; Russo E, 2014, NEUROL SCI, V35, P1793, DOI 10.1007/s10072-014-1842-1; Russo E, 2013, NEUROPHARMACOLOGY, V69, P25, DOI 10.1016/j.neuropharm.2012.09.019; Russo E, 2013, PHARMACOL RES, V70, P1, DOI 10.1016/j.phrs.2012.12.002; Russo E, 2012, MOL NEUROBIOL, V46, P662, DOI 10.1007/s12035-012-8314-5; Russo E, 2012, EXPERT OPIN INV DRUG, V21, P1371, DOI 10.1517/13543784.2012.705277; Russo E, 2011, BEHAV BRAIN RES, V225, P373, DOI 10.1016/j.bbr.2011.07.030; Russo E, 2011, EPILEPSIA, V52, P1341, DOI 10.1111/j.1528-1167.2011.03112.x; Russo E, 2010, EPILEPSIA, V51, P1560, DOI 10.1111/j.1528-1167.2009.02400.x; Sarkisova KY, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12477; Sarkisova K Yu, 2017, Dokl Biol Sci, V473, P39, DOI 10.1134/S0012496617020077; Sarkisova K Yu, 2008, Neurosci Behav Physiol, V38, P119, DOI 10.1007/s11055-008-0017-z; Sarkisova K, 2011, PROG NEURO-PSYCHOPH, V35, P854, DOI 10.1016/j.pnpbp.2010.11.010; Sarkisova KY, 2010, EPILEPSIA, V51, P146, DOI 10.1111/j.1528-1167.2009.02260.x; Sarkisova KY, 2006, BEHAV BRAIN RES, V166, P9, DOI 10.1016/j.bbr.2005.07.024; Scicchitano F, 2015, CURR DRUG TARGETS, V16, P747, DOI 10.2174/1389450116666150330114850; Sierra-Marcos A, 2015, EUR J NEUROL, V22, P402, DOI 10.1111/ene.12428; Sitnikova E, 2015, BRAIN RES, V1594, P305, DOI 10.1016/j.brainres.2014.10.067; Sitnikova E, 2011, BRAIN RES, V1377, P109, DOI 10.1016/j.brainres.2010.12.067; Teskey GC, 2004, EPILEPSY RES, V59, P25, DOI 10.1016/j.eplepsyres.2004.03.001; van de Bovenkamp-Janssen MC, 2004, J NEUROBIOL, V58, P467, DOI 10.1002/neu.10291; van Luijtelaar G, 2014, CURR MED CHEM, V21, P704; van Luijtelaar G, 2012, NEUROPHYSIOLOGY+, V43, P478, DOI 10.1007/s11062-012-9252-6; van Luijtelaar G, 2017, CURR PHARM DESIGN, V23, P5577, DOI 10.2174/1381612823666171017170226; van Luijtelaar G, 2013, NEUROBIOL DIS, V60, P126, DOI 10.1016/j.nbd.2013.08.013; van Vliet EA, 2011, EPILEPSIA, V52, P1319, DOI 10.1111/j.1528-1167.2011.03073.x; Vezzani A, 2013, NEUROPHARMACOLOGY, V69, P16, DOI 10.1016/j.neuropharm.2012.04.004; WARTER JM, 1988, NEUROPHARMACOLOGY, V27, P269, DOI 10.1016/0028-3908(88)90043-3; Wei Y, 2011, ANN NEUROL, V69, P119, DOI 10.1002/ana.22186; White HS, 2014, NEUROTHERAPEUTICS, V11, P373, DOI 10.1007/s13311-013-0250-1; Zhang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057445	80	11	11	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	DEC 1	2018	310				SI		54	62		10.1016/j.jneumeth.2018.05.020			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	HC0LM	WOS:000451489900007	29857008				2021-06-18	
J	Tierney, GJ; Simms, CK				Tierney, Gregory J.; Simms, Ciaran K.			Can tackle height influence head injury assessment risk in elite rugby union?	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Concussion; Head impact; Tackling; Injury prevention	VIDEO ANALYSIS; EPIDEMIOLOGY; CONCUSSION; EVENTS	Objectives: Tackle height laws are an area of controversy in rugby union. It is reported that the tackler is at most risk of a Head Injury Assessment (HIA). Therefore, the aim of this study was to use match video evidence of tackles in elite level rugby union to examine the effect of tackle heights on HIA risk for the tackler. Design: Qualitative observational case-control study. Methods: Each HIA (n = 74) and control tackle (n = 965) was categorised based on tackle direction (front- or side-on), tackle type (arm, shoulder or smother) and tackle height (upper trunk, mid-trunk, lower trunk, upper leg or lower leg). The Relative Risk (RR), 95% Confidence Interval (CI) and probability (p) values were calculated for each tackle height. Results: Intended primary contact at the upper trunk of the ball carrier had a greater propensity to result in a HIA for the tackler for front-on upper body shoulder tackles (RR = 1.48; 95%CI = 1.16-1.90; p < 0.01) and side-on upper body smother tackles (RR = 2.30; 95%CI = 1.82-2.92; p < 0.01). Intended primary contact at the upper leg of the ball carrier had a greater propensity to result in a HIA for the tackler for front-on (RR = 2.60; 95%CI = 1.70-3.97; p < 0.01) and side-on (RR = 3.34; 95%CI = 1.65-6.79; p < 0.01) lower body shoulder tackles. Conclusions: To reduce tackler HIA risk, the results suggest tackling below the upper trunk for upper body tackles. The results also suggest tackling at the lower trunk for lower body tackles and avoiding the upper legs. Prevention strategies should place emphasis on tackling lower risk body regions such as the mid- and lower trunk. (C) 2018 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Tierney, Gregory J.; Simms, Ciaran K.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin, Ireland	Tierney, GJ (corresponding author), Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin, Ireland.	gtierne@tcd.ie		Tierney, Gregory/0000-0002-4666-4473	Irish Research CouncilIrish Research Council for Science, Engineering and Technology	The authors would like to thank the Irish Research Council for funding this study.	Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Cross MJ, 2019, BRIT J SPORT MED, V53, P1021, DOI 10.1136/bjsports-2017-097912; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Gabbett TJ., 2007, INT J SPORTS SCI COA, V2, P467, DOI DOI 10.1260/174795407783359731; Hendricks S., 2016, BMJ OPEN SPORT EXERC, V2, DOI [10.1136/bmjsem-2015-000053, DOI 10.1136/BMJSEM-2015-000053]; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hopkins W., 2010, SPORTSCIENCE, V14, P49; Landis JR, 1977, BIOMETRICS, V15, P9; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Montgomery C, 2018, BRIT J SPORT MED, V52, P994, DOI 10.1136/bjsports-2016-096425; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Rugby Football Union, ENGL PROF RUGB INJ S; Scher A., 1978, DRUG RES, V5, P197; Tierney GJ., 2017, IRCOBI C P; Tierney GJ, 2015, IRCOBI C P; Tierney GJ, 2016, ISBS C P ARCH; Tierney GJ, 2018, MED SCI SPORT EXER, V50, P603, DOI 10.1249/MSS.0000000000001461; Tierney Gregory J, 2018, J Sci Med Sport, V21, P221, DOI 10.1016/j.jsams.2017.06.023; Tierney GJ, 2018, INT J SPORTS SCI COA, V13, P415, DOI 10.1177/1747954117751345; Tierney GJ, 2017, BRAIN INJURY, V31, P1925, DOI 10.1080/02699052.2017.1385853; Tierney Gregory J, 2018, Sports Biomech, V17, P33, DOI 10.1080/14763141.2016.1271905; Tierney GJ, 2016, BRAIN INJURY, V30, P1350, DOI 10.1080/02699052.2016.1193630; Tucker R, 2017, BRIT J SPORT MED, V51, P1152, DOI 10.1136/bjsports-2017-097895; Tucker R, 2017, BRIT J SPORT MED, V51, P1147, DOI 10.1136/bjsports-2017-097883; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774	29	11	11	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	DEC	2018	21	12					1210	1214		10.1016/j.jsams.2018.05.010			5	Sport Sciences	Sport Sciences	HF4FM	WOS:000454188600007	29801755	Green Accepted, Green Published			2021-06-18	
J	Radford, KD; Park, TY; Jaiswal, S; Pan, HN; Knutsen, A; Zhang, M; Driscoll, M; Osborne-Smith, LA; Dardzinski, BJ; Choi, KH				Radford, Kennett D.; Park, Thomas Y.; Jaiswal, Shalini; Pan, Hongna; Knutsen, Andrew; Zhang, Michael; Driscoll, Mercedes; Osborne-Smith, Lisa A.; Dardzinski, Bernard J.; Choi, Kwang H.			Enhanced fear memories and brain glucose metabolism (F-18-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats	TRANSLATIONAL PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DOSE-RESPONSE CHARACTERISTICS; ANIMAL-MODEL; NMDA ANTAGONIST; SEX-DIFFERENCES; EXTINCTION; CONSOLIDATION; LOCOMOTION; PSYCHOSIS; ACQUISITION	Ketamine is a multimodal dissociative anesthetic, which provides powerful analgesia for victims with traumatic injury. However, the impact of ketamine administration in the peri-trauma period on the development of post-traumatic stress disorder (PTSD) remains controversial. Moreover, there is a major gap between preclinical and clinical studies because they utilize different doses and routes of ketamine administration. Here, we investigated the effects of sub-anesthetic doses of intravenous (IV) ketamine infusion on fear memory and brain glucose metabolism (BGluM) in rats. Male Sprague-Dawley rats received an IV ketamine infusion (0, 2, 10, and 20 mg/kg, 2 h) or an intraperitoneal (IP) injection (0 and 10 mg/kg) following an auditory fear conditioning (3 pairings of tone and foot shock [0.6 mA, 1 s]) on day 0. Fear memory retrieval, fear extinction, and fear recall were tested on days 2, 3, and 4, respectively. The effects of IV ketamine infusion (0 and 10 mg/kg) on BGluM were measured using F-18-fluoro-deoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT). The IV ketamine infusion dose-dependently enhanced fear memory retrieval, delayed fear extinction, and increased fear recall in rats. The IV ketamine (10 mg/kg) increased BGluM in the hippocampus, amygdala, and hypothalamus, while decreasing it in the cerebellum. On the contrary, a single ketamine injection (10 mg/kg, IP) after fear conditioning facilitated fear memory extinction in rats. The current findings suggest that ketamine may produce differential effects on fear memory depending on the route and duration of ketamine administration.	[Radford, Kennett D.; Choi, Kwang H.] Uniformed Serv Univ Hlth Sci, Daniel K Inouye Grad Sch Nursing, Bethesda, MD 20814 USA; [Park, Thomas Y.; Zhang, Michael; Choi, Kwang H.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Park, Thomas Y.; Zhang, Michael; Choi, Kwang H.] Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; [Jaiswal, Shalini; Pan, Hongna; Knutsen, Andrew; Dardzinski, Bernard J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Driscoll, Mercedes] Walter Reed Natl Mil Med Ctr, Natl Capital Consortium, Psychiat Residency Program, Bethesda, MD 20814 USA; [Osborne-Smith, Lisa A.] Oregon Hlth & Sci Univ, Nurse Anesthesia Program, Portland, OR 97239 USA; [Dardzinski, Bernard J.] Uniformed Serv Univ Hlth Sci, Dept Radiol & Radiol Sci, Bethesda, MD 20814 USA	Choi, KH (corresponding author), Uniformed Serv Univ Hlth Sci, Daniel K Inouye Grad Sch Nursing, Bethesda, MD 20814 USA.; Choi, KH (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA.; Choi, KH (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD 20814 USA.	kwang.choi@usuhs.edu		Dardzinski, Bernard/0000-0001-7098-9131	Tri-Service Nursing Research Program [N16-P14]; Jonas Center for Nursing and Veterans Healthcare	This work was financially supported by a Tri-Service Nursing Research Program Grant #: N16-P14. K.D.R. is a Jonas Scholar (2016-2018) and is supported by the Jonas Center for Nursing and Veterans Healthcare. We would like to thank Dr. Irwin Lucki for the critical review of the manuscript.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Averill LA, 2017, NEUROSCI LETT, V649, P147, DOI 10.1016/j.neulet.2016.11.064; Baker JD, 1996, BEHAV NEUROSCI, V110, P618, DOI 10.1037/0735-7044.110.3.618; Becker A, 2003, PROG NEURO-PSYCHOPH, V27, P687, DOI 10.1016/S0278-5846(03)00080-0; Breier A, 1997, AM J PSYCHIAT, V154, P805; Burghardt NS, 2013, BIOL PSYCHIAT, V73, P1078, DOI 10.1016/j.biopsych.2012.10.012; Carlson PJ, 2013, BIOL PSYCHIAT, V73, P1213, DOI 10.1016/j.biopsych.2013.02.008; Carrier N, 2013, NEUROPHARMACOLOGY, V70, P27, DOI 10.1016/j.neuropharm.2012.12.009; Clifton NE, 2018, J PSYCHOPHARMACOL, V32, P156, DOI 10.1177/0269881117748903; COHEN ML, 1973, ANESTHESIOLOGY, V39, P370, DOI 10.1097/00000542-197310000-00003; Corlett PR, 2007, J PSYCHOPHARMACOL, V21, P238, DOI 10.1177/0269881107077716; Corlett PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065088; CROSBY G, 1982, ANESTHESIOLOGY, V56, P437, DOI 10.1097/00000542-198206000-00005; Davis Michael, 2011, Dialogues Clin Neurosci, V13, P463; Franceschelli A, 2015, NEUROSCIENCE, V290, P49, DOI 10.1016/j.neuroscience.2015.01.008; Gao M, 2016, ACTA PHARMACOL SIN, V37, P865, DOI 10.1038/aps.2016.5; Getova Damianka P, 2011, Folia Med (Plovdiv), V53, P53; Girgenti MJ, 2017, NEUROBIOL DIS, V100, P1, DOI 10.1016/j.nbd.2016.12.026; Goulart BK, 2010, NEUROSCIENCE, V167, P969, DOI 10.1016/j.neuroscience.2010.03.032; HETZLER BE, 1985, PHARMACOL BIOCHEM BE, V22, P653, DOI 10.1016/0091-3057(85)90291-6; Honsberger MJ, 2015, SCHIZOPHR RES, V164, P227, DOI 10.1016/j.schres.2015.02.009; Imre G, 2006, BRAIN RES BULL, V69, P338, DOI 10.1016/j.brainresbull.2006.01.010; Johnson PL, 2015, PHARMACOL BIOCHEM BE, V138, P174, DOI 10.1016/j.pbb.2015.09.021; Jovanovic T, 2012, NEUROPHARMACOLOGY, V62, P695, DOI 10.1016/j.neuropharm.2011.02.023; Juven-Wetzler A, 2014, EUR NEUROPSYCHOPHARM, V24, P469, DOI 10.1016/j.euroneuro.2013.08.007; Kotermanski SE, 2013, PHARMACOL BIOCHEM BE, V109, P67, DOI 10.1016/j.pbb.2013.05.005; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; Lally N, 2015, J PSYCHOPHARMACOL, V29, P596, DOI 10.1177/0269881114568041; Liu JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007548; MARIETTA MP, 1976, J PHARMACOL EXP THER, V196, P536; McGhee LL, 2014, MIL MED, V179, P41, DOI 10.7205/MILMED-D-13-00481; McGowan JC, 2017, NEUROPSYCHOPHARMACOL, V42, P1577, DOI 10.1038/npp.2017.19; Mion G, 2017, ANAESTHESIA, V72, P1476, DOI 10.1111/anae.14079; Moghaddam B, 1997, J NEUROSCI, V17, P2921; Moosavi M, 2012, EUR J PHARMACOL, V677, P107, DOI 10.1016/j.ejphar.2011.12.021; Morena M, 2017, BEHAV BRAIN RES, V329, P215, DOI 10.1016/j.bbr.2017.04.048; Morris C, 2009, ANAESTHESIA, V64, P532, DOI 10.1111/j.1365-2044.2008.05835.x; Palenicek T, 2011, NEUROPSYCHOBIOLOGY, V63, P202, DOI 10.1159/000321803; Park TY, 2017, EUR J NEUROSCI, V45, P922, DOI 10.1111/ejn.13542; Pollard M, 2012, BEHAV BRAIN RES, V227, P184, DOI 10.1016/j.bbr.2011.10.050; Radford KD, 2017, PHARMACOL BIOCHEM BE, V153, P130, DOI 10.1016/j.pbb.2016.12.014; Radvansky B. M, 2015, BIOMED RES INT, V2015, P1; Saur L, 2017, NEUROSCI LETT, V658, P6, DOI 10.1016/j.neulet.2017.08.026; Schonenberg M, 2008, J PSYCHOPHARMACOL, V22, P493, DOI 10.1177/0269881107082481; Silvestre J S, 1997, Depress Anxiety, V5, P29, DOI 10.1002/(SICI)1520-6394(1997)5:1<29::AID-DA5>3.0.CO;2-0; Travis CMG, 2015, PHARMACOL BIOCHEM BE, V139, P84, DOI 10.1016/j.pbb.2015.10.013; Trujillo KA, 2011, ILAR J, V52, P366, DOI 10.1093/ilar.52.3.366; Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P9, DOI 10.1016/S0924-977X(96)00039-9; WATERMAN AE, 1978, BRIT J ANAESTH, V50, P885, DOI 10.1093/bja/50.9.885; Wicking M, 2016, NEUROBIOL LEARN MEM, V136, P116, DOI 10.1016/j.nlm.2016.09.016; Winter H, 2004, AM J PSYCHIAT, V161, P2194, DOI 10.1176/appi.ajp.161.12.2194; Zhang LM, 2015, PSYCHOPHARMACOLOGY, V232, P663, DOI 10.1007/s00213-014-3697-9; Zhu YQ, 2016, J NUCL MED, V57, P1474, DOI 10.2967/jnumed.116.173443	53	11	11	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	NOV 30	2018	8								263	10.1038/s41398-018-0310-8			12	Psychiatry	Psychiatry	HD2CO	WOS:000452318900001	30504810	DOAJ Gold, Green Published			2021-06-18	
J	Jiang, YJ; Cao, SQ; Gao, LB; Wang, YY; Zhou, B; Hu, X; Pu, Y; Li, ZL; Wang, Q; Xiao, X; Zhao, L; Wang, S; Liang, WB; Zhang, L				Jiang, You-jing; Cao, Shu-qiang; Gao, Lin-bo; Wang, Yan-yun; Zhou, Bin; Hu, Xin; Pu, Yan; Li, Zhi-long; Wang, Qian; Xiao, Xiao; Zhao, Li; Wang, Shuan; Liang, Wei-bo; Zhang, Lin			Circular Ribonucleic Acid Expression Profile in Mouse Cortex after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						bioinformatic analysis; ceRNA; circular RNAs (circRNAs); RNA-seq; traumatic brain injury (TBI)	CONTROLLED CORTICAL IMPACT; PROTECTS CEREBRAL AUTOREGULATION; SPINAL-CORD-INJURY; NEURAL STEM-CELLS; HIPPOCAMPAL NECROSIS; ERK MAPK; RECEPTORS; KINASE; RNAS; PATHOPHYSIOLOGY	Traumatic brain injury (TBI) causes high rates of worldwide death and morbidity because of the complex secondary injury cascade. Circular ribonucleic acid (RNA) (circRNA), a type of RNA that forms a covalently closed continuous loop, may be involved in the regulation of secondary injury because it is expressed widely in the brain and contributes to a large class of post-transcriptional regulators. Deep RNA sequencing (RNA-seq) and bioinformatic analysis were performed to investigate the expression profile and function of circRNAs in the mouse cortex after controlled cortical impact (CCI). A total of 19,794 circRNAs were identified, and 1315 were annotated in circBase. There were 191 filtered differentially expressed circRNAs (98 for up-regulated and 93 for down-regulated). The gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses indicated that inflammation, cell death, and repair of damage were the main biological processes and molecular mechanisms related to altered circRNAs. The pathway-circRNA interaction network revealed three core circRNAs and five corepathways related to TBI. The circRNA-messenger RNA (mRNA) interaction network and competitive endogenous RNA (ceRNA) analysis suggested potential microRNA (miRNA) sponges and target mRNAs. In addition to five optimal circRNA-miRNA-mRNA pairs were analyzed, circRNA_16895-miRNA myosin-10 (Myo 10) was predicted to regulate fragment crystallizable gamma receptors (Fc gamma R)-mediated phagocytosis pathway. Four circRNAs were selected for quantitative real-time polymerase chain reaction analysis to validate the sequencing data. Our results provide promising functions of circRNAs aberrantly expressed in TBI to explore molecular mechanisms and potential therapeutic targets for its therapy.	[Jiang, You-jing; Cao, Shu-qiang; Pu, Yan; Li, Zhi-long; Wang, Qian; Xiao, Xiao; Zhao, Li; Wang, Shuan; Liang, Wei-bo; Zhang, Lin] Sichuan Univ, West China Sch Basic Sci & Forens Med, Dept Forens Genet, Chengdu 610041, Sichuan, Peoples R China; [Gao, Lin-bo; Wang, Yan-yun; Zhou, Bin; Zhang, Lin] Sichuan Univ, Lab Mol Translat Med,West China Univ Hosp 2, West China Inst Women & Childrens Hlth,Minist Edu, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Chengdu, Sichuan, Peoples R China; [Hu, Xin] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China; [Hu, Xin] Sichuan Univ, West China Hosp, West China Brain Res Ctr, Chengdu, Sichuan, Peoples R China	Liang, WB; Zhang, L (corresponding author), Sichuan Univ, West China Sch Basic Sci & Forens Med, Dept Forens Genet, Chengdu 610041, Sichuan, Peoples R China.	liangweibo@scu.edu.cn; zhanglin@scu.edu.cn	liang, weibo/G-8456-2011	liang, weibo/0000-0002-8487-3575	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471827]	We would like to thank Yuan-cun Zhao, Qi-zhao Ma, Ya-ping Song, and Xue-lian Zheng for their technical assistance. This work was supported by grants from the National Natural Science Foundation of China (No. 81471827).	Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Armstead WM, 2016, J NEUROTRAUM, V33, P1761, DOI 10.1089/neu.2015.4290; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Chen T, 2017, NEUROCHEM RES, V42, P3073, DOI 10.1007/s11064-017-2340-7; Chen W, 2016, TRENDS NEUROSCI, V39, P597, DOI 10.1016/j.tins.2016.06.006; Curvello V, 2017, BRAIN RES, V1670, P118, DOI 10.1016/j.brainres.2017.06.010; Deng Z.F., 2018, CEREB CORTEX 2018; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; Filiano AJ, 2017, NAT REV NEUROSCI, V18, P375, DOI 10.1038/nrn.2017.39; Finsterer J, 2014, INT J CARDIOL, V177, P322, DOI 10.1016/j.ijcard.2014.08.101; Fiorino A, 2016, INT J BIOCHEM CELL B, V78, P162, DOI 10.1016/j.biocel.2016.07.013; Gao Y, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0571-3; Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Herman DS, 2012, NEW ENGL J MED, V366, P619, DOI 10.1056/NEJMoa1110186; Hinson JT, 2015, SCIENCE, V349, P982, DOI 10.1126/science.aaa5458; Hipp N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01475-7; Hoppmann N, 2015, BRAIN, V138, P902, DOI 10.1093/brain/awu408; Ju XD, 2014, CEREB CORTEX, V24, P1259, DOI 10.1093/cercor/bhs407; Kipnis J, 2016, SCIENCE, V353, P766, DOI 10.1126/science.aag2638; Krishnamoorthy V, 2016, CHEST, V149, P1325, DOI 10.1016/j.chest.2015.12.014; Kuwahara M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12596; Kuwahara M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4555; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; Li D, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0841-6; Li D, 2017, BRAIN RES, V1654, P1, DOI 10.1016/j.brainres.2016.10.013; Li ML, 2017, CANCER LETT, V391, P20, DOI 10.1016/j.canlet.2016.12.027; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu D, 2016, FRONT GENET, V7, DOI [10.3389/fgene.2015.00053, 10.3389/fgene.2016.00053]; Lu KT, 2015, PFLUG ARCH EUR J PHY, V467, P1651, DOI 10.1007/s00424-014-1588-x; Lyu Q, 2017, CELL TRANSPLANT, V26, P1622, DOI 10.1177/0963689717723014; Ma CC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0367-2; Ma J., 2017, PLOS ONE, V12; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Mellios N, 2018, MOL PSYCHIATR, V23, P1051, DOI 10.1038/mp.2017.86; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Miller G, 2010, SCIENCE, V328, P297, DOI 10.1126/science.328.5976.297; Mo MS, 2017, ONCOTARGET, V8, P15, DOI 10.18632/oncotarget.13905; Modigliani SD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5335; Moon Y, 2011, NEUROREPORT, V22, P304, DOI 10.1097/WNR.0b013e3283460265; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Ozisik K, 2004, AM J TRANSPLANT, V4, P900, DOI 10.1111/j.1600-6143.2004.00448.x; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Saika R, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0884-8; Santra M, 2016, J NEUROCHEM, V136, P118, DOI 10.1111/jnc.13394; Schafer S, 2017, NAT GENET, V49, P46, DOI 10.1038/ng.3719; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Spaethling J, 2012, NEUROBIOL DIS, V46, P646, DOI 10.1016/j.nbd.2012.03.003; Sung JK, 2003, BRAIN RES, V959, P29, DOI 10.1016/S0006-8993(02)03717-4; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Venneti S, 2012, BRAIN PATHOL, V22, P522, DOI 10.1111/j.1750-3639.2011.00551.x; Wang CF, 2017, J NEUROTRAUM, V34, P2100, DOI 10.1089/neu.2016.4642; Wang WX, 2017, PROG NEURO-PSYCHOPH, V73, P104, DOI 10.1016/j.pnpbp.2016.02.011; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xia HP, 2010, J BIOL CHEM, V285, P36995, DOI 10.1074/jbc.M110.133744; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yang H, 2017, ACTA PHARMACOL SIN, V38, P168, DOI 10.1038/aps.2016.130; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yang TS, 2018, REDOX BIOL, V15, P159, DOI 10.1016/j.redox.2017.11.025; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; Zhao B, 2017, MED SCI MONITOR, V23, P1872, DOI 10.12659/MSM.901055; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215	70	11	13	5	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					1018	1028		10.1089/neu.2018.5647		NOV 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HQ4DT	WOS:000450807900001	30261810				2021-06-18	
J	Giacci, M; Fitzgerald, M				Giacci, Marcus; Fitzgerald, Melinda			Oligodendroglia Are Particularly Vulnerable to Oxidative Damage After Neurotrauma In Vivo	JOURNAL OF EXPERIMENTAL NEUROSCIENCE			English	Article						Neurotrauma; myelin; oligodendrocyte; oxidative damage	DEGENERATION; MACROPHAGES	In the paper "Oligodendroglia are particularly vulnerable to oxidative damage after neurotrauma in vivo,' we determined the extent of oxidative damage to specific cellular sub-populations and structures within regions vulnerable to secondary degeneration and assessed the effect this had on oligodendroglial function. Comparative assessment of oxidative damage demonstrated selective vulnerability of oligodendroglia, specifically oligodendrocyte progenitor cells (OPCs) to DNA oxidation in vivo. Immunohistochemical fate mapping along the oligodendroglial lineage showed a transient susceptibility of these cells to DNA oxidation, protein nitration, and lipid peroxidation, with mature oligodendrocytes derived immediately after injury more vulnerable to DNA oxidation than their counterparts existing at the time of injury or later derived. In situ hybridization demonstrated a reduction in myelin regulatory factor (MyRF) messenger RNA (mRNA) fluorescence in newly derived mature oligodendrocytes, suggesting a compromise in the production and maintenance of the myelin sheath in these cells. The data imply a deficit in the normal differentiation of OPCs to myelinating oligodendrocytes. associated with a transient increase in oxidative damage, which may contribute to the dysmyelinating phenotype seen at chronic time points after injury. Identifying and understanding the sources of this oxidative damage is integral for the development of therapeutic interventions for neurotrauma.	[Giacci, Marcus; Fitzgerald, Melinda] Univ Western Australia, Sch Biol Sci, Nedlands, WA, Australia; [Fitzgerald, Melinda] Curtin Univ, Curtin Hlth Innovat Res Inst, Belmont, MA USA; [Fitzgerald, Melinda] Perron Inst Neurol & Translat Sci, Sarich Neurosci Res Inst Bldg,8 Verdun St, Nedlands, WA 6009, Australia	Fitzgerald, M (corresponding author), Curtin Univ, Curtin Hlth Innovat Res Inst, Belmont, MA USA.; Fitzgerald, M (corresponding author), Perron Inst Neurol & Translat Sci, Sarich Neurosci Res Inst Bldg,8 Verdun St, Nedlands, WA 6009, Australia.	lindy.fitzgerald@curtin.edu.au	; Fitzgerald, Melinda/C-4235-2011	Giacci, Marcus/0000-0002-8330-678X; Fitzgerald, Melinda/0000-0002-4823-8179			BOISON D, 1995, J NEUROSCI, V15, P5502; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Doig RLO, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0380-1; El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671; Emery B, 2009, CELL, V138, P172, DOI 10.1016/j.cell.2009.04.031; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Giacci MK, 2018, J NEUROSCI, V38, P6491, DOI 10.1523/JNEUROSCI.1898-17.2018; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; Smith NM, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1227-0; Thorburne SK, 1996, J NEUROCHEM, V67, P1014	15	11	11	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1179-0695			J EXP NEUROSCI	J. Exp. Neurosci.	NOV 14	2018	12								1179069518810004	10.1177/1179069518810004			3	Neurosciences	Neurosciences & Neurology	HH4DM	WOS:000455670900001	30479489	DOAJ Gold, Green Published			2021-06-18	
J	Ostermann, RC; Joestl, J; Tiefenboeck, TM; Lang, N; Platzer, P; Hofbauer, M				Ostermann, Roman C.; Joestl, Julian; Tiefenboeck, Thomas M.; Lang, Nikolaus; Platzer, Patrick; Hofbauer, Marcus			Risk factors predicting prognosis and outcome of elderly patients with isolated traumatic brain injury	JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH			English	Article						Elderly patients; Isolated severe traumatic brain injuries (TBI); Respiratory failure; Outcome prediction	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; AGE; MORTALITY; IMPACT	BackgroundTraumatic brain injury (TBI), particularly in the elderly patient population, is known to be the single largest cause of death and disability worldwide. The purpose of this retrospective study was to evaluate clinical factors predicting poor outcome with special emphasis on the impact of respiratory failure (RF) on mortality in elderly patients with isolated severe TBI.MethodsAll elderly patients (age 65years) with isolated severe head injury, admitted to this level I trauma center, during a period of 18years (from January 1992 to December 2010) were identified from the trauma registry. The medical records were reviewed for demographics, mechanism of injury (MOI), GCS score at admission, RF, pupillary light reflex (LR), CT findings (subdural hematoma, subarachnoid hematoma, edema, midline-shift), and whether there was conservative treatment or surgical intervention and the Glasgow Outcome Score (GOS) at hospital discharge. Stepwise logistic regression analysis was used to identify risk factors for a poor prognosis and outcome.ResultsThe following variables influenced the mortality: respiratory failure, pupillary response, and the injury severity score (ISS). A significant increased risk of death was also found for patients with a midline shift of over 15mm.ConclusionsThe present study predicts a strong correlation between respiratory failure, pathological pupillary response, a higher ISS, and substantial midline shift with poor outcomes in elderly patients sustaining an isolated severe TBI.Trial registrationClinical trials: ID: NCT02386865. Registered 12 March 2015retrospectively registered.	[Ostermann, Roman C.; Joestl, Julian; Tiefenboeck, Thomas M.; Lang, Nikolaus; Platzer, Patrick; Hofbauer, Marcus] Med Univ Vienna, Dept Orthopaed & Trauma Surg, Div Trauma Surg, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Ostermann, Roman C.] Med Univ Vienna, St Vincent Hosp, Dept Orthopead & Trauma Surg, Div Trauma Surg,Shoulder & Sports Clin, Baumgasse 20A, A-1030 Vienna, Austria; [Platzer, Patrick] Karl Landsteiner Univ Hlth, Univ Hosp St Poelten, Dept Trauma Surg, St Polten, Austria	Ostermann, RC (corresponding author), Med Univ Vienna, Dept Orthopaed & Trauma Surg, Div Trauma Surg, Waehringer Guertel 18-20, A-1090 Vienna, Austria.; Ostermann, RC (corresponding author), Med Univ Vienna, St Vincent Hosp, Dept Orthopead & Trauma Surg, Div Trauma Surg,Shoulder & Sports Clin, Baumgasse 20A, A-1030 Vienna, Austria.	roman.ostermann@me.com		Tiefenboeck, Thomas/0000-0002-8698-8341			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1975, LANCET, V1, P480; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mitra B, 2008, ANZ J SURG, V78, P588, DOI 10.1111/j.1445-2197.2008.04579.x; Mohindra S, 2008, SURG NEUROL, V69, P474, DOI 10.1016/j.surneu.2007.02.031; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Ross A M, 1992, J Neurosci Nurs, V24, P88; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Ushewokunze S, 2004, BRIT J NEUROSURG, V18, P604, DOI 10.1080/02688690400022763; Wutzler S, 2015, INJURY, V46, P1706, DOI 10.1016/j.injury.2015.02.013	24	11	12	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-799X			J ORTHOP SURG RES	J. Orthop. Surg. Res.	NOV 3	2018	13								277	10.1186/s13018-018-0975-y			6	Orthopedics	Orthopedics	GZ1DO	WOS:000449106200001	30390698	DOAJ Gold, Green Published			2021-06-18	
J	Chi, NF; Hu, HH; Wang, CY; Chan, L; Peng, CK; Novak, V; Hu, CJ				Chi, Nai-Fang; Hu, Han-Hwa; Wang, Cheng-Yen; Chan, Lung; Peng, Chung-Kang; Novak, Vera; Hu, Chaur-Jong			Dynamic Cerebral Autoregulation Is an Independent Functional Outcome Predictor of Mild Acute Ischemic Stroke	STROKE			English	Article						arterial pressure; autoregulation; blood pressure; infarction; odds ratio; stroke	SPONTANEOUS BLOOD-PRESSURE; TRAUMATIC BRAIN-INJURY; SPONTANEOUS FLUCTUATIONS; HYPERTENSIVE PATIENTS; TRANSCRANIAL DOPPLER; NONLINEAR ASSESSMENT; OCCLUSIVE DISEASE; FLOW FLUCTUATIONS; CAROTID STENOSIS; THROMBOLYSIS	Background and Purpose Cerebral autoregulation is impaired in patients with acute ischemic stroke. The purpose of this study was to investigate whether dynamic cerebral autoregulation (dCA) indices constitute an independent functional outcome predictor of acute ischemic stroke. Methods In this study, 86 patients at days 3 to 7 after acute ischemic stroke and 40 age- and sex-matched controls were enrolled for assessing their dCA indices under spontaneous hemodynamic fluctuations. The dCA indices of patients with favorable outcomes (modified Rankin Scale score 1 at 3 months, n=65), patients with unfavorable outcomes (modified Rankin Scale score 2 at 3 months, n=21), and controls were compared. Results The dCA indices, namely the phase shift at very low frequency band (phase_VLF), in the patients with unfavorable outcomes were significantly worse than those in the patients with favorable outcomes. However, the phase_VLF in the patients with favorable outcomes did not differ from those in the controls. Impaired dCA was associated with elevated mean arterial pressure and large infarction volume but was also present in patients with normal mean arterial pressure or small infarction volume. Phase_VLF was a predictor of outcomes in the receiver operating characteristic analysis (area under the curve: 0.722; P<0.001). Multivariate analysis revealed that a phase_VLF value of <61 degrees was independently associated with unfavorable outcomes (odds ratio=4.90; P=0.024). Conclusions Phase_VLF is an independent functional outcome predictor of acute ischemic stroke.	[Chi, Nai-Fang; Hu, Chaur-Jong] Taipei Med Univ, Grad Inst Clin Med, Coll Med, 250 Wuxing St, Taipei 110, Taiwan; [Chi, Nai-Fang; Chan, Lung; Hu, Chaur-Jong] Taipei Med Univ, Sch Med, Dept Neurol, Coll Med, Taipei, Taiwan; [Chi, Nai-Fang; Hu, Han-Hwa; Chan, Lung; Hu, Chaur-Jong] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, Taipei, Taiwan; [Chi, Nai-Fang; Hu, Han-Hwa; Wang, Cheng-Yen; Chan, Lung; Hu, Chaur-Jong] Taipei Med Univ, Coll Med, Res Ctr Cerebrovasc Dis Treatment, Taipei, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Grad Inst Neural Regenerat Med, Coll Med Sci & Technol, Taipei, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Taipei Neurosci Inst, Taipei, Taiwan; [Chi, Nai-Fang] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan; [Peng, Chung-Kang] Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA; [Novak, Vera] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA	Hu, CJ (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Coll Med, 250 Wuxing St, Taipei 110, Taiwan.	chaurjongh@tmu.edu.tw	Chan, Lung/AAI-6349-2020; Chan, Lung/AAM-3231-2021; Peng, Chung-Kang/N-1308-2019; Chi, Nai-Fang/G-3561-2016	Chan, Lung/0000-0001-5795-4460; Peng, Chung-Kang/0000-0003-3666-9833; Chi, Nai-Fang/0000-0002-2204-4923	Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 106-2314-B-038-001, MOST 104-2314-B-038-021-MY3]	This study was supported by the Ministry of Science and Technology of Taiwan (MOST 106-2314-B-038-001, MOST 104-2314-B-038-021-MY3).	Ahmed N, 2009, STROKE, V40, P2442, DOI 10.1161/STROKEAHA.109.548602; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Brodie FG, 2009, CLIN SCI, V116, P513, DOI 10.1042/CS20080236; Castillo J, 2004, STROKE, V35, P520, DOI 10.1161/01.STR.0000109769.22917.B0; Castro P, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00113; Chi NF, 2017, ULTRASOUND MED BIOL, V43, P1307, DOI 10.1016/j.ultrasmedbio.2017.02.003; Claassen JAHR, 2016, J CEREBR BLOOD F MET, V36, P665, DOI 10.1177/0271678X15626425; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; de Jong DLK, 2016, ICP 2016, P115; FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351, DOI 10.2214/ajr.149.2.351; Fu CH, 2005, AM J HYPERTENS, V18, P1621, DOI 10.1016/j.amjhyper.2005.05.015; Guo ZN, 2015, SCI REP-UK, V5, DOI 10.1038/srep15269; Guo ZN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093213; Hu HH, 1999, J CEREBR BLOOD F MET, V19, P460, DOI 10.1097/00004647-199904000-00012; Hu K, 2008, CARDIOVASC ENG, V8, P60, DOI 10.1007/s10558-007-9045-5; Hu K, 2008, PHYSICA A, V387, P2279, DOI 10.1016/j.physa.2007.11.052; Immink RV, 2005, STROKE, V36, P2595, DOI 10.1161/01.STR.0000189624.06836.03; Immink RV, 2004, CIRCULATION, V110, P2241, DOI 10.1161/01.CIR.0000144472.08647.40; Ku HL, 2017, SCHIZOPHR RES, V188, P63, DOI 10.1016/j.schres.2017.01.015; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Leonardi-Bee J, 2002, STROKE, V33, P1315, DOI 10.1161/01.STR.0000014509.11540.66; Liu XY, 2015, J CEREBR BLOOD F MET, V35, P248, DOI 10.1038/jcbfm.2014.192; Manning LS, 2015, STROKE, V46, P1518, DOI 10.1161/STROKEAHA.115.009078; Moriwaki H, 2004, J HUM HYPERTENS, V18, P693, DOI 10.1038/sj.jhh.1001735; Novak V, 2003, NEUROLOGY, V60, P1657, DOI 10.1212/01.WNL.0000068023.14587.06; Oeinck M, 2013, STROKE, V44, P2722, DOI 10.1161/STROKEAHA.113.001913; Otite F, 2014, STROKE, V45, P677, DOI 10.1161/STROKEAHA.113.002630; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Reinhard M, 2012, ACTA NEUROL SCAND, V125, P156, DOI 10.1111/j.1600-0404.2011.01515.x; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Reinhard M, 2008, CEREBROVASC DIS, V26, P147, DOI 10.1159/000139662; Rivera-Lara L, 2017, CRIT CARE MED, V45, P695, DOI 10.1097/CCM.0000000000002251; Saura H, 2012, CEREBROVASC DIS, V33, P354, DOI 10.1159/000335836; Stead LG, 2005, NEUROLOGY, V65, P1179, DOI 10.1212/01.wnl.0000180939.24845.22; STRANDGAARD S, 1976, CIRCULATION, V53, P720, DOI 10.1161/01.CIR.53.4.720; Tang SC, 2008, J VASC SURG, V48, P88, DOI 10.1016/j.jvs.2008.02.025; van Beek AHEA, 2008, J CEREBR BLOOD F MET, V28, P1071, DOI 10.1038/jcbfm.2008.13; Vemmos KN, 2004, J INTERN MED, V255, P257, DOI 10.1046/j.1365-2796.2003.01291.x; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Xiong L, 2017, J NEUROL NEUROSUR PS, V88, P520, DOI 10.1136/jnnp-2016-314385	44	11	12	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2018	49	11					2605	2611		10.1161/STROKEAHA.118.022481			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	GX7RY	WOS:000447974800019	30355198	Bronze			2021-06-18	
J	Chitturi, J; Li, Y; Santhakumar, V; Kannurpatti, SS				Chitturi, Jyothsna; Li, Ying; Santhakumar, Vijayalakshmi; Kannurpatti, Sridhar S.			Early behavioral and metabolomic change after mild to moderate traumatic brain injury in the developing brain	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Sensorimotor behavior; Metabolomics; Glycolysis; TCA cycle; Mass spectrometry; Liquid chromatography; Pediatric; Glycolysis; Fluid percussion	N-ACETYL-ASPARTATE; METHYL-D-ASPARTATE; IMMATURE; RATS; SEVERITY; NEUROTOXICITY; METABOANALYST; DISTURBANCES; DYSFUNCTION; INHIBITION	Pathophysiology of developmental traumatic brain injury (TBI) is unique due to intrinsic differences in the developing brain. Energy metabolic studies of the brain during early development (P13 to P30) have indicated acute oxidative energy metabolic decreases below 24 h after TBI, which generally recovered by 48 h. However, marked neurodegeneration and altered neural functional connectivity have been observed at later stages into adolescence. As secondary neurodegeneration is most prominent during the first week after TBI in the rat model, we hypothesized that the subacute TBI-metabolome may contain predictive markers of neurodegeneration. Sham and TBI metabolomes were examined at 72 h after a mild to moderate intensity TBI in male Sprague-Dawley rats aged P31. Sensorimotor behavior was assessed at 24, 48 and 72 h after injury, followed by 72-hour postmortem brain removal for metabolomics using Liquid Chromatography/Mass Spectrometry (LC-MS) measurement. Broad TBI-induced metabolomic shifts occurred with relatively higher intensity in the injury-lateralized (ipsilateral) hemisphere. Intensity of metabolomic perturbation correlated with the extent of sensorimotor behavioral deficit. N-acetyl-aspartate (NAA) levels at 72 h after TBI, predicted the extent of neurodegeneration assessed histochemically 7-days post TBI. Results from the multivariate untargeted approach clearly distinguished metabolomic shifts induced by TBI. Several pathways including amino acid, fatty acid and energy metabolism continued to be affected at 72 h after TBI, whose collective effects may determine the overall pathological response after TBI in early development including neurodegeneration.	[Chitturi, Jyothsna; Kannurpatti, Sridhar S.] Rutgers New Jersey Med Sch, Dept Radiol, Adm Complex Bldg 5 ADMC5,30 Bergen St Room 575, Newark, NJ 07101 USA; [Li, Ying; Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, MSB-H-512,512,185 S Orange Ave, Newark, NJ 07103 USA; [Santhakumar, Vijayalakshmi] Univ Calif Riverside, Mol Cell & Syst Biol, Spieth 1308,3401 Watkins Dr, Riverside, CA 92521 USA	Kannurpatti, SS (corresponding author), Univ Med & Dent New Jersey, Dept Radiol, Rutgers Biomed & Hlth Sci, ADMC 5,Room 575,30 Bergen St, Newark, NJ 07101 USA.	jc2248@njms.rutgers.edu; yl691@njms.rutgers.edu; santhavi@njms.rutgers.edu; kannursr@njms.rutgers.edu	Santhakumar, Viji/K-4856-2019; Chitturi, Jyothsna/AAR-3986-2020	Santhakumar, Viji/0000-0001-6278-4187; 	New Jersey Commission on Brain Injury Research [CBIR15IRG010]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS097750]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097750, R01NS069861] Funding Source: NIH RePORTER	This study was supported by funding from the New Jersey Commission on Brain Injury Research (CBIR15IRG010; SK), and National Institutes of Health (R01NS097750; VS). The authors thank Drs. Guoan Zhang and Zhe Cheng from the Proteomics and Metabolomics Core Facility, Weill Cornell Medicine, New York, NY for assistance in sample preparation and performance of the LC-MS measurements.	Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Alessandri B, 2000, NEUROL RES, V22, P705; Bahado-Singh RO, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1044-3; Bahado-Singh RO, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-0957-1; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Daley M, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1131-5; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Emmerich T, 2017, NEUROMOL MED, V19, P122, DOI 10.1007/s12017-016-8436-4; Emmerich T, 2016, J NEUROTRAUM, V33, P1331, DOI 10.1089/neu.2015.4061; Glenn Thomas C, 2013, Acta Neurochir Suppl, V118, P115, DOI 10.1007/978-3-7091-1434-6_20; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; MCDONALD JW, 1988, ANN NEUROL, V24, P337; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; Murugan M, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00019; NETOPILOVA M, 1995, EPILEPSY RES, V20, P179, DOI 10.1016/0920-1211(94)00068-8; Oresic M, 2016, EBIOMEDICINE, V12, P118, DOI 10.1016/j.ebiom.2016.07.015; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Parent M, 2019, J NEUROTRAUM, V36, P601, DOI 10.1089/neu.2018.5741; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Quinn M, 2014, DIGEST LIVER DIS, V46, P527, DOI 10.1016/j.dld.2014.01.159; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Robertson CL, 2013, J NEUROTRAUM, V30, P2066, DOI 10.1089/neu.2013.3007; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schubring SR, 2012, NEUROSCI LETT, V506, P322, DOI 10.1016/j.neulet.2011.11.036; Sheth SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129735; TALLAN HH, 1956, J BIOL CHEM, V219, P257; Tang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096944; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Xia JG, 2010, BIOINFORMATICS, V26, P2342, DOI 10.1093/bioinformatics/btq418; Xia JG, 2010, NUCLEIC ACIDS RES, V38, pW71, DOI 10.1093/nar/gkq329; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Yi LZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21320; Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024; Zadori D, 2012, J NEUROL SCI, V322, P187, DOI 10.1016/j.jns.2012.06.004; Zheng F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182025; Zheng XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24125	52	11	11	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	NOV	2018	120						75	86		10.1016/j.neuint.2018.08.003			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GX5VR	WOS:000447819600008	30098378	Green Accepted, Bronze			2021-06-18	
J	Chou, W; Liu, YF; Lin, CH; Lin, MT; Chen, CC; Liu, WP; Chang, CP; Chio, CC				Chou, Willy; Liu, Yu-Fan; Lin, Cheng-Hsien; Lin, Mao-Tsun; Chen, Chi-Chun; Liu, Wen-Pin; Chang, Ching-Ping; Chio, Chung-Ching			Exercise Rehabilitation Attenuates Cognitive Deficits in Rats with Traumatic Brain Injury by Stimulating the Cerebral HSP20/BDNF/TrkB Signalling Axis	MOLECULAR NEUROBIOLOGY			English	Article						Physical exercise; Traumatic brain injury; Heat shock protein 20; Brain-derived neurotrophic factor	BETA-PROTEIN AGGREGATION; REDUCES INFARCT SIZE; NEUROTROPHIC FACTOR; AMYLOID-BETA; ALZHEIMERS-DISEASE; MODEL; CONCUSSION; ASSOCIATION; SEVERITY; TOXICITY	Physical exercise (PE) is an effective method for improving cognitive function among patients with traumatic brain injury (TBI). We previously demonstrated that PE with an infrared-sensing running wheel (ISRW) system provides strong neuroprotection in an experimental animal model of stroke. In this study, we used fluid percussion injury in rats to simulate mild TBI. For rats, we used both passive avoidance learning and the Y-maze tests to evaluate cognitive function. We investigated whether PE rehabilitation attenuated cognitive deficits in rats with TBI and determined the contribution of hippocampal and cortical expression of heat shock protein 20 (HSP20) to PE-mediated cognitive recovery. In addition to increasing hippocampal and cortical expression of HSP20, brain-derived neurotrophic factor (BDNF), and the tropomyosin receptor kinase B (TrkB) ratio, PE rehabilitation significantly attenuated brain contusion and improved cognitive deficits in the rat model. Furthermore, reducing hippocampal and cortical expression of HSP20 with an intracerebral injection of pSUPER hsp20 small interfering RNA significantly diminished the PE-induced overexpression of hippocampal and cortical BDNF and the TrkB ratio and also reversed the beneficial effect of PE in reducing neurotrauma and the cognitive deficits. A positive Pearson correlation was found between HSP20 and BDNF, as well as between HSP20 and TrkB, in the hippocampal and cortical tissues. We thus conclude that post-ischaemic ISRW exercise rehabilitation attenuates cognitive deficits, as well as brain contusions, in TBI rats by stimulating the cerebral HSP20/BDNF/TrkB signalling axis.	[Chou, Willy] Chi Mei Med Ctr, Dept Phys Med & Rehabil, Tainan 710, Taiwan; [Chou, Willy] Chia Nan Univ Pharm & Sci, Dept Recreat & Healthcare Management, Tainan 71710, Taiwan; [Liu, Yu-Fan; Lin, Cheng-Hsien; Lin, Mao-Tsun; Liu, Wen-Pin; Chang, Ching-Ping] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Liu, Yu-Fan] Univ Tsukuba, Fac Hlth & Sport Sci, Tsukuba, Ibaraki 3058574, Japan; [Lin, Cheng-Hsien] Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management, Tainan 710, Taiwan; [Chen, Chi-Chun] Natl Chin Yi Univ Technol, Dept Elect Engn, Taichung 41170, Taiwan; [Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Div Neurosurg, Tainan 710, Taiwan	Chang, CP (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan.; Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Div Neurosurg, Tainan 710, Taiwan.	jessica.cpchang@gmail.com; chiocc@ms28.hinet.net	Liu, Yu-Fan/AAE-9949-2020	Chang, Ching-Ping/0000-0003-0890-9414	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 104-2314-B-384 -003 -MY3, MOST 106-2314-B-384-001-MY3] Funding Source: Medline; Chi Mei Medical Center [CMFHT 10504] Funding Source: Medline		Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Archer T, 2012, NEUROTOX RES, V21, P418, DOI 10.1007/s12640-011-9297-0; Cameron RT, 2014, MOL CELL NEUROSCI, V61, P46, DOI 10.1016/j.mcn.2014.05.002; Chen A, 2013, BIOMED REP, V1, P167, DOI 10.3892/br.2012.48; Chen CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122394; d'Hemecourt P, 2011, CLIN SPORT MED, V30, P63, DOI 10.1016/j.csm.2010.08.008; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Eakin K, 2015, BRAIN NEUROTRAUMA MO; Eakin K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090617; Edwards HV, 2011, CELL SIGNAL, V23, P1447, DOI 10.1016/j.cellsig.2011.05.009; Franckeviciute Egle, 2006, Medicina (Kaunas), V42, P732; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Hosseini N, 2013, INT J PREVENTIVE MED, V4, P187; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Jeronimo-Santos A, 2015, CEREB CORTEX, V25, P3107, DOI 10.1093/cercor/bhu105; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Lin CM, 2015, EUR J CLIN INVEST, V45, P1297, DOI 10.1111/eci.12551; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Shen XF, 2013, INT J MOL SCI, V14, P21598, DOI 10.3390/ijms141121598; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tsai MC, 2015, J NEUROIMMUNE PHARM, V10, P45, DOI 10.1007/s11481-014-9570-0; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Wilhelmus MMM, 2006, BRAIN RES, V1089, P67, DOI 10.1016/j.brainres.2006.03.058; Wilhelmus MMM, 2009, NEUROBIOL AGING, V30, P229, DOI 10.1016/j.neurobiolaging.2007.06.001; Wilhelmus MMM, 2006, ACTA NEUROPATHOL, V111, P139, DOI 10.1007/s00401-005-0030-z; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Zhong BW, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/606934	37	11	11	0	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	NOV	2018	55	11					8602	8611		10.1007/s12035-018-1011-2			10	Neurosciences	Neurosciences & Neurology	GU7ID	WOS:000445493600029	29574629				2021-06-18	
J	Furay, E; Daley, M; Teixeira, PG; Coopwood, TB; Aydelotte, JD; Malesa, N; Tellinghuisen, C; Ali, S; Brown, LH; Brown, CVR				Furay, Elisa; Daley, Mitch; Teixeira, Pedro G.; Coopwood, Thomas B.; Aydelotte, Jayson D.; Malesa, Natalia; Tellinghuisen, Christian; Ali, Sadia; Brown, Lawrence H.; Brown, Carlos V. R.			Goal-directed platelet transfusions correct platelet dysfunction and may improve survival in patients with severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	48th Annual Meeting of the Western-Trauma-Association (WTA)	FEB 15-MAR 03, 2018	Whistler, CANADA	Western Trauma Assoc		Platelet dysfunction; TBI; TEG; Platelet transfusion	INTRACRANIAL HEMORRHAGE; ADENOSINE-DIPHOSPHATE; ANTIPLATELET THERAPY; COAGULOPATHY; COAGULATION; PROGRESSION; INHIBITION; RISK	BACKGROUND Platelet dysfunction, defined as adenosine diphosphate inhibition greater than 60% on thromboelastogram, is an independent predictor of increased mortality in patients with severe traumatic brain injury (TBI). We changed our practice to transfuse platelets for all patients with severe TBI and platelet dysfunction. We hypothesized that platelet transfusions would correct platelet dysfunction and improve mortality in patients with severe TBI. METHODS This retrospective review included adult trauma patients admitted to our Level I trauma center from July 2015 to October 2016 with severe TBI (head Abbreviated Injury Scale score 3) who presented with platelet dysfunction and subsequently received a platelet transfusion. Serial thromboelastograms were obtained to characterize the impact of platelet transfusion on clot strength. Subsequently, the platelet transfusion group was compared to a group of historical controls with severe TBI patients and platelet dysfunction who did not receive platelet transfusion. RESULTS A total of 35 patients with severe TBI presented with platelet dysfunction. Following platelet transfusion clot strength improved as represented by decreased K time, increased angle, maximum amplitude, and G-value, as well as correction of adenosine diphosphate inhibition. When comparing to 51 historic controls with severe TBI and platelet dysfunction, the 35 study patients who received a platelet transfusion had a lower mortality (9% vs. 35%; p = 0.005). In stepwise logistic regression, platelet transfusion was independently associated with decreased mortality (odds ratio, 0.23; 95% confidence interval, 0.06-0.92; p = 0.038). CONCLUSION In patients with severe TBI and platelet dysfunction, platelet transfusions correct platelet inhibition and may be associated with decreased mortality. LEVEL OF EVIDENCE Therapeutic, level II.	[Furay, Elisa; Daley, Mitch; Teixeira, Pedro G.; Coopwood, Thomas B.; Aydelotte, Jayson D.; Malesa, Natalia; Tellinghuisen, Christian; Ali, Sadia; Brown, Lawrence H.; Brown, Carlos V. R.] Dell Med Sch, Dept Surg & Perioperat Care, Austin, TX USA	Furay, E (corresponding author), Univ Texas Attn, Dell Seton Med Ctr, Gen Surg, 1500 Red River St, Austin, TX 78701 USA.	Efuray@ascension.org		Brown, Lawrence/0000-0002-5940-1840			Alexiou GA, 2014, BRAIN INJURY, V28, P438, DOI 10.3109/02699052.2014.888769; Briggs A, 2015, J SURG RES, V193, P802, DOI 10.1016/j.jss.2014.08.016; Carroll RC, 2009, TRANSL RES, V154, P34, DOI 10.1016/j.trsl.2009.04.001; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; Daley MJ, 2017, EUR J TRAUMA EMERG S, V43, P105, DOI 10.1007/s00068-016-0643-z; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Einersen PM, 2017, J TRAUMA ACUTE CARE, V82, P114, DOI 10.1097/TA.0000000000001270; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Faul M, 2002, NATL CTR INJURY PREV, P2002; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P121, DOI 10.1097/TA.0b013e3182a9cc95; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Leong LB, 2015, J EMERG MED, V49, P561, DOI 10.1016/j.jemermed.2015.02.023; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Sangkuhl K, 2011, PHARMACOGENET GENOM, V21, P516, DOI 10.1097/FPC.0b013e3283406323; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Sirajuddin S, 2016, J TRAUMA ACUTE CARE, V81, P328, DOI 10.1097/TA.0000000000001057; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; WikkelsO A, 2016, COCHRANE DB SYST REV, V22; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	33	11	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2018	85	5					881	887		10.1097/TA.0000000000002047			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GZ0NG	WOS:000449060100008	30124626				2021-06-18	
J	O'Rourke, A; Power, E; O'Halloran, R; Rietdijk, R				O'Rourke, Angela; Power, Emma; O'Halloran, Robyn; Rietdijk, Rachael			Common and distinct components of communication partner training programmes in stroke, traumatic brain injury and dementia	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						neuropathology; health communication; speech-language pathology; in-service training; communication partner training (CPT)	CONVERSATION THERAPY; APHASIA; PEOPLE; CARE; FACILITATORS; STRATEGIES; WORKING; SPEECH; ADULTS; TALK	Background: Communication partner training (CPT) programmes for health and care staff working with people with the neurologically based communication disorders associated with stroke, traumatic brain injury (TBI) and dementia are efficacious in improving communication. However, current programmes are lengthy and disorder specific, and therefore may not be suitable as staff training tools in environments with people with multiple communication disorders, and services with a variety of neurological populations. Aims: To identify common and distinct components of CPT programmes for stroke, TBI and dementia in order to determine whether there are common delivery methods and content that can be consolidated to improve implementation of CPT in health and care services. Methods & Procedures: A qualitative enquiry was used. Four CPT programmes targeting three disorders were identified from systematic reviews and literature searches. Programme data were recorded onto data sheets from manuals, study articles and supplementary materials, and were categorized using the Intervention Taxonomy (ITAX). Content analysis and elements of constant comparative analysis were employed to analyse the CPT programmes. Outcomes & Results: Delivery characteristics were similar across all four programmes. All were delivered face to face in either group or individual contexts. However, duration varied from 1 to 35 h. Six of the 12 categories of information provided were common across all programmes, including 'strategy' 'background to disorder', 'information about communication', 'information about program', 'negative behaviours to avoid' and 'purpose of program'. Programmes differed in the types of skill-building techniques used, with the most common being videos (3/4 programmes), discussions (2/4 programmes) and trainer demonstrations (2/4 programmes). While strategies provided to trained partners targeted similar domains of communication, only 3/96 individual strategies were common to all programmes. Conclusions & Implications: There are both common and distinct components in content and delivery methods across CPT programmes. Further research is needed to evaluate the distinct components of the programmes, to determine which individual strategies are efficacious, and which approach to skill-building techniques is most effective. The present study has contributed a comprehensive list of programme components, which can form a basis for describing and refining CPT programmes in future.	[O'Rourke, Angela; Power, Emma; Rietdijk, Rachael] Univ Sydney, Discipline Speech Pathol, Fac Hlth Sci, Sydney, NSW, Australia; [O'Halloran, Robyn] La Trobe Univ, Sch Allied Hlth, Discipline Speech Pathol, Melbourne, Vic, Australia	O'Rourke, A (corresponding author), Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia.; O'Rourke, A (corresponding author), POB 170, Lidcombe, NSW 1825, Australia.	aoro4068@uni.sydney.edu.au	Rietdijk, Rachael/J-6573-2012; Power, Emma/A-9263-2015	Rietdijk, Rachael/0000-0003-4343-4039; Power, Emma/0000-0002-2638-0406			Allwood R, 2017, SOC SCI MED, V191, P212, DOI 10.1016/j.socscimed.2017.09.014; Baikie E., 2002, SEXUAL RELATIONSHIP, V17, P289, DOI [10.1080/14681990220149095, DOI 10.1080/14681990220149095]; Beckley F, 2017, INT J LANG COMM DIS, V52, P197, DOI 10.1111/1460-6984.12265; Behn N, 2015, BRAIN INJURY, V29, P1554, DOI 10.3109/02699052.2015.1077992; Behn N, 2012, BRAIN INJURY, V26, P1702, DOI 10.3109/02699052.2012.722258; Broughton M, 2011, INT J NURS STUD, V48, P1436, DOI 10.1016/j.ijnurstu.2011.05.007; Burgio LD, 2001, GERONTOLOGIST, V41, P449, DOI 10.1093/geront/41.4.449; Chang HF, 2018, INT J LANG COMM DIS, V53, P1094, DOI 10.1111/1460-6984.12421; Conway ER, 2016, J CLIN NURS, V25, P1145, DOI 10.1111/jocn.13134; Crotty M., 1998, FDN SOCIAL RES MEANI; Czaja SJ, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0433-3; Eggenberger E, 2013, INT PSYCHOGERIATR, V25, P345, DOI 10.1017/S1041610212001664; Giles H., 1991, CONTEXTS ACCOMMODATI, P1, DOI DOI 10.1017/CBO9780511663673.001; GLASER BG, 1965, SOC PROBL, V12, P436, DOI 10.1525/sp.1965.12.4.03a00070; Hadely KA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-110; Hemsley B, 2013, APHASIOLOGY, V27, P706, DOI 10.1080/02687038.2012.748181; Hersh D, 2016, APHASIOLOGY, V30, P609, DOI 10.1080/02687038.2014.933520; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1055/s-0041-111066, 10.1136/bmj.g1687]; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Johansson MB, 2011, DISABIL REHABIL, V33, P51, DOI 10.3109/09638288.2010.486465; Johnson FM, 2017, INT J LANG COMM DIS, V52, P374, DOI 10.1111/1460-6984.12279; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Legg C, 2005, APHASIOLOGY, V19, P559, DOI 10.1080/02687030544000029; Lindsay M., 2016, GLOBAL STROKE GUIDEL; Lock S, 2001, INT J LANG COMM DIS, V36, P25, DOI 10.3109/13682820109177853; Lokker C, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0220-6; McDonald S., 2016, COMMUNICATION DISORD; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; O'Halloran R, 2009, INT J SPEECH-LANG PA, V11, P438, DOI 10.3109/17549500902741363; Papathanasiou I., 2016, APHASIA RELATED NEUR; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Pilnick A, 2002, SOCIOL HEALTH ILL, V24, P66, DOI 10.1111/1467-9566.00004; Polgar S., 2014, INTRO RES HLTH SCI, P33; Samuelsson C, 2017, INT J SPEECH-LANG PA, V19, P454, DOI 10.1080/17549507.2016.1221448; Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18; Schulz R, 2010, AM J HEALTH BEHAV, V34, P811; Shehata GA, 2015, J AFFECT DISORDERS, V172, P312, DOI 10.1016/j.jad.2014.10.027; Simmons-Mackie N, 2016, ARCH PHYS MED REHAB, V97, P2202, DOI 10.1016/j.apmr.2016.03.023; Simmons-Mackie N, 2014, INT J LANG COMM DIS, V49, P511, DOI 10.1111/1460-6984.12097; Stanyon MR, 2016, AGE AGEING, V45, P164, DOI 10.1093/ageing/afv161; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L., 2010, TBI EXPRESS SOCIAL C; Togher L, 2014, J HEAD TRAUMA REHAB, V29, P353, DOI 10.1097/HTR.0000000000000071; Vasse E, 2010, INT PSYCHOGERIATR, V22, P189, DOI 10.1017/S1041610209990615; Williams KN, 2009, AM J ALZHEIMERS DIS, V24, P11, DOI 10.1177/1533317508318472; Wiltshire GE, 2014, J SOC INCL, V5, P9, DOI 10.36251/josi.73; World Health Organization (WHO), 2012, INT CAR PEOPL DEM	48	11	11	1	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1368-2822	1460-6984		INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	NOV-DEC	2018	53	6					1150	1168		10.1111/1460-6984.12428			19	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	HC4LK	WOS:000451774800007	30295014				2021-06-18	
J	Shetty, T; Nguyen, JT; Cogsil, T; Tsiouris, AJ; Niogi, SN; Kim, EU; Dalal, A; Halvorsen, K; Cummings, K; Zhang, TH; Masdeu, JC; Mukherjee, P; Marinelli, L				Shetty, Teena; Nguyen, Joseph T.; Cogsil, Taylor; Tsiouris, Apostolos John; Niogi, Sumit N.; Kim, Esther U.; Dalal, Aashka; Halvorsen, Kristin; Cummings, Kelianne; Zhang, Tianhao; Masdeu, Joseph C.; Mukherjee, Pratik; Marinelli, Luca			Clinical Findings in a Multicenter MRI Study of Mild TBI	FRONTIERS IN NEUROLOGY			English	Article						mild traumatic brain injury; age; gender; neuropsychological assessments; concussion; imaging; white matter hyperintensities; risk factors	TRAUMATIC-BRAIN-INJURY; SPORT-RELATED CONCUSSION; WHITE-MATTER HYPERINTENSITIES; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; ADOLESCENT BRAIN; RECOVERY; METAANALYSIS; POPULATION; MATURATION	Background: Uncertainty continues to surround mild traumatic brain injury (mTBI) diagnosis, symptoms, prognosis, and outcome due in part to a lack of objective biomarkers of injury and recovery. As mTBI gains recognition as a serious public health epidemic, there is need to identify risk factors, diagnostic tools, and imaging biomarkers to help guide diagnosis and management. Methods: One hundred and eleven patients (15-50 years old) were enrolled acutely after mTBI and followed with up to four standardized serial assessments over 3 months. Each encounter included a clinical exam, neuropsychological assessment, and magnetic resonance imaging (MRI). Chi-square and linear mixed models were used to assess changes over time and determine potential biomarkers of mTBI severity and outcome. Results: The symptoms most frequently endorsed after mTBI were headache (91%), not feeling right (89%), fatigue (86%), and feeling slowed down (84%). Of the 104 mTBI patients with a processed MRI scan, 28 (27%) subjects had white matter changes which were deemed unrelated to age, and 26 of these findings were deemed unrelated to acute trauma. Of the neuropsychological assessments tested, 5- and 6-Digit Backward Recall, the modified Balance Error Scoring System (BESS), and Immediate 5-Word Recall significantly improved longitudinally in mTBI subjects and differentiated between mTBI subjects and controls. Female sex was found to increase symptom severity scores (SSS) at every time point. Age >= 25 years was correlated with increased SSS. Subjects aged >= 25 also did not improve longitudinally on 5-Digit Backward Recall, Immediate 5-Word Recall, or Single-Leg Stance of the BESS, whereas subjects < 25 years improved significantly. Patients who reported personal history of depression, anxiety, or other psychiatric disorder had higher SSS at each time point. Conclusions: The results of this study show that 5- and 6-Digit Backward Recall, the modified BESS, and Immediate 5-Word Recall should be considered useful in demonstrating cognitive and vestibular improvement during the mTBI recovery process. Clinicians should take female sex, older age, and history of psychiatric disorder into account when managing mTBI patients. Further study is necessary to determine the true prevalence of white matter changes in people with mTBI.	[Shetty, Teena; Cogsil, Taylor; Kim, Esther U.; Halvorsen, Kristin] Hosp Special Surg, Dept Neurol, 535 E 70th St, New York, NY 10021 USA; [Nguyen, Joseph T.] Hosp Special Surg, Biostat Core, 535 E 70th St, New York, NY 10021 USA; [Tsiouris, Apostolos John; Niogi, Sumit N.] Weill Cornell Med, Dept Radiol, New York, NY USA; [Dalal, Aashka] New York Med Coll, Valhalla, NY 10595 USA; [Cummings, Kelianne] GE Global Res Healthcare, Waukesha, WI USA; [Zhang, Tianhao] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Masdeu, Joseph C.] Houston Methodist Hosp, Dept Neurol, Houston, TX USA; [Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Marinelli, Luca] GE Global Res Ctr, Niskayuna, NY USA	Shetty, T (corresponding author), Hosp Special Surg, Dept Neurol, 535 E 70th St, New York, NY 10021 USA.	shettyt@hss.edu	Marinelli, Luca/AAB-5933-2021	Marinelli, Luca/0000-0001-7775-5952; Cogsil, Taylor/0000-0002-5127-7566	General Electric - National Football League Head Health Initiative; HSS Department of Neurology; Houston Methodist Foundation	The funding for this study was provided by the General Electric - National Football League Head Health Initiative.; We would like to thank previous research coordinators and volunteers Dan Zuchelli, Lorena Loci, Megan Parmenter, and Zachary Gulergun, all of whom were integral in enrolling patients and documenting study visits. We would like to thank the entirety of the GE/NFL Medical Advisory Board for their continued direction as well as Dr. Victor Miranda, Ajit Shankaranarayanan, and Amy Gallenberg for their efforts. Within HSS, Tzipora Kuba's research management was necessary for the successful completion of this project. Dr. Hollis Potter and the HSS Radiology Department, specifically Joo Jung and Wendy Diesing, played an instrumental role in the guidance and execution of the imaging portion of this study. Lastly, we would like to thank the HSS Department of Neurology for providing the facility and support necessary for this investigation and specifically Virgen Gonzalez-Alakham for her efforts with enrollment. At Houston Methodist, Drs. Kenneth Podell and Howard Derman referred and studied patients, Jennifer Garrett coordinated the study, and Dr. Armen Kocharian provided MRI support. The Chao, Graham, Harrison and Natz Funds of the Houston Methodist Foundation contributed support.	Arain M, 2013, NEUROPSYCH DIS TREAT, V9, P449, DOI 10.2147/NDT.S39776; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bin Zahid A, 2018, APPL NEUROPSYCH-ADUL, V25, P110, DOI 10.1080/23279095.2016.1248765; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hofmann E, 1992, EUR RADIOL, V2, P154; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lyoo IK, 2002, COMPR PSYCHIAT, V43, P361, DOI 10.1053/comp.2002.34636; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mustafi SM, 2018, J NEUROTRAUM, V35, P2653, DOI 10.1089/neu.2017.5158; National Research Council & Committee on sports- related concussions in youth, 2014, SPORTS RELATED CONCU; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Samson K., 2018, NEUROL TODAY, V18, P12, DOI [10.1097/01.NT.0000532091.01255.0b, DOI 10.1097/01.NT.0000532091.01255.0B]; Silverberg ND, 2014, BRAIN INJURY, V28, P1590, DOI 10.3109/02699052.2014.943287; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Vos PE, 2015, TRAUMATIC BRAIN INJU; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	42	11	11	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	OCT 23	2018	9								836	10.3389/fneur.2018.00836			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GX7ST	WOS:000447977500001	30405511	DOAJ Gold, Green Published			2021-06-18	
J	Madhavan, R; Joel, SE; Mullick, R; Cogsil, T; Niogi, SN; Tsiouris, AJ; Mukherjee, P; Masdeu, JC; Marinelli, L; Shetty, T				Madhavan, Radhika; Joel, Suresh E.; Mullick, Rakesh; Cogsil, Taylor; Niogi, Sumit N.; Tsiouris, A. John; Mukherjee, Pratik; Masdeu, Joseph C.; Marinelli, Luca; Shetty, Teena			Longitudinal Resting State Functional Connectivity Predicts Clinical Outcome in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						connectivity; fractional amplitude of low frequency fluctuations (fALFF); longitudinal; predict; resting state fMRI	TENSOR IMAGING FINDINGS; WHOLE-BRAIN; HIGH-RESOLUTION; HIGH-SCHOOL; CONCUSSION; NETWORKS; FMRI; MRI; ASSOCIATION; INFERENCES	Mild traumatic brain injury (mTBI) affects about 42 million people worldwide. It is often associated with headache, cognitive deficits, and balance difficulties but rarely shows any abnormalities on conventional computed tomography (CT) or magnetic resonance imaging (MRI). Although in most mTBI patients the symptoms resolve within 3 months, 10-15% of patients continue to exhibit symptoms beyond a year. Also, it is known that there exists a vulnerable period post-injury, when a second injury may exacerbate clinical prognosis. Identifying this vulnerable period may be critical for patient outcome, but very little is known about the neural underpinnings of mTBI and its recovery. In this work, we used advanced functional neuroimaging to study longitudinal changes in functional organization of the brain during the 3-month recovery period post-mTBI. Fractional amplitude of low frequency fluctuations (fALFF) measured from resting state functional MRI (rs-fMRI) was found to be associated with symptom severity score (SSS, r=-0.28, p=0.002). Decreased fALFF was observed in specific functional networks for patients with higher SSS, and fALFF returned to higher values when the patient recovered (lower SSS). In addition, functional connectivity of the same networks was found to be associated with concurrent SSS, and connectivity immediately after injury (<10 days) was capable of predicting SSS at a later time-point (3 weeks to 3 months, p<0.05). Specific networks including motor, default-mode, and visual networks were found to be associated with SSS (p<0.001), and connectivity between these networks predicted 3-month clinical outcome (motor and visual: p<0.001, default-mode: p<0.006). Our results suggest that functional connectivity in these networks comprise potential biomarkers for predicting mTBI recovery profiles and clinical outcome.	[Madhavan, Radhika; Joel, Suresh E.; Mullick, Rakesh] GE Global Res, Artificial Intelligence, Bangalore, Karnataka, India; [Mullick, Rakesh; Shetty, Teena] Hosp Special Surg, Dept Neurol, 535 E 70th St, New York, NY 10021 USA; [Niogi, Sumit N.; Tsiouris, A. John] Weill Cornell Med Coll, Dept Radiol, New York, NY USA; [Mukherjee, Pratik] Univ Calif San Francisco, Radiol & Bioengn, San Francisco, CA 94143 USA; [Masdeu, Joseph C.] Houston Methodist Hosp, Stanley H Appel Dept Neurol, Houston, TX USA; [Marinelli, Luca] GE Global Res, Biol & Phys, Niskayuna, NY USA	Madhavan, R; Joel, SE (corresponding author), GE Global Res, Plot 122,Export Promot Ind Pk,Phase 2, Bengaluru 560066, Karnataka, India.	radhika.madhavan@ge.com; suresh.joel@ge.com	Marinelli, Luca/AAB-5933-2021	Madhavan, Radhika/0000-0002-9833-437X; Cogsil, Taylor/0000-0002-5127-7566	GE/NFL Head Health Initiative (HHI)	We thank the General Electric Company (GE)/National Football League (NFL) Medical Advisory Board for their comments and advice. At GE, we thank Dr. Victor Miranda and Amy Gallenberg for their role in the execution of the study, and the neuro MRI team, in particular Pauline Worters, Matthew Middione, and Ajit Shankaranarayanan, for MRI pulse sequence design. We would also like to thank the technical and clinical staff at Hospital for Special Surgery, Houston Methodist Hospital, and University of California, San Francisco (specifically Nicholas Pojman, Nhu Nhu Nguyen, and Chelsea Camara) for their role in patient recruitment and data acquisition. The clinical staff at Hospital for Special Surgery included Kelianne Cummings, Lorena Loci, Dan Zuchelli, Megan Parmenter, and Kristin Halvorsen, all of whom were integral in recruiting patients and collecting data. Finally, we thank the GE/NFL Head Health Initiative (HHI) for sponsoring and funding the study.	Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Birn RM, 2012, NEUROIMAGE, V62, P864, DOI 10.1016/j.neuroimage.2012.01.016; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Carney N, 2014, NEUROSURGERY, V75, pS1, DOI 10.1227/NEU.0000000000000434; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Chachra P., 2017, ANN M ORG HUM BRAIN; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Dall'Acqua P, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00280; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jaiswal MK, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00148; Joel SE, 2011, MAGN RESON MED, V66, P644, DOI 10.1002/mrm.22818; Katz D.I., 2015, HDB CLIN NEUROLOGY, P131; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Madhavan R., 2016, 5 BIENN C REST STAT; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McInnes K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174847; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Preibisch C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136961; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Rashid B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00897; Ravishankar H, 2016, IEEE ENG MED BIO, P4071, DOI 10.1109/EMBC.2016.7591621; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Theadom A, 2014, J SCI MED SPORT, V17, P591, DOI 10.1016/j.jsams.2014.02.001; Todd N, 2016, NEUROIMAGE, V124, P32, DOI 10.1016/j.neuroimage.2015.08.056; Wang K, 2007, HUM BRAIN MAPP, V28, P967, DOI 10.1002/hbm.20324; Weissenbacher A, 2009, NEUROIMAGE, V47, P1408, DOI 10.1016/j.neuroimage.2009.05.005; Whitfield-Gabrieli S, 2009, P NATL ACAD SCI USA, V106, P1279, DOI 10.1073/pnas.0809141106; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhan J, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00027; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zou QH, 2008, J NEUROSCI METH, V172, P137, DOI 10.1016/j.jneumeth.2008.04.012	61	11	11	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2019	36	5					650	660		10.1089/neu.2018.5739		OCT 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR2BG	WOS:000446276100001	30024343				2021-06-18	
J	Cipriano, A; Pecori, A; Bionda, AE; Bardini, M; Frassi, F; Leoli, F; Lami, V; Ghiadoni, L; Santini, M				Cipriano, Alessandro; Pecori, Alessio; Bionda, Alessandra Eugenia; Bardini, Michele; Frassi, Francesca; Leoli, Francesco; Lami, Valentina; Ghiadoni, Lorenzo; Santini, Massimo			Intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: significant differences between direct oral anticoagulants and vitamin K antagonists	INTERNAL AND EMERGENCY MEDICINE			English	Article; Proceedings Paper	National Meeting of the Italian-Society-of-Emergency-Medicine	NOV 19, 2016	Napoli, ITALY	Italian Soc Emergency Med		Mild traumatic brain injury; Anticoagulation; Direct oral anticoagulants; Intracranialhemorrhage	MINOR HEAD-INJURY; PREINJURY WARFARIN USE; ATRIAL-FIBRILLATION; TASK-FORCE; METAANALYSIS; RISK; DABIGATRAN; OUTCOMES; MORTALITY; EFFICACY	Prognosis after mild traumatic brain injury (MTBI) on oral anticoagulant therapy (OAT) is uncertain. We evaluated the rate of immediate and delayed traumatic intracranial hemorrhage (ICH) comparing vitamin K antagonists (VKAs) to direct oral anticoagulants (DOACs) and the safety of a clinical management protocol. In this single-center prospective observational study, we enrolled 220 patients on OAT with MTBI. After a first negative CT scan, asymptomatic patients underwent a close neurological observation; if neurologically stable, they were discharged without a second CT scan and followed up for 1month. Out of the 220 patients, 206 met the inclusion criteria. 23 of them (11.2%) had a positive first CT scan for ICH. Only 1 (0.5%, 95% CI 0.0-1.4%) died because of ICH; no one required neurosurgical intervention. The observed prevalence rate of immediate ICH resulted statistically higher in VKAs-treated patients compared to those treated with DOACs (15.7 vs. 4.7%, RR 3.34, 95% CI 1.18-9.46, P<0.05). In the 1-month follow-up, 5 out of the 183 patients with a negative CT scan were lost. Out of the remaining 178 patients, only 3 showed a delayed ICH (1.7%, 95% CI 0.0-3.6%), 1of them died (0.6%, 95% CI 0.5-1.7%) and the others did not require neurosurgical intervention. DOACs resulted safer than VKAs also in the setting of MTBI. In our observation, the rate of delayed hemorrhage was relatively low. Patients presenting with a negative first CT scan and without neurological deterioration could be safely discharged after a short period of in-ward observation with a low rate of complications and without a second CT scan.	[Cipriano, Alessandro; Pecori, Alessio; Bionda, Alessandra Eugenia; Bardini, Michele; Frassi, Francesca; Leoli, Francesco; Lami, Valentina; Santini, Massimo] Azienda Osped Univ Pisana, UO Med Urgenza & Pronto Soccorso, Emergency Dept, Nuovo Santa Chiara Hosp, Pisa, Italy; [Ghiadoni, Lorenzo] Azienda Osped Univ Pisana, UO Med Urgenza Univ, Nuovo Santa Chiara Hosp, Emergency Dept, Pisa, Italy	Cipriano, A (corresponding author), Azienda Osped Univ Pisana, UO Med Urgenza & Pronto Soccorso, Emergency Dept, Nuovo Santa Chiara Hosp, Pisa, Italy.	a.cipriano@ao-pisa.toscana.it; a.pecori91@hotmail.it; a.e.bionda@gmail.com; michelebardini@tin.it; frassifrancesca@gmail.com; burgundioleoli@gmail.com; valentina.lami@gmail.com; lorenzo.ghiadoni@med.unipi.it; ma.santini@ao-pisa.toscana.it	Cipriano, Alessandro/ABG-8127-2020	Cipriano, Alessandro/0000-0001-7085-3621			Akhter M, 2018, INTERN EMERG MED, V13, P557, DOI 10.1007/s11739-017-1680-2; Alrajhi KN, 2015, J EMERG MED, V48, P137, DOI 10.1016/j.jemermed.2014.08.016; American College Of Surgeons' Committee on Trauma, 2013, ADV TRAUM LIF SUPP S, P2; [Anonymous], 2007, TRATTAMENTO TRAUMA C; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Chai-Adisaksopha C, 2015, J THROMB HAEMOST, V13, P2012, DOI 10.1111/jth.13139; Chauny JM, 2016, J EMERG MED, V51, P519, DOI 10.1016/j.jemermed.2016.05.045; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cohn B, 2014, J EMERG MED, V46, P410, DOI 10.1016/j.jemermed.2013.08.107; Collins CE, 2014, AM J SURG, V208, P544, DOI 10.1016/j.amjsurg.2014.05.019; Dentali F, 2017, INTERN EMERG MED, V12, P1087, DOI 10.1007/s11739-017-1725-6; Dentali F, 2012, CIRCULATION, V126, P2381, DOI 10.1161/CIRCULATIONAHA.112.115410; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Leiblich A, 2011, EMERG MED J, V28, P115, DOI 10.1136/emj.2009.079442; Li J, 2012, ANN EMERG MED, V59, P457, DOI 10.1016/j.annemergmed.2012.01.010; Lim BL, 2016, AM J EMERG MED, V34, P75, DOI 10.1016/j.ajem.2015.09.009; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance, 2014, HEAD INJ TRIAG ASS I; Nishijima DK, 2013, AM J EMERG MED, V31, P1244, DOI 10.1016/j.ajem.2013.04.035; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Prisco D, 2017, INTERN EMERG MED, V12, P387, DOI 10.1007/s11739-017-1628-6; Qaseem A, 2012, ANN INTERN MED, V156, P147, DOI 10.7326/0003-4819-156-2-201201170-00011; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Riccardi A, 2017, AM J EMERG MED, V35, P1317, DOI 10.1016/j.ajem.2017.03.072; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Schaefer JH, 2014, J CEREBR BLOOD F MET, V34, P870, DOI 10.1038/jcbfm.2014.31; Schulman S, 2010, J THROMB HAEMOST, V8, P202, DOI 10.1111/j.1538-7836.2009.03678.x; Tibshirani R, 2012, J R STAT SOC B, V74, P245, DOI 10.1111/j.1467-9868.2011.01004.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson D, 2017, NEUROLOGY, V88, P1693, DOI 10.1212/WNL.0000000000003886	36	11	11	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1828-0447	1970-9366		INTERN EMERG MED	Intern. Emerg. Med.	OCT	2018	13	7					1077	1087		10.1007/s11739-018-1806-1			11	Medicine, General & Internal	General & Internal Medicine	GX7PZ	WOS:000447967800015	29520701				2021-06-18	
J	Davidow, D; Quarrie, K; Viljoen, W; Burger, N; Readhead, C; Lambert, M; Jones, B; Hendricks, S				Davidow, Demi; Quarrie, Ken; Viljoen, Wayne; Burger, Nicholas; Readhead, Clint; Lambert, Mike; Jones, Ben; Hendricks, Sharief			Tackle technique of rugby union players during head impact tackles compared to injury free tackles	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Injury prevention; Head impact; Team sports; Training; Measurement	VIDEO ANALYSIS; PREVENTION; CONCUSSIONS; STRATEGIES; CONTACT; EVENTS; LEAGUE	Objectives: The majority of head injuries in rugby union occur during tackles in which the head receives an impact. Head impacted tackles may be a result of poor tackle technique. Therefore, the purpose of this study was to analyse ball-carrier and tackler technique proficiency in head impacted tackles and compare the technique proficiency to successfully completed tackles in real-match situations. Design: Retrospective video analysis. Methods: Video footage of head impacts with the 'head impacted player' (n = 157) and the opposing player 'impacting player' (n = 156) were scored for contact technique using a list of technical criteria and compared to contact technique scores of role and tackle-type matched injury-free, successful tackles (n = 170). Results: Ball-carriers contacting their head during front-on head impacted tackles (mean 6.4, 95% CI 5.6-7.1 AU, out of a total score of 14) scored significantly less than the 'impacting player' (mean 8.1, 95%CI 7.1-9.1 AU, p < 0.01, ES = 0.5, small) and successful ball-carriers (successful ball-carrier mean 9.4, 95% CI 8.9-9.9 AU, p <0.0001, ES = 1.1, moderate). Tackler contact proficiency scores during successful front-on tackles (mean 12.3, 95%CI 11.6-12.9 AU, out of a total score of 16) were significantly greater than tackler contact proficiency scores for the 'head impacted player' (mean 9.8, 95%CI 8.6-10.9, p < 0.001, ES = 0.8, moderate) and 'impacting player' (mean 9.3, 95%CI 8.4-10.1, p <0.0001, ES = 1.0, moderate). Conclusions: Both the ball-carrier and tackler have a technical deficiency when there is a head impact in matches. The implication of this finding is that players and coaches need to acknowledge that both the ball-carrier and tackler are responsible for each other's safety during the tackle. (C) 2018 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Davidow, Demi; Viljoen, Wayne; Burger, Nicholas; Readhead, Clint; Lambert, Mike; Hendricks, Sharief] Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, Rondebosch, South Africa; [Quarrie, Ken] New Zealand Rugby, Wellington, New Zealand; [Viljoen, Wayne; Readhead, Clint] South African Rugby Union, Cape Town, South Africa; [Lambert, Mike] Vrije Univ Amsterdam, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Lambert, Mike] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Jones, Ben; Hendricks, Sharief] Leeds Beckett Univ, Inst Sport Phys Act & Leisure, Leeds, W Yorkshire, England; [Jones, Ben] Yorkshire Carnegie Rugby Union Football Club, Leeds, W Yorkshire, England; [Jones, Ben] Rugby Football League, Leeds, W Yorkshire, England	Hendricks, S (corresponding author), Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, Rondebosch, South Africa.; Hendricks, S (corresponding author), Leeds Beckett Univ, Inst Sport Phys Act & Leisure, Leeds, W Yorkshire, England.	sharief.hendricks@uct.ac.za	Hendricks, Sharief/U-3278-2019	Hendricks, Sharief/0000-0002-3416-6266; Jones, Ben/0000-0002-4274-6236; Quarrie, Ken/0000-0003-1703-8489; Viljoen, Wayne/0000-0002-9432-6153			Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Burger N, 2017, AM J SPORT MED, V45, P278, DOI 10.1177/0363546516677548; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Hendricks S., 2016, BMJ OPEN SPORT EXERC, V2, DOI [10.1136/bmjsem-2015-000053, DOI 10.1136/BMJSEM-2015-000053]; Hendricks S, 2017, J SPORTS SCI, P1, DOI 10.1080/02640414.2017.1322216; Hendricks S, 2017, BRIT J SPORT MED, V51, P829, DOI 10.1136/bjsports-2016-096347; Hendricks S, 2015, INT J SPORTS SCI COA, V10, P949, DOI 10.1260/1747-9541.10.5.949; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2012, J SPORT SCI, V30, P1215, DOI 10.1080/02640414.2012.707328; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Mc Fie S, 2016, CLIN J SPORT MED, V26, P398, DOI 10.1097/JSM.0000000000000276; McCrory P, 2016, BRIT J SPORT MED, V2017, P838, DOI DOI 10.1136/BJSP0RTS-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Patricios J, 2014, CURR SPORT MED REP, V13, P142, DOI 10.1249/JSR.0000000000000049; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Roberts SP, 2017, AM J SPORT MED, V45, P480, DOI 10.1177/0363546516668296; Sewry N, 2015, INT J SPORTS SCI COA, V10, P1115, DOI 10.1260/1747-9541.10.6.1115; Tierney GJ, 2018, INT J SPORTS SCI COA, V13, P16, DOI 10.1177/1747954117711866; Tierney GJ, 2018, MED SCI SPORT EXER, V50, P603, DOI 10.1249/MSS.0000000000001461; Tierney GJ, 2018, J SCI MED SPORT, V21, P221, DOI 10.1016/j.jsams.2017.06.023; Tierney GJ, 2016, BRAIN INJURY, V30, P1350, DOI 10.1080/02699052.2016.1193630; Tucker R, 2017, BRIT J SPORT MED, V51, P1152, DOI 10.1136/bjsports-2017-097895; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Williams S, 2016, SCAND J MED SCI SPOR, V26, P101, DOI 10.1111/sms.12402; World Rugby, 2016, YEAR IN REV, P44	30	11	11	0	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	OCT	2018	21	10					1025	1031		10.1016/j.jsams.2018.04.003			7	Sport Sciences	Sport Sciences	GX9CQ	WOS:000448096500010	29803736				2021-06-18	
J	Hendricks, S; Till, K; Oliver, JL; Johnston, RD; Attwood, M; Brown, J; Drake, D; MacLeod, S; Mellalieu, SD; Treu, P; Jones, B				Hendricks, Sharief; Till, Kevin; Oliver, Jon L.; Johnston, Rich D.; Attwood, Matthew; Brown, James; Drake, David; MacLeod, Simon; Mellalieu, Stephen D.; Treu, Paul; Jones, Ben			Technical Skill Training Framework and Skill Load Measurements for the Rugby Union Tackle	STRENGTH AND CONDITIONING JOURNAL			English	Article						rugby; collision sports; tackle; skill training; skill conditioning; training load; injury prevention; performance	INJURY RISK; LEAGUE; PERFORMANCE; CONCUSSION; STRATEGIES; PARADOX; FATIGUE; ILLNESS; PART	Drawing from skill acquisition and development literature, we present a novel tackle skill training framework. The framework outlines the training purpose (technique proficiency, technique capacity, skill proficiency, and skill capacity), skill workload measurements (available information, task difficulty, rating of perceived challenge, and skill load), as well as the training conditions and coaching style for the tackle in rugby union. Using this framework and skill load measurements, we propose a preseason tackle training plan. this tackle skill framework and skill load measurements serve as potential preventive measures for tackle injury risk while improving players' tackle performance. For a video abstract of this article, see supplemental digital content 1 (see video, http://linksiww.com/scj/a243).	[Hendricks, Sharief; Brown, James] Univ Cape Town, Dept Human Biol, Div Exercise Sci & Sports Med, Cape Town, South Africa; [Hendricks, Sharief; Till, Kevin; Jones, Ben] Leeds Beckett Univ, Inst Sport Phys Act & Leisure, Leeds, W Yorkshire, England; [Till, Kevin; Jones, Ben] Yorkshire Carnegie Rugby Union Football Club, Leeds, W Yorkshire, England; [Oliver, Jon L.; Attwood, Matthew; Mellalieu, Stephen D.] Cardiff Metropolitan Univ, Cardiff Sch Sport & Heath Sci, Cardiff, S Glam, Wales; [Oliver, Jon L.] Auckland Univ Technol, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Johnston, Rich D.] Australian Catholic Univ, Sch Exercise Sci, Brisbane, Qld, Australia; [Johnston, Rich D.] Norths Devils Rugby Football League, Nundah, Qld, Australia; [Attwood, Matthew] Cardiff Metropolitan Univ, Rugby Union Football Club, Cardiff, S Glam, Wales; [Brown, James] Stellenbosch Univ, Inst Sport & Exercise Med, Stellenbosch, South Africa; [Brown, James] IOC, Res Ctr, Cape Town, South Africa; [Drake, David] Kingspan Stadium, Ulster Rugby, Belfast, Antrim, North Ireland; [MacLeod, Simon] Western Prov Rugby & Stormers, Cape Town, South Africa; [Jones, Ben] Rugby Football League, Leeds, W Yorkshire, England; [Till, Kevin; Jones, Ben] Leeds Rhinos Rugby League Club, Leeds, W Yorkshire, England	Hendricks, S (corresponding author), Univ Cape Town, Dept Human Biol, Div Exercise Sci & Sports Med, Cape Town, South Africa.; Hendricks, S (corresponding author), Leeds Beckett Univ, Inst Sport Phys Act & Leisure, Leeds, W Yorkshire, England.	sharief.hendricks01@gmail.com	Brown, James Craig/H-7637-2019; Till, Kevin/AAP-7379-2021; Mellalieu, Stephen/Y-5171-2019; Attwood, Matthew J/N-2057-2019	Brown, James Craig/0000-0002-7778-7783; Attwood, Matthew J/0000-0002-3911-1897; Mellalieu, Stephen/0000-0003-2868-3328; Jones, Ben/0000-0002-4274-6236			Brown JC, 2016, INT J SPORTS SCI COA, V11, P637, DOI 10.1177/1747954116667100; Burger N, 2017, AM J SPORT MED, V45, P278, DOI 10.1177/0363546516677548; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Burger N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005556; Campbell PG, 2018, INT J SPORT PHYSIOL, V13, P496, DOI 10.1123/ijspp.2017-0082; Cross MJ, 2016, INT J SPORT PHYSIOL, V11, P350, DOI 10.1123/ijspp.2015-0187; Davids KW, 2008, DYNAMICS SKILL ACQUI; den Hollander S, 2016, J SPORT SCI MED, V15, P501; Drew MK, 2016, SPORTS MED, V46, P861, DOI 10.1007/s40279-015-0459-8; Duthie G, 2005, J SPORT SCI, V23, P523, DOI 10.1080/02640410410001730188; Farrow D, 2017, SPORTS MED, V47, P1043, DOI 10.1007/s40279-016-0646-2; Finch CF, 2010, BRIT J SPORT MED, V44, P973, DOI 10.1136/bjsm.2008.056069; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Fraas MR, 2016, EUR J SPORT SCI, V16, P1212, DOI 10.1080/17461391.2016.1170207; Gabbett TJ, 2016, BRIT J SPORT MED, V50, P273, DOI 10.1136/bjsports-2015-095788; Gabbett TJ, 2011, J SCI MED SPORT, V14, P210, DOI 10.1016/j.jsams.2011.01.002; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Guadagnoli MA, 2004, J MOTOR BEHAV, V36, P212, DOI 10.3200/JMBR.36.2.212-224; Hendricks S., 2013, South African Journal of Sports Medicine, V25, P8; Hendricks S, 2016, BMJ OPEN SPORT EXERC; Hendricks S, 2017, INT J SPORTS SCI COA, V12, P708, DOI 10.1177/1747954117738880; Hendricks S, 2018, J SPORT SCI, V36, P522, DOI 10.1080/02640414.2017.1322216; Hendricks S, 2017, BRIT J SPORT MED, V51, P829, DOI 10.1136/bjsports-2016-096347; Hendricks S, 2015, INT J SPORTS SCI COA, V10, P949, DOI 10.1260/1747-9541.10.5.949; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hulin BT, 2016, BRIT J SPORT MED, V50, P231, DOI 10.1136/bjsports-2015-094817; Jones CM, 2017, SPORTS MED, V47, P943, DOI 10.1007/s40279-016-0619-5; LEVENTHAL H, 1965, J PERS SOC PSYCHOL, V2, P20, DOI 10.1037/h0022089; Mc Fie S, 2016, CLIN J SPORT MED, V26, P398, DOI 10.1097/JSM.0000000000000276; Patricios J, 2014, CURR SPORT MED REP, V13, P142, DOI 10.1249/JSR.0000000000000049; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Quarrie KL, 2017, BRIT J SPORT MED, V51, P421, DOI 10.1136/bjsports-2016-096191; Quarrie KL, 2013, J SCI MED SPORT, V16, P353, DOI 10.1016/j.jsams.2012.08.005; Read Dale, 2016, BMJ Open Sport Exerc Med, V2, pe000147, DOI 10.1136/bmjsem-2016-000147; Roberts SP, 2008, J SPORT SCI, V26, P825, DOI 10.1080/02640410801942122; Roberts SP, 2015, BRIT J SPORT MED, V49, P536, DOI 10.1136/bjsports-2013-092988; Ross L, 2011, THE PERSON AND THE S; Smart DJ, 2008, BRIT J SPORT MED, V42, P198, DOI 10.1136/bjsm.2007.040162; Soligard T, 2016, BRIT J SPORT MED, V50, P1030, DOI 10.1136/bjsports-2016-096581; Tierney GJ, 2018, INT J SPORTS SCI COA, V13, P16, DOI 10.1177/1747954117711866; Tierney Gregory J, 2018, J Sci Med Sport, V21, P221, DOI 10.1016/j.jsams.2017.06.023; Tucker R, 2017, BRIT J SPORT MED, V51, P1152, DOI 10.1136/bjsports-2017-097895; Tucker R, 2016, BRIT J SPORT MED, V50, P921, DOI 10.1136/bjsports-2016-096322; Wheeler KW, 2010, EUR J SPORT SCI, V10, P237, DOI 10.1080/17461391.2010.482595; Windt J, 2017, BRIT J SPORT MED, V51, P645, DOI 10.1136/bjsports-2016-095973; World Rugby, 2016, YEAR IN REV, P44; Ziv G, 2016, J STRENGTH COND RES, V30, P881, DOI 10.1519/JSC.0000000000001129	50	11	11	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1524-1602	1533-4295		STRENGTH COND J	Strength Cond. J.	OCT	2018	40	5					44	59		10.1519/SSC.0000000000000400			16	Sport Sciences	Sport Sciences	GV6XZ	WOS:000446264700005		Green Accepted			2021-06-18	
J	Lago, N; Pannunzio, B; Amo-Aparicio, J; Lopez-Vales, R; Peluffo, H				Lago, Natalia; Pannunzio, Bruno; Amo-Aparicio, Jesus; Lopez-Vales, Ruben; Peluffo, Hugo			CD200 modulates spinal cord injury neuroinflammation and outcome through CD200R1	BRAIN BEHAVIOR AND IMMUNITY			English	Article						CD200R1 blocking antibody; OX131; Microglia; Neuroinflammation; Immune receptor; Recombinant CD200; Therapeutic window; Neuroprotection; SCI	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; RECEPTOR; MICROGLIA; MICE; REGENERATION; MACROPHAGES; ACTIVATION; EXPRESSION	The interaction between CD200 and its receptor CD200R1 is among the central regulators of microglia and macrophage phenotype. However, it remains to be established whether, in the context of a traumatic CNS injury, CD200R1 act as a negative regulator of these particular innate immune cells, and if the exogenous delivery of CD200 may ameliorate neurological deficits. In the present study, we first evaluated whether preventing the local interaction between the pair CD200-CD200R1, by using a selective blocking antibody against CD200R1, has a role on functional and inflammatory outcome after contusion-induced spinal cord injury (SCI) in mice. The injection of the alpha CD200R1, but not control IgG1, into the lesioned spinal cord immediately after the SCI worsened locomotor performance and exacerbated neuronal loss and demyelination. At the neuroimmunological level, we observed that microglial cells and macrophages showed increased levels of iNOS and Ly6C upon CD200R1 blockade, indicating that the disruption of CD200R1 drove these cells towards a more pro-inflammatory phenotype. Moreover, although CD200R1 blockade had no effect in the initial infiltration of neutrophils into the lesioned spinal cord, it significantly impaired their clearance, which is a key sign of excessive inflammation. Interestingly, intraparenchymal injection of recombinant CD200-His immediately after the injury induced neuroprotection and robust and long-lasting locomotor recovery. In conclusion, this study reveals that interaction of CD200-CD200R1 plays a crucial role in limiting inflammation and lesion progression after SCI, and that boosting the stimulation of this pathway may constitute a new therapeutic approach.	[Lago, Natalia; Pannunzio, Bruno; Peluffo, Hugo] Inst Pasteur Montevideo, Neuroinflammat & Gene Therapy Lab, Mataojo 2020, Montevideo 11400, Uruguay; [Pannunzio, Bruno; Peluffo, Hugo] UDELAR, Dept Histol & Embryol, Fac Med, Montevideo, Uruguay; [Amo-Aparicio, Jesus; Lopez-Vales, Ruben] Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Inst Neurociencies, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Bellaterra 08193, Catalonia, Spain	Lago, N (corresponding author), Inst Pasteur Montevideo, Neuroinflammat & Gene Therapy Lab, Mataojo 2020, Montevideo 11400, Uruguay.	nlago@pasteur.edu.uy	Lopez-Vales, Ruben/E-2150-2011	Lopez-Vales, Ruben/0000-0001-7615-9550; Peluffo, Hugo/0000-0001-6111-8668; Lago, Natalia/0000-0002-5631-8558	Fundacio Marato TV3, Catalunya, Spain [110533]; Comision Sectorial de Investigacion Cientifica (CSIC-UDELAR), Uruguay; PEDECIBA, Uruguay; FOCEM (MERCOSUR Structural Convergence Fund) [COF 03/1111]; Banco de Seguros del Estado (BSE), Uruguay; Spanish Ministry of Economy and Competitiveness [SAF2010-17851, SAF2013-48431-R]; TERCEL	This work has been supported by grants from Fundacio Marato TV3 (110533), Catalunya, Spain; Comision Sectorial de Investigacion Cientifica (CSIC-UDELAR), Uruguay; PEDECIBA, Uruguay; FOCEM (MERCOSUR Structural Convergence Fund), COF 03/1111; and Banco de Seguros del Estado (BSE), Uruguay to NL and HP, and grants from the Spanish Ministry of Economy and Competitiveness (SAF2010-17851; SAF2013-48431-R) and TERCEL to RLV. We thank all members of the transgenic animal unit (UATE) of the Institut Pasteur de Montevideo.	ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Akkaya M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063325; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Borrego F, 2013, BLOOD, V121, P1951, DOI 10.1182/blood-2012-09-435057; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Castranio EL, 2017, NEUROBIOL DIS, V105, P1, DOI 10.1016/j.nbd.2017.05.006; Chen ZQ, 2008, TRANSPLANTATION, V86, P1116, DOI 10.1097/TP.0b013e318186fec2; Cohen M, 2017, J NEUROSCI, V37, P972, DOI 10.1523/JNEUROSCI.2199-16.2016; Coll-Miro M, 2016, P NATL ACAD SCI USA, V113, P1411, DOI 10.1073/pnas.1523212113; Costello DA, 2011, J BIOL CHEM, V286, P34722, DOI 10.1074/jbc.M111.280826; David Samuel, 2012, Handb Clin Neurol, V109, P485, DOI 10.1016/B978-0-444-52137-8.00030-9; Febinger HY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0386-5; Francos Quijorna I, 2017, J NEUROSCI OFFIC J S; Francos-Quijorna I, 2016, GLIA, V64, P2079, DOI 10.1002/glia.23041; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Klopstein A, 2012, J NEUROSCI, V32, P14478, DOI 10.1523/JNEUROSCI.0923-12.2012; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Liu YR, 2010, J NEUROSCI, V30, P2025, DOI 10.1523/JNEUROSCI.4272-09.2010; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyons A, 2007, J NEUROSCI, V27, P8309, DOI 10.1523/JNEUROSCI.1781-07.2007; Lyons A, 2009, BRAIN BEHAV IMMUN, V23, P1020, DOI 10.1016/j.bbi.2009.05.060; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Mott RT, 2004, GLIA, V46, P369, DOI 10.1002/glia.20009; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Painter MM, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0040-9; Peluffo H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0364-y; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Santos-Nogueira E, 2015, J NEUROSCI, V35, P10224, DOI 10.1523/JNEUROSCI.4703-14.2015; Schwab ME, 1996, PHYSIOL REV, V76, P319; Shrivastava K, 2012, J COMP NEUROL, V520, P2657, DOI 10.1002/cne.23062; Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889; Sun FJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0546-2; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Valente T, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00129; Wang YX, 2016, BRAIN RES, V1648, P380, DOI 10.1016/j.brainres.2016.07.045; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034	44	11	12	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2018	73						416	426		10.1016/j.bbi.2018.06.002			11	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	GU6QO	WOS:000445440900042	29870752				2021-06-18	
J	Lee, SH; Choi, BY; Kho, AR; Jeong, JH; Hong, DK; Kang, DH; Kang, BS; Song, HK; Choi, HC; Suh, SW				Lee, Song Hee; Choi, Bo Young; Kho, A. Ra; Jeong, Jeong Hyun; Hong, Dae Ki; Kang, Dong Hyeon; Kang, Beom Seok; Song, Hong Ki; Choi, Hui Chul; Suh, Sang Won			Inhibition of NADPH Oxidase Activation by Apocynin Rescues Seizure-Induced Reduction of Adult Hippocampal Neurogenesis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						epilepsy; pilocarpine; neuron death; NADPH-oxidase inhibitor; oxidative stress; neurogenesis	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; HYPOGLYCEMIC NEURONAL DEATH; DENTATE GYRUS; OXIDATIVE STRESS; STATUS EPILEPTICUS; PILOCARPINE MODEL; SUPEROXIDE; RAT; DAMAGE	Apocynin, also known as acetovanillone, is a natural organic compound structurally related to vanillin. Apocynin is known to be an inhibitor of NADPH (Nicotinamide adenine dinucleotide phosphate) oxidase activity and is highly effective in suppressing the production of superoxide. The neuroprotective effects of apocynin have been investigated in numerous brain injury settings, such as stroke, traumatic brain injury (TBI), and epilepsy. Our lab has demonstrated that TBI or seizure-induced oxidative injury and neuronal death were reduced by apocynin treatment. Several studies have also demonstrated that neuroblast production is transiently increased in the hippocampus after seizures. Here, we provide evidence confirming the hypothesis that long-term treatment with apocynin may enhance newly generated hippocampal neuronal survival by reduction of superoxide production after seizures. A seizure was induced by pilocarpine [(25 mg/kg intraperitoneal (i.p.)] injection. Apocynin was continuously injected for 4 weeks after seizures (once per day) into the intraperitoneal space. We evaluated neuronal nuclear antigen (NeuN), bromodeoxyuridine (BrdU), and doublecortin (DCX) immunostaining to determine whether treatment with apocynin increased neuronal survival and neurogenesis in the hippocampus after seizures. The present study indicates that long-term treatment of apocynin increased the number of NeuN(+) and DCX+ cells in the hippocampus after seizures. Therefore, this study suggests that apocynin treatment increased neuronal survival and neuroblast production by reduction of hippocampal oxidative injury after seizures.	[Lee, Song Hee; Choi, Bo Young; Kho, A. Ra; Jeong, Jeong Hyun; Hong, Dae Ki; Kang, Dong Hyeon; Kang, Beom Seok; Suh, Sang Won] Hallym Univ, Dept Physiol, Coll Med, Chunchon 24252, South Korea; [Song, Hong Ki; Choi, Hui Chul] Hallym Univ, Coll Med, Neurol, Chunchon 24252, South Korea; [Song, Hong Ki; Choi, Hui Chul; Suh, Sang Won] Hallym Inst Epilepsy Res, Chunchon 24252, South Korea	Suh, SW (corresponding author), Hallym Univ, Dept Physiol, Coll Med, Chunchon 24252, South Korea.; Song, HK; Choi, HC (corresponding author), Hallym Univ, Coll Med, Neurol, Chunchon 24252, South Korea.; Song, HK; Choi, HC; Suh, SW (corresponding author), Hallym Inst Epilepsy Res, Chunchon 24252, South Korea.	sshlee@hallym.ac.kr; bychoi@hallym.ac.kr; rnlduadkfk136@hallym.ac.kr; jd1422@hanmail.net; zxnm01220@gmail.com; ehdgus2728@naver.com; ttiger1993@gmail.com; hksong0@hanmail.net; dohchi@naver.com; swsuh@hallym.ac.kr		Hong, Dae-Ki/0000-0003-3769-3456; Choi, Bo Young/0000-0002-9579-3503	National Research Foundation of Korea (NRF)National Research Foundation of Korea [NRF-2017R1D1A1A09081190]; Hallym University Research Fund [HRF-201801-014]	This study was supported by funding from the National Research Foundation of Korea (NRF) (NRF-2017R1D1A1A09081190) to Sang Won Suh. This study was also supported by Hallym University Research Fund (HRF-201801-014).	Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cameron HA, 2015, ANNU REV PSYCHOL, V66, P53, DOI 10.1146/annurev-psych-010814-015006; Cattaneo F, 2014, INT J MOL SCI, V15, P19700, DOI 10.3390/ijms151119700; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi BY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0325-5; Choi BY, 2014, J TRACE ELEM MED BIO, V28, P474, DOI 10.1016/j.jtemb.2014.07.007; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Dingledine R, 2014, ADV EXP MED BIOL, V813, P109, DOI 10.1007/978-94-017-8914-1_9; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Freitas RM, 2005, FEBS J, V272, P1307, DOI 10.1111/j.1742-4658.2004.04537.x; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fujikawa DG, 2000, EPILEPSIA, V41, pS9, DOI 10.1111/j.1528-1157.2000.tb01549.x; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Hakami NY, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00150; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; Hattiangady B, 2008, EPILEPSIA, V49, P26, DOI 10.1111/j.1528-1167.2008.01635.x; Huang TT, 2012, SEMIN CELL DEV BIOL, V23, P738, DOI 10.1016/j.semcdb.2012.04.003; Kim JE, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.331; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048543; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Kralic JE, 2005, EUR J NEUROSCI, V22, P1916, DOI 10.1111/j.1460-9568.2005.04386.x; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Li NJ, 2005, AM J PHYSIOL-RENAL, V289, pF1048, DOI 10.1152/ajprenal.00416.2004; Liu JZ, 2010, SEIZURE-EUR J EPILEP, V19, P165, DOI 10.1016/j.seizure.2010.01.010; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Parent JM, 2002, PROG BRAIN RES, V135, P121; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; Pestana RRF, 2010, NEUROSCI LETT, V484, P187, DOI 10.1016/j.neulet.2010.08.049; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; Rotheneichner P, 2013, EPILEPSIA, V54, P40, DOI 10.1111/epi.12274; Russo R, 2018, NEUROBIOL AGING, V68, P123, DOI 10.1016/j.neurobiolaging.2018.02.025; SEKI T, 1993, J NEUROSCI, V13, P2351; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Simonyi Agnes, 2012, Front Biosci (Elite Ed), V4, P2183; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; van Rijckevorsel K, 2006, SEIZURE-EUR J EPILEP, V15, P227, DOI 10.1016/j.seizure.2006.02.019; Vejrazka M, 2005, BBA-GEN SUBJECTS, V1722, P143, DOI 10.1016/j.bbagen.2004.12.008; Wang J, 2018, FREE RADICAL BIO MED, V123, P62, DOI 10.1016/j.freeradbiomed.2018.05.069; Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x	48	11	12	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	OCT	2018	19	10							3087	10.3390/ijms19103087			15	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	GY9HB	WOS:000448951000242	30304850	DOAJ Gold, Green Published			2021-06-18	
J	Qi, LF; Xue, XH; Sun, JJ; Wu, QJ; Wang, HR; Guo, Y; Sun, BL				Qi, Lifeng; Xue, Xinhong; Sun, Jijun; Wu, Qingjian; Wang, Hongru; Guo, Yan; Sun, Baoliang			The Promising Effects of Transplanted Umbilical Cord Mesenchymal Stem Cells on the Treatment in Traumatic Brain Injury	JOURNAL OF CRANIOFACIAL SURGERY			English	Article						Cell factors; traumatic brain injury; umbilical cord mesenchymal stem cell	NEURAL PROGENITOR CELLS; LONG-TERM SURVIVAL; ANIMAL-MODEL; DELIVERY; CULTURE; STROKE	Many studies have reported the recovery ability of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for neural diseases. In this study, the authors explored the roles of UC-MSCs to treat the traumatic brain injury. Umbilical cord-derived mesenchymal stem cells were isolated from healthy neonatal rat umbilical cord immediately after delivery. The traumatic brain injury (TBI) model was formed by the classical gravity method. The authors detected the behavior changes and measured the levels of inflammatory factors, such as interleukin-1 beta and tumor necrosis factor-alpha by enzyme linked immunosorbent assay (ELISA) at 1, 2, 3, 4 weeks after transplantation between TBI treated and untreated with UC-MSCs. Simultaneously, the expression of glial cell line-derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) were measured by real-time-polymerase chain reaction and ELISA. The authors found that the group of transplantation UC-MSCs has a significant improvement than other group treated by phosphate buffered saline. In the behavioral test, the Neurological Severity Scores of UC-MSCs thorn TBI group were lower than TBI group (P<0.05), but not obviously higher than control group at 2, 3, and 4week, respectively. The inflammatory factors are significantly reduced comparison with TBI group (P<0.05), but both GDNF and BDNF were higher than TBI group (P<0.05). The results indicated that UC-MSCs might play an important role in TBI recovery through inhibiting the release of inflammatory factors and increasing the expression of GDNF and BDNF.	[Qi, Lifeng] Shandong Univ, Sch Med, Dept Neurol, Jinan, Shandong, Peoples R China; [Qi, Lifeng; Xue, Xinhong; Sun, Jijun; Wang, Hongru; Guo, Yan] Liaocheng Peoples Hosp, Dept Neurol, Liaocheng 252000, Peoples R China; [Qi, Lifeng; Xue, Xinhong; Sun, Jijun; Wang, Hongru; Guo, Yan] Taishan Med Univ, Liaocheng Clin Sch, Liaocheng 252000, Peoples R China; [Wu, Qingjian] Jining 1 Peoples Hosp, Dept Emergency, Jining 272011, Shandong, Peoples R China; [Sun, Baoliang] Taishan Med Univ, Affiliated Hosp, Key Lab Cerebral Microcirculat Univ Shandong, Dept Neurol, Tai An, Shandong, Peoples R China	Sun, BL (corresponding author), Liaocheng Peoples Hosp, Dept Neurol, Liaocheng 252000, Peoples R China.; Sun, BL (corresponding author), Taishan Med Univ, Liaocheng Clin Sch, Liaocheng 252000, Peoples R China.; Wu, QJ (corresponding author), Jining 1 Peoples Hosp, Dept Emergency, Jining 272011, Shandong, Peoples R China.	wqw110@163.com; blsun88@163.com	Qi, LI/AAF-3389-2019				Argenta LC, 2012, NEUROSURGERY, V70, P1281, DOI 10.1227/NEU.0b013e3182446760; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; Barilani M, 2015, STEM CELLS DEV, V24, P104, DOI 10.1089/scd.2014.0160; Benito C, 2017, J NEUROSCI, V37, P4255, DOI 10.1523/JNEUROSCI.3481-16.2017; Bieback Karen, 2016, Methods Mol Biol, V1416, P245, DOI 10.1007/978-1-4939-3584-0_14; Boltze J, 2012, CELL TRANSPLANT, V21, P1199, DOI 10.3727/096368911X589609; Bossolasco P, 2005, EXP NEUROL, V193, P312, DOI 10.1016/j.expneurol.2004.12.013; Cai Xin-Zhen, 2015, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V23, P1697, DOI 10.7534/j.issn.1009-2137.2015.06.031; Cerri S, 2015, STEM CELL TRANSL MED, V4, P1073, DOI 10.5966/sctm.2015-0023; Chen XD, 2018, CELL IMMUNOL, V326, P8, DOI 10.1016/j.cellimm.2017.06.006; Danielyan L, 2011, REJUV RES, V14, P3, DOI 10.1089/rej.2010.1130; Fuller GW, 2016, NEUROEPIDEMIOLOGY, V47, P1, DOI 10.1159/000445997; Gu Jian, 2014, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V22, P166, DOI 10.7534/j.issn.1009-2137.2014.01.032; Heo JS, 2013, NEUROSCIENCE, V238, P305, DOI 10.1016/j.neuroscience.2013.02.011; Huang B, 2012, J CONTROL RELEASE, V162, P464, DOI 10.1016/j.jconrel.2012.07.034; Kim DS, 2009, STEM CELLS DEV, V18, P511, DOI 10.1089/scd.2008.0050; Kronig M, 2015, ONCOTARGET, V6, P1302; Li H, 2015, CELL BIOL INT, V39, P84, DOI 10.1002/cbin.10355; McCredie VA, 2016, J TRAUMA ACUTE CARE, V80, P484, DOI 10.1097/TA.0000000000000922; Mortazavi Y, 2016, CELL J, V18; Noh YH, 2011, PEDIATR HEMAT ONCOL, V28, P682, DOI 10.3109/08880018.2011.599477; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Pham PV, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-56; Rafieemehr H, 2015, IRAN J ALLERGY ASTHM, V14, P596; Salehpour F, 2016, WORLD NEUROSURG, V87, P132, DOI 10.1016/j.wneu.2015.11.048; Spielman LJ, 2017, EUR J CELL BIOL, V96, P240, DOI 10.1016/j.ejcb.2017.03.004; Suzuki M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000689; Takano S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5706359; Udupa AN, 2015, PEDIATR ANESTH, V25, P309, DOI 10.1111/pan.12588; Uruma G, 2013, ANN NUCL MED, V27, P187, DOI 10.1007/s12149-012-0674-4; Wei N, 2013, CELL TRANSPLANT, V22, P977, DOI 10.3727/096368912X657251	31	11	11	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1049-2275	1536-3732		J CRANIOFAC SURG	J. Craniofac. Surg.	OCT	2018	29	7					1689	1692		10.1097/SCS.0000000000005042			4	Surgery	Surgery	HD3SX	WOS:000452441400046	30234712	Green Published, Other Gold			2021-06-18	
J	Di Battista, AP; Moes, KA; Shiu, MY; Hutchison, MG; Churchill, N; Thomas, SG; Rhind, SG				Di Battista, Alex P.; Moes, Katherine A.; Shiu, Maria Y.; Hutchison, Michael G.; Churchill, Nathan; Thomas, Scott G.; Rhind, Shawn G.			High-Intensity Interval Training Is Associated With Alterations in Blood Biomarkers Related to Brain Injury	FRONTIERS IN PHYSIOLOGY			English	Article						tau; PRDX-6; S100B; sport concussion; military medicine; MTBI	NEURON-SPECIFIC ENOLASE; MARATHON RUNNERS; OXIDATIVE STRESS; EXERCISE; TROPONIN; BARRIER; PEROXIREDOXIN; CONCUSSION; INCREASES; PLASMA	Purpose: Blood biomarkers are a useful tool to study concussion. However, their interpretation is complicated by a number of potential biological confounds, including exercise. This is particularly relevant in military and athletic settings where injury commonly occurs during physical exertion. The impact of high-intensity interval training (HIIT) on putative brain injury biomarkers remains under-examined. The purpose of this study was to observe the effects of HIIT on a panel of blood biomarkers associated with brain injury. Methods: Eleven healthy, recreationally active males (median age = 29.0, interquartile range = 26.0-31.5) performed HIIT on a bicycle ergometer (8-12 x 60-s intervals at 100% of peak power output, interspersed by 75-s recovery at 50 W) three times/week for 2 weeks. Peripheral blood samples were collected before and immediately after HIIT during the first and last training sessions. Plasma concentrations of s100 calcium-binding protein beta (S100B), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF), neurogranin (NRGN), peroxiredoxin (PRDX)-6, creatine kinase-BB isoenzyme (CKBB), visinin-like protein (VILIP)-1, von Willebrand factor (vWF), monocyte chemoattractant protein (MCP)-1, matrix metalloproteinase (MMP)-9, and total tau (T-tau) were quantitated by high-sensitivity MULTI-SPOT (R) immunoassay, on the MesoScale Diagnostics electrochemiluminescence detection platform. Differences in biomarker concentrations in response to HIIT were evaluated by partial least squares discriminant analysis (PLSDA) within a repeated-measures bootstrapped framework. Results: Ten of 12 biomarkers were increased pre-to-post HIIT; VILIP-1 remained unchanged, and GFAP was not statistically evaluated due to insufficient detectability. After 2 weeks of HIIT, T-tau was no longer significantly elevated pre-to-post HIIT, and significant attenuation was noted in the acute responses of NRGN, PRDX6, MMP-9, and vWF. In addition, compared to session 1, session 6 pre-exercise concentrations of NSE and VILIP-1 were significantly lower and higher, respectively. Conclusion: Blood biomarkers commonly associated with brain injury are significantly elevated in response to a single bout of HIIT. After a 2-week, six-session training protocol, this response was attenuated for some, but not all markers. While biomarkers continue to provide promise to concussion research, future studies are necessary to disentangle the common biological sequelae to both exercise and brain injury.	[Di Battista, Alex P.; Moes, Katherine A.; Shiu, Maria Y.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Di Battista, Alex P.; Hutchison, Michael G.; Thomas, Scott G.; Rhind, Shawn G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Churchill, Nathan] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Neurosci Program, Toronto, ON, Canada	Di Battista, AP (corresponding author), Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada.; Di Battista, AP (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.	dibattista.alex@gmail.com	Thomas, Scott G/G-4522-2012	Thomas, Scott G/0000-0002-5564-4271	Defence Research and Development Canada (DRDC) Technology Investment Fund	This study was funded by a Defence Research and Development Canada (DRDC) Technology Investment Fund.	Stocchero CMA, 2014, APPL PHYSIOL NUTR ME, V39, P340, DOI 10.1139/apnm-2013-0308; Bessa AL, 2016, J STRENGTH COND RES, V30, P311, DOI 10.1519/JSC.0b013e31828f1ee9; Blake TA, 2016, BRAIN INJURY, V30, P132, DOI 10.3109/02699052.2015.1093659; Bloomer RJ, 2008, GENDER MED, V5, P218, DOI 10.1016/j.genm.2008.07.002; Brinkmann C, 2012, EUR J APPL PHYSIOL, V112, P2277, DOI 10.1007/s00421-011-2203-x; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Bruunsgaard H, 2005, J LEUKOCYTE BIOL, V78, P819, DOI 10.1189/jlb.0505247; Buonora JE, 2015, J NEUROTRAUM, V32, P1805, DOI 10.1089/neu.2014.3736; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cook MD, 2013, J HUM HYPERTENS, V27, P388, DOI 10.1038/jhh.2012.48; Debad JD, 2004, MG ELEC CH, P359; Di Battista AP, 2018, BRAIN INJURY, V32, P575, DOI 10.1080/02699052.2018.1432892; Di Battista AP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159929; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; DILL DB, 1974, J APPL PHYSIOL, V37, P247; Dorneles GP, 2016, CYTOKINE, V77, P1, DOI 10.1016/j.cyto.2015.10.003; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Esterov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080100; Febbraio MA, 2007, J APPL PHYSIOL, V103, P376, DOI 10.1152/japplphysiol.00414.2007; Fu Qi, 2013, Handb Clin Neurol, V117, P147, DOI 10.1016/B978-0-444-53491-0.00013-4; Garber BG, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010780; Garber BG, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0325-5; Gibala MJ, 2015, J STRENGTH COND RES, V29, pS40, DOI 10.1519/JSC.0000000000001119; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; He XF, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00144; Hermann TS, 2011, AM J TRANSPLANT, V11, P536, DOI 10.1111/j.1600-6143.2010.03403.x; Inkabi S. E., 2017, SCI J LIFE SCI, V1, P31; Isgro MA, 2015, ADV EXP MED BIOL, V867, P125, DOI 10.1007/978-94-017-7215-0_9; Kaspar F, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5474837; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Kilianski J, 2017, J CLIN NEUROSCI, V45, P100, DOI 10.1016/j.jocn.2017.07.021; Kim HK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137567; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Koh Y, 2017, J EXERC REHABIL, V13, P472, DOI 10.12965/jer.1735066.533; Kyrolainen H, 2018, J SCI MED SPORT, V21, P1131, DOI 10.1016/j.jsams.2017.11.019; Laterza OF, 2006, CLIN CHEM, V52, P1713, DOI 10.1373/clinchem.2006.070912; Leggate M, 2010, CELL STRESS CHAPERON, V15, P827, DOI 10.1007/s12192-010-0192-z; Liang KY, 2010, ANN NEUROL, V68, P311, DOI 10.1002/ana.22096; Lindbloom EJ, 1999, AM HEART J, V138, P798, DOI 10.1016/S0002-8703(99)70199-7; LUBKE U, 1994, AM J PATHOL, V145, P175; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Marquez CMS, 2015, J APPL PHYSIOL, V119, P1363, DOI 10.1152/japplphysiol.00126.2015; Muley T, 2003, CLIN CHEM LAB MED, V41, P95, DOI 10.1515/CCLM.2003.017; Neumann JT, 2016, HEART, V102, P1251, DOI 10.1136/heartjnl-2016-309484; Nielsen AA, 2009, GENE, V442, P55, DOI 10.1016/j.gene.2009.04.003; Nierwinska K, 2008, J HUM KINET, V19, P83; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Pickering JW, 2016, HEART, V102, P1270, DOI 10.1136/heartjnl-2015-308505; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Rakobowchuk M, 2012, EXP PHYSIOL, V97, P375, DOI 10.1113/expphysiol.2011.062836; Reihmane D, 2012, SCAND J IMMUNOL, V76, P188, DOI 10.1111/j.1365-3083.2012.02720.x; Reihmane D, 2013, EUR J APPL PHYSIOL, V113, P851, DOI 10.1007/s00421-012-2491-9; Riuzzi F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12880-9; Roh HT, 2017, INT J SPORT NUTR EXE, V27, P239, DOI 10.1123/ijsnem.2016-0009; Saenz AJ, 2006, AM J CLIN PATHOL, V126, P185, DOI 10.1309/D7QU-F0HJ-MCYY-YY5A; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Shave R, 2010, J AM COLL CARDIOL, V56, P169, DOI 10.1016/j.jacc.2010.03.037; Souza-Silva Ana Angelica, 2016, Temperature (Austin), V3, P167, DOI 10.1080/23328940.2015.1132101; TSUNG SH, 1976, CLIN CHEM, V22, P173; Turner JE, 2013, FREE RADICAL RES, V47, P821, DOI 10.3109/10715762.2013.828836; Vasikaran SD, 2012, CLIN BIOCHEM, V45, P513, DOI 10.1016/j.clinbiochem.2012.01.011; von Holstein-Rathlou S, 2018, NEUROSCI LETT, V662, P253, DOI 10.1016/j.neulet.2017.10.035; Wadley AJ, 2015, FREE RADICAL RES, V49, P290, DOI 10.3109/10715762.2014.1000890; Wahl P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096024; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004; Woods JA, 2009, IMMUNOL ALLERGY CLIN, V29, P381, DOI 10.1016/j.iac.2009.02.011; Zwetsloot KA, 2014, J INFLAMM RES, V7, P9, DOI 10.2147/JIR.S54721	73	11	12	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-042X			FRONT PHYSIOL	Front. Physiol.	SEP 28	2018	9								1367	10.3389/fphys.2018.01367			10	Physiology	Physiology	GV2OS	WOS:000445931100001	30323770	DOAJ Gold, Green Published			2021-06-18	
J	Huie, JR; Diaz-Arrastia, R; Yue, JK; Sorani, MD; Puccio, AM; Okonkwo, DO; Manley, GT; Ferguson, AR				Huie, J. Russell; Diaz-Arrastia, Ramon; Yue, John K.; Sorani, Marco D.; Puccio, Ava M.; Okonkwo, David O.; Manley, Geoffrey T.; Ferguson, Adam R.		TRACK-TBI Investigators	Testing a Multivariate Proteomic Panel for Traumatic Brain Injury Biomarker Discovery: A TRACK-TBI Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; proteomics; TBI	COMMON DATA ELEMENTS; SERUM NEUROFILAMENT LIGHT; C-TERMINAL HYDROLASE-L1; MILD HEAD-INJURY; TRANSFORMING RESEARCH; INTRACRANIAL LESIONS; CLINICAL KNOWLEDGE; IMPACT MODELS; ACUTE-PHASE; S100B	The complex and heterogeneous nature of traumatic brain injury (TBI) has rendered the identification of diagnostic and prognostic biomarkers elusive. A single acute biomarker may not be sufficient to categorize injury severity and/or predict outcome. Using multivariate dimension reduction analyses, we tested the sensitivity and specificity of a multi-analyte panel of proteins as an ensemble biomarker for TBI. Serum was collected within 24h of injury in a cohort of 130 patients enrolled in the multi-center prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study and run on an array that measured 72 proteins. Using unsupervised principal components analysis, we first identified the subset of protein changes accounting for the most variance across patients. This yielded a group of 21 proteins that reflected an inverse relationship between inflammatory cytokines and regulators of anti-inflammation, and generated an individual inflammatory profile score for each patient. We then tested the association between these scores and computed tomography (CT) findings at hospital admission, as well as their prognostic association with functional recovery at 3 and 6 months (Glasgow Outcome Scale-Extended), and cognitive recovery at 6 months (California Verbal Learning Test, Second Edition) after injury. Inflammatory signatures were significantly increased in patients with positive CT findings, as well as in those who showed poor or incomplete recovery. Inflammation biomarker scores also showed significant sensitivity and specificity as a discriminator of these outcome measures (all areas under the curve [AUCs] >0.62). This proof of concept for the feasibility of multivariate biomarker identification demonstrates the prognostic validity of using a proteomic panel as a potential biomarker for TBI.	[Huie, J. Russell; Yue, John K.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA; [Huie, J. Russell; Yue, John K.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Ctr Trauma, San Francisco, CA 94143 USA; [Huie, J. Russell; Yue, John K.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Huie, J. Russell; Yue, John K.; Sorani, Marco D.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Puccio, Ava M.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Okonkwo, David O.; Ferguson, Adam R.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA	Ferguson, AR (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	Adam.ferguson@ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Hemphill, Claude/0000-0003-4019-7525; Ferguson, Adam/0000-0001-7102-1608; Sergot, Paulina/0000-0003-0796-8009	Department of Defense (DoD)United States Department of Defense [W81XWH-13-1-0441]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS069409, NS069409-02S1, NS086090, NS106899, NS088475]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088475, UG3NS106899, U01NS086090] Funding Source: NIH RePORTER	This work was supported by Department of Defense (DoD) grant W81XWH-13-1-0441 (G.T.M.), and NIH/NINDS grants NS069409 (G.T.M.), NS069409-02S1 (G.T.M.), NS086090 (G.T.M.), NS106899 (A.R.F.), and NS088475 (A.R.F.). TRACK-TBI investigators include (in alphabetical order): Opeolu M. Adeoye, MD, University of Cincinnati; Neeraj Badjatia, MD, University of Maryland, Baltimore; Kimberly D. Boase, BA, University of Washington; Yelena Bodien-Guller, PhD, Harvard/Spaulding Rehabilitation Hospital; Malcolm R. Bullock, MD, PhD, University of Miami; Randall M. Chesnut, MD, FCCM, FACS, University of Washington; John D. Corrigan, PhD, Ohio State University; Karen L. Crawford, MILS, University of Southern California; Ramon Diaz-Arrastia, MD, University of Pennsylvania; Sureyya S. Dikmen, PhD, University of Washington; Ann-Christine Duhaime, MD, Harvard/Massachusetts General Hospital; Richard G. Ellenbogen, MD, FACS, University of Washington; Frank Ezekiel, University of California, San Francisco; Venkata R. Feeser, MD, Virginia Commonwealth University; Joseph T. Giacino, PhD, Harvard/Spaulding Rehabilitation Hospital; Dana P. Goldman, PhD, University of Southern California; Luis Gonzales, BA, TIRR Memorial Hermann; Shankar P. Gopinath, MD, Baylor College of Medicine; Rao P. Gullapalli, PhD, MBA, University of Maryland, Baltimore; Jesse C. Hemphill, MD, University of California, San Francisco; Gillian A. Hotz, PhD, University of Miami; Joel H. Kramer, PsyD, University of California, San Francisco; Harvey Levin, PhD, Baylor College of Medicine; Christopher J. Lindsell, PhD, Vanderbilt University; Joan Machamer, MA, University of Washington; Christopher Madden, MD, UT Southwestern; Amy J. Markowitz, JD, University of California, San Francisco; Alastair Martin, PhD, University of California, San Francisco; Bruce E. Mathern, MD, Virginia Commonwealth University; Thomas W. McAllister, MD, Indiana University; Michael A. McCrea, PhD, Medical College of Wisconsin; Randall E. Merchant, PhD, Virginia Commonwealth University; Florence Noel, PhD, Baylor College of Medicine; Daniel P. Perl, MD, Uniformed Services University of the Health Sciences; Ava M. Puccio, RN, PhD, University of Pittsburgh; Miri Rabinowitz, PhD, University of Pittsburgh; Claudia S. Robertson, MD, Baylor College of Medicine; Jonathan Rosand, MD, MSC, Harvard/Massachusetts General Hospital; Angelle M. Sander, PhD, Baylor College of Medicine; Gabriela Satris, MSc, University of California, San Francisco; David M. Schnyer, PhD, University of Texas at Austin; Seth A. Seabury, PhD, University of Southern California; Paulina Sergot, MD, FACEP, Baylor College of Medicine; Mark Sherer, PhD, TIRR Memorial Hermann; Deborah M. Stein, MD, MPH, University of Maryland, Baltimore; Murray B. Stein, MD, MPH, FRCPC, University of California, San Diego; Sabrina R. Taylor, PhD, University of California, San Francisco; Nancy R. Temkin, PhD, University of Washington; Arthur W. Toga, PhD, University of Southern California; L. Christine Turtzo, MD, PhD, Uniformed Services University of the Health Sciences; Paul M. Vespa, MD, University of California, Los Angeles; Kevin K. Wang, PhD, University of Florida; Ross Zafonte, DO, Harvard/ Spaulding Rehabilitation Hospital; Zhiqun Zhang, MD, University of Florida. The authors also give special thanks to Amy J. Markowitz, JD for editorial assistance.	Alali AS, 2015, J NEUROTRAUM, V32, P581, DOI 10.1089/neu.2014.3495; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Barber RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142360; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; CATTELL RB, 1969, J GERONTOL, V24, P348, DOI 10.1093/geronj/24.3.348; Cervellin G, 2012, CLIN BIOCHEM, V45, P408, DOI 10.1016/j.clinbiochem.2012.01.006; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Ferguson AR, 2011, TRANSL STROKE RES, V2, P438, DOI 10.1007/s12975-011-0121-1; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lorente L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094370; Maas AIR, 2008, ACTA NEUROCHIR SUPPL, V101, P119; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nielson JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169490; Nielson JL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9581; O'Bryant SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028092; O'Bryant SE, 2010, ARCH NEUROL-CHICAGO, V67, P1077, DOI 10.1001/archneurol.2010.215; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Reith FCM, 2017, NEUROSURGERY, V80, P829, DOI 10.1093/neuros/nyw178; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Saatman K.E., 2008, CLASSIFICATION TRAUM; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811; Stetler-Stevenson WG, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127re6; Stevens J.P., 2012, APPL MULTIVARIATE ST; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep30168; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	52	11	11	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2019	36	1					100	110		10.1089/neu.2017.5449		SEP 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HF0PB	WOS:000445769900001	30084741	Green Published			2021-06-18	
J	Tao, L; Zhang, L; Gao, R; Jiang, F; Cao, JB; Liu, HX				Tao, Li; Zhang, Li; Gao, Rong; Jiang, Feng; Cao, Jianbo; Liu, Huixiang			Andrographolide Alleviates Acute Brain Injury in a Rat Model of Traumatic Brain Injury: Possible Involvement of Inflammatory Signaling	FRONTIERS IN NEUROSCIENCE			English	Article						andrographolide; inflammation; apoptosis; traumatic brain injury; neuroprotection	NF-KAPPA-B; MICROGLIAL ACTIVATION; FUNCTIONAL RECOVERY; INOS EXPRESSION; NEUROINFLAMMATION; PATHWAY; RESPONSES; DISEASE; NEURON; NEURODEGENERATION	Neuroinflammation plays an important role in secondary injury after traumatic brain injury (TBI). Andrographolide (Andro), a diterpenoid lactone isolated from Andrographis paniculata, has been demonstrated to exhibit anti-inflammatory activity in neurodegenerative disorders. This study therefore aimed to investigate the potential neuroprotective effects of Andra after TBI and explore the underlying mechanisms. In our study, we used a weight-dropped model to induce TBI in Sprague-Dawley rats, the neurological deficits were assessed using modified neurological severity scores, Fluoro-Jade B (FJB) and terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) staining were employed to examine neuronal degeneration and apoptosis after TBI, immunofluorescence was designed to investigate microglial activation. Quantitative Real-time PCR and ELISA were conducted to detect the expression levels of pro-inflammatory cytokines, Western blot was used to examine the expression level of proteins of relative signaling pathway. Our results showed that after Andro administration, the neurological deficit was attenuated, and the cerebral edema and apoptosis in brain tissues were also decreased following TBI. Both microglial activation and the expression of pro-inflammatory cytokines were significantly inhibited by Andro after TBI. Moreover, Andro inhibited NF-kappa B p65 subunit translocation and decreased the expression levels of phosphorylated extracellular signal regulated kinase (ERK) and p38 MAPK after TBI. Altogether, this study suggests that Andro could improve neurobehavioral function by inhibiting NF-kappa B and MAPK signaling pathway in TBI, which might provide a new approach for treating brain injury.	[Tao, Li; Cao, Jianbo] Zhangjiagang First Peoples Hosp, Dept Pharm, Suzhou, Peoples R China; [Tao, Li; Cao, Jianbo] Zhangjiagang First Peoples Hosp, Translat Med Ctr, Suzhou, Peoples R China; [Zhang, Li; Gao, Rong; Jiang, Feng; Liu, Huixiang] Zhangjiagang First Peoples Hosp, Dept Neurosurg, Suzhou, Peoples R China	Cao, JB (corresponding author), Zhangjiagang First Peoples Hosp, Dept Pharm, Suzhou, Peoples R China.; Cao, JB (corresponding author), Zhangjiagang First Peoples Hosp, Translat Med Ctr, Suzhou, Peoples R China.; Liu, HX (corresponding author), Zhangjiagang First Peoples Hosp, Dept Neurosurg, Suzhou, Peoples R China.	Caojianbo65@126.com; liuhuixianglab@sina.com					Batkhuu J, 2002, BIOL PHARM BULL, V25, P1169, DOI 10.1248/bpb.25.1169; Chan SJ, 2010, BRIT J PHARMACOL, V161, P668, DOI 10.1111/j.1476-5381.2010.00906.x; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chern CM, 2011, PLANTA MED, V77, P1669, DOI 10.1055/s-0030-1271019; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Eikelenboom P, 2010, NEURODEGENER DIS, V7, P38, DOI 10.1159/000283480; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gardner AJ, 2016, HAND CLINIC, V138, P207, DOI 10.1016/B978-0-12-802973-2.00012-4; He HF, 2018, DRUG DES DEV THER, V12, P629, DOI 10.2147/DDDT.S158313; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jin Q, 2014, BRAIN BEHAV IMMUN, V40, P131, DOI 10.1016/j.bbi.2014.03.003; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu DY, 2006, BIOCHEM PHARMACOL, V72, P992, DOI 10.1016/j.bcp.2006.06.038; Luo CL, 2013, BRAIN RES, V1502, P1, DOI 10.1016/j.brainres.2013.01.037; Lutton EM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03309-4; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Shen YC, 2002, BRIT J PHARMACOL, V135, P399, DOI 10.1038/sj.bjp.0704493; Skaper SD, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00072; Skaper SD, 2017, NEUROSCIENTIST, V23, P478, DOI 10.1177/1073858416687249; Tao L, 2018, BRAIN RES BULL, V140, P154, DOI 10.1016/j.brainresbull.2018.04.008; Tao L, 2014, J PHARMACOL SCI, V125, P364, DOI 10.1254/jphs.14025FP; Ullah N, 2011, NEUROPHARMACOLOGY, V61, P1248, DOI 10.1016/j.neuropharm.2011.06.031; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Wang YJ, 2007, CELL RES, V17, P933, DOI 10.1038/cr.2007.89; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Zhang HJ, 2018, INT J MOL MED, V42, P279, DOI 10.3892/ijmm.2018.3600; Zhao YY, 2017, NEUROCHEM INT, V111, P82, DOI 10.1016/j.neuint.2017.03.017; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	37	11	12	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	SEP 20	2018	12								657	10.3389/fnins.2018.00657			9	Neurosciences	Neurosciences & Neurology	GU2QZ	WOS:000445116300001	30294256	DOAJ Gold, Green Published			2021-06-18	
J	Prabhakara, KS; Kota, DJ; Jones, GH; Srivastava, AK; Cox, CS; Olson, SD				Prabhakara, Karthik S.; Kota, Daniel J.; Jones, Gregory H.; Srivastava, Amit K.; Cox, Charles S., Jr.; Olson, Scott D.			Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury	MOLECULAR THERAPY			English	Article							CONTROLLED CORTICAL IMPACT; DE-NOVO SYNTHESIS; AGOUTI RAT MODEL; RHEUMATOID-ARTHRITIS; T-LYMPHOCYTES; IMMUNOMODULATORY DRUG; CLINICAL-TRIAL; DENTATE GYRUS; DOUBLE-BLIND; LEFLUNOMIDE	Despite intensive research and clinical trials with numerous therapeutic treatments, traumatic brain injury (TBI) is a serious public health problem in the United States. There is no effective FDA-approved treatment to reduce morbidity and mortality associated with TBI. Inflammation plays a pivotal role in the pathogenesis of TBI. We looked to re-purpose existing drugs that reduce immune activation without broad immunosuppression. Teriflunomide, an FDA-approved drug, has been shown to modulate immunological responses outside of its ability to inhibit pyrimidine synthesis in rapidly proliferating cells. In this study, we tested the efficacy of teriflunomide to treat two different injury intensities in rat models of TBI. Our results show that teriflunomide restores blood-brain barrier integrity, decreases inflammation, and increases neurogenesis in the subgranular zone of the hippocampus. While we were unable to detect neurocognitive effects of treatment on memory and special learning abilities after treatment, a 2-week treatment following injury was sufficient to reduce neuroinflammation up to 120 days later.	[Prabhakara, Karthik S.; Jones, Gregory H.; Srivastava, Amit K.; Cox, Charles S., Jr.; Olson, Scott D.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat Surg, Program Childrens Regenerat Med, Houston, TX 77030 USA; [Kota, Daniel J.] Emory Univ, Sch Med, Emory Personalized Immunotherapy Core Labs, Atlanta, GA 30322 USA	Olson, SD (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St MSE R162, Houston, TX 77030 USA.	scott.d.olson@uth.tmc.edu		Olson, Scott/0000-0001-8032-3755; Srivastava, Amit/0000-0001-7554-7201	Genzyme SanofiSanofi-AventisGenzyme Corporation [GZ-2013-11010]	The authors would like to thank Genzyme Sanofi for providing teriflunomide and supporting this study through the Independent Investigatory Study award GZ-2013-11010.	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Albrecht DS, 2016, ACS CHEM NEUROSCI, V7, P470, DOI 10.1021/acschemneuro.6b00056; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Ambrosius B, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0829-2; BARTLETT RR, 1991, AGENTS ACTIONS, V32, P10, DOI 10.1007/BF01983301; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Burger D, 2003, RHEUMATOLOGY, V42, P89, DOI 10.1093/rheumatology/keg038; Cao WW, 1996, TRANSPL P, V28, P3079; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Clausen F, 2019, J NEUROTRAUM, V36, P201, DOI 10.1089/neu.2018.5636; Claussen MC, 2012, CLIN IMMUNOL, V142, P49, DOI 10.1016/j.clim.2011.02.011; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cutolo M, 2003, ANN RHEUM DIS, V62, P297, DOI 10.1136/ard.62.4.297; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Deage V, 1998, EUR CYTOKINE NETW, V9, P663; DeWitt DS, 2018, J NEUROTRAUM, V35, P2737, DOI 10.1089/neu.2018.5778; Dimitrova P, 2002, J IMMUNOL, V169, P3392, DOI 10.4049/jimmunol.169.6.3392; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; Fox RI, 1999, CLIN IMMUNOL, V93, P198, DOI 10.1006/clim.1999.4777; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Furman NET, 2018, CYTOM PART A, V93A, P182, DOI 10.1002/cyto.a.23267; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Groh J, 2017, MOL THER, V25, P1889, DOI 10.1016/j.ymthe.2017.04.021; Haghikia A, 2014, NAT REV NEUROL, V10, P183, DOI 10.1038/nrneurol.2014.42; He D, 2016, COCHRANE DATABASE SY, V3; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Herrmann ML, 2000, IMMUNOPHARMACOLOGY, V47, P273, DOI 10.1016/S0162-3109(00)00191-0; Iglesias-Bregna D, 2013, J PHARMACOL EXP THER, V347, P203, DOI 10.1124/jpet.113.205146; Jin YC, 2017, WORLD NEUROSURG, V100, P351, DOI 10.1016/j.wneu.2017.01.033; Korn T, 2004, J LEUKOCYTE BIOL, V76, P950, DOI 10.1189/jlb.0504308; Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Kraan MC, 2000, ARTHRITIS RHEUM, V43, P1488, DOI 10.1002/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G; Kraan MC, 2000, ARTHRITIS RHEUM, V43, P1820, DOI 10.1002/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li L, 2013, J NEUROIMMUNOL, V265, P82, DOI 10.1016/j.jneuroim.2013.10.003; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lynch MA, 2012, BRAIN BEHAV IMMUN, V26, P1, DOI 10.1016/j.bbi.2011.05.013; Manna SK, 1999, J IMMUNOL, V162, P2095; Merrill JE, 2009, J NEUROL, V256, P89, DOI 10.1007/s00415-009-0075-3; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; O'Connor P, 2016, NEUROLOGY, V86, P920, DOI 10.1212/WNL.0000000000002441; Oh J, 2014, THER ADV NEUROL DISO, V7, P239, DOI 10.1177/1756285614546855; Peterson TC, 2015, BEHAV BRAIN RES, V294, P254, DOI 10.1016/j.bbr.2015.08.007; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rowe RK, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1200-y; Ruckemann K, 1998, J BIOL CHEM, V273, P21682, DOI 10.1074/jbc.273.34.21682; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scott G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0445-y; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; Tajiri N, 2014, BRAIN RES, V1559, P65, DOI 10.1016/j.brainres.2014.02.041; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wostradowski T, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0715-3; Zeyda M, 2005, ARTHRITIS RHEUM-US, V52, P2730, DOI 10.1002/art.21255	68	11	11	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	SEP 5	2018	26	9					2152	2162		10.1016/j.ymthe.2018.06.022			11	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	GX5BY	WOS:000447756800009	30037655	Green Published, Other Gold			2021-06-18	
J	Bosco, FM; Gabbatore, I; Angeleri, R; Zettin, M; Parola, A				Bosco, F. M.; Gabbatore, I; Angeleri, R.; Zettin, M.; Parola, A.			Do executive function and theory of mind predict pragmatic abilities following traumatic brain injury? An analysis of sincere, deceitful and ironic communicative acts	JOURNAL OF COMMUNICATION DISORDERS			English	Article						Language; TBI; Theory of mind (ToM); Non-verbal Communication; Irony; Deceit; Communicative intention; Inferences; Cognitive pragmatics; Executive functions	PREFRONTAL LESIONS; SOCIAL COGNITION; MEMORY SPAN; ADULTS; IMPAIRMENT; COMPREHENSION; DEFICITS; DYSFUNCTION; CHILDREN; LANGUAGE	Quality of life and social integration are strongly influenced by the ability to communicate and previous research has shown that pragmatic ability can be specifically impaired in individuals with traumatic brain injury (TBI). In addition, TBI usually results in damage to the frontotemporal lobes with a consequent impairment of cognitive functions, i.e., attention, memory, executive function (EF) and theory of mind (ToM). The role of the underlying cognitive deficits in determining the communicative-pragmatic difficulties of an individual with TBI is not yet completely clear. This study examined the relationship between the ability to understand and produce various kinds of communicative acts, (i.e., sincere, deceitful and ironic) and the above-mentioned cognitive and ToM abilities following TBI. Thirty-five individuals with TBI and thirty-five healthy controls were given tasks assessing their ability to comprehend and produce sincere, deceitful and ironic communicative acts belonging to the linguistic and extralinguistic scales of the Assessment Battery for Communication (ABaCo), together with a series of EF and ToM tasks. The results showed that, when compared to healthy individuals, participants with TBI performed poorly overall in the comprehension and production of all the pragmatic phenomena investigated, (i.e., sincere, deceitful and ironic communicative acts), and they also exhibited impaired performance at the level of all the cognitive functions examined. Individuals with TBI also showed a decreasing trend in performance in dealing with sincere, deceitful and ironic communicative acts, on both the comprehension and production subscales of the linguistic and extralinguistic scales. Furthermore, a hierarchical regression analysis revealed that in patients with TBI but not in the controls EF had a significant effect on the comprehension of linguistic and extralinguistic irony only, while the percentage of explained variance increased with the inclusion of theory of mind. Indeed, ToM had a significant role in determining patients' performance in the extralinguistic production of sincere and deceitful communicative acts, linguistic and extralinguistic comprehension of deceit and the linguistic production of irony. However, with regard to the performance of patients with TBI in the various pragmatic tasks investigated, (i.e., sincere, deceitful and ironic communicative acts), EF was able to explain the pattern of patients' scores in the linguistic and extralinguistic comprehension but not in production ability. Furthermore, ToM seemed not to be able to explain the decreasing trend in the performance of patients in managing the various kinds of communicative acts investigated.	[Bosco, F. M.; Gabbatore, I; Parola, A.] Univ Turin, Dept Psychol, Via Po 14, I-10123 Turin, Italy; [Bosco, F. M.] Inst Neurosci Turin, Turin, Italy; [Zettin, M.] Ctr Puzzle, Turin, Italy; [Gabbatore, I] Univ Oulu, Child Language Res Ctr, Res Unit Logoped, Oulu, Finland; [Angeleri, R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Gabbatore, I (corresponding author), Univ Turin, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	ilaria.gabbatore@unito.it	Parola, alberto/AAK-3748-2020; bosco, francesca marina/B-6746-2013; Gabbatore, Ilaria/AAC-1925-2019	bosco, francesca marina/0000-0001-6101-8587; Gabbatore, Ilaria/0000-0002-9724-8066; PAROLA, ALBERTO/0000-0002-6039-0907			AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; Altman D, 1991, PRACTICAL STAT MED R; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2016, MINERVA PSICH, V57, P93; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bara B. G., 2010, LINGUISTIC PHILOS IN, V9, P182; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara BG., 2010, COGNITIVE PRAGMATICS; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosco F. M., 2018, ARCH CLIN NEUROPSYCH, DOI [10.1093/arclin/acy041acy041, DOI 10.1093/ARCLIN/ACY041ACY041]; Bosco F. M., 2017, APPL PSYCHOLINGUIST, P1; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2017, CORTEX, V94, P73, DOI 10.1016/j.cortex.2017.06.010; Bosco FM, 2017, BRAIN LANG, V168, P73, DOI 10.1016/j.bandl.2017.01.007; Bosco FM, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00021; Bosco FM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00166; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2014, CONSCIOUS COGN, V24, P84, DOI 10.1016/j.concog.2014.01.003; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Brizio A, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01011; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Byom L, 2017, INT J LANG COMM DIS, V52, P501, DOI 10.1111/1460-6984.12289; Byom LJ, 2012, INT J LANG COMM DIS, V47, P310, DOI 10.1111/j.1460-6984.2011.00102.x; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Conway ARA, 2005, PSYCHON B REV, V12, P769, DOI 10.3758/BF03196772; Cummings L, 2017, PERSP PRAGMAT PHILO, V11, P587, DOI 10.1007/978-3-319-47489-2_22; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Della Sala S., 1984, ADV HEPATIC ENCEPHAL, P448; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); ELITHORN A, 1964, BRIT J PSYCHOL, V55, P31, DOI 10.1111/j.2044-8295.1964.tb00895.x; ELITHORN A, 1955, J NEUROL NEUROSUR PS, V18, P287, DOI 10.1136/jnnp.18.4.287; Evans K, 2011, BRAIN INJURY, V25, P767, DOI 10.3109/02699052.2011.576307; Finch E, 2016, BRAIN INJURY, V30, P883, DOI 10.3109/02699052.2016.1146959; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Gabbatore I., 2017, NEURAL PLASTICITY 20; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Gabbatore L, 2014, MINERVA PSICHIATR, V55, P45; Galetto V, 2013, J NEUROLINGUIST, V26, P649, DOI 10.1016/j.jneuroling.2013.05.004; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Grice H., 1975, SYNTAX SEMANTICS; Happe F, 2002, MIND LANG, V17, P24, DOI 10.1111/1468-0017.00187; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Huber W., 1983, ITALIAN VERSION; Joanette Y., 2004, PROTOCOLE MONTREAL E; Johnco C, 2013, J ANXIETY DISORD, V27, P576, DOI 10.1016/j.janxdis.2012.10.004; Key-DeLyria SE, 2016, J SPEECH LANG HEAR R, V59, P759, DOI 10.1044/2016_JSLHR-L-15-0104; Key-DeLyria SE, 2016, AM J SPEECH-LANG PAT, V25, DOI 10.1044/2015_AJSLP-14-0111; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; LeBlanc J, 2014, INT J SPEECH-LANG PA, V16, P582, DOI 10.3109/17549507.2013.871335; Marini A, 2017, J NEUROLINGUIST, V44, P91, DOI 10.1016/j.jneuroling.2017.03.005; Marini A, 2014, NEUROPSYCHOLOGIA, V64, P282, DOI 10.1016/j.neuropsychologia.2014.09.042; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S., 2015, J NEUROPSYCHOL, V11, P291; McDonald S, 2016, APHASIOLOGY, V30, P801, DOI 10.1080/02687038.2015.1070948; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Morgan J. L., 1975, SYNTAX SEMANTICS, V3, P59, DOI DOI 10.1017/CBO9780511609213.004; Muller F., 2010, CORTEX, P1; Murphy A, 2015, APHASIOLOGY, V29, P151, DOI 10.1080/02687038.2014.959411; Novelli G., 1986, ARCH PSICOLOGIA NEUR; ORSINI A, 1987, ITAL J NEUROL SCI, V8, P539; Parola A, 2018, PSYCHIAT RES, V260, P144, DOI 10.1016/j.psychres.2017.11.051; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.1111/j.1467-8624.1989.tb02749.x; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.1111/j.1467-8624.1996.tb01824.x; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rigon A, 2016, J INT NEUROPSYCH SOC, V22, P705, DOI 10.1017/S1355617716000539; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Rowley DA, 2017, BRAIN INJURY, V31, P1564, DOI 10.1080/02699052.2017.1341645; Sacco K, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00048; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spinnler H., 1987, ITALIAN J NEUROLO S8, V6; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Sullivan JR, 2009, APPL NEUROPSYCHOL, V16, P62, DOI 10.1080/09084280802644243; TEASDALE G, 1974, LANCET, V2, P81; Thomas E, 2014, NEUROPSYCHOL REV, V24, P514, DOI 10.1007/s11065-014-9272-7; Tirassa M, 2006, CONSCIOUS COGN, V15, P197, DOI 10.1016/j.concog.2005.06.005; Tirassa M, 2006, COGN SYST RES, V7, P128, DOI 10.1016/j.cogsys.2006.01.002; Turkstra LS, 2018, NEUROPSYCHOLOGIA, V111, P117, DOI 10.1016/j.neuropsychologia.2018.01.016; Turkstra LS, 2017, BRAIN IMPAIR, V18, P49, DOI 10.1017/BrImp.2016.29; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Yang FG, 2010, NEUROPSYCHOLOGIA, V48, P1923, DOI 10.1016/j.neuropsychologia.2010.03.011	110	11	11	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	SEP-OCT	2018	75						102	117		10.1016/j.jcomdis.2018.05.002			16	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	GV7GV	WOS:000446290900008	29887277	Green Accepted			2021-06-18	
J	Bruce, JM; Echemendia, RJ; Meeuwisse, W; Hutchison, MG; Aubry, M; Comper, P				Bruce, Jared M.; Echemendia, Ruben J.; Meeuwisse, Willem; Hutchison, Michael G.; Aubry, Mark; Comper, Paul			Development of a risk prediction model among professional hockey players with visible signs of concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Sports; Ice hockey	METABOLIC BRAIN VULNERABILITY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; TEMPORAL WINDOW; VIDEO ANALYSIS; SPORT HELD; FOOTBALL; ZURICH; LEAGUE	Background Little research examines how to best identify concussed athletes. The purpose of the present study was to develop a preliminary risk decision model that uses visible signs (VS) and mechanisms of injury (MOI) to predict the likelihood of subsequent concussion diagnosis. Methods Coders viewed and documented VS and associated MOI for all NHL games over the course of the 2013-2014 and 2014-2015 regular seasons. After coding was completed, player concussions were identified from the NHL injury surveillance system and it was determined whether players exhibiting VS were subsequently diagnosed with concussions by club medical staff as a result of the coded event. Results Among athletes exhibiting VS, suspected loss of consciousness, motor incoordination or balance problems, being in a fight, having an initial hit from another player's shoulder and having a secondary hit on the ice were all associated with increased risk of subsequent concussion diagnosis. In contrast, having an initial hit with a stick was associated with decreased risk of subsequent concussion diagnosis. A risk prediction model using a combination of the above VS and MOI was superior to approaches that relied on individual VS and associated MOI (sensitivity=81%, specificity=72%, positive predictive value=26%). Conclusions Combined use of VS and MOI significantly improves a clinician's ability to identify players who need to be evaluated for possible concussion. A preliminary concussion prediction log has been developed from these data. Pending prospective validation, the use of these methods may improve early concussion detection and evaluation.	[Bruce, Jared M.; Echemendia, Ruben J.] Univ Missouri, Dept Psychol, 5030 Cherry Hall,Room 313, Kansas City, MO 64110 USA; [Echemendia, Ruben J.] Psychol & Neurobehav Associates, State Coll, PA USA; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Hutchison, Michael G.; Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada	Bruce, JM (corresponding author), Univ Missouri, Dept Psychol, 5030 Cherry Hall,Room 313, Kansas City, MO 64110 USA.	brucejm@umkc.edu	Echemendia, Ruben/R-6939-2019				Alessi AG, 2013, NEUROLOGY, V80, P2178, DOI 10.1212/WNL.0b013e31828d9c13; Arnould A, 2016, ANN PHYS REHABIL MED, V59, P18, DOI 10.1016/j.rehab.2015.09.002; Echemendia RJ., 2017, BR J SPORTS MED; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Group NCW, 2011, NHL CONC EV MAN PROT; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Makdissi G, 2016, J SCI MED SPORT, P1111; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Schwartz A, 2013, ANN NEUROL, V74, pA26, DOI 10.1002/ana.24031; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	17	11	11	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2018	52	17								10.1136/bjsports-2016-097091			7	Sport Sciences	Sport Sciences	GS4GO	WOS:000443598200013	28377444				2021-06-18	
J	Dennis, EL; Babikian, T; Alger, J; Rashid, F; Villalon-Reina, JE; Jin, Y; Olsen, A; Mink, R; Babbitt, C; Johnson, J; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Babikian, Talin; Alger, Jeffry; Rashid, Faisal; Villalon-Reina, Julio E.; Jin, Yan; Olsen, Alexander; Mink, Richard; Babbitt, Christopher; Johnson, Jeffrey; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			Magnetic resonance spectroscopy of fiber tracts in children with traumatic brain injury: A combined MRS - Diffusion MRI study	HUMAN BRAIN MAPPING			English	Article						diffusion MRI; longitudinal; MRS; pediatric; traumatic brain injury	CORPUS-CALLOSUM; AXONAL INJURY; MODERATE; TENSOR; TRAJECTORIES; RECOVERY; OUTCOMES; UCLA	Traumatic brain injury can cause extensive damage to the white matter (WM) of the brain. These disruptions can be especially damaging in children, whose brains are still maturing. Diffusion magnetic resonance imaging (dMRI) is the most commonly used method to assess WM organization, but it has limited resolution to differentiate causes of WM disruption. Magnetic resonance spectroscopy (MRS) yields spectra showing the levels of neurometabolites that can indicate neuronal/axonal health, inflammation, membrane proliferation/turnover, and other cellular processes that are on-going post-injury. Previous analyses on this dataset revealed a significant division within the msTBI patient group, based on interhemispheric transfer time (IHTT); one subgroup of patients (TBI-normal) showed evidence of recovery over time, while the other showed continuing degeneration (TBI-slow). We combined dMRI with MRS to better understand WM disruptions in children with moderate-severe traumatic brain injury (msTBI). Tracts with poorer WM organization, as shown by lower FA and higher MD and RD, also showed lower N-acetylaspartate (NAA), a marker of neuronal and axonal health and myelination. We did not find lower NAA in tracts with normal WM organization. Choline, a marker of inflammation, membrane turnover, or gliosis, did not show such associations. We further show that multi-modal imaging can improve outcome prediction over a single modality, as well as over earlier cognitive function measures. Our results suggest that demyelination plays an important role in WM disruption post-injury in a subgroup of msTBI children and indicate the utility of multi-modal imaging.	[Dennis, Emily L.; Rashid, Faisal; Villalon-Reina, Julio E.; Jin, Yan; Thompson, Paul M.] Univ Southern Calif, Keck Sch Med, Mary & Mark Stevens Inst Neuroimaging & Informat, Imaging Genet Ctr, Marina Del Rey, CA USA; [Dennis, Emily L.; Babikian, Talin; Olsen, Alexander; Asarnow, Robert F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Alger, Jeffry] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Alger, Jeffry] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA; [Alger, Jeffry] NeuroSpectroScopics LLC, Sherman Oaks, CA USA; [Olsen, Alexander] Norwegian Univ Sci & Technol, Dept Psychol, Trondheim, Norway; [Olsen, Alexander] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Mink, Richard] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA; [Mink, Richard] Los Angeles BioMed Res Inst, Torrance, CA USA; [Babbitt, Christopher] Miller Childrens Hosp, Long Beach, CA USA; [Johnson, Jeffrey] LAC USC Med Ctr, Dept Pediat, Los Angeles, CA USA; [Babikian, Talin; Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA USA; [Babikian, Talin; Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Neurol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Pediat, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Psychiat, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Radiol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Engn, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Ophthalmol, Los Angeles, CA USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Giza, Christopher C.; Asarnow, Robert F.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA	Dennis, EL (corresponding author), Univ Southern Calif, Keck Sch Med, 2025 Zonal Ave, Los Angeles, CA 90033 USA.	emily.dennis@ini.usc.edu	Dennis, Emily/AAD-5223-2021; Olsen, Alexander/P-5235-2019	Olsen, Alexander/0000-0001-8691-3860; Mink, Richard/0000-0002-7998-4713; Dennis, Emily/0000-0001-7112-4009	NICHDS [R01 HD061504]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99 NS096116]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 EB020403, R01 EB008432, R01 AG040060, R01 NS080655]; UCLA BIRC, UCLA Faculty Grants Program [R01 NS027544]; Child Neurology Foundation; UCLA Steve Tisch BrainSPORT Program; NCAA; U.S. Dept of DefenseUnited States Department of Defense; Today's and Tomorrow's Children Fund; Staglin IMHRO Center for Cognitive Neuroscience; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD087101, R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB020403, P41EB015922, R01EB008432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99NS096116, R01NS027544, R01NS080655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040060] Funding Source: NIH RePORTER	NICHDS, Grant/Award Number: R01 HD061504; NINDS, Grant/Award Number: K99 NS096116; NIH, Grant/Award Numbers: U54 EB020403, R01 EB008432, R01 AG040060, and R01 NS080655; UCLA BIRC, UCLA Faculty Grants Program, Grant/Award Number: R01 NS027544; Child Neurology Foundation; UCLA Steve Tisch BrainSPORT Program; NCAA; U.S. Dept of Defense; Today's and Tomorrow's Children Fund; Staglin IMHRO Center for Cognitive Neuroscience	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Babikian T, 2018, J NEUROTRAUM, V35, P1637, DOI 10.1089/neu.2017.5366; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Catani M, 2007, P NATL ACAD SCI USA, V104, P17163, DOI 10.1073/pnas.0702116104; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dennis E., 2018, NEUROSCIENTIST; Dennis EL, 2017, CHILD NERV SYST, V33, P1683, DOI 10.1007/s00381-017-3522-y; Dennis EL, 2017, NEUROIMAGE-CLIN, V15, P125, DOI 10.1016/j.nicl.2017.03.014; Dennis EL, 2017, NEUROLOGY, V88, P1392, DOI 10.1212/WNL.0000000000003808; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Ebel A, 2003, MAGN RESON IMAGING, V21, P113, DOI 10.1016/S0730-725X(02)00645-8; Ellis M. U., 2015, J NEUROTRAUMA; Ellis MU, 2016, J NEUROTRAUM, V33, P990, DOI 10.1089/neu.2015.4023; Ghosh N, 2017, DEV NEUROSCI-BASEL, V39, P413, DOI 10.1159/000475545; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Jin Y, 2014, NEUROIMAGE, V100, P75, DOI 10.1016/j.neuroimage.2014.04.048; Jin Y, 2011, I S BIOMED IMAGING, P822, DOI 10.1109/ISBI.2011.5872531; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Li BSY, 2003, MAGN RESON IMAGING, V21, P923, DOI 10.1016/S0730-725X(03)00181-4; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Maudsley AA, 2015, J NEUROTRAUM, V32, P1056, DOI 10.1089/neu.2014.3505; Moffett John R, 2013, Front Neuroenergetics, V5, P11, DOI 10.3389/fnene.2013.00011; Moran LM, 2016, J INT NEUROPSYCH SOC, V22, P512, DOI 10.1017/S1355617716000175; Parry L, 2004, CHILD NEUROPSYCHOL, V10, P248, DOI 10.1080/09297040490909279; Sabati M, 2015, MAGN RESON MED, V74, P1209, DOI 10.1002/mrm.25510; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wechsler D., 2003, WECHSLER INTELLIGENC; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	45	11	11	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	SEP	2018	39	9					3759	3768		10.1002/hbm.24209			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	GQ0AA	WOS:000441276600022	29749094	Bronze, Green Published, Green Accepted			2021-06-18	
J	O'Neill, B; Best, C; O'Neill, L; Ramos, SDS; Gillespie, A				O'Neill, Brian; Best, Catherine; O'Neill, Lauren; Ramos, Sara D. S.; Gillespie, Alex			Efficacy of a Micro-Prompting Technology in Reducing Support Needed by People With Severe Acquired Brain Injury in Activities of Daily Living: A Randomized Control Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						activities of daily living; assistive technology; brain injuries; caregiving; cognition; rehabilitation	ASSISTIVE TECHNOLOGY; NEUROBEHAVIORAL REHABILITATION; COST-BENEFITS; MEMORY AID; FIELD	Objective: To evaluate the effectiveness of an automated interactive prompting technology in supporting the morning routine of persons with acquired brain injury. The morning routine included maintaining personal hygiene and dressing. Setting: An inpatient neurorehabilitation hospital. Participants: Persons with acquired brain injury who required prompting when following their morning routine (n = 24), but were not limited by physical disability or dysphasia, took part in the study. Participants (67% with traumatic brain injury) had impairment on indices of memory and executive function. Design: A randomized control trial evaluated the effect of an automated interactive micro-prompting device on the number of prompts by trained staff required for successful completion of the morning routine. Main Measures: Study-specific checklists assessed sequence performance, errors, and verbal prompts required over baseline, rehabilitation as usual, intervention, and return to baseline conditions. Results: The intervention significantly reduced the support required to complete the task compared with usual rehabilitation. Conclusions: Micro-prompting technology is an effective assistive technology for cognition, which reduces support needs in people with significant cognitive impairments.	[O'Neill, Brian; O'Neill, Lauren; Ramos, Sara D. S.] Brain Injury Rehabil Trust, Graham Anderson House,1161 Springburn Rd, Glasgow G21 1UU, Lanark, Scotland; [O'Neill, Brian] Univ Glasgow, Mental Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Best, Catherine] Univ Stirling, Hlth Sci & Sport, Stirling, Scotland; [Gillespie, Alex] London Sch Econ, London, England	O'Neill, B (corresponding author), Brain Injury Rehabil Trust, Graham Anderson House,1161 Springburn Rd, Glasgow G21 1UU, Lanark, Scotland.	brian.oneill@thedtgroup.org			Chief Scientist Office, Scottish Government [CZH/4/598]; Disabilities Trust, a not-for-profit organization, parent charity of the Brain Injury Rehabilitation Trust	Research supported by a grant from the Chief Scientist Office, Scottish Government (CZH/4/598). The authors thank Michael Oddy, Paula Gribben, and Donna Lindop for consultation on the needs of persons with brain injury; Naomi Bowers for help with data collection; and rehabilitation support workers who allowed their scaffolding of sequences to be recorded and used in the development of Guide activity protocols. The authors are forever indebted to the service users who agreed to participate in the development and clinical trial phases of this study.; The article reports the efficacy of a micro-prompting device (called "Guide"), developed with support from the Chief Scientist Office, and, as an Android and iOS compatible application, with support from the Disabilities Trust, a not-for-profit organization, parent charity of the Brain Injury Rehabilitation Trust and, therefore, employer of SDSR, BON, and LON.	AlZoubi O, 2015, ASSIST TECHNOL, P47; Aunger R, 2010, TECHNOL FORECAST SOC, V77, P762, DOI 10.1016/j.techfore.2010.01.008; Boman IL, 2010, DISABIL REHABIL-ASSI, V5, P339, DOI 10.3109/17483100903131777; Cahn-Weiner Deborah A, 2002, Appl Neuropsychol, V9, P187, DOI 10.1207/S15324826AN0903_8; Gillespie A, 2015, ASSISTIVE TECHNOLOGY; Gillespie A, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI 10.1017/S1355617711001548; Jamieson M, 2014, NEUROPSYCHOL REHABIL, V24, P419, DOI 10.1080/09602011.2013.825632; Klarborg B, 2012, ACCIDENT ANAL PREV, V48, P57, DOI 10.1016/j.aap.2011.05.004; Lemoncello R, 2011, NEUROPSYCHOL REHABIL, V21, P825, DOI 10.1080/09602011.2011.618661; Lloyd J, 2009, NEUROPSYCHOL REHABIL, V19, P98, DOI 10.1080/09602010802117392; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; McLuhan M., 1964, UNDERSTANDING MEDIA; Mihailidis Alex, 2008, BMC Geriatr, V8, P28, DOI 10.1186/1471-2318-8-28; Moir J, 2014, THESIS; Mumford L., 1934, TECHNICS CIVILIZATIO; O'Neill B., 2013, SOCIAL CARE NEURODIS, V4, P17; O'Neill B, 2010, NEUROPSYCHOL REHABIL, V20, P509, DOI 10.1080/09602010903519652; O'Neill B, 2008, J ASSIST TECHNOL, V2, P22, DOI 10.1108/17549450200800015; Oddy M, 2013, BRAIN INJURY, V27, P1500, DOI 10.3109/02699052.2013.830332; Oddy M, 2013, NEUROREHABILITATION, V32, P781, DOI 10.3233/NRE-130902; Parish L, 2007, NEUROPSYCHOL REHABIL, V17, P230, DOI 10.1080/09602010600750675; Pea RD, 2004, J LEARN SCI, V13, P423, DOI 10.1207/s15327809jls1303_6; Peters C, 2014, ACM T ACCESS COMPUT, V5, DOI 10.1145/2579700; Plehn K, 2004, CLIN NEUROPSYCHOL, V18, P101, DOI 10.1080/13854040490507190; Rogers JC, 1999, J AM GERIATR SOC, V47, P1049, DOI 10.1111/j.1532-5415.1999.tb05226.x; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; Shepherd A, 2001, HIERARCHICAL TASK AN; Stone CA, 1998, J LEARN DISABIL-US, V31, P344, DOI 10.1177/002221949803100404; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Van Hulle A, 2006, BRAIN INJURY, V20, P101, DOI 10.1080/02699050500309684; Vygotsky L. S., 1994, The Vygotsky reader, P99; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wimo A, 2010, WORLD ALZHEIMER REPO; Wood RL, 2001, BRAIN DAM B, P107; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; Worthington AD, 2006, BRAIN INJURY, V20, P947, DOI 10.1080/02699050600888314; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	37	11	11	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2018	33	5					E33	E41		10.1097/HTR.0000000000000358			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	HB2QJ	WOS:000450886500005	29194177	Green Accepted			2021-06-18	
J	Pietropaoli, S; Leonetti, A; Cervetto, C; Venturini, A; Mastrantonio, R; Baroli, G; Persichini, T; Colasanti, M; Maura, G; Marcoli, M; Mariottini, P; Cervelli, M				Pietropaoli, Stefano; Leonetti, Alessia; Cervetto, Chiara; Venturini, Arianna; Mastrantonio, Roberta; Baroli, Giulia; Persichini, Tiziana; Colasanti, Marco; Maura, Guido; Marcoli, Manuela; Mariottini, Paolo; Cervelli, Manuela			Glutamate Excitotoxicity Linked to Spermine Oxidase Overexpression	MOLECULAR NEUROBIOLOGY			English	Article						EAAT; Oxidative stress; Polyamine metabolism; Seizures; Sulfasalazine; System x(c)(-) transporter	TRAUMATIC BRAIN-INJURY; ORNITHINE-DECARBOXYLASE; MOLECULAR PHARMACOLOGY; MOUSE MODEL; ACTIVATION; POLYAMINES; RELEASE; TRANSPORTERS	Excitotoxic stress has been associated with several different neurological disorders, and it is one of the main causes of neuronal degeneration and death. To identify new potential proteins that could represent key factors in excitotoxic stress and to study the relationship between polyamine catabolism and excitotoxic damage, a novel transgenic mouse line overexpressing spermine oxidase enzyme in the neocortex (Dach-SMOX) has been engineered. These transgenic mice are more susceptible to excitotoxic injury and display a higher oxidative stress, highlighted by 8-Oxo-2'-deoxyguanosine increase and activation of defense mechanisms, as demonstrated by the increase of nuclear factor erythroid 2-related factor 2 (Nrf-2) in the nucleus. In Dach-SMOX astrocytes and neurons, an alteration of the phosphorylated and non-phosphorylated subunits of glutamate receptors increases the kainic acid response in these mice. Moreover, a decrease in excitatory amino acid transporters and an increase in the system x(c)(-) transporter, a Nrf-2 target, was observed. Sulfasalazine, a system x(c)(-) transporter inhibitor, was shown to revert the increased susceptibility of Dach-SMOX mice treated with kainic acid. We demonstrated that astrocytes play a crucial role in this process: neuronal spermine oxidase overexpression resulted in an alteration of glutamate excitability, in glutamate uptake and efflux in astrocytes involved in the synapse. Considering the involvement of oxidative stress in many neurodegenerative diseases, Dach-SMOX transgenic mouse can be considered as a suitable in vivo genetic model to study the involvement of spermine oxidase in excitotoxicity, which can be considered as a possible therapeutic target.	[Pietropaoli, Stefano; Leonetti, Alessia; Mastrantonio, Roberta; Baroli, Giulia; Persichini, Tiziana; Colasanti, Marco; Mariottini, Paolo; Cervelli, Manuela] Univ Rome Roma Tre, Dept Sci, Viale Marconi 446, I-00146 Rome, Italy; [Cervetto, Chiara; Venturini, Arianna; Maura, Guido; Marcoli, Manuela] Univ Genoa, Dept Pharm, Sect Pharmacol & Toxicol, Viale Cembrano 4, I-16148 Genoa, Italy; [Maura, Guido; Marcoli, Manuela] Univ Genoa, Ctr Excellence Biomed Res, Viale Benedetto 15 5, I-16132 Genoa, Italy	Cervelli, M (corresponding author), Univ Rome Roma Tre, Dept Sci, Viale Marconi 446, I-00146 Rome, Italy.	stefano.pietropaoli@uniroma3.it; alessia.leonetti@uniroma3.it; cervetto@difar.unige.it; venturini@difar.unige.it; robena.mastrantonio@uniroma3.it; giulia.baroli@uniroma3.it; tiziana.persichini@uniroma3.it; marco.colasanti@uniroma3.it; maura@pharmatox.unige.it; marcoli@pharmatox.unige.it; paolo.mariottini@uniroma3.it; manuela.cervelli@uniroma3.it	Cervetto, Chiara/G-6404-2010; Cervelli, Manuela/ABC-6913-2020	Cervetto, Chiara/0000-0001-8290-3008; Cervelli, Manuela/0000-0001-8535-8279; Pietropaoli, Stefano/0000-0002-8423-9187	Roma Tre University [CAL/2016]; Ph.D. School (Department of Science)	This work was supported by the Roma Tre University contribution to the laboratories [CAL/2016] to M.C. and P.M. and by the Ph.D. School (Department of Science) contribution 2016 to S.P. and A.L.	Balkhi HM, 2014, INT J ADV RES, V2, P361; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bridges RJ, 2012, BRIT J PHARMACOL, V165, P20, DOI 10.1111/j.1476-5381.2011.01480.x; Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453; Cabungcal JH, 2013, BIOL PSYCHIAT, V73, P574, DOI 10.1016/j.biopsych.2012.09.020; Ceci R, 2017, FREE RADICAL BIO MED, V103, P216, DOI 10.1016/j.freeradbiomed.2016.12.040; Cervelli M, 2004, EUR J BIOCHEM, V271, P760, DOI 10.1111/j.1432-1033.2004.03979.x; Cervelli M, 2016, AMINO ACIDS, V48, P2283, DOI 10.1007/s00726-016-2273-5; Cervelli M, 2014, AMINO ACIDS, V46, P521, DOI 10.1007/s00726-013-1572-3; Cervelli M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064810; Cervelli M, 2013, J MOL EVOL, V76, P365, DOI 10.1007/s00239-013-9570-3; Cervelli M, 2012, AMINO ACIDS, V42, P441, DOI 10.1007/s00726-011-1014-z; Cervelli M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-555; Cervetto C, 2017, J NEUROCHEM, V140, P268, DOI 10.1111/jnc.13885; Cervetto C, 2016, NEUROMOL MED, V18, P50, DOI 10.1007/s12017-015-8377-3; Cervetto C, 2015, NEUROPHARMACOLOGY, V99, P396, DOI 10.1016/j.neuropharm.2015.08.011; Cervetto C, 2012, NEUROCHEM INT, V60, P768, DOI 10.1016/j.neuint.2012.02.034; Cervetto C, 2010, J PHARMACOL EXP THER, V332, P210, DOI 10.1124/jpet.109.154955; Chaturvedi R, 2012, GUT MICROBES, V3, P48, DOI 10.4161/gmic.19345; de Groot J, 2011, GLIA, V59, P1181, DOI 10.1002/glia.21113; Hediger MA, 1999, AM J PHYSIOL-RENAL, V277, pF487; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Mastrantonio R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149802; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; Pegg AE, 2008, AM J PHYSIOL-ENDOC M, V294, pE995, DOI 10.1152/ajpendo.90217.2008; Pellegrini-Giampietro DE, 2003, TRENDS NEUROSCI, V26, P9, DOI 10.1016/S0166-2236(02)00004-8; Polticelli F, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-90; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rea G, 2004, IUBMB LIFE, V56, P167, DOI 10.1080/15216540410001673996; Rosenblum LT, 2017, EXP NEUROL, V292, P145, DOI 10.1016/j.expneurol.2017.03.014; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; Smirnova OA, 2012, BIOCHIMIE, V94, P1876, DOI 10.1016/j.biochi.2012.04.023; Tavladoraki P, 2011, AMINO ACIDS, V40, P1115, DOI 10.1007/s00726-010-0735-8; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Uemura T, 2016, BIOCHEM BIOPH RES CO, V473, P630, DOI 10.1016/j.bbrc.2016.03.137; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Zahedi K, 2010, J NEUROTRAUM, V27, P515, DOI 10.1089/neu.2009.1097	42	11	11	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	SEP	2018	55	9					7259	7270		10.1007/s12035-017-0864-0			12	Neurosciences	Neurosciences & Neurology	GO9UK	WOS:000440453100012	29397558				2021-06-18	
J	Ryu, KM; Chang, SW				Ryu, Kyoung Min; Chang, Sung Wook			Heparin-free extracorporeal membrane oxygenation in a patient with severe pulmonary contusions and bronchial disruption	CLINICAL AND EXPERIMENTAL EMERGENCY MEDICINE			English	Article						Lung injury; Bronchi; Heparin; Extracorporeal membrane oxygenation	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; ANTICOAGULATION	Pulmonary contusion complicated with endobronchial hemorrhage is potentially life-threatening, particularly in patients with tracheobronchial tree disruption and severe airway bleeding after blunt trauma, and pose a high mortality risk. In such cases, extracorporeal membrane oxygenation (ECMO) can be used as a salvage treatment modality. However, the use of ECMO for moribund trauma patients with respiratory failure may be limited for several reasons, such as intractable bleeding. In this case report, we describe a patient with severe bilateral pulmonary contusions with tracheobronchial tree disruption that was successfully treated using heparin-free venovenous ECMO.	[Ryu, Kyoung Min; Chang, Sung Wook] Dankook Univ Hosp, Dept Thorac & Cardiovasc Surg, 201 Manghyang Ro, Cheonan 31116, South Korea; [Chang, Sung Wook] Dankook Univ Hosp, Trauma Ctr, Cheonan, South Korea	Chang, SW (corresponding author), Dankook Univ Hosp, Dept Thorac & Cardiovasc Surg, 201 Manghyang Ro, Cheonan 31116, South Korea.	changsw3@naver.com					Biscotti M, 2015, PERFUSION-UK, V30, P407, DOI 10.1177/0267659114554327; Bosarge PL, 2016, J TRAUMA ACUTE CARE, V81, P236, DOI 10.1097/TA.0000000000001068; Della Rocca G, 2013, CURR OPIN ANESTHESIO, V26, P40, DOI 10.1097/ACO.0b013e32835c4ea2; Hwang Jung Joo, 2013, Korean J Thorac Cardiovasc Surg, V46, P197, DOI 10.5090/kjtcs.2013.46.3.197; Kabon B, 2001, CHEST, V120, P1399, DOI 10.1378/chest.120.4.1399; Lamarche Y, 2010, INNOVATIONS, V5, P424, DOI 10.1097/IMI.0b013e3182029a83; Lee SH, 1996, KOREAN J THORAC CARD, V29, P208; Muellenbach RM, 2012, J TRAUMA ACUTE CARE, V72, P1444, DOI 10.1097/TA.0b013e31824d68e3; Oliver WC, 2009, SEMIN CARDIOTHORAC V, V13, P154, DOI 10.1177/1089253209347384	9	11	11	0	3	SEOUL KOREAN SOC EMERGENCY MEDICINE	SEOUL	101-3305, BROWNSTONE SEOUL, 464 CHEONGPA-RO, JUNG-GU, SEOUL, 06351, SOUTH KOREA	2383-4625			CLIN EXP EMERG MED	Clin. Exp. Emerg. Med.	SEP	2018	5	3					204	207		10.15441/ceem.17.252			4	Emergency Medicine	Emergency Medicine	GU1MM	WOS:000445026700010	29706054	Green Published, Other Gold			2021-06-18	
J	Xu, B; Lian, S; Li, SZ; Guo, JR; Wang, JF; Wang, D; Zhang, LP; Yang, HM				Xu, Bin; Lian, Shuai; Li, Shi-Ze; Guo, Jing-Ru; Wang, Jian-Fa; Wang, Di; Zhang, Li-Ping; Yang, Huan-Min			GABAB receptor mediate hippocampal neuroinflammation in adolescent male and female mice after cold expose	BRAIN RESEARCH BULLETIN			English	Article						Adolescent mouse; Cold stress; Cognition; Neuroinflammation; Neuronal death	TRAUMATIC BRAIN-INJURY; OPEN-FIELD TEST; NF-KAPPA-B; OXIDATIVE STRESS; WORKING-MEMORY; TNF-ALPHA; MICROGLIAL ACTIVATION; NEURONAL APOPTOSIS; ALZHEIMERS-DISEASE; SIGNALING PATHWAY	Stress induces many non-specific inflammatory responses in the mouse brain, especially during adolescence. Although the impact of stress on the brain has long been reported, the effects of cold stress on hippocampal neuroinflammation in adolescent mice are not well understood; furthermore, whether these effects are gender specific are also not well established. Adolescent male and female C57BL/6 mice were exposed to 4 degrees C temperatures for 12 h, after which behavior was assessed using the open field test. Using western blotting and immunohistochemistry we also assessed glial cell numbers and microglial activation, as well as inflammatory cytokine levels and related protein expression levels. We found that in mice subjected to cold stress: 1) There were significant behavioral changes; 2) neuronal nuclei densities were smaller and total cell numbers were significantly decreased; 3) nuclear factor (NF)-KB and phosphorylated AKT were upregulated; 4) pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha were also upregulated; and 5) microglia were activated, while glial fibrillary acid protein and ionized calcium-binding adapter molecule 1 protein expression increased. Taken together, these results indicate that cold stress induces pro-inflammatory cytokine upregulation that leads to neuroinflammation and neuronal apoptosis in the hippocampi of adolescent mice. We believe that these effects are influenced by a GABAB/Rap1B/AKT/NF-kappa B pathway. Finally, male mice were more sensitive to the effects of cold stress than were female mice.	[Xu, Bin; Lian, Shuai; Li, Shi-Ze; Guo, Jing-Ru; Wang, Jian-Fa; Wang, Di; Yang, Huan-Min] Heilongjiang Bayi Agr Univ, Coll Anim Sci & Vet Med, Daqing 163319, Peoples R China; [Zhang, Li-Ping] Heilongjiang Bayi Agr Univ, Coll Food Sci, Daqing 163319, Peoples R China	Yang, HM (corresponding author), Heilongjiang Bayi Agr Univ, Coll Anim Sci & Vet Med, Daqing 163319, Peoples R China.; Zhang, LP (corresponding author), Heilongjiang Bayi Agr Univ, Coll Food Sci, Daqing 163319, Peoples R China.	ZLP77@126.com; byndyhm@163.com	Lian, Shuai/AAF-9966-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31672513, 31471586, 31772695]; National Key Research and Development Program [2016YFD0501210]	This work was supported by the National Natural Science Foundation of China (project no. 31672513, no. 31471586 and no. 31772695), National Key Research and Development Program (project no. 2016YFD0501210)	Al'Absi M, 2002, PSYCHOPHYSIOLOGY, V39, P95, DOI 10.1017/S0048577202001543; Alves ND, 2018, BRAIN STRUCT FUNCT, V223, P415, DOI 10.1007/s00429-017-1490-3; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bollinger JL, 2016, BRAIN BEHAV IMMUN, V52, P88, DOI 10.1016/j.bbi.2015.10.003; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Chen J, 2010, J NEUROENDOCRINOL, V22, P1072, DOI 10.1111/j.1365-2826.2010.02054.x; Choleris E, 2001, NEUROSCI BIOBEHAV R, V25, P235, DOI 10.1016/S0149-7634(01)00011-2; Cohen S, 2012, P NATL ACAD SCI USA, V109, P5995, DOI 10.1073/pnas.1118355109; Coimbra-Costa D, 2017, REDOX BIOL, V12, P216, DOI 10.1016/j.redox.2017.02.014; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dong HW, 2009, P NATL ACAD SCI USA, V106, P11794, DOI 10.1073/pnas.0812608106; Duchesne A, 2012, BIOL PSYCHOL, V89, P99, DOI 10.1016/j.biopsycho.2011.09.009; Elzinga BM, 2005, BEHAV NEUROSCI, V119, P98, DOI 10.1037/0735-7044.119.1.98; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Felix-Ortiz AC, 2014, J NEUROSCI, V34, P586, DOI 10.1523/JNEUROSCI.4257-13.2014; Ferre S, 2010, BBA-MOL BASIS DIS, V1802, P952, DOI 10.1016/j.bbadis.2010.06.016; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Giedd JN, 2010, NEURON, V67, P728, DOI 10.1016/j.neuron.2010.08.040; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Guo WJ, 2018, CELL PHYSIOL BIOCHEM, V46, P2090, DOI 10.1159/000489449; Gur TL, 2017, BRAIN BEHAV IMMUN, V64, P50, DOI 10.1016/j.bbi.2016.12.021; He S, 2018, ENVIRON INT, V111, P295, DOI 10.1016/j.envint.2017.11.004; Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2; Huang TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029102; Jenniches I, 2016, BIOL PSYCHIAT, V79, P858, DOI 10.1016/j.biopsych.2015.03.033; Kim HG, 2013, BIOL PHARM BULL, V36, P1556, DOI 10.1248/bpb.b13-00268; Kim J, 2016, POLYM J, V48, P829, DOI 10.1038/pj.2016.37; Kim SH, 2012, INT J PSYCHOPHYSIOL, V83, P348, DOI 10.1016/j.ijpsycho.2011.12.001; Kogler L, 2015, HUM BRAIN MAPP, V36, P1028, DOI 10.1002/hbm.22683; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kumar S, 2014, J EXP MED, V211, P1741, DOI 10.1084/jem.20131706; Lawrence T, 2010, INT J BIOCHEM CELL B, V42, P519, DOI 10.1016/j.biocel.2009.12.016; Lee W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0324-6; Li JT, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00025; Li SJ, 2014, EUR REV MED PHARMACO, V18, P905; Lin CY, 2013, J CELL BIOCHEM, V114, P2061, DOI 10.1002/jcb.24553; Liu Y, 2017, BRAIN RES, V1670, P201, DOI 10.1016/j.brainres.2017.06.025; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Meehan C, 2017, BRAIN BEHAV IMMUN, V63, P8, DOI 10.1016/j.bbi.2016.07.144; Morgan CA, 2006, BIOL PSYCHIAT, V60, P722, DOI 10.1016/j.biopsych.2006.04.021; Morrissey MD, 2011, NEUROBIOL LEARN MEM, V95, P46, DOI 10.1016/j.nlm.2010.10.007; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Numakawa T, 2013, NEUROSCIENCE, V239, P157, DOI 10.1016/j.neuroscience.2012.09.073; Ostojic ZS, 2013, NEUROSCIENCE, V238, P39, DOI 10.1016/j.neuroscience.2013.01.072; Padgett CL, 2010, ADV PHARMACOL, V58, P123, DOI 10.1016/S1054-3589(10)58006-2; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; PREMKUMAR LS, 1994, J NEUROPHYSIOL, V71, P2570; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Raskin J, 2015, CURR ALZHEIMER RES, V12, P712, DOI 10.2174/1567205012666150701103107; Romeo RD, 2013, CURR DIR PSYCHOL SCI, V22, P140, DOI 10.1177/0963721413475445; Rosic NN, 2011, CELL STRESS CHAPERON, V16, P69, DOI 10.1007/s12192-010-0222-x; Saita E, 2016, BBA-MOL CELL BIOL L, V1861, P837, DOI 10.1016/j.bbalip.2016.01.003; Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302; Stone SSD, 2011, HIPPOCAMPUS, V21, P1348, DOI 10.1002/hipo.20845; Sugama S, 2007, NEUROSCIENCE, V146, P1388, DOI 10.1016/j.neuroscience.2007.02.043; Thompson CL, 2008, NEURON, V60, P1010, DOI 10.1016/j.neuron.2008.12.008; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; White MG, 2003, J NEUROCHEM, V87, P958, DOI 10.1046/j.1471-4159.2003.02077.x; Xiao CF, 2007, DEV NEUROBIOL, V67, P438, DOI 10.1002/dneu.20344; Xu DL, 2017, J EXP BIOL, V220, P2187, DOI 10.1242/jeb.153601; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yeager MP, 2009, CRIT CARE MED, V37, P2727, DOI 10.1097/CCM.0b013e3181a592b3; Yilmaz U, 2015, RADIOLOGE, V55, P386, DOI 10.1007/s00117-014-2796-2; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3	68	11	12	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	SEP	2018	142						163	175		10.1016/j.brainresbull.2018.07.011			13	Neurosciences	Neurosciences & Neurology	GY0PK	WOS:000448223400019	30031816				2021-06-18	
J	Geribaldi-Doldan, N; Carrasco, M; Murillo-Carretero, M; Dominguez-Garcia, S; Garcia-Cozar, FJ; Munoz-Miranda, JP; del Rio-Garcia, V; Verastegui, C; Castro, C				Geribaldi-Doldan, Noelia; Carrasco, Manuel; Murillo-Carretero, Maribel; Dominguez-Garcia, Samuel; Garcia-Cozar, Francisco J.; Pedro Munoz-Miranda, Juan; del Rio-Garcia, Valme; Verastegui, Cristina; Castro, Carmen			Specific inhibition of ADAM17/TACE promotes neurogenesis in the injured motor cortex	CELL DEATH & DISEASE			English	Article							ALPHA-CONVERTING ENZYME; TRAUMATIC BRAIN-INJURY; EPIDERMAL-GROWTH-FACTOR; PROGENITOR-CELL PROLIFERATION; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; NEURAL STEM-CELLS; SUBVENTRICULAR ZONE; ADULT BRAIN	Brain injuries in the adult mammalian brain are accompanied by a fast neurogenic response inside neurogenic niches. However, this response does not contribute to the generation of new neurons within damaged tissues like the cerebral cortex, which are essentially non-neurogenic. This occurs because injuries create a hostile environment that favors gliogenesis. Overexpression and sequential activation of the ADAM17/TGF alpha/EGFR signaling cascade are crucial for the generation of this gliogenic/non-neurogenic environment. Here, we demonstrate that chronic local infusion of a general metalloprotease inhibitor in areas of traumatic cortical injury in adult mice moderately increased the number of neuroblasts around the lesion, by facilitating the survival of neuroblasts and undifferentiated progenitors, which had migrated to the perilesional area from the subventricular zone. Next, we generated a dominant-negative version of ADAM17 metalloprotease, consisting of a truncated protein containing only the pro-domain (ADAM17-Pro). Specific inhibition of ADAM17 activity by ADAM17-Pro overexpression increased the generation of new neurons in vitro. Local overexpression of ADAM17-Pro in injured cortex in vivo, mediated by lentiviral vectors, dramatically increased the number of neuroblasts observed at the lesion 14 days after injury. Those neuroblasts were able to differentiate into cholinergic and GABAergic neurons 28 days after injury. We conclude that ADAM17 is a putative target to develop new therapeutic tools for the treatment of traumatic brain injury.	[Geribaldi-Doldan, Noelia; Carrasco, Manuel; Murillo-Carretero, Maribel; Dominguez-Garcia, Samuel; del Rio-Garcia, Valme; Castro, Carmen] Univ Cadiz, Fac Med, Area Fisiol, Cadiz, Spain; [Geribaldi-Doldan, Noelia; Carrasco, Manuel; Murillo-Carretero, Maribel; Dominguez-Garcia, Samuel; Garcia-Cozar, Francisco J.; Pedro Munoz-Miranda, Juan; del Rio-Garcia, Valme; Verastegui, Cristina; Castro, Carmen] Univ Cadiz, Inst Invest & Innovac Ciencias Biomed Prov Cadiz, Cadiz, Spain; [Garcia-Cozar, Francisco J.; Pedro Munoz-Miranda, Juan] Univ Cadiz, Area Inmunol, Fac Med, Cadiz, Spain; [Verastegui, Cristina] Univ Cadiz, Dept Anat, Fac Med, Cadiz, Spain	Castro, C (corresponding author), Univ Cadiz, Fac Med, Area Fisiol, Cadiz, Spain.; Castro, C (corresponding author), Univ Cadiz, Inst Invest & Innovac Ciencias Biomed Prov Cadiz, Cadiz, Spain.	carmen.castro@uca.es	Garcia, Samuel Dominguez/AAS-8879-2020; Doldan, Noelia Geribaldi/O-7286-2019; Carmen, Castro/C-7813-2009; Escolano, Cristina Verastegui/L-7264-2014; Doldan, Noelia Geribaldi/L-4478-2014; Garcia-Cozar, Francisco/A-6212-2013	Garcia, Samuel Dominguez/0000-0003-4319-3466; Doldan, Noelia Geribaldi/0000-0003-2149-9050; Carmen, Castro/0000-0002-6802-0572; Escolano, Cristina Verastegui/0000-0002-9342-2127; Garcia-Cozar, Francisco/0000-0003-3720-259X	Spanish Consejeria de Innovacion, Ciencia y Empleo, Junta de AndaluciaJunta de Andalucia [P10CTS6639]; Ministerio de Economia y Competitividad, MINECO/FEDER [BFU2015-68652-R]; Fundacion Rodriguez-Pascual 2015	This work was supported by the Spanish Consejeria de Innovacion, Ciencia y Empleo, Junta de Andalucia (Grant Numbers P10CTS6639), Ministerio de Economia y Competitividad (Grant Number BFU2015-68652-R, MINECO/FEDER), and Fundacion Rodriguez-Pascual 2015. We thank the animal facility (SEPA) of the University of Cadiz for their support and the Core Biomedical Research Facility (sc-IBM, University of Cadiz) where some of the experiments were performed. We thank J. Antonio Torres for his technical assistance. SD-G is a Fellow of the University of Cadiz (Plan Propio de Investigacion 2017).	ADRIAN EK, 1962, J NEUROPATH EXP NEUR, V21, P597, DOI 10.1097/00005072-196210000-00007; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; CAVANAGH JB, 1970, J ANAT, V106, P471; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Duan CL, 2015, GLIA, V63, P1660, DOI 10.1002/glia.22837; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gonzales PE, 2008, BIOCHEMISTRY-US, V47, P9911, DOI 10.1021/bi801049v; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Gonzalez-Perez O, 2009, STEM CELLS, V27, P2032, DOI 10.1002/stem.119; Hosseini-Sharifabad M, 2007, J NEUROSCI METH, V162, P206, DOI 10.1016/j.jneumeth.2007.01.009; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Liu JL, 1998, J NEUROSCI, V18, P7768; Llorens-Bobadilla E, 2015, CELL STEM CELL, V17, P329, DOI 10.1016/j.stem.2015.07.002; Magavi SS, 2002, DEV BRAIN RES, V134, P57, DOI 10.1016/S0165-3806(01)00316-9; Marin-Teva JL, 2011, NEURON GLIA BIOL, V7, P25, DOI 10.1017/S1740925X12000014; Milla ME, 2006, CELL BIOCHEM BIOPHYS, V44, P342, DOI 10.1385/CBB:44:3:342; Moraga A, 2014, FASEB J, V28, P4710, DOI 10.1096/fj.14-252452; Moreno-Lopez B, 2004, J NEUROSCI, V24, P85, DOI 10.1523/JNEUROSCI.1574-03.2004; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Paez-Gonzalez P, 2014, NAT NEUROSCI, V17, P934, DOI 10.1038/nn.3734; Parent JM, 1997, J NEUROSCI, V17, P3727; Rabaneda LG, 2008, FASEB J, V22, P3823, DOI 10.1096/fj.08-109306; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Romero-Grimaldi C, 2011, STEM CELLS, V29, P1628, DOI 10.1002/stem.710; Saha B, 2013, STEM CELL RES, V11, P965, DOI 10.1016/j.scr.2013.06.006; Seidenfaden R, 2006, MOL CELL NEUROSCI, V32, P187, DOI 10.1016/j.mcn.2006.04.003; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Tropepe V, 1997, J NEUROSCI, V17, P7850; Wei ZJ, 2015, MOL MED REP, V12, P63, DOI 10.3892/mmr.2015.3395; West M J, 2001, Folia Morphol (Warsz), V60, P11	44	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	AUG 28	2018	9								862	10.1038/s41419-018-0913-2			17	Cell Biology	Cell Biology	GR9MK	WOS:000443087500019	30154402	DOAJ Gold, Green Published			2021-06-18	
J	Andrews, RJ; Fonda, JR; Levin, LK; McGlinchey, RE; Milberg, WP				Andrews, Ryan J.; Fonda, Jennifer R.; Levin, Laura K.; McGlinchey, Regina E.; Milberg, William P.			Comprehensive analysis of the predictors of neurobehavioral symptom reporting in veterans	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; POSTCONCUSSION SYNDROME; OEF/OIF/OND VETERANS; VALIDITY; ASSOCIATION; DEPLOYMENT; IRAQ; PERFORMANCE	Objective This study assessed the strength of military-related concussion-, psychological-, and behavioralrelated measures to predict neurobehavioral symptom (NBS) reporting in order to help clarify the extent to which persistent NBS reflect lingering effects of concussion vs other psychological/behavioral factors among veterans. Methods Baseline analysis included 351 consecutively enrolled veterans in the Translational Research Center for Traumatic Brain Injury and Stress Disorders longitudinal cohort study. One hundred eighty-six returned for a follow-up evaluation averaging 24 months post baseline. The Neurobehavioral Symptom Inventory (NSI) was used to measure NBS reporting. Predictor variables included diagnosis of military-related mild traumatic brain injury (M-mTBI), psychological measures, including posttraumatic stress disorder, mood, anxiety, and substance abuse disorders, and behavioral measures, including self-reported current pain and sleep impairment. Hierarchical and multivariable regression analyses examined the relationships between the predictor variables and NSI scores. The k-fold cross-validation assessed generalizability and validity of the regressions. Results Baseline analysis revealed that psychological and behavioral conditions independently accounted for 42.5% of variance in the NSI total score compared to 1.5% for M-mTBI after controlling for psychological and behavioral conditions. Prospective analysis revealed that M-mTBI at baseline did not significantly predict NSI score at follow-up, while psychological and behavioral measures at baseline independently accounted for 24.5% of NSI variance. Posttraumatic stress disorder was the most consistent predictor. Cross-validation analyses supported generalizability of the results. Conclusions Psychological and behavioral-related measures are strong predictors of persistent NBS reporting in veterans, while M-mTBI is negligible. NBS more likely reflect influential comorbidities as opposed to brain injury, per se.	[Milberg, William P.] Boston Healthcare Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Boston, MA USA; Translat Res Ctr TBI & Stress Disorders, Boston, MA USA	Milberg, WP (corresponding author), Boston Healthcare Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Boston, MA USA.	william_milberg@hms.harvard.edu			US Department of Veterans Affairs through the Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research & Development Traumatic Brain Injury National Network Research Center [B9254-C]; VA Clinical Science Research & Development Merit Review [CX001327]; NIH NCCIH grant [R21 AT009430-01]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT009430] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001327, I50RX003001] Funding Source: NIH RePORTER	This study was supported by the US Department of Veterans Affairs through the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research & Development Traumatic Brain Injury National Network Research Center (B9254-C), a VA Clinical Science Research & Development Merit Review (CX001327), and NIH NCCIH grant (R21 AT009430-01).	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Amick MM, 2018, J HEAD TRAUMA REHAB, V33, pE30, DOI 10.1097/HTR.0000000000000308; [Anonymous], 2010, VA CONS C PRACT REC; Armistead-Jehle P, 2017, PHYS MED REH CLIN N, V28, P323, DOI 10.1016/j.pmr.2016.12.008; Bender SD, 2013, PSYCHOL INJ LAW, V6, P113, DOI 10.1007/s12207-013-9156-9; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Fonda JR, 2017, AM J EPIDEMIOL, V186, P220, DOI 10.1093/aje/kwx044; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Garber BG, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0325-5; Hastie T, 2009, ELEMENTS STAT LEARNI, P1, DOI DOI 10.1007/B94608; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kaplan DA, INFORM PAPER NEUROBE; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McGlinchey RE, 2017, INT J METHODS PSYCHI; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; O'Neil ME, COMPLICATIONS MILD T; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter SDS, 2016, J NEUROL NEUROSUR PS, V87, P1075, DOI 10.1136/jnnp-2015-312838; Roth R.S., 2013, INT J PHYS MED REHAB, V1, P105, DOI [https://doi.org/10.4172/2329-9096.1000105, DOI 10.4172/2329-9096.1000105, 10.4172/2329-9096.1000105]; Schwab K, 2017, NEUROLOGY, V88, P1571, DOI 10.1212/WNL.0000000000003839; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Waldron-Perrine B, 2014, MIL MED, V179, P856, DOI 10.7205/MILMED-D-13-00282; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Yarkoni T, 2017, PERSPECT PSYCHOL SCI, V12, P1100, DOI 10.1177/1745691617693393	39	11	11	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 21	2018	91	8					E732	E745		10.1212/WNL.0000000000006034			14	Clinical Neurology	Neurosciences & Neurology	GR1EJ	WOS:000442272400005	30054440	Green Published			2021-06-18	
J	Akande, M; Minneci, PC; Deans, KJ; Xiang, H; Cooper, JN				Akande, Manzilat; Minneci, Peter C.; Deans, Katherine J.; Xiang, Henry; Cooper, Jennifer N.			Association of Medicaid Expansion Under the Affordable Care Act With Outcomes and Access to Rehabilitation in Young Adult Trauma Patients	JAMA SURGERY			English	Article							LOW-INCOME ADULTS; LENGTH-OF-STAY; INSURANCE STATUS; BRAIN-INJURY; ETHNIC DISPARITIES; DIAGNOSIS MATRIX; RISK-FACTORS; SAFETY NET; MORTALITY; RACE	IMPORTANCE Trauma is the leading cause of death and disability among young adults in the United States. Young adults are also the age group most likely to be uninsured. Implementation of Medicaid expansion through the Affordable Care Act (ACA) has increased insurance coverage, but its associations with trauma care and outcomes among young adults nationwide remain unknown. We examined whether Medicaid expansion, in its first year, was associated with changes in insurance coverage and improved outcomes in young adults hospitalized for traumatic injury. OBJECTIVE To assess the associations of ACA Medicaid expansion with insurance coverage, in-hospital mortality, failure to rescue, access to rehabilitation, and unplanned readmissions among hospitalized young adult trauma patients across many US states. DESIGN, SETTING, AND PARTICIPANTS We used the Healthcare Cost and Utilization Project State Inpatient Databases to examine changes in insurance coverage and risk adjusted outcomes among young adults (age 19 to 44 years) who were hospitalized for injuries before and after Medicaid expansion and open enrollment occurred (2012-2013 vs 2014) in 11 US states that expanded Medicaid through the ACA. We also performed difference-in-difference analyses to compare these changes between 3 expansion states and 3 non-expansion states within the same geographic region. RESULTS Of the 141 187 trauma patients hospitalized across 11 Medicaid expansion states, 43 871 (31.1%) were women, and the mean (SD) age was 31.4 (7.6) years. Medicaid expansion was associated with an increase in Medicaid coverage from 16 229 individuals (16.7%) to 15 358 individuals (34.9%) (difference: 18.2%[95% CI, 16.5%-20.0%]; P<.001), a decrease in lack of insurance from 27 016 individuals (27.8%) to 5589 individuals (12.7%) (difference: -15.1% [95% CI, -16.8% to -13.5%]; P<.001), and an increase in discharge to rehabilitation from 9220 individuals (11.4%) to 4736 individuals (12.6%) (difference: 1.16%[95% CI, 0.55%-1.77%]; P<.001). We found no significant reductions in in-hospital mortality, failure to rescue, or unplanned readmissions. Similar results were found when 3 of these states were compared with 3 geographically and demographically similar states that had not enacted Medicaid expansion. CONCLUSIONS AND RELEVANCE The first year of implementation of Medicaid expansion and open enrollment across 11 selected US states was associated with significant increases in Medicaid coverage, reductions in uninsured rates, and increased access to postdischarge rehabilitation among young adults hospitalized for injury. However, this study found no significant reductions in in-hospital mortality, failure to rescue, or unplanned readmissions.	[Akande, Manzilat] Nationwide Childrens Hosp, Dept Crit Care Med, Columbus, OH 43205 USA; [Minneci, Peter C.; Deans, Katherine J.; Cooper, Jennifer N.] Nationwide Childrens Hosp, Res Inst, Ctr Surg Outcomes Res, 700 Childrens Dr,FB Ste 3A-3, Columbus, OH 43205 USA; [Minneci, Peter C.; Deans, Katherine J.; Cooper, Jennifer N.] Nationwide Childrens Hosp, Res Inst, Ctr Innovat Pediat Practice, 700 Childrens Dr,FB Ste 3A-3, Columbus, OH 43205 USA; [Minneci, Peter C.; Deans, Katherine J.] Nationwide Childrens Hosp, Dept Surg, Columbus, OH 43205 USA; [Xiang, Henry; Cooper, Jennifer N.] Nationwide Childrens Hosp, Res Inst, Ctr Pediat Trauma Res, Columbus, OH 43205 USA	Cooper, JN (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Surg Outcomes Res, 700 Childrens Dr,FB Ste 3A-3, Columbus, OH 43205 USA.; Cooper, JN (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Innovat Pediat Practice, 700 Childrens Dr,FB Ste 3A-3, Columbus, OH 43205 USA.	jennifer.cooper@nationwidechildrens.org		Cooper, Jennifer/0000-0001-7590-7166	Research Institute at Nationwide Children's HospitalOhio State University	The Research Institute at Nationwide Children's Hospital contributed all financial and material support for this research.	Agency for Healthcare Research and Quality. HCUP National Inpatient Sample (NIS), HEALTHC COST UT PROJ; Akande M, 2018, J SURG RES, V228, P42, DOI 10.1016/j.jss.2018.02.058; American Heart Association Health Forum, AHA ANN SURV DAT; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Arthur M, 2008, MED CARE, V46, P192, DOI 10.1097/MLR.0b013e31815b9d8e; Baicker K, 2013, NEW ENGL J MED, V368, P1713, DOI 10.1056/NEJMsa1212321; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bekelis K, 2015, ANN SURG, V262, P9, DOI 10.1097/SLA.0000000000001239; Bell TM, 2013, J TRAUMA ACUTE CARE, V75, P728, DOI 10.1097/TA.0b013e3182a53aaa; Blavin F, 2016, JAMA-J AM MED ASSOC, V316, P1475, DOI 10.1001/jama.2016.14765; Cheslik TG, 2016, J TRAUMA ACUTE CARE, V80, P1010, DOI 10.1097/TA.0000000000001052; Clark DE OT, 2010, ICDPIC STATA MODULE; Decker SL, 2014, JAMA INTERN MED, V174, P988, DOI 10.1001/jamainternmed.2014.518; DeNavas-Walt C., 2010, INCOME POVERTY HLTH; Duron VP, 2012, J TRAUMA ACUTE CARE, V73, P1093, DOI 10.1097/TA.0b013e31826fc844; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Fingerhut LA, 2006, INJURY PREV, V12, P24, DOI 10.1136/ip.2005.009076; Gerry JM, 2016, INJURY, V47, P197, DOI 10.1016/j.injury.2015.09.003; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2013, J TRAUMA ACUTE CARE, V74, P1195, DOI 10.1097/TA.0b013e31828c331d; Hamilton EC, 2016, J PEDIATR SURG, V51, P2048, DOI 10.1016/j.jpedsurg.2016.09.036; Han XS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144429; Henry J, 2015, GUIDE SUPREME COURTS; Henry J., 2012, STAT STAT ACT MED EX; Henry J. Kaiser Family Foundation, 2018, TOTAL MONTHLY MED CH; Ingraham AM, 2010, ANN SURG, V252, P358, DOI 10.1097/SLA.0b013e3181e623bf; Joseph B, 2016, J TRAUMA ACUTE CARE, V81, P427, DOI 10.1097/TA.0000000000001082; Laupland KB, 2010, INJURY, V41, P69, DOI 10.1016/j.injury.2009.06.006; Leukhardt WH, 2010, AM J SURG, V199, P348, DOI 10.1016/j.amjsurg.2009.09.021; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Medicaid.gov, 2018, KEEP AM HLTH MONTHL; Moore L, 2014, ANN SURG, V259, P374, DOI 10.1097/SLA.0b013e31828b0fae; Morris DS, 2014, INJURY, V45, P56, DOI 10.1016/j.injury.2013.04.029; National Center for Health Statistics, 2009, ICD 10 EXT CAUS INJ; National Center for Health Statistics, 2016, NCHS URB RUR CLASS S; National Center for Health Statistics, 2017, TOOLS FRAM TOOLS CAT; Nehra D, 2016, J AM COLL SURGEONS, V223, P755, DOI 10.1016/j.jamcollsurg.2016.09.001; Perl VJU, 2017, AM J SURG, V213, P870, DOI 10.1016/j.amjsurg.2017.03.036; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rosenthal MG, 2017, J TRAUMA ACUTE CARE, V83, P135, DOI 10.1097/TA.0000000000001540; Rudowitz R, 2017, MED ENROLLMENT SPEND; Rudowitz Robin, 2016, WHAT COVERAGE FINANC; Sabharwal S, 2007, J PEDIATR ORTHOPED, V27, P690, DOI 10.1097/BPO.0b013e3181425653; Salim A, 2010, J TRAUMA, V68, P211, DOI 10.1097/TA.0b013e3181a0e659; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Soberg HL, 2011, J TRAUMA, V71, P425, DOI 10.1097/TA.0b013e3181eff54f; Sommers B.D., 2013, MED MED RES REV, V3; Sommers BD, 2017, HEALTH AFFAIR, V36, P1119, DOI 10.1377/hlthaff.2017.0293; Sommers BD, 2015, JAMA-J AM MED ASSOC, V314, P366, DOI 10.1001/jama.2015.8421; Sommers BD, 2014, HEALTH AFFAIR, V33, P78, DOI 10.1377/hlthaff.2013.1087; Sommers BD, 2012, NEW ENGL J MED, V367, P1025, DOI 10.1056/NEJMsa1202099; Tepas JJ, 2011, J AM COLL SURGEONS, V212, P722, DOI 10.1016/j.jamcollsurg.2010.12.016; US Centers for Disease Control and Prevention, 2016, COST INJ VIOL US; US Centers for Disease Control and Prevention National Center for Health Statistics, 2016, DEATHS AND MORT; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Zogg CK, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.3609	57	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	AUG	2018	153	8							e181630	10.1001/jamasurg.2018.1630			11	Surgery	Surgery	GQ5US	WOS:000441758600003	29874372	Green Published			2021-06-18	
J	Chen, XB; Wang, ZL; Yang, QY; Zhao, FY; Qin, XL; Tang, XE; Du, JL; Chen, ZH; Zhang, K; Huang, FJ				Chen, Xian-Bing; Wang, Zi-Li; Yang, Qing-Yu; Zhao, Fang-Yu; Qin, Xiao-Li; Tang, Xian-E; Du, Jun-Long; Chen, Zong-Hai; Zhang, Kui; Huang, Fei-Jun			Diosgenin Glucoside Protects against Spinal Cord Injury by Regulating Autophagy and Alleviating Apoptosis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						spinal cord injury; autophagy; diosgenin glucoside; Rheb/mTOR signal pathway; miR-155-3p; apoptosis	PROMOTES FUNCTIONAL RECOVERY; SIGNALING PATHWAY; TRILLIUM-KAMTSCHATICUM; NEURONAL APOPTOSIS; REPERFUSION INJURY; UNDERGROUND PARTS; UP-REGULATION; RATS; BRAIN; MTOR	Spinal cord injury (SCI) is a severe traumatic lesion of central nervous system (CNS) with only a limited number of restorative therapeutic options. Diosgenin glucoside (DG), a major bioactive ingredient of Trillium tschonoskii Max., possesses neuroprotective effects through its antioxidant and anti-apoptotic functions. In this study, we investigated the therapeutic benefit and underlying mechanisms of DG treatment in SCI. We found that in Sprague-Dawley rats with traumatic SCI, the expressions of autophagy marker Light Chain 3 (LC3) and Beclin1 were decreased with concomitant accumulation of autophagy substrate protein p62 and ubiquitinated proteins, indicating an impaired autophagic activity. DG treatment, however, significantly attenuated p62 expression and upregulated the Rheb/mTOR signaling pathway (evidenced as Ras homolog enriched in brain) due to the downregulation of miR-155-3p. We also observed significantly less tissue injury and edema in the DG-treated group, leading to appreciable functional recovery compared to that of the control group. Overall, the observed neuroprotection afforded by DG treatment warrants further investigation on its therapeutic potential in SCI.	[Chen, Xian-Bing; Zhang, Kui; Huang, Fei-Jun] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China; [Chen, Xian-Bing; Wang, Zi-Li; Yang, Qing-Yu; Zhao, Fang-Yu; Qin, Xiao-Li; Tang, Xian-E; Du, Jun-Long; Chen, Zong-Hai] Hubei Univ Nationalities, Coll Med, Enshi 445000, Peoples R China	Huang, FJ (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.	1998023@hbmy.edu.cn; wangzili2018731@gmail.com; yangqingyuyqy@gmail.com; fangyuzhao584@gmail.com; xiaolitan965@gmail.com; tangx483@gmail.com; dujunlong666@gmail.com; chenzonghai666@gmail.com; zhk@scu.edu.cn; hfj@scu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81660672]	This work was financially supported by the National Natural Science Foundation of China (No. 81660672).	Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006; Bai LJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep42288; Brown HLD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044888; Campolo M, 2013, FASEB J, V27, P4489, DOI 10.1096/fj.13-234716; Cao MH, 2013, NEUROCHEM INT, V62, P406, DOI 10.1016/j.neuint.2013.01.025; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; Chen JJ, 2013, J MOL NEUROSCI, V51, P82, DOI 10.1007/s12031-013-0003-y; Chen MH, 2014, CELL TISSUE RES, V358, P277, DOI 10.1007/s00441-014-1946-1; [陈显兵 Chen Xianbing], 2015, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V40, P622; Cheung HH, 2011, ONCOGENE, V30, P3404, DOI 10.1038/onc.2011.60; Cripps RA, 2011, SPINAL CORD, V49, P493, DOI 10.1038/sc.2010.146; Dellago H, 2013, AGING CELL, V12, P446, DOI 10.1111/acel.12069; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Filip Agata, 2007, Postepy Biochem, V53, P413; Fournier AE, 2003, J NEUROSCI, V23, P1416; Gracias NG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4506; Greco R, 2018, J NEUROSCI RES, V96, P151, DOI 10.1002/jnr.24101; Gregory EN, 2010, NEUROSCIENCE, V169, P1392, DOI 10.1016/j.neuroscience.2010.05.067; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gu TT, 2014, BIOL OPEN, V3, P81, DOI 10.1242/bio.20136437; Hao HH, 2013, NEUROSCI BULL, V29, P484, DOI 10.1007/s12264-013-1355-6; Hartman NW, 2013, CELL REP, V5, P433, DOI 10.1016/j.celrep.2013.09.017; Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jovicic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054222; Jung SY, 2014, EXP THER MED, V7, P587, DOI 10.3892/etm.2013.1451; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu YJ, 2015, J CELL BIOCHEM, V116, P2870, DOI 10.1002/jcb.25234; Ono M, 2003, CHEM PHARM BULL, V51, P1328, DOI 10.1248/cpb.51.1328; Ono M, 2007, CHEM PHARM BULL, V55, P1093, DOI 10.1248/cpb.55.1093; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Shu QM, 2014, J MOL NEUROSCI, V54, P243, DOI 10.1007/s12031-014-0281-z; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534; Wang JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003697; Wang LJ, 2018, BIOMED PHARMACOTHER, V98, P516, DOI 10.1016/j.biopha.2017.12.046; Wu H, 2016, CAN J PHYSIOL PHARM, V94, P1291, DOI 10.1139/cjpp-2016-0228; Wu J, 2012, HUM IMMUNOL, V73, P31, DOI 10.1016/j.humimm.2011.10.003; Xu LJ, 2017, BIOMED PHARMACOTHER, V90, P524, DOI 10.1016/j.biopha.2017.03.105; Yan WJ, 2011, BRAIN RES, V1402, P109, DOI 10.1016/j.brainres.2011.05.049; Yang K, 2014, J INFECT DIS, V210, P89, DOI 10.1093/infdis/jiu002; Yin YM, 2015, SYNAPSE, V69, P139, DOI 10.1002/syn.21802; Yu QJ, 2016, LIFE SCI, V148, P86, DOI 10.1016/j.lfs.2016.02.005; Zhang C, 2017, REPROD FERT DEVELOP, V29, P768, DOI 10.1071/RD15230; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao J, 2015, J MOL NEUROSCI, V57, P595, DOI 10.1007/s12031-015-0642-2; Zou J, 2011, DEV CELL, V20, P97, DOI 10.1016/j.devcel.2010.11.020; 姜国良, 2013, [中国老年学杂志, Chinese Journal of Gerontology], V33, P1101	51	11	11	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	AUG	2018	19	8							2274	10.3390/ijms19082274			16	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	GR7LE	WOS:000442869800126	30072674	DOAJ Gold, Green Published			2021-06-18	
J	Henry, GK; Heilbronner, RL; Suhr, J; Gornbein, J; Wagner, E; Drane, DL				Henry, George K.; Heilbronner, Robert L.; Suhr, Julie; Gornbein, Jeffrey; Wagner, Eveleigh; Drane, Daniel L.			Illness Perceptions Predict Cognitive Performance Validity	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Performance validity; Symptom validity; Illness perceptions; Health beliefs; Cogniphobia; Symptom identity	MALINGERED NEUROCOGNITIVE DYSFUNCTION; PSYCHOGENIC NONEPILEPTIC SEIZURES; RESTRUCTURED FORM MMPI-2-RF; TRAUMATIC BRAIN-INJURY; COMMON-SENSE MODEL; MILD HEAD-INJURY; SYMPTOM VALIDITY; RESPONSE BIAS; DISSOCIATIVE TENDENCIES; FORENSIC SETTINGS	Objectives: The aim of this study was to investigate the relationship of psychological variables to cognitive performance validity test (PVT) results in mixed forensic and nonforensic clinical samples. Methods: Participants included 183 adults who underwent comprehensive neuropsychological examination. Criterion groups were formed, that is, Credible Group or Noncredible Group, based upon their performance on the Word Memory Test and other stand-alone and embedded PVT measures. Results: Multivariate logistic regression analysis identified three significant predictors of cognitive performance validity. These included two psychological constructs, for example, Cogniphobia (perception that cognitive effort will exacerbate neurological symptoms), and Symptom Identity (perception that current symptoms are the result of illness or injury), and one contextual factor (forensic). While there was no interaction between these factors, elevated scores were most often observed in the forensic sample, suggesting that these independently contributing intrinsic psychological factors are more likely to occur in a forensic environment. Conclusions: Illness perceptions were significant predictors of cognitive performance validity particularly when they reached very elevated levels. Extreme elevations were more common among participants in the forensic sample, and potential reasons for this pattern are explored.	[Henry, George K.; Gornbein, Jeffrey] UCLA, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Heilbronner, Robert L.] Chicago Neuropsychol Grp, Chicago, IL USA; [Heilbronner, Robert L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Suhr, Julie] Ohio Univ, Athens, OH 45701 USA; [Wagner, Eveleigh] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Drane, Daniel L.] Emory Univ, Sch Med, Atlanta, GA USA	Henry, GK (corresponding author), 11601 Wilshire Blvd,5th Floor, Los Angeles, CA 90025 USA.	GHenry0249@aol.com			NCS Pearson, Minneapolis, MN	Authors (G.H., R.H.) declare there was a fee for service for the 81 forensic referrals, while authors (J.S., J.G., W.E., D.D.) report no potential conflicts of interest. Partial funding was provided by NCS Pearson, Minneapolis, MN, for MMPI-2-RF scoring costs.	Amrhein C, 2008, J TRAUMA DISSOCIATIO, V9, P525, DOI 10.1080/15299730802226332; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Bandura A., 1997, SELF EFFICACY EXERCI; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Crombez G, 1998, BEHAV MODIF, V22, P62, DOI 10.1177/01454455980221004; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; DePrince AP, 1999, PSYCHOL SCI, V10, P449, DOI 10.1111/1467-9280.00185; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; Diefenbach MA, 1996, J SOC DISTRESS HOMEL, V5, P11, DOI 10.1007/BF02090456; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Drane DL, 2016, EPILEPSY BEHAV, V56, P131, DOI 10.1016/j.yebeh.2016.01.001; Forbey JD, 2013, ASSESSMENT, V20, P448, DOI 10.1177/1073191113478154; Forbey JD, 2011, J PERS ASSESS, V93, P556, DOI 10.1080/00223891.2011.608757; Fragale A., 2004, PERSONALITY SOCIAL P, V30, P226; Freyd JJ, 1998, APPL COGNITIVE PSYCH, V12, pS91, DOI 10.1002/(SICI)1099-0720(199812)12:7<S91::AID-ACP599>3.0.CO;2-Z; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2011, J PERS ASSESS, V93, P508, DOI 10.1080/00223891.2011.594132; Green P., 2005, GREENS WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Henry GK, 2013, CLIN NEUROPSYCHOL, V27, P509, DOI 10.1080/13854046.2012.739644; Ingram PB, 2016, CLIN NEUROPSYCHOL, V30, P473, DOI 10.1080/13854046.2016.1187769; Johnson S, 2008, MED UNEXPLAINED ILLN; Jones A, 2012, CLIN NEUROPSYCHOL, V26, P790, DOI 10.1080/13854046.2012.693202; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp S, 2008, J PSYCHOSOM RES, V65, P319, DOI 10.1016/j.jpsychores.2008.02.010; Kotor R.I., 2004, MULTIDIMENSIONAL IOW; Lamberty G. J., 2008, UNDERSTANDING SOMATI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Martelli M.F., 1999, KINESIOPHOBIA COGNIP; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Martin PK, 2015, ARCH CLIN NEUROPSYCH, V30, P377, DOI 10.1093/arclin/acv032; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nelson NW, 2011, CLIN NEUROPSYCHOL, V25, P716, DOI 10.1080/13854046.2011.579174; Nguyen CT, 2015, CLIN NEUROPSYCHOL, V29, P255, DOI 10.1080/13854046.2015.1033020; Peck CP, 2013, CLIN NEUROPSYCHOL, V27, P693, DOI 10.1080/13854046.2013.779032; Rogers R, 2011, J PSYCHOPATHOL BEHAV, V33, P355, DOI 10.1007/s10862-011-9222-0; Schroeder RW, 2016, CLIN NEUROPSYCHOL, V30, P515, DOI 10.1080/13854046.2016.1177118; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P757, DOI 10.1037/a0020825; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Slick D., 1997, VICTORIA SYMPTOM VAL; Snell DL, 2013, NEUROPSYCHOL REHABIL, V23, P333, DOI 10.1080/09658211.2012.758419; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Suhr J, 2012, CLIN NEUROPSYCHOL, V26, P1128, DOI 10.1080/13854046.2012.713121; Sweet J.J., 2008, CLIN ASSESSMENT MALI; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Todd D.D., 1998, CISC VIS NETW IND GL; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tutz G, 2006, BIOMETRICS, V62, P961, DOI 10.1111/j.1541-0420.2006.00578.x; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Vazquez-Justo E, 2003, PSYCHIAT CLIN NEUROS, V57, P251, DOI 10.1046/j.1440-1819.2003.00113.x; Weinman J., 1995, MEASURES HLTH PSYCHO; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Williamson DJ, 2012, CLIN NEUROPSYCHOL, V26, P588, DOI 10.1080/13854046.2012.670266; Williamson DJ, 2005, EPILEPSIA, V46, P74; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]	78	11	11	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2018	24	7					735	745		10.1017/S1355617718000218			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	GR6FA	WOS:000442739900009	29704907	Bronze			2021-06-18	
J	Mattugini, N; Merl-Pham, J; Petrozziello, E; Schindler, L; Bernhagen, J; Hauck, SM; Gotz, M				Mattugini, Nicola; Merl-Pham, Juliane; Petrozziello, Elisabetta; Schindler, Lisa; Bernhagen, Juergen; Hauck, Stefanie M.; Goetz, Magdalena			Influence of white matter injury on gray matter reactive gliosis upon stab wound in the adult murine cerebral cortex	GLIA			English	Article						astrocytes; brain injury; gray matter; microglia; NG2; proteomics; white matter	MIGRATION INHIBITORY FACTOR; SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; OLIGODENDROCYTE PRECURSOR CELLS; NEURAL STEM-CELLS; DATA-INDEPENDENT ACQUISITION; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; CORPUS-CALLOSUM; GLIAL SCAR	Traumatic brain injury frequently affects the cerebral cortex, yet little is known about the differential effects that occur if only the gray matter (GM) is damaged or if the injury also involves the white matter (WM). To tackle this important question and directly compare similarities and differences in reactive gliosis, we performed stab wound injury affecting GM and WM (GM+) and one restricted to the GM (GM-) in the adult murine cerebral cortex. First, we examined glial reactivity in the regions affected (WM and GM) and determined the influence of WM injury on reactive gliosis in the GM comparing the same area in the two injury paradigms. In the GM+ injury microglia proliferation is increased in the WM compared with GM, while proliferating astrocytes are more abundant in the GM than in the WM. Interestingly, WM lesion exerted a strong influence on the proliferation of the GM glial cells that was most pronounced at early stages, 3 days post lesion. While astrocyte proliferation was increased, NG2 glia proliferation was decreased in the GM+ compared with GM- lesion condition. Importantly, these differences were not observed when a lesion of the same size affected only the GM. Unbiased proteomic analyses further corroborate our findings in support of a profound difference in GM reactivity when WM is also injured and revealed MIF as a key regulator of NG2 glia proliferation.	[Mattugini, Nicola; Goetz, Magdalena] Ludwig Maximilians Univ Munchen, Biomed Ctr BMC, Physiol Genom, Grosshaderner Str 9, D-82152 Planegg Martinsried, Germany; [Mattugini, Nicola; Goetz, Magdalena] Ludwig Maximilians Univ Munchen, Dept Physiol Genom, Helmholtz Ctr Munich, Inst Stem Cell Res,Biomed Ctr BMC, Grosshaderner Str 9, D-82152 Planegg Martinsried, Germany; [Mattugini, Nicola] Ludwig Maximilians Univ Munchen, Grad Sch Syst Neurosci, Grosshaderner Str 2, D-82152 Planegg Martinsried, Germany; [Merl-Pham, Juliane; Hauck, Stefanie M.] Helmholtz Ctr Munich, Res Unit Prot Sci, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany; [Petrozziello, Elisabetta] Ludwig Maximilians Univ Munchen, Inst Immunol, Biomed Ctr BMC, Grosshadernerstr 9, D-82152 Planegg Martinsried, Germany; [Schindler, Lisa; Bernhagen, Juergen] Ludwig Maximilians Univ LMU Munich, Inst Stroke & Dementia Res ISD, Vasc Biol, D-81377 Munich, Germany; [Bernhagen, Juergen; Goetz, Magdalena] SyNergy Excellence Cluster, D-81377 Munich, Germany	Gotz, M (corresponding author), Ludwig Maximilians Univ Munchen, Biomed Ctr BMC, Physiol Genom, Grosshaderner Str 9, D-82152 Planegg Martinsried, Germany.	magdalena.goetz@helmholtz-muenchen.de	Merl-Pham, Juliane/N-7258-2014; Hauck, Stefanie/B-3300-2013	Merl-Pham, Juliane/0000-0002-3422-4083; Mattugini, Nicola/0000-0003-4489-1661; Hauck, Stefanie/0000-0002-1630-6827	German Research FoundationGerman Research Foundation (DFG) [SPP1757, SFB 870, EXC1010]	German Research Foundation, Grant/Award Numbers: SPP1757 and SFB 870; EXC1010 SyNergy	Adams KL, 2018, NAT NEUROSCI, V21, P9, DOI 10.1038/s41593-017-0033-9; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Arno B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6611; Ballabh P, 2004, PEDIATR RES, V56, P117, DOI 10.1203/01.PDR.0000130472.30874.FF; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Baumgart EV, 2012, GLIA, V60, P343, DOI 10.1002/glia.22269; Beliakoff J, 2008, MOL CELL BIOL, V28, P282, DOI 10.1128/MCB.00771-07; Ben Haim L, 2017, NAT REV NEUROSCI, V18, P31, DOI [10.1038/nm.2016.159, 10.1038/nrn.2016.159]; Ben Haim Lucile, 2015, Front Cell Neurosci, V9, P278, DOI 10.3389/fncel.2015.00278; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; Bruderer R, 2016, PROTEOMICS, V16, P2246, DOI 10.1002/pmic.201500488; Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Conboy L, 2011, MOL PSYCHIATR, V16, P533, DOI 10.1038/mp.2010.15; Dai JX, 2014, GLIA, V62, P2096, DOI 10.1002/glia.22729; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dewor M, 2007, FEBS LETT, V581, P4734, DOI 10.1016/j.febslet.2007.08.071; Dimou L, 2015, GLIA, V63, P1429, DOI 10.1002/glia.22859; Dimou L, 2008, J NEUROSCI, V28, P10434, DOI 10.1523/JNEUROSCI.2831-08.2008; Dimou L, 2014, PHYSIOL REV, V94, P709, DOI 10.1152/physrev.00036.2013; Djudjaj S, 2017, J AM SOC NEPHROL, V28, P3590, DOI 10.1681/ASN.2017020190; Doi T, 2017, J NEUROSCI, V37, P10290, DOI 10.1523/JNEUROSCI.1109-17.2017; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dumont CM, 2015, CELLS TISSUES ORGANS, V202, P52, DOI 10.1159/000446646; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endo M, 2017, GLIA, V65, P182, DOI 10.1002/glia.23086; Fern RF, 2014, GLIA, V62, P1780, DOI 10.1002/glia.22722; Fernandez-Klett F, 2014, BRAIN PATHOL, V24, P404, DOI 10.1111/bpa.12162; Fewings NL, 2017, J AUTOIMMUN, V78, P57, DOI 10.1016/j.jaut.2016.12.006; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Gallo V, 2014, NEURON, V83, P283, DOI 10.1016/j.neuron.2014.06.010; Gaupp S, 2011, J NEUROPATH EXP NEUR, V70, P1138, DOI 10.1097/NEN.0b013e31823b188b; Geiger T, 2010, MOL CELL PROTEOMICS, V9, P2252, DOI 10.1074/mcp.M110.001537; Gillet LC, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016717; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Goursaud S, 2009, J NEUROCHEM, V108, P1442, DOI 10.1111/j.1471-4159.2009.05889.x; Grosche A, 2016, MOL CELL PROTEOMICS, V15, P462, DOI 10.1074/mcp.M115.052183; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hammond TR, 2014, NEURON, V81, P588, DOI 10.1016/j.neuron.2013.11.015; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Han J, 2013, CELL DEATH DIFFER, V20, P1055, DOI 10.1038/cdd.2013.33; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; He DY, 2016, NAT NEUROSCI, V19, P678, DOI 10.1038/nn.4258; Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311; Heintz N, 2004, NAT NEUROSCI, V7, P483, DOI 10.1038/nn0504-483; Hsieh TH, 2017, CEREB CORTEX, V27, P5509, DOI 10.1093/cercor/bhw318; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Inacio AR, 2011, J CEREBR BLOOD F MET, V31, P1093, DOI 10.1038/jcbfm.2010.194; Jantzie LL, 2013, PEDIATR RES, V74, P658, DOI 10.1038/pr.2013.155; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Jeong HK, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-28; Ji SP, 2011, J MOL CELL BIOL, V3, P351, DOI 10.1093/jmcb/mjr009; Joutel A, 2017, CLIN SCI, V131, P635, DOI 10.1042/CS20160380; Kang SH, 2013, NAT NEUROSCI, V16, P571, DOI 10.1038/nn.3357; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Li XM, 2006, J BIOL CHEM, V281, P23748, DOI 10.1074/jbc.M508365200; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lizhnyak PN, 2015, EXPERT REV PROTEOMIC, V12, P75, DOI 10.1586/14789450.2015.1000869; Luedike P, 2012, CIRCULATION, V125, P1880, DOI 10.1161/CIRCULATIONAHA.111.069104; Lundgaard I, 2014, NEUROSCIENCE, V276, P161, DOI 10.1016/j.neuroscience.2013.10.050; Martin-Lopez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074039; McQueen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087227; Mehan ND, 2012, NEUROBIOL AGING, V33, P1857, DOI 10.1016/j.neurobiolaging.2011.09.029; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Moyon S, 2015, J NEUROSCI, V35, P4, DOI 10.1523/JNEUROSCI.0849-14.2015; Nemajerova A, 2007, CELL CYCLE, V6, P1030, DOI 10.4161/cc.6.9.4163; Nobs L, 2013, GLIA, V61, P1443, DOI 10.1002/glia.22533; Nyul-Toth A, 2016, AM J PHYSIOL-HEART C, V310, pH1702, DOI 10.1152/ajpheart.00774.2015; Ohta S, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0275-6; Pinnell N, 2015, IMMUNITY, V43, P870, DOI 10.1016/j.immuni.2015.10.007; Prins M, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0098-6; Psachoulia K, 2009, NEURON GLIA BIOL, V5, P57, DOI 10.1017/S1740925X09990354; Rex S, 2014, MINI-REV MED CHEM, V14, P1116; Rodriguez JP, 2014, J NEUROSCI, V34, P10285, DOI 10.1523/JNEUROSCI.4915-13.2014; RODRIGUEZ MS, 2014, CELL DEATH DIS, V5; Rosenzweig S, 2013, STROKE, V44, P2579, DOI 10.1161/STROKEAHA.113.001796; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Samanta J, 2015, NATURE, V526, P448, DOI 10.1038/nature14957; Schafer I, 2016, J CELL SCI, V129, P930, DOI 10.1242/jcs.172148; Schmidt F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040457; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Silver J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020602; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Simons D, 2011, J CELL MOL MED, V15, P668, DOI 10.1111/j.1582-4934.2010.01041.x; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Sohn JH, 2015, J NEUROSCI, V35, P3756, DOI 10.1523/JNEUROSCI.3454-14.2015; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Tabata H, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00114; Tillmann S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00115; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; TYSSELING VM, 2011, J NEUROINFLAMM, V8; Vigano F, 2013, NAT NEUROSCI, V16, P1370, DOI 10.1038/nn.3503; Wang YF, 2016, SCIENCE, V354, DOI 10.1126/science.aad6872; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Yang DB, 2017, CLIN CHIM ACTA, V469, P99, DOI 10.1016/j.cca.2017.03.030; Yang HJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10884; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhu Y, 2017, J NEUROSCI, V37, P2362, DOI 10.1523/JNEUROSCI.2751-16.2017	110	11	11	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG	2018	66	8					1644	1662		10.1002/glia.23329			19	Neurosciences	Neurosciences & Neurology	GN1BV	WOS:000438719700008	29573353				2021-06-18	
J	Peters, AJ; Villasana, LE; Schnell, E				Peters, Austin J.; Villasana, Laura E.; Schnell, Eric			Ketamine Alters Hippocampal Cell Proliferation and Improves Learning in Mice after Traumatic Brain Injury	ANESTHESIOLOGY			English	Article							ADULT NEUROGENESIS; NMDA; ACTIVATION; NEURONS; SYNAPTOGENESIS; ANESTHESIA; EXPRESSION; RECEPTORS; MICROGLIA; PROPOFOL	Background: Traumatic brain injury induces cellular proliferation in the hippocampus, which generates new neurons and glial cells during recovery. This process is regulated by N-methyl-d-aspartate-type glutamate receptors, which are inhibited by ketamine. The authors hypothesized that ketamine treatment after traumatic brain injury would reduce hippocampal cell proliferation, leading to worse behavioral outcomes in mice. Methods: Traumatic brain injury was induced in mice using a controlled cortical impact injury, after which mice (N = 118) received either ketamine or vehicle systemically for 1 week. The authors utilized immunohistochemical assays to evaluate neuronal, astroglial, and microglial cell proliferation and survival 3 days, 2 weeks, and 6 weeks postintervention. The Morris water maze reversal task was used to assess cognitive recovery. Results: Ketamine dramatically increased microglial proliferation in the granule cell layer of the hippocampus 3 days after injury (injury + vehicle, 2,800 +/- 2,700 cells/mm(3), n = 4; injury + ketamine, 11,200 +/- 6,600 cells/mm(3), n = 6; P = 0.012). Ketamine treatment also prevented the production of astrocytes 2 weeks after injury (sham + vehicle, 2,400 +/- 3,200 cells/mm(3), n = 13; injury + vehicle, 10,500 +/- 11,300 cells/mm(3), n = 12; P = 0.013 vs. sham + vehicle; sham + ketamine, 3,500 +/- 4,900 cells/mm(3), n = 14; injury + ketamine, 4,800 +/- 3,000 cells/mm(3), n = 13; P = 0.955 vs. sham + ketamine). Independent of injury, ketamine temporarily reduced neurogenesis (vehicle-exposed, 105,100 +/- 66,700, cells/mm(3), n = 25; ketamine-exposed, 74,300 +/- 29,200 cells/mm(3), n = 27; P = 0.031). Ketamine administration improved performance in the Morris water maze reversal test after injury, but had no effect on performance in sham-treated mice. Conclusions: Ketamine alters hippocampal cell proliferation after traumatic brain injury. Surprisingly, these changes were associated with improvement in a neurogenesis-related behavioral recall task, suggesting a possible benefit from ketamine administration after traumatic brain injury in mice. Future studies are needed to determine generalizability and mechanism.	[Peters, Austin J.; Villasana, Laura E.; Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR USA; [Schnell, Eric] Vet Affairs Portland Hlth Care Syst, Anesthesiol Serv, Portland, OR USA	Schnell, E (corresponding author), VA Portland Hlth Care Syst, 3170 SW US Vet Hosp Rd,P3ANES, Portland, OR 97239 USA.	schneler@ohsu.edu		Schnell, Eric/0000-0002-5623-5015	Foundation for Anesthesia Education and Research (Schaumburg, Illinois); BIRCWH K12 award through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Bethesda, Maryland); Office of Research on Women's Health (Bethesda, Maryland) [K12 HD 043488]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (Washington, D.C.)US Department of Veterans Affairs; Biomedical Laboratory Research and Development (Washington, D.C.) CDA-2 Award [005-10S]; Department of Veterans Affairs Merit Review AwardUS Department of Veterans Affairs [I01-BX002949]; Oregon Health and Science University (Portland, Oregon) Anesthesiology and Perioperative Medicine departmental funds; Oregon Clinical and Translational Research Institute (Portland, Oregon) [TL1TR000129]; National Institute for Neurological Disorders and Stroke (Bethesda, Maryland) [P30 NS061800]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043488] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS061800] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002949] Funding Source: NIH RePORTER	Primary funding for this project was provided by a Foundation for Anesthesia Education and Research (Schaumburg, Illinois) Research Fellowship Grant (to Dr. Peters). Additional funding was provided by a BIRCWH K12 award made possible through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Bethesda, Maryland) and the Office of Research on Women's Health (Bethesda, Maryland; grant No. K12 HD 043488; to Dr. Villasana), a Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (Washington, D.C.), Biomedical Laboratory Research and Development (Washington, D.C.) CDA-2 Award 005-10S (to Dr. Schnell), a Department of Veterans Affairs Merit Review Award I01-BX002949 (to Dr. Schnell), and Oregon Health and Science University (Portland, Oregon) Anesthesiology and Perioperative Medicine departmental funds. Supplementary equipment and developmental funds were provided by the Oregon Clinical and Translational Research Institute (Portland, Oregon) grant No. TL1TR000129 and National Institute for Neurological Disorders and Stroke (Bethesda, Maryland) grant No. P30 NS061800.	Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Arruda-Carvalho M, 2011, J NEUROSCI, V31, P15113, DOI 10.1523/JNEUROSCI.3432-11.2011; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Bell JD, 2017, ANESTH ANALG, V124, P1237, DOI 10.1213/ANE.0000000000001856; Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Blaiss C, 2011, J NEUROSCI, V454, P42; Bond A, 2015, STEM CELLS, V116, P1477; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1995, J NEUROSCI, V15, P4687; Chang LC, 2013, CNS NEUROSCI THER, V19, P390, DOI 10.1111/cns.12077; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clarke M, 2017, NEUROPHARMACOLOGY, V112, P210, DOI 10.1016/j.neuropharm.2016.04.021; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Duman RS, 2012, PHILOS T R SOC B, V367, P2475, DOI 10.1098/rstb.2011.0357; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Gambrill AC, 2011, P NATL ACAD SCI USA, V108, P5855, DOI 10.1073/pnas.1012676108; Garthe A, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00063; Gradari S, 2016, HIPPOCAMPUS, V26, P857, DOI 10.1002/hipo.22568; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hattiangady B, 2008, EPILEPSIA, V49, P26, DOI 10.1111/j.1528-1167.2008.01635.x; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Li Y, 2009, CURR TOP DEV BIOL, V87, P149, DOI 10.1016/S0070-2153(09)01205-8; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loix S, 2011, ACTA ANAESTH BELG, V62, P47; Mei XP, 2009, J NEUROCHEM, V109, P1691, DOI 10.1111/j.1471-4159.2009.06087.x; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morrens J, 2012, GLIA, V60, P159, DOI 10.1002/glia.21247; Parent JM, 2007, EPILEPSIA, V48, P69, DOI 10.1111/j.1528-1167.2007.01355.x; Petrus DS, 2009, EUR J NEUROSCI, V29, P244, DOI 10.1111/j.1460-9568.2008.06579.x; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Shibakawa YS, 2005, BRIT J ANAESTH, V95, P803, DOI 10.1093/bja/aei256; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Sleigh J, 2014, TRENDS ANAESTH CRIT, V4, P76, DOI 10.1016/j.tacc.2014.03.002; Soumier A, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0116-15.2016; Tan SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021328; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Tung A, 2008, ANESTH ANALG, V106, P1772, DOI 10.1213/ane.0b013e31816f2004; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; Villasana LE, 2014, EXP NEUROL, V261, P156, DOI 10.1016/j.expneurol.2014.05.016; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Wesseling H, 2015, J PROTEOME RES, V14, P411, DOI 10.1021/pr5009493; Winkelheide U, 2009, ACTA ANAESTH SCAND, V53, P528, DOI 10.1111/j.1399-6576.2009.01905.x; Yeung LY, 2009, TOXICOL LETT, V191, P275, DOI 10.1016/j.toxlet.2009.09.006; Yuhas Y, 2017, J NEUROIMMUNOL, V305, P75, DOI 10.1016/j.jneuroim.2016.12.017; Zanos P, 2016, NATURE, V533, P481, DOI 10.1038/nature17998	50	11	11	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2018	129	2					278	295		10.1097/ALN.0000000000002197			18	Anesthesiology	Anesthesiology	GN3QP	WOS:000438922500012	29734230	Green Accepted			2021-06-18	
J	Sun, JB; Li, Y; Cai, YF; Huang, Y; Liu, S; Yeung, PKK; Deng, MZ; Sun, GS; Zilundu, PLM; Hu, QS; An, RX; Zhou, LH; Wang, LX; Cheng, X				Sun, Jing-Bo; Li, Yan; Cai, Ye-Feng; Huang, Yan; Liu, Shu; Yeung, Patrick K. K.; Deng, Min-Zhen; Sun, Guang-Shun; Zilundu, Prince L. M.; Hu, Qian-Sheng; An, Rui-Xin; Zhou, Li-Hua; Wang, Li-Xin; Cheng, Xiao			Scutellarin protects oxygen/glucose-deprived astrocytes and reduces focal cerebral ischemic injury	NEURAL REGENERATION RESEARCH			English	Article						nerve regeneration; scutellarin; cerebral ischemic injury; oxygen glucose deprivation/reoxygenation; nicotinamide adenine dinucleotide phosphate oxidase 2; reactive oxygen species; connexin 43; neural regeneration	DIFFERENTIATED PC12 CELLS; HUMAN-NEUTROPHIL-ELASTASE; TRAUMATIC BRAIN-INJURY; NADPH OXIDASE; OXIDATIVE STRESS; ISCHEMIA/REPERFUSION INJURY; GAP-JUNCTIONS; CEREBROVASCULAR-DISEASE; REPERFUSION INJURY; DOWN-REGULATION	Scutellarin, a bioactive flavone isolated from Scutellaria baicalensis, has anti-inflammatory, anti-neurotoxic, anti-apoptotic and anti-oxidative effects and has been used to treat cardiovascular and cerebrovascular diseases in China. However, the mechanisms by which scutellarin mediates neuroprotection in cerebral ischemia remain unclear. The interaction between scutellarin and nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) was assessed by molecular docking study, which showed that scutellarin selectively binds to NOX2 with high affinity. Cultures of primary astrocytes isolated from the cerebral cortex of neonatal Sprague-Dawley rats were pretreated with 2, 10 or 50 mu M scutellarin for 30 minutes. The astrocytes were then subjected to oxygen/glucose deprivation by incubation for 2 hours in glucose-free Dulbecco's modified Eagle's medium in a 95% N-2/5% CO2 incubator, followed by simulated reperfusion for 22 hours. Cell viability was assessed by cell counting kit-8 assay. Expression levels of NOX2, connexin 43 and caspase-3 were assessed by western blot assay. Reactive oxygen species were measured spectrophotometrically. Pretreatment with 10 or 50 mu M scutellarin substantially increased viability, reduced the expression of NOX2 and caspase-3, increased the expression of connexin 43, and diminished the levels of reactive oxygen species in astrocytes subjected to ischemia-reperfusion. We also assessed the effects of scutellarin in vivo in the rat transient middle cerebral artery occlusion model of cerebral ischemia-reperfusion injury. Rats were given intraperitoneal injection of 100 mg/kg scutellarin 2 hours before surgery. The Bederson scale was used to assess neurological deficit, and 2,3,5-triphenyltetrazolium chloride staining was used to measure infarct size. Western blot assay was used to assess expression of NOX2 and connexin 43 in brain tissue. Enzyme-linked immunosorbent assay was used to detect 8-hydroxydeoxyguanosine (8-OHdG), 4-hydroxy-2-nonenal (4-HNE) and 3-nitrotyrosin (3-NT) in brain tissue. Immunofluorescence double staining was used to determine the co-expression of caspase-3 and NeuN. Pretreatment with scutellarin improved the neurological function of rats with focal cerebral ischemia, reduced infarct size, diminished the expression of NOX2, reduced levels of 8-OHdG, 4-HNE and 3-NT, and reduced the number of cells co-expressing caspase-3 and NeuN in the injured brain tissue. Furthermore, we examined the effect of the NOX2 inhibitor apocynin. Apocynin substantially increased connexin 43 expression in vivo and in vitro. Collectively, our findings suggest that scutellarin protects against ischemic injury in vitro and in vivo by downregulating NOX2, upregulating connexin 43, decreasing oxidative damage, and reducing apoptotic cell death.	[Sun, Jing-Bo; Li, Yan; Cai, Ye-Feng; Huang, Yan; Deng, Min-Zhen; Wang, Li-Xin; Cheng, Xiao] Guangdong Prov Hosp Tradit Chinese Med, Dept Neurol, Guangzhou, Guangdong, Peoples R China; [Sun, Jing-Bo; Li, Yan; Cai, Ye-Feng; Huang, Yan; Deng, Min-Zhen; Wang, Li-Xin; Cheng, Xiao] Guangzhou Univ Tradit Chinese Med, Dept Inst Clin Med 2, Guangzhou, Guangdong, Peoples R China; [Sun, Jing-Bo; Li, Yan; Cai, Ye-Feng; Huang, Yan; Deng, Min-Zhen; Wang, Li-Xin; Cheng, Xiao] Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China; [Sun, Jing-Bo; Li, Yan; Cai, Ye-Feng; Huang, Yan; Deng, Min-Zhen; Wang, Li-Xin; Cheng, Xiao] Guangdong Prov Chinese Emergency Key Lab, Guangzhou, Guangdong, Peoples R China; [Liu, Shu] An Hui Med Univ, Dept Anat, Hefei, Anhui, Peoples R China; [Yeung, Patrick K. K.] Univ Hong Kong, Dept Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Sun, Guang-Shun; Hu, Qian-Sheng] Sun Yat Sen Univ, Zhong Shan Sch Med, Sch Publ Hlth, Dept Prevent Med, Guangzhou, Guangdong, Peoples R China; [Zilundu, Prince L. M.; An, Rui-Xin; Zhou, Li-Hua] Sun Yat Sen Univ, Guangzhou Dept Anat, Zhong Shan Sch Med, Guangzhou, Guangdong, Peoples R China	Cheng, X (corresponding author), Guangdong Prov Hosp Tradit Chinese Med, Dept Neurol, Guangzhou, Guangdong, Peoples R China.; Cheng, X (corresponding author), Guangzhou Univ Tradit Chinese Med, Dept Inst Clin Med 2, Guangzhou, Guangdong, Peoples R China.; Cheng, X (corresponding author), Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China.; Cheng, X (corresponding author), Guangdong Prov Chinese Emergency Key Lab, Guangzhou, Guangdong, Peoples R China.	chengxiaolucky@126.com		ZILUNDU, PRINCE LM/0000-0002-8843-8853	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303115, 81774042, 81771353]; Natural Science Foundation of Guangdong Province of ChinaNational Natural Science Foundation of Guangdong Province [S2013040016915]; Science and Technology Program of Guangzhou City of China [201508020050, 201604020003]; Pearl River S & T Nova Program of Guangzhou; Postdoctoral Foundation of ChinaChina Postdoctoral Science Foundation [BBK42913K09, 201003345, BBH429151701]; Hong Kong Scholar Program; Guangzhou University of TCM 2017 High Level University Construction Program [A1-AFD018171Z11096]; Specialty Program of Guangdong Province Hospital of Traditional Chinese Medicine of China [YN2016MJ07, YN2015QN16, YN2015B2025]	This study was financially supported by the National Natural Science Foundation of China, No. 81303115, 81774042, 81771353; the Natural Science Foundation of Guangdong Province of China, No. S2013040016915; the Science and Technology Program of Guangzhou City of China, No. 201508020050, 201604020003; the Pearl River S & T Nova Program of Guangzhou, the Postdoctoral Foundation of China, No. BBK42913K09, 201003345, BBH429151701; a grant from the Hong Kong Scholar Program, Guangzhou University of TCM 2017 High Level University Construction Program, No. A1-AFD018171Z11096; a grant from the Specialty Program of Guangdong Province Hospital of Traditional Chinese Medicine of China, No. YN2016MJ07, YN2015QN16, YN2015B2025.	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Brennan-Minnella AM, 2015, ANTIOXID REDOX SIGN, V22, P161, DOI 10.1089/ars.2013.5767; Buch P, 2012, J ETHNOPHARMACOL, V142, P35, DOI 10.1016/j.jep.2012.04.007; Carbone F, 2015, ANTIOXID REDOX SIGN, V23, P460, DOI 10.1089/ars.2013.5778; Chai LJ, 2013, J ETHNOPHARMACOL, V150, P100, DOI 10.1016/j.jep.2013.08.011; Chen G, 2014, BRAIN, V137, P2193, DOI 10.1093/brain/awu140; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chen JH, 2014, TOXICOL APPL PHARM, V279, P294, DOI 10.1016/j.taap.2014.07.005; Chen XH, 2016, CELL MOL NEUROBIOL, V36, P541, DOI 10.1007/s10571-015-0235-1; Cheng X, 2013, NEUROSCIENCE, V241, P268, DOI 10.1016/j.neuroscience.2013.03.006; Cheng X, 2017, J ETHNOPHARMACOL, V198, P148, DOI 10.1016/j.jep.2017.01.004; Cheng X, 2012, MOL MED REP, V6, P750, DOI 10.3892/mmr.2012.987; Contreras JE, 2004, BRAIN RES REV, V47, P290, DOI 10.1016/j.brainresrev.2004.08.002; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Deng ZH, 2014, CELL MOL NEUROBIOL, V34, P871, DOI 10.1007/s10571-014-0066-5; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fan DF, 2016, BRAIN RES, V1633, P62, DOI 10.1016/j.brainres.2015.12.019; Fang M, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0219-6; Farahani R, 2005, GLIA, V50, P351, DOI 10.1002/glia.20213; Feng YH, 2016, ZHONGGUO ZUZHI GONGC, V20, P5953; Gao K, 2015, J CELL MOL MED, V19, P2469, DOI 10.1111/jcmm.12641; Garcia J, 2014, J MOL GRAPH MODEL, V51, P120, DOI 10.1016/j.jmgm.2014.05.002; Giaume C, 2010, BRAIN RES REV, V63, P160, DOI 10.1016/j.brainresrev.2009.11.005; Goldstein LB, 2006, STROKE, V37, P1583, DOI 10.1161/01.STR.0000223048.70103.F1; Guo C, 2012, J ETHNOPHARMACOL, V144, P768, DOI 10.1016/j.jep.2012.09.056; Guo H, 2011, CHINESE J PHYSIOL, V54, P399, DOI 10.4077/CJP.2011.AMM059; Guo LL, 2013, EXP TOXICOL PATHOL, V65, P579, DOI 10.1016/j.etp.2012.05.003; Hong H, 2004, PLANTA MED, V70, P427, DOI 10.1055/s-2004-818970; Jiang DP, 2011, AM J CHINESE MED, V39, P1193, DOI 10.1142/S0192415X11009494; Jiang DP, 2011, J KOREAN MED SCI, V26, P778, DOI 10.3346/jkms.2011.26.6.778; Jing YP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122781; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kahles T, 2013, ANTIOXID REDOX SIGN, V18, P1400, DOI 10.1089/ars.2012.4721; Li XJ, 2015, GLIA, V63, P1553, DOI 10.1002/glia.22826; Long LL, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/252530; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Ma MJ, 2013, BRAIN RES, V1519, P87, DOI 10.1016/j.brainres.2013.04.040; Manzanero S, 2013, NEUROCHEM INT, V62, P712, DOI 10.1016/j.neuint.2012.11.009; Nagy JI, 2000, BRAIN RES REV, V32, P29, DOI 10.1016/S0165-0173(99)00066-1; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; Olmez I, 2012, NEUROCHEM INT, V60, P208, DOI 10.1016/j.neuint.2011.11.009; Pei HT, 2012, INT J MOL SCI, V13, P2551, DOI 10.3390/ijms13032551; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Schmidt A, 2013, EXPERT OPIN EMERG DR, V18, P109, DOI 10.1517/14728214.2013.790363; Schulz R, 2015, PHARMACOL THERAPEUT, V153, P90, DOI 10.1016/j.pharmthera.2015.06.005; Shichinohe H, 2015, BRAIN RES, V1602, P53, DOI 10.1016/j.brainres.2015.01.022; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Song W, 2013, NEUROSCIENCE, V248, P136, DOI 10.1016/j.neuroscience.2013.05.063; Tang H, 2014, PHARMACOL BIOCHEM BE, V118, P51, DOI 10.1016/j.pbb.2014.01.003; Tang XN, 2012, NEUROL RES, V34, P338, DOI 10.1179/1743132812Y.0000000021; Tian L, 2016, ASIA PAC J CLIN TRIA, V1, P98; Upham BL, 2009, ANTIOXID REDOX SIGN, V11, P297, DOI 10.1089/ars.2008.2146; Wang LL, 2011, NEUROSCIENCE, V189, P397, DOI 10.1016/j.neuroscience.2011.04.070; Wang WJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146197; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Wang Z, 2016, LIFE SCI, V157, P200, DOI 10.1016/j.lfs.2016.01.018; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Xu M, 2016, ACTA PHARMACOL SIN, V37, P246, DOI 10.1038/aps.2015.125; Yuan Y, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0226-z; Zhang HF, 2015, N-S ARCH PHARMACOL, V388, P953, DOI 10.1007/s00210-015-1125-2; Zhang Y, 2018, J PHOTOCH PHOTOBIO B, V184, P1, DOI 10.1016/j.jphotobiol.2018.05.010; Zhou ZY, 2015, BIOCHEM BIOPH RES CO, V458, P656, DOI 10.1016/j.bbrc.2015.02.020	66	11	13	2	10	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	AUG	2018	13	8					1396	1407		10.4103/1673-5374.235293			12	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	GQ8SX	WOS:000442030300022	30106052	DOAJ Gold, Green Published			2021-06-18	
J	Wang, Y; Lan, Q				Wang, Y.; Lan, Q.			Long non-coding RNA AFAP1-AS1 accelerates invasion and predicts poor prognosis of glioma	EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES			English	Article						Glioma; LncRNA; AFAP1-AS1; Prognosis	MALIGNANT GLIOMA; HIGH EXPRESSION; CARCINOMA; CANCER; PROLIFERATION; METASTASIS; ADULTS	OBJECTIVE: The role of A FAP1-AS1 in glioma is not fully known. This study aims at investigating the expression of AFAP1-AS1 in glioma and its underlying mechanism. PATIENTS AND METHODS: AFAP1-AS1 expressions in brain tissues from 52 cases of glioma and 5 cases of traumatic brain injury were assessed using quantitative fluorescence polymerase chain reaction (PCR). The clinicopathological features of glioma were first recorded. The correlation between AFAP1-AS1 expression and prognosis of glioma was discussed. AFAP1-AS1 expressions in the glioma cell lines were further detected. After knockdown of AFAP1-AS1 in U87MG and U251 glioma cells, cell invasion was assessed by transwell assay. MMP2 and MMP9 expressions in glioma cells, which were important indicators of cell invasive-ness, were determined by Western blot. RESULTS: AFAP1-AS1 was upregulated in the glioma tissues compared with that in the control tissues. and the expression level was correlated with glioma grading and KPS scores. After knockdown of AFAP1-AS1, the invasion capacities of the glioma cells declined significantly, and the expressions of invasion-related proteins MMP2 and MMP9 also decreased significantly. CONCLUSIONS: lncRNA AFAP1-AS1 can considerably facilitate the invasion of glioma cells and acts as an independent predictor of malignancy and prognosis, which may also serve as a potential therapeutic target.	[Wang, Y.; Lan, Q.] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China; [Wang, Y.] Nantong Univ, Affiliated Hosp 2, Dept Neurosurg, Nan Tong, Peoples R China	Lan, Q (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China.	lanqingdoc@163.com			Scientific Research Programme of Nantong [GJZ16001]	The study was sponsored by a grant from the Scientific Research Programme of Nantong (No.: GJZ16001).	Bo H, 2015, ONCOTARGET, V6, P20404, DOI 10.18632/oncotarget.4057; Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006; Feng Y, 2017, EUR REV MED PHARMACO, V21, P3842; Han X, 2016, BIOL RES, V49, DOI 10.1186/s40659-016-0094-3; Lu X, 2016, TUMOR BIOL, V37, P9699, DOI 10.1007/s13277-016-4858-8; Luo HL, 2016, CANCER MED-US, V5, P2879, DOI 10.1002/cam4.848; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087; Ponting CP, 2010, HUM MOL GENET, V19, pR162, DOI 10.1093/hmg/ddq362; Simonetti G, 2014, NEUROL SCI, V35, P977, DOI 10.1007/s10072-014-1829-y; Soffietti R, 2014, CNS DRUGS, V28, P1127, DOI 10.1007/s40263-014-0215-x; Wang W, 2017, TURK NEUROSURG, V27, P174, DOI 10.5137/1019-5149.JTN.15462-15.0; Wu RF, 2016, MOL GENET GENOMICS, V291, P1013, DOI 10.1007/s00438-016-1179-y; Ye YB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0490-4; Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x; Zhang JY, 2016, INT J ONCOL, V48, P1590, DOI 10.3892/ijo.2016.3385; Zhou XL, 2016, MOL CARCINOGEN, V55, P2095, DOI 10.1002/mc.22454	16	11	11	0	1	VERDUCI PUBLISHER	ROME	VIA GREGORIO VII, ROME, 186-00165, ITALY	1128-3602			EUR REV MED PHARMACO	Eur. Rev. Med. Pharmacol. Sci.	AUG	2018	22	16					5223	5229					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GU2OD	WOS:000445108700026	30178845				2021-06-18	
J	Wendel, KM; Lee, JB; Affeldt, BM; Hamer, M; Harahap-Carrillo, IS; Pardo, AC; Obenaus, A				Wendel, Kara M.; Lee, Jeong Bin; Affeldt, Bethann M.; Hamer, Mary; Harahap-Carrillo, Indira S.; Pardo, Andrea C.; Obenaus, Andre			Corpus Callosum Vasculature Predicts White Matter Microstructure Abnormalities after Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blood vessel; closed-head injury; concussion; diffusion tensor imaging; myelin; oligodendrocytes	RAT-BRAIN; VULNERABILITY; EXPRESSION; DEMYELINATION; ANGIOGENESIS; PLASTICITY; RECOVERY; PROGRAM; PROTEIN; GLIOMAS	Emerging data suggest that pediatric traumatic brain injury (TBI) is associated with impaired developmental plasticity and poorer neuropsychological outcomes than adults with similar head injuries. Unlike adult mild TBI (mTBI), the effects of mTBI on white matter (WM) microstructure and vascular supply are not well understood in the pediatric population. The cerebral vasculature plays an important role providing necessary nutrients and removing waste. To address this critical element, we examined the microstructure of the corpus callosum (CC) following pediatric mTBI using diffusion tensor magnetic resonance imaging (DTI), and investigated myelin, oligodendrocytes, and vasculature of WM with immunohistochemistry (IHC). We hypothesized that pediatric mTBI leads to abnormal WM microstructure and impacts the vasculature within the CC, and that these alterations to WM vasculature contribute to the long-term altered microstructure. We induced in mice a closed-head injury (CHI) mTBI at post-natal day (P) 14; then at 4, 14, and 60 days post-injury (DPI) mice were sacrificed for analysis. We observed persistent changes in apparent diffusion coefficient (ADC) within the ipsilateral CC following mTBI, indicating microstructural changes, but surprisingly changes in myelin and oligodendrocyte densities were minimal. However, vascular features of the ipsilateral CC such as vessel density, length, and number of junctions were persistently altered following mTBI. Correlative analysis showed a strong inverse relationship between ADC and vessel density at 60 DPI, suggesting increased vessel density following mTBI may restrict WM diffusion characteristics. Our findings suggest that WM vasculature contributes to the long-term microstructural changes within the ipsilateral CC following mTBI.	[Wendel, Kara M.; Obenaus, Andre] Univ Calif Irvine, Irvine Sch Med, Dept Anat & Neurobiol, Irvine, CA USA; [Obenaus, Andre] Univ Calif Irvine, Irvine Sch Med, Dept Pediat, Irvine, CA USA; [Lee, Jeong Bin; Affeldt, Bethann M.; Hamer, Mary; Harahap-Carrillo, Indira S.; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA USA; [Pardo, Andrea C.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Obenaus, A (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Dept Pediat, 1022-1082 Hlth Sci Rd,Hewitt Hall,Room 2066, Irvine, CA 92617 USA.	obenausa@uci.edu	Pardo, Andrea/B-4836-2017	Pardo, Andrea/0000-0001-7767-8539	Loma Linda University	These studies were supported by Loma Linda University Grants to Promote Collaborative and Translation Research (GCAT). We would like to acknowledge Loma Linda University for the support for this study, Dr. Jane Johnson for generously providing the Asc11CreER: ccGFP CD-1 mice, and Mariann Howland for her contributions and assistance with the statistical analysis for this study.	Affeldt BM, 2017, INT J DEV NEUROSCI, V61, P1, DOI 10.1016/j.ijdevneu.2017.05.001; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bernklau I, 2016, FOOD RES INT, V89, P812, DOI 10.1016/j.foodres.2016.10.012; Bockhorst KH, 2008, J NEUROSCI RES, V86, P1520, DOI 10.1002/jnr.21607; Centers for Disease Control and Prevention, 2016, REP PED MILD TRAUM B; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Favrais G, 2011, ANN NEUROL, V70, P550, DOI 10.1002/ana.22489; Fischer I, 2005, BRAIN PATHOL, V15, P297; Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1; Gambardella L., 2012, TXB ANGIOGENESIS LYM, P189; Genc S, 2017, J NEUROTRAUM, V34, P798, DOI 10.1089/neu.2016.4584; Giacomini A, 2015, ANGIOGENESIS, V18, P499, DOI 10.1007/s10456-015-9481-6; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Ichkova A, 2017, NEUROCHEM INT, V111, P93, DOI 10.1016/j.neuint.2017.03.022; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kim EJ, 2007, J NEUROSCI, V27, P12764, DOI 10.1523/JNEUROSCI.3178-07.2007; KIMURA M, 1989, P NATL ACAD SCI USA, V86, P5661, DOI 10.1073/pnas.86.14.5661; Kom C, 2015, DEV CELL, V34, P5, DOI 10.1016/j.devcel.2015.06.004; Konigs M, 2018, BRAIN IMAGING BEHAV, V12, P29, DOI 10.1007/s11682-017-9673-3; Kreis T., 1999, GUIDEBOOK EXTRACELLU; Li N, 2014, J NEUROTRAUM, V31, P395, DOI 10.1089/neu.2013.3059; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Miller DJ, 2012, P NATL ACAD SCI USA, V109, P16480, DOI 10.1073/pnas.1117943109; Muramatsu K, 1997, STROKE, V28, P2281, DOI 10.1161/01.STR.28.11.2281; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Obenaus A, 2007, EPILEPSIA, V48, P11, DOI 10.1111/j.1528-1167.2007.01237.x; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; Sadeghi N, 2008, AM J NEURORADIOL, V29, P476, DOI 10.3174/ajnr.A0851; Salehi A, 2018, J CEREBR BLOOD F MET, V38, P274, DOI 10.1177/0271678X17744124; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semple BD, 2016, METHODS MOL BIOL, V1462, P325, DOI 10.1007/978-1-4939-3816-2_18; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Walchli T, 2015, NAT PROTOC, V10, P53, DOI 10.1038/nprot.2015.002; Wessa P., 2017, BAGPLOT V1 0 3 FREE; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	58	11	11	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2019	36	1					152	164		10.1089/neu.2018.5670		JUL 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HF0PB	WOS:000439628400001	29739276				2021-06-18	
J	Wintermark, M; Li, Y; Ding, VY; Xu, YD; Jiang, B; Ball, RL; Zeineh, M; Gean, A; Sanelli, P				Wintermark, Max; Li, Ying; Ding, Victoria Y.; Xu, Yingding; Jiang, Bin; Ball, Robyn L.; Zeineh, Michael; Gean, Alisa; Sanelli, Pina			Neuroimaging Radiological Interpretation System for Acute Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						clinical decision support; common data elements; CT; outcome; TBI	COMMON DATA ELEMENTS; CLASSIFICATION; VARIABILITY; MAMMOGRAPHY; LEXICON	The purpose of the study was to develop an outcome-based NeuroImaging Radiological Interpretation System (NIRIS) for patients with acute traumatic brain injury (TBI) that would standardize the interpretation of noncontrast head computer tomography (CT) scans and consolidate imaging findings into ordinal severity categories that would inform specific patient management actions and that could be used as a clinical decision support tool. We retrospectively identified all patients transported to our emergency department by ambulance or helicopter for whom a trauma alert was triggered per established criteria and who underwent a noncontrast head CT because of suspicion of TBI, between November 2015 and April 2016. Two neuroradiologists reviewed the noncontrast head CTs and assessed the TBI imaging common data elements (CDEs), as defined by the National Institutes of Health (NIH). Using descriptive statistics and receiver operating characteristic curve analyses to identify imaging characteristics and associated thresholds that best distinguished among outcomes, we classified patients into five mutually exclusive categories: 0-discharge from the emergency department; 1-follow-up brain imaging and/or admission; 2-admission to an advanced care unit; 3-neurosurgical procedure; 4-death up to 6 months after TBI. Sensitivity of NIRIS with respect to each patient's true outcome was then evaluated and compared with that of the Marshall and Rotterdam scoring systems for TBI. In our cohort of 542 patients with TBI, NIRIS was developed to predict discharge (182 patients), follow-up brain imaging/admission (187 patients), need for advanced care unit (151 patients), neurosurgical procedures (10 patients), and death (12 patients). NIRIS performed similarly to the Marshall and Rotterdam scoring systems in terms of predicting death. We developed an interpretation system for neuroimaging using the CDEs that informs specific patient management actions and could be used as a clinical decision support tool for patients with TBI. Our NIRIS classification, with evidence-based grouping of the CDEs into actionable categories, will need to be validated in different TBI populations.	[Wintermark, Max; Li, Ying; Xu, Yingding; Jiang, Bin; Zeineh, Michael] Stanford Univ, Dept Radiol, Neuroradiol Div, 300 Pasteur Dr,Room S047, Stanford, CA 94305 USA; [Ding, Victoria Y.; Ball, Robyn L.] Stanford Univ, Dept Med, Quantitat Sci Unit, Stanford, CA 94305 USA; [Gean, Alisa] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA; [Gean, Alisa] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA 94143 USA; [Sanelli, Pina] Northwell Hlth, Northwell Hofstra Sch Med, Dept Radiol, Manhasset, NY USA	Wintermark, M (corresponding author), Stanford Univ, Dept Radiol, Neuroradiol Div, 300 Pasteur Dr,Room S047, Stanford, CA 94305 USA.	Max.Wintermark@gmail.com					Baker JA, 1996, AM J ROENTGENOL, V166, P773, DOI 10.2214/ajr.166.4.8610547; Balleyguier C, 2007, EUR J RADIOL, V61, P192, DOI 10.1016/j.ejrad.2006.08.033; Burnside Elizabeth S, 2009, J Am Coll Radiol, V6, P851, DOI 10.1016/j.jacr.2009.07.023; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Edwards SD, 2013, MAGN RESON IMAGING C, V21, P483, DOI 10.1016/j.mric.2013.02.005; FAUL M, 2010, TRAUMATIC BRAIN INJU, DOI DOI 10.1016/J.NEUROIMAGE.2010.09.025; Grieve FM, 2010, BRIT J RADIOL, V83, P17, DOI 10.1259/bjr/16360063; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Krupinski EA, 2012, J DIGIT IMAGING, V25, P63, DOI 10.1007/s10278-011-9424-8; Langlotz Curtis P, 2009, J Am Coll Radiol, V6, P861, DOI 10.1016/j.jacr.2009.09.015; Lazarus E, 2006, RADIOLOGY, V239, P385, DOI 10.1148/radiol.2392042127; Lee B, 2017, CURR PROBL DIAGN RAD, V46, P186, DOI 10.1067/j.cpradiol.2016.11.005; Levy L, 2007, EUR J RADIOL, V61, P202, DOI 10.1016/j.ejrad.2006.08.035; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mercado CL, 2014, RADIOL CLIN N AM, V52, P481, DOI 10.1016/j.rcl.2014.02.008; Obenauer S, 2005, EUR RADIOL, V15, P1027, DOI 10.1007/s00330-004-2593-9; Plumb AAO, 2009, CLIN RADIOL, V64, P386, DOI 10.1016/j.crad.2008.11.009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Team R.C., 2000, R LANG DEF	21	11	11	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2018	35	22					2665	2672		10.1089/neu.2017.5311		JUL 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GZ0MO	WOS:000439648900001	29665763				2021-06-18	
J	Magalhaes, DM; Pereira, N; Rombo, DM; Beltrao-Cavacas, C; Sebastiao, AM; Valente, CA				Magalhaes, Daniela M.; Pereira, Noemia; Rombo, Diogo M.; Beltrao-Cavacas, Claudia; Sebastiao, Ana M.; Valente, Claudia A.			Ex vivo model of epilepsy in organotypic slices-a new tool for drug screening	JOURNAL OF NEUROINFLAMMATION			English	Article						Epilepsy; Organotypic slice cultures; Neuroinflammation; Gliosis; Proinflammatory cytokines; Interleukin-1 beta; NLRP3 inflammasome	INDUCED STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; CELL-DEATH; INFLAMMATORY CYTOKINES; NLRP3 INFLAMMASOME; INTERICTAL SPIKES; IN-VITRO; OXIDATIVE STRESS; RAT HIPPOCAMPUS	Background: Epilepsy is a prevalent neurological disorder worldwide. It is characterized by an enduring predisposition to generate seizures and its development is accompanied by alterations in many cellular processes. Organotypic slice cultures represent a multicellular environment with the potential to assess biological mechanisms, and they are used as a starting point for refining molecules for in vivo studies. Here, we investigated organotypic slice cultures as a model of epilepsy. Methods: We assessed, by electrophysiological recordings, the spontaneous activity of organotypic slices maintained under different culture protocols. Moreover, we evaluated, through molecular-based approaches, neurogenesis, neuronal death, gliosis, expression of proinflammatory cytokines, and activation of NLRP3 inflammasome (nucleotide-binding, leucine-rich repeat, pyrin domain) as biomarkers of neuroinflammation. Results: We demonstrated that organotypic slices, maintained under a serum deprivation culture protocol, develop epileptic-like activity. Furthermore, throughout a comparative study with slices that do not depict any epileptiform activity, slices with epileptiform activity were found to display significant differences in terms of inflammation-related features, such as (1) increased neuronal death, with higher incidence in CA1 pyramidal neurons of the hippocampus; (2) activation of astrocytes and microglia, assessed through western blot and immunohistochemistry; (3) upregulation of proinflammatory cytokines, specifically interleukin-1 beta (IL-1 beta), interleukin-6, and tumor necrosis factor a, revealed by qPCR; and (4) enhanced expression of NLRP3, assessed by western blot, together with increased NLRP3 activation, showed by IL-1 beta quantification. Conclusions: Thus, organotypic slice cultures gradually deprived of serum mimic the epileptic-like activity, as well as the inflammatory events associated with in vivo epilepsy. This system can be considered a new tool to explore the interplay between neuroinflammation and epilepsy and to screen potential drug candidates, within the inflammatory cascades, to reduce/halt epileptogenesis.	[Magalhaes, Daniela M.; Pereira, Noemia; Rombo, Diogo M.; Beltrao-Cavacas, Claudia; Sebastiao, Ana M.; Valente, Claudia A.] Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal; [Magalhaes, Daniela M.; Pereira, Noemia; Rombo, Diogo M.; Beltrao-Cavacas, Claudia; Sebastiao, Ana M.; Valente, Claudia A.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal	Valente, CA (corresponding author), Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal.; Valente, CA (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.	cvalentecastro@medicina.ulisboa.pt	Valente, CA/AAE-1250-2020	Valente, CA/0000-0001-5405-3130; Rombo, Diogo/0000-0002-9922-7381; Sebastiao, Ana M/0000-0001-9030-6115; Magalhaes, Daniela/0000-0002-1662-2002	FEDER through POR Lisboa 2020-Programa Operacional Regional de Lisboa, PORTUGAL 2020; Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BD/60386/2009];  [LISBOA-01-0145-FEDER-007391]	The funding reference is LISBOA-01-0145-FEDER-007391, and the project was cofunded by FEDER, through POR Lisboa 2020-Programa Operacional Regional de Lisboa, PORTUGAL 2020, and Fundacao para a Ciencia e a Tecnologia. Diogo M. Rombo was in receipt of a fellowship from Fundacao para a Ciencia e a Tecnologia, SFRH/BD/60386/2009.	Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Albus K, 2013, J NEUROSCI METH, V217, P1, DOI 10.1016/j.jneumeth.2013.04.014; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Aroeira RI, 2011, J NEUROCHEM, V118, P339, DOI 10.1111/j.1471-4159.2011.07197.x; Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Binder DK, 2006, GLIA, V54, P358, DOI 10.1002/glia.20394; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32; Chapleau CA, 2008, J NEUROSCI METH, V169, P182, DOI 10.1016/j.jneumeth.2007.12.006; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; Daviaud N, 2013, EXP NEUROL, V248, P429, DOI 10.1016/j.expneurol.2013.07.012; De Simoni A, 2003, J PHYSIOL-LONDON, V550, P135, DOI 10.1113/jphysiol.2003.039099; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Dingledine R, 2014, ADV EXP MED BIOL, V813, P109, DOI 10.1007/978-94-017-8914-1_9; Doussau F, 2017, EXPERT OPIN DRUG DIS, V12, P1011, DOI 10.1080/17460441.2017.1356285; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Edye M.E., 2014, INFLAMMASOME, V1, P36, DOI DOI 10.2478/INFL-2014-0004; Engel J., 2007, EPILEPSY COMPREHENSI; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Foresti ML, 2011, BRAIN RES REV, V66, P115, DOI 10.1016/j.brainresrev.2010.09.002; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Hamilton NB, 2010, NAT REV NEUROSCI, V11, P227, DOI 10.1038/nrn2803; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Heinemann U, 2006, MODELS OF SEIZURES AND EPILEPSY, P35, DOI 10.1016/B978-012088554-1/50006-2; Holopainen IE, 2005, NEUROCHEM RES, V30, P1521, DOI 10.1007/s11064-005-8829-5; Humpel C, 2015, NEUROSCIENCE, V305, P86, DOI 10.1016/j.neuroscience.2015.07.086; Jessberger S, 2005, EXP NEUROL, V196, P342, DOI 10.1016/j.expneurol.2005.08.010; Jessberger S, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020677; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Lee SB, 2010, APOPTOSIS, V15, P204, DOI 10.1007/s10495-009-0411-1; Li Q, 2016, MOL NEUROBIOL, V53, P4226, DOI 10.1007/s12035-015-9362-4; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Lossi L, 2009, PROG NEUROBIOL, V88, P221, DOI 10.1016/j.pneurobio.2009.01.002; Lukasiuk K, 2014, NEUROTHERAPEUTICS, V11, P319, DOI 10.1007/s13311-014-0261-6; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Meldrum BS, 2002, PROG BRAIN RES, V135, P3; Meng XF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0212-5; Mirrione MM, 2011, CLIN GENETIC ASPECTS; Naundorf B, 2005, J COMPUT NEUROSCI, V18, P297, DOI 10.1007/s10827-005-0329-8; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Parent JM, 2008, EPILEPSIA, V49, P19, DOI 10.1111/j.1528-1167.2008.01634.x; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Prinz M, 2011, GLIA, V59, P177, DOI 10.1002/glia.21104; Sadgrove MP, 2006, J COMP NEUROL, V497, P397, DOI 10.1002/cne.21000; Sarkisian MR, 2001, EPILEPSY BEHAV, V2, P201, DOI 10.1006/ebeh.2001.0193; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Staley KJ, 2011, NEUROSCI LETT, V497, P247, DOI 10.1016/j.neulet.2011.03.070; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vezzani A, 2002, EPILEPSIA, V43, P30, DOI 10.1046/j.1528-1157.43.s.5.14.x; Vezzani A, 2015, NEUROPHARMACOLOGY, V96, P70, DOI 10.1016/j.neuropharm.2014.10.027; Vezzani A, 2014, EPILEPSY CURR, V14, P3, DOI 10.5698/1535-7511-14.s2.3; Vezzani A, 2011, BIOMARK MED, V5, P607, DOI [10.2217/BMM.11.61, 10.2217/bmm.11.61]; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Vismer MS, 2015, FRONT NEURAL CIRCUIT, V9, DOI 10.3389/fncir.2015.00027; Vitaliti G, 2014, HUM VACC IMMUNOTHER, V10, P868, DOI 10.4161/hv.28400; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Walker L, 2012, EPILEPSY CURR, V12, P8, DOI 10.5698/1535-7511-12.1.8; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Yan XX, 2013, CURR TRANSL GERIATR, V1, P85; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	83	11	12	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUL 11	2018	15								203	10.1186/s12974-018-1225-2			18	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GM6FS	WOS:000438258400001	29996878	DOAJ Gold, Green Published			2021-06-18	
J	Garcia-Gonzalez, D; Race, NS; Voets, NL; Jenkins, DR; Sotiropoulos, SN; Acosta, G; Cruz-Haces, M; Tang, J; Shi, RY; Jerusalem, A				Garcia-Gonzalez, Daniel; Race, Nicholas S.; Voets, Natalie L.; Jenkins, Damian R.; Sotiropoulos, Stamatios N.; Acosta, Glen; Cruz-Haces, Marcela; Tang, Jonathan; Shi, Riyi; Jerusalem, Antoine			Cognition based bTBI mechanistic criteria; a tool for preventive and therapeutic innovations	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; MOOD DISORDERS; RAT MODEL; BLAST; DEFICITS; DAMAGE; INFLAMMATION; MICROSTRUCTURE; DYSFUNCTION	Blast-induced traumatic brain injury has been associated with neurodegenerative and neuropsychiatric disorders. To date, although damage due to oxidative stress appears to be important, the specific mechanistic causes of such disorders remain elusive. Here, to determine the mechanical variables governing the tissue damage eventually cascading into cognitive deficits, we performed a study on the mechanics of rat brain under blast conditions. To this end, experiments were carried out to analyse and correlate post-injury oxidative stress distribution with cognitive deficits on a live rat exposed to blast. A computational model of the rat head was developed from imaging data and validated against in vivo brain displacement measurements. The blast event was reconstructed in silico to provide mechanistic thresholds that best correlate with cognitive damage at the regional neuronal tissue level, irrespectively of the shape or size of the brain tissue types. This approach was leveraged on a human head model where the prediction of cognitive deficits was shown to correlate with literature findings. The mechanistic insights from this work were finally used to propose a novel protective device design roadmap and potential avenues for therapeutic innovations against blast traumatic brain injury.	[Garcia-Gonzalez, Daniel; Jerusalem, Antoine] Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England; [Race, Nicholas S.; Cruz-Haces, Marcela; Tang, Jonathan; Shi, Riyi] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Race, Nicholas S.] Indiana Univ Sch Med, Med Scientist Training Program, Indianapolis, IN 46202 USA; [Voets, Natalie L.] Univ Oxford, John Radcliffe Hosp, Oxford Ctr Funct MRI Brain, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England; [Jenkins, Damian R.] St Hughs Coll, Neurol, St Margarets Rd, Oxford OX2 6LE, England; [Jenkins, Damian R.] St Hughs Coll, Med & Physiol, St Margarets Rd, Oxford OX2 6LE, England; [Sotiropoulos, Stamatios N.] Univ Oxford, Ctr Funct MRI Brain, Oxford, England; [Sotiropoulos, Stamatios N.] Univ Nottingham, Sir Peter Mansfield Imaging Ctr, Sch Med, Queens Med Ctr, Nottingham, England; [Sotiropoulos, Stamatios N.] Univ Nottingham, NIHR Nottingham, Biomed Res Ctr, Queens Med Ctr, Nottingham, England; [Acosta, Glen; Shi, Riyi] Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Shi, Riyi] Purdue Univ, PULSe Interdisciplinary Life Sci Program, W Lafayette, IN 47907 USA; [Shi, Riyi] Purdue Univ, Purdue Inst Integrat Neurosci, W Lafayette, IN 47907 USA	Jerusalem, A (corresponding author), Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England.; Shi, RY (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.; Shi, RY (corresponding author), Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.; Shi, RY (corresponding author), Purdue Univ, PULSe Interdisciplinary Life Sci Program, W Lafayette, IN 47907 USA.; Shi, RY (corresponding author), Purdue Univ, Purdue Inst Integrat Neurosci, W Lafayette, IN 47907 USA.	riyi@purdue.edu; antoine.jerusalem@eng.ox.ac.uk	Sotiropoulos, Stamatios/I-1163-2019; Garcia-Gonzalez, Daniel/K-7349-2017	Sotiropoulos, Stamatios/0000-0003-4735-5776; Garcia-Gonzalez, Daniel/0000-0003-4692-3508; Race, Nicholas/0000-0002-2683-1692; Jerusalem, Antoine/0000-0001-5026-8038	European Union ERCEuropean Research Council (ERC) [306587]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS090244-01]; McDonnell Center for Systems Neuroscience at Washington University; EPSRC GrantUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/M02833X/1]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U54MH091657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS090244] Funding Source: NIH RePORTER	D.G.-G. and A.J. acknowledge funding from the European Union's Seventh Framework Programme (FP7 2007-2013) ERC Grant Agreement No. 306587. R.S. acknowledges the funding support from National Institute of Health (NS090244-01). Human MRI data were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. Finally, we would like to thank Dr. S Barhli and Prof. J Marrow for valuable assistance with the X-ray tomography; the machine used was bought from EPSRC Grant EP/M02833X/1 "University of Oxford: experimental equipment upgrade".	Abdallah CG, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.12; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bartlett E.L., 2017, J NEUROPHYSIOL, P9; Cebak JE, 2017, J NEUROTRAUM, V34, P1302, DOI 10.1089/neu.2016.4624; Centers for Disease Control and Prevention, 2013, BLAST INJ FACT SHEET; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chatelin Simon, 2013, Journal of Biorheology, V27, P26, DOI 10.1007/s12573-012-0055-6; Chen Z, 2016, J NEUROCHEM, V138, P328, DOI 10.1111/jnc.13639; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Clark RSB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180280; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Dassault Systemes Abaqus v6.14 Documentation, 2014, DASS SYST AB V6 14 D; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DeFelipe J, 2002, J NEUROCYTOL, V31, P299, DOI 10.1023/A:1024130211265; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dixit P, 2017, ARCH COMPUT METHOD E, V24, P979, DOI 10.1007/s11831-016-9196-x; Due MR, 2014, J NEUROCHEM, V128, P776, DOI 10.1111/jnc.12500; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Fu SH, 2014, N-S ARCH PHARMACOL, V387, P87, DOI 10.1007/s00210-013-0922-8; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Garcia-Gonzalez D, 2018, J MECH PHYS SOLIDS, V112, P209, DOI 10.1016/j.jmps.2017.12.001; Garcia-Gonzalez D, 2017, J MECH BEHAV BIOMED, V69, P342, DOI 10.1016/j.jmbbm.2017.01.012; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Giordano C, 2017, BIOMECH MODEL MECHAN, V16, P1269, DOI 10.1007/s10237-017-0887-5; Glasser MF, 2013, NEUROIMAGE, V80, P105, DOI 10.1016/j.neuroimage.2013.04.127; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gordon EM, 2018, J NEUROTRAUM, V35, P767, DOI 10.1089/neu.2017.5428; Grossman EJ, 2016, J NEUROTRAUM, V33, P163, DOI 10.1089/neu.2015.3965; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; Hammond FM, 2014, J HEAD TRAUMA REHAB, V29, P391, DOI 10.1097/01.HTR.0000438116.56228.de; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Jenkinson M., 2005, P 11 ANN M ORG HUM B; Jerusalem A, 2014, BIOMECH MODEL MECHAN, V13, P883, DOI 10.1007/s10237-013-0543-7; Jerusalem A, 2012, ACTA BIOMATER, V8, P3360, DOI 10.1016/j.actbio.2012.04.039; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kiseleva I, 2008, MECHANOSENSITIVITY N, V2; Lee Bruce, 2005, NeuroRx, V2, P372; Leung G, 2011, NEUROSCIENCE, V173, P150, DOI 10.1016/j.neuroscience.2010.11.018; Lin WM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/340936; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McAllister TW, 2016, NEUROPSYCHOPHARMACOL, V41, P1191, DOI 10.1038/npp.2015.282; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Milchenko M, 2013, NEUROINFORMATICS, V11, P65, DOI 10.1007/s12021-012-9160-3; Miller DR, 2017, BRAIN IMAGING BEHAV, V11, P1129, DOI 10.1007/s11682-016-9593-7; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Race N.S, PSYCHOSOCIAL DYSFUNC; Rahimzadeh T, 2015, J MECH PHYS SOLIDS, V85, P98, DOI 10.1016/j.jmps.2015.09.009; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rodriguez-Millan M, 2017, MATER DESIGN, V117, P58, DOI 10.1016/j.matdes.2016.12.081; Rodriguez-Rodriguez A, 2017, CLIN CHEM LAB MED; Scott G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0445-y; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shi R, J NEUROCHEMISTRY; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Song H, 2016, BEHAV BRAIN RES; Song S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16959; Spitz G, 2017, J NEUROTRAUM, V34, P807, DOI 10.1089/neu.2016.4527; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Stover JF, 2014, J NEUROTRAUM, V31, P1599, DOI 10.1089/neu.2014.3344; Strange BA, 2014, NAT REV NEUROSCI, V15, P655, DOI 10.1038/nrn3785; Tagge C.A, BRAIN, P1; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tse KM, 2015, ACCIDENT ANAL PREV, V79, P13, DOI 10.1016/j.aap.2015.03.012; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Walls MK, 2016, J NEUROSURG, V124, P675, DOI 10.3171/2015.1.JNS141571; Wang Chunyang, 2013, THESIS; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Watson C, 1998, RAT BRAIN STEREOTAXI, V3; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Zhang LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06827-3	88	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 6	2018	8								10273	10.1038/s41598-018-28271-7			14	Multidisciplinary Sciences	Science & Technology - Other Topics	GL9RD	WOS:000437673200047	29980750	DOAJ Gold, Green Published			2021-06-18	
J	Navarro, SM; Pettit, RW; Haeberle, HS; Frangiamore, SJ; Rahman, NM; Farrow, LD; Schickendantz, MS; Ramkumar, PN				Navarro, Sergio M.; Pettit, Rowland W.; Haeberle, Heather S.; Frangiamore, Salvatore J.; Rahman, Nadeem M.; Farrow, Lutul D.; Schickendantz, Mark S.; Ramkumar, Prem N.			Short-Term Impact of Concussion in the NHL: An Analysis of Player Longevity, Performance, and Financial Loss	JOURNAL OF NEUROTRAUMA			English	Article						economic decision analysis; head injuries/concussion; ice hockey; medical aspects of sports; performance	FOOTBALL LEAGUE PLAYERS; MENS ICE HOCKEY; RETURN; TIME	Many studies have focused on the long-term impact of concussions in professional sports, but few have investigated short-term effects. This study examines concussion effects on individual players in the National Hockey League (NHL) by assessing career length, performance, and salary. Contracts, transactions, injury reports, and performance statistics from 2008-17 were obtained from the official NHL online publication. Players who sustained a concussion were compared with the 2008-17 non-concussed player pool. Career length was analyzed using Kaplan-Meier survival curves and stratification of player age, experience, and longevity. Player performance and salary changes were evaluated between the years before versus after concussion. Performance and salary changes were compared against non-concussed NHL athletes before/after their career midpoints. Of the 2194 eligible NHL players in the 9-year period, 309 sustained 399 concussions resulting in injury protocol. The probability of playing a full NHL season post-concussion was significantly decreased compared with the non-concussed pool (p<0.05), specifically 65.0% versus 81.2% at 1 year into a player's career, 49.8% versus 67.4% at 2 years, and 14.6% versus 43.7% at 5 years. Performance was reduced at all non-goalie positions post-concussion (p<0.05). Players scored 2.5 points/year less following a concussion. The total annualized financial impact from salary reductions after 1 concussion was $57.0 million, with a decrease of $292,000 per year in contract value per athlete. This retrospective study demonstrates that NHL concussions resulting in injury protocol activation lead to shorter career lengths, earnings reductions, and decreased performance when compared with non-concussed controls.	[Navarro, Sergio M.; Pettit, Rowland W.; Haeberle, Heather S.] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA; [Frangiamore, Salvatore J.; Farrow, Lutul D.; Schickendantz, Mark S.; Ramkumar, Prem N.] Summa Hlth, Dept Orthoped Surg, Akron, OH USA; [Rahman, Nadeem M.] Cleveland Clin, Dept Anesthesiol, Cleveland, OH 44106 USA	Ramkumar, PN (corresponding author), 2049 E 100th St, Cleveland, OH 44195 USA.	premramkumar@gmail.com	Navarro, Sergio M/B-4287-2019; Navarro, Sergio M/K-8923-2019	Navarro, Sergio M/0000-0003-3455-1567; Haeberle, Heather/0000-0001-8341-8389			Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bonfield CM, 2014, PROG NEUROL SURG, V28, P161, DOI 10.1159/000358777; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Colon GAT, 2017, QUAL HEALTH RES, V27, P1077, DOI 10.1177/1049732316669339; de Beer J., 2008, CAN LEG ED ANN REV, V2, P61; Donaldson L, 2014, INJURY PREV, V20, DOI 10.1136/injuryprev-2013-041016; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Fino P.C., 2017, CLIN J SPORT MED; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Izraelski Jason, 2014, J Can Chiropr Assoc, V58, P346; Kuhn AW, 2016, AM J SPORT MED, V44, P2152, DOI 10.1177/0363546516638327; Kumar NS, 2014, AM J SPORT MED, V42, P2050, DOI 10.1177/0363546514539449; LaPrade RF, 2004, AM SOC TEST MATER, V1446, P40, DOI 10.1520/STP11607S; Ling H, 2017, NEUROPATH APPL NEURO, V43, P467, DOI 10.1111/nan.12425; Navarro SM, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117740847; Padaki AS, 2016, AM J SPORT MED, V44, P2263, DOI 10.1177/0363546516634679; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Plancher KD, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114550623; Samson K., 2012, NEUROL TODAY, V12, P13; Wasserman EB, 2015, AM J SPORT MED, V43, P1127, DOI 10.1177/0363546515576130; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X; Wilcox BJ, 2014, J ATHL TRAINING, V49, P514, DOI 10.4085/1062-6050-49.3.19	25	11	11	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	20					2391	2399		10.1089/neu.2017.5611		JUL 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GV6DE	WOS:000437231100001	29648975				2021-06-18	
J	Bier, B; Ouellet, E; Belleville, S				Bier, Bianca; Ouellet, Emilie; Belleville, Sylvie			Computerized Attentional Training and Transfer With Virtual Reality: Effect of Age and Training Type	NEUROPSYCHOLOGY			English	Article						dual-task; cognitive training; transfer; virtual-reality; aging	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; OLDER-ADULTS; MEMORY; REHABILITATION; INTERVENTIONS; PLASTICITY; DEFICITS; IMPACT; SKILL	Objective: The aims of this study were to assess whether computerized attentional training improves dual-tasking abilities in older adults and whether its effect and transfer are modulated by age and the type of training provided. This study also used virtual reality (VR) as a proxy to measure transfer in a real life related context. Method: Sixty participants (30 older and 30 younger adults) were randomized to either: (a) single-task training (two tasks practiced in focused attention; visual detection and alphanumeric equation task); or (b) divided attention variable-priority training (varying the amount of attention to put on each task when performed concurrently). Training effects were assessed at pre- and post-training with tasks similar to the one used in training. Transfer was measured with the virtual car ride, an immersive dual-task scenario and a self-reported questionnaire. Results: In older adults, variable-priority improved attentional control abilities and led to better transfer in the VR dual-task scenario compared with single-task. Younger adults benefited equally from the two types of training and transfer was found on the Alpha span task when performed concurrently in VR. Single-task improved the ability of all participants to carry out the tasks in the focused attention condition. No transfer effects were found on the self-reported measure for either training type or age. Conclusion: Attention remains plastic in old age and programs designed to improve attentional control might be beneficial to older adults. Importantly, training can produce transfer to more real life related tasks and transfer remains possible throughout the life span. General Scientific Summary This study shows the importance of selecting the appropriate training program on the basis of (a) what we want to improve and (b) the population to which it is addressed. Indeed, older adults were found to benefit to a larger extent than younger adults from a training targeting attentional control abilities (for which difficulties were found prior to training), and that this training gain may transfer to tasks of everyday life.	[Bier, Bianca; Ouellet, Emilie; Belleville, Sylvie] Inst Univ Geriatrie Montreal, Res Ctr, 4565 Queen Mary, Montreal, PQ H3W 1W5, Canada; [Bier, Bianca; Ouellet, Emilie; Belleville, Sylvie] Univ Montreal, Dept Psychol, Montreal, PQ, Canada	Belleville, S (corresponding author), Inst Univ Geriatrie Montreal, Res Ctr, 4565 Queen Mary, Montreal, PQ H3W 1W5, Canada.	sylvie.belleville@umontreal.ca					Allain P, 2014, J INT NEUROPSYCH SOC, V20, P468, DOI 10.1017/S1355617714000344; Anguera JA, 2013, NATURE, V501, P97, DOI 10.1038/nature12486; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Barker-Collo SL, 2009, STROKE, V40, P3293, DOI 10.1161/STROKEAHA.109.558239; Barnett SM, 2002, PSYCHOL BULL, V128, P612, DOI 10.1037//0033-2909.128.4.612; Belleville S, 1998, MEM COGNITION, V26, P572, DOI 10.3758/BF03201163; Belleville S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102710; Bherer L, 2005, PSYCHOL AGING, V20, P695, DOI 10.1037/0882-7974.20.4.695; Bherer L, 2008, EXP AGING RES, V34, P188, DOI 10.1080/03610730802070068; Bier B, 2014, AGE, V36, DOI 10.1007/s11357-014-9688-2; Boot WR, 2010, ACTA PSYCHOL, V135, P349, DOI 10.1016/j.actpsy.2010.09.005; Bransford J. D., 2000, LEARNING TRANSFER PE; Braver T. S., 2008, HDB AGING COGNITION, P311; Braver TS, 2001, J EXP PSYCHOL GEN, V130, P746, DOI 10.1037//0096-3445.130.4.746; Brehmer Y, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00063; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BUTTERFIELD EC, 1991, COGNITION INSTRUCT, V8, P69, DOI 10.1207/s1532690xci0801_3; Chandler MJ, 2016, NEUROPSYCHOL REV, V26, P225, DOI 10.1007/s11065-016-9330-4; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Corriveau-Lecavalier N., 2017, NEUROPSYCHOLOGICAL R; Cushman LA, 2008, NEUROLOGY, V71, P888, DOI 10.1212/01.wnl.0000326262.67613.fe; Dahlin E, 2008, SCIENCE, V320, P1510, DOI 10.1126/science.1155466; Derwinger A, 2003, AGING NEUROPSYCHOL C, V10, P202, DOI 10.1076/anec.10.3.202.16452; Erickson KI, 2010, CEREB CORTEX, V20, P2522, DOI 10.1093/cercor/bhp293; Fetta J, 2017, J NEUROSCI NURS, V49, P235, DOI 10.1097/JNN.0000000000000298; Gagnon LG, 2012, NEUROPSYCHOL REHABIL, V22, P809, DOI 10.1080/09602011.2012.691044; GOPHER D, 1989, ACTA PSYCHOL, V71, P147, DOI 10.1016/0001-6918(89)90007-3; GOPHER D, 1994, HUM FACTORS, V36, P387; Gopher D., 2007, ATTENTION THEORY PRA, V101, P209; HART SG, 1992, PROCEEDINGS OF THE HUMAN FACTORS SOCIETY, 36TH ANNUAL MEETING, VOLS 1 AND 2, P1291; HAWKINS HL, 1992, PSYCHOL AGING, V7, P643, DOI 10.1037/0882-7974.7.4.643; Jaeggi SM, 2014, MEM COGNITION, V42, P464, DOI 10.3758/s13421-013-0364-z; Jaeggi SM, 2011, P NATL ACAD SCI USA, V108, P10081, DOI 10.1073/pnas.1103228108; Karbach J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00048; Katz B., 2016, COGNITIVE TRAINING O, P157, DOI [10.1007/978-3-319-42662-4_15, DOI 10.1007/978-3-319-42662-4_15]; KRAMER AF, 1995, J EXP PSYCHOL-APPL, V1, P50, DOI 10.1037/1076-898X.1.1.50; Kramer AF, 1999, ACTA PSYCHOL, V101, P339, DOI 10.1016/S0001-6918(99)00011-6; Kuhn S., 2016, HDB PSYCHOL AGING, P105, DOI DOI 10.1016/B978-0-12-411469-2.00006-6; Lee H, 2012, BEHAV BRAIN RES, V232, P348, DOI 10.1016/j.bbr.2012.03.043; Leeb R, 2007, IEEE T NEUR SYS REH, V15, P473, DOI 10.1109/TNSRE.2007.906956; Lobato J, 2006, J LEARN SCI, V15, P431, DOI 10.1207/s15327809jls1504_1; Lovden M, 2010, PSYCHOL BULL, V136, P659, DOI 10.1037/a0020080; Lussier M., 2016, RESTORATIVE NEUROLOG, V35, P237; Lussier M, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00129; Lustig C, 2009, NEUROPSYCHOL REV, V19, P504, DOI 10.1007/s11065-009-9119-9; McDowd J. M., 2000, HDB AGING COGNITION, P221; MCDOWD JM, 1991, J GERONTOL, V46, pP340, DOI 10.1093/geronj/46.6.P340; Melby-Lervag M, 2013, DEV PSYCHOL, V49, P270, DOI 10.1037/a0028228; Milham MP, 2002, BRAIN COGNITION, V49, P277, DOI 10.1006/brcg.2001.1501; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; NEELY AS, 1993, EDUC GERONTOL, V19, P105, DOI 10.1080/0360127930190202; Noack H, 2009, RESTOR NEUROL NEUROS, V27, P435, DOI 10.3233/RNN-2009-0496; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Palmese CA, 2000, BRAIN INJURY, V14, P535; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Perkins D.N., 1992, INT ENCY ED, V2, P6452, DOI DOI 10.1016/B978-0-08-097086-8.92040-3; PERKINS DN, 1988, EDUC LEADERSHIP, V46, P22; Plancher G, 2010, NEUROPSYCHOLOGY, V24, P379, DOI 10.1037/a0018680; Rebok GW, 2014, J AM GERIATR SOC, V62, P16, DOI 10.1111/jgs.12607; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; SALTHOUSE TA, 1984, MEM COGNITION, V12, P613, DOI 10.3758/BF03213350; Saposnik G, 2016, LANCET NEUROL, V15, P1019, DOI 10.1016/S1474-4422(16)30121-1; Schuemie MJ, 2001, CYBERPSYCHOL BEHAV, V4, P183, DOI 10.1089/109493101300117884; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Shuchat J., 2012, NONPHARMACOL THER DE, V3, P35; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Stuss DT, 2007, J INT NEUROPSYCH SOC, V13, P120, DOI 10.1017/S1355617707070154; Voss MW, 2012, NEUROIMAGE, V59, P138, DOI 10.1016/j.neuroimage.2011.03.052; Waller D, 1998, PRESENCE-TELEOP VIRT, V7, P129, DOI 10.1162/105474698565631; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Zanardo F, 2006, AGING CLIN EXP RES, V18, P425, DOI 10.1007/BF03324839; Zendel BR, 2016, NEUROBIOL AGING, V47, P10, DOI 10.1016/j.neurobiolaging.2016.06.023; Zinke K, 2014, DEV PSYCHOL, V50, P304, DOI 10.1037/a0032982; Zinke K, 2012, GERONTOLOGY, V58, P79, DOI 10.1159/000324240	76	11	11	2	20	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2018	32	5					597	614		10.1037/neu0000417			18	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	GK8VT	WOS:000436509600008	29952612				2021-06-18	
J	Eckner, JT; O'Connor, KL; Broglio, SP; Ashton-Miller, JA				Eckner, James T.; O'Connor, Kathryn L.; Broglio, Steven P.; Ashton-Miller, James A.			Comparison of Head Impact Exposure Between Male and Female High School Ice Hockey Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; female athletes; head impact biomechanics; ice hockey; X-Patch	TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; GENDER-DIFFERENCES; SEX-DIFFERENCES; SOCCER PLAYERS; MUSCLE STRENGTH; UNITED-STATES; ACCELERATION	Background: Concussion incidence rates are higher among female than male athletes in sports played by both sexes. Biomechanical factors may play a role in observed sex-based differences in concussion incidence. Purpose: To compare head impact counts and magnitudes during sports participation between male and female high school ice hockey athletes. Study Design: Cohort study; Level of evidence, 2. Methods: Over 2 seasons, a total of 21 male and 19 female ice hockey athletes from a single high school were instrumented with impact-sensing adhesive skin patches worn over the mastoid process while participating in games and practices. The impact sensors recorded the number, magnitude (peak linear acceleration [PLA, g] and peak angular acceleration [PAA, rad/s(2)] of the head; Head Impact Telemetry severity profile [HITsp]), and location of impacts sustained during each instrumented session. Head impact counts, magnitudes, and locations were compared between the sexes. Results: Males experienced more head impacts than females during games (mean +/- SD: 7.7 +/- 3.0 vs 5.3 +/- 2.0, P < .001) as well as practices (4.3 +/- 1.6 vs 3.8 +/- 1.1, P = .002). Mean impact magnitudes were greater for females for PLA (18.8g +/- 1.7g vs 17.1g +/- 1.6g, P < .001) and HITsp (19.7 +/- 1.5 vs 17.7 +/- 1.4, P < .001), while mean PAA was greater for males (3057.6 +/- 2.0 rad/s(2) vs 2778.3 +/- 2.7 rad/s(2), P < .001). Female athletes experienced higher PLA, PAA, and HITsp magnitudes for the top 10%, 5%, and 1% of impacts (all P < .050). Males experienced more impacts to the front (34.3%) and back (31.7%) of the head, while females experienced more impacts to the side (43.1%) and top (4.1%) (x(2) = 295.70, df = 3, P < .001). Conclusion: While male high school ice hockey athletes experienced more head impacts than females, impact magnitudes tended to be higher for females.	[Eckner, James T.; O'Connor, Kathryn L.; Broglio, Steven P.; Ashton-Miller, James A.] Univ Michigan, Ann Arbor, MI 48109 USA; [Eckner, James T.] Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA; [O'Connor, Kathryn L.; Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Ashton-Miller, James A.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu		Van Pelt, Kathryn/0000-0002-5494-2357	University of Michigan Sport, Health and Activity Research and Policy Center for Women and Girls; Rehabilitation Medicine Scientist Training Program [K12HD001097]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23HD078502]; Proctor Gamble; Hologic; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078502, K12HD001097] Funding Source: NIH RePORTER	This research was supported by a pilot grant from the University of Michigan Sport, Health and Activity Research and Policy Center for Women and Girls. J.T.E. received effort support from the Rehabilitation Medicine Scientist Training Program (K12HD001097) and the National Institutes of Health (K23HD078502) during the study period. J.A.A.-M. and his Biomechanics Research Laboratory have partial support in the form of grants to the University of Michigan from Proctor & Gamble and Hologic for research that is unrelated to the topic of this article.	[Anonymous], 2016, 2014 15 HIGH SCH ATH; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Cortes N, 2017, AM J SPORT MED, V45, P2379, DOI 10.1177/0363546517706703; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2014, AM J SPORT MED, V42, P566, DOI 10.1177/0363546513517869; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Kerr ZY, 2017, AM J PREV MED, V53, P914, DOI 10.1016/j.amepre.2017.05.017; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; King DA, 2016, J NEUROSURG-PEDIATR, V18, P65, DOI 10.3171/2015.12.PEDS15605; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lennon A., 2015, THESIS; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Morin S., 2009, PLAY LIKE A GIRL; Morrison M., 2015, J BIOSENS BIOELECTRO, V6, P1; National Collegiate Athletic Association, 2017, NCAA SPORTS SPONS PA; Nevins D, 2015, PROCEDIA ENGINEER, V112, P175, DOI 10.1016/j.proeng.2015.07.195; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Reynolds BB, 2016, AM J SPORT MED, V44, P2947, DOI 10.1177/0363546516648442; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Siegmund G, 2015, INT RES COUNC BIOM 2; Staudte H W, 1994, Eur Spine J, V3, P155, DOI 10.1007/BF02190578; Svaldi DO, 2017, BRAIN IMAGING BEHAV, V11, P98, DOI 10.1007/s11682-016-9509-6; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; USA Hockey, 2017, 2015 2016 SEAS FIN R; Wilcox BJ, 2014, J ATHL TRAINING, V49, P514, DOI 10.4085/1062-6050-49.3.19; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	65	11	11	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2018	46	9					2253	2262		10.1177/0363546518777244			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GN4BM	WOS:000438958100028	29856659				2021-06-18	
J	Nourallah, B; Zeiler, FA; Calviello, L; Smielewski, P; Czosnyka, M; Menon, DK				Nourallah, Basil; Zeiler, Frederick A.; Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek; Menon, David K.			Critical thresholds for intracranial pressure vary over time in non-craniectomised traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						Neuromonitoring; Neurocritical care; Traumatic brain injury; Threshold; Intracranial pressure; Cerebral perfusion pressure	CEREBRAL PERFUSION-PRESSURE; CEREBROVASCULAR REACTIVITY; MORTALITY; IMPACT	Intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-guided therapy is central to neurocritical care for traumatic brain injury (TBI) patients. We sought to identify time-dependent critical thresholds for mortality and unfavourable outcome for ICP and CPP in non-craniectomised TBI patients. This is a retrospective cohort study of 355 patients with moderate-to-severe TBI who received ICP monitoring and were managed without decompressive craniectomy in a tertiary hospital neurocritical care unit. Patients were grouped in 2 x 2 tables according to survival/death or favourable/unfavourable outcomes at 6 months and serial thresholds of mean ICP and CPP, using increments of 0.1 and 0.5 mmHg respectively. Sequential chi-square analysis was performed, and the thresholds yielding the highest chi-square test statistic were taken as having the best discriminative value for outcome. This process was repeated over monitoring periods of 1, 3, 5 and 7 days and for each day of recording to establish time-dependent thresholds. The same analysis was performed for age and sex subgroups. Global ICP thresholds were 21.3 and 20.5 mmHg for mortality and unfavourable outcome respectively (p < 0.001). After the first day of ICP monitoring, ICP thresholds fell to between 15 and 20 mmHg and remained significant (p < 0.05). Significant time-dependent CPP thresholds for mortality or unfavourable outcome were often not identified, and no identifiable trends were produced. Critical ICP thresholds in non-craniectomised TBI patients vary with time and fall below established ICP targets after the first day of monitoring.	[Nourallah, Basil; Zeiler, Frederick A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Sect Brain Phys, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Nourallah, B (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England.	basilnourallah@gmail.com; umzeiler@myumanitoba.ca; lac76@cam.ac.uk; ps10011@cam.ac.uk; mc141@medschl.cam.ac.uk; dkm13@cam.ac.uk		Zeiler, Frederick/0000-0003-1737-0510; czosnyka, marek/0000-0003-2446-8006	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; European Union Framework Program 7 grant (CENTER-TBI) [602150]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI17C1790]	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery and the University of Manitoba Clinician Investigator Program.; These studies were supported by the National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to DKM. The authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150).; MC is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI17C1790).	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Calviello L, 2017, NEUROCRIT CARE, P1; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Maas AI, 2014, NEUROSURGERY, V76, P67; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; National Research Ethics Service, 2012, CHANG REM RES ETH CO; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Sauvigny T, 2017, J NEUROSURG, P1; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; UK Health Departments, 2011, GOV ARR RES ETH COMM; Vik A, 2008, RELATIONSHIP DOSE IN; Zeiler FA, 2018, J NEUROTRAUM, V35, P314, DOI 10.1089/neu.2017.5364	27	11	11	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUL	2018	160	7					1315	1324		10.1007/s00701-018-3555-3			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GJ0XT	WOS:000434978600003	29732476	Other Gold, Green Published			2021-06-18	
J	Ozinga, SJ; Linder, SM; Miller, M; Dey, T; Figler, R; Russman, AN; So, R; Rosenthal, AH; Cruickshank, J; Alberts, JL				Ozinga, Sarah J.; Linder, Susan M.; Miller, Mandy; Dey, Tanujit; Figler, Richard; Russman, Andrew N.; So, Richard; Rosenthal, Alan H.; Cruickshank, Jason; Alberts, Jay L.			Normative Performance on the Balance Error Scoring System by Youth, High School, and Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						postural stability; concussion; reference values; motor control	SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; CHILDREN; ADOLESCENTS; ASSESSMENTS; MATURATION	Context: Annually, more than 1 million youth athletes in the United States receive or are suspected of receiving a concussion. The Balance Error Scoring System (BESS) is the most commonly used clinical balance evaluation designed to provide a better understanding of the motor-control processes of individuals with concussion. Despite the widespread use of the BESS, a fundamental gap exists in applying this tool to young athletes, as normative values are lacking for this population. Objective: To determine age- and sex-specific normative values for the BESS in youth, high school, and collegiate athletes. Design: Cross-sectional study. Setting: Local youth sport organizations, high schools, and colleges. Patients or Other Participants: Student-athletes (N = 6762) completed preseason baseline concussion testing as part of a comprehensive concussion-management program. Groups were youth males aged 5 to 13 years (n = 360), high school males aged 14 to 18 years (n = 3743), collegiate males aged 19 to 23 years (n = 497), youth females aged 5 to 13 years (n = 246), high school females aged 14 to 18 years (n = 1673), and collegiate females aged 19 to 23 years (n = 243). Main Outcome Measure(s): Errors according to the BESS specifications. Results: Performance on the BESS was worse (P < .01) in youth athletes than in high school and collegiate athletes. In the youth and high school cohorts, females exhibited better scores than males (P < .05). Sex was not a factor for collegiate athletes. Data from the youth cohort were further subdivided into 4-year bins to evaluate potential motor-development differences. The error count was highest for 5- to 9-year-old males and decreased with age. Conclusions: Performance on the BESS depended on sex and age, particularly in youth athletes. These sex- and age-specific normative values provide a reference to facilitate and unify clinical decision making across multiple providers caring for youth athletes with concussions.	[Ozinga, Sarah J.; Linder, Susan M.; Miller, Mandy; Alberts, Jay L.] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44195 USA; [Linder, Susan M.; Figler, Richard; Russman, Andrew N.; Cruickshank, Jason; Alberts, Jay L.] Cleveland Clin, Concuss Ctr, Cleveland, OH 44195 USA; [Dey, Tanujit] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Figler, Richard] Cleveland Clin, Orthoped & Rheumatol Inst, Cleveland, OH 44195 USA; [So, Richard; Rosenthal, Alan H.] Cleveland Clin, Pediat Inst, Cleveland, OH 44195 USA	Alberts, JL (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave, Cleveland, OH 44195 USA.	albertj@ccf.org			Edward and Barbara Bell endowed chair	This study was supported by The Edward and Barbara Bell endowed chair (Dr Alberts).	Alsalaheen B, 2016, BRAIN INJURY, V30, P914, DOI 10.3109/02699052.2016.1146965; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gosselin G, 2015, CHIROPR MAN THER, V23, DOI 10.1186/s12998-014-0045-4; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hansen C, 2016, CLIN J SPORT MED, V26, P497, DOI 10.1097/JSM.0000000000000285; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Iverson GL, 2013, REHABIL RES PRACT, V2013, DOI 10.1155/2013/846418; Khanna NK, 2015, SPORTS HEALTH, V7, P341, DOI 10.1177/1941738115571508; Liu B, 2008, FRONT MED-PRC, V2, P361; Long JS, 2000, AM STAT, V54, P217, DOI 10.2307/2685594; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Olson B., 2012, 46 ANN CAN ATHL THER; Pawlowski B, 2003, AM J HUM BIOL, V15, P144, DOI 10.1002/ajhb.10136; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; PILLAI KCS, 1955, ANN MATH STAT, V26, P117, DOI 10.1214/aoms/1177728599; RIACH CL, 1987, DEV MED CHILD NEUROL, V29, P650; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shingala M. C., 2015, IJNTSE, V2, P22; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Winter DA, 1996, J NEUROPHYSIOL, V75, P2334; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	41	11	11	0	6	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL	2018	53	7					636	645		10.4085/1062-6050-129-17			10	Sport Sciences	Sport Sciences	GS8PB	WOS:000443973200003	30109948	Bronze, Green Published			2021-06-18	
J	Zeiler, FA; Donnelly, J; Nourallah, B; Thelin, EP; Calviello, L; Smielewski, P; Czosnyka, M; Ercole, A; Menon, DK				Zeiler, Frederick A.; Donnelly, Joseph; Nourallah, Basil; Thelin, Eric P.; Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek; Ercole, Ari; Menon, David K.			Intracranial and Extracranial Injury Burden as Drivers of Impaired Cerebrovascular Reactivity in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; dysautoregulation; imaging; injury burden; TBI	PRESSURE; AUTOREGULATION; SEVERITY	Impaired cerebrovascular reactivity has been associated with outcome following traumatic brain injury (TBI), but it is unknown how it is affected by trauma severity. Thus, we aimed to explore the relationship between intracranial (IC) and extracranial (EC) injury burden and cerebrovascular reactivity in TBI patients. We retrospectively included critically ill TBI patients. IC injury burden included detailed lesion and computerized tomography (CT) scoring (i.e., Marshall, Rotterdam, Helsinki, and Stockholm Scores) on admission. EC injury burden was characterized using the injury severity score (ISS) and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. Pressure reactivity index (PRx), pulse amplitude index (PAx), and RAC were used to assess autoregulation/cerebrovascular reactivity. We used univariate and multi-variate logistic regression techniques to explore relationships between IC and EC injury burden and autoregulation indices. A total of 358 patients were assessed. ISS and all IC CT scoring systems were poor predictors of impaired cerebrovascular reactivity. Only subdural hematomas and thickness of subarachnoid hemorrhage (SAH; p < 0.05, respectively) were consistently associated with dysfunctional cerebrovascular reactivity. High age (p < 0.01 for all) and admission APACHE II scores (p < 0.05 for all) were the two variables most strongly associated with abnormal cerebrovascular reactivity. In summary, diffuse IC injury markers (thickness of SAH and the presence of a subdural hematoma) and APACHE II were most associated with dysfunction in cerebrovascular reactivity after TBI. Standard CT scoring systems and evidence of macroscopic parenchymal damage are poor predictors, implicating potentially both microscopic injury patterns and host response as drivers of dysfunctional cerebrovascular reactivity. Age remains a major variable associated with cerebrovascular reactivity.	[Zeiler, Frederick A.; Nourallah, Basil; Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Donnelly, Joseph; Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Brain Phys Lab, Cambridge, England; [Thelin, Eric P.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Thelin, Eric P.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Zeiler, FA (corresponding author), Univ Manitoba, Dept Surg, Winnipeg, MB, Canada.	umzeiler@myumanitoba.ca	Ercole, Ari/B-6288-2009; Donnelly, Joseph/N-6803-2019; Thelin, Eric Peter/K-2144-2012; Donnelly, Joseph/E-9235-2018	Ercole, Ari/0000-0001-8350-8093; Donnelly, Joseph/0000-0002-6502-8069; Thelin, Eric Peter/0000-0002-2338-4364; Donnelly, Joseph/0000-0002-6502-8069; czosnyka, marek/0000-0003-2446-8006; Zeiler, Frederick/0000-0003-1737-0510	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund; Woolf Fisher Scholarship (New Zealand); National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Research Professorship; European Union Framework Program 7 grant (CENTER-TBI) [602150]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund.; JD is supported by a Woolf Fisher Scholarship (New Zealand).; These studies were supported by National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to DKM, and an NIHR Research Professorship to PJAH. Authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150)	Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zeiler F.A., 2017, J NEUROTRAUMA; Zeiler F.A., 2018, J NEUROTRAUMA; Zeiler FA, 2017, J NEUROTRAUM, V34, P3207, DOI 10.1089/neu.2017.5085	21	11	11	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1569	1577		10.1089/neu.2017.5595			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000436548100002	29431051				2021-06-18	
J	Rao, KVR; Iring, S; Younger, D; Kuriakose, M; Skotak, M; Alay, E; Gupta, RK; Chandra, N				Rao, Kakulavarapu V. Rama; Iring, Stephanie; Younger, Daniel; Kuriakose, Matthew; Skotak, Maciej; Alay, Eren; Gupta, Raj K.; Chandra, Namas			A Single Primary Blast-Induced Traumatic Brain Injury in a Rodent Model Causes Cell-Type Dependent Increase in Nicotinamide Adenine Dinucleotide Phosphate Oxidase Isoforms in Vulnerable Brain Regions	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; blast injury; 4-hydroxynonenal; microglia; neuron; NADPH oxidase; oxidative stress; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; NADPH-OXIDASE; OXIDATIVE STRESS; FREE-RADICALS; LIPID-PEROXIDATION; ACTIVATED MICROGLIA; SCALING RULES; INHIBITION; NOX2; INFLAMMATION	Blast-induced traumatic brain injury (bTBI) is a leading cause of morbidity in soldiers on the battlefield and in training sites with long-term neurological and psychological pathologies. Previous studies from our laboratory demonstrated activation of oxidative stress pathways after blast injury, but their distribution among different brain regions and their impact on the pathogenesis of bTBI have not been explored. The present study examined the protein expression of two isoforms: nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 and 2 (NOX1, NOX2), corresponding superoxide production, a downstream event of NOX activation, and the extent of lipid peroxidation adducts of 4-hydroxynonenal (4HNE) to a range of proteins. Brain injury was evaluated 4h after the shock-wave exposure, and immunofluorescence signal quantification was performed in different brain regions. Expression of NOX isoforms displayed a differential increase in various brain regions: in hippocampus and thalamus, there was the highest increase of NOX1, whereas in the frontal cortex, there was the highest increase of NOX2 expression. Cell-specific analysis of changes in NOX expression with respect to corresponding controls revealed that blast resulted in a higher increase of NOX1 and NOX 2 levels in neurons compared with astrocytes and microglia. Blast exposure also resulted in increased superoxide levels in different brain regions, and such changes were reflected in 4HNE protein adduct formation. Collectively, this study demonstrates that primary blast TBI induces upregulation of NADPH oxidase isoforms in different regions of the brain parenchyma and that neurons appear to be at higher risk for oxidative damage compared with other neural cells.	[Rao, Kakulavarapu V. Rama; Iring, Stephanie; Younger, Daniel; Kuriakose, Matthew; Skotak, Maciej; Alay, Eren; Chandra, Namas] New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, 111 Lock St, Newark, NJ 07102 USA; [Gupta, Raj K.] US Army, Med Res & Mat Command, Dept Def Blast Injury Res Program Coordinating Of, Ft Detrick, MD USA	Rao, KVR (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, 111 Lock St, Newark, NJ 07102 USA.	kakulava@njit.edu; namas.chandra@njit.edu	Skotak, Maciej/H-4769-2019	Skotak, Maciej/0000-0003-2584-7294; Alay, Eren/0000-0003-2523-0366	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [14059001, W81XWH-15-1-0303]	This work was supported by grant no. 14059001, W81XWH-15-1-0303, entitled "Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tubes" received from the U.S. Army Medical Research and Materiel Command. Authors greatly acknowledge the assistance of Arun Ravula, Debanjan Haldar, Jose Rodriguez, Yonatan Sheer, Madison Taylor, Smit Shah for tissue sectioning and experimental data analysis.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arlt S, 2002, CURR OPIN LIPIDOL, V13, P289, DOI 10.1097/00041433-200206000-00009; Banakou E, 2010, COMP BIOCHEM PHYS C, V152, P346, DOI 10.1016/j.cbpc.2010.06.001; Bandak F A, 2015, Handb Clin Neurol, V127, P89, DOI 10.1016/B978-0-444-52892-6.00006-4; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bochicchio GV, 2008, AM SURGEON, V74, P267; BROWN SA, 1992, J AM VET MED ASSOC, V200, P1849; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Carbone F, 2015, ANTIOXID REDOX SIGN, V23, P460, DOI 10.1089/ars.2013.5778; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; CHANDRA N, 2015, BRAIN NEUROTRAUMA MO; Chandra N, 2017, MIL MED, V182, P105, DOI 10.7205/MILMED-D-16-00144; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Coyoy A, 2013, NEUROCHEM INT, V62, P998, DOI 10.1016/j.neuint.2013.03.009; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FERNANDEZ V, 1985, ENDOCRINOLOGY, V117, P496, DOI 10.1210/endo-117-2-496; Friedman J, 2011, OXID STRESS APPL BAS, P19, DOI 10.1007/978-1-60327-514-9_2; Fu YH, 2013, BRAIN STRUCT FUNCT, V218, P1337, DOI 10.1007/s00429-012-0462-x; Guilarte TR, 2016, TRENDS PHARMACOL SCI, V37, P334, DOI 10.1016/j.tips.2016.02.008; Herculano-Houzel S, 2006, P NATL ACAD SCI USA, V103, P12138, DOI 10.1073/pnas.0604911103; Herculano-Houzel S, 2011, BRAIN BEHAV EVOLUT, V78, P302, DOI 10.1159/000330825; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; JESBERGER JA, 1991, INT J NEUROSCI, V57, P1, DOI 10.3109/00207459109150342; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Koppula S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/823902; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kuriakose M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161597; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7; Mattson MP, 1996, PERSPECT DEV NEUROBI, V3, P79; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Ferreira APO, 2014, PSYCHOPHARMACOLOGY, V231, P1935, DOI 10.1007/s00213-013-3336-x; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Park KW, 2008, J NEUROSCI RES, V86, P1053, DOI 10.1002/jnr.21571; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reid MW, 2015, MOL CELL NEUROSCI, V66, P123, DOI 10.1016/j.mcn.2015.03.014; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Schaur RJ, 2015, BIOMOLECULES, V5, P2247, DOI 10.3390/biom5042247; Schiavone S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.36; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Singleton J.A., 2013, BMJ OPEN, P3; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Sorce S, 2010, J NEUROSCI, V30, P11317, DOI 10.1523/JNEUROSCI.1491-10.2010; Stanger O, 2001, CLIN PHYSIOL, V21, P718, DOI 10.1046/j.1365-2281.2001.00381.x; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Tan X., 2013, ASME 2013 INT MECH E; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wang XK, 2005, MOL BRAIN RES, V140, P120, DOI 10.1016/j.molbrainres.2005.07.018; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009	77	11	11	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2077	2090		10.1089/neu.2017.5358		JUN 2018	14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000435148500001	29648986	Green Published, Bronze			2021-06-18	
J	Hammond, FM; Sherer, M; Malec, JF; Zafonte, RD; Dikmen, S; Bogner, J; Bell, KR; Barber, J; Temkin, N				Hammond, Flora M.; Sherer, Mark; Malec, James F.; Zafonte, Ross D.; Dikmen, Sureyya; Bogner, Jennifer; Bell, Kathleen R.; Barber, Jason; Temkin, Nancy			Amantadine Did Not Positively Impact Cognition in Chronic Traumatic Brain Injury: A Multi-Site, Randomized, Controlled Trial	JOURNAL OF NEUROTRAUMA			English	Article						amantadine; attention; brain injuries; cognition; executive function; memory	PSYCHOTROPIC MEDICATION USE; EFFICACY	Despite limited evidence to support the use of amantadine to enhance cognitive function after traumatic brain injury (TBI), the clinical use for this purpose is highly prevalent and is often based on inferred belief systems. The aim of this study was to assess effect of amantadine on cognition among individuals with a history of TBI and behavioral disturbance using a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100mg twice-daily versus placebo for 60 days. Included in the study were 119 individuals with two or more neuropsychological measures greater than 1 standard deviation below normative means from a larger study of 168 individuals with chronic TBI (>6 months post-injury) and irritability. Cognitive function was measured at treatment days 0, 28, and 60 with a battery of neuropsychological tests. Composite indices were generated: General Cognitive Index (included all measures), a Learning Memory Index (learning/memory measures), and Attention/Processing Speed Index (attention and executive function measures). Repeated-measures analysis of variance revealed statistically significant between-group differences favoring the placebo group at day 28 for General Cognitive Index (p=0.002) and Learning Memory Index (p=0.001), but not Attention/Processing Speed Index (p=0.25), whereas no statistically significant between-group differences were found at day 60. There were no statistically significant between-group differences on adverse events. Cognitive function in individuals with chronic TBI is not improved by amantadine 100mg twice-daily. In the first 28 days of use, amantadine may impede cognitive processing. However, the effect size was small and mean scores for both groups were generally within expectations for persons with history of complicated mild-to-severe TBI, suggesting that changes observed across assessments may not have functional significance. The use of amantadine to enhance cognitive function is not supported by these findings.	[Hammond, Flora M.; Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Hammond, Flora M.; Malec, James F.] Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA; [Hammond, Flora M.] Carolinas Rehabil, Dept Phys Med & Rehabil, Carolinas HealthCare Syst, Charlotte, NC USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA USA; [Dikmen, Sureyya; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Bell, Kathleen R.] Univ Texas Southwestern Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; [Barber, Jason; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Hammond, FM (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.Hammond@rhin.com		Bell, Kathleen/0000-0002-0928-2046	U.S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability, Independent Living, and Rehabilitation Research [H133A080035]	The research reported in this article was supported by U.S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability, Independent Living, and Rehabilitation Research grant H133A080035. This support included the funds to purchase amantadine. The study sponsor had no role in the design and conduct of this study; the collection, management, analysis, and interpretation of the data; or the preparation review, or approval of the manuscript.	Albrecht JS, 2017, AM J GERIAT PSYCHIAT, V25, P415, DOI 10.1016/j.jagp.2016.11.018; Beck AT., 1996, BECK DEPRESSION INVE, V2; Benton A, 1989, MULTILINGUAL APHASIA; Chow JJ, 2018, BEHAV BRAIN RES, V338, P40, DOI 10.1016/j.bbr.2017.10.013; Delis DC, 2000, CALIFORNIA VERBAL LE; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Distribution of IQ Scores, DISTR IQ SCOR; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Hammond FM, 2017, J HEAD TRAUMA REHAB, V32, P308, DOI 10.1097/HTR.0000000000000342; Hammond FM, 2015, J NEUROTRAUM, V32, P1230, DOI 10.1089/neu.2014.3803; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS256, DOI 10.1016/j.apmr.2015.01.025; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Mancini M, 2016, NEUROPHARMACOLOGY, V101, P341, DOI 10.1016/j.neuropharm.2015.10.015; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Polich G, 2018, J NEUROTRAUM, V35, P1205, DOI 10.1089/neu.2017.5506; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; SAS, 2011, STAT AN SOFTW; Schneider WN, 1999, BRAIN INJURY, V13, P863; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wechsler D., 1939, MEASUREMENT ADULT IN; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 1994, ARMY INDIVIDUAL TEST; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016	27	11	11	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	19					2298	2305		10.1089/neu.2018.5767		JUN 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GV3OA	WOS:000434866500001	29742960	Green Published, Bronze			2021-06-18	
J	Chang, JL; Hinrich, AJ; Roman, B; Norrbom, M; Rigo, F; Marr, RA; Norstrom, EM; Hastings, ML				Chang, Jennifer L.; Hinrich, Anthony J.; Roman, Brandon; Norrbom, Michaela; Rigo, Frank; Marr, Robert A.; Norstrom, Eric M.; Hastings, Michelle L.			Targeting Amyloid-beta Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-beta Production	MOLECULAR THERAPY			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DOWN-SYNDROME; EXPRESSION; DEMENTIA; MICE; IDENTIFICATION; PHARMACOLOGY; DUPLICATION; COMPLEXITY	Alterations in amyloid beta precursor protein (APP) have been implicated in cognitive decline in Alzheimer's disease (AD), which is accelerated in Down syndrome/Trisomy 21 (DS/TS21), likely due to the extra copy of the APP gene, located on chromosome 21. Proteolytic cleavage of APP generates amyloid-beta (A beta) peptide, the primary component of senile plaques associated with AD. Reducing A beta production is predicted to lower plaque burden and mitigate AD symptoms. Here, we designed a splice-switching antisense oligonucleotide (SSO) that causes skipping of the APP exon that encodes proteolytic cleavage sites required for A beta peptide production. The SSO induced exon skipping in Down syndrome cell lines, resulting in a reduction of A beta. Treatment of mice with the SSO resulted in widespread distribution in the brain accompanied by APP exon skipping and a reduction of A beta. Overall, we show that an alternatively spliced isoform of APP encodes a cleavage-incompetent protein that does not produce A beta peptide and that promoting the production of this isoform with an SSO can reduce Ab in vivo. These findings demonstrate the utility of using SSOs to induce a spliced isoform of APP to reduce Ab as a potential approach for treating AD.	[Chang, Jennifer L.; Hinrich, Anthony J.; Hastings, Michelle L.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Ctr Genet Dis, Dept Cell Biol & Anat, N Chicago, IL 60064 USA; [Chang, Jennifer L.; Hinrich, Anthony J.; Hastings, Michelle L.] Rosalind Franklin Univ Med & Sci, Sch Grad & Postdoctoral Studies, N Chicago, IL 60064 USA; [Roman, Brandon; Norstrom, Eric M.] Depaul Univ, Dept Biol Sci, Chicago, IL 60614 USA; [Norrbom, Michaela; Rigo, Frank] Ionis Pharmaceut, Carlsbad, CA 92010 USA; [Marr, Robert A.] Rosalind Franklin Univ Med & Sci, Dept Neurosci, N Chicago, IL 60064 USA	Hastings, ML (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Cell Biol & Anat, Chicago Med Sch, 3333 Green Bay Dr, N Chicago, IL 60064 USA.	michelle.hastings@rosalindfranklin.edu	Hastings, MICHELLE/AAK-6627-2021	Hastings, Michelle/0000-0002-4253-9261	RFUMS internal research funding; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10 OD 010662]	We thank Francine Jodelka for technical assistance and Gopal Thinakaran for the CTM-1 antibody. This work was financially supported by RFUMS internal research funding and NIH S10 OD 010662.	Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Alzheimer's Association, 2016, Alzheimers Dement, V12, P459; Andrew RJ, 2016, J BIOL CHEM, V291, P19235, DOI 10.1074/jbc.R116.746032; Antonarakis SE, 2017, NAT REV GENET, V18, P147, DOI 10.1038/nrg.2016.154; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Bennett CF, 2017, ANNU REV PHARMACOL, V57, P81, DOI 10.1146/annurev-pharmtox-010716-104846; Bird SM, 2016, NEUROSCI BIOBEHAV R, V64, P215, DOI 10.1016/j.neubiorev.2016.01.004; Castro P, 2017, J NEUROL, V264, P804, DOI 10.1007/s00415-016-8308-8; Chakravarthy M, 2017, THERANOSTICS, V7, P3933, DOI 10.7150/thno.21529; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Chauhan NB, 2007, NEUROSCIENCE, V146, P143, DOI 10.1016/j.neuroscience.2007.01.008; Chavez-Gutierrez L, 2012, EMBO J, V31, P2261, DOI 10.1038/emboj.2012.79; Cruts M, 2012, HUM MUTAT, V33, P1340, DOI 10.1002/humu.22117; Dawkins E, 2014, J NEUROCHEM, V129, P756, DOI 10.1111/jnc.12675; De Strooper B, 2016, CELL, V164, P603, DOI 10.1016/j.cell.2015.12.056; De Strooper B, 2014, CELL, V159, P721, DOI 10.1016/j.cell.2014.10.016; De Strooper B, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006304; Deyts C, 2016, TRENDS PHARMACOL SCI, V37, P390, DOI 10.1016/j.tips.2016.01.005; Doran E, 2017, J ALZHEIMERS DIS, V56, P459, DOI 10.3233/JAD-160836; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gaiteri C, 2016, NAT REV NEUROL, V12, P413, DOI 10.1038/nrneurol.2016.84; Glascock J, 2017, GENE THER, V24, P498, DOI 10.1038/gt.2017.39; Hafez DM, 2012, NEUROSCIENCE, V223, P465, DOI 10.1016/j.neuroscience.2012.07.038; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Havens MA, 2016, NUCLEIC ACIDS RES, V44, P6549, DOI 10.1093/nar/gkw533; Havens MA, 2013, WIRES RNA, V4, P247, DOI 10.1002/wrna.1158; Hinrich AJ, 2016, EMBO MOL MED, V8, P328, DOI 10.15252/emmm.201505846; Hua YM, 2007, PLOS BIOL, V5, P729, DOI 10.1371/journal.pbio.0050073; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jonsson T, 2012, NATURE, V488, P96, DOI 10.1038/nature11283; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Karch CM, 2015, BIOL PSYCHIAT, V77, P43, DOI 10.1016/j.biopsych.2014.05.006; Karch CM, 2014, NEURON, V83, P11, DOI 10.1016/j.neuron.2014.05.041; Khvorova A, 2017, NAT BIOTECHNOL, V35, P238, DOI 10.1038/nbt.3765; Kumar VB, 2000, PEPTIDES, V21, P1769, DOI 10.1016/S0196-9781(00)00339-9; Lanoiselee HM, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002270; Lentz JJ, 2013, NAT MED, V19, P345, DOI 10.1038/nm.3106; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marr R.A., 2014, FRONT AGING NEUROSCI, V6; McClorey G, 2015, CURR OPIN PHARMACOL, V24, P52, DOI 10.1016/j.coph.2015.07.005; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mockett BG, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00030; Muller UC, 2017, NAT REV NEUROSCI, V18, P281, DOI 10.1038/nrn.2017.29; Norstrom E, 2017, DISCOV MED, V23, P269; Prasher VP, 1998, ANN NEUROL, V43, P380, DOI 10.1002/ana.410430316; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Puzzo D, 2011, ANN NEUROL, V69, P819, DOI 10.1002/ana.22313; Rigo F, 2014, J PHARMACOL EXP THER, V350, P46, DOI 10.1124/jpet.113.212407; Rohn TT, 2000, J NEUROCHEM, V74, P2331, DOI 10.1046/j.1471-4159.2000.0742331.x; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Singer O, 2005, NAT NEUROSCI, V8, P1343, DOI 10.1038/nn1531; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Sleegers K, 2006, BRAIN, V129, P2977, DOI 10.1093/brain/awl203; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Stahl R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00410; Szaruga M, 2015, J EXP MED, V212, P2003, DOI 10.1084/jem.20150892; Takami M, 2009, J NEUROSCI, V29, P13042, DOI 10.1523/JNEUROSCI.2362-09.2009; Tcw J., 2017, COLD SPRING HARB PER, V7, DOI DOI 10.1101/CSHPERSPECT.A024539; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Van Cauwenberghe C, 2016, GENET MED, V18, P421, DOI 10.1038/gim.2015.117; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; Vetrivel KS, 2009, J BIOL CHEM, V284, P3793, DOI 10.1074/jbc.M808920200; Veugelen S, 2016, NEURON, V90, P410, DOI 10.1016/j.neuron.2016.03.010; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wan LL, 2017, CELL, V170, P5, DOI 10.1016/j.cell.2017.06.028; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Xia D, 2015, NEURON, V85, P967, DOI 10.1016/j.neuron.2015.02.010; Zheng H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-27	76	11	11	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	JUN 6	2018	26	6					1539	1551		10.1016/j.ymthe.2018.02.029			13	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	GO1DH	WOS:000439687900016	29628304	Green Published, Other Gold			2021-06-18	
J	Meydan, C; Bekenstein, U; Soreq, H				Meydan, Chanan; Bekenstein, Uriya; Soreq, Hermona			Molecular Regulatory Pathways Link Sepsis With Metabolic Syndrome: Non-coding RNA Elements Underlying the Sepsis/Metabolic Cross-Talk	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						metabolic syndrome; miRs; ncRNAs; sepsis; SNPs	CARDIAC RESYNCHRONIZATION THERAPY; HEART-FAILURE PATIENTS; CIRCULATING MICRORNA-30D; CARDIOMYOCYTE APOPTOSIS; CARDIOVASCULAR-DISEASE; POSTTRAUMATIC-STRESS; ATRIAL-FIBRILLATION; INFLAMMATORY REFLEX; CATHETER ABLATION; ADIPOSE-TISSUE	Sepsis and metabolic syndrome (MetS) are both inflammation-related entities with high impact for human health and the consequences of concussions Both represent imbalanced parasympathetic/cholinergic response to insulting triggers and variably uncontrolled inflammation that indicates shared upstream regulators, including short microRNAs (miRs) and long non-coding RNAs (IncRNAs). These may cross talk across multiple systems, leading to complex molecular and clinical outcomes. Notably, biomedical and RNA-sequencing based analyses both highlight new links between the acquired and inherited pathogenic, cardiac and inflammatory traits of sepsis/MetS. Those include the HOTAIR and MIAT IncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA. Implicating non-coding RNA regulators in sepsis and MetS may delineate novel high-value biomarkers and targets for intervention.	[Meydan, Chanan] Mayanei Hayeshua Med Ctr, Dept Internal Med, Bnei Braq, Israel; [Bekenstein, Uriya; Soreq, Hermona] Hebrew Univ Jerusalem, Edmond & Lilly Safra Ctr Brain Sci, Alexander Silberman Inst Life Sci, Dept Biol Chem, Jerusalem, Israel	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Edmond & Lilly Safra Ctr Brain Sci, Alexander Silberman Inst Life Sci, Dept Biol Chem, Jerusalem, Israel.	hermona.soreq@mail.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X; Meydan, Chanan/0000-0002-8824-6309	European Research CouncilEuropean Research Council (ERC)European Commission [321501]; Israeli Ministry of Science, Technology and SpaceMinistry of Science, Technology and Space (MOST), Israel [53140]; Legacy Heritage Science Initiative (LHSI) of The Israel Science Foundation [817/13]; Austrian Research Promotion Agency (FFG Bridge1 project; Osterreichische Forschungsforderungsgesellschaft) [853294]; Edmond and Lily Safra Center for Brain Sciences (ELSC); Howard and Diana Wendy pre-doctoral fellowship; Israel I-Core Center of Excellence for Mass Trauma [817/13]	This research was supported by the European Research Council (Advanced Award 321501), The Israeli Ministry of Science, Technology and Space, Grant No. 53140, The Israel I-Core Center of Excellence for Mass Trauma and The Legacy Heritage Science Initiative (LHSI) of The Israel Science Foundation Grant No. 817/13, The Austrian Research Promotion Agency (FFG Bridge1 project; Osterreichische Forschungsforderungsgesellschaft, Grant number 853294) and the Edmond and Lily Safra Center for Brain Sciences (ELSC, to HS); UB was supported by the Howard and Diana Wendy pre-doctoral fellowship.	Abbasi J, 2017, JAMA-J AM MED ASSOC, V318, P506, DOI 10.1001/jama.2017.7997; Alvarez-Dominguez JR, 2015, CELL METAB, V21, P764, DOI 10.1016/j.cmet.2015.04.003; Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI 10.1056/NEJMra1208623; Arner P, 2015, NAT REV ENDOCRINOL, V11, P276, DOI 10.1038/nrendo.2015.25; Aslan A, 2017, SHOCK, V48, P69, DOI 10.1097/SHK.0000000000000841; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barbash S, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.163; Barbash S, 2014, MOL BIOL EVOL, V31, P1237, DOI 10.1093/molbev/msu090; Barwari T, 2016, J AM COLL CARDIOL, V68, P2577, DOI 10.1016/j.jacc.2016.09.945; Bekenstein U, 2017, P NATL ACAD SCI USA, V114, pE4996, DOI 10.1073/pnas.1701201114; Berezikov E, 2011, NAT REV GENET, V12, P846, DOI 10.1038/nrg3079; Bopp C, 2008, CRIT CARE, V12, DOI 10.1186/cc6164; Cajander S, 2013, CRIT CARE, V17, DOI 10.1186/cc13046; Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925; Caserta S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28006; Chen Z, 2016, MOL METAB, V5, P164, DOI 10.1016/j.molmet.2015.12.003; Correia CN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00118; Hert M, 2012, NAT REV ENDOCRINOL, V8, P114, DOI 10.1038/nrendo.2011.156; de Simone G, 2007, DIABETES CARE, V30, P1851, DOI 10.2337/dc06-2152; Divakaran V, 2008, CIRC RES, V103, P1072, DOI 10.1161/CIRCRESAHA.108.183087; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Fedi M, 2008, J CLIN ENDOCR METAB, V93, P634, DOI 10.1210/jc.2007-1611; Galatzer-Levy IR, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.38; Gernapudi R, 2016, MOL CELL BIOL, V36, P30, DOI 10.1128/MCB.00702-15; Grassi G, 2007, HYPERTENSION, V49, P535, DOI 10.1161/01.HYP.0000255983.32896.b9; Greco S, 2012, DIABETES, V61, P1633, DOI 10.2337/db11-0952; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Hanin G, 2018, GUT, V67, P1124, DOI 10.1136/gutjnl-2016-312869; Hanin G, 2014, HUM MOL GENET, V23, P4569, DOI 10.1093/hmg/ddu170; Hanisch UK, 2008, TRENDS NEUROSCI, V31, P176, DOI 10.1016/j.tins.2008.01.005; Hube F, 2011, NUCLEIC ACIDS RES, V39, P513, DOI 10.1093/nar/gkq833; Ingelsson E, 2006, HEART, V92, P1409, DOI 10.1136/hrt.2006.089011; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Karolina DS, 2012, J CLIN ENDOCR METAB, V97, pE2271, DOI 10.1210/jc.2012-1996; Karpe F, 2015, NAT REV ENDOCRINOL, V11, P90, DOI 10.1038/nrendo.2014.185; Korostowski L, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002956; Krawczyk M, 2014, ELIFE, V3, DOI 10.7554/eLife.01776; Kumarswamy R, 2014, CIRC RES, V114, P1569, DOI 10.1161/CIRCRESAHA.114.303915; Lagos D, 2010, NAT CELL BIOL, V12, P513, DOI 10.1038/ncb2054; Lebow M, 2012, J NEUROSCI, V32, P6906, DOI 10.1523/JNEUROSCI.4012-11.2012; Lekkou A, 2004, CLIN DIAGN LAB IMMUN, V11, P161, DOI 10.1128/CDLI.11.1.161-167.2004; Li LM, 2010, CANCER RES, V70, P9798, DOI 10.1158/0008-5472.CAN-10-1001; Li MD, 2009, NAT REV GENET, V10, P225, DOI 10.1038/nrg2536; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Li ZH, 2014, P NATL ACAD SCI USA, V111, P1002, DOI 10.1073/pnas.1313768111; Lin T, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.70; Lin XL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006308; Liu LT, 2016, CARDIOVASC RES, V111, P56, DOI 10.1093/cvr/cvw078; Liu RX, 2017, NAT MED, V23, P859, DOI 10.1038/nm.4358; Liu YC, 2014, ARTERIOSCL THROM VAS, V34, P902, DOI 10.1161/ATVBAHA.113.303123; Luna JM, 2015, CELL, V160, P1099, DOI 10.1016/j.cell.2015.02.025; Ma HF, 2017, J VIROL, V91, DOI 10.1128/JVI.01897-16; Marfella R, 2013, EUR J HEART FAIL, V15, P1277, DOI 10.1093/eurjhf/hft088; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; Meisel C, 2009, AM J RESP CRIT CARE, V180, P640, DOI 10.1164/rccm.200903-0363OC; Melkman-Zehavi T, 2011, EMBO J, V30, P835, DOI 10.1038/emboj.2010.361; Melman YF, 2015, CIRCULATION, V131, P2202, DOI 10.1161/CIRCULATIONAHA.114.013220; Meydan C, 2016, TRENDS MOL MED, V22, P798, DOI 10.1016/j.molmed.2016.07.001; Montgomery RL, 2011, CIRCULATION, V124, P1537, DOI 10.1161/CIRCULATIONAHA.111.030932; Morais VA, 2014, SCIENCE, V344, P203, DOI 10.1126/science.1249161; Moran I, 2012, CELL METAB, V16, P435, DOI 10.1016/j.cmet.2012.08.010; Morchikh M, 2017, MOL CELL, V67, P387, DOI 10.1016/j.molcel.2017.06.020; Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; O'Neill S, 2015, OBES REV, V16, P1, DOI 10.1111/obr.12229; Pan W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053950; Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rapicavoli NA, 2013, ELIFE, V2, DOI 10.7554/eLife.00762; Reddy MA, 2014, DIABETES, V63, P4249, DOI 10.2337/db14-0298; Reinhart K, 2017, NEW ENGL J MED, V377, P414, DOI 10.1056/NEJMp1707170; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Salta E, 2016, EMBO MOL MED, V8, P1005, DOI 10.15252/emmm.201606520; Santulli G, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00015; Sardu C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006558; Sardu C, 2016, CIRCULATION, V133, pE388, DOI 10.1161/CIRCULATIONAHA.115.018205; Sardu C, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/7292564; Sardu C, 2015, PHARMACOGENOMICS, V16, P1863, DOI 10.2217/pgs.15.117; Sardu C, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-176; Sardu C, 2014, PHARMACOGENOMICS, V15, P1159, DOI [10.2217/PGS.14.76, 10.2217/pgs.14.76]; Shahreyar M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.26; Sonneville R, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-15; Sun J, 2016, SCI REP-UK, V6, DOI 10.1038/srep35421; Suzuki T, 2008, CIRC-HEART FAIL, V1, P242, DOI 10.1161/CIRCHEARTFAILURE.108.785485; Tang WF, 2016, J VIROL, V90, P1424, DOI 10.1128/JVI.02143-15; Tani H, 2012, GENOME RES, V22, P947, DOI 10.1101/gr.130559.111; Tracey KJ, 2010, NAT IMMUNOL, V11, P561, DOI 10.1038/ni0710-561; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Ulitsky I, 2016, NAT REV GENET, V17, P601, DOI 10.1038/nrg.2016.85; van der Poll T, 2008, LANCET INFECT DIS, V8, P32, DOI 10.1016/S1473-3099(07)70265-7; Vasilescu C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007405; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Viereck J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1475; Wang JJ, 2010, ATHEROSCLEROSIS, V210, P237, DOI 10.1016/j.atherosclerosis.2009.10.042; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang ZQ, 2017, CELL MOL LIFE SCI, V74, P1117, DOI 10.1007/s00018-016-2398-4; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528; Wu HW, 2016, BIOCHEM BIOPH RES CO, V471, P240, DOI 10.1016/j.bbrc.2016.01.117; Xu GY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166235; Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510; Zaghloul N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01673; Zampetaki A, 2012, CIRC RES, V110, P508, DOI 10.1161/CIRCRESAHA.111.247445; Zgheib C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177453; Zhang AQ, 2015, ANN SURG, V261, P189, DOI 10.1097/SLA.0000000000000687; Zhang D, 2016, CELL REP, V16, P757, DOI 10.1016/j.celrep.2016.06.040; Zhao XY, 2015, TRENDS BIOCHEM SCI, V40, P586, DOI 10.1016/j.tibs.2015.08.002	115	11	12	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	JUN 5	2018	11								189	10.3389/fnmol.2018.00189			14	Neurosciences	Neurosciences & Neurology	GI2IU	WOS:000434194200001	29922126	DOAJ Gold, Green Published			2021-06-18	
J	Chen, C; Peng, J; Sribnick, EA; Zhu, MT; Xiang, H				Chen, Cheng; Peng, Jin; Sribnick, Eric A.; Zhu, Motao; Xiang, Henry			Trend of Age-Adjusted Rates of Pediatric Traumatic Brain Injury in US Emergency Departments from 2006 to 2013	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article						traumatic brain injury; pediatric; emergency department; annual percent change	UNITED-STATES; SURVEILLANCE; CONCUSSION; VISITS; MILD; CARE	Objective: To use the 2006-2013 Nationwide Emergency Department Sample (NEDS) database to describe trends of age-adjusted rates of pediatric traumatic brain injuries (TBI) treated in U.S. emergency departments. Methods: Time trend analysis was conducted on age-adjusted rates among children 17 years in the U.S. The annual percent change (APC) was calculated by fitting a least squares regression to the logarithm of the rates, using the calendar year as an independent variable. Results: In males, motor-vehicle-related trauma (APC -2.5%) and severe TBI (APC -3.6%) decreased over the study time period. Conversely, concussion (APC 5.1%), unspecified head injury (APC 6.6%), fall-related TBI (APC 7.1%), and mild TBI (APC 5.9%) increased. In females, severe TBI (APC -3.3%) decreased over the study time period and concussion (APC 6.5%), unspecified head injury (APC 7.2%), fall-related TBI (APC 7.6%), and mild TBI (APC 6.8%) increased. Conclusion: The overall age-adjusted rates of pediatric TBI-related emergency department (ED) visits increased from 2006 to 2013, which is largely caused by pediatric mild TBIs, especially unspecified injury to the head (ICD-9-CM code 959.01) and concussion. In comparison, age-adjusted rates of pediatric severe TBIs decreased. A major contributing factor might be a reduced number of traffic-related head trauma.	[Chen, Cheng; Peng, Jin; Sribnick, Eric A.; Xiang, Henry] Nationwide Childrens Hosp, Res Inst, Ctr Pediat Trauma Res, Columbus, OH 43215 USA; [Chen, Cheng; Peng, Jin; Zhu, Motao; Xiang, Henry] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43215 USA; [Peng, Jin; Xiang, Henry] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA; [Sribnick, Eric A.; Zhu, Motao; Xiang, Henry] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43205 USA; [Sribnick, Eric A.] Nationwide Childrens Hosp, Dept Neurosurg, Columbus, OH 43205 USA	Xiang, H (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Pediat Trauma Res, Columbus, OH 43215 USA.; Xiang, H (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43215 USA.; Xiang, H (corresponding author), Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA.; Xiang, H (corresponding author), Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43205 USA.	chencheng616001@gmail.com; Jin.Peng@nationwidechildrens.org; Eric.Sribnick@nationwidechildrens.org; Motao.Zhu@nationwidechildrens.org; Henry.Xiang@nationwidechildrens.org	Sribnick, Eric/AAH-6693-2020	zhu, motao/0000-0001-5639-4801	Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01/HS2426301]; Health Resources and Services Administration of the US Department of Health and Human Services [R40MC30759]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS024263] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD085122, R01HD074594] Funding Source: NIH RePORTER	This research was supported by the Agency for Healthcare Research and Quality [grant number R01/HS2426301] and the Health Resources and Services Administration of the US Department of Health and Human Services [grant number R40MC30759]. The conclusions are those of authors and should not be construed as the official position or policy of the funding agencies.	[Anonymous], 1991, IARC Sci Publ, P1; [Anonymous], 2001, RATES TBI RELATED HO; [Anonymous], 2008, 110 C US; [Anonymous], 2000, 106 C US AM; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Beck B, 2016, MED J AUSTRALIA, V204, P407, DOI 10.5694/mja15.01369; Centers for Disease Control and Prevention, BRIDG RAC POP EST 19; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Chen C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040414; Collins Christy L, 2014, Inj Epidemiol, V1, P13; Cook Alan, 2014, J Trauma Acute Care Surg, V76, P47, DOI 10.1097/TA.0b013e3182ab0d5d; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dao J, 2012, NY TIMES; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Esteve J, 1994, IARC Sci Publ, P1; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Greene NH, 2015, INJURY PREV, V21, P325, DOI 10.1136/injuryprev-2014-041524; Hankey BF, 2000, CANCER CAUSE CONTROL, V11, P31, DOI 10.1023/A:1008953201688; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Kohn MA, 2004, ACAD EMERG MED, V11, P1, DOI 10.1197/S1069-656(03)00578-5; LaMotte Sandee, 2015, CNN; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marr AL., 2004, CENTRAL NERVOUS SYST; NIH/National Institute of Neurological Disorders and Stroke, 2017, WORS OUTC SERV MEMB; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Ries L. A. G., 1999, SEER CANC STAT REV 1; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Smith NA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0346; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thompson MC, 2014, BRAIN INJURY, V28, P431, DOI 10.3109/02699052.2014.887146; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; US Census Bureau, POP HOUS UN EST; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	37	11	11	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	JUN	2018	15	6							1171	10.3390/ijerph15061171			10	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	GK8SE	WOS:000436496900122	29874782	DOAJ Gold, Green Published			2021-06-18	
J	Dhall, SS; Haefeli, J; Talbott, JF; Ferguson, AR; Readdy, WJ; Bresnahan, JC; Beattie, MS; Pan, JZ; Manley, GT; Whetstone, WD				Dhall, Sanjay S.; Haefeli, Jenny; Talbott, Jason F.; Ferguson, Adam R.; Readdy, William J.; Bresnahan, Jacqueline C.; Beattie, Michael S.; Pan, Jonathan Z.; Manley, Geoffrey T.; Whetstone, William D.			Motor Evoked Potentials Correlate With Magnetic Resonance Imaging and Early Recovery After Acute Spinal Cord Injury	NEUROSURGERY			English	Article						Spinal cord injury; Evoked potentials; Intraoperative monitoring; BASIC score	SCOLIOSIS SURGERY; STIMULATION; IMPAIRMENT; SEVERITY	BACKGROUND: While the utilization of neurophysiologic intraoperative monitoring with motor evoked potentials (MEPs) has become widespread in surgery for traumatic spine fractures and spinal cord injury (SCI), clinical validation of its diagnostic and therapeutic benefit has been limited. OBJECTIVE: To describe the use of intraoperative MEP at a large level I trauma center and assess the prognostic capability of this technology. METHODS: The SCI REDCap database at our institution, a level I traumacenter, was queried for acute cervical SCI patients who underwent surgery with intraoperative monitoring between 2005 and 2011, yielding 32 patients. Of these, 23 patients had severe SCI (association impairment scale [AIS] A, B, C). We assessed preoperative and postoperative SCI severity (AIS grade), surgical data, use of steroids, and early magnetic resonance imaging (MRI) findings (preoperatively in 27 patients), including axial T2 MRI grade (Brain and Spinal Injury Center score). RESULTS: The presence of MEPs significantly predicted AIS at discharge (P<.001). In the group of severe SCI (ie, AIS A, B, C) patients with elicitable MEPs, AIS improved by an average of 1.5 grades (median = 1), as compared to the patients without elicitable MEP who improved on average 0.5 grades (median = 0, P<.05). In addition, axial MRI grade significantly correlated with MEP status. Patients without MEPs had a significantly higher axial MRI grade in comparison to the patients with MEPs (P<.001). CONCLUSION: In patients with severe SCI, MEPs predicted neurological improvement and correlated with axial MRI grade. These significant findings warrant future prospective studies of MEPs as a prognostic tool in SCI.	[Dhall, Sanjay S.; Haefeli, Jenny; Ferguson, Adam R.; Readdy, William J.; Bresnahan, Jacqueline C.; Beattie, Michael S.; Manley, Geoffrey T.; Whetstone, William D.] Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Rm M-779, San Francisco, CA 94143 USA; [Dhall, Sanjay S.; Haefeli, Jenny; Talbott, Jason F.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.; Pan, Jonathan Z.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Dhall, Sanjay S.; Haefeli, Jenny; Talbott, Jason F.; Ferguson, Adam R.; Readdy, William J.; Bresnahan, Jacqueline C.; Beattie, Michael S.; Pan, Jonathan Z.; Manley, Geoffrey T.; Whetstone, William D.] Transforming Res & Clin Knowledge Spinal Cord Inj, San Francisco, CA USA; [Talbott, Jason F.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Ferguson, Adam R.] SF VA Med Ctr, Dept Neurol Surg, San Francisco, CA USA; [Pan, Jonathan Z.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Whetstone, William D.] ZSFGH Emergency Ctr Neurocrit Emergencies, Dept Emergency Med, San Francisco, CA USA	Dhall, SS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Rm M-779, San Francisco, CA 94143 USA.	sanjaydhall@gmail.com	Beattie, Michael S/A-8953-2009	Ferguson, Adam/0000-0001-7102-1608	Department of Defense CDMRP award [SC120259]; Craig H. Nielsen Foundation	Partial support provided by Department of Defense CDMRP award SC120259 (MSB, GTM, JCB, WDW, ARF) and the Craig H. Nielsen Foundation (JH). The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; CALANCIE B, 1991, J NEUROSURG, V74, P897, DOI 10.3171/jns.1991.74.6.0897; Castellon AT, 2009, SPINE, V34, P2662, DOI 10.1097/BRS.0b013e3181bf151b; Consortium Spinal Cord Med, 2008, J SPINAL CORD MED, V31, P403; Costa P, 2014, SPINAL CORD, V52, P749, DOI 10.1038/sc.2014.138; Curt A, 1998, ARCH PHYS MED REHAB, V79, P81, DOI 10.1016/S0003-9993(98)90213-1; Davey NJ, 1999, EXP BRAIN RES, V127, P382, DOI 10.1007/s002210050806; Ellaway PH, 2007, J REHABIL RES DEV, V44, P69, DOI 10.1682/JRRD.2005.08.0140; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; Flanders AE, 1996, RADIOLOGY, V201, P649, DOI 10.1148/radiology.201.3.8939210; FORBES HJ, 1991, J BONE JOINT SURG BR, V73, P487; Hadley MN, 2013, NEUROSURGERY, V72, P40, DOI 10.1227/NEU.0b013e318276edda; Hurlbert RJ, 2013, NEUROSURGERY, V72, P93, DOI 10.1227/NEU.0b013e31827765c6; Kirshblum SC, 2002, AM J PHYS MED REHAB, V81, P502, DOI 10.1097/00002060-200207000-00006; Mabray MC, 2016, J NEUROTRAUM, V33, P954, DOI 10.1089/neu.2015.4093; NUWER MR, 1995, EVOKED POTENTIAL, V96, P6, DOI 10.1016/0013-4694(94)00235-D; Park JH, 2015, WORLD J CLIN CASES, V3, P765, DOI 10.12998/wjcc.v3.i9.765; Ryken TC, 2013, NEUROSURGERY, V72, P84, DOI 10.1227/NEU.0b013e318276ee16; Talbott JF, 2015, J NEUROSURG-SPINE, V23, P495, DOI 10.3171/2015.1.SPINE141033; Thirumala P, 2016, J CLIN NEUROSCI, V25, P122, DOI 10.1016/j.jocn.2015.10.010; Tsirikos AI, 2004, J SPINAL DISORD TECH, V17, P385, DOI 10.1097/01.bsd.0000095825.98982.1a; Wilson JR, 2012, J NEUROTRAUM, V29, P2263, DOI 10.1089/neu.2012.2417	22	11	11	1	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2018	82	6					870	876		10.1093/neuros/nyx320			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GO1GL	WOS:000439697700026	28973360				2021-06-18	
J	Doerfler, S; Faerber, J; McKhann, GM; Elliott, JP; Winn, HR; Kumar, M; Levine, J; Le Roux, PD				Doerfler, Sean; Faerber, Jennifer; McKhann, Guy M.; Elliott, J. Paul; Winn, H. Richard; Kumar, Monisha; Levine, Joshua; Le Roux, Peter D.			The Incidence and Impact of Secondary Cerebral Insults on Outcome After Aneurysmal Subarachnoid Hemorrhage	WORLD NEUROSURGERY			English	Article						Aneurysm; Hyperglycemia; Hypotension; Hypoxia; Intracranial hypertension; Intracranial pressure; Outcome; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; EXTRACEREBRAL ORGAN DYSFUNCTION; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; MEDICAL COMPLICATIONS; NEUROINTENSIVE CARE; HEMOGLOBIN CONCENTRATION; NEUROCRITICAL CARE; PERFUSION-PRESSURE; BLOOD-TRANSFUSION	INTRODUCTION: Secondary cerebral insults can adversely affect patients with traumatic brain injury. By contrast, the incidence of secondary cerebral insults after aneurysmal subarachnoid hemorrhage (SAH) and their impact on outcome have been less well studied. METHODS: Four hundred and twenty-one patients with SAH who underwent surgical occlusion of their ruptured aneurysm and who received intensive care unit care for >= 48 hours were retrospectively identified from a prospective observational database. Patients were managed according to standard recommendations for SAH. Three secondary cerebral insults were examined: hypotension (<90 mmHg systolic), hypoxia (PaO2 < 60 mm Hg), and hyperglycemia (>200 mg/dL). RESULTS: A secondary cerebral insult was observed in 309 (73.4%) patients including 135 (32.1%) who had multiple insults. There was an association between worse clinical grade and development of secondary insults (P = 0.0002), particularly multiple insults (P < 0.0001). When stratified by clinical grade, single (adjusted odds ratio [OR], 2.23; 95% confidence interval [CI], 1.10-4.51; P = 0.026) and multiple (adjusted OR, 4.37; 95% CI, 2.14-8.93; P < 0.0001) secondary cerebral insults were associated with worse outcome. In multivariate analysis and controlling for age, admission clinical grade, severity of SAH on computed tomography, intracerebral hematoma, increased intracranial pressure (>20 mm Hg), rebleed, intraoperative rupture, and hydrocephalus, secondary cerebral insults were independently associated with poor outcome (adjusted OR, 2.45; 95% CI, 1.20-5.02; P = 0.014). CONCLUSIONS: Secondary cerebral insults (hypoxia, hypotension, and hyperglycemia) are common after SAH, including among patients with a good clinical grade. These insults after SAH are associated with worse outcome. These data suggest that prevention of secondary cerebral insults may provide an opportunity to improve patient outcome after SAH.	[Doerfler, Sean] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Neurosurg, Philadelphia, PA 19104 USA; [Faerber, Jennifer] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat, Philadelphia, PA 19104 USA; [McKhann, Guy M.] Columbia Univ, Dept Neurosurg, New York, NY USA; [Elliott, J. Paul] Rocky Mt Neurosurg Alliance, Dept Neurosurg, Englewood, CO USA; [Winn, H. Richard] Mt Sinai Med Ctr, Dept Neurosurg, New York, NY 10029 USA; [Kumar, Monisha; Levine, Joshua] Univ Penn, Div Neurocrit Care, Philadelphia, PA 19104 USA; [Le Roux, Peter D.] Brain & Spine Ctr, Wynnewood, PA 19096 USA; [Le Roux, Peter D.] Lankenau Med Ctr, Lankenua Med Res Inst, Wynnewood, PA 19096 USA	Le Roux, PD (corresponding author), Brain & Spine Ctr, Wynnewood, PA 19096 USA.; Le Roux, PD (corresponding author), Lankenau Med Ctr, Lankenua Med Res Inst, Wynnewood, PA 19096 USA.	lerouxp@mlhs.org			Sharpe Foundation for Neurosurgical Research	Part of this work was supported by a grant from the Sharpe Foundation for Neurosurgical Research to P.L.R.	Ahmadian A, 2013, HEART LUNG VESSEL, V5, P168; Alvarez-Sabin J, 2004, STROKE, V35, P2493, DOI 10.1161/01.STR.0000143728.45516.c6; Anderson C, 2000, STROKE, V31, P1843; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Beaumont A, 2002, ACT NEUR S, V81, P217; Bonds BW, 2015, J TRAUMA ACUTE CARE, V79, P85, DOI 10.1097/TA.0000000000000698; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Chang HS, 2000, J NEUROSURG, V92, P971, DOI 10.3171/jns.2000.92.6.0971; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Coppadoro A, 2011, MINERVA ANESTESIOL, V77, P74; Cossu G, 2016, MINERVA ANESTESIOL, V82, P684; Cossu G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/628597; Dasenbrock HH, 2016, WORLD NEUROSURG, V88, P459, DOI 10.1016/j.wneu.2015.10.054; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Elf K, 2003, EUR J TRAUMA, V29, P74; Enblad P, 1997, J NEUROL NEUROSUR PS, V62, P512, DOI 10.1136/jnnp.62.5.512; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; Frazer D, 2007, NEUROSURGERY, V60, P434, DOI 10.1227/01.NEU.0000255335.72662.25; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Frykholm P, 2004, ACTA NEUROL SCAND, V109, P25, DOI 10.1034/j.1600-0404.2003.00174.x; Fujita Y, 2014, CHILD NERV SYST, V30, P1201, DOI 10.1007/s00381-014-2353-3; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; GIANNOTTA SL, 1991, NEUROSURGERY, V28, P531, DOI 10.1227/00006123-199104000-00008; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Guiza F, 2017, J NEUROTRAUM, V34, P2425, DOI 10.1089/neu.2016.4807; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Hall A, 2018, WORLD NEUROSURG, V109, P381, DOI 10.1016/j.wneu.2017.10.016; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Ingall T, 2000, STROKE, V31, P1054, DOI 10.1161/01.STR.31.5.1054; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kramer AH, 2008, CRIT CARE MED, V36, P2070, DOI 10.1097/CCM.0b013e31817c1095; Kreiter KT, 2002, STROKE, V33, P200, DOI 10.1161/hs0102.101080; Lackner P, 2017, CURR DRUG TARGETS, V18, P1417, DOI 10.2174/1389450117666160401124426; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Ledwith MB, 2010, J NEUROSCI NURS, V42, P280, DOI 10.1097/JNN.0b013e3181ecafd4; LEROUX PD, 1995, J NEUROSURG, V83, P394, DOI 10.3171/jns.1995.83.3.0394; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; LeRoux P, 2013, CURR OPIN CRIT CARE, V19, P83, DOI 10.1097/MCC.0b013e32835eba43; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1193-9; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; Naidech AM, 2005, ARCH NEUROL-CHICAGO, V62, P410, DOI 10.1001/archneur.62.3.410; Naidech AM, 2007, CRIT CARE MED, V35, P2383, DOI 10.1097/01.CCM.0000284516.17580.2C; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Nyholm L, 2012, ISRN NEUROL, V2012; Nyholm L, 2014, J NEUROSCI NURS, V46, P285, DOI 10.1097/JNN.0000000000000077; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Rabinstein Alejandro A, 2015, Acta Neurochir Suppl, V120, P239, DOI 10.1007/978-3-319-04981-6_40; ROPPER AH, 1984, J NEUROSURG, V60, P909, DOI 10.3171/jns.1984.60.5.0909; Ryttlefors M, 2007, NEUROSURGERY, V61, P704, DOI 10.1227/01.NEU.0000298898.38979.E3; Ryttlefors M, 2010, ACTA NEUROCHIR, V152, P241, DOI 10.1007/s00701-009-0496-x; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Scaravilli V, 2011, NEUROCRIT CARE, V15, P287, DOI 10.1007/s12028-011-9588-6; Schuiling WJ, 2005, NEUROCRIT CARE, V3, P1, DOI 10.1385/NCC:3:1:001; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Stein M, 2015, J CLIN NEUROSCI, V22, P530, DOI 10.1016/j.jocn.2014.08.026; Swanson EW, 2010, NEUROSURGERY, V66, P925, DOI 10.1227/01.NEU.0000368543.59446.A4; TIDSWELL P, 1995, NEUROLOGY, V45, P875; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Uyttenboogaart M, 2007, BRAIN, V130, P1626, DOI 10.1093/brain/awm087; van der Bilt IAC, 2009, NEUROLOGY, V72, P635, DOI 10.1212/01.wnl.0000342471.07290.07; Veeravagu A, 2014, WORLD NEUROSURG, V82, pE235, DOI 10.1016/j.wneu.2014.02.030; Verweij B H, 1996, J Craniomaxillofac Trauma, V2, P8; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wan H, 2014, EXPERT OPIN PHARMACO, V15, P231, DOI 10.1517/14656566.2014.865724; Wartenberg KE, 2006, CURR OPIN CRIT CARE, V12, P78, DOI 10.1097/01.ccx.0000216571.80944.65; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Wartenberg KE, 2007, 5 ANN NEUR CAR SOC M; Winn HR., 2004, MANAGEMENT CEREBRAL, P303; Zoerle T, 2015, CRIT CARE MED, V43, P168, DOI 10.1097/CCM.0000000000000670; Zygun D, 2005, CURR OPIN CRIT CARE, V11, P139, DOI 10.1097/01.ccx.0000155356.86241.c0	88	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2018	114						E483	E494		10.1016/j.wneu.2018.02.195			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8PI	WOS:000432959600055	29574224				2021-06-18	
J	Evers, KS; Atkinson, A; Barro, C; Fisch, U; Pfister, M; Huhn, EA; Lapaire, O; Kuhle, J; Wellmann, S				Evers, Katrina Suzanne; Atkinson, Andrew; Barro, Christian; Fisch, Urs; Pfister, Marc; Huhn, Evelyn A.; Lapaire, Olav; Kuhle, Jens; Wellmann, Sven			Neurofilament as Neuronal Injury Blood Marker in Preeclampsia	HYPERTENSION			English	Article						biomarker; blood-brain barrier; hypertension; preeclampsia; pregnancy	TRAUMATIC BRAIN-INJURY; LIGHT-CHAIN; CEREBROSPINAL-FLUID; CSF NEUROFILAMENT; CEREBRAL HEMODYNAMICS; PLASMA-LEVELS; PREGNANCY; BIOMARKER; HYPERTENSION; DIAGNOSIS	Preeclampsia has been shown to be associated with changes in cerebral structure and cognitive function later in life. Nf (neurofilaments) are specific scaffolding proteins of neurons, and their quantification in serum has been proposed as a biomarker for neuroaxonal injury. We performed a prospective, longitudinal, single-center study at the University Hospital of Basel to determine scrum Nf concentrations in pregnant women with singleton pregnancies and with high risk of preeclampsia or with early signs of preeclampsia. Enrollment started at 21 weeks of gestation, followed up with multiple visits until delivery, Sixty out of 197 women developed preeclampsia (30.5%), NIL (Nf light chain) was measured with a highly sensitive single molecule array (Simon) assay, in addition to the established preeclampsia markers sFlt-1 (soluble fins-like tyrosine kinase-1) and PIGF (placental growth factor). The most important independent predictors of Nit were maternal age, number of pregnancies, and proteinuria, NIL levels increased during pregnancy and were significantly higher in women developing preeclampsia. The discriminatory accuracy of NfL, PIGF, and sFlt-1 in receiver operating characteristic curves analysis (area under the curve) of the overall group was 0.68, 0.81, and 0,84, respectively, and in women older than 36 years 0.7, 0,62, and 0.79, respectively. We conclude that increased axonal injury serum marker NfL predicts preeclampsia particularly in older women, with an accuracy similar to the established angiogenic factors. NIL may serve as an early indicator of preeclampsia-induced changes in cerebral structure and may help to stratify disease management.	[Evers, Katrina Suzanne; Wellmann, Sven] Univ Basel, Childrens Hosp UKBB, Div Neonatol, Basel, Switzerland; [Atkinson, Andrew; Pfister, Marc] Univ Basel, Childrens Hosp UKBB, Div Paediat Pharmacol & Pharmacometr, Basel, Switzerland; [Atkinson, Andrew] Univ Hosp Bern, Dept Infect Dis, Bern, Switzerland; [Barro, Christian; Fisch, Urs; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Med, Basel, Switzerland; [Barro, Christian; Fisch, Urs; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland; [Barro, Christian; Fisch, Urs; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland; [Huhn, Evelyn A.; Lapaire, Olav] Univ Basel, Univ Hosp Basel, Div Obstet & Gynecol, Basel, Switzerland	Wellmann, S (corresponding author), Spitalstr 33, CH-4056 Basel, Switzerland.	sven.wellmann@ukbb.ch	Barro, Christian/AAO-3567-2021; Evers, Katrina/ABF-4388-2020; Huhn, Evelyn/AAG-7095-2020	Barro, Christian/0000-0002-7795-7383; Huhn, Evelyn/0000-0001-5382-1353; Evers, Katrina/0000-0002-0572-8709; Pfister, Marc/0000-0003-2597-1228	Gottfried und Julia Bangerter-Rhyner-Stiftung, Bern, Switzerland; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_160221]	This work was supported by the Gottfried und Julia Bangerter-Rhyner-Stiftung, Bern, Switzerland and the Swiss National Science Foundation (320030_160221).	Amburgey OA, 2010, HYPERTENSION, V56, P1003, DOI 10.1161/HYPERTENSIONAHA.110.158931; Axelsson M, 2011, J NEUROL, V258, P882, DOI 10.1007/s00415-010-5863-2; Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Bergman L, 2016, AM J HYPERTENS, V29, P1374, DOI 10.1093/ajh/hpw097; Bergman L, 2014, AM J HYPERTENS, V27, P1105, DOI 10.1093/ajh/hpu020; Block H Steven, 2014, Handb Clin Neurol, V121, P1595, DOI 10.1016/B978-0-7020-4088-7.00105-X; Burman J, 2014, ACTA NEUROL SCAND, V130, P81, DOI 10.1111/ane.12239; Bushnell C, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/858134; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Duckitt K, 2005, BRIT MED J, V330, P565, DOI 10.1136/bmj.38380.674340.E0; Fields JA, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.03.008; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gunnarsson M, 2011, ANN NEUROL, V69, P83, DOI 10.1002/ana.22247; Hakansson I, 2017, EUR J NEUROL, V24, P703, DOI 10.1111/ene.13274; Hammer ES, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-015-0575-8; Karumanchi SA, 2016, HYPERTENSION, V67, P1072, DOI 10.1161/HYPERTENSIONAHA.116.06421; Khalil M, 2013, MULT SCLER J, V19, P436, DOI 10.1177/1352458512458010; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Kuhle J, 2016, MULT SCLER J, V22, P1550, DOI 10.1177/1352458515623365; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kuhle J, 2015, NEUROLOGY, V84, P1639, DOI 10.1212/WNL.0000000000001491; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kuhle J, 2013, MULT SCLER J, V19, P1597, DOI 10.1177/1352458513482374; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Malmestrom C, 2003, NEUROLOGY, V61, P1720, DOI 10.1212/01.WNL.0000098880.19793.B6; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Meeter LH, 2016, ANN CLIN TRANSL NEUR, V3, P623, DOI 10.1002/acn3.325; Modvig S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077163; Oehm E, 2003, ULTRASOUND OBST GYN, V22, P395, DOI 10.1002/uog.183; Oehm E, 2006, CEREBROVASC DIS, V22, P204, DOI 10.1159/000093810; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; PHILLIPS SJ, 1992, ARCH INTERN MED, V152, P938, DOI 10.1001/archinte.152.5.938; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; ROYBURT M, 1991, Obstetrical and Gynecological Survey, V46, P656, DOI 10.1097/00006254-199110000-00002; Schoknecht K, 2015, SEMIN CELL DEV BIOL, V38, P35, DOI 10.1016/j.semcdb.2014.10.004; Schreurs MPH, 2013, FASEB J, V27, P1254, DOI 10.1096/fj.12-222216; Schwartz RB, 2000, RADIOLOGY, V217, P371, DOI 10.1148/radiology.217.2.r00nv44371; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Sibai BM, 2003, OBSTET GYNECOL, V102, P181, DOI 10.1016/S0029-7844(03)00475-7; Siepmann T, 2017, NEUROLOGY, V88, P1256, DOI 10.1212/WNL.0000000000003765; Singh P, 2011, J NEUROL SCI, V304, P117, DOI 10.1016/j.jns.2011.01.025; Steegers EAP, 2010, LANCET, V376, P631, DOI 10.1016/S0140-6736(10)60279-6; Stepan H, 2015, ULTRASOUND OBST GYN, V45, P241, DOI 10.1002/uog.14799; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Traenka C, 2015, CEREBROVASC DIS, V40, P222, DOI 10.1159/000440774; Tranquilli AL, 2014, PREGNANCY HYPERTENS, V4, P97, DOI [10.1016/j.preghy.2014.04.007, 10.1016/j.preghy.2014.02.001, 10.1016/j.preghy.2014.04.017]; Vettorazzi J, 2012, PREGNANCY HYPERTENS, V2, P101, DOI 10.1016/j.preghy.2011.11.004; Wellmann S, 2014, FETAL DIAGN THER, V36, P202, DOI 10.1159/000361016; Weydt P, 2016, ANN NEUROL, V79, P152, DOI 10.1002/ana.24552; Wikstrom AK, 2012, PREGNANCY HYPERTENS, V2, P398, DOI 10.1016/j.preghy.2012.03.001; Wilke C, 2016, J NEUROL NEUROSUR PS, V87, P1270, DOI 10.1136/jnnp-2015-312972; Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zunker P, 2000, ULTRASOUND OBST GYN, V16, P179, DOI 10.1046/j.1469-0705.2000.00194.x	62	11	12	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0194-911X	1524-4563		HYPERTENSION	Hypertension	JUN	2018	71	6					1178	1184		10.1161/HYPERTENSIONAHA.117.10314			7	Peripheral Vascular Disease	Cardiovascular System & Cardiology	GP6TZ	WOS:000441020300040	29686016	Bronze			2021-06-18	
J	Fischer, JA; Olufs, ZPG; Katzenberger, RJ; Wassarman, DA; Perouansky, M				Fischer, Julie A.; Olufs, Zachariah P. G.; Katzenberger, Rebeccah J.; Wassarman, David A.; Perouansky, Misha			Anesthetics Influence Mortality in a Drosophila Model of Blunt Trauma With Traumatic Brain Injury	ANESTHESIA AND ANALGESIA			English	Article							VOLATILE ANESTHETICS; ISOFLURANE; AGENTS; INFLAMMATION; ACTIVATION	BACKGROUND: Exposure to anesthetics is common in the majority of early survivors of life-threatening injuries. Whether and to what degree general anesthetics influence outcomes from major trauma is unknown. Potential confounding effects of general anesthetics on outcome measures are usually disregarded. We hypothesized that exposure to isoflurane or sevoflurane modulates the outcome from blunt trauma with traumatic brain injury (bTBI). METHODS: We tested the hypothesis in a novel model of bTBI implemented in Drosophila melanogaster. Fruit flies of the standard laboratory strain w(1118) were cultured under standard conditions. We titrated the severity of bTBI to a mortality index at 24 hours (MI24) of approximately 20% under control conditions. We administered standard doses of isoflurane and sevoflurane before, before and during, or after bTBI and measured the resulting MI24. We report the MI24 as mean standard deviation. RESULTS: Isoflurane or sevoflurane administered for 2 hours before bTBI reduced the MI24 from 22.3 +/- 2.6 to 10.4 +/- 1.8 (P < 10(-9), n = 12) and from 19.3 +/- 0.9 to 8.9 +/- 1.1 (P < .0001, n = 8), respectively. In contrast, administration of isoflurane after bTBI increased the MI24 from 18.5% +/- 4.3% to 25.3% +/- 9.1% (P = .0026, n = 22), while sevoflurane had no effect (22.4 +/- 7.1 and 21.5 +/- 5.8, n = 22). CONCLUSIONS: In a whole animal model of bTBI, general anesthetics were not indifferent with respect to early mortality. Therefore, collateral effects of general anesthetics should be considered in the interpretation of results obtained in vertebrate trauma models. Invertebrate model organisms can serve as a productive platform to interrogate anesthetic targets that mediate collateral effects and to inform trauma research in higher organisms about the potential impact of anesthetics on outcomes.	[Fischer, Julie A.; Olufs, Zachariah P. G.; Perouansky, Misha] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, 600 Highland Ave,B6-319 CSC, Madison, WI 53792 USA; [Fischer, Julie A.; Katzenberger, Rebeccah J.; Wassarman, David A.; Perouansky, Misha] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Genet, Madison, WI 53792 USA	Perouansky, M (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, 600 Highland Ave,B6-319 CSC, Madison, WI 53792 USA.	mperouansky@wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS091893, R01NS083596] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS091893, R01 NS083596] Funding Source: Medline		Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Cook RK, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r21; Cornett PM, 2008, MOL PHARMACOL, V74, P1261, DOI 10.1124/mol.108.049684; Dawson AG, 2013, FLY, V7, P112, DOI 10.4161/fly.24142; De Maio A, 2005, SHOCK, V23, P11, DOI 10.1097/01.shk.0000144134.03598.c5; Duronio RJ, 2017, DIS MODEL MECH, V10, P1381, DOI 10.1242/dmm.031203; Harisseh R, 2017, J CARDIOVASC PHARM, V69, P326, DOI 10.1097/FJC.0000000000000479; Jevtovic-Todorovic V, 2013, BRIT J ANAESTH, V111, P143, DOI 10.1093/bja/aet177; Katzenberger RJ, 2016, G3-GENES GENOM GENET, V6, P4151, DOI 10.1534/g3.116.036194; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Kichko TI, 2015, ANESTH ANALG, V120, P467, DOI 10.1213/ANE.0000000000000568; King EG, 2012, GENETICS, V191, P935, DOI 10.1534/genetics.112.138537; Kitano H, 2007, J CEREBR BLOOD F MET, V27, P1108, DOI 10.1038/sj.jcbfm.9600410; Kottler B, 2013, CURR BIOL, V23, P594, DOI 10.1016/j.cub.2013.02.021; Lee HT, 2004, ANESTHESIOLOGY, V101, P1313; Li JT, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/108928; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Mackay TFC, 2012, NATURE, V482, P173, DOI 10.1038/nature10811; Matta JA, 2008, P NATL ACAD SCI USA, V105, P8784, DOI 10.1073/pnas.0711038105; McMurtrey RJ, 2010, BRAIN RES, V1358, P184, DOI 10.1016/j.brainres.2010.08.015; Olufs ZPG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20720-7; Redel A, 2009, EXP BIOL MED, V234, P1186, DOI 10.3181/0902-RM-58; Staib-Lasarzik I, 2014, J NEUROTRAUM, V31, P1664, DOI 10.1089/neu.2013.3243; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stollings LM, 2016, ANESTHESIOLOGY, V125, P399, DOI 10.1097/ALN.0000000000001195; Tavare AN, 2012, INT J CANCER, V130, P1237, DOI 10.1002/ijc.26448; Tompkins RG, 2015, J TRAUMA ACUTE CARE, V78, P671, DOI 10.1097/TA.0000000000000568; Viera AJ, 2008, SOUTH MED J, V101, P730, DOI 10.1097/SMJ.0b013e31817a7ee4; Yuki K, 2008, FASEB J, V22, P4109, DOI 10.1096/fj.08-113324; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536	32	11	11	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2018	126	6					1979	1986		10.1213/ANE.0000000000002906			8	Anesthesiology	Anesthesiology	GG3GS	WOS:000432580900030	29596093	Bronze, Green Accepted			2021-06-18	
J	Karki, P; Hong, P; Johnson, J; Pajarillo, E; Son, DS; Aschner, M; Lee, EY				Karki, Pratap; Hong, Peter; Johnson, James, Jr.; Pajarillo, Edward; Son, Deok-Soo; Aschner, Michael; Lee, Eunsook Y.			Arundic Acid Increases Expression and Function of Astrocytic Glutamate Transporter EAAT1 Via the ERK, Akt, and NF-kappa B Pathways	MOLECULAR NEUROBIOLOGY			English	Article						Astrocytes; EAAT1; Arundic acid; NF-kappa B; Manganese	DEPENDENT TRANSCRIPTIONAL REGULATION; DELAYED INFARCT EXPANSION; PERMANENT FOCAL ISCHEMIA; CELL-SURFACE EXPRESSION; INDUCED UP-REGULATION; YIN YANG 1; ALZHEIMERS-DISEASE; MODULATING AGENT; DIFFERENTIAL EXPRESSION; DOPAMINERGIC-NEURONS	Glutamate is the major excitatory neurotransmitter in the brain, but excessive synaptic glutamate must be removed to prevent excitotoxic injury and death. Two astrocytic glutamate transporters, excitatory amino acid transporter (EAAT) 1 and 2, play a major role in eliminating excess glutamate from the synapse. Dysregulation of EAAT1 contributes to the pathogenesis of multiple neurological disorders, such as Alzheimer's disease (AD), ataxia, traumatic brain injuries, and glaucoma. In the present study, we investigated the effect of arundic acid on EAAT1 to determine its efficacy in enhancing the expression and function of EAAT1, and its possible mechanisms of action. The studies were carried out in human astrocyte H4 cells as well as in human primary astrocytes. Our findings show that arundic acid upregulated EAAT1 expression at the transcriptional level by activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B). Arundic acid increased astrocytic EAAT1 promoter activity, messenger RNA (mRNA)/protein levels, and glutamate uptake, while pharmacological inhibition of NF-kappa B ormutation on NF-kappa B binding sites in the EAAT1 promoter region abrogated these effects. Arundic acid increased NF-kappa B reporter activity and induced NF-kappa B nuclear translocation as well as its bindings to the EAAT1 promoter. Furthermore, arundic acid activated the Akt and ERK signaling pathways to enhance EAAT1 mRNA/protein levels. Finally, arundic acid attenuated manganese-induced decrease in EAAT1 expression by inhibiting expression of the transcription factor Ying Yang 1 (YY1). These results demonstrate that arundic acid increases the expression and function of EAAT1 via the Akt, ERK, and NF-kappa B signaling pathways, and reverses Mn-induced EAAT1 repression by inhibiting the Mn-induced YY1 activation.	[Karki, Pratap; Pajarillo, Edward; Lee, Eunsook Y.] Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32307 USA; [Hong, Peter; Johnson, James, Jr.; Son, Deok-Soo] Meharry Med Coll, Dept Physiol, Nashville, TN 37208 USA; [Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Lee, EY (corresponding author), Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32307 USA.	eunsook.lee@famu.edu			 [R01 ES024756];  [SC1 GM089630];  [SC1 CA200519];  [R01 ES10563];  [1R03 ES024849];  [1R21 ES025415]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [SC1CA200519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES010563, R21ES025415, R01ES024756, R03ES024849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [SC1GM089630, R25GM059994] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [U54MD007586] Funding Source: NIH RePORTER	The present study has been supported in part by R01 ES024756 (EL), SC1 GM089630 (EL), SC1 CA200519 (DS), R01 ES10563 (MA), 1R03 ES024849 (MA), and 1R21 ES025415 (MA).	Aguirre G, 2008, NEUROCHEM INT, V52, P1322, DOI 10.1016/j.neuint.2008.01.015; Allritz C, 2009, NEUROCHEM INT, V55, P22, DOI 10.1016/j.neuint.2008.12.020; Anderson CM, 2000, GLIA, V32, P1; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Asano T, 2005, CNS NEUROL DISORD-DR, V4, P127, DOI 10.2174/1568007053544084; Aschner Judy L., 2005, Molecular Aspects of Medicine, V26, P353, DOI 10.1016/j.mam.2005.07.003; Baltan S, 2011, J NEUROSCI, V31, P3990, DOI 10.1523/JNEUROSCI.5379-10.2011; BarPeled O, 1997, J NEUROCHEM, V69, P2571; Bonde C, 2003, NEUROCHEM INT, V43, P381, DOI 10.1016/S0197-0186(03)00025-1; BROUILLET EP, 1993, EXP NEUROL, V120, P89, DOI 10.1006/exnr.1993.1042; Carbone M, 2012, NEUROCHEM INT, V60, P31, DOI 10.1016/j.neuint.2011.10.017; Castro-Coronel Y, 2011, TOXICOL SCI, V122, P539, DOI 10.1093/toxsci/kfr126; Chen KH, 2011, J ALZHEIMERS DIS, V26, P755, DOI 10.3233/JAD-2011-110002; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; de Vries B, 2009, ARCH NEUROL-CHICAGO, V66, P97, DOI 10.1001/archneurol.2008.535; Dobson AW, 2004, ANN NY ACAD SCI, V1012, P115, DOI 10.1196/annals.1306.009; Duan SM, 1999, J NEUROSCI, V19, P10193; Erikson KM, 2007, TOXICOL SCI, V97, P459, DOI 10.1093/toxsci/kfm044; Fernandes RA, 2013, CURR MED CHEM, V20, P2315, DOI 10.2174/0929867311320180003; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Furuta A, 1997, J NEUROSCI, V17, P8363; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Ghosh M, 2011, J NEUROSCI, V31, P9159, DOI 10.1523/JNEUROSCI.0302-11.2011; Guilarte TR, 2010, ENVIRON HEALTH PERSP, V118, P1071, DOI 10.1289/ehp.0901748; Harada T, 1998, P NATL ACAD SCI USA, V95, P4663, DOI 10.1073/pnas.95.8.4663; Harada T, 2007, J CLIN INVEST, V117, P1763, DOI 10.1172/JCI30178; Hazell AS, 1997, NEUROCHEM RES, V22, P1443, DOI 10.1023/A:1021994126329; Himeda T, 2006, NEUROPHARMACOLOGY, V50, P329, DOI 10.1016/j.neuropharm.2005.09.014; Jarvis WD, 1997, MOL PHARMACOL, V52, P935; Jen JC, 2005, NEUROLOGY, V65, P529, DOI 10.1212/01.WNL.0000172638.58172.5a; Kanai H, 2004, PHARMACOGENOMICS J, V4, P336, DOI 10.1038/sj.tpj.6500269; Karki P, 2015, J BIOL CHEM, V290, P23725, DOI 10.1074/jbc.M115.649327; Karki P, 2014, GLIA, V62, P1270, DOI 10.1002/glia.22679; Karki P, 2014, MOL CELL BIOL, V34, P1280, DOI 10.1128/MCB.01176-13; Karki P, 2013, J BIOL CHEM, V288, P28975, DOI 10.1074/jbc.M113.483826; Kato H, 2004, BRAIN RES, V1030, P66, DOI 10.1016/j.brainres.2004.09.046; Kato H, 2003, J NEUROL SCI, V208, P9, DOI 10.1016/S0022-510X(02)00411-2; Kim SY, 2003, J NEUROCHEM, V87, P1485, DOI 10.1046/j.1471-4159.2003.02128.x; Lee ESY, 2009, J NEUROCHEM, V110, P530, DOI 10.1111/j.1471-4159.2009.06105.x; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Liang Z, 2002, J NEUROCHEM, V80, P807, DOI 10.1046/j.0022-3042.2002.00779.x; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; Matsui T, 2002, J CEREBR BLOOD F MET, V22, P711, DOI 10.1097/00004647-200206000-00010; Mori T, 2004, NEUROCHEM INT, V45, P381, DOI 10.1016/j.neuint.2003.06.001; Mutkus L, 2005, BIOL TRACE ELEM RES, V107, P221, DOI 10.1385/BTER:107:3:221; Naskar R, 2000, INVEST OPHTH VIS SCI, V41, P1940; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Oki C, 2008, CELL MOL NEUROBIOL, V28, P417, DOI 10.1007/s10571-007-9241-2; Pawlak J, 2005, MOL BRAIN RES, V138, P1, DOI 10.1016/j.molbrainres.2004.10.043; Platt SR, 2007, VET J, V173, P278, DOI 10.1016/j.tvjl.2005.11.007; Rauen T, 1998, CELL TISSUE RES, V291, P19; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Rosas S, 2007, J NEUROCHEM, V101, P1134, DOI 10.1111/j.1471-4159.2007.04517.x; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rozyczka J, 2004, BRAIN PATHOL, V14, P406; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Stice JP, 2012, SHOCK, V38, P128, DOI 10.1097/SHK.0b013e31825da754; Sun Y, 2012, J CELL SCI, V125, P4507, DOI 10.1242/jcs.105023; Suzuki K, 2001, J CELL SCI, V114, P3717; Swanson RA, 1997, J NEUROSCI, V17, P932; Takahashi K, 2015, CELL MOL LIFE SCI, V72, P3489, DOI 10.1007/s00018-015-1937-8; Tateishi N, 2002, J CEREBR BLOOD F MET, V22, P723, DOI 10.1097/00004647-200206000-00011; Toulany M, 2014, CANCER BIOL THER, V15, P317, DOI 10.4161/cbt.27311; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Winter JN, 2011, AM J PHYSIOL-CELL PH, V300, pC1172, DOI 10.1152/ajpcell.00504.2010; Yanagisawa M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.45	73	11	12	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUN	2018	55	6					5031	5046		10.1007/s12035-017-0709-x			16	Neurosciences	Neurosciences & Neurology	GF5FI	WOS:000431991500041	28812276	Green Accepted			2021-06-18	
J	Ni, HB; Rui, Q; Xu, YT; Zhu, J; Gao, F; Dang, BQ; Li, D; Gao, R; Chen, G				Ni, Haibo; Rui, Qin; Xu, Yitian; Zhu, Jun; Gao, Fan; Dang, Baoqi; Li, Di; Gao, Rong; Chen, Gang			RACK1 upregulation induces neuroprotection by activating the IRE1-XBP1 signaling pathway following traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						RACK1; IRE1; XBP1; Neuroprotection; Secondary brain injury; Traumatic brain injury	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; INDUCED APOPTOSIS; MESSENGER-RNA; NEURONS; HEMORRHAGE; EXPRESSION; RECEPTOR; IMPACT; MEMORY	Receptor for activated protein kinase C 1 (RACK1) is a multifaceted scaffolding protein known to be involved in the regulation of signaling events required for neuronal protection. In the present study, we investigated the role of RACK1 in secondary brain injury in a rat traumatic brain injury (TBI) model. A weight-drop TBI model was established in Sprague Dawley rats, and RACK1 in vivo knockdown and overexpression were performed 24 h before TBI insult. The IRE1 inhibitor 3,5-dibromosalicylaldehyde (DBSA) was administered by intracerebroventricular injection 1 h after TBI insult. Real-time PCR, Western blotting, immunofluorescence, neuronal apoptosis, brain water content, and neurological scores were evaluated. Our results revealed that TBI induced increased expression of endogenous RACK1, phosphorylated inositol-requiring enzyme 1 (p-IRE1), X-box binding protein-1 (XBP1) and glucose-regulated protein 78 (GRP78) in neurons. RACK1 overexpression significantly ameliorated neuronal apoptosis, blood-brain barrier disruption, brain edema and neurological deficits at 48 h after TBI, which was concomitant with upregulation of p-IRE1, XBP1 and GRP78 expression, while its knockdown induced the opposite effects. Furthermore, DBSA administration reversed the protective effects of RACK1 overexpression against brain injury and decreased the expression of p-IRE1, XBP1 and GRP78. In summary, the upregulation of RACK1 following brain contusion exerted neuroprotective effects against secondary brain injury, which were probably mediated by activation of the IRE1-XBP1 pathway.	[Ni, Haibo; Gao, Rong] First Peoples Hosp Zhangjiagang City, Dept Neurosurg, 68 Jiyang Western Rd, Suzhou 215006, Peoples R China; [Rui, Qin] First Peoples Hosp Zhangjiagang City, Dept Lab, Suzhou 215006, Peoples R China; [Xu, Yitian] Nanjing Med Univ, Dept Basic Med Sci, Nanjing 211166, Jiangsu, Peoples R China; [Zhu, Jun] Peoples Hosp Jingjicurg City, Dept Neurosurg, Taizhou 225300, Peoples R China; [Gao, Fan; Dang, Baoqi] Nanjing Univ Chinese Med, Dept Rehabil, Zhangjiagang Hosp Tradit Chinese Med, Suzhou 215006, Peoples R China; [Li, Di] First Peoples Hosp Zhangjiagang City, Dept Translat Med Ctr, Suzhou 215006, Peoples R China; [Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China; [Chen, Gang] Soochow Univ, Affiliated Hosp 1, Brain & Nerve Res Lab, Suzhou 215006, Peoples R China	Li, D; Gao, R (corresponding author), First Peoples Hosp Zhangjiagang City, Dept Neurosurg, 68 Jiyang Western Rd, Suzhou 215006, Peoples R China.	lidi715@163.com; ronggao_zjg@163.com	Xu, Yitian/AAH-9794-2019				Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Casas-Tinto S, 2011, HUM MOL GENET, V20, P2144, DOI 10.1093/hmg/ddr100; Feng DY, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12395; Goldenberg-Cohen N, 2012, APOPTOSIS, V17, P278, DOI 10.1007/s10495-011-0678-x; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hawryluk GWJ, 2016, NEUROSURG CLIN N AM, V27, P375, DOI 10.1016/j.nec.2016.05.002; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ito D, 2001, NEUROREPORT, V12, P4023, DOI 10.1097/00001756-200112210-00034; Jiang DD, 2015, SEMIN CANCER BIOL, V33, P48, DOI 10.1016/j.semcancer.2015.04.010; Koizumi N, 2001, PLANT PHYSIOL, V127, P949, DOI 10.1104/pp.010636; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li XY, 2015, J MOL NEUROSCI, V57, P63, DOI 10.1007/s12031-015-0577-7; Liu D, 2016, J MOL CELL BIOL, V8, P144, DOI 10.1093/jmcb/mjv066; Liu GL, 2011, BRAIN RES BULL, V84, P94, DOI 10.1016/j.brainresbull.2010.10.004; Liu LT, 2016, SCI REP-UK, V6, DOI 10.1038/srep20183; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Ma J, 2014, BIOCHEM J, V462, P489, DOI 10.1042/BJ20140235; Neasta J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160948; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Peng RJ, 2013, ONCOL REP, V30, P2195, DOI 10.3892/or.2013.2723; Peyrl A, 2002, ELECTROPHORESIS, V23, P152, DOI 10.1002/1522-2683(200201)23:1<152::AID-ELPS152>3.0.CO;2-T; Qiu YF, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000514; Shen HT, 2015, STROKE, V46, P2607, DOI 10.1161/STROKEAHA.115.009729; Sklan EH, 2006, PROG NEUROBIOL, V78, P117, DOI 10.1016/j.pneurobio.2005.12.002; Sun GZ, 2016, NEURAL REGEN RES, V11, P1260, DOI 10.4103/1673-5374.189190; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Valdes P, 2014, P NATL ACAD SCI USA, V111, P6804, DOI 10.1073/pnas.1321845111; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang HY, 2001, BIOL PSYCHIAT, V50, P364, DOI 10.1016/S0006-3223(01)01147-7; Wu J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0790-0; Wu J, 2016, CELL PHYSIOL BIOCHEM, V38, P847, DOI 10.1159/000443039; Xu X, 2015, J NEUROCHEM, V133, P134, DOI 10.1111/jnc.13052; Zhou T, 2015, ONCOL REP, V33, P3006, DOI 10.3892/or.2015.3920; Zhu JJ, 2016, LIFE SCI, V151, P115, DOI 10.1016/j.lfs.2016.02.014	38	11	11	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2018	304						102	113		10.1016/j.expneurol.2018.03.003			12	Neurosciences	Neurosciences & Neurology	GF3IF	WOS:000431838100010	29518365				2021-06-18	
J	Tollefsen, MH; Vik, A; Skandsen, T; Sandrod, O; Deane, SF; Rao, V; Moen, KG				Tollefsen, Marie Hexeberg; Vik, Anne; Skandsen, Toril; Sandrod, Oddrun; Deane, Susan Frances; Rao, Vidar; Moen, Kent Goran			Patients with Moderate and Severe Traumatic Brain Injury: Impact of Preinjury Platelet Inhibitor or Warfarin Treatment	WORLD NEUROSURGERY			English	Article						Craniocerebral trauma; Hematologic agents; Glasgow Coma Scale; Glasgow Outcome Scale; Platelet aggregation inhibitors; Tomography; X-ray computed	BLUNT HEAD TRAUMA; ANTIPLATELET AGENTS; HEMORRHAGIC PROGRESSION; MORTALITY; OUTCOMES; THERAPY; ANTICOAGULATION; CLASSIFICATION; METAANALYSIS; MANAGEMENT	OBJECTIVE: We aimed to examine the effect of preinjury antithrombotic medication on clinical and radiologic neuroworsening in traumatic brain injury (TBI) and study the effect on outcome. METHODS: A total of 184 consecutive patients >= 50 years old with moderate and severe TBI admitted to a level 1 trauma center were included. Neuroworsening was assessed clinically by using the Glasgow Coma Scale (GCS) score and radiologically by using the Rotterdam CT score on repeated time points. Functional outcome was assessed with the Glasgow Outcome Scale Extended 6 months after injury. RESULTS: The platelet inhibitor group (mean age, 77.3 years; n = 43) and the warfarin group (mean age, 73.2 years; n = 20) were significantly older than the non-user group (mean age, 63.7 years; n = 121; P <= 0.001). In the platelet inhibitor group 74% and in the warfarin group, 85% were injured by falls, Platelet inhibitors were not significantly associated with clinical or radiologic neuroworsening (P = 0.37-1.00), whereas warfarin increased the frequency of worsening in GCS score (P = 0.001-0.028) and Rotterdam CT score (P = 0.004), In-hospital mortality was higher in the platelet inhibitor group (28%; P = 0.030) and the warfarin group (50%; P < 0.001) compared with the nonuser group (13%). Platelet inhibitors did not predict mortality or worse outcome after adjustment for age, preinjury disability, GCS score, and Rotterdam CT score, whereas warfarin predicted both mortality and worse outcome. CONCLUSIONS: In this study of patients with moderate and severe TBI, preinjury platelet inhibitors did not cause neuroworsening or predict higher mortality or worse outcome. hi contrast, preinjury warfarin caused neuroworsening and was an independent risk factor for mortality and worse outcome at 6 months. Hence, fall prevention and liberal use of computed tomography examinations is important in this patient group.	[Tollefsen, Marie Hexeberg; Vik, Anne; Skandsen, Toril; Rao, Vidar; Moen, Kent Goran] Norwegian Univ Sci & Technol NTNU, Dept Neuromed & Movement Sci, Trondheim, Norway; [Vik, Anne; Rao, Vidar] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Skandsen, Toril] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Sandrod, Oddrun] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Anesthesiol & Intens Care Med, Trondheim, Norway; [Deane, Susan Frances] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Radiol & Nucl Med, Trondheim, Norway; [Moen, Kent Goran] Nord Trondelag Hosp Trust, Levanger Hosp, Dept Med Imaging, Levanger, Norway	Moen, KG (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Neuromed & Movement Sci, Trondheim, Norway.; Moen, KG (corresponding author), Nord Trondelag Hosp Trust, Levanger Hosp, Dept Med Imaging, Levanger, Norway.	kent.g.moen@ntnu.no					Allison RZ, 2017, NEUROCRIT CARE, V26, P80, DOI 10.1007/s12028-016-0303-5; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Batchelor JS, 2013, BRIT J NEUROSURG, V27, P12, DOI 10.3109/02688697.2012.705361; Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Choi R, 2014, NEUROLOGY S, V82; Cull JD, 2015, AM SURGEON, V81, P128; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Joseph B, 2014, J SURG RES, V186, P287, DOI 10.1016/j.jss.2013.08.009; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Norwegian Institute of Public Health, 2012, NORW PRESCR DAT 2007; Peck KA, 2014, J TRAUMA ACUTE CARE, V76, P431, DOI 10.1097/TA.0000000000000107; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Roe C, 2013, J REHABIL MED, V45, P734, DOI 10.2340/16501977-1198; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203	24	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2018	114						E209	E217		10.1016/j.wneu.2018.02.167			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8PI	WOS:000432959600023	29524716	Other Gold			2021-06-18	
J	Weber, ML; Dean, JHL; Hoffman, NL; Broglio, SP; McCrea, M; McAllister, TW; Schmidt, JD				Weber, Michelle L.; Dean, John-Henry L.; Hoffman, Nicole L.; Broglio, Steven P.; McCrea, Michael; McAllister, Thomas W.; Schmidt, Julianne D.		CARE Consortium Investigators	Influences of Mental Illness, Current Psychological State, and Concussion History on Baseline Concussion Assessment Performance	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussions; baseline assessments; anxiety; depression; concussion history	PROFESSIONAL FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; RECURRENT CONCUSSION; DEPRESSION; SYMPTOMS; RECOVERY; IMPACT; ASSOCIATION; DISTRESS	Background: A student-athlete's mental state, including history of trait anxiety and depression, or current psychological state may affect baseline concussion assessment performance. Purpose: (1) To determine if mental illness (anxiety, depression, anxiety with depression) influences baseline scores, (2) to determine if psychological state correlates with baseline performance, and (3) to determine if history of concussion affects Brief Symptom Inventory-18 (BSI-18) subscores of state anxiety, depression, and somatization. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A sample of 8652 collegiate student-athletes (54.5% males, 45.5% females) participated in the Concussion Assessment, Research and Education (CARE) Consortium. Baseline assessments included a demographic form, a symptom evaluation, Standardized Assessment of Concussion, Balance Error Scoring System, a psychological state assessment (BSI-18), and Immediate Post-concussion Assessment and Cognitive Test. Baseline scores were compared between individuals with a history of anxiety (n = 59), depression (n = 283), and anxiety with depression (n = 68) and individuals without a history of those conditions (n = 8242). Spearman's rho correlations were conducted to assess the relationship between baseline and psychological state subscores (anxiety, depression, somatization) ( = .05). Psychological state subscores were compared between individuals with a self-reported history of concussions (0, 1, 2, 3, 4+) using Kruskal-Wallis tests (alpha = .05). Results: Student-athletes with anxiety, depression, and anxiety with depression demonstrated higher scores in number of symptoms reported (anxiety, 4.3 +/- 4.2; depression, 5.2 +/- 4.8; anxiety with depression, 5.4 +/- 3.9; no anxiety/depression, 2.5 +/- 3.4), symptom severity (anxiety, 8.1 +/- 9.8; depression, 10.4 +/- 12.4; anxiety with depression, 12.4 +/- 10.7; no anxiety/depression, 4.1 +/- 6.9), and psychological distress in state anxiety (anxiety, 3.7 +/- 4.7; depression, 2.5 +/- 3.6; anxiety with depression, 3.8 +/- 4.2; no anxiety/depression, 0.8 +/- 1.8), depression (anxiety, 2.4 +/- 4.0; depression, 3.2 +/- 4.5; anxiety with depression, 3.8 +/- 4.8; no anxiety/depression, 0.8 +/- 1.8), and somatization (anxiety, 2.3 +/- 2.9; depression, 1.8 +/- 2.8; anxiety with depression, 2.2 +/- 2.4; no anxiety/depression, 0.9 +/- 1.7). A moderate positive relationship existed between all BSI-18 subscores and total symptom number (n = 8377; anxiety: r(s) = 0.43, P < .001; depression: r(s) = 0.42, P < .001; somatization: r(s) = 0.45, P < .001), as well as total symptom severity (anxiety: r(s) = 0.43, P < .001; depression: r(s) = 0.41, P < .001; somatization: r(s) = 0.45, P < .001). Anxiety, depression, and somatization subscores were greater among student-athletes that self-reported more concussions. Conclusion: Clinicians should be cognizant that student-athletes with a history of trait anxiety, depression, and anxiety with depression may report higher symptom score and severity at baseline. Individuals with extensive concussion history may experience greater state anxiety, depression, and somatization.	[Weber, Michelle L.; Hoffman, Nicole L.; Schmidt, Julianne D.] Univ Georgia, Dept Kinesiol, Concuss Res Lab, 330 River Rd, Athens, GA 30602 USA; [Dean, John-Henry L.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [Broglio, Steven P.] Univ Michigan, Injury Ctr, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Weber, ML (corresponding author), Univ Georgia, Dept Kinesiol, Concuss Res Lab, 330 River Rd, Athens, GA 30602 USA.	mlw76648@uga.edu		Dean, John-Henry/0000-0002-2783-0325; Master, Christina/0000-0002-6717-4270; Ortega, Justus/0000-0002-9931-5605; Chrisman, Sara/0000-0001-5373-7223; Clugston, James/0000-0002-2103-1039	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium; National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This project was supported, in part, by the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium and was funded, in part, by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick, MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151.	Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Cook NE, 2017, CLIN NEUROPSYCHOL, V31, P1341, DOI 10.1080/13854046.2017.1317031; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Esopenko C, 2017, J NEUROL NEUROSUR PS, V88, P512, DOI 10.1136/jnnp-2016-315260; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hedges L.V., 1985, STAT METHODS META AN; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lancaster MA, 2016, CLIN NEUROPSYCHOL, V30, P321, DOI 10.1080/13854046.2016.1138504; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Collegiate Athletic Association, 2014, CONC MAN DIAGN BEST; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Solomon GS, 2016, PHYSICIAN SPORTSMED, V44, P14, DOI 10.1080/00913847.2016.1121091; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; Yang JZ, 2015, DEV NEUROPSYCHOL, V40, P18, DOI 10.1080/87565641.2014.973499; Yengo-Kahn AM, 2015, PHYSICIAN SPORTSMED, V43, P227, DOI 10.1080/00913847.2015.1071638	35	11	11	1	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2018	46	7					1742	1751		10.1177/0363546518765145			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GH7IJ	WOS:000433616400030	29672135				2021-06-18	
J	Cai, YL; Wu, SJ; Zhao, W; Li, ZG; Wu, ZY; Ji, SB				Cai, Yunliang; Wu, Shaoju; Zhao, Wei; Li, Zhigang; Wu, Zheyang; Ji, Songbai			Concussion classification via deep learning using whole-brain white matter fiber strains	PLOS ONE			English	Article							INJURY PREDICTION; VERIFICATION; RESPONSES	Developing an accurate and reliable injury predictor is central to the biomechanical studies of traumatic brain injury. State-of-the-art efforts continue to rely on empirical, scalar metrics based on kinematics or model-estimated tissue responses explicitly pre-defined in a specific brain region of interest. They could suffer from loss of information. A single training dataset has also been used to evaluate performance but without cross-validation. In this study, we developed a deep learning approach for concussion classification using implicit features of the entire voxel-wise white matter fiber strains. Using reconstructed American National Football League (NFL) injury cases, leave-one-out cross-validation was employed to objectively compare injury prediction performances against two baseline machine learning classifiers (support vector machine (SVM) and random forest (RF)) and four scalar metrics via univariate logistic regression (Brain Injury Criterion (BrIC), cumulative strain damage measure of the whole brain (CSDM-WB) and the corpus callosum (CSDM-CC), and peak fiber strain in the CC). Feature-based machine learning classifiers including deep learning, SVM, and RF consistently outperformed all scalar injury metrics across all performance categories (e.g., leave-one-out accuracy of 0.828-0.862 vs. 0.690-0.776, and .632+ error of 0.148 +/- 0.176 vs. 0.207-0.292). Further, deep learning achieved the best cross-validation accuracy, sensitivity, AUC, and .632+ error. These findings demonstrate the superior performances of deep learning in concussion prediction and suggest its promise for future applications in biomechanical investigations of traumatic brain injury.	[Cai, Yunliang; Wu, Shaoju; Zhao, Wei; Ji, Songbai] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA; [Li, Zhigang] Dartmouth Coll, Geisel Sch Med, Dept Biomed Data Sci, Hanover, NH 03755 USA; [Wu, Zheyang] Worcester Polytech Inst, Dept Math Sci, Worcester, MA 01609 USA; [Ji, Songbai] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA	Ji, SB (corresponding author), Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.; Ji, SB (corresponding author), Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA.	sji@wpi.edu	Cai, Yunliang/AAF-2375-2019; WU, SHAOJU/S-1930-2019	Ji, Songbai/0000-0002-2886-5781	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS092853, R21 NS088781]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088781, R01NS092853] Funding Source: NIH RePORTER	Funding is provided by the NIH grants R01 NS092853 and R21 NS088781. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	A KB, 2015, ACAD EMERG MED, P22; Anderson Andrew E., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P171, DOI 10.1080/10255840601160484; Beleites C, 2005, CHEMOMETR INTELL LAB, V79, P91, DOI 10.1016/j.chemolab.2005.04.008; Bengio Yoshua, 2012, Neural Networks: Tricks of the Trade. Second Edition: LNCS 7700, P437, DOI 10.1007/978-3-642-35289-8_26; Bengio Y, 2013, IEEE T PATTERN ANAL, V35, P1798, DOI 10.1109/TPAMI.2013.50; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Billones CD, 2016, PROCEEDINGS OF THE 2016 IEEE REGION 10 CONFERENCE (TENCON), P3724, DOI 10.1109/TENCON.2016.7848755; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Cai Y, 2016, LECT NOTES COMPUT SC, V10154, P259, DOI 10.1007/978-3-319-55524-9_24; CDC, 2015, REP C TRAUM BRAIN IN, DOI [10.1161/HYPERTENSIONAHA.111.186106, DOI 10.1161/HYPERTENSIONAHA.111.186106]; Chen YW, 2006, STUD FUZZ SOFT COMP, V207, P315; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Cybenko G, 1989, MATH CONTROL SIGNAL; de Brebisson Alexandre, 2015, 2015 IEEE Conference on Computer Vision and Pattern Recognition Workshops (CVPRW), P20, DOI 10.1109/CVPRW.2015.7301312; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Eppinger RH, 1995, STAPP CAR CRASH J, V38, P145; Fan Y, 2005, LECT NOTES COMPUT SC, V3749, P1; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Giordano C, 2014, STAPP CAR CRASH J, P29; Graham R, 2014, SPORTS RELATED CONCU; Gray KR, 2013, NEUROIMAGE, V65, P167, DOI 10.1016/j.neuroimage.2012.09.065; Greenspan H, 2016, IEEE T MED IMAGING, V35, P1153, DOI 10.1109/TMI.2016.2553401; Gupta V, 2017, BIORXIV, DOI [10.1007/978-3-319-66182-7_63, DOI 10.1007/978-3-319-66182-7_63]; Guyon I, 2006, STUD FUZZ SOFT COMP, V207, P1; Hastie T., 2008, ELEMENTS STAT LEARNI, V2nd; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Hinton GE, 2006, SCIENCE, V313, P504, DOI 10.1126/science.1127647; Ioannidou A, 2017, ACM COMPUT SURV, V50, DOI 10.1145/3042064; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Jia YQ, 2014, PROCEEDINGS OF THE 2014 ACM CONFERENCE ON MULTIMEDIA (MM'14), P675, DOI 10.1145/2647868.2654889; Kamnitsas K, 2016, LECT NOTES COMPUT SC, V10154, P138, DOI 10.1007/978-3-319-55524-9_14; Khvostikov Alexander, 2018, 3D CNN BASED CLASSIF; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A.I., 2003, IRCOBI C LISB PORT, P1; Kingma D., 2014, 14126980 ARXIV; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kuo C, 2018, BIOMECH MODEL MECHAN, V17, P235, DOI 10.1007/s10237-017-0957-8; Lange N., 1997, J AM STAT ASSOC, V92, P1642, DOI [DOI 10.2307/2965437, 10.2307/2965437]; Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791; Lecun Y, 1998, NEURAL NETWORKS TRIC, P1689, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005; Nair V., 2010, P 27 INT C INT C MAC, P807, DOI DOI 10.0RG/PAPERS/432.PDF; Nasrabadi N. M., 2007, J ELECTRON IMAGING, V16, DOI [DOI 10.1117/1.2819119, 10.1117/1.2819119]; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Nisbet R, 2009, HDB STAT ANAL DATA M; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Ruck D, 1990, IEEE T; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Salakhutdinov R., 2009, J MACH LEARN RES, P448; Schmidhuber J, 2015, NEURAL NETWORKS, V61, P85, DOI 10.1016/j.neunet.2014.09.003; Shi J, 2018, IEEE J BIOMED HEALTH, V22, P173, DOI 10.1109/JBHI.2017.2655720; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Tibshirani R, 1996, NEURAL COMPUT, V8, P152, DOI 10.1162/neco.1996.8.1.152; Vu TD, 2017, INT CONF BIG DATA, P309, DOI 10.1109/BIGCOMP.2017.7881683; Wagner R, LEARNING CONVOLUTION; Wang SQ, 2017, LECT NOTES COMPUT SC, V10613, P373, DOI 10.1007/978-3-319-68600-4_43; Wu GR, 2013, LECT NOTES COMPUT SC, V8150, P649, DOI 10.1007/978-3-642-40763-5_80; YANAOKA T., 2015, TECHNICAL PAPER NO 2, DOI [10.4271/2015-01-1439, DOI 10.4271/2015-01-1439, 10.4271/2015- 01-1439]; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao W, 2017, ANN BIOMED ENG, V45, P2437, DOI 10.1007/s10439-017-1888-3; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P1709, DOI 10.1007/s10237-017-0915-5; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P449, DOI 10.1007/s10237-016-0829-7; Zhao W, 2016, J NEUROTRAUM, V33, P1834, DOI 10.1089/neu.2015.4239	68	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197992	10.1371/journal.pone.0197992			21	Multidisciplinary Sciences	Science & Technology - Other Topics	GH0HY	WOS:000433084300110	29795640	DOAJ Gold, Green Published			2021-06-18	
J	Liu, ZK; Ng, CF; Shiu, HT; Wong, HL; Chin, WC; Zhang, JF; Lam, PK; Poon, WS; Lau, CBS; Leung, PC; Ko, CH				Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Chin, Wai-Ching; Zhang, Jin-Fang; Lam, Ping-Kuen; Poon, Wai-Sang; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay			Neuroprotective effect of Da Chuanxiong Formula against cognitive and motor deficits in a rat controlled cortical impact model of traumatic brain injury	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						Chuanxiong Rhizoma; Gastrodiae Rhizoma; Da Chuanxiong Formula; Neuroprotective effect; Traumatic brain injury	GASTRODIA-ELATA BLUME; NEURAL STEM-CELLS; Z-LIGUSTILIDE; INFLAMMATORY RESPONSE; MICE; PATHWAY; PROLIFERATION; NEUROTOXICITY; EPIDEMIOLOGY; INVOLVEMENT	Ethnopharmacological relevance: Da Chuanxiong Formula (DCXF) is one of the famous herb pairs that contains dried rhizomes of Ligusticum chuanxiong Hort. and Gastrodia elan BI. in the mass ratio of 4:1. This classic representative traditional Chinese medicine has been widely used to treat brain diseases like headache and migraine caused by blood stasis and wind pathogen. However, the therapeutic effect of DCXF on traumatic brain injury (TBI) has not been reported yet. Aim of study: The present study was performed to investigate the neuroprotective effects of DCXF and its underlying mechanisms in the controlled cortical impact (CCI)-induced TBI rat model. Materials and methods: Male Sprague-Dawley rats were divided into four groups: Sham, TBI control, 1x DCXF (520.6 mg/kg) and 5X DCXF (2603.0 mg/kg). Two treatment groups (1X and 5X DCXF) were intragastrically administered daily for 7 days before CO-induced TBI and then DCXF treatments were continued post-TBI until the animal behavioral tests, including Morris water maze test, acceleration rotarod motor test and CatWalk quantitative gait analysis test, were done. The brain water content and blood brain barrier (BBB) integrity were measured by wet-dry weight method and Evans blue method, respectively. The number of neuron cells, neural stem cells (NSCs), GFAP positive cells (astrocyte) as well as Iba-1 positive cells (microglia) were determined by histology and immunohistochemistry. Results: Treatment with DCXF significantly improved the learning ability and memory retention in Morris water maze test, and remarkably enhanced motor performances in acceleration rotarod motor test and catwalk quantitative gait analysis test after TBI. Moreover, DCXF treatment was able to reduce BBB permeability, brain edema, microglia and astrocyte activation, improve the proliferation of NSCs and decrease neurons loss in the brain with TBI. Conclusions: The present study demonstrated that DCXF treatment could decrease BBB leakage and brain edema, reduce neuron loss, microglia and astrocyte activation, and increase NSCs proliferation, which may contribute to the cognitive and motor protection of DCXF in the TBI rats. It is the first time to provide potentially underlying mechanisms of the neuroprotective effect of DCXF on TBI-induced brain damage and functional outcomes.	[Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China; [Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, State Key Lab Phytochem & Plant Resources West Ch, Shatin, Hong Kong, Peoples R China; [Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen 518057, Peoples R China; [Zhang, Jin-Fang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China; [Chin, Wai-Ching; Lam, Ping-Kuen; Poon, Wai-Sang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China	Ko, CH (corresponding author), Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China.	liuzhikebee@163.com; ncf0000@hotmail.com; hoitingshiu@gmail.com; vhlwong@cuhk.edu.hk; donchin@surgery.cuhk.edu.hk; zhangjf06@gmail.com; lampingkuen@yahoo.com.hk; wpoon@surgery.cuhk.edu.hk; claralau@cuhk.edu.hk; pingcleung@cuhk.edu.hk; gohey@yahoo.com	Lau, Clara Bik-San/AAF-3989-2020; Poon, Wai Sang/F-1558-2011	Lau, Clara Bik-San/0000-0002-7409-1270; 	Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund [12134111]	This study was financially supported by the Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund (no. 12134111).	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Barzegar-Fallah N, 2016, BRAIN INJURY, V30, P926, DOI 10.3109/02699052.2016.1144083; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Chen D, 2011, J PHARMACOL EXP THER, V337, P663, DOI 10.1124/jpet.110.177055; Dai JN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021891; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Elovic EP, 2008, ARCH PHYS MED REHAB, V89, pS21, DOI 10.1016/j.apmr.2007.12.012; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Feng ZB, 2012, J ETHNOPHARMACOL, V144, P313, DOI 10.1016/j.jep.2012.09.014; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Ghosh S, 2017, FOOD CHEM TOXICOL, V103, P41, DOI 10.1016/j.fct.2017.02.028; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kao TK, 2013, EXP NEUROL, V247, P188, DOI 10.1016/j.expneurol.2013.04.010; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Lam PK, 2016, ACTA NEUROCHIR SUPPL, V122, P21, DOI 10.1007/978-3-319-22533-3_4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leo P., 2016, TRANSLATIONAL RES TR; Li JJ, 2015, BRAIN RES, V1595, P19, DOI 10.1016/j.brainres.2014.10.012; Liu BY, 2015, CHIN J TRAUMATOL, V18, P135, DOI 10.1016/j.cjtee.2015.04.002; Liu ZK, 2017, J ETHNOPHARMACOL, V196, P20, DOI 10.1016/j.jep.2016.12.014; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mishra SK, 2017, MOL CELL NEUROSCI, V78, P25, DOI 10.1016/j.mcn.2016.11.008; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Ng C. F., 2013, EVID-BASED COMPL ALT, V2013, P1; Ng CF, 2016, J ETHNOPHARMACOL, V185, P87, DOI 10.1016/j.jep.2016.03.018; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Pu QH, 2015, LIFE SCI, V121, P46, DOI 10.1016/j.lfs.2014.11.016; Ran X, 2011, PHARM BIOL, V49, P1180, DOI 10.3109/13880209.2011.576346; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Tian YM, 2010, NEUROSCI LETT, V474, P26, DOI 10.1016/j.neulet.2010.02.066; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Wang HN, 2014, BEHAV BRAIN RES, V266, P153, DOI 10.1016/j.bbr.2014.02.046; Wang L., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.3901/JME.2013.01.039; Wang XL, 2014, LIFE SCI, V114, P77, DOI 10.1016/j.lfs.2014.08.004; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xu W, 2016, NEUROCHEM INT, V100, P44, DOI 10.1016/j.neuint.2016.08.012; Yamamoto S, 2006, J SURG RES, V134, P307, DOI 10.1016/j.jss.2005.11.588; Yang B, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1076-2; Zhan HD, 2016, J ETHNOPHARMACOL, V189, P361, DOI 10.1016/j.jep.2016.06.057; Zhu MD, 2014, BRAIN RES BULL, V109, P54, DOI 10.1016/j.brainresbull.2014.10.002; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	51	11	11	3	35	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	MAY 10	2018	217						11	22		10.1016/j.jep.2018.02.004			12	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	GB9KO	WOS:000429392900003	29425850				2021-06-18	
J	Beaulieu-Bonneau, S; St-Onge, F; Blackburn, MC; Banville, A; Paradis-Giroux, AA; Ouellet, MC				Beaulieu-Bonneau, Simon; St-Onge, Frederic; Blackburn, Marie-Claude; Banville, Andree; Paradis-Giroux, Andree-Anne; Ouellet, Marie-Christine			Alcohol and Drug Use Before and During the First Year After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alcohol; drug; psychiatric disorders; rehabilitation; substance use; traumatic brain injury	SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; OUTCOMES; HISTORY; PREVALENCE; PATTERNS; MISUSE; RISK	Objectives: To compare individuals with mild and moderate/severe traumatic brain injury (TBI) on alcohol and drug use and substance use disorders before and in the first year post-TBI; to explore sociodemographic and injury-related variables associated with substance use disorders. Participants: A total of 225 adults hospitalized in a level I trauma center after TBI. Design: Observational cohort study with retrospective (pre-TBI) and prospective (4, 8, and 12 months post-TBI) assessments. Main measures:Mini International Neuropsychiatric Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Results: The percentage of participants using alcohol or drug declined shortly after the injury (4 months) but increased closer to preinjury levels by the end of the first year. Post-TBI alcohol use was higher after mild than moderate/severe TBI, but drug use was similar. About 11% of participants met criteria for a substance use disorder in the first year after TBI. Younger age, not being in a relationship, and suspected substance intoxication at the time of TBI were associated with the presence of a post-TBI substance use disorder. Conclusion: Individuals with milder injuries return to alcohol use earlier than those with more severe injuries. Given that substance use may alter recovery, preventive recommendations and systematic follow-ups are warranted regardless of injury severity and access to rehabilitation.	[Beaulieu-Bonneau, Simon; St-Onge, Frederic; Blackburn, Marie-Claude; Banville, Andree; Ouellet, Marie-Christine] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada; [Beaulieu-Bonneau, Simon; St-Onge, Frederic; Paradis-Giroux, Andree-Anne; Ouellet, Marie-Christine] Ctr Interdisciplinaire Rech Readaptat & Integrat, 525 Boul Wilfrid Hamel, Quebec City, PQ G1M 2S8, Canada	Beaulieu-Bonneau, S (corresponding author), Ctr Interdisciplinaire Rech Readaptat & Integrat, 525 Boul Wilfrid Hamel, Quebec City, PQ G1M 2S8, Canada.	simon.beaulieu-bonneau.1@ulaval.ca		Ouellet, Marie-Christine/0000-0003-3477-1893; Beaulieu-Bonneau, Simon/0000-0002-9544-5023	Fonds de Recherche du Quebec-Sante (FRQ-S) [16375]	This study was supported by a grant from the Fonds de Recherche du Quebec-Sante (FRQ-S; 16375).	Allen DN, 2009, APPL NEUROPSYCHOL, V16, P186, DOI 10.1080/09084280903098687; Alway Y, 2016, PSYCHOL MED, V46, P1331, DOI 10.1017/S0033291715002986; Andelic Nada, 2010, J Trauma Manag Outcomes, V4, P6, DOI 10.1186/1752-2897-4-6; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Babor T.F., 1992, GUIDELINES USE PRIMA; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 1997, REHAB PSYCHOL, V42, P13; Bryce S, 2015, J HEAD TRAUMA REHAB, V30, pE40, DOI 10.1097/HTR.0000000000000091; Butt P., 2011, ALCOHOL HLTH CANADA; Cahalan D, 1969, AM DRINKING PRACTICE, P131; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; De Guise E, 2009, BRAIN INJURY, V23, P853, DOI 10.1080/02699050903283221; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Gwet KL, 2008, BRIT J MATH STAT PSY, V61, P29, DOI 10.1348/000711006X126600; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Kolakowsky-Hayner SA, 2001, BRAIN INJURY, V15, P53, DOI 10.1080/02699050150209138; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Leonard EA, 2016, J TRAUMA NURS, V23, P103, DOI 10.1097/JTN.0000000000000194; Ministere de la Sante et des Services Sociaux du Quebec Societe d'assurance Automobile du Quebec, 2005, OR MIN TRAUM CRAN CE; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Pagulayan KF, 2016, J NEUROTRAUM, V33, P1390, DOI 10.1089/neu.2015.4071; Pandit V, 2014, J SURG RES, V190, P634, DOI 10.1016/j.jss.2014.04.039; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Ponsford J, 2013, J CLIN EXP NEUROPSYC, V35, P103, DOI 10.1080/13803395.2012.752437; Ponsford J, 2012, J HEAD TRAUMA REHAB, V27, P342, DOI 10.1097/HTR.0b013e318265a576; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Statistics Canada, 2012, MENT HLTH PROF CAN C; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Vungkhanching M, 2007, J HEAD TRAUMA REHAB, V22, P167, DOI 10.1097/01.HTR.0000271117.19652.98; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397	48	11	11	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2018	33	3					E51	E60		10.1097/HTR.0000000000000341			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GJ7HA	WOS:000435555500006	28926484				2021-06-18	
J	Crichton, A; Anderson, V; Oakley, E; Greenham, M; Hearps, S; Delzoppo, C; Beauchamp, MH; Hutchison, JS; Guerguerian, AM; Boutis, K; Babl, FE				Crichton, Alison; Anderson, Vicki; Oakley, Ed; Greenham, Mardee; Hearps, Stephen; Delzoppo, Carmel; Beauchamp, Miriam H.; Hutchison, James S.; Guerguerian, Anne-Marie; Boutis, Kathy; Babl, Franz E.		Biomarker Quality Life Children	Fatigue Following Traumatic Brain Injury in Children and Adolescents: A Longitudinal Follow-Up 6 to 12 Months After Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescent; brain injuries; child; fatigue; longitudinal studies; preschool child; sleep-wake disorders	QUALITY-OF-LIFE; SICKLE-CELL-DISEASE; MINOR HEAD-INJURY; MULTIDIMENSIONAL FATIGUE; PEDIATRIC-PATIENTS; RELIABILITY; PEDSQL(TM); SCALE; CONCUSSION; PREDICTION	Background: Longitudinal fatigue data in children suffering from traumatic brain injury (TBI) are lacking. Objectives: To examine the effects of time postinjury (6-12 months) and injury severity on fatigue after childhood TBI. Secondarily, we compared fatigue 12 months postinjury against published control data. Setting: Three tertiary children's hospitals across Australia (n = 1) and Canada (n = 2). Participants: Parents (n = 109) of children (mean [M] = 9.9 years at injury; range, 1.0-16.9 years) admitted to one of 3 participating hospitals with mild (n = 69) or moderate/severe (n = 37) TBI. Design: Longitudinal prospective study. Measures:Primary: Pediatric Quality of Life Multidimensional Fatigue Scale (total, general, sleep/rest, and cognitive), rated by parents 6 and 12 months postinjury. Secondary: Pediatric Injury Functional Outcome Scale (fatigue and sleep items, rated on recruitment and 6 and 12 months postinjury). Demographic and children data were collected at recruitment. Results: Mixed-models analysis demonstrated nonsignificant effects of time (6 vs 12 months postinjury) on multidimensional fatigue scores. Cognitive fatigue worsened over time. Moderate/severe TBI was associated with worse fatigue 12 months postinjury (general, P = .03; cognitive, P = .02). Across all severities, fatigue 12 months postinjury was significantly worse compared with control data (total fatigue, P < .001; all domains, all Ps < .025). Conclusion: Fatigue remains significant at 12 months since injury, particularly for those with moderate/severe TBI.	[Crichton, Alison; Anderson, Vicki; Oakley, Ed; Greenham, Mardee; Delzoppo, Carmel; Babl, Franz E.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Crichton, Alison] Monash Childrens, Victorian Peadiat Rehabil Serv, Melbourne, Vic, Australia; [Anderson, Vicki] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Crichton, Alison; Greenham, Mardee] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic, Australia; [Oakley, Ed; Babl, Franz E.] Univ Melbourne, Dept Peadiat, Melbourne, Vic, Australia; [Oakley, Ed; Delzoppo, Carmel; Babl, Franz E.] RCH, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Beauchamp, Miriam H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Hutchison, James S.; Guerguerian, Anne-Marie] Hosp Sick Children HSK, Neurosci & Mental Hlth Res Program, Toronto, ON, Canada; [Hutchison, James S.; Guerguerian, Anne-Marie; Boutis, Kathy] Hosp Sick Children HSK, Toronto, ON, Canada; [Hutchison, James S.; Boutis, Kathy] Univ Toronto, Toronto, ON, Canada	Crichton, A (corresponding author), Murdoch Childrens Res Inst, Crit Care & Neurosci Theme, 50 Flemington Rd, Parkville, Vic 3052, Australia.	ali.crichton@mcri.edu.au	Hearps, Stephen/L-6853-2016; Greenham, Mardee/AAR-1711-2020		Ontario Neurotrauma Foundation, Toronto, Canada; Victorian Neurotrauma Initiative, Melbourne, Australia; Moving Ahead Seed Grant; National Health and Medical Research Council Postgraduate Scholarship, Canberra, Australia [GNT 1075048]; Neurosciences Victoria Brain and Mind Scholarship, Melbourne, Australia; Victorian Government's Infrastructure Support Program, Melbourne, Australia; National Health and Medical Research Council Centre for Research Excellence Grant in Paediatric Emergency Medicine, Canberra, Australia; Royal Children's Hospital Foundation grant	This work is supported by a jointly awarded grant from The Ontario Neurotrauma Foundation, Toronto, Canada, and The Victorian Neurotrauma Initiative, Melbourne, Australia (Vicki Anderson and Jamie Hutchison, awarded 2011); a Moving Ahead Seed Grant (Alison Crichton, awarded 2012); a National Health and Medical Research Council Postgraduate Scholarship, Canberra, Australia (Alison Crichton, awarded 2014, GNT 1075048); a Neurosciences Victoria Brain and Mind Scholarship, Melbourne, Australia (Alison Crichton, awarded 2012); the Victorian Government's Infrastructure Support Program, Melbourne, Australia, and in part funded by a National Health and Medical Research Council Centre for Research Excellence Grant in Paediatric Emergency Medicine, Canberra, Australia. Franz E. Babl was in part funded by a Royal Children's Hospital Foundation grant.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Briggs-Gowan M, 2006, BRIEF INFANT TODDLER; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2013, NEUROREHABILITATION, V32, P875, DOI 10.3233/NRE-130912; CARTER BD, 1995, PEDIATRICS, V95, P179; CHAPMAN SB, 2007, BRAIN INJ PROF, V3, P10; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Chiang YC, 2008, CANCER NURS, V31, pE1, DOI 10.1097/01.NCC.0000305732.03464.29; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crichton A, 2015, PEDIATRICS, V135, pE1015, DOI 10.1542/peds.2014-2440; Crichton AJ, 2017, J HEAD TRAUMA REHAB, V32, P107, DOI 10.1097/HTR.0000000000000248; Dampier C, 2010, PEDIATR BLOOD CANCER, V55, P485, DOI 10.1002/pbc.22497; Eddy L, 2007, J SPEC PEDIATR NURS, V12, P105, DOI 10.1111/j.1744-6155.2007.00099.x; Ewing-Cobbs L, 2014, J PEDIATR PSYCHOL, V39, P653, DOI 10.1093/jpepsy/jsu018; Falk AC, 2013, SCAND J CARING SCI, V27, P51, DOI 10.1111/j.1471-6712.2012.00999.x; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Gold JI, 2009, CLIN J PAIN, V25, P407, DOI 10.1097/AJP.0b013e318192bfb1; Goodman R, 2000, EUR CHILD ADOLES PSY, V9, P129, DOI 10.1007/s007870050008; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hilger T, 2009, ADV CLIN EXP MED, V18, P169; Hinds PS, 2013, PEDIATR BLOOD CANCER, V60, P402, DOI 10.1002/pbc.24233; Holland AA, 2014, CHILD NEUROPSYCHOL, V20, P71, DOI 10.1080/09297049.2012.748888; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Jonsson CCA, 2014, INT J REHABIL RES, V37, P317, DOI 10.1097/MRR.0000000000000073; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; MacAllister WS, 2009, MULT SCLER J, V15, P1502, DOI 10.1177/1352458509345902; Meeske K, 2004, CANCER, V101, P2116, DOI 10.1002/cncr.20609; Mollayeva T, 2014, NEUROSCI BIOBEHAV R, V47, P684, DOI 10.1016/j.neubiorev.2014.10.024; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Nagane M, 2004, PSYCHOL REP, V95, P48, DOI 10.2466/pr0.95.1.48-52; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; Palmer SN, 2007, PEDIATR BLOOD CANCER, V49, P287, DOI 10.1002/pbc.21026; Panepinto JA, 2014, PEDIATR BLOOD CANCER, V61, P171, DOI 10.1002/pbc.24776; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Ryan NP, 2016, CORTEX, V83, P222, DOI 10.1016/j.cortex.2016.07.020; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Selewski DT, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-29; StataCorp, 2015, STAT STAT SOFTW REL; Stone LL, 2010, CLIN CHILD FAM PSYCH, V13, P254, DOI 10.1007/s10567-010-0071-2; Sumpter R, 2011, BRAIN INJURY, V25, P1288, DOI 10.3109/02699052.2011.613090; Taylor H. G., 2010, PEDIAT TRAUMATIC BRA, P145; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; Varni JW, 2004, J RHEUMATOL, V31, P2494; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	56	11	11	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2018	33	3					200	209		10.1097/HTR.0000000000000330			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GJ7HA	WOS:000435555500125	28926479				2021-06-18	
J	Kerr, ZY; Zuckerman, SL; Wasserman, EB; Vander Vegt, CB; Yengo-Kahn, A; Buckley, TA; Solomon, GS; Sills, AK; Dompier, TP				Kerr, Zachary Y.; Zuckerman, Scott L.; Wasserman, Erin B.; Vander Vegt, Christina B.; Yengo-Kahn, Aaron; Buckley, Thomas A.; Solomon, Gary S.; Sills, Allen K.; Dompier, Thomas P.			Factors associated with post-concussion syndrome in high school student-athletes	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain injuries; Adolescent; Sports; Epidemiology	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; PROLONGED RECOVERY; PREDICTORS; TIME; EPIDEMIOLOGY; PREVALENCE; CONSENSUS; SYMPTOMS	Objectives: To identify factors associated with post-concussion syndrome (PCS) among a national sample of high school student-athletes from the 2011/12-2013/14 academic years. Design: Ambispective cohort study from sports injury surveillance data. Methods: Sport-related concussion data originated from the National Athletic Treatment, Injury and Outcomes Network (NATION) surveillance program, consisting of 27 sports from a convenience sample of 196 high schools across 26 states. All SRCs were reported by certified athletic trainers. The PCS and non-PCS groups consisted of concussed individuals with symptoms resolution time of >4 weeks and <= 2 weeks, respectively. Logistic regression estimated the association of athlete and concussion characteristics on the odds of PCS, and calculated adjusted odds ratios (OR) and 95% confidence intervals (CI). Results: Overall, 1334 concussed high school athletes met inclusion criteria: 215 in the PCS group and 1119 in the non-PCS group. In the multivariable analysis, concussion symptoms associated with increased odds of PCS included: retrograde amnesia (OR=3.01, 95%CI: 1.31-6.91), difficulty concentrating (OR=2.72, 95%CI: 1.56-4.77), disorientation (OR=1.86; 95%CI: 1.04-3.33), insomnia (OR=2.79; 95%CI: 1.62-4.80), loss of balance (OR=1.76; 95%CI: 1.00-3.10), sensitivity to noise (OR=1.80; 95%CI: 1.02-3.17), and visual disturbance (OR=2.21; 95%CI: 1.23-3.97). Sex and recurrent concussion were not associated with PCS. Conclusions: As in previous research, somatic and cognitive symptoms were associated with PCS. The identification of factors associated with PCS may assist clinicians in identifying concussed athletes at greater risk of having longer symptom resolution time.Copyright (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Wasserman, Erin B.; Vander Vegt, Christina B.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC USA; [Zuckerman, Scott L.; Yengo-Kahn, Aaron; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Med Ctr East, Nashville, TN 37212 USA; [Zuckerman, Scott L.; Yengo-Kahn, Aaron; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Wasserman, Erin B.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA; [Vander Vegt, Christina B.] Univ N Carolina, Human Movement Sci Curriculum, Chapel Hill, NC USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Dompier, Thomas P.] Lebanon Valley Coll, Dept Athlet Training, Annville, PA USA	Kerr, ZY (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu	Solomon, Gary/K-9011-2019; Yengo-Kahn, Aaron/AAV-7647-2020; Buckley, Thomas A/B-7525-2016	Yengo-Kahn, Aaron/0000-0002-5989-3064; Buckley, Thomas A/0000-0002-0515-0150; Wasserman, Erin/0000-0001-5957-5878; Kerr, Zachary/0000-0003-1423-1259	National Athletic Trainers' Association Research and Education Foundation; BioCrossroads; Central Indiana Corporate Partnership Foundation	Funding for this study was provided by the National Athletic Trainers' Association Research and Education Foundation and BioCrossroads in partnership with the Central Indiana Corporate Partnership Foundation. The organizations that funded this study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the study sponsors. We thank the many athletic trainers who have volunteered their time and efforts to submit data to NATION. Their efforts are greatly appreciated and have had a tremendously positive effect on the safety of high school student-athletes.	*AM PSCH ASS, 2000, DIAGN STAT MAN MENT; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Centers for Medicare and Medicaid Services, 2017, ICD9CM DIAGN PROC CO; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Currie DW, 2016, J HEAD TRAUMA REHAB, DOI [10.1097/htr.0000000000000240, DOI 10.1097/HTR.0000000000000240.PUBLISHED]; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Kerr ZY, 2016, JAMA PEDIATR, V170, P647, DOI 10.1001/jamapediatrics.2016.0073; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lombardi NJ, 2016, ORTHOPEDICS, V39, pE944, DOI 10.3928/01477447-20160623-10; Luoto TM, 2015, BRAIN INJURY, V29, P565, DOI 10.3109/02699052.2014.1002421; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rose SC, 2015, BRAIN INJURY, V29, P798, DOI 10.3109/02699052.2015.1004756; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Zuckerman SL, 2015, INT J SPORTS MED, V36, P419, DOI 10.1055/s-0034-1395587; Zuckerman Scott L, 2016, Neurosurgery, V63 Suppl 1, P102, DOI 10.1227/NEU.0000000000001280; Zuckerman SL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15593; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	29	11	11	1	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2018	21	5					447	452		10.1016/j.jsams.2017.08.025			6	Sport Sciences	Sport Sciences	GF8NY	WOS:000432230800004	28939003				2021-06-18	
J	Li, L; Ma, XY; Pandey, S; Deng, XY; Chen, SY; Cui, DM; Gao, L				Li, Lei; Ma, Xiaoye; Pandey, Sajan; Deng, Xianyu; Chen, Songyu; Cui, Daming; Gao, Liang			The Most-Cited Works in Severe Traumatic Brain Injury: A Bibliometric Analysis of the 100 Most Cited Articles	WORLD NEUROSURGERY			English	Article						Bibliometric analysis; Citation classics; Severe traumatic brain injury	IMPACT; JOURNALS; PATTERNS	BACKGROUND: There is an abundance of works published on severe traumatic brain injury (sTBI). Bibliometric analyses aim to provide a macroscopic view of research activities regarding sTBI and are helpful in determining the most impactful studies within this field. METHODS: We performed a generalized search using the database of Web of Science, organized the references by the number of citations, and reviewed full length-articles for the top-100 most-cited articles on sTBI. The articles were classified according to focus. RESULTS: The top-100 articles were cited on average 326.4 times per paper. The Journal of Neurosurgery published the greatest number of top-100 cited articles (9 of 100). Authors from the United States published the majority (67%) of the most-cited articles. The most popular categories were "reviews and guidelines" and "etiology and epidemiology." CONCLUSIONS: The present study provides a cross-sectional summary of the 100 most-cited articles on sTBI, highlighting areas of research needing further investigation and development.	[Li, Lei; Pandey, Sajan; Deng, Xianyu; Chen, Songyu; Cui, Daming; Gao, Liang] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Neurosurg, Shanghai, Peoples R China; [Ma, Xiaoye] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Neurol, Shanghai, Peoples R China	Cui, DM (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Neurosurg, Shanghai, Peoples R China.	damingcui@hotmail.com			Health and Family Planning Commission [03.02.16.001]	This work was supported by Health and Family Planning Commission Grant 03.02.16.001, to Liang Gao. The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.	Adams H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002353; Alotaibi NM, 2016, WORLD NEUROSURG, V89, P587, DOI 10.1016/j.wneu.2015.11.072; Arunachalam L, 2017, ANN SURG, V265, P1141, DOI 10.1097/SLA.0000000000001795; Carter CS, 2015, BIOL PSYCHIAT, V78, P434, DOI 10.1016/j.biopsych.2015.08.004; Charleswell C, 2015, J EPIDEMIOL COMMUN H, V69, P290, DOI 10.1136/jech-2014-204239; Coller BS, 2015, BLOOD, V126, P2548, DOI 10.1182/blood-2015-09-659581; Gal D, 2017, EUR HEART J, V38, P1249, DOI 10.1093/eurheartj/ehw459; GARFIELD E, 1987, JAMA-J AM MED ASSOC, V257, P52, DOI 10.1001/jama.257.1.52; Hirshman BR, 2016, ANN NEUROL, V79, P169, DOI 10.1002/ana.24569; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Kim HJ, 2016, NEUROIMAGE, V139, P149, DOI 10.1016/j.neuroimage.2016.06.029; Leng ZK, 2013, NEURAL REGEN RES, V8, P1286, DOI 10.3969/j.issn.1673-5374.2013.14.005; Leopold S, 2015, CLIN ORTHOP RELAT R, V473, P3695, DOI 10.1007/s11999-015-4516-2; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Loomes DE, 2013, GASTROENTEROLOGY, V144, P673, DOI 10.1053/j.gastro.2013.02.013; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; Mimouni M, 2016, OPHTHALMOLOGY, V123, P1824, DOI 10.1016/j.ophtha.2016.04.034; Pagel PS, 2015, ANESTHESIOLOGY, V123, P683, DOI 10.1097/ALN.0000000000000737; Parikh LI, 2017, OBSTET GYNECOL, V129, P243, DOI 10.1097/AOG.0000000000001852; Ponsford J, 2014, J HEAD TRAUMA REHAB, V29, P321, DOI 10.1097/HTR.0000000000000072; Raheja A, 2016, J NEUROSURG, V125, P631, DOI 10.3171/2015.6.JNS15674; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sardanelli F, 2014, RADIOLOGY, V272, P533, DOI 10.1148/radiol.14131730; Sharma B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00879; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Sweileh WM, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0476-7	26	11	11	2	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2018	113						E82	E87		10.1016/j.wneu.2018.01.164			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8JD	WOS:000432942700011	29409928				2021-06-18	
J	Lynall, RC; Blackburn, JT; Guskiewicz, KM; Marshall, SW; Plummer, P; Mihalik, JP				Lynall, Robert C.; Blackburn, J. Troy; Guskiewicz, Kevin M.; Marshall, Stephen W.; Plummer, Prudence; Mihalik, Jason P.			Reaction Time and Joint Kinematics During Functional Movement in Recently Concussed Individuals	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Mild traumatic brain injury; Rehabilitation	EXTREMITY MUSCULOSKELETAL INJURY; SPORT-RELATED CONCUSSION; GAIT BALANCE CONTROL; FOOTBALL PLAYERS; POSTURAL CONTROL; SYMPTOM-FREE; STABILITY; ADOLESCENTS; TRUNK; RISK	Objective: To compare movement reaction time and joint kinematics between athletes with recent concussion and matched control recreational athletes during 3 functional tasks. Design: Cross-sectional. Setting: Laboratory. Participants: College-aged recreational athletes (N = 30) comprising 2 groups (15 participants each): (1) recent concussion group (median time since concussion, 126d; range, 28-432d) and (2) age- and sex-matched control group with no recent concussions. Interventions: We investigated movement reaction time and joint kinematics during 3 tasks: (1) jump landing, (2) anticipated cut, and (3) unanticipated cut. Main Outcome Measures: Reaction time and reaction time cost (jump landing reaction time cut reaction time/jump landing reaction time x 100%), along with trunk, hip, and knee joint angles in the sagittal and frontal planes at initial ground contact. Results: There were no reaction time between-group differences, but the control group displayed improved reaction time cost (10.7%) during anticipated cutting compared with the concussed group (0.8%; P = .030). The control group displayed less trunk flexion than the concussed group during the nondominant anticipated cut (5.1 difference; P = .022). There were no other kinematic between-group differences (P >=.079). Conclusions: We observed subtle reaction time and kinematic differences between individuals with recent concussion and those without concussion more than a month after return to activity after concussion. The clinical interpretation of these findings remains unclear, but may have future implications for postconcussion management and rehabilitation. (C) 2018 by the American Congress of Rehabilitation Medicine	[Lynall, Robert C.] Univ Georgia, Dept Kinesiol, UGA Concuss Res Lab, Athens, GA 30602 USA; [Lynall, Robert C.; Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Lynall, Robert C.; Blackburn, J. Troy; Guskiewicz, Kevin M.; Plummer, Prudence; Mihalik, Jason P.] Univ N Carolina, Dept Allied Hlth Sci, Human Movement Sci Curriculum, Chapel Hill, NC USA; [Blackburn, J. Troy] Univ N Carolina, Dept Exercise & Sport Sci, Neuromusc Res Lab, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Plummer, Prudence] Univ N Carolina, Dept Allied Hlth Sci, Div Phys Therapy, Chapel Hill, NC USA	Lynall, RC (corresponding author), 330 River Rd, Athens, GA 30677 USA.	rlynall@uga.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640	University of North Carolina at Chapel Hill Junior Faculty Development Award	Supported by The University of North Carolina at Chapel Hill Junior Faculty Development Award.	Blackburn JT, 2008, CLIN BIOMECH, V23, P313, DOI 10.1016/j.clinbiomech.2007.10.003; Blackburn JT, 2009, J ATHL TRAINING, V44, P174, DOI 10.4085/1062-6050-44.2.174; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Dubose DF, 2017, MED SCI SPORT EXER, V49, P167, DOI 10.1249/MSS.0000000000001067; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2010, NEUROLOGY, V74, pA202; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Fino P.C., 2017, CLIN J SPORT MED; Frank B, 2013, AM J SPORT MED, V41, P2676, DOI 10.1177/0363546513496625; HENRY FM, 1960, RES QUART, V31, P448, DOI 10.1080/10671188.1960.10762052; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; Lapointe A.P, 2017, INT J PSYCHOPHYSIOL; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McNevin NH, 2002, HUM MOVEMENT SCI, V21, P187, DOI 10.1016/S0167-9457(02)00095-7; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Riemann BL, 2002, J ATHL TRAINING, V37, P71; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Teel EF, 2013, J SCI MED SPORT, V16, P190, DOI 10.1016/j.jsams.2012.09.007	36	11	11	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2018	99	5					880	886		10.1016/j.apmr.2017.12.011			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	GE7CG	WOS:000431387000008	29337022				2021-06-18	
J	Okur, SC; Erdogan, S; Demir, CS; Gunel, G; Karaoz, E				Okur, Sibel Caglar; Erdogan, Sinan; Demir, Cansu Subasi; Gunel, Gulsen; Karaoz, Erdal			The Effect of Umbilical Cord-derived Mesenchymal Stem Cell Transplantation in a Patient with Cerebral Palsy: A Case Report	INTERNATIONAL JOURNAL OF STEM CELLS			English	Article						Cerebral palsy; Mesenchymal stem cell; Rehabilitation	TRAUMATIC BRAIN-INJURY; STROMAL CELLS; PRECURSORS; THERAPIES	Background: Cerebral Palsy (CP) is the most common motor disability reason of childhood that occurs secondarily to non-progressive damage in the brain whose development is still ongoing. Methods: 6-year-old dystonic-spastic male CP patient received allogenic mesenchymal stem cells treatment four times as 1x10(6)/kg in intrathecal and intravenous administration of Umbilical Cord-derived mesenchymal stem cells (UC-MSCs) ways. Before and after the treatment, the patient was followed-up with FIM (Functional Independent Measurement), GMFCS (Gross Motor Function Classification System 88), Tardieu Scale, TCMS (Trunk Control Measurement Scale), MACS (Manual Ability Classification Scale), CFSS (Communication Function Classification System) for 18 months and received intensive rehabilitation. Results: Improvements were observed especially in functional scales except for the Tardieu Scale, and no adverse effects were detected aside from a slight pain in the back. Conclusion: Wider future case studies on UC-MSCs will enable us to assess the efficacy of UC-MSCs which have positive impacts especially on functional scales.	[Okur, Sibel Caglar] Hlth Sci Univ, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Phys Therapy & Rehab, Istanbul, Turkey; [Erdogan, Sinan; Karaoz, Erdal] Istinye Univ, Fac Med, Dept Histol & Embryol, Istanbul, Turkey; [Demir, Cansu Subasi; Gunel, Gulsen; Karaoz, Erdal] Istinye Univ, Ctr Stem Cell & Tissue Engn Res & Practice, Istanbul, Turkey; [Karaoz, Erdal] Liv Hosp, Ctr Regenerat Med & Stem Cell Mfg LivMedCell, Istanbul, Turkey	Okur, SC (corresponding author), Hlth Dr Sadi Konuk Educ & Res Hosp, Dept Phys Med & Rehabil, Tevfik Saglam Cad 11, TR-34147 Istanbul, Turkey.	sibelcaglarokur@gmail.com	Karaoz, Erdal/AAO-1470-2020; Caglar Okur, Sibel/U-3126-2017	Caglar Okur, Sibel/0000-0002-4015-5977			Azari MF, 2010, CURR NEUROPHARMACOL, V8, P316, DOI 10.2174/157015910793358204; Broughton BRS, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00066; Cruz-Martinez P, 2014, REGEN MED, V9, P579, DOI [10.2217/RME.14.38, 10.2217/rme.14.38]; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Goldstein M, 2004, J PEDIATR-US, V145, pS42, DOI 10.1016/j.jpeds.2004.05.022; Han Hoon, 2011, J Med Case Rep, V5, P562, DOI 10.1186/1752-1947-5-562; Ichim Thomas E, 2010, Int Arch Med, V3, P30, DOI 10.1186/1755-7682-3-30; Kim Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0236-5; Koman LA, 2004, LANCET, V363, P1619, DOI 10.1016/S0140-6736(04)16207-7; Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mehta T, 2008, TRANSPL P, V40, P1145, DOI 10.1016/j.transproceed.2008.03.026; Nelson KB, 2003, NEW ENGL J MED, V349, P1765, DOI 10.1056/NEJMsb035364; Paneth N, 2006, CLIN PERINATOL, V33, P251, DOI 10.1016/j.clp.2006.03.011; Phermthai T, 2017, CYTOTHERAPY, V19, P990, DOI 10.1016/j.jcyt.2017.04.004; Purandare Chaitanya, 2012, Case Rep Transplant, V2012, P825289, DOI 10.1155/2012/825289; Rengasamy M, 2016, INDIAN J MED RES, V144, P852, DOI 10.4103/ijmr.IJMR_1842_15; Sankar V, 2003, NEUROSCIENCE, V118, P11, DOI 10.1016/S0306-4522(02)00929-6; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Vaquero J, 2017, CYTOTHERAPY, V19, P349, DOI 10.1016/j.jcyt.2016.12.002; Wang Liming, 2013, Case Rep Transplant, V2013, P146347, DOI 10.1155/2013/146347; Wei CC, 2014, CELL TRANSPLANT, V23, P505, DOI 10.3727/096368914X678328	24	11	12	0	11	KOREAN SOC STEM CELL RESEARCH	BANPO-DONG	CATHOLIC UNIV KOREA 505, INST BIOMEDICAL INDUSTRY, BANPO-DONG, SEOCHO-GU 00000, SOUTH KOREA	2005-3606	2005-5447		INT J STEM CELLS	Int J. Stem Cells	MAY	2018	11	1					141	147		10.15283/ijsc17077			7	Cell & Tissue Engineering; Cell Biology	Cell Biology	GH4TE	WOS:000433396400015	29699386	Other Gold, Green Published			2021-06-18	
J	Barberini, DJ; Aleman, M; Aristizabal, F; Spriet, M; Clark, KC; Walker, NJ; Galuppo, LD; Amorim, RM; Woolard, KD; Borjesson, DL				Barberini, Danielle Jaqueta; Aleman, Monica; Aristizabal, Fabio; Spriet, Mathieu; Clark, Kaitlin C.; Walker, Naomi J.; Galuppo, Larry D.; Amorim, Rogerio Martins; Woolard, Kevin D.; Borjesson, Dori L.			Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses	STEM CELL RESEARCH & THERAPY			English	Article						Mesenchymal stem cells; Intrathecal; Neurology; Scintigraphy; Adipose tissue; Cerebrospinal fluid	SPINAL-CORD-INJURY; EQUINE PROTOZOAL MYELOENCEPHALITIS; TRAUMATIC BRAIN-INJURY; BONE-MARROW; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; IN-VIVO; NEUROLOGICAL DISEASES; DISTAL LIMB; FOLLOW-UP	Background: It is currently unknown if the intrathecal administration of a high dose of allogeneic mesenchymal stem cells (MSCs) is safe, how MSCs migrate throughout the vertebral canal after intrathecal administration, and whether MSCs are able to home to a site of injury. The aims of the study were: 1) to evaluate the safety of intrathecal injection of 100 million allogeneic adipose-derived MSCs (ASCs); 2) to assess the distribution of ASCs after atlanto-occipital (AO) and lumbosacral (LS) injection in healthy horses; and 3) to determine if ASCs homed to the site of injury in neurologically diseased horses. Methods: Six healthy horses received 100 x 10(6) allogeneic ASCs via AO (n = 3) or LS injection (n = 3). For two of these horses, ASCs were radiolabeled with technetium and injected AO (n = 1) or LS (n = 1). Neurological examinations were performed daily, and blood and cerebrospinal fluid (CSF) were evaluated prior to and at 30 days after injection. Scintigraphic images were obtained immediately postinjection and at 30 mins, 1 h, 5 h, and 24 h after injection. Three horses with cervical vertebral compressive myelopathy (CVCM) received 100 x 106 allogeneic ASCs labeled with green fluorescent protein (GFP) via AO injection and were euthanized 1-2 weeks after injection for a full nervous system necropsy. CSF parameters were compared using a paired student's t test. Results: There were no significant alterations in blood, CSF, or neurological examinations at any point after either AO or LS ASC injections into healthy horses. The radioactive signal could be identified all the way to the lumbar area after AO ASC injection. After LS injection, the signal extended caudally but only a minimal radioactive signal extended further cranially. GFP-labeled ASCs were not present at the site of disease at either 1 or 2 weeks following intrathecal administration. Conclusions: The intrathecal injection of allogeneic ASCs was safe and easy to perform in horses. The AO administration of ASCs resulted in better distribution within the entire subarachnoid space in healthy horses. ASCs could not be found after 7 or 15 days of injection at the site of injury in horses with CVCM.	[Barberini, Danielle Jaqueta; Clark, Kaitlin C.; Walker, Naomi J.; Woolard, Kevin D.; Borjesson, Dori L.] Univ Calif Davis, Vet Inst Regenerat Cures, Davis, CA 95616 USA; [Barberini, Danielle Jaqueta; Clark, Kaitlin C.; Walker, Naomi J.; Woolard, Kevin D.; Borjesson, Dori L.] Univ Calif Davis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; [Aleman, Monica] Univ Calif Davis, Dept Med & Epidemiol, Davis, CA 95616 USA; [Aristizabal, Fabio; Spriet, Mathieu; Galuppo, Larry D.] Univ Calif Davis, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Amorim, Rogerio Martins] Sao Paulo State Univ Julio de Mesquita Filho UNES, Dept Vet Clin, Botucatu, SP, Brazil	Borjesson, DL (corresponding author), Univ Calif Davis, Vet Inst Regenerat Cures, Davis, CA 95616 USA.; Borjesson, DL (corresponding author), Univ Calif Davis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA.	dlborjesson@ucdavis.edu	Amorim, Rogerio Martins/C-1713-2012	Amorim, Rogerio Martins/0000-0003-3750-5857	Center for Equine Health; State of California satellite wagering fund; Sao Paulo Research Foundation (FAPESP/CAPES), Brazil [2014/20550-8]	This project was supported by a generous gift from the Haas Family and by the Center for Equine Health with funds provided by the State of California satellite wagering fund and contributions by private donors. Danielle J. Barberini was supported by grant #2014/20550-8, Sao Paulo Research Foundation (FAPESP/CAPES), Brazil. The funding agencies played no role in the development of the study, collection, analysis and interpretation of the data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.	Aleman M, 2007, JAVMA-J AM VET MED A, V230, P378, DOI 10.2460/javma.230.3.378; Audigie F, 2004, VET RADIOL ULTRASOUN, V45, P340, DOI 10.1111/j.1740-8261.2004.04065.x; Bauer G, 2008, MOL THER, V16, P1308, DOI 10.1038/mt.2008.93; Carrade DD, 2012, CELL MED, V4, P1, DOI 10.3727/215517912X647217; Carvalho AM, 2014, EQUINE VET J, V46, P635, DOI 10.1111/evj.12173; Chen BKK, 2015, TRANSFUSION, V55, P1013, DOI 10.1111/trf.12938; Cohen JA, 2013, J NEUROL SCI, V333, P43, DOI 10.1016/j.jns.2012.12.009; Cole C, 2014, TREATMENT EQUINE NER, P192; Dang SP, 2014, AUTOPHAGY, V10, P1301, DOI 10.4161/auto.28771; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Dubey JP, 2015, VET PARASITOL, V209, P1, DOI 10.1016/j.vetpar.2015.01.026; Galleu A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7828; Gershwin LJ, 2012, VACCINE, V30, P7615, DOI 10.1016/j.vaccine.2012.10.029; Glavaski-Joksimovic A, 2013, EXP NEUROL, V247, P25, DOI 10.1016/j.expneurol.2013.03.016; Harris VK, 2012, J NEUROL SCI, V313, P167, DOI 10.1016/j.jns.2011.08.036; Hu DZ, 2004, CHINESE MED J-PEKING, V117, P1576; Jarocha D, 2015, CELL TRANSPLANT, V24, P661, DOI 10.3727/096368915X687796; Johnson AL, 2013, J VET INTERN MED, V27, P596, DOI 10.1111/jvim.12061; Johnson PJ, 2000, EQUINE VET EDUC, V12, P7, DOI 10.1111/j.2042-3292.2000.tb01755.x; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Jung DI, 2009, J NEUROL SCI, V285, P67, DOI 10.1016/j.jns.2009.05.027; Karussis D, 2013, J NEUROL SCI, V324, P1, DOI 10.1016/j.jns.2012.09.031; Kerkis I, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0248-1; Kishk NA, 2013, J CLIN NEUROSCI, V20, P304, DOI 10.1016/j.jocn.2012.04.013; Laroni A, 2015, IMMUNOL LETT, V168, P183, DOI 10.1016/j.imlet.2015.08.007; Lee HJ, 2012, NEUROBIOL AGING, V33, P588, DOI 10.1016/j.neurobiolaging.2010.03.024; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Levine JM, 2008, JAVMA-J AM VET MED A, V233, P1453, DOI 10.2460/javma.233.9.1453; Li Y, 2012, BLOOD, V120, P3436, DOI 10.1182/blood-2012-03-420612; Liang J, 2009, MULT SCLER J, V15, P644, DOI 10.1177/1352458509104590; Lin P, 2014, MOL THER, V22, P160, DOI 10.1038/mt.2013.221; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Liu J, 2013, CYTOTHERAPY, V15, P185, DOI 10.1016/j.jcyt.2012.09.005; Liu M, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0319-y; Lunn D. P., 1989, Equine Veterinary Education, V1, P94, DOI 10.1111/j.2042-3292.1989.tb01355.x; Maia L, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0361-5; MAYHEW IG, 1975, CORNELL VET, V65, P500; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Meyerrose TE, 2008, STEM CELLS, V26, P1713, DOI 10.1634/stemcells.2008-0008; Meyerrose TE, 2007, STEM CELLS, V25, P220, DOI 10.1634/stemcells.2006-0243; Nauta AJ, 2006, BLOOD, V108, P2114, DOI 10.1182/blood-2005-11-011650; Noth U, 2010, ADV DRUG DELIVER REV, V62, P765, DOI 10.1016/j.addr.2010.04.004; Owens SD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5830103; Pease A, 2012, VET RADIOL ULTRASOUN, V53, P92, DOI 10.1111/j.1740-8261.2011.01855.x; Pezzanite LM, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0053-x; Pusterla N, 2014, VET J, V200, P332, DOI 10.1016/j.tvjl.2014.03.014; Reed SM, 2016, J VET INTERN MED, V30, P491, DOI 10.1111/jvim.13834; Reed S, 2008, EQUINE NEUROLOGY, P283; Sahraian MA, 2014, ARCH NEUROSCI, V1, P71, DOI 10.5812/archneurosci.13687; Sato M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3735; Satti HS, 2016, CYTOTHERAPY, V18, P518, DOI 10.1016/j.jcyt.2016.01.004; Schwarz B, 2006, EQUINE VET EDUC, V18, P243, DOI 10.1111/j.2042-3292.2006.tb00456.x; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Silver J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020602; Singh Udai P, 2010, Front Biosci (Schol Ed), V2, P993; Sole A, 2013, EQUINE VET J, V45, P726, DOI 10.1111/evj.12063; Sole A, 2012, EQUINE VET J, V44, P594, DOI 10.1111/j.2042-3306.2011.00530.x; Spriet M, 2015, VET RADIOL ULTRASOUN, V56, P327, DOI 10.1111/vru.12243; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Vernau W, 2008, CLINICAL BIOCHEMISTRY OF DOMESTIC ANIMALS, 6TH EDITION, P769, DOI 10.1016/B978-0-12-370491-7.00026-X; Villanova M, 2015, AM J PHYS MED REHAB, V94, P410, DOI 10.1097/PHM.0000000000000309; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Xia P, 2015, INT ORTHOP, V39, P2363, DOI 10.1007/s00264-015-2785-8; Yousefifard M, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0295-2; Zeira O, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0402-9; Zhang J, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0240-9	67	11	11	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	APR 10	2018	9								96	10.1186/s13287-018-0849-6			11	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	GC4DX	WOS:000429735100002	29631634	DOAJ Gold, Green Published			2021-06-18	
J	van Hedel, HJA; Severini, G; Scarton, A; O'Brien, A; Reed, T; Gaebler-Spira, D; Egan, T; Meyer-Heim, A; Graser, J; Chua, K; Zutter, D; Schweinfurther, R; Moller, JC; Paredes, LP; Esquenazi, A; Berweck, S; Schroeder, S; Warken, B; Chan, A; Devers, A; Petioky, J; Paik, NJ; Kim, WS; Bonato, P; Boninger, M				van Hedel, Hubertus J. A.; Severini, Giacomo; Scarton, Alessandra; O'Brien, Anne; Reed, Tamsin; Gaebler-Spira, Deborah; Egan, Tara; Meyer-Heim, Andreas; Graser, Judith; Chua, Karen; Zutter, Daniel; Schweinfurther, Raoul; Moller, J. Carsten; Paredes, Liliana P.; Esquenazi, Alberto; Berweck, Steffen; Schroeder, Sebastian; Warken, Birgit; Chan, Anne; Devers, Amber; Petioky, Jakub; Paik, Nam-Jong; Kim, Won-Seok; Bonato, Paolo; Boninger, Michael		ARTIC network	Advanced Robotic Therapy Integrated Centers (ARTIC): an international collaboration facilitating the application of rehabilitation technologies	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							SPINAL-CORD-INJURY; SUBACUTE STROKE PATIENTS; DRIVEN GAIT ORTHOSIS; CEREBRAL-PALSY; INTERRATER RELIABILITY; WALKING ABILITY; CHILDREN; PREVALENCE; CLASSIFICATION; RECOVERY	Background: The application of rehabilitation robots has grown during the last decade. While meta-analyses have shown beneficial effects of robotic interventions for some patient groups, the evidence is less in others. We established the Advanced Robotic Therapy Integrated Centers (ARTIC) network with the goal of advancing the science and clinical practice of rehabilitation robotics. The investigators hope to exploit variations in practice to learn about current clinical application and outcomes. The aim of this paper is to introduce the ARTIC network to the clinical and research community, present the initial data set and its characteristics and compare the outcome data collected so far with data from prior studies. Methods: ARTIC is a pragmatic observational study of clinical care. The database includes patients with various neurological and gait deficits who used the driven gait orthosis Lokomat (R) as part of their treatment. Patient characteristics, diagnosis-specific information, and indicators of impairment severity are collected. Core clinical assessments include the 10-Meter Walk Test and the Goal Attainment Scaling. Data from each Lokomat (R) training session are automatically collected. Results: At time of analysis, the database contained data collected from 595 patients (cerebral palsy: n = 208; stroke: n = 129; spinal cord injury: n = 93; traumatic brain injury: n = 39; and various other diagnoses: n = 126). At onset, average walking speeds were slow. The training intensity increased from the first to the final therapy session and most patients achieved their goals. Conclusions: The characteristics of the patients matched epidemiological data for the target populations. When patient characteristics differed from epidemiological data, this was mainly due to the selection criteria used to assess eligibility for Lokomat (R) training. While patients included in randomized controlled interventional trials have to fulfill many inclusion and exclusion criteria, the only selection criteria applying to patients in the ARTIC database are those required for use of the Lokomat (R). We suggest that the ARTIC network offers an opportunity to investigate the clinical application and effectiveness of rehabilitation technologies for various diagnoses. Due to the standardization of assessments and the use of a common technology, this network could serve as a basis for researchers interested in specific interventional studies expanding beyond the Lokomat (R).	[van Hedel, Hubertus J. A.; Meyer-Heim, Andreas; Graser, Judith] Univ Childrens Hosp Zurich, Rehabil Ctr Children & Adolescents, Muhlebergstr 104, CH-8910 Affoltern Am Albis, Switzerland; [Severini, Giacomo; Scarton, Alessandra; O'Brien, Anne; Bonato, Paolo] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA; [Severini, Giacomo] Univ Coll Dublin, Dublin, Ireland; [Reed, Tamsin] Wellington Hosp, Acute Neurol Rehabil Unit, London, England; [Gaebler-Spira, Deborah; Egan, Tara] Shirley Ryan AbilityLab, Chicago, IL USA; [Chua, Karen] Tan Tock Seng Hosp Rehabil Ctr, Singapore, Singapore; [Zutter, Daniel; Schweinfurther, Raoul; Moller, J. Carsten; Paredes, Liliana P.] Rehaklin Zihlschlacht, Ctr Neurol Rehabil, Zihlschlacht, Switzerland; [Esquenazi, Alberto] MossRehab, Dept Phys Med & Rehabil, Philadelphia, PA USA; [Berweck, Steffen] Schon Klin Vogtareuth, Epilepsy Ctr Children & Adolescents, Clin Neuropediat & Neurol Rehabil, Vogtareuth, Germany; [Schroeder, Sebastian; Warken, Birgit] Ludwig Maximilians Univ Munchen, Hauner Childrens Hosp, Paediat Neurol Dev Med & Social Paediat, Munich, Germany; [Chan, Anne; Devers, Amber] Sheltering Arms Phys Rehabil Ctr, Richmond, VA USA; [Petioky, Jakub] Rehabil Ctr Kladruby, Kladruby, Czech Republic; [Paik, Nam-Jong; Kim, Won-Seok] Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, Seongnam, South Korea; [Boninger, Michael] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Boninger, Michael] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA	van Hedel, HJA (corresponding author), Univ Childrens Hosp Zurich, Rehabil Ctr Children & Adolescents, Muhlebergstr 104, CH-8910 Affoltern Am Albis, Switzerland.	hubertus.vanhedel@kispi.uzh.ch	/AAW-2804-2020; , 김원석/AAJ-2334-2020; Berweck, Steffen/N-1422-2013; van Hedel, Hubertus/AAL-3818-2021; Bonato, Paolo/AAH-6111-2019	/0000-0003-2619-765X; , 김원석/0000-0002-1199-5707; Bonato, Paolo/0000-0002-1818-1714; Wee, Seng Kwee/0000-0002-5206-6269; Graser, Judith/0000-0002-9921-8581; van Hedel, Hubertus/0000-0002-9577-5049; Aurich (-Schuler), Tabea/0000-0002-1724-6846; Severini, Giacomo/0000-0002-2289-9331; Paik, Nam-Jong/0000-0002-5193-8678	Hocoma AG, Volketswil, Switzerland; Swiss Foundation for Children with Cerebral Palsy; Maxi-Foundation	Funding for meetings in person has been financed by institutional or third party money of each network member. Hocoma AG, Volketswil, Switzerland (company) currently supports this network by means of financial support for programming the database and online meetings. Hocoma also provided personnel resources to aid communication between network members. Grants were obtained from the Swiss Foundation for Children with Cerebral Palsy and the Maxi-Foundation to further develop the database.	Alcobendas-Maestro M, 2012, NEUROREHAB NEURAL RE, V26, P1058, DOI 10.1177/1545968312448232; Arnao V, 2016, INT J STROKE, V11, P287, DOI 10.1177/1747493016632245; Aurich T, 2015, NEUROPEDIATRICS, V46, P248, DOI 10.1055/s-0035-1550150; Aurich-Schuler T, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0287-1; Bang DH, 2016, NEUROREHABILITATION, V38, P343, DOI 10.3233/NRE-161325; Bax M, 2005, DEV MED CHILD NEUROL, V47, P571, DOI 10.1017/S001216220500112X; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Bouwens SFM, 2009, CLIN REHABIL, V23, P310, DOI 10.1177/0269215508101744; Boyd LA, 2017, INT J STROKE, V12, P480, DOI 10.1177/1747493017714176; Brutsch K, 2011, J REHABIL MED, V43, P493, DOI 10.2340/16501977-0802; Center NSCIS, 2016, COMPL PUBL VERS 2016; Christensen D, 2014, DEV MED CHILD NEUROL, V56, P59, DOI 10.1111/dmcn.12268; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Curt A, 2004, SPINAL CORD, V42, P1, DOI 10.1038/sj.sc.3101558; Dorenkamp S, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00067; Druzbicki M, 2013, J REHABIL MED, V45, P358, DOI 10.2340/16501977-1114; Esclarin-Ruz A, 2014, ARCH PHYS MED REHAB, V95, P1023, DOI 10.1016/j.apmr.2013.12.017; Esquenazi A, 2013, PM&R, V5, P280, DOI 10.1016/j.pmrj.2012.10.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085; Field-Fote EC, 2011, PHYS THER, V91, P48, DOI 10.2522/ptj.20090359; Gandhi P, 2017, J NEUROTRAUM, V34, P1713, DOI 10.1089/neu.2016.4501; Graser JV, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0538-y; Gregson JM, 2000, AGE AGEING, V29, P223, DOI 10.1093/ageing/29.3.223; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1055/s-0041-111066, 10.1136/bmj.g1687]; Hurn J, 2006, CLIN REHABIL, V20, P756, DOI 10.1177/0269215506070793; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelley CP, 2013, DISABIL REHABIL-ASSI, V8, P161, DOI 10.3109/17483107.2012.714052; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Labruyere R, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-4; Labruyere R, 2013, RES DEV DISABIL, V34, P3906, DOI 10.1016/j.ridd.2013.07.031; Lam T, 2015, J REHABIL RES DEV, V52, P113, DOI 10.1682/JRRD.2014.03.0090; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; Mehrholz J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub4; Mehrholz J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006876.pub4; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub3; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Ornstein SM, 2013, J AM BOARD FAM MED, V26, P518, DOI 10.3122/jabfm.2013.05.130012; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Rossier P, 2001, ARCH PHYS MED REHAB, V82, P9, DOI 10.1053/apmr.2001.9396; Salbach NM, 2001, ARCH PHYS MED REHAB, V82, P1204, DOI 10.1053/apmr.2001.24907; Schuler TA, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-78; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; Sellier E, 2010, EUR J EPIDEMIOL, V25, P635, DOI 10.1007/s10654-010-9474-0; Steenbeek D, 2005, CLIN REHABIL, V19, P274, DOI 10.1191/0269215505cr859oa; Steenbeek D, 2007, DEV MED CHILD NEUROL, V49, P550, DOI 10.1111/j.1469-8749.2007.00550.x; Steenbeek D, 2010, ARCH PHYS MED REHAB, V91, P429, DOI 10.1016/j.apmr.2009.10.013; Swinnen E, 2014, TOP STROKE REHABIL, V21, P87, DOI 10.1310/tsr2102-87; Swinnen E, 2012, MULT SCLER INT, V2012, DOI 10.1155/2012/240274; Swinnen E, 2010, J REHABIL MED, V42, P520, DOI 10.2340/16501977-0538; Tollanes MC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012777; Traumatic Brain Injury Model Systems National Data and Statistical Center, 2016, NAT DAT 2016 PROF PE; van Hedel H, 2006, SPINAL CORD, V44, P352, DOI 10.1038/sj.sc.3101853; van Hedel HJ, 2005, ARCH PHYS MED REHAB, V86, P190, DOI 10.1016/j.apmr.2004.02.010; van Hedel HJA, 2009, NEUROREHAB NEURAL RE, V23, P343, DOI 10.1177/1545968308324224; van Kammen K, 2016, CLIN BIOMECH, V36, P65, DOI 10.1016/j.clinbiomech.2016.04.013; van Nunen MPM, 2015, DISABIL REHABIL-ASSI, V10, P141, DOI 10.3109/17483107.2013.873489; Veerbeek JM, 2014, KNGF CLIN PRACTICE G; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Wallard L, 2017, EUR J PAEDIATR NEURO, V21, P557, DOI 10.1016/j.ejpn.2017.01.012; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Whiteneck G, 2009, J SPINAL CORD MED, V32, P249; Wirz M, 2017, J NEUROTRAUM, V34, P1891, DOI 10.1089/neu.2016.4643	66	11	11	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1743-0003		J NEUROENG REHABIL	J. NeuroEng. Rehabil.	APR 6	2018	15								30	10.1186/s12984-018-0366-y			16	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	GC7WD	WOS:000430003200001	29625628	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Busl, KM				Busl, Katharina Maria			Nosocomial Infections in the Neurointensive Care Unit	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Nosocomial infections; Hospital -acquired pneumonia; Ventriculitis; Urinary tract infection; EVD-related infection	TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; LENGTH-OF-STAY; VENTILATOR-ASSOCIATED PNEUMONIA; HOSPITAL-ACQUIRED PNEUMONIA; DELAYED CEREBRAL-ISCHEMIA; NEUROSURGICAL BACTERIAL-MENINGITIS; ANEURYSMAL SUBARACHNOID HEMORRHAGE; VENTRICULOSTOMY-RELATED INFECTIONS; CLOSTRIDIUM-DIFFICILE INFECTIONS	Infectious complications in the neurointensive care unit (neuro-ICU) are common, including pneumonia, urinary tract infection, bloodstream infection, and intracranial infection. The neuro-ICU population poses a specific challenge in the diagnosis of infections, because of the high incidence of fever in acutely brain injured patients. Furthermore, susceptibility to infections is likely enhanced by brain injury (induced immune modulation). This article reviews the concept of brain injury-induced immune modulation, and summarizes available data and knowledge on nosocomial meningitis and ventriculitis, and systemic infectious complications in patients with traumatic brain injury, ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and status epilepticus.	[Busl, Katharina Maria] Univ Florida, Dept Neurol, Coll Med, McKnight Brain Inst L3-100,1149 Newell Dr, Gainesville, FL 32610 USA	Busl, KM (corresponding author), Univ Florida, Dept Neurol, Coll Med, McKnight Brain Inst L3-100,1149 Newell Dr, Gainesville, FL 32610 USA.	Katharina.busl@neurology.ufl.edu					Ala-Kokko TI, 2006, ANAESTH INTENS CARE, V34, P639, DOI 10.1177/0310057X0603400509; Alleyne CH, 2000, NEUROSURGERY, V47, P1124, DOI 10.1097/00006123-200011000-00020; Alsumrain M, 2013, J INTENSIVE CARE MED, V28, P118, DOI 10.1177/0885066612437512; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Arabi Y, 2005, AM J INFECT CONTROL, V33, P137, DOI 10.1016/j.ajic.2004.11.008; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Aslanyan S, 2004, EUR J NEUROL, V11, P49, DOI 10.1046/j.1468-1331.2003.00749.x; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Badjatia N, 2010, NEUROSURGERY, V66, P696, DOI 10.1227/01.NEU.0000367618.42794.AA; Bakovic D, 2013, CLIN PHYSIOL FUNCT I, V33, P30, DOI 10.1111/j.1475-097X.2012.01156.x; Beer R, 2008, J NEUROL, V255, P1617, DOI 10.1007/s00415-008-0059-8; Beer R, 2010, CURR OPIN CRIT CARE, V16, P117, DOI 10.1097/MCC.0b013e328338cb5f; Beer R, 2009, NEUROCRIT CARE, V10, P363, DOI 10.1007/s12028-008-9155-y; Bellinger DL, 2008, CELL IMMUNOL, V252, P27, DOI 10.1016/j.cellimm.2007.09.005; Bercault N, 2001, CRIT CARE MED, V29, P2303, DOI 10.1097/00003246-200112000-00012; Berger C, 2002, CRIT CARE MED, V30, P1778, DOI 10.1097/00003246-200208000-00017; Bhimraj A, 2012, CLEV CLIN J MED, V79, P393, DOI 10.3949/ccjm.79gr.12003; Bleck TP, 2010, EPILEPSY CURR, V10, P31, DOI 10.1111/j.1535-7511.2009.01345.x; Blomstedt G C, 1992, Neurosurg Clin N Am, V3, P375; Bobo LD, 2011, CHEST, V140, P1643, DOI 10.1378/chest.11-0556; Bociaga-Jasik M, 2012, ADV MED SCI-POLAND, V57, P142, DOI 10.2478/v10039-012-0013-y; Boehme AK, 2013, J STROKE CEREBROVASC, V22, pE582, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.020; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; Bratzler Dale W, 2013, Am J Health Syst Pharm, V70, P195, DOI 10.2146/ajhp120568; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Brouwer MC, 2012, LANCET, V380, P1684, DOI 10.1016/S0140-6736(12)61185-4; Brown EM, 2000, BRIT J NEUROSURG, V14, P7; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Camacho EF, 2011, INFECTION, V39, P47, DOI 10.1007/s15010-010-0073-5; Cardozo Júnior Luis Carlos Maia, 2014, Rev. bras. ter. intensiva, V26, P148, DOI 10.5935/0103-507X.20140022; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Cazzadori A, 1997, RESP MED, V91, P193, DOI 10.1016/S0954-6111(97)90038-X; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chamorro A, 2007, J NEUROL SCI, V252, P29, DOI 10.1016/j.jns.2006.10.001; Chang LL, 2011, BRAIN BEHAV IMMUN, V25, P260, DOI 10.1016/j.bbi.2010.09.017; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Chauv S, 2016, NEUROCRIT CARE, V25, P128, DOI 10.1007/s12028-016-0254-x; Chen C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101961; Chen YY, 2005, INFECT CONT HOSP EP, V26, P281, DOI 10.1086/502540; Chen ZQ, 2012, CLIN CHIM ACTA, V413, P1512, DOI 10.1016/j.cca.2012.06.018; Chumbler NR, 2010, NEUROEPIDEMIOLOGY, V34, P193, DOI 10.1159/000289350; Cinotti R, 2014, EUR J CLIN MICROBIOL, V33, P823, DOI 10.1007/s10096-013-2020-8; Citerio G, 2015, CRIT CARE MED, V43, P1630, DOI 10.1097/CCM.0000000000001019; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; Conen A, 2008, CLIN INFECT DIS, V47, P73, DOI 10.1086/588298; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Coutinho LG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-326; Crabtree SJ, 2011, BURNS, V37, P42, DOI 10.1016/j.burns.2010.06.008; Croce MA, 2013, J TRAUMA ACUTE CARE, V74, P354, DOI 10.1097/TA.0b013e31827a0c65; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; de Almeida SM, 2009, CLIN CHEM LAB MED, V47, P755, DOI 10.1515/CCLM.2009.160; Dellit TH, 2014, INFECT CONT HOSP EP, V35, P589, DOI 10.1086/675828; Desai A, 2009, J NEUROS-PEDIATR, V4, P184, DOI 10.3171/2009.4.PEDS08279; Dettenkofer M, 1999, ACTA NEUROCHIR, V141, P1303, DOI 10.1007/s007010050434; Dettenkofer M, 2001, J NEUROL, V248, P959, DOI 10.1007/s004150170048; Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4; Ding RY, 2000, DYSPHAGIA, V15, P51, DOI 10.1007/s004550010001; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; Divani AA, 2015, NEUROCRIT CARE, V22, P234, DOI 10.1007/s12028-014-0065-x; Douds GL, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/479865; Dziedzic T, 2007, J NEUROL SCI, V252, P53, DOI 10.1016/j.jns.2006.10.007; Dziewas R, 2004, J NEUROL NEUROSUR PS, V75, P852, DOI 10.1136/jnnp.2003.019075; Emerson CB, 2012, INFECT CONT HOSP EP, V33, P539, DOI 10.1086/665725; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Enderson BL, 2007, J TRAUMA, V62, P33; Fichtner J, 2010, J NEUROSURG, V112, P840, DOI 10.3171/2009.8.JNS091297; Flibotte JJ, 2004, NEUROCRIT CARE, V1, P61, DOI 10.1385/NCC:1:1:61; Foreman PM, 2016, J NEUROSURG, V125, P1383, DOI 10.3171/2015.10.JNS151959; Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA; Fukui MB, 2001, AM J NEURORADIOL, V22, P1510; Garey KW, 2008, J HOSP INFECT, V70, P142, DOI 10.1016/j.jhin.2008.06.026; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P794, DOI 10.1001/archsurg.2011.41; Grau AJ, 1999, J NEUROL SCI, V171, P115, DOI 10.1016/S0022-510X(99)00261-0; Griesshammer M, 1999, J INTERN MED, V245, P295, DOI 10.1046/j.1365-2796.1999.00452.x; Haeusler KG, 2008, CEREBROVASC DIS, V25, P50, DOI 10.1159/000111499; Hallevi H, 2008, NEUROLOGY, V70, P848, DOI 10.1212/01.wnl.0000304930.47751.75; Hamidon B. B., 2003, SMJ Singapore Medical Journal, V44, P344; Hanna H, 2004, INFECT CONT HOSP EP, V25, P646, DOI 10.1086/502455; Hannawi Y, 2013, CEREBROVASC DIS, V35, P430, DOI 10.1159/000350199; Heimes J, 2011, SURG INFECT, V12, P99, DOI 10.1089/sur.2009.028; Higgins TL, 2003, CRIT CARE MED, V31, P45, DOI 10.1097/00003246-200301000-00007; Hilker R, 2003, STROKE, V34, P975, DOI 10.1161/01.STR.0000063373.70993.CD; Hinduja A, 2015, AM J CRIT CARE, V24, P227, DOI 10.4037/ajcc2015422; Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9; Hoffmann S, 2012, STROKE, V43, P2617, DOI 10.1161/STROKEAHA.112.653055; Holevar M, 2009, J TRAUMA, V67, P870, DOI 10.1097/TA.0b013e3181b5a960; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Hopkins SJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-255; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Howitz MF, 2014, EPIDEMIOL INFECT, V142, P1300, DOI 10.1017/S0950268813001878; Hug A, 2009, STROKE, V40, P3226, DOI 10.1161/STROKEAHA.109.557967; Hull E, 2017, CLIN NEUROL NEUROSUR, V157, P95, DOI 10.1016/j.clineuro.2017.03.021; Hwang BY, 2010, NEUROCRIT CARE, V13, P141, DOI 10.1007/s12028-010-9382-x; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ingeman A, 2011, STROKE, V42, P3214, DOI 10.1161/STROKEAHA.110.610881; Jacobs DG, 1998, J NATL MED ASSOC, V90, P417; Ji RJ, 2014, STROKE, V45, P2620, DOI 10.1161/STROKEAHA.114.005023; Ji RJ, 2013, CRIT CARE, V17, DOI 10.1186/cc13130; Ji RJ, 2013, STROKE, V44, P1303, DOI 10.1161/STROKEAHA.111.000598; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jovanovic B, 2015, INT J INFECT DIS, V38, P46, DOI 10.1016/j.ijid.2015.07.005; Kammersgaard L P, 2001, J Stroke Cerebrovasc Dis, V10, P217, DOI 10.1053/jscd.2001.30366; Kasius KM, 2010, CEREBROVASC DIS, V29, P576, DOI 10.1159/000306645; Katzan IL, 2007, NEUROLOGY, V68, P1938, DOI 10.1212/01.wnl.0000263187.08969.45; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; Kenneally C, 2007, CHEST, V132, P418, DOI 10.1378/chest.07-0202; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kestle JRW, 2006, J NEUROSURG, V105, P177, DOI 10.3171/ped.2006.105.3.177; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim JH, 2012, WORLD NEUROSURG, V77, P135, DOI 10.1016/j.wneu.2011.04.017; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; KORINEK AM, 1992, ANN FR ANESTH, V11, P711, DOI 10.1016/S0750-7658(05)80795-6; Korinek AM, 2006, NEUROSURGERY, V59, P126, DOI 10.1227/01.NEU.0000220477.47323.92; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kourbeti IS, 2015, J NEUROSURG, V122, P1113, DOI 10.3171/2014.8.JNS132557; Kourbeti IS, 2011, BRIT J NEUROSURG, V25, P9, DOI 10.3109/02688697.2010.500411; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Kwan J, 2007, ACTA NEUROL SCAND, V115, P331, DOI 10.1111/j.1600-0404.2006.00783.x; Kwon HM, 2006, AM J INFECT CONTROL, V34, P64, DOI 10.1016/j.ajic.2005.06.011; Laban KG, 2015, INT J STROKE, V10, P763, DOI 10.1111/ijs.12494; LABORDE G, 1993, ANAESTHESIST, V42, P724; Lackner P, 2008, NEUROCRIT CARE, V8, P360, DOI 10.1007/s12028-008-9071-1; Lakshminarayan K, 2010, STROKE, V41, P2849, DOI 10.1161/STROKEAHA.110.597039; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Launey Y, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0689-4; Leib SL, 1999, CLIN INFECT DIS, V29, P69, DOI 10.1086/520184; Li YR, 2015, CLIN BIOCHEM, V48, P50, DOI 10.1016/j.clinbiochem.2014.10.007; Liu ZH, 2015, CRIT CARE MED, V43, P2416, DOI 10.1097/CCM.0000000000001188; Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378; Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639; Lozier AP, 2008, NEUROSURGERY, V62, P688, DOI [10.1227/01.NEU.0000017465.78245.6C, 10.1227/01.neu.0000316273.35833.7c]; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492; MAHE V, 1995, ANN FR ANESTH, V14, P8, DOI 10.1016/S0750-7658(05)80144-3; Maramattom BV, 2006, NEUROCRIT CARE, V5, P115, DOI 10.1385/NCC:5:2:115; Marciniak C, 2009, AM J PHYS MED REHAB, V88, P30, DOI 10.1097/PHM.0b013e3181909b73; Marra AR, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-42; Martinez R, 2002, INTENS CARE MED, V28, P208, DOI 10.1007/s00134-001-1176-3; Martino R, 2005, STROKE, V36, P2756, DOI 10.1161/01.STR.0000190056.76543.eb; May Addison K, 2006, Surg Infect (Larchmt), V7, P409, DOI 10.1089/sur.2006.7.409; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; McClelland S, 2007, CLIN INFECT DIS, V45, P55, DOI 10.1086/518580; McDonald LC, 2006, EMERG INFECT DIS, V12, P409, DOI 10.3201/eid1203.051064; McMahon CJ, 2013, J NEUROINTERV SURG, V5, P512, DOI 10.1136/neurintsurg-2012-010386; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; MOLLMAN HD, 1986, J NEUROSURG, V64, P902, DOI 10.3171/jns.1986.64.6.0902; Monton C, 1999, CRIT CARE MED, V27, P1745, DOI 10.1097/00003246-199909000-00008; Moore F, 2013, J TRAUMA ACUTE CARE, V74, P360; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mracsko E, 2014, BRAIN BEHAV IMMUN, V41, P200, DOI 10.1016/j.bbi.2014.05.015; Munoz-Gomez S, 2015, HEART LUNG, V44, P158, DOI 10.1016/j.hrtlng.2015.01.003; Muroi C, 2013, NEUROSURGERY, V72, P367, DOI 10.1227/NEU.0b013e31828048ce; Musa SA, 2010, NEUROCRIT CARE, V13, P87, DOI 10.1007/s12028-010-9374-x; Musa SA, 2011, J CARDIOTHOR VASC AN, V25, P263, DOI 10.1053/j.jvca.2010.05.004; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; Muttaiyah S, 2008, J MED MICROBIOL, V57, P207, DOI 10.1099/jmm.0.47518-0; NAROTAM PK, 1994, NEUROSURGERY, V34, P409, DOI 10.1227/00006123-199403000-00004; Oda S, 2005, CYTOKINE, V29, P169, DOI 10.1016/j.cyto.2004.10.010; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; OHGA S, 1994, ARCH DIS CHILD, V70, P123, DOI 10.1136/adc.70.2.123; Ohwaki K, 2008, NEUROCRIT CARE, V8, P271, DOI 10.1007/s12028-007-9007-1; Ovbiagele Bruce, 2006, J Stroke Cerebrovasc Dis, V15, P209; PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786; Maskin LP, 2013, CLIN NEUROL NEUROSUR, V115, P1820, DOI 10.1016/j.clineuro.2013.05.034; Pegoli M, 2015, J NEUROSURG, V122, P414, DOI 10.3171/2014.10.JNS14290; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Pfausler B, 2004, ACTA NEUROCHIR, V146, P477, DOI 10.1007/s00701-004-0258-8; Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Poon WS, 1998, ACT NEUR S, V71, P146; Prasad R, 2014, PEDIATR NEUROL, V50, P60, DOI 10.1016/j.pediatrneurol.2013.08.016; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Prass K, 2006, STROKE, V37, P2607, DOI 10.1161/01.STR.0000240409.68739.2b; Pryor JP, 2007, J TRAUMA, V62, P61; Raad I, 2007, LANCET INFECT DIS, V7, P645, DOI 10.1016/S1473-3099(07)70235-9; Ramanan M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0712-z; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Razine Rachid, 2012, Int Arch Med, V5, P26, DOI 10.1186/1755-7682-5-26; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Reichert MCF, 2002, AM J INFECT CONTROL, V30, P158, DOI 10.1067/mic.2002.119925; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Riquelme R, 1996, AM J RESP CRIT CARE, V154, P1450, DOI 10.1164/ajrccm.154.5.8912763; Robinson TG, 2003, STROKE, V34, P705, DOI 10.1161/01.STR.0000058493.94875.9F; Roos YBWEM, 2000, J NEUROL NEUROSUR PS, V68, P337, DOI 10.1136/jnnp.68.3.337; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Rosengart AJ, 2007, STROKE, V38, P2315, DOI 10.1161/STROKEAHA.107.484360; Saloheimo P, 2006, STROKE, V37, P487, DOI 10.1161/01.STR.0000198868.78546.fc; Saposnik G, 2008, STROKE, V39, P2522, DOI 10.1161/STROKEAHA.107.507145; Savardekar Amey, 2013, Surg Neurol Int, V4, P24, DOI 10.4103/2152-7806.107894; Schade RP, 2006, J NEUROSURG, V104, P101, DOI 10.3171/jns.2006.104.1.101; Schade RP, 2005, J NEUROSURG, V102, P229, DOI 10.3171/jns.2005.102.2.0229; Schirmer-Mikalsen K, 2013, ACTA ANAESTH SCAND, V57, P46, DOI 10.1111/j.1399-6576.2012.02785.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoch B, 2008, ZBL NEUROCHIR, V69, P80, DOI 10.1055/s-2007-1022559; Schultz M, 1993, J Neurosci Nurs, V25, P158; Seguin P, 2014, CRIT CARE MED, V42, P1, DOI 10.1097/CCM.0b013e3182a2770f; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Sellars C, 2007, STROKE, V38, P2284, DOI 10.1161/STROKEAHA.106.478156; SHAFER SQ, 1993, J NATL MED ASSOC, V85, P31; Singh TD, 2017, J NEUROSURG SCI, V61, P117, DOI 10.23736/S0390-5616.16.03298-7; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Stenehjem E, 2012, INFECT DIS CLIN N AM, V26, P89, DOI 10.1016/j.idc.2011.09.006; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Sykora M, 2008, CRIT CARE MED, V36, P3074, DOI 10.1097/CCM.0b013e31818b306d; Sykora M, 2011, STROKE, V42, P1218, DOI 10.1161/STROKEAHA.110.604637; Takahashi W, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2014.02.020; Tang RB, 2001, CHILD NERV SYST, V17, P453, DOI 10.1007/s003810000422; Tarkowski E, 1998, SCAND J IMMUNOL, V47, P30; Titsworth WL, 2013, STROKE, V44, P3154, DOI 10.1161/STROKEAHA.111.000204; Tripathy S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00082; Upadya A, 2004, J CRIT CARE, V19, P16, DOI 10.1016/j.jcrc.2004.02.004; van de Beek D, 2009, ARCH NEUROL-CHICAGO, V66, P1076, DOI 10.1001/archneurol.2009.176; Vargas M, 2006, STROKE, V37, P461, DOI 10.1161/01.STR.0000199138.73365.b3; Vergouwen MDI, 2011, STROKE, V42, P3093, DOI 10.1161/STROKEAHA.111.619510; Vergouwen MDI, 2011, STROKE, V42, P924, DOI 10.1161/STROKEAHA.110.597914; Viallon A, 2011, CRIT CARE, V15, DOI 10.1186/cc10254; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Walter U, 2013, EUR J NEUROL, V20, P153, DOI 10.1111/j.1468-1331.2012.03818.x; Walter U, 2007, J NEUROL, V254, P1323, DOI 10.1007/s00415-007-0520-0; Wang F, 2013, APMIS, V121, P197, DOI 10.1111/j.1600-0463.2012.02956.x; Wang JP, 2015, BRAIN BEHAV IMMUN, V43, P172, DOI 10.1016/j.bbi.2014.07.022; Wang KW, 2013, J NEUROSURG, V118, P358, DOI 10.3171/2012.10.JNS127; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Weimar C, 2002, EUR NEUROL, V48, P133, DOI 10.1159/000065512; Weisfelt M, 2007, J HOSP INFECT, V66, P71, DOI 10.1016/j.jhin.2007.02.017; Westendorp WF, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-110; Wong GK, 2008, J CLIN NEUROSCI, V15, P654, DOI 10.1016/j.jocn.2007.03.011; Yang CC, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-289; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; Zarrouk V, 2007, CLIN INFECT DIS, V44, P1555, DOI 10.1086/518169; Ziai WC, 2006, CRIT CARE CLIN, V22, P661, DOI 10.1016/j.ccc.2006.11.009; Zolldann D, 2005, INFECT CONT HOSP EP, V26, P726, DOI 10.1086/502610; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	239	11	13	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2018	29	2					299	+		10.1016/j.nec.2017.11.008			17	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GB6MJ	WOS:000429183000010	29502719				2021-06-18	
J	Campos-Pires, R; Koziakova, M; Yonis, A; Pau, A; Macdonald, W; Harris, K; Edge, CJ; Franks, NP; Mahoney, PF; Dickinson, R				Campos-Pires, Rita; Koziakova, Mariia; Yonis, Amina; Pau, Ashni; Macdonald, Warren; Harris, Katie; Edge, Christopher J.; Franks, Nicholas P.; Mahoney, Peter F.; Dickinson, Robert			Xenon Protects against Blast-Induced Traumatic Brain Injury in an In Vitro Model	JOURNAL OF NEUROTRAUMA			English	Article						blast-induced neurotrauma; blast traumatic brain injury; neuroprotection; primary blast injury; TBI; xenon	D-ASPARTATE RECEPTOR; HIPPOCAMPAL SLICE CULTURES; CENTRAL-NERVOUS-SYSTEM; NITROUS-OXIDE; COMPETITIVE-INHIBITION; HYPOXIA-ISCHEMIA; GLYCINE SITE; ORGANOTYPIC CULTURES; TERM NEUROPROTECTION; CARDIAC-ARREST	The aim of this study was to evaluate the neuroprotective efficacy of the inert gas xenon as a treatment for patients with blast-induced traumatic brain injury in an in vitro laboratory model. We developed a novel blast traumatic brain injury model using C57BL/6N mouse organotypic hippocampal brain-slice cultures exposed to a single shockwave, with the resulting injury quantified using propidium iodide fluorescence. A shock tube blast generator was used to simulate open field explosive blast shockwaves, modeled by the Friedlander waveform. Exposure to blast shockwave resulted in significant (p < 0.01) injury that increased with peak-overpressure and impulse of the shockwave, and which exhibited a secondary injury development up to 72h after trauma. Blast-induced propidium iodide fluorescence overlapped with cleaved caspase-3 immunofluorescence, indicating that shock-wave-induced cell death involves apoptosis. Xenon (50% atm) applied 1h after blast exposure reduced injury 24h (p < 0.01), 48h (p < 0.05), and 72h (p < 0.001) later, compared with untreated control injury. Xenon-treated injured slices were not significantly different from uninjured sham slices at 24h and 72h. We demonstrate for the first time that xenon treatment after blast traumatic brain injury reduces initial injury and prevents subsequent injury development in vitro. Our findings support the idea that xenon may be a potential first-line treatment for those with blast-induced traumatic brain injury.	[Campos-Pires, Rita; Koziakova, Mariia; Yonis, Amina; Pau, Ashni; Harris, Katie; Dickinson, Robert] Imperial Coll London, Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England; [Campos-Pires, Rita; Koziakova, Mariia; Macdonald, Warren; Dickinson, Robert] Imperial Coll London, Dept Bioengn, Royal British Leg Ctr Blast Injury Studies, London, England; [Macdonald, Warren] Imperial Coll London, Dept Bioengn, London, England; [Edge, Christopher J.; Franks, Nicholas P.] Imperial Coll London, Dept Life Sci, London, England; [Edge, Christopher J.] Royal Berkshire Hosp NHS Fdn Trust, Dept Anaesthet, Reading, Berks, England; [Mahoney, Peter F.] ICT Ctr, Med Directorate Joint Force Command, Royal Ctr Def Med, Birmingham, W Midlands, England	Dickinson, R (corresponding author), Imperial Coll London, Sir Ernst Chain Bldg, London SW7 2AZ, England.	r.dickinson@imperial.ac.uk		Franks, Nicholas/0000-0003-4874-4212	Royal Centre for Defence Medicine, Birmingham, United Kingdom; Royal British Legion Centre for Blast Injury Studies, Imperial College London, United Kingdom; Medical Research Council, London, United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_PC_13064, MR/N027736/1]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_13064, MR/N027736/1, G0901892] Funding Source: researchfish	Study is supported by: Royal Centre for Defence Medicine, Birmingham, United Kingdom, Royal British Legion Centre for Blast Injury Studies, Imperial College London, United Kingdom. Medical Research Council, London, United Kingdom (MC_PC_13064; MR/N027736/1).	Abraini JH, 2005, ANN NY ACAD SCI, V1053, P289, DOI 10.1196/annals.1344.025; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Banks P, 2010, ANESTHESIOLOGY, V112, P614, DOI 10.1097/ALN.0b013e3181cea398; Bantel C, 2010, ANESTHESIOLOGY, V112, P623, DOI 10.1097/ALN.0b013e3181cf894a; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Campos-Pires R., 2016, BLAST INJURY SCI ENG, P173; Campos-Pires R, 2015, CRIT CARE MED, V43, P149, DOI 10.1097/CCM.0000000000000624; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Giacalone M, 2013, CLIN J PAIN, V29, P639, DOI 10.1097/AJP.0b013e31826b12f5; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Harris K, 2013, ANESTHESIOLOGY, V119, P1137, DOI 10.1097/ALN.0b013e3182a2a265; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Laitio R, 2016, JAMA-J AM MED ASSOC, V315, P1120, DOI 10.1001/jama.2016.1933; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Miller AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00020; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Petersen-Felix S, 1998, BRIT J ANAESTH, V81, P742, DOI 10.1093/bja/81.5.742; PITTINGER CB, 1953, ANESTHESIOLOGY, V14, P10, DOI 10.1097/00000542-195301000-00002; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Shu Y, 2010, ANESTHESIOLOGY, V113, P360, DOI 10.1097/ALN.0b013e3181d960d7; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Thoresen M, 2009, J CEREBR BLOOD F MET, V29, P707, DOI 10.1038/jcbfm.2008.163; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Vogel EW, 2016, J NEUROTRAUM, V33, P652, DOI 10.1089/neu.2015.4045; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f	50	11	13	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	8					1037	1044		10.1089/neu.2017.5360			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GC0DM	WOS:000429447100007	29285980	Green Published, Bronze			2021-06-18	
J	Peres, CMA; Caldas, JGMP; Puglia, P; de Andrade, AF; da Silva, IAF; Teixeira, MJ; Figueiredo, EG				Peres, Carlos Michel A.; Caldas, Jose Guilherme M. P.; Puglia, Paulo, Jr.; de Andrade, Almir F.; da Silva, Igor A. F.; Teixeira, Manoel J.; Figueiredo, Eberval G.			Endovascular management of acute epidural hematomas: clinical experience with 80 cases	JOURNAL OF NEUROSURGERY			English	Article						epidural hematoma; traumatic brain injury; middle meningeal artery; pseudoaneurysm; embolization; endovascular treatment; vascular disorders	MIDDLE MENINGEAL ARTERY; CHRONIC SUBDURAL-HEMATOMA; TRAUMATIC PSEUDOANEURYSM; CONSERVATIVE MANAGEMENT; NONOPERATIVE MANAGEMENT; EMBOLIZATION; HEMORRHAGE; SURGERY	OBJECTIVE Small acute epidural hematomas (EDHs) treated conservatively carry a nonmeasurable risk of late enlargement due to middle meningeal artery (MMA) lesions. Patients with EDHs need to stay hospitalized for several days, with neurological supervision and repeated CT scans. In this study, the authors analyzed the safety and efficacy of the embolization of the involved MMA and associated lesions. METHODS The study group consisted of 80 consecutive patients harboring small-to medium-sized EDHs treated by MMA embolization between January 2010 and December 2014. A literature review cohort was used as a control group. RESULTS The causes of head injury were falls, traffic-related accidents (including car, motorcycle, and pedestrian vs vehicle accidents), and assaults. The EDH topography was mainly temporal (lateral or pole). Active contrast leaking from the MMA was seen in 57.5%; arteriovenous fistulas between the MMA and diploic veins were seen in 10%; and MMA pseudoaneurysms were found in 13.6% of the cases. Embolizations were performed under local anesthesia in 80% of the cases, with N-butyl-2-cyanoacrylate, polyvinyl alcohol particles, or gelatin sponge (or a combination of these), obtaining MMA occlusion and complete resolution of the vascular lesions. All patients underwent follow-up CT scans between 1 and 7 days after the embolization. In the 80 cases in this series, no increase in size of the EDH was observed and the clinical evolution was uneventful, without Glasgow Coma Scale score modification after embolization and with no need for surgical evacuation. In contrast, the control cohort from the literature consisted of 471 patients, 82 (17.4%) of whom shifted from conservative treatment to surgical evacuation. CONCLUSIONS This study suggests that MMA embolization is a highly effective and safe method to achieve size stabilization in nonsurgically treated acute EDHs.	[Peres, Carlos Michel A.] Hosp Univ Francisca Mendes, 1085 Ave Via Lactea, BR-69060085 Manaus, AM, Brazil; [Caldas, Jose Guilherme M. P.; Puglia, Paulo, Jr.] Univ Sao Paulo, Sch Med, Div Neuroradiol, Sao Paulo, Brazil; [de Andrade, Almir F.; da Silva, Igor A. F.; Teixeira, Manoel J.; Figueiredo, Eberval G.] Univ Sao Paulo, Sch Med, Div Neurosurg, Sao Paulo, Brazil	Peres, CMA (corresponding author), Hosp Univ Francisca Mendes, 1085 Ave Via Lactea, BR-69060085 Manaus, AM, Brazil.	cmaperes@usp.br	Peres, Carlos Michel Albuquerque/E-4104-2017; Caldas, Jose Guilherme M P/M-2554-2017; Peres, Carlos Michel Albuquerque/N-1694-2019; Figueiredo, Eberval Gadelha/H-3488-2012	Peres, Carlos Michel Albuquerque/0000-0001-6606-3432; 			Balmer B, 2006, CHILD NERV SYST, V22, P363, DOI 10.1007/s00381-005-1254-x; Basamh M, 2016, CAN J NEUROL SCI, V43, P74, DOI 10.1017/cjn.2015.232; Bruneau M, 2002, SURG NEUROL, V57, P174, DOI 10.1016/S0090-3019(01)00668-1; Bullock M Ross, 2006, Neurosurgery, V58, pS7; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; de Andrade AF, 2001, WORLD J SURG, V25, P1186; de Andrade AF, 2008, NEUROSURGERY, V62, P416, DOI 10.1227/01.neu.0000316008.11388.f2; Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500; HAMILTON M, 1992, AM J NEURORADIOL, V13, P853; Hashimoto Takao, 2013, Surg Neurol Int, V4, P104, DOI 10.4103/2152-7806.116679; Jamous MA, 2009, PEDIATR NEUROSURG, V45, P181, DOI 10.1159/000218200; Khan MB, 2014, CHILD NERV SYST, V30, P1249, DOI 10.1007/s00381-014-2391-x; Kim Dong Ho, 2015, Korean J Neurotrauma, V11, P167, DOI 10.13004/kjnt.2015.11.2.167; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; Lammy S, 2013, BRIT J NEUROSURG, V27, P383, DOI 10.3109/02688697.2012.717981; Mandai S, 2000, J NEUROSURG, V93, P686, DOI 10.3171/jns.2000.93.4.0686; Misaki K, 2008, NEUROL MED-CHIR, V48, P208, DOI 10.2176/nmc.48.208; Nayil K, 2012, TURK NEUROSURG, V22, P239, DOI 10.5137/1019-5149.JTN.3165-10.1; Offner PJ, 2006, AM J SURG, V192, P801, DOI 10.1016/j.amjsurg.2006.08.047; Ohshima T, 2012, NEUROL MED-CHIR, V52, P829, DOI 10.2176/nmc.52.829; Paiva WS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413916; Paiva WS, 2010, CASE REP MED, V2010, DOI 10.1155/2010/219572; Protasoni M, 2011, J NEUROSURG, V114, P1723, DOI 10.3171/2010.12.JNS101732; Ross IB, 2009, J NEUROSURG, V110, P1247, DOI 10.3171/2008.7.JNS0883; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; Shah Q, 2005, AM J NEURORADIOL, V26, P2530; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Suzuki S, 2004, AM J NEURORADIOL, V25, P1177; Takahashi K, 2002, NEUROL SURG TOKYO, V30, P535; Tsutsumi M, 2002, SURG NEUROL, V58, P325, DOI 10.1016/S0090-3019(02)00834-0; Wang CH, 2007, SURG NEUROL, V68, P676, DOI 10.1016/j.surneu.2006.11.048; Wu XH, 2014, J CRANIOFAC SURG, V25, pE111, DOI 10.1097/SCS.0000000000000450	32	11	13	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2018	128	4					1044	1050		10.3171/2016.11.JNS161398			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GB4QJ	WOS:000429045500243	28409733	Bronze			2021-06-18	
J	Shi, XD; Bai, YA; Zhang, GD; Liu, YG; Xiao, H; Liu, XG; Zhang, W				Shi, Xiaodong; Bai, Yunan; Zhang, Guodong; Liu, Yuguang; Xiao, Hang; Liu, Xiaogang; Zhang, Wei			Effects of over-expression of SOD2 in bone marrow-derived mesenchymal stem cells on traumatic brain injury	CELL AND TISSUE RESEARCH			English	Article						Traumatic brain injury (TBI); Mesenchymal stem cell (MSC); Superoxide dismutase 2 (SOD2); Oxidative stress; Antioxidant	OXIDATIVE STRESS; STROMAL CELLS; PHASE-I; THERAPY; DISEASE; CANCER; OVEREXPRESSION; IMPACT; RAT	Intravenous administration of bone marrow-derived mesenchymal stem cells (BM-MSCs) has been shown to promote nerve cell regeneration following traumatic brain injury (TBI). As the anti-oxidant defense systems in neuronal tissue including superoxide dismutase 2 (SOD2) are crucial to defend cell against oxidative stress. We proposed a new stratege to increase the therapeutic effect of MSCs by preventing cells death from oxidative stress. We overexpressed SOD2 in BM-MSCs, transplanted these MSCs into TBI model mice, assessed the protective effect of SOD2 against oxidation-induced apoptosis in BM-MSCs both in vitro and in vivo, evaluated brain functional recovery by the rotarod behavioral test, and tested the oxidation status of TBI mice brain after BM-MSCs transplantation by monitoring the superoxide dismutase, glutathione and malonaldehyde level. We found over-expression of SOD2 protected BM-MSCs from H2O2-induced cell apoptosis. Injection of SOD2 over-expressed BM-MSCs attenuated neuro-inflammation in the ipsilateral cortex of TBI mice, and protected TBI mice against loss of blood-brain barrier integrity. Furthermore, the rotarod behavioral test showed functional recovery of TBI mice after MSC treatment. Our experiments indicated that SOD2-over-expressed BM-MSCs have an improved therapeutic effect on brain injury treatment in TBI mice.	[Shi, Xiaodong; Liu, Yuguang; Zhang, Wei] Qilu Hosp, Wenhuaxi Rd, Jinan 250014, Shandong, Peoples R China; [Shi, Xiaodong; Bai, Yunan; Zhang, Guodong; Xiao, Hang; Liu, Xiaogang] Weifang Yidu Cent Hosp, Dept Neurosurg, 4138 Linglongshan Rd, Qingzhou 262500, Shandong, Peoples R China	Liu, YG (corresponding author), Qilu Hosp, Wenhuaxi Rd, Jinan 250014, Shandong, Peoples R China.; Bai, YA (corresponding author), Weifang Yidu Cent Hosp, Dept Neurosurg, 4138 Linglongshan Rd, Qingzhou 262500, Shandong, Peoples R China.	baiyunanydzx@sina.com; liuyuguangsddx@163.com			Medical and Healthy Technology Development Program of Shandong Province [2015WS0069]	This work was supported by Medical and Healthy Technology Development Program of Shandong Province (2015WS0069).	Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180; Barman A, 2016, INDIAN J PSYCHOL MED, V38, P172, DOI 10.4103/0253-7176.183086; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Gavioli M, 2005, DIS COLON RECTUM, V48, P1851, DOI 10.1007/s10350-005-0133-6; Hasan A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00028; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Hynes K, 2016, SEMIN ARTHRITIS RHEU, V46, P1, DOI 10.1016/j.semarthrit.2016.02.008; Ikebe C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/951512; LAZARUS HM, 1995, BONE MARROW TRANSPL, V15, P935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Meseguer-Olmo L, 2017, NUCL MED BIOL, V46, P36, DOI 10.1016/j.nucmedbio.2016.12.003; Moghadasali R, 2013, EXP TOXICOL PATHOL, V65, P595, DOI 10.1016/j.etp.2012.06.002; Nargesi AA, 2017, CURR GENE THER, V17, P29, DOI 10.2174/1566523217666170412110724; Peired AJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4798639; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rooney GE, 2008, TISSUE ENG PT A, V14, P681, DOI 10.1089/tea.2007.0260; Salehi H, 2017, ANN ANAT, V210, P52, DOI 10.1016/j.aanat.2016.11.010; Sevivas N, 2017, AM J SPORT MED, V45, P179, DOI 10.1177/0363546516657827; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tseng WL, 2017, CELL TRANSPLANT, V26, P513, DOI 10.3727/096368916X694265; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Wang SH, 2016, CURR MOL PHARMACOL, V9, P289, DOI 10.2174/1874467208666150928153758; Xu LJ, 2010, GLIA, V58, P1042, DOI 10.1002/glia.20985; Yi HG, 2016, KOREAN J PHYSIOL PHA, V20, P63, DOI 10.4196/kjpp.2016.20.1.63; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010; Zhang XM, 2016, AM J TRANSL RES, V8, P4017; Zhang ZQ, 2017, ONCOTARGET, V8, P7791, DOI 10.18632/oncotarget.13954; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310	30	11	13	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	APR	2018	372	1					67	75		10.1007/s00441-017-2716-7			9	Cell Biology	Cell Biology	GA0ZM	WOS:000428044400007	29082445				2021-06-18	
J	Silva, PE; Maldaner, V; Vieira, L; de Carvalho, KL; Gomes, H; Melo, P; Babault, N; Cipriano, G; Durigan, JLQ				Silva, Paulo Eugenio; Maldaner, Vinicius; Vieira, Luciana; de Carvalho, Karina Livino; Gomes, Hedian; Melo, Priscilla; Babault, Nicolas; Cipriano, Gerson, Jr.; Quagliotti Durigan, Joao Luiz			Neuromuscular electrophysiological disorders and muscle atrophy in mechanically-ventilated traumatic brain injury patients: New insights from a prospective observational study	JOURNAL OF CRITICAL CARE			English	Article						Chronaxie; Critical illness polyneuropathy; Intensive care unit-acquired weakness; Neuromuscular disorder; Neuromuscular electrical stimulation; Rehabilitation	INTENSIVE-CARE-UNIT; ELECTRICAL-STIMULATION; ACQUIRED WEAKNESS; CRITICAL ILLNESS; MILLIAMPERAGE REQUIREMENTS; PERIPHERAL-NERVE; ILL PATIENTS; FIBER TYPES; CHRONAXIE; STRENGTH	Purpose: It is unclear whether the muscular changes in mechanically-ventilated traumatic brain injury patients (TBI) are only associated with disuse or additionally to neuromuscular electrophysiological disorders (NED). The correlation between muscle atrophy and NED may affect functional outcomes and rehabilitation programs significantly. Material and methods: An observational study was performed to investigate the presence of NED and muscle atrophy in TBI patients undergoing mechanical ventilation. NED was diagnosed by the stimulus electrodiagnosis test when chronaxie was >= 1000 mu s. The muscle structure (thickness and echogenicity) was assessed by B-mode ultrasound. Tibialis anterior (TA), rectus femoris (RF), and biceps brachialis (BB) muscles were analyzed. Patients were followed from the first day of admission in the intensive care unit (ICU) to the fourteenth day. Results: Twenty-two patients were analyzed. An increase of 48% in NED from day 1 to day 14 was detected in TA (p = 0.004). All muscles presented a significant decrease in thickness (similar to 18%, p < 0.05), but echogenicity increased only in TA (19%), p < 0.01 and RF (23%), p < 0.01. Conclusions: Mechanically-ventilated patients with TBI developed NED in addition to changes inmuscle structure during their stay in the ICU. (C) 2017 Elsevier Inc. All rights reserved.	[Silva, Paulo Eugenio] Univ Brasilia, Univ Hosp Brasilia, Phys Therapy Div, Brasilia, DF, Brazil; [Silva, Paulo Eugenio; Vieira, Luciana; Melo, Priscilla] Univ Brasilia, Hlth Sci & Technol PhD Program, Brasilia, DF, Brazil; [Silva, Paulo Eugenio; Maldaner, Vinicius] Hosp Base Dist Fed, Phys Therapy Div, Brasilia, DF, Brazil; [Maldaner, Vinicius] Hlth Sci Master Program, Hlth Sci Sch, Brasilia, DF, Brazil; [Vieira, Luciana] Hosp Base Dist Fed, Clin Res Ctr, Brasilia, DF, Brazil; [de Carvalho, Karina Livino] Univ Brasilia, Rehabil Sci Master Program, Brasilia, DF, Brazil; [Gomes, Hedian] Fisioterapia Integrada Brasilia, Phys Therapy Div, Brasilia, DF, Brazil; [Babault, Nicolas] Univ Bourgogne Franche Comte, INSERM, Cognit Act & Plast Senorimotrice U1093, Dijon, France; [Babault, Nicolas] Univ Bourgogne Franche Comte, UFR STAPS, Dijon, France; [Cipriano, Gerson, Jr.; Quagliotti Durigan, Joao Luiz] Univ Brasilia, Phys Therapy Div, Brasilia, DF, Brazil	Silva, PE (corresponding author), Univ Hosp Brasilia, Phys Therapy Div, SGAN, Quadra 604,Ave L2 Norte S-N, BR-70840901 Brasilia, DF, Brazil.	pauloeugenio.bsb@gmail.com	Cipriano, Gerson/S-5314-2019; da Silva, Vinicius Z M/A-1306-2016; Gerson C, G Cipriano/K-6317-2014; Babault, Nicolas/D-7541-2013; Durigan, Joao Luiz Quagliotti/D-1110-2012	Cipriano, Gerson/0000-0001-6323-7003; da Silva, Vinicius Z M/0000-0002-7804-7517; Gerson C, G Cipriano/0000-0001-6323-7003; Babault, Nicolas/0000-0001-6563-503X; Durigan, Joao Luiz Quagliotti/0000-0002-7511-5289; Silva, Paulo Eugenio/0000-0001-9153-0848	Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF) [193.000.862/2014]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [447529/2014-5, 310359/2014-7]; CAPES (Programa Ciencias sem Fronteiras, Pesquisador Visitante Especial)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88881.068106/2014-01]	This work was supported by the Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF; Process number: 193.000.862/2014); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq Process number: 447529/2014-5; 310359/2014-7) and by CAPES (Programa Ciencias sem Fronteiras, Pesquisador Visitante Especial; Process number: 88881.068106/2014-01).	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Arts IMP, 2010, MUSCLE NERVE, V41, P32, DOI 10.1002/mus.21458; Batt J, 2013, AM J RESP CRIT CARE, V187, P238, DOI 10.1164/rccm.201205-0954SO; Bednarik J, 2003, INTENS CARE MED, V29, P1505, DOI 10.1007/s00134-003-1858-0; Bloomfield SA, 1997, MED SCI SPORT EXER, V29, P197, DOI 10.1097/00005768-199702000-00006; Bolton CF, 2005, MUSCLE NERVE, V32, P140, DOI 10.1002/mus.20304; Bolton CF, 1996, INTENS CARE MED, V22, P841; Bostock H, 1998, MUSCLE NERVE, V21, P137, DOI 10.1002/(SICI)1097-4598(199802)21:2<137::AID-MUS1>3.0.CO;2-C; Botter A, 2011, EUR J APPL PHYSIOL, V111, P2461, DOI 10.1007/s00421-011-2093-y; Brown A, 2003, J CELL BIOL, V160, P817, DOI 10.1083/jcb.200212017; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Dirks ML, 2015, CLIN SCI, V128, P357, DOI 10.1042/CS20140447; Dorsch S, 2012, ARCH PHYS MED REHAB, V93, P1072, DOI 10.1016/j.apmr.2012.01.005; ELDER GCB, 1982, J APPL PHYSIOL, V53, P1473; Fenzi F, 2003, ACTA NEUROPATHOL, V106, P75, DOI 10.1007/s00401-003-0704-3; Fernandes LFRM, 2016, BRAZ J PHYS THER, V20, P126, DOI 10.1590/bjpt-rbf.2014.0138; Gondin J, 2011, EUR J APPL PHYSIOL, V111, P2473, DOI 10.1007/s00421-011-2101-2; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Grimm A, 2013, CRIT CARE, V17, DOI 10.1186/cc13050; Gruther W, 2010, J REHABIL MED, V42, P593, DOI 10.2340/16501977-0564; Hargens AR, 2016, J APPL PHYSIOL, V120, P891, DOI 10.1152/japplphysiol.00935.2015; Harper NJN, 2001, BRIT J ANAESTH, V87, P625, DOI 10.1093/bja/87.4.625; HENRIKSSONLARSEN KB, 1983, HISTOCHEM J, V15, P167, DOI 10.1007/BF01042285; Hermans G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0993-7; Hirose T, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.02.010; Itoh S, 2016, IEEE ENG MED BIO, P5845, DOI 10.1109/EMBC.2016.7592057; JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3; Kho ME, 2015, J CRIT CARE, V30, P32, DOI 10.1016/j.jcrc.2014.09.014; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390; Lacomis D, 2013, MUSCLE NERVE, V47, P452, DOI 10.1002/mus.23615; Lapicque L, 1909, COMPTES RENDUS SOC B, P280; Latronico N, 1996, LANCET, V347, P1579, DOI 10.1016/S0140-6736(96)91074-0; Latronico N, 2014, F1000RESEARCH, P3; Latronico N, 2007, CRIT CARE, V11, DOI 10.1186/cc5671; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maffiuletti NA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-137; Maffiuletti NA, 2011, EUR J APPL PHYSIOL, V111, P2391, DOI 10.1007/s00421-011-2133-7; Medeiros FVA, 2015, BRAZ J PHYS THER, V19, P466, DOI 10.1590/bjpt-rbf.2014.0114; Parry SM, 2015, J CRIT CARE, V30, DOI 10.1016/j.jcrc.2015.05.024; Parry SM, 2013, CRIT CARE MED, V41, P2406, DOI 10.1097/CCM.0b013e3182923642; Paternostro-Sluga T, 2002, AM J PHYS MED REHAB, V81, P253, DOI 10.1097/00002060-200204000-00003; Peviani SM, 2010, NEUROL RES, V32, P891, DOI 10.1179/174313209X459093; Pieber K, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0046-0; Pillen S, 2008, MUSCLE NERVE, V37, P679, DOI 10.1002/mus.21015; Pillen S, 2006, ULTRASOUND MED BIOL, V32, P1315, DOI 10.1016/j.ultrasmedbio.2006.05.028; Poulsen JB, 2011, CRIT CARE MED, V39, P456, DOI 10.1097/CCM.0b013e318205c7bc; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Recoskie BJ, 2009, PHYS MED BIOL, V54, P5965, DOI 10.1088/0031-9155/54/19/020; Rodriguez PO, 2011, J CRIT CARE, V27, P1; Routsi C, 2010, CRIT CARE, V14, DOI 10.1186/cc8987; Schuhfried O, 2005, IEEE T NEUR SYS REH, V13, P105, DOI 10.1109/TNSRE.2005.843439; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Segers J, 2014, J CRIT CARE, V29, P1082, DOI 10.1016/j.jcrc.2014.06.024; Seymour JM, 2009, THORAX, V64, P418, DOI 10.1136/thx.2008.103986; Sharma B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00879; Silva PE, 2017, J CRIT CARE, V37, P141, DOI 10.1016/j.jcrc.2016.09.012; Stevens Robert D, 2009, Crit Care Med, V37, pS299, DOI 10.1097/CCM.0b013e3181b6ef67; ten Haaf D, 2017, AM J PHYS MED REHAB, V96, P634, DOI 10.1097/PHM.0000000000000711; Tillquist M, 2014, JPEN-PARENTER ENTER, V38, P886, DOI 10.1177/0148607113501327; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Wijayatilake DS, 2015, CURR OPIN ANESTHESIO, V28, P525, DOI 10.1097/ACO.0000000000000236	64	11	12	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	APR	2018	44						87	94		10.1016/j.jcrc.2017.10.026			8	Critical Care Medicine	General & Internal Medicine	FY1IL	WOS:000426565300017	29078131	Bronze			2021-06-18	
J	Abidi, AH; Presley, CS; Dabbous, M; Tipton, DA; Mustafa, SM; Moore, BM				Abidi, Ammaar H.; Presley, Chaela S.; Dabbous, Mustafa; Tipton, David A.; Mustafa, Suni M.; Moore, Bob M., II			Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts	ARCHIVES OF ORAL BIOLOGY			English	Article						Endocannabinoids; Cannabis; Cytokine; Chemokine; Inflammation; Periodontal inflammation	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; HUMAN PERIODONTAL-LIGAMENT; TRAUMATIC BRAIN-INJURY; PORPHYROMONAS-GINGIVALIS; CB2 RECEPTORS; INVERSE AGONIST; NUCLEAR-FACTOR; IN-VITRO; CELLS	Objectives: Approximately 65 million adults in the US have periodontitis, causing tooth loss and decreased quality of life. Cannabinoids modulate immune responses, and endocannabinoids are prevalent during oral cavity inflammation. Targets for intervention in periodontal inflammation are cannabinoid type 1 and 2 receptors (CB1R, CB2R), particularly CB2R because its levels increase during inflammation. We previously demonstrated that SMM-189 (CB2R inverse agonist) decreased pro-inflammatory cytokine production in primary microglial cells. The hypothesis of this study was that cannabinoids anandamide (AEA), HU-308 (CB2R selective agonist), and SMM-189 decrease pro-inflammatory IL-6 and MCP-1 production by primary human periodontal ligament fibroblasts (hPDLFs) stimulated with P. gingivalis LPS, TNF-alpha, or IL-1 beta. Design: Cytotoxic effects of cannabinoid compounds (10(-4)-10(-6.5) M), LPS (1-1000 ng/ml), TNF alpha (10 ng/ml) and IL-1 beta (1 ng/ml) were assessed by measuring effects on cellular dehydrogenase activity. IL-6 and MCP-1 production were measured using Mesoscale Discovery (MSD) Human Pro-Inflammatory IL-6 and MSD Human Chemokine MCP-1 kits and analyzed using MSD Sector 2400 machine. Results: EC50 values for AEA, SMM-189, and HU-308 were 16 mu M, 13 mu M, and 7.3 mu M respectively. LPS (1 mu g/ml), TNF-alpha (10 ng/ml), and IL-1 beta (1 ng/ml) increased IL-6 and MCP-1 production, which were inhibited by AEA, SMM-189, and HU-308. AEA alone significantly increased IL-6, but not MCP-1 levels, but the other cannabinoids alone had no effect. Conclusion: The effective inhibition of LPS, TNF-alpha, IL-1 beta stimulated IL-6 and MCP-1 production by CB2R ligands in hPDLFs suggests that targeting the endocannabinoid system may lead to development of novel drugs for periodontal therapy, aiding strategies to improve oral health.	[Abidi, Ammaar H.] Univ Tennessee, Hlth Sci Ctr, Coll Dent, Dept Gen Practice Dent, Memphis, TN USA; [Abidi, Ammaar H.; Presley, Chaela S.; Mustafa, Suni M.; Moore, Bob M., II] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Dabbous, Mustafa; Tipton, David A.] Univ Tennessee, Hlth Sci Ctr, Coll Dent, Dept Biosci Res, Memphis, TN USA; [Dabbous, Mustafa] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Microbiol Immunol & Biochem, Memphis, TN USA	Moore, BM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA.	bmoore@uthsc.edu		Abidi, Ammaar/0000-0003-1826-9377			Agarwal S, 1998, INFECT IMMUN, V66, P932, DOI 10.1128/IAI.66.3.932-937.1998; Ardila CM, 2010, J PERIODONTAL RES, V45, P557, DOI 10.1111/j.1600-0765.2010.01274.x; Axmann R, 2009, ARTHRITIS RHEUM-US, V60, P2747, DOI 10.1002/art.24781; Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365-2826.2008.01675.x; Beklen A, 2007, J DENT RES, V86, P347, DOI 10.1177/154405910708600409; Borner C, 2009, J BIOL CHEM, V284, P35450, DOI 10.1074/jbc.M109.006338; Bu W, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00449; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Correa F, 2010, GLIA, V58, P135, DOI 10.1002/glia.20907; Craig RG, 2003, J CLIN PERIODONTOL, V30, P1075, DOI 10.1046/j.0303-6979.2003.00421.x; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990; Demuth DG, 2006, LIFE SCI, V78, P549, DOI 10.1016/j.lfs.2005.05.055; Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373; FELDMAN RS, 1983, J CLIN PERIODONTOL, V10, P131, DOI 10.1111/j.1600-051X.1983.tb02201.x; Gemmell E, 1997, PERIODONTOL 2000, V14, P112, DOI 10.1111/j.1600-0757.1997.tb00194.x; Graves D. T., 2011, J ORAL MICROBIOLOGY, V3; Gui H, 2014, RHEUMATOLOGY, V53, P802, DOI 10.1093/rheumatology/ket447; Gutierrez-Venegas G, 2006, LIFE SCI, V78, P2577, DOI 10.1016/j.lfs.2005.10.033; HANAZAWA S, 1993, INFECT IMMUN, V61, P5219, DOI 10.1128/IAI.61.12.5219-5224.1993; Hatakeyama J, 2003, ORAL MICROBIOL IMMUN, V18, P14, DOI 10.1034/j.1399-302X.2003.180103.x; Holt SC, 1999, PERIODONTOL 2000, V20, P168, DOI 10.1111/j.1600-0757.1999.tb00162.x; Jean-Gilles L, 2015, ACTA PHYSIOL, V214, P63, DOI 10.1111/apha.12474; Jiang YL, 1996, INFECT IMMUN, V64, P4450, DOI 10.1128/IAI.64.11.4450-4455.1996; Juttler E, 2004, NEUROPHARMACOLOGY, V47, P580, DOI 10.1016/j.neuropharm.2004.05.009; Kaplan B. L. F., 2007, J IMMUNOL S, V178, pS175; Kaplan BLF, 2008, BIOCHEM PHARMACOL, V76, P726, DOI 10.1016/j.bcp.2008.06.022; Kim J, 2006, ODONTOLOGY, V94, P10, DOI 10.1007/s10266-006-0060-6; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Koziel J, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0408-9; Kozono S, 2010, BIOCHEM BIOPH RES CO, V394, P928, DOI 10.1016/j.bbrc.2010.03.080; Kreitzer FR, 2009, PHARMACOL THERAPEUT, V122, P83, DOI 10.1016/j.pharmthera.2009.01.005; Kusumoto Y, 2004, J PERIODONTOL, V75, P370, DOI 10.1902/jop.2004.75.3.370; Loesche WJ, 2001, CLIN MICROBIOL REV, V14, P727, DOI 10.1128/CMR.14.4.727-752.2001; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Mackie B., 2009, BEHAV NEUROBIOLOGY E; Merighi S, 2012, BRIT J PHARMACOL, V165, P1773, DOI 10.1111/j.1476-5381.2011.01673.x; Montecucco F, 2008, AM J PHYSIOL-HEART C, V294, pH1145, DOI 10.1152/ajpheart.01328.2007; Morandini ACF, 2010, J PERIODONTOL, V81, P310, DOI 10.1902/jop.2009.090375; Nakajima Y, 2006, FEBS LETT, V580, P613, DOI 10.1016/j.febslet.2005.12.079; NIDCR NIoDaCR, 2013, PER GUM DIS; Okada N, 1997, J PERIODONTAL RES, V32, P559, DOI 10.1111/j.1600-0765.1997.tb00932.x; Ossola CA, 2016, J PERIODONTOL, V87, P725, DOI 10.1902/jop.2016.150612; Ossola CA, 2012, INFLAMM RES, V61, P941, DOI 10.1007/s00011-012-0485-z; Ozaki K, 1996, ORAL MICROBIOL IMMUN, V11, P109, DOI 10.1111/j.1399-302X.1996.tb00344.x; Ozdemir B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107407; Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8; Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159; Qian H, 2010, J PERIODONTAL RES, V45, P504, DOI 10.1111/j.1600-0765.2009.01265.x; Qian H, 2013, OPEN J STOMATOLOGY, V3, P44; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; REINHARDT RA, 1993, J CLIN PERIODONTOL, V20, P225, DOI 10.1111/j.1600-051X.1993.tb00348.x; SAFKAN B, 1984, J CLIN PERIODONTOL, V11, P515, DOI 10.1111/j.1600-051X.1984.tb00903.x; Soares GMS, 2012, J APPL ORAL SCI, V20, P295, DOI 10.1590/S1678-77572012000300002; Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005; Tabrizi MA, 2016, CHEM REV, V116, P519, DOI 10.1021/acs.chemrev.5b00411; TAKAHASHI K, 1994, J PERIODONTOL, V65, P147, DOI 10.1902/jop.1994.65.2.147; Tishler M, 1999, RHEUMATOL INT, V18, P125, DOI 10.1007/s002960050070; Toguri JT, 2014, BRIT J PHARMACOL, V171, P1448, DOI 10.1111/bph.12545; WAITE IM, 1981, J PERIODONTAL RES, V16, P100, DOI 10.1111/j.1600-0765.1981.tb00953.x; Wang PL, 2002, CRIT REV ORAL BIOL M, V13, P132, DOI 10.1177/154411130201300204; Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365; YAMAZAKI K, 1994, J ORAL PATHOL MED, V23, P347, DOI 10.1111/j.1600-0714.1994.tb00074.x	65	11	12	2	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0003-9969	1879-1506		ARCH ORAL BIOL	Arch. Oral Biol.	MAR	2018	87						79	85		10.1016/j.archoralbio.2017.12.005			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	FY9TB	WOS:000427208700010	29274621				2021-06-18	
J	Brenner, LA; Forster, JE; Hoffberg, AS; Matarazzo, BB; Hostetter, TA; Signoracci, G; Simpson, GK				Brenner, Lisa A.; Forster, Jeri E.; Hoffberg, Adam S.; Matarazzo, Bridget B.; Hostetter, Trisha A.; Signoracci, Gina; Simpson, Grahame K.			Window to Hope: A Randomized Controlled Trial of a Psychological Intervention for the Treatment of Hopelessness Among Veterans With Moderate to Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive behavior therapy; depression; hopelessness; randomized controlled trial; replication; suicide ideation; suicide prevention; traumatic brain injury; Veterans	NEUROPSYCHIATRIC INTERVIEW MINI; SUICIDAL IDEATION; INDIVIDUALS; RELIABILITY; VALIDITY; THERAPY	Objective: To evaluate the efficacy of a psychological intervention to reduce moderate to severe hopelessness among Veterans with moderate to severe traumatic brain injury (TBI). Design: Two-arm parallel group, controlled, randomized crossover trial, with 3-month follow-up for those initially allocated to treatment. Participants were randomly allocated in blocks of 4 on a 1: 1 ratio to treatment (n = 15) or waitlist (n = 20) groups. Setting: A Veterans Affairs Medical Center. Participants: Veterans between the ages of 26 and 65 years, with a history of moderate to severe TBI, and moderate to severe hopelessness. Interventions: A 20-hour manualized small group cognitive-behavioral intervention. Main Outcome Measures: Beck Hopelessness Scale (primary), Beck Depression Inventory, and Beck Scale for Suicide Ideation. Results: A significant difference between groups was found for postintervention scores on the Beck Hopelessness Scale (P =.03). Significant decreases were maintained at followup. For those initially allocated to the waitlist group who completed the intervention, treatment gains were noted in decreased hopelessness (P =.01) and depression (P =.003). Conclusions: Findings from this trial provide additional support for the efficacy of this method of psychological treatment of hopelessness among individuals with moderate to severe TBI.	[Brenner, Lisa A.; Forster, Jeri E.; Hoffberg, Adam S.; Matarazzo, Bridget B.; Hostetter, Trisha A.; Signoracci, Gina] VA Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Brenner, Lisa A.; Forster, Jeri E.; Signoracci, Gina] Univ Colorado Anschutz Med Campus, Dept Phys Med & Rehabil, Aurora, CO USA; [Brenner, Lisa A.; Matarazzo, Bridget B.; Signoracci, Gina] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO USA; [Brenner, Lisa A.] Univ Colorado Anschutz Med Campus, Dept Neurol, Aurora, CO USA; [Simpson, Grahame K.] Univ Sydney New South Wales, Brain Injury Rehabil Res Grp, Ingham Inst Appl Med Res, Sydney, NSW, Australia; [Simpson, Grahame K.] Univ Sydney New South Wales, John Walsh Ctr Rehabil Res, Kolling Inst, Sydney, NSW, Australia	Brenner, LA (corresponding author), Rocky Mt MIRECC, VA Eastern Colorado Hlth Care Syst, 1055 Clermont St, Denver, CO 80220 USA.	Lisa.Brenner@va.gov	Brenner, Lisa A./AAG-2442-2019; Signoracci, Gina M./Q-3782-2019; Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Hoffberg, Adam/0000-0002-7036-936X	Military Suicide Research Consortium (MSRC); Office of the Assistant Secretary of Defense for Health Affairs [W81XWEI-10-2-0178]; VA Rocky Mountain MIRE CC	This work was supported by the Military Suicide Research Consortium (MSRC), an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs (under Award No. W81XWEI-10-2-0178, Proposal No. 09162006). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the MSRC or the Department of Defense. Additional support was provided by the VA Rocky Mountain MIRE CC.	Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Beck A., 1988, MANUAL BECK HOPELESS; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1985, AM J PSYCHIAT, V142, P559; BECK AT, 1993, BECK SCALE SUICIDAL; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Freedland KE, 2011, PSYCHOSOM MED, V73, P323, DOI 10.1097/PSY.0b013e318218e1fb; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Hopewell S, 2008, LANCET, V371, P281, DOI 10.1016/S0140-6736(07)61835-2; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Makel MC, 2012, PERSPECT PSYCHOL SCI, V7, P537, DOI 10.1177/1745691612460688; Matarazzo BB, 2014, BRAIN INJURY, V28, P1238, DOI 10.3109/02699052.2014.916419; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; MOHER D, 2010, BMJ BRIT MED J, V0340; OTTENBACHER KJ, 1995, ARCH PHYS MED REHAB, V76, P123, DOI 10.1016/S0003-9993(95)80021-2; Schmidt S, 2009, REV GEN PSYCHOL, V13, P90, DOI 10.1037/a0015108; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson GK, 2011, J HEAD TRAUMA REHAB, V26, P290, DOI 10.1097/HTR.0b013e3182225250; Wagenmakers EJ, 2012, PERSPECT PSYCHOL SCI, V7, P632, DOI 10.1177/1745691612463078; Whiting DL, 2012, BRAIN IMPAIR, V13, P360, DOI 10.1017/BrImp.2012.28	26	11	11	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2018	33	2					E64	E73		10.1097/HTR.0000000000000351			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GN6AI	WOS:000439152200007	29084101				2021-06-18	
J	Brickell, TA; French, LM; Lippa, SM; Lange, RT				Brickell, Tracey A.; French, Louis M.; Lippa, Sara M.; Lange, Rael T.			Characteristics and Health Outcomes of Post-9/11 Caregivers of US Service Members and Veterans Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver; polytrauma; posttraumatic stress; service member; traumatic brain injury; Veteran	CENTERED PREVENTIVE INTERVENTION; FAMILY CAREGIVERS; BURDEN; PARENT; BLAST; SYMPTOMS; CHILDREN; IMPACT; SPOUSE; CARE	Objectives: To (a) characterize a sample of post-9/11 caregivers providing help to service members and veterans (SMV) following traumatic brain injury (TBI), (b) examine the level of support provided, and (c) determine caregiver health and well-being outcomes. Setting: Military treatment facility. Participants: Caregivers (N = 278) of SMVs who sustained a mild, moderate, severe, or penetrating TBI (96.0% female; 86.0% spouse/partner; age: M = 38.7 years, SD = 10.4). Participants were divided into 3 groups on the basis of the level of support provided (low, medium, high). Design: Prospective observational. Main Measures: Caregiver Appraisal Scale, SF-36v2 Health Survey, Mayo-Portland Adaptability Inventory-4, Caregiver Questionnaire. Results: The majority of caregivers were helping an SMV with mild TBI and comorbid posttraumatic stress disorder/depression, who was injured in a blast-related incident during combat. Caregivers helped predominantly with activities of daily living and/or instrumental activities of daily living and spent more than 40 hours per week providing care. High-support caregivers were more likely to be caring for an SMV with comorbid posttraumatic stress disorder, report poor physical and mental health outcomes, and have a negative impact on employment and finances. Conclusions: A better understanding of protective factors is required to ensure that burden of care does not exceed the caregiver's health and financial capacity, or undermine the care, well-being, and recovery of the SMV.	[Brickell, Tracey A.; French, Louis M.; Lippa, Sara M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.; Lippa, Sara M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Fac Med, Vancouver, BC, Canada	Brickell, TA (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 51,Room 1502B,4954 N Palmer Rd, Bethesda, MD 20889 USA.	tbrickell@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	This material is based upon work supported by the Defense and Veterans Brain Injury Center. Portions of these data were presented at the North American Brain Injury Association conference, Tampa, Florida.	Baker A, 2017, CLIN REHABIL, V31, P45, DOI 10.1177/0269215516639357; Bayen E, 2017, SUPPORT CARE CANCER, V25, P245, DOI 10.1007/s00520-016-3397-6; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; Beardslee W, 2011, PREV SCI, V12, P339, DOI 10.1007/s11121-011-0234-5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Charlifue SB, 2016, SPINAL CORD, V54, P732, DOI 10.1038/sc.2016.25; Cozza SJ, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P259, DOI 10.1007/978-1-4419-7064-0_13; Dillahunt-Aspillaga C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082896; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; French L. M., 2012, NEUROPSYCHOLOGICAL A, P127; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Griffin JM, 2014, MILITARY DEPLOYMENT; Griffin JM, 2017, AM J ORTHOPSYCHIAT, V87, P139, DOI 10.1037/ort0000207; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Griffin JM, 2009, J REHABIL RES DEV, V46, P879, DOI 10.1682/JRRD.2008.08.0104; Harding R, 2015, J PAIN SYMPTOM MANAG, V50, P445, DOI 10.1016/j.jpainsymman.2015.04.005; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P663, DOI 10.1007/978-0-387-76978-3_21; Kim Y, 2012, PSYCHO-ONCOLOGY, V21, P273, DOI 10.1002/pon.1888; Kratz AL, 2017, NEUROPSYCHOL REHABIL, V27, P16, DOI 10.1080/09602011.2015.1051056; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lester P, 2016, J AM ACAD CHILD PSY, V55, P14, DOI 10.1016/j.jaac.2015.10.009; Lester P, 2012, AM J PUBLIC HEALTH, V102, pS48, DOI 10.2105/AJPH.2010.300088; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Manskow US, 2015, J HEAD TRAUMA REHAB, V30, P411, DOI 10.1097/HTR.0000000000000085; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Monk JK, 2017, J MARITAL FAM THER, V43, P448, DOI 10.1111/jmft.12230; National Alliance for Caregiving, 2008, CAR VET SERV HOM; Ramchand R, 2009, HIDDEN HEROES AM MIL; Saban KL, 2016, J REHABIL RES DEV, V53, P681, DOI 10.1682/JRRD.2015.07.0143; Saltzman WR, 2016, FAM PROCESS, V55, P633, DOI 10.1111/famp.12238; Smeets SM, 2012, ARCH PHYS MED REHAB, V93, P834, DOI 10.1016/j.apmr.2011.10.029; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Teixeira RJ, 2013, PSYCHO-ONCOLOGY, V22, P1587, DOI 10.1002/pon.3173; Van Houtven CH, 2012, INQUIRY-J HEALTH CAR, V49, P339, DOI 10.5034/inquiryjrnl_49.04.01; van Wijnen HGFM, 2017, CLIN REHABIL, V31, P1267, DOI 10.1177/0269215516686155; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Ware JE, 2007, USERS MANUAL SF 36V2	43	11	11	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2018	33	2					133	145		10.1097/HTR.0000000000000384			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GN6AI	WOS:000439152200014	29517593				2021-06-18	
J	Capo-Aponte, JE; Beltran, TA; Walsh, DV; Cole, WR; Dumayas, JY				Capo-Aponte, Jose E.; Beltran, Thomas A.; Walsh, David V.; Cole, Wesley R.; Dumayas, Joseph Y.			Validation of Visual Objective Biomarkers for Acute Concussion	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health System Research Symposium (MHSRS)	2016	FL				TRAUMATIC BRAIN-INJURY; CONVERGENCE INSUFFICIENCY; DYSFUNCTIONS; RELIABILITY; RECOVERY; VISION; SIZE	Objective: Despite an increase in the awareness and diagnosis of mild traumatic brain injury (mTBI), there remains a paucity of data examining the comparative efficacy of available assessments. This study aims to validate visual functions as potential biomarkers for mTBI. Methods: This case-control correlational design utilizes military personnel diagnosed with acute (<= 72 h post-injury) mTBI (n = 100) and age-matched controls (n = 100) to examine the relative effectiveness of the pupillary light reflex (PLR), near point of convergence (NPC) break, King-Devick (KD) test time, and Convergence Insufficiency Symptom Survey (CISS) score to discriminate between participants with mTBI. Results: Three of the eight PLR parameters (i.e., average constriction velocity (ACV), average dilation velocity (ADV), and 75% re-dilation time; all p < 0.001) were affected in mTBI participants. Similarly, NPC break, KD test time, and CISS scores showed a statistically significant difference between groups (all p < 0.001). Area under the curve showed that ADV (0.82) and NPC (0.74) have the higher predictive values of all objective parameters. Conclusions: ADV, ACV, and NPC break are objective visual functions markedly affected in the acute mTBI group compared with controls; therefore, we proposed that they could be used as biomarkers for acute mTBI.	[Capo-Aponte, Jose E.; Dumayas, Joseph Y.] Womack Army Med Ctr, Dept Optometry, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA; [Beltran, Thomas A.] Womack Army Med Ctr, Dept Clin Invest, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA; [Walsh, David V.] US Army, Vis Protect & Performance Div, Aeromed Res Lab, 6901 Farrel Rd, Ft Rucker, AL 36362 USA; [Cole, Wesley R.] Womack Army Med Ctr, Dept Brain Injury Med, Def & Vet Brain Injury Ctr, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA	Capo-Aponte, JE (corresponding author), Womack Army Med Ctr, Dept Optometry, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA.				Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command; FY13 Department of Defense Army Rapid Innovation Fund Research Program of the Office of the Congressionally Directed Medical Research Programs [W81XWH-14-C-0048]	This research was funded by the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command and FY13 Department of Defense Army Rapid Innovation Fund Research Program of the Office of the Congressionally Directed Medical Research Programs under contract no. W81XWH-14-C-0048.	Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Capo-Aponte JE., 2013, J SPINE S, V4, P1; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; CDC, INJ PREV CONTR TRAUM; Centers for Disease Control and Prevention, C MILD TRAUM BRAIN I; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Hults Kathryn N, 2006, J Neurosci Nurs, V38, P447; Kasthurirangan S, 2006, VISION RES, V46, P1393, DOI 10.1016/j.visres.2005.07.004; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Loewenfeld I. E., 1979, TOPICS NEURO OPHTHAL, P124; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Papa L., 2015, BRAIN NEUROTRAUMA MO; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schmid KE, 2012, FRONT NEUROL, V3, P1; Silverberg ND, 2014, BRAIN INJURY, V28, P1590, DOI 10.3109/02699052.2014.943287; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Thiagarajan P, 2015, BRAIN INJURY, V29, P1420, DOI 10.3109/02699052.2015.1045029; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Ventura RE, 2015, SEMIN NEUROL, V35, P599, DOI 10.1055/s-0035-1563567; Walsh DV, 2016, J NEUROL SCI, V370, P305, DOI 10.1016/j.jns.2016.09.014; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127	33	11	11	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR-APR	2018	183			S			9	17		10.1093/milmed/usx166			9	Medicine, General & Internal	General & Internal Medicine	GC0JM	WOS:000429463600003	29635572	Bronze			2021-06-18	
J	Norheim, N; Kissinger-Knox, A; Cheatham, M; Webbe, F				Norheim, Nicole; Kissinger-Knox, Alicia; Cheatham, Megan; Webbe, Frank			Performance of college athletes on the 10-item word list of SCAT5	BMJ OPEN SPORT & EXERCISE MEDICINE			English	Article								Objectives The Sport Concussion Assessment Tool-5 (SCAT5) was published in 2017; however, normative performance within the college athlete population on the optional 10-item word list has not been described. This study reports normative values for immediate memory trials, total immediate memory score and delayed recall of the 10-item word list. Methods The SCAT5 was administered as part of the preparticipation medical testing to 514 collegiate studentathletes, aged 17-23 (M=19.65, SD=1.40; 64% male) prior to the 2017-2018 athletic season. Results On the SCAT5's optional 10-item word list, with a total possible immediate memory score of 30, participants recalled an average of 20.57 (SD=3.22) words over three learning trials, with an average for trial 3 of 8.13 (SD=1.32). The average delayed memory score was 6.59 (SD=1.85). Small but significant demographic comparisons were found. Women scored higher on both immediate and delayed recall, non-native speakers scored higher on delayed recall, and Black/African-American athletes scored lower than White athletes on immediate, and lower than White and Hispanic/Latino athletes on delayed recall. Conclusion The 10-item word list on the SCAT5 eliminates the ceiling effect observed on the five-item word list of the SCAT3, therefore, increasing its clinical utility in the diagnosis of sports-related concussions. Significant demographic differences suggest use of category-specific norms for sex, native language and race/ ethnicity.	[Norheim, Nicole; Kissinger-Knox, Alicia; Cheatham, Megan; Webbe, Frank] Florida Inst Technol, Dept Psychol, Melbourne, FL 32901 USA	Webbe, F (corresponding author), Florida Inst Technol, Dept Psychol, Melbourne, FL 32901 USA.	webbe@fit.edu		Webbe, Frank/0000-0002-4370-5698			[Anonymous], 2017, Br J Sports Med, V51, P851, DOI 10.1136/bjsports-2017-097506SCAT5; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BLEECKER ML, 1988, J CLIN PSYCHOL, V44, P403, DOI 10.1002/1097-4679(198805)44:3<403::AID-JCLP2270440315>3.0.CO;2-0; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Fernandes MA, 2007, CAN J EXP PSYCHOL, V61, P128, DOI 10.1037/cjep2007014; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Kisser JE, 2012, ARCH CLIN NEUROPSYCH, V27, P749, DOI 10.1093/arclin/acs082; KRAMER JH, 1988, J CLIN PSYCHOL, V44, P907, DOI 10.1002/1097-4679(198811)44:6<907::AID-JCLP2270440610>3.0.CO;2-8; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; Lundervold AJ, 2019, J ATTEN DISORD, V23, P1188, DOI 10.1177/1087054715580842; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; NOTT CR, 1968, J VERB LEARN VERB BE, V7, P1065, DOI 10.1016/S0022-5371(68)80069-6; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	18	11	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2398-9459	2055-7647		BMJ OPEN SPORT EXERC	BMJ Open Sport Exerc. Med.	MAR	2018	4	1							e000412	10.1136/bmjsem-2018-000412			5	Sport Sciences	Sport Sciences	VJ4QA	WOS:000596798200110	30167321	DOAJ Gold, Green Published			2021-06-18	
J	Plourde, V; Hrabok, M; Sherman, EMS; Brooks, BL				Plourde, Vickie; Hrabok, Marianne; Sherman, Elisabeth M. S.; Brooks, Brian L.			Validity of a Computerized Cognitive Battery in Children and Adolescents with Neurological Diagnoses	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Childhood neurologic disorders; Assessment; Convergent and divergent validity	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; PROCESSING SPEED; IMPACT	Objective: Little is known about the validity of computerized cognitive batteries, such as CNS Vital Signs (CNSVS), in pediatric patients. The purpose of this study was to examine convergent and divergent validity of the CNSVS in a clinical pediatric sample with neurological diagnoses. Method: Participants included 123 pediatric patients assessed in a tertiary care setting as part of clinical care. CNSVS (Memory, Psychomotor Speed, Reaction Time, Complex Attention, and Cognitive Flexibility domains, and a Neurocognition Index) and paper-and-pencil neuropsychological measures assessing learning, memory, processing speed, reaction time, attention, and executive functioning were administered Results: Most correlations between CNSVS domain scores and neuropsychological measures assessing similar constructs were medium in strength. With the exception of stronger correlations between psychomotor speed tests, correlations between tests of similar constructs were not significantly higher than those between dissimilar constructs. Conclusions: These results provide support for validity of the CNSVS battery, but also caution that many abilities are inter-correlated.	[Plourde, Vickie; Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Plourde, Vickie; Brooks, Brian L.] Univ Calgary, Cumming Sch Med, Dept Paediat, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada; [Hrabok, Marianne] Alberta Hlth Serv, Addict & Mental Hlth, Edmonton, AB, Canada; [Hrabok, Marianne] Univ Alberta, Dept Psychiat, Fac Med & Dent, Edmonton, AB, Canada; [Sherman, Elisabeth M. S.] Copeman Healthcare Ctr, Calgary, AB, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Brain Injury & Rehabil Program, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Cumming Sch Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Fac Arts, Dept Psychol, Calgary, AB, Canada	Plourde, V (corresponding author), Univ Calgary, Cumming Sch Med, Dept Paediat, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	vickie.plourde@ucalgary.ca		Plourde, Vickie/0000-0002-0098-5431	Integrated Concussion Research Program at the University of Calgary; Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute; Alberta Innovates Health Solutions; Cumming School of Medicine at the University of Calgary; Alberta Innovates [201610079] Funding Source: researchfish	Dr. Brian Brooks acknowledges salary funding from the Canadian Institutes of Health Research (CIHR). Dr. Vickie Plourde was financially supported for her fellowship by the Alberta Children's Hospital Research Institute, the Integrated Concussion Research Program at the University of Calgary, Cumming School of Medicine at the University of Calgary, and Alberta Innovates Health Solutions.	Bauer RM, 2012, CLIN NEUROPSYCHOL, V26, P177, DOI 10.1080/13854046.2012.663001; Bilder RM, 2011, J INT NEUROPSYCH SOC, V17, P7, DOI 10.1017/S1355617710001396; Bozkurt H., 2016, APPL NEUROPSYCHOLOGY; Brooks BL, 2014, J NEUROTRAUM, V31, P1744, DOI 10.1089/neu.2014.3356; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Brooks BL, 2011, J CHILD NEUROL, V26, P786, DOI 10.1177/0883073810391532; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Crook T. H., 2009, NEUROPSYCHOLOGICAL A, P84; De Marco AP, 2016, J CHILD NEUROL, V31, P68, DOI 10.1177/0883073814559645; Dede E., 2015, NEUROLOGY PSYCHIAT B, V21, P128, DOI DOI 10.1016/J.NPBR.2015.07.003; Delis D, 1994, MANUAL CALIFORNIA VE; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Korkman M., 2007, NEPSY 2 CLIN INTERPR; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Newman JB, 2013, CLIN NEUROPSYCHOL, V27, P779, DOI 10.1080/13854046.2013.789552; Ozer S., 2015, CHILD NEUROPSYCHOLOG; Parsey CM, 2013, CLIN NEUROPSYCHOL, V27, P1328, DOI 10.1080/13854046.2013.834971; Sherman EMS, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P873, DOI 10.1007/978-0-387-76978-3_30; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Wechsler D., 2003, WECHSLER INTELLIGENC	22	11	11	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2018	33	2					247	253		10.1093/arclin/acx067			7	Psychology, Clinical; Psychology	Psychology	FY4QD	WOS:000426808700011	28981565	Bronze, Green Published			2021-06-18	
J	Rojas-Carvajal, M; Fornaguera, J; Mora-Gallegos, A; Brenes, JC				Rojas-Carvajal, Mijail; Fornaguera, Jaime; Mora-Gallegos, Andrea; Brenes, Juan C.			Testing experience and environmental enrichment potentiated open-field habituation and grooming behaviour in rats	ANIMAL BEHAVIOUR			English	Article						animal model; arousal; environmental enrichment; grooming; nonassociative learning; stress	TRAUMATIC BRAIN-INJURY; FORCED SWIMMING TEST; SPRAGUE-DAWLEY RATS; SPATIAL MEMORY; DEFENSIVE BEHAVIORS; DENTATE GYRUS; TIME-COURSE; ADULT RATS; STRESS; ANXIETY	In laboratory rats, one of the most used paradigms to assess habituation to novelty is the open-field test. Environmental enrichment has proved to be a reliable way to enhance open-field test habituation. Experiment 1, therefore, was designed to test whether grooming behaviour in the open-field test increases concomitantly with the habituation of exploratory behaviours (locomotion and rearing behaviour, an alert upright posture). To this aim, after a baseline measure, rats were raised in environmentally enriched and standard housing conditions and then tested 30 and 60 days later. As some grooming subtypes are differentially displayed in the open-field test, we hypothesized that only the grooming subtype that included longer and more complex sequences (e.g. body licking) would increase with habituation. We found that environmental enrichment enhanced short-term (within days) and long-term (between days) open-field test habituation, and increased grooming, particularly body licking. To provide evidence that grooming in the open-field test is part of the habituation process and not a by-product of environmental enrichment, habituation was promoted by exposing a different group of rats that had been reared in standard housing to four consecutive open-field tests in experiment 2. We supposed that the diminution of exploratory open-field test behaviours would be accompanied by an increase in body licking. We found that as locomotion and rearing behaviour decreased, body licking increased gradually both within and between days, suggesting that the appearance of more complex and longer grooming sequences are part of a de-arousal inhibition system subserving novelty habituation. A detailed analysis of grooming, therefore, may provide information about the emotional state of the rat that cannot otherwise be obtained from assessing exploratory activity. (C) 2018 The Association for the Study of Animal Behaviour. Published by Elsevier Ltd. All rights reserved.	[Rojas-Carvajal, Mijail; Fornaguera, Jaime; Mora-Gallegos, Andrea; Brenes, Juan C.] Univ Costa Rica, Neurosci Res Ctr, San Jose 115012060, Costa Rica; [Fornaguera, Jaime] Univ Costa Rica, Sch Med, Biochem Dept, San Jose, Costa Rica; [Brenes, Juan C.] Univ Costa Rica, Inst Psychol Res, San Jose, Costa Rica	Rojas-Carvajal, M (corresponding author), Univ Costa Rica, Neurosci Res Ctr, San Jose 115012060, Costa Rica.	mijail.rojas.ca@gmail.com		Rojas-Carvajal, Mijail/0000-0002-6077-7829	University of Costa Rica [837-B7-603, 837-B5-184, 837-B5-185, 723-B4-192]; Support Found for Final Graduation Work, Vice-Rectory of Research, University of Costa Rica; grant Young Researcher in Psychology, Institute for Psychological Research, University of Costa Rica	This research was partially supported by the projects 837-B7-603, 837-B5-184, 837-B5-185 and 723-B4-192, Vice-Rectory of Research, University of Costa Rica. This work was awarded with the Support Found for Final Graduation Work, Vice-Rectory of Research, University of Costa Rica, and also with the grant Young Researcher in Psychology, Institute for Psychological Research, University of Costa Rica.	Almeida Maria Camila, 2015, Temperature (Austin), V2, P483, DOI 10.1080/23328940.2015.1095270; Amador GJ, 2015, J EXP BIOL, V218, P3164, DOI 10.1242/jeb.103937; Barbelivien A, 2006, BEHAV BRAIN RES, V169, P231, DOI 10.1016/j.bbr.2006.01.012; Benaroya-Milshtein N, 2004, EUR J NEUROSCI, V20, P1341, DOI 10.1111/j.1460-9568.2004.03587.x; Bengston SE, 2014, ANIM BEHAV, V93, P105, DOI 10.1016/j.anbehav.2014.04.022; BENNETT EL, 1969, SCIENCE, V163, P825, DOI 10.1126/science.163.3869.825; Bennett JC, 2006, NEUROBIOL LEARN MEM, V85, P139, DOI 10.1016/j.nlm.2005.09.003; BERRIDGE KC, 1992, EXP BRAIN RES, V90, P275; Blanchard DC, 2008, HBK BEHAV NEUROSCI, V17, P63, DOI 10.1016/S1569-7339(07)00005-7; Blanchard RJ, 2001, NEUROSCI BIOBEHAV R, V25, P587, DOI 10.1016/S0149-7634(01)00043-4; BOWLING SL, 1993, NEUROPHARMACOLOGY, V32, P885, DOI 10.1016/0028-3908(93)90144-R; Brenes JC, 2008, NEUROSCI LETT, V436, P278, DOI 10.1016/j.neulet.2008.03.045; Brenes JC, 2016, J COMP NEUROL, V524, P1586, DOI 10.1002/cne.23842; Brenes JC, 2009, BEHAV BRAIN RES, V197, P125, DOI 10.1016/j.bbr.2008.08.014; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Carter GG, 2015, HORM BEHAV, V75, P150, DOI 10.1016/j.yhbeh.2015.10.006; Collymore C, 2015, J AM ASSOC LAB ANIM, V54, P280; DELIUS JD, 1967, NATURE, V214, P1259, DOI 10.1038/2141259a0; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; Diaz-Moran S., 2014, WORLD J NEUROSCI, V04, P1; DOYLE G., 1959, ANIMAL BEHAVIOR, V7, P18, DOI 10.1016/0003-3472(59)90025-9; Elliott BM, 2005, BEHAV BRAIN RES, V165, P187, DOI 10.1016/j.bbr.2005.06.025; EWER RF, 1967, NATURE, V216, P686, DOI 10.1038/216686a0; Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9; FENTRESS JC, 1968, ANIM BEHAV, V16, P135, DOI 10.1016/0003-3472(68)90124-3; Fernandez-Teruel A, 2002, PHARMACOL BIOCHEM BE, V73, P225, DOI 10.1016/S0091-3057(02)00784-0; Fernandez-Teruel A, 2016, NAT REV NEUROSCI, V17, P591, DOI 10.1038/nrn.2016.102; Fuzesi T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11937; Gagliano H, 2014, HORM BEHAV, V66, P793, DOI 10.1016/j.yhbeh.2014.11.002; GROVES P M, 1970, Psychological Review, V77, P419, DOI 10.1037/h0029810; Hong WZ, 2014, CELL, V158, P1348, DOI 10.1016/j.cell.2014.07.049; Hughes RN, 2010, PHARMACOL BIOCHEM BE, V94, P534, DOI 10.1016/j.pbb.2009.11.008; ISAACSON RL, 1983, BRAIN RES BULL, V11, P289, DOI 10.1016/0361-9230(83)90162-4; JOLLES J, 1979, BEHAV NEURAL BIOL, V25, P563, DOI 10.1016/S0163-1047(79)90362-5; Kalueff AV, 2016, NAT REV NEUROSCI, V17, P45, DOI 10.1038/nrn.2015.8; Kalueff AV, 2005, J NEUROSCI METH, V143, P169, DOI 10.1016/j.jneumeth.2004.10.001; KAMETANI H, 1988, ANN NY ACAD SCI, V525, P101, DOI 10.1111/j.1749-6632.1988.tb38599.x; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kruk MR, 1998, NEUROSCI BIOBEHAV R, V23, P163, DOI 10.1016/S0149-7634(98)00018-9; Kuzumaki N, 2011, HIPPOCAMPUS, V21, P127, DOI 10.1002/hipo.20775; LAMMERS JHCM, 1987, BRAIN RES, V418, P1, DOI 10.1016/0006-8993(87)90956-5; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Maegele M, 2015, PHYSIOL RES, V64, P129, DOI 10.33549/physiolres.932664; Marques MR, 2014, BEHAV BRAIN RES, V263, P149, DOI 10.1016/j.bbr.2014.01.007; Martin JGA, 2008, ANIM BEHAV, V75, P309, DOI 10.1016/j.anbehav.2007.05.026; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Molesti S, 2013, ANIM BEHAV, V86, P169, DOI 10.1016/j.anbehav.2013.05.008; Mora-Gallegos A, 2015, NEUROBIOL LEARN MEM, V118, P96, DOI 10.1016/j.nlm.2014.11.012; Moritz KE, 2014, RESTOR NEUROL NEUROS, V32, P701, DOI 10.3233/RNN-140414; MOYAHO A, 1995, ANIM BEHAV, V50, P61, DOI 10.1006/anbe.1995.0221; Neugebauer NM, 2004, DEV BRAIN RES, V153, P213, DOI 10.1016/j.devbrainres.2004.09.001; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Pena Y, 2006, BEHAV BRAIN RES, V174, P181, DOI 10.1016/j.bbr.2006.07.007; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Poon Chi-Sang, 2006, Behav Brain Funct, V2, P29, DOI 10.1186/1744-9081-2-29; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rau V, 2009, STRESS, V12, P125, DOI 10.1080/10253890802137320; RENNER MJ, 1986, DEV PSYCHOBIOL, V19, P303, DOI 10.1002/dev.420190403; ROBERTS WW, 1988, ANN NY ACAD SCI, V525, P363, DOI 10.1111/j.1749-6632.1988.tb38620.x; Rojas-Carvajal M., 2016, 2 FALAN C; Rojas-Carvajal M., 2016, 46 ANN M SOC NEUR; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; ROTH KA, 1979, NEUROSCI BIOBEHAV R, V3, P247, DOI 10.1016/0149-7634(79)90012-5; Roy V, 2001, PHYSIOL BEHAV, V74, P313, DOI 10.1016/S0031-9384(01)00561-3; Saenz JCB, 2006, BEHAV BRAIN RES, V169, P57, DOI 10.1016/j.bbr.2005.12.001; Sampedro-Piquero P, 2014, PHYSIOL BEHAV, V129, P118, DOI 10.1016/j.physbeh.2014.02.048; Schrijver NCA, 2002, PHARMACOL BIOCHEM BE, V73, P209, DOI 10.1016/S0091-3057(02)00790-6; Schuch CP, 2016, BEHAV BRAIN RES, V304, P42, DOI 10.1016/j.bbr.2016.02.010; Sequeira-Cordero A, 2014, NEUROSCIENCE, V265, P95, DOI 10.1016/j.neuroscience.2014.01.047; SEYFARTH RM, 1980, ANIM BEHAV, V28, P798, DOI 10.1016/S0003-3472(80)80140-0; Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002; Song C, 2016, NAT REV NEUROSCI, V17, DOI 10.1038/nrn.2016.103; Spradley JM, 2012, ACTA DERM-VENEREOL, V92, P515, DOI 10.2340/00015555-1364; SPRUIJT BM, 1992, PHYSIOL REV, V72, P825; THIESSEN DD, 1988, ANN NY ACAD SCI, V525, P27, DOI 10.1111/j.1749-6632.1988.tb38593.x; TINBERGEN N., 1952, QUART REV BIOL, V27, P1; Turner KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093411; Valles A, 2000, AM J PHYSIOL-REG I, V279, pR1138; VANERP AMM, 1994, BEHAV BRAIN RES, V65, P47, DOI 10.1016/0166-4328(94)90072-8; Varty GB, 2000, BIOL PSYCHIAT, V47, P864, DOI 10.1016/S0006-3223(99)00269-3; Veloso A. W. N, 2016, PSYCHOL NEUROSCI, V9, P91, DOI DOI 10.1037/PNE0000038; WELKER WI, 1959, J COMP PHYSIOL PSYCH, V52, P106, DOI 10.1037/h0042241; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982; Zimmermann A, 2001, BEHAV BRAIN RES, V121, P11, DOI 10.1016/S0166-4328(00)00377-6	86	11	13	3	17	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0003-3472	1095-8282		ANIM BEHAV	Anim. Behav.	MAR	2018	137						225	235		10.1016/j.anbehav.2018.01.018			11	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	FZ2TQ	WOS:000427436600024					2021-06-18	
J	Rui, Q; Ni, HB; Gao, F; Dang, BQ; Li, D; Gao, R; Chen, G				Rui, Qin; Ni, Haibo; Gao, Fan; Dang, Baoqi; Li, Di; Gao, Rong; Chen, Gang			LRRK2 Contributes to Secondary Brain Injury Through a p38/Drosha Signaling Pathway After Traumatic Brain Injury in Rats	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						LRRK2; p38; Drosha; traumatic brain injury; secondary brain injury	SUBARACHNOID HEMORRHAGE; PARKINSONS; ACTIVATION; INHIBITION; PATHOPHYSIOLOGY; PHOSPHORYLATION; DYSFUNCTION; MECHANISMS; MICRORNA	Leucine-rich repeat kinase 2 (LRRK2) is widely expressed in the brain and exerts neurotoxicity in Parkinson's disease. The p38/Drosha signaling activation has been reported to increase cell death under stress. This study was designed to investigate the potential role and mechanism of LRRK2 in secondary brain injury after traumatic brain injury (TBI). A total of 130 male Sprague-Dawley rats were examined using a weight-drop model of TBI. The rats received the specific LRRK2 inhibitor PF-06447475 or LRRK2 pDNA alone or in combination with Drosha pDNA. Real-time PCR, western blot, immunofluorescence, neuronal apoptosis, brain water content, and neurological score analyses were conducted. Our results showed that after TBI, endogenous LRRK2 expression and p38 phosphorylation were increased, whereas Drosha expression was inhibited. Administration of the LRRK2 inhibitor PF-06447475 significantly reduced neuronal apoptosis, brain water content, and blood-brain barrier permeability 12 h after TBI and ameliorated neurological deficits 72 h after TBI, which was concomitant with decreased p38 phosphorylation and increased Drosha expression. Conversely, LRRK2 overexpression induced the opposite effect. Moreover, the neurotoxic effects of LRRK2 on TBI were also eliminated by Drosha overexpression. Altogether, these findings demonstrate the importance of TBI-induced LRRK2 upregulation during the induction of post-traumatic neurological injury, which may be partially mediated through a p38/Drosha signaling pathway.	[Rui, Qin; Gao, Rong] First Peoples Hosp Zhangjiagang, Dept Lab, Suzhou, Peoples R China; [Ni, Haibo] First Peoples Hosp Zhangjiagang, Dept Neurosurg, Suzhou, Peoples R China; [Gao, Fan; Dang, Baoqi] Nanjing Univ Chinese Med, Dept Rehabil, Zhangjiagang Hosp Tradit Chinese Med, Suzhou, Peoples R China; [Li, Di] First Peoples Hosp Zhangjiagang, Dept Translat Med Ctr, Suzhou, Peoples R China; [Chen, Gang] Soochow Univ, Dept Neurosurg, Affiliated Hosp 1, Suzhou, Peoples R China; [Chen, Gang] Soochow Univ, Brain & Nerve Res Lab, Affiliated Hosp 1, Suzhou, Peoples R China	Gao, R (corresponding author), First Peoples Hosp Zhangjiagang, Dept Lab, Suzhou, Peoples R China.; Li, D (corresponding author), First Peoples Hosp Zhangjiagang, Dept Translat Med Ctr, Suzhou, Peoples R China.	lidilab@sina.com; lidi715@163.com					Aguado LC, 2017, NATURE, V547, P114, DOI 10.1038/nature22990; Atashrazm F, 2016, CLIN PHARMACOL-ADV A, V8, P177, DOI 10.2147/CPAA.S102191; Bae JR, 2015, BMB REP, V48, P243, DOI 10.5483/BMBRep.2015.48.5.032; Casili G, 2018, J NEUROTRAUM, V35, P1437, DOI 10.1089/neu.2017.5260; Cookson MR, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0564-y; Dash PK, 2016, J NEUROSCI, V36, P2809, DOI 10.1523/JNEUROSCI.3197-15.2016; Devyatov AA, 2017, B EXP BIOL MED+, V163, P195, DOI 10.1007/s10517-017-3764-4; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Dixon KJ, 2017, PHYS MED REH CLIN N, V28, P215, DOI 10.1016/j.pmr.2016.12.001; Feng DY, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12395; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gillardon F, 2012, NEUROSCIENCE, V208, P41, DOI 10.1016/j.neuroscience.2012.02.001; Gloeckner CJ, 2009, J NEUROCHEM, V109, P959, DOI 10.1111/j.1471-4159.2009.06024.x; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Ho DH, 2017, BIOCHEM BIOPH RES CO, V482, P1088, DOI 10.1016/j.bbrc.2016.11.163; Hong SG, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003706; Hsu CH, 2010, NEURODEGENER DIS, V7, P68, DOI 10.1159/000285509; Hsu CH, 2010, J NEUROCHEM, V112, P1593, DOI 10.1111/j.1471-4159.2010.06568.x; Islam MS, 2017, BIOCHEM SOC T, V45, P163, DOI 10.1042/BST20160264; Kang UB, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600092; Kim B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034693; Kim KY, 2015, BIOCHEM BIOPH RES CO, V464, P236, DOI 10.1016/j.bbrc.2015.06.125; Kim T, 2017, J CEREBR BLOOD F MET, V37, P1910, DOI 10.1177/0271678X17694186; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee H, 2017, BIOCHEM SOC T, V45, P131, DOI 10.1042/BST20160262; Li D, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0841-6; Lin X, 2009, NEURON, V64, P807, DOI 10.1016/j.neuron.2009.11.006; Mechtler P, 2017, RNA BIOL, V14, P1508, DOI 10.1080/15476286.2017.1342934; Moehle MS, 2012, J NEUROSCI, V32, P1602, DOI 10.1523/JNEUROSCI.5601-11.2012; Parisiadou L, 2014, NAT NEUROSCI, V17, P367, DOI 10.1038/nn.3636; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Shen HT, 2015, STROKE, V46, P2607, DOI 10.1161/STROKEAHA.115.009729; Tang Zhaohua, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P928; Tsika E, 2012, CURR NEUROL NEUROSCI, V12, P251, DOI 10.1007/s11910-012-0265-8; Verma M, 2014, BBA-MOL BASIS DIS, V1842, P1273, DOI 10.1016/j.bbadis.2013.11.005; Wang XL, 2012, HUM MOL GENET, V21, P1931, DOI 10.1093/hmg/dds003; Wang Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep33577; Wei L, 2014, CLIN EXP PHARMACOL P, V41, P134, DOI 10.1111/1440-1681.12186; Wu J, 2016, STROKE, V47, P1319, DOI 10.1161/STROKEAHA.115.011552; Yang H, 2017, ACTA PHARMACOL SIN, V38, P168, DOI 10.1038/aps.2016.130; Yang P, 2016, EXP NEUROL, V283, P157, DOI 10.1016/j.expneurol.2016.06.010; Yang Q, 2015, MOL CELL, V57, P721, DOI 10.1016/j.molcel.2015.01.004; Yokota Takanori, 2009, Brain and Nerve (Tokyo), V61, P167; You WC, 2016, J NEUROL SCI, V367, P224, DOI 10.1016/j.jns.2016.06.021; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020; Zhao ZL, 2017, PROTEIN CELL, V8, P801, DOI 10.1007/s13238-017-0414-6	46	11	11	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	MAR 1	2018	12								51	10.3389/fncel.2018.00051			15	Neurosciences	Neurosciences & Neurology	FX9FE	WOS:000426401200001	29545743	DOAJ Gold, Green Published			2021-06-18	
J	Tarazi, A; Tator, CH; Wennberg, R; Ebraheem, A; Green, REA; Collela, B; Saverino, C; Khodadadi, M; Misquitta, K; Tartaglia, MC				Tarazi, Apameh; Tator, Charles H.; Wennberg, Richard; Ebraheem, Ahmed; Green, Robin E. A.; Collela, Brenda; Saverino, Christina; Khodadadi, Mozghan; Misquitta, Karen; Tartaglia, Maria Carmela			Motor Function in Former Professional Football Players with History of Multiple Concussions	JOURNAL OF NEUROTRAUMA			English	Article						chronic traumatic encephalopathy; concussion; professional athletes	TRAUMATIC BRAIN-INJURY; DISEASE; SPORT; ENCEPHALOPATHY; STATEMENT; SPECTRUM	The objective of this study was to assess the incidence of motor impairment in former professional Canadian Football League (ex-CFL) players with multiple concussions. We investigated motor symptoms and signs in 45 ex-CFL players with multiple concussions and 25 age- and education-matched healthy controls with no history of concussion. Neurological assessment included items from the SCAT3 (Sport Concussion Assessment Tool 3) and the Unified Parkinson's Disease Rating Scale part III (UPDRS-Part III). A performance-based measurement of manual motor function was undertaken using the Grooved Pegboard test. Cognition was measured with patient-reported outcomes for memory, executive and behavioral symptoms as well as performance-based measures of memory and executive function. Symptoms of anxiety and depression were measured using the Personality Assessment Inventory. There was no significant difference between the ex-CFL players and controls on the UPDRS-Part III scores, and neither group reported clinically significant motor complaints. Ex-CFL players did not perform differently from control subjects on the Grooved Pegboard test. In contrast, with regard to cognitive and mood testing, players were more symptomatic: The ex-CFL players reported significantly more memory (77.8% vs. 16%, respectively, p<0.001), executive (53.3% vs. 8%, respectively, p<0.001), and behavioral symptoms (66.7% vs. 20%, respectively, p<0.001). No significant differences were found when comparing ex-CFL players and controls in performance on memory and executive tests. In summary, in a group of retired CFL players who self-reported declines in memory, executive and behavioral symptoms, no motor symptoms were reported and no motor signs were detected.	[Tarazi, Apameh; Tator, Charles H.; Wennberg, Richard; Ebraheem, Ahmed; Green, Robin E. A.; Collela, Brenda; Khodadadi, Mozghan; Tartaglia, Maria Carmela] Canadian Concuss Ctr, Toronto, ON, Canada; [Tarazi, Apameh; Tator, Charles H.; Wennberg, Richard; Khodadadi, Mozghan; Tartaglia, Maria Carmela] Toronto Western Hosp, Concuss Res Clin, Toronto, ON, Canada; [Tator, Charles H.; Tartaglia, Maria Carmela] Univ Toronto, Krembil Res Inst, Div Brain Imaging & Behav Syst Neurosci, Toronto, ON, Canada; [Tator, Charles H.] Toronto Western Hosp, Krembil Neurosci Ctr, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Wennberg, Richard; Tartaglia, Maria Carmela] Toronto Western Hosp, Krembil Neurosci Ctr, Dept Med, Div Neurol, Toronto, ON, Canada; [Misquitta, Karen; Tartaglia, Maria Carmela] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; [Green, Robin E. A.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Green, Robin E. A.; Collela, Brenda] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Green, Robin E. A.; Collela, Brenda; Saverino, Christina] Toronto Rehabil Inst, Toronto, ON, Canada	Tartaglia, MC (corresponding author), Toronto Western Hosp, 399 Bathurst St,WW5-449, Toronto, ON M5T 2S8, Canada.	Carmela.tartaglia@uhn.ca		Green, Robin/0000-0001-9451-3963			Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dadar M., 2016, ALZHEIMERS DEMENT, V12, pP71; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Esopenko C, 2017, J NEUROL NEUROSUR PS, V88, P512, DOI 10.1136/jnnp-2016-315260; Fournier CN, 2015, NEUROLOGY, V84, P1788, DOI 10.1212/WNL.0000000000001522; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Goswami R, 2014, BRAIN INJURY, V28, P592; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Misquitta K., 2016, ALZHEIMERS DEMENT, V12, pP1110; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Multani N, 2016, J NEUROL, V263, P1332, DOI 10.1007/s00415-016-8141-0; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9	33	11	11	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	8					1003	1007		10.1089/neu.2017.5290		MAR 2018	5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GC0DM	WOS:000426666000001	29256818				2021-06-18	
J	Servatius, RJ; Spiegler, KM; Handy, JD; Pang, KCH; Tsao, JW; Mazzola, CA				Servatius, Richard J.; Spiegler, Kevin M.; Handy, Justin D.; Pang, Kevin C. H.; Tsao, Jack W.; Mazzola, Catherine A.			Neurocognitive and Fine Motor Deficits in Asymptomatic Adolescents during the Subacute Period after Concussion	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; cognitive function; pediatric brain injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HEAD-TO-HEAD; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; RECOVERY; PREDICTORS; NETWORKS; CHILDREN; OUTCOMES	Adolescents are at high risk for sustaining concussions. There is considerable controversy regarding the sensitivity of neurocognitive tests to detect and track dysfunction in the aftermath of concussion. Two neurocognitive test batteries were compared during the subacute phase of recovery from concussion to determine sensitivity to concussion. Adolescents (ages 11-17 years) with a concussion diagnosis (eight males, seven females, 9-69 days after injury) were recruited through a concussion clinic and compared with community nonconcussed volunteers (11 males, three females). Adolescents completed the online version of the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT) on a desktop computer and the Defense Automated Neurobehavioral Assessment (DANA) on a handheld device, as well as the Grooved Pegboard Test, which assessed manual dexterity and motor speed. There were no differences in self-reported symptoms on the Post-Concussion Symptom Scale comparing concussed and nonconcussed adolescents. No significant between-groups differences were observed in ImPACT performance. Performance deficits were apparent for the DANA assessment, reflecting lower throughput scores for simple reaction time and response inhibition parameters in those with concussion. Concussed adolescents also had slower Grooved Pegboard Test performance when using the nondominant hand. Both the DANA test battery and the Grooved Pegboard Test appear to have promise as tools to detect persistent cognitive and motor dysfunction in the subacute period after concussion.	[Servatius, Richard J.; Handy, Justin D.; Pang, Kevin C. H.; Mazzola, Catherine A.] Rutgers State Univ, Rutgers Biomed Hlth Sci Pharmacol Physiol & Neuro, Newark, NJ USA; [Servatius, Richard J.; Spiegler, Kevin M.; Pang, Kevin C. H.] Rutgers State Univ, Grad Sch Biomed Sci, Newark, NJ USA; [Servatius, Richard J.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA; [Handy, Justin D.] Cent New York Res Corp, Syracuse, NY USA; [Tsao, Jack W.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Tsao, Jack W.] Le Bonheur Childrens Hosp, Childrens Fdn, Res Inst, Memphis, TN USA; [Mazzola, Catherine A.] Morristown Med Ctr, Morristown, NJ USA	Servatius, RJ (corresponding author), Upstate Univ Hosp, Dept Psychiat, 750 East Adams St, Syracuse, NY 13210 USA.	servatir@upstate.edu		Spiegler, Kevin/0000-0002-9271-5825	Stress & Motivated Behavior Institute; Veterans AffairsUS Department of Veterans Affairs [I01BX000132] Funding Source: NIH RePORTER	The research team would like to acknowledge the efforts and contributions of Meghan Crippen and Sreeya Komaravolu in conducting this research study. Financial support was provided by the Stress & Motivated Behavior Institute.	Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; Balaban C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162168; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Borich M, 2015, J NEUROTRAUM, V32, P265, DOI 10.1089/neu.2013.3269; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lathan C, 2013, MIL MED, V178, P365, DOI 10.7205/MILMED-D-12-00438; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McDevitt J, 2016, INT J SPORTS MED, V37, P738, DOI 10.1055/s-0042-100470; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Nelson LD, 2017, J INT NEUROPSYCH SOC, V23, P293, DOI 10.1017/S1355617717000157; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Newsome MR, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00116; Pang KCH, 2015, J NEUROTRAUM, V32, P801, DOI 10.1089/neu.2014.3451; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rieger BP, 2013, BRAIN INJURY, V27, P169, DOI 10.3109/02699052.2012.729290; Schmidt JD, 2017, J NEUROTRAUM, V34, P1571, DOI 10.1089/neu.2016.4668; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; Teel E, 2016, NEUROPSYCHOLOGY, V30, P474, DOI 10.1037/neu0000261; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Trites R, 1977, NEUROPSYCHOLOGICAL T; Urban KJ, 2017, J NEUROTRAUM, V34, P816, DOI 10.1089/neu.2016.4502; Virji-Babul N, 2014, J NEUROTRAUM, V31, P1914, DOI 10.1089/neu.2014.3450; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wright WG, 2017, DISABIL REHABIL, V39, P1564, DOI 10.1080/09638288.2016.1226432	39	11	11	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	8					1008	1014		10.1089/neu.2017.5314		FEB 2018	7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GC0DM	WOS:000424831100001	29278998				2021-06-18	
J	Anderson, M; Elmer, J; Shutter, L; Puccio, A; Alexander, S				Anderson, Maighdlin; Elmer, Jonathan; Shutter, Lori; Puccio, Ava; Alexander, Sheila			Integrating Quantitative Pupillometry Into Regular Care in a Neurotrauma Intensive Care Unit	JOURNAL OF NEUROSCIENCE NURSING			English	Article						critical care; intensive care unit (ICU); neurological pupil index (NPi); neurotrauma; nursing; pupillometer; technology; traumatic brain injury (TBI)	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; DILATED PUPILS; NORMATIVE DATA; SCALE; RELIABILITY; DEATH; SCORE; SIZE	In the setting of acute traumatic brain injury (TBI), an abnormal pupil assessment may suggest a worsening intracranial lesion. Early detection of pupillary changes may expedite emergent care to improve outcomes. Automated, handheld pupillometers have been commercially available for 20 years, and several studies suggest that their use may facilitate early recognition of worsening injury and intracranial hypertension. The use of pupillometry as a bedside tool in the routine care of patients with severe TBI (Glasgow Coma Scale score 8) has not been described. We performed a quality improvement project to implement routine use of quantitative pupillometry in our neurotrauma intensive care unit. Nursing staff were trained on device use and the project's aims in a 30-minute in-service session. Nurses caring for severe TBI patients completed standard pupil assessments using (a) a flashlight and (b) a pupillometer to quantify pupil size and reactivity (Neurological Pupil index) every hour. Abnormal results were reported to on-call providers. We administered surveys to evaluate knowledge, practical use of the pupillometer data, and satisfaction with the device every 3 months. Data were available for 22 nurses at 4 separate time points. Staff were positive about their ability to use and understand the device (mu = 8.7 and 9.1, respectively, on a 10-point scale) and reported that it added value to patient care and critical decision-making. Use of automated pupillometry is acceptable to nursing staff in a neurotrauma intensive care unit, and staff believed that pupillometry results enhanced clinical decision-making.	[Anderson, Maighdlin] UPMC, Pittsburgh, PA 15213 USA; [Elmer, Jonathan] Univ Pittsburgh, Sch Med, Dept Emergency, Pittsburgh, PA USA; [Elmer, Jonathan; Shutter, Lori] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Shutter, Lori] Univ Pittsburgh, Sch Med, Crit Care Med, Educ, Pittsburgh, PA USA; [Shutter, Lori] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Shutter, Lori; Puccio, Ava] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Puccio, Ava; Alexander, Sheila] Univ Pittsburgh, Sch Nursing, Dept Acute & Tertiary Care, Pittsburgh, PA 15261 USA; [Puccio, Ava] Univ Pittsburgh, Sch Nursing, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Puccio, Ava] Univ Pittsburgh, Sch Med, Dept Acute & Tertiary Care, Pittsburgh, PA USA; [Alexander, Sheila] Univ Pittsburgh, Sch Nursing, Dept Crit Care Med, Pittsburgh, PA 15261 USA	Anderson, M (corresponding author), UPMC, Pittsburgh, PA 15213 USA.	andersonmw@upmc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Carney N, 2016, NEUROSURGERY, P1, DOI [10.1227/NEU.0000000000001432, DOI 10.1227/NEU.0000000000001432]; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Clark A, 2006, EMERG MED J, V23, P440, DOI 10.1136/emj.2005.030247; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Couret D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1239-z; Egea-Guerrero JJ, 2012, TRANSPL P, V44, P2050, DOI 10.1016/j.transproceed.2012.07.070; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Karamanos E, 2014, AM J SURG, V208, P363, DOI 10.1016/j.amjsurg.2013.10.026; Kerr RG, 2016, AM J CRIT CARE, V25, P213, DOI 10.4037/ajcc2016554; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McNett M, 2017, J NEUROSCI NURS, V49, P229, DOI 10.1097/JNN.0000000000000290; National Institute of Neurological Disorders and Stroke, 2002, TRAUM BRAIN INJ HOP; Olson DM, 2017, J NEUROSCI NURS, V49, P251, DOI 10.1097/JNN.0000000000000296; Olson DM, 2016, NEUROCRIT CARE, V24, P251, DOI 10.1007/s12028-015-0182-1; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Rogers EM., 2003, DIFFUSION INNOVATION, V5th ed; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; US Department of Health and Human Services Centers for Disease Control and Prevention & National Center for Injury Prevention and Control, 2016, TBI GET FACTS INJ PR; Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012	27	11	11	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	FEB	2018	50	1					30	36		10.1097/JNN.0000000000000333			7	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	FS6VG	WOS:000419935900010	29303836				2021-06-18	
J	Berger, RP; Saladino, RA; Fromkin, J; Heineman, E; Suresh, S; McGinn, T				Berger, Rachel P.; Saladino, Richard A.; Fromkin, Janet; Heineman, Emily; Suresh, Srinivasan; McGinn, Tom			Development of an electronic medical record-based child physical abuse alert system	JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION			English	Article						child abuse; physical abuse; electronic medical record	TRAUMATIC BRAIN-INJURY; UNITED-STATES; YOUNG-CHILDREN; HEAD TRAUMA; INFANTS; FRACTURES; GUIDELINE; IDENTIFICATION; MALTREATMENT; DIAGNOSIS	Objective: Physical abuse is a leading cause of pediatric morbidity and mortality. Physicians do not consistently screen for abuse, even in high-risk situations. Alerts in the electronic medical record may help improve screening rates, resulting in early identification and improved outcomes. Methods: Triggers to identify children <2 years old at risk for physical abuse were coded into the electronic medical record at a freestanding pediatric hospital with a level 1 trauma center. The system was run in "silent mode"; physicians were unaware of the system, but study personnel received data on children who triggered the alert system. Sensitivity, specificity, and negative and positive predictive values of the child abuse alert system for identifying physical abuse were calculated. Results: Thirty age-specific triggers were embedded into the electronic medical record. From October 21, 2014, through April 6, 2015, the system was in silent mode. All 226 children who triggered the alert system were considered subjects. Mean (SD) age was 9.1 (6.5) months. All triggers were activated at least once. Sensitivity was 96.8% (95% CI, 92.4-100.0%), specificity was 98.5% (95% CI, 98.3.5-98.7), and positive and negative predictive values were 26.5% (95% CI, 21.2-32.8%) and 99.9% (95% CI, 99.9-100.0%), respectively, for identifying children <2 years old with possible, probable, or definite physical abuse. Discussion/Conclusion: Triggers embedded into the electronic medical record can identify young children with who need to be evaluated for physical abuse with high sensitivity and specificity.	[Berger, Rachel P.; Saladino, Richard A.; Fromkin, Janet; Heineman, Emily; Suresh, Srinivasan] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA; [McGinn, Tom] Hofstra Northwell Sch Med, Dept Med, Manhasset, NY USA	Berger, RP (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Child Advocacy, Dept Pediat, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	rachel.berger@chp.edu			 [PCORI-AD-12-11-4956]	The study was supported by PCORI-AD-12-11-4956. The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute, its Board of Governors or Methodology Committee.	American Cancer Society, 2012, CANC IN CHILDR; Anderst JD, 2013, PEDIATRICS, V131, pE1314, DOI 10.1542/peds.2013-0195; Berger RP, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3756; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Cebul RD, 2011, NEW ENGL J MED, V365, P825, DOI 10.1056/NEJMsa1102519; Christian CW, 2015, PEDIATRICS, V135, pE1337, DOI 10.1542/peds.2015-0356; Eckenrode J, 2014, PEDIATRICS, V133, P454, DOI 10.1542/peds.2013-1707; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; Flaherty EG, 2014, PEDIATRICS, V133, pE477, DOI 10.1542/peds.2013-3793; Gill JM, 2011, ANN FAM MED, V9, P22, DOI 10.1370/afm.1172; Guenther E, 2010, J PEDIATR-US, V157, P821, DOI 10.1016/j.jpeds.2010.04.072; Guerra CE, 2007, J GEN INTERN MED, V22, P1681, DOI 10.1007/s11606-007-0396-9; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WK, 2006, PEDIATR EMERG CARE, V22, P211, DOI 10.1097/01.pec.0000208180.94166.dd; Lane WG, 2007, CLIN ORTHOP RELAT R, P219, DOI 10.1097/BLO.0b013e31805c0849; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Lanier P, 2014, J DEV BEHAV PEDIATR, V35, P419, DOI 10.1097/DBP.0000000000000083; Madlon-Kay DJ, 2012, J AM BOARD FAM MED, V25, P437, DOI 10.3122/jabfm.2012.04.110307; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Pierce MC, 2009, PEDIATR EMERG CARE, V25, P845, DOI 10.1097/PEC.0b013e3181c06217; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Schiff GD, 2012, BMJ QUAL SAF, V21, P89, DOI 10.1136/bmjqs-2011-000590; Shiffman RN, 1999, J AM MED INFORM ASSN, V6, P104, DOI 10.1136/jamia.1999.0060104; Smythe MA, 2012, AM J HEALTH-SYST PH, V69, P241, DOI 10.2146/ajhp110313; Thackeray JD, 2007, PEDIATR EMERG CARE, V23, P735, DOI 10.1097/PEC.0b013e3181568039; Thorpe EL, 2014, PEDIATR EMERG CARE, V30, P771, DOI 10.1097/PEC.0000000000000257; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Vernacchio L, 2007, PEDIATRICS, V120, P281, DOI 10.1542/peds.2006-3601; Wood JN, 2012, PEDIATRICS, V130, P853, DOI 10.1542/peds.2012-0244; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	35	11	11	3	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1067-5027	1527-974X		J AM MED INFORM ASSN	J. Am. Med. Inf. Assoc.	FEB	2018	25	2					142	149		10.1093/jamia/ocx063			8	Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics	Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics	FV9TC	WOS:000424930900006	28641385	Green Published			2021-06-18	
J	Burton, RL; O'Connell, ME				Burton, Rachel L.; O'Connell, Megan E.			Telehealth Rehabilitation for Cognitive Impairment: Randomized Controlled Feasibility Trial	JMIR RESEARCH PROTOCOLS			English	Article						cognitive rehabilitation; Alzheimer disease; dementia; telehealth	QUALITY-OF-LIFE; EARLY ALZHEIMERS-DISEASE; ZARIT BURDEN INTERVIEW; TRAUMATIC BRAIN-INJURY; PSYCHOMETRIC PROPERTIES; MULTIPLE-SCLEROSIS; DEMENTIA; PEOPLE; TELEREHABILITATION; INTERVENTION	Background: Nonpharmacological interventions are needed to support the function of older adults struggling with subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and dementia due to Alzheimer disease (AD). Telerehabilitation aims to provide rehabilitation at a distance, but cognitive rehabilitation by videoconferencing has not been explored. Objective: The objective of this study was to compare goal-oriented cognitive rehabilitation delivered in-person with videoconferencing to determine whether telehealth cognitive rehabilitation appears feasible. Methods: Random assignment to in-person or telehealth videoconferencing cognitive rehabilitation with a combined between-subjects, multiple baseline single-case experimental design, cognitive rehabilitation was delivered by a therapist to 6 participants with SCI (n=4), MCI (n=1), or dementia due to AD (n=1). Results: Two of the 6 participants randomly assigned to the telehealth condition withdrew before beginning the intervention. For those who participated in the intervention, 6 out of 6 goals measured with the Canadian Occupational Performance Measure improved for those in the in-person group, and 7 out of 9 goals improved for those in the telehealth group. Conclusions: Delivery of cognitive rehabilitation by telehealth appeared feasible but required modifications such as greater reliance on caregivers and clients for manipulating materials.	[Burton, Rachel L.; O'Connell, Megan E.] Univ Saskatchewan, Dept Psychol, 9 Campus Dr, Saskatoon, SK, Canada	O'Connell, ME (corresponding author), Univ Saskatchewan, Dept Psychol, 9 Campus Dr, Saskatoon, SK, Canada.	megan.oconnell@usask.ca			Alzheimer Society of Canada	RLB was supported by a doctoral award from the Alzheimer Society of Canada.	Bahar-Fuchs A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003260.pub2; Barton C, 2011, TELEMED E-HEALTH, V17, P789, DOI 10.1089/tmj.2011.0083; Beck JS., 2011, COGNITIVE THERAPY BA; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; Bedard Michel, 2004, Can J Rural Med, V9, P15; Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Brooks JBB, 2011, ARQ NEURO-PSIQUIAT, V69, P887, DOI 10.1590/S0004-282X2011000700007; Bird M, 2001, NEUROPSYCHOL REHABIL, V11, P357, DOI 10.1080/09602010042000042; Bourgeois MS, 2003, J COMMUN DISORD, V36, P361, DOI 10.1016/S0021-9924(03)00051-0; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Bucks RS, 1996, AGE AGEING, V25, P113, DOI 10.1093/ageing/25.2.113; Burton R, 2016, NEUROREHABILITATION, V39, P329, DOI 10.3233/NRE-161364; Carswell Anne, 2004, Can J Occup Ther, V71, P210; Clare L, 2003, AGING MENT HEALTH, V7, P15, DOI 10.1080/1360786021000045854; Clare L, 2008, NEUROPSYCHOLOG REHAB, P1; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; Clare L, 1999, NEUROCASE, V5, P37, DOI 10.1080/13554799908404063; Clare L, 2011, CLIN GERONTOLOGIST, V34, P220, DOI 10.1080/07317115.2011.555937; Clare L, 2010, AM J GERIAT PSYCHIAT, V18, P928, DOI 10.1097/JGP.0b013e3181d5792a; DALBELLOHAAS VPM, 2014, RURAL REMOTE HLTH, V14; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dobson D, 2009, EVIDENCE BASED PRACT; Finkelstein J, 2008, J REHABIL RES DEV, V45, P1361, DOI 10.1682/JRRD.2008.01.0001; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gervasi O, 2010, VIRTUAL REAL-LONDON, V14, P131, DOI 10.1007/s10055-009-0149-7; Greene CJ, 2010, J CONSULT CLIN PSYCH, V78, P746, DOI 10.1037/a0020158; Jackson JC, 2012, CRIT CARE MED, V40, P1088, DOI 10.1097/CCM.0b013e3182373115; Kazdin A. E., 2011, SINGLE CASE RES DESI; Kurz AF, 2011, INT PSYCHOGERIATR, V23, P1364, DOI 10.1017/S1041610211001001; Law M., 2005, CANADIAN OCCUPATIONA, V4th ed; Logsdon R. G., 1999, J MENTAL HLTH AGING, V5, P21, DOI DOI 10.1037/T00930-000; Lorig K, 2012, J APPL GERONTOL, V31, P423, DOI 10.1177/0733464810389806; Man DWK, 2006, NEUROREHABILITATION, V21, P205; Martin-Khan M, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.004; MATYAS TA, 1990, J APPL BEHAV ANAL, V23, P341, DOI 10.1901/jaba.1990.23-341; McMahon C. M., 2003, CLIN PSYCHOL, V7, P50, DOI DOI 10.1080/13284200410001707483; Morgan DG, 2009, AGING MENT HEALTH, V13, P17, DOI 10.1080/13607860802154432; Ng EMW, 2013, BRAIN INJURY, V27, P548, DOI 10.3109/02699052.2013.766927; O'Connell ME, 2014, DEMENTIA-LONDON, V13, P382, DOI 10.1177/1471301212474143; O'Rourke N, 2003, GERONTOLOGIST, V43, P121, DOI 10.1093/geront/43.1.121; O'Sullivan M, 2015, AGING NEUROPSYCHOL C, V22, P280, DOI 10.1080/13825585.2014.927818; Pain H, 2016, J TELEMEDICINE TE S1, V13, P46, DOI 10.1258/135763307781645095; Perales J, 2013, INT PSYCHOGERIATR, V25, P691, DOI 10.1017/S1041610212002293; Provencher V, 2008, AM J ALZHEIMERS DIS, V23, P47, DOI 10.1177/1533317507307228; Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46; Ridgeway V, 1994, TEST EVERYDAY ATTENT; Rogante M, 2010, NEUROREHABILITATION, V27, P287, DOI 10.3233/NRE-2010-0612; Romanow Roy J., 2002, BUILDING VALUES FUTU; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Serafini JD, 2007, SOC WORK HEALTH CARE, V44, P225, DOI 10.1300/J010v44n03_07; Siebern AT, 2010, MED CLIN N AM, V94, P581, DOI 10.1016/j.mcna.2010.02.005; Silberman SA, 2008, INSOMNIA WORKBOOK; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Smith JD, 2012, PSYCHOL METHODS, V17, P510, DOI 10.1037/a0029312; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Statistics Canada, 2010, SEN; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tam Sing-Fai, 2003, Occup Ther Int, V10, P20, DOI 10.1002/oti.175; Thivierge Stephanie, 2008, Neuropsychiatr Dis Treat, V4, P987; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; von Steinbuchel Nicole, 2006, Eur J Ageing, V3, P116, DOI 10.1007/s10433-006-0024-2; Wampold BE, 2015, WORLD PSYCHIATRY, V14, P270, DOI 10.1002/wps.20238; Wilson B, 1984, CLIN MANAGEMENTM MEM, P86; Wilson B.A., 2008, RIVERMEAD BEHAV MEMO; Wilson BA, 2003, STUD NEUROPSYCHOL DE, P1; World Health Organization, 2010, TEL OPP DEV MEMB STA; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI DOI 10.1080/110381299443771	69	11	12	1	9	JMIR PUBLICATIONS, INC	TORONTO	59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA	1929-0748			JMIR RES PROTOC	JMIR RES. Protoc.	FEB	2018	7	2							e43	10.2196/resprot.9420			18	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	GG7ZB	WOS:000432916000028	29422453	DOAJ Gold, Green Published			2021-06-18	
J	Hendrickson, P; Pridgeon, J; Temkin, NR; Videtta, W; Petroni, G; Lujan, S; Guadagnoli, N; Urbina, Z; Pahnke, PB; Godoy, D; Pinero, G; Lora, FS; Aguilera, S; Rubiano, AM; Morejon, CS; Jibaja, M; Lopez, H; Romero, R; Dikmen, S; Chaddock, K; Chesnut, RM				Hendrickson, Peter; Pridgeon, James; Temkin, Nancy R.; Videtta, Walter; Petroni, Gustavo; Lujan, Silvia; Guadagnoli, Nahuel; Urbina, Zulma; Pahnke, Perla Blanca; Godoy, Daniel; Pinero, Gustavo; Lora, Freddy Sandi; Aguilera, Sergio; Rubiano, Andres M.; Morejon, Caridad Soler; Jibaja, Manuel; Lopez, Hubiel; Romero, Ricardo; Dikmen, Sureyya; Chaddock, Kelley; Chesnut, Randall M.			Development of a Severe Traumatic Brain Injury Consensus-Based Treatment Protocol Conference in Latin America	WORLD NEUROSURGERY			English	Article						Consensus treatment protocol; Global health; Intracranial hypertension; Intracranial pressure monitoring; Neurocritical care; Severe traumatic brain injury	EPIDEMIOLOGY; GUIDELINES; MANAGEMENT	BACKGROUND: Severe traumatic brain injury (sTBI) is a significant global health problem disproportionately affecting low-and middle-income countries (LMICs). Management of intracranial hypertension in sTBI is crucial to survival and optimal recovery. Practitioners in high-income countries routinely use intracranial pressure (ICP) monitors although their usefulness has been questioned. ICP monitors are usually unavailable in LMICs. No consensus-based/tested protocols or literature exists for sTBI treatment without ICP monitoring. METHODS: Investigators developed serial SurveyMonkey surveys for Latin American neurointensivists and neurosurgeons to determine current practice. These clinicians had extensive routine ongoing experience in sTBI without ICP monitoring. Surveys were administered and analyzed before/during/after a 2015 Buenos Aires consensus conference. Investigators identified areas of convergence blinded from colleagues' responses. A 47-clinician task force, representing 15 countries, who routinely manage patients with sTBI without monitors developed consensus-based treatment guidelines during a 3-day facilitated conference. RESULTS: Elements were added to the protocol at an 80% agreement threshold. Follow-on surveys resolved remaining elements to 97% agreement. The protocol addresses both tapering (on improvement) and neuroworsening. Staged treatment options were identified, plus unique clinical practice issues. This process introduced a research method to a large multidisciplinary group of LMIC clinicians. This report describes the process used to develop an LMIC-specific protocol that is transferable to other diseases/injuries. The protocol is being tested in 5 LMICs. - CONCLUSIONS: We derived consensus-based guidelines for sTBI treatment without ICP monitoring, and introduced a research method to a large multidisciplinary group of LMIC clinicians naive to such methods.	[Hendrickson, Peter; Pridgeon, James; Temkin, Nancy R.; Dikmen, Sureyya; Chaddock, Kelley; Chesnut, Randall M.] Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA; [Videtta, Walter] Hosp Nacl Prof Alejandro Posadas, Buenos Aires, DF, Argentina; [Petroni, Gustavo; Lujan, Silvia] Hosp Emergencia Dr Clemente Alvarez, Rosario, Argentina; [Guadagnoli, Nahuel] Hosp Privado Rosario, Hosp Emergencia, Rosario, Argentina; [Urbina, Zulma] Hosp Erasmo Meoz ICU 1, Cucuta, Colombia; [Pahnke, Perla Blanca] Hosp Municipal Urgencias, Cordoba, Argentina; [Urbina, Zulma] Sanatorio Pasteur, Catamarca, Argentina; [Pinero, Gustavo] Leonidas Lucero Hosp, Bahia Blanca, Buenos Aires, Argentina; [Lora, Freddy Sandi] Hosp Obrero 1 La Paz, La Paz, Bolivia; [Aguilera, Sergio] Hosp Reg, Inqu, Chile; [Rubiano, Andres M.] El Bosque Univ, Meditech Fdn, Neiva, Colombia; [Morejon, Caridad Soler] Ameijeiras Hosp, Havana, Cuba; [Jibaja, Manuel] Hosp Eugenio Espejo, Quito, Ecuador; [Lopez, Hubiel] Hosp Gen de la Plaza de la Salud, Santo Domingo, Dominican Rep; [Romero, Ricardo] Fdn Clin Campbell, Barranquilla, Colombia	Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA.	chesnutr@uw.edu	Di Napoli, Mario/J-6418-2014; RUBIANO, ANDRES M/K-6704-2012; Gallardo, Angel Jesus Lacerda/AAZ-9478-2020	Di Napoli, Mario/0000-0001-9609-4926; RUBIANO, ANDRES M/0000-0001-8931-3254; Gallardo, Angel Jesus Lacerda/0000-0001-9171-2000; ROMERO FIGUEROA, RICARDO LUIS/0000-0002-3124-8717; Chesnut, Randall/0000-0001-6377-3666	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS080648] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS080648] Funding Source: NIH RePORTER		Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Murphy MK, 1998, HEALTH TECHNOL ASSES, V2, P1, DOI DOI 10.3310/hta2030; Murray CJL, 1996, GLOBAL HLTH STAT; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thangaratinam S, 2005, OBSTET GYNAECOL, V7, P120, DOI 10.1576/toag.7.2.120.27071; World Health Organization, 2002, WORLD HLTH REPORT 20	15	11	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	FEB	2018	110						E952	E957		10.1016/j.wneu.2017.11.142			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FX1ZT	WOS:000425856900122	29203307	Green Accepted			2021-06-18	
J	Kirov, II; Whitlow, CT; Zamora, C				Kirov, Ivan I.; Whitlow, Christopher T.; Zamora, Carlos			Susceptibility-Weighted Imaging and Magnetic Resonance Spectroscopy in Concussion	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article						Magnetic resonance spectroscopy (MRS); Mild traumatic brain injury (mTBI); Concussion; SWI; Susceptibility-weighted imaging	TRAUMATIC BRAIN-INJURY; PROTON MR SPECTROSCOPY; DIFFUSE AXONAL INJURY; SPORTS-RELATED CONCUSSION; N-ACETYLASPARTATE; CORPUS-CALLOSUM; TEMPORAL WINDOW; IN-VIVO; MILD; CHILDREN	Although susceptibility-weighted imaging (SWI) studies have suggested an increased number of microhemorrhages in concussion, most show no significant differences compared with controls. There have been mixed results on using SWI to predict neurologic outcomes. Drawbacks include inability to time microhemorrhages and difficulty in attributing them to the concussion. Magnetic resonance spectroscopy (MRS) in concussion can identify metabolic abnormalities, with many studies showing correlations with clinical outcome. Applications in individual patients are impeded by conflicting data and lack of consensus on an optimal protocol. Therefore, currently MRS has most utility in group-level comparisons designed to reveal the pathophysiology of concussion.	[Kirov, Ivan I.] NYU, Sch Med, Bernard & Irene Schwartz Ctr Biomed Imaging, Ctr Adv Imaging Innovat & Res CAI2R,Dept Radiol, 660 First Ave,421, New York, NY 10016 USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Clin Translat Sci Inst, Dept Radiol, Div Neuroradiol, Med Ctr Blvd, Winston Salem, NC 27157 USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Clin Translat Sci Inst, Dept Biomed Engn, 1 Med Ctr Blvd, Winston Salem, NC 27106 USA; [Zamora, Carlos] Univ N Carolina, Sch Med, Dept Radiol, Div Neuroradiol, CB 7510,3327 Old Infirm, Chapel Hill, NC 27599 USA	Zamora, C (corresponding author), Univ N Carolina, Sch Med, Dept Radiol, Div Neuroradiol, CB 7510,3327 Old Infirm, Chapel Hill, NC 27599 USA.	carlos_zamora@med.unc.edu	Zamora, Carlos/J-5249-2019; Kirov, Ivan/I-2792-2019	Zamora, Carlos/0000-0001-8532-9646; Kirov, Ivan/0000-0001-5641-8578			Aaen GS, 2010, PEDIATRICS, V125, P295, DOI 10.1542/peds.2008-3312; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Barker P, 2010, PULSE SEQUENCES PROT; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Benarroch EE, 2008, NEUROLOGY, V70, P1353, DOI 10.1212/01.wnl.0000311267.63292.6c; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Blanke ML, 2009, FRONT NEUROSCI, P283; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chang K, 2014, AM J NEURORADIOL, V35, P1091, DOI 10.3174/ajnr.A3818; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Choe MC, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0573-9; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dean PJA, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.292; DeGraaf RA, 2007, IN VIVO NMR SPECTROS, P61; Denk C, 2010, J MAGN RESON IMAGING, V31, P185, DOI 10.1002/jmri.21995; Dhandapani S, 2014, J CLIN NEUROSCI, V21, P745, DOI 10.1016/j.jocn.2013.07.038; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P241, DOI 10.3171/2015.1.PEDS14510; Faul M, TRAUMATIC BRAIN INJU; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Gujar SK, 2005, J NEURO-OPHTHALMOL, V25, P217, DOI 10.1097/01.wno.0000177307.21081.81; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Hoch SE, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3710; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Jansen JFA, 2006, RADIOLOGY, V240, P318, DOI 10.1148/radiol.2402050314; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P965, DOI 10.1097/TA.0000000000000161; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lyeth BG, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00217; Maudsley AA, 2015, J NEUROTRAUM, V32, P1056, DOI 10.1089/neu.2014.3505; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2015, J NEUROTRAUM, V32, P1759, DOI 10.1089/neu.2014.3833; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mountford CE, 2010, CHEM REV, V110, P3060, DOI 10.1021/cr900250y; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Ong BC, 2010, J MED IMAG RADIAT ON, V54, P435, DOI 10.1111/j.1754-9485.2010.02208.x; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Prost RW, 1997, MAGN RESON MED, V37, P615, DOI 10.1002/mrm.1910370422; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Shams S, 2015, AM J NEURORADIOL, V36, P1089, DOI 10.3174/ajnr.A4248; Shin SS, 2017, BRAIN IMAGING BEHAV, V11, P591, DOI 10.1007/s11682-017-9684-0; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sivak S, 2014, BRAIN INJURY, V28, P341, DOI 10.3109/02699052.2013.865270; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P550, DOI 10.1007/s11682-015-9424-2; Tao JJ, 2015, NEURAL REGEN RES, V10, P1879, DOI 10.4103/1673-5374.170322; TEASDALE G, 1974, LANCET, V2, P81; Thomas B, 2008, NEURORADIOLOGY, V50, P105, DOI 10.1007/s00234-007-0316-z; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Trifan G, 2017, MAGN RESON IMAGING, V37, P243, DOI 10.1016/j.mri.2016.12.009; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Widerstrom-Noga E, 2016, J NEUROTRAUM, V33, P1380, DOI 10.1089/neu.2015.4098; Wintermark M, 2015, AM J NEURORADIOL, V36, pE12, DOI 10.3174/ajnr.A4254; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	109	11	11	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	FEB	2018	28	1					91	+		10.1016/j.nic.2017.09.007			17	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FR3UA	WOS:000418990900010	29157856				2021-06-18	
J	Langdon, R; Taraman, S				Langdon, Raquel; Taraman, Sharief			Posttraumatic Headache	PEDIATRIC ANNALS			English	Article							TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL THERAPY; POSTCONCUSSION SYNDROME; PLUS AMITRIPTYLINE; ACUTE CONCUSSION; CHRONIC MIGRAINE; CHILDREN; ADOLESCENTS; MANAGEMENT	After sustaining a concussion or mild traumatic brain injury, headaches are one of the most common complaints. The pathophysiologic changes that occur in the setting of injury likely contribute to or cause posttraumatic headaches. Posttraumatic headaches often present as migraine or tension-type headaches. Unlike pain from other types of injuries, headaches following mild traumatic brain injury are more likely to persist. Preexisting conditions such as migraine and mood disorders may influence posttraumatic headache and complicate management. Patients are at high risk to overuse abortive medications and develop medication overuse headache. Headache hygiene and early education are essential for effective management. Abortive medications include nonsteroidal anti-inflammatory drugs and triptans. Preventive medications include tricyclic antidepressants and antiepileptics. Patients who fail outpatient therapies may benefit from referral for intravenous medications in the emergency department. Patients with persistent posttraumatic headache may benefit from multimodal treatments including physical rehabilitation and pain-focused cognitive-behavioral therapies.	[Langdon, Raquel] Childrens Natl Hlth Syst, Ctr Neurosci & Behav Hlth, Pediat Headache, Washington, DC USA; [Langdon, Raquel] George Washington Univ, Child Neurol, Washington, DC 20052 USA; [Taraman, Sharief] Childrens Hosp Orange Cty, Dept Pediat Neurol, 505 S Main St,Suite 1200, Orange, CA 92668 USA; [Taraman, Sharief] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA	Taraman, S (corresponding author), Childrens Hosp Orange Cty, Dept Pediat Neurol, 505 S Main St,Suite 1200, Orange, CA 92668 USA.	staraman@choc.org		Taraman, Sharief/0000-0003-2108-2490			Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bock S, 2015, CHILD NERV SYST, V31, P2111, DOI 10.1007/s00381-015-2846-8; Chan S, 2015, AM J EMERG MED, V33, P635, DOI 10.1016/j.ajem.2015.01.053; Colman I, 2004, NEUROLOGY, V62, P1695, DOI 10.1212/01.WNL.0000127304.91605.BA; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Giza Christopher C, 2014, Continuum (Minneap Minn), V20, P1545, DOI 10.1212/01.CON.0000458975.78766.11; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hamalainen ML, 1997, NEUROLOGY, V48, P103, DOI 10.1212/WNL.48.1.103; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heyer GL, 2014, PEDIATR NEUROL, V50, P464, DOI 10.1016/j.pediatrneurol.2014.01.040; Kacperski J, 2016, HEADACHE, V56, P36, DOI 10.1111/head.12737; Kroner JW, 2016, HEADACHE, V56, P711, DOI 10.1111/head.12795; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher Jeffrey S, 2014, Continuum (Minneap Minn), V20, P1552, DOI 10.1212/01.CON.0000458974.78766.58; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ng QX, 2017, HEADACHE, V57, P349, DOI 10.1111/head.13016; O'Brien HL, 2010, CURR TREAT OPTION NE, V12, P178, DOI 10.1007/s11940-010-0069-6; Pinchefsky E, 2015, PEDIATR NEUROL, V52, P270, DOI 10.1016/j.pediatrneurol.2014.10.015; Pinchefsky E, 2015, PEDIATR NEUROL, V52, P263, DOI 10.1016/j.pediatrneurol.2014.10.013; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Powers SW, 2013, JAMA-J AM MED ASSOC, V310, P2622, DOI 10.1001/jama.2013.282533; Seeger TA, 2015, J CHILD NEUROL, V30, P1142, DOI 10.1177/0883073814553973; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Wilson Maria-Carmen B, 2006, Curr Pain Headache Rep, V10, P387, DOI 10.1007/s11916-006-0065-4; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	33	11	11	0	2	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0090-4481	1938-2359		PEDIATR ANN	Pediatr. Ann.	FEB	2018	47	2					E61	E68		10.3928/19382359-20180131-01			8	Pediatrics	Pediatrics	FX2UX	WOS:000425919900006	29446796				2021-06-18	
J	Marwitz, JH; Sima, AP; Kreutzer, JS; Dreer, LE; Bergquist, TF; Zafonte, R; Johnson-Greene, D; Felix, ER				Marwitz, Jennifer H.; Sima, Adam P.; Kreutzer, Jeffrey S.; Dreer, Laura E.; Bergquist, Thomas F.; Zafonte, Ross; Johnson-Greene, Douglas; Felix, Elizabeth R.			Longitudinal Examination of Resilience After Traumatic Brain Injury: A Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Psychological; Rehabilitation; Resilience; psychological	DISABILITY RATING-SCALE; CONNOR-DAVIDSON RESILIENCE; MILITARY SERVICE MEMBERS; LIFE SATISFACTION; CD-RISC; TBI-QOL; PREDICTORS; OUTCOMES; REHABILITATION; TRAJECTORIES	Objectives: To evaluate (1) the trajectory of resilience during the first year after a moderate-severe traumatic brain injury (TBI); (2) factors associated with resilience at 3, 6, and 12 months postinjury; and (3) changing relationships over time between resilience and other factors. Design: Longitudinal analysis of an observational cohort. Setting: Five inpatient rehabilitation centers. Participants: Patients with TBI (N=195) enrolled in the resilience module of the TBI Model Systems study with data collected at 3-, 6-, and 12 month follow-up. Interventions: Not applicable. Main Outcome Measure: Connor-Davidson Resilience Scale. Results: Initially, resilience levels appeared to be stable during the first year postinjury. Individual growth curve models were used to examine resilience over time in relation to demographic, psychosocial, and injury characteristics. After adjusting for these characteristics, resilience actually declined over time. Higher levels of resilience were related to nonminority status, absence of preinjury substance abuse, lower anxiety and disability level, and greater life satisfaction. Conclusions: Resilience is a construct that is relevant to understanding brain injury outcomes and has potential value in planning clinical interventions. (C) 2017 by the American Congress of Rehabilitation Medicine	[Marwitz, Jennifer H.; Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Dept Phys Med & Rehabil, Rochester, MN USA; [Zafonte, Ross] Harvard Med Sch, Massachusetts Gen Hosp, Brigham & Womens Hosp, Spaulding Rehabil Hosp,Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Johnson-Greene, Douglas] Univ Miami, Miller Sch Med, Dept Phys Med & Rehabil, Miami, FL 33136 USA	Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Box 980542, Richmond, VA 23298 USA.	jennifer.marwitz@vcuhealth.org	Felix, Elizabeth/AAD-6356-2021	Felix, Elizabeth/0000-0002-6239-715X; Sima, Adam/0000-0001-8426-9987	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0030, 90DP0033, 90DP0034, 90DP0039, 90DP0044, 90DP0046]	The contents of this manuscript were developed under grants from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant nos. 90DP0030, 90DP0033, 90DP0034, 90DP0039, 90DP0044, 90DP0046). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government.	Bertisch H, 2014, NEUROREHABILITATION, V34, P573, DOI 10.3233/NRE-141059; Bogner J. A, 2017, J HEAD TRAUMA REHABI; Brown SA, 2001, AM J PHYS MED REHAB, V80, P196, DOI 10.1097/00002060-200103000-00009; Campbell-Sills L, 2007, J TRAUMA STRESS, V20, P1019, DOI 10.1002/jts.20271; Campbell-Sills L, 2009, J PSYCHIATR RES, V43, P1007, DOI 10.1016/j.jpsychires.2009.01.013; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Edwards LJ, 2008, STAT MED, V27, P6137, DOI 10.1002/sim.3429; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hanks RA, 2016, REHABIL PSYCHOL, V61, P269, DOI 10.1037/rep0000069; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Juengst SB, 2015, REHABIL PSYCHOL, V60, P353, DOI 10.1037/rep0000056; Kenward MG, 2009, COMPUT STAT DATA AN, V53, P2583, DOI 10.1016/j.csda.2008.12.013; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Kreutzer JS, 2016, ARCH PHYS MED REHAB, V97, P708, DOI 10.1016/j.apmr.2015.12.003; Lange RT, 2016, J HEAD TRAUMA REHAB, V31, P62, DOI 10.1097/HTR.0000000000000149; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Losoi H, 2015, J HEAD TRAUMA REHAB, V30, pE24, DOI 10.1097/HTR.0000000000000055; Lukow HR, 2015, J HEAD TRAUMA REHAB, V30, P241, DOI 10.1097/HTR.0000000000000137; Malec JF, 2012, ARCH PHYS MED REHAB, V93, P1603, DOI 10.1016/j.apmr.2012.04.003; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Merritt VC, 2015, BRAIN INJURY, V29, P1325, DOI 10.3109/02699052.2015.1043948; Norris FH, 2009, SOC SCI MED, V68, P2190, DOI 10.1016/j.socscimed.2009.03.043; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pooley JA, 2010, AUST COMMUNITY PSYCH, V22, P30; Post MW, 2012, ARCH PHYS MED REHAB, V93, P1832, DOI 10.1016/j.apmr.2012.03.025; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sullivan KA, 2016, NEUROPSYCHOL REV, V26, P173, DOI 10.1007/s11065-016-9317-1; Sullivan KA, 2015, REHABIL PSYCHOL, V60, P147, DOI 10.1037/rep0000037; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; Wagnild G M, 1993, J Nurs Meas, V1, P165; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P540, DOI 10.1016/j.apmr.2010.12.002; Williams MW, 2014, REHABIL PSYCHOL, V59, P298, DOI 10.1037/a0037164	37	11	11	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2018	99	2					264	271		10.1016/j.apmr.2017.06.013			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FU7YX	WOS:000424069800007	28734937				2021-06-18	
J	Moffet, EW; Zens, TJ; Haines, KL; Beems, MV; McQuistion, KM; Leverson, GE; Agarwal, SK				Moffet, Eric W.; Zens, Tiffany J.; Haines, Krista L.; Beems, Megan V.; McQuistion, Kaitlyn M.; Leverson, Glen E.; Agarwal, Suresh K.			Race, insurance status, and traumatic brain injury outcomes before and after enactment of the Affordable Care Act	SURGERY			English	Article; Proceedings Paper	Association-for-Academic-Surgery/Society-of-University-Surgeons 12th Annual Meeting of the Academic-Surgical-Congress (ASC)	FEB 07-09, 2017	Las Vegas, NV	Acad Surg Congress, Assoc Acad Surg, Soc Univ Surg			UNITED-STATES; RACIAL/ETHNIC DISPARITIES; ETHNIC DISPARITIES; CENTER DESIGNATION; HELMET LAWS; DATA-BANK; LEVEL I; IMPACT; MORTALITY; HYPERTENSION	Background. The Affordable Care Act aims to improve patient outcomes. Race/ethnicity and insurance status impact outcomes after traumatic brain injury. We sought to gauge the Affordable Care Act's effect on outcomes after traumatic brain injury, as graded by race/ethnicity and insurance status. Methods. The National Trauma Data Bank was utilized to identify traumatic brain injury patients before and after the Affordable Care Act. Patient outcomes comprised of hospital duration of stay, in-hospital mortality, discharge to rehabilitation, and surgical procedures. Using regression analysis, we evaluated the impact of race/ethnicity and insurance status on traumatic brain injury outcomes, then compared them before and after the Affordable Care Act. Results. Mortality decreased for blacks (odds ratio =0.96 [confidence interval 0.83-1.10] to odds ratio =0.79 [confidence interval = 0.70-0.89], and Hispanics (odds ratio = 1.03 [confidence interval = 0.90-1.17] to odds ratio = 0.79 [confidence interval = 0.70-0.89]). Mortality increased for the uninsured (odds ratio = 1.28 [confidence interval =1.11-1.47] to odds ratio = 1.40 [confidence interval = 1.24-1.58]). Medicaid patients underwent decreased duration of stay, (coefficient = 2.75 [confidence interval = 2.49-3.02] to coefficient = 2.17, [confidence interval =1.98-2.37]), discharge to rehabilitation (odds ratio = 1.15, [confidence interval = 1.04-1.26] to odds ratio = 0.95 [confidence interval = 0.87-1.03]), and surgical procedures (odds ratio = 1.28 [confidence interval = 1.13-1.45] to odds ratio = 1.18, [confidence interval = 1.07-1.30]), while mortality remained unchanged. Conclusion. After the Affordable Care Act traumatic brain injury mortality decreased for blacks and Hispanics, but increased for the uninsured. Decreasing trends in resource consumption were also evident, especially for Medicaid patients. These results may illustrate altered delivery of care. (C) 2017 Elsevier Inc. All rights reserved.	[Moffet, Eric W.; Zens, Tiffany J.; Haines, Krista L.; Beems, Megan V.; McQuistion, Kaitlyn M.; Leverson, Glen E.; Agarwal, Suresh K.] Univ Wisconsin, Dept Surg, Div Trauma & Acute Care Surg, Sch Med & Publ Hlth, 600 Highland Ave G5-335, Madison, WI 53792 USA	Agarwal, SK (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, 600 Highland Ave G5-335, Madison, WI 53792 USA.	emoffet@wisc.edu		Haines, Krista/0000-0002-2056-1820	University of Wisconsin Shapiro Summer Research Program	We thank the University of Wisconsin Shapiro Summer Research Program for supporting this research.	Abrams Melinda, 2015, Issue Brief (Commonw Fund), V12, P1; Agency for Healthcare Research and Quality, 2014, AGENCY HEALTHCARE RE; Alban RF, 2010, AM SURGEON, V76, P1108; [Anonymous], 2016, KEY FACTS UN POP; [Anonymous], 2013, HLTH REF IMPL TIM; [Anonymous], 2010, HLTH REF COMM COL IM; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Blumenthal D, 2015, NEW ENGL J MED, V372, P2451, DOI 10.1056/NEJMhpr1503614; Brasel KJ, 2002, J SURG RES, V107, P223, DOI 10.1006/jsre.2002.6512; Chen J, 2016, MED CARE, V54, P140, DOI 10.1097/MLR.0000000000000467; Cheslik TG, 2016, J TRAUMA ACUTE CARE, V80, P1010, DOI 10.1097/TA.0000000000001052; Collins Sara R, 2016, Issue Brief (Commonw Fund), V24, P1; Damberg C L., 2007, ENV SCAN PAY PERFORM; Dao H, 2012, J TRAUMA ACUTE CARE, V72, P638, DOI 10.1097/TA.0b013e318243d9ca; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Duane TM, 2012, J TRAUMA ACUTE CARE, V72, P641; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faul M, 2015, WEST J EMERG MED, V16, P98, DOI 10.5811/westjem.2014.10.22837; Ferdinand KC, 2015, CURR MED RES OPIN, V31, P913, DOI 10.1185/03007995.2015.1029894; Galewitz P., 2012, BOOM TRAUMA CTR CAN; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Gardizi E, 2014, ARCH PHYS MED REHAB, V95, P2396, DOI 10.1016/j.apmr.2014.06.004; Haider AH, 2012, J AM COLL SURGEONS, V214, P756, DOI 10.1016/j.jamcollsurg.2011.12.013; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Hwabejire JO, 2013, JAMA SURG, V148, P956, DOI 10.1001/jamasurg.2013.2148; James J, 2012, HLTH AFFAIRS; Joseph B, 2016, J TRAUMA ACUTE CARE, V81, P427, DOI 10.1097/TA.0000000000001082; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McQuistion K, 2016, J SURG RES, V205, P261, DOI 10.1016/j.jss.2016.06.087; Meehan WP, 2013, J PEDIATR-US, V163, P726, DOI 10.1016/j.jpeds.2013.03.073; Mueller M, 2015, AM J HYPERTENS, V28, P699, DOI 10.1093/ajh/hpu233; Nott MT, 2015, AUSTRALAS J AGEING, V34, pE1, DOI 10.1111/ajag.12151; Obama B, 2016, JAMA-J AM MED ASSOC, V316, P525, DOI 10.1001/jama.2016.9797; Rosenstock S, 2014, J URBAN HEALTH, V91, P873, DOI 10.1007/s11524-013-9861-4; Scott JW, 2016, MED CARE, V54, P818, DOI 10.1097/MLR.0000000000000586; Scott JW, 2015, J AM COLL SURGEONS, V221, P495, DOI 10.1016/j.jamcollsurg.2015.03.032; Selassie AW, 2014, J HEAD TRAUMA REHAB, V29, pE8, DOI 10.1097/HTR.0b013e3182976ad3; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sood N, 2012, HEALTH AFFAIR, V31, P2043, DOI 10.1377/hlthaff.2012.0382; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Uninsurance loMUCotCo, 2001, COV MATT INS HLTH CA; Valderrama AL, 2013, MMWR-MORBID MORTAL W, V62, P351; Waters TM, 2015, JAMA INTERN MED, V175, P347, DOI 10.1001/jamainternmed.2014.5486; Zogg CK, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.3609; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	49	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	FEB	2018	163	2					251	258		10.1016/j.surg.2017.09.006			8	Surgery	Surgery	FV1JL	WOS:000424317300002	29146230				2021-06-18	
J	Salam, AP; Borsini, A; Zunszain, PA				Salam, A. P.; Borsini, A.; Zunszain, P. A.			Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders	MOLECULAR PSYCHIATRY			English	Article							CANDIDA-ALBICANS INFECTION; MAJOR DEPRESSIVE DISORDER; MOLECULAR-PATTERNS DAMPS; INTERFERON-ALPHA THERAPY; TRAUMATIC BRAIN-INJURY; HOST-DEFENSE; NEURODEGENERATIVE DISEASE; MICROGLIAL ACTIVATION; IMMUNOLOGICAL MEMORY; BCG VACCINATION	Historically, only cells of the adaptive immune system have been considered capable of retaining memory for infectious challenges. Recently, however, cells of the innate immune system have been shown to be capable of displaying long-term functional memory following a single immunostimulatory challenge, leading to enhanced production of proinflammatory molecules upon other subsequent, and temporally distant, immunostimulatory challenges. This effect has been termed 'trained innate immunity', and is underwritten by stable epigenetic changes in immune and metabolic pathways. Importantly, the long-term training of innate immune cells can occur as a result of infectious as well as and non-infectious challenges, including stress. Given the role that both stress and an activated immune system have in neuropathology, innate immune training has important implications for our understanding and treatment of neuropsychiatric disorders. This review focuses on the evidence for trained innate immunity and highlights some insights into its relevance for psychiatric diseases.	Kings Coll London, Inst Psychiat Psychol Neurosci, Dept Psychol Med, London, England	Salam, AP (corresponding author), Kings Coll London, Inst Psychiat Psychol Neurosci, London SE5 9NU, England.	alexsalam@doctors.org.uk	Borsini, Alessandra/P-5180-2017	Borsini, Alessandra/0000-0003-4410-7865	National Institute for Health Research (NIHR) Biomedical Research Centre-Francis Crick Institute Clinical Training Fellowship; NIHR Maudsley Biomedical Research Centre	APS is supported by a National Institute for Health Research (NIHR) Biomedical Research Centre-Francis Crick Institute Clinical Training Fellowship. PAZ and AB are supported by the NIHR Maudsley Biomedical Research Centre.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aricioglu F, 2016, KLIN PSIKOFARMAKOL B, V26, P429, DOI 10.5455/bcp.20161123044657; Bakunina N, 2015, IMMUNOLOGY, V144, P365, DOI 10.1111/imm.12443; Bekkering S, 2014, ARTERIOSCL THROM VAS, V34, P1731, DOI 10.1161/ATVBAHA.114.303887; Beumer W, 2012, J LEUKOCYTE BIOL, V92, P959, DOI 10.1189/jlb.0212100; Bilbo SD, 2005, J NEUROSCI, V25, P8000, DOI 10.1523/JNEUROSCI.1748-05.2005; BISTONI F, 1986, INFECT IMMUN, V51, P668, DOI 10.1128/IAI.51.2.668-674.1986; BISTONI F, 1988, J MED VET MYCOL, V26, P285; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bland ST, 2010, NEUROSCI LETT, V474, P52, DOI 10.1016/j.neulet.2010.03.006; Borsini A, 2015, TRENDS NEUROSCI, V38, P145, DOI 10.1016/j.tins.2014.12.006; Cao M, 2015, FRONT CELL NEUROSCI, V9, P12; Capuron L, 1999, NEW ENGL J MED, V340, P1370, DOI 10.1056/NEJM199904293401716; Celik C, 2010, PROG NEURO-PSYCHOPH, V34, P372, DOI 10.1016/j.pnpbp.2010.01.002; Chauhan VS, 2009, GLIA, V57, P414, DOI 10.1002/glia.20770; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Condliffe AM, 1998, CLIN SCI, V94, P461, DOI 10.1042/cs0940461; Delves PJ, 2011, ROITTS ESSENTIAL IMM; Depino AM, 2015, NEUROSCIENCE, V299, P56, DOI 10.1016/j.neuroscience.2015.04.065; Dieperink E, 2003, PSYCHOSOMATICS, V44, P104, DOI 10.1176/appi.psy.44.2.104; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fleshner M, 2004, PSYCHONEUROENDOCRINO, V29, P1142, DOI 10.1016/j.psyneuen.2004.01.007; Fleshner M, 2013, BRAIN BEHAV IMMUN, V27, P1, DOI 10.1016/j.bbi.2012.08.012; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Giovanoli S, 2013, SCIENCE, V339, P1095, DOI 10.1126/science.1228261; Glover V, 2011, J CHILD PSYCHOL PSYC, V52, P356, DOI 10.1111/j.1469-7610.2011.02371.x; Hauser P, 2002, MOL PSYCHIATR, V7, P942, DOI 10.1038/sj.mp.4001119; Ifrim DC, 2014, CLIN VACCINE IMMUNOL, V21, P534, DOI 10.1128/CVI.00688-13; Jensen KJ, 2015, J INFECT DIS, V211, P956, DOI 10.1093/infdis/jiu508; Jeon SW, 2016, WORLD J PSYCHIATR, V6, P283, DOI 10.5498/wjp.v6.i3.283; Jones KA, 2013, MOL CELL NEUROSCI, V53, P52, DOI 10.1016/j.mcn.2012.10.002; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Khandaker GM, 2015, LANCET PSYCHIAT, V2, P258, DOI 10.1016/S2215-0366(14)00122-9; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Knuesel I, 2014, NAT REV NEUROL, V10, P643, DOI 10.1038/nrneurol.2014.187; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Maekawa T, 2009, EMBO J, V29, P196; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Manson J, 2012, BRIT J SURG, V99, P12, DOI 10.1002/bjs.7717; Martin SF, 2014, CELL MOL LIFE SCI, V71, P4115, DOI 10.1007/s00018-014-1676-2; Maslanik T, 2013, BRAIN BEHAV IMMUN, V28, P54, DOI 10.1016/j.bbi.2012.10.014; Matt U, 2015, CELL MOL LIFE SCI, V72, P1059, DOI 10.1007/s00018-014-1780-3; Michael B., 2013, MED, P11; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Netea MG, 2015, NAT IMMUNOL, V16, P675, DOI 10.1038/ni.3178; Netea MG, 2013, EUR J CLIN INVEST, V43, P881, DOI 10.1111/eci.12132; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; Pariante CM, 1999, LANCET, V354, P131, DOI 10.1016/S0140-6736(98)04793-X; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Poli A, 2013, J IMMUNOL, V190, P5355, DOI 10.4049/jimmunol.1203401; Puntener U, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-146; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Ramirez K, 2015, BRAIN BEHAV IMMUN, V46, P212, DOI 10.1016/j.bbi.2015.01.016; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ramos HJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003039; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; RENAULT PF, 1987, ARCH INTERN MED, V147, P1577, DOI 10.1001/archinte.147.9.1577; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sandman CA, 2015, BIOL PSYCHIAT, V77, P324, DOI 10.1016/j.biopsych.2014.06.025; Schaafsma W, 2015, BRAIN BEHAV IMMUN, V48, P205, DOI 10.1016/j.bbi.2015.03.013; Schaefer M, 2003, HEPATOLOGY, V37, P443, DOI 10.1053/jhep.2003.50031; Schroder K, 2006, IMMUNOBIOLOGY, V211, P511, DOI 10.1016/j.imbio.2006.05.007; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Soczynska JK, 2012, BEHAV BRAIN RES, V235, P302, DOI 10.1016/j.bbr.2012.07.026; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Talge NM, 2007, J CHILD PSYCHOL PSYC, V48, P245, DOI 10.1111/j.1469-7610.2006.01714.x; TRIBOULEY J, 1978, CR SOC BIOL, V172, P902; van den Bergh BRH, 2008, NEUROPSYCHOPHARMACOL, V33, P536, DOI 10.1038/sj.npp.1301450; VANTWOUT JW, 1992, SCAND J IMMUNOL, V36, P713; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Williamson LL, 2011, J NEUROSCI, V31, P15511, DOI 10.1523/JNEUROSCI.3688-11.2011; Wynne AM, 2009, INTEGR COMP BIOL, V49, P254, DOI 10.1093/icb/icp009; Ye M, 2014, BIOCHEM CELL BIOL, V92, P337, DOI 10.1139/bcb-2014-0030; Yirmiya R, 2015, TRENDS NEUROSCI, V38, P637, DOI 10.1016/j.tins.2015.08.001; Yoshida K, 2015, NAT IMMUNOL, V16, P1034, DOI 10.1038/ni.3257; Zheng X, 2015, DRUG DISCOV TODAY, V20, P562, DOI 10.1016/j.drudis.2015.03.015	79	11	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	FEB	2018	23	2					170	176		10.1038/mp.2017.186			7	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	FT8ZM	WOS:000423441700003	29230022	Bronze			2021-06-18	
J	Staniloiu, A; Markowitsch, HJ; Kordon, A				Staniloiu, Angelica; Markowitsch, Hans J.; Kordon, Andreas			Psychological causes of autobiographical amnesia: A study of 28 cases	NEUROPSYCHOLOGIA			English	Article						Stress; Mild traumatic brain injury; Culture; Forensic context; Fugue; Effort; Anterograde amnesia	PERSISTENT ANTEROGRADE AMNESIA; FUNCTIONAL RETROGRADE-AMNESIA; GENDER-DIFFERENCES; PSYCHOGENIC AMNESIA; EPISODIC MEMORY; BRAIN; DISSOCIATION; RETRIEVAL; STRESS; TRAUMA	Autobiographical amnesia is found in patients with focal or diffuse brain damage ("organic amnesia"), but also without overt brain damage (at least when measured with conventional brain imaging methods). This last condition is usually named dissociative amnesia at present, and was originally described as hysteria. Classically and traditionally, dissociative amnesia is seen as a disorder that causes retrograde amnesia in the autobiographical domain in the aftermath of incidents of major psychological stress or trauma. In the present study one of the probably largest published collections of patients (28) with psychogenically caused autobiographical amnesia, who were assessed with comprehensive neuropsychological tests, will be described and documented in order to identify variables which are central for the occurrence of dissociative amnesia. The presented cases demonstrate that autobiographical amnesia without direct brain damage can have very mixed clinical presentations, causes and consequences. The described cases of psychogenic amnesia are clustered according to a number of manifestations and features, which include a reduced effort to perform cognitively at a normal level, a forensic background, anterograde (instead of retrograde) autobiographical amnesia, the fugue condition, concurrent somatic diseases, and their appearance in childhood and youth. It is concluded that autobiographical amnesia of a psychogenic origin may occur within a variety of symptom pictures. For all patients, it probably serves a protective function by offering them a mechanism to exit a life situation which appears to them unmanageable or adverse.	[Staniloiu, Angelica; Markowitsch, Hans J.] Univ Bielefeld, Physiol Psychol, Bielefeld, Germany; [Staniloiu, Angelica] Univ Bucharest, Dept Psychol, Bucharest, Romania; [Staniloiu, Angelica] Sunnybrook Hlth Sci Ctr, Traumat Brain Injury Clin, Toronto, ON, Canada; [Staniloiu, Angelica] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Kordon, Andreas] Oberbergklin Hornberg, Hornberg, Germany; [Kordon, Andreas] Univ Freiburg, Dept Psychiat, Freiburg, Germany	Markowitsch, HJ (corresponding author), Univ Bielefeld, Dept Physiol Psychol, POB 10 01 31, D-33501 Bielefeld, Germany.	hjmarkowitsch@uni-bielefeld.de					American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th; Anderson MC, 2014, TRENDS COGN SCI, V18, P279, DOI 10.1016/j.tics.2014.03.002; Baddeley A., 1994, DOORS PEOPLE TEST; Barbarotto R, 1996, NEUROPSYCHOLOGIA, V34, P575, DOI 10.1016/0028-3932(95)00141-7; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Bartsch T, 2010, LANCET NEUROL, V9, P205, DOI 10.1016/S1474-4422(09)70344-8; Beven J.P., 2004, INT J FORENSIC MENT, V1, P33; Borsutzky S., 2006, TESTBATTERIE ERFASSU; Bowers D., 1991, FLORIDA AFFECT BATTE; Brand M, 2009, PSYCHIAT RES-NEUROIM, V174, P32, DOI 10.1016/j.pscychresns.2009.03.008; Brand M, 2009, BRAIN COGNITION, V69, P279, DOI 10.1016/j.bandc.2008.08.003; Breitenstein C., 1996, NEUROLOGIE REHABILIT, V2, P93; Bremner J.D., 2010, PSYCHOL BULL, V136, P1, DOI DOI 10.1037/A0018021; Breuer J., 1895, STUDIEN OBER HYSTERI; Brickenkamp R., 1998, D2 TEST ATTENTION, V1st US ed; Calabrese P, 2000, EISAI; Charcot J.M., 1892, REV MED, V12, P81; Coons PM, 1992, DISSOCIATION, V5, P73; Dalenberg CJ, 2014, PSYCHOL BULL, V140, P911, DOI 10.1037/a0036685; Dalenberg CJ, 2012, PSYCHOL BULL, V138, P550, DOI 10.1037/a0027447; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; Diseth TH, 2005, NORD J PSYCHIAT, V59, P278, DOI 10.1080/08039480500213683; Dong DB, 2017, SCHIZOPHR RES, V185, P41, DOI 10.1016/j.schres.2017.01.005; ELLISON G, 1994, BRAIN RES REV, V19, P223, DOI 10.1016/0165-0173(94)90012-4; Estupina FJ, 2012, SPAN J PSYCHOL, V15, P275, DOI 10.5209/rev_SJOP.2012.v15.n1.37334; Fahrenberg J., 2001, FREIHURGER PERSONLIC; Fink GR, 1996, J NEUROSCI, V16, P4275; Flechsig P, 1896, GEHIRN UND SEELE; Forstl H, 2008, ACTA PSYCHIAT SCAND, V118, P499, DOI 10.1111/j.1600-0447.2008.01269.x; Fujiwara E, 2008, CORTEX, V44, P29, DOI 10.1016/j.cortex.2005.09.001; Gast U., 2004, STRUKTURIERTES KLIN; Giesbrecht T, 2008, PSYCHOL BULL, V134, P617, DOI 10.1037/0033-2909.134.5.617; Giger P, 2010, J FORENSIC PSYCHOL P, V10, P440, DOI 10.1080/15228932.2010.489875; Hafner H., 2008, KONING WIRD BESEITIG; Harting C., 2000, WECHSLER MEMORY SCAL; Hering E., 1870, P VIENN 30 MAY MDCCC; Hessel A, 2001, DIAGNOSTICA, V47, P27, DOI 10.1026//0012-1924.47.1.27; Heubrock D., 2000, TESTBATTERIE FORENSI; Janet P., 1907, MAJOR SYMPTOMS HYSTE, V2nd; Janet P., 1893, REV GENERALE SCI, V4, P167; K?hner C, 2006, BECK DEPRESSIONSINVE; Kessler J, 1997, J CLIN EXP NEUROPSYC, V19, P604, DOI 10.1080/01688639708403746; Koch C, 2016, NAT REV NEUROSCI, V17, P307, DOI 10.1038/nrn.2016.22; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; KOPELMAN MD, 1994, NEUROPSYCHOLOGIA, V32, P675, DOI 10.1016/0028-3932(94)90028-0; Kritchevsky M, 2004, LEARN MEMORY, V11, P213, DOI 10.1101/lm.71404; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Kruse K, 2010, SEIN GERLACHTNIS VER; LaBar KS, 2006, NAT REV NEUROSCI, V7, P54, DOI 10.1038/nrn1825; Langnickel R, 2010, SIGMUND FREUD HEUTE, P149; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lehr S, 2005, MEHRFACHWAHL WORTSCH; Leplow B, 1997, DIAGNOSTICA, V43, P192; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Maaranen P, 2005, J NERV MENT DIS, V193, P690, DOI 10.1097/01.nmd.0000181353.69821.44; Markowitsch HJ, 2016, HAND CLINIC, V139, P419, DOI 10.1016/B978-0-12-801772-2.00036-9; Markowitsch H J, 1997, Cogn Neuropsychiatry, V2, P135, DOI 10.1080/135468097396379; Markowitsch H. J, 2013, ISRN NEUROSCI; Markowitsch H. J., 2015, PERSONLICHKEITSSTORU, V19, P1; Markowitsch H. J., 2017, OXFORD HDB HIST CLIN; Markowitsch HJ, 2013, CORTEX, V49, P1494, DOI 10.1016/j.cortex.2012.05.020; Markowitsch HJ, 2012, LANCET, V380, P1429, DOI 10.1016/S0140-6736(11)61304-4; Markowitsch HJ, 2011, CONSCIOUS COGN, V20, P16, DOI 10.1016/j.concog.2010.09.005; Markowitsch Hans J, 2008, Handb Clin Neurol, V88, P155, DOI 10.1016/S0072-9752(07)88007-9; Markowitsch HJ, 1999, CORTEX, V35, P243, DOI 10.1016/S0010-9452(08)70797-4; Markowitsch HJ, 2000, NEUROPSY NEUROPSY BE, V13, P60; Markowitsch HJ, 1999, NEUROCASE, V5, P189, DOI 10.1093/neucas/5.3.189; Markowitsch HJ, 1998, NEUROPSYCHOLOGIA, V36, P77, DOI 10.1016/S0028-3932(97)00093-6; Markowitsch HJ, 1996, NEUROCASE, V2, P357; Markowitsch HJ, 2002, CORTEX, V38, P651, DOI 10.1016/S0010-9452(08)70030-3; Markowitsch HJ, 1997, PSYCHIAT RES-NEUROIM, V74, P119, DOI 10.1016/S0925-4927(97)03041-2; Markowitsch HJ, 1999, COGNITIVE NEUROSCIENCE OF MEMORY, P193; Markowitsch HJ, 1999, CURR OPIN PSYCHIATR, V12, P331, DOI 10.1097/00001504-199905000-00014; MARKOWITSCH HJ, 1990, TRANSIENT GLOBAL AMN; Maudsley H., 1870, BODY MIND INQUIRY TH; Meynert T, 1884, PSYCHIAT KLIN ERKRAN; Minnich R., 2008, FORGETTING DAD; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Mubarik Ateeq, 2016, Trends Psychiatry Psychother., V38, P198, DOI 10.1590/2237-6089-2015-0088; Nazeri A., 2016, BIOL PSYCHIAT; Nelson KD, 2004, PSYCHOL REV, V111, P486, DOI 10.1037/0033-295X.111.2.486; NICHOLAS LE, 1989, APHASIOLOGY, V3, P569, DOI 10.1080/02687038908249023; OBrien JT, 1997, BRIT J PSYCHIAT, V170, P199; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; PAKKENBERG B, 1992, SCHIZOPHR RES, V7, P95, DOI 10.1016/0920-9964(92)90038-7; Park CH, 2017, SCHIZOPHR RES, V188, P82, DOI 10.1016/j.schres.2017.01.025; Parwatikar S. D., 1990, TRANSIENT GLOBAL AMN, P191; Paulus C., 2012, SAARBRUCKER PERSONLI; Reinhardt S, 2008, ALCOHOL ALCOHOLISM, V43, P334, DOI 10.1093/alcalc/agn004; Reinhold N, 2007, J NEUROPSYCHOL, V1, P53, DOI 10.1348/174866407X180819; Reinhold N, 2009, NEUROPSYCHOLOGIA, V47, P2197, DOI 10.1016/j.neuropsychologia.2009.01.037; Rinne T., 2007, TRAUMATIC DISSOCIATI, P139; Schmand B, 2005, AMSTERDAMER KURZZEIT; Seidl U., 2006, WARUM MENSCHEN SICH, P286; SEIFFGEKRENKE I, 1993, J ADOLESCENCE, V16, P285, DOI 10.1006/jado.1993.1026; Seitz L, 2017, BRAIN IMAGING BEHAV; SPITZ HH, 1982, DEV PSYCHOL, V18, P922, DOI 10.1037/0012-1649.18.6.922; Spitzer C, 2003, PSYCHOPATHOLOGY, V36, P65, DOI 10.1159/000070360; Spitzer C, 2008, BUNDESGESUNDHEITSBLA, V51, P46, DOI 10.1007/s00103-008-0418-8; Spreen O., 1998, COMPENDIUM NEUROPSYC; Staniloiu A, 2017, DISSOCIATIVE DISORDE; Staniloiu A, 2015, INT ENCY SOCIAL BEHA, V1, P651; Staniloiu A, 2012, FRONT PSYCHOL, V3, P1; Staniloiu A, 2011, ADV BRAIN IMAGING, P11; Staniloiu A, 2012, FUNCTIONAL IMPAIRMEN, P87; Staniloiu A, 2017, DISSOZIATION MIGRATI; Staniloiu A., 2014, SUSTAINABLE DEV NURT, P22; Staniloiu A, 2012, J LIT THEORY, V6, P103, DOI 10.1515/jlt-2011-0012; Staniloiu A, 2014, LANCET PSYCHIAT, V1, P226, DOI 10.1016/S2215-0366(14)70279-2; Staniloiu A, 2012, BRAIN SCI, V2, P101, DOI 10.3390/brainsci2020101; Staniloiu A, 2010, CONSCIOUS COGN, V19, P778, DOI 10.1016/j.concog.2010.06.024; Staniloiu A, 2010, Z PSYCHOL, V218, P96, DOI 10.1027/0044-3409/a000017; Stone J, 2006, BRIT J PSYCHIAT, V188, P204, DOI 10.1192/bjp.188.3.204; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tramoni E, 2009, NEUROPSYCHOLOGIA, V47, P611, DOI 10.1016/j.neuropsychologia.2008.11.012; Tulving E., 2005, MISSING LINK COGNITI, P3, DOI [DOI 10.1093/ACPROF:OSO/9780195161564.003.0001, 10.1093/acprof:oso/9780195161564.003.0001]; Wittchen H. U., 1997, STRUKTURIERTES KLIN; World Health Organization, 2010, INT CLASS MENT BEH D; Yang J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168239	121	11	11	3	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	2018	110				SI		134	147		10.1016/j.neuropsychologia.2017.10.017			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	FY9TZ	WOS:000427211100014	29050993				2021-06-18	
J	Strollo, BP; Bennett, GJ; Chopko, MS; Guo, WA				Strollo, Brian P.; Bennett, Gregory J.; Chopko, Michael S.; Guo, Weidun Alan			Timing of venous thromboembolism chemoprophylaxis after traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article							INTRACRANIAL HEMORRHAGE; RESPONSE RATES; GUIDELINES; PROPHYLAXIS; PREVENTION; MANAGEMENT; RISK	Objectives: Currently no national standard exists on optimal timing to initiate VTE chemoprophylaxis after traumatic brain injury (TBI). We designed this survey to assess current practice regarding the timing of VTE chemoprophylaxis after TBI. Methods: All the EAST members were surveyed online. Participants reported demographics, and responses to questions regarding VTE chemoprophylaxis in TBI and timing of chemoprophylaxis in 2 hypothetical clinical scenarios of TBI. Results: Three hundred and ninety-one full responses were collected (response rate 30.9%). Most respondents (75%) reported the decision to initiate VTE chemoprophylaxis with a consensus between the neurosurgery and trauma/critical care services. While 76% of respondents reported experience of seeing pulmonary embolism without chemoprophylaxis, 44% witnessed progression of TBI after VTE chemoprophylaxis. Approximately 50% considered their practice of VTE chemoprophylaxis in TBI patients to be conservative. Almost 50% reported no standardized protocol in their institutions. While 1/3 of the members believed guidelines exist, another 1/3 believed no guidelines available. Responses to two clinical scenarios showed various approaches regarding the timing of VTE chemoprophylaxis. Conclusions: Currently there is a wide variability in the practice patterns regarding the timing of VTE chemoprophylaxis in TBI patients. This survey reinforces the need for further investigation to guide clinical practice. (C) 2017 Elsevier Inc. All rights reserved.	[Strollo, Brian P.; Bennett, Gregory J.; Chopko, Michael S.; Guo, Weidun Alan] Univ Buffalo SUNY, Dept Surg, Buffalo, NY 14260 USA; [Bennett, Gregory J.] Erie Cty Med Ctr & Labs, Dept Neurosurg, Buffalo, NY USA; [Strollo, Brian P.] Univ Louisville, Dept Surg, Louisville, KY 40292 USA	Guo, WA (corresponding author), Univ Buffalo SUNY, Dept Surg, Buffalo, NY 14260 USA.	waguo@buffalo.edu					Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z; ACS/ TQIP, 2016, BEST PRACT MAN TRAUM; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Carney N, 2016, GUIDELINES MANAGEMEN; CZAJA R, 1994, ANN INTERN MED, V120, P602, DOI 10.7326/0003-4819-120-7-199404010-00012; Depew AJ, 2008, AM SURGEON, V74, P906; Dillman D.A., 2000, MAIL INTERNET SURVEY; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gabbay J, 2004, BRIT MED J, V329, P1013, DOI 10.1136/bmj.329.7473.1013; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Grabo D, US ARMY I SURG RES J; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Jamjoom AAB, 2016, BRIT J NEUROSURG, V30, P240, DOI 10.3109/02688697.2016.1161170; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kshettry VR, 2014, J CLIN NEUROSCI, V21, P282, DOI 10.1016/j.jocn.2013.07.003; Mesa-Galan LA, 2016, J TRAUMA ACUTE CARE; Meyer RM, 2017, J NEUROSURG, V126, P1047, DOI 10.3171/2016.4.JNS16101; Robertson J, 2005, PHARMACOEPIDEM DR S, V14, P571, DOI 10.1002/pds.1126; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Salottolo K, 2011, J TRAUMA, V70, P19, DOI 10.1097/TA.0b013e318207c54d; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; Sheehan K, 2006, J COMPUT-MEDIAT COMM, V6, P621, DOI DOI 10.1111/J.1083-6101.2001.TB00117.X; Valle EJ, 2014, J TRAUMA ACUTE CARE, V77, P243, DOI 10.1097/TA.0000000000000307; Zachariah J, 2016, NEUROCRIT CARE	25	11	11	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	FEB	2018	43						75	80		10.1016/j.jcrc.2017.08.012			6	Critical Care Medicine	General & Internal Medicine	FQ7DK	WOS:000418522800014	28850931				2021-06-18	
J	Titus, DJ; Wilson, NM; Alcazar, O; Calixte, DA; Dietrich, WD; Gurney, ME; Atkins, CM				Titus, David J.; Wilson, Nicole M.; Alcazar, Oscar; Calixte, Dale A.; Dietrich, W. Dalton; Gurney, Mark E.; Atkins, Coleen M.			A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Cognition; Fluid Percussion Injury; Hippocampus; Memory; Phosphodiesterase; Traumatic brain injury	LONG-TERM POTENTIATION; KNOCK-DOWN; PHOSPHODIESTERASE 4B; HIPPOCAMPAL NEUROGENESIS; RECOGNITION MEMORY; ALZHEIMERS-DISEASE; IMPROVES MEMORY; SPLICE VARIANTS; MICE DEFICIENT; UNITED-STATES	Traumatic brain injury (TBI) significantly decreases cyclic AMP (cAMP) signaling which produces long-term synaptic plasticity deficits and chronic learning and memory impairments. Phosphodiesterase 4 (PDE4) is a major family of cAMP hydrolyzing enzymes in the brain and of the four PDE4 subtypes, PDE4D in particular has been found to be involved in memory formation. Although most PDE4 inhibitors target all PDE4 subtypes, PDE4D can be targeted with a selective, negative allosteric modulator, D159687. In this study, we hypothesized that treating animals with D159687 could reverse the cognitive deficits caused by TBI. To test this hypothesis, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury. After 3 months of recovery, animals were treated with D159687 (0.3 mg/kg, intraperitoneally) at 30 min prior to cue and contextual fear conditioning, acquisition in the water maze or during a spatial working memory task. Treatment with D159687 had no significant effect on these behavioral tasks in non-injured, sham animals, but did reverse the learning and memory deficits in chronic TBI animals. Assessment of hippocampal slices at 3 months post-TBI revealed that D159687 reversed both the depression in basal synaptic transmission in area CA1 as well as the late-phase of long-term potentiation. These results demonstrate that a negative allosteric modulator of PDE4D may be a potential therapeutic to improve chronic cognitive dysfunction following TBI.	[Titus, David J.; Wilson, Nicole M.; Alcazar, Oscar; Calixte, Dale A.; Dietrich, W. Dalton; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14 Terrace, Miami, FL 33136 USA; [Gurney, Mark E.] Tetra Discovery Partners Inc, 38 Fulton St West,Suite 303, Grand Rapids, MI 49503 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14 Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu			National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS069721, R01 NS056072, R44 MH091791]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH091791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS069721] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD023579] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01 NS069721 to C.M.A., R01 NS056072 to C.M.A. and W.D.D. and R44 MH091791 to M.E.G.) and The Miami Project to Cure Paralysis. We thank Concepcion Furones, Jonathan Mendoza, Rosmery Santos and Kevin Sikah for technical support.	Atkins C.M., 2010, EUR J NEUROSCI, V28, P35; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brullo C, 2016, EUR J MED CHEM, V124, P82, DOI 10.1016/j.ejmech.2016.08.018; Bruno O, 2011, BRIT J PHARMACOL, V164, P2054, DOI 10.1111/j.1476-5381.2011.01524.x; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; BUTLER MG, 1988, AM J MED GENET, V30, P971, DOI 10.1002/ajmg.1320300416; Cherry JA, 1999, J COMP NEUROL, V407, P287; Chong J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002309.pub4; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Clapcote SJ, 2007, NEURON, V54, P387, DOI 10.1016/j.neuron.2007.04.015; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Del Rosso James Q, 2016, J Clin Aesthet Dermatol, V9, P43; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Dlaboga D, 2006, BRAIN RES, V1096, P104, DOI 10.1016/j.brainres.2006.04.032; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frieden T. R., 2015, REPORT C TRAUMATIC B; Giralt A, 2011, HUM MOL GENET, V20, P4232, DOI 10.1093/hmg/ddr351; Gurney ME, 2015, NEUROTHERAPEUTICS, V12, P49, DOI 10.1007/s13311-014-0309-7; Gurney ME, 2011, HANDB EXP PHARMACOL, V204, P167, DOI 10.1007/978-3-642-17969-3_7; Hansen RT, 2015, CURR PHARM DESIGN, V21, P291; He Z, 2011, ACS CHEM NEUROSCI, V2, P600, DOI 10.1021/cn2000487; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kalgutkar AS, 2004, XENOBIOTICA, V34, P755, DOI 10.1080/00498250400005682; Kaname T, 2014, CELL SIGNAL, V26, P2446, DOI 10.1016/j.cellsig.2014.07.025; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee H, 2012, AM J HUM GENET, V90, P746, DOI 10.1016/j.ajhg.2012.03.004; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Lindstrand A, 2014, J MED GENET, V51, P45, DOI 10.1136/jmedgenet-2013-101937; Linglart A, 2012, J CLIN ENDOCR METAB, V97, pE2328, DOI 10.1210/jc.2012-2326; Lynch DC, 2013, HUM MUTAT, V34, P97, DOI 10.1002/humu.22222; Maren S, 1997, NEUROBIOL LEARN MEM, V67, P142, DOI 10.1006/nlme.1996.3752; Michot C, 2012, AM J HUM GENET, V90, P740, DOI 10.1016/j.ajhg.2012.03.003; Miro X, 2002, SYNAPSE, V45, P259, DOI 10.1002/syn.10100; Mori F, 2010, J CHEM NEUROANAT, V40, P36, DOI 10.1016/j.jchemneu.2010.03.004; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Oliva AA, 2012, J NEUROCHEM, V123, P1019, DOI 10.1111/jnc.12049; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Press NJ, 2009, PROGR MED CHEM, V47, P37, DOI 10.1016/S0079-6468(08)00202-6; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rampersad SN, 2010, J BIOL CHEM, V285, P33614, DOI 10.1074/jbc.M110.140004; Ricciarelli R, 2017, SCI REP-UK, V7, DOI 10.1038/srep46320; Richter W, 2005, BIOCHEM J, V388, P803, DOI 10.1042/BJ20050030; Robichaud A, 2001, NEUROPHARMACOLOGY, V40, P262, DOI 10.1016/S0028-3908(00)00142-8; Rutten K, 2008, PSYCHOPHARMACOLOGY, V196, P643, DOI 10.1007/s00213-007-0999-1; Rutten K, 2008, EUR J NEUROSCI, V28, P625, DOI 10.1111/j.1460-9568.2008.06349.x; Rutten K, 2009, NEUROPSYCHOPHARMACOL, V34, P1914, DOI 10.1038/npp.2009.24; Schaefer TL, 2012, GENES BRAIN BEHAV, V11, P614, DOI 10.1111/j.1601-183X.2012.00796.x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sierksma ASR, 2014, NEUROPHARMACOLOGY, V77, P120, DOI 10.1016/j.neuropharm.2013.09.015; Siuciak JA, 2008, PSYCHOPHARMACOLOGY, V197, P115, DOI 10.1007/s00213-007-1014-6; Tilley DG, 2005, MOL PHARMACOL, V68, P596, DOI 10.1124/mol.105.014126; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Titus DJ, 2016, J NEUROSCI, V36, P7095, DOI 10.1523/JNEUROSCI.3212-15.2016; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Wang ZZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11332; Wang ZZ, 2013, BRIT J PHARMACOL, V168, P1001, DOI 10.1111/j.1476-5381.2012.02225.x; Wilson NM, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00005; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang C, 2017, SCI REP-UK, V7, DOI 10.1038/srep40115; Zhang C, 2014, J ALZHEIMERS DIS, V38, P269, DOI 10.3233/JAD-122236; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537; Zhang HT, 2009, CURR PHARM DESIGN, V15, P1688, DOI 10.2174/138161209788168092	69	11	11	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	FEB	2018	148						38	49		10.1016/j.nlm.2017.12.008			12	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Behavioral Sciences; Neurosciences & Neurology; Psychology	FZ9ED	WOS:000427911500006	29294383	Green Accepted, Bronze			2021-06-18	
J	Verberne, D; Moulaert, V; Verbunt, J; van Heugten, C				Verberne, Daan; Moulaert, Veronique; Verbunt, Jeanine; van Heugten, Caroline			Factors predicting quality of life and societal participation after survival of a cardiac arrest: A prognostic longitudinal cohort study	RESUSCITATION			English	Article						Cardiac arrest; Quality of life; Societal participation; Predictors	TRAUMATIC BRAIN-INJURY; FOCUSED FOLLOW-UP; ANEURYSMAL SUBARACHNOID HEMORRHAGE; COMMUNITY INTEGRATION; STAND STILL; EVENT SCALE; VALIDATION; SYMPTOMS; STROKE; REHABILITATION	Aim: For those patients who suffer unfavourable outcome after survival of cardiac arrest, it is important to know whether this can be predicted at an early stage. Support can subsequently be provided. This study aimed to identify early prognostic factors of quality of life (QOL) and societal participation at one year post-cardiac arrest. Methods: The design was a prospective longitudinal cohort study following cardiac arrest survivors up to one year. Prognostic personal, injury-related, function-related and subjective outcome factors were selected and entered into a hierarchical regression model to assess whether they were predictive of QOL and societal participation at one year post-cardiac arrest. Results: Hundred and ten cardiac arrest survivors were included. Not having a partner, more functional limitations (at two weeks) and cognitive complaints were significantly predictive of lower physical QOL, while higher levels of anxiety and depression symptoms (at three months) were significant predictors of mental QOL. A neurological history and higher levels of anxiety and depression symptoms were significantly predictive of lower brain injury-specific QOL. Societal participation was only predicted by premorbid functioning. Conclusion: This study identified prognostic factors of QOL and societal participation one year after survival of cardiac arrest. Screening of these factors in early stages can identify those survivors with possibly unfavourable QOL at one year post cardiac arrest. For those survivors, preventive and targeted interventions may be offered. (C) 2017 Elsevier B.V. All rights reserved.	[Verberne, Daan; van Heugten, Caroline] Maastricht Univ, Dept Psychiat & Neuropsychol, Fac Hlth Med & Neurosci, Sch Mental Hlth & Neurosci MHeNS, POB 616, NL-6200 MD Maastricht, Netherlands; [Moulaert, Veronique; Verbunt, Jeanine] Adelante, Ctr Expertise Rehabil & Audiol, NL-6432 CC Hoensbroek, Netherlands; [Moulaert, Veronique] Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil Med, NL-9713 GZ Groningen, Netherlands; [Verbunt, Jeanine] Maastricht Univ, Dept Rehabil Med, Sch Publ Hlth & Primary Care, CAPHRI, POB 616, NL-6200 MD Maastricht, Netherlands; [van Heugten, Caroline] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, Fac Psychol & Neurosci, POB 616, NL-6200 MD Maastricht, Netherlands; [van Heugten, Caroline] Limburg Brain Injury Ctr, POB 616, NL-6200 MD Maastricht, Netherlands	van Heugten, C (corresponding author), Maastricht Univ, Sch Mental Hlth & Neurosci MHeNs, PO 616 UNS 40, NL-6200 MD Maastricht, Netherlands.	c.vanheugten@maastrichtuniversity.nl			Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [ZonMw 920-03-373]; Fonds Nuts Ohra [0602-069]; Stichting Elisabeth Strouven	This work was supported by the Netherlands Organisation for Health Research and Development (ZonMw 920-03-373); Fonds Nuts Ohra (0602-069) and Stichting Elisabeth Strouven. These funding agencies did not play a role in the study design; collection, analysis and interpretation of the data; writing the manuscript; or decisions in where to submit the manuscript.	Alderson AL, 2003, ARCH PHYS MED REHAB, V84, P668, DOI 10.1016/S0003-9993(03)04842-6; Bennett JA, 2002, HEART LUNG, V31, P262, DOI 10.1067/mhl.2002.124554; Boosman H, 2017, NEUROPSYCHOL REHABIL, V27, P581, DOI 10.1080/09602011.2015.1113996; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; de Haan R, 1993, Ned Tijdschr Geneeskd, V137, P917; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Green CR, 2015, ANAESTH INTENS CARE, V43, P568, DOI 10.1177/0310057X1504300504; Haacke C, 2006, STROKE, V37, P193, DOI 10.1161/01.STR.0000196990.69412.fb; Hochstenbach JB, 2001, ARCH PHYS MED REHAB, V82, P1360, DOI 10.1053/apmr.2001.25970; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Larsson IM, 2014, RESUSCITATION, V85, P215, DOI 10.1016/j.resuscitation.2013.09.017; Middelkamp W, 2007, CLIN REHABIL, V21, P425, DOI 10.1177/0269215507075307; Moulaert VRM, 2017, NEUROREHAB NEURAL RE, V31, P530, DOI 10.1177/1545968317697032; Moulaert VRM, 2016, RESUSCITATION, V106, P30, DOI 10.1016/j.resuscitation.2016.06.015; Moulaert VRM, 2015, INT J CARDIOL, V193, P8, DOI 10.1016/j.ijcard.2015.04.229; Moulaert VRM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-34; Moulaert VRMP, 2011, CLIN REHABIL, V25, P867, DOI 10.1177/0269215511399937; Moulaert VRMP, 2010, J REHABIL MED, V42, P553, DOI 10.2340/16501977-0547; Moulaert Veronique R M P, 2007, BMC Cardiovasc Disord, V7, P26, DOI 10.1186/1471-2261-7-26; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Nys GMS, 2006, J NEUROL SCI, V247, P149, DOI 10.1016/j.jns.2006.04.005; Orbo M, 2015, J REHABIL MED, V47, P860, DOI 10.2340/16501977-1998; Passier PECA, 2012, NEUROREHABILITATION, V30, P137, DOI 10.3233/NRE-2012-0737; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turnbull JC, 2000, ARCH PHYS MED REHAB, V81, P1034, DOI 10.1053/apmr.2000.7162; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; van Mierlo M, 2017, DISABIL REHABIL, V13, P1; Visser-Meily JMA, 2009, STROKE, V40, P1526, DOI 10.1161/STROKEAHA.108.531277; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; World Health Organization, 2001, INT CLASS FUNCT DIS	36	11	11	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	FEB	2018	123						51	57		10.1016/j.resuscitation.2017.11.069			7	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	FR7BZ	WOS:000419222600014	29223603	Green Published			2021-06-18	
J	Wallace, J; Covassin, T; Moran, R				Wallace, Jessica; Covassin, Tracey; Moran, Ryan			Racial Disparities in Concussion Knowledge and Symptom Recognition in American Adolescent Athletes	JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES			English	Article						Concussion; Symptoms of concussion; African-American; Adolescents	TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; 2ND-IMPACT SYNDROME; FOOTBALL PLAYERS; CHILDREN; SPORTS; YOUTH; RACE	Background The purpose of this study was to identify if knowledge of concussion differences exists between communities that service underserved, African-American athletes compared to white athletes, and to explore differences in concussion knowledge between African-American and white athletes with and without access to an athletic trainer. Methods Five hundred seventy-seven adolescent athletes ranging in age from 13 to 18 from 14 schools in the USA completed a one-time pencil and paper survey instrument. Data were collected from September 2014 to April 2015. All athletes included in the study received concussion education implemented (i.e., Centers for Disease Control and Prevention (CDC) Heads UP documents) by state concussion law. Knowledge of concussion scores were determined by summing the total correct responses to the 35 questions. Race (white or African-American) and access to an athletic trainer were the independent variables explored. Results White high school athletes have increased concussion knowledge compared to African-American athletes (p < 0.001). African-American athletes less frequently recognized all correct signs and symptoms of concussion compared to white athletes. African-American athletes with access to an athletic trainer have more knowledge than African-American athletes without access to an athletic trainer (p = 0.003). Conclusions White athletes had more concussion knowledge than African-American athletes; however, African-Americans that had access to an athletic trainer at their respective school were more likely to identify the signs and symptoms of concussion compared to African-Americans that did not have access to an athletic trainer. This further accentuates the health disparity that occurs in high school athletics, in regard to the presence of an athletic trainer and their influence on an athlete's health and safety.	[Wallace, Jessica] Youngstown State Univ, 1 Univ Plaza,307L Beeghly Ctr, Youngstown, OH 44512 USA; [Covassin, Tracey] Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48824 USA; [Moran, Ryan] North Dakota State Univ, Bentson Bunker Fieldhouse,Room 1,Dept 2620, Fargo, ND 58101 USA	Wallace, J (corresponding author), Youngstown State Univ, 1 Univ Plaza,307L Beeghly Ctr, Youngstown, OH 44512 USA.	jwallace02@ysu.edu			Pentacost Foundation; Blue Cross Blue; Shield of Michigan Foundation; Michigan State University Graduate School	This project was supported by grants from the Pentacost Foundation, Blue Cross Blue, Shield of Michigan Foundation, and Michigan State University Graduate School.	Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Centers for Disease Control and Prevention Web site, 2011, CONC MILD TBI; Coakley J., 2007, SPORT SOC ISSUES CON; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gourley M. M., 2010, AWARENESS RECOGNITIO, P1; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; National Collegiate Athletic Association, SPORT SPONS PART DEM; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Vicente R., RACE ETHNICITY 19990; Wallace J., 2017, J ATHL TRAIN; WATSON BC, 1989, J NEGRO EDUC, V58, P309, DOI 10.2307/2295664	25	11	11	0	3	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	2197-3792	2196-8837		J RACIAL ETHN HEALTH	J. Racial Ethn. Health Disparities	FEB	2018	5	1					221	228		10.1007/s40615-017-0361-1			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GC0DL	WOS:000429447000024	28389906				2021-06-18	
J	Kong, T; Park, JM; Jang, JH; Kim, CY; Bae, SH; Choi, Y; Jeong, YH; Kim, C; Chang, SW; Kim, J; Moon, J				Kong, TaeHo; Park, Ji-Min; Jang, Ji Hyon; Kim, C-Yoon; Bae, Sang-Hun; Choi, Yuri; Jeong, Yun-Hwa; Kim, Chul; Chang, Sung Woon; Kim, Joopyung; Moon, Jisook			Immunomodulatory effect of CD200-positive human placenta-derived stem cells in the early phase of stroke	EXPERIMENTAL AND MOLECULAR MEDICINE			English	Article							MESENCHYMAL STROMAL CELLS; REGULATORY T-CELLS; TRAUMATIC BRAIN-INJURY; BONE-MARROW; ALZHEIMERS-DISEASE; ISCHEMIC-STROKE; CONDITIONED MEDIUM; CEREBRAL-ISCHEMIA; RATS; TRANSPLANTATION	Human placenta amniotic membrane-derived mesenchymal stem cells (AMSCs) regulate immune responses, and this property can be exploited to treat stroke patients via cell therapy. We investigated the expression profile of AMSCs cultured under hypoxic conditions and observed interesting expression changes in various genes involved in immune regulation. CD200, an anti-inflammatory factor and positive regulator of TGF-beta, was more highly expressed under hypoxic conditions than normoxic conditions. Furthermore, AMSCs exhibited inhibition of pro-inflammatory cytokine expression in co-cultures with LPS-primed BV2 microglia, and this effect was decreased in CD200-silenced AMSCs. The AMSCs transplanted into the ischemic rat model of stroke dramatically inhibited the expression of pro-inflammatory cytokines and up-regulated CD200, as compared with the levels in the sham-treated group. Moreover, decreased microglia activation in the boundary region and improvements in behavior were confirmed in AMSC-treated ischemic rats. The results suggested that the highly expressed CD200 from the AMSCs in a hypoxic environment modulates levels of inflammatory cytokines and microglial activation, thus increasing the therapeutic recovery potential after hypoxic-ischemic brain injury, and further demonstrated the immunomodulatory function of AMSCs in a stroke model.	[Kong, TaeHo; Park, Ji-Min; Kim, C-Yoon; Bae, Sang-Hun; Choi, Yuri; Jeong, Yun-Hwa; Moon, Jisook] CHA Univ, Coll Life Sci, Dept Biotechnol, Pangyo Ro 335 Beon Gil, Seongnam Si, Gyeonggi Do, South Korea; [Kong, TaeHo; Park, Ji-Min; Bae, Sang-Hun; Jeong, Yun-Hwa; Kim, Chul; Moon, Jisook] Bundang CHA Gen Hosp, Gen Res Inst, Seongnam Si, South Korea; [Jang, Ji Hyon; Chang, Sung Woon] CHA Univ, Bundang CHA Med Ctr, Dept OB & GYN, Bundang, South Korea; [Kim, C-Yoon] Seoul Natl Univ, Coll Vet Med, Dept Lab Anim Med, Seoul, South Korea; [Kim, Joopyung] CHA Univ, Sch Med, Bundang CHA Hosp, Dept Neurosurg, Seongnam Si, South Korea	Moon, J (corresponding author), CHA Univ, Coll Life Sci, Dept Biotechnol, Pangyo Ro 335 Beon Gil, Seongnam Si, Gyeonggi Do, South Korea.	jmoon@cha.ac.kr			Bio & Medical Technology Development Program through the National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [NRF-2017M3A9B4025699, NRF-2017M3A9B4025709]	This study was supported by Bio & Medical Technology Development Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (NRF-2017M3A9B4025699 and NRF-2017M3A9B4025709).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; Calio ML, 2014, FREE RADICAL BIO MED, V70, P141, DOI 10.1016/j.freeradbiomed.2014.01.024; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Collins E, 2014, J IMMUNOL, V193, P4381, DOI 10.4049/jimmunol.1401636; de Andrade AVG, 2015, STEM CELLS DEV, V24, P1374, DOI 10.1089/scd.2014.0563; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Donega V, 2014, EXP NEUROL, V261, P53, DOI 10.1016/j.expneurol.2014.06.009; Dooley D, 2014, PHARMACOL THERAPEUT, V141, P21, DOI 10.1016/j.pharmthera.2013.08.001; Du LL, 2016, LIFE SCI, V149, P51, DOI 10.1016/j.lfs.2016.02.050; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12; Holmannova Drahomira, 2012, Acta Medica (Hradec Kralove), V55, P12; Ishimaru N, 2008, J IMMUNOL, V180, P6997, DOI 10.4049/jimmunol.180.10.6997; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kim EY, 2014, BMB REP, V47, P135, DOI 10.5483/BMBRep.2014.47.3.289; Kim KS, 2016, CELL TRANSPLANT, V25, P1145, DOI 10.3727/096368915X688263; Kim KS, 2013, NEUROBIOL AGING, V34, P2408, DOI 10.1016/j.neurobiolaging.2013.03.029; Kim YK, 2016, PROG NEURO-PSYCHOPH, V64, P277, DOI 10.1016/j.pnpbp.2015.06.008; Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r134; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Malcherek G, 2014, LEUKEMIA, V28, P2388, DOI 10.1038/leu.2014.273; Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601; Meuth SG, 2008, J NEUROIMMUNOL, V194, P62, DOI 10.1016/j.jneuroim.2007.11.013; Nicholls SM, 2015, EXP EYE RES, V130, P1, DOI 10.1016/j.exer.2014.11.006; Olajide OA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/459723; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Reynolds AD, 2007, J LEUKOCYTE BIOL, V82, P1083, DOI 10.1189/jlb.0507296; Salgado AJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00249; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shi M, 2011, CLIN EXP IMMUNOL, V164, P1, DOI 10.1111/j.1365-2249.2011.04327.x; Tsai MJ, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-5; Uccelli A, 2015, ANN NY ACAD SCI, V1351, P114, DOI 10.1111/nyas.12815; Vaine CA, 2014, ADV IMMUNOL, V121, P191, DOI 10.1016/B978-0-12-800100-4.00005-2; Wang LQ, 2014, CNS NEUROSCI THER, V20, P317, DOI 10.1111/cns.12216; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Wright GP, 2009, P NATL ACAD SCI USA, V106, P19078, DOI 10.1073/pnas.0907396106; Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492; Yin F, 2014, BRAIN RES, V1561, P1, DOI 10.1016/j.brainres.2014.02.047; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770	51	11	13	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1226-3613	2092-6413		EXP MOL MED	Exp. Mol. Med.	JAN 12	2018	50								e425	10.1038/emm.2017.233			12	Biochemistry & Molecular Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Research & Experimental Medicine	FZ3JW	WOS:000427485000002	29328072	DOAJ Gold, Green Published			2021-06-18	
J	Nguyen, T; Fan, T; George, SR; Perreault, ML				Tuan Nguyen; Fan, Theresa; George, Susan R.; Perreault, Melissa L.			Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus	FRONTIERS IN AGING NEUROSCIENCE			English	Article						GSK-3; lithium; neuronal oscillations; coherence; hippocampus; prefrontal cortex; spatial memory	GLYCOGEN-SYNTHASE KINASE-3; FRAGILE-X-SYNDROME; EUTHYMIC BIPOLAR DISORDER; HUMAN THETA-OSCILLATIONS; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; WORKING-MEMORY TASK; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY	Glycogen synthase kinase-3 (GSK-3) plays a critical role in cognitive dysfunction associated with Alzheimer's disease (AD), yet the mechanism by which GSK-3 alters cognitive processes in other disorders, such as schizophrenia, remains unknown. In the present study, we demonstrated a role for GSK-3 in the direct regulation of neuronal oscillations in hippocampus (HIP) and prelimbic cortex (PL). A comparison of the GSK-3 inhibitors SB 216763 and lithium demonstrated disparate effects of the drugs on spatial memory and neural oscillatory activity in HIP and PL. SB 216763 administration improved spatial memory whereas lithium treatment had no effect. Analysis of neuronal local field potentials in anesthetized animals revealed that whereas both repeated SB 216763 (2.5 mg/kg) and lithium (100 mg/kg) induced a theta frequency spike in HIP at approximately 10 Hz, only SB 216763 treatment induced an overall increase in theta power (4-12 Hz) compared to vehicle. Acute administration of either drug suppressed slow (32-59 Hz) and fast (61-100 Hz) gamma power. In PL, both drugs induced an increase in theta power. Repeated SB 216763 increased HIP-PL coherence across all frequencies except delta, whereas lithium selectively suppressed delta coherence. These findings demonstrate that GSK-3 plays a direct role in the regulation of theta oscillations in regions critically involved in cognition, and highlight a potential mechanism by which GSK-3 may contribute to cognitive decline in disorders of cognitive dysfunction.	[Tuan Nguyen; Fan, Theresa; George, Susan R.; Perreault, Melissa L.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada; [George, Susan R.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Perreault, Melissa L.] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON, Canada	Perreault, ML (corresponding author), Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.; Perreault, ML (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON, Canada.	perreaum@uoguelph.ca	Perreault, Melissa L/N-2867-2017; George, Susan R/P-9669-2018; George, Susan/W-7494-2019	Perreault, Melissa L/0000-0002-5775-8950; 	W. Garfield Weston Foundation [RR150081]	This work was supported by a grant from the W. Garfield Weston Foundation (to MP and SG) (grant #: RR150081).	Al Banchaabouchi M, 2004, PHARMACOL BIOCHEM BE, V79, P607, DOI 10.1016/j.pbb.2004.09.015; Ances BM, 2008, INT REV PSYCHIATR, V20, P89, DOI 10.1080/09540260701877670; Avrahami L, 2013, J BIOL CHEM, V288, P1295, DOI 10.1074/jbc.M112.409250; Balaraman Y, 2006, CELL MOL LIFE SCI, V63, P1226, DOI 10.1007/s00018-005-5597-y; Basar E, 2016, INT J PSYCHOPHYSIOL, V103, P135, DOI 10.1016/j.ijpsycho.2015.02.004; Basar Erol, 2013, Suppl Clin Neurophysiol, V62, P19; Basar-Eroglu C, 2007, INT J PSYCHOPHYSIOL, V64, P39, DOI 10.1016/j.ijpsycho.2006.07.007; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Benchenane K, 2010, NEURON, V66, P921, DOI 10.1016/j.neuron.2010.05.013; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Blasi G, 2013, AM J PSYCHIAT, V170, P868, DOI 10.1176/appi.ajp.2012.12070908; Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847; Bourne C, 2013, ACTA PSYCHIAT SCAND, V128, P149, DOI 10.1111/acps.12133; Bradley CA, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00013; Broersen LM, 2000, PROG BRAIN RES, V126, P79; Buzsaki G, 2013, NEURON, V80, P751, DOI 10.1016/j.neuron.2013.10.002; Cavanagh JF, 2014, TRENDS COGN SCI, V18, P414, DOI 10.1016/j.tics.2014.04.012; Chan MH, 2012, SCHIZOPHR RES, V136, P96, DOI 10.1016/j.schres.2012.01.024; Chen P, 2007, MOL PHARMACOL, V72, P40, DOI 10.1124/mol.107.034942; Clapcote SJ, 2007, NEURON, V54, P387, DOI 10.1016/j.neuron.2007.04.015; Cohen MX, 2011, CURR BIOL, V21, P1900, DOI 10.1016/j.cub.2011.09.036; Contestabile A, 2013, J CLIN INVEST, V123, P348, DOI 10.1172/JCI64650; Crofton EJ, 2017, NEUROPHARMACOLOGY, V117, P49, DOI 10.1016/j.neuropharm.2017.01.020; Daglas R, 2016, EUR PSYCHIAT, V31, P20, DOI 10.1016/j.eurpsy.2015.09.460; Dai MX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044117; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; de Vasconcellos APS, 2005, NEUROBIOL LEARN MEM, V84, P102, DOI 10.1016/j.nlm.2005.05.002; Decloedt EH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005401; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Forlenza OV, 2016, CURR ALZHEIMER RES, V13, P879, DOI 10.2174/1567205013666160219112854; Franklin AV, 2014, BIOL PSYCHIAT, V75, P198, DOI 10.1016/j.biopsych.2013.08.003; GIVENS B, 1994, J NEUROSCI, V14, P3578; Goldfarb M, 2007, NEURON, V55, P449, DOI 10.1016/j.neuron.2007.07.006; Gong EJ, 2011, NEUROBIOL DIS, V44, P223, DOI 10.1016/j.nbd.2011.07.005; Graybeal C, 2011, NAT NEUROSCI, V14, P1507, DOI 10.1038/nn.2954; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Guadagna S, 2012, NEUROPHARMACOLOGY, V62, P2208, DOI 10.1016/j.neuropharm.2012.01.014; Guo WX, 2012, HUM MOL GENET, V21, P681, DOI 10.1093/hmg/ddr501; Guo WP, 2010, BIOCHEM CELL BIOL, V88, P649, DOI 10.1139/O09-189; Harris AZ, 2015, ANNU REV NEUROSCI, V38, P171, DOI 10.1146/annurev-neuro-071714-034111; Helfrich RF, 2016, TRENDS COGN SCI, V20, P916, DOI 10.1016/j.tics.2016.09.007; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Herrmann CS, 2005, CLIN NEUROPHYSIOL, V116, P2719, DOI 10.1016/j.clinph.2005.07.007; Howlett DR, 2004, BRAIN RES, V1017, P130, DOI 10.1016/j.brainres.2004.05.029; Hu SX, 2009, NEUROBIOL DIS, V33, P193, DOI 10.1016/j.nbd.2008.10.007; Huang HC, 2006, CURR DRUG TARGETS, V7, P1389, DOI 10.2174/1389450110607011389; Hyman JM, 2010, FRONT INTEGR NEUROSC, V4, DOI 10.3389/neuro.07.002.2010; Igarashi KM, 2015, CURR OPIN NEUROBIOL, V35, P163, DOI 10.1016/j.conb.2015.09.005; James TF, 2015, BBA-GEN SUBJECTS, V1850, P832, DOI 10.1016/j.bbagen.2015.01.011; JOFFE RT, 1988, J CLIN PSYCHOPHARM, V8, P425; Jones MW, 2005, PLOS BIOL, V3, P2187, DOI 10.1371/journal.pbio.0030402; Kahana MJ, 1999, NATURE, V399, P781, DOI 10.1038/21645; Kalweit AN, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00036; Keri S, 2009, NEUROCHEM INT, V55, P606, DOI 10.1016/j.neuint.2009.06.002; King MK, 2013, GENES BRAIN BEHAV, V12, P723, DOI 10.1111/gbb.12071; King MR, 2013, J NEUROSCI RES, V91, P506, DOI 10.1002/jnr.23192; Kinney GG, 1999, J PHARMACOL EXP THER, V291, P99; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korotkova T, 2018, NEUROSCI BIOBEHAV R, V85, P65, DOI 10.1016/j.neubiorev.2017.09.004; Kwon JS, 1999, ARCH GEN PSYCHIAT, V56, P1001, DOI 10.1001/archpsyc.56.11.1001; Lee J, 2017, NEUROSCIENCE, V358, P124, DOI 10.1016/j.neuroscience.2017.06.039; Lemercier CE, 2017, SCHIZOPHR RES, V188, P118, DOI 10.1016/j.schres.2017.01.017; Letendre SL, 2006, AIDS, V20, P1885, DOI 10.1097/01.aids.0000244208.49123.1b; Li M, 2011, SCHIZOPHR RES, V133, P165, DOI 10.1016/j.schres.2011.09.013; Li YC, 2009, J NEUROSCI, V29, P15551, DOI 10.1523/JNEUROSCI.3336-09.2009; LINNOILA M, 1986, J CLIN PSYCHOPHARM, V6, P356; Lipina TV, 2013, NEUROPHARMACOLOGY, V64, P205, DOI 10.1016/j.neuropharm.2012.06.032; Lipina TV, 2012, NEUROPHARMACOLOGY, V62, P1252, DOI 10.1016/j.neuropharm.2011.02.020; Lipina TV, 2011, SYNAPSE, V65, P234, DOI 10.1002/syn.20839; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu SJ, 2003, J NEUROCHEM, V87, P1333, DOI 10.1046/j.1471-4159.2003.02070.x; Llorens-Martin M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00046; Lodge DJ, 2009, J NEUROSCI, V29, P2344, DOI 10.1523/JNEUROSCI.5419-08.2009; Logothetis NK, 2003, J NEUROSCI, V23, P3963; Maksimovic M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100188; Malhi GS, 2013, CNS DRUGS, V27, P135, DOI 10.1007/s40263-013-0039-0; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Maqbool M, 2016, EUR J MED CHEM, V107, P63, DOI 10.1016/j.ejmech.2015.10.018; Martinez A, 2008, J ALZHEIMERS DIS, V15, P181; Mas-Herrero E, 2016, NEUROIMAGE, V143, P166, DOI 10.1016/j.neuroimage.2016.08.024; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Matsunaga S, 2015, J ALZHEIMERS DIS, V48, P403, DOI 10.3233/JAD-150437; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Medina M, 2010, CURR PHARM DESIGN, V16, P2790, DOI 10.2174/138161210793176581; Mesbah-Oskui L, 2015, NPJ SCHIZOPHR, V1, DOI 10.1038/npjschz.2015.11; Miller AMP, 2017, NEUROBIOL LEARN MEM, V145, P59, DOI 10.1016/j.nlm.2017.08.010; Missonnier P, 2010, J NEURAL TRANSM, V117, P489, DOI 10.1007/s00702-010-0384-9; MITZDORF U, 1985, PHYSIOL REV, V65, P37; Monks PJ, 2004, BIPOLAR DISORD, V6, P550, DOI 10.1111/j.1399-5618.2004.00147.x; Muyllaert D, 2008, GENES BRAIN BEHAV, V7, P57, DOI 10.1111/j.1601-183X.2007.00376.x; Nakazono T, 2017, FRONT SYST NEUROSCI, V11, DOI 10.3389/fnsys.2017.00048; Nocjar C, 2007, NEUROSCIENCE, V150, P774, DOI 10.1016/j.neuroscience.2007.09.063; Noh MY, 2013, BIOCHEM BIOPH RES CO, V435, P274, DOI 10.1016/j.bbrc.2013.04.065; Numakawa T, 2004, HUM MOL GENET, V13, P2699, DOI 10.1093/hmg/ddh280; Nunes MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142267; Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104; O'Neill PK, 2013, J NEUROSCI, V33, P14211, DOI 10.1523/JNEUROSCI.2378-13.2013; Onishi T, 2011, J NEUROCHEM, V119, P1330, DOI 10.1111/j.1471-4159.2011.07532.x; Pardo M, 2017, EUR J NEUROSCI, V45, P490, DOI 10.1111/ejn.13446; Parsaei L, 2016, BRAIN RES BULL, V127, P1, DOI 10.1016/j.brainresbull.2016.07.007; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Peineau S, 2008, BRIT J PHARMACOL, V153, pS428, DOI 10.1038/bjp.2008.2; Peineau S, 2007, NEURON, V53, P703, DOI 10.1016/j.neuron.2007.01.029; Pesaran B, 2002, NAT NEUROSCI, V5, P805, DOI 10.1038/nn890; Pfennig A, 2014, INT J BIPOLAR DISORD, V2, DOI 10.1186/s40345-014-0016-7; Raghavachari S, 2001, J NEUROSCI, V21, P3175, DOI 10.1523/JNEUROSCI.21-09-03175.2001; Rama S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10163; ROUX F, 2014, SCI ENG ETHICS, V18, P16, DOI DOI 10.1016/J.TICS.2013.10.010; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Schifitto G, 2009, J NEUROVIROL, V15, P176, DOI 10.1080/13550280902758973; Schmiedt C, 2005, COGNITIVE BRAIN RES, V25, P936, DOI 10.1016/j.cogbrainres.2005.09.015; Scott L, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.010; Senturk V, 2007, BIPOLAR DISORD, V9, P136, DOI 10.1111/j.1399-5618.2007.00481.x; Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025; Seres I, 2010, NEUROCHEM INT, V56, P906, DOI 10.1016/j.neuint.2010.03.018; Sharifzadeh M, 2005, EUR J PHARMACOL, V511, P159, DOI 10.1016/j.ejphar.2005.01.041; Shavkunov AS, 2013, J BIOL CHEM, V288, P19370, DOI 10.1074/jbc.M112.445924; SHAW ED, 1987, J ABNORM PSYCHOL, V96, P64, DOI 10.1037/0021-843X.96.1.64; Spiegelberg BD, 2005, J BIOL CHEM, V280, P5400, DOI 10.1074/jbc.M407890200; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stip E, 2000, J AFFECT DISORDERS, V60, P147, DOI 10.1016/S0165-0327(99)00178-0; Syed H, 2015, MOL MED REP, V12, P7649, DOI 10.3892/mmr.2015.4351; Takashima A, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P309; Tamura M, 2016, NEURON, V89, P1100, DOI 10.1016/j.neuron.2016.01.025; Tang H, 2013, MOL NEUROBIOL, V48, P404, DOI 10.1007/s12035-013-8414-x; Tesche CD, 1999, J COGNITIVE NEUROSCI, V11, P424, DOI 10.1162/089892999563517; Tian MJ, 2012, FEBS LETT, V586, P3737, DOI 10.1016/j.febslet.2012.09.004; Tsaltas E, 2007, BEHAV BRAIN RES, V177, P51, DOI 10.1016/j.bbr.2006.11.003; Uhlhaas PJ, 2008, SCHIZOPHRENIA BULL, V34, P927, DOI 10.1093/schbul/sbn062; Uhlhaas PJ, 2010, NAT REV NEUROSCI, V11, P100, DOI 10.1038/nrn2774; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Vasconcellos APS, 2003, PHYSIOL BEHAV, V79, P143, DOI 10.1016/S0031-9384(03)00113-6; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Villette V, 2010, J NEUROSCI, V30, P10991, DOI 10.1523/JNEUROSCI.6284-09.2010; Wang X, 2016, BIOCHEM BIOPH RES CO, V473, P428, DOI 10.1016/j.bbrc.2016.03.024; Watase K, 2007, PLOS MED, V4, P836, DOI 10.1371/journal.pmed.0040182; WEINGARTNER H, 1985, PSYCHOPHARMACOLOGY, V86, P472, DOI 10.1007/BF00427911; Wickens RH, 2017, BEHAV PHARMACOL, V28, P262, DOI 10.1097/FBP.0000000000000283; Wildburger NC, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00080; Wingo AP, 2009, J CLIN PSYCHIAT, V70, P1588, DOI 10.4088/JCP.08r04972; Yanagita T, 2009, NEUROPHARMACOLOGY, V57, P311, DOI 10.1016/j.neuropharm.2009.05.006; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Yuskaitis CJ, 2010, BIOCHEM PHARMACOL, V79, P632, DOI 10.1016/j.bcp.2009.09.023; Zhang XM, 2016, SCI REP-UK, V6, DOI 10.1038/srep21948; Zhang X, 2011, J ALZHEIMERS DIS, V24, P739, DOI 10.3233/JAD-2011-101875; Zhao R, 2016, SYNAPSE, V70, P461, DOI 10.1002/syn.21922; Zheng WH, 2013, NEUROREPORT, V24, P560, DOI 10.1097/WNR.0b013e3283623725	148	11	11	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	JAN 12	2018	9								434	10.3389/fnagi.2017.00434			15	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	FS6DD	WOS:000419887200001	29375364	DOAJ Gold, Green Published			2021-06-18	
S	Albornoz, EA; Woodruff, TM; Gordon, R		Cordero, MD; AlcocerGomez, E		Albornoz, Eduardo A.; Woodruff, Trent M.; Gordon, Richard			Inflammasomes in CNS Diseases	INFLAMMASOMES: CLINICAL AND THERAPEUTIC IMPLICATIONS	Experientia Supplementum		English	Article; Book Chapter						Neuroinflammation; Neurodegeneration; NLRP3; Inflammasome; Microglia; IL-1 beta; ASC	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PATTERN-RECOGNITION RECEPTORS; NLRP3 INFLAMMASOME; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; IMMUNE-RESPONSE	Neuroinflammation is a common pathological feature in almost all neurological diseases and is a response triggered as a consequence of the chronic activation of the innate immune response in the CNS against a variety of stimuli, including infection, traumatic brain injury, toxic metabolites, aggregated proteins, or autoimmunity. Crucial mediators of this neurinflammatory process are the intracellular protein complexes known as inflammasomes which can be triggered by pathogens as well as pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). However, chronic inflammasome activation can eventually result in cellular death and tissue damage, leading to the release of DAMPs that can reactivate the inflammasome, thereby propagating a vicious cycle of inflammation. The primary cells involved in CNS inflammasome activation are the immunocompetent microglia and the infiltrating macrophages into the CNS. However, astrocytes and neurons also express inflammasomes, and the understanding of how they are engaged in the pathogenesis of a variety of neurological diseases is crucial to develop effective therapeutic approaches for CNS pathologies that are propagated by chronic inflammasome activation. This chapter covers the activation mechanisms of relevant inflammasomes in the brain and summarizes their roles in the pathogenesis and progression of different neurological conditions.	[Albornoz, Eduardo A.; Woodruff, Trent M.; Gordon, Richard] Univ Queensland, Sch Biomed Sci, Fac Med, Brisbane, Qld, Australia; [Gordon, Richard] Univ Queensland, UQ Ctr Clin Res, Fac Med, Brisbane, Qld, Australia	Gordon, R (corresponding author), Univ Queensland, Sch Biomed Sci, Fac Med, Brisbane, Qld, Australia.; Gordon, R (corresponding author), Univ Queensland, UQ Ctr Clin Res, Fac Med, Brisbane, Qld, Australia.	r.gordon1@uq.edu.au	Albornoz, Eduardo A/D-2681-2017; Woodruff, Trent M./B-4861-2009; Woodruff, Trent/AAS-4629-2020; Gordon, Richard/E-8222-2016	Albornoz, Eduardo A/0000-0002-9976-6350; Woodruff, Trent M./0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X; Gordon, Richard/0000-0003-2478-4607			Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Alboni S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-9; Alcocer-Gomez E, 2014, BRAIN BEHAV IMMUN, V36, P111, DOI 10.1016/j.bbi.2013.10.017; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Barclay W, 2017, BRAIN PATHOL, V27, P213, DOI 10.1111/bpa.12477; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Barrington J, 2017, BRAIN PATHOL, V27, P205, DOI 10.1111/bpa.12476; Boxer MB, 2010, CHEMMEDCHEM, V5, P730, DOI 10.1002/cmdc.200900531; Bruck W, 2005, J NEUROL, V252, P10, DOI 10.1007/s00415-005-2011-5; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Coureuil M, 2017, NAT REV MICROBIOL, V15, P149, DOI 10.1038/nrmicro.2016.178; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504; Doens D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-48; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Fann DYW, 2018, MOL NEUROBIOL, V55, P1082, DOI 10.1007/s12035-017-0394-9; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedrich RP, 2010, P NATL ACAD SCI USA, V107, P1942, DOI 10.1073/pnas.0904532106; Furman D, 2017, NAT MED, V23, P174, DOI 10.1038/nm.4267; Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Guo CQ, 2017, ACS CHEM NEUROSCI, V8, P2194, DOI 10.1021/acschemneuro.7b00124; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Gustot A, 2015, BIOCHEM J, V471, P323, DOI 10.1042/BJ20150617; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Hancock DB, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-6; Heidary M, 2014, J NEUROL SCI, V343, P41, DOI 10.1016/j.jns.2014.05.013; Heneka MT, 2017, BRAIN PATHOL, V27, P220, DOI 10.1111/bpa.12483; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Holtzman D.M., 2012, COLD SPRING HARBOR P, V2, pA006148; Huang WX, 2004, MULT SCLER J, V10, P482, DOI 10.1191/1352458504ms1071oa; Inoue M, 2013, AUTOIMMUN DIS, V2013, DOI 10.1155/2013/859145; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Kabba JA, 2018, CELL MOL NEUROBIOL, V38, P53, DOI 10.1007/s10571-017-0504-2; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim JY, 2015, ONCOTARGET, V6, P44161, DOI 10.18632/oncotarget.6592; Klein RS, 2017, NAT IMMUNOL, V18, P132, DOI 10.1038/ni.3656; Koyuncu OO, 2013, CELL HOST MICROBE, V13, P379, DOI 10.1016/j.chom.2013.03.010; Kuklina EV, 2012, EXPERT REV NEUROTHER, V12, P199, DOI [10.1586/ern.11.99, 10.1586/ERN.11.99]; Kumar M, 2013, J VIROL, V87, P3655, DOI 10.1128/JVI.02667-12; Lammerding L, 2016, NEUROENDOCRINOLOGY, V103, P460, DOI 10.1159/000439435; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lawana V, 2017, J NEUROIMMUNE PHARM, V12, P624, DOI 10.1007/s11481-017-9746-5; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Liang YR, 2015, BRAIN RES, V1622, P43, DOI 10.1016/j.brainres.2015.06.008; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Lipinska K, 2014, J IMMUNOL METHODS, V411, P66, DOI 10.1016/j.jim.2014.05.018; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Losy J, 2001, ACTA NEUROL SCAND, V104, P171, DOI 10.1034/j.1600-0404.2001.00356.x; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Lu M, 2014, NEUROBIOL AGING, V35, P421, DOI 10.1016/j.neurobiolaging.2013.08.015; Luo XG, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-12; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Man SM, 2014, P NATL ACAD SCI USA, V111, P7403, DOI 10.1073/pnas.1402911111; Mao ZJ, 2017, NEUROCHEM RES, V42, P1104, DOI 10.1007/s11064-017-2185-0; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mhyre Timothy R, 2012, Subcell Biochem, V65, P389, DOI 10.1007/978-94-007-5416-4_16; Ming X, 2002, J NEUROL SCI, V197, P9, DOI 10.1016/S0022-510X(02)00030-8; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Nyul-Toth A, 2017, BRAIN BEHAV IMMUN, V64, P220, DOI 10.1016/j.bbi.2017.04.010; Obeso JA, 2010, NAT MED, V16, P653, DOI 10.1038/nm.2165; Panov A, 2005, J BIOL CHEM, V280, P42026, DOI 10.1074/jbc.M508628200; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Ross J, 2007, NEUROPHARMACOLOGY, V53, P638, DOI 10.1016/j.neuropharm.2007.07.015; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Russo FB, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12744; Sajnani G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002547; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Schapira AHV, 2006, NAT REV DRUG DISCOV, V5, P845, DOI 10.1038/nrd2087; Shi MQ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00292; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Spittau B, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00194; Tan MS, 2014, CELL DEATH DIS E, V1382, P5; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Thonnings S, 2016, CLIN MICROBIOL INFEC, V22, P725, DOI 10.1016/j.cmi.2016.06.006; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158; Waisman A, 2015, TRENDS IMMUNOL, V36, P625, DOI 10.1016/j.it.2015.08.005; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang W, 2016, P NATL ACAD SCI USA, V113, P9587, DOI 10.1073/pnas.1610099113; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White CS, 2017, BRAIN PATHOL, V27, P223, DOI 10.1111/bpa.12478; Wu JH, 2010, J CLIN IMMUNOL, V30, P693, DOI 10.1007/s10875-010-9425-2; Wyss-Coray T, 2016, NATURE, V539, P180, DOI 10.1038/nature20411; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Ye XC, 2017, EXP NEUROL, V292, P46, DOI 10.1016/j.expneurol.2017.03.002; Yiannopoulou KG, 2013, THER ADV NEUROL DISO, V6, P19, DOI 10.1177/1756285612461679; Yong VW, 2010, NEUROSCIENTIST, V16, P408, DOI 10.1177/1073858410371379; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zhang P, 2016, MOVEMENT DISORD, V31, P366, DOI 10.1002/mds.26488; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3	114	11	11	0	2	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1023-294X		978-3-319-89390-7; 978-3-319-89389-1	EXPERIENTIA SUPPL	Exp. Suppl.		2018	108						41	60		10.1007/978-3-319-89390-7_3	10.1007/978-3-319-89390-7		20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	BL8LR	WOS:000456615100003	30536167				2021-06-18	
J	Cheng, SX; Xu, ZW; Yi, TL; Sun, HT; Yang, C; Yu, ZQ; Yang, XS; Jin, XH; Tu, Y; Zhang, S				Cheng, Shi-Xiang; Xu, Zhong-Wei; Yi, Tai-Long; Sun, Hong-Tao; Yang, Cheng; Yu, Ze-Qi; Yang, Xiao-Sa; Jin, Xiao-Han; Tu, Yue; Zhang, Sai			iTRAQ-Based Quantitative Proteomics Reveals the New Evidence Base for Traumatic Brain Injury Treated with Targeted Temperature Management	NEUROTHERAPEUTICS			English	Article						Targeted temperature management; Traumatic brain injury; Proteomics; Isobaric tags for relative and absolute quantitation; Cerebrospinal fluid	PHARMACOLOGICALLY INDUCED HYPOTHERMIA; LARGE GENE LISTS; MILD HYPOTHERMIA; RODENT MODELS; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; RATS; MECHANISMS; EXPRESSION	This study aimed to investigate the effects of targeted temperature management (TTM) modulation on traumatic brain injury (TBI) and the involved mechanisms using quantitative proteomics technology. SH-SY5Y and HT-22 cells were subjected to moderate stretch injury using the cell injury controller (CIC), followed by incubation at TTM (mild hypothermia, 32 degrees C), or normothermia (37 degrees C). The real-time morphological changes, cell cycle phase distribution, death, and cell viability were evaluated. Moderate TBI was produced by the controlled cortical impactor (CCI), and the effects of TTM on the neurological damage, neurodegeneration, cerebrovascular histopathology, and behavioral outcome were determined in vivo. Results showed that TTM treatment prevented TBI-induced neuronal necrosis in the brain, achieved a substantial reduction in neuronal death both in vitro and in vivo, reduced cortical lesion volume and neuronal loss, attenuated cerebrovascular histopathological damage, brain edema, and improved behavioral outcome. Using an iTRAQ proteomics approach, proteins that were significantly associated with TTM in experimental TBI were identified. Importantly, changes in four candidate molecules (plasminogen [PLG], antithrombin III [AT III], fibrinogen gamma chain [FGG], transthyretin [TTR]) were verified using TBI rat brain tissues and TBI human cerebrospinal fluid (CSF) samples. This study is one of the first to investigate the neuroprotective effects of TTM on the proteome of human and experimental models of TBI, providing an overall landscape of the TBI brain proteome and a scientific foundation for further assessment of candidate molecules associated with TTM for the promotion of reparative strategies post-TBI.	[Cheng, Shi-Xiang; Yi, Tai-Long; Sun, Hong-Tao; Yang, Cheng; Yu, Ze-Qi; Yang, Xiao-Sa; Tu, Yue; Zhang, Sai] Logist Univ Chinese Peoples Armed Police Force PA, Tianjin Key Lab Neurotrauma Repair, Inst Traumat Brain Injury & Neurosci, Ctr Neurol & Neurosurg,Affiliated Hosp, Tianjin, Peoples R China; [Xu, Zhong-Wei; Jin, Xiao-Han] Logist Univ Chinese Peoples Armed Police Force PA, Cent Lab, Tianjin, Peoples R China	Cheng, SX; Tu, Y; Zhang, S (corresponding author), Logist Univ Chinese Peoples Armed Police Force PA, Tianjin Key Lab Neurotrauma Repair, Inst Traumat Brain Injury & Neurosci, Ctr Neurol & Neurosurg,Affiliated Hosp, Tianjin, Peoples R China.	shixiangcheng@vip.126.com; ytumail@vip.126.com; zhangsai718@vip.126.com		yi, tailong/0000-0002-7092-2444	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31200809]; Science & Technology Program of Tianjin, China [15ZXLCSY00040];  [AWS15J001]	This work was supported by grants from the National Natural Science Foundation of China (31200809), Science & Technology Program of Tianjin, China (15ZXLCSY00040), and Technology Research Projects (AWS15J001).	Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Benoit CE, 2011, TRENDS PHARMACOL SCI, V32, P43, DOI 10.1016/j.tips.2010.10.002; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Chahrour O, 2015, J PHARMACEUT BIOMED, V113, P2, DOI 10.1016/j.jpba.2015.04.013; Cheng SX, 2013, THER HYPOTHERMIA TEM, V3, P132, DOI 10.1089/ther.2013.0005; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Diller KR, 2009, ANNU REV BIOMED ENG, V11, P135, DOI 10.1146/annurev-bioeng-061008-124908; Doll H, 2010, J NEUROTRAUM, V27, P2245, DOI 10.1089/neu.2010.1505; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Fujita M, 2017, J NEUROTRAUMA, V19; Fujita M, 2012, J NEUROTRAUM, V29, P1491, DOI 10.1089/neu.2011.2278; Garland P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047552; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Jin G, 2014, SURGERY, V156, P221, DOI 10.1016/j.surg.2014.03.038; Jin XH, 2017, BBA-PROTEINS PROTEOM, V1865, P1207, DOI 10.1016/j.bbapap.2017.07.003; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kell DB, 2004, BIOESSAYS, V26, P99, DOI 10.1002/bies.10385; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Lei J, 2015, CONTEMP CLIN TRIALS, V40, P9, DOI 10.1016/j.cct.2014.11.008; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Loov C, 2015, J NEUROTRAUM, V32, P244, DOI 10.1089/neu.2014.3517; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nunnally ME, 2011, CRIT CARE MED, V39, P1113, DOI 10.1097/CCM.0b013e318206bab2; Oda Y, 2011, J CEREBR BLOOD F MET, V31, P1143, DOI 10.1038/jcbfm.2010.208; Ottens AK, 2010, J NEUROTRAUM, V27, P1837, DOI 10.1089/neu.2010.1374; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Sharma R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173798; Silasi G, 2011, THER HYPOTHERMIA TEM, V1, P87, DOI 10.1089/ther.2011.0005; Szczygielski J, 2017, J NEUROTRAUM, V34, P1623, DOI 10.1089/neu.2016.4615; Thelin E. P., 2016, BRAIN INJURY FRONT N, V7, P23, DOI [10.3389/fneur.2016.0002327014178, DOI 10.3389/FNEUR.2016.0002327014178]; Thelin EP, 2016, BEHAV BRAIN RES; Thelin EP, 2017, ACTA NEUROCHIR, V159, P209, DOI 10.1007/s00701-016-3046-3; Thelin EP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1450-y; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; Ul Amin F, 2017, SCI REP-UK, V7, DOI 10.1038/srep40753; Urbano LA, 2012, CURR NEUROL NEUROSCI, V12, P580, DOI 10.1007/s11910-012-0304-5; Yang DB, 2017, CLIN CHIM ACTA, V469, P99, DOI 10.1016/j.cca.2017.03.030; Zhai LH, 2013, PROTEOMICS, V13, P2229, DOI 10.1002/pmic.201200591; Zhang HB, 2017, BRAIN INJURY, V31, P406, DOI 10.1080/02699052.2016.1225984; Zhao CC, 2017, J NEUROTRAUM, V34, P1636, DOI 10.1089/neu.2016.4759; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	60	11	14	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2018	15	1					216	232		10.1007/s13311-017-0591-2			17	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	FU8CV	WOS:000424080900020	29247448	Bronze, Green Published			2021-06-18	
J	Delaney, JS; Caron, JG; Correa, JA; Bloom, GA				Delaney, Jeffrey Scott; Caron, Jeffrey G.; Correa, Jose A.; Bloom, Gordon A.			Why Professional Football Players Chose Not to Reveal Their Concussion Symptoms During a Practice or Game	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; symptoms; professional; football; reasons	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SOCCER PLAYERS; EDUCATION; MANAGEMENT; DIAGNOSIS; IMPACT; HOCKEY	Objective: To determine why professional football players in Canada decided not to seek medical attention during a game or practice when they believed they had suffered a concussion. Design: Retrospective survey. Setting: Preseason Canadian Football League training camps. Participants: Four hundred fifty-four male professional football players. Main Outcome Measures: Reasons athletes did not seek medical attention for a presumed concussion during the previous season, how often this occurred and how important these reasons were in the decision process. Results: One hundred six of the 454 respondents (23.4%) believed they had suffered a concussion during their previous football season and 87 of the 106 (82.1%) did not seek medical attention for a concussion at least once during that season. The response "Did not feel the concussion was serious/severe and felt you could still continue to play with little danger to yourself" was the most commonly listed reason (49/106) for not seeking medical attention for a presumed concussion. Many players answered that they did not seek medical attention because they did not want to be removed from a game (42/106) and/or they did not want to risk missing future games (41/106) by being diagnosed with a concussion. Conclusions: Some professional football players who believed they had suffered a concussion chose not to seek medical attention at the time of injury. Players seemed educated about the concussion evaluation process and possible treatment guidelines, but this knowledge did not necessarily translate into safe and appropriate behavior at the time of injury.	[Delaney, Jeffrey Scott] McGill Sport Med Clin, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada; [Delaney, Jeffrey Scott] McGill Univ, Hlth Ctr, Dept Emergency Med, Montreal, PQ, Canada; [Caron, Jeffrey G.; Correa, Jose A.; Bloom, Gordon A.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada; [Correa, Jose A.] McGill Univ, Dept Math, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca			Canadian Football League Players Association (CFLPA)	The authors would like to thank the players and team therapists of the Canadian Football League (CFL) for their help in collecting data. We would also like to thank the CFL league management and the Canadian Football League Players Association (CFLPA) for their assistance and support in completing this study.	Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Caron JG, 2015, INJURY PREV, V21, P301, DOI 10.1136/injuryprev-2014-041479; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Caron JG, 2017, J SPORTS SCI, P1; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P870, DOI 10.1136/bjsports-2017-097508; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Huber BR, 2016, PHYS MED REH CLIN N, V27, P503, DOI 10.1016/j.pmr.2015.12.007; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kroshus E, 2015, HEALTH EDUC BEHAV, V42, P153, DOI 10.1177/1090198114543011; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McDonald K., 2017, COMMUNICATION; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Mrazik M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-094848; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Schwarzer R, 2008, APPL PSYCHOL-INT REV, V57, P1, DOI 10.1111/j.1464-0597.2007.00325.x; Seravalli F., 2016, NHL USE CONCUSSION S; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Wagner-McGough S., 2016, NEW NFL RULE GIVES C; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031	39	11	13	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2018	28	1					1	12		10.1097/JSM.0000000000000495			12	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GB0JM	WOS:000428732000003	29064867				2021-06-18	
J	Donker-Cools, BHPM; Schouten, MJE; Wind, H; Frings-Dresen, MHW				Donker-Cools, Birgit H. P. M.; Schouten, Maria J. E.; Wind, Haije; Frings-Dresen, Monique H. W.			Return to work following acquired brain injury: the views of patients and employers	DISABILITY AND REHABILITATION			English	Article						Acquired brain injury; traumatic brain injury; stroke; return to work; qualitative research; barriers; facilitators	VOCATIONAL-REHABILITATION; QUALITATIVE RESEARCH; SOUTH-AFRICA; PEOPLE; PERSPECTIVES; CANCER; INDIVIDUALS; EXPERIENCES; SURVIVORS	Purpose: To investigate which factors are experienced as facilitators of or barriers to return to work (RTW), or as solutions to RTW-problems, by patients with acquired brain injury (ABI) and by employers. Design: Qualitative study. Method: Ten patients with ABI and seven employers participated in semi-structured interviews. Patients and employers were unrelated. Transcripts were open coded. Factors perceived to be facilitators, barriers, or solutions to RTW-problems were grouped on a thematic basis. Results: Both patients and employers distinguished patient-related and work-related facilitators. When questioned about barriers, both patients and employers emphasized the importance of work-related factors such as sensory overload at the workplace and condition-related factors such as fatigue. Patients regarded poor guidance and support as barriers, but employers did not. Employers and patients suggested that solutions to RTW-problems were work-related, if necessary backed up by professional supervision. Patients also mentioned the need for understanding and acceptance of the limitations resulting from ABI. Conclusions: Both patients and employers mentioned work-related and patient-related facilitators, work-related and condition-related barriers, and work-related solutions to RTW-problems. Patients mentioned lack of guidance and support as barriers, and stressed the need for understanding and acceptance of the limitations resulting from ABI in any RTW-solution.	[Donker-Cools, Birgit H. P. M.; Schouten, Maria J. E.; Wind, Haije; Frings-Dresen, Monique H. W.] Univ Amsterdam, Acad Med Ctr, Dept Coronel Inst Occupat Hlth, POB 22700, NL-1100 DE Amsterdam, Netherlands; [Donker-Cools, Birgit H. P. M.; Schouten, Maria J. E.; Wind, Haije; Frings-Dresen, Monique H. W.] Res Ctr Insurance Med, Amsterdam, Netherlands	Donker-Cools, BHPM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Coronel Inst Occupat Hlth, POB 22700, NL-1100 DE Amsterdam, Netherlands.	b.h.cools@amc.uva.nl		Schouten, Maria/0000-0002-5844-3408			Amir Z, 2010, J OCCUP REHABIL, V20, P435, DOI 10.1007/s10926-009-9197-9; Coole C, 2013, J OCCUP REHABIL, V23, P406, DOI 10.1007/s10926-012-9401-1; de Vries G, 2012, J AFFECT DISORDERS, V136, P1017, DOI 10.1016/j.jad.2011.06.035; Dionne CE, 2013, J OCCUP REHABIL, V23, P280, DOI 10.1007/s10926-012-9399-4; Donker-Cools BH, 2015, DISABIL REHABIL, P1; Donker-Cools BHPM, 2016, BRAIN INJURY, V30, P113, DOI 10.3109/02699052.2015.1090014; Dorland HF, 2016, SUPPORT CARE CANCER, V24, P261, DOI 10.1007/s00520-015-2764-z; Foy CML, 2014, J OCCUP REHABIL, V24, P533, DOI 10.1007/s10926-013-9488-z; Kuluski K, 2014, INT J QUAL STUD HEAL, V9, DOI 10.3402/qhw.v9.22252; Lundqvist A, 2012, BRAIN INJURY, V26, P1574, DOI 10.3109/02699052.2012.698363; Morrison TL, 2014, CAN J OCCUP THER, V81, P163, DOI 10.1177/0008417414534398; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; Saunders SL, 2014, J OCCUP REHABIL, V24, P100, DOI 10.1007/s10926-013-9436-y; Soeker MS, 2012, WORK, V43, P171, DOI 10.3233/WOR-2012-1413; Soeker MS, 2012, WORK, V42, P589, DOI 10.3233/WOR-2012-1414; Stergiou-Kita M, 2012, J OCCUP REHABIL, V22, P166, DOI 10.1007/s10926-011-9332-2; Tamminga SJ, 2012, SCAND J WORK ENV HEA, V38, P144, DOI 10.5271/sjweh.3199; Tiedtke C, 2014, J OCCUP REHABIL, V24, P399, DOI 10.1007/s10926-013-9465-6; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tyerman A, 2012, NEUROREHABILITATION, V31, P51, DOI 10.3233/NRE-2012-0774; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2016, DISABIL REHABIL, V38, P62, DOI 10.3109/09638288.2015.1017057; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	24	11	11	2	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2018	40	2					185	191		10.1080/09638288.2016.1250118			7	Rehabilitation	Rehabilitation	FQ7WX	WOS:000418575300008	27830952	Other Gold			2021-06-18	
J	Lopez-Garcia, I; Gero, D; Szczesny, B; Szoleczky, P; Olah, G; Modis, K; Zhang, KL; Gao, JL; Wu, P; Sowers, LC; DeWitt, D; Prough, DS; Szabo, C				Lopez-Garcia, Isabel; Gero, Domokos; Szczesny, Bartosz; Szoleczky, Petra; Olah, Gabor; Modis, Katalin; Zhang, Kangling; Gao, Jungling; Wu, Ping; Sowers, Lawrence C.; DeWitt, Doug; Prough, Donald S.; Szabo, Csaba			Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; CELLULAR INJURY; DAMAGE; INHIBITION; APOPTOSIS; ISCHEMIA; DIFFERENTIATION	Background and PurposeWe hypothesized that an in vitro, stretch-based model of neural injury may be useful to identify compounds that decrease the cellular damage in neurotrauma. Experimental ApproachWe screened three neural cell lines (B35, RN33B and SH-SY5Y) subjected to two differentiation methods and selected all-trans-retinoic acid-differentiated B35 rat neuroblastoma cells subjected to rapid stretch injury, coupled with a subthreshold concentration of H2O2, for the screen. The model induced marked alterations in gene expression and proteomic signature of the cells and culminated in delayed cell death (LDH release) and mitochondrial dysfunction [reduced 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) conversion]. Follow-up studies utilized human stem cell-derived neurons subjected to rapid stretch injury. Key ResultsFrom screening of a composite library of 3500 drugs, five drugs (when applied in a post-treatment regimen relative to stretch injury) improved both LDH and MTT responses. The effects of rifampicin were investigated in further detail. Rifampicin reduced cell necrosis and apoptosis and improved cellular bioenergetics. In a second model (stretch injury in human stem cell-derived neurons), rifampicin pretreatment attenuated LDH release, protected against the loss of neurite length and maintained neuron-specific class III -tubulin immunoreactivity. Conclusions and ImplicationsWe conclude that the current model is suitable for medium-throughput screening to identify compounds with neuroprotective potential. Rifampicin, when applied either in pre- or post-treatment, improves the viability of neurons subjected to stretch injury and protects against neurite loss. Rifampicin may be a candidate for repurposing for the therapy of traumatic brain injury.	[Lopez-Garcia, Isabel; Gero, Domokos; Szczesny, Bartosz; Szoleczky, Petra; Olah, Gabor; Modis, Katalin; DeWitt, Doug; Prough, Donald S.; Szabo, Csaba] Univ Texas Med Branch, Dept Anesthesiol, 601 Harborside Dr,Bldg 21,Room 4-202J, Galveston, TX 77555 USA; [Zhang, Kangling; Sowers, Lawrence C.] Univ Texas Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; [Gao, Jungling; Wu, Ping] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	Szabo, C (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, 601 Harborside Dr,Bldg 21,Room 4-202J, Galveston, TX 77555 USA.	szabocsaba@aol.com	Prough, Donald S/G-5793-2013; Gero, Domokos/F-7853-2017	Prough, Donald S/0000-0001-7994-532X; Gero, Domokos/0000-0002-3132-3465	Moody Endowment (Galveston, TX, USA)	This work was supported by a grant from the Moody Endowment (Galveston, TX, USA).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Biagini G, 1997, CLIN SCI, V93, P401, DOI 10.1042/cs0930401; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brouwer MC, 2013, LANCET INFECT DIS, V13, P2, DOI 10.1016/S1473-3099(12)70274-8; Chao C, 2016, MOL MED, DOI [10.2119/molmed.2016.00102<original-structure ref = info:doi/10.2119/molmed.2016.00102></original-structure>, DOI 10.2119/M0LMED.2016.00102]; Chazotte B., 2011, LABELING NUCL DNA HO, V1; Chong WS, 2012, KOREAN J ANESTHESIOL, V62, P166, DOI 10.4097/kjae.2012.62.2.166; Croslan DR, 2008, BRAIN RES, V1210, P39, DOI 10.1016/j.brainres.2008.02.059; Curtis MJ, 2015, BRIT J PHARMACOL, V172, P3461, DOI 10.1111/bph.12856; Dailey L, 2001, J CELL PHYSIOL, V186, P315, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1046>3.0.CO;2-Y; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; DeWitt D S, 1995, New Horiz, V3, P376; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Fukuda K, 2010, INVEST OPHTH VIS SCI, V51, P3629, DOI 10.1167/iovs.09-4107; Gero D, 2015, BRIT J PHARMACOL, V172, P4817, DOI 10.1111/bph.13252; Gero D, 2013, DIABETES, V62, P953, DOI 10.2337/db12-0789; Glass TF, 2004, NEUROBIOL DIS, V17, P378, DOI 10.1016/j.nbd.2004.07.017; Gollapudi S, 2003, J CLIN IMMUNOL, V23, P11, DOI 10.1023/A:1021944113833; Harford-Wright E, 2010, NEUROSCI LETT, V481, P26, DOI 10.1016/j.neulet.2010.06.044; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Kilic U, 2004, ACTA NEUROPATHOL, V108, P65, DOI 10.1007/s00401-004-0867-6; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Lamprecht MR, 2016, J NEUROTRAUMA; Laskowitz D., 2016, TRANSLATIONAL RES TR; Li Y, 2010, BRAIN RES, V1330, P131, DOI 10.1016/j.brainres.2010.03.034; Loeb MB, 2004, J AM GERIATR SOC, V52, P381, DOI 10.1111/j.1532-5415.2004.52109.x; Modis K, 2013, FASEB J, V27, P601, DOI 10.1096/fj.12-216507; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Morrison SJ, 2001, CURR BIOL, V11, pR349, DOI 10.1016/S0960-9822(01)00191-9; Muramoto M, 2003, NEUROPHARMACOLOGY, V45, P394, DOI 10.1016/S0028-3908(03)00168-0; Nicholas D, 2015, MOL CELL PROTEOMICS, V14, P15, DOI 10.1074/mcp.M113.035089; Olsen JV, 2009, MOL CELL PROTEOMICS, V8, P2759, DOI 10.1074/mcp.M900375-MCP200; Park IH, 2008, IMMUNOPHARM IMMUNOT, V30, P837, DOI [10.1080/08923970802135732, 10.1080/08923970802135732 ]; Pearn ML, 2016, CELL MOL NEUROBIOL; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Rodrigues CMP, 2000, J NEUROCHEM, V75, P2368, DOI 10.1046/j.1471-4159.2000.0752368.x; Skotak M, 2012, J NEUROSCI METH, V205, P159, DOI 10.1016/j.jneumeth.2012.01.001; Smeda JS, 2011, J CEREBR BLOOD F MET, V31, P476, DOI 10.1038/jcbfm.2010.110; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037; Szabo C, 2005, CRIT CARE MED, V33, pS530, DOI 10.1097/01.CCM.0000187002.88999.CF; Tang K, 2015, DEV GROWTH DIFFER, V57, P109, DOI 10.1111/dgd.12204; te Brake L, 2015, INT J ANTIMICROB AG, V45, P496, DOI 10.1016/j.ijantimicag.2014.12.027; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; TYNDALE RF, 1994, J NEUROSCI, V14, P5417; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Wang N, 2010, ANAL CHEM, V82, P2262, DOI 10.1021/ac9023022; WASIL M, 1988, BIOCHEM PHARMACOL, V37, P775, DOI 10.1016/0006-2952(88)90159-1; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; WHITE LA, 1994, J NEUROIMMUNOL, V49, P135, DOI 10.1016/0165-5728(94)90189-9; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Yerramasetti R, 2002, J CLIN IMMUNOL, V22, P37, DOI 10.1023/A:1014256603539; Yuan LQ, 2014, ARCH BIOCHEM BIOPHYS, V558, P10, DOI 10.1016/j.abb.2014.05.028; Yulug B, 2004, BRAIN RES, V996, P76, DOI 10.1016/j.brainres.2003.10.012; Yulug B, 2014, BRAIN RES BULL, V107, P37, DOI 10.1016/j.brainresbull.2014.05.007	62	11	11	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2018	175	2			SI		284	300		10.1111/bph.13642			17	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FS2HR	WOS:000419599900010	27723079	Bronze, Green Published			2021-06-18	
J	Martin, JL; Wu, D				Martin, Jean-Louis; Wu, Dan			Pedestrian fatality and impact speed squared: Cloglog modeling from French national data	TRAFFIC INJURY PREVENTION			English	Article						Crash; pedestrian; impact speed; fatality; statistical modeling	MOTOR-VEHICLE COLLISIONS; ROAD CRASH CASUALTIES; LIGHT TRUCK VEHICLES; INJURY SEVERITY; PASSENGER CARS; HEAD-INJURY; RISK; FRANCE; PROTECTION; POLICE	Objective: The present study estimates pedestrians' risk of death according to impact speed when hit by a passenger car in a frontal collision.Methods: Data were coded for all fatal crashes in France in 2011 and for a random sample of 1/20th of all road injuries for the same year and weighted to take into account police underreporting of mild injury. A cloglog model was used to optimize risk adjustment for high collision speeds. The fit of the model on the data was also improved by using the square of the impact speed, which best matches the energy dissipated in the collision.Results: Modeling clearly demonstrated that the risk of death was very close to 1 when impact speeds exceeded 80km/h. For speeds less than 40km/h, because data representative of all crashes resulting in injury were used, the estimated risk of death was fairly low. However, although the curve seemed deceptively flat below 50km/h, the risk of death in fact rose 2-fold between 30 and 40km/h and 6-fold between 30 and 50km/h. For any given speed, the risk of death was much higher for more elderly subjects, especially those over 75years of age. These results concern frontal crashes involving a passenger car. Collisions involving trucks are far less frequent, but half result in the pedestrian being run over, incurring greater mortality.Conclusions: For impact speeds below 60km/h, the shape of the curve relating probability of death to impact speed was very similar to those reported in recent rigorous studies. For higher impact speeds, the present model allows the curve to rise ever more steeply, giving a much better fit to observed data. The present results confirm that, when a pedestrian is struck by a car, impact speed is a major risk factor, thus providing a supplementary argument for strict speed limits in areas where pedestrians are highly exposed.	[Martin, Jean-Louis; Wu, Dan] Univ Lyon 1, UMRESTTE UMR T 9405, IFSTTAR, Lyon, France	Martin, JL (corresponding author), Univ Lyon 1, UMRESTTE UMR T 9405, IFSTTAR, Lyon, France.; Martin, JL (corresponding author), Univ Lyon 1, IFSTTAR, UMRESTTE, 25 Ave Francois Mitterrand, F-69675 Bron, France.	jean-louis.martin@ifsttar.fr	Martin, Jean-Louis/X-6588-2019	Martin, Jean-Louis/0000-0002-3426-9601	French National Research AgencyFrench National Research Agency (ANR)	Funding was provided by the French National Research Agency.	Alhajyaseen WKM, 2013, ACCIDENT ANAL PREV, V50, P175, DOI 10.1016/j.aap.2012.04.006; Amoros E, 2008, EUR J PUBLIC HEALTH, V18, P360, DOI 10.1093/eurpub/ckn018; Amoros E, 2007, J TRAUMA, V62, P482, DOI 10.1097/01.ta.0000202546.49273.f9; Amoros E, 2006, ACCIDENT ANAL PREV, V38, P627, DOI 10.1016/j.aap.2005.11.006; Ashton S, 1982, P 24 STAPP CAR CRASH, P609; Badea-Romero A, 2013, ACCIDENT ANAL PREV, V50, P1140, DOI 10.1016/j.aap.2012.09.024; Ballesteros MF, 2004, ACCIDENT ANAL PREV, V36, P73, DOI 10.1016/S0001-4575(02)00129-X; Consentino F, 2010, COMPUT STAT DATA AN, V54, P2284, DOI 10.1016/j.csda.2010.04.009; Crandall JR, 2002, BRIT MED J, V324, P1145, DOI 10.1136/bmj.324.7346.1145; Crocetta G, 2015, ACCIDENT ANAL PREV, V79, P56, DOI 10.1016/j.aap.2015.03.009; Davis GA, 2001, TRANSPORT RES REC, P108, DOI 10.3141/1773-13; del Fueyo RS, 2015, PEDESTRIAN FATAL HEA; Demetriades D, 2004, J AM COLL SURGEONS, V199, P382, DOI 10.1016/j.jamcollsurg.2004.03.027; Depriester J-P, 2005, COMPARISON SEVERAL M; Desapriya E, 2010, TRAFFIC INJ PREV, V11, P48, DOI 10.1080/15389580903390623; Elvik R., 1999, TRANSPORT RES REC, V1665, P33; Fugger TF, 2000, IMECHE CONF TRANS, V2000, P107; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Gupta Vishal, 2013, Stapp Car Crash J, V57, P139; Hamacher M, 2009, 21 INT C ENH SAF VEH; Han Y, 2012, TRAFFIC INJ PREV, V13, P507, DOI 10.1080/15389588.2012.661111; Hannawald L., 2004, EQUAL EFFECTIVENESS; Helmer T, 2010, IRCOBI C HAN GERM 20; Henary Basem Y, 2003, Annu Proc Assoc Adv Automot Med, V47, P105; Henary Basem Y, 2006, Traffic Inj Prev, V7, P182, DOI 10.1080/15389580500516414; Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192; Kim JK, 2008, ACCIDENT ANAL PREV, V40, P1695, DOI 10.1016/j.aap.2008.06.005; Koya, 2013, AM J THEOR APPL STAT, V2, P268, DOI [10.11648/j.ajtas.20130206.25, DOI 10.11648/J.AJTAS.20130206.25]; Kroyer HRG, 2014, ACCIDENT ANAL PREV, V62, P143, DOI 10.1016/j.aap.2013.09.007; Kutner M.H., 2004, APPL LINEAR STAT MOD; Mallory Ann, 2012, Ann Adv Automot Med, V56, P13; Martin JL, 2008, ACCIDENT ANAL PREV, V40, P1811, DOI 10.1016/j.aap.2008.07.001; Martin JL, 2011, 55 ANN AAAM C 2011 P; McCullagh P., 1989, GEN LINEAR MODELS; Observatoire National Interministeriel de Securite Routiere (ONISR), 2014, SEC ROUT FRANC BIL L; Okamoto Yutaka, 2003, Traffic Inj Prev, V4, P74, DOI 10.1080/15389580309856; OTTE D, 1999, P INT IRCOBI C BIOM, P329; Pulugurtha SS, 2011, ACCIDENT ANAL PREV, V43, P439, DOI 10.1016/j.aap.2010.09.014; Rau H, 2000, VERKEHRSUNFALL FAHRZ, V12, P341; Richards D, 2012, ACCIDENT ANAL PREV, V47, P16, DOI 10.1016/j.aap.2012.01.009; Richards DC., 2010, RELATIONSHIP SPEED R; Richmond SA, 2014, ACCIDENT ANAL PREV, V71, P222, DOI 10.1016/j.aap.2014.05.022; Richmond SA, 2014, INJURY PREV, V20, P155, DOI 10.1136/injuryprev-2012-040717; Rosen E, 2011, ACCIDENT ANAL PREV, V43, P25, DOI 10.1016/j.aap.2010.04.003; Rosen E, 2009, ACCIDENT ANAL PREV, V41, P536, DOI 10.1016/j.aap.2009.02.002; Roudsari Bahman S, 2005, Traffic Inj Prev, V6, P185; Roudsari BS, 2004, INJURY PREV, V10, P154, DOI 10.1136/ip.2003.003814; Rubin DB., 1987, MULTIPLE IMPUTATION; Tefft BC, 2013, ACCIDENT ANAL PREV, V50, P871, DOI 10.1016/j.aap.2012.07.022; Toor A, 2003, THEORETICAL VS EMPIR; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Watanabe Ryosuke, 2012, Stapp Car Crash J, V56, P269; WHO, 2015, WHO GLOB STAT REP RO; World Health Organization (WHO), 2013, PED SAF ROAD SAF MAN; Zegeer CV, 2012, ACCIDENT ANAL PREV, V44, P3, DOI 10.1016/j.aap.2010.12.007; Zhu MT, 2013, INJURY PREV, V19, P227, DOI 10.1136/injuryprev-2012-040594	56	11	13	1	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2018	19	1					94	101		10.1080/15389588.2017.1332408			8	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	FN0UP	WOS:000415696600016	28557669				2021-06-18	
J	McDonald, S; Rushby, JA; Dalton, KI; Allen, SK; Parks, N				McDonald, Skye; Rushby, Jacqueline A.; Dalton, Katie I.; Allen, Samantha K.; Parks, Nicklas			The role of abnormalities in the corpus callosum in social cognition deficits after Traumatic Brain Injury	SOCIAL NEUROSCIENCE			English	Article						Traumatic brain injury; white matter; diffuse axonal injury; social cognition	MEDIAL PREFRONTAL CORTEX; UNDERSTANDING SARCASM; NEURAL BASIS; AGENESIS; PERCEPTION; DAMAGE; ADOLESCENTS; RECOGNITION; IMPAIRMENT; AWARENESS	The corpus callosum (CC) is vulnerable to severe traumatic brain injury (TB!). Social cognition requires integration of non-verbal and verbal information in order to understand social behaviour and may be compromised if the CC is damaged. 17 adults with severe, chronic TBI and 17 control participants underwent structural MRI and Diffusion Tensor Imaging. A region of interest analysis examined fractional anisotropy (FA) and mean diffusivity (MD) across regions of the CC. Performance on The Awareness of Social Inference Test (TASIT): part 1 (emotion recognition) and parts 2 and 3 (social inference), was examined in relation to FA and MD. Across participants, higher genu FA values were related to higher TASIT part 3 scores. Increased splenium FA was associated with better performance for TASIT parts 1-3. There was no association between DTI values and TASIT in the controls alone. In the TBI group, FA of the genu and splenium was correlated with TASIT part 3. The pattern of performance was similar when controlling for nonsocial cognitive ability. In conclusion, social information is complex and multi-modal requiring inter-hemispheric connection. People with TBI, regardless of focal grey matter injury, may lose social cognitive ability due to trauma related changes to the corpus callosum.	[McDonald, Skye; Rushby, Jacqueline A.; Dalton, Katie I.; Allen, Samantha K.; Parks, Nicklas] Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Rushby, Jacqueline/D-1820-2010	McDonald, Skye/0000-0003-0723-6094; Rushby, Jacqueline/0000-0002-5018-638X	National Health and Medical Research Council [Centre of Research Excellence in Brain Recovery] [1023043, 1081923]; Australian Research CouncilAustralian Research Council [1094083, 15010026]	Study funded by National Health and Medical Research Council [Centre of Research Excellence in Brain Recovery 1023043, Project Grant 1081923] and by the Australian Research Council [Discovery Project 1094083., Discovery Project 15010026].	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Brown WS, 2005, NEUROPSYCHOLOGIA, V43, P906, DOI 10.1016/j.neuropsychologia.2004.09.008; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2010, NEUROPSYCHOL REHABIL, V20, P739, DOI 10.1080/09602011003794583; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; D'Argembeau A, 2007, J COGNITIVE NEUROSCI, V19, P935, DOI 10.1162/jocn.2007.19.6.935; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Genova HM, 2015, SOC NEUROSCI-UK, V10, P27, DOI 10.1080/17470919.2014.959618; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Honan CA, 2016, CLIN NEUROPSYCHOL, V30, P243, DOI 10.1080/13854046.2015.1136691; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Lacuey N, 2016, BRAIN STRUCT FUNCT, V221, P2695, DOI 10.1007/s00429-015-1065-0; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., LOSS NEURAL CONNECTI; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; Mitchell JP, 2005, NEUROIMAGE, V28, P757, DOI 10.1016/j.neuroimage.2005.03.011; Mitchell JP, 2005, J COGNITIVE NEUROSCI, V17, P1306, DOI 10.1162/0898929055002418; Murray RJ, 2015, HUM BRAIN MAPP, V36, P1304, DOI 10.1002/hbm.22703; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; Paul LK, 2004, ARCH CLIN NEUROPSYCH, V19, P215, DOI 10.1016/S0887-6177(03)00024-6; Paul LK, 2003, BRAIN LANG, V85, P313, DOI 10.1016/S0093-934X(03)00062-2; Paul LK, 2014, BRAIN, V137, P1813, DOI 10.1093/brain/awu070; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Reitan R. M, 1992, TRAIL MAKING TEST; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Shallice, 1997, HAYLING BRIXTON TEST; Shamay SG, 2002, BRAIN COGNITION, V48, P558, DOI 10.1006/brcg.2001.1417; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Symington SH, 2010, SOC NEUROSCI-UK, V5, P296, DOI 10.1080/17470910903462419; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xiong KL, 2014, BRAIN RES, V1591, P86, DOI 10.1016/j.brainres.2014.10.030; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	62	11	11	1	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1747-0919	1747-0927		SOC NEUROSCI-UK	Soc. Neurosci.		2018	13	4					471	479		10.1080/17470919.2017.1356370			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	GF8UF	WOS:000432248300007	28712330				2021-06-18	
J	Nabaweesi, R; Ramakrishnaiah, RH; Aitken, ME; Rettiganti, MR; Luo, CQ; Maxson, RT; Glasier, CM; Kenney, PJ; Robbins, JM				Nabaweesi, Rosemary; Ramakrishnaiah, Raghu H.; Aitken, Mary E.; Rettiganti, Mallikarjuna R.; Luo, Chunqiao; Maxson, Robert T.; Glasier, Charles M.; Kenney, Phillip J.; Robbins, James M.			Injured Children Receive Twice the Radiation Dose at Nonpediatric Trauma Centers Compared With Pediatric Trauma Centers	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY			English	Article						Effective radiation dose; nonpediatric hospitals; CT scan	EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; EXPOSURE	Background: Use of cranial CT scans in children has been increasing, in part due to increased awareness of sports-related concussions. CT is the largest contributor to medical radiation exposure, a risk factor for cancer. Long-term cancer risks of CT scans can be two to three times higher for children than for adults because children are more radiosensitive and have a longer lifetime in which to accumulate exposure from multiple scans. Study Aim: To compare the radiation exposure injured children receive when imaged at nonpediatric hospitals (NPHs) versus pediatric hospitals. Methods: Injured children younger than 18 years who received a CT scan at a referring hospital during calendar years (CYs) 2010 and 2013 were included. Patient-level factors included demographics, mode of transportation, and Injury Severity Score, and hospital-level factors included region of state, radiology services, and hospital type and size. Our primary outcome of interest was the effective radiation dose. Results: Four hundred eighty-seven children were transferred to the pediatric trauma center during CYs 2010 and 2013, with a median age of 7.2 years (interquartile range 5-13). The median effective radiation dose received at NPHs was twice that received at the pediatric trauma center (3.8versus 1.6 mSv, P< .001). Results were confirmed in independent and paired analyses, after controlling for mode of transportation, emergency department disposition, level of injury severity, and at the NPH trauma center level, hospital type, size, region, and radiology services location. Conclusion: NPHs have the potential to substantially reduce the medical radiation received by injured children. Pediatric CT protocols should be considered.	[Nabaweesi, Rosemary; Aitken, Mary E.; Robbins, James M.] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72202 USA; [Nabaweesi, Rosemary; Aitken, Mary E.; Rettiganti, Mallikarjuna R.; Luo, Chunqiao; Robbins, James M.] Arkansas Childrens Res Inst, Little Rock, AR USA; [Ramakrishnaiah, Raghu H.; Glasier, Charles M.] Univ Arkansas Med Sci, Coll Med, Dept Pediat Radiol, Little Rock, AR 72202 USA; [Maxson, Robert T.] Univ Arkansas Med Sci, Coll Med, Dept Pediat Surg, Little Rock, AR 72202 USA; [Kenney, Phillip J.] Univ Arkansas Med Sci, Coll Med, Dept Radiol, Little Rock, AR 72202 USA; [Rettiganti, Mallikarjuna R.; Luo, Chunqiao] Univ Arkansas Med Sci, Coll Med, Dept Biostat, Little Rock, AR 72202 USA	Nabaweesi, R (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Coll Med, Res Inst, 1 Childrens Way,Slot 512-26, Little Rock, AR 72202 USA.	rnabaweesi@uams.edu		Aitken, Mary/0000-0002-8318-9755	Arkansas Biosciences Institute; major research component of the Arkansas Tobacco Settlement Proceeds Act; Marion B. Lyon Revocable Trust-New Scientist Development award	Rosemary Nabaweesi was supported in part by the Arkansas Biosciences Institute, the major research component of the Arkansas Tobacco Settlement Proceeds Act of 2000, and the Marion B. Lyon Revocable Trust-New Scientist Development award. The authors have no conflicts of interest related to the material discussed in this article.	Agarwal S, 2015, AM J ROENTGENOL, V205, P409, DOI 10.2214/AJR.14.13715; Agency for Research and Healthcare Quality, 2008, HEALTHC COST UT PROJ; Goske MJ, 2014, PEDIATR RADIOL, V44, P403, DOI 10.1007/s00247-014-3076-z; Graves JM, 2014, J AM COLL RADIOL, V11, P717, DOI 10.1016/j.jacr.2013.12.002; Graves JM, 2014, J AM COLL RADIOL, V11, P161, DOI 10.1016/j.jacr.2013.07.004; Journy N, 2016, J RADIOL PROT, V36, pN1, DOI 10.1088/0952-4746/36/1/N1; Kharbanda AB, 2013, J TRAUMA ACUTE CARE, V74, P907, DOI 10.1097/TA.0b013e318287883e; Kim PK, 2004, J TRAUMA, V57, P510, DOI 10.1097/01.TA.0000141028.97753.67; Kirsch TD, 2011, J EMERG MED, V41, P302, DOI 10.1016/j.jemermed.2010.06.030; Kocher KE, 2011, ANN EMERG MED, V58, P452, DOI 10.1016/j.annemergmed.2011.05.020; Korley FK, 2015, J HEAD TRAUMA REHABI; Linet MS, 2009, PEDIATR RADIOL, V39, pS4, DOI 10.1007/s00247-008-1026-3; Mahesh M, 2012, J AM COLL RADIOL, V9, P931, DOI 10.1016/j.jacr.2012.09.021; Mahesh Mahadevappa, 2011, Pediatr Radiol, V41 Suppl 2, P493, DOI 10.1007/s00247-011-2169-1; Nabaweesi R, 2016, J AM COLL RADIOL; Strauss KJ, 2010, AM J ROENTGENOL, V194, P868, DOI 10.2214/AJR.09.4091; Thomas KE, 2008, PEDIATR RADIOL, V38, P645, DOI 10.1007/s00247-008-0794-0; Wylie MC, 2014, PEDIATR EMERG CARE, V30, P680, DOI 10.1097/PEC.0000000000000227; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	19	11	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1546-1440			J AM COLL RADIOL	J. Am. Coll. Radiol.		2018	15	1	A				58	64		10.1016/j.jacr.2017.06.035			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	FS3EX	WOS:000419663400018	28847467				2021-06-18	
J	O'Hern, S; Oxley, J				O'Hern, Steve; Oxley, Jennie			Fatal cyclist crashes in Australia	TRAFFIC INJURY PREVENTION			English	Article						Cyclists; fatalities; road safety; injury mechanism	BICYCLING INJURIES; RISK-TAKING; VICTORIA; HELMETS; SAFETY	Objectives: The number of casualty road crashes in Australia has steadily reduced over the past few decades; however, a concurrent reduction has not been achieved for crashes involving cyclists. This has resulted in a disproportionate overrepresentation of cyclists in fatal injury statistics. This article explores the contributing factors and injury mechanisms among coronial reported fatal cyclist crashes in Australia. Methods: The National Coronial Information System (NCIS) is a remote data entry and retrieval system containing detailed coronial information managed by the Victorian Department of Justice and Regulation. All coroner-reported closed cases involving a cyclist fatality in Australia from 2006 to 2015 were extracted from the database. In total, 336 cases in the NCIS database involving a cyclist fatality that occurred within the road reserve throughout Australia were identified and extracted for analysis. Variables in the analyses included age, gender, mechanism of injury, medical cause of death, time of incident, modes of transport involved, speed limit, road geometry, police narratives, and toxicology reports. The NCIS data were supplemented with spatial information using the geographic coordinates of the crash. Geographic information was utilized to gather information regarding various location characteristics such as speed limits and road geometry. Descriptive analysis techniques were performed on the data to examine key variables. Analyses also included cross-tabulation and Pearson's chi-squared tests (chi(2)) for comparison of variables collected. All analyses were undertaken at a level of significance (alpha) of .05. Effect size was assessed using Cramer's V statistic (phi(c)). Results: The majority of fatal outcome crashes occurred in New South Wales (27.4%), followed by Victoria (25.9%) and Queensland (22.0%), and the majority involved male cyclists aged between 35 and 64 years. Those aged between 18 and 34 years were the next most frequent group of fatally injured cyclists. Helmet use was reported in 62.2% of cases. When reported, 19.6% of cyclists were not wearing a helmet at the time of the incident. The presence of alcohol was detected in 14.6% of postmortem examinations and illicit drugs including tetrahydrocannabinol, opioids, and methamphetamine were identified in 17.6% of cases. Analysis of the road characteristics identified a relatively even split between crashes that occurred in low speed environments (60 km/h and below; 51.2%) and higher speed environments (48.8%). Crash counterparts commonly involved light vehicles (31.3%) and heavy vehicles (38.4%), with approximately one quarter (23.8%) being single-vehicle crashes (i.e., bicycle only). Analyses of injury information identified that cyclists most commonly sustained multiple injuries (38.8%). Injuries to the head (31.3%), chest (4.8%), neck (3.4%), and brain (2.0%) were also commonly reported. Conclusions: The findings provide insight into key contributing factors and injury characteristics of fatal cyclist crashes in Australia and can inform and guide the development of effective infrastructure designs and strategies to reduce cyclist trauma.	[O'Hern, Steve; Oxley, Jennie] Monash Univ, Accid Res Ctr, 21 Alliance Way, Clayton, Vic 3800, Australia	O'Hern, S (corresponding author), Monash Univ, Accid Res Ctr, 21 Alliance Way, Clayton, Vic 3800, Australia.	steve.ohern@monash.edu	O'Hern, Steve/AAX-1624-2020	Oxley, Jennie/0000-0002-7519-1994; O'Hern, Steve/0000-0002-7961-3875	Australian Research CouncilAustralian Research Council [LP130100380]	This project was supported by the Australian Research Council Grant Number: LP130100380. The project is a collaborative partnership between Monash University, University of Melbourne, Curtin University, Main Roads WA, VicRoads, The Transport Accident Commission (TAC), The Cycling Promotion Fund, and the Amy Gillett Foundation.	Andersson AL, 2002, INJURY, V33, P467, DOI 10.1016/S0020-1383(02)00028-1; [Anonymous], 2013, FOC CYCL COP GUID DE; Australian Bicycle Council, 2010, AUSTR NAT CYCL STRAT; Australian Bureau of Statistics, 2011, AUSTR STAT GEOGR STA, V5; Bauman A., 2008, CYCLING GETTING AUST; Biegler P., 2012, MACCS MONASH ALFRED; Boufous S, 2013, INJURY PREV, V49, P404; Boufous S, 2016, INJURY PREV, V22, P284, DOI 10.1136/injuryprev-2015-041681; Boufous S, 2012, ACCIDENT ANAL PREV, V49, P404, DOI 10.1016/j.aap.2012.03.011; Bureau of Infrastructure Transport and Regional Economics, 2016, ROAD TRAUM AUSTR 201; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; City of Portland Bureau of Transportation, 2010, PORTL BIC PLAN 2030; Cobey KD, 2013, EVOL PSYCHOL-US, V11, P350, DOI 10.1177/147470491301100206; Corben B, 2000, INJURY REDUCTION MEA; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; de Hartog JJ, 2010, ENVIRON HEALTH PERSP, V118, P1109, DOI 10.1289/ehp.0901747; Fishman E, 2012, J AUSTRALAS COLL ROA, V23, P19; Garrard J, 2010, J AUSTRALAS COLL ROA, V21, P37; Garrard J., 2009, ACTIVE TRANSPORT ADU; Greater London Authority, 2013, MAYORS VIS CYCL LOND; Heesch KC, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-106; Heesch KC, 2011, ACCIDENT ANAL PREV, V43, P2085, DOI 10.1016/j.aap.2011.05.031; Hillman M., 1992, CYCLING HLTH SAFETY; Infrastructure Australia, 2009, CYCL INFR AUSTR CIT; Institute for Road Safety Research, 2017, CYCL SWOV FACT SHEET; Kugelberg FC, 2007, FORENSIC SCI INT, V165, P10, DOI 10.1016/j.forsciint.2006.05.004; Mitra B, 2017, EMERG MED AUSTRALAS, V29, P96, DOI 10.1111/1742-6723.12682; O'Hern S, 2015, J TRANSP HEALTH, V2, P79, DOI 10.1016/j.jth.2014.09.016; Pai CW, 2014, ACCIDENT ANAL PREV, V62, P191, DOI 10.1016/j.aap.2013.09.008; Prati G, 2018, TRANSPORT REV, V38, P184, DOI 10.1080/01441647.2017.1314391; Schepers P, 2014, ACCIDENT ANAL PREV, V62, P331, DOI 10.1016/j.aap.2013.03.032; Sikic M, 2009, MED J AUSTRALIA, V190, P353, DOI 10.5694/j.1326-5377.2009.tb02446.x; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; Victorian Government, 2012, CYCL FUT 2013 2023 V; Woodcock J, 2009, LANCET, V374, P1930, DOI 10.1016/S0140-6736(09)61714-1	36	11	11	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2018	19			2			S27	S31		10.1080/15389588.2018.1497166			5	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	HQ5UO	WOS:000462478300005	30335520				2021-06-18	
J	O'Reilly, K; Wilson, N; Peters, K				O'Reilly, Kate; Wilson, Nathan; Peters, Kath			Narrative literature review: Health, activity and participation issues for women following traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; women; gender; social participation; identity; employment; sexuality; physical complications	LIFE SATISFACTION; SEX-DIFFERENCES; DEPRESSION; SYMPTOMS; OUTCOMES; GENDER; SEVERITY; IMPACT; MEN	Objective: This narrative review will draw attention to the current limitations within the literature related to women following traumatic brain injury in order to stimulate discussion and inform future directions for research.Background: There is a wide-ranging body of research about traumatic brain injury with the higher incidence of brain injury among males reflected in this body of work. As a result, the specific gendered issues facing women with traumatic brain injury are not as well understood.Method: A search of electronic databases was conducted using the terms traumatic brain injury, brain injury, women, participation, concussion and outcomes.Results: The 36 papers revealed the following five themes (1) Relationships and life satisfaction; (2) Perception of self and body image; (3) Meaningful occupation; (4) Sexuality and sexual health; and (5) Physical function.Conclusions: Without research, which focuses specifically on the experience of women and girls with traumatic brain injury there is a risk that clinical care, policy development and advocacy services will not effectively accommodate them.Implications for rehabilitationExploring the gendered issues women may experience following traumatic brain injury will enhance clinicians understanding of the unique challenges they face. Such information has the potential to guide future directions for research, policy, and practice.Screening women for hormonal imbalances such as hypopituitarism following traumatic brain injury is recommended as this may assist clinicians in addressing the far reaching implications in regard to disability, quality of life and mood.The growing literature regarding the cumulative effect of repeat concussions following domestic violence and women's increased risk of sport-related concussion may assist clinicians in advocating for appropriate rehabilitation and community support services.	[O'Reilly, Kate; Wilson, Nathan; Peters, Kath] Western Sydney Univ, Sch Nursing & Midwifery, Locked Bag 1797, Penrith, NSW 2751, Australia	O'Reilly, K (corresponding author), Western Sydney Univ, Sch Nursing & Midwifery, Locked Bag 1797, Penrith, NSW 2751, Australia.	Kate.Oreilly@westernsydney.edu.au	Peters, Kath/ABF-9495-2020; Wilson, Nathan/ABF-9708-2020	Wilson, Nathan/0000-0002-6979-2099; Peters, Kath/0000-0001-5299-2863			Alston M, 2012, AUST SOC WORK, V65, P39, DOI 10.1080/0312407X.2011.594898; Andelic N, 2015, J NEUROL, V262, P523, DOI 10.1007/s00415-014-7595-1; Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Arslanian-Engoren C, 2011, JOGNN-J OBST GYN NEO, V40, P337, DOI 10.1111/j.1552-6909.2011.01234.x; Australian Institute of Health and Welfare, 2007, BULLETIN, V55; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brain Injury Association of Queensland, 2007, ACQ BRAIN INJ FACTS; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cassidy D, 2014, ARCH PHYS MED REH S2, V9532, P278; Colantonio A, 2016, ARCH PHYS MED REHAB, V97, pS1, DOI 10.1016/j.apmr.2015.12.002; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; Colantonio A, 2010, J WOMENS HEALTH, V19, P1109, DOI 10.1089/jwh.2009.1740; Corrigan JD, 2001, CLIN J WOMENS HLTH, V1, P184; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Despins EH, 2016, ARCH PHYS MED REHAB, V97, pS26, DOI 10.1016/j.apmr.2014.06.023; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Goldin Y, 2014, J HEAD TRAUMA REHAB, V29, P418, DOI 10.1097/HTR.0b013e31829cf76d; Haag HL, 2016, ARCH PHYS MED REHAB, V97, pS64, DOI 10.1016/j.apmr.2014.12.018; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Helps Y., 2008, INJURY RES STAT SERI, V45; Howes H, 2005, PSYCHOL HEALTH, V20, P129, DOI 10.1080/0887044042000272903; Howes HFR, 2005, BRAIN INJURY, V19, P403, DOI 10.1080/02699050400025158; Jacobsson L, 2013, J REHABIL MED, V45, P1010, DOI 10.2340/16501977-1204; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McLean AM, 2014, DISABIL REHABIL, V36, P1409, DOI 10.3109/09638288.2013.834986; McLean LL, 2016, QUAL REP, V21, P1118; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nalder E, 2016, ARCH PHYS MED REHAB, V97, pS46, DOI 10.1016/j.apmr.2014.07.428; O'Reilly K., 2015, J AUSTRALASIAN REHAB, V18, P18; Paquette M, 2014, SOC SCI MED, V59, P1047; Paquette MC, 2002, J NUTR EDUC BEHAV, V34, P172, DOI 10.1016/S1499-4046(06)60087-0; Parks Jennifer K, 2010, Proc (Bayl Univ Med Cent), V23, P355; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Puscheck E., 2015, CLIN GYNECOLOGY; Ranganathan P, 2016, BRAIN INJURY, V30, P452, DOI 10.3109/02699052.2016.1144081; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Saban KL, 2011, J WOMENS HEALTH, V20, P179, DOI 10.1089/jwh.2010.2334; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P1331, DOI 10.1016/j.apmr.2012.03.037; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stergiou-Kita M, 2016, ARCH PHYS MED REHAB, V97, pS40, DOI 10.1016/j.apmr.2015.04.008; Stewart AL, 1992, MEASURING FUNCTIONIN; Strizzi J, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/247479; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Toor GK, 2016, ARCH PHYS MED REHAB, V97, pS54, DOI 10.1016/j.apmr.2015.02.010; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; Vokes T., 2015, CLIN GYNECOLOGY; Wilson NJ, 2012, INTELLECT DEV DISAB, V50, P261, DOI 10.1352/1934-9556-50.3.261; World Health Organization, 2002, DISABIL HLTH; Xiong C, 2016, DISABIL HEALTH J, V9, P439, DOI 10.1016/j.dhjo.2015.12.002	59	11	12	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2018	40	19					2331	2342		10.1080/09638288.2017.1334838			12	Rehabilitation	Rehabilitation	GO4ZI	WOS:000440026500015	28585486				2021-06-18	
J	Owens, JA; Spitz, G; Ponsford, JL; Dymowski, AR; Willmott, C				Owens, Jacqueline Anne; Spitz, Gershon; Ponsford, Jennie Louise; Dymowski, Alicia Rhian; Willmott, Catherine			An investigation of white matter integrity and attention deficits following traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; attention; processing speed; diffusion tensor imaging; tract-based spatial statistics	INFORMATION-PROCESSING SPEED; MEMORY; ASSOCIATION; DYSFUNCTION; DTI	Objective: This study aimed to investigate the association between white matter tracts and multiple aspects of attention and working memory deficits in a relatively acute traumatic brain injury (TBI) sample.Method: Neuropsychological measures of attention and working memory were administered to 20 participants with complicated mild-to-very severe TBI and 20 control participants. Tract-based spatial statistics was used to assess fractional anisotropy (FA) and mean diffusivity (MD) of white matter tracts for 15 TBI participants and 20 controls.Results: When compared to controls, participants with TBI were found to have lower FA (p<0.001) and higher MD (p<0.001) values in the majority of white matter tracts. TBI participants were also slower to complete tasks including Trail Making Test, Hayling, computerized Selective Attention Task, n-back and Symbol Digit Modalities Test (p<0.001), when compared to controls. When controlling for age and estimated premorbid intelligence, slowed information processing speed following TBI was found to be associated with FA values in the corpus callosum, superior longitudinal fasciculus, cingulum, inferior fronto-occipital fasciculi, corona radiata and cerebral white matter.Conclusion: The results highlight the widespread damage associated with TBI, as well as the impact of these alterations on information processing speed.	[Owens, Jacqueline Anne; Spitz, Gershon; Ponsford, Jennie Louise; Dymowski, Alicia Rhian; Willmott, Catherine] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [Owens, Jacqueline Anne; Spitz, Gershon; Ponsford, Jennie Louise; Dymowski, Alicia Rhian; Willmott, Catherine] Epworth HealthCare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Owens, Jacqueline Anne; Spitz, Gershon; Ponsford, Jennie Louise; Dymowski, Alicia Rhian; Willmott, Catherine] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia	Owens, JA (corresponding author), Monash Univ, 18 Innovat Walk Bldg 17,Clayton Campus, Melbourne, Vic 3800, Australia.	Jacqueline.Owens@monash.edu	Willmott, Catherine/AAA-5105-2019; Ponsford, Jennie/H-8341-2014	Willmott, Catherine/0000-0001-8517-9035; Ponsford, Jennie/0000-0003-0430-125X			Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN, P59; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Deary IJ, 2010, NAT REV NEUROSCI, V11, P201, DOI 10.1038/nrn2793; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dymowski AR, 2015, J CLIN EXP NEUROPSYC, V37, P1024, DOI 10.1080/13803395.2015.1074663; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kourtidou P, 2013, J HEAD TRAUMA REHAB, V28, P433, DOI 10.1097/HTR.0b013e3182585d06; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Nelson HE, 1982, NATL ADULT READING T; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2004, COGNITIVE BEHAV REHA; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ruff RM, 1995, RUFF 2 7 SELECTIVE A; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1991, SYMBOL DIGIT MODALIT; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Tabachnick BG, 2007, USING MULTIVARIATE S; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	11	12	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	6					776	783		10.1080/02699052.2018.1451656			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GE9BZ	WOS:000431526200012	29565696				2021-06-18	
J	Salisbury, JP; Keshav, NU; Sossong, AD; Sahin, NT				Salisbury, Joseph P.; Keshav, Neha U.; Sossong, Anthony D.; Sahin, Ned T.			Concussion Assessment With Smartglasses: Validation Study of Balance Measurement Toward a Lightweight, Multimodal, Field-Ready Platform	JMIR MHEALTH AND UHEALTH			English	Article						postural balance; wearable technology; accelerometry; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; RANDOMIZED CLINICAL-TRIAL; ERROR SCORING SYSTEM; SOCIAL COMMUNICATION; AUDITORY BIOFEEDBACK; NIH TOOLBOX; ICE HOCKEY; MILITARY; REHABILITATION; RELIABILITY	Background: Lightweight and portable devices that objectively measure concussion-related impairments could improve injury detection and critical decision-making in contact sports and the military, where brain injuries commonly occur but remain underreported. Current standard assessments often rely heavily on subjective methods such as symptom self-reporting. Head-mounted wearables, such as smartglasses, provide an emerging platform for consideration that could deliver the range of assessments necessary to develop a rapid and objective screen for brain injury Standing balance assessment, one parameter that may inform a concussion diagnosis, could theoretically be performed quantitatively using current off-the-shelf smartglasses with an internal accelerometer. However, the validity of balance measurement using smartglasses has not been investigated. Objective: This study aimed to perform preliminary validation of a smartglasses-based balance accelerometer measure (BAM) compared with the well-described and characterized waist-based BAM. Methods: Forty-two healthy individuals (26 male, 16 female; mean age 23.8 [SD 5.2] years) participated in the study. Following the BAM protocol, each subject performed 2 trials of 6 balance stances while accelerometer and gyroscope data were recorded from smartglasses (Glass Explorer Edition). Test-retest reliability and correlation were determined relative to waist-based BAM as used in the National Institutes of Health's Standing Balance Toolbox. Results: Balance measurements obtained using a head-mounted wearable were highly correlated with those obtained through a waist-mounted accelerometer (Spearman rho, rho=.85). Test-retest reliability was high (intraclass correlation coefficient, ICC2,1=0.85, 95% CI 0.81-0.88) and in good agreement with waist balance measurements (ICC2,1=0.84, 95% CI 0.80-0.88). Considering the normalized path length magnitude across all 3 axes improved interdevice correlation (rho=.90) while maintaining test-retest reliability (ICC2,1=0.87, 95% CI 0.83-0.90). All subjects successfully completed the study, demonstrating the feasibility of using a head-mounted wearable to assess balance in a healthy population. Conclusions: Balance measurements derived from the smartglasses-based accelerometer were consistent with those obtained using a waist-mounted accelerometer. Additional research is necessary to determine to what extent smartglasses-based accelerometry measures can detect balance dysfunction associated with concussion. However, given the potential for smartglasses to perform additional concussion-related assessments in an integrated, wearable platform, continued development and validation of a smartglasses-based balance assessment is warranted. This approach could lead to a wearable platform for real-time assessment of concussion-related impairments that could be further augmented with telemedicine capabilities to integrate professional clinical guidance. Smartglasses may be superior to fully immersive virtual reality headsets for this application, given their lighter weight and reduced likelihood of potential safety concerns.	[Salisbury, Joseph P.; Sossong, Anthony D.; Sahin, Ned T.] TIAX LLC, Neural Sensing & Biometr Div, Lexington, MA USA; [Salisbury, Joseph P.; Keshav, Neha U.; Sossong, Anthony D.; Sahin, Ned T.] Brain Power LLC, Empowerment Lab, 1 Broadway 14th Fl, Cambridge, MA 02142 USA; [Sossong, Anthony D.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Sossong, Anthony D.] Harvard Med Sch, Boston, MA USA; [Sahin, Ned T.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA	Sahin, NT (corresponding author), Brain Power LLC, Empowerment Lab, 1 Broadway 14th Fl, Cambridge, MA 02142 USA.	sahin@post.harvard.edu	Salisbury, Joseph/L-3294-2019	Salisbury, Joseph/0000-0002-9448-9024; Sossong, Anthony/0000-0001-9969-234X; Keshav, Neha/0000-0003-4307-2955	United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-14-C-0007]; Office of the Assistant Secretary of Defense for Health Affairs, through the Autism Research Program [W81XWH-17-1-0449]	This study is based upon work supported by the United States Army Medical Research and Materiel Command under Contract No. W81XWH-14-C-0007 (awarded to TIAX, LLC). Additional work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Autism Research Program under Award No. W81XWH-17-1-0449. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The authors thank Alyk Moomaw for her help in preparing the manuscript. The authors thank Google, Inc for generous support and the Glass team at X (formerly Google X) for technical guidance on Glass development.	Abdullah KG, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0535-3; Amick R.Z., 2015, THE J, V4, P40, DOI [10.7309/jmtm.4.2.6, DOI 10.7309/JMTM.4.2.6]; Amick RZ, 2013, INT J APPL SCI TECHN, V3, P97, DOI DOI 10.13140/2.1.1568.8324; ANDERSON TW, 1954, J AM STAT ASSOC, V49, P765, DOI 10.2307/2281537; Baumel A, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0776-6; Burghart M, 2017, CURR RES CONCUSSION, V4, pe1, DOI [10.1055/s-0036-1597914, DOI 10.1055/S-0036-1597914]; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll Linda, 2012, CONCUSSION CRISIS AN; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Connelly C, 2017, INJURY, V48, P64, DOI 10.1016/j.injury.2016.08.025; Coughlin S. S., 2012, POSTTRAUMATIC STRESS; Defense and Veterans Brain Injury Center, 2016, DOD WORLDW NUMB TBI; Dozza M, 2005, ARCH PHYS MED REHAB, V86, P1401, DOI 10.1016/j.apmr.2004.12.036; Dozza M, 2007, EXP BRAIN RES, V178, P37, DOI 10.1007/s00221-006-0709-y; Fino PC, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0812-7; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gil-Gomez JA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-30; Global Industry Analysts Inc., STRAT SMART AUGM REA; Goble DJ, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-12; Guskiewicz Kevin, 2014, Neurosurgery, V75 Suppl 4, pS113, DOI 10.1227/NEU.0000000000000494; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Johnson MAL, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0311-8; Keshav NU, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.8534; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kinsella BG, 2017, FRONT ROBOT AI, V4, DOI 10.3389/frobt.2017.00031; Kraus J. F., 1999, REHABILITATION ADULT, P3; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Kvedar JC, 2016, NAT BIOTECHNOL, V34, P239, DOI 10.1038/nbt.3495; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange B, 2011, IEEE ENG MED BIO, P1831, DOI 10.1109/IEMBS.2011.6090521; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Liu RP, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00145; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; LUPTON SD, 1990, J IMMUNOL, V144, P3592; Lutz Otto Hans-Martin, 2017, Current Directions in Biomedical Engineering, V3, P53, DOI 10.1515/cdbme-2017-0012; Madhushri P, 2016, IEEE ENG MED BIO, P3117, DOI 10.1109/EMBC.2016.7591389; Madhushri P, 2016, INFORMATION, V7, DOI 10.3390/info7030047; Mancini M, 2010, EUR J PHYS REHAB MED, V46, P239; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Marchetti GF, 2013, J VESTIBUL RES-EQUIL, V23, P227, DOI 10.3233/VES-130490; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Mellone S, 2012, GAIT POSTURE, V36, P163, DOI 10.1016/j.gaitpost.2012.02.006; Mitrasinovic S, 2015, TECHNOL HEALTH CARE, V23, P381, DOI 10.3233/THC-150910; Myers L., 2006, ENCY STAT SCI; Ozdalga E, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1994; Paavola JM, 2013, J NOVEL PHYSIOTHERAP, V3, P129, DOI DOI 10.4172/2165-7025.1000129; Patterson JA, 2014, INT J SPORTS PHYS TH, V9, P135; Phillips T, 2015, SPORT J, V8; Prosperini L, 2013, NEUROREHAB NEURAL RE, V27, P516, DOI 10.1177/1545968313478484; Reuben DB, 2013, NEUROLOGY, V80, pS65, DOI 10.1212/WNL.0b013e3182872e01; Rine RM, 2013, NEUROLOGY, V80, pS25, DOI 10.1212/WNL.0b013e3182872c6a; Saldana SJ, 2017, CLIN INTERV AGING, V12, DOI 10.2147/CIA.S141251; Schmid Kara E, 2012, Front Neurol, V3, P90, DOI 10.3389/fneur.2012.00090; Shah Nirtal, 2016, JMIR Rehabil Assist Technol, V3, pe4, DOI 10.2196/rehab.4511; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Slotkin J., 2012, NIH TOOLBOX TECHNICA; Smith AM, 2017, CLIN J SPORT MED, V27, P503, DOI 10.1097/JSM.0000000000000412; Thompson JWG, 2012, J CLIN SPORT PSYCHOL, V6, P22, DOI 10.1123/jcsp.6.1.22; Vargha A, 1998, J EDUC BEHAV STAT, V23, P170; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Venugopalan J, 2013, IEEE ENG MED BIO, P4625, DOI 10.1109/EMBC.2013.6610578; Vincenzo JL, 2016, AGING CLIN EXP RES, V28, P679, DOI 10.1007/s40520-015-0471-8; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wright WG, 2017, DISABIL REHABIL, V39, P1564, DOI 10.1080/09638288.2016.1226432; Youssef AR, 2017, EXPERT REV MED DEVIC, V14, P481, DOI 10.1080/17434440.2017.1325319; Zar J. H., 1998, ENCY BIOSTATISTICS; Zhao Y, 2016, J NEUROL, V263, P1156, DOI 10.1007/s00415-016-8115-2; Zoeller T, INTRACLASS CORRELATI	76	11	11	2	6	JMIR PUBLICATIONS, INC	TORONTO	59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA	2291-5222			JMIR MHEALTH UHEALTH	JMIR mHealth uHealth	JAN	2018	6	1							e15	10.2196/mhealth.8478			12	Health Care Sciences & Services; Medical Informatics	Health Care Sciences & Services; Medical Informatics	GH8XB	WOS:000433951300025	29362210	DOAJ Gold, Green Published			2021-06-18	
J	Tierney, GJ; Joodaki, H; Krosshaug, T; Forman, JL; Crandall, JR; Simms, CK				Tierney, Gregory J.; Joodaki, Hamed; Krosshaug, Tron; Forman, Jason L.; Crandall, Jeff R.; Simms, Ciaran K.			Assessment of model-based image-matching for future reconstruction of unhelmeted sport head impact kinematics	SPORTS BIOMECHANICS			English	Article						Concussion; rugby; image processing	RUGBY UNION; INSTRUMENTED MOUTHGUARD; PROFESSIONAL FOOTBALL; HUMAN MOTION; INJURY; CONCUSSION; ACCELERATION; VELOCITY	Player-to-player contact inherent in many unhelmeted sports means that head impacts are a frequent occurrence. Model-Based Image-Matching (MBIM) provides a technique for the assessment of three-dimensional linear and rotational motion patterns from multiple camera views of a head impact event, but the accuracy is unknown for this application. The goal of this study is to assess the accuracy of the MBIM method relative to reflective marker-based motion analysis data for estimating six degree of freedom head displacements and velocities in a staged pedestrian impact scenario at 40 km/h. Results showed RMS error was under 20 mm for all linear head displacements and 0.01-0.04 rad for head rotations. For velocities, the MBIM method yielded RMS errors between 0.42 and 1.29 m/s for head linear velocities and 3.53-5.38 rad/s for angular velocities. This method is thus beneficial as a tool to directly measure six degree of freedom head positional data from video of sporting head impacts, but velocity data is less reliable. MBIM data, combined in future with velocity/acceleration data from wearable sensors could be used to provide input conditions and evaluate the outputs of multibody and finite element head models for brain injury assessment of sporting head impacts.	[Tierney, Gregory J.; Simms, Ciaran K.] Trinity Coll Dublin, Dept Mech & Mfg Engn, Trinity Ctr Bioengn, Dublin, Ireland; [Joodaki, Hamed; Forman, Jason L.; Crandall, Jeff R.] Univ Virginia, Ctr Appl Biomech, Charlottesville, VA USA; [Krosshaug, Tron] Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, Oslo, Norway	Tierney, GJ (corresponding author), Trinity Coll Dublin, Dept Mech & Mfg Engn, Trinity Ctr Bioengn, Dublin, Ireland.	gtierne@tcd.ie	Simms, Ciaran/K-3100-2019	Simms, Ciaran/0000-0001-5564-1620	Irish Research CouncilIrish Research Council for Science, Engineering and Technology	Acknowledgement should be given to The Irish Research Council for funding this study.	Allison M. A., 2013, INT RES COUNC BIOM I; Alvarez M., 2007, IEEE 10 INT S WORKL; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Collins H, 2012, PUBLIC UNDERST SCI, V21, P904, DOI 10.1177/0963662511407991; Elliott JR, 2012, P I MECH ENG K-J MUL, V226, P266, DOI 10.1177/1464419311430176; Forman J. L., 2015, INT RES COUNC BIOM I; Forman Jason L, 2015, Stapp Car Crash J, V59, P401; Frechede B., 2007, ENH SAF VEH LYON FRA; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hendricks S, 2012, J SPORT SCI, V30, P1215, DOI 10.1080/02640414.2012.707328; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Kerrigan J. R., 2005, EXP SAF VEH C WASH D; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Krosshaug T, 2005, J BIOMECH, V38, P919, DOI 10.1016/j.jbiomech.2004.04.033; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mok KM, 2011, GAIT POSTURE, V34, P71, DOI 10.1016/j.gaitpost.2011.03.014; Newman J., 1999, INT RES COUNC BIOM I; OReilly O., 2008, INTERMEDIATE DYNAMIC, DOI [10.1017/CBO9780511791352, DOI 10.1017/CBO9780511791352]; Parent DP, 2011, INT J CRASHWORTHINES, V16, P633, DOI 10.1080/13588265.2011.616114; Patton DA, 2015, J APPL BIOMECH, V31, P264, DOI 10.1123/jab.2014-0223; Patton DA, 2012, P I MECH ENG P-J SPO, V226, P177, DOI 10.1177/1754337112438305; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Richards JG, 1999, HUM MOVEMENT SCI, V18, P589, DOI 10.1016/S0167-9457(99)00023-8; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Tierney G. J., 2015, INT RES COUNC BIOM I; Tierney GJ, 2016, BRAIN INJURY, V30, P1350, DOI 10.1080/02699052.2016.1193630; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Yamazaki J, 2015, MED SCI SPORT EXER, V47, P1113, DOI 10.1249/MSS.0000000000000511	37	11	11	1	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1476-3141	1752-6116		SPORT BIOMECH	Sport. Biomech.		2018	17	1					33	47		10.1080/14763141.2016.1271905			15	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	FU5GG	WOS:000423880500003		Green Accepted			2021-06-18	
J	Yu, NZ; Hu, S; Hao, Z				Yu, Nianzu; Hu, Si; Hao, Zheng			BENIFICIAL EFFECT OF STACHYDRINE ON THE TRAUMATIC BRAIN INJURY INDUCED NEURODEGENERATION BY ATTENUATING THE EXPRESSIONS OF AKT/MTOR/PI3K AND TLR4/NF kappa-B PATHWAY	TRANSLATIONAL NEUROSCIENCE			English	Article						Stachydrine; Traumatic brain injury; Apoptosis; Inflammation; TLR-4	OXIDATIVE STRESS	Present investigation aims to explore the protective effect of stachydrine against traumatic brain injury (TBI) and also investigate the molecular mechanism of its action. TBI was induced by the fall a hammer (450 g) from the height of 1.5 m. and later stachydrine was administered for 2 weeks starting 2 hr after the induction of TBI. Effect of stachydrine was determined by estimating modified neurological severity score (mNSS), percentage of water content in the brain and cognitive dysfunction in TBI rats. Moreover western blot assay, histopathology and enzyme linked immunosorbent assay (ELISA) tests were used to determine the effect of stachydrine on TBI injured rats. Result of the report suggests that stachydrine reduces the mNSS and percentage of water content in the brain and also attenuates the cognitive dysfunction in TBI injured rats. However data of western blot assay reports that stachydrine reduces the expression of PI3K/m-TOR/Akt pathway in the brain tissues of TBI rats. Concentration of interleukin (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha) and interferon gamma (INF-gamma)was reduces in stachydrine treated group than TBI group. Moreover expression of Nuclear factor-kappa B/Toll-like receptor 4 (NF-kappa B/TLR-4) protein was also decreased in stachydrine treated group than TBI group. Histopathology study on brain tissue reveals that the percentage of apoptotic cells was also reduced in stachydrine treated group than TBI group. Data of this investigation concludes that stachydrine protects the neuronal injury by attenuating the phosphatidylinositide 3-kinases/mammalian target of rapamycin/Protein kinase B (PI3K/m-TOR/Akt) and NF-kappa B/TLR-4 pathway in TBI injured rats.	[Yu, Nianzu; Hu, Si; Hao, Zheng] Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang 330006, Jiangxi, Peoples R China	Hao, Z (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang 330006, Jiangxi, Peoples R China.	Holdsworthmope@yahoo.com					Barman A, 2016, INDIAN J PSYCHOL MED, V38, P172, DOI 10.4103/0253-7176.183086; Chen HH, 2017, AM J TRANSL RES, V9, P4250; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; He HF, 2018, DRUG DES DEV THER, V12, P629, DOI 10.2147/DDDT.S158313; Hu YY, 2016, MICROB PATHOGENESIS, V99, P51, DOI 10.1016/j.micpath.2016.08.006; Jellusova J, 2016, CRIT REV BIOCHEM MOL, V51, P359, DOI 10.1080/10409238.2016.1215288; Kitagishi Yasuko, 2012, Depress Res Treat, V2012, P752563, DOI 10.1155/2012/752563; Li XF, 2018, INT J MOL MED, V42, P1917, DOI 10.3892/ijmm.2018.3794; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Michinaga S, 2015, INT J MOL SCI, V16, P9949, DOI 10.3390/ijms16059949; Mikhed Y, 2015, INT J MOL SCI, V16, P15918, DOI 10.3390/ijms160715918; Popescu C, 2015, J Med Life, V8, P272; Rathee P, 2012, NAT PROD RES, V26, P1737, DOI 10.1080/14786419.2011.608673; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Zhang Chen, 2014, BMC Complement Altern Med, V14, P474, DOI 10.1186/1472-6882-14-474; Zhang RH, 2018, PHYTOCHEMISTRY, V147, P167, DOI 10.1016/j.phytochem.2017.12.016; Zhao LL, 2017, INT IMMUNOPHARMACOL, V48, P102, DOI 10.1016/j.intimp.2017.05.002	20	11	12	2	3	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	2081-3856	2081-6936		TRANSL NEUROSCI	Transl. Neurosci.	JAN	2018	9	1					175	182		10.1515/tnsci-2018-0026			8	Neurosciences	Neurosciences & Neurology	HK4KV	WOS:000457903200001	30687544	DOAJ Gold, Green Published			2021-06-18	
J	Adeleye, AO; Ogun, MI				Adeleye, Amos O.; Ogun, Millicent I.			Clinical Epidemiology of Head Injury from Road-Traffic Trauma in a Developing Country in the Current Era	FRONTIERS IN NEUROLOGY			English	Article						road-traffic injury; head injury; motor-vehicle crash; motorcycle crash; Nigeria; developing countries	BRAIN-INJURY; NIGERIA; CARE; PREDICTION; MODERATE	Objectives: Africa and other Asian low middle-income countries account for the greatest burden of the global road-traffic injury (RTI)-related head injury (HI). This study set out to describe the incidence, causation, and severity of RTI-related HI and associated injuries in a Nigerian academic neurosurgical practice. Methods: This is a retrospective cross-sectional analysis of RTI-related HI from a prospective HI registry in an academic neurosurgery practice in Nigeria. Results: All-terrain RTI accounted for 80.6% (833/1,034) of HI over a 7-year study period. All age groups were involved, mean 33.06 years (SD 18.30), mode 21-30, 231/833 (27.7%). The male: female ratio was 631: 202, approximate to 3: 1. The road trauma occurred exclusively from motorcycle-and motor-vehicle crash (MCC/MVC), MCC caused 56.8% (473/833) of these; the victims were vulnerable road users (VRU) in 74%, and > 90% belong in the low socioeconomic class. Using the Glasgow Coma Scale grading, the HI was moderate/severe in 52%; loss of consciousness occurred in 93%, the Abbreviated Injury Severity-head > 3 in 74%, and computed tomography (CT) Rotterdam score > 3 in 52%. Significant extracranial injuries occurred in many organ systems, 421/833 (50.5%) having Injury Severity Score (ISS) > 25. Surgical lesions included extensive brain contusions in 157 (18.8%); acute extradural hematoma in 34 (4.1%); acute subdural hematoma in 32 (3.8%); and traumatic intracerebral hemorrhage in 27 (3.2%), but only 97 (11.6%) received operative care for various logistic reasons. The in-hospital outcome was good in 71.3% and poor in 28.7%; the statistically significant (p < 0.001) determinants of this outcome profile were the severity of the HI, the CT Rotterdam score, and the ISS. Conclusion: In this study from Nigeria, RTI-related HI emanates from significant trauma to vulnerable road users and are caused exclusively by motorcycles and motor vehicles.	[Adeleye, Amos O.] Univ Ibadan, Coll Med, Dept Surg, Div Neurol Surg, Ibadan, Nigeria; [Adeleye, Amos O.] UCH, Dept Neurol Surg, Ibadan, Nigeria; [Ogun, Millicent I.] UCH, Clin Nursing Dept, Ibadan, Nigeria	Adeleye, AO (corresponding author), Univ Ibadan, Coll Med, Dept Surg, Div Neurol Surg, Ibadan, Nigeria.; Adeleye, AO (corresponding author), UCH, Dept Neurol Surg, Ibadan, Nigeria.	femdoy@yahoo.com					Adeleye A O, 2017, Ann Ib Postgrad Med, V15, P34; Adeleye AO, 2009, NEUROEPIDEMIOLOGY, V32, P136, DOI 10.1159/000182821; Adeleye AO, 2010, TURK NEUROSURG, V20, P430, DOI 10.5137/1019-5149.JTN.3038-10.1; Adeolu AA, 2013, WORLD NEUROSURG, V80, P251, DOI 10.1016/j.wneu.2012.11.063; Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; Chandran A, 2012, TRAFFIC INJ PREV, V13, P11, DOI 10.1080/15389588.2011.633289; Chichom-Mefire A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2290-4; ELGINDI S, 2001, REV ESPANOLA NEUROPS, V3, P3; Faried A, 2017, WORLD NEUROSURG, V100, P195, DOI 10.1016/j.wneu.2016.12.133; Guerrier G, 2015, AUST NZ J PUBL HEAL, V39, P188, DOI 10.1111/1753-6405.12362; Ibrahim NA, 2017, PREHOSP DISASTER MED, V32, P424, DOI 10.1017/S1049023X17006410; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kareem Abdul, 2003, Malays J Med Sci, V10, P31; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MUHAMMAD I, 1990, E AFR MED J, V67, P447; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; OHAEGBULAM SC, 1978, AFR J MED MED SCI, V7, P23; Peden Margie, 2005, Int J Inj Contr Saf Promot, V12, P85, DOI 10.1080/15660970500086130; Solagberu BA, 2006, INJURY PREV, V12, P266, DOI 10.1136/ip.2005.011221; Solagberu BA, 2015, TRAFFIC INJ PREV, V16, P184, DOI 10.1080/15389588.2014.921817; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Tripathi M, 2014, NEUROL INDIA, V62, P610, DOI 10.4103/0028-3886.149382	25	11	11	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	DEC 15	2017	8								695	10.3389/fneur.2017.00695			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FQ0UH	WOS:000418071700001	29326652	DOAJ Gold, Green Published			2021-06-18	
J	Abboud, T; Mende, KC; Jung, R; Czorlich, P; Vettorazzi, E; Priefler, M; Kluge, S; Westphal, M; Regelsberger, J				Abboud, Tammam; Mende, Klaus Christian; Jung, Roman; Czorlich, Patrick; Vettorazzi, Eik; Priefler, Marion; Kluge, Stefan; Westphal, Manfred; Regelsberger, Jan			Prognostic Value of Early S100 Calcium Binding Protein B and Neuron-Specific Enolase in Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage: A Pilot Study	WORLD NEUROSURGERY			English	Article						Intracranial aneurysm; NSE; S100; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; LONG-TERM OUTCOMES; S-100 PROTEIN; CEREBROSPINAL-FLUID; ISCHEMIC-STROKE; SERUM; DAMAGE; PREDICTION; VASOSPASM; BIOMARKER	BACKGROUND: This prospective study was undertaken to investigate the value of early S100 calcium binding protein B (S100B) and neuron-specific enolase (NSE) in prognosticating outcome in patients with poorgrade aneurysmal subarachnoid hemorrhage and to develop a statistical model and cutoff values for clinical practice. METHODS: Between 2012 and 2014, patients with poor-grade subarachnoid hemorrhage (Hunt and Hess grade 3-5) who were admitted within 24 hours after hemorrhage were prospectively enrolled. Serum NSE and S100B levels were assayed once daily during the first 3 days after hemorrhage. Patient characteristics, Glasgow Coma Scale score, Hunt and Hess grade, and Fisher grade at admission were recorded. Glasgow Outcome Scale (GOS) score was obtained at 6 months and dichotomized as poor (score 1-3) or good (score 4-5). Logistic regression and receiver operating characteristic curve were used to assess the value of S100B and NSE in predicting outcome, and cutoff values were calculated using conditional interference trees. RESULTS: The study included 52 patients. Hunt and Hess grade was 3 in 23 patients, 4 in 15 patients, and 5 in 14 patients. S100B range was 0.07-5.62 mu g/L (mean 0.87 mu g/L +/- 1.06). NSE range was 5.7-94.2 mu g/L (mean 16.1 mu g/L +/- 10.5). At 6-month follow-up, 23 patients (44.2%) had a poor outcome, and 29 patients (55.8%) had a good outcome. Both S100B at day 1 (P = 0.004; cutoff 0.202 mu g/L) and NSE at day 1 (P = 0.047; cutoff 9.4 mu g/L) predicted good outcome with a specificity of 100%. The specificity of mean S100B in detecting patients with poor outcome reached 100% (P = 0.003) when combined with mean NSE levels. CONCLUSIONS: S100B and NSE measured during the first 3 days after hemorrhage showed, separately and combined, a significant predictive value in prognosticating clinical outcome in patients with poor-grade subarachnoid hemorrhage. A multicenter study with a large patient cohort is necessary to validate the above-mentioned cutoff values for clinical practice.	[Abboud, Tammam; Mende, Klaus Christian; Czorlich, Patrick; Westphal, Manfred; Regelsberger, Jan] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany; [Jung, Roman] Univ Med Ctr Hamburg Eppendorf, Dept Clin Chem, Hamburg, Germany; [Vettorazzi, Eik] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Priefler, Marion; Kluge, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care, Hamburg, Germany; [Abboud, Tammam] Univ Med Ctr Gottingen, Dept Neurosurg, Gottingen, Germany	Abboud, T (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany.; Abboud, T (corresponding author), Univ Med Ctr Gottingen, Dept Neurosurg, Gottingen, Germany.	tammamabboud@gmail.com	Czorlich, Patrick/H-8934-2019; Vettorazzi, Eik/B-8130-2019	Vettorazzi, Eik/0000-0002-3737-6402; Mende, Klaus Christian/0000-0003-4317-1718			Abboud T, 2015, ACTA NEUROCHIR, V157, P763, DOI 10.1007/s00701-015-2369-9; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; Gelderblom M, 2013, NEUROBIOL DIS, V59, P177, DOI 10.1016/j.nbd.2013.07.017; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Guo ZD, 2011, ACTA NEUROCHIR SUPPL, V110, P63, DOI 10.1007/978-3-7091-0353-1_11; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; JENNETT B, 1975, LANCET, V1, P480; Lai PMR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151853; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Moritz S, 2010, J NEUROSURG ANESTH, V22, P21, DOI 10.1097/ANA.0b013e3181bdf50d; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Prohl J, 2007, CRIT CARE MED, V35, P1230, DOI 10.1097/01.CCM.0000261892.10559.85; Quintard H, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1200-1; Raheja A, 2016, J NEUROSURG, V125, P631, DOI 10.3171/2015.6.JNS15674; Rinkel GJE, 2011, LANCET NEUROL, V10, P349, DOI 10.1016/S1474-4422(11)70017-5; Rivero-Arias Oliver, 2010, Cost Eff Resour Alloc, V8, P6, DOI 10.1186/1478-7547-8-6; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Sanchez-Pena P, 2008, CRIT CARE MED, V36, P2267, DOI 10.1097/CCM.0b013e3181809750; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Selakovic Vesna, 2003, Med Pregl, V56, P326, DOI 10.2298/MPNS0308326S; Shim JH, 2012, CEREBROVASC DIS, V34, P38, DOI 10.1159/000338786; THELIN EP, 2016, CRIT CARE, V20; Turck N, 2010, INTENS CARE MED, V36, P107, DOI 10.1007/s00134-009-1641-y; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181	34	11	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2017	108						669	675		10.1016/j.wneu.2017.09.074			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FN3CU	WOS:000415874900089	28943424				2021-06-18	
J	Davanzo, JR; Sieg, EP; Timmons, SD				Davanzo, Justin R.; Sieg, Emily P.; Timmons, Shelly D.			Management of Traumatic Brain Injury	SURGICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Neurotrauma; Secondary injury; Intracranial monitoring; Intracranial pressure; Craniotomy; Craniectomy; Decompression	SEVERE HEAD-INJURY; VENOUS THROMBOEMBOLISM PROPHYLAXIS; BLUNT CEREBROVASCULAR INJURIES; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; INTRACRANIAL-PRESSURE; POSTTRAUMATIC SEIZURES; DECOMPRESSIVE CRANIECTOMY; MODERATE HYPOTHERMIA; ANTIPLATELET THERAPY	Traumatic brain injury remains a serious public health problem, causing death and disability for millions. To maximize outcomes in the face of a complex injury to a complex organ, a variety of advanced neuromonitoring techniques may be used to guide surgical and medical decision making. Because of the heterogeneity of injury types and the plethora of treatment confounders present in this patient population, the scientific study of specific interventions is challenging. This challenge highlights the need for a firm understanding of the anatomy and pathophysiology of brain injuries when making clinical decisions in the intensive care unit.	[Davanzo, Justin R.; Sieg, Emily P.; Timmons, Shelly D.] Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Neurosurg, 30 Hope Dr,EC 110, Hershey, PA 17033 USA	Timmons, SD (corresponding author), Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Neurosurg, 30 Hope Dr,EC 110, Hershey, PA 17033 USA.	stimmons@mac.com					Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0; Bardt TF, 1998, ACT NEUR S, V71, P153; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Bullock M Ross, 2006, Neurosurgery, V58, pS56; Bullock M Ross, 2006, Neurosurgery, V58, pS47; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2005, WEB BAS INJ STAT QUE; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Daley MJ, 2015, AM SURGEON, V81, P207; De Fazio M, 2011, NEUROCRIT CARE, V14, P91, DOI 10.1007/s12028-010-9494-3; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Eriksson EA, 2012, J TRAUMA ACUTE CARE, V72, P1345, DOI 10.1097/TA.0b013e318249a0f4; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farooqui A, 2013, J NEUROSURG, V119, P1576, DOI 10.3171/2013.8.JNS13424; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591; Kang TM, 2002, ANN PHARMACOTHER, V36, P1453; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kowski AB, 2016, EPILEPSY BEHAV, V54, P150, DOI 10.1016/j.yebeh.2015.11.009; Kudsk KA, 2003, AM J SURG, V185, P16, DOI 10.1016/S0002-9610(02)01146-7; Kudsk KA, 1998, NUTRITION, V14, P541, DOI 10.1016/S0899-9007(98)00047-1; Kwiatt ME, 2012, J TRAUMA ACUTE CARE, V73, P625, DOI 10.1097/TA.0b013e318265cab9; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marion DW, 2006, NEUROSURGERY, V58, P655; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Miller PR, 2001, J TRAUMA, V51, P285; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; National Vital Statistics System (NVSS), 2006, DAT SOURC MAINT CDC; NISSENSON AR, 1979, WESTERN J MED, V131, P277; Ratilal B, 2008, J NEUROS-PEDIATR, V1, P48, DOI 10.3171/PED-08/01/048; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Seguin P, 2014, CRIT CARE MED, V42, P1, DOI 10.1097/CCM.0b013e3182a2770f; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Timmons SD, 2010, CRIT CARE MED, V38, pS431, DOI 10.1097/CCM.0b013e3181ec57ab; Torbic H, 2013, AM J HEALTH-SYST PH, V70, P759, DOI 10.2146/ajhp120203; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wang X, 2013, CRIT CARE, V17, DOI 10.1186/cc12608; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WATRIDGE CB, 1989, J NEUROSURG, V71, P854, DOI 10.3171/jns.1989.71.6.0854; WINKLER SR, 1995, SURG NEUROL, V43, P59, DOI 10.1016/0090-3019(95)80039-J; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348	83	11	11	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	DEC	2017	97	6					1237	+		10.1016/j.suc.2017.08.001			19	Surgery	Surgery	FQ8PO	WOS:000418625200005	29132507				2021-06-18	
J	Puchert, M; Pelkner, F; Stein, G; Angelov, DN; Boltze, J; Wagner, DC; Odoardi, F; Flugel, A; Streit, WJ; Engele, J				Puchert, Malte; Pelkner, Fabian; Stein, Gregor; Angelov, Doychin N.; Boltze, Johannes; Wagner, Daniel-Christoph; Odoardi, Francesca; Fluegel, Alexander; Streit, Wolfgang J.; Engele, Juergen			Astrocytic expression of the CXCL12 receptor, CXCR7/ACKR3 is a hallmark of the diseased, but not developing CNS	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						CXCR7; CXCR4; Astrocytes; Glia limitans; MCAO; EAE; Spinal cord compression; Cerebral infarction; Alzheimer's disease	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMPROVES FUNCTIONAL RECOVERY; NEURAL PROGENITOR CELLS; EPIDERMAL-GROWTH-FACTOR; SPINAL-CORD-INJURY; HUMAN GLIOMA-CELLS; CHEMOKINE RECEPTOR; REACTIVE ASTROGLIOSIS	Based on our previous demonstration of CXCR7 as the major mediator of CXCL12 signaling in cultured astrocytes, we have now compared astrocytic expression of the CXCL12 receptors, CXCR7 and CXCR4, during CNS development and disease. In addition, we asked whether disease-associated conditions/factors affect expression of CXCL12 receptors in astrocytes. In the late embryonic rat brain, CXCR7(+)/GFAP(+) cells were restricted to the ventricular/subventricular zone while CXCR4 was widely absent from GFAP-positive cells. In the early postnatal and adult brain, CXCR7 and CXCR4 were almost exclusively expressed by GFAP-immunoreactive astrocytes forming the superficial glia limitans. Contrasting the situation in the intact CNS, a striking increase in astrocytic CXCR7 expression was detectable in the cortex of rats with experimental brain infarcts, in the spinal cord of rats with experimental autoimmune encephalomyelitis (EAE) and after mechanical compression, as well as in the in infarcted human cerebral cortex and in the hippocampus of Alzheimer's disease patients. None of these pathologies was associated with substantial increases in astrocytic CXCR4 expression. Screening of various disease-associated factors/conditions further revealed that CXCR7 expression of cultured cortical astrocytes increases with IFN gamma as well as under hypoxic conditions whereas CXCR7 expression is attenuated following treatment with IFN beta. Again, none of the treatments affected CXCR4 expression in cultured astrocytes. Together, these findings support the hypothesis of a crucial role of astrocytic CXCR7 in the progression of various CNS pathologies.	[Puchert, Malte; Pelkner, Fabian; Engele, Juergen] Univ Leipzig, Inst Anat, Liebigstr 13, D-04103 Leipzig, Germany; [Stein, Gregor] Cologne Univ Hosp, Uniklin Koln, Dept Orthoped & Trauma Surg, D-50924 Cologne, Germany; [Angelov, Doychin N.] Univ Cologne, Inst Anat 1, Joseph Stelzrnann Str 9, D-50924 Cologne, Germany; [Boltze, Johannes] Univ Lubeck, Fraunhofer Res Inst Marine Biotechnol, Dept Med Cell Technol, Monkhofer Weg 239a, D-23562 Lubeck, Germany; [Boltze, Johannes] Univ Lubeck, Inst Med & Marine Biotechnol, Monkhofer Weg 239a, D-23562 Lubeck, Germany; [Wagner, Daniel-Christoph] Inst Pathol, Bldg 706,Langenbeckstr 1, D-55131 Mainz, Germany; [Odoardi, Francesca; Fluegel, Alexander] Univ Med Ctr Gottingen, Dept Neuroimmunol, Inst Multiple Sclerosis Res, Waldweg 33, D-37073 Gottingen, Germany; [Streit, Wolfgang J.] Univ Florida, Dept Neurosci, 1149 Newell Dr, Gainesville, FL 32610 USA	Engele, J (corresponding author), Univ Leipzig, Inst Anat, Liebigstr 13, D-04103 Leipzig, Germany.	engj@medizin.uni-leipzig.de		Angelov, Doychin/0000-0003-1436-9119; Boltze, Johannes/0000-0003-3956-4164	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16K01948] Funding Source: KAKEN		Abe P, 2014, DEVELOPMENT, V141, P1857, DOI 10.1242/dev.104224; Alvarez JI, 2007, J NEUROIMMUNOL, V187, P102, DOI 10.1016/j.jneuroim.2007.05.005; Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Arthur V.A.a.B., 2013, GLIAL PHYSL PATHOPHY, P105, DOI [10.1002/9781118402061.ch4, DOI 10.1002/9781118402061.CH4]; Banisadr G, 2016, J NEUROIMMUNE PHARM, V11, P26, DOI 10.1007/s11481-015-9616-y; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Berahovich RD, 2010, IMMUNOL LETT, V133, P112, DOI 10.1016/j.imlet.2010.06.010; Berahovich RD, 2010, J IMMUNOL, V185, P5130, DOI 10.4049/jimmunol.1001660; Bonavia R, 2003, TOXICOL LETT, V139, P181, DOI 10.1016/S0378-4274(02)00432-0; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Chen Q, 2015, STEM CELLS, V33, P2574, DOI 10.1002/stem.2022; Chen TJ, 2016, CLIN CHIM ACTA, V454, P6, DOI 10.1016/j.cca.2015.12.033; Cruz-Orengo L, 2011, J EXP MED, V208, P327, DOI 10.1084/jem.20102010; Doll DN, 2014, AGING DIS, V5, P294, DOI 10.14336/AD.2014.0500294; Ehtesham M, 2013, J NEURO-ONCOL, V113, P153, DOI 10.1007/s11060-013-1108-4; Esencay M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-347; Filous AR, 2016, PROG NEUROBIOL; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Gu XL, 2016, MOL NEUROBIOL, V53, P2807, DOI 10.1007/s12035-015-9151-0; Guo MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090518; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Haydon PG, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020438; ISSAZADEH S, 1995, J NEUROIMMUNOL, V61, P205, DOI 10.1016/0165-5728(95)00100-G; Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110-000000000-00000; Klein RS, 2001, DEVELOPMENT, V128, P1971; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Krumbholz M, 2006, BRAIN, V129, P200, DOI 10.1093/brain/awh680; Laske C, 2008, J ALZHEIMERS DIS, V15, P451; Lee E, 2013, PIGM CELL MELANOMA R, V26, P58, DOI 10.1111/pcmr.12024; Li MZ, 2008, PROG NEUROBIOL, V84, P116, DOI 10.1016/j.pneurobio.2007.11.003; Li MZ, 2011, GLIA, V59, P108, DOI 10.1002/glia.21080; Lin CCJ, 2017, NAT NEUROSCI, V20, P396, DOI 10.1038/nn.4493; Lin RH, 2015, BRAIN RES, V1628, P327, DOI 10.1016/j.brainres.2015.04.029; Lipfert J, 2013, NEUROPATH APPL NEURO, V39, P667, DOI 10.1111/nan.12015; Liu B, 2006, J NEUROSCI, V26, P7532, DOI 10.1523/JNEUROSCI.1004-06.2006; Liu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059750; Liu HB, 2010, BIOCHEM BIOPH RES CO, V401, P509, DOI 10.1016/j.bbrc.2010.09.076; Liu SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055290; Liu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103938; Liu Z., 2015, PROG NEUROBIOL; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Ma JH, 2015, NEUROL RES, V37, P50, DOI 10.1179/1743132814Y.0000000399; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MacVicar B. A., 2015, COLD SPRING HARB PER, V7; Manthou M, 2017, RESTOR NEUROL NEUROS, V35, P185, DOI 10.3233/RNN-160691; McColl SR, 2004, LAB INVEST, V84, P1418, DOI 10.1038/labinvest.3700155; Molofsky AV, 2015, GLIA, V63, P1320, DOI 10.1002/glia.22836; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Odemis V, 2010, J CELL SCI, V123, P1081, DOI 10.1242/jcs.062810; Ottum PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00539; Ozsoy O, 2012, RESTOR NEUROL NEUROS, V30, P363, DOI 10.3233/RNN-2012-110203; Parachikova A, 2007, NEUROBIOL DIS, V28, P143, DOI 10.1016/j.nbd.2007.07.001; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; PIKE CJ, 1994, NEUROSCIENCE, V63, P517, DOI 10.1016/0306-4522(94)90547-9; Platel JC, 2016, NEUROSCIENCE, V323, P20, DOI 10.1016/j.neuroscience.2015.10.053; Puchert M, 2014, CELL TISSUE RES, V355, P239, DOI 10.1007/s00441-013-1747-y; Pugazhenthi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069585; Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107; Reaux-Le Goazigo A, 2013, PROG NEUROBIOL, V104, P67, DOI 10.1016/j.pneurobio.2013.02.001; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rodriguez-Arellano JJ, 2016, NEUROSCIENCE, V323, P170, DOI 10.1016/j.neuroscience.2015.01.007; Romain B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-58; Ruscher K, 2013, J CEREBR BLOOD F MET, V33, P1225, DOI 10.1038/jcbfm.2013.71; Schonemeier B, 2008, J NEUROIMMUNOL, V198, P39, DOI 10.1016/j.jneuroim.2008.04.010; Schonemeier B, 2008, J COMP NEUROL, V510, P207, DOI 10.1002/cne.21780; Schousboe Arne, 2013, Front Endocrinol (Lausanne), V4, P102, DOI 10.3389/fendo.2013.00102; Semler J, 2011, J NEUROTRAUM, V28, P1247, DOI 10.1089/neu.2010.1737; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Sin WX, 2012, IMMUNOL RES, V53, P25, DOI 10.1007/s12026-012-8293-7; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Stumm RK, 2002, J NEUROSCI, V22, P5865; Sun WF, 2014, INFLAMM RES, V63, P287, DOI 10.1007/s00011-013-0699-8; Tanabe S, 1997, J IMMUNOL, V159, P905; Tarnowski M, 2010, MOL CANCER RES, V8, P1, DOI 10.1158/1541-7786.MCR-09-0259; Thelen M, 2008, J NEUROIMMUNOL, V198, P9, DOI 10.1016/j.jneuroim.2008.04.020; Tissir F, 2004, DEV BRAIN RES, V149, P63, DOI 10.1016/j.devbrainres.2004.01.002; Tiveron MC, 2010, J NEUROIMMUNOL, V224, P72, DOI 10.1016/j.jneuroim.2010.05.011; Walters MJ, 2014, BRIT J CANCER, V110, P1179, DOI 10.1038/bjc.2013.830; Wang WY, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.49; Wang YL, 2011, NEURON, V69, P61, DOI 10.1016/j.neuron.2010.12.005; Wirth F, 2013, J NEUROTRAUM, V30, P453, DOI 10.1089/neu.2012.2653; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	86	11	12	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	DEC	2017	85						105	118		10.1016/j.mcn.2017.09.001			14	Neurosciences	Neurosciences & Neurology	FO8FE	WOS:000417117400010	28889992				2021-06-18	
J	Rajagopal, R; Swaminathan, G; Nair, S; Joseph, M				Rajagopal, Ramanan; Swaminathan, Ganesh; Nair, Shalini; Joseph, Mathew			Hyponatremia in Traumatic Brain Injury: A Practical Management Protocol	WORLD NEUROSURGERY			English	Article						Fludrocortisone; Hyponatremia; Natriuresis; Traumatic brain injury	DIURETIC HORMONE SIADH; INAPPROPRIATE SECRETION; NEUROSURGICAL PATIENTS; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; FLUDROCORTISONE; CONSEQUENCES; NATRIURESIS; THERAPY; DISEASE	BACKGROUND: Hyponatremia (defined as serum sodium <135 mEq/L) is the most common electrolyte abnormality in traumatic brain injury (TBI) and is also an independent predictor of poor neurologic outcome. The reported incidence of hyponatremia varies widely in literature reports, and there is continuing difficulty in clearly differentiating between the 2 common causes of hyponatremia with natriuresis: the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt wasting (CSW). We encounter hyponatremia frequently in our practice, and we therefore decided to review data from our center to estimate the incidence of hyponatremia and the results of our management strategies, and attempt to formulate simple guidelines for the correction of hyponatremia in TBI. METHODS: A retrospective analysis of 1500 consecutively admitted patients with TBI was performed by the use of electronic records and radiographic review. Hyponatremia was defined as serum sodium <135 mEq/L, and natriuresis as a urine spot sodium of more than >40 mEq/L. The incidence of TBI, its management, and the effect of fludrocortisone were evaluated. RESULTS: The incidence of hyponatremia was 13.2%. Early therapy with fludrocortisone significantly reduced the duration of hospital stay (P < 0.05). Traumatic subarachnoid hemorrhage was the most common abnormality on the admission computed tomographic scan in patients who experienced hyponatremia. CONCLUSION: Early initiation of fludrocortisone in the setting of hyponatremia with natriuresis decreases the hospital stay. This protocol is probably safer in a tropical country where fluid restriction might be harmful. It also eliminates the need to differentiate between SIADH and CSW.	[Rajagopal, Ramanan; Swaminathan, Ganesh; Nair, Shalini; Joseph, Mathew] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India	Rajagopal, R (corresponding author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India.	ramanashiva@gmail.com					Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Bussmann C, 2001, CHILD NERV SYST, V17, P58; Diringer MN, 2006, NEUROLOGIST, V12, P117, DOI 10.1097/01.nrl.0000215741.01699.77; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; Gill G, 2006, CLIN ENDOCRINOL, V65, P246, DOI 10.1111/j.1365-2265.2006.02583.x; ISHIKAWA SE, 1987, ANN INTERN MED, V106, P187, DOI 10.7326/0003-4819-106-2-187; Kinik ST, 2001, PEDIATR NEUROSURG, V35, P216, DOI 10.1159/000050424; Kirkman MA, 2013, NEUROCRIT CARE, V18, P406, DOI 10.1007/s12028-012-9805-y; Kurokawa Y, 1996, SURG NEUROL, V46, P500, DOI 10.1016/S0090-3019(96)00034-1; Lohani S, 2011, WORLD NEUROSURG, V76, P355, DOI 10.1016/j.wneu.2011.03.042; Meng XF, 2016, J NEUROSURG ANESTH, V28, P21, DOI 10.1097/ANA.0000000000000192; Mori T, 1999, J NEUROSURG, V91, P947, DOI 10.3171/jns.1999.91.6.0947; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Sajadieh A, 2009, AM J MED, V122, P679, DOI 10.1016/j.amjmed.2008.11.033; Sherlock M, 2009, POSTGRAD MED J, V85, P171, DOI 10.1136/pgmj.2008.072819; SIVAKUMAR V, 1994, NEUROSURGERY, V34, P269, DOI 10.1227/00006123-199402000-00010; Sterns RH, 2008, J AM SOC NEPHROL, V19, P194, DOI 10.1681/ASN.2007101118; Verbalis JG, 2013, AM J MED, V126, pS5, DOI 10.1016/j.amjmed.2013.07.006; VINGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50, DOI 10.1007/BF01400528; WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206; Yumoto T, 2015, ACTA MED OKAYAMA, V69, P213	24	11	11	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2017	108						529	533		10.1016/j.wneu.2017.09.013			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FN3CU	WOS:000415874900069	28899834				2021-06-18	
J	Richardson, JD; Ketcheson, F; King, L; Shnaider, P; Marlborough, M; Thompson, A; Elhai, JD				Richardson, J. Don; Ketcheson, F.; King, L.; Shnaider, P.; Marlborough, M.; Thompson, A.; Elhai, J. D.			Psychiatric comorbidity pattern in treatment-seeking veterans	PSYCHIATRY RESEARCH			English	Article						Posttraumatic stress disorder; Major depression; Canadian Forces	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; CANADIAN ARMED-FORCES; TRAUMATIC BRAIN-INJURY; LATENT CLASS ANALYSIS; PEACEKEEPING VETERANS; MILITARY PERSONNEL; CARE UTILIZATION; PTSD; AFGHANISTAN	This study investigated comorbidity patterns in treatment-seeking veterans and currently-serving Canadian Forces members of an outpatient mental health clinic from September 2006-September 2014. Using a retrospective cohort design, latent class analysis was conducted to determine latent classes of comorbidity (including posttraumatic stress disorder [PTSD], major depressive disorder [MDD], generalized anxiety disorder, panic disorder, and alcohol use disorder [AUD]). Multiple logistic regression was used to determine which covariates (age, gender, number of deployments, and service duration) were predictors of latent class membership. Among the 486 participants, 79.2% had more than one probable mental health condition. The most common co morbidity was PTSD and MDD (61.5%), followed by PTSD and GAD (52.3%). Among those with PTSD, almost all (95%) had a subsequent condition, predominantly MDD (82.6% of those with PTSD had MDD). A two-class model was the best fitting model with a high comorbidity and a low comorbidity class. Older age and shorter service duration significantly increased the probability of being in the high comorbidity class when not controlling for member status. Results showed that treatment-seeking veterans and military personnel have high rates of comorbidity, particularly alongside PTSD. Therefore, it is critical for clinicians to be able to assess and treat comorbidity.	[Ketcheson, F.; King, L.; Marlborough, M.] Parkwood Hosp, Operat Stress Injury Clin, London, ON, Canada; [Richardson, J. Don] Western Univ, London, ON, Canada; [Richardson, J. Don] McMaster Univ, Hamilton, ON, Canada; [Shnaider, P.] St Josephs Healthcare Hamilton, Hamilton, ON, Canada; [Thompson, A.] Canadian Forces Hlth Serv Grp, Dept Natl Def, Ottawa, ON, Canada; [Elhai, J. D.] Univ Toledo, Toledo, OH USA	Richardson, JD (corresponding author), Parkwood Inst, Arthur J Hobbins Bldg Zone D,550 Wellington Rd, London, ON N6C 0A7, Canada.	jdonrichardson@gmail.com	Elhai, Jon D/U-1901-2017; Richardson, J Don/X-5123-2018	Elhai, Jon D/0000-0001-5205-9010; Richardson, J Don/0000-0002-2927-6735; Shnaider, Philippe/0000-0003-4879-7306			Aakre JM, 2014, PSYCHIAT SERV, V65, P1066, DOI 10.1176/appi.ps.201300117; Adler DA, 2011, PSYCHIAT SERV, V62, P39, DOI 10.1176/ps.62.1.pss6201_0039; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2013, RET HOM IR AFGH ASS, DOI [10.17226/13499, DOI 10.17226/13499]; Armour C, 2015, PSYCHIAT RES, V228, P1, DOI 10.1016/j.psychres.2015.03.011; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Bergman B.P., 2016, J CLIN PSYCHIAT, pe1; Boulos D, 2013, CAN MED ASSOC J, V185, pE545, DOI 10.1503/cmaj.122120; Campbell DG, 2007, J GEN INTERN MED, V22, P711, DOI 10.1007/s11606-006-0101-4; Contractor A.A., 2015, J PSYCHIAT RES; Forbes D, 2010, J TRAUMA STRESS, V23, P340, DOI 10.1002/jts.20526; Garber BG, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0325-5; Haley RW, 1998, AM J EPIDEMIOL, V148, P315, DOI 10.1093/oxfordjournals.aje.a009645; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Haskell SG, 2010, J WOMENS HEALTH, V19, P267, DOI 10.1089/jwh.2008.1262; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kessler R.C., 2014, JAMA PSYCHIAT; Kozaric-Kovacic D, 2005, MIL MED, V170, P223, DOI 10.7205/MILMED.170.3.223; Litz BT, 1997, AM J PSYCHIAT, V154, P178; Lockwood E, 2014, PSYCHOL INJ LAW, V7, P108, DOI 10.1007/s12207-014-9189-8; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; McMillan K.A., 2017, J NERV MENT DISORD; Murdoch M, 2003, MED CARE, V41, P536, DOI 10.1097/00005650-200304000-00009; Naifeh JA, 2010, PSYCHOL ASSESSMENT, V22, P666, DOI 10.1037/a0019783; Nelson C, 2011, MIL MED, V176, P156, DOI 10.7205/MILMED-D-10-00252; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Orsillo SM, 1996, J NERV MENT DIS, V184, P307, DOI 10.1097/00005053-199605000-00007; Pearson C., 2014, STAT CANADA; Resnick SG, 2008, J REHABIL RES DEV, V45, P427, DOI 10.1682/JRRD.2007.06.0093; Richardson JD, 2006, J CLIN PSYCHIAT, V67, P1240, DOI 10.4088/JCP.v67n0810; Richardson JD, 2014, J CLIN PSYCHIAT, V75, pE1299, DOI 10.4088/JCP.13m08796; Rosellini AJ, 2015, DEPRESS ANXIETY, V32, P493, DOI 10.1002/da.22364; Rusu C, 2016, CAN J PSYCHIAT, V61, p46S, DOI 10.1177/0706743716628856; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; St Cyr K, 2014, PSYCHIAT RES, V218, P148, DOI 10.1016/j.psychres.2014.03.038; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Weathers F., 1993, PTSD CHECLDIST PCL R; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wisco BE, 2014, J CLIN PSYCHIAT, V75, P1338, DOI 10.4088/JCP.14m09328; Zamorski MA, 2016, CAN J PSYCHIAT, V61, p26S, DOI 10.1177/0706743716628854	43	11	12	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	DEC	2017	258						488	493		10.1016/j.psychres.2017.08.091			6	Psychiatry	Psychiatry	FN7FQ	WOS:000416184500076	28899613				2021-06-18	
J	Rolland, JS				Rolland, John S.			Neurocognitive Impairment: Addressing Couple and Family Challenges	FAMILY PROCESS			English	Article						Neurocognitive Impairment; Dementia; Family Caregivers; Biopsychosocial	TRAUMATIC BRAIN-INJURY; CONTROLLED-TRIAL; DEMENTIA; INTERVENTIONS; METAANALYSIS; CAREGIVERS; DISEASE	Conditions involving neurocognitive impairment pose enormous challenges to couples and families. However, research and practice tend to focus narrowly on immediate issues for individual caregivers and their dyadic relationship with the affected member. A broad family systems approach with attention to family processes over time is needed in training, practice, and research. In this paper, Rolland's Family Systems Illness model provides a guiding framework to consider the interaction of different psychosocial types of neurocognitive conditions and their evolution over time with individual, couple, and family life-course development. Discussion addresses key family and couple issues with mild-to-severe cognitive impairment and progressive dementias, including: communication, multigenerational legacies, threatened future neurocognitive disability, ambiguous loss, decisional capacity, reaching limits, placement decisions, issues for adult children and spousal caregivers, and the transformation of intimate bonds. Principles and guidelines are offered to help couples and families master complex challenges, deepen bonds, and forge positive pathways ahead.	[Rolland, John S.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [Rolland, John S.] Chicago Ctr Family Hlth, 20 N Wacker Dr,1442, Chicago, IL 60606 USA	Rolland, JS (corresponding author), Chicago Ctr Family Hlth, 20 N Wacker Dr,1442, Chicago, IL 60606 USA.	john.rolland@northwestern.edu					Ablitt A, 2009, AGING MENT HEALTH, V13, P497, DOI 10.1080/13607860902774436; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Batsch N.L., 2012, WORLD ALZHEIMER REPO; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Benbow SM, 2014, INT PSYCHOGERIATR, V26, P2037, DOI 10.1017/S1041610214001343; Boss P., 2011, LOVING SOMEONE WHO H; Boss P, 2010, PASTOR PSYCHOL, V59, P137, DOI 10.1007/s11089-009-0264-0; Carr D, 2010, J MARRIAGE FAM, V72, P743, DOI 10.1111/j.1741-3737.2010.00728.x; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Daniels K.J., 2007, FAMILIES, V25, P162; Dassel KB, 2017, GERONTOLOGIST, V57, P319, DOI 10.1093/geront/gnv148; FISHER L, 1994, FAM PROCESS, V33, P305, DOI 10.1111/j.1545-5300.1994.00305.x; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Godwin EE, 2011, J HEAD TRAUMA REHAB, V26, P43, DOI 10.1097/HTR.0b013e3182048f54; Hartmann M, 2010, PSYCHOTHER PSYCHOSOM, V79, P136, DOI 10.1159/000286958; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; Imber-Black E., 2012, NORMAL FAMILY PROCES, P483; Joling KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030936; Kasper J., 2016, DISABILITY CARE NEED; Kazak AE., 2006, FAM SYST HLTH, V24, P381, DOI [DOI 10.1037/1091-7527.24.4.381, 10.1037/1091-7527.24.4.381]; Kreutzer JS, 2010, NEUROREHABILITATION, V27, P19, DOI 10.3233/NRE-2010-0578; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI DOI 10.1037/1091-7527.26.1.69; Lindquist LK, 2017, J NEUROPSYCH CLIN N, V29, P254, DOI 10.1176/appi.neuropsych.16050100; Lum TY, 2008, HEALTH CARE FINANC R, V30, P35; Martire LM, 2010, ANN BEHAV MED, V40, P325, DOI 10.1007/s12160-010-9216-2; McDaniel S.H., 2014, MED FAMILY THERAPY I; Mittelman M., 2013, CAREGIVING ALZHEIMER, P17; Mittelman MS, 2008, AM J GERIAT PSYCHIAT, V16, P893, DOI 10.1097/JGP.0b013e3181898095; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Peek CJ, 2015, FAM SYST HEALTH, V33, P86, DOI 10.1037/fsh0000128; Rolland J. S., 1994, FAMILIES ILLNESS DIS; Rolland J. S., 2016, EXPANDING FAMILY LIF, P430; Rolland J. S., HELPING COU IN PRESS; Rolland JS, 2017, FAM SYST HEALTH, V35, P7, DOI 10.1037/fsh0000250; ROLLAND JS, 1990, FAM PROCESS, V29, P229, DOI 10.1111/j.1545-5300.1990.00229.x; Rolland JS, 2006, INDIVIDUALS FAMILIES, P139; Schulz R, 2004, AM J GERIAT PSYCHIAT, V12, P240, DOI 10.1176/appi.ajgp.12.3.240; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Shields CG, 2012, J MARITAL FAM THER, V38, P265, DOI 10.1111/j.1752-0606.2011.00269.x; Smith G. E., 2013, CAREGIVING ALZHEIMER, P3; The CDC NIH DoD and VA Leadership Panel, 2013, C TRAUM BRAIN INJ US; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Walsh F., 2016, STRENGTHENING FAMILY; Walsh F., 2016, EXPANDING FAMILY LIF, V5th ed., P339; Weihs K., 2002, FAMILIES SYSTEMS HLT, V20, P7, DOI [10.1037/h0089481, DOI 10.1037/H0089481]; Weingarten K, 2012, FAM PROCESS, V51, P440, DOI 10.1111/j.1545-5300.2012.01412.x; Weingarten K, 2010, FAM PROCESS, V49, P5, DOI 10.1111/j.1545-5300.2010.01305.x; Werner Perla, 2013, Alzheimers Dement, V9, pe74, DOI 10.1016/j.jalz.2012.02.006; Wood BL, 2008, FAM PROCESS, V47, P21, DOI 10.1111/j.1545-5300.2008.00237.x; Wright L.M, 2009, BELIEFS ILLNESS MODE; Zarit S., 2013, CARING ALZHEIMERS DI; Zuelsdorff M., 2017, LIFETIME STRESSFUL E	52	11	11	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0014-7370	1545-5300		FAM PROCESS	Fam. Process	DEC	2017	56	4					799	818		10.1111/famp.12316			20	Psychology, Clinical; Family Studies	Psychology; Family Studies	FP0GG	WOS:000417276800002	28887888				2021-06-18	
J	Roy-O'Reilly, M; Ritzel, RM; Conway, SE; Staff, I; Fortunato, G; McCullough, LD				Roy-O'Reilly, Meaghan; Ritzel, Rodney M.; Conway, Sarah E.; Staff, Ilene; Fortunato, Gilbert; McCullough, Louise D.			CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke	TRANSLATIONAL STROKE RESEARCH			English	Article						Stroke; Eotaxin; CCLL1; Inflammation; Neuroinflammation; Ischemia	RECEPTOR CCR3; EXPRESSION; CHEMOKINE; BRAIN; CELLS	Circulating levels of the pro-inflammatory cytokine C-C motif chemokine 11 (CCL11, also known as eotaxin-1) are increased in several animal models of neuroinflammation, including traumatic brain injury and Alzheimer's disease. Increased levels of CCL11 have also been linked to decreased neurogenesis in mice. We hypothesized that circulating CCL11 levels would increase following ischemic stroke in mice and humans, and that higher CCL11 levels would correlate with poor long-term recovery in patients. As predicted, circulating levels of CCL11 in both young and aged mice increased significantly 24 h after experimental stroke. However, ischemic stroke patients showed decreased CCL11 levels compared to controls 24 h after stroke. Interestingly, lower post-stroke CCL11 levels were predictive of increased stroke severity and independently predictive of poorer functional outcomes in patients 12 months after ischemic stroke. These results illustrate important differences in the peripheral inflammatory response to ischemic stroke between mice and human patients. In addition, it suggests CCL11 as a candidate biomarker for the prediction of acute and long-term functional outcomes in ischemic stroke patients.	[Roy-O'Reilly, Meaghan; McCullough, Louise D.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA; [Ritzel, Rodney M.] Univ Connecticut, Hlth Ctr, Dept Neurosci, Farmington, CT 06032 USA; [Conway, Sarah E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Conway, Sarah E.; Staff, Ilene; Fortunato, Gilbert; McCullough, Louise D.] Hartford Hosp, 80 Seymour St, Hartford, CT 06106 USA	McCullough, LD (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA.; McCullough, LD (corresponding author), Hartford Hosp, 80 Seymour St, Hartford, CT 06106 USA.	Louise.D.McCullough@uth.tmc.edu	McCullough, Louise/R-2824-2019	Ritzel, Rodney/0000-0002-0160-2930; Roy-O'Reilly, Meaghan/0000-0002-6824-885X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS094543, NS076293, 1F30NS098628]; Hartford Hospital Research Department; Russell and Diana Hawkins Family Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094543, F30NS098628, R21NS076293] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health NS094543 and NS076293 (to LDM) and the Hartford Hospital Research Department, and the Russell and Diana Hawkins Family Foundation Discovery Fellowships to the Graduate School at UTHealth (to MAR) and the National Institutes of Health 1F30NS098628 (to MAR).	Adar T, 2014, CLIN IMMUNOL, V153, P199, DOI 10.1016/j.clim.2014.04.012; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; de Paulis A, 2001, INT ARCH ALLERGY IMM, V124, P146, DOI 10.1159/000053694; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Emanuele E, 2006, ATHEROSCLEROSIS, V186, P140, DOI 10.1016/j.atherosclerosis.2005.07.002; Erickson MA, 2014, J PHARMACOL EXP THER, V349, P497, DOI 10.1124/jpet.114.213074; Flurkey K., 2007, MOUSE BIOMEDICAL RES, P637, DOI [DOI 10.1016/B978-012369454-6/50074-1, 10.1016/B978-012369454-6/50074-1.]; Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Huber A. K., 2016, CLIN IMMUNOL; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Manwani B, 2014, STROKE, V45, P571, DOI 10.1161/STROKEAHA.113.002944; Manwani B, 2011, BRAIN BEHAV IMMUN, V25, P1689, DOI 10.1016/j.bbi.2011.06.015; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Mir A, 2002, AM J GASTROENTEROL, V97, P1452, DOI 10.1016/S0002-9270(02)04043-1; Miyamasu M, 2000, INT ARCH ALLERGY IMM, V122, P54, DOI 10.1159/000053634; Parajuli B, 2015, GLIA, V63, P2274, DOI 10.1002/glia.22892; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Targowski T, 2005, J INVEST ALLERG CLIN, V15, P277; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Zschaler J, 2014, CRIT REV IMMUNOL, V34, P433	25	11	11	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2017	8	6					578	584		10.1007/s12975-017-0545-3			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FK1JM	WOS:000413236900007	28634890	Green Accepted			2021-06-18	
J	Sen, N				Sen, Nilkantha			An insight into the vision impairment following traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article							RETINAL GANGLION-CELLS; OCULOMOTOR NERVE PALSY; MINOR HEAD TRAUMA; OPTIC-NERVE; COMPUTED-TOMOGRAPHY; AXONAL INJURY; DAMAGE; NEUROPROTECTION; NEUROPATHY; MORTALITY	Traumatic brain injury (TBI) is one of the major cause of morbidity and mortality and it affects more than 1.7 million Americans each year. Depending on its location and severity, TBI leads to structural and functional damage in several parts of the brain such as cranial nerves, optic nerve tract or other circuitry involved in vision, and occipital lobe. As a result, the function associated with vision processing and perception are significantly affected and cause blurred vision, double vision, decreased peripheral vision and blindness. In this mini-review, we will focus the recent progress made to understand the pathology and underlying cellular/molecular mechanisms involved in the impairment of the integrity of visual systems following TBI. (C) 2017 Elsevier Ltd. All rights reserved.	[Sen, Nilkantha] Augusta Univ, Dept Neurosci & Regenerat Med, 1120 15th St,CA 2018, Augusta, GA 30907 USA	Sen, N (corresponding author), Augusta Univ, Dept Neurosci & Regenerat Med, 1120 15th St,CA 2018, Augusta, GA 30907 USA.	nsen@augusta.edu	Sen, Nilkantha/AAW-9788-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1EY025622, RO1NS094516]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY025622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094516] Funding Source: NIH RePORTER	N.S is supported by funding from NIH (RO1EY025622 and RO1NS094516).	Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; Atkins Edward J, 2008, Rev Neurol Dis, V5, P73; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; BROOKS AMV, 1984, BRIT J OPHTHALMOL, V68, P838, DOI 10.1136/bjo.68.11.838; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; Caesar R, 2003, EYE, V17, P661, DOI 10.1038/sj.eye.6700420; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Chen CC, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.016311; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; Cui DM, 2017, CNS NEUROSCI THER, V23, P106, DOI 10.1111/cns.12633; De Leeuw M, 2015, J FORENSIC LEG MED, V36, P43, DOI 10.1016/j.jflm.2015.08.009; Dhaliwal A, 2006, J NEURO-OPHTHALMOL, V26, P4, DOI 10.1097/01.wno.0000204661.48806.1d; DOMINGO Z, 1993, BRIT J NEUROSURG, V7, P141, DOI 10.3109/02688699309103470; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Coello AF, 2010, J NEUROSURG, V113, P547, DOI 10.3171/2010.6.JNS091620; Gauguet Jean-Marc, 2008, Radiol Case Rep, V3, P124, DOI 10.2484/rcr.v3i1.124; Giacci MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104565; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hall ANB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159442; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hassan A, 2002, CLIN EXP OPHTHALMOL, V30, P273, DOI 10.1046/j.1442-9071.2002.00534.x; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jang SH, 2015, J NEURO-OPHTHALMOL, V35, P270, DOI 10.1097/WNO.0000000000000249; KEANE JR, 1992, NEUROL CLIN, V10, P849; Kim E, 2013, J KOREAN NEUROSURG S, V54, P434, DOI 10.3340/jkns.2013.54.5.434; KROHEL GB, 1979, AM J OPHTHALMOL, V88, P254, DOI 10.1016/0002-9394(79)90474-4; Lee Bruce, 2005, NeuroRx, V2, P372; Legrand A, 2013, CRIT CARE, V17, DOI 10.1186/cc12589; Levin Leonard A, 2004, Ophthalmol Clin North Am, V17, P455, DOI 10.1016/j.ohc.2004.05.008; Levkovitch-Verbin H, 2004, EYE, V18, P1066, DOI 10.1038/sj.eye.6701576; Ma M, 2012, J NEUROTRAUM, V29, P2555, DOI 10.1089/neu.2012.2473; Magharious M. M., 2011, JOVE-J VIS EXP, V51, P2241, DOI DOI 10.3791/2241; Maissan IM, 2015, J NEUROSURG, V123, P743, DOI 10.3171/2014.10.JNS141197; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Masquere P, 2013, CRIT CARE, V17, DOI 10.1186/cc12728; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; McCann J D, 1994, Curr Opin Ophthalmol, V5, P3, DOI 10.1097/00055735-199412000-00002; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moreau F, 2013, CEREBROVASC DIS EXTR, V3, P130, DOI 10.1159/000355024; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Sarkies N, 2004, EYE, V18, P1122, DOI 10.1038/sj.eye.6701571; Sawhney R, 2003, EYE, V17, P667, DOI 10.1038/sj.eye.6700411; Schumann P, 2013, CRANIOMAX TRAUM REC, V6, P75, DOI 10.1055/s-0033-1343783; Sekhon MS, 2014, NEUROCRIT CARE, V21, P245, DOI 10.1007/s12028-014-0003-y; Simon GJB, 2006, J NEUROTRAUM, V23, P1072, DOI 10.1089/neu.2006.23.1072; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Steinsapir KD, 2011, AM J OPHTHALMOL, V151, P928, DOI 10.1016/j.ajo.2011.02.007; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Van Stavern GP, 2001, J NEURO-OPHTHALMOL, V21, P112, DOI 10.1097/00041327-200106000-00012; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Vien L, 2017, OPTOMETRY VISION SCI, V94, P125, DOI 10.1097/OPX.0000000000000899; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; WARNER JEA, 1995, INT OPHTHALMOL CLIN, V35, P57, DOI 10.1097/00004397-199503510-00007; Warner N, 2010, CURR OPIN OPHTHALMOL, V21, P459, DOI 10.1097/ICU.0b013e32833f00c9; Young A. M., 2016, PEDIAT RES	62	11	11	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		103	107		10.1016/j.neuint.2017.01.019			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600011	28163060	Green Accepted			2021-06-18	
J	Snell, DL; Iverson, GL; Panenka, WJ; Silverberg, ND				Snell, Deborah L.; Iverson, Grant L.; Panenka, William J.; Silverberg, Noah D.			Preliminary Validation of the World Health Organization Disability Assessment Schedule 2.0 for Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						mTBI; outcome measures; 12 item WHODAS 2.0	POST-CONCUSSION SYMPTOMS; CHRONIC PAIN; PREDICTION; INTERVIEW; 12-ITEM; VERSION; MINI	The purpose of this study is to examine the reliability, factor structure, and validity of the World Health Organization Disability Assessment Schedule (WHODAS 2.0 12 item version) in a sample of patients who were slow to recover from a mild traumatic brain injury (mTBI). Participants were 79 adults with mTBI recruited from one of four specialty outpatient clinics in Vancouver, Canada. The WHODAS 2.0 12 item version is a disease-nonspecific measure of disability representing six International Classification of Disability, Functioning, and Health activity and participation domains including cognition, mobility, self-care, interpersonal functioning, life activities, and participation. Results of analyses showed that the WHODAS 2.0 had high internal consistency and adequate construct and concurrent validity. A three factor structure emerged in this sample. The scale differentiated between patients with good and those with poor outcomes based on post-concussion syndrome, psychiatric, and pain status. Participants with multiple comorbidities reported the most disability on the WHODAS. Concurrent validity was also supported by lower WHODAS scores in participants who had returned to work versus those who had not. To our knowledge, this is the first study to evaluate the psychometric properties of the WHODAS 2.0 in a sample of people with mTBI. In summary, the WHODAS was sensitive to post-concussion syndrome after mTBI, as well as to health conditions that commonly co-occur with mTBI (e.g., mental health problems and chronic pain).	[Snell, Deborah L.] Univ Otago, Burwood Hosp, Canterbury Dist Hlth Board, Concuss Clin,Dept Orthopaed Surg & Musculoskeleta, Christchurch, New Zealand; [Iverson, Grant L.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA; [Panenka, William J.] Univ British Columbia, Dept Psychiat, British Columbia Neuropsychiat Program, Vancouver, BC, Canada; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Rehabil Res Program, GF Strong Rehab Ctr,Rehabil Res Program, Vancouver, BC, Canada	Silverberg, ND (corresponding author), Univ British Columbia, Div Phys Med & Rehabil, Rehabil Res Program, GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570; Panenka, William/0000-0001-7143-6512	Specific Priorities Research Grant from WorkSafeBC [RS2014-SP03]; Clinician Scientist Career Development Award from the Vancouver Coastal Health Research Institute	We thank research assistants Mary Ellen Johnson and Sabrina Khan as well as the clinical staff at our recruitment sites, including Kelsey Davies, Jennifer Loffree, Grace Boutilier, and Trish Mahoney (GF Strong Rehab Centre); Deanna Yells, Heather MacNeil, and Rod Macdonald (Fraser Health Concussion Clinic); Denise Silva and Lesley Norris (Back in Motion); and Karilyn Lao, Wayne Tang, and Cyrus Huang (LifeMark). This study was funded by a Specific Priorities Research Grant from WorkSafeBC (# RS2014-SP03). Dr. Silverberg receives salary support from a Clinician Scientist Career Development Award from the Vancouver Coastal Health Research Institute.	Andrews G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008343; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P343, DOI 10.1080/13854046.2013.774438; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; de Guise E, 2016, APPL NEUROPSYCH-ADUL, V23, P213, DOI 10.1080/23279095.2015.1038747; Derrett S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044909; Dixon JK, 2005, STAT METHODS HLTH CA, V5, P321; Federici S, 2017, DISABIL REHABIL, V39, P2347, DOI 10.1080/09638288.2016.1223177; Friedland D, 2016, J NEUROL NEUROSUR PS, V87, P1068, DOI 10.1136/jnnp-2015-312193; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; IBM Corporation, 2016, BM SPSS STAT MAC VER; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Kuo CY, 2015, INT J ENV RES PUB HE, V12, P4116, DOI 10.3390/ijerph120404116; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; MacLeod MA, 2016, INT J METH PSYCH RES, V25, P243, DOI 10.1002/mpr.1523; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Resnik L, 2017, ARCH PHYS MED REHAB, V98, P561, DOI 10.1016/j.apmr.2016.08.463; Saltychev M, 2017, CLIN REHABIL, V31, P262, DOI 10.1177/0269215516631385; Sen A, 2002, BRIT MED J, V324, P860, DOI 10.1136/bmj.324.7342.860; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2017, J NEUROTRAUM, V34, P363, DOI 10.1089/neu.2016.4443; Silverberg ND, 2016, CLIN J SPORT MED, V26, P226, DOI 10.1097/JSM.0000000000000241; Sjonnesen K, 2016, CAN J PSYCHIAT, V61, P227, DOI 10.1177/0706743716632514; Smedema SM, 2016, J REHABIL, V82, P28; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stalnacke BM, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/528265; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Theadom A., 2017, ARCH PHYS MED REHABI; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Ustun TB, 2010, MEASURING HLTH DISAB; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Weeks M, 2016, CAN J PSYCHIAT, V61, p56S, DOI 10.1177/0706743716628853; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2001, ICF INT CLASFUNCT	41	11	12	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2017	34	23					3256	3261		10.1089/neu.2017.5234			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FN9HM	WOS:000416341700006	28895491				2021-06-18	
J	Zeiler, FA; Lo, BWY; Akoth, E; Silvaggio, J; Kaufmann, AM; Teitelbaum, J; West, M				Zeiler, F. A.; Lo, B. W. Y.; Akoth, E.; Silvaggio, J.; Kaufmann, A. M.; Teitelbaum, J.; West, M.			Predicting Outcome in Subarachnoid Hemorrhage (SAH) Utilizing the Full Outline of UnResponsiveness (FOUR) Score	NEUROCRITICAL CARE			English	Article						Full Outline of UnResponsiveness; SAH; Aneurysm; Subarachnoid hemorrhage; Outcome prediction	TRAUMATIC BRAIN-INJURY; COMA SCALE; NEUROSURGICAL PATIENTS; VALIDATION	Existing scoring systems for aneurysmal subarachnoid hemorrhage (SAH) patients fail to accurately predict patient outcome. Our goal was to prospectively study the Full Outline of UnResponsiveness (FOUR) score as applied to newly admitted aneurysmal SAH patients. All adult patients presenting to Health Sciences Center in Winnipeg from January 2013 to July 2015 (2.5 year period) with aneurysmal SAH were prospectively enrolled in this study. All patients were followed up to 6 months. FOUR score was calculated upon admission, with repeat calculation at 7 and 14 days. The primary outcomes were: mortality, as well as dichotomized 1- and 6-month Glasgow Outcome Scale (GOS) and modified Rankin Scale (mRS) values. Sixty-four patients were included, with a mean age of 54.2 years (range 26-85 years). The mean FOUR score upon admission pre- and post-external ventricular drain (EVD) was 10.3 (range 0-16) and 11.1 (range 3-16), respectively. There was a statistically significant association between pre-EVD FOUR score (total, eye, respiratory and motor sub-scores) with mortality, 1-month GOS, and 6-month GOS/mRS (p < 0.05 in all). The day 7 total, eye, respiratory, and motor FOUR scores were associated with mortality, 1-month GOS/mRS, and 6-month GOS/mRS (p < 0.05 in all). The day 14 total, eye, respiratory, and motor FOUR scores were associated with 6-month GOS (p < 0.05 in all). The day 7 cumulative FOUR score was associated with the development of clinical vasospasm (p < 0.05). The FOUR score at admission and day 7 post-SAH is associated with mortality, 1-month GOS/mRS, and 6-month GOS/mRS. The FOUR score at day 14 post-SAH is associated with 6-month GOS. The brainstem sub-score was not associated with 1- or 6-month primary outcomes.	[Zeiler, F. A.; Akoth, E.; Silvaggio, J.; Kaufmann, A. M.; West, M.] Univ Manitoba, Hlth Sci Ctr, Dept Surg, Sect Neurosurg, GB-1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada; [Zeiler, F. A.] Univ Manitoba, Clinician Investigator Program, Winnipeg, MB, Canada; [Zeiler, F. A.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Lo, B. W. Y.] McGill Univ, Montreal Neurol Inst, Sect Neurosurg & Neurocrit Care, Montreal, PQ, Canada; [Lo, B. W. Y.; Teitelbaum, J.] Montreal Neurol Inst, Sect Neurocrit Care, Montreal, PQ, Canada	Zeiler, FA (corresponding author), Univ Manitoba, Hlth Sci Ctr, Dept Surg, Sect Neurosurg, GB-1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.; Zeiler, FA (corresponding author), Univ Manitoba, Clinician Investigator Program, Winnipeg, MB, Canada.; Zeiler, FA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England.	umzeiler@myumanitoba.ca; Benjamin.lo@mcgill.ca; eakoth@exchange.hsc.mb.ca; JSilvaggio@exchange.hsc.mb.ca; akaufmann@exchange.hsc.mb.ca; jteitelbaum@hotmail.com; MWest@exchange.hsc.mb.ca		Teitelbaum, Jeanne/0000-0002-9834-3882; Zeiler, Frederick/0000-0003-1737-0510	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund.	Akavipat P, 2011, ACTA MED OKAYAMA, V65, P205; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Chen BX, 2013, ACTA NEUROCHIR, V155, P2133, DOI 10.1007/s00701-013-1854-2; DRAKE CG, 1988, J NEUROSURG, V68, P985; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kramer AA, 2012, CRIT CARE MED, V40, P2671, DOI 10.1097/CCM.0b013e318258fd88; Okasha AS, 2014, NEUROCRIT CARE, V21, P496, DOI 10.1007/s12028-014-9995-6; Oshiro EM, 1997, NEUROSURGERY, V41, P140, DOI 10.1097/00006123-199707000-00029; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	12	11	12	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2017	27	3					381	391		10.1007/s12028-017-0396-5			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FN7DT	WOS:000416179300011	28382509				2021-06-18	
J	Zheng, YK; Dong, XQ; Du, Q; Wang, H; Yang, DB; Zhu, Q; Che, ZH; Shen, YF; Jiang, L; Hu, W; Wang, KY; Yu, WH				Zheng, Yong-Ke; Dong, Xiao-Qiao; Du, Quan; Wang, Hao; Yang, Ding-Bo; Zhu, Qiang; Che, Zhi-Hao; Shen, Yong-Feng; Jiang, Li; Hu, Wei; Wang, Ke-Yi; Yu, Wen-Hua			Comparison of plasma copeptin and multiple biomarkers for assessing prognosis of patients with aneurysmal subarachnoid hemorrhage	CLINICA CHIMICA ACTA			English	Article						Aneurysm; Subarachnoid hemorrhage; Copeptin; Cerebral vasospasm; Prognosis; Biomarkers	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; INTRACEREBRAL HEMORRHAGE; ISCHEMIC-STROKE; CEREBROSPINAL-FLUID; NF-H; SERUM; PREDICTION; VASOSPASM; MORTALITY	Background: Increased plasma copeptin concentrations are related to poor prognosis after aneurysmal subarachnoid hemorrhage (aSAH). The aim of this study was to assess prognostic significance of plasma copeptin detection compared with glial fibrillary astrocyte protein, myelin basic protein, S100B, phosphorylated axonal neurofilament subunit H, neuron-specific enolase, tau and ubiquitin carboxyl-terminal hydrolase L1 in aSAH. Methods: We detected plasma concentrations of the aforementioned biomarkers in 105 healthy controls using ELISA. Their predictive ability for symptomatic cerebral vasospasm and 6-month poor outcome (Glasgow Outcome Scale score of 1-3) were compared. Results: Plasma concentrations of the preceding biomarkers were highly correlated with World Federation of Neurological Surgeons subarachnoid hemorrhage scale (WFNS) scores as well as were significantly higher in patients with symptomatic cerebral vasospasm than in those without symptomatic cerebral vasospasm and in patients with poor outcome than in those with good outcome. In terms of area under receiver operating characteristic curve, their predictive value for symptomatic cerebral vasospasm and 6-month poor outcome was in the range of WFNS scores. Plasma copeptin concentration, but not plasma concentrations of other biomarkers, statistically significantly improved the predictive performance of WFNS scores. Conclusions: Copeptin in plasma might have the potential to be a useful prognostic biomarker for aSAH.	[Zheng, Yong-Ke; Hu, Wei] Nanjing Med Univ, Dept Intens Care Unit, Hangzhou Peoples Hosp 1, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China; [Dong, Xiao-Qiao; Du, Quan; Wang, Hao; Yang, Ding-Bo; Zhu, Qiang; Che, Zhi-Hao; Shen, Yong-Feng; Jiang, Li; Yu, Wen-Hua] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, Ke-Yi] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Cent Lab, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China	Yu, WH (corresponding author), Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	hzwenhuayu@163.com			Zhejiang Province Medical and Health Project; Hangzhou Medical Research Fund Project	The authors thank all staffs in Department of Neurosurgery, the Hangzhou First Peoples Hospital (Hangzhou, China) for their technical support. This study was supported financially by Zhejiang Province Medical and Health Project and Hangzhou Medical Research Fund Project.	Aksu F, 2016, CLIN LAB, V62, P2387, DOI 10.7754/Clin.Lab.2016.160532; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Cavus UY, 2014, EUR J TRAUMA EMERG S, V40, P373, DOI 10.1007/s00068-013-0357-4; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Lopez ZRD, 2015, CLIN CHEM LAB MED, V53, pE179, DOI 10.1515/cclm-2014-1189; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Dong XQ, 2011, PEPTIDES, V32, P253, DOI 10.1016/j.peptides.2010.11.021; DRAKE CG, 1988, J NEUROSURG, V68, P985; Etminan N, 2017, HAND CLINIC, V140, P195, DOI 10.1016/B978-0-444-63600-3.00012-X; Fenske W, 2012, J CLIN ENDOCR METAB, V97, P3426, DOI 10.1210/jc.2012-1981; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Freynhofer MK, 2012, WIEN MED WOCHENSCHR, V162, P489, DOI 10.1007/s10354-012-0148-2; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Fung C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053191; Grasso Giovanni, 2017, Surg Neurol Int, V8, P11, DOI 10.4103/2152-7806.198738; Grimm JW, 2015, J EMERG NURS, V41, P281, DOI 10.1016/j.jen.2014.12.018; Helbok R, 2015, J NEUROL NEUROSUR PS, V86, P79, DOI 10.1136/jnnp-2013-307326; Hirashima Y, 2001, NEUROL RES, V23, P715, DOI 10.1179/016164101101199225; Jaja BNR, 2015, J NEUROSURG, V122, P644, DOI 10.3171/2014.10.JNS132694; Kellermann I, 2016, CLIN NEUROL NEUROSUR, V145, P79, DOI 10.1016/j.clineuro.2016.04.005; Kiiski H, 2016, J NEUROL SCI, V361, P144, DOI 10.1016/j.jns.2015.12.046; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Lai PMR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151853; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lin C, 2013, PEPTIDES, V42, P43, DOI 10.1016/j.peptides.2013.01.015; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Russell JA, 2009, CRIT CARE MED, V37, P749, DOI 10.1097/CCM.0b013e318194d117; Serrone JC, 2015, EXPERT REV NEUROTHER, V15, P367, DOI 10.1586/14737175.2015.1018892; Shen YF, 2015, CLIN CHIM ACTA, V448, P155, DOI 10.1016/j.cca.2015.06.024; Staub D, 2009, CLIN CHIM ACTA, V399, P69, DOI 10.1016/j.cca.2008.09.016; Tamargo RJ, 2012, CRIT CARE, V16, DOI 10.1186/cc10594; Tawk RG, 2016, NEUROSURGERY, V78, P487, DOI 10.1227/NEU.0000000000001140; Tiebosch IACW, 2013, NEUROCRIT CARE, V18, P96, DOI 10.1007/s12028-012-9692-2; Tsakaldimis G, 2015, HELL J NUCL MED, V18, P103; Tu WJ, 2017, NEUROLOGY, V88, P1899, DOI 10.1212/WNL.0000000000003937; Wang CB, 2016, J DIABETES COMPLICAT, V30, P1532, DOI 10.1016/j.jdiacomp.2016.07.030; Wei ZJ, 2014, NEUROL SCI, V35, P1673, DOI 10.1007/s10072-014-1809-2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Xu Q, 2017, HYPERTENS RES, V40, P465, DOI 10.1038/hr.2016.165; Yang DB, 2014, PEPTIDES, V58, P26, DOI 10.1016/j.peptides.2014.05.015; Yu GF, 2012, PEPTIDES, V33, P164, DOI 10.1016/j.peptides.2011.11.017; Yu WH, 2014, CLIN CHIM ACTA, V433, P174, DOI 10.1016/j.cca.2014.03.014; Zhang AM, 2013, EXP THER MED, V5, P467, DOI 10.3892/etm.2012.804; Zhang RY, 2017, MOL NEUROBIOL, V54, P169, DOI 10.1007/s12035-015-9626-z; Zhang X, 2012, PEPTIDES, V33, P336, DOI 10.1016/j.peptides.2012.01.011; Zhang ZY, 2014, PEPTIDES, V60, P13, DOI 10.1016/j.peptides.2014.07.016; Zhu XD, 2011, CRIT CARE, V15, DOI 10.1186/cc10575; Zweifel C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-34	53	11	13	1	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	DEC	2017	475						64	69		10.1016/j.cca.2017.10.009			6	Medical Laboratory Technology	Medical Laboratory Technology	FP5NS	WOS:000417666800011	29037840				2021-06-18	
